Filter by: Display page Set page size Total 8778
Name
Label
Description
DataType
Groups
120 Sample Arm
Phase 2 data. Arm from which 120 minute blood sample was taken.
Text
120 Sample by
Phase 2 data. Initials/ID of staff member 120 minute blood sample was taken by
Text
120 Sample Site
Phase 2 data. Site of 120 minute sample blood sample taken
Text
None
Phase 2 data. 35 daytime hours for Phase 2? (frist wear of Actiheart only). Used for Study cooridination purposes not for analysis. Use wear varibles in main AH dataset for analysis. 0 = no; 1 = yes;
Categorical
Feeling lonely console by eating
Phase 2 data. When I feel lonely; I console myself by eating. 1 = Definitely true; 2 = Mostly true; 3 = Mostly false; 4 = Definitely false;
Categorical
Re-scored item 3FEQ_10lonelyconsoleeating_P2
Phase 2 data. Derived by re-scoring item 3FEQ_10lonelyconsoleeating_P2; score of 1 as 4; 2 as 3; 3 as 2 and 4 as 1 (assessed and cleaned only in the subset n = 4810). When I feel lonely; I console myself by eating. 1 = Definitely false; 2 = Mostly false; 3 = Mostly true; 4 = Definitely true (a decimal value was allowed for answers with a range); -1 = missing data; -9 = questionnaire not completed;
Categorical
Hold back on eating control weight
Phase 2 data. I consciously hold back at meals in order not to weight gain. 1 = Definitely true; 2 = Mostly true; 3 = Mostly false; 4 = Definitely false;
Categorical
Re-scored item 3FEQ_11holdbackatmeals
Phase 2 data. Derived by re-scoring item 3FEQ_11holdbackatmeals_P2; score of 1 as 4; 2 as 3; 3 as 2 and 4 as 1 (assessed and cleaned only in the subset n = 4810).I consciously hold back at meals in order not to weight gain. 1 = Definitely false; 2 = Mostly false; 3 = Mostly true; 4 = Definitely true (a decimal value was allowed for answers with a range); -1 = missing data; -9 = questionnaire not completed;
Categorical
Do not eat some food make me fat
Phase 2 data. I do not eat some foods because they make me fat. 1 = Definitely true; 2 = Mostly true; 3 = Mostly false; 4 = Definitely false;
Categorical
Re-scored item 3FEQfeq_12foodmakemefat_P2
Phase 2 data. Derived by re-scoring item 3FEQfeq_12foodmakemefat_P2; score of 1 as 4; 2 as 3; 3 as 2 and 4 as 1 (assessed and cleaned only in the subset n = 4810).I do not eat some foods because they make me fat. 1 = Definitely false; 2 = Mostly false; 3 = Mostly true; 4 = Definitely true (a decimal value was allowed for answers with a range); -1 = missing data; -9 = questionnaire not completed;
Categorical
Always hungry to eat any time
Phase 2 data. I am always hungry enough to eat at any time. 1 = Definitely true; 2 = Mostly true; 3 = Mostly false; 4 = Definitely false;
Categorical
Re-scored item 3FEQ_13hungryeatanytime_P2
Phase 2 data. Derived by re-scoring item 3FEQ_13hungryeatanytime_P2; score of 1 as 4; 2 as 3; 3 as 2 and 4 as 1 (assessed and cleaned only in the subset n = 4810).I am always hungry enough to eat at any time. 1 = Definitely false; 2 = Mostly false; 3 = Mostly true; 4 = Definitely true (a decimal value was allowed for answers with a range); -1 = missing data; -9 = questionnaire not completed;
Categorical
Often feel hungry frequency
Phase 2 data. How often do you feel hungry? 1 = Only at meal times; 2 = Sometimes between meals; 3 = Often between meals; 4 = Almost always;
Categorical
Derived from 3FEQ_14oftenfeelhungry_P2
Phase 2 data. Derived from item 3FEQ_14oftenfeelhungry_P2 (assessed and cleaned only in the subset n = 4810). Note all scores were left the same apart from -1 scores which were removed. How often do you feel hungry? Please note that rarely and never have been recoded as 1. 1 = Only at meal times; 2 = Sometimes between meals; 3 = Often between meals; 4 = Almost always; -1 = missing data; -9 = questionnaire not completed;
Categorical
Avoid stocking up on tempting foods
Phase 2 data. How frequently do you avoid stocking up on tempting foods? 1 = Almost never; 2 = Seldom; 3 = Usually; 4 = Almost always;
Categorical
Derived from 3FEQ_15stockinguptemptingfoods_P2
Phase 2 data. Derived from item 3FEQ_15stockinguptemptingfoods_P2 (assessed and cleaned only in the subset n = 4810). Note all scores were left the same apart from -1 scores which were removed. How frequently do you avoid stocking up® on tempting foods? 1 = Almost never; 2 = Seldom; 3 = Usually; 4 = Almost always; -9 = questionnaire not completed;
Categorical
Consciously eat less food
Phase 2 data. How likely are you to consciously eat less than you want? 1 = Unlikely; 2 = Slightly likely; 3 = Moderately likely; 4 = Very likely;
Categorical
Derived from 3FEQ_16consciouslyeatless_P2
Phase 2 data. Derived from item 3FEQ_16consciouslyeatless_P2 (assessed and cleaned only in the subset n = 4810). Note all scores were left the same apart from -1 scores which were removed. 1 = Unlikely; 2 = Slightly likely; 3 = Moderately likely; 4 = Very likely; -9 = questionnaire not completed;
Categorical
Binge eating
Phase 2 data. Do you go on eating binges though you are not hungry? 1 = Never; 2 = Rarely; 3 = Sometimes; 4 = At least once a week;
Categorical
Derived from 3FEQ_17eatingbingeswhennothungry_P2
Phase 2 data. Derived from item 3FEQ_17eatingbingeswhennothungry_P2 (assessed and cleaned only in the subset n = 4810). Note all scores were left the same apart from -1 scores which were removed. Do you go on eating binges though you are not hungry? 1 = Never; 2 = Rarely; 3 = Sometimes; 4 = At least once a week; -1 = missing data; -9 = questionnaire not completed;
Categorical
Scale of restraint on eating
Phase 2 data. On a scale of 1 to 8 where 1 means no restraint in eating (eating whatever you want whenever you want it) and 8 means total restraint (constantly limiting food intake and never giving in); what number would you give yourself? 1 = 1 (no restraint in eating ie eating whatever you want and whenever you want it); 2 = 2; 3 = 34 = 4; 5 = 5; 6 = 6; 7 = 7; 8 = 8 (total restraint ie constantly limiting food and never giving in);
Categorical
Re-scored item 3FEQ_ 18scaleofrestraint_P2
Phase 2 data. Derived by re-scoring item 3FEQ_ 18scaleofrestraint_P2; score of 1 or 2 as 1; 3 or 4 as 2; 5 or 6 as 3 and 7 or 8 as 4 (assessed and cleaned only in the subset n = 4810). On a scale of 1 to 4 with regards to restraint in eating what number would you give yourself? Where 1 means no restraint in eating and 4 means total restraint. 1 = 1; 2 = 2; 3 = 3; 4 = 4; -9 = questionnaire not completed; -1 = missing data (this also includes answers which were not consecutive);
Categorical
Smell of meat makes eating more
Phase 2 data. When I smell a sizzling steak or juicy piece of meat I find it very difficult to keep from eating even if I have just finished a meal. 1 = Definitely true; 2 = Mostly true; 3 = Mostly false; 4 = definitely false; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Re-scored item 3FEQ_1smellofmeat_P2
Phase 2 data. Derived by re-scoring item 3FEQ_1smellofmeat_P2 score of 1 as 4; 2 as 3; 3 as 2 and 4 as 1 (assessed and cleaned only in the subset n = 4810). When I smell a sizzling steak or juicy piece of meat I find it very difficult to keep from eating even if I have just finished a meal. 1 = Definitely false; 2 = Mostly false; 3 = Mostly true; 4 = Definitely true (a decimal value was allowed for answers with a range); -1 = missing data; -9 = questionnaire not completed;
Categorical
Small helpings to control weight
Phase 2 data. I deliberately take small helpings as a means of controlling my weight. 1 = Definitely true; 2 = Mostly true; 3 = Mostly false; 4 = Definitely false;
Categorical
Re-scored item 3FEQ_2smallhelpings_P2
Phase 2 data. Derived by re-scoring item 3FEQ_2smallhelpings_P2 score of 1 as 4; 2 as 3; 3 as 2 and 4 as 1 (assessed and cleaned only in the subset n = 4810).I deliberately take small helpings as a means of controlling my weight. 1 = Definitely false; 2 = Mostly false; 3 = Mostly true; 4 = Definitely true (a decimal value was allowed for answers with a range); -1 = missing data; -9 = questionnaire not completed;
Categorical
Eating when anxious
Phase 2 data. When I feel anxious; I find myself eating. 1 = Definitely true; 2 = Mostly true; 3 = Mostly false; 4 = Definitely false;
Categorical
Re-scored item 3FEQ_3anxiousandeating_P2
Phase 2 data. Derived by re-scoring item 3FEQ_3anxiousandeating_P2 score of 1 as 4; 2 as 3; 3 as 2 and 4 as 1 (assessed and cleaned only in the subset n = 4810).When I feel anxious I find myself eating. 1 = Definitely false; 2 = Mostly false; 3 = Mostly true; 4 = Definitely true (a decimal value was allowed for answers with a range); -1 = missing data; -9 = questionnaire not completed;
Categorical
Cant stop eating
Phase 2 data. Sometimes when I start eating; I just can't seem to stop. 1 = Definitely true; 2 = Mostly true; 3 = Mostly false; 4 = Definitely false;
Categorical
Re-scored item 3FEQ_4startedeatingcantstop_P2
Phase 2 data. Derived by re-scoring item 3FEQ_4startedeatingcantstop_P2 score of 1 as 4; 2 as 3; 3 as 2 and 4 as 1 (assessed and cleaned only in the subset n = 4810).Sometimes when I start eating I just cannot seem to stop. 1 = Definitely false; 2 = Mostly false; 3 = Mostly true; 4 = Definitely true (a decimal value was allowed for answers with a range); -1 = missing data; -9 = questionnaire not completed;
Categorical
When with someone eat more
Phase 2 data. Being with someone who is eating often makes me hungry enough to eat also. 1 = Definitely true; 2 = Mostly true; 3 = Mostly false; 4 = Definitely false;
Categorical
Re-scored item 3FEQ_5withsomeoneeating_P2
Phase 2 data. Derived by re-scoring item 3FEQ_5withsomeoneeating_P2 score of 1 as 4; 2 as 3; 3 as 2 and 4 as 1 (assessed and cleaned only in the subset n = 4810).Being with someone who is eating often makes me hungry enough to eat also. 1 = Definitely false; 2 = Mostly false; 3 = Mostly true; 4 = Definitely true (a decimal value was allowed for answers with a range); -1 = missing data; -9 = questionnaire not completed;
Categorical
Overeat when feeling down
Phase 2 data. When I feel blue; I often overeat. 1 = Definitely true; 2 = Mostly true; 3 = Mostly false; 4 = Definitely false;
Categorical
Re-scored item 3FEQ_6blueandovereating_P2
Phase 2 data. Derived by re-scoring item 3FEQ_6blueandovereating_P2 score of 1 as 4; 2 as 3; 3 as 2 and 4 as 1 (assessed and cleaned only in the subset n = 4810).When I feel blue I often overeat. 1 = Definitely false; 2 = Mostly false; 3 = Mostly true; 4 = Definitely true (a decimal value was allowed for answers with a range); -1 = missing data; -9 = questionnaire not completed;
Categorical
Delicacy eat right away
Phase 2 data. When I see a real delicacy; I often get so hungry that I have to eat right away. 1 = Definitely true; 2 = Mostly true; 3 = Mostly false; 4 = Definitely false;
Categorical
Re-scored item 3FEQ_7delicacyandeatingrightaway_P2
Phase 2 data. Derived by re-scoring item 3FEQ_7delicacyandeatingrightaway_P2; score of 1 as 4; 2 as 3; 3 as 2 and 4 as 1 (assessed and cleaned only in the subset n = 4810).When I see a real delicacy I often get so hungry that I have to eat right away. 1 = Definitely false; 2 = Mostly false; 3 = Mostly true; 4 = Definitely true (a decimal value was allowed for answers with a range); -1 = missing data; -9 = questionnaire not completed;
Categorical
Hungry bottomless pit
Phase 2 data. I get so hungry that my stomach often seems like a bottomless pit. 1 = Definitely true; 2 = Mostly true; 3 = Mostly false; 4 = Definitely false;
Categorical
Re-scored item 3FEQ_8hungrybottomlesspit_P2
Phase 2 data. Derived by re-scoring item 3FEQ_8hungrybottomlesspit_P2; score of 1 as 4; 2 as 3; 3 as 2 and 4 as 1 (assessed and cleaned only in the subset n = 4810).I get so hungry that my stomach often seems like a bottomless pit. 1 = Definitely false; 2 = Mostly false; 3 = Mostly true; 4 = Definitely true (a decimal value was allowed for answers with a range); -1 = missing data; -9 = questionnaire not completed;
Categorical
Hunger stops finish food on plate
Phase 2 data. I am always hungry so it is hard for me to stop eating before I finish the food on my plate. 1 = Definitely true; 2 = Mostly true; 3 = Mostly false; 4 = Definitely false;
Categorical
Re-scored item 3FEQ_9finishfoodonplate_P2
Phase 2 data. Derived by re-scoring item 3FEQ_9finishfoodonplate_P2; score of 1 as 4; 2 as 3; 3 as 2 and 4 as 1 (assessed and cleaned only in the subset n = 4810).I am always hungry so it is hard for me to stop eating before I finish the food on my plate. 1 = Definitely false; 2 = Mostly false; 3 = Mostly true; 4 = Definitely true (a decimal value was allowed for answers with a range); -1 = missing data; -9 = questionnaire not completed;
Categorical
Date finished to fill in e3FEQ qnr
Phase 2 data. Date the participant finished filling in the Electronic Online 3FEQ questionnaire.
Date
Date started to fill in e3FEQ qnr
Phase 2 data. Date the participant started to fill in the Electronic Online 3FEQ questionnaire.
Date
None
Phase 2 data. Data status variable to log user progress. Has the volunteer started filling in the eForm? 0 = no; 1 = yes;
Categorical
None
Phase 2 data. Data status variable to log user progress. Has the volunteer finished filling in the eForm? 0 = no; 1 = yes;
Categorical
e3FEQ questionnaire participant ID
Phase 2 data. Electronic 3FEQ questionnaire-specicifc participant ID number.
Text
e3FEQ questionnaire ID number
Phase 2 data. Electronic 3FEQ questionnaire ID number for version control.
Text
e3FEQ questionnaire ID name
Phase 2 data. Electronic 3FEQ questionnaire ID name for version control.
Text
Study phase e3FEQ questionnaire
Phase 2 data. Study phase the Electronic 3FEQ questionnaire was used for.
Text
Time finished to fill in e3FEQ qnr
Phase 2 data. Time the participant finished filling in the Electronic Online3FEQ questionnaire.
Time
Time started to fill in e3FEQ qnr
Phase 2 data. Time the participant started to fill in the Electronic Online 3FEQ questionnaire.
Time
None
Phase 2 data. Please enter your 3-digit pin (on electronic form).
Integer
e3FEQ questionnaire version date
Phase 2 data. Electronic 3FEQ questionnaire version date for version control.
Text
e3FEQ questionnaire version no
Phase 2 data. Electronic 3FEQ questionnaire version number for version control.
Integer
e3FEQ qnr web form version no
Phase 2 data. Electronic 3FEQ questionnaire web form version number for version control.
Text
Score for emotional eating
Phase 2 data. Score for Emotional Eating subscale of 3FEQ_EmotionalRAW_P2 on a scale of 0-100 (raw score - lowest possible raw score)/possible raw score range) * 100 (assessed and cleaned only in the subset n = 4810).Derived by calculating ((3FEQ_EmotionalRAW-3)/9)*100. -1 = missing data; number = score; -9 = questionnaire not completed;
Categorical
Score for restrained eating
Phase 2 data. Score for Restrained Eating subscale of 3FEQ_RestraintRAW_P2 on a scale of 0-100 (assessed and cleaned only in the subset n = 4810).Derived by calculating (raw score - lowest possible raw score)/possible raw score range) * 100 ((3FEQ_RestraintRAW-6)/18)*100. -1 = missing data; -9 = questionnaire not completed;
Categorical
Score for uncontrolled eating
Phase 2 data. Score for Uncontrolled Eating subscale of 3FEQ_UncontrolledRAW on a scale of 0-100 (raw score - lowest possible raw score)/possible raw score range) * 100 (assessed and cleaned only in the subset n = 4810).Derived by calculating ((3FEQ_UncontrolledRAW-9)/27)*100. -1 = missing data; number = score; -9 = questionnaire not completed;
Categorical
Visible fat
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads What did you do with the visible fat on your meat? 1 = Ate most of the fat; 2 = Ate some of the fat; 3 = Ate as little as possible; 4 = Did not eat meat; -1 = left blank; -5 = more than one selected;
Categorical
Grilled frequency
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads How often did you eat grilled or roast meat
Categorical
None
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads How well cooked did you usually have grilled or roast meat? 1 = Well done/dark brown; 2 = Medium; 3 = Lightly cooked/rare; 4 = Did not eat meat; -1 = left blank; -5 = more than one selected;
Categorical
Cooking salt use
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads How often did you add salt to food while cooking? 1 = Always; 2 = Usually; 3 = Sometimes; 4 = Rarely; -1 = left blank; -5 = more than one selected;
Categorical
Table salt use
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads How often did you add salt to any food at the table? 5 = Never; -1 = left blank; -5 = more than one selected;
Categorical
Salt substitute used
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Did you regularly use a salt substitute? 2 = Yes; 3 = No; -1 = left blank; -5 = more than one selected;
Categorical
Brand of salt subsitute
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Brand of salt substitute
Text
Supplements use
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Have you taken any vitamins during the past year? 2 = Yes; 3 = No; -1 = left blank; -5 = more than one selected;
Categorical
Brand of vitamin supplement 1
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Name and brand of supplements
Text
Frequency of vitamin supplement 1
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Frequency of supplements
Text
Brand of vitamin supplement 2
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Name and brand of supplements
Text
Frequency of vitamin supplement 2
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Frequency of supplements
Text
Brand of vitamin supplement 3
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Name and brand of supplements
Text
Frequency of vitamin supplement 3
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Frequency of supplements
Text
Brand of vitamin supplement 4
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Name and brand of supplements
Text
Frequency of vitamin supplement 4
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Frequency of supplements
Text
Brand of vitamin supplement 5
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Name and brand of supplements
Text
Frequency of vitamin supplement 5
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Frequency of supplements
Text
Brand of vitamin supplement 6
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Name and brand of supplements
Text
Frequency of vitamin supplement 6
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Frequency of supplements
Text
Brand of vitamin supplement 7
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Name and brand of supplements
Text
Frequency of vitamin supplement 7
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Frequency of supplements
Text
Brand of vitamin supplement 8
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Name and brand of supplements
Text
Frequency of vitamin supplement 8
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Frequency of supplements
Text
Name of other food 1 eaten more than once per week
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Text
Number of times food 1 eaten each week
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Categorical
Usual serving size for food 1
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Categorical
Name of other food 2 eaten more than once per week
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Text
Number of times food 2 eaten each week
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Categorical
Usual serving size for food 2
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Categorical
Name of other food 3 eaten more than once per week
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Text
Number of times food 3 eaten each week
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Categorical
Usual serving size for food 3
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Categorical
Name of other food 4 eaten
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Text
Number of times food 4 eaten each week
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Categorical
Usual serving size for food 4
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Categorical
Name of other food 5 eaten
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Text
Number of times food 5 eaten each week
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Categorical
Usual serving size for food 5
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Categorical
Name of other food 6 eaten
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Text
Number of times food 6 eaten each week
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Categorical
Usual serving size for food 6
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Other foods eaten
Categorical
Milk amount
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads How much milk did you drink each day including milk with tea coffee cereals etc? 1 = None; 2 = Quarter of a pint; 3 = Half a pint; 4 = Three quarters of a pint; 5 = One pint; 6 = More than one pint; -1 = left blank; -5 = more than one selected;
Categorical
Brand breakfast cereal 1
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Brand of breakfast cereal.
Text
Type breakfast cereal 1
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Type of breakfast cereal.
Text
Brand breakfast cereal 2
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Brand of breakfast cereal.
Text
Type breakfast cereal 2
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Type of breakfast cereal.
Text
Fat used for frying
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads What kind of fat did you most often use for frying roasting grilling etc
Categorical
Other frying fat
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads If you used vegetable oil please give type eg. corn sun?ower
Text
Fat used for baking
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads What kind of fat did you most often use for baking cakes etc
Categorical
Other baking fat
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads If you used vegetable oil please give type eg. corn sun?ower
Text
Eat home fried food
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads How often did you eat food that was fried at home
Categorical
Eat away fried food
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads How often did you eat food that was fried at home
Categorical
General cmnts wrist acc day1
Phase 2 data. General comments (wrist accelerometer) on day 1 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -2 = no data entered AND wrist acc column header crossed through; -8 = text illegible
Text
General cmnts wrist acc day2
Phase 2 data. General comments (wrist accelerometer) on day 2 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -2 = no data entered AND wrist acc column header crossed through; -8 = text illegible
Text
General cmnts wrist acc day3
Phase 2 data. General comments (wrist accelerometer) on day 3 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -2 = no data entered AND wrist acc column header crossed through; -8 = text illegible
Text
General cmnts wrist acc day4
Phase 2 data. General comments (wrist accelerometer) on day 4 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -2 = no data entered AND wrist acc column header crossed through; -8 = text illegible
Text
General cmnts wrist acc day5
Phase 2 data. General comments (wrist accelerometer) on day 5 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -2 = no data entered AND wrist acc column header crossed through; -8 = text illegible
Text
General cmnts wrist acc day6
Phase 2 data. General comments (wrist accelerometer) on day 6 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -2 = no data entered AND wrist acc column header crossed through; -8 = text illegible
Text
General cmnts wrist acc day7
Phase 2 data. General comments (wrist accelerometer) on day 7 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -2 = no data entered AND wrist acc column header crossed through; -8 = text illegible
Text
Reason take off wrist acc day1
Phase 2 data. Reason for taking off (wrist accelerometer) on day 1 of wearing Actiheart and wrist accelerometer; example provided on form is CHANGE ELECTRODES. -1 = left blank or crossed through; -8 = text illegible
Text
Reason take off wrist acc day2
Phase 2 data. Reason for taking off (wrist accelerometer) on day 2 of wearing Actiheart and wrist accelerometer; example provided on form is CHANGE ELECTRODES. -1 = left blank or crossed through; -8 = text illegible
Text
Reason take off wrist acc day3
Phase 2 data. Reason for taking off (wrist accelerometer) on day 3 of wearing Actiheart and wrist accelerometer; example provided on form is CHANGE ELECTRODES. -1 = left blank or crossed through; -8 = text illegible
Text
Reason take off wrist acc day4
Phase 2 data. Reason for taking off (wrist accelerometer) on day 4 of wearing Actiheart and wrist accelerometer; example provided on form is CHANGE ELECTRODES. -1 = left blank or crossed through; -8 = text illegible
Text
Reason take off wrist acc day5
Phase 2 data. Reason for taking off (wrist accelerometer) on day 5 of wearing Actiheart and wrist accelerometer; example provided on form is CHANGE ELECTRODES. -1 = left blank or crossed through; -8 = text illegible
Text
Reason take off wrist acc day6
Phase 2 data. Reason for taking off (wrist accelerometer) on day 6 of wearing Actiheart and wrist accelerometer; example provided on form is CHANGE ELECTRODES. -1 = left blank or crossed through; -8 = text illegible
Text
Reason take off wrist acc day7
Phase 2 data. Reason for taking off (wrist accelerometer) on day 7 of wearing Actiheart and wrist accelerometer; example provided on form is CHANGE ELECTRODES. -1 = left blank or crossed through; -8 = text illegible
Text
Time wrist acc taken off day1
Phase 2 data. What time did you take off the wrist accelerometer on day 1 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time wrist acc taken off day2
Phase 2 data. What time did you take off the wrist accelerometer on day 2 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time wrist acc taken off day3
Phase 2 data. What time did you take off the wrist accelerometer on day 3 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time wrist acc taken off day4
Phase 2 data. What time did you take off the wrist accelerometer on day 4 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time wrist acc taken off day5
Phase 2 data. What time did you take off the wrist accelerometer on day 5 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time wrist acc taken off day6
Phase 2 data. What time did you take off the wrist accelerometer on day 6 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time wrist acc taken off day7
Phase 2 data. What time did you take off the wrist accelerometer on day 7 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Final date Wrist monitor taken off
Phase 2 data. Date of Final time taken off wrist accelerometer monitor dd/mm/yyyy. -1 = left blank or crossed through; -8 = text illegible
Date
Final time Wrist monitor taken off
Phase 2 data. Date of Final time taken off wrist accelerometer monitor (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Date
Time wrist acc put back on day1
Phase 2 data. What time did you put the wrist accelerometer back on on day 1 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time wrist acc put back on day2
Phase 2 data. What time did you put the wrist accelerometer back on on day 2 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time wrist acc put back on day3
Phase 2 data. What time did you put the wrist accelerometer back on on day 3 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time wrist acc put back on day4
Phase 2 data. What time did you put the wrist accelerometer back on on day 4 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time wrist acc put back on day5
Phase 2 data. What time did you put the wrist accelerometer back on on day 5 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time wrist acc put back on day6
Phase 2 data. What time did you put the wrist accelerometer back on on day 6 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time wrist acc put back on day7
Phase 2 data. What time did you put the wrist accelerometer back on on day 7 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
ace_inhibitor
Phase 2 data. Binary variable indicating whether a drug from the ace inhibitor class was prescribed. 0: No 1: Yes
Categorical
Cln variable: Active comp games hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Active computer games. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Active computer games hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Active computer games. -1 = left blank. DO NOT USE THIS VARIABLE. Use ActiveComputerHr_CLEAN_P2 instead.
Real
Cln variable: Active comp games min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Active computer games. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Active computer games min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Active computer games. -1 = left blank. DO NOT USE THIS VARIABLE. Use ActiveComputerMin_CLEAN_P2 instead.
Real
Cln variable: Active computer games
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Active computer games. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed;
Categorical
Active computer games
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Active computer games. PAPER FORMS ONLY: Data entered using data entry template with 1-3-4-5-6-7-8 codes. 1 = none; 3 = once in last 4 wks; 4 = 2-3 times in last 4 wks; 5 = once a week; 6 = 2-3 times a wk; 7 = 4-5 times a week; 8 = every day; -1 = left blank; -5 = more than 1 selected; ELECTRONIC FORMS: 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; DO NOT USE THIS VARIABLE. Use ActiveComputer_CLEAN_P2 instead.
Real
Active computer games
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Active computer games. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Total AEE discounting resting
Phase 2 data. Derived with method 2. Total activity energy expenditure discounting resting net METhrs/d
Real
ACTMETS inc of unaccounted hrs
Phase 2 data. Derived with method 2. Activity EE inc AEE for unaccounted time for active getting about net METhrs/d
Real
Cln variable: Other activity 1 hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Other activity 1. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Other activity 1 hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Other activity 1. -1 = left blank. DO NOT USE THIS VARIABLE. Use Act_Other1Hr_CLEAN_P2 instead.
Real
Cln variable: Other activity 1 min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Other activity 1. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Other activity 1 min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Other activity 1. -1 = left blank. DO NOT USE THIS VARIABLE. Use Act_Other1Min_CLEAN_P2 instead.
Real
Name of other acitivity
Phase 2 data. Name of Other activity 1. -1 = left blank;
Text
Cln variable: Other activity 1
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Other activity 1 (with no similarity to any listed). Error codes cleaned by DMT; -10 error codes cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank;
Categorical
Other activity 1
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Other activity 1 (with no similarity to any listed). Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Cln variable: Other activity 2 hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Other activity 2. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Other activity 2 hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Other activity 2. -1 = left blank. DO NOT USE THIS VARIABLE. Use Act_Other2Hr_CLEAN_P2 instead.
Real
Other activity 1
Phase 2 data. Questionnaire reads D14. You should try and classify all the activities you do in the list above. If however you do activities which have no similarity with any of those listed above please mention here. Other activity 1. PAPER FORMS ONLY: Data entered using data entry template with 1-3-4-5-6-7-8 codes. 1 = none; 3 = once in last 4 wks; 4 = 2-3 times in last 4 wks; 5 = once a week; 6 = 2-3 times a wk; 7 = 4-5 times a week; 8 = every day; -1 = left blank; -5 = more than 1 selected; ELECTRONIC FORMS: 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; DO NOT USE THIS VARIABLE. Use Act_Other1_CLEAN_P2 instead.
Categorical
Cln variable: Other activity 2 min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Other activity 2. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Other activity 2 min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Other activity 2. -1 = left blank. DO NOT USE THIS VARIABLE. Use Act_Other2Min_CLEAN_P2 instead.
Real
Name of other acitivity
Phase 2 data. Name of Other activity 2. -1 = left blank;
Text
Cln variable: Other activity 2
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Other activity 1 (with no similarity to any listed). Error codes cleaned by DMT; -10 error codes cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank;
Categorical
Other activity 2
Phase 2 data. Questionnaire reads D14. You should try and classify all the activities you do in the list above. If however you do activities which have no similarity with any of those listed above please mention here. Other activity 2. PAPER FORMS ONLY: Data entered using data entry template with 1-3-4-5-6-7-8 codes. 1 = none; 3 = once in last 4 wks; 4 = 2-3 times in last 4 wks; 5 = once a week; 6 = 2-3 times a wk; 7 = 4-5 times a week; 8 = every day; -1 = left blank; -5 = more than 1 selected; ELECTRONIC FORMS: 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; DO NOT USE THIS VARIABLE. Use Act_Other2_CLEAN_P2 instead.
Categorical
Other activity 2
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Other activity 2 (with no similarity to any listed). Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Other Sports
Phase 2 data. Asked on electronic form only. Hence where left blank data could still exist for Act_Other1Text_P2 and Act_Other2Text_P2 as it has come from the paper questionnaire. 1 = yes; 2 = no; blank or = data not collected so instead use Act_Other1Text_P2 and Act_Other2Text_P2;
Categorical
Overall total bone mineral content
Phase 2 data. Overall total bone mass (bone mineral content) in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Overall total bone mineral content
Phase 2 data. Overall total bone mass (bone mineral content) in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD04i_iDEXA_Total_bone_mass_P2); -9 = Missing data;
Real
Overall total tissue fat mass
Phase 2 data. Overall total fat mass (tissue fat mass) in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Overall total tissue fat mass
Phase 2 data. Overall total fat mass(tissue fat mass) in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD05i_iDEXA_Total_fat_mass_P2AD05i_iDEXA_Total_fat_mass_P2); -9 = Missing data;
Real
Overall total tissue lean mass
Phase 2 data. Overall total lean mass (tissue lean mass) in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Overall total tissue lean mass
Phase 2 data. Overall total lean mass (tissue lean mass) in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD06i_iDEXA_Total_lean_mass_P2); -9 = Missing data;
Real
Overall left bone mineral content
Phase 2 data. Overall left bone mineral content in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Overall left bone mineral content
Phase 2 data. Overall left bone mineral content in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD07i_iDEXA_Left_total_bone_mass_P2); -9 = Missing data;
Real
Overall left tissue fat mass
Phase 2 data. Overall left tissue fat mass in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Overall left tissue fat mass
Phase 2 data. Overall left tissue fat mass in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD08i_iDEXA_Left_total_fat_mass_P2); -9 = Missing data;
Real
Overall left tissue lean mass
Phase 2 data. Overall left tissue lean mass in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Overall left tissue lean mass
Phase 2 data. Overall left tissue lean mass in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD09i_iDEXA_Left_total_lean_mass_P2); -9 = Missing data;
Real
Overall right bone mineral content
Phase 2 data. Overall right bone mineral content in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Overall right bone mineral content
Phase 2 data. Overall right bone mineral content in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD10i_iDEXA_Right_total_bone_mass_P2); -9 = Missing data;
Real
Overall right tissue fat mass
Phase 2 data. Overall right tissue fat mass in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Overall right tissue fat mass
Phase 2 data. Overall right tissue fat mass in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD11i_iDEXA_Right_total_fat_mass_P2); -9 = Missing data;
Real
Overall right tissue lean mass
Phase 2 data. Overall right tissue lean mass in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Overall right tissue lean mass
Phase 2 data. Overall right tissue lean mass in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD12i_iDEXA_Right_total_lean_mass_P2); -9 = Missing data;
Real
Total bone mineral content of 2 arms
Phase 2 data. Total bone mineral content of two arms in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Total bone mineral content of 2arms
Phase 2 data. Total bone mineral content of two arms in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD13i_iDEXA_arms_bone_mass_P2); -9 = Missing data;
Real
Total tissue fat mass of 2 arms
Phase 2 data. Total tissue fat mass of two arms in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Total tissue fat mass of two arms
Phase 2 data. Total tissue fat mass of two arms in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD14i_iDEXA_arms_fat_mass_P2); -9 = Missing data;
Real
Total tissue lean mass of 2 arms
Phase 2 data. Total tissue lean mass of two arms in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Total tissue lean mass of two arms
Phase 2 data. Total tissue lean mass of two arms in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD15i_iDEXA_arms_lean_mass_P2); -9 = Missing data;
Real
Bone mineral content in left arm
Phase 2 data. Bone mineral content in left arm in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Bone mineral content in left arm
Phase 2 data. Bone mineral content in left arm in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD16i_iDEXA_Left_arm_bone_mass_P2); -9 = Missing data;
Real
Tissue fat mass in left arm
Phase 2 data. Tissue fat mass in left arm in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue fat mass in left arm
Phase 2 data. tissue fat mass in left arm in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD17i_iDEXA_Left_arm_fat_mass_P2); -9 = Missing data;
Real
Tissue lean mass in left arm
Phase 2 data. Tissue lean mass in left arm in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue lean mass in left arm
Phase 2 data. tissue lean mass in left arm in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD18i_iDEXA_Left_arm_lean_mass_P2); -9 = Missing data;
Real
Bone mineral content in right arm
Phase 2 data. Bone mineral content in right arm in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Bone mineral content in right arm
Phase 2 data. bone mineral content in right arm in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD19i_iDEXA_Right_arm_bone_mass_P2); -9 = Missing data;
Real
Tissue fat mass in right arm
Phase 2 data. Tissue fat mass in right arm in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue fat mass in right arm
Phase 2 data. tissue fat mass in right arm in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD20i_iDEXA_Right_arm_fat_mass_P2); -9 = Missing data;
Real
Tissue lean mass in right arm
Phase 2 data. Tissue lean mass in right arm in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue lean mass in right arm
Phase 2 data. tissue lean mass in right arm in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD21i_iDEXA_Right_arm_lean_mass_P2); -9 = Missing data;
Real
Bone mineral content trunk torso pelvis
Phase 2 data. Bone mineral content of trunk (torso and pelvis) in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Bone mineral content of trunk
Phase 2 data. Bone mineral content of trunk in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD22i_iDEXA_Trunk_bone_mass_P2); -9 = Missing data;
Real
Tissue fat mass trunk torso pelvis
Phase 2 data. Tissue fat mass of trunk (torso and pelvis) in grams for Phase 2 data. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue fat mass of trunk
Phase 2 data. Tissue fat mass of trunk in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD23i_iDEXA_Trunk_fat_mass_P2); -9 = Missing data;
Real
Tissue lean mass trunk torso pelvis
Phase 2 data. Tissue lean mass of trunk (torso and pelvis) in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue lean mass of trunk
Phase 2 data. Tissue lean mass of trunk in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD24i_iDEXA_Trunk_lean_mass_P2); -9 = Missing data;
Real
Bone mineral content left trunk
Phase 2 data. Bone mineral content of left trunk in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Bone mineral content of left trunk
Phase 2 data. bone mineral content of left trunk in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD25i_iDEXA_Left_trunk_bone_mass_P2); -9 = Missing data;
Real
Tissue fat mass left trunk
Phase 2 data. Tissue fat mass of left trunk in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue fat mass of left trunk
Phase 2 data. Tissue fat mass of left trunk in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD26i_iDEXA_Left_trunk_fat_mass_P2); -9 = Missing data;
Real
Tissue lean mass of left trunk
Phase 2 data. Tissue lean mass of left trunk in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue lean mass of left trunk
Phase 2 data. Tissue lean mass of left trunk in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD27i_iDEXA_Left_trunk_lean_mass_P2); -9 = Missing data;
Real
Bone mineral content right trunk
Phase 2 data. Bone mineral content of right trunk in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Bone mineral content of right trunk
Phase 2 data. Bone mineral content of right trunk in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD28i_iDEXA_Right_trunk_bone_mass_P2); -9 = Missing data;
Real
Tissue fat mass of right trunk
Phase 2 data. Tissue fat mass of right trunk in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue fat mass of right trunk
Phase 2 data. Tissue fat mass of right trunk in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD29i_iDEXA_Right_trunk_fat_mass_P2); -9 = Missing data;
Real
Tissue lean mass of right trunk
Phase 2 data. Tissue lean mass of right trunk in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue lean mass of right trunk
Phase 2 data. Tissue lean mass of right trunk in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD30i_iDEXA_Right_trunk_lean_mass_P2); -9 = Missing data;
Real
Bone mineral content android waist area
Phase 2 data. Bone mineral content of android (waist area) in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Bone mineral content android area
Phase 2 data. Bone mineral content of android(waist area) in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD31i_iDEXA_Android_bone_mass_P2); -9 = Missing data;
Real
Tissue fat mass android waist area
Phase 2 data. tissue fat mass of android (waist area) in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Bone mineral mass of android area
Phase 2 data. bone mineral mass of android(waist area) in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD32i_iDEXA_Android_fat_mass_P2); -9 = Missing data;
Real
Tissue lean mass android waist area
Phase 2 data. Tissue lean mass of android (waist area) in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue lean mass of android area
Phase 2 data. tissue lean mass of android(waist area) in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD33i_iDEXA_Android_lean_mass_P2); -9 = Missing data;
Real
Bone mineral content gynoid Hip area
Phase 2 data. Bone mineral content of gynoid (Hip area) in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Bone mineral content of gynoid area
Phase 2 data. Bone mineral content of gynoid(Hip area) in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD34i_iDEXA_Gynoid_bone_mass_P2); -9 = Missing data;
Real
Tissue fat mass of gynoid Hip area
Phase 2 data. tissue fat mass of gynoid (Hip area) in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue fat mass of gynoid area
Phase 2 data. Tissue fat mass of gynoid (Hip area) in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD35i_iDEXA_Gynoid_fat_mass_P2); -9 = Missing data;
Real
Tissue lean mass of gynoid Hip area
Phase 2 data. Tissue lean mass of gynoid (Hip area) in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue lean mass of gynoid area
Phase 2 data. Tissue lean mass of gynoid(Hip area) in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD36i_iDEXA_Gynoid_lean_mass_P2); -9 = Missing data;
Real
Bone mineral content of two legs
Phase 2 data. Bone mineral content of two legs in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Bone mineral content of two legs
Phase 2 data. Bone mineral content of two legs in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD37i_iDEXA_legs_bone_mass_P2); -9 = Missing data;
Real
Tissue fat mass of two legs
Phase 2 data. Tissue fat mass of two legs in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue fat mass of two legs
Phase 2 data. Tissue fat mass of two legs in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD38i_iDEXA_legs_fat_mass_P2); -9 = Missing data;
Real
Tissue lean mass of two legs
Phase 2 data. Tissue lean mass of two legs in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue lean mass of two legs
Phase 2 data. Tissue lean mass of two legs in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD39i_iDEXA_legs_lean_mass_P2); -9 = Missing data;
Real
Bone mineral content left leg
Phase 2 data. Bone mineral content left leg in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Bone mineral content left leg
Phase 2 data. Bone mineral content left leg in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD40i_iDEXA_Left_leg_bone_mass_P2); -9 = Missing data;
Real
Tissue fat mass of left leg
Phase 2 data. Tissue fat mass of left leg in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue fat mass of left leg
Phase 2 data. Tissue fat mass of left leg in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD41i_iDEXA_Left_leg_fat_mass_P2); -9 = Missing data;
Real
Tissue lean mass of left leg
Phase 2 data. Tissue lean mass of left leg in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue lean mass of left leg
Phase 2 data. Tissue lean mass of left leg in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD42i_iDEXA_Left_leg_lean_mass_P2); -9 = Missing data;
Real
Bone mineral content right leg
Phase 2 data. Bone mineral content right leg in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Bone mineral content right leg
Phase 2 data. Bone mineral content right leg in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD43i_iDEXA_Right_leg_bone_mass_P2); -9 = Missing data;
Real
Tissue fat mass of right leg
Phase 2 data. Tissue fat mass of right leg in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue fat mass of right leg
Phase 2 data. Tissue fat mass of right leg in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD44i_iDEXA_Right_leg_fat_mass_P2); -9 = Missing data;
Real
Tissue lean mass of right leg
Phase 2 data. Tissue lean mass of right leg in grams. Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Tissue lean mass of right leg
Phase 2 data. Tissue lean mass of right leg in grams. Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD45i_iDEXA_Right_leg_lean_mass_P2); -9 = Missing data;
Real
Percent overall body fat from DEXA
Phase 2 data. Percent overall body fat from DEXA. Regenerated percentage body fat (overall fat) using a 3 compartment model (fat mass; fat free; mass bone mineral mass). Calculated as (100* fat mass / (total mass * 1000). Raw data from DEXA Lunar Prodigy processed with enhanced analysis. -9 = Missing data;
Real
Body fat percent DEXA
Phase 2 data. Regenerated percentage body fat (overall fat) using a 3 compartment model (fat mass; fat free mass; bone mineral mass). Calculated as (100* fat mass / (total mass * 1000). Raw data from DEXA Lunar Prodigy processed with basic analysis. DO NOT USE THIS VARIABLE. Use iDEXA equivalent instead (AD47i_iDEXA_body_fat_percent_P2); -9 = Missing data;
Real
Symmetry method applied
Phase 2 data. If symmetry method was applied it is indicated whether it was left or right. Where symmetry method was used arm was omitted from scan as volunteer was too broad for the scanner. Therefore the values of the arm within the scanner was used to recalculate overall Body composition. Calculation and or check: Identified by Fenland_Symmetry_Calculations.xls and iDEXA estimate.
Text
VAT within Android region in cm3
Phase 2 data. Visceral Adipose Tissue (VAT) within the Android region in cm3. Raw data from DEXA Lunar Prodigy reprocessed with iDEXA software. The iDEXA algorithm did not work in volunteers who were too broad or had too little fat around the abdomen so it produced an output of 0. These were changed to -7 afterwards by the Data Man team.
Real
VAT within Android region in grams
Phase 2 data. Visceral Adipose Tissue (VAT) within the Android region in grams. Raw data from DEXA Lunar Prodigy reprocessed with iDEXA software. The iDEXA algorithm did not work in volunteers who were too broad or had too little fat around the abdomen so it produced an output of 0. These were changed to -7 afterwards by the Data Man team.
Real
SCAT within Android region in grams
Phase 2 data. Subcutaneous Adipose Tissue within the Android region in grams. generated by the anthro team = iDEXA Android fat mass g - iDEXA VAT g. Calculation and or check: iDEXA Android fat mass - iDEXA VAT g.
Real
Total fat mass leg and head areas
Phase 2 data. Total fat mass of leg and head areas in grams. Generated by the anthro team iDEXA Total fat mass g - (iDEXA Trunk fat mass g + iDEXA arms fat mass g). Calculation and or check: Total fat mass - (Trunk fat mass + Arms fat mass).
Real
Total bone mineral density
Phase 2 data. Total bone mineral density. Regenerated by the anthro team iDEXA total bone mineral content/iDEXA area. Calculation and or check: checked against BMD generated by the DEXA - it was recalculated where the symmetry method was applied.
Real
Total Mass regenerated from DEXA
Phase 2 data. Total Mass regenerated from DEXA. Regenerated mass by the anthro team (fat mass(grams) + fat free mass(grams) + bone mineral mass(grams))/1000. Calculation and or check: Sum of total bone; lean; fat masses. comparison with weight.
Real
Categories of iDEXA scan
Phase 2 data. Background data information code generated by Anthropometry team. Request with AD58i_DEXA_Comments for further clarification.
Categorical
iDEXA Comments
Phase 2 data. Comments provided by Anthropometry team regarding processing the data. Variable AD49_DEXA_Comments should be requested too.
Text
Comments relevant to admin data
Phase 2 data. General comments provided on phase 2 study participation study samples tests etc.
Text
Cln variable:Highimpactaerobics hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. High impact or step aerobics. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
High impact or step aerobics hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. High impact or step aerobics. -1 = left blank. DO NOT USE THIS VARIABLE. Use AerobicsHighHr_CLEAN_P2 instead.
Real
Cln variable:Highimpactaerobics min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. High impact or step aerobics. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
High impact or step aerobics min
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. High impact or step aerobics. -1 = left blank. DO NOT USE THIS VARIABLE. Use AerobicsHighMin_CLEAN_P2 instead.
Real
Cln variable: High impact aerobics
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. High impact or step aerobics. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
High impact or step aerobics
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. High impact or step aerobics. DO NOT USE THIS VARIABLE. Use AerobicsHigh_CLEAN_P2 instead.
Real
High impact or step aerobics
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. High impact or step aerobics. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Cln variable: Other aerobics hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Other types of aerobics. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Other types of aerobics hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Other types of aerobics. -1 = left blank. DO NOT USE THIS VARIABLE. Use aerobicsOtherHr_CLEAN_P2 instead.
Real
Cln variable: Other aerobics min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Other types of aerobics. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Other types of aerobics min
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Other types of aerobics. -1 = left blank. DO NOT USE THIS VARIABLE. Use aerobicsOtherMin_CLEAN_P2 instead.
Real
Cln variable: Other erobics
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Other types of aerobics. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Other types of aerobics
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Other types of aerobics. DO NOT USE THIS VARIABLE. Use aerobicsOther_CLEAN_P2 instead.
Real
Other types of aerobics
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Other types of aerobics. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Age at test derived
Phase 2 data. Derived age at test in decimals to reflect true age (eg 35.9 instead of 35) at phase 2 visit in years and decimals ( the actual date of the phase 2 visit). Please note that this is a decimal number which does not reflect months.
Real
Age at test as reported by pt
Phase 2 data. Data as entered on Study database. Age at test as reported by participant during phase 2 site visit.
Real
AH comments
Phase 2 data. AH comments for Phase 2 data. Contains comments on treadmill test fasting information. Cleaned information held in main AH dataset for analysis. This has not been checked for identifaible information.
Text
Cmnts diary sheet AH Wrist Mon
Phase 2 data. General comments left on Diary sheet for actiheart and Wrist accelerometer monitor. The name of the variable the comment relates to has been provided where possible. -1 = no comments provided; -8 = text illegible
Text
Date day 1 of AhAccMon Worn
Phase 2 data. Date of day 1 of wearing Actiheart and wrist accelerometer dd/mm/yyyy. -1 = left blank or crossed through; -8 = text illegible
Date
Day Name of day 1 of AhAccMon Worn
Phase 2 data. Name of day of day 1 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -8 = text illegible
Text
Date day 2 of AhAccMon Worn
Phase 2 data. Date of day 2 of wearing Actiheart and wrist accelerometer dd/mm/yyyy. -1 = left blank or crossed through; -8 = text illegible
Date
Day Name of day 2 of AhAccMon Worn
Phase 2 data. Name of day of day 2 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -8 = text illegible
Text
Date day 3 of AhAccMon Worn
Phase 2 data. Date of day 3 of wearing Actiheart and wrist accelerometer dd/mm/yyyy. -1 = left blank or crossed through; -8 = text illegible
Date
Day Name of day 3 of AhAccMon Worn
Phase 2 data. Name of day of day 3 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -8 = text illegible
Text
Date day 4 of AhAccMon Worn
Phase 2 data. Date of day 4 of wearing Actiheart and wrist accelerometer dd/mm/yyyy. -1 = left blank or crossed through; -8 = text illegible
Date
Day Name of day 4 of AhAccMon Worn
Phase 2 data. Name of day of day 4 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -8 = text illegible
Text
Date day 5 of AhAccMon Worn
Phase 2 data. Date of day 5 of wearing Actiheart and wrist accelerometer dd/mm/yyyy. -1 = left blank or crossed through; -8 = text illegible
Date
Day Name of day 5 of AhAccMon Worn
Phase 2 data. Name of day of day 5 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -8 = text illegible
Text
Date day 6 of AhAccMon Worn
Phase 2 data. Date of day 6 of wearing Actiheart and wrist accelerometer dd/mm/yyyy. -1 = left blank or crossed through; -8 = text illegible
Date
Name of day6 Ah Acc Mon Worn
Phase 2 data. Name of day of day 6 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -8 = text illegible
Text
Date day 7 of AhAccMon Worn
Phase 2 data. Date of day 7 of wearing Actiheart and wrist accelerometer dd/mm/yyyy. -1 = left blank or crossed through; -8 = text illegible
Date
Name of day7 Ah Acc Mon Worn
Phase 2 data. Name of day of day 7 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -8 = text illegible
Text
No of times AH Wrist Mon worn
Phase 2 data. Number Of times actiheart and wrist worn accelerometer diary sheets have been completed. For each time the date of completion has been entered. -1 = only one copy completed
Real
General cmnts actiheart mon on day1
Phase 2 data. General comments (actiheart monitor) on day 1 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -8 = text illegible
Text
General cmnts actiheart mon on day2
Phase 2 data. General comments (actiheart monitor) on day 2 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -8 = text illegible
Text
General cmnts actiheart mon on day3
Phase 2 data. General comments (actiheart monitor) on day 3 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -8 = text illegible
Text
General cmnts actiheart mon on day4
Phase 2 data. General comments (actiheart monitor) on day 4 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -8 = text illegible
Text
General cmnts actiheart mon on day5
Phase 2 data. General comments (actiheart monitor) on day 5 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -8 = text illegible
Text
General cmnts actiheart mon on day6
Phase 2 data. General comments (actiheart monitor) on day 6 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -8 = text illegible
Text
General cmnts actiheart mon on day7
Phase 2 data. General comments (actiheart monitor) on day 7 of wearing Actiheart and wrist accelerometer. -1 = left blank or crossed through; -8 = text illegible
Text
Time actiheart mon taken off day1
Phase 2 data. What time did you take off the actiheart monitor on day 1 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time actiheart mon taken off day2
Phase 2 data. What time did you take off the actiheart monitor on day 2 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time actiheart mon taken off day3
Phase 2 data. What time did you take off the actiheart monitor on day 3 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time actiheart mon taken off day4
Phase 2 data. What time did you take off the actiheart monitor on day 4 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time actiheart mon taken off day5
Phase 2 data. What time did you take off the actiheart monitor on day 5 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time actiheart mon taken off day6
Phase 2 data. What time did you take off the actiheart monitor on day 6 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time actiheart mon taken off day7
Phase 2 data. What time did you take off the actiheart monitor on day 7 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Final date AH monitor taken off
Phase 2 data. Date of Final time taken off Actiheart monitor dd/mm/yyyy. -1 = left blank or crossed through; -8 = text illegible
Date
Final time AH monitor taken off
Phase 2 data. Date of Final time taken off Actiheart monitor (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Date
Time actiheart mon put back on day1
Phase 2 data. What time did you put the actiheart monitor back on on day 1 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time actiheart mon put back on day2
Phase 2 data. What time did you put the actiheart monitor back on on day 2 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time actiheart mon put back on day3
Phase 2 data. What time did you put the actiheart monitor back on on day 3 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time actiheart mon put back on day4
Phase 2 data. What time did you put the actiheart monitor back on on day 4 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time actiheart mon put back on day5
Phase 2 data. What time did you put the actiheart monitor back on on day 5 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time actiheart mon put back on day6
Phase 2 data. What time did you put the actiheart monitor back on on day 6 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time actiheart mon put back on day7
Phase 2 data. What time did you put the actiheart monitor back on on day 7 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Reason take off actiheart mon day1
Phase 2 data. Reason for taking off (actiheart monitor) on day 1 of wearing Actiheart and wrist accelerometer; example provided on form is CHANGE ELECTRODES. -1 = left blank or crossed through; -8 = text illegible
Text
Reason take off actiheart mon day2
Phase 2 data. Reason for taking off (actiheart monitor) on day 2 of wearing Actiheart and wrist accelerometer; example provided on form is CHANGE ELECTRODES. -1 = left blank or crossed through; -8 = text illegible
Text
Reason take off actiheart mon day3
Phase 2 data. Reason for taking off (actiheart monitor) on day 3 of wearing Actiheart and wrist accelerometer; example provided on form is CHANGE ELECTRODES. -1 = left blank or crossed through; -8 = text illegible
Text
Reason take off actiheart mon day4
Phase 2 data. Reason for taking off (actiheart monitor) on day 4 of wearing Actiheart and wrist accelerometer; example provided on form is CHANGE ELECTRODES. -1 = left blank or crossed through; -8 = text illegible
Text
Reason take off actiheart mon day5
Phase 2 data. Reason for taking off (actiheart monitor) on day 5 of wearing Actiheart and wrist accelerometer; example provided on form is CHANGE ELECTRODES. -1 = left blank or crossed through; -8 = text illegible
Text
Reason take off actiheart mon day6
Phase 2 data. Reason for taking off (actiheart monitor) on day 6 of wearing Actiheart and wrist accelerometer; example provided on form is CHANGE ELECTRODES. -1 = left blank or crossed through; -8 = text illegible
Text
Reason take off actiheart mon day7
Phase 2 data. Reason for taking off (actiheart monitor) on day 7 of wearing Actiheart and wrist accelerometer; example provided on form is CHANGE ELECTRODES. -1 = left blank or crossed through; -8 = text illegible
Text
Barcode error comments
Phase 2 data. Actiheart and wrist accelerometer diary sheet barcode scanning error comment. -1 = no issues to report
Text
Time finish wrk day1 AhAcc Mon Worn
Phase 2 data. What time did you finish work on day 1 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time finish wrk day2 AhAcc Mon Worn
Phase 2 data. What time did you finish work on day 2 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time finish wrk day3 AhAcc Mon Worn
Phase 2 data. What time did you finish work on day 3 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time finish wrk day4 AhAcc Mon Worn
Phase 2 data. What time did you finish work on day 4 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time finish wrk day5 AhAcc Mon Worn
Phase 2 data. What time did you finish work on day 5 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time finish wrk day6 AhAcc Mon Worn
Phase 2 data. What time did you finish work on day 6 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time finish wrk day7 AhAcc Mon Worn
Phase 2 data. What time did you finish work on day 7 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Get up time day2 Ah Acc Mon Worn
Phase 2 data. What time did you get up on day 2 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Get up time day3 Ah Acc Mon Worn
Phase 2 data. What time did you get up on day 3 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Get up time day4 Ah Acc Mon Worn
Phase 2 data. What time did you get up on day 4 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Get up time day5 Ah Acc Mon Worn
Phase 2 data. What time did you get up on day 5 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Get up time day6 Ah Acc Mon Worn
Phase 2 data. What time did you get up on day 6 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Get up time day7 Ah Acc Mon Worn
Phase 2 data. What time did you get up on day 7 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time went sleep day1 AhAcc Mon Worn
Phase 2 data. What time did you go to sleep on day 1 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time went sleep day2 AhAcc Mon Worn
Phase 2 data. What time did you go to sleep on day 2 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time went sleep day3 AhAcc Mon Worn
Phase 2 data. What time did you go to sleep on day 3 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time went sleep day4 AhAcc Mon Worn
Phase 2 data. What time did you go to sleep on day 4 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time went sleep day5 AhAcc Mon Worn
Phase 2 data. What time did you go to sleep on day 5 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time went sleep day6 AhAcc Mon Worn
Phase 2 data. What time did you go to sleep on day 6 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Not wrk day1 Ah Acc Mon Worn
Phase 2 data. What time did you start work on day 1 of wearing Actiheart and wrist accelerometer (24 hr format)? 1 = did not work (box ticked); -1 = not ticked (worked)
Categorical
Not wrk day2 Ah Acc Mon Worn
Phase 2 data. What time did you start work on day 2 of wearing Actiheart and wrist accelerometer (24 hr format)? 1 = did not work (box ticked); -1 = not ticked (worked)
Categorical
Not wrk day3 Ah Acc Mon Worn
Phase 2 data. What time did you start work on day 3 of wearing Actiheart and wrist accelerometer (24 hr format)? 1 = did not work (box ticked); -1 = not ticked (worked)
Categorical
Not wrk day4 Ah Acc Mon Worn
Phase 2 data. What time did you start work on day 4 of wearing Actiheart and wrist accelerometer (24 hr format)? 1 = did not work (box ticked); -1 = not ticked (worked)
Categorical
Not wrk day5 Ah Acc Mon Worn
Phase 2 data. What time did you start work on day 5 of wearing Actiheart and wrist accelerometer (24 hr format)? 1 = did not work (box ticked); -1 = not ticked (worked)
Categorical
Not wrk day6 Ah Acc Mon Worn
Phase 2 data. What time did you start work on day 6 of wearing Actiheart and wrist accelerometer (24 hr format)? 1 = did not work (box ticked); -1 = not ticked (worked)
Categorical
Not wrk day7 Ah Acc Mon Worn
Phase 2 data. What time did you start work on day 7 of wearing Actiheart and wrist accelerometer (24 hr format)? 1 = did not work (box ticked); -1 = not ticked (worked)
Categorical
AH wrist acc qnr version date
Phase 2 data. Actiheart and wrist accelerometer diary sheet questionnaire version date.
Date
AH wrist acc qnr version no
Phase 2 data. Actiheart and wrist accelerometer diary sheet questionnaire version number.
Real
Time start wrk day1 Ah Acc Mon Worn
Phase 2 data. What time did you start work on day 1 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time start wrk day2 Ah Acc Mon Worn
Phase 2 data. What time did you start work on day 2 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time start wrk day3 Ah Acc Mon Worn
Phase 2 data. What time did you start work on day 3 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time start wrk day4 Ah Acc Mon Worn
Phase 2 data. What time did you start work on day 4 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time start wrk day5 Ah Acc Mon Worn
Phase 2 data. What time did you start work on day 5 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time start wrk day6 Ah Acc Mon Worn
Phase 2 data. What time did you start work on day 6 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Time start wrk day7 Ah Acc Mon Worn
Phase 2 data. What time did you start work on day 7 of wearing Actiheart and wrist accelerometer (24 hr format). -1 = left blank or crossed through; -8 = text illegible
Time
Investigation Date
Phase 2 data. When was Subject Measured?
Date
RT longitudinal sweep made: Quality
Phase 2 data. What was the quality of the RT Longitudinal Sweep that was Made? -1 = Unable to be determined; -9 = Missing data; 1 = A(highest); 2 = B; 3 = C(lowest);
Categorical
RT transverse sweep made: Quality
Phase 2 data. What was the quality of the RT transverse Sweep that was Made? -1 = Unable to be determined; -9 = Missing data; 1 = A(highest); 2 = B; 3 = C(lowest);
Categorical
LT longitudinal sweep made: Quality
Phase 2 data. What was the quality of the LT longitudinal sweep that was Made? -1 = Unable to be determined; -9 = Missing data; 1 = A(highest); 2 = B; 3 = C(lowest);
Categorical
LT transverse sweep made: Quality
Phase 2 data. What was the quality of the LT transverse sweep that was Made? -1 = Unable to be determined; -9 = Missing data; 1 = A(highest); 2 = B; 3 = C(lowest);
Categorical
Quality of Repeat sweep
Phase 2 data. What was the quality of the Repeat sweep (representative segment) that was Made? -1 = Unable to be determined; -9 = Missing data; 1 = A(highest); 2 = B; 3 = C(lowest);
Categorical
Scoring criteria 1
Phase 2 data. What was the (Increased) echo reflectivity liver parenchyma (in comparison with kidney) score? Scored from 1 (highest quality) to 4 (lowest quality).
Categorical
Scoring criteria 2
Phase 2 data. What was the (Decreased) visualization of intra-hepatic vasculature score? Scored from 1 (highest quality) to 4 (lowest quality). -1 = Unable to be determined; -9 = Missing data; 1 = Normal; 2 = Mild; 3 = Moderate; 4 = Severe;
Categorical
Scoring criteria 3
Phase 2 data. What was the Attenuation of ultrasound beam impaired penetration score? Scored from 1 (highest quality) to 4 (lowest quality). -1 = Unable to be determined; -9 = Missing data; 1 = Normal; 2 = Mild; 3 = Moderate; 4 = Severe;
Categorical
Total score Category
Phase 2 data. Provides the Assessed Category from total score. Normal = 4 or less; Mild = 5 to 7; Moderate = 8 to 10; Severe = 11 or more;
Categorical
Liver ultrasound comments
Phase 2 data. The comment made on theTotal score Category
Text
Inter frozen quality
Phase 2 data. What was the quality of the Repeat sweep (representative segment) that was Made? -1 = Unable to be determined; -9 = Missing data; 1 = A(highest); 2 = B; 3 = C(lowest);
Categorical
Albumin 0 minutes
Phase 2 data. Serum Albumin measurement taken at 0 minutes in g/L
Real
Units of alcohol consumed per week
Phase 2 data. Alcohol Units Per Week in Phase 2 data. Phase 2 unit definition: 1 unit is equivalent to 1/2 pint of beer ; 1/2 glass of wine; 1 single measure of spirits; 1 glass of sherry; This is different from phase 1 unit definition. Used for participant feedback only. Not for analysis. Used set of alcohol consumption variables derived from general questionnaire instead.
Real
Alcohol_EPI_weekend
Phase 2 data. Current alcohol consumption on fri-sat-sun History / Status. Derived from GenQ Qs by DM team JAVA script. Pls request G_Alcohol variable as well. Codes of 1; 3 and 9 for G_ALCOHOL are recoded as 9 in this variable. 0 = never; 1 = ex; 2 = current; 9 = not known;
Categorical
Alcohol consumption weekday
Phase 2 data. Current alcohol consumption on mon-tue-wed-thu History / Status. Derived from GenQ Qs by DM team JAVA script. Pls request G_Alcohol variable as well. Codes of 1; 3 and 9 for G_ALCOHOL are recoded as 9 in this variable. 0 = never; 1 = ex; 2 = current; 9 = not known;
Categorical
AlkPhos 0 minutes
Phase 2 data. Serum Alkaline Phosphatase measurement taken at 0 minutes in U/L
Integer
Alt 0 minutes
Phase 2 data. Serum Alt measurement taken at 0 minutes in U/L
Integer
aneamia
Phase 2 data. Binary variable indicating whether a drug from the anemia medication class was prescribed. 0 = No; 1 = Yes;
Categorical
None
Phase 2 data. ANML signal normalization scale factor (0.005% mix)
Real
None
Phase 2 data. ANML signal normalization scale factor (0.5% mix)
Real
None
Phase 2 data. ANML signal normalization scale factor (20% mix)
Real
Anno tool complete
Phase 2 data. Annotation tool completed? 1 = yes;
Categorical
Anno tool email sent date
Phase 2 data. Date Annotation tool email sent off.
Date
Anno tool invite sent date
Phase 2 data. Date Annotation tool invite sent off.
Date
Anthro data sourec
Phase 2 data. Tracker variable created by DMT. 1 = paper; 2 = electronic; 3 = private network study db; 9 = paper and electronic;
Real
antidepressants
Phase 2 data. Binary variable indicating whether a drug from the antidepressant class was prescribed. 0 = No; 1 = Yes;
Categorical
None
Phase 2 data. Date of the apppointment which the participant ACTUALLY attended so appointment status = 2. Where participant had 2 or more appointments with status 2 the most recent date has been entered here.
Date
Arrival Time
Phase 2 data. Clinical visit arrival time
Time
Assay team run observation
Phase 2 data. Assay team run observation
Text
asthma_BA
Phase 2 data. Binary variable indicating whether a drug from the asthma: beta agonist class was prescribed. 0 = No; 1 = Yes;
Categorical
asthma_other
Phase 2 data. Binary variable indicating whether a drug from the asthma: other class was prescribed. 0 = No; 1 = Yes;
Categorical
asthma_steroids
Phase 2 data. Binary variable indicating whether a drug from the asthma: steroid class was prescribed. 0 = No; 1 = Yes;
Categorical
Cln variable: Backpack Mountain hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Backpacking Or Mountain Climbing. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Backpacking Mountain Climbing hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Backpacking Or Mountain Climbing. -1 = left blank. DO NOT USE THIS VARIABLE. Use BackPackMountainClimbHr_CLEAN_P2 instead.
Real
Cln variable: Backpack Mountain min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Backpacking Or Mountain Climbing. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Backpacking Mountain Climbing min
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Backpacking Or Mountain Climbing. -1 = left blank. DO NOT USE THIS VARIABLE. Use BackPackMountainClimbMin_CLEAN_P2 instead.
Real
Cln variable: Backpack Mountain
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Backpacking Or Mountain Climbing. CLEANED. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Backpacking or Mountain Climbing
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Backpacking Or Mountain Climbing. DO NOT USE THIS VARIABLE. Use BackPackMountainClimb_CLEAN_P2 instead.
Real
Backpacking or Mountain Climbing
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Backpacking Or Mountain Climbing. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
2D Barcode of aliquot
Phase 2 data. 2D Barcode of aliquot
Text
beta_blocker
Phase 2 data. Binary variable indicating whether a drug from the beta blocker class was prescribed. 0 = No; 1 = Yes;
Categorical
Bilirubin 0 minutes
Phase 2 data. Serum Total Bili (Bilirubin) measurement taken at 0 minutes in umol/L
Integer
Biochem Imported
Phase 2 data. Biochemistry Imported? Data from study database. 0 = No; 1 = Yes;
Categorical
Biochem Manual Edit Warning
Phase 2 data. Variable present in Fenland study database which indicates if there are any issues with biochemistry data collected. 0 = No; 1 = Yes;
Categorical
Biochem Received Date
Phase 2 data. Date Phase 2 biochem sample was received in lab.
Date
None
Phase 2 data. BioChemistry Import variable (leptin results only?). Fields with Data
Integer
None
Phase 2 data. BioChemistry Import variable (leptin results only?). Fields with Data
Text
None
Phase 2 data. BioChemistry Import variable (leptin results only?). Fields with Data
Integer
None
Phase 2 data. BioChemistry Import variable (leptin results only?). Fields with Data
Text
None
Phase 2 data. BioChemistry Import variable (leptin results only?). Fields with Data
Date
None
Phase 2 data. BioChemistry Import variable (leptin results only?). Fields with Data
Integer
None
Phase 2 data. BioChemistry Import variable (leptin results only?). Fields with Data
Integer
Body Fat Percent Cons Device
Phase 2 data. Derived variable from Anthro data. To clarify whether BodyFatPercent_Cons data is DEXA data (AD47_DEXA_body_fat_percent_P2) or Tanita data (E_TANITA_BodyFatPcnt_P2). (Indicates the type of device that was used for reporting body fat percent for BodyFatPercent_Cons_P2).
Real
Body Fat Percent Cons
Phase 2 data. Derived variable from Anthro data. This is AD47_DEXA_body_fat_percent_P2 data if it is available (since this is better data) if not it is E_TANITA_BodyFatPcnt_P2 data.
Real
Cln variable: Bowling hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Avg duration of bowling (indoor lawn or 10-pin). Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Bowling hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Avg duration of bowling (indoor lawn or 10-pin). -1 = left blank. DO NOT USE THIS VARIABLE. Use bowlingHr_CLEAN_P2 instead.
Real
Cln variable: Bowling min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Avg duration of bowling (indoor lawn or 10-pin). Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Bowling min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Avg duration of bowling (indoor lawn or 10-pin). -1 = left blank. DO NOT USE THIS VARIABLE. Use bowlingMin_CLEAN_P2 instead.
Real
Cln variable: Bowling
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Bowling (indoor lawn or 10-pin). Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Bowling
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks.Bowling. DO NOT USE THIS VARIABLE. Use bowling_CLEAN_P2 instead.
Real
Bowling
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Bowling (indoor lawn or 10-pin). Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
First Diastolic Blood Pressure
Phase 2 data. First Diastolic Blood Pressure Measurement - BPDia1 in mmHg/min
Real
Second Diastolic Blood Pressure
Phase 2 data. Second Diastolic Blood Pressure Measurement - BPDia2 in mmHg/min
Real
Third Diastolic Blood Pressure
Phase 2 data. Third Diastolic Blood Pressure Measurement -BPDia3 in mmHg/min
Real
First Pulse Rate Measurement
Phase 2 data. First Pulse Rate Measurement - BPPR1 in beats/min bpm
Real
Second Pulse Rate Measurement
Phase 2 data. Second Pulse Rate Measuremen - BPPR2 in beats/min bpm
Real
Third Pulse Rate Measurement
Phase 2 data. Third Pulse Rate Measurement - BPPR3 in beats/min bpm
Real
First Systolic Blood Pressure
Phase 2 data. First Systolic Blood Pressure Measurement - BPSys1 in mmHg/min
Real
Second Systolic Blood Pressure
Phase 2 data. Second Systolic Blood Pressure Measurement - BPSys2 in mmHg/min
Real
Third Systolic Blood Pressure
Phase 2 data. Third Systolic Blood Pressure Measuremen - BPSys3 in mmHg/min
Real
White bread and rolls
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Brown bread and rolls
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Wholemeal bread and rolls
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Cream crackers; cheese biscuits
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Crispbread eg Ryvita
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Calcium 0 minutes
Phase 2 data. Serum Calcium measurement taken at 0 minutes in mmol/l
Real
calcium_channel_blocker
Phase 2 data. Binary variable indicating whether a drug from the calcium channel blocker class was prescribed. 0 = No; 1 = Yes;
Categorical
Quality of the AH treadmill trace
Phase 2 data. The quality of the AH treadmill trace: 1 = pass; 0 = fail;
Categorical
Porridge; Readybrek
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Breakfast cereal
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Cholestrol 0 minutes
Phase 2 data. Serum Cholesterol measurement taken at 0 minutes in mmol/l
Real
Total Chol to HDLChol ratio 0 min
Phase 2 data. Total cholestrol to HDL cholestrol ratio measurement taken at 0 minutes
Real
Cln variable: BMI
Phase 2 data. Cleaned BMI calculated as weight in kilograms divided by height in meters squared from CL_HeightCM_P2 and CL_WeightKG_P2. Recommended BMI Varible
Real
Cln variable: Height code
Phase 2 data. Cleaned Height code 1 = No measures; 2 = DEXA height measurement from DEXA image
Categorical
Cln variable: Height
Phase 2 data. Cleaned Height in centimetres (if E_HeightCM_P2 not = to ALT_Height_P2
Real
Cln variable: Weight code
Phase 2 data. Cleaned Weight code 1 = No measures; 2 = DEXA Weight measurement from DEXA
Categorical
Cln variable: Weight
Phase 2 data. Cleaned Weight in centimetres (if E_WeightCM_P2 not = to ALT_Weight_P2
Real
Cln variable: Combat sports hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Combat sports (martial arts boxing or wrestling). Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Combat sports hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Combat sports (martial arts boxing or wrestling). -1 = left blank. DO NOT USE THIS VARIABLE. Use CombatsSportsHr_CLEAN_P2 instead.
Real
Cln variable: Combat sports min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Combat sports (martial arts boxing or wrestling). Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Combat sports min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Combat sports (martial arts boxing or wrestling). -1 = left blank. DO NOT USE THIS VARIABLE. Use CombatsSportsMin_CLEAN_P2 instead.
Real
Cln variable: Combat sports
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Combat sports (martial arts boxing or wrestling). Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Combat sports
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Martial arts boxing or wrestling. DO NOT USE THIS VARIABLE. Use CombatsSports_CLEAN_P2 instead.
Real
Combat sports
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Combat sports (martial arts boxing or wrestling). Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Insulin NEFA comments
Phase 2 data. Lab comments relating to heparin samples used for insulin and NEFA analysis for phase 2
Text
Cmnt geocodeing Cln work postcode
Phase 2 data. Comment related to geocodeing of phase 2 cleaned work postcode
Text
Commute domain AEE
Phase 2 data. Derived with method 2. Commute domain activity energy expenditure net METhrs/d
Real
Commute domain energy expenditure
Phase 2 data. Derived with method 2. Commute domain energy expenditure METhrs/d
Real
Commute domain PAEE
Phase 2 data. Derived with method 2. Commute domain activity energy expenditure kJ/kg/d
Real
Cln variable: Competitive running hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Competitive Running. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Competitive Running hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Competitive Running. -1 = left blank. DO NOT USE THIS VARIABLE. Use compRunHr_CLEAN_P2 instead.
Real
Cln variable: Competitive running min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Competitive Running. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Competitive Running min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Competitive Running. -1 = left blank. DO NOT USE THIS VARIABLE. Use compRunMin_CLEAN_P2 instead.
Real
Cln variable: Competitive running
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Competitive Running. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Competitive Running
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Competitive Running. DO NOT USE THIS VARIABLE. Use compRun_CLEAN_P2 instead.
Real
Competitive Running
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Competitive Running. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Cln variable: Computer wkday post6pm
Phase 2 data. Computer use at home but not at work (eg internet email playstation Xbox Gameboy and Wii; non-active games only). Hours of home computer use per day on a weekday after 6 pm. Average over the last 4 weeks. Data not quite the same as phase 1 data for Computerweekdaypost6pm. Error codes cleaned by DM team with this rule: RELATIVE. And then -10 error codes cleaned by PA team. 1 = none; 2 = less than 1 hr a day; 3 = 1 to 2 hrs a day; 4 = 2 to 3 hrs a day; 5 = 3 to 4 hrs a day; 6 = more than 4 hrs a day; -1 = left blank;
Categorical
Hrs homecomputer use wkday post 6pm
Phase 2 data. Questionnaire reads D3. Computer use at home but not at work (eg internet email playstation Xbox Gameboy and Wii; non-active games only). Hours of home computer use per day on a weekday after 6 pm. Average over the last 4 weeks. Data not quite the same as phase 1 data for Computerweekdaypost6pm. DO NOT USE THIS VARIABLE. Use Computerweekdaypost6pmDiff_CLEAN_P2 instead. 1 = none; 2 = less than 1 hr a day; 3 = 1 to 2 hrs a day; 4 = 2 to 3 hrs a day; 5 = 3 to 4 hrs a day; 6 = more than 4 hrs a day;
Categorical
Cln variable: Computer wkday pre6pm
Phase 2 data. Computer use at home but not at work (eg internet email playstation Xbox Gameboy and Wii; non-active games only). Hours of home computer use per day on a weekday before 6 pm. Average over the last 4 weeks. Data not quite the same as phase 1 data for Computerweekdaypre6pm. Error codes cleaned by DM team with this rule: RELATIVE. And then -10 error codes cleaned by PA team. 1 = none; 2 = less than 1 hr a day; 3 = 1 to 2 hrs a day; 4 = 2 to 3 hrs a day; 5 = 3 to 4 hrs a day; 6 = more than 4 hrs a day; -1 = left blank;
Categorical
Hrs home computer use wkday pre 6pm
Phase 2 data. Questionnaire reads D3. Computer use at home but not at work (eg internet email playstation Xbox Gameboy and Wii; non-active games only). Hours of home computer use per day on a weekday before 6 pm. Average over the last 4 weeks. Data not quite the same as phase 1 data for Computerweekdaypre6pm. DO NOT USE THIS VARIABLE. Use Computerweekdaypre6pmDiff_CLEAN_P2 instead. 1 = none; 2 = less than 1 hr a day; 3 = 1 to 2 hrs a day; 4 = 2 to 3 hrs a day; 5 = 3 to 4 hrs a day; 6 = more than 4 hrs a day;
Categorical
Cln variable: Computer wknd post6pm
Phase 2 data. Computer use at home but not at work (eg internet email playstation Xbox Gameboy and Wii; non-active games only). Hours of home computer use on a weekend after 6 pm. Average over the last 4 weeks. Data not quite the same as phase 1 data for Computerweekendpost6pm. Error codes cleaned by DM team with this rule: RELATIVE. And then -10 error codes cleaned by PA team. 1 = none; 2 = less than 1 hr a day; 3 = 1 to 2 hrs a day; 4 = 2 to 3 hrs a day; 5 = 3 to 4 hrs a day; 6 = more than 4 hrs a day; -1 = left blank;
Categorical
Hrs homecomputer use wknday post6pm
Phase 2 data. Questionnaire reads D3. Computer use at home but not at work (eg internet email playstation Xbox Gameboy and Wii; non-active games only). Hours of home computer use on a weekend after 6 pm. Average over the last 4 weeks. Data not quite the same as phase 1 data for Computerweekendpost6pm. DO NOT USE THIS VARIABLE. Use Computerweekendpost6pmDiff_CLEAN_P2 instead. 1 = none; 2 = less than 1 hr a day; 3 = 1 to 2 hrs a day; 4 = 2 to 3 hrs a day; 5 = 3 to 4 hrs a day; 6 = more than 4 hrs a day;
Categorical
Cln variable: Computer wknd pre6pm
Phase 2 data. Computer use at home but not at work (eg internet email playstation Xbox Gameboy and Wii; non-active games only). Hours of home computer use per day on a weekend before 6 pm. Average over the last 4 weeks. Data not quite the same as phase 1 data for Computerweekendpre6pm. Error codes cleaned by DM team with this rule: RELATIVE. And then -10 error codes cleaned by PA team. 1 = none; 2 = less than 1 hr a day; 3 = 1 to 2 hrs a day; 4 = 2 to 3 hrs a day; 5 = 3 to 4 hrs a day; 6 = more than 4 hrs a day; -1 = left blank;
Categorical
Hrs homecomputer use wknday pre 6pm
Phase 2 data. Questionnaire reads D3. Computer use at home but not at work (eg internet email playstation Xbox Gameboy and Wii; non-active games only). Hours of home computer use per day on a weekend before 6 pm. Average over the last 4 weeks. Data not quite the same as phase 1 data for Computerweekendpre6pm. DO NOT USE THIS VARIABLE. Use Computerweekendpre6pmDiff_CLEAN_P2 instead. 1 = none; 2 = less than 1 hr a day; 3 = 1 to 2 hrs a day; 4 = 2 to 3 hrs a day; 5 = 3 to 4 hrs a day; 6 = more than 4 hrs a day;
Categorical
Cln variable: Conditioning exercise hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Conditioning Exercises (eg using a bike or rowing machine). Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Conditioning Exercises hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Conditioning Exercises (eg using a bike or rowing machine). -1 = left blank. DO NOT USE THIS VARIABLE. Use conditionExerciseHr_CLEAN_P2 instead.
Real
Cln variable: Conditioning exercise min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Conditioning Exercises (eg using a bike or rowing machine). Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Conditioning Exercises min
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Conditioning Exercises (eg using a bike or rowing machine). -1 = left blank. DO NOT USE THIS VARIABLE. Use conditionExerciseMin_CLEAN_P2 instead.
Real
Cln variable: Conditioning exercise
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Conditioning Exercises (eg using a bike or rowing machine). Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Conditioning Exercises
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Conditioning Exercises (eg using a bike or rowing machine). DO NOT USE THIS VARIABLE. Use conditionExercise_CLEAN_P2 instead.
Real
Conditioning Exercises
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Conditioning Exercises (eg using a bike or rowing machine). Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Corrected calcium 0 minutes
Phase 2 data. Corrected calcium measurement taken at 0 minutes in mmol/l
Real
Supermarket count around home 1km buffer p2
Number of supermarkets around participants home postcode unit within a 1 kilometer Euclidean buffer in phase 2. Variable for analyses relating to the food environment.
Real
Takeaway count around home 1km buffer p2
Number of takeaway outlets around participants home postcode unit within a 1 kilometer Euclidean buffer in phase 2. Variable for analyses relating to the food environment.
Real
Supermarket count around home 1mile buffer p2
Number of supermarkets around participants home postcode unit within a 1 mile Euclidean buffer in phase 2. Variable for analyses relating to the food environment.
Real
Takeaway count around home 1mile buffer p2
Number of takeaway outlets around participants home postcode unit within a 1 mile Euclidean buffer in phase 2. Variable for analyses relating to the food environment.
Real
Supermarket count around home 400m buffer p2
Number of supermarket outlets around participants home postcode unit within a 400 meter Euclidean buffer in phase 2. Variable for analyses relating to the food environment.
Real
Takeaway count around home 400m buffer p2
Number of takeaway outlets around participants home postcode unit within a 400 meter Euclidean buffer in phase 2. Variable for analyses relating to the food environment.
Real
Supermarket count around home 800m buffer p2
Number of supermarkets around participants home postcode unit within a 800 meter Euclidean buffer in phase 2. Variable for analyses relating to the food environment.
Real
Takeaway count around home 800m buffer p2
Number of takeaway outlets around participants home postcode unit within a 800 meter Euclidean buffer in phase 2. Variable for analyses relating to the food environment.
Real
Supermarket count around work 1km buffer p2
Number of supermarkets around participants work postcode unit within a 1 kilometer Euclidean buffer in phase 2. Variable for analyses relating to the food environment.
Real
Takeaway count around work 1km buffer p2
Number of takeaway outlets around participants work postcode unit within a 1 kilometer Euclidean buffer in phase 2. Variable for analyses relating to the food environment.
Real
Supermarket count around work 1mile buffer p2
Number of supermarkets around participants work postcode unit within a 1 mile Euclidean buffer in phase 2. Variable for analyses relating to the food environment.
Real
Takeaway count around work 1mile buffer p2
Number of takeaway outlets around participants work postcode unit within a 1 mile Euclidean buffer in phase 2. Variable for analyses relating to the food environment.
Real
Supermarket count around work 400m buffer p2
Number of supermarket outlets around participants work postcode unit within a 400 meter Euclidean buffer in phase 2. Variable for analyses relating to the food environment.
Real
Takeaway count around work 400m buffer p2
Number of takeaway outlets around participants work postcode unit within a 400 meter Euclidean buffer in phase 2. Variable for analyses relating to the food environment.
Real
Supermarket count around work 800m buffer p2
Number of supermarkets around participants work postcode unit within a 800 meter Euclidean buffer in phase 2. Variable for analyses relating to the food environment.
Real
Takeaway count around work 800m buffer p2
Number of takeaway outlets around participants work postcode unit within a 800 meter Euclidean buffer in phase 2. Variable for analyses relating to the food environment.
Real
Creatinine 0 minutes
Phase 2 data. Serum Creatinine measurement taken at 0 minutes in umol/l
Real
Cln variable: Cricket hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Cricket. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Cricket hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Cricket. -1 = left blank. DO NOT USE THIS VARIABLE. Use cricketHr_CLEAN_P2 instead.
Real
Cln variable: Cricket min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Cricket. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Cricket min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Cricket. -1 = left blank. DO NOT USE THIS VARIABLE. Use cricketMin_CLEAN_P2 instead.
Real
Cln variable: Cricket
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Cricket. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Cricket
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Cricket. DO NOT USE THIS VARIABLE. Use cricket_CLEAN_P2 instead.
Real
Cricket
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Cricket. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Cln variable: Cycling pleasure hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Cycling For Pleasure (not as a means of transport). Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team.
Real
Cycling for Pleasure hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Cycling For Pleasure (not as a means of transport). -1 = left blank. DO NOT USE THIS VARIABLE. Use cyclePleasureHr_CLEAN_P2 instead.
Real
Cln variable: Cycling pleasure min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Cycling For Pleasure (not as a means of transport). Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Cycling for Pleasure min
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Cycling For Pleasure (not as a means of transport). -1 = left blank. DO NOT USE THIS VARIABLE. Use cyclePleasureMin_CLEAN_P2 instead.
Real
Cln variable: Cycling pleasure
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Cycling For Pleasure (not as a means of transport). Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Cycling for Pleasure
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Cycling For Pleasure (not as a means of transport). DO NOT USE THIS VARIABLE. Use cyclePleasure_CLEAN_P2 instead.
Real
Cycling for Pleasure
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Cycling For Pleasure (not as a means of transport). Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Cln variable: Racing hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Racing Or Rough Terrain Cycling. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Racing or Rough Terrain Cycling hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Racing Or Rough Terrain Cycling. -1 = left blank. DO NOT USE THIS VARIABLE. Use cyclingRacingRoughHr_CLEAN_P2 instead.
Real
Cln variable: Racing min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Racing Or Rough Terrain Cycling. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Racing or Rough Terrain Cycling min
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Racing Or Rough Terrain Cycling. -1 = left blank. DO NOT USE THIS VARIABLE. Use cyclingRacingRoughMin_CLEAN_P2 instead.
Real
Cln variable: Racing
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Racing Or Rough Terrain Cycling. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Racing or Rough Terrain Cycling
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Racing Or Rough Terrain Cycling. DO NOT USE THIS VARIABLE. Use cyclingRacingRough_CLEAN_P2 instead.
Real
Racing or Rough Terrain Cycling
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Racing Or Rough Terrain Cycling. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Low calorie low fat salad cream tablespoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Salad Cream Mayonnaise tablespoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
French Dressing tablespoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Other Salad Dressing tablespoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Butter teaspoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Hard margarine eg Stork Krona teaspoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Polyunsaturated margarine eg Flora sunflower teaspoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Other soft margarine eg Blue Band Stork teaspoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Low fat spread; eg Outline; Gold
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Very low fat spread teaspoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Single or sour cream tablespoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Double or clotted cream tablespoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Low fat yogurt fromage frais 125g carton
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Full fat or Greek yogurt 125g carton
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Dairy desserts 125g carton
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Cheese eg Cheddar Brie Edam medium serving
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Cottage cheese
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Eggs as boiled; fried; scrambled etc one
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Quiche medium serving
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Cln variable: Dancing hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Dancing (eg ballroom or disco). Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Dancing hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Dancing (eg ballroom or disco). -1 = left blank. DO NOT USE THIS VARIABLE. Use dancingHr_CLEAN_P2 instead.
Real
Cln variable: Dancing min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Dancing (eg ballroom or disco). Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Dancing min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Dancing (eg ballroom or disco). -1 = left blank. DO NOT USE THIS VARIABLE. Use dancingMin_CLEAN_P2 instead.
Real
Cln variable: Dancing
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Dancing (eg ballroom or disco). Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Dancing
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Dancing (eg ballroom or disco). DO NOT USE THIS VARIABLE. Use dancing_CLEAN_P2 instead.
Real
Dancing
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Dancing (eg ballroom or disco). Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Date Report Sent
Phase 2 data. Date participant feedback Report was sent
Date
Days AH monitor worn free living
Phase 2 data. Number of days ActiHeart monitor was worn during free living (first wear of Actiheart only). Used for Study cooridination purposes not for analysis. Use wear varibles in main AH dataset for analysis.
Integer
Departure Time
Phase 2 data. Clinical visit departure time
Time
M_DEXAEnt
Phase 2 data. M_DEXAEnt NOT RELEASED
Categorical
DEXA method
Phase 2 data. DEXA method used for positioning of volunteer. No DEXA; Normal; Symmetry; 1/2 body;
Text
M_DEXAUsed
Phase 2 data. M_DEXAUsed NOT RELEASED
Categorical
DEXA App lean mass
Phase 2 data. Data derived by data management team by adding up data for AD15_DEXA_arms_lean_mass and AD39_DEXA_legs_lean_mass and rounding to 2 decimals.
Real
DEXA Sample Check
Phase 2 data. DEXA CRF Check done? 0 = no; 1 = yes;
Categorical
Ethnicity used fo DEXA
Phase 2 data. Ethnicity used fo DEXA. For Dexa dataset only. Should not be used to indicate participant ethnicity. Use variables derived from general questionniare instead
Text
DEXA ethnicity
Phase 2 data. DEXA ethnicity enterd by operator. White; Asian; Black; Hispanic; Other; -9 = Missing data; -1 = Unable to be determined;
Real
DEXA ethnicity
Phase 2 data. DEXA ethnicity enterd at phase 2 by operator. White; Asian; Black; Hispanic; Other; -9 = Missing data; -1 = Unable to be determined;
Real
DEXA Periph fat mass
Phase 2 data. Data derived by data management team by adding up data for AD14_DEXA_arms_fat_mass and AD38_DEXA_legs_fat_mass and rounding to 2 decimals.
Real
M_DEXAQCFail
Phase 2 data. M_DEXAQCFail NOT RELEASED
Categorical
M_DEXARevReq
Phase 2 data. M_DEXARevReq NOT RELEASED
Categorical
M_DEXAReviewed
Phase 2 data. M_DEXAReviewed NOT RELEASED
Categorical
Diabetes Diagnosed
Phase 2 data. Particpant reported. Phase 2 participants were asked over the phone; when booking their clinical visits; if they had been diagnosed with diabetes since their phase 1 visit. For recruitment at baseline it was not asked because one of the exclusion criteria for recruitment was a diabetes diagnosis. 1 = Has been diagnosed with diabetes since baseline; 0 = not diagnosed with diabetes since baseline
Integer
Diabetes Status
Phase 2 data. Diabetes status of participant. This was used for study coordiniation purposes and participant feedback. It should NOT be used for analysis. The definition of raised and normal was based on WHO guidlines at the time of the visit and would have changed part way through the study. Use Glucose and HBA1c results to derive diabetes staus for analysis. 1 = HbA1C and OGTT normal; 2 = HbA1C and OGTT Raised; 3 = HbA1C raised and OGTT normal; 4 = HbA1C normal and OGTT raised;
Categorical
Avg dist to closest 5 supermarkets home p2
Average distance to the closest 5 supermarkets from participants home postcode unit in phase 2. Variable for analyses relating to the food environment.
Real
Avg dist to closest 5 takeaways home p2
Average distance to the closest 5 takeaway food outlets from participants home postcode unit in phase 2. Variable for analyses relating to the food environment.
Real
Dist to closest supermarket home p2
Distance to the nearest supermarket from participants home postcode unit in phase 2. Variable for analyses relating to the food environment.
Real
Dist to closest takeaway home p2
Distance to the nearest takeaway food outlet from participants home postcode unit in phase 2. Variable for analyses relating to the food environment.
Real
Dist to closest supermarket work p2
Distance to the nearest supermarket from participants work postcode unit in phase 2. Variable for analyses relating to the food environment.
Real
Dist to closest takeaway work p2
Distance to the nearest takeaway food outlet from participants work postcode unit in phase 2. Variable for analyses relating to the food environment.
Real
Avg dist to closest 5 supermarkets work p2
Average distance to the closest 5 supermarkets from participants work postcode unit in phase 2. Variable for analyses relating to the food environment.
Real
Avg dist to closest 5 takeaways work p2
Average distance to the closest 5 takeaway food outlets from participants work postcode unit in phase 2. Variable for analyses relating to the food environment.
Real
diuretic
Phase 2 data. Binary variable indicating whether a drug from the diuretic class was prescribed. 0: No 1: Yes
Categorical
Cln variable: DIY hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. DIY (eg carpentry home or car maintenance). Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
DIY hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. DIY (eg carpentry home or car maintenance). -1 = left blank. DO NOT USE THIS VARIABLE. Use dIYHr_CLEAN_P2 instead.
Real
Cln variable: DIY min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. DIY (eg carpentry home or car maintenance). Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
DIY min
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. DIY (eg carpentry home or car maintenance). -1 = left blank. DO NOT USE THIS VARIABLE. Use dIYMin_CLEAN_P2 instead.
Real
Cln variable: DIY
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. DIY (eg carpentry home or car maintenance). Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
DIY
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. DIY (eg carpentry home or car maintenance). DO NOT USE THIS VARIABLE. Use dIY_CLEAN_P2 instead.
Real
DIY
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. DIY (eg carpentry home or car maintenance). Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Dominant hand grip strength 1st
Phase 2 data. Dominant hand grip strength 1st measurement
Real
Dominant hand grip strength 2nd
Phase 2 data. Dominant hand grip strength 2nd measurement
Real
Dominant hand
Phase 2 data. Dominant hand. Left or right.
Text
Spirits; eg gin brandy whisky vodka single
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Low calorie or diet fizzy soft drinks glass
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Fizzy soft drinks
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Pure fruit juice 100% orange juice glass
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Fruit squash or cordial glass
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Tea cup
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Coffee instant or ground cup
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Coffee decaffeinated cup
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Coffee whitener
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Cocoa hot chocolate cup
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Horlicks Ovaltine cup
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Wine glass
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Beer lager or cider half pint
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Port sherry vermouth liqueurs glass
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
EFT In house Complete
Phase 2 data. In House Executive Function test completed? 1 = yes;
Categorical
EFT Online Complete
Phase 2 data. Online Executive Function test completed? 0 = no; 1 = yes;
Categorical
Electrodes used Arbo or Red dot
Phase 2 data. Data as entered on Study database. Electrodes used Arbo or Red dot For study coordination purposes and QC only.
Text
None
Phase 2 data.
Real
None
Phase 2 data.
Real
Events Book Entry
Phase 2 data. Was there an entry in the Adverse Events books related to the Phase 2 Clinical visit? 0 = no; 1 = yes;
Categorical
Cln variable: Exercise Weights hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Exercise With Weights. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Exercise With Weights hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Exercise With Weights. -1 = left blank. DO NOT USE THIS VARIABLE. Use exerciseWeightsHr_CLEAN_P2 instead.
Real
Cln variable: Exercise Weights min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Exercise With Weights. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Exercise With Weights min
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Exercise With Weights. -1 = left blank. DO NOT USE THIS VARIABLE. Use exerciseWeightsMin_CLEAN_P2 instead.
Real
Cln variable: Exercise Weights
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Exercise With Weights. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Exercise With Weights
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Exercise With Weights. DO NOT USE THIS VARIABLE. Use exerciseWeights_CLEAN_P2 instead.
Real
Exercise With Weights
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Exercise With Weights. CLEANED. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Anthro code
Phase 2 data. Coding of anthropometry team data. Request with E_AnthroComment for further information. 8 = Correct extreme value; 9 = poor quality data;
Real
Anthro Team Comment
Phase 2 data. Data provided by Anthropometry team. Comments provided by Anthro team on the data they have derived. Not available in release 1-5. Request with E_AnthroCode.
Text
Average of all hip measurements
Phase 2 data. Data provided by Anthropometry team. Average of all hip measurements. If 2 measurements were taken: (hip1+hip2)/2 and (hip1+hip2+hip3)/3 if a third measurement was taken. -1 = Unable to be determined; -9 = Missing data;
Real
Average of all Waist measurements
Phase 2 data. Data provided by Anthropometry team. Average of all waist measurements. If 2 measurements were taken: (waist1+waist2)/2 and (waist1+waist2+waist3)/3 if a third measurement was taken. -1 = Unable to be determined; -9 = Missing data;
Real
Body Fat percentage
Phase 2 data. Data provided by Anthropometry team. Body Fat percent derived by in house prediction equations based on impedance and anthropometry values which were validated against DEXA values. The following equations were used in men: 16.34649+(Ht2Im*0.6493159)+( Weight*0.1334669)-(AgeAtTest *0.0801411) and in women: 13.09247+(Ht2Im*0.6587483)+( Weight*0.0914326)-(AgeAtTest *0.0660596) to generate fat free mass (Ht2Im = height2/Impedance). Fat mass (weight - fat free mass) then percentage body fat (fat mass / (weight/100)) were derived. Further information on the validity can be provided by requesting the BIARegeneratedBodyFatPcnt document. -1 = unable to be determined; -7 = 0 values replaced; -9 = Missing data;
Real
Body Mass Index
Phase 2 data. Data provided by Anthropometry team. BMI (E_Weight / E_Height Squared). -1 = Unable to be determined;
Real
Comment for Cln E_Height Data
Phase 2 data. Comment for phase 2 cleaned E_Height Data (in E_Height_Cl_P2) Provided by Anthropometry team.
Text
Cln variable: height data
Phase 2 data. Replaces data for E_Height_P2. Cleaned phase 2 data provided by Anthropometry team. Height measurement in centimetres (data source: either from E_Height_P2 or where missing or incorrect a height estimate was taken from the phase 2 DEXA scan). -9 = Missing data;
Real
Height measurement in centimetres
Phase 2 data. Data provided by Anthropometry team. Height measurement in centimetres. This is data from the study database which has been QCd by the Anthropometry team. Any data issues have been corrected by the study team. Data checking is performed by comparing data from the DEXA machine and the study db. Any discrepancies are flagged and resolved. -9 = Missing data; Replaced by E_Height_Cl_P2
Real
First Hip Measurement
Phase 2 data. Data provided by Anthropometry team. First Hip Measurement in centimetres. -1 = Unable to be determined; -9 = Missing data;
Real
Second Hip Measurement
Phase 2 data. Data provided by Anthropometry team. Second Hip Measurement in centimetres. -1 = Unable to be determined; -9 = Missing data;
Real
Third Hip Measurement
Phase 2 data. Data provided by Anthropometry team. Third Hip Measurement in centimetres. -1 = Unable to be determined; -9 = Missing data;
Real
Sex
Phase 2 data. Participants gender checked and cleaned by Anthropometry team. Available for participants with Anthro data only. M = male; F = female; -9 = Missing data;
Categorical
Body fat percent Tanita
Phase 2 data. Data provided by Anthropometry team. Body Fat% by BIA (Bioelectrical Impedance Analysis) devise. -1 = Unable to be determined; -9 = Missing data;
Real
Tanita Impedance
Phase 2 data. Data provided by Anthropometry team. Bioelectrical Impedance for the whole body (right foot to right hand) in Ohm. -1 = Unable to be determined; -9 = Missing data;
Integer
Tanita left arm Impedance
Phase 2 data. Data provided by Anthropometry team. Bioelectrical Impedance for the left arm in Ohm. -1 = Unable to be determined; -9 = Missing data;
Integer
Tanita left leg Impedance
Phase 2 data. Data provided by Anthropometry team. Bioelectrical Impedance for the left leg in Ohm. -1 = Unable to be determined; -9 = Missing data;
Integer
Tanita right arm Impedance
Phase 2 data. Data provided by Anthropometry team. Bioelectrical Impedance for the right arm in Ohm. -1 = Unable to be determined; -9 = Missing data;
Integer
Tanita right leg Impedance
Phase 2 data. Data provided by Anthropometry team. Bioelectrical Impedance for the right leg in Ohm. -1 = Unable to be determined; -9 = Missing data;
Integer
Test date
Phase 2 data. Data provided by Anthropometry team. Date of Test (DOT). -9 = Missing data;
Date
Ultrasound Medial
Phase 2 data. Data provided by Anthropometry team. Medial (depth of visceral abdominal tissue) ultrasound measurement in centimetres.
Real
Ultrasound Subcutaneous
Phase 2 data. Data provided by Anthropometry team. Subcutaneous (Depth of abdominal subcutaneous tissue) ultrasound measurement in centimetres.
Real
First Waist Measurement
Phase 2 data. Data provided by Anthropometry team. First Waist Measurement in centimetres. -1 = Unable to be determined; -9 = Missing data;
Real
Second Waist Measurement
Phase 2 data. Data provided by Anthropometry team. Second Waist Measurement in centimetres. -1 = Unable to be determined; -9 = Missing data;
Real
Third Waist Measurement
Phase 2 data. Data provided by Anthropometry team. Third Waist Measurement in centimetres (appended only if waist 1 and 2 differed by greater than 3 cm). -1 = Unable to be determined; -9 = Missing data;
Real
Waist to hip ratio
Phase 2 data. Waist to hip ratio. Data provided by Anthropometry team.
Real
Weight measurement in kilograms
Phase 2 data. Data provided by Anthropometry team. Weight measurement in kilograms. -9 = Missing data;
Real
Fasting Sample Arm
Phase 2 data. Arm from which fasting blood sample was taken.
Text
Fasting Sample by
Phase 2 data. Initials/ID of staff member fasting blood sample was taken by
Text
Fasting Sample Site
Phase 2 data. Site of fasting sample blood sample taken
Text
No of brothers and sisters
Phase 2 data. How many brothers and sisters do or did you have (Please do not include any adopted family members or step-brothers/sisters/parents). For data entry: enter all text as is and where ? used = female ? = male
Text
No of sisters
Phase 2 data. Total number of sisters. Please do not include step-sisters. For data entry: Enter number as is. NB this number should be interpreted based on the full text in the previous variable - SiblingTotaltext. -1 = no number of sister or brother given
Real
No of brothers
Phase 2 data. Total number of brothers. Please do not include step-brothers. For data entry: Enter number as is. NB this number should be interpreted based on the full text in the previous variable - SiblingTotaltext.-1 = no number of sister or brother given
Real
Mother diabetes has/had
Phase 2 data. Mother has/had diabetes. Please do not include step-mother. Please do not include gestational diabetes. 2 = yes; 3 = No; 4 = Not known; -1 = left blank; -10 = answer plus additional text;
Categorical
Age mother at diabetes diagnosis
Phase 2 data. Approximate age at diabetes diagnosis of mother. 1 = <10; 2 = 10-19; 3 = 20-29; 4 = 30-39; 5 = 40-49; 6 = 50-59; 7 = 60-69; 8 = 70+; 9 = Not known; -1 = left blank; -5 = more than one selected;
Categorical
Father diabetes has/had
Phase 2 data. Father has/had diabetes. Please do not include step-father. Please do not include gestational diabetes. 2 = yes; 3 = No; 4 = Not known; -1 = left blank; -10 = answer plus additional text;
Categorical
Age father at diabetes diagnosis
Phase 2 data. Approximate age at diabetes diagnosis of father. 1 = <10; 2 = 10-19; 3 = 20-29; 4 = 30-39; 5 = 40-49; 6 = 50-59; 7 = 60-69; 8 = 70+; 9 = Not known; -1 = left blank; -5 = more than one selected;
Categorical
Type of sibling 01
Phase 2 data. Type of sibling 01. 1 = sister; 2 = brother; 3 = half sister; 4 = half brother; -1 = left blank; -7 = sibling type not on questionnaire; -10 = answer plus additional text;
Categorical
Sibling 01 has/had diabetes
Phase 2 data. Sibling 01 has/had diabetes. Please do not include gestational diabetes. 2 = yes; 3 = No; 4 = Not known; -1 = left blank; -10 = answer plus additional text;
Categorical
Age Sibling 01 at diabetes diag
Phase 2 data. Approximate age at diabetes diagnosis of sibling 01. 1 = <10; 2 = 10-19; 3 = 20-29; 4 = 30-39; 5 = 40-49; 6 = 50-59; 7 = 60-69; 8 = 70+; 9 = Not known; -1 = left blank; -5 = more than one selected;
Categorical
Type of sibling 02
Phase 2 data. Type of sibling 02. 1 = sister; 2 = brother; 3 = half sister; 4 = half brother; -1 = left blank; -7 = sibling type not on questionnaire; -10 = answer plus additional text;
Categorical
Sibling 02 has/had diabetes
Phase 2 data. Sibling 02 has/had diabetes. Please do not include gestational diabetes. 2 = yes; 3 = No; 4 = Not known; -1 = left blank; -10 = answer plus additional text;
Categorical
Age Sibling 02 at diabetes diag
Phase 2 data. Approximate age at diabetes diagnosis of sibling 02. 1 = <10; 2 = 10-19; 3 = 20-29; 4 = 30-39; 5 = 40-49; 6 = 50-59; 7 = 60-69; 8 = 70+; 9 = Not known; -1 = left blank; -5 = more than one selected;
Categorical
Type of sibling 03
Phase 2 data. Type of sibling 03. 1 = sister; 2 = brother; 3 = half sister; 4 = half brother; -1 = left blank; -7 = sibling type not on questionnaire; -10 = answer plus additional text;
Categorical
Sibling 03 has/had diabetes
Phase 2 data. Sibling 03 has/had diabetes. Please do not include gestational diabetes. 2 = yes; 3 = No; 4 = Not known; -1 = left blank; -10 = answer plus additional text;
Categorical
Age Sibling 03 at diabetes diag
Phase 2 data. Approximate age at diabetes diagnosis of sibling 03. 1 = <10; 2 = 10-19; 3 = 20-29; 4 = 30-39; 5 = 40-49; 6 = 50-59; 7 = 60-69; 8 = 70+; 9 = Not known; -1 = left blank; -5 = more than one selected;
Categorical
Type of sibling 04
Phase 2 data. Type of sibling 04. 1 = sister; 2 = brother; 3 = half sister; 4 = half brother; -1 = left blank; -7 = sibling type not on questionnaire; -10 = answer plus additional text;
Categorical
Sibling 04 has/had diabetes
Phase 2 data. Sibling 04 has/had diabetes. Please do not include gestational diabetes. 2 = yes; 3 = No; 4 = Not known; -1 = left blank; -10 = answer plus additional text;
Categorical
Age Sibling 04 at diabetes diag
Phase 2 data. Approximate age at diabetes diagnosis of sibling 04. 1 = <10; 2 = 10-19; 3 = 20-29; 4 = 30-39; 5 = 40-49; 6 = 50-59; 7 = 60-69; 8 = 70+; 9 = Not known; -1 = left blank; -5 = more than one selected;
Categorical
Type of sibling 05
Phase 2 data. Type of sibling 05. 1 = sister; 2 = brother; 3 = half sister; 4 = half brother; -1 = left blank; -7 = sibling type not on questionnaire; -10 = answer plus additional text;
Categorical
Sibling 05 has/had diabetes
Phase 2 data. Sibling 05 has/had diabetes. Please do not include gestational diabetes. 2 = yes; 3 = No; 4 = Not known; -1 = left blank; -10 = answer plus additional text;
Categorical
Age Sibling 05 at diabetes diag
Phase 2 data. Approximate age at diabetes diagnosis of sibling 05. 1 = <10; 2 = 10-19; 3 = 20-29; 4 = 30-39; 5 = 40-49; 6 = 50-59; 7 = 60-69; 8 = 70+; 9 = Not known; -1 = left blank; -5 = more than one selected;
Categorical
Type of sibling 06
Phase 2 data. Type of sibling 06. 1 = sister; 2 = brother; 3 = half sister; 4 = half brother; -1 = left blank; -7 = sibling type not on questionnaire; -10 = answer plus additional text;
Categorical
Sibling 06 has/had diabetes
Phase 2 data. Sibling 06 has/had diabetes. Please do not include gestational diabetes. 2 = yes; 3 = No; 4 = Not known; -1 = left blank; -10 = answer plus additional text;
Categorical
Age Sibling 06 at diabetes diag
Phase 2 data. Approximate age at diabetes diagnosis of sibling 06. 1 = <10; 2 = 10-19; 3 = 20-29; 4 = 30-39; 5 = 40-49; 6 = 50-59; 7 = 60-69; 8 = 70+; 9 = Not known; -1 = left blank; -5 = more than one selected;
Categorical
Type of sibling 07
Phase 2 data. Type of sibling 07. 1 = sister; 2 = brother; 3 = half sister; 4 = half brother; -1 = left blank; -7 = sibling type not on questionnaire; -10 = answer plus additional text;
Categorical
Sibling 07 has/had diabetes
Phase 2 data. Sibling 07 has/had diabetes. Please do not include gestational diabetes. 2 = yes; 3 = No; 4 = Not known; -1 = left blank; -10 = answer plus additional text;
Categorical
Age Sibling 07 at diabetes diag
Phase 2 data. Approximate age at diabetes diagnosis of sibling 07. 1 = <10; 2 = 10-19; 3 = 20-29; 4 = 30-39; 5 = 40-49; 6 = 50-59; 7 = 60-69; 8 = 70+; 9 = Not known; -1 = left blank; -5 = more than one selected;
Categorical
Type of sibling 08
Phase 2 data. Type of sibling 08. 1 = sister; 2 = brother; 3 = half sister; 4 = half brother; -1 = left blank; -7 = sibling type not on questionnaire; -10 = answer plus additional text;
Categorical
Sibling 08 has/had diabetes
Phase 2 data. Sibling 08 has/had diabetes. Please do not include gestational diabetes. 2 = yes; 3 = No; 4 = Not known; -1 = left blank; -10 = answer plus additional text;
Categorical
Age Sibling 08 at diabetes diag
Phase 2 data. Approximate age at diabetes diagnosis of sibling 08. 1 = <10; 2 = 10-19; 3 = 20-29; 4 = 30-39; 5 = 40-49; 6 = 50-59; 7 = 60-69; 8 = 70+; 9 = Not known; -1 = left blank; -5 = more than one selected;
Categorical
Type of sibling 09
Phase 2 data. Type of sibling 09. 1 = sister; 2 = brother; 3 = half sister; 4 = half brother; -1 = left blank; -7 = sibling type not on questionnaire; -10 = answer plus additional text;
Categorical
Sibling 09 has/had diabetes
Phase 2 data. Sibling 09 has/had diabetes. Please do not include gestational diabetes. 2 = yes; 3 = No; 4 = Not known; -1 = left blank; -10 = answer plus additional text;
Categorical
Age Sibling 09 at diabetes diag
Phase 2 data. Approximate age at diabetes diagnosis of sibling 09. 1 = <10; 2 = 10-19; 3 = 20-29; 4 = 30-39; 5 = 40-49; 6 = 50-59; 7 = 60-69; 8 = 70+; 9 = Not known; -1 = left blank; -5 = more than one selected;
Categorical
Type of sibling 10
Phase 2 data. Type of sibling 10. 1 = sister; 2 = brother; 3 = half sister; 4 = half brother; -1 = left blank; -7 = sibling type not on questionnaire; -10 = answer plus additional text;
Categorical
Sibling 10 has/had diabetes
Phase 2 data. Sibling 10 has/had diabetes. Please do not include gestational diabetes. 2 = yes; 3 = No; 4 = Not known; -1 = left blank; -10 = answer plus additional text;
Categorical
Age Sibling 10 at diabetes diag
Phase 2 data. Approximate age at diabetes diagnosis of sibling 10. 1 = <10; 2 = 10-19; 3 = 20-29; 4 = 30-39; 5 = 40-49; 6 = 50-59; 7 = 60-69; 8 = 70+; 9 = Not known; -1 = left blank; -5 = more than one selected;
Categorical
Family History entry comments
Phase 2 data. Any additional text written on the questionnaire
Text
Date finished eFamHist qnr
Phase 2 data. Date the participant finished filling in the Electronic Online FamHist questionnaire.
Date
Date started eFamHist qnr
Phase 2 data. Date the participant started to fill in the Electronic Online FamHist questionnaire.
Date
eFamHist qnr pt ID no
Phase 2 data. Electronic FamHist questionnaire-specicifc participant ID number.
Text
None
Phase 2 data. Please enter your 3-digit pin (on electronic form).
Text
eFamHist qnr ID no
Phase 2 data. Electronic FamHist questionnaire ID number for version control.
Text
eFamHist qnr ID name
Phase 2 data. Electronic FamHist questionnaire ID name for version control.
Text
Study phase eFamHist qnr
Phase 2 data. Study phase the Electronic FamHist questionnaire was used for.
Text
Time finished eFamHist qnr
Phase 2 data. Time the participant finished filling in the Electronic Online FamHist questionnaire.
Text
Time started eFamHist qnr
Phase 2 data. Time the participant started to fill in the Electronic Online FamHist questionnaire.
Text
eFamHist qnr version date
Phase 2 data. Electronic FamHist questionnaire version date for version control.
Text
eFamHist qnr version no
Phase 2 data. Electronic FamHist questionnaire version number for version control.
Text
eFamHist qnr web form version no
Phase 2 data. Electronic FamHist questionnaire web form version number for version control.
Text
Five Year Age Group
Phase 2 data. Age group the volunteer belonged to at the time of their phase 2 clinical appointment where age groups have been split up into groups of 5 years. Derived by data management team based on AgeAtTest_DM_Attended_P2. Can be used where precise age cannot be released or in not required.
Text
Flag incomplete questionnaire
Phase 2 data. Derived with method 2. Flag those that did not complete questionnaire (1 = Not complete)
Categorical
Flag shift worker
Phase 2 data. 1=Noted as shift worker 2=Multiple sleep times reported (but not ticked shift)
Categorical
Cln variable: Floor exercises hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Floor Exercises(eg stretching bending keep fit or yoga). Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Floor Exercises hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Floor Exercises(eg stretching bending keep fit or yoga). -1 = left blank. DO NOT USE THIS VARIABLE. Use floorExerciseHr_CLEAN_P2 instead.
Real
Cln variable: Floor exercises min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Floor Exercises(eg stretching bending keep fit or yoga). Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Floor Exercises min
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Floor Exercises(eg stretching bending keep fit or yoga). -1 = left blank. DO NOT USE THIS VARIABLE. Use floorExerciseMin_CLEAN_P2 instead.
Real
Cln variable: Floor exercises
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Floor Exercises (eg stretching bending keep fit or yoga). Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Floor Exercises
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Floor Exercises(eg stretching bending keep fit or yoga). DO NOT USE THIS VARIABLE. Use floorExercise_CLEAN_P2 instead.
Real
Floor Exercises
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Floor Exercises (eg stretching bending keep fit or yoga). Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Cln variable: Football Hockey hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Football Rugby Or Hockey. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Football Rugby or Hockey hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Football Rugby Or Hockey. -1 = left blank. DO NOT USE THIS VARIABLE. Use footballRugbyHockeyHr_CLEAN_P2 instead.
Real
Cln variable: Football Hockey min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Football Rugby Or Hockey. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Football Rugby or Hockey mins
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Football Rugby Or Hockey. -1 = left blank. DO NOT USE THIS VARIABLE. Use footballRugbyHockeyMin_CLEAN_P2 instead.
Real
Cln variable: Football Hockey
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Football Rugby Or Hockey. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Football Rugby or Hockey
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Football Rugby Or Hockey. DO NOT USE THIS VARIABLE. Use footballRugbyHockey_CLEAN_P2 instead.
Real
Football Rugby or Hockey
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Football Rugby Or Hockey. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Free Living data quality reviewed
Phase 2 data. Data as entered on Study database. For study coordination purposes and QC only. Has Free Living data quality been reviewed? 0 = no; 1 = yes;
Categorical
Free living data
Phase 2 data. Data as entered on Study database. For study coordination purposes and QC only. Is free living data available? 0 = no; 1 = yes;
Categorical
Test-Free living date match
Phase 2 data. Data as entered on Study database. For study coordination and QC purposes only. Is the 1st date of the free living data the same as the test date? Yes or blank
Text
Test-Free living date not match
Phase 2 data. Data as entered on Study database. For study coordination purposes and QC only. If the 1st date of the free living data is not the same as the test date provide a reason why not.
Text
Tinned Fruit
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Dried Fruit
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Apples 1 fruit
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Pears 1 fruit
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Oranges satsumas mandarins 1 fruit
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Grapefruit half
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Bananas 1 fruit
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Grapes medium serving
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Melon 1 slice
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Peaches Plums Apricots 1 fruit
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Strawberries Raspberries Kiwi Fruit medium serving
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
GammaGT 0 minutes
Phase 2 data. Serum GGT (Gamma GT) measurement taken at 0 minutes in U/l
Integer
calibration method applied
Phase 2 data. Calibration method applied to data file. Offset and scale with temperature (which uses both an offset and scaling factor for each axis) or offset only with temperature (which uses just the offsets).
Text
calibration type
Phase 2 data. Calibration type used. Single file; multi file or fail. Single file calibration uses the calibration factors from the file itself. Multi-file calibration uses calibration factors from all files in the processing database (all datasets) that have used the same device. Fail indicates that the file has failed calibration and therefore the results are unusable and have been set to missing.
Text
Device serial number
Phase 2 data. Device serial number of monitor used for data collection.
Integer
Proportion time spent >= 0 milli-g
Phase 2 data. Proportion of time spent above >=0 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 0 milli-g
Phase 2 data. Proportion of time spent above >=0 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 0 milli-g consolidated
Phase 2 data. Proportion of time spent above >=0 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 1000 milli-g
Phase 2 data. Proportion of time spent above >=1000 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 1000 milli-g
Phase 2 data. Proportion of time spent above >=1000 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Proportion timespent >= 1000 milli-g
Phase 2 data. Proportion of time spent above >=1000 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 100 milli-g
Phase 2 data. Proportion of time spent above >=100 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 100 milli-g
Phase 2 data. Proportion of time spent above >=100 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 100 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=100 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 105 milli-g
Phase 2 data. Proportion of time spent above >=105 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 105 milli-g
Phase 2 data. Proportion of time spent above >=105 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 105 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=105 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 10 milli-g
Phase 2 data. Proportion of time spent above >=10 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 10 milli-g
Phase 2 data. Proportion of time spent above >=10 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 10 milli-g consolidated
Phase 2 data. Proportion of time spent above >=10 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 110 milli-g
Phase 2 data. Proportion of time spent above >=110 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 110 milli-g
Phase 2 data. Proportion of time spent above >=110 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 110 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=110 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 115 milli-g
Phase 2 data. Proportion of time spent above >=115 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 115 milli-g
Phase 2 data. Proportion of time spent above >=115 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 115 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=115 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 120 milli-g
Phase 2 data. Proportion of time spent above >=120 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 120 milli-g
Phase 2 data. Proportion of time spent above >=120 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 120 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=120 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 125 milli-g
Phase 2 data. Proportion of time spent above >=125 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 125 milli-g
Phase 2 data. Proportion of time spent above >=125 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 125 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=125 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 130 milli-g
Phase 2 data. Proportion of time spent above >=130 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 130 milli-g
Phase 2 data. Proportion of time spent above >=130 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 130 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=130 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 135 milli-g
Phase 2 data. Proportion of time spent above >=135 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 135 milli-g
Phase 2 data. Proportion of time spent above >=135 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 135 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=135 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 140 milli-g
Phase 2 data. Proportion of time spent above >=140 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 140 milli-g
Phase 2 data. Proportion of time spent above >=140 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 140 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=140 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 145 milli-g
Phase 2 data. Proportion of time spent above >=145 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 145 milli-g
Phase 2 data. Proportion of time spent above >=145 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 145 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=145 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 150 milli-g
Phase 2 data. Proportion of time spent above >=150 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 150 milli-g
Phase 2 data. Proportion of time spent above >=150 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 150 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=150 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 15 milli-g
Phase 2 data. Proportion of time spent above >=15 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 15 milli-g
Phase 2 data. Proportion of time spent above >=15 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 15 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=15 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 160 milli-g
Phase 2 data. Proportion of time spent above >=160 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 160 milli-g
Phase 2 data. Proportion of time spent above >=160 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 160 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=160 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 170 milli-g
Phase 2 data. Proportion of time spent above >=170 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 170 milli-g
Phase 2 data. Proportion of time spent above >=170 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 170 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=170 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 180 milli-g
Phase 2 data. Proportion of time spent above >=180 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 180 milli-g
Phase 2 data. Proportion of time spent above >=180 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 180 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=180 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 190 milli-g
Phase 2 data. Proportion of time spent above >=190 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 190 milli-g
Phase 2 data. Proportion of time spent above >=190 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 190 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=190 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 1 milli-g
Phase 2 data. Proportion of time spent above >=1 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 1 milli-g
Phase 2 data. Proportion of time spent above >=1 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 1 milli-g consolidated
Phase 2 data. Proportion of time spent above >=1 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 2000 milli-g
Phase 2 data. Proportion of time spent above >=2000 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 2000 milli-g
Phase 2 data. Proportion of time spent above >=2000 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Proportion timespent >= 2000 milli-g
Phase 2 data. Proportion of time spent above >=2000 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 200 milli-g
Phase 2 data. Proportion of time spent above >=200 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 200 milli-g
Phase 2 data. Proportion of time spent above >=200 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 200 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=200 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 20 milli-g
Phase 2 data. Proportion of time spent above >=20 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 20 milli-g
Phase 2 data. Proportion of time spent above >=20 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 20 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=20 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 210 milli-g
Phase 2 data. Proportion of time spent above >=210 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 210 milli-g
Phase 2 data. Proportion of time spent above >=210 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 210 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=210 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 220 milli-g
Phase 2 data. Proportion of time spent above >=220 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 220 milli-g
Phase 2 data. Proportion of time spent above >=220 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 220 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=220 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 230 milli-g
Phase 2 data. Proportion of time spent above >=230 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 230 milli-g
Phase 2 data. Proportion of time spent above >=230 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 230 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=230 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 240 milli-g
Phase 2 data. Proportion of time spent above >=240 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 240 milli-g
Phase 2 data. Proportion of time spent above >=240 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 240 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=240 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 250 milli-g
Phase 2 data. Proportion of time spent above >=250 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 250 milli-g
Phase 2 data. Proportion of time spent above >=250 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 250 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=250 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 25 milli-g
Phase 2 data. Proportion of time spent above >=25 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 25 milli-g
Phase 2 data. Proportion of time spent above >=25 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 25 milli-g consolidated
Phase 2 data. Proportion of time spent above >=25 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 260 milli-g
Phase 2 data. Proportion of time spent above >=260 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 260 milli-g
Phase 2 data. Proportion of time spent above >=260 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 260 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=260 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 270 milli-g
Phase 2 data. Proportion of time spent above >=270 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 270 milli-g
Phase 2 data. Proportion of time spent above >=270 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 270 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=270 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 280 milli-g
Phase 2 data. Proportion of time spent above >=280 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 280 milli-g
Phase 2 data. Proportion of time spent above >=280 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 280 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=280 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 290 milli-g
Phase 2 data. Proportion of time spent above >=290 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 290 milli-g
Phase 2 data. Proportion of time spent above >=290 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 290 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=290 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 2 milli-g
Phase 2 data. Proportion of time spent above >=2 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 2 milli-g
Phase 2 data. Proportion of time spent above >=2 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 2 milli-g consolidated
Phase 2 data. Proportion of time spent above >=2 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 3000 milli-g
Phase 2 data. Proportion of time spent above >=3000 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 3000 milli-g
Phase 2 data. Proportion of time spent above >=3000 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Proportion timespent >= 3000 milli-g
Phase 2 data. Proportion of time spent above >=3000 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 300 milli-g
Phase 2 data. Proportion of time spent above >=300 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 300 milli-g
Phase 2 data. Proportion of time spent above >=300 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 300 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=300 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 30 milli-g
Phase 2 data. Proportion of time spent above >=30 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 30 milli-g
Phase 2 data. Proportion of time spent above >=30 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 30 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=30 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 35 milli-g
Phase 2 data. Proportion of time spent above >=35 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 35 milli-g
Phase 2 data. Proportion of time spent above >=35 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 35 milli-g consolidated
Phase 2 data. Proportion of time spent above >=35 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 3 milli-g
Phase 2 data. Proportion of time spent above >=3 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 3 milli-g
Phase 2 data. Proportion of time spent above >=3 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 3 milli-g consolidated
Phase 2 data. Proportion of time spent above >=3 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 4000 milli-g
Phase 2 data. Proportion of time spent above >=4000 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 4000 milli-g
Phase 2 data. Proportion of time spent above >=4000 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Proportion timespent >= 4000 milli-g
Phase 2 data. Proportion of time spent above >=4000 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 400 milli-g
Phase 2 data. Proportion of time spent above >=400 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 400 milli-g
Phase 2 data. Proportion of time spent above >=400 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 400 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=400 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 40 milli-g
Phase 2 data. Proportion of time spent above >=40 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 40 milli-g
Phase 2 data. Proportion of time spent above >=40 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 40 milli-g consolidated
Phase 2 data. Proportion of time spent above >=40 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 45 milli-g
Phase 2 data. Proportion of time spent above >=45 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 45 milli-g
Phase 2 data. Proportion of time spent above >=45 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 45 milli-g consolidated
Phase 2 data. Proportion of time spent above >=45 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 4 milli-g
Phase 2 data. Proportion of time spent above >=4 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 4 milli-g
Phase 2 data. Proportion of time spent above >=4 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 4 milli-g consolidated
Phase 2 data. Proportion of time spent above >=4 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 500 milli-g
Phase 2 data. Proportion of time spent above >=500 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 500 milli-g
Phase 2 data. Proportion of time spent above >=500 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 500 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=500 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 50 milli-g
Phase 2 data. Proportion of time spent above >=50 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 50 milli-g
Phase 2 data. Proportion of time spent above >=50 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 50 milli-g consolidated
Phase 2 data. Proportion of time spent above >=50 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 55 milli-g
Phase 2 data. Proportion of time spent above >=55 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 55 milli-g
Phase 2 data. Proportion of time spent above >=55 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 55 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=55 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 5 milli-g
Phase 2 data. Proportion of time spent above >=5 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 5 milli-g
Phase 2 data. Proportion of time spent above >=5 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 5 milli-g consolidated
Phase 2 data. Proportion of time spent above >=5 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 600 milli-g
Phase 2 data. Proportion of time spent above >=600 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 600 milli-g
Phase 2 data. Proportion of time spent above >=600 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 600 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=600 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 60 milli-g
Phase 2 data. Proportion of time spent above >=60 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 60 milli-g
Phase 2 data. Proportion of time spent above >=60 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 60 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=60 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 65 milli-g
Phase 2 data. Proportion of time spent above >=65 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 65 milli-g
Phase 2 data. Proportion of time spent above >=65 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 65 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=65 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 700 milli-g
Phase 2 data. Proportion of time spent above >=700 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 700 milli-g
Phase 2 data. Proportion of time spent above >=700 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 700 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=700 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 70 milli-g
Phase 2 data. Proportion of time spent above >=70 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 70 milli-g
Phase 2 data. Proportion of time spent above >=70 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 70 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=70 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 75 milli-g
Phase 2 data. Proportion of time spent above >=75 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 75 milli-g
Phase 2 data. Proportion of time spent above >=75 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 75 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=75 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 800 milli-g
Phase 2 data. Proportion of time spent above >=800 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 800 milli-g
Phase 2 data. Proportion of time spent above >=800 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Proportion time spent >= 800 milli-g
Phase 2 data. Proportion of time spent above >=800 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 80 milli-g
Phase 2 data. Proportion of time spent above >=80 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 80 milli-g
Phase 2 data. Proportion of time spent above >=80 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 80 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=80 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 85 milli-g
Phase 2 data. Proportion of time spent above >=85 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 85 milli-g
Phase 2 data. Proportion of time spent above >=85 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 85 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=85 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 900 milli-g
Phase 2 data. Proportion of time spent above >=900 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 900 milli-g
Phase 2 data. Proportion of time spent above >=900 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Proportion time spent >= 900 milli-g
Phase 2 data. Proportion of time spent above >=900 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 90 milli-g
Phase 2 data. Proportion of time spent above >=90 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 90 milli-g
Phase 2 data. Proportion of time spent above >=90 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 90 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=90 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Proportion time spent >= 95 milli-g
Phase 2 data. Proportion of time spent above >=95 milli-g (sleep imputed). The acceleration value is calculated as ENMO (euclidean norm minus one). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Proportion time spent >= 95 milli-g
Phase 2 data. Proportion of time spent above >=95 milli-g (no sleep imputed / standard output). The acceleration value is calculated as ENMO (euclidean norm minus one). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Time spent >= 95 milli-gconsolidated
Phase 2 data. Proportion of time spent above >=95 milli-g (consolidated). The acceleration value is calculated as ENMO (euclidean norm minus one). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Average acceleration ENMO Friday
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by day of week (Friday) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 10
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 10) (9:00-10:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 11
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 11) (10:00-11:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 12
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 12) (11:00-12:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 13
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 13) (12:00-13:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 14
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 14) (13:00-14:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 15
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 15) (14:00-15:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 16
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 16) (15:00-16:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 17
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 17) (16:00-17:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 18
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 18) (17:00-18:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 19
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 19) (18:00-19:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 1
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 1) (0:00-1:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 20
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 20) (19:00-20:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 21
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 21) (20:00-21:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 22
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 22) (21:00-22:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 23
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 23) (22:00-23:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 24
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 24) (23:00-00:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 2
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 2) (1:00-2:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 3
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 3) (2:00-3:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 4
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 4) (3:00-4:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 5
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 5) (4:00-5:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 6
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 6) (5:00-6:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 7
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 7) (6:00-7:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 8
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 8) (7:00-8:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg acceleration by hr of day hr 9
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by hour of day (hr 9) (8:00-9:00) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Average acceleration imputed
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) in milli-g; (sleep imputed). This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn.
Real
Average acceleration ENMO Monday
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by day of week (Monday) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Average acceleration non-imputed
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) in milli-g; (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Avg accel milli-g consolidated
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) in milli-g; (consolidated). Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1).
Real
Average acceleration ENMO Saturday
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by day of week (Saturday) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Average acceleration ENMO Sunday
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by day of week (Sunday) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Average acceleration ENMO Thursday
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by day of week (Thursday) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Average acceleration ENMO Tuesday
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by day of week (Tuesday) across the full data file (mg) (no sleep imputed / standard output) . This is the standard output (original) variable meaning no sleep imputation has been done.
Real
Average acceleration ENMO Wednesday
Phase 2 data. Average acceleration (euclidean norm minus one (ENMO)) by day of week (Wednesday) across the full data file (mg) (no sleep imputed / standard output). This is the standard output (original) variable meaning no sleep imputation has been done.
Real
File error after calibration single file
Phase 2 data. The absolute difference between 1g and the Euclidean Norm of the values of the three axes; averaged per file; after calibration (mg). Single file calibration.
Real
File error before calibration single file
Phase 2 data. The absolute difference between 1g and the Euclidean Norm of the values of the three axes; averaged per file; before calibration (mg). Single file calibration.
Real
First date timestamp
Phase 2 data. First date timestamp of hdf5 file (Stata formatted).
DateTime
Flag to indicate anomaly
Phase 2 data. Binary flag to indicate file had anomaly (1=anomaly present). Anomaly detected and fixed during processing.
Categorical
Flag to indicate axis issue
Phase 2 data. Binary flag to indicate there was an issue with one of the axis during the recording (1 = file had technical axis issue affecting integrity of data). Data set to missing.
Categorical
Flag to indicate = <1 hr valid data
Phase 2 data. Binary flag to indicate file had less than 1 hour of valid data (1= <1hour of data).
Categorical
Flag for data missing Pwear
Phase 2 data. Flag variable that can be used to condition the data on to protect against potential bias caused by data missing at certain times of day (i.e. missing in certain Pwear quadrants). It is advisable to ensure that data are distributed across the 24-hour period and use an inclusion criteria relating to compliance. This variable indicates: 0 = Insufficient wear time (Pwear <48 hours and three Pwear_quads <9 hours wear); 1 = Pwear >=48 hours and all four Pwear_quads >=9 hours; 2 = Pwear >=48 hours and three Pwear_quads >=9 hours (<9 hours in morning quad (midnight-6am)).
Categorical
Flag to indicate imputed data used
Phase 2 data. Binary flag (imputed=1) indicates if the imputed data has been used in the consolidated variables for this dataset. In some instances where data is likely to be excluded non-randomly; imputation may be required. Most commonly this is observed with night recording with systematic non-adherence to wearing a monitor during sleep in a 24-hr protocol. The Pwear variable has been set to 1 during the night (midnight-6am); to impute sleep when the monitor was flagged as non-wear during those times. These data are imputed proportional to the amount of days the monitor was worn so as not to inflate wear-time over the recording period. During the creation of the consolidated variables; the standard output variables (means and intensity categories) have been updated with the imputed data if certain criteria are met (limited night data i.e. include=2). These variables are indicated in the label with consolidated.
Categorical
Last date timestamp
Phase 2 data. Last date timestamp of hdf5 file (Stata formatted).
DateTime
File error after calibration multi-file
Phase 2 data. The absolute difference between 1g and the Euclidean Norm of the values of the three axes; averaged per file; after calibration (mg). Multi-file calibration.
Real
File error before calibration multi-file
Phase 2 data. The absolute difference between 1g and the Euclidean Norm of the values of the three axes; averaged per file; before calibration (mg). Multi-file calibration.
Real
Threshold set still bout detection
Phase 2 data. Threshold set for still bout detection (milli-g). Still bouts are flagged during processing as periods of time where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) fall below this threshold.
Integer
Processing epoch (seconds)
Phase 2 data. Frequency at which the data has been processed; in seconds. This may not reflect the raw frequency the monitor recorded in; instead is the level the data were collapsed to for the processing.
Integer
Pwear afternoon imputed
Phase 2 data. Number of valid hours worn during free-living in the afternoon quadrant (between 12:00-18:00); across the full data file (sleep imputed). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn. This variable indicates the total wear time between 12:00-18:00; across the whole data file; in hours.
Real
Pwear afternoon total time
Phase 2 data. Number of valid hours worn during free-living in the afternoon quadrant (between 12:00-18:00); across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 12:00-18:00; across the whole data file; in hours.
Real
No of hrs during free-living 12-18
Phase 2 data. Number of valid hours worn during free-living in the afternoon quadrant (between 12:00-18:00); across the full data file (consolidated). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1). This variable indicates the total wear time between 12:00-18:00; across the whole data file; in hours.
Real
Pwear Friday hrs non-imputed
Phase 2 data. Number of valid hours worn during free-living on a Friday; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time on a Friday; across the whole data file; in hours.
Real
Pwear by hr of day hr10 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 09:00-10:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 09:00-10:00; across the whole data file; in hours.
Real
Pwear by hr of day hr11 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 10:00-11:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 10:00-11:00; across the whole data file; in hours.
Real
Wkday afternoon pwear imputed
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 12:00-18:00) on weekdays (Monday-Friday); across the full data file (sleep imputed). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn. This variable indicates the total wear time between 12:00-18:00 on weekdays; across the whole data file; in hours.
Real
Wkday Pwear afternoon total time
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 12:00-18:00) on weekdays (Monday-Friday); across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 12:00-18:00 on weekdays; across the whole data file; in hours.
Real
Pwear wkday 12-18
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 12:00-18:00) on weekdays (Monday-Friday); across the full data file (consolidated). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1). This variable indicates the total wear time between 12:00-18:00 on weekdays; across the whole data file; in hours.
Real
Wkend afternoon pwear imputed
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 12:00-18:00) on weekend days (Saturday and Sunday); across the full data file (sleep imputed). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn. This variable indicates the total wear time between 12:00-18:00 on weekend days; across the whole data file; in hours.
Real
Wkend Pwear afternoon total time
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 12:00-18:00) on weekend days (Saturday and Sunday); across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 12:00-18:00 on weekend days; across the whole data file; in hours.
Real
Pwear wkend 12-18
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 12:00-18:00) on weekend days (Saturday and Sunday); across the full data file (consolidated). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1). This variable indicates the total wear time between 12:00-18:00 on weekend days; across the whole data file; in hours.
Real
Pwear by hr of day hr12 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 11:00-12:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 11:00-12:00; across the whole data file; in hours.
Real
Pwear by hr of day hr13 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 12:00-13:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 12:00-13:00; across the whole data file; in hours.
Real
Pwear by hr of day hr14 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 13:00-14:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 13:00-14:00; across the whole data file; in hours.
Real
Pwear by hr of day hr15 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 14:00-15:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 14:00-15:00; across the whole data file; in hours.
Real
Pwear by hr of day hr16 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 15:00-16:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 15:00-16:00; across the whole data file; in hours.
Real
Pwear by hr of day hr17 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 16:00-17:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 16:00-17:00; across the whole data file; in hours.
Real
Pwear by hr of day hr18 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 17:00-18:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 17:00-18:00; across the whole data file; in hours.
Real
Pwear by hr of day hr19 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 18:00-19:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 18:00-19:00; across the whole data file; in hours.
Real
Pwear by hr of day hr 1 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 00:00-01:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 00:00-01:00; across the whole data file; in hours.
Real
Pwear by hr of day hr20 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 19:00-20:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 19:00-20:00; across the whole data file; in hours.
Real
Pwear by hr of day hr21 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 20:00-21:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 20:00-21:00; across the whole data file; in hours.
Real
Pwear by hr of day hr22 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 21:00-22:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 21:00-22:00; across the whole data file; in hours.
Real
Pwear by hr of day hr23 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 22:00-23:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 22:00-23:00; across the whole data file; in hours.
Real
Pwear by hr of day hr24 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 23:00-00:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 23:00-00:00; across the whole data file; in hours.
Real
Pwear by hr of day hr 2 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 01:00-02:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 01:00-02:00; across the whole data file; in hours.
Real
Pwear by hr of day hr 3 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 02:00-03:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 02:00-03:00; across the whole data file; in hours.
Real
Pwear by hr of day hr 4 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 03:00-04:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 03:00-04:00; across the whole data file; in hours.
Real
Pwear by hr of day hr 5 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 04:00-05:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 04:00-05:00; across the whole data file; in hours.
Real
Pwear by hr of day hr 6 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 05:00-06:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 05:00-06:00; across the whole data file; in hours.
Real
Pwear by hr of day hr 7 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 06:00-07:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 06:00-07:00; across the whole data file; in hours.
Real
Pwear by hr of day hr 8 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 07:00-08:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 07:00-08:00; across the whole data file; in hours.
Real
Pwear by hr of day hr 9 non-imputed
Phase 2 data. Number of valid hours worn during free-living between 08:00-09:00; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 08:00-09:00; across the whole data file; in hours.
Real
Pwear Monday hrs non-imputed
Phase 2 data. Number of valid hours worn during free-living on a Monday; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time on a Monday; across the whole data file; in hours.
Real
Pwear imputed
Phase 2 data. Time integral of wear probability based on accelerometry (number of hours considered worn during free-living) (sleep imputed). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn. This variable indicates the total wear time across the whole data file in hours.
Real
Pwear morning imputed
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 00:00-06:00); across the full data file (sleep imputed). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn. This variable indicates the total wear time between 00:00-06:00; across the whole data file; in hours.
Real
Pwear morning total time
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 00:00-06:00); across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 00:00-06:00; across the whole data file; in hours.
Real
No of hrs during free-living 00-06
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 00:00-06:00); across the full data file (consolidated). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1). This variable indicates the total wear time between 00:00-06:00; across the whole data file; in hours.
Real
Wkday morning pwear imputed
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 00:00-06:00) on weekdays (Monday-Friday); across the full data file (sleep imputed). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn. This variable indicates the total wear time between 00:00-06:00 on weekdays; across the whole data file; in hours.
Real
Wkday Pwear morning total time
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 00:00-06:00) on weekdays (Monday-Friday); across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 00:00-06:00 on weekdays; across the whole data file; in hours.
Real
Pwear night total time
Phase 2 data. Number of valid hours worn during free-living in the night quadrant (between 18:00-00:00); across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 18:00-00:00; across the whole data file; in hours.
Real
Pwear noon total time
Phase 2 data. Number of valid hours worn during free-living in the noon quadrant (between 06:00-12:00); across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 06:00-12:00; across the whole data file; in hours.
Real
Pwear total time
Phase 2 data. Time integral of wear probability based on accelerometry (number of hours considered worn during free-living) (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time across the whole data file; in hours.
Real
Pwear wkday 00-06
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 00:00-06:00) on weekdays (Monday-Friday); across the full data file (consolidated). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1). This variable indicates the total wear time between 00:00-06:00 on weekdays; across the whole data file; in hours.
Real
Wkend morning pwear imputed
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 00:00-06:00) on weekend days (Saturday and Sunday); across the full data file (sleep imputed). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn. This variable indicates the total wear time between 00:00-06:00 on weekend days; across the whole data file; in hours.
Real
Wkend Pwear morning total time
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 00:00-06:00) on weekend days (Saturday and Sunday); across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 00:00-06:00 on weekend days; across the whole data file; in hours.
Real
Pwear wkend 00-06
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 00:00-06:00) on weekend days (Saturday and Sunday); across the full data file (consolidated). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1). This variable indicates the total wear time between 00:00-06:00 on weekend days; across the whole data file; in hours.
Real
Pwear night imputed
Phase 2 data. Number of valid hours worn during free-living in the night quadrant (between 18:00-00:00); across the full data file (sleep imputed). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn. This variable indicates the total wear time between 18:00-00:00; across the whole data file; in hours.
Real
No of hrs during free-living 18-00
Phase 2 data. Number of valid hours worn during free-living in the night quadrant (between 18:00-00:00); across the full data file (consolidated). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1). This variable indicates the total wear time between 18:00-00:00; across the whole data file; in hours.
Real
Pwear Saturday hrs non-imputed
Phase 2 data. Number of valid hours worn during free-living on a Saturday; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time on a Saturday; across the whole data file; in hours.
Real
Pwear Sunday hrs non-imputed
Phase 2 data. Number of valid hours worn during free-living on a Sunday; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time on a Sunday; across the whole data file; in hours.
Real
Wkday night pwear imputed
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 18:00-00:00) on weekdays (Monday-Friday); across the full data file (sleep imputed). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn. This variable indicates the total wear time between 18:00-00:00 on weekdays; across the whole data file; in hours.
Real
Wkday Pwear night total time
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 18:00-00:00) on weekdays (Monday-Friday); across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 18:00-00:00 on weekdays; across the whole data file; in hours.
Real
Pwear wkday 18-00
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 18:00-00:00) on weekdays (Monday-Friday); across the full data file (consolidated). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1). This variable indicates the total wear time between 18:00-00:00 on weekdays; across the whole data file; in hours.
Real
Wkend night pwear imputed
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 18:00-00:00) on weekend days (Saturday and Sunday); across the full data file (sleep imputed). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn. This variable indicates the total wear time between 18:00-00:00 on weekend days; across the whole data file; in hours.
Real
Wkend Pwear night total time
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 18:00-00:00) on weekend days (Saturday and Sunday); across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 18:00-00:00 on weekend days; across the whole data file; in hours.
Real
Pwear wkend 18-00
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 18:00-00:00) on weekend days (Saturday and Sunday); across the full data file (consolidated). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1). This variable indicates the total wear time between 18:00-00:00 on weekend days; across the whole data file; in hours.
Real
Pwear Thursday hrs non-imputed
Phase 2 data. Number of valid hours worn during free-living on a Thursday; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time on a Thursday; across the whole data file; in hours.
Real
Pwear Tuesday hrs non-imputed
Phase 2 data. Number of valid hours worn during free-living on a Tuesday; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time on a Tuesday; across the whole data file; in hours.
Real
Pwear Wednesday hrs non-imputed
Phase 2 data. Number of valid hours worn during free-living on a Wednesday; across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time on a Wednesday; across the whole data file; in hours.
Real
Pwear noon imputed
Phase 2 data. Number of valid hours worn during free-living in the noon quadrant (between 06:00-12:00); across the full data file (sleep imputed). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn. This variable indicates the total wear time between 06:00-12:00; across the whole data file; in hours.
Real
No of hrs during free-living 06-12
Phase 2 data. Number of valid hours worn during free-living in the noon quadrant (between 06:00-12:00); across the full data file (consolidated). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1). This variable indicates the total wear time between 06:00-12:00; across the whole data file; in hours.
Real
Wkday noon pwear imputed
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 06:00-12:00) on weekdays (Monday-Friday); across the full data file (sleep imputed). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn. This variable indicates the total wear time between 06:00-12:00 on weekdays; across the whole data file; in hours.
Real
Wkday Pwear noon total time
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 06:00-12:00) on weekdays (Monday-Friday); across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 06:00-12:00 on weekdays; across the whole data file; in hours.
Real
Pwear wkday 06-12
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 06:00-12:00) on weekdays (Monday-Friday); across the full data file (consolidated). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1). This variable indicates the total wear time between 06:00-12:00 on weekdays; across the whole data file; in hours.
Real
Wkend noon pwear imputed
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 06:00-12:00) on weekend days (Saturday and Sunday); across the full data file (sleep imputed). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn. This variable indicates the total wear time between 06:00-12:00 on weekend days; across the whole data file; in hours.
Real
Wkday Pwear total time
Phase 2 data. Number of valid hours worn during free-living over weekdays (Monday-Friday); across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time on weekdays; across the whole data file; in hours.
Real
Wkend Pwear total time
Phase 2 data. Number of valid hours worn during free-living over weekend days (Saturday and Sunday); across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time on weekend days; across the whole data file; in hours.
Real
No of hours file was recording for
Phase 2 data. Number of hours file was recording for. The is the whole length of the file itself; regardless of whether it is being worn.
Real
Wkend Pwear noon total time
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 06:00-12:00) on weekend days (Saturday and Sunday); across the full data file (no sleep imputed / standard output). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This is the standard output (original) variable meaning no sleep imputation has been done. This variable indicates the total wear time between 06:00-12:00 on weekend days; across the whole data file; in hours.
Real
Pwear wkend 06-12
Phase 2 data. Number of valid hours worn during free-living in the morning quadrant (between 06:00-12:00) on weekend days (Saturday and Sunday); across the full data file (consolidated). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1). This variable indicates the total wear time between 06:00-12:00 on weekend days; across the whole data file; in hours.
Real
Total wear time
Phase 2 data. Time integral of wear probability based on accelerometry (number of hours considered worn during free-living) (consolidated). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1). This variable indicates the total wear time across the whole data file; in hours.
Real
Wkday pwear imputed
Phase 2 data. Number of valid hours worn during free-living over weekdays (Monday-Friday); across the full data file (sleep imputed). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn. This variable indicates the total wear time on weekdays; across the whole data file; in hours.
Real
Wkday valid hrs during free-living
Phase 2 data. Number of valid hours worn during free-living over weekdays (Monday-Friday); across the full data file (consolidated). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1). This variable indicates the total wear time on weekdays; across the whole data file; in hours.
Real
Wkend pwear imputed
Phase 2 data. Number of valid hours worn during free-living over weekend days (Saturday and Sunday); across the full data file (sleep imputed). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. This imputed variable is derived from imputing sleep data if certain criteria of limited night data are met (i.e. not worn between 00:00-06:00). Pwear is set to 1 during these hours to impute sleep if not worn. This variable indicates the total wear time on weekend days; across the whole data file; in hours.
Real
Start date of free-living recording
Phase 2 data. Date of first day of free-living recording (Stata formatted). This date is regardless of whether the monitor was actually being worn; it is simply when the monitor started recording.
Date
Time resolution of processed data
Phase 2 data. The time resolution of the processed data outputted from accelerometry processing pipeline (pampro) and used by the post-processing scripts (minutes).
Integer
Location of GENEActiv wrist monitor
Phase 2 data. Location of the GENEActiv wrist monitor when worn for free-living (left/right). If wrist location was unknown; variable left as missing.
Text
Cln variable: Mode of transport
Phase 2 data. Which form of transport have you used MOST OFTEN in the last 4 weeks apart from your journey to and from work. Please tick one only. 1 = car - motor vehicle; 2 = walking; 3 = public transport; 4 = cycling; -1 = left blank; Error codes cleaned by DM team with this rule: CASE_TEXT. And then -10 errors cleaned by PA team.
Categorical
Mode of transport
Phase 2 data. Questionnaire reads D1. Getting about. Which form of transport have you used MOST OFTEN in the last 4 weeks apart from your journey to and from work. Please tick one box only. DO NOT USE THIS VARIABLE. Use Gettingabout_CLEAN_P2 instead. 1 = car - motor vehicle; 2 = walking; 3 = public transport; 4 = cycling;
Categorical
Wkend valid hrs during free-living
Phase 2 data. Number of valid hours worn during free-living over weekend days (Saturday and Sunday); across the full data file (consolidated). Non-wear periods are calculated as periods of time >=60 mins where the standard devigorous intensity activitytion of each of the three axes (x; y and z of the raw; triaxial accelerometry data) is <13mg. Both of these criteria are used to determine wear probability. Consolidated variable derived from either the original data (i.e. non-imputed) or imputed data where sleep has been imputed if certain criteria of limited night data are met (i.e. where inclusion criteria include= 2 (for details of inclusion criteria; see include variable)). In instances when the imputed data has been used in the consolidated variable; this will have a binary flag (imputed = 1). This variable indicates the total wear time on weekend days; across the whole data file; in hours.
Real
Glucose 0 minutes
Phase 2 data. Fasting Serum Glucose measurement taken at 0 minutes in mmol/l
Real
Glucose 120 minutes
Phase 2 data. 3 hour Glucose measurement taken at 120 minutes in mmol/l
Real
Glucose drink time
Phase 2 data. Time glucose drink was drunk by participant. For QC and filed team use. Not for analysis
Time
Cln variable: Golf hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Golf. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Golf hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Golf. -1 = left blank. DO NOT USE THIS VARIABLE. Use golfHr_CLEAN_P2 instead.
Real
Cln variable: Golf min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Golf. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Golf min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Golf. -1 = left blank. DO NOT USE THIS VARIABLE. Use golfMin_CLEAN_P2 instead.
Real
Cln variable: Golf
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Golf. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Golf
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Golf. DO NOT USE THIS VARIABLE. Use golf_CLEAN_P2 instead.
Real
Golf
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Golf. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
GPS issued to participants
Phase 2 data. Data as entered on Study database. For study coordination purposes and QC only. Has GPS been issued to participant? 0 = no; 1 = yes;
Categorical
Body outline yourself age 30
Phase 2 data. Questionnaire reads E9. Which of the diagrams shown below best depicts your body outline at a given age and that of your parents when they were middle aged? Yourself at Age 30. Image 1 slimmest = 1 to Image 9 fattest = 9
Real
Pt taking any tablets or medicines
Phase 2 data. Questionnaire reads: Are you taking any tablets or medicines at the moment? 2 = yes; 3 = No;
Categorical
BNF code
Phase 2 data. Questionnaire reads: Which drugs and reasons? BNF Code
Text
Dosage of the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
Name of the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
Reason for taking the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
BNF code
Phase 2 data. Questionnaire reads: Which drugs and reasons? BNF Code
Real
Dosage of the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Real
Name of the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
Reason for taking the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
BNF code
Phase 2 data. Questionnaire reads: Which drugs and reasons? BNF Code
Real
Dosage of the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
Name of the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
Reason for taking the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
BNF code
Phase 2 data. Questionnaire reads: Which drugs and reasons? BNF Code
Text
Dosage of the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
Name of the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
Reason for taking the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
BNF code
Phase 2 data. Questionnaire reads: Which drugs and reasons? BNF Code
Real
Dosage of the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
Name of the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
Reason for taking the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
BNF code
Phase 2 data. Questionnaire reads: Which drugs and reasons? BNF Code
Text
Dosage of the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
Name of the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
Reason for taking the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
BNF code
Phase 2 data. Questionnaire reads: Which drugs and reasons? BNF Code
Text
Dosage of the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
Name of the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
Reason for taking the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
BNF code
Phase 2 data. Questionnaire reads: Which drugs and reasons? BNF Code
Text
Dosage of the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
Name of the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
Reason for taking the drugs
Phase 2 data. Questionnaire reads: Which drugs and reasons?
Text
Heart problems
Phase 2 data. Questionnaire reads A3. 1. Has your doctor ever told you that you have heart trouble? 2 = yes; 3 = no;
Categorical
Chest pain or discomfort
Phase 2 data. Questionnaire reads A3. 2. Have you ever had any pain or discomfort in your chest? If no proceed to question 7. If yes please answer also the next 4 questions. 2 = yes; 3 = no;
Categorical
Dicomfort when walking uphill
Phase 2 data. Questionnaire reads A3. 3. Do you experience this discomfort when you walk uphill or hurry? (from GQV1_A5cChestPainUphill GQV3_A5cChestPainUphill GQV4_A5cChestPainUphill) (raw info of gq_chestpain_uphill). 2 = yes; 3 = no;
Categorical
Discomfort in wlking ordinary pace
Phase 2 data. Questionnaire reads A3. 4. Do you experience this discomfort when you walk at an ordinary pace on the level? (from GQV1_A5dChestPainNormalPace GQV3_A5dChestPainNormalPace GQV4_A5dChestPainNormalPace) (raw info of gq_chestpain_normal). 2 = yes; 3 = no;
Categorical
Disomfort while walking
Phase 2 data. Questionnaire reads A3. 5. What do you do if you experience this discomfort while walking? 1 = Stop or slow down; 2 = Carry on
Categorical
Disomfort when standing still
Phase 2 data. Questionnaire reads A3. 6. If you stand still; what happens to this discomfort? 1 = It goes away; 2 = It remains the same or gets worse
Categorical
Feel faint or spells of dizziness
Phase 2 data. Questionnaire reads A3. 7. Do you often feel faint or have spells of severe dizziness? 2 - yes; 3 = no;
Categorical
Blood pressure too high
Phase 2 data. Questionnaire reads A3. 8. Has a doctor ever told you that your blood pressure was too high? 2 - yes; 3 = no;
Categorical
Taking treatment for high BP
Phase 2 data. Questionnaire reads A3. 9. If you have been told that your blood pressure was too high; are you now on treatment? 2 - yes; 3 = no;
Categorical
Bone or joint problem
Phase 2 data. Questionnaire reads A3. 10. Has your doctor ever told you that you have a bone or joint problem such as arthritis that has been aggravated by exercise or might be made worse by exercise? 2 - yes; 3 = no;
Categorical
Pregnant
Phase 2 data. Questionnaire reads A3. 11. Are you pregant? 2 = yes; 3 = no;
Categorical
Reason not following acitivity prog
Phase 2 data. Questionnaire reads A3. 12. Is there any reason you know of that means you should not follow an activity programme even if you wanted to? 2 - yes; 3 = no;
Categorical
Walk unaided 10 minutes
Phase 2 data. Questionnaire reads A3. 13. Can you walk unaided for 10 minutes at a moderate pace? 2 - yes; 3 = no;
Categorical
Ever smoked
Phase 2 data. Questionnaire reads A4. Smoking. Have you ever smoked? 2 = yes; 3 = no;
Categorical
Smoke now
Phase 2 data. Questionnaire reads A4. Smoking. Do you smoke now? 2 = yes; 3 = No;
Categorical
Age smoking started
Phase 2 data. Questionnaire reads A4. Smoking. At what age did you start smoking? Please enter age in years.
Real
Year smoking quitted
Phase 2 data. Questionnaire reads A4. Smoking. If you have stopped smoking in which year did you quit.
Real
Number of cigarettes a day
Phase 2 data. Questionnaire reads A4. Smoking. How much do you or did you smoke a day on average? Number of cigarettes a day
Real
Number of cheroots a day
Phase 2 data. Questionnaire reads A4. Smoking. How much do you or did you smoke a day on average? Number of cheroots a day
Real
Number of cigars a day
Phase 2 data. Questionnaire reads A4. Smoking. How much do you or did you smoke a day on average? Number of cigars a day
Real
Tobacco in a week
Phase 2 data. Questionnaire reads A4. Smoking. How much do you or did you smoke a day on average? Amount in grams of tobacco in a week
Real
Age of first menstrual period
Phase 2 data. Questionnaire reads A5.1. How old were you when you had your first menstrual period? 2 = I Dont Know; 3 = I have never had a period;
Categorical
Still having menstrual period
Phase 2 data. Questionnaire reads A5.2. Are you still having menstrual periods? 2 = yes; 3 = No;
Categorical
Date 1st day of last menstrual period
Phase 2 data. Questionnaire reads A6.1. On what date was the first day of your last menstrual period?
Real
Days between menstrual periods
Phase 2 data. Questionnaire reads A6.2. About how many days are there usually from the first day of one menstrual period to the first day of the next?
Real
Irregular cycles
Phase 2 data. Questionnaire reads A6.3. Do you have irregular cycles? (i.e. you cannot predict within 5 days in either direction when your next period will start) 2 = yes; 3 = No;
Categorical
Reached menopause
Phase 2 data. Questionnaire reads A7.1. Have you reached the menopause? (i.e. your periods have now stopped completely and you believe permanently; and your last period was at least six months ago) 2 = Yes; 3 = No; 4 = Dont Know because I am taking HRT and therefore am unsure whether I have reached natural menopause;
Categorical
Age when periods stopped
Phase 2 data. Questionnaire reads A7.2. How old were you when your periods stopped completely and permanently? YEARS of age
Real
Age unkown when periods stopped
Phase 2 data. Questionnaire reads A7.2. How old were you when your periods stopped completely and permanently? Dont Know
Categorical
Reason for periods stopping
Phase 2 data. Questionnaire reads A7.3. What was the reason for your periods stopping? 1 = Natural menopause; 3 = Natural menopause while on HRT or contraception; 2 = Surgery (e.g.hysterectomy/removal of ovaries); 4 = Dont know
Categorical
Other reasons for periods stopping
Phase 2 data. Questionnaire reads IF NO A7c. What was the reason for your periods stopping? Other; specify
Text
Mother's age of Menopause
Phase 2 data. Questionnaire reads IF NO A7d. What was your mother’s age of natural menopause? (see exclusions above) YEARS of age
Real
Mother's age of natural menopause
Phase 2 data. Questionnaire reads IF NO A7d. What was your mother’s age of natural menopause? (see exclusions above) Dont know
Real
When voice break
Phase 2 data. Questionnaire reads A8a. When did your voice break? 1 = Younger than average; 2 = About average age; 3 = Older than average; 4 = Dont know;
Categorical
Age of voice break
Phase 2 data. Questionnaire reads A8b. If known; at what age did your voice break? YEARS of age
Real
Age of voice break not known
Phase 2 data. Questionnaire reads A8b. If known; at what age did your voice break? Dont know
Real
When facial hair started to grow
Phase 2 data. Questionnaire reads A9a. When did you start to grow facial hair? 1 = Younger than average; 2 = About average age; 3 = Older than average; 4 = Dont know;
Categorical
Age of facial hair
Phase 2 data. Questionnaire reads A9b. If known; at what age did you grow facial hair? YEARS of age
Real
Age of facial hair not known
Phase 2 data. Questionnaire reads A9b. If known; at what age did you grow facial hair? Dont know
Real
gq_alc_change_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived Alc frequency categories
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Alc frequency/week
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Alc exposure grams of ethanol/week
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
gq_alc_units_beer_wd_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
gq_alc_units_beer_we_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived Alc exposure UK units/week
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
gq_alc_units_fortwine_wd_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
gq_alc_units_fortwine_we_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
gq_alc_units_spirits_wd_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
gq_alc_units_spirits_we_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
gq_alc_units_wine_wd_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
gq_alc_units_wine_we_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
gq_alc_wd_g_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
gq_alc_wd_units_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
gq_alc_we_g_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
gq_alc_we_units_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Own a car or van
Phase 2 data. Questionnaire reads B10. Do you own a car or van? 2 = yes; 3 = no;
Categorical
Tv or computer in bedroom
Phase 2 data. Questionnaire reads B11. Do you have a TV or computer in your bedroom?
Categorical
Own house
Phase 2 data. Questionnaire reads B12. Do you own or rent the home where you live? Own it/buying it 2 = yes; 3 = no; -1 = left blank; -5 = more than one selected;
Categorical
Rent house
Phase 2 data. Questionnaire reads B12. Do you own or rent the home where you live? Rent it. 2 = yes; 3 = no; -1 = left blank; -5 = more than one selected;
Categorical
Marital status
Phase 2 data. Questionnaire reads B13. What is your marital status? This data is also captured with GQV3_C12MaritalStatus. You should request that data too. Not asked in GQV1. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Marit and data derived into: gq_marit_DER. Please request those variables instead. 1 = single; 2 = married or living as married; 3 = widowed; 4 = separated; 5 = divorced;
Categorical
Work full time
Phase 2 data. Questionnaire reads B1. What is your current work status? In work full time i.e. more than 30 hours per week. 2 = yes; 3 = no;
Categorical
Work part time
Phase 2 data. Questionnaire reads B1. What is your current work status? Part time work i.e. less than 30 hours per week. 2 = yes; 3 = no;
Categorical
Work keeping house
Phase 2 data. Questionnaire reads B1. What is your current work status? Keeping house. 2 = yes; 3 = no;
Categorical
Retired
Phase 2 data. Questionnaire reads B1. What is your current work status? Wholly retired from work. 2 = yes; 3 = no;
Categorical
Starting a new job
Phase 2 data. Questionnaire reads B1. What is your current work status? Waiting to start a new job already obtained. 2 = yes; 3 = no;
Categorical
Unemployed
Phase 2 data. Questionnaire reads B1. What is your current work status? Unemployed and looking for work. 2 = yes; 3 = no;
Categorical
Temporary out of work
Phase 2 data. Questionnaire reads B1. What is your current work status? Out of work as temporarily sick. 2 = yes; 3 = no;
Categorical
Sick or disabled
Phase 2 data. Questionnaire reads B1. What is your current work status? Permanently sick or disabled. 2 = yes; 3 = no;
Categorical
Work other
Phase 2 data. Questionnaire reads B1. What is your current work status? If other please specify.
Real
Self employed
Phase 2 data. Questionnaire reads B2. Employee or self employed; Do (did) you work as an employee or are (were) you self-employed? 1 = Employee; 2 = Self employed with employees; 3 = Self employed without employees;
Categorical
No of employees at work
Phase 2 data. Questionnaire reads B3. Number of employees; For employees: indicate below how many people work (worked) for your employer at the place where you work (worked). For self-employed: indicate below how many people you employ (employed). 1 = 1 to 24 people; 2 = 25 or more people;
Categorical
Supervise other employees
Phase 2 data. Questionnaire reads B4. Supervisory status; Do (did) you supervise any other employees? A supervisor or foreman is responsible for overseeing the work of other employees on a day to day basis. 2 = yes; 3 = no;
Categorical
Occupation type
Phase 2 data. Questionnaire reads B5. Occupation type; Please tick one box which best describes the sort of work you do. If you are not working now; please tick a box to show what you did in your last job. This data is also captured with GQV3_C5Occupation (but not in GQV1). You should request that data too. 1 = Modern professional ; 2 = Clerical; 3 = Senior manager; 4 = Technical; 5 = Semi-routine; 6 = Routine; 7 = Middle management; 8 = Traditional professional;
Categorical
School leaving certificate
Phase 2 data. Questionnaire reads B6. Do you have any of the following qualifications? (tick all applicable). School Leaving certificate. This data is also captured with GQV1_DMC4aSLC or GQV3_C6aSLC. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Edu_SLC and data derived into: gq_edu_slc_DER. Please request those variables instead. 2 = yes
Categorical
CSE qualification
Phase 2 data. Questionnaire reads B6. Do you have any of the following qualifications? (tick all applicable). CSE. This data is also captured with GQV1_DMC4bCSE or GQV3_C6bCSE. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Edu_CSE and data derived into: gq_edu_cse_DER. Please request those variables instead. 2 = yes
Categorical
GCE qualification
Phase 2 data. Questionnaire reads B6. Do you have any of the following qualifications? (tick all applicable). GCE O level or GCSE. This data is also captured with GQV1_DMC4cGCSE or GQV3_C6cGCSE. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Edu_GCSE and data derived into: gq_edu_gcse_DER. Please request those variables instead. 2 = yes
Categorical
Matriculation
Phase 2 data. Questionnaire reads B6. Do you have any of the following qualifications? (tick all applicable). Matriculation. This data is also captured with GQV1_DMC4dMatriculation or GQV3_C6dMatriculation. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Edu_matricul and data derived into: gq_edu_matricul_DER. Please request those variables instead. 2 = yes
Categorical
A levels
Phase 2 data. Questionnaire reads B6. Do you have any of the following qualifications? (tick all applicable). GCE A Level AS level Highers This data is also captured with GQV1_DMc4eALevels or GQV3_C6eALevels. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Edu_Alev and data derived into: gq_edu_alev_DER. Please request those variables instead. 2 = yes
Categorical
Technical qualifications
Phase 2 data. Questionnaire reads B6. Do you have any of the following qualifications? (tick all applicable). Technical College exams City and Guilds. This data is also captured with GQV1_DMC4fC_G or GQV3_C6fC_G. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Edu_TechCG and data derived into: gq_edu_techcg_DER. Please request those variables instead. 2 = yes
Categorical
HND or GNVQ
Phase 2 data. Questionnaire reads B6. Do you have any of the following qualifications? (tick all applicable). HND or GNVQ. This data is also captured with GQV1_DMC4gHND or GQV3_C6gHND_NVQ. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Edu_HND_NVQ and data derived into: gq_edu_hnd_nvq_DER. Please request those variables instead. 2 = yes
Categorical
Apprenticeship
Phase 2 data. Questionnaire reads B6. Do you have any of the following qualifications? (tick all applicable). Completed Apprenticeship. This data is also captured with GQV1_DMC4hApprenticeship or GQV3_C6hApprenticeship. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Edu_apprentice and data derived into: gq_edu_apprentice_DER. Please request those variables instead. 2 = yes
Categorical
Secretarial
Phase 2 data. Questionnaire reads B6. Do you have any of the following qualifications? (tick all applicable). Secretarial College Exams. This data is also captured with GQV1_DMC4iSecretarial or GQV3_C6iSecretarial. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Edu_secret and data derived into: gq_edu_secret_DER. Please request those variables instead. 2 = yes
Categorical
Teaching Diploma
Phase 2 data. Questionnaire reads B6. Do you have any of the following qualifications? (tick all applicable). Teaching Diploma HNC NVQ. This data is also captured with GQV1_DMC4jHMC or GQV3_C6jHNC. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Edu_HNC and data derived into: gq_edu_hnc_DER. Please request those variables instead. 2 = yes
Categorical
University degree
Phase 2 data. Questionnaire reads B6. Do you have any of the following qualifications? (tick all applicable). University Degree. This data is also captured with GQV1_DMC4kDegree or GQV3_C6kDegree. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Edu_degree and data derived into: gq_edu_degree_DER. Please request those variables instead. 2 = yes
Categorical
Trade certificates
Phase 2 data. Questionnaire reads B6. Do you have any of the following qualifications? (tick all applicable). Trade Certificates. This data is also captured with GQV1_DMC4lTradeCertificate or GQV3_C6lTradeCertificate. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Edu_trade and data derived into: gq_edu_trade_DER. Please request those variables instead. 2 = yes
Categorical
Other qualifications
Phase 2 data. Questionnaire reads B6. Do you have any of the following qualifications? (tick all applicable). Other please describe. This data is also captured with GQV1_DMC4mOther or GQV3_C6mOther. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Edu_others and data derived into: gq_edu_others_DER. Please request those variables instead.
Text
No qualifications
Phase 2 data. Questionnaire reads B6. Do you have any of the following qualifications? (tick all applicable). None. This data is also captured with GQV1_DMC4nNone or GQV3_C6nNone. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Edu_none and data derived into: gq_edu_none_DER. Please request those variables instead. 2 = yes
Categorical
Age full time education finished
Phase 2 data. Questionnaire reads B7. At what age did you finish full time education (in years)? This data is also captured with GQV1_DMC42aAgeEndFTE or GQV3_C7AgeEndFTE. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Edu_age and data derived into: gq_edu_age_DER. Please request those variables instead.
Real
Household Income
Phase 2 data. Questionnaire reads B8. Please can you indicate what your household income is. 1 = < £2000; 2 = £20000 - <£40000; 3 = > £40000 - <£60000; 4 = £60000 - <£80000; 5 = £80000 and above;
Categorical
No of people in household
Phase 2 data. Questionnaire reads B9. How many people are there in your household? (including children)
Real
gq_bodwt_y20_kg_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived Bone problems worse by exercise
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived How often eat breakfast
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Eat snack foods using PC
Phase 2 data. Questionnaire reads C10. Apart from meals how often do you eat snack foods while using PC; tablet; smartphone or similar electronic device? 1 = Never or rarely; 2 = Occasionally; 3 = Usually; 4 = Always;
Categorical
Main meal between 6am - 8am
Phase 2 data. Questionnaire reads Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a main meal: between 6am - 8am cooked dish e.g. meat with potatoes; pizza; lasagne; fish and chips; burgers; fried breakfast. This data is also captured with GQV1_D601aMain or GQV3_D601aMain. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Main0204 and data derived into: gq_eat_main0204_DER. Please request those variables instead. 2 = yes
Categorical
Light meal between 6am - 8am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a light meal between: 6am - 8am E.g. porridge; cereal; toast; sandwiches; soup; salad; omelette. This data is also captured with GQV1_D601bLight or GQV3_D601bLight. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Light0204 and data derived into: gq_eat_light0204_DER. Please request those variables instead. 2 = yes
Categorical
Snack between 6am - 8am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a snack between: 6am - 8am E.g. biscuit; cake; fruit; sweets; chocolate; crisps; nuts; ice cream. This data is also captured with GQV1_D601cSnack or GQV3_D601cSnack. You should request that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Snack0204 and data derived into: gq_eat_snack0204_DER. Please request those variables instead. 2 = yes
Categorical
Drink only snack between 6am - 8am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a drink only snack between: 6am - 8am E.g. drinks with some milk or sugar in; not low calorie drinks or water. This data is also captured with GQV1_D601dDrink or GQV3_D601dDrink. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Drink0204 and data derived into: gq_eat_drink0204_DER. Please request those variables instead. 2 = yes
Categorical
Main meal between 8am - 10am
Phase 2 data. Questionnaire reads Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a main meal between: 8am - 10am cooked dish e.g. meat with potatoes; pizza; lasagne; fish and chips; burgers; fried breakfast. This data is also captured with GQV1_D602aMain or GQV3_D602aMain. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Main0406 and data derived into: gq_eat_main0406_DER. Please request those variables instead. 2 = yes
Categorical
Light meal between 8am - 10am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a light meal between: 8am - 10am E.g. porridge; cereal; toast; sandwiches; soup; salad; omelette. This data is also captured with GQV1_D602bLight or GQV3_D602bLight. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Light0406 and data derived into: gq_eat_light0406_DER. Please request those variables instead. 2 = yes
Categorical
Snack between 8am - 10am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a snack between: 8am - 10am E.g. biscuit; cake; fruit; sweets; chocolate; crisps; nuts; ice cream. This data is also captured with GQV1_D602cSnack or GQV3_D602cSnack. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Snack0406 and data derived into: gq_eat_snack0406_DER. Please request those variables instead. 2 = yes
Categorical
Drink only snack between 8am - 10am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a drink only snack between: 8am - 10am E.g. drinks with some milk or sugar in; not low calorie drinks or water. This data is also captured with GQV1_D602dDrink or GQV3_D602dDrink. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Drink0406 and data derived into: gq_eat_drink0406_DER. Please request those variables instead. 2 = yes
Categorical
Main meal between 10am - 12am
Phase 2 data. Questionnaire reads Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a main meal between: 10am - 12am cooked dish e.g. meat with potatoes; pizza; lasagne; fish and chips; burgers; fried breakfast. This data is also captured with GQV1_D603aMain or GQV3_D603aMain. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Main0608 and data derived into: gq_eat_main0608_DER. Please request those variables instead. 2 = yes
Categorical
Light meal between 10am - 12pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a light meal between: 10am - 12pm E.g. porridge; cereal; toast; sandwiches; soup; salad; omelette. This data is also captured with GQV1_D603bLight or GQV3_D603bLight. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Light0608 and data derived into: gq_eat_light0608_DER. Please request those variables instead. 2 = yes
Categorical
Snack between 10am - 12pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a snack between: 10am - 12pm E.g. biscuit; cake; fruit; sweets; chocolate; crisps; nuts; ice cream. This data is also captured with GQV1_D603cSnack or GQV3_D603cSnack. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Snack0608 and data derived into: gq_eat_snack0608_DER. Please request those variables instead. 2 = yes
Categorical
Drink only snack btwn 10am - 12pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a drink only snack between: 10am - 12pm E.g. drinks with some milk or sugar in; not low calorie drinks or water. This data is also captured with GQV1_D603dDrink or GQV3_D603dDrink. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Drink0608 and data derived into: gq_eat_drink0608_DER. Please request those variables instead. 2 = yes
Categorical
Main meal between 12pm - 2pm
Phase 2 data. Questionnaire reads Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a main meal between: 12pm - 2pm cooked dish e.g. meat with potatoes; pizza; lasagne; fish and chips; burgers; fried breakfast. This data is also captured with GQV1_D604aMain or GQV3_D604aMain. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Main0810 and data derived into: gq_eat_main0810_DER. Please request those variables instead. 2 = yes
Categorical
Light meal between 12pm - 2pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a light meal between: 12pm -2pm E.g. porridge; cereal; toast; sandwiches; soup; salad; omelette. This data is also captured with GQV1_D604bLight or GQV3_D604bLight. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Light0810 and data derived into: gq_eat_light0810_DER. Please request those variables instead. 2 = yes
Categorical
Snack between 12pm - 2pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a snack between: 12pm - 2pm E.g. biscuit; cake; fruit; sweets; chocolate; crisps; nuts; ice cream. This data is also captured with GQV1_D604cSnack or GQV3_D604cSnack. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Snack0810 and data derived into: gq_eat_snack0810_DER. Please request those variables instead. 2 = yes
Categorical
Drink only snack between 12pm - 2pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a drink only snack between: 12pm - 2pm E.g. drinks with some milk or sugar in; not low calorie drinks or water. This data is also captured with GQV1_D604dDrink or GQV3_D604dDrink. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Drink0810 and data derived into: gq_eat_drink0810_DER. Please request those variables instead. 2 = yes
Categorical
Main meal between 2pm - 4pm
Phase 2 data. Questionnaire reads Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a main meal between: 2pm - 4pm cooked dish e.g. meat with potatoes; pizza; lasagne; fish and chips; burgers; fried breakfast. This data is also captured with GQV1_D605aMain or GQV3_D605aMain. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Main1012 and data derived into: gq_eat_main1012_DER. Please request those variables instead. 2 = yes
Categorical
Light meal between 2pm - 4pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a light meal between: 2pm - 4pm E.g. porridge; cereal; toast; sandwiches; soup; salad; omelette. This data is also captured with GQV1_D605bLight or GQV3_D605bLight. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Light1012 and data derived into: gq_eat_light1012_DER. Please request those variables instead. 2 = yes
Categorical
Snack between 2pm - 4pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a snack between: 2pm - 4pm E.g. biscuit; cake; fruit; sweets; chocolate; crisps; nuts; ice cream. This data is also captured with GQV1_D605cSnack or GQV3_D605cSnack. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Snack1012 and data derived into: gq_eat_snack1012_DER. Please request those variables instead. 2 = yes
Categorical
Drink only snack between 2pm - 4pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a drink only snack between: 2pm - 4pm E.g. drinks with some milk or sugar in; not low calorie drinks or water. This data is also captured with GQV1_D605dDrink or GQV3_D605dDrink. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Drink1012 and data derived into: gq_eat_drink1012_DER. Please request those variables instead. 2 = yes
Categorical
Main meal between 4pm - 6pm
Phase 2 data. Questionnaire reads Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a main meal between: 4pm - 6pm cooked dish e.g. meat with potatoes; pizza; lasagne; fish and chips; burgers; fried breakfast. This data is also captured with GQV1_D606aMain or GQV3_D606aMain. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Main1214 and data derived into: gq_eat_main1214_DER. Please request those variables instead. 2 = yes
Categorical
Light meal between 4pm - 6pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a light meal between: 4pm - 6pm E.g. porridge; cereal; toast; sandwiches; soup; salad; omelette. This data is also captured with GQV1_D606bLight or GQV3_D606bLight. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Light1214 and data derived into: gq_eat_light1214_DER. Please request those variables instead. 2 = yes
Categorical
Snack between 4pm -6pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a snack between: 4pm - 6pm E.g. biscuit; cake; fruit; sweets; chocolate; crisps; nuts; ice cream. This data is also captured with GQV1_D606cSnack or GQV3_D606cSnack. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Snack1214 and data derived into: gq_eat_snack1214_DER. Please request those variables instead. 2 = yes
Categorical
Drink only snack between 4pm - 6pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a drink only snack between: 4pm - 6pm E.g. drinks with some milk or sugar in; not low calorie drinks or water. This data is also captured with GQV1_D606dDrink or GQV3_D606dDrink. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Drink1214 and data derived into: gq_eat_drink1214_DER. Please request those variables instead. 2 = yes
Categorical
Main meal between 6pm - 8pm
Phase 2 data. Questionnaire reads Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a main meal between: 6pm - 8pm cooked dish e.g. meat with potatoes; pizza; lasagne; fish and chips; burgers; fried breakfast. This data is also captured with GQV1_D607aMain or GQV3_D607aMain. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Main1416 and data derived into: gq_eat_main1416_DER. Please request those variables instead. 2 = yes
Categorical
Light meal between 6pm - 8pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a light meal between: 6pm - 8pm E.g. porridge; cereal; toast; sandwiches; soup; salad; omelette. This data is also captured with GQV1_D607bLight or GQV3_D607bLight. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Light1416 and data derived into: gq_eat_light1416_DER. Please request those variables instead. 2 = yes
Categorical
Snack between 6pm -8pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a snack between: 6pm - 8pm E.g. biscuit; cake; fruit; sweets; chocolate; crisps; nuts; ice cream. This data is also captured with GQV1_D607cSnack or GQV3_D607cSnack. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Snack1416 and data derived into: gq_eat_snack1416_DER. Please request those variables instead. 2 = yes
Categorical
Drink only snack between 6pm - 8pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a drink only snack between: 6pm - 8pm E.g. drinks with some milk or sugar in; not low calorie drinks or water. This data is also captured with GQV1_D607dDrink or GQV3_D607dDrink. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Drink1416 and data derived into: gq_eat_drink1416_DER. Please request those variables instead. 2 = yes
Categorical
Main meal between 8pm - 10pm
Phase 2 data. Questionnaire reads Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a main meal between: 8pm - 10pm cooked dish e.g. meat with potatoes; pizza; lasagne; fish and chips; burgers; fried breakfast. This data is also captured with GQV1_D608aMain or GQV3_D608aMain. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Main1618 and data derived into: gq_eat_main1618_DER. Please request those variables instead. 2 = yes
Categorical
Light meal between 8pm - 10pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a light meal between: 8pm - 10pm E.g. porridge; cereal; toast; sandwiches; soup; salad; omelette. This data is also captured with GQV1_D608bLight or GQV3_D608bLight. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Light1618 and data derived into: gq_eat_light1618_DER. Please request those variables instead. 2 = yes
Categorical
Snack between 8pm -10pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a snack between: 8pm - 10pm E.g. biscuit; cake; fruit; sweets; chocolate; crisps; nuts; ice cream. This data is also captured with GQV1_D608cSnack or GQV3_D608cSnack. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Snack1618 and data derived into: gq_eat_snack1618_DER. Please request those variables instead. 2 = yes
Categorical
Drink only snack between 8pm - 10pm
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a drink only snack between: 8pm - 10pm E.g. drinks with some milk or sugar in; not low calorie drinks or water. This data is also captured with GQV1_D608dDrink or GQV3_D608dDrink. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Drink1618 and data derived into: gq_eat_drink1618_DER. Please request those variables instead. 2 = yes
Categorical
Main meal between 10pm - 12am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a main meal between: 10pm - 12am cooked dish e.g. meat with potatoes; pizza; lasagne; fish and chips; burgers; fried breakfast. This data is also captured with GQV1_D609aMain or GQV3_D609aMain. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Main1820 and data derived into: gq_eat_main1820_DER. Please request those variables instead. 2 = yes
Categorical
Light meal between 10pm - 12am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a light meal between: 10pm - 12am E.g.porridge; cereal; toast; sandwiches; soup; salad; omelette. This data is also captured with GQV1_D609bLight or GQV3_D609bLight. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Light1820 and data derived into: gq_eat_light1820_DER. Please request those variables instead. 2 = yes
Categorical
Snack between 10pm -12am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a snack between: 10pm - 12am E.g. biscuit; cake; fruit; sweets; chocolate; crisps; nuts; ice cream. This data is also captured with GQV1_D609cSnack or GQV3_D609cSnack. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Snack1820 and data derived into: gq_eat_snack1820_DER. Please request those variables instead. 2 = yes
Categorical
Drink only snack btwn 10pm - 12am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a drink only snack between: 10pm - 12am E.g. drinks with some milk or sugar in; not low calorie drinks or water. This data is also captured with GQV1_D609dDrink or GQV3_D609dDrink. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Drink1820 and data derived into: gq_eat_drink1820_DER. Please request those variables instead. 2 = yes
Categorical
Main meal between 12am - 2am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a main meal between: 12am - 2am cooked dish e.g. meat with potatoes; pizza; lasagne; fish and chips; burgers; fried breakfast. This data is also captured with GQV1_D610aMain or GQV3_D610aMain. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Main2022 and data derived into: gq_eat_main2022_DER. Please request those variables instead. 2 = yes
Categorical
Light meal between 12am - 2am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a light meal between: 12am - 2am E.g. porridge; cereal; toast; sandwiches; soup; salad; omelette. This data is also captured with GQV1_D610bLight or GQV3_D610bLight. You should request that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Light2022 and data derived into: gq_eat_light2022_DER. Please request those variables instead. 2 = yes
Categorical
Snack between 12am - 2am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a snack between: 12am - 2am E.g. biscuit; cake; fruit; sweets; chocolate; crisps; nuts; ice cream. This data is also captured with GQV1_D610cSnack or GQV3_D610cSnack. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Snack2022 and data derived into: gq_eat_snack2022_DER. Please request those variables instead. 2 = yes
Categorical
Drink only snack between 12am - 2am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a drink only snack between: 12am - 2am E.g. drinks with some milk or sugar in; not low calorie drinks or water. This data is also captured with GQV1_D610dDrink or GQV3_D610dDrink. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Drink2022 and data derived into: gq_eat_drink2022_DER. Please request those variables instead. 2 = yes
Categorical
Main meal between 2am - 4am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a main meal between: 2am - 4am cooked dish e.g. meat with potatoes; pizza; lasagne; fish and chips; burgers; fried breakfast. This data is also captured with GQV1_D611aMain or GQV3_D611aMain. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Main2224 and data derived into: gq_eat_main2224_DER. Please request those variables instead. 2 = yes
Categorical
Light meal between 2am - 4am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a light meal between: 2am - 4am E.g. porridge; cereal; toast; sandwiches; soup; salad; omelette. This data is also captured with GQV1_D611bLight or GQV3_D611bLight. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Light2224 and data derived into: gq_eat_light2224_DER. Please request those variables instead. 2 = yes
Categorical
Snack between 2am - 4am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a snack between: 2am - 4am E.g. biscuit; cake; fruit; sweets; chocolate; crisps; nuts; ice cream. This data is also captured with GQV1_D611cSnack or GQV3_D611cSnack. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Snack2224 and data derived into: gq_eat_snack2224_DER. Please request those variables instead. 2 = yes
Categorical
Drink only snack between 2am - 4am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a drink only snack between: 2am - 4am E.g. drinks with some milk or sugar in; not low calorie drinks or water. This data is also captured with GQV1_D611dDrink or GQV3_D611dDrink. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Drink2224 and data derived into: gq_eat_drink2224_DER. Please request those variables instead. 2 = yes
Categorical
Main meal between 4am - 6am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a main meal between: 4am - 6am cooked dish e.g. meat with potatoes; pizza; lasagne; fish and chips; burgers; fried breakfast. This data is also captured with GQV1_D612aMain or GQV3_D612aMain. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Main2402 and data derived into: gq_eat_main2402_DER. Please request those variables instead. 2 = yes
Categorical
Light meal between 4am - 6am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a light meal between: 4am - 6am E.g. porridge; cereal; toast; sandwiches; soup; salad; omelette. This data is also captured with GQV1_D612bLight or GQV3_D612bLight. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Light2402 and data derived into: gq_eat_light2402_DER. Please request those variables instead. 2 = yes
Categorical
Snack between 4am - 6am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a snack between: 4am - 6am E.g. biscuit; cake; fruit; sweets; chocolate; crisps; nuts; ice cream. This data is also captured with GQV1_D612cSnack or GQV3_D612cSnack. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Snack2402 and data derived into: gq_eat_snack2402_DER. Please request those variables instead. 2 = yes
Categorical
Drink only snack between 4am - 6am
Phase 2 data. Questionnaire reads C11. Eating patterns: In the table below; describe the meals or snacks you usually eat during a 24hour period. Tick the boxes that best describe what you eat and when. You may tick more than one box per line. Had a drink only snack between: 4am - 6am E.g. drinks with some milk or sugar in; not low calorie drinks or water. This data is also captured with GQV1_D612dDrink or GQV3_D612dDrink. You should be given that data too. All phase 1 data from all 3 GenQs was merged into new variable: GQ_Eat_Drink2402 and data derived into: gq_eat_drink2402_DER. Please request those variables instead. 2 = yes
Categorical
Savoury snacks plus usual meals
Phase 2 data. Questionnaire reads C12. We are interested in how often you had snacks or drinks while watching TV in the last 4 weeks in addition to your usual meals. Only think of snacks in addition to your breakfast; lunch or dinner. Please tick one box only per line. In the last 4 weeks on average how often did you have the following snacks or drinks while watching TV in addition to your breakfast; lunch or dinner? Savoury snacks(crisps;salted nuts) 1 = None; 2 = 1-2 times a week; 3 = 3-4 times a week; 4 = 5-6 times a week; 5 = Once a day; 6 = 2 times a day; 7 = 3 times a day; 8 = 4 times a day; 9 = 5 times a day; 10 = More than 5 a day;
Categorical
Sweets cakes bisct plus usual meals
Phase 2 data. Questionnaire reads C12. We are interested in how often you had snacks or drinks while watching TV in the last 4 weeks in addition to your usual meals. Only think of snacks in addition to your breakfast; lunch or dinner. Please tick one box only per line. In the last 4 weeks on average how often did you have the following snacks or drinks while watching TV in addition to your breakfast; lunch or dinner? Sweets; chocolate bars; cakes; biscuits. 1 = None; 2 = 1-2 times a week; 3 = 3-4 times a week; 4 = 5-6 times a week; 5 = Once a day; 6 = 2 times a day; 7 = 3 times a day; 8 = 4 times a day; 9 = 5 times a day; 10 = More than 5 a day;
Categorical
Icecream chocolate plus usual meals
Phase 2 data. Questionnaire reads C12. We are interested in how often you had snacks or drinks while watching TV in the last 4 weeks in addition to your usual meals. Only think of snacks in addition to your breakfast; lunch or dinner. Please tick one box only per line. In the last 4 weeks on average how often did you have the following snacks or drinks while watching TV in addition to your breakfast; lunch or dinner? Ice cream; chocolate mousse. 1 = None; 2 = 1-2 times a week; 3 = 3-4 times a week; 4 = 5-6 times a week; 5 = Once a day; 6 = 2 times a day; 7 = 3 times a day; 8 = 4 times a day; 9 = 5 times a day; 10 = More than 5 a day;
Categorical
Yoghurt rice pudd plus usual meals
Phase 2 data. Questionnaire reads C12. We are interested in how often you had snacks or drinks while watching TV in the last 4 weeks in addition to your usual meals. Only think of snacks in addition to your breakfast; lunch or dinner. Please tick one box only per line. In the last 4 weeks on average how often did you have the following snacks or drinks while watching TV in addition to your breakfast; lunch or dinner? Yoghurt; rice pudding. 1 = None; 2 = 1-2 times a week; 3 = 3-4 times a week; 4 = 5-6 times a week; 5 = Once a day; 6 = 2 times a day; 7 = 3 times a day; 8 = 4 times a day; 9 = 5 times a day; 10 = More than 5 a day;
Categorical
Soda in addition to usual meals
Phase 2 data. Questionnaire reads C12. We are interested in how often you had snacks or drinks while watching TV in the last 4 weeks in addition to your usual meals. Only think of snacks in addition to your breakfast; lunch or dinner. Please tick one box only per line. In the last 4 weeks on average how often did you have the following snacks or drinks while watching TV in addition to your breakfast; lunch or dinner? Soda. 1 = None; 2 = 1-2 times a week; 3 = 3-4 times a week; 4 = 5-6 times a week; 5 = Once a day; 6 = 2 times a day; 7 = 3 times a day; 8 = 4 times a day; 9 = 5 times a day; 10 = More than 5 a day;
Categorical
Alcoholic drinks plus usual meals
Phase 2 data. Questionnaire reads C12. We are interested in how often you had snacks or drinks while watching TV in the last 4 weeks in addition to your usual meals. Only think of snacks in addition to your breakfast; lunch or dinner. Please tick one box only per line. In the last 4 weeks on average how often did you have the following snacks or drinks while watching TV in addition to your breakfast; lunch or dinner? Alcoholic drinks. 1 = None; 2 = 1-2 times a week; 3 = 3-4 times a week; 4 = 5-6 times a week; 5 = Once a day; 6 = 2 times a day; 7 = 3 times a day; 8 = 4 times a day; 9 = 5 times a day; 10 = More than 5 a day;
Categorical
Fruit juice plus usual meals
Phase 2 data. Questionnaire reads C12. We are interested in how often you had snacks or drinks while watching TV in the last 4 weeks in addition to your usual meals. Only think of snacks in addition to your breakfast; lunch or dinner. Please tick one box only per line. In the last 4 weeks on average how often did you have the following snacks or drinks while watching TV in addition to your breakfast; lunch or dinner? Fruit juice. 1 = None; 2 = 1-2 times a week; 3 = 3-4 times a week; 4 = 5-6 times a week; 5 = Once a day; 6 = 2 times a day; 7 = 3 times a day; 8 = 4 times a day; 9 = 5 times a day; 10 = More than 5 a day;
Categorical
Squash plus usual meals
Phase 2 data. Questionnaire reads C12. We are interested in how often you had snacks or drinks while watching TV in the last 4 weeks in addition to your usual meals. Only think of snacks in addition to your breakfast; lunch or dinner. Please tick one box only per line. In the last 4 weeks on average how often did you have the following snacks or drinks while watching TV in addition to your breakfast; lunch or dinner? Squash. 1 = None; 2 = 1-2 times a week; 3 = 3-4 times a week; 4 = 5-6 times a week; 5 = Once a day; 6 = 2 times a day; 7 = 3 times a day; 8 = 4 times a day; 9 = 5 times a day; 10 = More than 5 a day;
Categorical
Milk shake plus usual meals
Phase 2 data. Questionnaire reads C12. We are interested in how often you had snacks or drinks while watching TV in the last 4 weeks in addition to your usual meals. Only think of snacks in addition to your breakfast; lunch or dinner. Please tick one box only per line. In the last 4 weeks on average how often did you have the following snacks or drinks while watching TV in addition to your breakfast; lunch or dinner? Milk; milkshake; hot chocolate. 1 = None; 2 = 1-2 times a week; 3 = 3-4 times a week; 4 = 5-6 times a week; 5 = Once a day; 6 = 2 times a day; 7 = 3 times a day; 8 = 4 times a day; 9 = 5 times a day; 10 = More than 5 a day;
Categorical
Tea or coffee plus usual meals
Phase 2 data. Questionnaire reads C12. We are interested in how often you had snacks or drinks while watching TV in the last 4 weeks in addition to your usual meals. Only think of snacks in addition to your breakfast; lunch or dinner. Please tick one box only per line. In the last 4 weeks on average how often did you have the following snacks or drinks while watching TV in addition to your breakfast; lunch or dinner? Tea or coffee. 1 = None; 2 = 1-2 times a week; 3 = 3-4 times a week; 4 = 5-6 times a week; 5 = Once a day; 6 = 2 times a day; 7 = 3 times a day; 8 = 4 times a day; 9 = 5 times a day; 10 = More than 5 a day;
Categorical
Other snack splus usual meals
Phase 2 data. Questionnaire reads C12. We are interested in how often you had snacks or drinks while watching TV in the last 4 weeks in addition to your usual meals. Only think of snacks in addition to your breakfast; lunch or dinner. Please tick one box only per line. In the last 4 weeks on average how often did you have the following snacks or drinks while watching TV in addition to your breakfast; lunch or dinner? Other. 1 = None; 2 = 1-2 times a week; 3 = 3-4 times a week; 4 = 5-6 times a week; 5 = Once a day; 6 = 2 times a day; 7 = 3 times a day; 8 = 4 times a day; 9 = 5 times a day; 10 = More than 5 a day;
Categorical
Name of the other text
Phase 2 data. Questionnaire reads C12. We are interested in how often you had snacks or drinks while watching TV in the last 4 weeks in addition to your usual meals. Only think of snacks in addition to your breakfast; lunch or dinner. Please tick one box only per line. In the last 4 weeks on average how often did you have the following snacks or drinks while watching TV in addition to your breakfast; lunch or dinner? Other (text)
Text
Special diets: Weight watchers
Phase 2 data. Questionnaire reads C13. Special diets. Please tick to show if you are currently on any of the following special diets. Weight watchers. 1 = Less than 6 months; 2 = More than 6 months;
Categorical
Special diets: Slimming world
Phase 2 data. Questionnaire reads C13. Special diets. Please tick to show if you are currently on any of the following special diets. Slimming world. 1 = Less than 6 months; 2 = More than 6 months;
Categorical
Low fat diet
Phase 2 data. Questionnaire reads C13. Special diets. Please tick to show if you are currently on any of the following special diets. Low fat diet. 1 = Less than 6 months; 2 = More than 6 months;
Categorical
Low carbohydrate diet
Phase 2 data. Questionnaire reads C13. Special diets. Please tick to show if you are currently on any of the following special diets. Low carbohydrate diet eg Atkins diet.
Categorical
Vegetarian diet
Phase 2 data. Questionnaire reads C13. Special diets. Please tick to show if you are currently on any of the following special diets. Vegetarian. 1 = Less than 6 months; 2 = More than 6 months;
Categorical
Vegan diet
Phase 2 data. Questionnaire reads C13. Special diets. Please tick to show if you are currently on any of the following special diets. Vegan. 1 = Less than 6 months; 2 = More than 6 months;
Categorical
Kosher diet
Phase 2 data. Questionnaire reads C13. Special diets. Please tick to show if you are currently on any of the following special diets. Kosher. 1 = Less than 6 months; 2 = More than 6 months;
Categorical
Halal
Phase 2 data. Questionnaire reads C13. Special diets. Please tick to show if you are currently on any of the following special diets. Halal. 1 = Less than 6 months; 2 = More than 6 months;
Categorical
Other diet
Phase 2 data. Questionnaire reads C13. Special diets. Please tick to show if you are currently on any of the following special diets. Other. 1 = Less than 6 months; 2 = More than 6 months;
Categorical
Special diets: Jenny Craig
Phase 2 data. Questionnaire reads C13. Special diets. Please tick to show if you are currently on any of the following special diets. Jenny Craig. 1 = Less than 6 months; 2 = More than 6 months;
Categorical
Drank alcohol in the past 1 year
Phase 2 data. Questionnaire reads C1. During the past 1 year; how often did you drink alcoholic drinks of any kind? Please only tick one box. 1 = Never or rarely; 2 = About once a month; 3 = 1-2 times per week; 4 = 3-4 times per week; 5 = Almost every day; 6 = Every day;
Categorical
Alcohol consumption changed
Phase 2 data. Questionnaire reads C2. Has your current alcohol consumption changed significantly compared with that of some years ago? Please only tick one box. 1 = My consumption has increased a lot; 2 = My consumption has slightly increased; 3 = I currently consume a similar amount as before; 4 = My consumption has slightly decreased; 5 = My consumption has decreased a lot; 6 = In the past and at present I have been consuming little or no alcohol;
Categorical
Units alcohol consumed wkday beer
Phase 2 data. Questionnaire reads C3. In a typical week; how many units of alcohol do you consume during weekdays (Monday through Thursday) and weekends (Friday through Sunday)? With 1 unit equivalent to 1/2 pint of Beer; Lager; or cider. Number of units.
Real
Units alcohol consumed wkday wine
Phase 2 data. Questionnaire reads C3. In a typical week; how many units of alcohol do you consume during weekdays (Monday through Thursday) and weekends (Friday through Sunday)? With 1 unit equivalent to 1/2 glass of Wine. Number of units.
Real
Units alcohol consumedwkday spirits
Phase 2 data. Questionnaire reads C3. In a typical week; how many units of alcohol do you consume during weekdays (Monday through Thursday) and weekends (Friday through Sunday)? With 1 unit equivalent to 1 single measure of Spirits. Number of units.
Real
Units beer consumed wknd day
Phase 2 data. Questionnaire reads C3. In a typical week; how many units of alcohol do you consume during weekdays (Monday through Thursday) and weekends (Friday through Sunday)? With 1 unit equivalent to 1/2 pint of Beer; Lager; or cider. Number of units.
Real
Units wine consumed wknd day
Phase 2 data. Questionnaire reads C3. In a typical week; how many units of alcohol do you consume during weekdays (Monday through Thursday) and weekends (Friday through Sunday)? With 1 unit equivalent to 1/2 glass of Wine. Number of units.
Real
Units spirits consumed wknd day
Phase 2 data. Questionnaire reads C3. In a typical week; how many units of alcohol do you consume during weekdays (Monday through Thursday) and weekends (Friday through Sunday)? With 1 unit equivalent to 1 single measure of Spirits. Number of units.
Real
Units fortifiedwine consumed wkday
Phase 2 data. Questionnaire reads C3. In a typical week; how many units of alcohol do you consume during weekdays (Monday through Thursday) and weekends (Friday through Sunday)? Fortified wine (such as sherry Cinzano Campari) With 1 unit equivalent to 1 glass of sherry. Number of units.
Real
Breakfast frequency
Phase 2 data. Questionnaire reads C4. How often do you usually eat breakfast? 1 = Never or rarely; 2 = 1-2 times per week; 3 = 3-5 times per week; 4 = More than 5 times per week
Categorical
Units fortwine consumed wkndday
Phase 2 data. Questionnaire reads C3. In a typical week; how many units of alcohol do you consume during weekdays (Monday through Thursday) and weekends (Friday through Sunday)? Fortified wine (such as sherry Cinzano Campari) With 1 unit equivalent to 1 glass of sherry. Number of units.
Real
Home delivery or take-away meals
Phase 2 data. Questionnaire reads C5. When eating your main meal at home; how often do you usually eat the following: Home delivery or take-away meals; 1 = Never or rarely; 2 = 1-2 times per week; 3 = 3-5 times per week; 4 = More than 5 times per week
Categorical
Ready-made meals or prepared foods
Phase 2 data. Questionnaire reads C5. When eating your main meal at home; how often do you usually eat the following: Ready-made meals/prepared foods; 1 = Never or rarely; 2 = 1-2 times per week; 3 = 3-5 times per week; 4 = More than 5 times per week
Categorical
Home cooked meals
Phase 2 data. Questionnaire reads C5. When eating your main meal at home; how often do you usually eat the following: Home cooked meals; 1 = Never or rarely; 2 = 1-2 times per week; 3 = 3-5 times per week; 4 = More than 5 times per week
Categorical
Meal ate outside of home
Phase 2 data. Questionnaire reads C6. On average how often do you eat a meal outside of the home (restaurants; pubs; fast-food outlets; etc)? 1 = Less than once a week; 2 = Once a week; 3 = 2-4 times a week; 4 = 5-6 times a week; 5 = Once a day; 6 = More than once a day;
Categorical
Ate meal watching tv or video
Phase 2 data. Questionnaire reads C7. How often do you eat your meal while watching television or video? 1 = Less than once a week; 2 = Once a week; 3 = 2-4 times a week; 4 = 5-6 times a week; 5 = Once a day; 6 = More than once a day;
Categorical
Ate meal using PC or similar device
Phase 2 data. Questionnaire reads C8. How often do you eat your meal while using PC; tablet; smartphone or similar electronic device? 1 = Less than once a week; 2 = Once a week; 3 = 2-4 times a week; 4 = 5-6 times a week; 5 = Once a day; 6 = More than once a day;
Categorical
Eat snack foods watching TV
Phase 2 data. Questionnaire reads C9. Apart from meals how often do you eat snack foods while watching television? 1 = Never or rarely; 2 = Occasionally; 3 = Usually; 4 = Always;
Categorical
Derived Action taken after chest discomfort from walking
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Chest pain ever
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Chest discomfort from walking
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Chest discomfort after stopping
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Chest discomfort from walking uphill
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Weekday go to bed time
Phase 2 data. Questionnaire reads C15. Sleeping patterns. Think about what time you went to sleep and you got up on a typical day in the last 4 weeks. If you had variable sleeping patterns (eg you did shift work) please record the typical time you went to bed and got up on weekdays and on weekend days. Please use 24 hr clock format. At what time did you go to bed on a weekday? -1 = left blank;
Time
Weekday wake time
Phase 2 data. Questionnaire reads C15. Sleeping patterns. Think about what time you went to sleep and you got up on a typical day in the last 4 weeks. If you had variable sleeping patterns (eg you did shift work) please record the typical time you went to bed and got up on weekdays and on weekend days. Please use 24 hr clock format. At what time did you wake up on a weekday? -1 = left blank;
Time
Weekend day go to bed time
Phase 2 data. Questionnaire reads C15. Sleeping patterns. Think about what time you went to sleep and you got up on a typical day in the last 4 weeks. If you had variable sleeping patterns (eg you did shift work) please record the typical time you went to bed and got up on weekdays and on weekend days. Please use 24 hr clock format. At what time did you go to bed on a weekend day? -1 = left blank;
Time
Weekend day wake time
Phase 2 data. Questionnaire reads C15. Sleeping patterns. Think about what time you went to sleep and you got up on a typical day in the last 4 weeks. If you had variable sleeping patterns (eg you did shift work) please record the typical time you went to bed and got up on weekdays and on weekend days. Please use 24 hr clock format. At what time did you wake up on a weekend day? -1 = left blank;
Time
Journey to Work1 from
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
Mode of trsprt for journey to Wrk1
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. 1 = Walk; 2 = Cycle; 3 = Bus/train; 4 = Car/motorcycle
Categorical
Journey to Work1 to
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
Journey to Work2 from
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
Mode of trsprt for journey to Wrk2
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. 1 = Walk; 2 = Cycle; 3 = Bus/train; 4 = Car/motorcycle
Categorical
Journey to Work2 to
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
Journey to Work3 from
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
Mode of trsprt for journey to Wrk3
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. 1 = Walk; 2 = Cycle; 3 = Bus/train; 4 = Car/motorcycle
Categorical
Journey to Work3 to
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
Journey to Work4 from
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
Mode of trsprt for journey to Wrk4
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. 1 = Walk; 2 = Cycle; 3 = Bus/train; 4 = Car/motorcycle
Categorical
Journey to Work4 to
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
Time at work from
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
Time at work to
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
None
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
Return from Wrk1 mode of transport
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. 1 = Walk; 2 = Cycle; 3 = Bus/train; 4 = Car/motorcycle
Categorical
Time return from wrk1
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
None
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
Return from Wrk2 mode of transport
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. 1 = Walk; 2 = Cycle; 3 = Bus/train; 4 = Car/motorcycle
Categorical
Time return from wrk2
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
None
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
Return from Wrk3 mode of transport
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. 1 = Walk; 2 = Cycle; 3 = Bus/train; 4 = Car/motorcycle
Categorical
Time return from wrk3
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
None
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
Return from Wrk4 mode of transport
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. 1 = Walk; 2 = Cycle; 3 = Bus/train; 4 = Car/motorcycle
Categorical
Time return from wrk4
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. Time
Time
Do not travel direct to work
Phase 2 data. Questionnaire reads D16. Transportation/commuting patterns for work. Think about how you got to work on a typical day in the last 4 weeks. Which main mode(s) of transport did you use and what time did you start (different parts of) your journey to work? Similarly; think of your journey home which may or may not be the same sequence; just in reverse. Please use 24hr clock format; e.g. 08:30 and 16:30. If your usual journey home involves going vigorous intensity activity another location; include that in the table. 1 = I dont usually travel direct from work to home.
Categorical
Derived food tolerance to some foods
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
gq_diet_fast_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived gluten-free diet
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Special diet - Halal diet
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Special diet - Kosher diet
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived lacto-free diet
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Special diet - Low carbohydrate diet
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Special diet - Low fat diet
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Other special diets
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Diet w/o meat
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Special diet - Slimmers World diet
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Special diet - Vegan diet
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Special diet - Vegetarian diet
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Diet for wt manage/loss
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Special diet - Weight Watchers diet
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Overall health rating
Phase 2 data. Questionnaire reads Self-Perceived Health Status. Mark the box that best describes your answer. E1. Overall; how would you rate your health during the past 4 weeks? 1 = Excellent; 2 = Very good; 3 = Good; 4 = Fair; 5 = Poor; 6 = Very poor
Categorical
PA limited by health problems
Phase 2 data. Questionnaire reads Self-Perceived Health Status. Mark the box that best describes your answer. E2. During the past 4 weeks; how much did physical health problems limit your usual physical activities (walking; climbing stairs)? 1 = Not at all; 2 = Very little; 3 = Somewhat; 4 = Quite a lot; 5 = Could not do physical activities;
Categorical
Daily activities limited by health
Phase 2 data. Questionnaire reads Self-Perceived Health Status. Mark the box that best describes your answer. E3. During the past 4 weeks; how much difficulty did you have doing your daily work; both inside and outside the home; because of your physical health? 1 = Not at all; 2 = Very little; 3 = Somewhat; 4 = Quite a lot; 5 = Could not do daily work;
Categorical
Body pain
Phase 2 data. Questionnaire reads Self-Perceived Health Status. Mark the box that best describes your answer. E4. How much bodily pain have you had during the past 4 weeks? 1 = None; 2 = Very mild; 3 = Mild; 4 = Moderate; 5 = Severe; 6 = Very severe;
Categorical
Energy
Phase 2 data. Questionnaire reads Self-Perceived Health Status. Mark the box that best describes your answer. E5. During the past 4 weeks; how much energy did you have? 1 = Very much; 2 = Quite a bit; 3 = Some; 4 = A little; 5 = None;
Categorical
Social activities limited by health
Phase 2 data. Questionnaire reads Self-Perceived Health Status. Mark the box that best describes your answer. E6. During the past 4 weeks; how much did your physical health or emotional problems limit your usual social activities with family or friends? 1 = Not at all; 2 = Very little; 3 = Somewhat; 4 = Quite a lot; 5 = Could not do social activities;
Categorical
Emotional problems
Phase 2 data. Questionnaire reads Self-Perceived Health Status. Mark the box that best describes your answer. E7. During the past 4 weeks; how much have you been bothered by emotional problems (such as feeling anxious; depressed or irritable)? 1 = Not at all; 2 = Slightly; 3 = Moderately; 4 = Quite a lot; 5 = Extremely;
Categorical
Other activities limited by emotional problems
Phase 2 data. Questionnaire reads Self-Perceived Health Status. Mark the box that best describes your answer. E8. During the past 4 weeks; how much did personal or emotional problems keep you from doing your usual work; studies; or other daily activities? 1 = Not at all; 2 = Very little; 3 = Somewhat; 4 = Quite a lot; 5 = Could not do daily activities;
Categorical
Body outline yourself age 10
Phase 2 data. Questionnaire reads E9. Which of the diagrams shown below best depicts your body outline at a given age and that of your parents when they were middle aged? Yourself at Age 10. Image 1 slimmest = 1 to Image 9 fattest = 9
Real
Body outline yourself age 20
Phase 2 data. Questionnaire reads E9. Which of the diagrams shown below best depicts your body outline at a given age and that of your parents when they were middle aged? Yourself at Age 20. Image 1 slimmest = 1 to Image 9 fattest = 9
Real
Body outline yourself age 40
Phase 2 data. Questionnaire reads E9. Which of the diagrams shown below best depicts your body outline at a given age and that of your parents when they were middle aged? Yourself at Age 40. Image 1 slimmest = 1 to Image 9 fattest = 9
Real
Body outline yourself age current
Phase 2 data. Questionnaire reads E9. Which of the diagrams shown below best depicts your body outline at a given age and that of your parents when they were middle aged? Yourself Currently. Image 1 slimmest = 1 to Image 9 fattest = 9
Real
Body outline Fthr middle age
Phase 2 data. Questionnaire reads E9. Which of the diagrams shown below best depicts your body outline at a given age and that of your parents when they were middle aged? Father in middle age. Image 1 slimmest = 1 to Image 9 fattest = 9
Real
Weight at age 20 in Kg
Phase 2 data. Questionnaire reads E9. Approximately how much did you weigh when you were about 20 years old? In Kg
Real
Weight at age 20 in lbs
Phase 2 data. Questionnaire reads E9. Approximately how much did you weigh when you were about 20 years old? In lbs
Real
Weight at age 20 in Stone
Phase 2 data. Questionnaire reads E9. Approximately how much did you weigh when you were about 20 years old? In Stone
Real
Body outline Mthr middle age
Phase 2 data. Questionnaire reads E9. Which of the diagrams shown below best depicts your body outline at a given age and that of your parents when they were middle aged? Mother in middle age. Image 1 slimmest = 1 to Image 9 fattest = 9
Real
Derived How often eat out
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Drink only snack 2-4am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Drink only snack 4-6am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Drink only snack 6-8am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Drink only snack 8-10am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Drink only snack 10am-12pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Drink only snack 12-2pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Drink only snack 2-4pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Drink only snack 4-6pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Drink only snack 6-8pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Drink only snack 8-10pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Drink only snack 10-12am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Drink only snack 0-2am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Light meal 2-4am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Light meal 4-6am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Light meal 6-8am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Light meal 8-10am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Light meal 10am-12pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Light meal 12-2pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Light meal 2-4pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Light meal 4-6pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Light meal 6-8pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Light meal 8-10pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Light meal 10pm-12am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Light meal 0-2am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Main meal 2-4am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Main meal 4-6am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Main meal 6-8am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Main meal 8-10am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Main meal 10am-12pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Main meal 12-2pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Main meal 2-4pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Main meal 4-6pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Main meal 6-8pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Main meal 8-10pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Main meal 10pm-12am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Main meal 0-2am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Snack 2-4am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Snack 4-6am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Snack 6-8am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Snack 8-10am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Snack 10am-12pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Snack 12-2pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Snack 2-4pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Snack 4-6pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Snack 6-8pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Snack 8-10pm
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Snack 10pm-12am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Snack 0-2am
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Age finished full time education
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived A level qualification
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Completed apprenticeship
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived CSE qualification
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived University degree qualification
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived O level or GCSE qualification
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived HNC or NVQ qualification
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived HND or GNVQ qualification
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Matriculation qualification
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Other qualifications
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Secretarial College qualification
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived School Leaving Certificate
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Technical or C&G qualification
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Trade certificate qualification
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Number of people employed
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Occupation type
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Supervisory status without numbers
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Employment type with employee data
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Feel faint or dizzy
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
gq_hearttrouble_dr_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived How often eat home cooked meals
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Dr reported high blood pressure
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Treatment for high blood pressure
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Household income
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Job status - full time >30 h/wk
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Job status - house-keeping
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Job status - obtained new job
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Job status others
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Job status - part time <30 h/wk
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Job status - retired
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Job status - permanently sick
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Job status - temporarily sick
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Job status - unemployed
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Marital status
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived any current medication
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds are you taking any tablets or medicines at the moment? Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = yes; 3 = no; -1 = left blank;
Categorical
Derived ACE inhibitor
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - ACE inhibitor (eg perindopril; enalapril; lisinipril; ramipril). Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Any self-reported medications
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Any self-reported meds including unclassified meds: 1 - weight loss drugs (orlistat; xenital); 2 - drugs for smoking cessation; alcoholism; nasal discomfort; non-specific migraine; 3 - device for contraception; 4 - tamoxifen; zoledex; anastrozole; exemestane or other anti-cancer drugs; 5 - related to specific organs (eg thyroid; prostate; bladder; lung; eye; bone; skin; joint) unless noted on pain killers or autoimmune diseases. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Angiotensin receptor blocker
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Angio II receptor blocker (eg losartan; olmesartan; telmisartan; valsartan). Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Aspirin
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Aspirin. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -3 = yes for pain non-cardiac purpose; -1 = left blank;
Categorical
Derived Drugs for autoimmune diseases
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Drugs for an autoimmune disease (eg carbimazole; azathioprine; dovobet; fludrocortisone; hydroxychloroquine; methotrexate; sulfasalazine) including: 1 - gastro-intestinal conditions with a reason for Colitis or Coeliac disease; 2 - rheumatoid arthritis; psoriasis; systemic lupus erythematosus; 3 - multiple sclerosis; 4 - Addisons or Graves or Hashimotos diseases - not including non-specific arthritis; osteoarthritis; asthma; gout; irritable-bowel syndrome and other immunological diseases without autoimmunity. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Beta blocker
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Beta blocker (eg atenolol; bisoprolol; carvediol; levobunolol; emtoprolol; sotalol; propranolol) not including beta-blokers used as an eye drop. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -5 = yes for psychiatric symptoms rather than migraine; -3 = yes for migraine; -1 = left blank;
Categorical
Derived Drugs for irritable bowel syndrome or constipation or others
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Drugs related to bowel conditions (alverine; azathioprine; buscopan; lactulose ;lansoprazole; mebeverine; senna) including laxatives or IBS or others: marked if use of drugs for gastro-intestinal conditions indicated IBS; Colitis; Coeliac disease or Crohns disease. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Drugs acting on the central nervous system
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Any drugs acting on a central nervous system including 1 - pain killers; 2 - psychiatric disorders; 3 - acid reflax. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Anti-depressant for depression; mood; anxiety or stress
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Anti-depressant coded for depression anxiety stress panic attack (eg citalopram; dosulepin; duloxetine; escitalopram; fluoxetine; mirtazapine; paroxetine; prozac; seroxat; quetiapine; sertraline; venlafaxine; zopiclone). Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Any cardiovascular drugs except blood-clotting drug eg tranexamte
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Any cardiovascular drugs except blood-clotting drug (eg tranexamic acid) for menstrual blood loss. Broad categories are lipid-lowering drugs; ace inhibitors; ARB; beta blockers; diuretics; nitrates; Ca channele blockers; anticoagulants. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -5 = yes indicated for non-cardiac use (eg beta-blockers for migraine); -1 = left blank;
Categorical
Derived Diuretics
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Diuretics (eg frusemide; hydrochlorothiazide; indapamide; spironolactone; zestoretic) including diuretic drugs used for water retention - not including ones used as eye drop. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Anti-diabetic medications metformin for polycystic ovary syndrome
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Anti-diabetic meds (metformin) - all for polycystic ovary syndrome - participants should be free from diabetes at baseline. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Drugs for gastric conditions
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Drugs for gastric conditions (eg gaviscon; lansoprazole; omeprazole; ranitidine) including acid reflux; a heartburn symptom or others caused by a gastrointestinal side-effect of other drugs. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Herbal supplements including non-herbal ones eg ginko
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Herbal supplements including plant oils for menopausal symptoms or other specific conditions (eg black cohosh; primrose oil; St Johns wort) - also including non-herbal plant-origin supplements (ginko; garlic and others). Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Exogenous hormone including testosterone - not for endometriosis
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Exogenous hormone use (GQV1_A3HRT accounted for) (eg estradiol; elleste; climesse; climagest; sandrena; premarine; premique; progynova; tibolone; vagefem; provera; testosterone) 1 - including testosteron use among men; 2 - not including non-hormonal agents for menopausal conditions (drugs for osteoporosis ; psychiatric drugs ; St Johns Wort ; primrose oil ; black cohosh); 3 - not including exogenous hormone use for endometriosis or for excess menstual blood loss; 4 - including HRT requiring transdermal dosage. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; 3 = no self-reported; -1 = left blank;
Categorical
Derived Drugs against infection
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Drugs (eg flucoxacillin; lymecycline; aciclovir; metronidazole; amoxicillin ) against 1 - fungal infection including terbinafine; 2 - topical abnormality with use of lymecycline; minocycline; ocytetracycline; 3 - urinary tract infection; 4 - HIV. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Any lipid lowering drug including omega-3 PUFA as BNF defines
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Any lipid lowering drug (including omega-3 PUFA as BNF lists). Bile acid sequestrants are not included if use for a intestinal disorder was specified. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Nitrates including meds for transdermal dosage
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Nitrates (eg trinitrate; GTNspray; nicorandil) including meds for transdermal dosage - considered as a cardiac drug unless notified. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived NSAIDs for any purpose not including aspirin
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - NSAIDs for any purpose (eg celecoxib; diclofenac; etodolac; ibuprofen; meloxicam; naprosyn; omeprazole) 1 - not including aspirin (see gq_med_asp); 2 - not including topical ones (eg eumovate cream); 3 - coded in use of a gastrointestinal med against NSAID use. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Drugs for inflammation including NSAIDS antihistamine and others
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Drugs for inflammatory conditions (not including eczema) 1 - irritable bowel syndrome; crohn; coeliac disease and colitus; 2 - asthma; 3 - inflammatory arthritis; including gout; non-autoimmune diseases and autoimmune diseases; 4 - topical medicine if specifically lupus or psoriasis was noted; 5 -hay fever; allergy; epipen for anaphylaxis; 6 - use of NSAIDS; 7 - antihistamine drugs (eg promethazine; hydroxyzine; acrivastine; desloratadine; fexofenadine; levocetirizine; loratadine; mizolastine). Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Dietary supplements oils vitamins minerals for any reasons
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Dietary supplements (oils; vitamins; minerals) (eg iron; calcium; zinc; vitamin D). Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Oral contraceptive not including non-oral ones
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Oral contraceptives (eg cerazetta; cilest; depo; gedarel; loestrin; marvelon; micronor; ovranette; yasmin); 1 - not including non-oral contraception eg (implanon; mirena coil); 2 - including cerazette for any reasons; 3 - birth control interpreted as oral contraceptive use; 4 - not including contraceptive drugs used for endometriosis or abnormal menstruation. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -7 = not applicable/answered but undetermined; -1 = left blank;
Categorical
Derived NSAIDs or others used for pain
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - NSAIDs or others used for pain as gq_med_pain - including aspirin and beta-blocker used against migrane or for migraine profilaxis. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Any pain killers not classified as NSAIDs; aspirin; b-blockers
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Any pain killers not classified as NSAIDs or aspirin (eg paracetamol; almotriptan; eletriptan; frovatriptan; naratriptan; rizatriptan; sumatriptan; zolmitriptan; pizotifen) or beta-blockers (propranol used for migraine). Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Drugs to aid sleeping - not necessarily sleeping disorder
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Drugs to aid sleeping (etmazapam; mirtazapine; zopiclone) - mixed with a drug acting on central nervous system to suppress pain or other discomfort. Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
Derived Statin
Phase 2 Derived variables from General Questionnaire. Data collected at Patient clinical visit. Current self-reported meds - Statin (eg atorvastatin; pravastatin; rosuvastatin and simvastatin). Derived after cleaning and harmonisation from GQ_A2xCurrentMedsName_P2; GQ_A2xCurrentMedsDose_P2; GQ_A2xCurrentMedsReason_P2; GQ_A2xCurrentMedsBNFCode_P2 where x is one of the letters from a to h. 2 = Yes self-reported; -1 = left blank;
Categorical
gq_menstr_lastdate_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived Number of people in household
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived Occup Clerical and intermediate
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Occup Middle or junir managers
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Occup Modern professional
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Occup Routine manual and service occupations
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Occup Semi-routine manual and service occupations
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Occup Senior manager or administrators
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Occup Technical and craft
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Occup Traditional professional occupations
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Own a car or van
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Own house
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Any reason not to do PA
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Pregnancy status
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived How often eat ready meals
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Rent house
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Self perceived health - Emotional problems limiting daily activities
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Self perceived health - Emotional problems
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Self perceived health - Energy level
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Self perceived health - Self recorded health
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Self perceived health - Bodily pain
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Self perceived health - Physical Activity limited by health problems
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Selfperceivedhealth - Health/emotional issues impacting social activity
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Selfperceivedhealth - Difficult to do daily work due to health problems
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Age started smoking
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived Smoke currently daily or occasionally
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Smoking habits
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Smoking duration years
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived Ever smoked
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Smoke exposure grams/day
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived N cheroots smoked per day
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived N cigars per day
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived N cigarettes per day
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived Smoking pack-years N x years
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived Grams of tobacco per week
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived Year stopped smoking
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived How often eat take-away
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
gq_tvbedroom_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Derived How often drink alcohol while watching TV
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Meal while watching TV
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Fruit juice while watching TV
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Ice cream while watching TV
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Milk while watching TV
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Other snacks while watching TV
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Savoury snacks while watching TV
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Soda or coke while watching TV
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Squash while watching TV
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Sweets while watching TV
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Tea or coffee while watching TV
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
Derived Yoghurt while watching TV
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Categorical
gq_voicebroke_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
gq_walkunaided10mins_DER_p2
Data derived from Fenland Phase 2 General Questionnaire data. Data Dictionary entry not available - please contact Data management for more details.
Real
Calculated age of pt first visit
Phase 2 data. Calculated age of participant at first visit; rounded down to whole year.
Real
Alcohol Amount Consumption weekend
Phase 2 data. Alcohol consumption amount averaged per weekend day across fri-sat-sun. Please note: in phase 1 1 unit was defined as 1/2 pint of beer or 1 glass of wine or 1 single measure of spirits or 1 glass of sherry. For phase 2 the units were defined as 1/2 pint of beer or 1/2 glass of wine or 1 single measure of spirits or 1 glass of sherry. Derived from GenQ Qs by DM team JAVA script. Calculation: (Beer + Wine + Spirits+ Fort Wine)/3
Real
Alcohol amount consumption weekday
Phase 2 data. Alcohol consumption amount averaged per weekday across mon-tue-wed-thu. Derived from GenQ Qs by DM team JAVA script. Please note: in phase 1; 1 unit was defined as 1/2 pint of beer or 1 glass of wine or 1 single measure of spirits or 1 glass of sherry. For phase 2 the units were defined as 1/2 pint of beer or 1/2 glass of wine or 1 single measure of spirits or 1 glass of sherry. Calculation: (Beer + Wine + Spirits+ Fort Wine)/4
Real
Alcohol consumption frequency
Phase 2 data. Alcohol consumption frequency. Derived from GenQ Qs by DM team JAVA script. 1 = Occasional; 2 = 1-2/week; 3 = 3-4/week; 4 = Daily; 9 = not known; 0 = never;
Categorical
Alcohol Consumption weekend
Phase 2 data. Current Alcohol Consumption on fri-sat-sun History / Status. Derived from GenQ Qs by DM team JAVA script. If units of beer/wine/spirits and/or fortified wine = >0 then this is automatically adjusted to 4 = current; 0 = never; 1 = not current; 2 = ex; 3 = ever; 4 = current; 9 = not known;
Categorical
Alcohol History
Phase 2 data. Current Alcohol Consumption on mon-tue-wed-thu History / Status. Derived from GenQ Qs by DM team JAVA script. If units of beer/wine/spirits and/or fortified wine = >0 then this is automatically adjusted to 4 = current; 0 = never; 1 = not current; 2 = ex; 3 = ever; 4 = current; 9 = not known;
Categorical
Beer Drinking Status weekend
Phase 2 data. Current Beer Drinking Status on fri-sat-sun. Derived from GenQ Qs by DM team JAVA script. 1 = yes does drink beer; 9 = not known; 0 = no does not drink beer;
Categorical
Beer drinking status weekday
Phase 2 data. Current Beer Drinking Status on mon-tue-wed-thu. Derived from GenQ Qs by DM team JAVA script. 1 = yes does drink beer; 9 = not known; 0 = no does not drink beer;
Categorical
Fort Wine Drinking Status wknd
Phase 2 data. Current Fortified Wine Drinking Status on fri-sat-sun e.g.sherry. Derived from GenQ Qs by DM team JAVA script. 1 = yes does drink Fortified Wine; 9 = not known; 0 = no does not drink Fortified Wine;
Categorical
Fortified Wine drink status weekday
Phase 2 data. Current Fortified Wine Drinking Status on mon-tue-wed-thu e.g.sherry. Derived from GenQ Qs by DM team JAVA script. 1 = yes does drink Fortified Wine; 9 = not known; 0 = no does not drink Fortified Wine;
Categorical
Insulin CLEANED Comment
Heparin Insulin measurement CLEANED comment (on threshold).
Text
Insulin CLEANED
Heparin Insulin measurement CLEANED in pmol/l. Left blank if not measured (reason provided in Threshold variable). (note on threshold value provided in Comment variable). Lower threshold: no verified threshold available.
Real
Insulin CLEANED Threshold
Heparin Insulin measurement CLEANED Threshold.
Categorical
Cln variable: Leptin comment
Phase 2 data. Serum Leptin measurement CLEANED comment (on threshold).
Text
Cln variable: Leptin measurement
Phase 2 data. Phase 2 Serum Leptin measurement in ng/ml CLEANED. Left blank if not measured (reason provided in Threshold variable). (note on threshold value provided in Comment variable). Lower threshold: 0.1 -88.8 = measured but results below threshold value;
Real
Cln variable: Leptin threshold
Phase 2 data. Phase 2 Serum Leptin measurement CLEANED threshold. 1 = Average value; 2 = value less than threshold; 3 = Single value; -1 = Blank (not measured); -2 = sample problem; -3 = Interference; -4 = Unsuitable; -5 = Insufficient; -9 = Everything else; 0 = No sample;
Categorical
NEFA CLEANED Comment
Heparin NEFA measurement CLEANED comment (on threshold).
Text
NEFA CLEANED
Heparin NEFA measurement CLEANED in umol/l. Left blank if not measured (reason provided in Threshold variable). (note on threshold value provided in Comment variable). Lower threshold: 50.
Real
NEFA CLEANED Threshold
Heparin NEFA measurement CLEANED Threshold.
Categorical
Smoking Amount in grams
Phase 2 data. Current Smoking Amount in grams equivalents either cigarettes pipes or cigars. Derived from GenQ Qs by DM team JAVA script. Rules: 1 cigarette = 1.25 g. 1 cheroot = 2 cigarettes 1 cigar = 3 cigarettes. Calculation: CIGARETTES*1.25 + CHEROOTS*2*1.25 + CIGARS*3*1.25 + TOBACCO/7
Real
Smoking Amount in cigarettes
Phase 2 data. Current Smoking Amount in cigarette equivalents. Derived from GenQ Qs by DM team JAVA script. Rules: 1 cigarette = 1.25 g. 1 cheroot = 2 cigarettes 1 cigar = 3 cigarettes. Calculation: CIGARETTES + CHEROOTS*2 + CIGARS*3
Integer
Smoking Duration
Phase 2 data. Derived from GenQ Qs by DM team JAVA script. Current number of Years of Smoking. Blank if not calculated. Has been replaced by gq_sm_dur_DER.
Integer
Smoking History
Phase 2 data. Current Smoking Consumption History / Status. Data derived by DM team from GenQ Qs on smoking If number of cigarettes/ cheroots/ cigars and/ or tobacco >0 then this category gets adjusted automatically. 1 = not current (never or ex); 2 =Ex (former); 3 =Ever (former or current); 4 = Current; 9 = Not known; 0 = never;
Categorical
Smoking type
Phase 2 data. Predominant smoking type(s). Derived from GenQ Qs by DM team JAVA script. 1 = cigarettes (chosen even if any of the other options has been ticked); 2 = cheroots-cigars (chosen if cigarettes = 0 and either cheroots or cigars >0); 9 = not known; -1 = non smoker (chosen if all of them are left blank or 0 AND smoking category = Never);
Categorical
Smoking Years Stopped
Phase 2 data. Derived from GenQ Qs by DM team JAVA script. Current number of Years Stopped Smoking. Blank if not calculated.
Integer
Spirits Drinking Status weekend
Phase 2 data. Current Spirits Drinking Status on fri-sat-sun. Derived from GenQ Qs by DM team JAVA script. 1 = yes does drink spirits; 9 = not known; 0 = no does not drink spirits;
Categorical
Spirits drinking status weekday
Phase 2 data. Current Spirits Drinking Status on mon-tue-wed-thu. Derived from GenQ Qs by DM team JAVA script. 1 = yes does drink spirits; 9 = not known; 0 = no does not drink spirits;
Categorical
Cln variable: Urine Albumin cmnt
Phase 2 data. Urine Albumin measurement CLEANED comment (on threshold).
Text
Cln variable: UrAlbumin measurement
Phase 2 data. Urine Albumin measurement CLEANED. Left blank if not measured (reason provided in Threshold variable). (note on threshold value provided in Comment variable). Lower threshold: 2.5. -88.8 = measured but results below threshold value;
Real
Cln variable: Ur Albumin threshold
Phase 2 data. Urine Albumin measurement CLEANED Threshold. 1 = Average value; 2 = value less than threshold; 3 = Single value; -1 = Blank (not measured); -2 = sample problem; -3 = Interference; -4 = Unsuitable; -5 = Insufficient; -9 = Everything else; 0 = No sample;
Categorical
Cln variable: UrCreatinine cmnt
Phase 2 data. Urine Creatinine measurement CLEANED comment (on threshold).
Text
Cln variable: Urine Creatinine
Phase 2 data. Urine Creatinine measurement CLEANED in mmol/l. Left blank if not measured (reason provided in Threshold variable). (note on threshold value provided in Comment variable). Lower threshold: none. -88.8 = measured but results below threshold value;
Real
Cln variable:UrCreatinine threshold
Phase 2 data. Urine Creatinine measurement CLEANED Threshold. 1 = Average value; 2 = value less than threshold; 3 = Single value; -1 = Blank (not measured); -2 = sample problem; -3 = Interference; -4 = Unsuitable; -5 = Insufficient; -9 = Everything else; 0 = No sample;
Categorical
G_VitaminCResult_Com
Vitamin C Result CLEANED comment (on threshold).
Text
G_VitaminCResult
Vitamin C Result CLEANED in umol/l. Left blank if not measured (reason provided in Threshold variable). (note on threshold value provided in Comment variable). Lower threshold: 10.
Real
G_VitaminCResult_Threshold
Vitamin C Result CLEANED Threshold.
Categorical
Wine Drinking Status weekend
Phase 2 data. Current Wine Drinking Status on fri-sat-sun. Derived from GenQ Qs by DM team JAVA script. 1 = yes does drink wine; 9 = not known; 0 = no does not drink wine;
Categorical
Wine drinking status weekday
Phase 2 data. Current Wine Drinking Status on mon-tue-wed-thu. Derived from GenQ Qs by DM team JAVA script. 1 = yes does drink wine; 9 = not known; 0 = no does not drink wine;
Categorical
Hand Grip Exclusion Check
Phase 2 data. Hand grip safety check done before hand grip test?. 0 = no; 1 = yes;
Categorical
Hba1C0 MM
Phase 2 data. Hba1C measurement taken at 0 minutes in mmol (IFCC output). Participants will either have Hba1C0_MM or Hba1C0_PC depending on when they are tested earlier on in the study the lab measured Hba1C0 in percentage
Real
Hba1C0 in percentage
Phase 2 data. Hba1C measurement taken at 0 minutes as a percentage (DCCT output) . Participants will either have Hba1C0_MM or Hba1C0_PC depending on when they are tested (earlier on in the study the lab measured Hba1C0 in percentage
Real
HDL 0 minutes
Phase 2 data. Serum HDL cholestrol measurement taken at 0 minutes in mmol/l
Real
Cln variable: Heavy gardening hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Digging shovelling or chopping wood. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Heavy gardening hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Digging shovelling or chopping wood. -1 = left blank. DO NOT USE THIS VARIABLE. Use HeavyGardeningHr_CLEAN_P2 instead.
Real
Cln variable: Heavy gardening min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Digging shovelling or chopping wood. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Heavy gardening min
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Digging shovelling or chopping wood. -1 = left blank. DO NOT USE THIS VARIABLE. Use HeavyGardeningMin_CLEAN_P2 instead.
Real
Cln variable: Heavy Gardening
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Heavy Gardening - Digging shovelling or chopping wood. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Heavy gardening
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Digging shovelling or chopping wood. DO NOT USE THIS VARIABLE. Use HeavyGardening_CLEAN_P2 instead.
Real
Heavy Gardening
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Heavy Gardening - Digging shovelling or chopping wood. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
None
Phase 2 data. Hemocue glucose measurement taken at 120 minutes. mmol/l
Real
None
Phase 2 data. Third Hemocue glucose measurement taken at 0 minutes. mmol/l
Real
Hemocue Used
Phase 2 data. Indication whether or not a hemocue test was used 0 = no; -1 = yes;
Categorical
Land use mix P2
Phase 2 data: Herfindahl-Hirschman Index: A measure of how mixed the land uses in a neighbourhood are. There were 5 possible land uses contained in a neighbourhood; including residential; commercial; institutional/governmental; recreational and mixed landuses. (Range: 0 to 10000; 10000=least mixed; 0=most mixed) HHI = Sk(pk*100)^2 p is the proportion of land area devoted to the specific land use (k) in each buffer. As for the LUM entropy score; the proportions (pk) were calculated as the land area devoted to a specific land use divided by the total area of walkable land uses in each buffer. Note: LUM=10;000 (i.e. no mix) if none or only one of the relevant land uses fell into the buffer. Data Source: OS MasterMap Topography Layer Data (December 2016) AddressBase Premium Data (OS Managed GB Set)
Real
Home postcode
Phase 2 data. Questionnaire reads D12. What is the postcode for your home address? Data as entered by the participant. -1 = left blank
Text
Home domain AEE
Phase 2 data. Derived with method 2. Home domain activity energy expenditure net METhrs/d
Real
Uniuqe value for home postcode district
Phase 2 data. Random unique value for home postcode district in Phase 2 data. Duplicate values indicate that home postcode is in the same postcode district (i.e. that participants are clustered within districts). -1 is missing home postcode
Integer
Home domain energy expenditure
Phase 2 data. Derived with method 2. Home domain energy expenditure METhrs/d
Real
Participant postcode
Phase 2 data. Participant postcode phase 2 is valid and lives within the study area of Cambridgeshire (1=yes; 2=no; -9=missing as participant declined to participate)
Categorical
Home domain PAEE
Phase 2 data. Derived with method 2. Home domain activity energy expenditure kJ/kg/d
Real
Unique value for home postcode sector
Phase 2 data. Random unique value for home postcode sector in Phase 2 data. Duplicate values indicate that home postcode is in the same postcode sector (i.e. that participants are clustered within sectors). -1 is missing home postcode
Integer
Cnt of supermarkets 1 mile Pts home
Phase 2 data. Count of supermarkets within a 1 mile Eucladian distance of participants' home Fenland phase 2 (-9 = missing)
Integer
Cnt of takeaways 1 mile Pts home
Phase 2 data. Count of takeaways within a 1 mile Eucladian distance of participants' home Fenland phase 2 (-9 = missing)
Integer
Cln variable: Horse riding hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Horse riding. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Horse riding hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Horse riding. -1 = left blank. DO NOT USE THIS VARIABLE. Use HorseBasedHr_CLEAN_P2 instead.
Real
Cln variable: Horse riding min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Horse riding. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Horse riding min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Horse riding. -1 = left blank. DO NOT USE THIS VARIABLE. Use HorseBasedMin_CLEAN_P2 instead.
Real
Cln variable: Horse riding
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Horse riding. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Horse riding
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Horse riding. DO NOT USE THIS VARIABLE. Use HorseBased_CLEAN_P2 instead.
Real
Horse riding
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Horse riding. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Pt relocated home postcode
Phase 2 data. Participant relocated as home postcode differed between phases 1 and 2 (-9 = missing; 1 = not relocated 2 = relocated)
Categorical
HR Actiheart Entered
Phase 2 data. Heart Rate and Achtiheart data entered? 0 = no; 1 = yes;
Categorical
Cln variable: Hunting hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Hunting shooting fishing. Error codes cleand by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Hunting Shooting Fishing hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Fishing. -1 = left blank. DO NOT USE THIS VARIABLE. Use HuntingShootingFishingHr_CLEAN_P2 instead.
Real
Cln variable: Hunting min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Hunting shooting fishing. Error codes cleand by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Hunting Shooting Fishing min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Fishing. -1 = left blank. DO NOT USE THIS VARIABLE. Use HuntingShootingFishingMin_CLEAN_P2 instead.
Real
Cln variable: Hunting
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Hunting shooting fishing. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Hunting Shooting Fishing
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Fishing. DO NOT USE THIS VARIABLE. Use HuntingShootingFishing_CLEAN_P2 instead.
Real
Fishing
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Fishing. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Hybridization control scale factor
Phase 2 data. Hybridization control scale factor
Real
Cln variable: Ice-Skating hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Ice-Skating. Error codes cleand by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Ice or roller skating hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Ice-Skating. -1 = left blank.DO NOT USE THIS VARIABLE. Use iceSkatingHr_CLEAN_P2 instead.
Real
Cln variable: Ice-Skating min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Ice-Skating. Error codes cleand by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Ice or roller skating min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Ice-Skating. -1 = left blank.DO NOT USE THIS VARIABLE. Use iceSkatingMin_CLEAN_P2 instead.
Real
Cln variable: Ice-Skating
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Ice-Skating. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Ice or roller skating
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Ice or roller skating. DO NOT USE THIS VARIABLE. Use iceSkating_CLEAN_P2 instead.
Real
Ice-Skating
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Ice-Skating. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
iDEXA Height measurement
Phase 2 data. Height measurement in centimetres. Raw data from DEXA Lunar Prodigy reprocessed with iDEXA software. Calculation and or check: Direct comparison with study support data.
Real
iDEXA Weight measurement
Phase 2 data. Weight measurement in kilograms. Raw data from DEXA Lunar Prodigy reprocessed with iDEXA software. Calculation and or check: Direct comparison with study support data.
Real
iDEXA App lean mass
Phase 2 data. Data derived by data management team by adding up data for AD15i_iDEXA_arms_lean_mass and AD39i_iDEXA_legs_lean_mass and rounding to 2 decimals.
Integer
iDEXA Periph fat mass
Phase 2 data. Data derived by data management team by adding up data for AD14i_iDEXA_arms_fat_mass and AD38i_iDEXA_legs_fat_mass and rounding to 2 decimals.
Integer
IMD_decile
Phase 2 data. IMD decile is England wide deprivation deciles attributed to their postcode. Decile 1 is most deprived.
Categorical
IMD_rank
Phase 2 data. IMD rank is the England-wide ranking of the LSOA in which each postcode is located; where a lower rank is more deprived (i.e. 1 is most deprived). This variable would allow anyone accessing the data to create their own relative measure of deprivation (e.g. quintiles) within the Fenland cohort.
Real
IMD work Easting
Phase 2 data. Easting for phase 2 work postcode based on Work_postcode_cleaned_P2
Real
IMD work Northing
Phase 2 data. Northing for phase 2 work postcode based on Work_postcode_cleaned_P2
Real
Insulin Raw
Phase 2 data. Heparin biomarker Insulin measurement in pmol/l. Raw data; Cleaned data provide in variable G_Insulin with x_Threshold and x_Com variables provided for clarification. Lower threshold: none. Test date is the date of visit for Fenland Phase 2 data.
Real
Int24 food survey Alcohol(g)
Phase 2 data. Intake 24 Food Intake survey - Alcohol (g)
Real
Int24 food survey food brand
Phase 2 data. Intake 24 Food Intake survey brand. Asda; Tesco; Other; N/A
Text
Int24 food survey Calcium(mg)
Phase 2 data. Intake 24 Food Intake survey - Calcium (mg)
Real
Int24 food survey Carbohydrate(g)
Phase 2 data. Intake 24 Food Intake survey - Carbohydrate (g)
Real
Int24 food survey Cholesterol(mg)
Phase 2 data. Intake 24 Food Intake survey - Cholesterol (mg)
Real
Int24 food survey Energy(kcal)
Phase 2 data. Intake 24 Food Intake survey - Energy (kcal)
Real
Int24 food survey Energy(kj)
Phase 2 data. Intake 24 Food Intake survey - Energy (kj)
Real
Int24 food survey Fat(g)
Phase 2 data. Intake 24 Food Intake survey - Fat (g)
Real
Int24 food survey Folate(µg)
Phase 2 data. Intake 24 Food Intake survey - Folate (µg)
Real
Int24 food survey food desc En
Phase 2 data. Intake 24 Food Intake survey food description in English
Text
Int24 food surv food desc local
Phase 2 data. Intake 24 Food Intake survey food description in the local language
Text
Int24 food survey food group code
Phase 2 data. Intake 24 Food Intake survey food group code. 2 = ; 4 = ; etc
Text
Int24 food surv food group desc En
Phase 2 data. Intake 24 Food Intake survey food group description in English
Text
Int24 food surv foodgrp desc local
Phase 2 data. Intake 24 Food Intake survey food group description in the local language
Text
Int24 food survey food ID
Phase 2 data. Intake 24 Food Intake survey food ID. 1 = ; 2 = ; 3 = ; 4 = ; 5 = ; 6 = ; 7 = ; 8 = ; 9 = ; 10 = ;
Real
Int24 food survey food code
Phase 2 data. Intake 24 Food Intake survey food code. Lookup table
Text
Int24 food survey Iron(mg)
Phase 2 data. Intake 24 Food Intake survey - Iron (mg)
Real
Int24 food survey food leftovers
Phase 2 data. Intake 24 Food Intake survey leftovers after meal?
Text
Int24 food surv food leftoversimage
Phase 2 data. Intake 24 Food Intake survey meal leftovers image name
Text
Int24 food survey Meal ID
Phase 2 data. Intake 24 Food Intake survey meal ID. 1 = ; 2 = ; 3 = ; 4 = ; 5 = ; 6 = ;
Real
Int24 food survey Meal name
Phase 2 data. Intake 24 Food Intake survey meal name.Choices are Afternoon snack or drink; biscuit; Biscuit; Breakfast; drink; Early snack or drink; Evening meal; evening snack or drink; Late snack or drink;
Text
Int24 food survey food desc missing
Phase 2 data. Intake 24 Food Intake survey - description of foods reported as missing. This is an optional free text field completed by participant if they report a missing food
Text
Int24 food survey amt eaten missing
Phase 2 data. Intake 24 Food Intake survey - amount eaten of foods reported as missing. This is an optional free text field completed by participant if they report a missing food. Note: we are aware that the description does not match the Field Name for this variable but the Description is correct
Text
Int24 food survey missing methods
Phase 2 data. Intake 24 Food Intake survey - cooking method of foods reported as missing. This is an optional free text field completed by participant if they report a missing food. Note: we are aware that the description does not match the Field Name for this variable but the Description is correct
Text
Int24 food survey Non-milk
Phase 2 data. Intake 24 Food Intake survey - Non-milk extrinsic sugars (g)
Real
Int24 food surv nutrient table code
Phase 2 data. Intake 24 Food Intake survey nutrient table code from nutrient lookup table recorded in INT24_nutrient_table_code
Text
Int24 food surv nutrient table name
Phase 2 data. Intake 24 Food Intake survey nutrient table name used to lookup Nutrients. NDNS only option available
Text
Int24 food survey food portion size
Phase 2 data. Intake 24 Food Intake survey meal portion size in g/ml
Real
Int24 food survey Protein(g)
Phase 2 data. Intake 24 Food Intake survey - Protein (g)
Real
Int24 food survey food ready meal
Phase 2 data. Intake 24 Food Intake survey ready meal? Yes or no
Text
Int24 food survey reasonable amount
Phase 2 data. Intake 24 Food Intake survey. Reasonable amount? Yes or no
Text
Int24 food survey Saturated fatty
Phase 2 data. Intake 24 Food Intake survey - Saturated fatty acids (g)
Real
Int24 food survey search term
Phase 2 data. Intake 24 Food Intake survey search term. Search term as entered by participant
Text
Int24 food survey Selenium(µg)
Phase 2 data. Intake 24 Food Intake survey - Selenium (µg)
Real
Int24 food surv food serving image
Phase 2 data. Intake 24 Food Intake survey food serving image
Text
Int24 food survey food serving size
Phase 2 data. Intake 24 Food Intake survey food servig size in g/ml
Real
Int24 food survey Sodium(mg)
Phase 2 data. Intake 24 Food Intake survey - Sodium (mg)
Real
Int24 food survey start time
Phase 2 data. Intake 24 Food Intake survey start time
Time
Int24 food surv submission time
Phase 2 data. Intake 24 Food Intake survey submssion time
Time
Survey ID for the Intake24 recall
Phase 2 data. A unique identifier for the Intake24 recall
Text
Int24 food surv completion time
Phase 2 data. Intake 24 Food Intake survey time taken to complete survey
Text
Int24 food survey Total sugars(g)
Phase 2 data. Intake 24 Food Intake survey - Total sugars (g)
Real
Int24 food survey Vitamin A(µg)
Phase 2 data. Intake 24 Food Intake survey - Vitamin A (µg)
Real
Int24 food survey Vitamin C(mg)
Phase 2 data. Intake 24 Food Intake survey - Vitamin C (mg)
Real
Int24 food survey Vitamin D(µg)
Phase 2 data. Intake 24 Food Intake survey - Vitamin D (µg)
Real
Int24 food survey Vitamin E(mg)
Phase 2 data. Intake 24 Food Intake survey - Vitamin E (mg)
Real
Int24 food survey Zinc(mg)
Phase 2 data. Intake 24 Food Intake survey - Zinc (mg)
Real
Cln variable: Jogging hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Jogging. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Jogging hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Jogging. -1 = left blank. DO NOT USE THIS VARIABLE. Use jogHr_CLEAN_P2 instead.
Real
Cln variable: Jogging min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Jogging. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Jogging min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Jogging. -1 = left blank. DO NOT USE THIS VARIABLE. Use jogMin_CLEAN_P2 instead.
Real
Cln variable: Jogging
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Jogging. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Jogging
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Jogging. DO NOT USE THIS VARIABLE. Use jog_CLEAN_P2 instead.
Real
Jogging
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Jogging. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Junction density P2
Phase 2 data: The number of three-or-more way intersections falling inside of the 800-metre street network buffers divided by the area of the buffer (km2): Data Source 2016 OS MasterMap Integrated Transport Network Layer
Real
LDL 0 minutes
Phase 2 data. Serum LDL cholestrol (calculated) at 0 minutes in mmol/l
Real
Leisure domain AEE
Phase 2 data. Derived with method 2. Leisure domain activity energy expenditure net METhrs/d
Real
Leisure domain energy expenditure
Phase 2 data. Derived with method 2. Leisure domain energy expenditure METhrs/d
Real
Leisure domain PAEE
Phase 2 data. Derived with method 2. Leisure domain activity energy expenditure kJ/kg/d
Real
Serum Leptin RAW
Phase 2 data. Leptin measurement for phase 2 sample. Only has data for 10 samples which were part of the PPARA set. Serum biomarker Leptin measurement RAW in ng/ml. Raw data; cleaned data provided in variable G_Leptin with x_Threshold and x_Com variables provided for clarification.
Real
lipid_lowering
Phase 2 data. Binary variable indicating whether a drug from the lipid lowering agent class was prescribed. 0: No 1: Yes
Categorical
Liver Scan Done
Phase 2 data. Liver scan done? Data from study database. Please note this variable is not complete as it was not available at the start of the study and data should not be used for analysis. 1 = yes; 0 = no;
Categorical
Liver Score Taken
Phase 2 data. Liver Score Taken? From Study Database. Do not release. Use liver score variables from Anthro team 0 = no; 1 = yes;
Categorical
Land use mix P2
Phase 2 data: The Shannon Entropy Index: A measure of how mixed land uses most relevant for PA are in a neighbourhood (Range: 0 to 1; 1= most mixed; 0=least mixed) LUM=(-1) Sk(pklnpk)/ln N p is the proportion of land area devoted to the specific land use (k) in each buffer divided by lnN N is the number of land uses under consideration. In this case N=5 (i.e. residential; commercial; institutional/governmental; recreational and mixed areas) The proportions (pk) were calculated as the land area devoted to a specific land use divided by the total area of walkable land uses in each buffer. Note: LUM=0 (i.e.; no mix) if none or only one of the relevant land uses fell into the buffer. Data Source: OS MasterMap Topography Layer Data (December 2016) AddressBase Premium Data (OS Managed GB Set)
Real
Max obs HR during treadmill test
Phase 2 data. Maximum observed Heart rate during treadmill test. (Highest value observed during treadmill test).
Real
None
Phase 2 data. Any comments which are relevant to measurement data such as weight smoking alcohol intake waist and hip measurements.
Text
Measurement entered
Phase 2 data. Measurements entered? Data from study database.
Categorical
Savoury pies
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Liver pate liver sausage
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Fried fish in batter
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Fish Fingers fish cakes
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Other white fish fresh or frozen
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Oily fish fresh or canned
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Shellfish eg crab prawns mussels
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Fish Roe taramasalata
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Beef roast steak mince stew or casserole
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Beefburgers
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Pork roast chops stew or slices
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Lambs roast chops or stew
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Chicken or other poultry
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Bacon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Ham
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Corned Beef Luncheon meats
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Sausages
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Cln variable: Media weekday post6pm
Phase 2 data. Hours of TV DVD or video watched per day on a weekday after 6 pm. Average over the last 4 weeks. Error codes cleaned by DM team with this rule: RELATIVE. And then -10 errors cleaned by PA team.
Real
Hrs Media viewed weekday post 6pm
Phase 2 data. Questionnaire reads D2. TV; DVD or video viewing. Hours of TV DVD or video watched per day on a weekday after 6 pm. Average over the last 4 weeks. DO NOT USE THIS VARIABLE. Use Mediaweekdaypost6pm_CLEAN_P2 instead. 1 = none; 2 = less than 1 hr a day; 3 = 1 to 2 hrs a day; 4 = 2 to 3 hrs a day; 5 = 3 to 4 hrs a day; 6 = more than 4 hrs a day;
Categorical
Cln variable: Media weekday pre6pm
Phase 2 data. Hours of TV DVD or video watched per day on a weekday before 6 pm. Average over the last 4 weeks. Error codes cleaned by DM team with this rule: RELATIVE. And then -10 errors cleaned by PA team.
Real
Hrs Media viewed weekday pre 6pm
Phase 2 data. Questionnaire reads D2. TV; DVD or video viewing. Hours of TV DVD or video watched per day on a weekday before 6 pm. Average over the last 4 weeks. DO NOT USE THIS VARIABLE. Use Mediaweekdaypre6pm_CLEAN_P2 instead. 1 = none; 2 = less than 1 hr a day; 3 = 1 to 2 hrs a day; 4 = 2 to 3 hrs a day; 5 = 3 to 4 hrs a day; 6 = more than 4 hrs a day;
Categorical
Cln variable: Media weekend post6pm
Phase 2 data. Hours of TV DVD or video watched per day on a weekend after 6 pm. Average over the last 4 weeks. Error codes cleaned by DM team with this rule: RELATIVE. And then -10 errors cleaned by PA team.
Real
Hrs Media viewed weekend post 6pm
Phase 2 data. Questionnaire reads D2. TV; DVD or video viewing. Hours of TV DVD or video watched per day on a weekend after 6 pm. Average over the last 4 weeks. DO NOT USE THIS VARIABLE. Use Mediaweekendpost6pm_CLEAN_P2 instead. 1 = none; 2 = less than 1 hr a day; 3 = 1 to 2 hrs a day; 4 = 2 to 3 hrs a day; 5 = 3 to 4 hrs a day; 6 = more than 4 hrs a day;
Categorical
Cln variable: Media weekend pre6pm
Phase 2 data. Hours of TV DVD or video watched per day on a weekend before 6 pm. Average over the last 4 weeks. Error codes cleaned by DM team with this rule: RELATIVE. And then -10 errors cleaned by PA team.
Real
Hrs Media viewed weekend pre 6pm
Phase 2 data. Questionnaire reads D2. TV; DVD or video viewing. Hours of TV DVD or video watched per day on a weekend before 6 pm. Average over the last 4 weeks. DO NOT USE THIS VARIABLE. Use Mediaweekendpre6pm_CLEAN_P2 instead. 1 = none; 2 = less than 1 hr a day; 3 = 1 to 2 hrs a day; 4 = 2 to 3 hrs a day; 5 = 3 to 4 hrs a day; 6 = more than 4 hrs a day;
Categorical
metformin
Phase 2 data. Binary variable indicating whether a drug from the metforminr class was prescribed. 0: No 1: Yes
Categorical
Time spent at moderate intensity activity work not inc
Phase 2 data. Derived with method 2. Time spent at moderate intensity activity; No work and no other acts hrs/d
Real
Time spent at moderate intensity activity work inc
Phase 2 data. Derived with method 2. Time spent at moderate intensity activity; Work inc but no other acts hrs/d
Real
Cln variable: Moving the lawn hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Mowing the lawn. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Mowing hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Mowing the lawn. -1 = left blank. DO NOT USE THIS VARIABLE. Use mowingHr_CLEAN_P2 instead.
Real
Cln variable: Moving the lawn min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Mowing the lawn. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Mowing min
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Mowing the lawn. -1 = left blank. DO NOT USE THIS VARIABLE. Use mowingMin_CLEAN_P2 instead.
Real
Cln variable: Moving the lawn
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Mowing the lawn.Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Mowing
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Mowing the lawn. DO NOT USE THIS VARIABLE. Use mowing_CLEAN_P2 instead.
Real
Mowing the lawn
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Mowing the lawn. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Cln variable:Musical instrument hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Musical instrument playing or singing. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Musical instrument playing hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Musical Instrument Playing Or Singing. -1 = left blank. DO NOT USE THIS VARIABLE. Use musicalInstrumentSingingHr_CLEAN_P2 instead.
Real
Cln variable:Musical instrument min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Musical instrument playing or singing. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Musical instrument playing min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Musical Instrument Playing Or Singing. -1 = left blank. DO NOT USE THIS VARIABLE. Use musicalInstrumentSingingMin_CLEAN_P2 instead.
Real
Cln variable: Musical instrument
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Musical instrument playing or singing. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Musical instrument playing
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Musical instrument playing or singing. DO NOT USE THIS VARIABLE. Use musicalInstrumentSinging_CLEAN_P2 instead.
Real
Musical Instrument Playing
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Musical Instrument Playing Or Singing. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Time spent moderate vigorous intensities wrk not inc
Phase 2 data. Derived with method 2. Time spent at mod+vig intensities; No work and no other acts hrs/d
Real
Time spent at moderate vigorous intensities work inc
Phase 2 data. Derived with method 2. Time spent at mod+vig intensities; Work inc but no other acts hrs/d
Real
NEFA Raw
Phase 2 data. Heparin biomarker NEFA measurement RAW in umol/l. Raw data; cleaned data provided in variable G_NEFA with x_Threshold and x_Com variables provided for clarification.
Real
Home network dist 5 supermarket p2
Home average network distance to five closest supermarkets in phase 2
Integer
Home network dist 5 takeaway p2
Home average network distance to five closest takeaways in phase 2
Integer
Home network dist closest supermarket p2
Home network distance to closest supermarkets in phase 2
Integer
Home network distance closest takeaway p2
Home network distance to closest takeaways in phase 2
Integer
Work network dist 5 supermarket p2
Work average network distance to five closest supermarkets in phase 2
Integer
Work network dist 5 takeaway p2
Work average network distance to five closest takeaways in phase 2
Integer
Work network dist closest supermarket p2
Work network distance to closest supermarkets in phase 2
Integer
Work network distance closest takeaway p2
Work network distance to closest takeaways in phase 2
Integer
Cln variable: Netball hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Netball Volleyball Or Basketball. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Netball volleyball basketball hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Netball Volleyball Or Basketball. -1 = left blank. DO NOT USE THIS VARIABLE. Use netVolleyBasketBallHr_CLEAN_P2 instead.
Real
Cln variable: Netball min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Netball Volleyball Or Basketball. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Netball volleyball basketball min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Netball Volleyball Or Basketball. -1 = left blank. DO NOT USE THIS VARIABLE. Use netVolleyBasketBallMin_CLEAN_P2 instead.
Real
Cln variable: Netball
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Netball Volleyball Or Basketball. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Netball volleyball basketball
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Netball volleyball or basketball. DO NOT USE THIS VARIABLE. Use netVolleyBasketBall_CLEAN_P2 instead.
Real
Netball Volleyball or Basketball
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Netball Volleyball Or Basketball. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Median signal normalization scale factor (0.005% mix)
Phase 2 data. Median signal normalization scale factor (0.005% mix)
Real
Median signal normalization scale factor (0.5% mix)
Phase 2 data. Median signal normalization scale factor (0.5% mix)
Real
Median signal normalization scale factor (20% mix)
Phase 2 data. Median signal normalization scale factor (20% mix)
Real
Beta blockers
Phase 2 data. Data as entered on Study database. Is volunteer on beta blockers? Use version in PA dataset instead 0 = no; 1 = yes;
Categorical
Cln variable: Other household hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Other household activities - eg hoovering. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Other household activities hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Other household activities (eg hoovering). -1 = left blank. DO NOT USE THIS VARIABLE. Use OtherHouseholdHr_CLEAN_P2 instead.
Real
Cln variable: Other household min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Other household activities - eg hoovering. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Other household activities min
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Other household activities (eg hoovering). -1 = left blank. DO NOT USE THIS VARIABLE. Use OtherHouseholdMin_CLEAN_P2 instead.
Real
Cln variable: Other household
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Other household activities - eg hoovering. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Other household activities
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Other household activities (eg hoovering). DO NOT USE THIS VARIABLE. Use OtherHousehold_CLEAN_P2 instead.
Real
Other household activities
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Other household activities (eg hoovering). Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
PAEE
Phase 2 data. Derived with method 2. Physical activity energy expenditure kJ/kg/d
Real
Overall neighbourhood physical activity environment (PAE) index P2
Phase 2 data: The sum of z-scores of junction density; the LUM entropy score; and population density variables. A higher score = higher walkability based on these three metrics
Real
Paid employment in the last 4 weeks
Phase 2 data. Phase 2 var derived by DMT from flipping Paidemployment_v2_P2. Please answer this section only if you have been in paid employment at any time during the last 4 weeks or you have done regular organised voluntary work. Have you been in employment during the last 4 weeks? 1 = no; 2 = yes; -1 = left blank; -5 = more than one selected;
Categorical
Employment in the last 4 weeks
Phase 2 data. Questionnaire reads D5. Have you been in employment in the last 4 weeks? DO NOT USE THIS VARIABLE. Use Paidemployment_P2 instead. 1 = no; 2 = yes;
Categorical
Avg daily PA Level AH free living
Phase 2 data. Average daily Physical Activity Level during AH free living (PAL). Average PAL score (TEE/REE) as calculated using Adult: Group Act/Group HR (Old) in commercial software for purpose of volunteer feedback ONLY. This should NOT be used for data analysis.
Real
Percentage of green space/park area P2
Phase 2 data: Percentage of area in neighbourhood buffer covered by green spaces/parks %: Data Source OS MasterMap Topography Layer Data (December 2016) AddressBase Premium Data (OS Managed GB Set)
Real
None
Phase 2 data. Fenland Phase 1 or Phase 2 sample from
Text
Sample Plate identifier
Phase 2 data. Sample Plate identifier
Integer
Date sample plate was run
Phase 2 data. Date sample plate was run
Text
Pizza
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Potatoes Boiled; mashed; instant or jacket
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Chips
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Roast potatoes
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Potato Salad
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
White Rice
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Brown Rice
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
White or green pasta
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Wholemeal Pasta
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Lasagne moussaka
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Population density P2
Phase 2 data: The number of usual residents in a postcode area divided by the area (km2) of that specific postcode area. Data Source: Office for National Statistics 2011 Census
Real
Rational sensible approach
Phase 2 data. Questionnaire reads 10. I tend to value and follow a rational sensible approach to things. 1 = Agree strongly; 2 = Somewhat agree; 3 = Somewhat disagree; 4 = Disagree strongly; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Often act without thinking
Phase 2 data. Questionnaire reads 11. When I am upset I often act without thinking. 1 = Agree strongly; 2 = Somewhat agree; 3 = Somewhat disagree; 4 = Disagree strongly; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Welcome new experiences
Phase 2 data. Questionnaire reads 12. I welcome new and exciting experiences and sensations even if they are a little frightening and unconventional. 1 = Agree strongly; 2 = Somewhat agree; 3 = Somewhat disagree; 4 = Disagree strongly; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Feeling rejected
Phase 2 data. Questionnaire reads 13. When I feel rejected I will often say things that I later regret. 1 = Agree strongly; 2 = Somewhat agree; 3 = Somewhat disagree; 4 = Disagree strongly; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Learn to fly an airplane
Phase 2 data. Questionnaire reads 14. I would like to learn to fly an airplane. 1 = Agree strongly; 2 = Somewhat agree; 3 = Somewhat disagree; 4 = Disagree strongly; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Sensation of skiing very fast
Phase 2 data. Questionnaire reads 15. I would enjoy the sensation of skiing very fast down a high mountain slope. 1 = Agree strongly; 2 = Somewhat agree; 3 = Somewhat disagree; 4 = Disagree strongly; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Think carefully before acting
Phase 2 data. Questionnaire reads 16. I usually think carefully before doing anything. 1 = Agree strongly; 2 = Somewhat agree; 3 = Somewhat disagree; 4 = Disagree strongly; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
None
Phase 2 data. Questionnaire reads 17. Which would you rather have? 1 = £45 in three days; 2 - £70 in three months; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Like to see things through
Phase 2 data. Questionnaire reads 1. I generally like to see things through to the end. 1 = Agree strongly; 2 = Somewhat agree; 3 = Somewhat disagree; 4 = Disagree strongly; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Thinking careful and purposeful
Phase 2 data. Questionnaire reads 2. My thinking is usually careful and purposeful. 1 = Agree strongly; 2 = Somewhat agree; 3 = Somewhat disagree; 4 = Disagree strongly; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Unfinished tasks really bother me
Phase 2 data. Questionnaire reads 3. Unfinished tasks really bother me. 1 = Agree strongly; 2 = Somewhat agree; 3 = Somewhat disagree; 4 = Disagree strongly; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Think things over
Phase 2 data. Questionnaire reads 4. I like to stop and think things over before I do them. 1 = Agree strongly; 2 = Somewhat agree; 3 = Somewhat disagree; 4 = Disagree strongly; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Regret when feeling bad
Phase 2 data. Questionnaire reads 5.When I feel bad; I will often do things I later regret in order to make myself feel better now. 1 = Agree strongly; 2 = Somewhat agree; 3 = Somewhat disagree; 4 = Disagree strongly; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Hate to stop
Phase 2 data. Questionnaire reads 6. Once I get going on something I hate to stop. 1 = Agree strongly; 2 = Somewhat agree; 3 = Somewhat disagree; 4 = Disagree strongly; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Feel bad cant stop
Phase 2 data. Questionnaire reads 7. Sometimes when I feel bad; I can’t seem to stop what I am doing even though it is making me feel worse. 1 = Agree strongly; 2 = Somewhat agree; 3 = Somewhat disagree; 4 = Disagree strongly; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Enjoy taking risks
Phase 2 data. Questionnaire reads 8. I quite enjoy taking risks. 1 = Agree strongly; 2 = Somewhat agree; 3 = Somewhat disagree; 4 = Disagree strongly; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Finish what I start
Phase 2 data. Questionnaire reads 9. I finish what I start. 1 = Agree strongly; 2 = Somewhat agree; 3 = Somewhat disagree; 4 = Disagree strongly; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Date finished ePersonality qnr
Phase 2 data. Date the participant finished filling in the Electronic Online Personality questionnaire.
Date
Date started ePersonality qnr
Phase 2 data. Date the participant started to fill in the Electronic Online Personality questionnaire.
Date
ePersonality qnr pt ID no
Phase 2 data. Electronic Personality questionnaire-specicifc participant ID number.
Text
ePersonality qnr ID no
Phase 2 data. Electronic Personality questionnaire ID number for version control.
Text
ePersonality qnr ID name
Phase 2 data. Electronic Personality questionnaire ID name for version control.
Text
Study phase ePersonality qnr
Phase 2 data. Study phase the Electronic Personality questionnaire was used for.
Text
Time finished ePersonality qnr
Phase 2 data. Time the participant finished filling in the Electronic OnlinePersonality questionnaire.
Time
Time started ePersonality qnr
Phase 2 data. Time the participant started to fill in the Electronic Online Personality questionnaire.
Time
ePersonality qnr version date
Phase 2 data. Electronic Personality questionnaire version date for version control.
Text
ePersonality qnr version no
Phase 2 data. Electronic Personality questionnaire version number for version control.
Text
ePersonality qnr webform version no
Phase 2 data. Electronic Personality questionnaire web form version number for version control.
Text
Predict max HR based on on age
Phase 2 data. Prediction of volunteers maximal heart rate based on on age. Tanaka equation: 208-0.7*age in years
Real
Pregnancy Exclusion Check
Phase 2 data. Pregnancy exclusion check done prior to DEXA scan? 0 = no; 1 = yes;
Categorical
None
Phase 2 data. Activity energy expenditure based on combined acceleration and heart rate using group cal (kJ/kg/day); Pwear based on acceleration only signal. Where possible; a specific group equation is derived for that study using data from the IC tests. Where this is not possible; the most appropriate equation from another study will have been applied in the calculation of the group estimated physical activity energy expenditure results. Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 0 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 0 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 2.25 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 2.25 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 2.5 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 2.5 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 2.75 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 2.75 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 3 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 3 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 3.25 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 3.25 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 3.5 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 3.5 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 3.75 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 3.75 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 4 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 4 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 4.25 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 4.25 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 4.5 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 4.5 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = .075 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = .075 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 4.75 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 4.75 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 5 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 5 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 6 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 6 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 7 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 7 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 8 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 8 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 9 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 9 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = .25 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = .25 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = .5 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = .5 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = .75 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = .75 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 1 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 1 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 1.25 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 1.25 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 1.5 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 1.5 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 1.75 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 1.75 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 2 m/s2 using PwAcc
Phase 2 data. Fraction of time spent < = 2 m/s2 (PW_acc). Based on acceleration only signal using Pwear from acceleration only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Flagged due to correction of ACC
Phase 2 data. Binary flag to indicate if an adjustment in ACC was needed 1 = YES. Refer to min_ACC_obs for details(Measured/Derived from or related to Acitheart Monitor/Data )
Categorical
Avg acc PwHRAcc
Phase 2 data. Average acceleration; trunk longitudinal axis (m/s2) based on Pwear from combined heart rate and acceleration signal(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Avg acc PwAcc
Phase 2 data. Average acceleration; trunk longitudinal axis (m/s2). Based on Pwear from acceleration signal only(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Age (years)
Phase 2 data. Age (years). Age at Date of Fenland visit - used in PA calculations
Integer
Cmnts on files with issues
Phase 2 data. Further details relating to any notable corruptions made for Free-living or calibration traces. May also indicate whether action has been taken. Further details of further action to be taken may be found in AH_Recommendation(Measured/Derived from or related to Acitheart Monitor/Data )
Text
Flagged problem relating to FL accl
Phase 2 data. Indicates whether a problem has been flagged with the trace relating to the free-living accelerometry signal during manual review process. Details as to what problem is can be found in AH_Comments; any action taken (or that needs to be taken) can be found in AH_Recommendations. Should it relate to alternative models being needed then this model will have been applied already if using PAEE_consolidated and the other main variables affected will have been set to missing. 1 = YES(Measured/Derived from or related to Acitheart Monitor/Data )
Categorical
Flag problem relating to calibration Test
Phase 2 data. Indicates whether a problem has been flagged with the trace relating to the calibration test used. Details as to what problem is can be found in AH_Comments; any action taken (or that needs to be taken) can be found in AH_Recommendations. Should it relate to alternative models being needed then this model will have been applied already if using PAEE_consolidated and the other main variables affected will have been set to missing. 1 = YES(Measured/Derived from or related to Acitheart Monitor/Data )
Categorical
Flagged possible clinical irregular
Phase 2 data. Indicates whether a problem has been flagged with the trace relating to a possible clinical irregularity. This will have been noted during the manual review process and is not a diagnosis (and has not been confirmed by a clinician from this trace). Details as to what problem is can be found in AH_Comments; any action taken (or that needs to be taken) can be found in AH_Recommendations. Should it relate to alternative models being needed then this model will have been applied already if using PAEE_consolidated and the other main variables affected will have been set to missing. 1 = YES(Measured/Derived from or related to Acitheart Monitor/Data )
Categorical
Flagged problem relating to FL HR
Phase 2 data. Indicates whether a problem has been flagged with the trace relating to the free-living heart rate signal during manual review process. Details as to what problem is can be found in AH_Comments; any action taken (or that needs to be taken) can be found in AH_Recommendations. Should it relate to alternative models being needed then this model will have been applied already if using PAEE_consolidated and the other main variables affected will have been set to missing. 1 = YES(Measured/Derived from or related to Acitheart Monitor/Data )
Categorical
Flagged problem with trace
Phase 2 data. Indicates whether a problem has been flagged with the trace during manual review process. Details as to what problem is can be found in AH_Comments; any action taken (or that needs to be taken) can be found in AH_Recommendations. Should it relate to alternative models being needed then this model will have been applied already if using PAEE_consolidated and the other main variables affected will have been set to missing. 1 = YES(Measured/Derived from or related to Acitheart Monitor/Data )
Categorical
Flagged problem relating to SHR est
Phase 2 data. Indicates whether a problem has been flagged with the trace relating to the sleeping heart rate that has been used. Details as to what problem is can be found in AH_Comments; any action taken (or that needs to be taken) can be found in AH_Recommendations. Should it relate to alternative models being needed then this model will have been applied already if using PAEE_consolidated and the other main variables affected will have been set to missing. 1 = YES(Measured/Derived from or related to Acitheart Monitor/Data )
Categorical
Suggestions on files with issues
Phase 2 data. Suggestions on further action that may be needed relating to a corruption in a trace. Where its relate to alternative models being needed then this model will have been applied already if using PAEE_consolidated and the other main variables affected will have been set to missing(Measured/Derived from or related to Acitheart Monitor/Data )
Text
Intercept regression mdn HR recovery time(0-1.5min) treadmill
Phase 2 data. Intercept; regression of median heart rate against recovery time (0-1.5min)- Treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Offset residual regression of rest phase
Phase 2 data. Offset; residual regression of rest phase(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept term regression mdn HR test time(omit frst 2.5min) treadmill
Phase 2 data. Intercept; regression of median heart rate against testtime (omit first 2.5min) - Treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Offset residual regression treadmill test recovery phases
Phase 2 data. Offset; residual regression of treadmill test and recovery phases(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept regression mdn HR test time omit frst 1min
Phase 2 data. Intercept; regression of median heart rate against testtime (omit first 1min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Offset residual regression of test-recovery phases
Phase 2 data. Offset; residual regression of test and recovery phases(Measured/Derived from or related to Acitheart Monitor/Data )
Real
None
Phase 2 data. Indication of which method has been used to derive individual calibration and fitness values for treadmill variables. Median = 0; Regressed = 1. Median is default method; regressed is selected as alternative to deal with noisy HR or responses that are very different from reference (Measured/Derived from or related to Acitheart Monitor/Data )
Categorical
Square root term regression mdn HR test time(omit frst 2.5min) treadmill
Phase 2 data. Square root term; regression of median heart rate against testtime (omit first 2.5min) - Treadmill Test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Square root regression mdn HR test time omit frst 1min
Phase 2 data. Square root term; regression of median heart rate against testtime (omit first 1min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Square term regression mdn HR recovery time(0-1.5min) treadmill
Phase 2 data. Square term; regression of median heart rate against recovery time (0-1.5min) - treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Square term regression mdn HR test time(omit frst 2.5min) treadmill
Phase 2 data. Square term; regression of median heart rate against testtime (omit first 2.5min) -Treadmill Test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Square term regression mdn HR test time omit frst 1min
Phase 2 data. Square term; regression of median heart rate against testtime (omit first 1min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Quadratic term regression mdn HR test time(omit frst 2.5min) treadmill
Phase 2 data. Quadratic term; regression of median heart rate against testtime (omit first 2.5min) - Treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Quadractic term regression mdn HR test time omit frst 1min
Phase 2 data. Quadratic term; regression of median heart rate against testtime (omit first 1min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Betablocker
Phase 2 data. Betablocked: 1 = yes; 0 = no. Participant has indicated they are taking betablocker medication. This does not include eye drops that may contain small amounts of betablockers. Used for Physical activity calculations
Categorical
Linear term regression mdn HR recovery time(0-1.5min) treadmill
Phase 2 data. Linear term; regression of median heart rate against recovery time (0-1.5min) - treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tilt residual regression of rest phase
Phase 2 data. Tilt; residual regression of rest phase(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Linear term regression mdn HR test time(omit frst 2.5min) treadmill
Phase 2 data. Linear term; regression of median heart rate against testtime (omit first 2.5min) - Treadmill Test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tilt residual regression treadmill test recovery phases
Phase 2 data. Tilt; residual regression of treadmill test and recovery phases(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Linear term regression mdn HR test time omit frst 1min
Phase 2 data. Linear term; regression of median heart rate against testtime (omit first 1min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tilt residual regression of test-recovery phases
Phase 2 data. Tilt; residual regression of test and recovery phases(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3.5METs bouts >= 10min
Phase 2 data. Fraction of time spent > = 3.5METs in bouts > = 10min. The fraction of time in bouts lasting longer than 10 minutes; above or equal to 3.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3.5METs bouts >= 15min
Phase 2 data. Fraction of time spent > = 3.5METs in bouts > = 15min. The fraction of time in bouts lasting longer than 15 minutes; above or equal to 3.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3.5METs bouts >= 1min
Phase 2 data. Fraction of time spent > = 3.5METs in bouts > = 1min. The fraction of time in bouts lasting longer than 1 minute above or equal to 3.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3.5METs bouts >= 20min
Phase 2 data. Fraction of time spent > = 3.5METs in bouts > = 20min. The fraction of time in bouts lasting longer than 20 minutes; above or equal to 3.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3.5METs bouts >= 2min
Phase 2 data. Fraction of time spent > = 3.5METs in bouts > = 2min. The fraction of time in bouts lasting longer than 2 minutes; above or equal to 3.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3.5METs bouts >= 30min
Phase 2 data. Fraction of time spent > = 3.5METs in bouts > = 30min. The fraction of time in bouts lasting longer than 30 minutes; above or equal to 3.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3.5METs bouts >= 3min
Phase 2 data. Fraction of time spent > = 3.5METs in bouts > = 3min. The fraction of time in bouts lasting longer than 3 minutes; above or equal to 3.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3.5METs bouts >= 4min
Phase 2 data. Fraction of time spent > = 3.5METs in bouts > = 4min. The fraction of time in bouts lasting longer than 4 minutes; above or equal to 3.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3.5METs bouts >= 5min
Phase 2 data. Fraction of time spent > = 3.5METs in bouts > = 5min. The fraction of time in bouts lasting longer than 5 minutes; above or equal to 3.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3.5METs bouts >= 6min
Phase 2 data. Fraction of time spent > = 3.5METs in bouts > = 6min. The fraction of time in bouts lasting longer than 6 minutes; above or equal to 3.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3.5METs bouts >= 7min
Phase 2 data. Fraction of time spent > = 3.5METs in bouts > = 7min. The fraction of time in bouts lasting longer than 7 minutes; above or equal to 3.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3.5METs bouts >= 8min
Phase 2 data. Fraction of time spent > = 3.5METs in bouts > = 8min. The fraction of time in bouts lasting longer than 8 minutes; above or equal to 3.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3.5METs bouts >= 9min
Phase 2 data. Fraction of time spent > = 3.5METs in bouts > = 9min. The fraction of time in bouts lasting longer than 9 minutes; above or equal to 3.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 4METs bouts >= 10min
Phase 2 data. Fraction of time spent > = 4METs in bouts > = 10min. The fraction of time in bouts lasting longer than 10 minutes; above or equal to 4METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 4METs bouts >= 15min
Phase 2 data. Fraction of time spent > = 4METs in bouts > = 15min. The fraction of time in bouts lasting longer than 15 minutes; above or equal to 4METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 4METs bouts >= 1min
Phase 2 data. Fraction of time spent > = 4METs in bouts > = 1min. The fraction of time in bouts lasting longer than 1 minute above or equal to 4METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 4METs bouts >= 20min
Phase 2 data. Fraction of time spent > = 4METs in bouts > = 20min. The fraction of time in bouts lasting longer than 20 minutes; above or equal to 4METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 4METs bouts >= 2min
Phase 2 data. Fraction of time spent > = 4METs in bouts > = 2min. The fraction of time in bouts lasting longer than 2 minutes; above or equal to 4METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 4METs bouts >= 30min
Phase 2 data. Fraction of time spent > = 4METs in bouts > = 30min. The fraction of time in bouts lasting longer than 30 minutes; above or equal to 4METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 4METs bouts >= 3min
Phase 2 data. Fraction of time spent > = 4METs in bouts > = 3min. The fraction of time in bouts lasting longer than 3 minutes; above or equal to 4METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 4METs bouts >= 4min
Phase 2 data. Fraction of time spent > = 4METs in bouts > = 4min. The fraction of time in bouts lasting longer than 4 minutes; above or equal to 4METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 4METs bouts >= 5min
Phase 2 data. Fraction of time spent > = 4METs in bouts > = 5min. The fraction of time in bouts lasting longer than 5 minutes; above or equal to 4METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 4METs bouts >= 6min
Phase 2 data. Fraction of time spent > = 4METs in bouts > = 6min. The fraction of time in bouts lasting longer than 6 minutes; above or equal to 4METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 4METs bouts >= 7min
Phase 2 data. Fraction of time spent > = 4METs in bouts > = 7min. The fraction of time in bouts lasting longer than 7 minutes; above or equal to 4METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 4METs bouts >= 8min
Phase 2 data. Fraction of time spent > = 4METs in bouts > = 8min. The fraction of time in bouts lasting longer than 8 minutes; above or equal to 4METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 4METs bouts >= 9min
Phase 2 data. Fraction of time spent > = 4METs in bouts > = 9min. The fraction of time in bouts lasting longer than 9 minutes; above or equal to 4METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 5METs bouts >= 10min
Phase 2 data. Fraction of time spent > = 5METs in bouts > = 10min. The fraction of time in bouts lasting longer than 10 minutes; above or equal to 5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 5METs bouts >= 15min
Phase 2 data. Fraction of time spent > = 5METs in bouts > = 15min. The fraction of time in bouts lasting longer than 15 minutes; above or equal to 5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 5METs bouts >= 1min
Phase 2 data. Fraction of time spent > = 5METs in bouts > = 1min. The fraction of time in bouts lasting longer than 1 minute above or equal to 5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 5METs bouts >= 20min
Phase 2 data. Fraction of time spent > = 5METs in bouts > = 20min. The fraction of time in bouts lasting longer than 20 minutes; above or equal to 5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 5METs bouts >= 2min
Phase 2 data. Fraction of time spent > = 5METs in bouts > = 2min. The fraction of time in bouts lasting longer than 2 minutes; above or equal to 5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 5METs bouts >= 30min
Phase 2 data. Fraction of time spent > = 5METs in bouts > = 30min. The fraction of time in bouts lasting longer than 30 minutes; above or equal to 5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 5METs bouts >= 3min
Phase 2 data. Fraction of time spent > = 5METs in bouts > = 3min. The fraction of time in bouts lasting longer than 3 minutes; above or equal to 5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 5METs bouts >= 4min
Phase 2 data. Fraction of time spent > = 5METs in bouts > = 4min. The fraction of time in bouts lasting longer than 4 minutes; above or equal to 5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 5METs bouts >= 5min
Phase 2 data. Fraction of time spent > = 5METs in bouts > = 5min. The fraction of time in bouts lasting longer than 5 minutes; above or equal to 5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 5METs bouts >= 6min
Phase 2 data. Fraction of time spent > = 5METs in bouts > = 6min. The fraction of time in bouts lasting longer than 6 minutes; above or equal to 5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 5METs bouts >= 7min
Phase 2 data. Fraction of time spent > = 5METs in bouts > = 7min. The fraction of time in bouts lasting longer than 7 minutes; above or equal to 5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 5METs bouts >= 8min
Phase 2 data. Fraction of time spent > = 5METs in bouts > = 8min. The fraction of time in bouts lasting longer than 8 minutes; above or equal to 5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 5METs bouts >= 9min
Phase 2 data. Fraction of time spent > = 5METs in bouts > = 9min. The fraction of time in bouts lasting longer than 9 minutes; above or equal to 5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 6METs bouts >= 10min
Phase 2 data. Fraction of time spent > = 6METs in bouts > = 10min. The fraction of time in bouts lasting longer than 10 minutes; above or equal to 6METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 6METs bouts >= 15min
Phase 2 data. Fraction of time spent > = 6METs in bouts > = 15min. The fraction of time in bouts lasting longer than 15 minutes; above or equal to 6METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 6METs bouts >= 1min
Phase 2 data. Fraction of time spent > = 6METs in bouts > = 1min. The fraction of time in bouts lasting longer than 1 minute above or equal to 6METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 6METs bouts >= 20min
Phase 2 data. Fraction of time spent > = 6METs in bouts > = 20min. The fraction of time in bouts lasting longer than 20 minutes; above or equal to 6METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 6METs bouts >= 2min
Phase 2 data. Fraction of time spent > = 6METs in bouts > = 2min. The fraction of time in bouts lasting longer than 2 minutes; above or equal to 6METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 6METs bouts >= 30min
Phase 2 data. Fraction of time spent > = 6METs in bouts > = 30min. The fraction of time in bouts lasting longer than 30 minutes; above or equal to 6METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 6METs bouts >= 3min
Phase 2 data. Fraction of time spent > = 6METs in bouts > = 3min. The fraction of time in bouts lasting longer than 3 minutes; above or equal to 6METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 6METs bouts >= 4min
Phase 2 data. Fraction of time spent > = 6METs in bouts > = 4min. The fraction of time in bouts lasting longer than 4 minutes; above or equal to 6METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 6METs bouts >= 5min
Phase 2 data. Fraction of time spent > = 6METs in bouts > = 5min. The fraction of time in bouts lasting longer than 5 minutes; above or equal to 6METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 6METs bouts >= 6min
Phase 2 data. Fraction of time spent > = 6METs in bouts > = 6min. The fraction of time in bouts lasting longer than 6 minutes; above or equal to 6METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 6METs bouts >= 7min
Phase 2 data. Fraction of time spent > = 6METs in bouts > = 7min. The fraction of time in bouts lasting longer than 7 minutes; above or equal to 6METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 6METs bouts >= 8min
Phase 2 data. Fraction of time spent > = 6METs in bouts > = 8min. The fraction of time in bouts lasting longer than 8 minutes; above or equal to 6METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 6METs bouts >= 9min
Phase 2 data. Fraction of time spent > = 6METs in bouts > = 9min. The fraction of time in bouts lasting longer than 9 minutes; above or equal to 6METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time bouts >= 10min; >= 2METs
Phase 2 data. Fraction of time spent > = 2METs in bouts > = 10min. The fraction of time in bouts lasting longer than 10 minutes; above or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time bouts >= 15min; >= 2METs
Phase 2 data. Fraction of time spent > = 2METs in bouts > = 15min. The fraction of time in bouts lasting longer than 15 minutes; above or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time bouts >= 1min; >= 2METs
Phase 2 data. Fraction of time spent > = 2METs in bouts > = 1min. The fraction of time in bouts lasting longer than 1 minute; above or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time bouts >= 20min; >= 2METs
Phase 2 data. Fraction of time spent > = 2METs in bouts > = 20min. The fraction of time in bouts lasting longer than 20 minutes; above or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time bouts >= 2min; >= 2METs
Phase 2 data. Fraction of time spent > = 2METs in bouts > = 2min. The fraction of time in bouts lasting longer than 2 minutes; above or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time bouts >= 30min; >= 2METs
Phase 2 data. Fraction of time spent > = 2METs in bouts > = 30min. The fraction of time in bouts lasting longer than 30 minutes; above or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time bouts >= 3min; >= 2METs
Phase 2 data. Fraction of time spent > = 2METs in bouts > = 3min. The fraction of time in bouts lasting longer than 3 minutes; above or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time bouts >= 4min; >= 2METs
Phase 2 data. Fraction of time spent > = 2METs in bouts > = 4min. The fraction of time in bouts lasting longer than 4 minutes; above or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time bouts >= 5min; >= 2METs
Phase 2 data. Fraction of time spent > = 2METs in bouts > = 5min. The fraction of time in bouts lasting longer than 5 minutes; above or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time bouts >= 6min; >= 2METs
Phase 2 data. Fraction of time spent > = 2METs in bouts > = 6min. The fraction of time in bouts lasting longer than 6 minutes; above or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time bouts >= 7min; >= 2METs
Phase 2 data. Fraction of time spent > = 2METs in bouts > = 7min. The fraction of time in bouts lasting longer than 7 minutes; above or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time bouts >= 8min; >= 2METs
Phase 2 data. Fraction of time spent > = 2METs in bouts > = 8min. The fraction of time in bouts lasting longer than 8 minutes; above or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time bouts >= 9min; >= 2METs
Phase 2 data. Fraction of time spent > = 2METs in bouts > = 9min. The fraction of time in bouts lasting longer than 9 minutes; above or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time in bouts >= 10min
Phase 2 data. Fraction of time spent > = 2.5METs in bouts > = 10min. The fraction of time in bouts lasting longer than 10 minutes; above or equal to 2.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time in bouts >= 15min
Phase 2 data. Fraction of time spent > = 2.5METs in bouts > = 15min. The fraction of time in bouts lasting longer than 15 minutes; above or equal to 2.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time in bouts >= 1min
Phase 2 data. Fraction of time spent > = 2.5METs in bouts > = 1min. The fraction of time in bouts lasting longer than 1 minute above or equal to 2.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time in bouts >= 20min
Phase 2 data. Fraction of time spent > = 2.5METs in bouts > = 20min. The fraction of time in bouts lasting longer than 20 minutes; above or equal to 2.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time in bouts >= 2min
Phase 2 data. Fraction of time spent > = 2.5METs in bouts > = 2min. The fraction of time in bouts lasting longer than 2 minutes; above or equal to 2.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time in bouts >= 30min
Phase 2 data. Fraction of time spent > = 2.5METs in bouts > = 30min. The fraction of time in bouts lasting longer than 30 minutes; above or equal to 2.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time in bouts >= 3min
Phase 2 data. Fraction of time spent > = 2.5METs in bouts > = 3min. The fraction of time in bouts lasting longer than 3 minutes; above or equal to 2.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time in bouts >= 4min
Phase 2 data. Fraction of time spent > = 2.5METs in bouts > = 4min. The fraction of time in bouts lasting longer than 4 minutes; above or equal to 2.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time in bouts >= 5min
Phase 2 data. Fraction of time spent > = 2.5METs in bouts > = 5min. The fraction of time in bouts lasting longer than 5 minutes; above or equal to 2.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time in bouts >= 6min
Phase 2 data. Fraction of time spent > = 2.5METs in bouts > = 6min. The fraction of time in bouts lasting longer than 6 minutes; above or equal to 2.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time in bouts >= 7min
Phase 2 data. Fraction of time spent > = 2.5METs in bouts > = 7min. The fraction of time in bouts lasting longer than 7 minutes; above or equal to 2.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time in bouts >= 8min
Phase 2 data. Fraction of time spent > = 2.5METs in bouts > = 8min. The fraction of time in bouts lasting longer than 8 minutes; above or equal to 2.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time in bouts >= 9min
Phase 2 data. Fraction of time spent > = 2.5METs in bouts > = 9min. The fraction of time in bouts lasting longer than 9 minutes; above or equal to 2.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3METs bouts >= 10min
Phase 2 data. Fraction of time spent > = 3METs in bouts > = 10min. The fraction of time in bouts lasting longer than 10 minutes; above or equal to 3METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3METs bouts >= 15min
Phase 2 data. Fraction of time spent > = 3METs in bouts > = 15min. The fraction of time in bouts lasting longer than 15 minutes; above or equal to 3METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3METs bouts >= 1min
Phase 2 data. Fraction of time spent > = 3METs in bouts > = 1min. The fraction of time in bouts lasting longer than 1 minute above or equal to 3METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3METs bouts >= 20min
Phase 2 data. Fraction of time spent > = 3METs in bouts > = 20min. The fraction of time in bouts lasting longer than 20 minutes; above or equal to 3METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3METs bouts >= 2min
Phase 2 data. Fraction of time spent > = 3METs in bouts > = 2min. The fraction of time in bouts lasting longer than 2 minutes; above or equal to 3METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3METs bouts >= 30min
Phase 2 data. Fraction of time spent > = 3METs in bouts > = 30min. The fraction of time in bouts lasting longer than 30 minutes; above or equal to 3METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3METs bouts >= 3min
Phase 2 data. Fraction of time spent > = 3METs in bouts > = 3min. The fraction of time in bouts lasting longer than 3 minutes; above or equal to 3METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3METs bouts >= 4min
Phase 2 data. Fraction of time spent > = 3METs in bouts > = 4min. The fraction of time in bouts lasting longer than 4 minutes; above or equal to 3METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3METs bouts >= 5min
Phase 2 data. Fraction of time spent > = 3METs in bouts > = 5min. The fraction of time in bouts lasting longer than 5 minutes; above or equal to 3METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3METs bouts >= 6min
Phase 2 data. Fraction of time spent > = 3METs in bouts > = 6min. The fraction of time in bouts lasting longer than 6 minutes; above or equal to 3METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3METs bouts >= 7min
Phase 2 data. Fraction of time spent > = 3METs in bouts > = 7min. The fraction of time in bouts lasting longer than 7 minutes; above or equal to 3METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3METs bouts >= 8min
Phase 2 data. Fraction of time spent > = 3METs in bouts > = 8min. The fraction of time in bouts lasting longer than 8 minutes; above or equal to 3METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent >= 3METs bouts >= 9min
Phase 2 data. Fraction of time spent > = 3METs in bouts > = 9min. The fraction of time in bouts lasting longer than 9 minutes; above or equal to 3METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent <= 1METs bouts >= 120min
Phase 2 data. Fraction of time spent < = 1METs in bouts > = 120min. The fraction of time in bouts lasting longer than 120 minutes; below or equal to 1METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent <= 1METs bouts >= 150min
Phase 2 data. Fraction of time spent < = 1METs in bouts > = 150min. The fraction of time in bouts lasting longer than 150 minutes; below or equal to 1METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent <= 1METs bouts >= 15min
Phase 2 data. Fraction of time spent < = 1METs in bouts > = 15min. The fraction of time in bouts lasting longer than 15 minutes; below or equal to 1METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent <= 1METs bouts >= 180min
Phase 2 data. Fraction of time spent < = 1METs in bouts > = 180min. The fraction of time in bouts lasting longer than 180 minutes; below or equal to 1METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent <= 1METs bouts >= 20min
Phase 2 data. Fraction of time spent < = 1METs in bouts > = 20min. The fraction of time in bouts lasting longer than 20 minutes; below or equal to 1METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent <= 1METs bouts >= 210min
Phase 2 data. Fraction of time spent < = 1METs in bouts > = 210min. The fraction of time in bouts lasting longer than 210 minutes; below or equal to 1METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent <= 1METs bouts >= 240min
Phase 2 data. Fraction of time spent < = 1METs in bouts > = 240min. The fraction of time in bouts lasting longer than 240 minutes; below or equal to 1METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent <= 1METs bouts >= 300min
Phase 2 data. Fraction of time spent < = 1METs in bouts > = 300min. The fraction of time in bouts lasting longer than 300 minutes; below or equal to 1METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent <= 1METs bouts >= 30min
Phase 2 data. Fraction of time spent < = 1METs in bouts > = 30min. The fraction of time in bouts lasting longer than 30 minutes; below or equal to 1METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent <= 1METs bouts >= 45min
Phase 2 data. Fraction of time spent < = 1METs in bouts > = 45min. The fraction of time in bouts lasting longer than 45 minutes; below or equal to 1METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent <= 1METs bouts >= 60min
Phase 2 data. Fraction of time spent < = 1METs in bouts > = 60min. The fraction of time in bouts lasting longer than 60 minutes; below or equal to 1METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr time spent <= 1METs bouts >= 90min
Phase 2 data. Fraction of time spent < = 1METs in bouts > = 90min. The fraction of time in bouts lasting longer than 90 minutes; below or equal to 1METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr Tmespent <= 1.05METs bouts >= 120min
Phase 2 data. Fraction of time spent < = 1.05METs in bouts > = 120min. The fraction of time in bouts lasting longer than 120 minutes; below or equal to 1.05METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr Tmespent <= 1.05METs bouts >= 150min
Phase 2 data. Fraction of time spent < = 1.05METs in bouts > = 150min. The fraction of time in bouts lasting longer than 150 minutes; below or equal to 1.05METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 1.05METs bouts >= 15min
Phase 2 data. Fraction of time spent < = 1.05METs in bouts > = 15min. The fraction of time in bouts lasting longer than 15 minutes; below or equal to 1.05METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr Tmespent <= 1.05METs bouts >= 180min
Phase 2 data. Fraction of time spent < = 1.05METs in bouts > = 180min. The fraction of time in bouts lasting longer than 180 minutes; below or equal to 1.05METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 1.05METs bouts >= 20min
Phase 2 data. Fraction of time spent < = 1.05METs in bouts > = 20min. The fraction of time in bouts lasting longer than 20 minutes; below or equal to 1.05METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr Tmespent <= 1.05METs bouts >= 210min
Phase 2 data. Fraction of time spent < = 1.05METs in bouts > = 210min. The fraction of time in bouts lasting longer than 210 minutes; below or equal to 1.05METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr Tmespent <= 1.05METs bouts >= 240min
Phase 2 data. Fraction of time spent < = 1.05METs in bouts > = 240min. The fraction of time in bouts lasting longer than 240 minutes; below or equal to 1.05METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr Tmespent <= 1.05METs bouts >= 300min
Phase 2 data. Fraction of time spent < = 1.05METs in bouts > = 300min. The fraction of time in bouts lasting longer than 300 minutes; below or equal to 1.05METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 1.05METs bouts >= 30min
Phase 2 data. Fraction of time spent < = 1.05METs in bouts > = 30min. The fraction of time in bouts lasting longer than 30 minutes; below or equal to 1.05METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 1.05METs bouts >= 45min
Phase 2 data. Fraction of time spent < = 1.05METs in bouts > = 45min. The fraction of time in bouts lasting longer than 45 minutes; below or equal to 1.05METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 1.05METs bouts >= 60min
Phase 2 data. Fraction of time spent < = 1.05METs in bouts > = 60min. The fraction of time in bouts lasting longer than 60 minutes; below or equal to 1.05METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 1.05METs bouts >= 90min
Phase 2 data. Fraction of time spent < = 1.05METs in bouts > = 90min. The fraction of time in bouts lasting longer than 90 minutes; below or equal to 1.05METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.125METs bouts >= 120min
Phase 2 data. Fraction of time spent < = 1.125METs in bouts > = 120min. The fraction of time in bouts lasting longer than 120 minutes; below or equal to 1.125METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.125METs bouts >= 150min
Phase 2 data. Fraction of time spent < = 1.125METs in bouts > = 150min. The fraction of time in bouts lasting longer than 150 minutes; below or equal to 1.125METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.125METs bouts >= 15min
Phase 2 data. Fraction of time spent < = 1.125METs in bouts > = 15min. The fraction of time in bouts lasting longer than 15 minutes; below or equal to 1.125METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.125METs bouts >= 180min
Phase 2 data. Fraction of time spent < = 1.125METs in bouts > = 180min. The fraction of time in bouts lasting longer than 180 minutes; below or equal to 1.125METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.125METs bouts >= 20min
Phase 2 data. Fraction of time spent < = 1.125METs in bouts > = 20min. The fraction of time in bouts lasting longer than 20 minutes; below or equal to 1.125METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.125METs bouts >= 210min
Phase 2 data. Fraction of time spent < = 1.125METs in bouts > = 210min. The fraction of time in bouts lasting longer than 210 minutes; below or equal to 1.125METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.125METs bouts >= 240min
Phase 2 data. Fraction of time spent < = 1.125METs in bouts > = 240min. The fraction of time in bouts lasting longer than 240 minutes; below or equal to 1.125METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.125METs bouts >= 300min
Phase 2 data. Fraction of time spent < = 1.125METs in bouts > = 300min. The fraction of time in bouts lasting longer than 300 minutes; below or equal to 1.125METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.125METs bouts >= 30min
Phase 2 data. Fraction of time spent < = 1.125METs in bouts > = 30min. The fraction of time in bouts lasting longer than 30 minutes; below or equal to 1.125METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.125METs bouts >= 45min
Phase 2 data. Fraction of time spent < = 1.125METs in bouts > = 45min. The fraction of time in bouts lasting longer than 45 minutes; below or equal to 1.125METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.125METs bouts >= 60min
Phase 2 data. Fraction of time spent < = 1.125METs in bouts > = 60min. The fraction of time in bouts lasting longer than 60 minutes; below or equal to 1.125METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.125METs bouts >= 90min
Phase 2 data. Fraction of time spent < = 1.125METs in bouts > = 90min. The fraction of time in bouts lasting longer than 90 minutes; below or equal to 1.125METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.25METs bouts >= 120min
Phase 2 data. Fraction of time spent < = 1.25METs in bouts > = 120min. The fraction of time in bouts lasting longer than 120 minutes; below or equal to 1.25METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.25METs bouts >= 150min
Phase 2 data. Fraction of time spent < = 1.25METs in bouts > = 150min. The fraction of time in bouts lasting longer than 150 minutes; below or equal to 1.25METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.25METs bouts >= 15min
Phase 2 data. Fraction of time spent < = 1.25METs in bouts > = 15min. The fraction of time in bouts lasting longer than 15 minutes; below or equal to 1.25METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.25METs bouts >= 180min
Phase 2 data. Fraction of time spent < = 1.25METs in bouts > = 180min. The fraction of time in bouts lasting longer than 180 minutes; below or equal to 1.25METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.25METs bouts >= 20min
Phase 2 data. Fraction of time spent < = 1.25METs in bouts > = 20min. The fraction of time in bouts lasting longer than 20 minutes; below or equal to 1.25METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.25METs bouts >= 210min
Phase 2 data. Fraction of time spent < = 1.25METs in bouts > = 210min. The fraction of time in bouts lasting longer than 210 minutes; below or equal to 1.25METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.25METs bouts >= 240min
Phase 2 data. Fraction of time spent < = 1.25METs in bouts > = 240min. The fraction of time in bouts lasting longer than 240 minutes; below or equal to 1.25METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.25METs bouts >= 300min
Phase 2 data. Fraction of time spent < = 1.25METs in bouts > = 300min. The fraction of time in bouts lasting longer than 300 minutes; below or equal to 1.25METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.25METs bouts >= 30min
Phase 2 data. Fraction of time spent < = 1.25METs in bouts > = 30min. The fraction of time in bouts lasting longer than 30 minutes; below or equal to 1.25METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.25METs bouts >= 45min
Phase 2 data. Fraction of time spent < = 1.25METs in bouts > = 45min. The fraction of time in bouts lasting longer than 45 minutes; below or equal to 1.25METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.25METs bouts >= 60min
Phase 2 data. Fraction of time spent < = 1.25METs in bouts > = 60min. The fraction of time in bouts lasting longer than 60 minutes; below or equal to 1.25METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.25METs bouts >= 90min
Phase 2 data. Fraction of time spent < = 1.25METs in bouts > = 90min. The fraction of time in bouts lasting longer than 90 minutes; below or equal to 1.25METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.5METs bouts >= 120min
Phase 2 data. Fraction of time spent < = 1.5METs in bouts > = 120min. The fraction of time in bouts lasting longer than 120 minutes; below or equal to 1.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.5METs bouts >= 150min
Phase 2 data. Fraction of time spent < = 1.5METs in bouts > = 150min. The fraction of time in bouts lasting longer than 150 minutes; below or equal to 1.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.5METs bouts >= 15min
Phase 2 data. Fraction of time spent < = 1.5METs in bouts > = 15min. The fraction of time in bouts lasting longer than 15 minutes; below or equal to 1.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.5METs bouts >= 180min
Phase 2 data. Fraction of time spent < = 1.5METs in bouts > = 180min. The fraction of time in bouts lasting longer than 180 minutes; below or equal to 1.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.5METs bouts >= 20min
Phase 2 data. Fraction of time spent < = 1.5METs in bouts > = 20min. The fraction of time in bouts lasting longer than 20 minutes; below or equal to 1.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.5METs bouts >= 210min
Phase 2 data. Fraction of time spent < = 1.5METs in bouts > = 210min. The fraction of time in bouts lasting longer than 210 minutes; below or equal to 1.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.5METs bouts >= 240min
Phase 2 data. Fraction of time spent < = 1.5METs in bouts > = 240min. The fraction of time in bouts lasting longer than 240 minutes; below or equal to 1.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.5METs bouts >= 300min
Phase 2 data. Fraction of time spent < = 1.5METs in bouts > = 300min. The fraction of time in bouts lasting longer than 300 minutes; below or equal to 1.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.5METs bouts >= 30min
Phase 2 data. Fraction of time spent < = 1.5METs in bouts > = 30min. The fraction of time in bouts lasting longer than 30 minutes; below or equal to 1.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.5METs bouts >= 45min
Phase 2 data. Fraction of time spent < = 1.5METs in bouts > = 45min. The fraction of time in bouts lasting longer than 45 minutes; below or equal to 1.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.5METs bouts >= 60min
Phase 2 data. Fraction of time spent < = 1.5METs in bouts > = 60min. The fraction of time in bouts lasting longer than 60 minutes; below or equal to 1.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.5METs bouts >= 90min
Phase 2 data. Fraction of time spent < = 1.5METs in bouts > = 90min. The fraction of time in bouts lasting longer than 90 minutes; below or equal to 1.5METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.75METs bouts >= 120min
Phase 2 data. Fraction of time spent < = 1.75METs in bouts > = 120min. The fraction of time in bouts lasting longer than 120 minutes; below or equal to 1.75METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.75METs bouts >= 150min
Phase 2 data. Fraction of time spent < = 1.75METs in bouts > = 150min. The fraction of time in bouts lasting longer than 150 minutes; below or equal to 1.75METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.75METs bouts >= 15min
Phase 2 data. Fraction of time spent < = 1.75METs in bouts > = 15min. The fraction of time in bouts lasting longer than 15 minutes; below or equal to 1.75METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.75METs bouts >= 180min
Phase 2 data. Fraction of time spent < = 1.75METs in bouts > = 180min. The fraction of time in bouts lasting longer than 180 minutes; below or equal to 1.75METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.75METs bouts >= 20min
Phase 2 data. Fraction of time spent < = 1.75METs in bouts > = 20min. The fraction of time in bouts lasting longer than 20 minutes; below or equal to 1.75METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.75METs bouts >= 210min
Phase 2 data. Fraction of time spent < = 1.75METs in bouts > = 210min. The fraction of time in bouts lasting longer than 210 minutes; below or equal to 1.75METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.75METs bouts >= 240min
Phase 2 data. Fraction of time spent < = 1.75METs in bouts > = 240min. The fraction of time in bouts lasting longer than 240 minutes; below or equal to 1.75METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.75METs bouts >= 300min
Phase 2 data. Fraction of time spent < = 1.75METs in bouts > = 300min. The fraction of time in bouts lasting longer than 300 minutes; below or equal to 1.75METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.75METs bouts >= 30min
Phase 2 data. Fraction of time spent < = 1.75METs in bouts > = 30min. The fraction of time in bouts lasting longer than 30 minutes; below or equal to 1.75METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.75METs bouts >= 45min
Phase 2 data. Fraction of time spent < = 1.75METs in bouts > = 45min. The fraction of time in bouts lasting longer than 45 minutes; below or equal to 1.75METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.75METs bouts >= 60min
Phase 2 data. Fraction of time spent < = 1.75METs in bouts > = 60min. The fraction of time in bouts lasting longer than 60 minutes; below or equal to 1.75METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Tmespent <= 1.75METs bouts >= 90min
Phase 2 data. Fraction of time spent < = 1.75METs in bouts > = 90min. The fraction of time in bouts lasting longer than 90 minutes; below or equal to 1.75METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 2METs bouts >= 120min
Phase 2 data. Fraction of time spent < = 2METs in bouts > = 120min. The fraction of time in bouts lasting longer than 120 minutes; below or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 2METs bouts >= 150min
Phase 2 data. Fraction of time spent < = 2METs in bouts > = 150min. The fraction of time in bouts lasting longer than 150 minutes; below or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 2METs bouts >= 15min
Phase 2 data. Fraction of time spent < = 2METs in bouts > = 15min. The fraction of time in bouts lasting longer than 15 minutes; below or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 2METs bouts >= 180min
Phase 2 data. Fraction of time spent < = 2METs in bouts > = 180min. The fraction of time in bouts lasting longer than 180 minutes; below or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 2METs bouts >= 20min
Phase 2 data. Fraction of time spent < = 2METs in bouts > = 20min. The fraction of time in bouts lasting longer than 20 minutes; below or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 2METs bouts >= 210min
Phase 2 data. Fraction of time spent < = 2METs in bouts > = 210min. The fraction of time in bouts lasting longer than 210 minutes; below or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 2METs bouts >= 240min
Phase 2 data. Fraction of time spent < = 2METs in bouts > = 240min. The fraction of time in bouts lasting longer than 240 minutes; below or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 2METs bouts >= 300min
Phase 2 data. Fraction of time spent < = 2METs in bouts > = 300min. The fraction of time in bouts lasting longer than 300 minutes; below or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 2METs bouts >= 30min
Phase 2 data. Fraction of time spent < = 2METs in bouts > = 30min. The fraction of time in bouts lasting longer than 30 minutes; below or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 2METs bouts >= 45min
Phase 2 data. Fraction of time spent < = 2METs in bouts > = 45min. The fraction of time in bouts lasting longer than 45 minutes; below or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 2METs bouts >= 60min
Phase 2 data. Fraction of time spent < = 2METs in bouts > = 60min. The fraction of time in bouts lasting longer than 60 minutes; below or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fr timespent <= 2METs bouts >= 90min
Phase 2 data. Fraction of time spent < = 2METs in bouts > = 90min. The fraction of time in bouts lasting longer than 90 minutes; below or equal to 2METs.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Obs translated by branch box 1
Phase 2 data. Fraction of observations translated by branch box 1 (%HR weighting)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Obs translated by branch box 2
Phase 2 data. Fraction of observations translated by branch box 2 (%HR weighting)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Obs translated by branch box 3
Phase 2 data. Fraction of observations translated by branch box 3 (%HR weighting)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Obs translated by branch box 4
Phase 2 data. Fraction of observations translated by branch box 4 (%HR weighting)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Obs translated by branch box 5
Phase 2 data. Fraction of observations translated by branch box 5 (%HR weighting)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Obs translated by branch box 6
Phase 2 data. Fraction of observations translated by branch box 6 (%HR weighting)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn HR branched model
Phase 2 data. Mean reliance of heart rate estimate in branched model(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Protocol for treadmill test processing
Phase 2 data. Protocol used for treadmill test processing (Measured/Derived from or related to Acitheart Monitor/Data )
Text
No of days btwn Individual calibration
Phase 2 data. Number of days between individual calibration test and start of free-living file(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Prevent diurnal bias
Phase 2 data. Explained variation from regression of physical activity energy expenditure using morning and midnight axes. Allows for adjustments to be made to prevent diurnal bias where possible(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Recording frequency of FL data
Phase 2 data. Recording frequency in which the data has been processed in seconds. This may not reflect the raw frequency the monitor recorded in.(Measured/Derived from or related to Acitheart Monitor/Data )
Time
Upper test time limit derived fast wlk calibration
Phase 2 data. Upper test time limit for deriving fast walk calibration (min)(Measured/Derived from or related to Acitheart Monitor/Data )
Integer
Lower test time limit derived fast wlk calibration
Phase 2 data. Lower test time limit for deriving fast walk calibration (min)(Measured/Derived from or related to Acitheart Monitor/Data )
Integer
Suggestion for consolidated Fitness
Phase 2 data. Fitness (VO2 ml/kg/min) using the highest available calibration test. Priority order: Treadmill then Walk. Treadmill used if treadmill duration > = 10mins and useable HR quality. Energy cost for treadmill based on predicted energy expenditure from Brage et al 2007 (JAP). Submaximal response extrapolated to max HR (Tanaka 2001). Walk used if walk duration > = 1 and useable HR quality. Energy cost for Walk based on Ludlow 2016.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fitness source
Phase 2 data. Indicates which test was used for each participant for Fitness_Consolidated. 1 = Treadmill 2 = Self paced Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Categorical
Flex HR above Sleep grp-calibrationrated
Phase 2 data. Flex HR above Sleep; used for group-calibrated estimates (bpm). Reference Brage et a JAP2007(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Flex HR offset (bpm)
Phase 2 data. Added to calculation to reflect for rest and not sleep HR(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Name grp equation used PAE
Phase 2 data. Name of group equation used for physical activity energy estimates. Group equations are used where no individual calibration is available. Usually derived from individual calibration tests that exist within the population already or a similar demographic population.(Measured/Derived from or related to Acitheart Monitor/Data )
Text
Height (metres)
Phase 2 data. Height (metres) used in all Physical activity estimates
Real
Hemisphere of the data collected
Phase 2 data. Hemisphere in which the data was collected(Measured/Derived from or related to Acitheart Monitor/Data )
Categorical
Highest branch model
Phase 2 data. Highest available branch model to be used in the data set 1 = Treadmill with VO2; 2 = Treadmill without VO2; 4 = Step Test; 6 = Walk test derived from treadmill protocol; 7 = Group equation; 8 = Walk test. Please note these are coded and do not necessarily reflect validity order.(Measured/Derived from or related to Acitheart Monitor/Data )
Categorical
Avg HRaS free living recording
Phase 2 data. Average heart rate above sleep during free-living recording(Measured/Derived from or related to Acitheart Monitor/Data )
Real
HR variability from FL during rest
Phase 2 data. Heart rate variability from Free-living data during rest (ms). Calculated from LT variability data collected from Actiheart monitor (uses difference between 2nd fastest and 2nd slowest beat per epoch)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
HR from FL during rest
Phase 2 data. Heart rate from Free-living data during rest used to calculate HRV_rest (bpm). ACC observations = 0 and HR observations at or below SHR(+10) (Measured/Derived from or related to Acitheart Monitor/Data )
Real
Date time of ibi file2 start
Phase 2 data. Date and time of ibi file2 start (if applicable)(Measured/Derived from or related to Acitheart Monitor/Data )
DateTime
Start time of treadmill test file
Phase 2 data. Real start time of treadmill test file (Actiheart monitor started recording)(Measured/Derived from or related to Acitheart Monitor/Data )
DateTime
Individually calibration branch flex
Phase 2 data. Using individually calibrated branch flex parameter? YES/NO(Measured/Derived from or related to Acitheart Monitor/Data )
Text
Scaling HR accept zone recovery phase
Phase 2 data. Scaling HR acceptance zone for treadmill test recovery phase. Widening or narrowing of heart rate acceptance zone to aid cleaning and ensure only clean heart rate is included as much as possible(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Scaling HR acceptance zone rest phase
Phase 2 data. Scaling HR acceptance zone for rest phase. Widening or narrowing of heart rate acceptance zone to aid cleaning and ensure only clean heart rate is included as much as possible(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Scaling HR accept zone test phase
Phase 2 data. Scaling HR acceptance zone for treadmill test phase. Widening or narrowing of heart rate acceptance zone to aid cleaning and ensure only clean heart rate is included as much as possible(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Shift of HR reference recvry phase
Phase 2 data. Shift of HR reference for recovery phase of treadmill test (center of acceptance zone). Cleaning variable; indicates if the reference phase of heart which is deemed cleaned and useable has been shifted to ensure clean data only is included as much as possible. +10 indicates it have shifted up 10bpm (Measured/Derived from or related to Acitheart Monitor/Data )
Integer
Shift of HR reference for rest phase
Phase 2 data. Shift of HR reference for rest phase (center of acceptance zone). Cleaning variable; indicates if the reference phase of heart which is deemed cleaned and useable has been shifted to ensure clean data only is included as much as possible. +10 indicates it have shifted up 10bpm (Measured/Derived from or related to Acitheart Monitor/Data )
Integer
Shift of HR reference test phase
Phase 2 data. Shift of HR reference for test phase of treadmill test (center of acceptance zone). Cleaning variable; indicates if the reference phase of heart which is deemed cleaned and useable has been shifted to ensure clean data only is included as much as possible. +10 indicates it have shifted up 10bpm (Measured/Derived from or related to Acitheart Monitor/Data )
Integer
% tme spent btwn 1.5-3MET t/mill
Phase 2 data. Fraction of time spent between 1.5-3METs (rmr); acceleration and heart rate using t/mill no VO2 calibration; This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation. This is individually calibrated using a multi-point slope based estimate from the treadmill test. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spent btwn 1.5-3MET 3min wlk calibration
Phase 2 data. Fraction of time spent between 1.5-3METs (rmr);d acceleration and heart rate using 3-min walk calibration (from treadmill test). This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation. This is individually calibrated using a 1pt calibration from 3min walk phase of treadmill protocol. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spent btwn 1.5-3MET grp calibration
Phase 2 data. Fraction of time spent between 1.5-3METs (rmr); acceleration and heart rate using group calibration. Where possible; a specific group equation is derived for that study using data from the IC tests. Where this is not possible; the most appropriate equation from another study will have been applied in the calculation of the group estimated physical activity energy expenditure results. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation. Equation used is indicated in GROUP_EQUATION. Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spent btwn 1.5-3MET 200m wlk calibration
Phase 2 data. Fraction of time spent between 1.5-3METs (rmr); acceleration and heart rate using self paced 200m walk calibration. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation. This is individually calibrated using a 1pt estimate from the self paced walk test. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt btwn 1.5-3MET std t/mill
Phase 2 data. Fraction of time between 1.5-3METs (std); acceleration and heart rate using t/mill no VO2 calibration . This variable uses the resting metabolic rate as defined in STANDARD_MET; same for every individual. This is individually calibrated using a multi-point slope based estimate from the treadmill test. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt btwn 1.5-3MET std 3minwlk calibration
Phase 2 data. Fraction of time between 1.5-3METs (std); acceleration and heart rate using 3-min walk calibration. This variable uses the resting metabolic rate as defined in STANDARD_MET; same for every individual. This is individually calibrated using a 1pt calibration from 3min walk phase of treadmill protocol. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt btwn 1.5-3MET std 200mwlk calibration
Phase 2 data. Fraction of time between 1.5-3METs (std); acceleration and heart rate using self paced 200m walk calibration. This variable uses the resting metabolic rate as defined in STANDARD_MET; same for every individual. This is individually calibrated using a 1pt estimate from the self paced walk test. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spent <= 1.5MET using t/mill
Phase 2 data. Fraction of time spent < = 1.5 MET (rmr); acceleration and heart rate using t/mill; no VO2 calibration. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation. This is individually calibrated using a multi-point slope based estimate from the treadmill test. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spent <= 1.5MET using 3min wlk calibration
Phase 2 data. Fraction of time spent < = 1.5 MET (rmr); acceleration and heart rate using 3-min walk calibration; This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation. This is individually calibrated using a 1pt calibration from 3min walk phase of treadmill protocol. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt btwn 1.5-3MET std grp calibration
Phase 2 data. Fraction of time between 1.5-3METs (std); acceleration and heart rate using group calibration. This variable uses the resting metabolic rate calculation as defined in STANDARD_MET; same for every individual. Where possible; a specific group equation is derived for that study using data from the IC tests. Where this is not possible; the most appropriate equation from another study will have been applied in the calculation of the group estimated physical activity energy expenditure results. Equation used is indicated in GROUP_EQUATION. Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spent <= 1.5MET using grp calibration
Phase 2 data. Fraction of time spent < = 1.5 MET (rmr); acceleration and heart rate using group calibration; This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation. Where possible; a specific group equation is derived for that study using data from the IC tests. Where this is not possible; the most appropriate equation from another study will have been applied in the calculation of the group estimated physical activity energy expenditure results. Equation used is indicated in GROUP_EQUATION. Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spent <= 1.5MET using 200m wlk calibration
Phase 2 data. Fraction of time spent < = 1.5 MET (rmr); acceleration and heart rate using self paced 200m walk calibration; This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation. This is individually calibrated using a 1pt estimate from the self paced walk test. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spent <= 1.5METstd t/mill
Phase 2 data. Fraction of time spent < = 1.5 MET (std) acceleration and heart rate using t/mill; no VO2 calibration. This variable uses the resting metabolic rate as defined in STANDARD_MET; same for every individual. This is individually calibrated using a multi-point slope based estimate from the treadmill test. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spent <= 1.5METstd 3min wlk calibration
Phase 2 data. Fraction of time spent < = 1.5 MET (std); acceleration and heart rate using 3-min walk calibration; This variable uses the resting metabolic rate calculation as defined in STANDARD_MET; same for every individual. This is individually calibrated using a 1pt calibration from 3min walk phase of treadmill protocol. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spent <= 1.5METstd grp calbiration
Phase 2 data. Fraction of time spent < = 1.5 MET (std); acceleration and heart rate using group calibration; This variable uses the resting metabolic rate calculation as defined in STANDARD_MET; same for every individual. Where possible; a specific group equation is derived for that study using data from the IC tests. Where this is not possible; the most appropriate equation from another study will have been applied in the calculation of the group estimated physical activity energy expenditure results. Equation used is indicated in GROUP_EQUATION. Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spent <= 1.5METstd 200m wlk calibration
Phase 2 data. Fraction of time spent < = 1.5 MET (std); acceleration and heart rate using self paced 200m walk calibration; This variable uses the resting metabolic rate as defined in STANDARD_MET; same for every individual. This is individually calibrated using a 1pt estimate from the self paced walk test. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spent >= 3MET using t/mill
Phase 2 data. Fraction of time spent above 3MET (rmr); acceleration and heart rate using t/mill; no VO2 calibration. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation. This is individually calibrated using a multi-point slope based estimate from the treadmill test. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spent >= 3MET using 3min wlk calibration
Phase 2 data. Fraction of time spent above 3MET(rmr); acceleration and heart rate using 3-min walk calibration; This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation. This is individually calibrated using a 1pt calibration from 3min walk phase of treadmill protocol. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spent >= 3MET using 200m wlk calibration
Phase 2 data. Fraction of time spent above 3MET (rmr); acceleration and heart rate using self paced 200m walk calibration; This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation. This is individually calibrated using a 1pt estimate from the self paced walk test. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spent >= 3MET using grp calibration
Phase 2 data. Fraction of time spent above 3MET (rmr); acceleration and heart rate using group calibration; This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation. Where possible; a specific group equation is derived for that study using data from the IC tests. Where this is not possible; the most appropriate equation from another study will have been applied in the calculation of the group estimated physical activity energy expenditure results. Equation used is indicated in GROUP_EQUATION. Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt >= 3MET std using t/mill
Phase 2 data. Fraction of time above 3METs (std); acceleration and heart rate using t/mill no VO2 calibration. This variable uses the resting metabolic rate as defined in STANDARD_MET; same for every individual. This is individually calibrated using a multi-point slope based estimate from the treadmill test. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt >= 3MET std using 3min wlk calibration
Phase 2 data. Fraction of time above 3METs (std); acceleration and heart rate using 3-min walk calibration. This variable uses the resting metabolic rate as defined in STANDARD_MET; same for every individual. This is individually calibrated using a 1pt calibration from 3min walk phase of treadmill protocol. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt >= 3MET std using grp calibration
Phase 2 data. Fraction of time above 3METs (std); acceleration and heart rate using group calibration. This variable uses the resting metabolic rate calculation as defined in STANDARD_MET; same for every individual. Where possible; a specific group equation is derived for that study using data from the IC tests. Where this is not possible; the most appropriate equation from another study will have been applied in the calculation of the group estimated physical activity energy expenditure results. Equation used is indicated in GROUP_EQUATION. Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt >= 3MET std 200m wlk calibration
Phase 2 data. Fraction of time above 3METs (std); acceleration and heart rate using self paced 200m walk calibration. This variable uses the resting metabolic rate as defined in STANDARD_MET; same for every individual. This is individually calibrated using a 1pt estimate from the self paced walk test. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Diurnal PAEE gradient midnight
Phase 2 data. Diurnal PAEE gradient; 12pm-12am axis(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Test time early lowest exercise HR occurs
Phase 2 data. Earliest time during treadmill test at which lowest exercise heart rate occurs (based on first derivative)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Lowest observed ACC reading
Phase 2 data. Lowest observed ACC reading in file (before adjustment). Some historical monitors presented issues regarding accelerometres meaning no movement periods were not recorded as zero. This is less common with the more recent monitors; however data is still checked for this error. File indicates lowest acc in file (should be 0)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Diurnal PAEE gradient 6pm-6am axis
Phase 2 data. Diurnal PAEE gradient; 6pm-6am axis(Measured/Derived from or related to Acitheart Monitor/Data )
Real
None
Phase 2 data. Energy expenditure from acceleration (kJ/kg/day). Ignores Pwear and assumes all observations are valid. Present for all those who have a valid free-living file i.e file present; no corruptions deemed to acceleration estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
None
Phase 2 data. Activity energy expenditure based on combined acceleration and heart rate using group cal (kJ/kg/day); All Pwear set to 1. All observations considered valid. Where possible; a specific group equation is derived for that study using data from the IC tests. Where this is not possible; the most appropriate equation from another study will have been applied in the calculation of the group estimated physical activity energy expenditure results. Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
New lowest observed ACC reading
Phase 2 data. If variable min_ACC_obs is not 0 then adjustments are made and new min acc displayed here. If no adjustment was needed this variable value will be . to indicate blank(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Peak run mdn HRaS last min treadmill test
Phase 2 data. Peak running median Heart Rate above sleep (HRaS) during last min of treadmill test bpm(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Peak run mdn HRaS treadmill test
Phase 2 data. Peak running median Heart Rate above Sleep (HRaS) during treadmill test bpm(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mean Obs resting HRaS rest test
Phase 2 data. mean observed resting heart rate above sleep during rest test from valid rest test observations(Measured/Derived from or related to Acitheart Monitor/Data )
Real
25th Percentile obs HRaS rest test
Phase 2 data. 25th percentile observed resting heart rate above sleep during rest test from valid rest test observations(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Scaled AEE based on acceleration
Phase 2 data. Scaled Physical Activity Energy Expenditure results based on acceleration only signal. If using an ACC only signal model then the estimate will have been scaled based on the relationship between PAEE_Branch (highest available) and PAEE_ACC and a mean taken from all individuals who have valid estimates for both and Pwear>48hr with >8hrs Pwear in each day quadrant (Morning; noon; afternoon; night). This is the scale factor for each participant that was included in producing mean scale factor for acceleration.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Scaled HR based on flexHR model
Phase 2 data. Scaled Physical Activity Energy Expenditure results based on heart rate only signal. If using an HR only signal model then the estimate will have been scaled based on the relationship between PAEE_Branch (highest available) and PAEE_HR (highest available) and a mean taken from all individuals who have valid estimates for both and Pwear>48hr with >8hrs Pwear in each day quadrant (Morning; noon; afternoon; night). This is the scale factor for each individual that was included in producing mean scale factor for heart rate only models(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mean PAEE by Acceleration model
Phase 2 data. Mean Physical Activity energy expenditure based on acceleration only. Pwear taken from combined heart rate and acceleration signal(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mean PAEE by Acc PwACC weighted
Phase 2 data. Mean Physical Activity energy expenditure based on acceleration only. Pwear taken acceleration signal only (Measured/Derived from or related to Acitheart Monitor/Data )
Real
AEE combined acc HR using t/mill
Phase 2 data. Activity energy expenditure based on combined acceleration and heart rate using treadmill no VO2 (kJ/kg/day). This is used when the calibration test data are of sufficient quality to derive calibration factors and will be multiple point – if test duration is sufficient to derive slope-based estimate; e.g. >9.5 mins test duration. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
AEE combined acc HR using 3min wlk calibration
Phase 2 data. Activity energy expenditure based on combined acceleration and heart rate using 3-min walk calibration from treadmill test (no VO2) (kJ/kg/day). Uses 1pt calibration to derive estimate where duration may not be sufficient for multiple point calibration. Those with sufficient treadmill length and quality for slope based will also have a 1pt calibration. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
AEE combined acc HR using grp calibration
Phase 2 data. Activity energy expenditure based on combined acceleration and heart rate using group cal (kJ/kg/day). Where possible; a specific group equation is derived for that study using data from the IC tests. Where this is not possible; the most appropriate equation from another study will have been applied in the calculation of the group estimated physical activity energy expenditure results. Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
AEE combined acc HR using 200m wlk calibration
Phase 2 data. Activity energy expenditure based on combined acceleration and heart rate using self paced 200m walk cal (kJ/kg/day). 1pt calibration used for those who undertook walk test. Present for all those who have a valid individual calibration file (as above) and valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Suggestion for consolidated AEE
Phase 2 data. Consolidated Physical Activity Energy Expenditure estimate where the highest available individually calibrated method has been used. Priority order multi point Treadmill (Branch2); 1pt Treadmill (Branch6); 1pt Walk test (Branch8); Group (Branch7). Where recommendations suggest alternative to branch equation is needed (due to possible corruption with the trace) then this model will have been scaled (as per paascaled_acc or paeescaled_hr) and used for this variable(Measured/Derived from or related to Acitheart Monitor/Data )
Real
AEE flexHR using 3-min walk
Phase 2 data. Activity energy expenditure based on flexHR model using 3-min walk calibration from treadmill tests; no VO2 (kJ/kg/day). Based on Pwear from combined heart rate and acc signals(Measured/Derived from or related to Acitheart Monitor/Data )
Real
AEE flexHR using slow walk calibration
Phase 2 data. Activity energy expenditure based on flexHR model using slow walk cal; no VO2; based on Pwear from heart rate only signal(Measured/Derived from or related to Acitheart Monitor/Data )
Real
AEE flexHR model using group calibration
Phase 2 data. Activity energy expenditure based on flexHR model using group calibration (kJ/kg/day). Based on Pwear from combined heart rate and acc signals(Measured/Derived from or related to Acitheart Monitor/Data )
Real
AEE flexHR using group calibration
Phase 2 data. Activity energy expenditure based on flexHR model using group cal (kJ/kg/day); based on Pwear from heart rate only signal(Measured/Derived from or related to Acitheart Monitor/Data )
Real
AEE flexHR self paced 200m walk
Phase 2 data. Activity energy expenditure based on flexHR model using self paced 200m walk calibration (kJ/kg/day). Based on Pwear from combined heart rate and acc signals(Measured/Derived from or related to Acitheart Monitor/Data )
Real
AEE flexHR self paced 200m walk calibration
Phase 2 data. Activity energy expenditure based on flexHR model using self paced 200m walk cal (kJ/kg/day); based on Pwear from heart rate only signal(Measured/Derived from or related to Acitheart Monitor/Data )
Real
AEE based on flexHR model
Phase 2 data. Activity energy expenditure based on flexHR model using t/mill calibration; no VO2 (kJ/kg/day). Based on Pwear from combined heart rate and acc signals(Measured/Derived from or related to Acitheart Monitor/Data )
Real
AEE flexHR using t/mill calibration
Phase 2 data. Activity energy expenditure based on flexHR model using t/mill calibration; no VO2; based on Pwear from heart rate only signal(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Predicted Resting Metabolic Rate
Phase 2 data. Predicted Resting Metabolic Rate using Oxford 2005 equation (J/min/kg)
Real
Pwear acceleration only 3PM-9PM
Phase 2 data. Number of hrs considered worn recorded during free-living; 3PM-9PM. Valid hour is where the monitor is considered as being worn based on the acceleration only signal(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Pwear acceleration only 3AM-9AM
Phase 2 data. Number of hrs considered worn recorded during free-living; 3AM-9AM. Valid hour is where the monitor is considered as being worn based on the acceleration only signal(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Pwear acceleration only 9PM-3AM
Phase 2 data. Number of hrs considered worn recorded during free-living; 9PM-3AM. Valid hour is where the monitor is considered as being worn based on the acceleration only signal(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Pwear acceleration only 9AM-3PM
Phase 2 data. Number of hrs considered worn recorded during free-living; 9AM-3PM. Valid hour is where the monitor is considered as being worn based on the acceleration only signal(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Pwear based on acceleration signal
Phase 2 data. Amount of time monitor is considered worn (and therefore data in included in estimates) based on the acceleration signal (Measured/Derived from or related to Acitheart Monitor/Data )
Real
Pwear acceleration only weekend
Phase 2 data. Number of hours worn which fall on a weekend day (Saturday and Sunday). Based on acceleration only signal(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Pwear acceleration only weekday
Phase 2 data. Number of hours considered worn which fall on a weekday (Monday - Friday). Based on acceleration only signal(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Pwear 3PM-9PM
Phase 2 data. Number of hrs considered worn recorded during free-living; 3PM-9PM. Valid hour is where the monitor is considered as being worn based on the combined hear rate and acceleration signals(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Consolidated Pwear
Phase 2 data. Amount of time (hrs) monitor is considered worn (and therefore data in included in estimates) for based on which model has been used for PAEE_Consolidated. Those where no notable corruptions have been flagged will use Pwear (wear time based on combined HR and ACC models). Suggest inclusion criteria based on this variable (as well as quadrant Pwear variables).(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept regression Pwear
Phase 2 data. Intercept from double-sine regression model of Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Pwear based on heart rate
Phase 2 data. Amount of time monitor is considered worn (and therefore data in included in estimates) based on the combined heart rate signal(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mean density of information
Phase 2 data. Mean density of information (mean Pwear)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Noon-midnight Diurnal density
Phase 2 data. Density of information along the noon-midnight axis(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Midnight coefficient regression Pwear
Phase 2 data. Midnight coefficient from double-sine regression model of Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Afternoon-morning Diurnal density
Phase 2 data. Density of information along the afternoon-morning axis(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Pwear 3AM-9AM
Phase 2 data. Number of hrs considered worn recorded during free-living; 3AM-9AM. Valid hour is where the monitor is considered as being worn based on the combined hear rate and acceleration signals(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Morning coefficient regression Pwear
Phase 2 data. Morning coefficient from double-sine regression model of Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Pwear 9PM-3AM
Phase 2 data. Number of hrs considered worn recorded during free-living; 9PM-3AM. Valid hour is where the monitor is considered as being worn based on the combined hear rate and acceleration signals(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Pwear 9AM-3PM
Phase 2 data. Number of hrs considered worn recorded during free-living; 9AM-3PM. Valid hour is where the monitor is considered as being worn based on the combined hear rate and acceleration signals(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Pwear based on HR-acceleration
Phase 2 data. Amount of time monitor is considered worn for (and therefore data in included in estimates) based on the combined heart rate and acceleration signal(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Pwear Spring
Phase 2 data. Seasonal parameter: avg info density on AUTUMN-SPRING axis. Hemisphere-adjusted(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Pwear weekend
Phase 2 data. Number of hours worn which fall on a weekend day (Saturday and Sunday). Based on combined heart rate and acceleration signals(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Pwear Winter
Phase 2 data. Seasonal parameter: avg info density on SUMMER-WINTER axis. Hemisphere-adjusted ) (-1 to +1)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Pwear weekday
Phase 2 data. Number of hours considered worn which fall on a weekday (Monday - Friday). Based on combined heart rate and acceleration signals(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Total length of file recording
Phase 2 data. Total length of file recording (regardless of whether monitor is worn). This indicates time from monitor set up until download (or monitor reaches memory/battery capacity)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Duration of treadmill test recovery phase
Phase 2 data. Duration of treadmill test recovery phase (min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Duration of rest test (min)
Phase 2 data. Duration of rest test (min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Start time of rest test
Phase 2 data. Real start time of supine rest test. (Measured/Derived from or related to Acitheart Monitor/Data )
DateTime
Mdn trunk acceleration min 10 of rest test
Phase 2 data. Median trunk acceleration m/s2; min 10 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration min 1 of rest test
Phase 2 data. Median trunk acceleration m/s2; min 1 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration min 2 of rest test
Phase 2 data. Median trunk acceleration m/s2; min 2 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration min 3 of rest test
Phase 2 data. Median trunk acceleration m/s2; min 3 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration min 4 of rest test
Phase 2 data. Median trunk acceleration m/s2; min 4 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration min 5 of rest test
Phase 2 data. Median trunk acceleration m/s2; min 5 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration min 6 of rest test
Phase 2 data. Median trunk acceleration m/s2; min 6 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration min 7 of rest test
Phase 2 data. Median trunk acceleration m/s2; min 7 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration min 8 of rest test
Phase 2 data. Median trunk acceleration m/s2; min 8 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration min 9 of rest test
Phase 2 data. Median trunk acceleration m/s2; min 9 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HRabovesleep min 10 rest test
Phase 2 data. Median heart rate above sleep bpm; min 10 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR abovesleep min 1 rest test
Phase 2 data. Median heart rate above sleep bpm; min 1 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR abovesleep min 2 rest test
Phase 2 data. Median heart rate above sleep bpm; min 2 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR abovesleep min 3 rest test
Phase 2 data. Median heart rate above sleep bpm; min 3 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR abovesleep min 4 rest test
Phase 2 data. Median heart rate above sleep bpm; min 4 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR abovesleep min 5 rest test
Phase 2 data. Median heart rate above sleep bpm; min 5 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR abovesleep min 6 rest test
Phase 2 data. Median heart rate above sleep bpm; min 6 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR abovesleep min 7 rest test
Phase 2 data. Median heart rate above sleep bpm; min 7 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR abovesleep min 8 rest test
Phase 2 data. Median heart rate above sleep bpm; min 8 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR abovesleep min 9 rest test
Phase 2 data. Median heart rate above sleep bpm; min 9 of supine rest test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Rest HRaS anchor point
Phase 2 data. Rest heart rate above Sleep; used as heart rate anchor point for all calibration levels. Uses SHR variable in calculation(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error term residual regression of rest phase(1st pass)
Phase 2 data. Error term; residual regression of rest phase (1st pass)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error term residual regression treadmill test recovery phases(1st pass)
Phase 2 data. Error term; residual regression of treadmill test and recovery phases (1st pass)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error term regression mdn HR recovery time(0-1.5min) treadmill
Phase 2 data. Error term; regression of median heart rate against recovery time (0-1.5 min) - Treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error term regression mdn HR test time(omit frst 2.5min) treadmill
Phase 2 data. Error term; regression of median heart rate against testtime (omit first 2.5min) - Treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error term residual regression treadmill test recovery phases (2nd pass)
Phase 2 data. Error term; residual regression of treadmill test and recovery phases (2nd pass)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Sex
Phase 2 data. Sex (0 = female; 1 = male) used in all physical activity estimates
Categorical
Error INT_stdMET_highIC_BRANCH_cat0
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat0(Measured/Derived from or related to Acitheart Monitor/Data )
Real
ErrorINT_stdMET_highIC_BRANCH_cat10
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat10(Measured/Derived from or related to Acitheart Monitor/Data )
Real
ErrorINT_stdMET_highIC_BRANCH_cat11
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat11(Measured/Derived from or related to Acitheart Monitor/Data )
Real
ErrorINT_stdMET_highIC_BRANCH_cat12
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat12(Measured/Derived from or related to Acitheart Monitor/Data )
Real
ErrorINT_stdMET_highIC_BRANCH_cat13
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat13(Measured/Derived from or related to Acitheart Monitor/Data )
Real
ErrorINT_stdMET_highIC_BRANCH_cat14
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat14(Measured/Derived from or related to Acitheart Monitor/Data )
Real
ErrorINT_stdMET_highIC_BRANCH_cat15
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat15(Measured/Derived from or related to Acitheart Monitor/Data )
Real
ErrorINT_stdMET_highIC_BRANCH_cat16
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat16(Measured/Derived from or related to Acitheart Monitor/Data )
Real
ErrorINT_stdMET_highIC_BRANCH_cat17
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat17(Measured/Derived from or related to Acitheart Monitor/Data )
Real
ErrorINT_stdMET_highIC_BRANCH_cat18
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat18(Measured/Derived from or related to Acitheart Monitor/Data )
Real
ErrorINT_stdMET_highIC_BRANCH_cat19
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat19(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error INT_stdMET_highIC_BRANCH_cat1
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat1(Measured/Derived from or related to Acitheart Monitor/Data )
Real
ErrorINT_stdMET_highIC_BRANCH_cat20
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat20(Measured/Derived from or related to Acitheart Monitor/Data )
Real
ErrorINT_stdMET_highIC_BRANCH_cat21
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat21(Measured/Derived from or related to Acitheart Monitor/Data )
Real
ErrorINT_stdMET_highIC_BRANCH_cat22
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat22(Measured/Derived from or related to Acitheart Monitor/Data )
Real
ErrorINT_stdMET_highIC_BRANCH_cat23
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat23(Measured/Derived from or related to Acitheart Monitor/Data )
Real
ErrorINT_stdMET_highIC_BRANCH_cat24
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat24(Measured/Derived from or related to Acitheart Monitor/Data )
Real
ErrorINT_stdMET_highIC_BRANCH_cat25
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat25(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error INTstdMEThighIC_BRANCH_cat26
Phase 2 data. Standard Error relating to variable se_INTstdMEThighIC_BRANCH_cat26(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error INTstdMEThighIC_BRANCH_cat27
Phase 2 data. Standard Error relating to variable se_INTstdMEThighIC_BRANCH_cat27(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error INT_stdMET_highIC_BRANCH_cat2
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat2(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error INT_stdMET_highIC_BRANCH_cat3
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat3(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error INT_stdMET_highIC_BRANCH_cat4
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat4(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error INT_stdMET_highIC_BRANCH_cat5
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat5(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error INT_stdMET_highIC_BRANCH_cat6
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat6(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error INT_stdMET_highIC_BRANCH_cat7
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat7(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error INT_stdMET_highIC_BRANCH_cat8
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat8(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error INT_stdMET_highIC_BRANCH_cat9
Phase 2 data. Standard Error relating to variable INT_stdMET_highIC_BRANCH_cat9(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Std error relating to PAEE Branch2
Phase 2 data. Standard error relating to variable physical activity energy expenditure Branch2(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Std error relating to PAEE Branch6
Phase 2 data. Standard error relating to variable physical activity energy expenditure Branch6(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Std error relating to PAEE Branch7
Phase 2 data. Standard error relating to variable physical activity energy expenditure Branch7(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Std error relating to PAEE Branch8
Phase 2 data. Standard error relating to variable physical activity energy expenditure Branch8(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Sleep HR beats/min
Phase 2 data. Sleep heart rate beats/min value used for free-living analysis. Usually derived from associated Free-living recording. If no Free-living recording present then Fenland 1 SHR may be used. If this is also not present then it may be estimated from Rest test. Whether sleeping heart rate has been estimated is indicated in the AH_COMMENTS and AH_FLAG_SHR variables(Measured/Derived from or related to Acitheart Monitor/Data )
Integer
AEE simple weight grp calbiration
Phase 2 data. Activity energy expenditure based on combined acceleration and heart rate using group cal (kJ/kg/day). Not adjusted for diurnal bias. Where possible; a specific group equation is derived for that study using data from the IC tests. Where this is not possible; the most appropriate equation from another study will have been applied in the calculation of the group estimated physical activity energy expenditure results. Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Denominator std intensity MET cat
Phase 2 data. Value used as the denominator in the standard intensity MET categories - standard for everyone(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Start date of free-living recording
Phase 2 data. Date of first day of free-living recording (days past 1/1/1960)(Measured/Derived from or related to Acitheart Monitor/Data )
Date
Start day wk of free-living record
Phase 2 data. Start day of week of free-living recording (1 = Monday; 2 = Tuesday; 3 = Wednesday; 4 = Thursday; 5 = Friday; 6 = Saturday; 7 = Sunday)(Measured/Derived from or related to Acitheart Monitor/Data )
Categorical
Start day yr of free-living record
Phase 2 data. Start day of year of free-living recording (days past Dec 31st)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Start time of free-living recording
Phase 2 data. Start time of free-living recording (minutes past 00:00)(Measured/Derived from or related to Acitheart Monitor/Data )
Time
Type of data treadmill test calibration
Phase 2 data. Variable defines which type of data from the monitor has been able to be used for treadmill test calibration. GREEN indicates high quality HR data available and so full ibi data from Actiheart could be used for calibration. ORANGE indicates lower quality heart data available from Actiheart and so alternative heart rate from Polar monitor has been manually inputted into file(Measured/Derived from or related to Acitheart Monitor/Data )
Text
Duration treadmill test completed
Phase 2 data. Duration of treadmill Test completed (min); varies per participant(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Start time of actual treadmill test
Phase 2 data. Real start time of actual treadmill test; calibration protocol noted in calibration_protocol(Measured/Derived from or related to Acitheart Monitor/Data )
DateTime
Test time latest lowest exercise HR occurs
Phase 2 data. Latest time during treadmill test at which lowest exercise heart rate occurs (based on first derivative)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Time spentbelow FlexHR -5bpm
Phase 2 data. Fraction of time spent below FlexHR -5bpm (derived from treadmill)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Time spentbelow FlexHR +5bpm
Phase 2 data. Fraction of time spent below FlexHR +5bpm (derived from treadmill)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Ttime spentbelow FlexHR
Phase 2 data. Fraction of time spent below FlexHR (derived from treadmill)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Clock time change detected
Phase 2 data. Indicates whether the free-living wear cross over a clock change period ; -1 = clocks went backward during wear; 1 = clocks went forwards during wear. Data has been adjusted to remove duplicate data or avoid missing data(Measured/Derived from or related to Acitheart Monitor/Data )
Categorical
Time after beginning of treadmill test beyond which obs are included
Phase 2 data. Time after beginning of treadmill test beyond which observations are included(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Time resolution intermediate processing
Phase 2 data. Level of intermediate processing before summary level variables produced. E.g Hourly data (60mins) which can then be further summarised to daily/summary level where required. This is stipulated pre-processing(Measured/Derived from or related to Acitheart Monitor/Data )
Time
Within-record time trend MET/hr
Phase 2 data. Within-record time trend MET/hr. Adj for diurnal rhythm and weekend(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Transition HRaS
Phase 2 data. Transition heart rate above Sleep; used as heart rate branching point (b1/b2); all calibration levels. Reference Brage et al JAP2007(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept 1pt calibration
Phase 2 data. Intercept used for 1pt calibration derived from treadmill test (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Beta-coefficient 1pt calibration
Phase 2 data. Beta coefficient used for 1pt calibration derived from treadmill test (J/kg/beat)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mean HRaS btwn 4-5 min (1pt calibration)
Phase 2 data. Mean heart rate above sleep between 4 and 5 min (used for 1pt calibration) from treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 10
Phase 2 data. Median trunk acceleration m/s2; minute 10 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 11
Phase 2 data. Median trunk acceleration m/s2; minute 11 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 12
Phase 2 data. Median trunk acceleration m/s2; minute 12 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 13
Phase 2 data. Median trunk acceleration m/s2; minute 13 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 14
Phase 2 data. Median trunk acceleration m/s2; minute 14 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 15
Phase 2 data. Median trunk acceleration m/s2; minute 15 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 16
Phase 2 data. Median trunk acceleration m/s2; minute 16 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 17
Phase 2 data. Median trunk acceleration m/s2; minute 17 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 18
Phase 2 data. Median trunk acceleration m/s2; minute 18 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 19
Phase 2 data. Median trunk acceleration m/s2; minute 19 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 1
Phase 2 data. Median trunk acceleration m/s2; minute 1 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 20
Phase 2 data. Median trunk acceleration m/s2; minute 20 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 21
Phase 2 data. Median trunk acceleration m/s2; minute 21 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 2
Phase 2 data. Median trunk acceleration m/s2; minute 2 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 3
Phase 2 data. Median trunk acceleration m/s2; minute 3 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 4
Phase 2 data. Median trunk acceleration m/s2; minute 4 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 5
Phase 2 data. Median trunk acceleration m/s2; minute 5 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 6
Phase 2 data. Median trunk acceleration m/s2; minute 6 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 7
Phase 2 data. Median trunk acceleration m/s2; minute 7 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 8
Phase 2 data. Median trunk acceleration m/s2; minute 8 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median trunk acceleration min 9
Phase 2 data. Median trunk acceleration m/s2; minute 9 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Sleep HR treadmill test analysis
Phase 2 data. Sleeping heart rate used for treadmill test analysis. Usually derived from associated Free-living recording. If no Free-living recording present then Fenland 1 SHR may be used. If this is also not present then it may be estimated from Rest test. Whether sleeping heart rate has been estimated is indicated in the AH_COMMENTS and AH_FLAG_SHR variables(Measured/Derived from or related to Acitheart Monitor/Data )
Integer
Mean HRaS fast wlk calibration 8 -10min
Phase 2 data. Mean heart rate above sleep (HRaS) between 8 and 10min (used for fast walk calibration)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept HRaS-PAEE mdn HR treadmill test
Phase 2 data. Intercept of heart rate above sleep-physical activity energy expenditure relationship using median heart rate during treadmill (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept HRaS-PAEE mdn HR frst 10min treadmill test
Phase 2 data. Intercept; heart rate above sleep-physical activity energy expenditure relationship (med heart rate); first 10min treadmill test (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept HRaS-PAEE mdn HR frst 15min treadmill test
Phase 2 data. Intercept; heart rate above sleep-physical activity energy expenditure relationship (med heart rate); first 15min treadmill test (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept HRaS-PAEE mdn HR treadmill test uncensored
Phase 2 data. Intercept of heart rate above sleep-physical activity energy expenditure relationship using median heart rate during t/mill (uncensored) (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Applied intercept of HRaS-PAEE
Phase 2 data. Applied intercept of heart rate above sleep-physical activity energy expenditure (est) relationship; tread.calibration (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept HRaS-PAEE regressioned HR treadmill test
Phase 2 data. Intercept of heart rate above sleep-physical activity energy expenditure relationship using regressed HR during treadmill (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept HRaS-PAEE treadmill calibration
Phase 2 data. Intercept of heart rate above sleep-physical activity energy expenditure (est) relationship; tread.calibration (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
HRaS estPAI ratio fast wlk calibration 8-10min
Phase 2 data. heart rate above sleep/estPAI ratio; fast walk calibration (8 to 10min) (J/kg/beat)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Slope HRaS-PAEE mdn HR treadmill test
Phase 2 data. Slope of heart rate above sleep-physical activity energy expenditure relationship using median heart rate during treadmill (J/kg/beat)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Slope HRaS-PAEE mdn HR frst 10min treadmill test
Phase 2 data. Slope; heart rate above sleep-physical activity energy expenditure relationship (med heart rate); first 10min treadmill test (J/kg/beat)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Slope HRaS-PAEE mdn HR frst 15min treadmill test
Phase 2 data. Slope; heart rate above sleep-physical activity energy expenditure relationship (med heart rate); first 15min treadmill test (J/kg/beat)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Slope HRaS-PAEE mdn HR treadmill test uncensored
Phase 2 data. Slope of heart rate above sleep-physical activity energy expenditure relationship using median HR during treadmill test (uncensored)(J/kg/beat)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Applied beta coefficient HRaS-PAEE
Phase 2 data. Applied beta coefficient of heart rate above sleep-physical activity energy expenditure (est) relationship; tread.cal. (J/kg/beat)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Slope HRaS-PAEE regression HR treadmill test
Phase 2 data. Slope of heart rate above sleep-physical activity energy expenditure relationship using regressed HR during treadmill (J/kg/beat)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Beta coefficient HRaS-PAEE treadmill calibration
Phase 2 data. Beta coefficient of heart rate above sleep-physical activity energy expenditure (est) relationship; tread.cal. (J/kg/beat)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
PAEE at 40bpm above SHR 1-pt
Phase 2 data. Point; treadmill test 1-pt calibration curve: physical activity energy expenditure @ 40bpm above sleeping heart rate (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
PAEE at 40bpm above SHR
Phase 2 data. Point; appl treadmill test calibration curve: physical activity energy expenditure @ 40bpm above sleeping heart rate (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
PAI at 40bpm from fast walk calibration
Phase 2 data. Point (physical activity intensity @ 40bpm) on calibration curve resulting from fast walk calibration (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Treadmill test VO2max estimate
Phase 2 data. Treadmill test VO2max estimate (ml O2/min/kg) using estimated physical activity energy expenditure. Estimate present if treadmill duration > = 10mins and useable HR quality. Energy cost based on predicted energy expenditure from Brage et al 2007 (JAP). Submaximal response extrapolated to max HR (Tanaka 2001)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Treadmill test VO2max HighPt model
Phase 2 data. Treadmill test VO2max estimate (ml O2/min/kg) using estimated physical activity energy expenditure (HighPt model)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Treadmill VO2max estimate >15mins
Phase 2 data. Treadmill VO2max estimate (ml O2/min/kg) using estimated physical activity energy expenditure (disregard data >15mins)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Applied flex HR treadmill test
Phase 2 data. Applied flex heart rate from treadmill test (beats/min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept fast walk calibration
Phase 2 data. Intercept used for fast walk calibration derived from treadmill test (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Beta-coefficient fast walk calibration
Phase 2 data. Beta-coefficient used for fast walk calibration derived from treadmill test (J/kg/beat)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Avg HRaS rolling mdn btwn min 4-5
Phase 2 data. Average heart rate above sleep from rolling median heart rate above sleep between min 4 and 5 during treadmill(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Avg HRaS regressioned btwn min 4-5
Phase 2 data. Average heart rate above sleep from regressed heart rate above sleep between min 4 and 5 during treadmill (Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 10
Phase 2 data. Median heart rate above sleep bpm; minute 10 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 11
Phase 2 data. Median heart rate above sleep bpm; minute 11 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 12
Phase 2 data. Median heart rate above sleep bpm; minute 12 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 13
Phase 2 data. Median heart rate above sleep bpm; minute 13 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 14
Phase 2 data. Median heart rate above sleep bpm; minute 14 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 15
Phase 2 data. Median heart rate above sleep bpm; minute 15 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 16
Phase 2 data. Median heart rate above sleep bpm; minute 16 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 17
Phase 2 data. Median heart rate above sleep bpm; minute 17 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 18
Phase 2 data. Median heart rate above sleep bpm; minute 18 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 19
Phase 2 data. Median heart rate above sleep bpm; minute 19 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 1
Phase 2 data. Median heart rate above sleep bpm; minute 1 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 20
Phase 2 data. Median heart rate above sleep bpm; minute 20 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 21
Phase 2 data. Median heart rate above sleep bpm; minute 21 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 2
Phase 2 data. Median heart rate above sleep bpm; minute 2 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 3
Phase 2 data. Median heart rate above sleep bpm; minute 3 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 4
Phase 2 data. Median heart rate above sleep bpm; minute 4 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 5
Phase 2 data. Median heart rate above sleep bpm; minute 5 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 6
Phase 2 data. Median heart rate above sleep bpm; minute 6 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 7
Phase 2 data. Median heart rate above sleep bpm; minute 7 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 8
Phase 2 data. Median heart rate above sleep bpm; minute 8 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep bpm min 9
Phase 2 data. Median heart rate above sleep bpm; minute 9 of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
PAEE at age-pred max HR 1-pt
Phase 2 data. Point; treadmill test 1-pt calibration curve: physical activity energy expenditure @ age-pred. max heart rate (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
PAI age-pred maxHR fast walk calibration
Phase 2 data. Point (physical activity intensity @ age-pred. max heart rate) on calibration curve resulting from fast walk calibration (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
PAEE at age-pred max HR
Phase 2 data. Point; appl treadmill test calibration curve: physical activity energy expenditure @ age-pred. max heart rate (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
PAEE at age-pred max HR (trunc15)
Phase 2 data. Point; appl treadmill calibration curve (truncated to 15mins): physical activity energy expenditure @ age-pred. max heart rate (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Estimated max HR above sleep
Phase 2 data. Estimated max HR above sleep (208 - 0.7*age - shr - 20*betablocker)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median est. PAI last 2min of test
Phase 2 data. Median estimated physical activity intensity during last 2min of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HRaS last 2min of test
Phase 2 data. Median heart rate above sleep during last 2min of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
1-min rec HRaS treadmill test global regression
Phase 2 data. 1-min recovery heart rate above sleep from treadmill test based on global regression (beats/min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
1-min rec HRaS treadmill test 90-sec regression
Phase 2 data. 1-min recovery heart rate above sleep from treadmill test based on 90-sec regression (beats/min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mean HRaS TimeRisePoint (+/-.25min)
Phase 2 data. Mean heart rate above sleep (HRaS) at TimeRisePoint (+/-.25min) from treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Date of treadmill test
Phase 2 data. Date of treadmill test(Measured/Derived from or related to Acitheart Monitor/Data )
Date
No valid obs treadmill test recovery phase
Phase 2 data. Number of valid observations from treadmill test recovery phase. Data must be annotated as within the annotated treadmill test recovery period from participant's visit; be between 0-90sec within that phase and not have been masked out as noisy during cleaning stage(Measured/Derived from or related to Acitheart Monitor/Data )
Integer
No of valid observations rest test data
Phase 2 data. Number of valid observations from rest test data. Data must be annotated as within the annotated rest test period from participant's visit and occur between 3-10mins and not have been masked out as noisy during cleaning stage(Measured/Derived from or related to Acitheart Monitor/Data )
Integer
No valid obs treadmill test data 8-10min
Phase 2 data. Number of valid observations from treadmill test data 8-10mins. Data must be annotated as within the annotated treadmill test period from 8-10mins from participant's visit and not have been masked out as noisy during cleaning stage(Measured/Derived from or related to Acitheart Monitor/Data )
Integer
No valid obs treadmill test last 2 min test
Phase 2 data. Number of valid observations from treadmill test during last 2 minutes. Data must be annotated as within the annotated treadmill test period in last 2 minutes from participant's visit and not have been masked out as noisy during cleaning stage(Measured/Derived from or related to Acitheart Monitor/Data )
Integer
No of valid obs during treadmill test data
Phase 2 data. Number of valid observations from treadmill test data. Data must be annotated as within the annotated treadmill test period from participant's visit; occur after time indicated in Time_excluded_beginTest and not have been masked out as noisy during cleaning stage(Measured/Derived from or related to Acitheart Monitor/Data )
Integer
Time distribution of valid HR pts 10%ile treadmill test
Phase 2 data. Time distribution of valid HR points (10th percentile) -Treadmill Test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Time distribution of valid HR pts 25%ile treadmill test
Phase 2 data. Time distribution of valid HR points (25th percentile) -Treadmill Test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Time distribution of valid HR pts 50%ile treadmill test
Phase 2 data. Time distribution of valid HR points (50th percentile) -Treadmill Test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Time distribution of valid HR pts 75%ile treadmill test
Phase 2 data. Time distribution of valid HR points (75th percentile) -Treadmill Test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Time distribution of valid HR pts 90%ile treadmill test
Phase 2 data. Time distribution of valid HR points (90th percentile) -Treadmill Test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Upper test time slow walk calibrationrartion
Phase 2 data. Upper test time limit for deriving slow walk calibration (min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Lower test time slow walk calibration
Phase 2 data. Lower test time limit for deriving slow walk calibration (min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept 1pt calibration walk test
Phase 2 data. Intercept used for 1pt calibration derived from walk test (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Beta-coefficient 1pt calibration walk test
Phase 2 data. Beta coefficient used for 1pt calibration derived from Walk test (J/kg/beat)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mean HRaS between 1 and 3 min
Phase 2 data. Mean heart rate above sleep (HRaS) between 1 and 3 min (used for 1pt calibration) for walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration sec 120 of walk test
Phase 2 data. Median trunk acceleration m/s2; sec 120 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration sec 150 of walk test
Phase 2 data. Median trunk acceleration m/s2; sec 150 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration sec 180 of walk test
Phase 2 data. Median trunk acceleration m/s2; sec 180 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration sec 210 of walk test
Phase 2 data. Median trunk acceleration m/s2; sec 210 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration sec 240 of walk test
Phase 2 data. Median trunk acceleration m/s2; sec 240 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration sec 270 of walk test
Phase 2 data. Median trunk acceleration m/s2; sec 270 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration sec 300 of walk test
Phase 2 data. Median trunk acceleration m/s2; sec 300 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration sec 30 of walk test
Phase 2 data. Median trunk acceleration m/s2; sec 30 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration sec 330 of walk test
Phase 2 data. Median trunk acceleration m/s2; sec 330 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration sec 360 of walk test
Phase 2 data. Median trunk acceleration m/s2; sec 360 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration sec 390 of walk test
Phase 2 data. Median trunk acceleration m/s2; sec 390 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration sec 420 of walk test
Phase 2 data. Median trunk acceleration m/s2; sec 420 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration sec 60 of walk test
Phase 2 data. Median trunk acceleration m/s2; sec 60 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mdn trunk acceleration sec 90 of walk test
Phase 2 data. Median trunk acceleration m/s2; sec 90 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Sleep HR value used Walk test analysis
Phase 2 data. Sleeping heart rate used for walk test analysis. Usually derived from associated Free-living recording. If no Free-living recording present then Fenland 1 SHR may be used. If this is also not present then it may be estimated from Rest test. Whether sleeping heart rate has been estimated is indicated in the AH_COMMENTS and AH_FLAG_SHR variables.(Measured/Derived from or related to Acitheart Monitor/Data )
Integer
Intercept of HRaS-PAEE mdn HR wlk
Phase 2 data. Intercept of HRaS-PAEE relationship using median HR during walk (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept of HRaS-PAEE wlk uncensored
Phase 2 data. Intercept of HRaS-PAEE relationship using median HR during t/walk (uncensored) (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Applied intercept of HRaS-PAEE wlk calibration
Phase 2 data. Applied intercept of HRaS-PAEE (est) relationship; walk calibration (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept of HRaS-PAEE regressioned HR wlk
Phase 2 data. Intercept of HRaS-PAEE relationship using regressed HR during walk (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept of HRaS-PAEE wlk calibration
Phase 2 data. Intercept of HRaS-PAEE (est) relationship; walk calibration (J/min/kg)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept regression mdn HR rectime 0-1min
Phase 2 data. Intercept; regression of median heart rate against rectime (0-1min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Intercept regression mdn HR rectime 0-1.5min
Phase 2 data. Intercept; regression of median heart rate against rectime (0-1.5min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Methd to derive individual calibration fitness value walk test
Phase 2 data. Indication of which method has been used to derive individual calibration and fitness values for walk test. Median = 0; Regressed = 1. Median is default method; regressed is selected as alternative to deal with noisy HR or responses that are very different from reference (Measured/Derived from or related to Acitheart Monitor/Data )
Categorical
Square term regression mdn HR rectime 0-1min
Phase 2 data. Square term; regression of median heart rate against rectime (0-1min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Square term regression mdn HR rectime 0-1.5min
Phase 2 data. Square term; regression of median heart rate against rectime (0-1.5min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Slope of HRaS-PAEE mdn HR wlk
Phase 2 data. Slope of HRaS-PAEE relationship using median HR during walk (J/kg/beat)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Slope of HRaS-PAEE wlk uncensored
Phase 2 data. Slope of HRaS-PAEE relationship using median HR during walk (uncensored)(J/kg/beat)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Applied beta coefficient of HRaS-PAEE wlk calibration
Phase 2 data. Applied beta coefficient of HRaS-PAEE (est) relationship; walk calibration (J/kg/beat)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Slope of HRaS-PAEE regressioned HR wlk
Phase 2 data. Slope of HRaS-PAEE relationship using regressed HR during walk (J/kg/beat)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Beta coefficient of HRaS-PAEE wlk calibration
Phase 2 data. Beta coefficient of HRaS-PAEE (est) relationship; walk calibration (J/kg/beat) (Measured/Derived from or related to Acitheart Monitor/Data )
Real
Linear term regression mdn HR rectime 0-1min
Phase 2 data. Linear term; regression of median heart rate against rectime (0-1min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Linear term regression mdn HR rectime 0-1.5min
Phase 2 data. Linear term; regression of median heart rate against rectime (0-1.5min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Protocol for walk test processing
Phase 2 data. Protocol used for walk test processing (Measured/Derived from or related to Acitheart Monitor/Data )
Text
Distance covered during walk test
Phase 2 data. Distance covered during walk test (metres)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
PAEE at 40bpm above sleep HR walk test 1pt calibration
Phase 2 data. Point; walk test 1-pt calibration curve: PAEE @ 40bpm above SHR (J/min/kg). Physical Activity energy expenditure at 40bpm above sleeping heart rate applied from the walk test using 1pt calibration.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
PAEE at 40bpm above sleeping HR walk test
Phase 2 data. Point; applied walk test calibration curve: PAEE @ 40bpm above SHR (J/min/kg). Physical Activity energy expenditure at 40bpm above sleeping heart rate applied from the walk test calibration curve.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fitness estimate derived from walk test
Phase 2 data. VO2max estimate (ml O2/min/kg). Fitness estimate derived from the Walk test. Estimate present if walk duration > = 1 and useable HR quality. Energy cost based on Ludlow 2016(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Flex HR derived from walk test
Phase 2 data. Flex heart rate that has been derived from the walk test (beats/min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Avg HRaS rolling mdn btwn min 1-3
Phase 2 data. Average heart rate above sleep (HRaS) from rolling median heart rate above sleep between min 1 and 3 during walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
AvgHRaS regressioned HRaS btwn min 1-3
Phase 2 data. Average heart rate above sleep (HRaS) from regressed heart rate above sleep between min 1 and 3 during walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep sec 120 of walk test
Phase 2 data. Median heart rate above sleep bpm; sec 120 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep sec 150 of walk test
Phase 2 data. Median heart rate above sleep bpm; sec 150 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep sec 180 of walk test
Phase 2 data. Median heart rate above sleep bpm; sec 180 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep sec 210 of walk test
Phase 2 data. Median heart rate above sleep bpm; sec 210 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep sec 240 of walk test
Phase 2 data. Median heart rate above sleep bpm; sec 240 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep sec 270 of walk test
Phase 2 data. Median heart rate above sleep bpm; sec 270 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep sec 300 of walk test
Phase 2 data. Median heart rate above sleep bpm; sec 300 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep sec 30 of walk test
Phase 2 data. Median heart rate above sleep bpm; sec 30 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep sec 330 of walk test
Phase 2 data. Median heart rate above sleep bpm; sec 330 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep sec 360 of walk test
Phase 2 data. Median heart rate above sleep bpm; sec 360 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep sec 390 of walk test
Phase 2 data. Median heart rate above sleep bpm; sec 390 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep sec 420 of walk test
Phase 2 data. Median heart rate above sleep bpm; sec 420 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep sec 60 of walk test
Phase 2 data. Median heart rate above sleep bpm; sec 60 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HR above sleep sec 90 of walk test
Phase 2 data. Median heart rate above sleep bpm; sec 90 of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Start time of walk file
Phase 2 data. Real start time of walk test file (Actiheart monitor started recording)(Measured/Derived from or related to Acitheart Monitor/Data )
DateTime
Scaling HR acceptance zone for walk test recovery phase
Phase 2 data. Scaling HR acceptance zone for walk test recovery phase. Widening or narrowing of heart rate acceptance zone to aid cleaning and ensure only clean heart rate is included as much as possible(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Scaling HR acceptance zone walk test
Phase 2 data. Scaling HR acceptance zone for walk test phase. Widening or narrowing of heart rate acceptance zone to aid cleaning and ensure only clean heart rate is included as much as possible(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Shift of HR reference for recovery phase walk test
Phase 2 data. Shift of HR reference for rec phase of walk test (center of acceptance zone). Cleaning variable; indicates if the reference phase of heart which is deemed cleaned and useable has been shifted to ensure clean data only is included as much as possible. +10 indicates it have shifted up 10bpm (Measured/Derived from or related to Acitheart Monitor/Data )
Integer
Shift of HR reference for test phase walk test
Phase 2 data. Shift of HR reference for test phase of walk test (center of acceptance zone). Cleaning variable; indicates if the reference phase of heart which is deemed cleaned and useable has been shifted to ensure clean data only is included as much as possible. +10 indicates it have shifted up 10bpm (Measured/Derived from or related to Acitheart Monitor/Data )
Integer
PAEE age predicted max HR walk test 1pt calibration
Phase 2 data. Point; walk test 1-pt calibration curve: PAEE @ age-pred. max HR (J/min/kg). Physical Activity energy expenditure age-predicted maximum heart rate above sleeping heart rate applied from the walk test using 1pt calibration.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
PAEE at age predicted max HRaS walk test calibration
Phase 2 data. Point; applied walk test calibration curve: PAEE @ age-pred. max HR (J/min/kg). Physical Activity energy expenditure at age predicted maximum heart rate above sleeping heart rate applied from the walk test calibration curve.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Estimated max HR above sleep
Phase 2 data. Estimated maximum HR above sleep (HRaS) (208 - 0.7*age - shr - 20*betablocker) based on Tanaka equation (2001)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mean HRaS last minute of Walk test
Phase 2 data. Mean Heart Rate above Sleep during last minute of Walk test bpm(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Earliest time walk test lowest exercise HR occurs
Phase 2 data. Earliest time during walk test at which lowest exercise heart rate occurs (based on first derivative)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Peak running median HRaS last min walk test
Phase 2 data. Peak running median Heart Rate above Sleep (HRaS)during last min of Walk test bpm(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Peak running median HRaS Walk test
Phase 2 data. Peak running median Heart Rate above Sleep (HRaS) during Walk test bpm(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median est. PAI last 2min of walk test
Phase 2 data. Median estimated physical activity intensity during last 2 minutes of walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Median HRaS last 2min of walk test
Phase 2 data. Median heart rate above sleep (HRaS) during last 2min of walk test;(Measured/Derived from or related to Acitheart Monitor/Data )
Real
1-min recovery HRaS walk test global regression
Phase 2 data. 1-min recovery heart rate above sleep from walk test based on global regression (beats/min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
1-min recovery HRaS walk test 90-sec regression
Phase 2 data. 1-min recovery heart rate above sleep from walk test based on 90-sec regression (beats/min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
45sec rec HRaS Walk Test global regression
Phase 2 data. 45sec recovery heart rate above sleep from walk test based on global regression (beats/min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
45sec rec HRaS Walk Test 60sec regression
Phase 2 data. 45sec recovery heart rate above sleep from walk test based on 60sec regression (beats/min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Duration of walk test recovery phase
Phase 2 data. Duration of walk test recovery phase (min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Mean HRaS TimeRisePoint +/-.25min
Phase 2 data. Mean heart rate above sleep (HRaS) at TimeRisePoint (+/-.25min) from walk test (Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error term residual regression of test-recovery phases(1stpass)
Phase 2 data. Error term; residual regression of test and recovery phases (1st pass)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error term regression mdn HR rectime 0-1min
Phase 2 data. Error term; regression of median heart rate against rectime (0-1 min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error term regression mdn HR rectime 0-1.5min
Phase 2 data. Error term; regression of median heart rate against rectime (0-1.5 min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error term regression mdn HR test time omit frst 1min
Phase 2 data. Error term; regression of median heart rate against testtime (omit first 1min)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Error term residual regression of test-recovery phases(2ndpass)
Phase 2 data. Error term; residual regression of test and recovery phases (2nd pass)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Walking speed during walk test
Phase 2 data. Walking speed during walk test (km/hr). This has been calculated using distance (km) divided by duration of test (hrs)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Data type monitor used walk test
Phase 2 data. Variable defines which type of data from the monitor has been able to be used for walk test calibration. GREEN indicates high quality HR data available and so full ibi data from Actiheart could be used for calibration. ORANGE indicates lower quality heart data available from Actiheart and so alternative heart rate from Polar monitor has been manually inputted into file(Measured/Derived from or related to Acitheart Monitor/Data )
Text
Date of Walk test
Phase 2 data. Date of Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Date
Start time of walk test
Phase 2 data. Real start time of actual walk test; calibration protocol noted in WALK_calibration_protocol(Measured/Derived from or related to Acitheart Monitor/Data )
DateTime
Duration of Walk Test completed
Phase 2 data. Duration of Walk Test completed (min); varies per participant(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Latest time walk test lowest exercise HR occurs
Phase 2 data. Latest time during walk test at which lowest exercise heart rate occurs (based on first derivative)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Time after beginning of walk test
Phase 2 data. Time after beginning of walk test beyond which observations are included(Measured/Derived from or related to Acitheart Monitor/Data )
Real
No of valid obs during walk test recovery
Phase 2 data. Number of valid observations during walk test recovery phase. Data must be annotated as within the annotated walk test recovery period from participants' visit; be between 0-90sec within that phase and not have been masked out as noisy during cleaning stage(Measured/Derived from or related to Acitheart Monitor/Data )
Integer
No of valid observations walk test data
Phase 2 data. Number of valid observations from walk test data. Data must be annotated as within the annotated walk test period from participant's visit; occur after time indicated in WALK_Time_excluded_beginTest and not have been masked out as noisy during cleaning stage(Measured/Derived from or related to Acitheart Monitor/Data )
Integer
Time distribution of valid HR 10th percentile
Phase 2 data. Time distribution of valid HR points (10th percentile) - Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Time distribution of valid HR 25th percentile
Phase 2 data. Time distribution of valid HR points (25th percentile) - Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Time distribution of valid HR 50th percentile
Phase 2 data. Time distribution of valid HR points (50th percentile) - Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Time disttribution of valid HR 75th percentile
Phase 2 data. Time distribution of valid HR points (75th percentile) - Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Time distribution of valid HR 90th percentile
Phase 2 data. Time distribution of valid HR points (90th percentile) - Walk test(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Obs Pwear indicated being worn
Phase 2 data. Number of observations where probability of wear is indicated as being worn (unit is dependant on intermediate time resolution)(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Weight (kg)
Phase 2 data. Weight (kg) used in all physical activity estimates
Real
Acceleration 2 Min lag
Phase 2 data. Threshold for acceleration for 2mins at which point observations are diverted into branch box 5(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Reason for failing sample
Phase 2 data. Reason for failing sample: 1 = Assaynotes: EXCLUDE SAMPLE FROM ADAT; 2 = scaling factor < 0.25 or > 4; 3 = ANML fraction used < 30%
Integer
Reason for flaging sample
Phase 2 data. Reason for flaging sample: 1=scaling factor <0.4 or > 2.5
Integer
Questionnaires completed
Phase 2 data. Questionnaires Complete? 0 = no; 1 = yes;
Categorical
Questionnaire version
Phase 2 data. Data in variable RPAQ_Qversion as cleaned by data management team where free text was changed to codes. 8 = Version 8 29/09/2004; 9 = FEN_RPAQ_9.1_05/05/2007
Text
Fraction of time spent< = 0 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 0 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 2.25 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 2.25 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 2.5 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 2.5 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 2.75 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 2.75 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 3 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 3 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 3.25 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 3.25 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 3.5 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 3.5 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 3.75 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 3.75 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 4 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 4 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 4.25 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 4.25 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 4.5 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 4.5 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = .075 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = .075 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 4.75 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 4.75 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 5 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 5 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 6 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 6 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 7 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 7 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 8 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 8 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 9 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 9 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = .25 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = .25 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = .5 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = .5 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fractionof time spent< = .75 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = .75 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 1 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 1 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 1.25 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 1.25 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 1.5 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 1.5 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 1.75 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 1.75 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction of time spent< = 2 m/s2 acceleration only
Phase 2 data. Fraction of time spent < = 2 m/s2. Based on acceleration only signal using Pwear from combined estimate(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 1MET highlC
Phase 2 data. Fraction of time spent < = 1 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 3.5MET highlC
Phase 2 data. Fraction of time spent < = 3.5 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 3.75MET highlC
Phase 2 data. Fraction of time spent < = 3.75 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 4MET highlC
Phase 2 data. Fraction of time spent < = 4 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 4.25MET highlC
Phase 2 data. Fraction of time spent < = 4.25 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 4.5MET highlC
Phase 2 data. Fraction of time spent < = 4.5 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 4.75MET highlC
Phase 2 data. Fraction of time spent < = 4.75 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 5MET highlC
Phase 2 data. Fraction of time spent < = 5 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 5.25MET highlC
Phase 2 data. Fraction of time spent < = 5.25 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 5.5MET highlC
Phase 2 data. Fraction of time spent < = 5.5 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 5.75MET highlC
Phase 2 data. Fraction of time spent < = 5.75 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 1.25MET highlC
Phase 2 data. Fraction of time spent < = 1.25 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 6MET highlC
Phase 2 data. Fraction of time spent < = 6 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 7MET highlC
Phase 2 data. Fraction of time spent < = 7 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 8MET highlC
Phase 2 data. Fraction of time spent < = 8 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 9MET highlC
Phase 2 data. Fraction of time spent < = 9 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 10MET highlC
Phase 2 data. Fraction of time spent < = 10 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 11MET highlC
Phase 2 data. Fraction of time spent < = 11 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 1.05MET highlC
Phase 2 data. Fraction of time spent < = 1.05 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 1.125MET highlC
Phase 2 data. Fraction of time spent < = 1.125 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 1.5MET highlC
Phase 2 data. Fraction of time spent < = 1.5 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 1.75MET highlC
Phase 2 data. Fraction of time spent < = 1.75 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 2MET highlC
Phase 2 data. Fraction of time spent < = 2 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 2.25MET highlC
Phase 2 data. Fraction of time spent < = 2.25 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 2.5MET highlC
Phase 2 data. Fraction of time spent < = 2.5 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 2.75MET highlC
Phase 2 data. Fraction of time spent < = 2.75 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 3MET highlC
Phase 2 data. Fraction of time spent < = 3 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 3.25MET highlC
Phase 2 data. Fraction of time spent < = 3.25 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate calculation individualised for each person from the Oxford2005 equation.(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 1MET std highlC
Phase 2 data. Fraction of time spent < = 1 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 3.5MET std highlC
Phase 2 data. Fraction of time spent < = 3.5 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 3.75MET std highlC
Phase 2 data. Fraction of time spent < = 3.75 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 4MET std highlC
Phase 2 data. Fraction of time spent < = 4 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 4.25MET std highlC
Phase 2 data. Fraction of time spent < = 4.25 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 4.5MET std highlC
Phase 2 data. Fraction of time spent < = 4.5 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 4.75MET std highlC
Phase 2 data. Fraction of time spent < = 4.75 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 5MET std highlC
Phase 2 data. Fraction of time spent < = 5 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 5.25MET std highlC
Phase 2 data. Fraction of time spent < = 5.25 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 5.5MET std highlC
Phase 2 data. Fraction of time spent < = 5.5 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 5.75 METs using highlC
Phase 2 data. Fraction of time spent < = 5.75 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 1.25MET std highlC
Phase 2 data. Fraction of time spent < = 1.25 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 6 METs using highlC
Phase 2 data. Fraction of time spent < = 6 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 7 METs using highlC
Phase 2 data. Fraction of time spent < = 7 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 8 METs using highlC
Phase 2 data. Fraction of time spent < = 8 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 9 METs using highlC
Phase 2 data. Fraction of time spent < = 9 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 10 METs using highlC
Phase 2 data. Fraction of time spent < = 10 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 11 METs using highlC
Phase 2 data. Fraction of time spent < = 11 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 1.05 METs using highlC
Phase 2 data. Fraction of time spent < = 1.05 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Fraction time spent< = 1.125 METs using highlC
Phase 2 data. Fraction of time spent < = 1.125 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 1.5MET std highlC
Phase 2 data. Fraction of time spent < = 1.5 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 1.75MET std highlC
Phase 2 data. Fraction of time spent < = 1.75 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 2MET std highlC
Phase 2 data. Fraction of time spent < = 2 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 2.25MET std highlC
Phase 2 data. Fraction of time spent < = 2.25 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 2.5MET std highlC
Phase 2 data. Fraction of time spent < = 2.5 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 2.75MET std highlC
Phase 2 data. Fraction of time spent < = 2.75 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 3MET std highlC
Phase 2 data. Fraction of time spent < = 3 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
% tme spnt <= 3.25MET std highlC
Phase 2 data. Fraction of time spent < = 3.25 METs using the highest available calibration level. Priority order of calibration levels is multi-point treadmill (B2); 1pt treadmill (B6); 1pt self paced walk (B8) and group equation (B7). Present for all those who have a valid free-living file i.e file present; no corruptions deemed to affect combined acc and heart rate estimate and >20hrs Pwear. This variable uses the resting metabolic rate as defined in STANDARD_MET and is the same for every individual(Measured/Derived from or related to Acitheart Monitor/Data )
Real
Rash reported from wearing monitor
Phase 2 data. Rash reported by participant from wearing monitor? For use by study coordination and PA teams. Not for analysis. 0 = no; 1 = yes;
Categorical
REE during AH free living
Phase 2 data. Resting Energy Expenditure during AH free living (REE) - Average daily estimated resting energy expenditure calculated vigorous intensity activity Schofield equation in kcal/day. For participant feedback only. Not for analysis
Real
Repeat Appointment Declined
Phase 2 data. Flag to show if Repeat OGTT appointment was declined by the participant . 0 = no; 1 = yes;
Categorical
Repeat Glucose 0 minutes
Phase 2 data. Repeat Glucose measurement taken at 0 minutes in mmol/l
Real
Repeat Glucose 120 minutes
Phase 2 data. Repeat Glucose measurement taken at 120 minutes in mmol/l
Real
Repeat GP Letter Sent
Phase 2 data. Date Repeat General Practionars Letter Sent
Date
Repeat Glucose Imported
Phase 2 data. Repeat Glucose data imported. 0 = no; 1 = yes;
Categorical
Repeat appointment Needed
Phase 2 data. Flag to show if Repeat OGTT appointment was suggested for the participant . 0 = no; 1 = yes;
Categorical
Report Page Entered
Phase 2 data. Report Page Entered? From Study database
Categorical
Resting heart rate feedback only
Phase 2 data. Resting heart rate For participant feedback only. Not for analysis
Integer
Rest Start Time
Phase 2 data. Real start time for the rest test. Hrs:Mins:Secs
Time
Result Status
Phase 2 data. Status of Results entry in study database. 0 = Initial data incomplete;1 = 1st GP letter pending;2 = Repeat data incomplete;3 = 2nd GP letter pending;4 = Report data incomplete;5 = Report pending;6 = Only Admin/US left;7 = Finished;
Categorical
Normalization acceptance criteria for all row scale factors
Phase 2 data. Normalization acceptance criteria for all row scale factors
Text
Cln variable: Rowing hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Rowing. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Rowing hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Rowing. -1 = left blank. DO NOT USE THIS VARIABLE. Use rowingHr_CLEAN_P2 instead.
Real
Cln variable: Rowing min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Rowing. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Rowing min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Rowing. -1 = left blank. DO NOT USE THIS VARIABLE. Use rowingMin_CLEAN_P2 instead.
Real
Cln variable: Rowing
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Rowing. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Rowing
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Rowing. DO NOT USE THIS VARIABLE. Use rowing_CLEAN_P2 instead.
Real
Rowing
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Rowing. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Cln variable: Sailing hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode.Sailing windsurfing or boating. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Sailing wind-surfing or boating hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Sailing Wind-Surfing Or Boating. -1 = left blank. DO NOT USE THIS VARIABLE. Use sailingWindsurfBoatingHr_CLEAN_P2 instead.
Real
Cln variable: Sailing min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Sailing windsurfing or boating. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Sailing wind-surfing or boating min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Sailing Wind-Surfing Or Boating. -1 = left blank. DO NOT USE THIS VARIABLE. Use sailingWindsurfBoatingMin_CLEAN_P2 instead.
Real
Cln variable: Sailing
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Sailing windsurfing or boating. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Sailing wind-surfing or boating
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Sailing wind-surfing or boating. DO NOT USE THIS VARIABLE. Use sailingWindsurfBoating_CLEAN_P2 instead.
Real
Sailing Wind-Surfing or Boating
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Sailing Wind-Surfing Or Boating. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Supplemental sample information
Phase 2 data. Supplemental sample information
Text
Sample Dispatch Time
Phase 2 data. Time of sample dispatch
Text
Assay team sample observation
Phase 2 data. Assay team sample observation
Text
Sample or QC; Calibrator; Buffer
Phase 2 data. Sample or QC; Calibrator; Buffer
Real
ID of Scanner used to analyze slide
Phase 2 data. ID of Scanner used to analyze slide
Text
Aptamer SeqId: 10000-28 | Target: CRBB2 | UniProt: P43320
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10000-28 | Target: CRBB2 | UniProt: P43320 | TargetFullName: Beta-crystallin B2 | Organisim: human | Apparent_Kd_M: 1.238894E-10
Real
Aptamer SeqId: 10001-7 | Target: c-Raf | UniProt: P04049
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10001-7 | Target: c-Raf | UniProt: P04049 | TargetFullName: RAF proto-oncogene serine/threonine-protein kinase | Organisim: human | Apparent_Kd_M: 1.176058E-11
Real
Aptamer SeqId: 10003-15 | Target: ZNF41 | UniProt: P51814
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10003-15 | Target: ZNF41 | UniProt: P51814 | TargetFullName: Zinc finger protein 41 | Organisim: human | Apparent_Kd_M: 4.333333E-11
Real
Aptamer SeqId: 10006-25 | Target: ELK1 | UniProt: P19419
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10006-25 | Target: ELK1 | UniProt: P19419 | TargetFullName: ETS domain-containing protein Elk-1 | Organisim: human | Apparent_Kd_M: 3.372673E-12
Real
Aptamer SeqId: 10008-43 | Target: GUC1A | UniProt: P43080
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10008-43 | Target: GUC1A | UniProt: P43080 | TargetFullName: Guanylyl cyclase-activating protein 1 | Organisim: human | Apparent_Kd_M: 5.2627E-11
Real
Aptamer SeqId: 10011-65 | Target: OCRL | UniProt: Q01968
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10011-65 | Target: OCRL | UniProt: Q01968 | TargetFullName: Inositol polyphosphate 5-phosphatase OCRL-1 | Organisim: human | Apparent_Kd_M: 7.245927E-11
Real
Aptamer SeqId: 10012-5 | Target: SPDEF | UniProt: O95238
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10012-5 | Target: SPDEF | UniProt: O95238 | TargetFullName: SAM pointed domain-containing Ets transcription factor | Organisim: human | Apparent_Kd_M: 1.347432E-10
Real
Aptamer SeqId: 10013-34 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10013-34 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.95E-10
Real
Aptamer SeqId: 10014-31 | Target: SLUG | UniProt: O43623
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10014-31 | Target: SLUG | UniProt: O43623 | TargetFullName: Zinc finger protein SNAI2 | Organisim: human | Apparent_Kd_M: 1.84026E-11
Real
Aptamer SeqId: 10015-119 | Target: KCAB2 | UniProt: Q13303
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10015-119 | Target: KCAB2 | UniProt: Q13303 | TargetFullName: Voltage-gated potassium channel subunit beta-2 | Organisim: human | Apparent_Kd_M: 7.988599E-11
Real
Aptamer SeqId: 10021-1 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10021-1 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 7.880228E-11
Real
Aptamer SeqId: 10022-207 | Target: POLH | UniProt: Q9Y253
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10022-207 | Target: POLH | UniProt: Q9Y253 | TargetFullName: DNA polymerase eta | Organisim: human | Apparent_Kd_M: 2.339392E-11
Real
Aptamer SeqId: 10023-32 | Target: VDR | UniProt: P11473
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10023-32 | Target: VDR | UniProt: P11473 | TargetFullName: Vitamin D3 receptor | Organisim: human | Apparent_Kd_M: 3.01131E-11
Real
Aptamer SeqId: 10024-44 | Target: HOGA1 | UniProt: Q86XE5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10024-44 | Target: HOGA1 | UniProt: Q86XE5 | TargetFullName: 4-hydroxy-2-oxoglutarate aldolase; mitochondrial | Organisim: human | Apparent_Kd_M: 3.335377E-11
Real
Aptamer SeqId: 10030-8 | Target: MutY homolog | UniProt: Q9UIF7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10030-8 | Target: MutY homolog | UniProt: Q9UIF7 | TargetFullName: Adenine DNA glycosylase | Organisim: human | Apparent_Kd_M: 5.121143E-12
Real
Aptamer SeqId: 10034-16 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10034-16 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.360763E-11
Real
Aptamer SeqId: 10035-6 | Target: DUS4 | UniProt: Q13115
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10035-6 | Target: DUS4 | UniProt: Q13115 | TargetFullName: Dual specificity protein phosphatase 4 | Organisim: human | Apparent_Kd_M: 2.030154E-11
Real
Aptamer SeqId: 10036-201 | Target: ZHX3 | UniProt: Q9H4I2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10036-201 | Target: ZHX3 | UniProt: Q9H4I2 | TargetFullName: Zinc fingers and homeoboxes protein 3 | Organisim: human | Apparent_Kd_M: 4.105641E-10
Real
Aptamer SeqId: 10037-98 | Target: SIG12 | UniProt: Q96PQ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10037-98 | Target: SIG12 | UniProt: Q96PQ1 | TargetFullName: Sialic acid-binding Ig-like lectin 12 | Organisim: human | Apparent_Kd_M: 4.449146E-12
Real
Aptamer SeqId: 10040-63 | Target: P73L | UniProt: Q9H3D4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10040-63 | Target: P73L | UniProt: Q9H3D4 | TargetFullName: Tumor protein 63 | Organisim: human | Apparent_Kd_M: 4.363197E-11
Real
Aptamer SeqId: 10041-3 | Target: HNF4A | UniProt: P41235
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10041-3 | Target: HNF4A | UniProt: P41235 | TargetFullName: Hepatocyte nuclear factor 4-alpha | Organisim: human | Apparent_Kd_M: 6.65E-11
Real
Aptamer SeqId: 10042-8 | Target: SGK3 | UniProt: Q96BR1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10042-8 | Target: SGK3 | UniProt: Q96BR1 | TargetFullName: Serine/threonine-protein kinase Sgk3 | Organisim: human | Apparent_Kd_M: 3.191409E-12
Real
Aptamer SeqId: 10043-31 | Target: BRD4 | UniProt: O60885
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10043-31 | Target: BRD4 | UniProt: O60885 | TargetFullName: Bromodomain-containing protein 4 | Organisim: human | Apparent_Kd_M: 1.866373E-10
Real
Aptamer SeqId: 10044-12 | Target: WN10A | UniProt: Q9GZT5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10044-12 | Target: WN10A | UniProt: Q9GZT5 | TargetFullName: Protein Wnt-10a | Organisim: human | Apparent_Kd_M: 3.182479E-11
Real
Aptamer SeqId: 10045-47 | Target: CUL3 | UniProt: Q13618
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10045-47 | Target: CUL3 | UniProt: Q13618 | TargetFullName: Cullin-3 | Organisim: human | Apparent_Kd_M: 1.776801E-11
Real
Aptamer SeqId: 10046-55 | Target: cIAP-1 | UniProt: Q13490
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10046-55 | Target: cIAP-1 | UniProt: Q13490 | TargetFullName: Baculoviral IAP repeat-containing protein 2 | Organisim: human | Apparent_Kd_M: 9.546274E-11
Real
Aptamer SeqId: 10047-12 | Target: NCF-2 | UniProt: P19878
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10047-12 | Target: NCF-2 | UniProt: P19878 | TargetFullName: Neutrophil cytosol factor 2 | Organisim: human | Apparent_Kd_M: 4.088833E-12
Real
Aptamer SeqId: 10048-7 | Target: PEBB | UniProt: Q13951
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10048-7 | Target: PEBB | UniProt: Q13951 | TargetFullName: Core-binding factor subunit beta | Organisim: human | Apparent_Kd_M: 2.017085E-11
Real
Aptamer SeqId: 10049-112 | Target: TERF1 | UniProt: P54274
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10049-112 | Target: TERF1 | UniProt: P54274 | TargetFullName: Telomeric repeat-binding factor 1 | Organisim: human | Apparent_Kd_M: 3.819645E-11
Real
Aptamer SeqId: 10053-5 | Target: ILK1 | UniProt: Q13418
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10053-5 | Target: ILK1 | UniProt: Q13418 | TargetFullName: Integrin-linked protein kinase | Organisim: human | Apparent_Kd_M: 1.035866E-11
Real
Aptamer SeqId: 10054-3 | Target: GAN | UniProt: Q9H2C0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10054-3 | Target: GAN | UniProt: Q9H2C0 | TargetFullName: Gigaxonin | Organisim: human | Apparent_Kd_M: 2.214327E-10
Real
Aptamer SeqId: 10056-5 | Target: FOXM1 | UniProt: Q08050
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10056-5 | Target: FOXM1 | UniProt: Q08050 | TargetFullName: Forkhead box protein M1 | Organisim: human | Apparent_Kd_M: 5.910351E-12
Real
Aptamer SeqId: 10058-1 | Target: RD23A | UniProt: P54725
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10058-1 | Target: RD23A | UniProt: P54725 | TargetFullName: UV excision repair protein RAD23 homolog A | Organisim: human | Apparent_Kd_M: 3.117482E-12
Real
Aptamer SeqId: 10063-10 | Target: FANCL | UniProt: Q9NW38
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10063-10 | Target: FANCL | UniProt: Q9NW38 | TargetFullName: E3 ubiquitin-protein ligase FANCL | Organisim: human | Apparent_Kd_M: 2.332352E-10
Real
Aptamer SeqId: 10064-12 | Target: RBBP9 | UniProt: O75884
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10064-12 | Target: RBBP9 | UniProt: O75884 | TargetFullName: Putative hydrolase RBBP9 | Organisim: human | Apparent_Kd_M: 1.619919E-10
Real
Aptamer SeqId: 10070-22 | Target: PLCG2 | UniProt: P16885
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10070-22 | Target: PLCG2 | UniProt: P16885 | TargetFullName: 1-phosphatidylinositol 4;5-bisphosphate phosphodiesterase gamma-2 | Organisim: human | Apparent_Kd_M: 5.696257E-12
Real
Aptamer SeqId: 10073-22 | Target: TYDP1 | UniProt: Q9NUW8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10073-22 | Target: TYDP1 | UniProt: Q9NUW8 | TargetFullName: Tyrosyl-DNA phosphodiesterase 1 | Organisim: human | Apparent_Kd_M: 7.088563E-13
Real
Aptamer SeqId: 10074-128 | Target: BRD2 | UniProt: P25440
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10074-128 | Target: BRD2 | UniProt: P25440 | TargetFullName: Bromodomain-containing protein 2 | Organisim: human | Apparent_Kd_M: 4.346809E-12
Real
Aptamer SeqId: 10075-75 | Target: ACBD6 | UniProt: Q9BR61
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10075-75 | Target: ACBD6 | UniProt: Q9BR61 | TargetFullName: Acyl-CoA-binding domain-containing protein 6 | Organisim: human | Apparent_Kd_M: 2.572721E-12
Real
Aptamer SeqId: 10076-1 | Target: AP4M1 | UniProt: O00189
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10076-1 | Target: AP4M1 | UniProt: O00189 | TargetFullName: AP-4 complex subunit mu-1 | Organisim: human | Apparent_Kd_M: 9.288883E-12
Real
Aptamer SeqId: 10078-5 | Target: BAG3 | UniProt: O95817
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10078-5 | Target: BAG3 | UniProt: O95817 | TargetFullName: BAG family molecular chaperone regulator 3 | Organisim: human | Apparent_Kd_M: 2.483126E-11
Real
Aptamer SeqId: 10080-9 | Target: EI2BA | UniProt: Q14232
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10080-9 | Target: EI2BA | UniProt: Q14232 | TargetFullName: Translation initiation factor eIF-2B subunit alpha | Organisim: human | Apparent_Kd_M: 2.872901E-12
Real
Aptamer SeqId: 10081-17 | Target: SATB2 | UniProt: Q9UPW6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10081-17 | Target: SATB2 | UniProt: Q9UPW6 | TargetFullName: DNA-binding protein SATB2 | Organisim: human | Apparent_Kd_M: 5.985787E-12
Real
Aptamer SeqId: 10082-251 | Target: NFL | UniProt: P07196
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10082-251 | Target: NFL | UniProt: P07196 | TargetFullName: Neurofilament light polypeptide | Organisim: human | Apparent_Kd_M: 1.951223E-12
Real
Aptamer SeqId: 10085-25 | Target: STAR | UniProt: P49675
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10085-25 | Target: STAR | UniProt: P49675 | TargetFullName: Steroidogenic acute regulatory protein; mitochondrial | Organisim: human | Apparent_Kd_M: 3.465383E-11
Real
Aptamer SeqId: 10086-39 | Target: CBS | UniProt: P35520
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10086-39 | Target: CBS | UniProt: P35520 | TargetFullName: Cystathionine beta-synthase | Organisim: human | Apparent_Kd_M: 3.895135E-11
Real
Aptamer SeqId: 10087-10 | Target: Alpha crystallin A chain
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10087-10 | Target: Alpha crystallin A chain | UniProt: P02489 | TargetFullName: Alpha-crystallin A chain | Organisim: human | Apparent_Kd_M: 6.003705E-11
Real
Aptamer SeqId: 10088-37 | Target: APT | UniProt: P07741
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10088-37 | Target: APT | UniProt: P07741 | TargetFullName: Adenine phosphoribosyltransferase | Organisim: human | Apparent_Kd_M: 1.475618E-11
Real
Aptamer SeqId: 10089-7 | Target: ASML | UniProt: O95671
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10089-7 | Target: ASML | UniProt: O95671 | TargetFullName: N-acetylserotonin O-methyltransferase-like protein | Organisim: human | Apparent_Kd_M: 4.406495E-12
Real
Aptamer SeqId: 10336-3 | Target: CHIP | UniProt: Q9UNE7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10336-3 | Target: CHIP | UniProt: Q9UNE7 | TargetFullName: E3 ubiquitin-protein ligase CHIP | Organisim: human | Apparent_Kd_M: 3.43E-11
Real
Aptamer SeqId: 10339-48 | Target: NSE | UniProt: P09104
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10339-48 | Target: NSE | UniProt: P09104 | TargetFullName: Gamma-enolase | Organisim: human | Apparent_Kd_M: 1.69E-10
Real
Aptamer SeqId: 10342-55 | Target: PIAS4 | UniProt: Q8N2W9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10342-55 | Target: PIAS4 | UniProt: Q8N2W9 | TargetFullName: E3 SUMO-protein ligase PIAS4 | Organisim: human | Apparent_Kd_M: 9.37E-11
Real
Aptamer SeqId: 10344-334 | Target: IL-10 Ra | UniProt: Q13651
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10344-334 | Target: IL-10 Ra | UniProt: Q13651 | TargetFullName: Interleukin-10 receptor subunit alpha | Organisim: human | Apparent_Kd_M: 1.75E-10
Real
Aptamer SeqId: 10346-5 | Target: STAT3 | UniProt: P40763
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10346-5 | Target: STAT3 | UniProt: P40763 | TargetFullName: Signal transducer and activator of transcription 3 | Organisim: human | Apparent_Kd_M: 9.46E-12
Real
Aptamer SeqId: 10356-21 | Target: c-Jun | UniProt: P05412
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10356-21 | Target: c-Jun | UniProt: P05412 | TargetFullName: Transcription factor AP-1 | Organisim: human | Apparent_Kd_M: 3.3E-10
Real
Aptamer SeqId: 10361-25 | Target: OAS1 | UniProt: P00973
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10361-25 | Target: OAS1 | UniProt: P00973 | TargetFullName: 2'-5'-oligoadenylate synthase 1 | Organisim: human | Apparent_Kd_M: 3.5E-12
Real
Aptamer SeqId: 10362-35 | Target: c-Myc | UniProt: P01106
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10362-35 | Target: c-Myc | UniProt: P01106 | TargetFullName: Myc proto-oncogene protein | Organisim: human | Apparent_Kd_M: 2.8E-11
Real
Aptamer SeqId: 10363-13 | Target: SMAD3 | UniProt: P84022
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10363-13 | Target: SMAD3 | UniProt: P84022 | TargetFullName: Mothers against decapentaplegic homolog 3 | Organisim: human | Apparent_Kd_M: 1.44E-11
Real
Aptamer SeqId: 10364-6 | Target: SMAD2 | UniProt: Q15796
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10364-6 | Target: SMAD2 | UniProt: Q15796 | TargetFullName: Mothers against decapentaplegic homolog 2 | Organisim: human | Apparent_Kd_M: 2.73E-11
Real
Aptamer SeqId: 10365-132 | Target: IL-23 | UniProt: P29460|Q9NPF7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10365-132 | Target: IL-23 | UniProt: P29460|Q9NPF7 | TargetFullName: Interleukin-23 | Organisim: human | Apparent_Kd_M: 1.76E-12
Real
Aptamer SeqId: 10366-11 | Target: PDGFRA | UniProt: P16234
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10366-11 | Target: PDGFRA | UniProt: P16234 | TargetFullName: Platelet-derived growth factor receptor alpha | Organisim: human | Apparent_Kd_M: 4.66E-11
Real
Aptamer SeqId: 10367-62 | Target: IL-12 | UniProt: P29459|P29460
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10367-62 | Target: IL-12 | UniProt: P29459|P29460 | TargetFullName: Interleukin-12 | Organisim: human | Apparent_Kd_M: 1.56E-11
Real
Aptamer SeqId: 10370-21 | Target: STAT1 | UniProt: P42224
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10370-21 | Target: STAT1 | UniProt: P42224 | TargetFullName: Signal transducer and activator of transcription 1-alpha/beta | Organisim: human | Apparent_Kd_M: 4.71E-12
Real
Aptamer SeqId: 10372-18 | Target: STAT6 | UniProt: P42226
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10372-18 | Target: STAT6 | UniProt: P42226 | TargetFullName: Signal transducer and activator of transcription 6 | Organisim: human | Apparent_Kd_M: 2.06E-10
Real
Aptamer SeqId: 10390-21 | Target: ZNRF3 | UniProt: Q9ULT6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10390-21 | Target: ZNRF3 | UniProt: Q9ULT6 | TargetFullName: E3 ubiquitin-protein ligase ZNRF3 | Organisim: human | Apparent_Kd_M: 2.453366E-12
Real
Aptamer SeqId: 10391-1 | Target: ANGL3 | UniProt: Q9Y5C1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10391-1 | Target: ANGL3 | UniProt: Q9Y5C1 | TargetFullName: Angiopoietin-related protein 3 | Organisim: human | Apparent_Kd_M: 7.620613E-13
Real
Aptamer SeqId: 10396-6 | Target: Mcl-1 | UniProt: Q07820
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10396-6 | Target: Mcl-1 | UniProt: Q07820 | TargetFullName: Induced myeloid leukemia cell differentiation protein Mcl-1 | Organisim: human | Apparent_Kd_M: 1.376639E-11
Real
Aptamer SeqId: 10416-79 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10416-79 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.130314E-11
Real
Aptamer SeqId: 10418-36 | Target: STX12 | UniProt: Q86Y82
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10418-36 | Target: STX12 | UniProt: Q86Y82 | TargetFullName: Syntaxin-12 | Organisim: human | Apparent_Kd_M: 2.916097E-11
Real
Aptamer SeqId: 10419-1 | Target: SCAR5 | UniProt: Q6ZMJ2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10419-1 | Target: SCAR5 | UniProt: Q6ZMJ2 | TargetFullName: Scavenger receptor class A member 5 | Organisim: human | Apparent_Kd_M: 2.215019E-11
Real
Aptamer SeqId: 10424-31 | Target: NPDC1 | UniProt: Q9NQX5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10424-31 | Target: NPDC1 | UniProt: Q9NQX5 | TargetFullName: Neural proliferation differentiation and control protein 1 | Organisim: human | Apparent_Kd_M: 4.638109E-11
Real
Aptamer SeqId: 10425-3 | Target: B4GT5 | UniProt: O43286
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10425-3 | Target: B4GT5 | UniProt: O43286 | TargetFullName: Beta-1;4-galactosyltransferase 5 | Organisim: human | Apparent_Kd_M: 8.817908E-11
Real
Aptamer SeqId: 10426-21 | Target: GOSR2 | UniProt: O14653
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10426-21 | Target: GOSR2 | UniProt: O14653 | TargetFullName: Golgi SNAP receptor complex member 2 | Organisim: human | Apparent_Kd_M: 1.182692E-11
Real
Aptamer SeqId: 10427-2 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10427-2 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.12E-12
Real
Aptamer SeqId: 10428-1 | Target: KI2S2 | UniProt: P43631
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10428-1 | Target: KI2S2 | UniProt: P43631 | TargetFullName: Killer cell immunoglobulin-like receptor 2DS2 | Organisim: human | Apparent_Kd_M: 1.621698E-11
Real
Aptamer SeqId: 10430-31 | Target: 4F2 | UniProt: P08195
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10430-31 | Target: 4F2 | UniProt: P08195 | TargetFullName: 4F2 cell-surface antigen heavy chain | Organisim: human | Apparent_Kd_M: 6.037419E-12
Real
Aptamer SeqId: 10432-3 | Target: K1644 | UniProt: Q3SXP7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10432-3 | Target: K1644 | UniProt: Q3SXP7 | TargetFullName: Uncharacterized protein KIAA1644 | Organisim: human | Apparent_Kd_M: 5.78541E-11
Real
Aptamer SeqId: 10435-2 | Target: ASPG | UniProt: P20933
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10435-2 | Target: ASPG | UniProt: P20933 | TargetFullName: N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase | Organisim: human | Apparent_Kd_M: 9.55E-10
Real
Aptamer SeqId: 10438-19 | Target: CSF2R | UniProt: P15509
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10438-19 | Target: CSF2R | UniProt: P15509 | TargetFullName: Granulocyte-macrophage colony-stimulating factor receptor subunit alpha | Organisim: human | Apparent_Kd_M: 1.562259E-11
Real
Aptamer SeqId: 10440-26 | Target: ACAM | UniProt: Q9H6B4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10440-26 | Target: ACAM | UniProt: Q9H6B4 | TargetFullName: CXADR-like membrane protein | Organisim: human | Apparent_Kd_M: 2.304908E-11
Real
Aptamer SeqId: 10442-1 | Target: TM190 | UniProt: Q8WZ59
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10442-1 | Target: TM190 | UniProt: Q8WZ59 | TargetFullName: Transmembrane protein 190 | Organisim: human | Apparent_Kd_M: 4.599096E-11
Real
Aptamer SeqId: 10445-20 | Target: ApoM | UniProt: O95445
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10445-20 | Target: ApoM | UniProt: O95445 | TargetFullName: Apolipoprotein M | Organisim: human | Apparent_Kd_M: 3.107137E-10
Real
Aptamer SeqId: 10447-18 | Target: PABP3 | UniProt: Q9H361
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10447-18 | Target: PABP3 | UniProt: Q9H361 | TargetFullName: Polyadenylate-binding protein 3 | Organisim: human | Apparent_Kd_M: 1.58E-11
Real
Aptamer SeqId: 10449-31 | Target: TMM46 | UniProt: Q6UWI4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10449-31 | Target: TMM46 | UniProt: Q6UWI4 | TargetFullName: Protein shisa-2 homolog | Organisim: human | Apparent_Kd_M: 1.898698E-10
Real
Aptamer SeqId: 10451-11 | Target: NUCB1 | UniProt: Q02818
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10451-11 | Target: NUCB1 | UniProt: Q02818 | TargetFullName: Nucleobindin-1 | Organisim: human | Apparent_Kd_M: 8.039013E-12
Real
Aptamer SeqId: 10452-24 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10452-24 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 6.027581E-11
Real
Aptamer SeqId: 10453-7 | Target: CEA20 | UniProt: Q6UY09
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10453-7 | Target: CEA20 | UniProt: Q6UY09 | TargetFullName: Carcinoembryonic antigen-related cell adhesion molecule 20 | Organisim: human | Apparent_Kd_M: 1.566371E-10
Real
Aptamer SeqId: 10454-99 | Target: DJC16 | UniProt: Q9Y2G8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10454-99 | Target: DJC16 | UniProt: Q9Y2G8 | TargetFullName: DnaJ homolog subfamily C member 16 | Organisim: human | Apparent_Kd_M: 4.035398E-12
Real
Aptamer SeqId: 10455-196 | Target: IL-31 | UniProt: Q6EBC2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10455-196 | Target: IL-31 | UniProt: Q6EBC2 | TargetFullName: Interleukin-31 | Organisim: human | Apparent_Kd_M: 3.972659E-11
Real
Aptamer SeqId: 10461-57 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10461-57 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 7.219871E-11
Real
Aptamer SeqId: 10462-14 | Target: INSL5 | UniProt: Q9Y5Q6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10462-14 | Target: INSL5 | UniProt: Q9Y5Q6 | TargetFullName: Insulin-like peptide INSL5 | Organisim: human | Apparent_Kd_M: 6.563576E-12
Real
Aptamer SeqId: 10464-6 | Target: ANTR1 | UniProt: Q9H6X2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10464-6 | Target: ANTR1 | UniProt: Q9H6X2 | TargetFullName: Anthrax toxin receptor 1 | Organisim: human | Apparent_Kd_M: 3.621896E-10
Real
Aptamer SeqId: 10467-58 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10467-58 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.78488E-11
Real
Aptamer SeqId: 10471-25 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10471-25 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 7.816717E-12
Real
Aptamer SeqId: 10476-23 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10476-23 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.029042E-10
Real
Aptamer SeqId: 10477-162 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10477-162 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.766345E-11
Real
Aptamer SeqId: 10485-56 | Target: MAGE-4 | UniProt: P43358
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10485-56 | Target: MAGE-4 | UniProt: P43358 | TargetFullName: Melanoma-associated antigen 4 | Organisim: human | Apparent_Kd_M: 5.189515E-11
Real
Aptamer SeqId: 10489-19 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10489-19 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 4.240188E-12
Real
Aptamer SeqId: 10490-3 | Target: RPN1 | UniProt: P04843
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10490-3 | Target: RPN1 | UniProt: P04843 | TargetFullName: Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 | Organisim: human | Apparent_Kd_M: 1.720938E-12
Real
Aptamer SeqId: 10491-21 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10491-21 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 4.582074E-11
Real
Aptamer SeqId: 10494-48 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10494-48 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.081063E-10
Real
Aptamer SeqId: 10495-10 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10495-10 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 6.709518E-11
Real
Aptamer SeqId: 10496-11 | Target: CaCC | UniProt: A8K7I4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10496-11 | Target: CaCC | UniProt: A8K7I4 | TargetFullName: Calcium-activated chloride channel regulator 1 | Organisim: human | Apparent_Kd_M: 3.054818E-10
Real
Aptamer SeqId: 10497-242 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10497-242 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.731456E-10
Real
Aptamer SeqId: 10499-1 | Target: T106A | UniProt: Q96A25
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10499-1 | Target: T106A | UniProt: Q96A25 | TargetFullName: Transmembrane protein 106A | Organisim: human | Apparent_Kd_M: 1.215218E-10
Real
Aptamer SeqId: 10501-3 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10501-3 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 9.588051E-11
Real
Aptamer SeqId: 10502-15 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10502-15 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.484789E-12
Real
Aptamer SeqId: 10503-55 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10503-55 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.163683E-10
Real
Aptamer SeqId: 10504-6 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10504-6 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 5.845493E-12
Real
Aptamer SeqId: 10506-53 | Target: PGRC2 | UniProt: O15173
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10506-53 | Target: PGRC2 | UniProt: O15173 | TargetFullName: Membrane-associated progesterone receptor component 2 | Organisim: human | Apparent_Kd_M: 3.063879E-12
Real
Aptamer SeqId: 10507-166 | Target: sperm protein 10 | UniProt: P26436
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10507-166 | Target: sperm protein 10 | UniProt: P26436 | TargetFullName: Acrosomal protein SP-10 | Organisim: human | Apparent_Kd_M: 1.142748E-10
Real
Aptamer SeqId: 10510-62 | Target: SCIMP | UniProt: Q6UWF3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10510-62 | Target: SCIMP | UniProt: Q6UWF3 | TargetFullName: SLP adapter and CSK-interacting membrane protein | Organisim: human | Apparent_Kd_M: 3.66484E-10
Real
Aptamer SeqId: 10511-10 | Target: Collagen alpha-3(VI) | UniProt: P12111
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10511-10 | Target: Collagen alpha-3(VI) | UniProt: P12111 | TargetFullName: Collagen alpha-3(VI) chain | Organisim: human | Apparent_Kd_M: 2.16179E-11
Real
Aptamer SeqId: 10512-13 | Target: IL3RB | UniProt: P32927
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10512-13 | Target: IL3RB | UniProt: P32927 | TargetFullName: Cytokine receptor common subunit beta | Organisim: human | Apparent_Kd_M: 1.541846E-11
Real
Aptamer SeqId: 10513-13 | Target: CSEN | UniProt: Q9Y2W7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10513-13 | Target: CSEN | UniProt: Q9Y2W7 | TargetFullName: Calsenilin | Organisim: human | Apparent_Kd_M: 3.615028E-11
Real
Aptamer SeqId: 10514-5 | Target: PGD2 synthase | UniProt: P41222
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10514-5 | Target: PGD2 synthase | UniProt: P41222 | TargetFullName: Prostaglandin-H2 D-isomerase | Organisim: human | Apparent_Kd_M: 1.87172E-11
Real
Aptamer SeqId: 10516-53 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10516-53 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.947234E-11
Real
Aptamer SeqId: 10518-14 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10518-14 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 5.299399E-11
Real
Aptamer SeqId: 10521-10 | Target: MXRA8 | UniProt: Q9BRK3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10521-10 | Target: MXRA8 | UniProt: Q9BRK3 | TargetFullName: Matrix-remodeling-associated protein 8 | Organisim: human | Apparent_Kd_M: 3.395888E-12
Real
Aptamer SeqId: 10522-167 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10522-167 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 7.289894E-11
Real
Aptamer SeqId: 10527-22 | Target: DHX9 | UniProt: Q08211
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10527-22 | Target: DHX9 | UniProt: Q08211 | TargetFullName: ATP-dependent RNA helicase A | Organisim: human | Apparent_Kd_M: 1.992942E-11
Real
Aptamer SeqId: 10529-19 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10529-19 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 5.01845E-11
Real
Aptamer SeqId: 10530-8 | Target: PSB6 | UniProt: P28072
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10530-8 | Target: PSB6 | UniProt: P28072 | TargetFullName: Proteasome subunit beta type-6 | Organisim: human | Apparent_Kd_M: 6.015654E-10
Real
Aptamer SeqId: 10531-18 | Target: RASN | UniProt: P01111
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10531-18 | Target: RASN | UniProt: P01111 | TargetFullName: GTPase NRas | Organisim: human | Apparent_Kd_M: 4.119602E-11
Real
Aptamer SeqId: 10533-1 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10533-1 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.839458E-11
Real
Aptamer SeqId: 10534-40 | Target: PARP | UniProt: P09874
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10534-40 | Target: PARP | UniProt: P09874 | TargetFullName: Poly ADP-ribose polymerase 1 | Organisim: human | Apparent_Kd_M: 5.630502E-11
Real
Aptamer SeqId: 10535-25 | Target: CX6A2 | UniProt: Q02221
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10535-25 | Target: CX6A2 | UniProt: Q02221 | TargetFullName: Cytochrome c oxidase subunit 6A2; mitochondrial | Organisim: human | Apparent_Kd_M: 2.605286E-11
Real
Aptamer SeqId: 10539-30 | Target: C99L2 | UniProt: Q8TCZ2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10539-30 | Target: C99L2 | UniProt: Q8TCZ2 | TargetFullName: CD99 antigen-like protein 2 | Organisim: human | Apparent_Kd_M: 7.189129E-10
Real
Aptamer SeqId: 10546-2 | Target: TSEAR | UniProt: Q8WU66
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10546-2 | Target: TSEAR | UniProt: Q8WU66 | TargetFullName: Thrombospondin-type laminin G domain and EAR repeat-containing protein | Organisim: human | Apparent_Kd_M: 2.713605E-10
Real
Aptamer SeqId: 10547-42 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10547-42 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 9.772629E-12
Real
Aptamer SeqId: 10548-35 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10548-35 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.848974E-11
Real
Aptamer SeqId: 10550-37 | Target: BMP RIB | UniProt: O00238
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10550-37 | Target: BMP RIB | UniProt: O00238 | TargetFullName: Bone morphogenetic protein receptor type-1B | Organisim: human | Apparent_Kd_M: 3.616782E-10
Real
Aptamer SeqId: 10551-7 | Target: LAT | UniProt: O43561
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10551-7 | Target: LAT | UniProt: O43561 | TargetFullName: Linker for activation of T-cells family member 1 | Organisim: human | Apparent_Kd_M: 1.758048E-10
Real
Aptamer SeqId: 10552-88 | Target: NKG2F | UniProt: O43908
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10552-88 | Target: NKG2F | UniProt: O43908 | TargetFullName: NKG2-F type II integral membrane protein | Organisim: human | Apparent_Kd_M: 6.016723E-12
Real
Aptamer SeqId: 10553-8 | Target: TOIP2 | UniProt: Q8NFQ8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10553-8 | Target: TOIP2 | UniProt: Q8NFQ8 | TargetFullName: Torsin-1A-interacting protein 2 | Organisim: human | Apparent_Kd_M: 1.530337E-11
Real
Aptamer SeqId: 10554-23 | Target: BGAL | UniProt: P16278
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10554-23 | Target: BGAL | UniProt: P16278 | TargetFullName: Beta-galactosidase | Organisim: human | Apparent_Kd_M: 7.730195E-11
Real
Aptamer SeqId: 10557-6 | Target: TEX29 | UniProt: Q8N6K0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10557-6 | Target: TEX29 | UniProt: Q8N6K0 | TargetFullName: Testis-expressed sequence 29 protein | Organisim: human | Apparent_Kd_M: 7.220938E-12
Real
Aptamer SeqId: 10558-26 | Target: PCDH9 | UniProt: Q9HC56
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10558-26 | Target: PCDH9 | UniProt: Q9HC56 | TargetFullName: Protocadherin-9 | Organisim: human | Apparent_Kd_M: 1.333987E-10
Real
Aptamer SeqId: 10560-1 | Target: ITM2C | UniProt: Q9NQX7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10560-1 | Target: ITM2C | UniProt: Q9NQX7 | TargetFullName: Integral membrane protein 2C | Organisim: human | Apparent_Kd_M: 6.835532E-12
Real
Aptamer SeqId: 10561-5 | Target: PGRP-I-alpha | UniProt: Q96LB9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10561-5 | Target: PGRP-I-alpha | UniProt: Q96LB9 | TargetFullName: Peptidoglycan recognition protein 3 | Organisim: human | Apparent_Kd_M: 2.494541E-11
Real
Aptamer SeqId: 10562-42 | Target: NETO2 | UniProt: Q8NC67
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10562-42 | Target: NETO2 | UniProt: Q8NC67 | TargetFullName: Neuropilin and tolloid-like protein 2 | Organisim: human | Apparent_Kd_M: 5.001589E-11
Real
Aptamer SeqId: 10563-13 | Target: LYSM3 | UniProt: Q7Z3D4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10563-13 | Target: LYSM3 | UniProt: Q7Z3D4 | TargetFullName: LysM and putative peptidoglycan-binding domain-containing protein 3 | Organisim: human | Apparent_Kd_M: 5.509922E-11
Real
Aptamer SeqId: 10565-19 | Target: SLIK3 | UniProt: O94933
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10565-19 | Target: SLIK3 | UniProt: O94933 | TargetFullName: SLIT and NTRK-like protein 3 | Organisim: human | Apparent_Kd_M: 8.958962E-12
Real
Aptamer SeqId: 10569-28 | Target: MFAP2 | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10569-28 | Target: MFAP2 | UniProt: | TargetFullName: Microfibrillar-associated protein 2 | Organisim: human | Apparent_Kd_M: 1.336087E-10
Real
Aptamer SeqId: 10571-14 | Target: MGAT1 | UniProt: P26572
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10571-14 | Target: MGAT1 | UniProt: P26572 | TargetFullName: Alpha-1;3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase | Organisim: human | Apparent_Kd_M: 1.026508E-11
Real
Aptamer SeqId: 10572-65 | Target: CST8 | UniProt: O60676
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10572-65 | Target: CST8 | UniProt: O60676 | TargetFullName: Cystatin-8 | Organisim: human | Apparent_Kd_M: 6.868947E-11
Real
Aptamer SeqId: 10574-10 | Target: b2-Microglobulin | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10574-10 | Target: b2-Microglobulin | UniProt: | TargetFullName: Beta-2-microglobulin | Organisim: human | Apparent_Kd_M: 3.855881E-12
Real
Aptamer SeqId: 10575-31 | Target: PUF60 | UniProt: Q9UHX1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10575-31 | Target: PUF60 | UniProt: Q9UHX1 | TargetFullName: Poly(U)-binding-splicing factor PUF60 | Organisim: human | Apparent_Kd_M: 3.791703E-12
Real
Aptamer SeqId: 10580-14 | Target: SFTA2 | UniProt: Q6UW10
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10580-14 | Target: SFTA2 | UniProt: Q6UW10 | TargetFullName: Surfactant-associated protein 2 | Organisim: human | Apparent_Kd_M: 2.491013E-11
Real
Aptamer SeqId: 10582-36 | Target: SG196 | UniProt: Q9H5K3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10582-36 | Target: SG196 | UniProt: Q9H5K3 | TargetFullName: Protein O-mannose kinase | Organisim: human | Apparent_Kd_M: 1.342557E-10
Real
Aptamer SeqId: 10583-1 | Target: TM108 | UniProt: Q6UXF1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10583-1 | Target: TM108 | UniProt: Q6UXF1 | TargetFullName: Transmembrane protein 108 | Organisim: human | Apparent_Kd_M: 1.605435E-10
Real
Aptamer SeqId: 10584-7 | Target: NDUS4 | UniProt: O43181
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10584-7 | Target: NDUS4 | UniProt: O43181 | TargetFullName: NADH dehydrogenase ubiquinone iron-sulfur protein 4; mitochondrial | Organisim: human | Apparent_Kd_M: 2.432584E-11
Real
Aptamer SeqId: 10588-39 | Target: SIAT9 | UniProt: Q9UNP4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10588-39 | Target: SIAT9 | UniProt: Q9UNP4 | TargetFullName: Lactosylceramide alpha-2;3-sialyltransferase | Organisim: human | Apparent_Kd_M: 4.334023E-11
Real
Aptamer SeqId: 10589-7 | Target: RET1L | UniProt: Q5VY80
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10589-7 | Target: RET1L | UniProt: Q5VY80 | TargetFullName: Retinoic acid early transcript 1L protein | Organisim: human | Apparent_Kd_M: 2.192516E-10
Real
Aptamer SeqId: 10593-14 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10593-14 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.7512E-10
Real
Aptamer SeqId: 10600-24 | Target: CLGN | UniProt: O14967
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10600-24 | Target: CLGN | UniProt: O14967 | TargetFullName: Calmegin | Organisim: human | Apparent_Kd_M: 6.299843E-11
Real
Aptamer SeqId: 10603-1 | Target: HIS3 | UniProt: P15516
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10603-1 | Target: HIS3 | UniProt: P15516 | TargetFullName: Histatin-3 | Organisim: human | Apparent_Kd_M: 1.066727E-11
Real
Aptamer SeqId: 10605-22 | Target: APMAP | UniProt: Q9HDC9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10605-22 | Target: APMAP | UniProt: Q9HDC9 | TargetFullName: Adipocyte plasma membrane-associated protein | Organisim: human | Apparent_Kd_M: 5.630031E-11
Real
Aptamer SeqId: 10606-34 | Target: TOIP1 | UniProt: Q5JTV8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10606-34 | Target: TOIP1 | UniProt: Q5JTV8 | TargetFullName: Torsin-1A-interacting protein 1 | Organisim: human | Apparent_Kd_M: 1.550677E-12
Real
Aptamer SeqId: 10607-4 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10607-4 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 5.36797E-12
Real
Aptamer SeqId: 10608-9 | Target: HIS1 | UniProt: P15515
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10608-9 | Target: HIS1 | UniProt: P15515 | TargetFullName: Histatin-1 | Organisim: human | Apparent_Kd_M: 4.501146E-10
Real
Aptamer SeqId: 10610-8 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10610-8 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.354963E-11
Real
Aptamer SeqId: 10612-18 | Target: PLOD3 | UniProt: O60568
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10612-18 | Target: PLOD3 | UniProt: O60568 | TargetFullName: Procollagen-lysine;2-oxoglutarate 5-dioxygenase 3 | Organisim: human | Apparent_Kd_M: 9.427786E-13
Real
Aptamer SeqId: 10613-33 | Target: CASC4 | UniProt: Q6P4E1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10613-33 | Target: CASC4 | UniProt: Q6P4E1 | TargetFullName: Protein CASC4 | Organisim: human | Apparent_Kd_M: 2.74337E-11
Real
Aptamer SeqId: 10615-18 | Target: MYP0 | UniProt: P25189
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10615-18 | Target: MYP0 | UniProt: P25189 | TargetFullName: Myelin protein P0 | Organisim: human | Apparent_Kd_M: 6.128802E-12
Real
Aptamer SeqId: 10616-67 | Target: PDXL2 | UniProt: Q9NZ53
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10616-67 | Target: PDXL2 | UniProt: Q9NZ53 | TargetFullName: Podocalyxin-like protein 2 | Organisim: human | Apparent_Kd_M: 4.298275E-12
Real
Aptamer SeqId: 10618-190 | Target: megalin | UniProt: P98164
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10618-190 | Target: megalin | UniProt: P98164 | TargetFullName: Low-density lipoprotein receptor-related protein 2 | Organisim: human | Apparent_Kd_M: 7.808546E-12
Real
Aptamer SeqId: 10620-21 | Target: PSP-94 | UniProt: P08118
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10620-21 | Target: PSP-94 | UniProt: P08118 | TargetFullName: Beta-microseminoprotein | Organisim: human | Apparent_Kd_M: 8.14832E-13
Real
Aptamer SeqId: 10621-26 | Target: PRR16 | UniProt: Q569H4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10621-26 | Target: PRR16 | UniProt: Q569H4 | TargetFullName: Protein Largen | Organisim: human | Apparent_Kd_M: 3.872804E-11
Real
Aptamer SeqId: 10622-9 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10622-9 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.496621E-12
Real
Aptamer SeqId: 10623-19 | Target: MUC1 | UniProt: P15941
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10623-19 | Target: MUC1 | UniProt: P15941 | TargetFullName: Mucin-1 | Organisim: human | Apparent_Kd_M: 2.389687E-12
Real
Aptamer SeqId: 10624-45 | Target: ISK13 | UniProt: Q1W4C9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10624-45 | Target: ISK13 | UniProt: Q1W4C9 | TargetFullName: Serine protease inhibitor Kazal-type 13 | Organisim: human | Apparent_Kd_M: 3.100195E-12
Real
Aptamer SeqId: 10627-87 | Target: APLP2 | UniProt: Q06481
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10627-87 | Target: APLP2 | UniProt: Q06481 | TargetFullName: Amyloid-like protein 2 | Organisim: human | Apparent_Kd_M: 3.523689E-13
Real
Aptamer SeqId: 10630-5 | Target: HTAI2 | UniProt: Q9BUP3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10630-5 | Target: HTAI2 | UniProt: Q9BUP3 | TargetFullName: Oxidoreductase HTATIP2 | Organisim: human | Apparent_Kd_M: 2.92304E-11
Real
Aptamer SeqId: 10637-50 | Target: K1324 | UniProt: Q6UXG2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10637-50 | Target: K1324 | UniProt: Q6UXG2 | TargetFullName: UPF0577 protein KIAA1324 | Organisim: human | Apparent_Kd_M: 6.845908E-12
Real
Aptamer SeqId: 10638-1 | Target: TINF2 | UniProt: Q9BSI4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10638-1 | Target: TINF2 | UniProt: Q9BSI4 | TargetFullName: TERF1-interacting nuclear factor 2 | Organisim: human | Apparent_Kd_M: 5.426284E-12
Real
Aptamer SeqId: 10639-1 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10639-1 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.35E-10
Real
Aptamer SeqId: 10640-9 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10640-9 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 5.993581E-13
Real
Aptamer SeqId: 10643-16 | Target: NOE3 | UniProt: Q96PB7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10643-16 | Target: NOE3 | UniProt: Q96PB7 | TargetFullName: Noelin-3 | Organisim: human | Apparent_Kd_M: 3.850645E-12
Real
Aptamer SeqId: 10645-72 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10645-72 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.130259E-11
Real
Aptamer SeqId: 10647-18 | Target: ASCC1 | UniProt: Q8N9N2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10647-18 | Target: ASCC1 | UniProt: Q8N9N2 | TargetFullName: Activating signal cointegrator 1 complex subunit 1 | Organisim: human | Apparent_Kd_M: 3.035603E-11
Real
Aptamer SeqId: 10655-43 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10655-43 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.100349E-12
Real
Aptamer SeqId: 10658-28 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10658-28 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 4.617205E-11
Real
Aptamer SeqId: 10659-49 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10659-49 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.12665E-11
Real
Aptamer SeqId: 10660-33 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10660-33 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 6.360944E-11
Real
Aptamer SeqId: 10661-4 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10661-4 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.496104E-11
Real
Aptamer SeqId: 10663-42 | Target: INSI1 | UniProt: O15503
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10663-42 | Target: INSI1 | UniProt: O15503 | TargetFullName: Insulin-induced gene 1 protein | Organisim: human | Apparent_Kd_M: 2.074754E-11
Real
Aptamer SeqId: 10665-30 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10665-30 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.126561E-11
Real
Aptamer SeqId: 10666-7 | Target: GNPTG | UniProt: Q9UJJ9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10666-7 | Target: GNPTG | UniProt: Q9UJJ9 | TargetFullName: N-acetylglucosamine-1-phosphotransferase subunit gamma | Organisim: human | Apparent_Kd_M: 2.799442E-12
Real
Aptamer SeqId: 10667-78 | Target: CA185 | UniProt: Q5T7R7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10667-78 | Target: CA185 | UniProt: Q5T7R7 | TargetFullName: Uncharacterized protein C1orf185 | Organisim: human | Apparent_Kd_M: 1.099445E-11
Real
Aptamer SeqId: 10668-5 | Target: STX4 | UniProt: Q12846
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10668-5 | Target: STX4 | UniProt: Q12846 | TargetFullName: Syntaxin-4 | Organisim: human | Apparent_Kd_M: 1.656652E-11
Real
Aptamer SeqId: 10671-67 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10671-67 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.90391E-12
Real
Aptamer SeqId: 10672-75 | Target: SP-B | UniProt: P07988
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10672-75 | Target: SP-B | UniProt: P07988 | TargetFullName: Pulmonary surfactant-associated protein B | Organisim: human | Apparent_Kd_M: 6.508364E-11
Real
Aptamer SeqId: 10675-223 | Target: TMX2 | UniProt: Q9Y320
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10675-223 | Target: TMX2 | UniProt: Q9Y320 | TargetFullName: Thioredoxin-related transmembrane protein 2 | Organisim: human | Apparent_Kd_M: 1.04137E-10
Real
Aptamer SeqId: 10677-9 | Target: NDUB4 | UniProt: O95168
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10677-9 | Target: NDUB4 | UniProt: O95168 | TargetFullName: NADH dehydrogenase ubiquinone 1 beta subcomplex subunit 4 | Organisim: human | Apparent_Kd_M: 3.254193E-11
Real
Aptamer SeqId: 10692-48 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10692-48 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.240477E-12
Real
Aptamer SeqId: 10693-43 | Target: KLRG2 | UniProt: A4D1S0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10693-43 | Target: KLRG2 | UniProt: A4D1S0 | TargetFullName: Killer cell lectin-like receptor subfamily G member 2 | Organisim: human | Apparent_Kd_M: 4.771176E-11
Real
Aptamer SeqId: 10695-12 | Target: WF10B | UniProt: Q8IUB3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10695-12 | Target: WF10B | UniProt: Q8IUB3 | TargetFullName: Protein WFDC10B | Organisim: human | Apparent_Kd_M: 1.600743E-11
Real
Aptamer SeqId: 10699-52 | Target: LRP1 | UniProt: Q07954
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10699-52 | Target: LRP1 | UniProt: Q07954 | TargetFullName: Prolow-density lipoprotein receptor-related protein 1 | Organisim: human | Apparent_Kd_M: 4.13069E-11
Real
Aptamer SeqId: 10700-10 | Target: IGS11 | UniProt: Q5DX21
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10700-10 | Target: IGS11 | UniProt: Q5DX21 | TargetFullName: Immunoglobulin superfamily member 11 | Organisim: human | Apparent_Kd_M: 1.996639E-11
Real
Aptamer SeqId: 10701-30 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10701-30 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.759508E-11
Real
Aptamer SeqId: 10702-1 | Target: COSA1 | UniProt: Q2UY09
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10702-1 | Target: COSA1 | UniProt: Q2UY09 | TargetFullName: Collagen alpha-1(XXVIII) chain | Organisim: human | Apparent_Kd_M: 2.274225E-11
Real
Aptamer SeqId: 10703-203 | Target: SDS3 | UniProt: Q9H7L9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10703-203 | Target: SDS3 | UniProt: Q9H7L9 | TargetFullName: Sin3 histone deacetylase corepressor complex component SDS3 | Organisim: human | Apparent_Kd_M: 1.139953E-11
Real
Aptamer SeqId: 10704-91 | Target: LRMP | UniProt: Q12912
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10704-91 | Target: LRMP | UniProt: Q12912 | TargetFullName: Lymphoid-restricted membrane protein | Organisim: human | Apparent_Kd_M: 1.551691E-11
Real
Aptamer SeqId: 10705-14 | Target: SIA7C | UniProt: Q8NDV1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10705-14 | Target: SIA7C | UniProt: Q8NDV1 | TargetFullName: Alpha-N-acetylgalactosaminide alpha-2;6-sialyltransferase 3 | Organisim: human | Apparent_Kd_M: 2.608496E-11
Real
Aptamer SeqId: 10708-3 | Target: GON2 | UniProt: O43555
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10708-3 | Target: GON2 | UniProt: O43555 | TargetFullName: Progonadoliberin-2 | Organisim: human | Apparent_Kd_M: 4.00928E-11
Real
Aptamer SeqId: 10710-23 | Target: ZPBP2 | UniProt: Q6X784
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10710-23 | Target: ZPBP2 | UniProt: Q6X784 | TargetFullName: Zona pellucida-binding protein 2 | Organisim: human | Apparent_Kd_M: 4.664906E-12
Real
Aptamer SeqId: 10713-151 | Target: CLM7 | UniProt: A8K4G0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10713-151 | Target: CLM7 | UniProt: A8K4G0 | TargetFullName: CMRF35-like molecule 7 | Organisim: human | Apparent_Kd_M: 7.037155E-12
Real
Aptamer SeqId: 10714-7 | Target: ACE | UniProt: P12821
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10714-7 | Target: ACE | UniProt: P12821 | TargetFullName: Angiotensin-converting enzyme | Organisim: human | Apparent_Kd_M: 4.050056E-10
Real
Aptamer SeqId: 10715-5 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10715-5 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.791798E-11
Real
Aptamer SeqId: 10716-35 | Target: PSMD5 | UniProt: Q16401
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10716-35 | Target: PSMD5 | UniProt: Q16401 | TargetFullName: 26S proteasome non-ATPase regulatory subunit 5 | Organisim: human | Apparent_Kd_M: 2.372455E-11
Real
Aptamer SeqId: 10721-76 | Target: HSP 70 | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10721-76 | Target: HSP 70 | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 5.83598E-11
Real
Aptamer SeqId: 10722-13 | Target: KSYK | UniProt: P43405
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10722-13 | Target: KSYK | UniProt: P43405 | TargetFullName: Tyrosine-protein kinase SYK | Organisim: human | Apparent_Kd_M: 7.513084E-12
Real
Aptamer SeqId: 10723-41 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10723-41 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.708834E-10
Real
Aptamer SeqId: 10731-10 | Target: HS3S5 | UniProt: Q8IZT8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10731-10 | Target: HS3S5 | UniProt: Q8IZT8 | TargetFullName: Heparan sulfate glucosamine 3-O-sulfotransferase 5 | Organisim: human | Apparent_Kd_M: 5.034756E-11
Real
Aptamer SeqId: 10734-339 | Target: G3ST2 | UniProt: Q9H3Q3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10734-339 | Target: G3ST2 | UniProt: Q9H3Q3 | TargetFullName: Galactose-3-O-sulfotransferase 2 | Organisim: human | Apparent_Kd_M: 1.417874E-10
Real
Aptamer SeqId: 10737-96 | Target: Serpin B1 | UniProt: P30740
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10737-96 | Target: Serpin B1 | UniProt: P30740 | TargetFullName: Leukocyte elastase inhibitor | Organisim: human | Apparent_Kd_M: 1.002494E-11
Real
Aptamer SeqId: 10748-216 | Target: PCDB2 | UniProt: Q9Y5E7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10748-216 | Target: PCDB2 | UniProt: Q9Y5E7 | TargetFullName: Protocadherin beta-2 | Organisim: human | Apparent_Kd_M: 2.041404E-11
Real
Aptamer SeqId: 10749-18 | Target: HSP 70 | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10749-18 | Target: HSP 70 | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 8.183436E-11
Real
Aptamer SeqId: 10752-8 | Target: CDYL2 | UniProt: Q8N8U2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10752-8 | Target: CDYL2 | UniProt: Q8N8U2 | TargetFullName: Chromodomain Y-like protein 2 | Organisim: human | Apparent_Kd_M: 1.776828E-11
Real
Aptamer SeqId: 10753-31 | Target: ADAM7 | UniProt: Q9H2U9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10753-31 | Target: ADAM7 | UniProt: Q9H2U9 | TargetFullName: Disintegrin and metalloproteinase domain-containing protein 7 | Organisim: human | Apparent_Kd_M: 1.90314E-12
Real
Aptamer SeqId: 10754-113 | Target: Prokineticin-2 | UniProt: Q9HC23
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10754-113 | Target: Prokineticin-2 | UniProt: Q9HC23 | TargetFullName: Prokineticin-2 | Organisim: human | Apparent_Kd_M: 9.853775E-11
Real
Aptamer SeqId: 10756-34 | Target: UCN3 | UniProt: Q969E3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10756-34 | Target: UCN3 | UniProt: Q969E3 | TargetFullName: Urocortin-3 | Organisim: human | Apparent_Kd_M: 1.531645E-10
Real
Aptamer SeqId: 10758-2 | Target: KERA | UniProt: O60938
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10758-2 | Target: KERA | UniProt: O60938 | TargetFullName: Keratocan | Organisim: human | Apparent_Kd_M: 5.926528E-11
Real
Aptamer SeqId: 10760-107 | Target: GRIA4 | UniProt: P48058
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10760-107 | Target: GRIA4 | UniProt: P48058 | TargetFullName: Glutamate receptor 4 | Organisim: human | Apparent_Kd_M: 8.570896E-11
Real
Aptamer SeqId: 10761-5 | Target: TMED2 | UniProt: Q15363
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10761-5 | Target: TMED2 | UniProt: Q15363 | TargetFullName: Transmembrane emp24 domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 5.48175E-10
Real
Aptamer SeqId: 10762-2 | Target: KLRG2 | UniProt: A4D1S0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10762-2 | Target: KLRG2 | UniProt: A4D1S0 | TargetFullName: Killer cell lectin-like receptor subfamily G member 2 | Organisim: human | Apparent_Kd_M: 1.364762E-10
Real
Aptamer SeqId: 10767-52 | Target: GPR64 | UniProt: Q8IZP9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10767-52 | Target: GPR64 | UniProt: Q8IZP9 | TargetFullName: G-protein coupled receptor 64 | Organisim: human | Apparent_Kd_M: 8.684941E-11
Real
Aptamer SeqId: 10772-21 | Target: CGAT2 | UniProt: Q8N6G5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10772-21 | Target: CGAT2 | UniProt: Q8N6G5 | TargetFullName: Chondroitin sulfate N-acetylgalactosaminyltransferase 2 | Organisim: human | Apparent_Kd_M: 2.168157E-11
Real
Aptamer SeqId: 10781-19 | Target: CLC4G | UniProt: Q6UXB4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10781-19 | Target: CLC4G | UniProt: Q6UXB4 | TargetFullName: C-type lectin domain family 4 member G | Organisim: human | Apparent_Kd_M: 3.750748E-11
Real
Aptamer SeqId: 10785-8 | Target: LRC52 | UniProt: Q8N7C0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10785-8 | Target: LRC52 | UniProt: Q8N7C0 | TargetFullName: Leucine-rich repeat-containing protein 52 | Organisim: human | Apparent_Kd_M: 2.409164E-10
Real
Aptamer SeqId: 10791-21 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10791-21 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.602132E-11
Real
Aptamer SeqId: 10798-4 | Target: CLM2 | UniProt: Q496F6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10798-4 | Target: CLM2 | UniProt: Q496F6 | TargetFullName: CMRF35-like molecule 2 | Organisim: human | Apparent_Kd_M: 4.902529E-12
Real
Aptamer SeqId: 10800-15 | Target: Collagen-binding protein
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10800-15 | Target: Collagen-binding protein | UniProt: P50454 | TargetFullName: Serpin H1 | Organisim: human | Apparent_Kd_M: 4.438532E-11
Real
Aptamer SeqId: 10803-22 | Target: HSP 70 | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10803-22 | Target: HSP 70 | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 5.6742E-11
Real
Aptamer SeqId: 10809-14 | Target: KLRB1 | UniProt: Q12918
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10809-14 | Target: KLRB1 | UniProt: Q12918 | TargetFullName: Killer cell lectin-like receptor subfamily B member 1 | Organisim: human | Apparent_Kd_M: 5.428431E-11
Real
Aptamer SeqId: 10814-7 | Target: CD1A | UniProt: P06126
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10814-7 | Target: CD1A | UniProt: P06126 | TargetFullName: T-cell surface glycoprotein CD1a | Organisim: human | Apparent_Kd_M: 1.661939E-10
Real
Aptamer SeqId: 10815-2 | Target: HABP4 | UniProt: Q5JVS0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10815-2 | Target: HABP4 | UniProt: Q5JVS0 | TargetFullName: Intracellular hyaluronan-binding protein 4 | Organisim: human | Apparent_Kd_M: 3.471928E-11
Real
Aptamer SeqId: 10816-150 | Target: PILRA isoform FDF03-M14
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10816-150 | Target: PILRA isoform FDF03-M14 | UniProt: Q9UKJ1 | TargetFullName: Paired immunoglobulin-like type 2 receptor alpha isoform FDF03-M14 | Organisim: human | Apparent_Kd_M: 1.835519E-11
Real
Aptamer SeqId: 10817-26 | Target: TO20L | UniProt: Q6UXN7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10817-26 | Target: TO20L | UniProt: Q6UXN7 | TargetFullName: TOMM20-like protein 1 | Organisim: human | Apparent_Kd_M: 3.735161E-11
Real
Aptamer SeqId: 10818-36 | Target: ASM | UniProt: P17405
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10818-36 | Target: ASM | UniProt: P17405 | TargetFullName: Sphingomyelin phosphodiesterase | Organisim: human | Apparent_Kd_M: 1.091323E-10
Real
Aptamer SeqId: 10823-19 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10823-19 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 4.488799E-11
Real
Aptamer SeqId: 10825-12 | Target: VSI10 | UniProt: Q8N0Z9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10825-12 | Target: VSI10 | UniProt: Q8N0Z9 | TargetFullName: V-set and immunoglobulin domain-containing protein 10 | Organisim: human | Apparent_Kd_M: 7.159368E-11
Real
Aptamer SeqId: 10827-67 | Target: LIGO3 | UniProt: P0C6S8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10827-67 | Target: LIGO3 | UniProt: P0C6S8 | TargetFullName: Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 3 | Organisim: human | Apparent_Kd_M: 2.106725E-11
Real
Aptamer SeqId: 10830-5 | Target: K0494 | UniProt: O75071
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10830-5 | Target: K0494 | UniProt: O75071 | TargetFullName: EF-hand calcium-binding domain-containing protein 14 | Organisim: human | Apparent_Kd_M: 1.229157E-11
Real
Aptamer SeqId: 10832-24 | Target: B4GT6 | UniProt: Q9UBX8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10832-24 | Target: B4GT6 | UniProt: Q9UBX8 | TargetFullName: Beta-1;4-galactosyltransferase 6 | Organisim: human | Apparent_Kd_M: 5.91E-11
Real
Aptamer SeqId: 10833-64 | Target: HHIP | UniProt: Q96QV1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10833-64 | Target: HHIP | UniProt: Q96QV1 | TargetFullName: Hedgehog-interacting protein | Organisim: human | Apparent_Kd_M: 5.787966E-11
Real
Aptamer SeqId: 10835-25 | Target: A4GCT | UniProt: Q9UNA3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10835-25 | Target: A4GCT | UniProt: Q9UNA3 | TargetFullName: Alpha-1;4-N-acetylglucosaminyltransferase | Organisim: human | Apparent_Kd_M: 5.85932E-11
Real
Aptamer SeqId: 10842-7 | Target: GCNT4 | UniProt: Q9P109
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10842-7 | Target: GCNT4 | UniProt: Q9P109 | TargetFullName: Beta-1;3-galactosyl-O-glycosyl-glycoprotein beta-1;6-N-acetylglucosaminyltransferase 4 | Organisim: human | Apparent_Kd_M: 3.379379E-11
Real
Aptamer SeqId: 10847-1 | Target: SIG15 | UniProt: Q6ZMC9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10847-1 | Target: SIG15 | UniProt: Q6ZMC9 | TargetFullName: Sialic acid-binding Ig-like lectin 15 | Organisim: human | Apparent_Kd_M: 4.203997E-12
Real
Aptamer SeqId: 10848-137 | Target: BTNL3 | UniProt: Q6UXE8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10848-137 | Target: BTNL3 | UniProt: Q6UXE8 | TargetFullName: Butyrophilin-like protein 3 | Organisim: human | Apparent_Kd_M: 1.53409E-10
Real
Aptamer SeqId: 10851-77 | Target: IL27B | UniProt: Q14213
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10851-77 | Target: IL27B | UniProt: Q14213 | TargetFullName: Interleukin-27 subunit beta | Organisim: human | Apparent_Kd_M: 2.841632E-11
Real
Aptamer SeqId: 10852-114 | Target: HNRDL | UniProt: O14979
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10852-114 | Target: HNRDL | UniProt: O14979 | TargetFullName: Heterogeneous nuclear ribonucleoprotein D-like | Organisim: human | Apparent_Kd_M: 1.746954E-12
Real
Aptamer SeqId: 10866-60 | Target: P4R3A | UniProt: Q6IN85
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10866-60 | Target: P4R3A | UniProt: Q6IN85 | TargetFullName: Serine/threonine-protein phosphatase 4 regulatory subunit 3A | Organisim: human | Apparent_Kd_M: 1.525652E-10
Real
Aptamer SeqId: 10876-300 | Target: BRAT1 | UniProt: Q6PJG6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10876-300 | Target: BRAT1 | UniProt: Q6PJG6 | TargetFullName: BRCA1-associated ATM activator 1 | Organisim: human | Apparent_Kd_M: 3.12E-10
Real
Aptamer SeqId: 10880-38 | Target: F163B | UniProt: P0C2L3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10880-38 | Target: F163B | UniProt: P0C2L3 | TargetFullName: Protein FAM163B | Organisim: human | Apparent_Kd_M: 4.507201E-11
Real
Aptamer SeqId: 10882-12 | Target: Desmocollin-1 | UniProt: Q08554
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10882-12 | Target: Desmocollin-1 | UniProt: Q08554 | TargetFullName: Desmocollin-1 | Organisim: human | Apparent_Kd_M: 2.019101E-11
Real
Aptamer SeqId: 10885-36 | Target: CF089 | UniProt: Q6UWU4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10885-36 | Target: CF089 | UniProt: Q6UWU4 | TargetFullName: Bombesin receptor-activated protein C6orf89 | Organisim: human | Apparent_Kd_M: 1.443445E-11
Real
Aptamer SeqId: 10888-4 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10888-4 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.498489E-10
Real
Aptamer SeqId: 10889-2 | Target: MRAP2 | UniProt: Q96G30
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10889-2 | Target: MRAP2 | UniProt: Q96G30 | TargetFullName: Melanocortin-2 receptor accessory protein 2 | Organisim: human | Apparent_Kd_M: 1.270566E-10
Real
Aptamer SeqId: 10890-135 | Target: LCTL | UniProt: Q6UWM7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10890-135 | Target: LCTL | UniProt: Q6UWM7 | TargetFullName: Lactase-like protein | Organisim: human | Apparent_Kd_M: 6.446244E-11
Real
Aptamer SeqId: 10892-8 | Target: OSMR | UniProt: Q99650
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10892-8 | Target: OSMR | UniProt: Q99650 | TargetFullName: Oncostatin-M-specific receptor subunit beta | Organisim: human | Apparent_Kd_M: 8.083383E-11
Real
Aptamer SeqId: 10895-28 | Target: TM11B | UniProt: Q86T26
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10895-28 | Target: TM11B | UniProt: Q86T26 | TargetFullName: Transmembrane protease serine 11B | Organisim: human | Apparent_Kd_M: 8.550133E-12
Real
Aptamer SeqId: 10900-272 | Target: STMN2 | UniProt: Q93045
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10900-272 | Target: STMN2 | UniProt: Q93045 | TargetFullName: Stathmin-2 | Organisim: human | Apparent_Kd_M: 1.737892E-10
Real
Aptamer SeqId: 10902-53 | Target: APRV1 | UniProt: Q53RT3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10902-53 | Target: APRV1 | UniProt: Q53RT3 | TargetFullName: Retroviral-like aspartic protease 1 | Organisim: human | Apparent_Kd_M: 3.082898E-11
Real
Aptamer SeqId: 10903-50 | Target: STX8 | UniProt: Q9UNK0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10903-50 | Target: STX8 | UniProt: Q9UNK0 | TargetFullName: Syntaxin-8 | Organisim: human | Apparent_Kd_M: 3.130163E-12
Real
Aptamer SeqId: 10907-116 | Target: NTRI | UniProt: Q9P121
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10907-116 | Target: NTRI | UniProt: Q9P121 | TargetFullName: Neurotrimin | Organisim: human | Apparent_Kd_M: 4.044327E-11
Real
Aptamer SeqId: 10908-2 | Target: GLT13 | UniProt: Q8IUC8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10908-2 | Target: GLT13 | UniProt: Q8IUC8 | TargetFullName: Polypeptide N-acetylgalactosaminyltransferase 13 | Organisim: human | Apparent_Kd_M: 4.063708E-11
Real
Aptamer SeqId: 10910-6 | Target: CEAM4 | UniProt: O75871
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10910-6 | Target: CEAM4 | UniProt: O75871 | TargetFullName: Carcinoembryonic antigen-related cell adhesion molecule 4 | Organisim: human | Apparent_Kd_M: 1.234926E-10
Real
Aptamer SeqId: 10914-4 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10914-4 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 4.81236E-11
Real
Aptamer SeqId: 10916-44 | Target: PLA2R | UniProt: Q13018
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10916-44 | Target: PLA2R | UniProt: Q13018 | TargetFullName: Secretory phospholipase A2 receptor | Organisim: human | Apparent_Kd_M: 2.012947E-11
Real
Aptamer SeqId: 10917-40 | Target: GBGT2 | UniProt: O14610
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10917-40 | Target: GBGT2 | UniProt: O14610 | TargetFullName: Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-T2 | Organisim: human | Apparent_Kd_M: 1.047676E-10
Real
Aptamer SeqId: 10924-258 | Target: NEUFC | UniProt: Q8WUJ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10924-258 | Target: NEUFC | UniProt: Q8WUJ1 | TargetFullName: Neuferricin | Organisim: human | Apparent_Kd_M: 4.094834E-11
Real
Aptamer SeqId: 10927-65 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10927-65 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 4.446156E-11
Real
Aptamer SeqId: 10933-107 | Target: CABP8 | UniProt: Q9BXU9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10933-107 | Target: CABP8 | UniProt: Q9BXU9 | TargetFullName: Calcium-binding protein 8 | Organisim: human | Apparent_Kd_M: 2.860373E-10
Real
Aptamer SeqId: 10938-13 | Target: sLFA-3 | UniProt: P19256
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10938-13 | Target: sLFA-3 | UniProt: P19256 | TargetFullName: Lymphocyte function-associated antigen 3 | Organisim: human | Apparent_Kd_M: 1.002097E-11
Real
Aptamer SeqId: 10939-16 | Target: PKHA4 | UniProt: Q9H4M7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10939-16 | Target: PKHA4 | UniProt: Q9H4M7 | TargetFullName: Pleckstrin homology domain-containing family A member 4 | Organisim: human | Apparent_Kd_M: 1.515076E-11
Real
Aptamer SeqId: 10940-25 | Target: SRCA | UniProt: Q86TD4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10940-25 | Target: SRCA | UniProt: Q86TD4 | TargetFullName: Sarcalumenin | Organisim: human | Apparent_Kd_M: 3.869524E-10
Real
Aptamer SeqId: 10943-36 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10943-36 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.043494E-10
Real
Aptamer SeqId: 10945-11 | Target: Syntaxin-6 | UniProt: O43752
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10945-11 | Target: Syntaxin-6 | UniProt: O43752 | TargetFullName: Syntaxin-6 | Organisim: human | Apparent_Kd_M: 1.788194E-11
Real
Aptamer SeqId: 10948-14 | Target: PLD3 | UniProt: Q8IV08
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10948-14 | Target: PLD3 | UniProt: Q8IV08 | TargetFullName: Phospholipase D3 | Organisim: human | Apparent_Kd_M: 1.078237E-11
Real
Aptamer SeqId: 10949-59 | Target: RLA2 | UniProt: P05387
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10949-59 | Target: RLA2 | UniProt: P05387 | TargetFullName: 60S acidic ribosomal protein P2 | Organisim: human | Apparent_Kd_M: 7.832073E-12
Real
Aptamer SeqId: 10953-14 | Target: CLC2A | UniProt: Q6UVW9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10953-14 | Target: CLC2A | UniProt: Q6UVW9 | TargetFullName: C-type lectin domain family 2 member A | Organisim: human | Apparent_Kd_M: 2.36885E-11
Real
Aptamer SeqId: 10955-4 | Target: CLC10 | UniProt: Q8IUN9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10955-4 | Target: CLC10 | UniProt: Q8IUN9 | TargetFullName: C-type lectin domain family 10 member A | Organisim: human | Apparent_Kd_M: 5.624377E-10
Real
Aptamer SeqId: 10956-82 | Target: GCSH | UniProt: P23434
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10956-82 | Target: GCSH | UniProt: P23434 | TargetFullName: Glycine cleavage system H protein; mitochondrial | Organisim: human | Apparent_Kd_M: 1.389349E-10
Real
Aptamer SeqId: 10959-125 | Target: BET1L | UniProt: Q9NYM9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10959-125 | Target: BET1L | UniProt: Q9NYM9 | TargetFullName: BET1-like protein | Organisim: human | Apparent_Kd_M: 7.497972E-11
Real
Aptamer SeqId: 10961-15 | Target: TIG3 | UniProt: Q9UL19
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10961-15 | Target: TIG3 | UniProt: Q9UL19 | TargetFullName: Retinoic acid receptor responder protein 3 | Organisim: human | Apparent_Kd_M: 3.263711E-12
Real
Aptamer SeqId: 10962-46 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10962-46 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.720592E-12
Real
Aptamer SeqId: 10974-20 | Target: ISK7 | UniProt: P58062
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10974-20 | Target: ISK7 | UniProt: P58062 | TargetFullName: Serine protease inhibitor Kazal-type 7 | Organisim: human | Apparent_Kd_M: 1.625032E-10
Real
Aptamer SeqId: 10975-59 | Target: MUCL1 | UniProt: Q96DR8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10975-59 | Target: MUCL1 | UniProt: Q96DR8 | TargetFullName: Mucin-like protein 1 | Organisim: human | Apparent_Kd_M: 2.372352E-10
Real
Aptamer SeqId: 10977-55 | Target: UCMA | UniProt: Q8WVF2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10977-55 | Target: UCMA | UniProt: Q8WVF2 | TargetFullName: Unique cartilage matrix-associated protein | Organisim: human | Apparent_Kd_M: 1.033724E-12
Real
Aptamer SeqId: 10978-39 | Target: SOM2 | UniProt: P01242
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10978-39 | Target: SOM2 | UniProt: P01242 | TargetFullName: Growth hormone variant | Organisim: human | Apparent_Kd_M: 8.315765E-12
Real
Aptamer SeqId: 10981-56 | Target: NRG3 | UniProt: P56975
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10981-56 | Target: NRG3 | UniProt: P56975 | TargetFullName: Pro-neuregulin-3; membrane-bound isoform | Organisim: human | Apparent_Kd_M: 1.951561E-11
Real
Aptamer SeqId: 10990-21 | Target: LRRK2 | UniProt: Q5S007
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 10990-21 | Target: LRRK2 | UniProt: Q5S007 | TargetFullName: Leucine-rich repeat serine/threonine-protein kinase 2 | Organisim: human | Apparent_Kd_M: 1.304061E-10
Real
Aptamer SeqId: 11067-13 | Target: Osteocalcin | UniProt: P02818
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11067-13 | Target: Osteocalcin | UniProt: P02818 | TargetFullName: Osteocalcin | Organisim: human | Apparent_Kd_M: 3.89E-11
Real
Aptamer SeqId: 11071-1 | Target: IL-5 | UniProt: P05113
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11071-1 | Target: IL-5 | UniProt: P05113 | TargetFullName: Interleukin-5 | Organisim: human | Apparent_Kd_M: 2.15E-10
Real
Aptamer SeqId: 11089-7 | Target: IgA | UniProt: P01876|P01877
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11089-7 | Target: IgA | UniProt: P01876|P01877 | TargetFullName: Immunoglobulin A | Organisim: human | Apparent_Kd_M: 1.85E-10
Real
Aptamer SeqId: 11094-104 | Target: LPPL | UniProt: Q05315
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11094-104 | Target: LPPL | UniProt: Q05315 | TargetFullName: Galectin-10 | Organisim: human | Apparent_Kd_M: 1.64E-10
Real
Aptamer SeqId: 11096-57 | Target: HEMK2 | UniProt: Q9Y5N5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11096-57 | Target: HEMK2 | UniProt: Q9Y5N5 | TargetFullName: HemK methyltransferase family member 2 | Organisim: human | Apparent_Kd_M: 1.97E-10
Real
Aptamer SeqId: 11098-1 | Target: PDXK | UniProt: O00764
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11098-1 | Target: PDXK | UniProt: O00764 | TargetFullName: Pyridoxal kinase | Organisim: human | Apparent_Kd_M: 3.68E-11
Real
Aptamer SeqId: 11101-18 | Target: TLR4 | UniProt: O00206
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11101-18 | Target: TLR4 | UniProt: O00206 | TargetFullName: Toll-like receptor 4 | Organisim: human | Apparent_Kd_M: 3.03E-11
Real
Aptamer SeqId: 11102-22 | Target: REG4 | UniProt: Q9BYZ8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11102-22 | Target: REG4 | UniProt: Q9BYZ8 | TargetFullName: Regenerating islet-derived protein 4 | Organisim: human | Apparent_Kd_M: 2.92E-12
Real
Aptamer SeqId: 11103-24 | Target: HSP 27 | UniProt: P04792
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11103-24 | Target: HSP 27 | UniProt: P04792 | TargetFullName: Heat shock protein beta-1 | Organisim: human | Apparent_Kd_M: 1.85E-10
Real
Aptamer SeqId: 11104-13 | Target: YKL-40 | UniProt: P36222
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11104-13 | Target: YKL-40 | UniProt: P36222 | TargetFullName: Chitinase-3-like protein 1 | Organisim: human | Apparent_Kd_M: 1.33E-12
Real
Aptamer SeqId: 11105-171 | Target: Alpha enolase | UniProt: P06733
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11105-171 | Target: Alpha enolase | UniProt: P06733 | TargetFullName: Alpha-enolase | Organisim: human | Apparent_Kd_M: 5.04E-12
Real
Aptamer SeqId: 11107-25 | Target: TEN3 | UniProt: Q9P273
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11107-25 | Target: TEN3 | UniProt: Q9P273 | TargetFullName: Teneurin-3 | Organisim: human | Apparent_Kd_M: 1.541733E-11
Real
Aptamer SeqId: 11109-56 | Target: SVEP1 | UniProt: Q4LDE5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11109-56 | Target: SVEP1 | UniProt: Q4LDE5 | TargetFullName: Sushi; von Willebrand factor type A; EGF and pentraxin domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 7.95891E-12
Real
Aptamer SeqId: 11110-4 | Target: TM119 | UniProt: Q4V9L6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11110-4 | Target: TM119 | UniProt: Q4V9L6 | TargetFullName: Transmembrane protein 119 | Organisim: human | Apparent_Kd_M: 8.430286E-12
Real
Aptamer SeqId: 11112-18 | Target: KISHA | UniProt: Q8TBQ9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11112-18 | Target: KISHA | UniProt: Q8TBQ9 | TargetFullName: Protein kish-A | Organisim: human | Apparent_Kd_M: 7.725425E-12
Real
Aptamer SeqId: 11116-16 | Target: CK087 | UniProt: Q6NUJ2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11116-16 | Target: CK087 | UniProt: Q6NUJ2 | TargetFullName: Uncharacterized protein C11orf87 | Organisim: human | Apparent_Kd_M: 1.614555E-10
Real
Aptamer SeqId: 11117-2 | Target: SPT20 | UniProt: Q8TB22
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11117-2 | Target: SPT20 | UniProt: Q8TB22 | TargetFullName: Spermatogenesis-associated protein 20 | Organisim: human | Apparent_Kd_M: 5.416315E-12
Real
Aptamer SeqId: 11118-107 | Target: RAB17 | UniProt: Q9H0T7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11118-107 | Target: RAB17 | UniProt: Q9H0T7 | TargetFullName: Ras-related protein Rab-17 | Organisim: human | Apparent_Kd_M: 2.684152E-10
Real
Aptamer SeqId: 11120-49 | Target: NAT14 | UniProt: Q8WUY8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11120-49 | Target: NAT14 | UniProt: Q8WUY8 | TargetFullName: N-acetyltransferase 14 | Organisim: human | Apparent_Kd_M: 8.399935E-12
Real
Aptamer SeqId: 11122-97 | Target: SPG21 | UniProt: Q9NZD8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11122-97 | Target: SPG21 | UniProt: Q9NZD8 | TargetFullName: Maspardin | Organisim: human | Apparent_Kd_M: 1.387156E-11
Real
Aptamer SeqId: 11126-102 | Target: TRIO | UniProt: O75962
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11126-102 | Target: TRIO | UniProt: O75962 | TargetFullName: Triple functional domain protein | Organisim: human | Apparent_Kd_M: 6.739278E-12
Real
Aptamer SeqId: 11128-29 | Target: T132C | UniProt: Q8N3T6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11128-29 | Target: T132C | UniProt: Q8N3T6 | TargetFullName: Transmembrane protein 132C | Organisim: human | Apparent_Kd_M: 3.766379E-11
Real
Aptamer SeqId: 11129-66 | Target: BMP15 | UniProt: O95972
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11129-66 | Target: BMP15 | UniProt: O95972 | TargetFullName: Bone morphogenetic protein 15 | Organisim: human | Apparent_Kd_M: 1.250595E-10
Real
Aptamer SeqId: 11130-158 | Target: CACB4 | UniProt: O00305
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11130-158 | Target: CACB4 | UniProt: O00305 | TargetFullName: Voltage-dependent L-type calcium channel subunit beta-4 | Organisim: human | Apparent_Kd_M: 3.257101E-12
Real
Aptamer SeqId: 11134-30 | Target: RF1ML | UniProt: Q9UGC7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11134-30 | Target: RF1ML | UniProt: Q9UGC7 | TargetFullName: Peptide chain release factor 1-like; mitochondrial | Organisim: human | Apparent_Kd_M: 4.411247E-11
Real
Aptamer SeqId: 11135-5 | Target: RM55 | UniProt: Q7Z7F7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11135-5 | Target: RM55 | UniProt: Q7Z7F7 | TargetFullName: 39S ribosomal protein L55; mitochondrial | Organisim: human | Apparent_Kd_M: 1.101351E-11
Real
Aptamer SeqId: 11137-43 | Target: IL3RB | UniProt: P32927
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11137-43 | Target: IL3RB | UniProt: P32927 | TargetFullName: Cytokine receptor common subunit beta | Organisim: human | Apparent_Kd_M: 3.172483E-11
Real
Aptamer SeqId: 11138-16 | Target: RUNX3 | UniProt: Q13761
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11138-16 | Target: RUNX3 | UniProt: Q13761 | TargetFullName: Runt-related transcription factor 3 | Organisim: human | Apparent_Kd_M: 1.764095E-11
Real
Aptamer SeqId: 11139-4 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11139-4 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.227058E-11
Real
Aptamer SeqId: 11140-56 | Target: CO1A1 | UniProt: P02452
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11140-56 | Target: CO1A1 | UniProt: P02452 | TargetFullName: Collagen alpha-1(I) chain | Organisim: human | Apparent_Kd_M: 7.311312E-12
Real
Aptamer SeqId: 11142-11 | Target: ANGL1 | UniProt: O95841
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11142-11 | Target: ANGL1 | UniProt: O95841 | TargetFullName: Angiopoietin-related protein 1 | Organisim: human | Apparent_Kd_M: 7.061599E-12
Real
Aptamer SeqId: 11143-32 | Target: NOE3 | UniProt: Q96PB7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11143-32 | Target: NOE3 | UniProt: Q96PB7 | TargetFullName: Noelin-3 | Organisim: human | Apparent_Kd_M: 5.431442E-11
Real
Aptamer SeqId: 11144-10 | Target: DB116 | UniProt: Q30KQ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11144-10 | Target: DB116 | UniProt: Q30KQ4 | TargetFullName: Beta-defensin 116 | Organisim: human | Apparent_Kd_M: 1.560015E-11
Real
Aptamer SeqId: 11145-72 | Target: K154L | UniProt: Q6ZVL6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11145-72 | Target: K154L | UniProt: Q6ZVL6 | TargetFullName: UPF0606 protein KIAA1549L | Organisim: human | Apparent_Kd_M: 4.963045E-12
Real
Aptamer SeqId: 11146-4 | Target: TBX22 | UniProt: Q9Y458
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11146-4 | Target: TBX22 | UniProt: Q9Y458 | TargetFullName: T-box transcription factor TBX22 | Organisim: human | Apparent_Kd_M: 1.316523E-12
Real
Aptamer SeqId: 11147-17 | Target: TRML1 | UniProt: Q86YW5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11147-17 | Target: TRML1 | UniProt: Q86YW5 | TargetFullName: Trem-like transcript 1 protein | Organisim: human | Apparent_Kd_M: 8.455481E-12
Real
Aptamer SeqId: 11149-3 | Target: TLR1 | UniProt: Q15399
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11149-3 | Target: TLR1 | UniProt: Q15399 | TargetFullName: Toll-like receptor 1 | Organisim: human | Apparent_Kd_M: 3.711778E-11
Real
Aptamer SeqId: 11152-46 | Target: kallikrein 13 | UniProt: Q9UKR3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11152-46 | Target: kallikrein 13 | UniProt: Q9UKR3 | TargetFullName: Kallikrein-13 | Organisim: human | Apparent_Kd_M: 2.586503E-12
Real
Aptamer SeqId: 11154-3 | Target: NF2L1 | UniProt: Q14494
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11154-3 | Target: NF2L1 | UniProt: Q14494 | TargetFullName: Nuclear factor erythroid 2-related factor 1 | Organisim: human | Apparent_Kd_M: 6.727296E-12
Real
Aptamer SeqId: 11155-16 | Target: CO6A5 | UniProt: A8TX70
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11155-16 | Target: CO6A5 | UniProt: A8TX70 | TargetFullName: Collagen alpha-5(VI) chain | Organisim: human | Apparent_Kd_M: 4.595556E-11
Real
Aptamer SeqId: 11157-35 | Target: HSP 70 | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11157-35 | Target: HSP 70 | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 1.152693E-11
Real
Aptamer SeqId: 11158-40 | Target: BICR1 | UniProt: Q6ZP65
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11158-40 | Target: BICR1 | UniProt: Q6ZP65 | TargetFullName: Bicaudal D-related protein 1 | Organisim: human | Apparent_Kd_M: 1.126791E-10
Real
Aptamer SeqId: 11160-56 | Target: RN122 | UniProt: Q9H9V4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11160-56 | Target: RN122 | UniProt: Q9H9V4 | TargetFullName: RING finger protein 122 | Organisim: human | Apparent_Kd_M: 1.401754E-11
Real
Aptamer SeqId: 11161-5 | Target: SPG20 | UniProt: Q8N0X7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11161-5 | Target: SPG20 | UniProt: Q8N0X7 | TargetFullName: Spartin | Organisim: human | Apparent_Kd_M: 6.513137E-12
Real
Aptamer SeqId: 11162-37 | Target: EQTN | UniProt: Q9NQ60
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11162-37 | Target: EQTN | UniProt: Q9NQ60 | TargetFullName: Equatorin | Organisim: human | Apparent_Kd_M: 2.792528E-10
Real
Aptamer SeqId: 11163-7 | Target: F162B | UniProt: Q5T6X4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11163-7 | Target: F162B | UniProt: Q5T6X4 | TargetFullName: Protein FAM162B | Organisim: human | Apparent_Kd_M: 5.380156E-11
Real
Aptamer SeqId: 11164-7 | Target: TEN2 | UniProt: Q9NT68
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11164-7 | Target: TEN2 | UniProt: Q9NT68 | TargetFullName: Teneurin-2 | Organisim: human | Apparent_Kd_M: 1.665816E-11
Real
Aptamer SeqId: 11167-6 | Target: MTMR1 | UniProt: Q13613
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11167-6 | Target: MTMR1 | UniProt: Q13613 | TargetFullName: Myotubularin-related protein 1 | Organisim: human | Apparent_Kd_M: 6.963717E-12
Real
Aptamer SeqId: 11168-3 | Target: MEG10 | UniProt: Q96KG7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11168-3 | Target: MEG10 | UniProt: Q96KG7 | TargetFullName: Multiple epidermal growth factor-like domains protein 10 | Organisim: human | Apparent_Kd_M: 1.173269E-11
Real
Aptamer SeqId: 11171-25 | Target: filamin A | UniProt: P21333
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11171-25 | Target: filamin A | UniProt: P21333 | TargetFullName: Filamin-A | Organisim: human | Apparent_Kd_M: 2.089282E-12
Real
Aptamer SeqId: 11173-29 | Target: MILR1 | UniProt: Q7Z6M3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11173-29 | Target: MILR1 | UniProt: Q7Z6M3 | TargetFullName: Allergin-1 | Organisim: human | Apparent_Kd_M: 1.649194E-11
Real
Aptamer SeqId: 11174-8 | Target: THS7A | UniProt: Q9UPZ6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11174-8 | Target: THS7A | UniProt: Q9UPZ6 | TargetFullName: Thrombospondin type-1 domain-containing protein 7A | Organisim: human | Apparent_Kd_M: 1.532943E-11
Real
Aptamer SeqId: 11175-45 | Target: PCAT2 | UniProt: Q7L5N7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11175-45 | Target: PCAT2 | UniProt: Q7L5N7 | TargetFullName: Lysophosphatidylcholine acyltransferase 2 | Organisim: human | Apparent_Kd_M: 1.237341E-10
Real
Aptamer SeqId: 11177-16 | Target: K2C5 | UniProt: P13647
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11177-16 | Target: K2C5 | UniProt: P13647 | TargetFullName: Keratin; type II cytoskeletal 5 | Organisim: human | Apparent_Kd_M: 4.45E-12
Real
Aptamer SeqId: 11178-21 | Target: SVEP1 | UniProt: Q4LDE5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11178-21 | Target: SVEP1 | UniProt: Q4LDE5 | TargetFullName: Sushi; von Willebrand factor type A; EGF and pentraxin domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 1.748007E-11
Real
Aptamer SeqId: 11179-7 | Target: TSSK1 | UniProt: Q9BXA7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11179-7 | Target: TSSK1 | UniProt: Q9BXA7 | TargetFullName: Testis-specific serine/threonine-protein kinase 1 | Organisim: human | Apparent_Kd_M: 6.274946E-11
Real
Aptamer SeqId: 11180-17 | Target: SMRC1 | UniProt: Q92922
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11180-17 | Target: SMRC1 | UniProt: Q92922 | TargetFullName: SWI/SNF complex subunit SMARCC1 | Organisim: human | Apparent_Kd_M: 1.992654E-11
Real
Aptamer SeqId: 11185-145 | Target: GCH1 | UniProt: P30793
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11185-145 | Target: GCH1 | UniProt: P30793 | TargetFullName: GTP cyclohydrolase 1 | Organisim: human | Apparent_Kd_M: 1.104633E-11
Real
Aptamer SeqId: 11186-12 | Target: TMM52 | UniProt: Q8NDY8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11186-12 | Target: TMM52 | UniProt: Q8NDY8 | TargetFullName: Transmembrane protein 52 | Organisim: human | Apparent_Kd_M: 8.893346E-11
Real
Aptamer SeqId: 11187-11 | Target: CL12A | UniProt: Q5QGZ9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11187-11 | Target: CL12A | UniProt: Q5QGZ9 | TargetFullName: C-type lectin domain family 12 member A | Organisim: human | Apparent_Kd_M: 2.253832E-12
Real
Aptamer SeqId: 11190-129 | Target: YMEL1 | UniProt: Q96TA2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11190-129 | Target: YMEL1 | UniProt: Q96TA2 | TargetFullName: ATP-dependent zinc metalloprotease YME1L1 | Organisim: human | Apparent_Kd_M: 7.291078E-11
Real
Aptamer SeqId: 11192-168 | Target: TINAL | UniProt: Q9GZM7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11192-168 | Target: TINAL | UniProt: Q9GZM7 | TargetFullName: Tubulointerstitial nephritis antigen-like | Organisim: human | Apparent_Kd_M: 7.359185E-13
Real
Aptamer SeqId: 11193-27 | Target: HNF1A | UniProt: P20823
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11193-27 | Target: HNF1A | UniProt: P20823 | TargetFullName: Hepatocyte nuclear factor 1-alpha | Organisim: human | Apparent_Kd_M: 2.274209E-12
Real
Aptamer SeqId: 11194-6 | Target: SIT1 | UniProt: Q9Y3P8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11194-6 | Target: SIT1 | UniProt: Q9Y3P8 | TargetFullName: Signaling threshold-regulating transmembrane adapter 1 | Organisim: human | Apparent_Kd_M: 4.017099E-11
Real
Aptamer SeqId: 11196-31 | Target: Collagen alpha-3(VI) | UniProt: P12111
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11196-31 | Target: Collagen alpha-3(VI) | UniProt: P12111 | TargetFullName: Collagen alpha-3(VI) chain | Organisim: human | Apparent_Kd_M: 2.681462E-11
Real
Aptamer SeqId: 11198-37 | Target: CR3L1 | UniProt: Q96BA8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11198-37 | Target: CR3L1 | UniProt: Q96BA8 | TargetFullName: Cyclic AMP-responsive element-binding protein 3-like protein 1 | Organisim: human | Apparent_Kd_M: 4.267596E-11
Real
Aptamer SeqId: 11201-19 | Target: TRUA | UniProt: Q9Y606
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11201-19 | Target: TRUA | UniProt: Q9Y606 | TargetFullName: tRNA pseudouridine synthase A; mitochondrial | Organisim: human | Apparent_Kd_M: 1.636963E-11
Real
Aptamer SeqId: 11202-70 | Target: TBX5 | UniProt: Q99593
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11202-70 | Target: TBX5 | UniProt: Q99593 | TargetFullName: T-box transcription factor TBX5 | Organisim: human | Apparent_Kd_M: 5.466399E-12
Real
Aptamer SeqId: 11204-80 | Target: CXAR | UniProt: P78310
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11204-80 | Target: CXAR | UniProt: P78310 | TargetFullName: Coxsackievirus and adenovirus receptor | Organisim: human | Apparent_Kd_M: 6.542611E-11
Real
Aptamer SeqId: 11205-10 | Target: Integrin beta-7 | UniProt: P26010
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11205-10 | Target: Integrin beta-7 | UniProt: P26010 | TargetFullName: Integrin beta-7 | Organisim: human | Apparent_Kd_M: 9.254597E-12
Real
Aptamer SeqId: 11207-3 | Target: Macrophage scavenger receptor
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11207-3 | Target: Macrophage scavenger receptor | UniProt: P21757 | TargetFullName: Macrophage scavenger receptor types I and II | Organisim: human | Apparent_Kd_M: 1.502653E-11
Real
Aptamer SeqId: 11208-15 | Target: NAGPA | UniProt: Q9UK23
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11208-15 | Target: NAGPA | UniProt: Q9UK23 | TargetFullName: N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase | Organisim: human | Apparent_Kd_M: 1.629906E-11
Real
Aptamer SeqId: 11211-7 | Target: TBCE | UniProt: Q15813
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11211-7 | Target: TBCE | UniProt: Q15813 | TargetFullName: Tubulin-specific chaperone E | Organisim: human | Apparent_Kd_M: 3.524042E-12
Real
Aptamer SeqId: 11212-7 | Target: TXND5 | UniProt: Q8NBS9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11212-7 | Target: TXND5 | UniProt: Q8NBS9 | TargetFullName: Thioredoxin domain-containing protein 5 | Organisim: human | Apparent_Kd_M: 1.948882E-12
Real
Aptamer SeqId: 11214-40 | Target: DNJB9 | UniProt: Q9UBS3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11214-40 | Target: DNJB9 | UniProt: Q9UBS3 | TargetFullName: DnaJ homolog subfamily B member 9 | Organisim: human | Apparent_Kd_M: 7.616224E-12
Real
Aptamer SeqId: 11215-6 | Target: CAD15 | UniProt: P55291
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11215-6 | Target: CAD15 | UniProt: P55291 | TargetFullName: Cadherin-15 | Organisim: human | Apparent_Kd_M: 1.69365E-11
Real
Aptamer SeqId: 11217-16 | Target: CTBP1 | UniProt: Q13363
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11217-16 | Target: CTBP1 | UniProt: Q13363 | TargetFullName: C-terminal-binding protein 1 | Organisim: human | Apparent_Kd_M: 2.84218E-10
Real
Aptamer SeqId: 11218-84 | Target: TPMT | UniProt: P51580
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11218-84 | Target: TPMT | UniProt: P51580 | TargetFullName: Thiopurine S-methyltransferase | Organisim: human | Apparent_Kd_M: 9.119764E-12
Real
Aptamer SeqId: 11219-95 | Target: FGFP3 | UniProt: Q8TAT2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11219-95 | Target: FGFP3 | UniProt: Q8TAT2 | TargetFullName: Fibroblast growth factor-binding protein 3 | Organisim: human | Apparent_Kd_M: 1.314533E-10
Real
Aptamer SeqId: 11220-53 | Target: CJ105 | UniProt: Q8TEF2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11220-53 | Target: CJ105 | UniProt: Q8TEF2 | TargetFullName: Uncharacterized protein C10orf105 | Organisim: human | Apparent_Kd_M: 2.377041E-10
Real
Aptamer SeqId: 11222-62 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11222-62 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.163176E-10
Real
Aptamer SeqId: 11223-1 | Target: TM154 | UniProt: Q6P9G4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11223-1 | Target: TM154 | UniProt: Q6P9G4 | TargetFullName: Transmembrane protein 154 | Organisim: human | Apparent_Kd_M: 4.605634E-12
Real
Aptamer SeqId: 11226-16 | Target: UBE3A | UniProt: Q05086
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11226-16 | Target: UBE3A | UniProt: Q05086 | TargetFullName: Ubiquitin-protein ligase E3A | Organisim: human | Apparent_Kd_M: 4.130147E-12
Real
Aptamer SeqId: 11227-31 | Target: TBL2 | UniProt: Q9Y4P3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11227-31 | Target: TBL2 | UniProt: Q9Y4P3 | TargetFullName: Transducin beta-like protein 2 | Organisim: human | Apparent_Kd_M: 5.562146E-11
Real
Aptamer SeqId: 11228-37 | Target: RIC3 | UniProt: Q7Z5B4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11228-37 | Target: RIC3 | UniProt: Q7Z5B4 | TargetFullName: Protein RIC-3 | Organisim: human | Apparent_Kd_M: 3.240254E-10
Real
Aptamer SeqId: 11229-16 | Target: ERN1 | UniProt: O75460
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11229-16 | Target: ERN1 | UniProt: O75460 | TargetFullName: Serine/threonine-protein kinase/endoribonuclease IRE1 | Organisim: human | Apparent_Kd_M: 2.714274E-11
Real
Aptamer SeqId: 11230-12 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11230-12 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 5.176771E-12
Real
Aptamer SeqId: 11231-12 | Target: ADXL | UniProt: Q6P4F2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11231-12 | Target: ADXL | UniProt: Q6P4F2 | TargetFullName: Adrenodoxin-like protein; mitochondrial | Organisim: human | Apparent_Kd_M: 3.427036E-11
Real
Aptamer SeqId: 11237-49 | Target: PCOC1 | UniProt: Q15113
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11237-49 | Target: PCOC1 | UniProt: Q15113 | TargetFullName: Procollagen C-endopeptidase enhancer 1 | Organisim: human | Apparent_Kd_M: 3.632229E-12
Real
Aptamer SeqId: 11239-49 | Target: TMPS6 | UniProt: Q8IU80
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11239-49 | Target: TMPS6 | UniProt: Q8IU80 | TargetFullName: Transmembrane protease serine 6 | Organisim: human | Apparent_Kd_M: 1.746197E-10
Real
Aptamer SeqId: 11241-8 | Target: ARLY | UniProt: P04424
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11241-8 | Target: ARLY | UniProt: P04424 | TargetFullName: Argininosuccinate lyase | Organisim: human | Apparent_Kd_M: 1.200677E-11
Real
Aptamer SeqId: 11242-33 | Target: TGM1 | UniProt: P22735
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11242-33 | Target: TGM1 | UniProt: P22735 | TargetFullName: Protein-glutamine gamma-glutamyltransferase K | Organisim: human | Apparent_Kd_M: 1.352349E-10
Real
Aptamer SeqId: 11243-90 | Target: GPR110 | UniProt: Q5T601
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11243-90 | Target: GPR110 | UniProt: Q5T601 | TargetFullName: Adhesion G-protein coupled receptor F1 | Organisim: human | Apparent_Kd_M: 4.533773E-11
Real
Aptamer SeqId: 11247-20 | Target: NAGS | UniProt: Q8N159
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11247-20 | Target: NAGS | UniProt: Q8N159 | TargetFullName: N-acetylglutamate synthase; mitochondrial | Organisim: human | Apparent_Kd_M: 3.978105E-12
Real
Aptamer SeqId: 11248-43 | Target: HEM4 | UniProt: P10746
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11248-43 | Target: HEM4 | UniProt: P10746 | TargetFullName: Uroporphyrinogen-III synthase | Organisim: human | Apparent_Kd_M: 3.881034E-12
Real
Aptamer SeqId: 11252-30 | Target: LRCH4 | UniProt: O75427
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11252-30 | Target: LRCH4 | UniProt: O75427 | TargetFullName: Leucine-rich repeat and calponin homology domain-containing protein 4 | Organisim: human | Apparent_Kd_M: 1.060243E-11
Real
Aptamer SeqId: 11254-13 | Target: PPN | UniProt: O95428
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11254-13 | Target: PPN | UniProt: O95428 | TargetFullName: Papilin | Organisim: human | Apparent_Kd_M: 4.304814E-11
Real
Aptamer SeqId: 11257-1 | Target: DHPR | UniProt: P09417
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11257-1 | Target: DHPR | UniProt: P09417 | TargetFullName: Dihydropteridine reductase | Organisim: human | Apparent_Kd_M: 1.951395E-12
Real
Aptamer SeqId: 11258-41 | Target: MAdCAM-1 | UniProt: Q13477
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11258-41 | Target: MAdCAM-1 | UniProt: Q13477 | TargetFullName: Mucosal addressin cell adhesion molecule 1 | Organisim: human | Apparent_Kd_M: 1.358852E-10
Real
Aptamer SeqId: 11260-47 | Target: SPA4L | UniProt: Q8TC36
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11260-47 | Target: SPA4L | UniProt: Q8TC36 | TargetFullName: SUN domain-containing protein 5 | Organisim: human | Apparent_Kd_M: 1.084406E-10
Real
Aptamer SeqId: 11262-39 | Target: TRABD | UniProt: Q9H4I3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11262-39 | Target: TRABD | UniProt: Q9H4I3 | TargetFullName: TraB domain-containing protein | Organisim: human | Apparent_Kd_M: 1.168341E-10
Real
Aptamer SeqId: 11263-57 | Target: CASQ1 | UniProt: P31415
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11263-57 | Target: CASQ1 | UniProt: P31415 | TargetFullName: Calsequestrin-1 | Organisim: human | Apparent_Kd_M: 4.338953E-10
Real
Aptamer SeqId: 11264-33 | Target: XDH | UniProt: P47989
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11264-33 | Target: XDH | UniProt: P47989 | TargetFullName: Xanthine dehydrogenase/oxidase | Organisim: human | Apparent_Kd_M: 1.003404E-11
Real
Aptamer SeqId: 11265-8 | Target: Retinal dehydrogenase 1 | UniProt: P00352
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11265-8 | Target: Retinal dehydrogenase 1 | UniProt: P00352 | TargetFullName: Retinal dehydrogenase 1 | Organisim: human | Apparent_Kd_M: 2.371671E-11
Real
Aptamer SeqId: 11266-8 | Target: SELPL | UniProt: Q14242
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11266-8 | Target: SELPL | UniProt: Q14242 | TargetFullName: P-selectin glycoprotein ligand 1 | Organisim: human | Apparent_Kd_M: 4.61E-11
Real
Aptamer SeqId: 11270-17 | Target: CHC10 | UniProt: Q8WYQ3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11270-17 | Target: CHC10 | UniProt: Q8WYQ3 | TargetFullName: Coiled-coil-helix-coiled-coil-helix domain-containing protein 10; mitochondrial | Organisim: human | Apparent_Kd_M: 4.425639E-12
Real
Aptamer SeqId: 11273-176 | Target: GSTT2 | UniProt: P0CG30
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11273-176 | Target: GSTT2 | UniProt: P0CG30 | TargetFullName: Glutathione S-transferase theta-2B | Organisim: human | Apparent_Kd_M: 3.218031E-10
Real
Aptamer SeqId: 11275-94 | Target: LRP1B | UniProt: Q9NZR2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11275-94 | Target: LRP1B | UniProt: Q9NZR2 | TargetFullName: Low-density lipoprotein receptor-related protein 1B | Organisim: human | Apparent_Kd_M: 2.069559E-11
Real
Aptamer SeqId: 11277-23 | Target: ATF6A | UniProt: P18850
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11277-23 | Target: ATF6A | UniProt: P18850 | TargetFullName: Cyclic AMP-dependent transcription factor ATF-6 alpha | Organisim: human | Apparent_Kd_M: 1.463131E-12
Real
Aptamer SeqId: 11278-4 | Target: COL11A2 | UniProt: P13942
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11278-4 | Target: COL11A2 | UniProt: P13942 | TargetFullName: Collagen alpha-2(XI) chain | Organisim: human | Apparent_Kd_M: 7.40327E-12
Real
Aptamer SeqId: 11279-42 | Target: GABR1 | UniProt: Q9UBS5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11279-42 | Target: GABR1 | UniProt: Q9UBS5 | TargetFullName: Gamma-aminobutyric acid type B receptor subunit 1 | Organisim: human | Apparent_Kd_M: 8.626112E-12
Real
Aptamer SeqId: 11280-6 | Target: DCE1 | UniProt: Q99259
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11280-6 | Target: DCE1 | UniProt: Q99259 | TargetFullName: Glutamate decarboxylase 1 | Organisim: human | Apparent_Kd_M: 9.593671E-11
Real
Aptamer SeqId: 11281-6 | Target: GRB7 | UniProt: Q14451
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11281-6 | Target: GRB7 | UniProt: Q14451 | TargetFullName: Growth factor receptor-bound protein 7 | Organisim: human | Apparent_Kd_M: 7.343696E-12
Real
Aptamer SeqId: 11283-13 | Target: DCAF5 | UniProt: Q96JK2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11283-13 | Target: DCAF5 | UniProt: Q96JK2 | TargetFullName: DDB1- and CUL4-associated factor 5 | Organisim: human | Apparent_Kd_M: 1.144763E-12
Real
Aptamer SeqId: 11284-24 | Target: LAIR1 | UniProt: Q6GTX8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11284-24 | Target: LAIR1 | UniProt: Q6GTX8 | TargetFullName: Leukocyte-associated immunoglobulin-like receptor 1 | Organisim: human | Apparent_Kd_M: 1.555293E-12
Real
Aptamer SeqId: 11286-78 | Target: SELS | UniProt: Q9BQE4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11286-78 | Target: SELS | UniProt: Q9BQE4 | TargetFullName: Selenoprotein S | Organisim: human | Apparent_Kd_M: 6.059991E-12
Real
Aptamer SeqId: 11287-14 | Target: Cytochrome b5 | UniProt: P00167
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11287-14 | Target: Cytochrome b5 | UniProt: P00167 | TargetFullName: Cytochrome b5 | Organisim: human | Apparent_Kd_M: 2.333026E-11
Real
Aptamer SeqId: 11288-26 | Target: 5NTC | UniProt: P49902
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11288-26 | Target: 5NTC | UniProt: P49902 | TargetFullName: Cytosolic purine 5'-nucleotidase | Organisim: human | Apparent_Kd_M: 9.045895E-11
Real
Aptamer SeqId: 11289-31 | Target: KC1D | UniProt: P48730
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11289-31 | Target: KC1D | UniProt: P48730 | TargetFullName: Casein kinase I isoform delta | Organisim: human | Apparent_Kd_M: 2.26584E-11
Real
Aptamer SeqId: 11291-73 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11291-73 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.066854E-11
Real
Aptamer SeqId: 11292-13 | Target: SCAR3 | UniProt: Q6AZY7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11292-13 | Target: SCAR3 | UniProt: Q6AZY7 | TargetFullName: Scavenger receptor class A member 3 | Organisim: human | Apparent_Kd_M: 4.570475E-11
Real
Aptamer SeqId: 11293-14 | Target: LRRN1 | UniProt: Q6UXK5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11293-14 | Target: LRRN1 | UniProt: Q6UXK5 | TargetFullName: Leucine-rich repeat neuronal protein 1 | Organisim: human | Apparent_Kd_M: 1.24384E-11
Real
Aptamer SeqId: 11297-54 | Target: NOTC2 | UniProt: Q04721
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11297-54 | Target: NOTC2 | UniProt: Q04721 | TargetFullName: Neurogenic locus notch homolog protein 2 | Organisim: human | Apparent_Kd_M: 1.738868E-11
Real
Aptamer SeqId: 11300-32 | Target: SORT | UniProt: Q99523
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11300-32 | Target: SORT | UniProt: Q99523 | TargetFullName: Sortilin | Organisim: human | Apparent_Kd_M: 3.848463E-11
Real
Aptamer SeqId: 11302-237 | Target: TENR | UniProt: Q92752
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11302-237 | Target: TENR | UniProt: Q92752 | TargetFullName: Tenascin-R | Organisim: human | Apparent_Kd_M: 8.088612E-11
Real
Aptamer SeqId: 11303-7 | Target: SAMH1 | UniProt: Q9Y3Z3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11303-7 | Target: SAMH1 | UniProt: Q9Y3Z3 | TargetFullName: Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 | Organisim: human | Apparent_Kd_M: 9.93323E-12
Real
Aptamer SeqId: 11307-33 | Target: WWP1 | UniProt: Q9H0M0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11307-33 | Target: WWP1 | UniProt: Q9H0M0 | TargetFullName: NEDD4-like E3 ubiquitin-protein ligase WWP1 | Organisim: human | Apparent_Kd_M: 5.145084E-12
Real
Aptamer SeqId: 11308-8 | Target: CR3L4 | UniProt: Q8TEY5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11308-8 | Target: CR3L4 | UniProt: Q8TEY5 | TargetFullName: Cyclic AMP-responsive element-binding protein 3-like protein 4 | Organisim: human | Apparent_Kd_M: 2.659548E-11
Real
Aptamer SeqId: 11311-79 | Target: RAG-1 | UniProt: P15918
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11311-79 | Target: RAG-1 | UniProt: P15918 | TargetFullName: V(D)J recombination-activating protein 1 | Organisim: human | Apparent_Kd_M: 8.855031E-10
Real
Aptamer SeqId: 11312-40 | Target: PMS2 | UniProt: P54278
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11312-40 | Target: PMS2 | UniProt: P54278 | TargetFullName: Mismatch repair endonuclease PMS2 | Organisim: human | Apparent_Kd_M: 1.498974E-11
Real
Aptamer SeqId: 11313-100 | Target: PHS | UniProt: P61457
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11313-100 | Target: PHS | UniProt: P61457 | TargetFullName: Pterin-4-alpha-carbinolamine dehydratase | Organisim: human | Apparent_Kd_M: 3.721893E-11
Real
Aptamer SeqId: 11315-148 | Target: PPM1D | UniProt: O15297
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11315-148 | Target: PPM1D | UniProt: O15297 | TargetFullName: Protein phosphatase 1D | Organisim: human | Apparent_Kd_M: 4.301776E-12
Real
Aptamer SeqId: 11319-106 | Target: MRE11 | UniProt: P49959
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11319-106 | Target: MRE11 | UniProt: P49959 | TargetFullName: Double-strand break repair protein MRE11 | Organisim: human | Apparent_Kd_M: 1.072669E-11
Real
Aptamer SeqId: 11320-29 | Target: CHFR | UniProt: Q96EP1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11320-29 | Target: CHFR | UniProt: Q96EP1 | TargetFullName: E3 ubiquitin-protein ligase CHFR | Organisim: human | Apparent_Kd_M: 3.831788E-11
Real
Aptamer SeqId: 11324-3 | Target: PXDNL | UniProt: A1KZ92
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11324-3 | Target: PXDNL | UniProt: A1KZ92 | TargetFullName: Peroxidasin-like protein | Organisim: human | Apparent_Kd_M: 1.021713E-11
Real
Aptamer SeqId: 11325-8 | Target: BTG2 | UniProt: P78543
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11325-8 | Target: BTG2 | UniProt: P78543 | TargetFullName: Protein BTG2 | Organisim: human | Apparent_Kd_M: 1.006572E-10
Real
Aptamer SeqId: 11327-56 | Target: CLK2 | UniProt: P49760
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11327-56 | Target: CLK2 | UniProt: P49760 | TargetFullName: Dual specificity protein kinase CLK2 | Organisim: human | Apparent_Kd_M: 3.87731E-11
Real
Aptamer SeqId: 11328-9 | Target: USB1 | UniProt: Q9BQ65
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11328-9 | Target: USB1 | UniProt: Q9BQ65 | TargetFullName: U6 snRNA phosphodiesterase | Organisim: human | Apparent_Kd_M: 2.370659E-11
Real
Aptamer SeqId: 11330-15 | Target: CSK2B | UniProt: P67870
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11330-15 | Target: CSK2B | UniProt: P67870 | TargetFullName: Casein kinase II subunit beta | Organisim: human | Apparent_Kd_M: 1.199878E-10
Real
Aptamer SeqId: 11333-82 | Target: RHG25 | UniProt: P42331
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11333-82 | Target: RHG25 | UniProt: P42331 | TargetFullName: Rho GTPase-activating protein 25 | Organisim: human | Apparent_Kd_M: 1.493645E-12
Real
Aptamer SeqId: 11334-7 | Target: LIRB3 | UniProt: O75022
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11334-7 | Target: LIRB3 | UniProt: O75022 | TargetFullName: Leukocyte immunoglobulin-like receptor subfamily B member 3 | Organisim: human | Apparent_Kd_M: 6.260214E-12
Real
Aptamer SeqId: 11336-9 | Target: FANCF | UniProt: Q9NPI8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11336-9 | Target: FANCF | UniProt: Q9NPI8 | TargetFullName: Fanconi anemia group F protein | Organisim: human | Apparent_Kd_M: 8.479839E-13
Real
Aptamer SeqId: 11338-49 | Target: BLK | UniProt: P51451
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11338-49 | Target: BLK | UniProt: P51451 | TargetFullName: Tyrosine-protein kinase BLK | Organisim: human | Apparent_Kd_M: 7.463648E-12
Real
Aptamer SeqId: 11342-59 | Target: PXDC2 | UniProt: Q6UX71
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11342-59 | Target: PXDC2 | UniProt: Q6UX71 | TargetFullName: Plexin domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 4.491959E-12
Real
Aptamer SeqId: 11347-9 | Target: Transaldolase | UniProt: P37837
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11347-9 | Target: Transaldolase | UniProt: P37837 | TargetFullName: Transaldolase | Organisim: human | Apparent_Kd_M: 3.35318E-12
Real
Aptamer SeqId: 11348-132 | Target: P4HA2 | UniProt: O15460
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11348-132 | Target: P4HA2 | UniProt: O15460 | TargetFullName: Prolyl 4-hydroxylase subunit alpha-2 | Organisim: human | Apparent_Kd_M: 3.9946E-11
Real
Aptamer SeqId: 11350-30 | Target: CHIP | UniProt: Q9UNE7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11350-30 | Target: CHIP | UniProt: Q9UNE7 | TargetFullName: E3 ubiquitin-protein ligase CHIP | Organisim: human | Apparent_Kd_M: 6.541949E-12
Real
Aptamer SeqId: 11351-233 | Target: NHEJ1 | UniProt: Q9H9Q4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11351-233 | Target: NHEJ1 | UniProt: Q9H9Q4 | TargetFullName: Non-homologous end-joining factor 1 | Organisim: human | Apparent_Kd_M: 1.50951E-10
Real
Aptamer SeqId: 11352-42 | Target: TITIN | UniProt: Q8WZ42
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11352-42 | Target: TITIN | UniProt: Q8WZ42 | TargetFullName: Titin | Organisim: human | Apparent_Kd_M: 2.45321E-11
Real
Aptamer SeqId: 11354-21 | Target: Phospholipase C-beta-1 | UniProt: Q9NQ66
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11354-21 | Target: Phospholipase C-beta-1 | UniProt: Q9NQ66 | TargetFullName: 1-phosphatidylinositol 4;5-bisphosphate phosphodiesterase beta-1 | Organisim: human | Apparent_Kd_M: 1.985473E-11
Real
Aptamer SeqId: 11355-10 | Target: IF5A2 | UniProt: Q9GZV4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11355-10 | Target: IF5A2 | UniProt: Q9GZV4 | TargetFullName: Eukaryotic translation initiation factor 5A-2 | Organisim: human | Apparent_Kd_M: 4.034939E-11
Real
Aptamer SeqId: 11356-19 | Target: DGC14 | UniProt: Q96DF8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11356-19 | Target: DGC14 | UniProt: Q96DF8 | TargetFullName: Protein DGCR14 | Organisim: human | Apparent_Kd_M: 3.232215E-12
Real
Aptamer SeqId: 11358-15 | Target: GRB10 | UniProt: Q13322
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11358-15 | Target: GRB10 | UniProt: Q13322 | TargetFullName: Growth factor receptor-bound protein 10 | Organisim: human | Apparent_Kd_M: 2.51165E-12
Real
Aptamer SeqId: 11360-39 | Target: RRM1 | UniProt: P23921
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11360-39 | Target: RRM1 | UniProt: P23921 | TargetFullName: Ribonucleoside-diphosphate reductase large subunit | Organisim: human | Apparent_Kd_M: 4.871925E-12
Real
Aptamer SeqId: 11361-73 | Target: TP | UniProt: P19971
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11361-73 | Target: TP | UniProt: P19971 | TargetFullName: Thymidine phosphorylase | Organisim: human | Apparent_Kd_M: 1.545557E-11
Real
Aptamer SeqId: 11363-58 | Target: AQP4 | UniProt: P55087
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11363-58 | Target: AQP4 | UniProt: P55087 | TargetFullName: Aquaporin-4 | Organisim: human | Apparent_Kd_M: 1.468242E-10
Real
Aptamer SeqId: 11364-18 | Target: MFN1 | UniProt: Q8IWA4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11364-18 | Target: MFN1 | UniProt: Q8IWA4 | TargetFullName: Mitofusin-1 | Organisim: human | Apparent_Kd_M: 2.140551E-11
Real
Aptamer SeqId: 11365-17 | Target: TEN4 | UniProt: Q6N022
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11365-17 | Target: TEN4 | UniProt: Q6N022 | TargetFullName: Teneurin-4 | Organisim: human | Apparent_Kd_M: 1.354983E-11
Real
Aptamer SeqId: 11368-32 | Target: KAD2 | UniProt: P54819
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11368-32 | Target: KAD2 | UniProt: P54819 | TargetFullName: Adenylate kinase 2; mitochondrial | Organisim: human | Apparent_Kd_M: 7.465696E-12
Real
Aptamer SeqId: 11369-23 | Target: ADHX | UniProt: P11766
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11369-23 | Target: ADHX | UniProt: P11766 | TargetFullName: Alcohol dehydrogenase class-3 | Organisim: human | Apparent_Kd_M: 6.484281E-12
Real
Aptamer SeqId: 11370-20 | Target: INP5E | UniProt: Q9NRR6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11370-20 | Target: INP5E | UniProt: Q9NRR6 | TargetFullName: 72 kDa inositol polyphosphate 5-phosphatase | Organisim: human | Apparent_Kd_M: 3.346285E-11
Real
Aptamer SeqId: 11371-1 | Target: GP101 | UniProt: Q96P66
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11371-1 | Target: GP101 | UniProt: Q96P66 | TargetFullName: Probable G-protein coupled receptor 101 | Organisim: human | Apparent_Kd_M: 8.325254E-12
Real
Aptamer SeqId: 11372-2 | Target: ZNF18 | UniProt: P17022
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11372-2 | Target: ZNF18 | UniProt: P17022 | TargetFullName: Zinc finger protein 18 | Organisim: human | Apparent_Kd_M: 1.006891E-11
Real
Aptamer SeqId: 11375-49 | Target: FOXL2 | UniProt: P58012
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11375-49 | Target: FOXL2 | UniProt: P58012 | TargetFullName: Forkhead box protein L2 | Organisim: human | Apparent_Kd_M: 3.69467E-12
Real
Aptamer SeqId: 11377-19 | Target: ADH7 | UniProt: P40394
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11377-19 | Target: ADH7 | UniProt: P40394 | TargetFullName: Alcohol dehydrogenase class 4 mu/sigma chain | Organisim: human | Apparent_Kd_M: 8.262866E-12
Real
Aptamer SeqId: 11378-37 | Target: KSYK | UniProt: P43405
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11378-37 | Target: KSYK | UniProt: P43405 | TargetFullName: Tyrosine-protein kinase SYK | Organisim: human | Apparent_Kd_M: 2.606212E-11
Real
Aptamer SeqId: 11380-84 | Target: RBM24 | UniProt: Q9BX46
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11380-84 | Target: RBM24 | UniProt: Q9BX46 | TargetFullName: RNA-binding protein 24 | Organisim: human | Apparent_Kd_M: 3.916686E-12
Real
Aptamer SeqId: 11381-56 | Target: PRPS1 | UniProt: P60891
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11381-56 | Target: PRPS1 | UniProt: P60891 | TargetFullName: Ribose-phosphate pyrophosphokinase 1 | Organisim: human | Apparent_Kd_M: 1.637295E-10
Real
Aptamer SeqId: 11382-5 | Target: BIEA | UniProt: P53004
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11382-5 | Target: BIEA | UniProt: P53004 | TargetFullName: Biliverdin reductase A | Organisim: human | Apparent_Kd_M: 4.655074E-12
Real
Aptamer SeqId: 11383-41 | Target: Keratin 7 | UniProt: P08729
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11383-41 | Target: Keratin 7 | UniProt: P08729 | TargetFullName: Keratin; type II cytoskeletal 7 | Organisim: human | Apparent_Kd_M: 3.774261E-11
Real
Aptamer SeqId: 11387-3 | Target: ATF6B | UniProt: Q99941
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11387-3 | Target: ATF6B | UniProt: Q99941 | TargetFullName: Cyclic AMP-dependent transcription factor ATF-6 beta | Organisim: human | Apparent_Kd_M: 5.340755E-11
Real
Aptamer SeqId: 11388-75 | Target: HE4 | UniProt: Q14508
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11388-75 | Target: HE4 | UniProt: Q14508 | TargetFullName: WAP four-disulfide core domain protein 2 | Organisim: human | Apparent_Kd_M: 4.231434E-11
Real
Aptamer SeqId: 11390-24 | Target: Carbonic Anhydrase VIII | UniProt: P35219
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11390-24 | Target: Carbonic Anhydrase VIII | UniProt: P35219 | TargetFullName: Carbonic anhydrase-related protein | Organisim: human | Apparent_Kd_M: 1.519319E-10
Real
Aptamer SeqId: 11391-69 | Target: MVK | UniProt: Q03426
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11391-69 | Target: MVK | UniProt: Q03426 | TargetFullName: Mevalonate kinase | Organisim: human | Apparent_Kd_M: 1.006672E-10
Real
Aptamer SeqId: 11395-5 | Target: FAK2 | UniProt: Q14289
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11395-5 | Target: FAK2 | UniProt: Q14289 | TargetFullName: Protein-tyrosine kinase 2-beta | Organisim: human | Apparent_Kd_M: 2.221677E-11
Real
Aptamer SeqId: 11396-39 | Target: DNAI1 | UniProt: Q9UI46
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11396-39 | Target: DNAI1 | UniProt: Q9UI46 | TargetFullName: Dynein intermediate chain 1; axonemal | Organisim: human | Apparent_Kd_M: 1.213198E-10
Real
Aptamer SeqId: 11401-181 | Target: RN146 | UniProt: Q9NTX7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11401-181 | Target: RN146 | UniProt: Q9NTX7 | TargetFullName: E3 ubiquitin-protein ligase RNF146 | Organisim: human | Apparent_Kd_M: 1.34719E-11
Real
Aptamer SeqId: 11402-17 | Target: KMT2C | UniProt: Q8NEZ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11402-17 | Target: KMT2C | UniProt: Q8NEZ4 | TargetFullName: Histone-lysine N-methyltransferase 2C | Organisim: human | Apparent_Kd_M: 7.477804E-13
Real
Aptamer SeqId: 11405-150 | Target: CARD9 | UniProt: Q9H257
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11405-150 | Target: CARD9 | UniProt: Q9H257 | TargetFullName: Caspase recruitment domain-containing protein 9 | Organisim: human | Apparent_Kd_M: 5.481957E-11
Real
Aptamer SeqId: 11406-82 | Target: ACAD8 | UniProt: Q9UKU7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11406-82 | Target: ACAD8 | UniProt: Q9UKU7 | TargetFullName: Isobutyryl-CoA dehydrogenase; mitochondrial | Organisim: human | Apparent_Kd_M: 8.817498E-11
Real
Aptamer SeqId: 11407-57 | Target: PLS3 | UniProt: Q9NRY6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11407-57 | Target: PLS3 | UniProt: Q9NRY6 | TargetFullName: Phospholipid scramblase 3 | Organisim: human | Apparent_Kd_M: 1.907302E-10
Real
Aptamer SeqId: 11416-23 | Target: FBXL4 | UniProt: Q9UKA2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11416-23 | Target: FBXL4 | UniProt: Q9UKA2 | TargetFullName: F-box/LRR-repeat protein 4 | Organisim: human | Apparent_Kd_M: 3.399846E-11
Real
Aptamer SeqId: 11421-10 | Target: EHD4 | UniProt: Q9H223
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11421-10 | Target: EHD4 | UniProt: Q9H223 | TargetFullName: EH domain-containing protein 4 | Organisim: human | Apparent_Kd_M: 1.95482E-12
Real
Aptamer SeqId: 11422-2 | Target: DLX3 | UniProt: O60479
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11422-2 | Target: DLX3 | UniProt: O60479 | TargetFullName: Homeobox protein DLX-3 | Organisim: human | Apparent_Kd_M: 2.261342E-11
Real
Aptamer SeqId: 11424-4 | Target: FAAA | UniProt: P16930
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11424-4 | Target: FAAA | UniProt: P16930 | TargetFullName: Fumarylacetoacetase | Organisim: human | Apparent_Kd_M: 1.516339E-11
Real
Aptamer SeqId: 11425-31 | Target: RUFY1 | UniProt: Q96T51
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11425-31 | Target: RUFY1 | UniProt: Q96T51 | TargetFullName: RUN and FYVE domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 8.882174E-11
Real
Aptamer SeqId: 11428-31 | Target: PDLI1 | UniProt: O00151
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11428-31 | Target: PDLI1 | UniProt: O00151 | TargetFullName: PDZ and LIM domain protein 1 | Organisim: human | Apparent_Kd_M: 1.50722E-11
Real
Aptamer SeqId: 11429-80 | Target: hnRNP C1/C2 | UniProt: P07910
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11429-80 | Target: hnRNP C1/C2 | UniProt: P07910 | TargetFullName: Heterogeneous nuclear ribonucleoproteins C1/C2 | Organisim: human | Apparent_Kd_M: 2.998584E-10
Real
Aptamer SeqId: 11430-49 | Target: DTX1 | UniProt: Q86Y01
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11430-49 | Target: DTX1 | UniProt: Q86Y01 | TargetFullName: E3 ubiquitin-protein ligase DTX1 | Organisim: human | Apparent_Kd_M: 1.656404E-10
Real
Aptamer SeqId: 11431-235 | Target: RECQ1 | UniProt: P46063
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11431-235 | Target: RECQ1 | UniProt: P46063 | TargetFullName: ATP-dependent DNA helicase Q1 | Organisim: human | Apparent_Kd_M: 6.150412E-12
Real
Aptamer SeqId: 11432-11 | Target: PQBP1 | UniProt: O60828
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11432-11 | Target: PQBP1 | UniProt: O60828 | TargetFullName: Polyglutamine-binding protein 1 | Organisim: human | Apparent_Kd_M: 4.914578E-11
Real
Aptamer SeqId: 11433-11 | Target: TECT2 | UniProt: Q96GX1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11433-11 | Target: TECT2 | UniProt: Q96GX1 | TargetFullName: Tectonic-2 | Organisim: human | Apparent_Kd_M: 2.801294E-10
Real
Aptamer SeqId: 11436-6 | Target: AINX | UniProt: Q16352
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11436-6 | Target: AINX | UniProt: Q16352 | TargetFullName: Alpha-internexin | Organisim: human | Apparent_Kd_M: 1.202525E-10
Real
Aptamer SeqId: 11438-6 | Target: DNJB2 | UniProt: P25686
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11438-6 | Target: DNJB2 | UniProt: P25686 | TargetFullName: DnaJ homolog subfamily B member 2 | Organisim: human | Apparent_Kd_M: 4.403681E-12
Real
Aptamer SeqId: 11439-88 | Target: RHPN2 | UniProt: Q8IUC4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11439-88 | Target: RHPN2 | UniProt: Q8IUC4 | TargetFullName: Rhophilin-2 | Organisim: human | Apparent_Kd_M: 2.00107E-11
Real
Aptamer SeqId: 11440-58 | Target: SOCS-3 | UniProt: O14543
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11440-58 | Target: SOCS-3 | UniProt: O14543 | TargetFullName: Suppressor of cytokine signaling 3 | Organisim: human | Apparent_Kd_M: 1.818662E-11
Real
Aptamer SeqId: 11441-11 | Target: PYGL | UniProt: P06737
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11441-11 | Target: PYGL | UniProt: P06737 | TargetFullName: Glycogen phosphorylase; liver form | Organisim: human | Apparent_Kd_M: 6.144466E-12
Real
Aptamer SeqId: 11442-1 | Target: DNER | UniProt: Q8NFT8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11442-1 | Target: DNER | UniProt: Q8NFT8 | TargetFullName: Delta and Notch-like epidermal growth factor-related receptor | Organisim: human | Apparent_Kd_M: 7.910162E-11
Real
Aptamer SeqId: 11444-49 | Target: RPC6 | UniProt: Q9H1D9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11444-49 | Target: RPC6 | UniProt: Q9H1D9 | TargetFullName: DNA-directed RNA polymerase III subunit RPC6 | Organisim: human | Apparent_Kd_M: 1.091556E-11
Real
Aptamer SeqId: 11448-34 | Target: GALK1 | UniProt: P51570
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11448-34 | Target: GALK1 | UniProt: P51570 | TargetFullName: Galactokinase | Organisim: human | Apparent_Kd_M: 7.342014E-11
Real
Aptamer SeqId: 11449-22 | Target: CAZA1 | UniProt: P52907
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11449-22 | Target: CAZA1 | UniProt: P52907 | TargetFullName: F-actin-capping protein subunit alpha-1 | Organisim: human | Apparent_Kd_M: 1.701582E-11
Real
Aptamer SeqId: 11454-87 | Target: EIF3G | UniProt: O75821
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11454-87 | Target: EIF3G | UniProt: O75821 | TargetFullName: Eukaryotic translation initiation factor 3 subunit G | Organisim: human | Apparent_Kd_M: 1.35251E-12
Real
Aptamer SeqId: 11456-2 | Target: MAGBA | UniProt: Q96LZ2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11456-2 | Target: MAGBA | UniProt: Q96LZ2 | TargetFullName: Melanoma-associated antigen B10 | Organisim: human | Apparent_Kd_M: 4.188535E-10
Real
Aptamer SeqId: 11457-53 | Target: GALE | UniProt: Q14376
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11457-53 | Target: GALE | UniProt: Q14376 | TargetFullName: UDP-glucose 4-epimerase | Organisim: human | Apparent_Kd_M: 5.462034E-10
Real
Aptamer SeqId: 11458-30 | Target: PCBP1 | UniProt: Q15365
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11458-30 | Target: PCBP1 | UniProt: Q15365 | TargetFullName: Poly(rC)-binding protein 1 | Organisim: human | Apparent_Kd_M: 5.14996E-12
Real
Aptamer SeqId: 11459-81 | Target: ELL | UniProt: P55199
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11459-81 | Target: ELL | UniProt: P55199 | TargetFullName: RNA polymerase II elongation factor ELL | Organisim: human | Apparent_Kd_M: 9.497402E-11
Real
Aptamer SeqId: 11462-8 | Target: RBM9 | UniProt: O43251
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11462-8 | Target: RBM9 | UniProt: O43251 | TargetFullName: RNA binding protein fox-1 homolog 2 | Organisim: human | Apparent_Kd_M: 2.982274E-12
Real
Aptamer SeqId: 11464-9 | Target: RELB | UniProt: Q01201
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11464-9 | Target: RELB | UniProt: Q01201 | TargetFullName: Transcription factor RelB | Organisim: human | Apparent_Kd_M: 2.132116E-10
Real
Aptamer SeqId: 11465-4 | Target: GP135 | UniProt: Q8IZ08
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11465-4 | Target: GP135 | UniProt: Q8IZ08 | TargetFullName: Probable G-protein coupled receptor 135 | Organisim: human | Apparent_Kd_M: 2.548581E-11
Real
Aptamer SeqId: 11468-15 | Target: RBM19 | UniProt: Q9Y4C8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11468-15 | Target: RBM19 | UniProt: Q9Y4C8 | TargetFullName: Probable RNA-binding protein 19 | Organisim: human | Apparent_Kd_M: 4.328854E-12
Real
Aptamer SeqId: 11476-43 | Target: VPS4A | UniProt: Q9UN37
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11476-43 | Target: VPS4A | UniProt: Q9UN37 | TargetFullName: Vacuolar protein sorting-associated protein 4A | Organisim: human | Apparent_Kd_M: 3.520462E-12
Real
Aptamer SeqId: 11480-1 | Target: Aldehyde dehydrogenase; class 3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11480-1 | Target: Aldehyde dehydrogenase; class 3 | UniProt: P30838 | TargetFullName: Aldehyde dehydrogenase; dimeric NADP-preferring | Organisim: human | Apparent_Kd_M: 9.846936E-12
Real
Aptamer SeqId: 11481-25 | Target: TIMD3 | UniProt: Q8TDQ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11481-25 | Target: TIMD3 | UniProt: Q8TDQ0 | TargetFullName: Hepatitis A virus cellular receptor 2 | Organisim: human | Apparent_Kd_M: 1.016071E-11
Real
Aptamer SeqId: 11486-26 | Target: ZN174 | UniProt: Q15697
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11486-26 | Target: ZN174 | UniProt: Q15697 | TargetFullName: Zinc finger protein 174 | Organisim: human | Apparent_Kd_M: 4.627589E-12
Real
Aptamer SeqId: 11490-42 | Target: UBL4A | UniProt: P11441
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11490-42 | Target: UBL4A | UniProt: P11441 | TargetFullName: Ubiquitin-like protein 4A | Organisim: human | Apparent_Kd_M: 1.17721E-12
Real
Aptamer SeqId: 11493-169 | Target: DYL2 | UniProt: Q96FJ2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11493-169 | Target: DYL2 | UniProt: Q96FJ2 | TargetFullName: Dynein light chain 2; cytoplasmic | Organisim: human | Apparent_Kd_M: 1.491885E-12
Real
Aptamer SeqId: 11494-4 | Target: ELL2 | UniProt: O00472
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11494-4 | Target: ELL2 | UniProt: O00472 | TargetFullName: RNA polymerase II elongation factor ELL2 | Organisim: human | Apparent_Kd_M: 6.618677E-12
Real
Aptamer SeqId: 11510-31 | Target: Apo L1 | UniProt: O14791
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11510-31 | Target: Apo L1 | UniProt: O14791 | TargetFullName: Apolipoprotein L1 | Organisim: human | Apparent_Kd_M: 1.21E-9
Real
Aptamer SeqId: 11513-92 | Target: CD38 | UniProt: P28907
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11513-92 | Target: CD38 | UniProt: P28907 | TargetFullName: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | Organisim: human | Apparent_Kd_M: 9.91E-13
Real
Aptamer SeqId: 11514-196 | Target: CD59 | UniProt: P13987
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11514-196 | Target: CD59 | UniProt: P13987 | TargetFullName: CD59 glycoprotein | Organisim: human | Apparent_Kd_M: 2.15E-11
Real
Aptamer SeqId: 11516-7 | Target: FABPL | UniProt: P07148
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11516-7 | Target: FABPL | UniProt: P07148 | TargetFullName: Fatty acid-binding protein; liver | Organisim: human | Apparent_Kd_M: 1.12E-10
Real
Aptamer SeqId: 11530-37 | Target: HEM3 | UniProt: P08397
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11530-37 | Target: HEM3 | UniProt: P08397 | TargetFullName: Porphobilinogen deaminase | Organisim: human | Apparent_Kd_M: 2.720652E-12
Real
Aptamer SeqId: 11531-24 | Target: GI24 | UniProt: Q9H7M9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11531-24 | Target: GI24 | UniProt: Q9H7M9 | TargetFullName: V-type immunoglobulin domain-containing suppressor of T-cell activation | Organisim: human | Apparent_Kd_M: 1.856786E-11
Real
Aptamer SeqId: 11534-6 | Target: LRIT3 | UniProt: Q3SXY7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11534-6 | Target: LRIT3 | UniProt: Q3SXY7 | TargetFullName: Leucine-rich repeat; immunoglobulin-like domain and transmembrane domain-containing protein 3 | Organisim: human | Apparent_Kd_M: 1.886034E-10
Real
Aptamer SeqId: 11536-9 | Target: MYSM1 | UniProt: Q5VVJ2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11536-9 | Target: MYSM1 | UniProt: Q5VVJ2 | TargetFullName: Histone H2A deubiquitinase MYSM1 | Organisim: human | Apparent_Kd_M: 2.673174E-11
Real
Aptamer SeqId: 11537-12 | Target: TFR2 | UniProt: Q9UP52
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11537-12 | Target: TFR2 | UniProt: Q9UP52 | TargetFullName: Transferrin receptor protein 2 | Organisim: human | Apparent_Kd_M: 4.017576E-10
Real
Aptamer SeqId: 11538-216 | Target: DCMC | UniProt: O95822
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11538-216 | Target: DCMC | UniProt: O95822 | TargetFullName: Malonyl-CoA decarboxylase; mitochondrial | Organisim: human | Apparent_Kd_M: 9.866022E-11
Real
Aptamer SeqId: 11539-4 | Target: ATPK | UniProt: P56134
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11539-4 | Target: ATPK | UniProt: P56134 | TargetFullName: ATP synthase subunit f; mitochondrial | Organisim: human | Apparent_Kd_M: 3.210803E-10
Real
Aptamer SeqId: 11540-37 | Target: FOXO3A | UniProt: O43524
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11540-37 | Target: FOXO3A | UniProt: O43524 | TargetFullName: Forkhead box protein O3 | Organisim: human | Apparent_Kd_M: 1.192288E-11
Real
Aptamer SeqId: 11542-11 | Target: TM230 | UniProt: Q96A57
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11542-11 | Target: TM230 | UniProt: Q96A57 | TargetFullName: Transmembrane protein 230 | Organisim: human | Apparent_Kd_M: 6.819256E-11
Real
Aptamer SeqId: 11543-84 | Target: LIMA1 | UniProt: Q9UHB6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11543-84 | Target: LIMA1 | UniProt: Q9UHB6 | TargetFullName: LIM domain and actin-binding protein 1 | Organisim: human | Apparent_Kd_M: 4.248212E-10
Real
Aptamer SeqId: 11544-39 | Target: PHF3 | UniProt: Q92576
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11544-39 | Target: PHF3 | UniProt: Q92576 | TargetFullName: PHD finger protein 3 | Organisim: human | Apparent_Kd_M: 1.735531E-11
Real
Aptamer SeqId: 11546-7 | Target: CYGB | UniProt: Q8WWM9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11546-7 | Target: CYGB | UniProt: Q8WWM9 | TargetFullName: Cytoglobin | Organisim: human | Apparent_Kd_M: 2.873131E-11
Real
Aptamer SeqId: 11547-84 | Target: MUSK | UniProt: O15146
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11547-84 | Target: MUSK | UniProt: O15146 | TargetFullName: Muscle; skeletal receptor tyrosine-protein kinase | Organisim: human | Apparent_Kd_M: 9.378678E-12
Real
Aptamer SeqId: 11548-84 | Target: MPIP1 | UniProt: P30304
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11548-84 | Target: MPIP1 | UniProt: P30304 | TargetFullName: M-phase inducer phosphatase 1 | Organisim: human | Apparent_Kd_M: 2.600792E-11
Real
Aptamer SeqId: 11549-6 | Target: ISL1 | UniProt: P61371
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11549-6 | Target: ISL1 | UniProt: P61371 | TargetFullName: Insulin gene enhancer protein ISL-1 | Organisim: human | Apparent_Kd_M: 3.233525E-11
Real
Aptamer SeqId: 11551-16 | Target: HM20B | UniProt: Q9P0W2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11551-16 | Target: HM20B | UniProt: Q9P0W2 | TargetFullName: SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related | Organisim: human | Apparent_Kd_M: 1.31035E-11
Real
Aptamer SeqId: 11556-19 | Target: ARFG1 | UniProt: Q8N6T3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11556-19 | Target: ARFG1 | UniProt: Q8N6T3 | TargetFullName: ADP-ribosylation factor GTPase-activating protein 1 | Organisim: human | Apparent_Kd_M: 6.205927E-11
Real
Aptamer SeqId: 11557-3 | Target: SMUF1 | UniProt: Q9HCE7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11557-3 | Target: SMUF1 | UniProt: Q9HCE7 | TargetFullName: E3 ubiquitin-protein ligase SMURF1 | Organisim: human | Apparent_Kd_M: 1.228872E-10
Real
Aptamer SeqId: 11560-76 | Target: NFAC4 | UniProt: Q14934
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11560-76 | Target: NFAC4 | UniProt: Q14934 | TargetFullName: Nuclear factor of activated T-cells; cytoplasmic 4 | Organisim: human | Apparent_Kd_M: 9.199133E-12
Real
Aptamer SeqId: 11561-32 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11561-32 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.99856E-10
Real
Aptamer SeqId: 11562-9 | Target: DPOE2 | UniProt: P56282
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11562-9 | Target: DPOE2 | UniProt: P56282 | TargetFullName: DNA polymerase epsilon subunit 2 | Organisim: human | Apparent_Kd_M: 2.499615E-12
Real
Aptamer SeqId: 11563-51 | Target: SYTL4 | UniProt: Q96C24
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11563-51 | Target: SYTL4 | UniProt: Q96C24 | TargetFullName: Synaptotagmin-like protein 4 | Organisim: human | Apparent_Kd_M: 2.941549E-11
Real
Aptamer SeqId: 11565-58 | Target: ZNF23 | UniProt: P17027
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11565-58 | Target: ZNF23 | UniProt: P17027 | TargetFullName: Zinc finger protein 23 | Organisim: human | Apparent_Kd_M: 2.752785E-11
Real
Aptamer SeqId: 11566-48 | Target: Keratin 72 | UniProt: Q14CN4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11566-48 | Target: Keratin 72 | UniProt: Q14CN4 | TargetFullName: Keratin; type II cytoskeletal 72 | Organisim: human | Apparent_Kd_M: 9.118237E-12
Real
Aptamer SeqId: 11567-23 | Target: ZNF10 | UniProt: P21506
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11567-23 | Target: ZNF10 | UniProt: P21506 | TargetFullName: Zinc finger protein 10 | Organisim: human | Apparent_Kd_M: 3.624214E-11
Real
Aptamer SeqId: 11568-2 | Target: FKB1B | UniProt: P68106
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11568-2 | Target: FKB1B | UniProt: P68106 | TargetFullName: Peptidyl-prolyl cis-trans isomerase FKBP1B | Organisim: human | Apparent_Kd_M: 1.283366E-11
Real
Aptamer SeqId: 11570-94 | Target: BAP29 | UniProt: Q9UHQ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11570-94 | Target: BAP29 | UniProt: Q9UHQ4 | TargetFullName: B-cell receptor-associated protein 29 | Organisim: human | Apparent_Kd_M: 2.172304E-11
Real
Aptamer SeqId: 11571-75 | Target: NKG2E | UniProt: Q07444
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11571-75 | Target: NKG2E | UniProt: Q07444 | TargetFullName: NKG2-E type II integral membrane protein | Organisim: human | Apparent_Kd_M: 1.297699E-10
Real
Aptamer SeqId: 11572-4 | Target: DYN2 | UniProt: P50570
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11572-4 | Target: DYN2 | UniProt: P50570 | TargetFullName: Dynamin-2 | Organisim: human | Apparent_Kd_M: 1.081032E-11
Real
Aptamer SeqId: 11573-3 | Target: SRSF6 | UniProt: Q13247
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11573-3 | Target: SRSF6 | UniProt: Q13247 | TargetFullName: Serine/arginine-rich splicing factor 6 | Organisim: human | Apparent_Kd_M: 4.136621E-11
Real
Aptamer SeqId: 11582-63 | Target: DNJA2 | UniProt: O60884
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11582-63 | Target: DNJA2 | UniProt: O60884 | TargetFullName: DnaJ homolog subfamily A member 2 | Organisim: human | Apparent_Kd_M: 4.478575E-11
Real
Aptamer SeqId: 11587-5 | Target: MGAP | UniProt: Q8IWI9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11587-5 | Target: MGAP | UniProt: Q8IWI9 | TargetFullName: MAX gene-associated protein | Organisim: human | Apparent_Kd_M: 6.000809E-11
Real
Aptamer SeqId: 11590-5 | Target: RBM23 | UniProt: Q86U06
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11590-5 | Target: RBM23 | UniProt: Q86U06 | TargetFullName: Probable RNA-binding protein 23 | Organisim: human | Apparent_Kd_M: 2.876709E-12
Real
Aptamer SeqId: 11591-43 | Target: PRC1 | UniProt: O43663
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11591-43 | Target: PRC1 | UniProt: O43663 | TargetFullName: Protein regulator of cytokinesis 1 | Organisim: human | Apparent_Kd_M: 1.323006E-11
Real
Aptamer SeqId: 11592-1 | Target: ELAV1 | UniProt: Q15717
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11592-1 | Target: ELAV1 | UniProt: Q15717 | TargetFullName: ELAV-like protein 1 | Organisim: human | Apparent_Kd_M: 1.174819E-11
Real
Aptamer SeqId: 11593-21 | Target: MIG | UniProt: Q07325
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11593-21 | Target: MIG | UniProt: Q07325 | TargetFullName: C-X-C motif chemokine 9 | Organisim: human | Apparent_Kd_M: 3.580832E-11
Real
Aptamer SeqId: 11596-47 | Target: ZN75D | UniProt: P51815
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11596-47 | Target: ZN75D | UniProt: P51815 | TargetFullName: Zinc finger protein 75D | Organisim: human | Apparent_Kd_M: 1.408011E-11
Real
Aptamer SeqId: 11601-26 | Target: DHX8 | UniProt: Q14562
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11601-26 | Target: DHX8 | UniProt: Q14562 | TargetFullName: ATP-dependent RNA helicase DHX8 | Organisim: human | Apparent_Kd_M: 4.476594E-12
Real
Aptamer SeqId: 11606-22 | Target: DNJB6 | UniProt: O75190
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11606-22 | Target: DNJB6 | UniProt: O75190 | TargetFullName: DnaJ homolog subfamily B member 6 | Organisim: human | Apparent_Kd_M: 2.269239E-11
Real
Aptamer SeqId: 11607-15 | Target: BRD1 | UniProt: O95696
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11607-15 | Target: BRD1 | UniProt: O95696 | TargetFullName: Bromodomain-containing protein 1 | Organisim: human | Apparent_Kd_M: 3.318534E-12
Real
Aptamer SeqId: 11608-5 | Target: MLP3B | UniProt: Q9GZQ8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11608-5 | Target: MLP3B | UniProt: Q9GZQ8 | TargetFullName: Microtubule-associated proteins 1A/1B light chain 3B | Organisim: human | Apparent_Kd_M: 2.099031E-12
Real
Aptamer SeqId: 11614-29 | Target: ERH | UniProt: P84090
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11614-29 | Target: ERH | UniProt: P84090 | TargetFullName: Enhancer of rudimentary homolog | Organisim: human | Apparent_Kd_M: 2.795803E-12
Real
Aptamer SeqId: 11615-16 | Target: DAPP1 | UniProt: Q9UN19
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11615-16 | Target: DAPP1 | UniProt: Q9UN19 | TargetFullName: Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide | Organisim: human | Apparent_Kd_M: 2.188846E-12
Real
Aptamer SeqId: 11616-9 | Target: HSF1 | UniProt: Q00613
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11616-9 | Target: HSF1 | UniProt: Q00613 | TargetFullName: Heat shock factor protein 1 | Organisim: human | Apparent_Kd_M: 6.895782E-13
Real
Aptamer SeqId: 11617-1 | Target: LFA-1 alpha-L chain | UniProt: P20701
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11617-1 | Target: LFA-1 alpha-L chain | UniProt: P20701 | TargetFullName: Integrin alpha-L | Organisim: human | Apparent_Kd_M: 8.034004E-12
Real
Aptamer SeqId: 11618-83 | Target: MYB | UniProt: P10242
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11618-83 | Target: MYB | UniProt: P10242 | TargetFullName: Transcriptional activator Myb | Organisim: human | Apparent_Kd_M: 4.142378E-11
Real
Aptamer SeqId: 11626-7 | Target: UB2V1 | UniProt: Q13404
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11626-7 | Target: UB2V1 | UniProt: Q13404 | TargetFullName: Ubiquitin-conjugating enzyme E2 variant 1 | Organisim: human | Apparent_Kd_M: 1.087697E-11
Real
Aptamer SeqId: 11633-89 | Target: AHSA1 | UniProt: O95433
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11633-89 | Target: AHSA1 | UniProt: O95433 | TargetFullName: Activator of 90 kDa heat shock protein ATPase homolog 1 | Organisim: human | Apparent_Kd_M: 1.452417E-11
Real
Aptamer SeqId: 11634-32 | Target: RGS10 | UniProt: O43665
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11634-32 | Target: RGS10 | UniProt: O43665 | TargetFullName: Regulator of G-protein signaling 10 | Organisim: human | Apparent_Kd_M: 9.688991E-12
Real
Aptamer SeqId: 11636-33 | Target: Transgelin-2 | UniProt: P37802
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11636-33 | Target: Transgelin-2 | UniProt: P37802 | TargetFullName: Transgelin-2 | Organisim: human | Apparent_Kd_M: 1.799983E-11
Real
Aptamer SeqId: 11638-42 | Target: B3GT2 | UniProt: O43825
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11638-42 | Target: B3GT2 | UniProt: O43825 | TargetFullName: Beta-1;3-galactosyltransferase 2 | Organisim: human | Apparent_Kd_M: 2.377031E-11
Real
Aptamer SeqId: 11643-73 | Target: DTX3L | UniProt: Q8TDB6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11643-73 | Target: DTX3L | UniProt: Q8TDB6 | TargetFullName: E3 ubiquitin-protein ligase DTX3L | Organisim: human | Apparent_Kd_M: 1.083751E-11
Real
Aptamer SeqId: 11645-9 | Target: P4HA1 | UniProt: P13674
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11645-9 | Target: P4HA1 | UniProt: P13674 | TargetFullName: Prolyl 4-hydroxylase subunit alpha-1 | Organisim: human | Apparent_Kd_M: 4.507759E-11
Real
Aptamer SeqId: 11646-4 | Target: Carbohydrate sulfotransferase 9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11646-4 | Target: Carbohydrate sulfotransferase 9 | UniProt: Q7L1S5 | TargetFullName: Carbohydrate sulfotransferase 9 | Organisim: human | Apparent_Kd_M: 1.954101E-11
Real
Aptamer SeqId: 11647-6 | Target: Frizzled-10 | UniProt: Q9ULW2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11647-6 | Target: Frizzled-10 | UniProt: Q9ULW2 | TargetFullName: Frizzled-10 | Organisim: human | Apparent_Kd_M: 3.29741E-11
Real
Aptamer SeqId: 11649-3 | Target: SMAP1 | UniProt: Q8IYB5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11649-3 | Target: SMAP1 | UniProt: Q8IYB5 | TargetFullName: Stromal membrane-associated protein 1 | Organisim: human | Apparent_Kd_M: 2.631188E-11
Real
Aptamer SeqId: 11653-69 | Target: SC6A9 | UniProt: P48067
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11653-69 | Target: SC6A9 | UniProt: P48067 | TargetFullName: Sodium- and chloride-dependent glycine transporter 1 | Organisim: human | Apparent_Kd_M: 1.571875E-11
Real
Aptamer SeqId: 11654-77 | Target: NRSN1 | UniProt: Q8IZ57
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11654-77 | Target: NRSN1 | UniProt: Q8IZ57 | TargetFullName: Neurensin-1 | Organisim: human | Apparent_Kd_M: 2.027308E-11
Real
Aptamer SeqId: 11656-110 | Target: EVL | UniProt: Q9UI08
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11656-110 | Target: EVL | UniProt: Q9UI08 | TargetFullName: Ena/VASP-like protein | Organisim: human | Apparent_Kd_M: 2.647818E-11
Real
Aptamer SeqId: 11657-86 | Target: SOCS7 | UniProt: O14512
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11657-86 | Target: SOCS7 | UniProt: O14512 | TargetFullName: Suppressor of cytokine signaling 7 | Organisim: human | Apparent_Kd_M: 1.686113E-11
Real
Aptamer SeqId: 11659-31 | Target: EPN4 | UniProt: Q14677
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11659-31 | Target: EPN4 | UniProt: Q14677 | TargetFullName: Clathrin interactor 1 | Organisim: human | Apparent_Kd_M: 7.429775E-12
Real
Aptamer SeqId: 11661-11 | Target: NALP1 | UniProt: Q9C000
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11661-11 | Target: NALP1 | UniProt: Q9C000 | TargetFullName: NACHT; LRR and PYD domains-containing protein 1 | Organisim: human | Apparent_Kd_M: 1.207723E-11
Real
Aptamer SeqId: 11664-32 | Target: ARFG2 | UniProt: Q8N6H7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11664-32 | Target: ARFG2 | UniProt: Q8N6H7 | TargetFullName: ADP-ribosylation factor GTPase-activating protein 2 | Organisim: human | Apparent_Kd_M: 1.096836E-11
Real
Aptamer SeqId: 11666-72 | Target: RGS8 | UniProt: P57771
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11666-72 | Target: RGS8 | UniProt: P57771 | TargetFullName: Regulator of G-protein signaling 8 | Organisim: human | Apparent_Kd_M: 9.674182E-12
Real
Aptamer SeqId: 11667-29 | Target: TENC1 | UniProt: Q63HR2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11667-29 | Target: TENC1 | UniProt: Q63HR2 | TargetFullName: Tensin-2 | Organisim: human | Apparent_Kd_M: 8.085797E-12
Real
Aptamer SeqId: 11669-39 | Target: SO5A1 | UniProt: Q9H2Y9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11669-39 | Target: SO5A1 | UniProt: Q9H2Y9 | TargetFullName: Solute carrier organic anion transporter family member 5A1 | Organisim: human | Apparent_Kd_M: 1.902073E-11
Real
Aptamer SeqId: 11671-19 | Target: BRPF1 | UniProt: P55201
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11671-19 | Target: BRPF1 | UniProt: P55201 | TargetFullName: Peregrin | Organisim: human | Apparent_Kd_M: 6.541351E-12
Real
Aptamer SeqId: 11672-17 | Target: KI16B | UniProt: Q96L93
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11672-17 | Target: KI16B | UniProt: Q96L93 | TargetFullName: Kinesin-like protein KIF16B | Organisim: human | Apparent_Kd_M: 1.44505E-11
Real
Aptamer SeqId: 11677-17 | Target: ZDH14 | UniProt: Q8IZN3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11677-17 | Target: ZDH14 | UniProt: Q8IZN3 | TargetFullName: Probable palmitoyltransferase ZDHHC14 | Organisim: human | Apparent_Kd_M: 1.786119E-11
Real
Aptamer SeqId: 11678-105 | Target: CXD2 | UniProt: Q9UKL4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11678-105 | Target: CXD2 | UniProt: Q9UKL4 | TargetFullName: Gap junction delta-2 protein | Organisim: human | Apparent_Kd_M: 2.878914E-11
Real
Aptamer SeqId: 11681-8 | Target: NUPL | UniProt: P52594
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11681-8 | Target: NUPL | UniProt: P52594 | TargetFullName: Arf-GAP domain and FG repeat-containing protein 1 | Organisim: human | Apparent_Kd_M: 1.193746E-11
Real
Aptamer SeqId: 11682-7 | Target: TXNIP | UniProt: Q9H3M7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11682-7 | Target: TXNIP | UniProt: Q9H3M7 | TargetFullName: Thioredoxin-interacting protein | Organisim: human | Apparent_Kd_M: 4.724425E-11
Real
Aptamer SeqId: 11683-19 | Target: GGA3 | UniProt: Q9NZ52
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11683-19 | Target: GGA3 | UniProt: Q9NZ52 | TargetFullName: ADP-ribosylation factor-binding protein GGA3 | Organisim: human | Apparent_Kd_M: 9.685567E-12
Real
Aptamer SeqId: 11690-47 | Target: APC7 | UniProt: Q9UJX3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11690-47 | Target: APC7 | UniProt: Q9UJX3 | TargetFullName: Anaphase-promoting complex subunit 7 | Organisim: human | Apparent_Kd_M: 1.297959E-10
Real
Aptamer SeqId: 11692-21 | Target: SHC4 | UniProt: Q6S5L8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11692-21 | Target: SHC4 | UniProt: Q6S5L8 | TargetFullName: SHC-transforming protein 4 | Organisim: human | Apparent_Kd_M: 2.690458E-10
Real
Aptamer SeqId: 11696-7 | Target: RABP2 | UniProt: P29373
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11696-7 | Target: RABP2 | UniProt: P29373 | TargetFullName: Cellular retinoic acid-binding protein 2 | Organisim: human | Apparent_Kd_M: 3.355675E-12
Real
Aptamer SeqId: 11699-16 | Target: TP4A2 | UniProt: Q12974
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11699-16 | Target: TP4A2 | UniProt: Q12974 | TargetFullName: Protein tyrosine phosphatase type IVA 2 | Organisim: human | Apparent_Kd_M: 4.432672E-11
Real
Aptamer SeqId: 11708-2 | Target: LCN1 | UniProt: P31025
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11708-2 | Target: LCN1 | UniProt: P31025 | TargetFullName: Lipocalin-1 | Organisim: human | Apparent_Kd_M: 2.046388E-10
Real
Aptamer SeqId: 11709-29 | Target: CPT1B | UniProt: Q92523
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11709-29 | Target: CPT1B | UniProt: Q92523 | TargetFullName: Carnitine O-palmitoyltransferase 1; muscle isoform | Organisim: human | Apparent_Kd_M: 2.005406E-10
Real
Aptamer SeqId: 11715-1 | Target: PO2F1 | UniProt: P14859
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11715-1 | Target: PO2F1 | UniProt: P14859 | TargetFullName: POU domain; class 2; transcription factor 1 | Organisim: human | Apparent_Kd_M: 3.00754E-11
Real
Aptamer SeqId: 11716-28 | Target: LRIT2 | UniProt: A6NDA9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11716-28 | Target: LRIT2 | UniProt: A6NDA9 | TargetFullName: Leucine-rich repeat; immunoglobulin-like domain and transmembrane domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 5.475047E-11
Real
Aptamer SeqId: 11816-84 | Target: JAK2 | UniProt: O60674
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11816-84 | Target: JAK2 | UniProt: O60674 | TargetFullName: Tyrosine-protein kinase JAK2 | Organisim: human | Apparent_Kd_M: 3.0E-11
Real
Aptamer SeqId: 11825-27 | Target: PRGC1 | UniProt: Q9UBK2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11825-27 | Target: PRGC1 | UniProt: Q9UBK2 | TargetFullName: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha | Organisim: human | Apparent_Kd_M: 1.880125E-10
Real
Aptamer SeqId: 11827-7 | Target: RORG | UniProt: P51449
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11827-7 | Target: RORG | UniProt: P51449 | TargetFullName: Nuclear receptor ROR-gamma | Organisim: human | Apparent_Kd_M: 6.136328E-13
Real
Aptamer SeqId: 11837-7 | Target: GITR | UniProt: Q9Y5U5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11837-7 | Target: GITR | UniProt: Q9Y5U5 | TargetFullName: Tumor necrosis factor receptor superfamily member 18 | Organisim: human | Apparent_Kd_M: 2.22E-11
Real
Aptamer SeqId: 11838-130 | Target: FA38A | UniProt: Q92508
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11838-130 | Target: FA38A | UniProt: Q92508 | TargetFullName: Piezo-type mechanosensitive ion channel component 1 | Organisim: human | Apparent_Kd_M: 5.429152E-12
Real
Aptamer SeqId: 11860-3 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11860-3 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.211488E-11
Real
Aptamer SeqId: 11872-9 | Target: PCDGD | UniProt: Q9Y5G3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11872-9 | Target: PCDGD | UniProt: Q9Y5G3 | TargetFullName: Protocadherin gamma-B1 | Organisim: human | Apparent_Kd_M: 8.767742E-11
Real
Aptamer SeqId: 11895-21 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11895-21 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 7.810143E-11
Real
Aptamer SeqId: 11910-27 | Target: DLX4 | UniProt: Q92988
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11910-27 | Target: DLX4 | UniProt: Q92988 | TargetFullName: Homeobox protein DLX-4 | Organisim: human | Apparent_Kd_M: 7.651296E-11
Real
Aptamer SeqId: 11911-13 | Target: LRC4B | UniProt: Q9NT99
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11911-13 | Target: LRC4B | UniProt: Q9NT99 | TargetFullName: Leucine-rich repeat-containing protein 4B | Organisim: human | Apparent_Kd_M: 1.15025E-10
Real
Aptamer SeqId: 11912-45 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11912-45 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.128134E-10
Real
Aptamer SeqId: 11917-8 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11917-8 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.38571E-11
Real
Aptamer SeqId: 11918-54 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11918-54 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.742954E-11
Real
Aptamer SeqId: 11919-84 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11919-84 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.105959E-11
Real
Aptamer SeqId: 11926-23 | Target: P34 | UniProt: Q6PD74
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11926-23 | Target: P34 | UniProt: Q6PD74 | TargetFullName: Alpha- and gamma-adaptin-binding protein p34 | Organisim: human | Apparent_Kd_M: 3.16237E-11
Real
Aptamer SeqId: 11927-3 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11927-3 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.627136E-11
Real
Aptamer SeqId: 11934-9 | Target: INT3 | UniProt: Q68E01
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11934-9 | Target: INT3 | UniProt: Q68E01 | TargetFullName: Integrator complex subunit 3 | Organisim: human | Apparent_Kd_M: 1.363192E-11
Real
Aptamer SeqId: 11939-11 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11939-11 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 8.896691E-11
Real
Aptamer SeqId: 11952-1 | Target: IGDC3 | UniProt: Q8IVU1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11952-1 | Target: IGDC3 | UniProt: Q8IVU1 | TargetFullName: Immunoglobulin superfamily DCC subclass member 3 | Organisim: human | Apparent_Kd_M: 1.388076E-10
Real
Aptamer SeqId: 11955-1 | Target: RHG01 | UniProt: Q07960
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11955-1 | Target: RHG01 | UniProt: Q07960 | TargetFullName: Rho GTPase-activating protein 1 | Organisim: human | Apparent_Kd_M: 6.291374E-11
Real
Aptamer SeqId: 11967-23 | Target: RABP1 | UniProt: P29762
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11967-23 | Target: RABP1 | UniProt: P29762 | TargetFullName: Cellular retinoic acid-binding protein 1 | Organisim: human | Apparent_Kd_M: 2.433921E-11
Real
Aptamer SeqId: 11969-5 | Target: S100A2 | UniProt: P29034
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11969-5 | Target: S100A2 | UniProt: P29034 | TargetFullName: Protein S100-A2 | Organisim: human | Apparent_Kd_M: 1.091208E-10
Real
Aptamer SeqId: 11986-30 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11986-30 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.580557E-11
Real
Aptamer SeqId: 11988-24 | Target: PTPRH | UniProt: Q9HD43
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11988-24 | Target: PTPRH | UniProt: Q9HD43 | TargetFullName: Receptor-type tyrosine-protein phosphatase H | Organisim: human | Apparent_Kd_M: 3.489357E-11
Real
Aptamer SeqId: 11989-35 | Target: EMC1 | UniProt: Q8N766
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11989-35 | Target: EMC1 | UniProt: Q8N766 | TargetFullName: ER membrane protein complex subunit 1 | Organisim: human | Apparent_Kd_M: 1.679051E-10
Real
Aptamer SeqId: 11993-227 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 11993-227 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.503586E-11
Real
Aptamer SeqId: 12001-7 | Target: ZO1 | UniProt: Q07157
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12001-7 | Target: ZO1 | UniProt: Q07157 | TargetFullName: Tight junction protein ZO-1 | Organisim: human | Apparent_Kd_M: 3.444973E-10
Real
Aptamer SeqId: 12008-3 | Target: CD7 | UniProt: P09564
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12008-3 | Target: CD7 | UniProt: P09564 | TargetFullName: T-cell antigen CD7 | Organisim: human | Apparent_Kd_M: 4.018155E-11
Real
Aptamer SeqId: 12012-33 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12012-33 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 6.829407E-11
Real
Aptamer SeqId: 12014-19 | Target: PTPS | UniProt: Q03393
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12014-19 | Target: PTPS | UniProt: Q03393 | TargetFullName: 6-pyruvoyl tetrahydrobiopterin synthase | Organisim: human | Apparent_Kd_M: 4.570922E-11
Real
Aptamer SeqId: 12016-60 | Target: CBL | UniProt: P22681
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12016-60 | Target: CBL | UniProt: P22681 | TargetFullName: E3 ubiquitin-protein ligase CBL | Organisim: human | Apparent_Kd_M: 1.495529E-12
Real
Aptamer SeqId: 12018-84 | Target: TPK1 | UniProt: Q9H3S4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12018-84 | Target: TPK1 | UniProt: Q9H3S4 | TargetFullName: Thiamin pyrophosphokinase 1 | Organisim: human | Apparent_Kd_M: 1.50718E-10
Real
Aptamer SeqId: 12020-39 | Target: PMGE | UniProt: P07738
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12020-39 | Target: PMGE | UniProt: P07738 | TargetFullName: Bisphosphoglycerate mutase | Organisim: human | Apparent_Kd_M: 1.479729E-11
Real
Aptamer SeqId: 12022-12 | Target: SMAD4 | UniProt: Q13485
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12022-12 | Target: SMAD4 | UniProt: Q13485 | TargetFullName: Mothers against decapentaplegic homolog 4 | Organisim: human | Apparent_Kd_M: 6.754043E-11
Real
Aptamer SeqId: 12030-82 | Target: Desmin | UniProt: P17661
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12030-82 | Target: Desmin | UniProt: P17661 | TargetFullName: Desmin | Organisim: human | Apparent_Kd_M: 7.501904E-12
Real
Aptamer SeqId: 12033-3 | Target: BUB1 | UniProt: O43683
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12033-3 | Target: BUB1 | UniProt: O43683 | TargetFullName: Mitotic checkpoint serine/threonine-protein kinase BUB1 | Organisim: human | Apparent_Kd_M: 4.273254E-11
Real
Aptamer SeqId: 12034-28 | Target: CAP 1 | UniProt: Q01518
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12034-28 | Target: CAP 1 | UniProt: Q01518 | TargetFullName: Adenylyl cyclase-associated protein 1 | Organisim: human | Apparent_Kd_M: 1.994169E-10
Real
Aptamer SeqId: 12041-33 | Target: HS71L | UniProt: P34931
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12041-33 | Target: HS71L | UniProt: P34931 | TargetFullName: Heat shock 70 kDa protein 1-like | Organisim: human | Apparent_Kd_M: 5.126939E-10
Real
Aptamer SeqId: 12046-51 | Target: TADBP | UniProt: Q13148
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12046-51 | Target: TADBP | UniProt: Q13148 | TargetFullName: TAR DNA-binding protein 43 | Organisim: human | Apparent_Kd_M: 1.39184E-10
Real
Aptamer SeqId: 12329-21 | Target: KS6A1 | UniProt: Q15418
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12329-21 | Target: KS6A1 | UniProt: Q15418 | TargetFullName: Ribosomal protein S6 kinase alpha-1 | Organisim: human | Apparent_Kd_M: 2.248191E-10
Real
Aptamer SeqId: 12332-7 | Target: EF2K | UniProt: O00418
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12332-7 | Target: EF2K | UniProt: O00418 | TargetFullName: Eukaryotic elongation factor 2 kinase | Organisim: human | Apparent_Kd_M: 2.704565E-11
Real
Aptamer SeqId: 12333-87 | Target: RPIA | UniProt: P49247
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12333-87 | Target: RPIA | UniProt: P49247 | TargetFullName: Ribose-5-phosphate isomerase | Organisim: human | Apparent_Kd_M: 9.081164E-11
Real
Aptamer SeqId: 12334-25 | Target: cSHMT | UniProt: P34896
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12334-25 | Target: cSHMT | UniProt: P34896 | TargetFullName: Serine hydroxymethyltransferase; cytosolic | Organisim: human | Apparent_Kd_M: 8.212984E-12
Real
Aptamer SeqId: 12338-27 | Target: EGFLA | UniProt: Q63HQ2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12338-27 | Target: EGFLA | UniProt: Q63HQ2 | TargetFullName: Pikachurin | Organisim: human | Apparent_Kd_M: 7.166281E-12
Real
Aptamer SeqId: 12340-17 | Target: SYAC | UniProt: P49588
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12340-17 | Target: SYAC | UniProt: P49588 | TargetFullName: Alanine--tRNA ligase; cytoplasmic | Organisim: human | Apparent_Kd_M: 1.497827E-12
Real
Aptamer SeqId: 12341-8 | Target: DUS6 | UniProt: Q16828
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12341-8 | Target: DUS6 | UniProt: Q16828 | TargetFullName: Dual specificity protein phosphatase 6 | Organisim: human | Apparent_Kd_M: 1.792609E-10
Real
Aptamer SeqId: 12343-14 | Target: CENB2 | UniProt: Q15057
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12343-14 | Target: CENB2 | UniProt: Q15057 | TargetFullName: Arf-GAP with coiled-coil; ANK repeat and PH domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 1.33647E-10
Real
Aptamer SeqId: 12345-4 | Target: APC10 | UniProt: Q9UM13
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12345-4 | Target: APC10 | UniProt: Q9UM13 | TargetFullName: Anaphase-promoting complex subunit 10 | Organisim: human | Apparent_Kd_M: 7.275293E-11
Real
Aptamer SeqId: 12347-29 | Target: CCM2 | UniProt: Q9BSQ5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12347-29 | Target: CCM2 | UniProt: Q9BSQ5 | TargetFullName: Cerebral cavernous malformations 2 protein | Organisim: human | Apparent_Kd_M: 2.936135E-11
Real
Aptamer SeqId: 12348-46 | Target: SYSM | UniProt: Q9NP81
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12348-46 | Target: SYSM | UniProt: Q9NP81 | TargetFullName: Serine--tRNA ligase; mitochondrial | Organisim: human | Apparent_Kd_M: 1.817599E-11
Real
Aptamer SeqId: 12350-86 | Target: ETS2 | UniProt: P15036
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12350-86 | Target: ETS2 | UniProt: P15036 | TargetFullName: Protein C-ets-2 | Organisim: human | Apparent_Kd_M: 2.76E-12
Real
Aptamer SeqId: 12352-70 | Target: ARRD3 | UniProt: Q96B67
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12352-70 | Target: ARRD3 | UniProt: Q96B67 | TargetFullName: Arrestin domain-containing protein 3 | Organisim: human | Apparent_Kd_M: 4.620349E-12
Real
Aptamer SeqId: 12355-223 | Target: RRFM | UniProt: Q96E11
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12355-223 | Target: RRFM | UniProt: Q96E11 | TargetFullName: Ribosome-recycling factor; mitochondrial | Organisim: human | Apparent_Kd_M: 7.620073E-11
Real
Aptamer SeqId: 12356-65 | Target: Sorcin | UniProt: P30626
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12356-65 | Target: Sorcin | UniProt: P30626 | TargetFullName: Sorcin | Organisim: human | Apparent_Kd_M: 1.525527E-10
Real
Aptamer SeqId: 12357-41 | Target: SNP29 | UniProt: O95721
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12357-41 | Target: SNP29 | UniProt: O95721 | TargetFullName: Synaptosomal-associated protein 29 | Organisim: human | Apparent_Kd_M: 1.229383E-10
Real
Aptamer SeqId: 12358-6 | Target: IGBP1 | UniProt: P78318
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12358-6 | Target: IGBP1 | UniProt: P78318 | TargetFullName: Immunoglobulin-binding protein 1 | Organisim: human | Apparent_Kd_M: 3.743409E-12
Real
Aptamer SeqId: 12361-102 | Target: RRAS2 | UniProt: P62070
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12361-102 | Target: RRAS2 | UniProt: P62070 | TargetFullName: Ras-related protein R-Ras2 | Organisim: human | Apparent_Kd_M: 4.69992E-11
Real
Aptamer SeqId: 12363-70 | Target: TRIB2 | UniProt: Q92519
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12363-70 | Target: TRIB2 | UniProt: Q92519 | TargetFullName: Tribbles homolog 2 | Organisim: human | Apparent_Kd_M: 2.012574E-11
Real
Aptamer SeqId: 12365-108 | Target: RUVB1 | UniProt: Q9Y265
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12365-108 | Target: RUVB1 | UniProt: Q9Y265 | TargetFullName: RuvB-like 1 | Organisim: human | Apparent_Kd_M: 5.321349E-11
Real
Aptamer SeqId: 12366-16 | Target: CRGD | UniProt: P07320
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12366-16 | Target: CRGD | UniProt: P07320 | TargetFullName: Gamma-crystallin D | Organisim: human | Apparent_Kd_M: 3.501916E-11
Real
Aptamer SeqId: 12367-52 | Target: MACOI | UniProt: Q8N5G2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12367-52 | Target: MACOI | UniProt: Q8N5G2 | TargetFullName: Macoilin | Organisim: human | Apparent_Kd_M: 5.047972E-11
Real
Aptamer SeqId: 12368-18 | Target: PCAF | UniProt: Q92831
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12368-18 | Target: PCAF | UniProt: Q92831 | TargetFullName: Histone acetyltransferase KAT2B | Organisim: human | Apparent_Kd_M: 1.588979E-11
Real
Aptamer SeqId: 12370-30 | Target: Apo F | UniProt: Q13790
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12370-30 | Target: Apo F | UniProt: Q13790 | TargetFullName: Apolipoprotein F | Organisim: human | Apparent_Kd_M: 2.042036E-11
Real
Aptamer SeqId: 12373-73 | Target: TRA2B | UniProt: P62995
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12373-73 | Target: TRA2B | UniProt: P62995 | TargetFullName: Transformer-2 protein homolog beta | Organisim: human | Apparent_Kd_M: 1.703666E-12
Real
Aptamer SeqId: 12374-8 | Target: PA1B3 | UniProt: Q15102
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12374-8 | Target: PA1B3 | UniProt: Q15102 | TargetFullName: Platelet-activating factor acetylhydrolase IB subunit gamma | Organisim: human | Apparent_Kd_M: 7.239859E-12
Real
Aptamer SeqId: 12376-85 | Target: p19-INK4d | UniProt: P55273
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12376-85 | Target: p19-INK4d | UniProt: P55273 | TargetFullName: Cyclin-dependent kinase 4 inhibitor D | Organisim: human | Apparent_Kd_M: 9.783931E-12
Real
Aptamer SeqId: 12378-71 | Target: TPSN | UniProt: O15533
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12378-71 | Target: TPSN | UniProt: O15533 | TargetFullName: Tapasin | Organisim: human | Apparent_Kd_M: 4.18689E-11
Real
Aptamer SeqId: 12381-26 | Target: CBR1 | UniProt: P16152
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12381-26 | Target: CBR1 | UniProt: P16152 | TargetFullName: Carbonyl reductase NADPH 1 | Organisim: human | Apparent_Kd_M: 1.055064E-11
Real
Aptamer SeqId: 12382-2 | Target: DDX58 | UniProt: O95786
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12382-2 | Target: DDX58 | UniProt: O95786 | TargetFullName: Probable ATP-dependent RNA helicase DDX58 | Organisim: human | Apparent_Kd_M: 5.723584E-12
Real
Aptamer SeqId: 12384-92 | Target: CSN7B | UniProt: Q9H9Q2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12384-92 | Target: CSN7B | UniProt: Q9H9Q2 | TargetFullName: COP9 signalosome complex subunit 7b | Organisim: human | Apparent_Kd_M: 5.613975E-11
Real
Aptamer SeqId: 12385-4 | Target: CAN3 | UniProt: P20807
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12385-4 | Target: CAN3 | UniProt: P20807 | TargetFullName: Calpain-3 | Organisim: human | Apparent_Kd_M: 6.451892E-11
Real
Aptamer SeqId: 12386-11 | Target: AMPB | UniProt: Q9H4A4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12386-11 | Target: AMPB | UniProt: Q9H4A4 | TargetFullName: Aminopeptidase B | Organisim: human | Apparent_Kd_M: 4.953123E-11
Real
Aptamer SeqId: 12387-7 | Target: PDLI4 | UniProt: P50479
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12387-7 | Target: PDLI4 | UniProt: P50479 | TargetFullName: PDZ and LIM domain protein 4 | Organisim: human | Apparent_Kd_M: 2.82277E-12
Real
Aptamer SeqId: 12389-4 | Target: ORC6 | UniProt: Q9Y5N6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12389-4 | Target: ORC6 | UniProt: Q9Y5N6 | TargetFullName: Origin recognition complex subunit 6 | Organisim: human | Apparent_Kd_M: 3.142377E-12
Real
Aptamer SeqId: 12391-27 | Target: PDZD7 | UniProt: Q9H5P4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12391-27 | Target: PDZD7 | UniProt: Q9H5P4 | TargetFullName: PDZ domain-containing protein 7 | Organisim: human | Apparent_Kd_M: 6.550686E-12
Real
Aptamer SeqId: 12392-30 | Target: ARL1 | UniProt: P40616
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12392-30 | Target: ARL1 | UniProt: P40616 | TargetFullName: ADP-ribosylation factor-like protein 1 | Organisim: human | Apparent_Kd_M: 9.031801E-11
Real
Aptamer SeqId: 12394-53 | Target: CP054 | UniProt: Q6UWD8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12394-53 | Target: CP054 | UniProt: Q6UWD8 | TargetFullName: Transmembrane protein C16orf54 | Organisim: human | Apparent_Kd_M: 5.331602E-11
Real
Aptamer SeqId: 12395-86 | Target: SYDM | UniProt: Q6PI48
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12395-86 | Target: SYDM | UniProt: Q6PI48 | TargetFullName: Aspartate--tRNA ligase; mitochondrial | Organisim: human | Apparent_Kd_M: 1.14468E-12
Real
Aptamer SeqId: 12396-19 | Target: HIBCH | UniProt: Q6NVY1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12396-19 | Target: HIBCH | UniProt: Q6NVY1 | TargetFullName: 3-hydroxyisobutyryl-CoA hydrolase; mitochondrial | Organisim: human | Apparent_Kd_M: 3.184377E-12
Real
Aptamer SeqId: 12398-15 | Target: PAX4 | UniProt: O43316
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12398-15 | Target: PAX4 | UniProt: O43316 | TargetFullName: Paired box protein Pax-4 | Organisim: human | Apparent_Kd_M: 7.158009E-12
Real
Aptamer SeqId: 12399-194 | Target: CCD50 | UniProt: Q8IVM0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12399-194 | Target: CCD50 | UniProt: Q8IVM0 | TargetFullName: Coiled-coil domain-containing protein 50 | Organisim: human | Apparent_Kd_M: 3.570673E-11
Real
Aptamer SeqId: 12400-25 | Target: UBE2T | UniProt: Q9NPD8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12400-25 | Target: UBE2T | UniProt: Q9NPD8 | TargetFullName: Ubiquitin-conjugating enzyme E2 T | Organisim: human | Apparent_Kd_M: 1.005069E-11
Real
Aptamer SeqId: 12401-3 | Target: STALP | UniProt: Q96FJ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12401-3 | Target: STALP | UniProt: Q96FJ0 | TargetFullName: AMSH-like protease | Organisim: human | Apparent_Kd_M: 1.202619E-12
Real
Aptamer SeqId: 12403-30 | Target: RB39B | UniProt: Q96DA2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12403-30 | Target: RB39B | UniProt: Q96DA2 | TargetFullName: Ras-related protein Rab-39B | Organisim: human | Apparent_Kd_M: 1.69271E-11
Real
Aptamer SeqId: 12406-119 | Target: ARHI | UniProt: O95661
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12406-119 | Target: ARHI | UniProt: O95661 | TargetFullName: GTP-binding protein Di-Ras3 | Organisim: human | Apparent_Kd_M: 2.292574E-11
Real
Aptamer SeqId: 12408-333 | Target: RB22A | UniProt: Q9UL26
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12408-333 | Target: RB22A | UniProt: Q9UL26 | TargetFullName: Ras-related protein Rab-22A | Organisim: human | Apparent_Kd_M: 1.155068E-10
Real
Aptamer SeqId: 12409-90 | Target: RAB7B | UniProt: Q96AH8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12409-90 | Target: RAB7B | UniProt: Q96AH8 | TargetFullName: Ras-related protein Rab-7b | Organisim: human | Apparent_Kd_M: 5.217415E-12
Real
Aptamer SeqId: 12411-60 | Target: MAX | UniProt: P61244
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12411-60 | Target: MAX | UniProt: P61244 | TargetFullName: Protein max | Organisim: human | Apparent_Kd_M: 4.30455E-12
Real
Aptamer SeqId: 12415-122 | Target: EDF1 | UniProt: O60869
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12415-122 | Target: EDF1 | UniProt: O60869 | TargetFullName: Endothelial differentiation-related factor 1 | Organisim: human | Apparent_Kd_M: 1.7442E-11
Real
Aptamer SeqId: 12417-46 | Target: TPRKB | UniProt: Q9Y3C4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12417-46 | Target: TPRKB | UniProt: Q9Y3C4 | TargetFullName: EKC/KEOPS complex subunit TPRKB | Organisim: human | Apparent_Kd_M: 5.677964E-11
Real
Aptamer SeqId: 12420-10 | Target: GPD1L | UniProt: Q8N335
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12420-10 | Target: GPD1L | UniProt: Q8N335 | TargetFullName: Glycerol-3-phosphate dehydrogenase 1-like protein | Organisim: human | Apparent_Kd_M: 4.033287E-11
Real
Aptamer SeqId: 12422-143 | Target: LX15B | UniProt: O15296
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12422-143 | Target: LX15B | UniProt: O15296 | TargetFullName: Arachidonate 15-lipoxygenase B | Organisim: human | Apparent_Kd_M: 3.190444E-11
Real
Aptamer SeqId: 12423-38 | Target: A1CF | UniProt: Q9NQ94
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12423-38 | Target: A1CF | UniProt: Q9NQ94 | TargetFullName: APOBEC1 complementation factor | Organisim: human | Apparent_Kd_M: 2.13E-10
Real
Aptamer SeqId: 12424-107 | Target: THYN1 | UniProt: Q9P016
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12424-107 | Target: THYN1 | UniProt: Q9P016 | TargetFullName: Thymocyte nuclear protein 1 | Organisim: human | Apparent_Kd_M: 2.898899E-12
Real
Aptamer SeqId: 12425-104 | Target: ARF6 | UniProt: P62330
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12425-104 | Target: ARF6 | UniProt: P62330 | TargetFullName: ADP-ribosylation factor 6 | Organisim: human | Apparent_Kd_M: 7.460557E-11
Real
Aptamer SeqId: 12426-19 | Target: MOL1B | UniProt: Q9H8S9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12426-19 | Target: MOL1B | UniProt: Q9H8S9 | TargetFullName: MOB kinase activator 1A | Organisim: human | Apparent_Kd_M: 6.276468E-11
Real
Aptamer SeqId: 12427-8 | Target: MPIP2 | UniProt: P30305
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12427-8 | Target: MPIP2 | UniProt: P30305 | TargetFullName: M-phase inducer phosphatase 2 | Organisim: human | Apparent_Kd_M: 1.258088E-10
Real
Aptamer SeqId: 12428-2 | Target: LYPL1 | UniProt: Q5VWZ2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12428-2 | Target: LYPL1 | UniProt: Q5VWZ2 | TargetFullName: Lysophospholipase-like protein 1 | Organisim: human | Apparent_Kd_M: 2.485231E-10
Real
Aptamer SeqId: 12430-78 | Target: PAIP1 | UniProt: Q9H074
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12430-78 | Target: PAIP1 | UniProt: Q9H074 | TargetFullName: Polyadenylate-binding protein-interacting protein 1 | Organisim: human | Apparent_Kd_M: 1.900245E-10
Real
Aptamer SeqId: 12431-13 | Target: PELO | UniProt: Q9BRX2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12431-13 | Target: PELO | UniProt: Q9BRX2 | TargetFullName: Protein pelota homolog | Organisim: human | Apparent_Kd_M: 9.636296E-12
Real
Aptamer SeqId: 12432-23 | Target: CYBP | UniProt: Q9HB71
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12432-23 | Target: CYBP | UniProt: Q9HB71 | TargetFullName: Calcyclin-binding protein | Organisim: human | Apparent_Kd_M: 3.600995E-12
Real
Aptamer SeqId: 12433-8 | Target: ARL11 | UniProt: Q969Q4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12433-8 | Target: ARL11 | UniProt: Q969Q4 | TargetFullName: ADP-ribosylation factor-like protein 11 | Organisim: human | Apparent_Kd_M: 5.559117E-11
Real
Aptamer SeqId: 12434-25 | Target: K0174 | UniProt: P53990
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12434-25 | Target: K0174 | UniProt: P53990 | TargetFullName: IST1 homolog | Organisim: human | Apparent_Kd_M: 8.48345E-12
Real
Aptamer SeqId: 12436-84 | Target: GST omega-1 | UniProt: P78417
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12436-84 | Target: GST omega-1 | UniProt: P78417 | TargetFullName: Glutathione S-transferase omega-1 | Organisim: human | Apparent_Kd_M: 5.070662E-12
Real
Aptamer SeqId: 12437-18 | Target: ULK3 | UniProt: Q6PHR2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12437-18 | Target: ULK3 | UniProt: Q6PHR2 | TargetFullName: Serine/threonine-protein kinase ULK3 | Organisim: human | Apparent_Kd_M: 1.856171E-11
Real
Aptamer SeqId: 12438-127 | Target: 3MG | UniProt: P29372
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12438-127 | Target: 3MG | UniProt: P29372 | TargetFullName: DNA-3-methyladenine glycosylase | Organisim: human | Apparent_Kd_M: 7.565242E-12
Real
Aptamer SeqId: 12439-67 | Target: ISGF3 | UniProt: Q00978
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12439-67 | Target: ISGF3 | UniProt: Q00978 | TargetFullName: Interferon regulatory factor 9 | Organisim: human | Apparent_Kd_M: 2.333164E-11
Real
Aptamer SeqId: 12442-4 | Target: RHOD | UniProt: O00212
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12442-4 | Target: RHOD | UniProt: O00212 | TargetFullName: Rho-related GTP-binding protein RhoD | Organisim: human | Apparent_Kd_M: 1.938291E-11
Real
Aptamer SeqId: 12444-39 | Target: NR5A2 | UniProt: O00482
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12444-39 | Target: NR5A2 | UniProt: O00482 | TargetFullName: Nuclear receptor subfamily 5 group A member 2 | Organisim: human | Apparent_Kd_M: 1.383146E-10
Real
Aptamer SeqId: 12445-50 | Target: ANR27 | UniProt: Q96NW4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12445-50 | Target: ANR27 | UniProt: Q96NW4 | TargetFullName: Ankyrin repeat domain-containing protein 27 | Organisim: human | Apparent_Kd_M: 6.790518E-12
Real
Aptamer SeqId: 12449-16 | Target: PPIH | UniProt: O43447
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12449-16 | Target: PPIH | UniProt: O43447 | TargetFullName: Peptidyl-prolyl cis-trans isomerase H | Organisim: human | Apparent_Kd_M: 3.102887E-11
Real
Aptamer SeqId: 12450-42 | Target: PMVK | UniProt: Q15126
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12450-42 | Target: PMVK | UniProt: Q15126 | TargetFullName: Phosphomevalonate kinase | Organisim: human | Apparent_Kd_M: 2.758734E-11
Real
Aptamer SeqId: 12451-62 | Target: BACH1 | UniProt: O14867
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12451-62 | Target: BACH1 | UniProt: O14867 | TargetFullName: Transcription regulator protein BACH1 | Organisim: human | Apparent_Kd_M: 1.196644E-10
Real
Aptamer SeqId: 12452-32 | Target: SV422 | UniProt: Q86Y97
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12452-32 | Target: SV422 | UniProt: Q86Y97 | TargetFullName: Histone-lysine N-methyltransferase SUV420H2 | Organisim: human | Apparent_Kd_M: 1.510694E-11
Real
Aptamer SeqId: 12453-161 | Target: NXF1 | UniProt: Q9UBU9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12453-161 | Target: NXF1 | UniProt: Q9UBU9 | TargetFullName: Nuclear RNA export factor 1 | Organisim: human | Apparent_Kd_M: 2.260108E-11
Real
Aptamer SeqId: 12454-105 | Target: NTM1A | UniProt: Q9BV86
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12454-105 | Target: NTM1A | UniProt: Q9BV86 | TargetFullName: N-terminal Xaa-Pro-Lys N-methyltransferase 1 | Organisim: human | Apparent_Kd_M: 1.394544E-11
Real
Aptamer SeqId: 12455-48 | Target: MYNN | UniProt: Q9NPC7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12455-48 | Target: MYNN | UniProt: Q9NPC7 | TargetFullName: Myoneurin | Organisim: human | Apparent_Kd_M: 8.305494E-11
Real
Aptamer SeqId: 12456-5 | Target: F263 | UniProt: Q16875
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12456-5 | Target: F263 | UniProt: Q16875 | TargetFullName: 6-phosphofructo-2-kinase/fructose-2;6-bisphosphatase 3 | Organisim: human | Apparent_Kd_M: 4.275194E-11
Real
Aptamer SeqId: 12457-10 | Target: MTND | UniProt: Q9BV57
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12457-10 | Target: MTND | UniProt: Q9BV57 | TargetFullName: 1;2-dihydroxy-3-keto-5-methylthiopentene dioxygenase | Organisim: human | Apparent_Kd_M: 9.917517E-11
Real
Aptamer SeqId: 12458-79 | Target: CHP1 | UniProt: Q99653
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12458-79 | Target: CHP1 | UniProt: Q99653 | TargetFullName: Calcineurin B homologous protein 1 | Organisim: human | Apparent_Kd_M: 1.617079E-11
Real
Aptamer SeqId: 12459-13 | Target: PKHA1 | UniProt: Q9HB21
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12459-13 | Target: PKHA1 | UniProt: Q9HB21 | TargetFullName: Pleckstrin homology domain-containing family A member 1 | Organisim: human | Apparent_Kd_M: 4.520747E-12
Real
Aptamer SeqId: 12460-18 | Target: PSA7 | UniProt: O14818
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12460-18 | Target: PSA7 | UniProt: O14818 | TargetFullName: Proteasome subunit alpha type-7 | Organisim: human | Apparent_Kd_M: 7.258758E-12
Real
Aptamer SeqId: 12461-8 | Target: SIRT5 | UniProt: Q9NXA8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12461-8 | Target: SIRT5 | UniProt: Q9NXA8 | TargetFullName: NAD-dependent protein deacylase sirtuin-5; mitochondrial | Organisim: human | Apparent_Kd_M: 1.196735E-10
Real
Aptamer SeqId: 12462-20 | Target: SETMR | UniProt: Q53H47
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12462-20 | Target: SETMR | UniProt: Q53H47 | TargetFullName: Histone-lysine N-methyltransferase SETMAR | Organisim: human | Apparent_Kd_M: 1.647694E-12
Real
Aptamer SeqId: 12463-7 | Target: KLH13 | UniProt: Q9P2N7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12463-7 | Target: KLH13 | UniProt: Q9P2N7 | TargetFullName: Kelch-like protein 13 | Organisim: human | Apparent_Kd_M: 2.025991E-11
Real
Aptamer SeqId: 12466-7 | Target: ROA1 | UniProt: P09651
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12466-7 | Target: ROA1 | UniProt: P09651 | TargetFullName: Heterogeneous nuclear ribonucleoprotein A1 | Organisim: human | Apparent_Kd_M: 2.743758E-12
Real
Aptamer SeqId: 12469-19 | Target: MARE1 | UniProt: Q15691
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12469-19 | Target: MARE1 | UniProt: Q15691 | TargetFullName: Microtubule-associated protein RP/EB family member 1 | Organisim: human | Apparent_Kd_M: 8.979129E-13
Real
Aptamer SeqId: 12471-47 | Target: STAU1 | UniProt: O95793
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12471-47 | Target: STAU1 | UniProt: O95793 | TargetFullName: Double-stranded RNA-binding protein Staufen homolog 1 | Organisim: human | Apparent_Kd_M: 2.987069E-12
Real
Aptamer SeqId: 12473-48 | Target: KCTD5 | UniProt: Q9NXV2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12473-48 | Target: KCTD5 | UniProt: Q9NXV2 | TargetFullName: BTB/POZ domain-containing protein KCTD5 | Organisim: human | Apparent_Kd_M: 1.102293E-10
Real
Aptamer SeqId: 12475-48 | Target: CLIC5 | UniProt: Q9NZA1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12475-48 | Target: CLIC5 | UniProt: Q9NZA1 | TargetFullName: Chloride intracellular channel protein 5 | Organisim: human | Apparent_Kd_M: 4.279657E-13
Real
Aptamer SeqId: 12476-50 | Target: TIGAR | UniProt: Q9NQ88
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12476-50 | Target: TIGAR | UniProt: Q9NQ88 | TargetFullName: Fructose-2;6-bisphosphatase TIGAR | Organisim: human | Apparent_Kd_M: 1.031891E-11
Real
Aptamer SeqId: 12477-42 | Target: TSN | UniProt: Q15631
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12477-42 | Target: TSN | UniProt: Q15631 | TargetFullName: Translin | Organisim: human | Apparent_Kd_M: 2.780946E-11
Real
Aptamer SeqId: 12478-15 | Target: RL30 | UniProt: P62888
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12478-15 | Target: RL30 | UniProt: P62888 | TargetFullName: 60S ribosomal protein L30 | Organisim: human | Apparent_Kd_M: 2.16501E-11
Real
Aptamer SeqId: 12479-50 | Target: KAP1 | UniProt: P31321
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12479-50 | Target: KAP1 | UniProt: P31321 | TargetFullName: cAMP-dependent protein kinase type I-beta regulatory subunit | Organisim: human | Apparent_Kd_M: 2.24592E-11
Real
Aptamer SeqId: 12480-9 | Target: OTUD5 | UniProt: Q96G74
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12480-9 | Target: OTUD5 | UniProt: Q96G74 | TargetFullName: OTU domain-containing protein 5 | Organisim: human | Apparent_Kd_M: 1.289452E-10
Real
Aptamer SeqId: 12482-5 | Target: BPTF | UniProt: Q12830
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12482-5 | Target: BPTF | UniProt: Q12830 | TargetFullName: Nucleosome-remodeling factor subunit BPTF | Organisim: human | Apparent_Kd_M: 5.780334E-11
Real
Aptamer SeqId: 12483-62 | Target: RORB | UniProt: Q92753
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12483-62 | Target: RORB | UniProt: Q92753 | TargetFullName: Nuclear receptor ROR-beta | Organisim: human | Apparent_Kd_M: 4.435893E-11
Real
Aptamer SeqId: 12484-67 | Target: PIPNB | UniProt: P48739
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12484-67 | Target: PIPNB | UniProt: P48739 | TargetFullName: Phosphatidylinositol transfer protein beta isoform | Organisim: human | Apparent_Kd_M: 2.261349E-11
Real
Aptamer SeqId: 12486-8 | Target: GLRX2 | UniProt: Q9NS18
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12486-8 | Target: GLRX2 | UniProt: Q9NS18 | TargetFullName: Glutaredoxin-2; mitochondrial | Organisim: human | Apparent_Kd_M: 5.525319E-12
Real
Aptamer SeqId: 12488-9 | Target: MCTS1 | UniProt: Q9ULC4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12488-9 | Target: MCTS1 | UniProt: Q9ULC4 | TargetFullName: Malignant T-cell-amplified sequence 1 | Organisim: human | Apparent_Kd_M: 6.614786E-11
Real
Aptamer SeqId: 12490-92 | Target: LTOR3 | UniProt: Q9UHA4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12490-92 | Target: LTOR3 | UniProt: Q9UHA4 | TargetFullName: Ragulator complex protein LAMTOR3 | Organisim: human | Apparent_Kd_M: 2.274545E-10
Real
Aptamer SeqId: 12493-42 | Target: OTUB2 | UniProt: Q96DC9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12493-42 | Target: OTUB2 | UniProt: Q96DC9 | TargetFullName: Ubiquitin thioesterase OTUB2 | Organisim: human | Apparent_Kd_M: 1.1591E-11
Real
Aptamer SeqId: 12494-99 | Target: GBRL2 | UniProt: P60520
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12494-99 | Target: GBRL2 | UniProt: P60520 | TargetFullName: Gamma-aminobutyric acid receptor-associated protein-like 2 | Organisim: human | Apparent_Kd_M: 1.340299E-12
Real
Aptamer SeqId: 12497-29 | Target: SDOS | UniProt: Q9BRJ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12497-29 | Target: SDOS | UniProt: Q9BRJ7 | TargetFullName: Tudor-interacting repair regulator protein | Organisim: human | Apparent_Kd_M: 4.067927E-12
Real
Aptamer SeqId: 12498-12 | Target: TX1B3 | UniProt: O14907
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12498-12 | Target: TX1B3 | UniProt: O14907 | TargetFullName: Tax1-binding protein 3 | Organisim: human | Apparent_Kd_M: 2.687606E-11
Real
Aptamer SeqId: 12499-108 | Target: SH3G2 | UniProt: Q99962
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12499-108 | Target: SH3G2 | UniProt: Q99962 | TargetFullName: Endophilin-A1 | Organisim: human | Apparent_Kd_M: 1.141512E-11
Real
Aptamer SeqId: 12500-88 | Target: SAE2 | UniProt: Q9UBT2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12500-88 | Target: SAE2 | UniProt: Q9UBT2 | TargetFullName: SUMO-activating enzyme subunit 2 | Organisim: human | Apparent_Kd_M: 2.007443E-11
Real
Aptamer SeqId: 12501-10 | Target: TBCA | UniProt: O75347
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12501-10 | Target: TBCA | UniProt: O75347 | TargetFullName: Tubulin-specific chaperone A | Organisim: human | Apparent_Kd_M: 1.568968E-11
Real
Aptamer SeqId: 12503-5 | Target: SPR1 | UniProt: Q15743
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12503-5 | Target: SPR1 | UniProt: Q15743 | TargetFullName: Ovarian cancer G-protein coupled receptor 1 | Organisim: human | Apparent_Kd_M: 5.822689E-11
Real
Aptamer SeqId: 12504-26 | Target: LMOD1 | UniProt: P29536
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12504-26 | Target: LMOD1 | UniProt: P29536 | TargetFullName: Leiomodin-1 | Organisim: human | Apparent_Kd_M: 4.278385E-12
Real
Aptamer SeqId: 12507-16 | Target: IP3KC | UniProt: Q96DU7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12507-16 | Target: IP3KC | UniProt: Q96DU7 | TargetFullName: Inositol-trisphosphate 3-kinase C | Organisim: human | Apparent_Kd_M: 1.041991E-10
Real
Aptamer SeqId: 12508-9 | Target: CHMP3 | UniProt: Q9Y3E7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12508-9 | Target: CHMP3 | UniProt: Q9Y3E7 | TargetFullName: Charged multivesicular body protein 3 | Organisim: human | Apparent_Kd_M: 3.895319E-12
Real
Aptamer SeqId: 12509-115 | Target: COMD1 | UniProt: Q8N668
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12509-115 | Target: COMD1 | UniProt: Q8N668 | TargetFullName: COMM domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 2.723342E-11
Real
Aptamer SeqId: 12510-3 | Target: STAP1 | UniProt: Q9ULZ2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12510-3 | Target: STAP1 | UniProt: Q9ULZ2 | TargetFullName: Signal-transducing adaptor protein 1 | Organisim: human | Apparent_Kd_M: 4.245091E-11
Real
Aptamer SeqId: 12511-83 | Target: S41A2 | UniProt: Q96JW4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12511-83 | Target: S41A2 | UniProt: Q96JW4 | TargetFullName: Solute carrier family 41 member 2 | Organisim: human | Apparent_Kd_M: 1.497555E-11
Real
Aptamer SeqId: 12513-8 | Target: GLTP | UniProt: Q9NZD2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12513-8 | Target: GLTP | UniProt: Q9NZD2 | TargetFullName: Glycolipid transfer protein | Organisim: human | Apparent_Kd_M: 4.574007E-12
Real
Aptamer SeqId: 12514-16 | Target: METTL1 | UniProt: Q9UBP6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12514-16 | Target: METTL1 | UniProt: Q9UBP6 | TargetFullName: tRNA (guanine-N(7)-)-methyltransferase | Organisim: human | Apparent_Kd_M: 3.690007E-12
Real
Aptamer SeqId: 12515-45 | Target: UCK2 | UniProt: Q9BZX2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12515-45 | Target: UCK2 | UniProt: Q9BZX2 | TargetFullName: Uridine-cytidine kinase 2 | Organisim: human | Apparent_Kd_M: 2.034347E-11
Real
Aptamer SeqId: 12516-13 | Target: TEAD4 | UniProt: Q15561
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12516-13 | Target: TEAD4 | UniProt: Q15561 | TargetFullName: Transcriptional enhancer factor TEF-3 | Organisim: human | Apparent_Kd_M: 3.556776E-12
Real
Aptamer SeqId: 12517-52 | Target: TFAR19 | UniProt: O14737
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12517-52 | Target: TFAR19 | UniProt: O14737 | TargetFullName: Programmed cell death protein 5 | Organisim: human | Apparent_Kd_M: 2.141943E-11
Real
Aptamer SeqId: 12518-289 | Target: PB1 | UniProt: Q86U86
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12518-289 | Target: PB1 | UniProt: Q86U86 | TargetFullName: Protein polybromo-1 | Organisim: human | Apparent_Kd_M: 2.496419E-12
Real
Aptamer SeqId: 12521-3 | Target: CDN2C | UniProt: P42773
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12521-3 | Target: CDN2C | UniProt: P42773 | TargetFullName: Cyclin-dependent kinase 4 inhibitor C | Organisim: human | Apparent_Kd_M: 3.082374E-10
Real
Aptamer SeqId: 12522-6 | Target: RD23B | UniProt: P54727
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12522-6 | Target: RD23B | UniProt: P54727 | TargetFullName: UV excision repair protein RAD23 homolog B | Organisim: human | Apparent_Kd_M: 7.914259E-12
Real
Aptamer SeqId: 12524-18 | Target: SAT2 | UniProt: Q96F10
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12524-18 | Target: SAT2 | UniProt: Q96F10 | TargetFullName: Diamine acetyltransferase 2 | Organisim: human | Apparent_Kd_M: 1.161003E-12
Real
Aptamer SeqId: 12527-50 | Target: THA | UniProt: P10827
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12527-50 | Target: THA | UniProt: P10827 | TargetFullName: Thyroid hormone receptor alpha | Organisim: human | Apparent_Kd_M: 2.065385E-10
Real
Aptamer SeqId: 12528-40 | Target: WRIP1 | UniProt: Q96S55
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12528-40 | Target: WRIP1 | UniProt: Q96S55 | TargetFullName: ATPase WRNIP1 | Organisim: human | Apparent_Kd_M: 1.411507E-12
Real
Aptamer SeqId: 12529-32 | Target: FKBP6 | UniProt: O75344
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12529-32 | Target: FKBP6 | UniProt: O75344 | TargetFullName: Inactive peptidyl-prolyl cis-trans isomerase FKBP6 | Organisim: human | Apparent_Kd_M: 3.440024E-11
Real
Aptamer SeqId: 12530-14 | Target: CKS-1 | UniProt: P61024
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12530-14 | Target: CKS-1 | UniProt: P61024 | TargetFullName: Cyclin-dependent kinases regulatory subunit 1 | Organisim: human | Apparent_Kd_M: 3.036649E-12
Real
Aptamer SeqId: 12531-5 | Target: ERVV1 | UniProt: B6SEH8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12531-5 | Target: ERVV1 | UniProt: B6SEH8 | TargetFullName: Endogenous retrovirus group V member 1 Env polyprotein | Organisim: human | Apparent_Kd_M: 2.998967E-11
Real
Aptamer SeqId: 12532-28 | Target: UB2R1 | UniProt: P49427
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12532-28 | Target: UB2R1 | UniProt: P49427 | TargetFullName: Ubiquitin-conjugating enzyme E2 R1 | Organisim: human | Apparent_Kd_M: 2.274402E-11
Real
Aptamer SeqId: 12533-135 | Target: CYH2 | UniProt: Q99418
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12533-135 | Target: CYH2 | UniProt: Q99418 | TargetFullName: Cytohesin-2 | Organisim: human | Apparent_Kd_M: 5.342089E-12
Real
Aptamer SeqId: 12534-10 | Target: CACO2 | UniProt: Q13137
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12534-10 | Target: CACO2 | UniProt: Q13137 | TargetFullName: Calcium-binding and coiled-coil domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 1.128326E-12
Real
Aptamer SeqId: 12535-2 | Target: XRCC1 | UniProt: P18887
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12535-2 | Target: XRCC1 | UniProt: P18887 | TargetFullName: DNA repair protein XRCC1 | Organisim: human | Apparent_Kd_M: 3.137685E-11
Real
Aptamer SeqId: 12536-46 | Target: MTMR6 | UniProt: Q9Y217
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12536-46 | Target: MTMR6 | UniProt: Q9Y217 | TargetFullName: Myotubularin-related protein 6 | Organisim: human | Apparent_Kd_M: 4.394765E-12
Real
Aptamer SeqId: 12537-88 | Target: PURA | UniProt: Q00577
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12537-88 | Target: PURA | UniProt: Q00577 | TargetFullName: Transcriptional activator protein Pur-alpha | Organisim: human | Apparent_Kd_M: 1.382628E-11
Real
Aptamer SeqId: 12538-19 | Target: RGS7 | UniProt: P49802
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12538-19 | Target: RGS7 | UniProt: P49802 | TargetFullName: Regulator of G-protein signaling 7 | Organisim: human | Apparent_Kd_M: 2.662997E-12
Real
Aptamer SeqId: 12540-25 | Target: RHOG | UniProt: P84095
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12540-25 | Target: RHOG | UniProt: P84095 | TargetFullName: Rho-related GTP-binding protein RhoG | Organisim: human | Apparent_Kd_M: 3.791045E-11
Real
Aptamer SeqId: 12543-76 | Target: ZN560 | UniProt: Q96MR9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12543-76 | Target: ZN560 | UniProt: Q96MR9 | TargetFullName: Zinc finger protein 560 | Organisim: human | Apparent_Kd_M: 3.021541E-12
Real
Aptamer SeqId: 12546-1 | Target: SMTN | UniProt: P53814
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12546-1 | Target: SMTN | UniProt: P53814 | TargetFullName: Smoothelin | Organisim: human | Apparent_Kd_M: 4.487986E-12
Real
Aptamer SeqId: 12548-75 | Target: RRAGC | UniProt: Q9HB90
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12548-75 | Target: RRAGC | UniProt: Q9HB90 | TargetFullName: Ras-related GTP-binding protein C | Organisim: human | Apparent_Kd_M: 5.094915E-13
Real
Aptamer SeqId: 12549-33 | Target: PTGD2 | UniProt: O60760
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12549-33 | Target: PTGD2 | UniProt: O60760 | TargetFullName: Hematopoietic prostaglandin D synthase | Organisim: human | Apparent_Kd_M: 1.54E-12
Real
Aptamer SeqId: 12551-3 | Target: ITCH | UniProt: Q96J02
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12551-3 | Target: ITCH | UniProt: Q96J02 | TargetFullName: E3 ubiquitin-protein ligase Itchy homolog | Organisim: human | Apparent_Kd_M: 1.675886E-10
Real
Aptamer SeqId: 12553-5 | Target: VRK1 | UniProt: Q99986
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12553-5 | Target: VRK1 | UniProt: Q99986 | TargetFullName: Serine/threonine-protein kinase VRK1 | Organisim: human | Apparent_Kd_M: 4.77347E-11
Real
Aptamer SeqId: 12554-10 | Target: RA51D | UniProt: O75771
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12554-10 | Target: RA51D | UniProt: O75771 | TargetFullName: DNA repair protein RAD51 homolog 4 | Organisim: human | Apparent_Kd_M: 8.93053E-13
Real
Aptamer SeqId: 12556-7 | Target: UBE2C | UniProt: O00762
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12556-7 | Target: UBE2C | UniProt: O00762 | TargetFullName: Ubiquitin-conjugating enzyme E2 C | Organisim: human | Apparent_Kd_M: 1.160877E-10
Real
Aptamer SeqId: 12557-18 | Target: NOVA1 | UniProt: P51513
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12557-18 | Target: NOVA1 | UniProt: P51513 | TargetFullName: RNA-binding protein Nova-1 | Organisim: human | Apparent_Kd_M: 4.7819E-13
Real
Aptamer SeqId: 12558-3 | Target: UBS3B | UniProt: Q8TF42
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12558-3 | Target: UBS3B | UniProt: Q8TF42 | TargetFullName: Ubiquitin-associated and SH3 domain-containing protein B | Organisim: human | Apparent_Kd_M: 1.25975E-12
Real
Aptamer SeqId: 12560-9 | Target: NT5C | UniProt: Q8TCD5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12560-9 | Target: NT5C | UniProt: Q8TCD5 | TargetFullName: 5'(3')-deoxyribonucleotidase; cytosolic type | Organisim: human | Apparent_Kd_M: 7.559983E-12
Real
Aptamer SeqId: 12562-1 | Target: PKN1 | UniProt: Q16512
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12562-1 | Target: PKN1 | UniProt: Q16512 | TargetFullName: Serine/threonine-protein kinase N1 | Organisim: human | Apparent_Kd_M: 5.227653E-12
Real
Aptamer SeqId: 12563-2 | Target: TFIP8 | UniProt: O95379
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12563-2 | Target: TFIP8 | UniProt: O95379 | TargetFullName: Tumor necrosis factor alpha-induced protein 8 | Organisim: human | Apparent_Kd_M: 8.035078E-12
Real
Aptamer SeqId: 12564-9 | Target: NIP7 | UniProt: Q9Y221
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12564-9 | Target: NIP7 | UniProt: Q9Y221 | TargetFullName: 60S ribosome subunit biogenesis protein NIP7 homolog | Organisim: human | Apparent_Kd_M: 4.802456E-12
Real
Aptamer SeqId: 12568-14 | Target: KEAP1 | UniProt: Q14145
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12568-14 | Target: KEAP1 | UniProt: Q14145 | TargetFullName: Kelch-like ECH-associated protein 1 | Organisim: human | Apparent_Kd_M: 6.786016E-12
Real
Aptamer SeqId: 12569-25 | Target: TCP-1-epsilon | UniProt: P48643
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12569-25 | Target: TCP-1-epsilon | UniProt: P48643 | TargetFullName: T-complex protein 1 subunit epsilon | Organisim: human | Apparent_Kd_M: 8.858026E-12
Real
Aptamer SeqId: 12571-14 | Target: ARL3 | UniProt: P36405
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12571-14 | Target: ARL3 | UniProt: P36405 | TargetFullName: ADP-ribosylation factor-like protein 3 | Organisim: human | Apparent_Kd_M: 2.691809E-11
Real
Aptamer SeqId: 12572-236 | Target: EFS | UniProt: O43281
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12572-236 | Target: EFS | UniProt: O43281 | TargetFullName: Embryonal Fyn-associated substrate | Organisim: human | Apparent_Kd_M: 1.349348E-11
Real
Aptamer SeqId: 12573-80 | Target: TRIM3 | UniProt: O75382
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12573-80 | Target: TRIM3 | UniProt: O75382 | TargetFullName: Tripartite motif-containing protein 3 | Organisim: human | Apparent_Kd_M: 9.259938E-13
Real
Aptamer SeqId: 12574-36 | Target: Endothelin 2 | UniProt: P20800
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12574-36 | Target: Endothelin 2 | UniProt: P20800 | TargetFullName: Endothelin-2 | Organisim: human | Apparent_Kd_M: 1.580506E-11
Real
Aptamer SeqId: 12575-30 | Target: C1TC | UniProt: P11586
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12575-30 | Target: C1TC | UniProt: P11586 | TargetFullName: C-1-tetrahydrofolate synthase; cytoplasmic | Organisim: human | Apparent_Kd_M: 1.92E-12
Real
Aptamer SeqId: 12576-21 | Target: MAGE-3 | UniProt: P43357
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12576-21 | Target: MAGE-3 | UniProt: P43357 | TargetFullName: Melanoma-associated antigen 3 | Organisim: human | Apparent_Kd_M: 1.107127E-11
Real
Aptamer SeqId: 12577-100 | Target: FLAP endonuclease-1 | UniProt: P39748
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12577-100 | Target: FLAP endonuclease-1 | UniProt: P39748 | TargetFullName: Flap endonuclease 1 | Organisim: human | Apparent_Kd_M: 3.330899E-11
Real
Aptamer SeqId: 12578-13 | Target: ARF3 | UniProt: P61204
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12578-13 | Target: ARF3 | UniProt: P61204 | TargetFullName: ADP-ribosylation factor 3 | Organisim: human | Apparent_Kd_M: 1.190505E-12
Real
Aptamer SeqId: 12580-7 | Target: PSB5 | UniProt: P28074
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12580-7 | Target: PSB5 | UniProt: P28074 | TargetFullName: Proteasome subunit beta type-5 | Organisim: human | Apparent_Kd_M: 1.406713E-10
Real
Aptamer SeqId: 12581-39 | Target: IMPA2 | UniProt: O14732
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12581-39 | Target: IMPA2 | UniProt: O14732 | TargetFullName: Inositol monophosphatase 2 | Organisim: human | Apparent_Kd_M: 2.425769E-12
Real
Aptamer SeqId: 12583-77 | Target: ARAF | UniProt: P10398
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12583-77 | Target: ARAF | UniProt: P10398 | TargetFullName: Serine/threonine-protein kinase A-Raf | Organisim: human | Apparent_Kd_M: 5.041812E-12
Real
Aptamer SeqId: 12585-39 | Target: ERCC1 | UniProt: P07992
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12585-39 | Target: ERCC1 | UniProt: P07992 | TargetFullName: DNA excision repair protein ERCC-1 | Organisim: human | Apparent_Kd_M: 2.900142E-11
Real
Aptamer SeqId: 12587-65 | Target: ARL2 | UniProt: P36404
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12587-65 | Target: ARL2 | UniProt: P36404 | TargetFullName: ADP-ribosylation factor-like protein 2 | Organisim: human | Apparent_Kd_M: 1.303963E-10
Real
Aptamer SeqId: 12590-67 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12590-67 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 7.435277E-11
Real
Aptamer SeqId: 12591-27 | Target: Oligophrenin-1 | UniProt: O60890
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12591-27 | Target: Oligophrenin-1 | UniProt: O60890 | TargetFullName: Oligophrenin-1 | Organisim: human | Apparent_Kd_M: 6.091172E-13
Real
Aptamer SeqId: 12593-33 | Target: PDRG1 | UniProt: Q9NUG6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12593-33 | Target: PDRG1 | UniProt: Q9NUG6 | TargetFullName: p53 and DNA damage-regulated protein 1 | Organisim: human | Apparent_Kd_M: 1.329381E-11
Real
Aptamer SeqId: 12594-5 | Target: GRAN | UniProt: P28676
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12594-5 | Target: GRAN | UniProt: P28676 | TargetFullName: Grancalcin | Organisim: human | Apparent_Kd_M: 6.678882E-12
Real
Aptamer SeqId: 12595-11 | Target: TMOD1 | UniProt: P28289
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12595-11 | Target: TMOD1 | UniProt: P28289 | TargetFullName: Tropomodulin-1 | Organisim: human | Apparent_Kd_M: 2.025523E-12
Real
Aptamer SeqId: 12597-68 | Target: Autophagy protein 5 | UniProt: Q9H1Y0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12597-68 | Target: Autophagy protein 5 | UniProt: Q9H1Y0 | TargetFullName: Autophagy protein 5 | Organisim: human | Apparent_Kd_M: 1.048805E-11
Real
Aptamer SeqId: 12599-10 | Target: URP2 | UniProt: Q86UX7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12599-10 | Target: URP2 | UniProt: Q86UX7 | TargetFullName: Fermitin family homolog 3 | Organisim: human | Apparent_Kd_M: 4.161688E-11
Real
Aptamer SeqId: 12603-87 | Target: PABP4 | UniProt: Q13310
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12603-87 | Target: PABP4 | UniProt: Q13310 | TargetFullName: Polyadenylate-binding protein 4 | Organisim: human | Apparent_Kd_M: 3.064232E-12
Real
Aptamer SeqId: 12604-16 | Target: SCMH1 | UniProt: Q96GD3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12604-16 | Target: SCMH1 | UniProt: Q96GD3 | TargetFullName: Polycomb protein SCMH1 | Organisim: human | Apparent_Kd_M: 5.041708E-13
Real
Aptamer SeqId: 12605-1 | Target: Exosome component 3 | UniProt: Q9NQT5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12605-1 | Target: Exosome component 3 | UniProt: Q9NQT5 | TargetFullName: Exosome complex component RRP40 | Organisim: human | Apparent_Kd_M: 9.14872E-12
Real
Aptamer SeqId: 12612-37 | Target: PSB1 | UniProt: P20618
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12612-37 | Target: PSB1 | UniProt: P20618 | TargetFullName: Proteasome subunit beta type-1 | Organisim: human | Apparent_Kd_M: 5.872088E-12
Real
Aptamer SeqId: 12616-45 | Target: NRBP | UniProt: Q9UHY1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12616-45 | Target: NRBP | UniProt: Q9UHY1 | TargetFullName: Nuclear receptor-binding protein | Organisim: human | Apparent_Kd_M: 1.150009E-11
Real
Aptamer SeqId: 12617-2 | Target: STK24 | UniProt: Q9Y6E0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12617-2 | Target: STK24 | UniProt: Q9Y6E0 | TargetFullName: Serine/threonine-protein kinase 24 | Organisim: human | Apparent_Kd_M: 1.45173E-12
Real
Aptamer SeqId: 12618-50 | Target: Aldo-keto reductase 1C1 | UniProt: Q04828
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12618-50 | Target: Aldo-keto reductase 1C1 | UniProt: Q04828 | TargetFullName: Aldo-keto reductase family 1 member C1 | Organisim: human | Apparent_Kd_M: 2.472798E-11
Real
Aptamer SeqId: 12619-14 | Target: Protein phophatase 2Ca | UniProt: P35813
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12619-14 | Target: Protein phophatase 2Ca | UniProt: P35813 | TargetFullName: Protein phosphatase 1A | Organisim: human | Apparent_Kd_M: 8.190032E-11
Real
Aptamer SeqId: 12620-3 | Target: Septin-11 | UniProt: Q9NVA2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12620-3 | Target: Septin-11 | UniProt: Q9NVA2 | TargetFullName: Septin-11 | Organisim: human | Apparent_Kd_M: 1.668901E-11
Real
Aptamer SeqId: 12621-55 | Target: PP2AAA | UniProt: P30153
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12621-55 | Target: PP2AAA | UniProt: P30153 | TargetFullName: Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform | Organisim: human | Apparent_Kd_M: 1.347587E-11
Real
Aptamer SeqId: 12622-96 | Target: ASH1L | UniProt: Q9NR48
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12622-96 | Target: ASH1L | UniProt: Q9NR48 | TargetFullName: Histone-lysine N-methyltransferase ASH1L | Organisim: human | Apparent_Kd_M: 2.011191E-12
Real
Aptamer SeqId: 12623-84 | Target: JARD2 | UniProt: Q92833
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12623-84 | Target: JARD2 | UniProt: Q92833 | TargetFullName: Protein Jumonji | Organisim: human | Apparent_Kd_M: 4.996536E-11
Real
Aptamer SeqId: 12625-138 | Target: KLHL7 | UniProt: Q8IXQ5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12625-138 | Target: KLHL7 | UniProt: Q8IXQ5 | TargetFullName: Kelch-like protein 7 | Organisim: human | Apparent_Kd_M: 1.626664E-11
Real
Aptamer SeqId: 12626-6 | Target: SENP7 | UniProt: Q9BQF6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12626-6 | Target: SENP7 | UniProt: Q9BQF6 | TargetFullName: Sentrin-specific protease 7 | Organisim: human | Apparent_Kd_M: 4.247094E-12
Real
Aptamer SeqId: 12627-97 | Target: ATG7 | UniProt: O95352
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12627-97 | Target: ATG7 | UniProt: O95352 | TargetFullName: Ubiquitin-like modifier-activating enzyme ATG7 | Organisim: human | Apparent_Kd_M: 1.235696E-10
Real
Aptamer SeqId: 12628-31 | Target: LANC2 | UniProt: Q9NS86
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12628-31 | Target: LANC2 | UniProt: Q9NS86 | TargetFullName: LanC-like protein 2 | Organisim: human | Apparent_Kd_M: 2.297732E-12
Real
Aptamer SeqId: 12630-8 | Target: ARFP2 | UniProt: P53365
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12630-8 | Target: ARFP2 | UniProt: P53365 | TargetFullName: Arfaptin-2 | Organisim: human | Apparent_Kd_M: 1.888015E-12
Real
Aptamer SeqId: 12632-14 | Target: ARY1 | UniProt: P18440
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12632-14 | Target: ARY1 | UniProt: P18440 | TargetFullName: Arylamine N-acetyltransferase 1 | Organisim: human | Apparent_Kd_M: 8.013042E-11
Real
Aptamer SeqId: 12633-3 | Target: PTN9 | UniProt: P43378
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12633-3 | Target: PTN9 | UniProt: P43378 | TargetFullName: Tyrosine-protein phosphatase non-receptor type 9 | Organisim: human | Apparent_Kd_M: 7.368138E-12
Real
Aptamer SeqId: 12634-79 | Target: BCAR3 | UniProt: O75815
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12634-79 | Target: BCAR3 | UniProt: O75815 | TargetFullName: Breast cancer anti-estrogen resistance protein 3 | Organisim: human | Apparent_Kd_M: 1.685386E-12
Real
Aptamer SeqId: 12635-9 | Target: TRDMT | UniProt: O14717
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12635-9 | Target: TRDMT | UniProt: O14717 | TargetFullName: tRNA (cytosine(38)-C(5))-methyltransferase | Organisim: human | Apparent_Kd_M: 1.972537E-12
Real
Aptamer SeqId: 12636-113 | Target: SMYD2 | UniProt: Q9NRG4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12636-113 | Target: SMYD2 | UniProt: Q9NRG4 | TargetFullName: N-lysine methyltransferase SMYD2 | Organisim: human | Apparent_Kd_M: 1.212417E-10
Real
Aptamer SeqId: 12637-7 | Target: CACP | UniProt: P43155
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12637-7 | Target: CACP | UniProt: P43155 | TargetFullName: Carnitine O-acetyltransferase | Organisim: human | Apparent_Kd_M: 1.769701E-12
Real
Aptamer SeqId: 12641-3 | Target: I5P2 | UniProt: P32019
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12641-3 | Target: I5P2 | UniProt: P32019 | TargetFullName: Type II inositol 1;4;5-trisphosphate 5-phosphatase | Organisim: human | Apparent_Kd_M: 7.103134E-13
Real
Aptamer SeqId: 12643-4 | Target: ARRB1 | UniProt: P49407
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12643-4 | Target: ARRB1 | UniProt: P49407 | TargetFullName: Beta-arrestin-1 | Organisim: human | Apparent_Kd_M: 4.903937E-12
Real
Aptamer SeqId: 12644-63 | Target: PURA2 | UniProt: P30520
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12644-63 | Target: PURA2 | UniProt: P30520 | TargetFullName: Adenylosuccinate synthetase isozyme 2 | Organisim: human | Apparent_Kd_M: 4.688279E-11
Real
Aptamer SeqId: 12646-2 | Target: RPE | UniProt: Q96AT9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12646-2 | Target: RPE | UniProt: Q96AT9 | TargetFullName: Ribulose-phosphate 3-epimerase | Organisim: human | Apparent_Kd_M: 1.659856E-11
Real
Aptamer SeqId: 12647-52 | Target: SETD2 | UniProt: Q9BYW2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12647-52 | Target: SETD2 | UniProt: Q9BYW2 | TargetFullName: Histone-lysine N-methyltransferase SETD2 | Organisim: human | Apparent_Kd_M: 5.400826E-12
Real
Aptamer SeqId: 12650-43 | Target: GNAI3 | UniProt: P08754
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12650-43 | Target: GNAI3 | UniProt: P08754 | TargetFullName: Guanine nucleotide-binding protein G(k) subunit alpha | Organisim: human | Apparent_Kd_M: 3.989319E-11
Real
Aptamer SeqId: 12651-21 | Target: PDK2 | UniProt: Q15119
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12651-21 | Target: PDK2 | UniProt: Q15119 | TargetFullName: Pyruvate dehydrogenase (acetyl-transferring) kinase isozyme 2; mitochondrial | Organisim: human | Apparent_Kd_M: 8.44694E-11
Real
Aptamer SeqId: 12652-37 | Target: SAHH2 | UniProt: O43865
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12652-37 | Target: SAHH2 | UniProt: O43865 | TargetFullName: Adenosylhomocysteinase 2 | Organisim: human | Apparent_Kd_M: 7.031602E-13
Real
Aptamer SeqId: 12653-13 | Target: CSNK1G2 | UniProt: P78368
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12653-13 | Target: CSNK1G2 | UniProt: P78368 | TargetFullName: Casein kinase I isoform gamma-2 | Organisim: human | Apparent_Kd_M: 5.382137E-12
Real
Aptamer SeqId: 12655-30 | Target: SNAB | UniProt: Q9H115
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12655-30 | Target: SNAB | UniProt: Q9H115 | TargetFullName: Beta-soluble NSF attachment protein | Organisim: human | Apparent_Kd_M: 6.605605E-11
Real
Aptamer SeqId: 12656-1 | Target: KLC1 | UniProt: Q07866
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12656-1 | Target: KLC1 | UniProt: Q07866 | TargetFullName: Kinesin light chain 1 | Organisim: human | Apparent_Kd_M: 5.226167E-13
Real
Aptamer SeqId: 12657-2 | Target: FCL | UniProt: Q13630
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12657-2 | Target: FCL | UniProt: Q13630 | TargetFullName: GDP-L-fucose synthase | Organisim: human | Apparent_Kd_M: 2.092768E-11
Real
Aptamer SeqId: 12658-72 | Target: PANK3 | UniProt: Q9H999
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12658-72 | Target: PANK3 | UniProt: Q9H999 | TargetFullName: Pantothenate kinase 3 | Organisim: human | Apparent_Kd_M: 7.970779E-12
Real
Aptamer SeqId: 12659-13 | Target: GTPB9 | UniProt: Q9NTK5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12659-13 | Target: GTPB9 | UniProt: Q9NTK5 | TargetFullName: Obg-like ATPase 1 | Organisim: human | Apparent_Kd_M: 2.580965E-12
Real
Aptamer SeqId: 12661-44 | Target: GBRL1 | UniProt: Q9H0R8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12661-44 | Target: GBRL1 | UniProt: Q9H0R8 | TargetFullName: Gamma-aminobutyric acid receptor-associated protein-like 1 | Organisim: human | Apparent_Kd_M: 8.205888E-13
Real
Aptamer SeqId: 12662-82 | Target: ECH1 | UniProt: Q13011
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12662-82 | Target: ECH1 | UniProt: Q13011 | TargetFullName: Delta(3;5)-Delta(2;4)-dienoyl-CoA isomerase; mitochondrial | Organisim: human | Apparent_Kd_M: 2.156588E-13
Real
Aptamer SeqId: 12663-1 | Target: THTR | UniProt: Q16762
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12663-1 | Target: THTR | UniProt: Q16762 | TargetFullName: Thiosulfate sulfurtransferase | Organisim: human | Apparent_Kd_M: 9.347957E-12
Real
Aptamer SeqId: 12664-19 | Target: PTN13 | UniProt: Q12923
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12664-19 | Target: PTN13 | UniProt: Q12923 | TargetFullName: Tyrosine-protein phosphatase non-receptor type 13 | Organisim: human | Apparent_Kd_M: 3.723006E-12
Real
Aptamer SeqId: 12665-16 | Target: ILF2 | UniProt: Q12905
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12665-16 | Target: ILF2 | UniProt: Q12905 | TargetFullName: Interleukin enhancer-binding factor 2 | Organisim: human | Apparent_Kd_M: 3.074766E-11
Real
Aptamer SeqId: 12667-2 | Target: GUAD | UniProt: Q9Y2T3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12667-2 | Target: GUAD | UniProt: Q9Y2T3 | TargetFullName: Guanine deaminase | Organisim: human | Apparent_Kd_M: 2.423289E-11
Real
Aptamer SeqId: 12668-7 | Target: VPS4B | UniProt: O75351
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12668-7 | Target: VPS4B | UniProt: O75351 | TargetFullName: Vacuolar protein sorting-associated protein 4B | Organisim: human | Apparent_Kd_M: 1.174434E-10
Real
Aptamer SeqId: 12669-30 | Target: HECW1 | UniProt: Q76N89
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12669-30 | Target: HECW1 | UniProt: Q76N89 | TargetFullName: E3 ubiquitin-protein ligase HECW1 | Organisim: human | Apparent_Kd_M: 6.161533E-12
Real
Aptamer SeqId: 12670-15 | Target: RAD1 | UniProt: O60671
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12670-15 | Target: RAD1 | UniProt: O60671 | TargetFullName: Cell cycle checkpoint protein RAD1 | Organisim: human | Apparent_Kd_M: 1.138265E-11
Real
Aptamer SeqId: 12671-35 | Target: ST1B1 | UniProt: O43704
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12671-35 | Target: ST1B1 | UniProt: O43704 | TargetFullName: Sulfotransferase family cytosolic 1B member 1 | Organisim: human | Apparent_Kd_M: 1.270875E-12
Real
Aptamer SeqId: 12675-14 | Target: SYDC | UniProt: P14868
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12675-14 | Target: SYDC | UniProt: P14868 | TargetFullName: Aspartate--tRNA ligase; cytoplasmic | Organisim: human | Apparent_Kd_M: 3.574687E-13
Real
Aptamer SeqId: 12676-1 | Target: PACN1 | UniProt: Q9BY11
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12676-1 | Target: PACN1 | UniProt: Q9BY11 | TargetFullName: Protein kinase C and casein kinase substrate in neurons protein 1 | Organisim: human | Apparent_Kd_M: 2.467782E-12
Real
Aptamer SeqId: 12677-164 | Target: FLII | UniProt: Q13045
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12677-164 | Target: FLII | UniProt: Q13045 | TargetFullName: Protein flightless-1 homolog | Organisim: human | Apparent_Kd_M: 4.504943E-12
Real
Aptamer SeqId: 12678-66 | Target: SNRPA | UniProt: P09012
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12678-66 | Target: SNRPA | UniProt: P09012 | TargetFullName: U1 small nuclear ribonucleoprotein A | Organisim: human | Apparent_Kd_M: 3.444969E-12
Real
Aptamer SeqId: 12681-63 | Target: UBP21 | UniProt: Q9UK80
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12681-63 | Target: UBP21 | UniProt: Q9UK80 | TargetFullName: Ubiquitin carboxyl-terminal hydrolase 21 | Organisim: human | Apparent_Kd_M: 5.224247E-11
Real
Aptamer SeqId: 12682-5 | Target: KAT3 | UniProt: Q6YP21
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12682-5 | Target: KAT3 | UniProt: Q6YP21 | TargetFullName: Kynurenine--oxoglutarate transaminase 3 | Organisim: human | Apparent_Kd_M: 4.580661E-12
Real
Aptamer SeqId: 12683-156 | Target: DPYL5 | UniProt: Q9BPU6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12683-156 | Target: DPYL5 | UniProt: Q9BPU6 | TargetFullName: Dihydropyrimidinase-related protein 5 | Organisim: human | Apparent_Kd_M: 4.478376E-12
Real
Aptamer SeqId: 12684-5 | Target: ADSV | UniProt: Q9Y6U3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12684-5 | Target: ADSV | UniProt: Q9Y6U3 | TargetFullName: Adseverin | Organisim: human | Apparent_Kd_M: 5.970319E-12
Real
Aptamer SeqId: 12685-57 | Target: HOME2 | UniProt: Q9NSB8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12685-57 | Target: HOME2 | UniProt: Q9NSB8 | TargetFullName: Homer protein homolog 2 | Organisim: human | Apparent_Kd_M: 1.508906E-12
Real
Aptamer SeqId: 12686-15 | Target: THTM | UniProt: P25325
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12686-15 | Target: THTM | UniProt: P25325 | TargetFullName: 3-mercaptopyruvate sulfurtransferase | Organisim: human | Apparent_Kd_M: 4.854884E-11
Real
Aptamer SeqId: 12687-2 | Target: DECR | UniProt: Q16698
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12687-2 | Target: DECR | UniProt: Q16698 | TargetFullName: 2;4-dienoyl-CoA reductase; mitochondrial | Organisim: human | Apparent_Kd_M: 2.744848E-12
Real
Aptamer SeqId: 12688-115 | Target: KS6A6 | UniProt: Q9UK32
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12688-115 | Target: KS6A6 | UniProt: Q9UK32 | TargetFullName: Ribosomal protein S6 kinase alpha-6 | Organisim: human | Apparent_Kd_M: 9.154435E-12
Real
Aptamer SeqId: 12689-56 | Target: ARC1B | UniProt: O15143
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12689-56 | Target: ARC1B | UniProt: O15143 | TargetFullName: Actin-related protein 2/3 complex subunit 1B | Organisim: human | Apparent_Kd_M: 1.048608E-11
Real
Aptamer SeqId: 12690-33 | Target: SEP10 | UniProt: Q9P0V9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12690-33 | Target: SEP10 | UniProt: Q9P0V9 | TargetFullName: Septin-10 | Organisim: human | Apparent_Kd_M: 1.304484E-10
Real
Aptamer SeqId: 12691-44 | Target: GLYM | UniProt: P34897
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12691-44 | Target: GLYM | UniProt: P34897 | TargetFullName: Serine hydroxymethyltransferase; mitochondrial | Organisim: human | Apparent_Kd_M: 4.208966E-12
Real
Aptamer SeqId: 12692-56 | Target: DOT1L | UniProt: Q8TEK3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12692-56 | Target: DOT1L | UniProt: Q8TEK3 | TargetFullName: Histone-lysine N-methyltransferase; H3 lysine-79 specific | Organisim: human | Apparent_Kd_M: 1.694187E-11
Real
Aptamer SeqId: 12693-2 | Target: SH3L1 | UniProt: O75368
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12693-2 | Target: SH3L1 | UniProt: O75368 | TargetFullName: SH3 domain-binding glutamic acid-rich-like protein | Organisim: human | Apparent_Kd_M: 3.387694E-11
Real
Aptamer SeqId: 12694-28 | Target: DIM1 | UniProt: Q9UNQ2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12694-28 | Target: DIM1 | UniProt: Q9UNQ2 | TargetFullName: Probable dimethyladenosine transferase | Organisim: human | Apparent_Kd_M: 5.29781E-12
Real
Aptamer SeqId: 12695-62 | Target: KLH12 | UniProt: Q53G59
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12695-62 | Target: KLH12 | UniProt: Q53G59 | TargetFullName: Kelch-like protein 12 | Organisim: human | Apparent_Kd_M: 4.02378E-12
Real
Aptamer SeqId: 12696-166 | Target: ANM3 | UniProt: O60678
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12696-166 | Target: ANM3 | UniProt: O60678 | TargetFullName: Protein arginine N-methyltransferase 3 | Organisim: human | Apparent_Kd_M: 2.849719E-12
Real
Aptamer SeqId: 12697-30 | Target: PI42A | UniProt: P48426
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12697-30 | Target: PI42A | UniProt: P48426 | TargetFullName: Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Organisim: human | Apparent_Kd_M: 1.116151E-11
Real
Aptamer SeqId: 12698-72 | Target: IMA4 | UniProt: O00629
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12698-72 | Target: IMA4 | UniProt: O00629 | TargetFullName: Importin subunit alpha-3 | Organisim: human | Apparent_Kd_M: 1.259179E-11
Real
Aptamer SeqId: 12699-28 | Target: TCP-1-theta | UniProt: P50990
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12699-28 | Target: TCP-1-theta | UniProt: P50990 | TargetFullName: T-complex protein 1 subunit theta | Organisim: human | Apparent_Kd_M: 3.41935E-12
Real
Aptamer SeqId: 12700-9 | Target: ACLY | UniProt: P53396
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12700-9 | Target: ACLY | UniProt: P53396 | TargetFullName: ATP-citrate synthase | Organisim: human | Apparent_Kd_M: 1.33174E-11
Real
Aptamer SeqId: 12701-1 | Target: EIF1B | UniProt: O60739
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12701-1 | Target: EIF1B | UniProt: O60739 | TargetFullName: Eukaryotic translation initiation factor 1b | Organisim: human | Apparent_Kd_M: 8.649285E-13
Real
Aptamer SeqId: 12702-13 | Target: PELI2 | UniProt: Q9HAT8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12702-13 | Target: PELI2 | UniProt: Q9HAT8 | TargetFullName: E3 ubiquitin-protein ligase pellino homolog 2 | Organisim: human | Apparent_Kd_M: 6.465873E-13
Real
Aptamer SeqId: 12703-6 | Target: NEK7 | UniProt: Q8TDX7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12703-6 | Target: NEK7 | UniProt: Q8TDX7 | TargetFullName: Serine/threonine-protein kinase Nek7 | Organisim: human | Apparent_Kd_M: 1.584063E-12
Real
Aptamer SeqId: 12704-26 | Target: SH2D3 | UniProt: Q8N5H7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12704-26 | Target: SH2D3 | UniProt: Q8N5H7 | TargetFullName: SH2 domain-containing protein 3C | Organisim: human | Apparent_Kd_M: 1.777053E-11
Real
Aptamer SeqId: 12705-9 | Target: HERC1 | UniProt: Q15751
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12705-9 | Target: HERC1 | UniProt: Q15751 | TargetFullName: Probable E3 ubiquitin-protein ligase HERC1 | Organisim: human | Apparent_Kd_M: 8.865585E-13
Real
Aptamer SeqId: 12706-2 | Target: MRCKA | UniProt: Q5VT25
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12706-2 | Target: MRCKA | UniProt: Q5VT25 | TargetFullName: Serine/threonine-protein kinase MRCK alpha | Organisim: human | Apparent_Kd_M: 4.120254E-11
Real
Aptamer SeqId: 12707-26 | Target: DPYL3 | UniProt: Q14195
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12707-26 | Target: DPYL3 | UniProt: Q14195 | TargetFullName: Dihydropyrimidinase-related protein 3 | Organisim: human | Apparent_Kd_M: 2.103954E-11
Real
Aptamer SeqId: 12708-91 | Target: LMBL2 | UniProt: Q969R5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12708-91 | Target: LMBL2 | UniProt: Q969R5 | TargetFullName: Lethal(3)malignant brain tumor-like protein 2 | Organisim: human | Apparent_Kd_M: 2.446667E-11
Real
Aptamer SeqId: 12709-63 | Target: H1X | UniProt: Q92522
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12709-63 | Target: H1X | UniProt: Q92522 | TargetFullName: Histone H1x | Organisim: human | Apparent_Kd_M: 5.807372E-12
Real
Aptamer SeqId: 12711-19 | Target: CXA8 | UniProt: P48165
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12711-19 | Target: CXA8 | UniProt: P48165 | TargetFullName: Gap junction alpha-8 protein | Organisim: human | Apparent_Kd_M: 9.412742E-12
Real
Aptamer SeqId: 12712-9 | Target: HM20A | UniProt: Q9NP66
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12712-9 | Target: HM20A | UniProt: Q9NP66 | TargetFullName: High mobility group protein 20A | Organisim: human | Apparent_Kd_M: 6.957338E-12
Real
Aptamer SeqId: 12713-365 | Target: RGS19 | UniProt: P49795
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12713-365 | Target: RGS19 | UniProt: P49795 | TargetFullName: Regulator of G-protein signaling 19 | Organisim: human | Apparent_Kd_M: 2.636758E-10
Real
Aptamer SeqId: 12714-38 | Target: AP1G2 | UniProt: O75843
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12714-38 | Target: AP1G2 | UniProt: O75843 | TargetFullName: AP-1 complex subunit gamma-like 2 | Organisim: human | Apparent_Kd_M: 8.971671E-13
Real
Aptamer SeqId: 12715-30 | Target: DCP1B | UniProt: Q8IZD4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12715-30 | Target: DCP1B | UniProt: Q8IZD4 | TargetFullName: mRNA-decapping enzyme 1B | Organisim: human | Apparent_Kd_M: 1.598127E-11
Real
Aptamer SeqId: 12716-3 | Target: ZN175 | UniProt: Q9Y473
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12716-3 | Target: ZN175 | UniProt: Q9Y473 | TargetFullName: Zinc finger protein 175 | Organisim: human | Apparent_Kd_M: 7.710597E-11
Real
Aptamer SeqId: 12717-65 | Target: TOX3 | UniProt: O15405
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12717-65 | Target: TOX3 | UniProt: O15405 | TargetFullName: TOX high mobility group box family member 3 | Organisim: human | Apparent_Kd_M: 1.652798E-12
Real
Aptamer SeqId: 12718-43 | Target: PIN4 | UniProt: Q9Y237
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12718-43 | Target: PIN4 | UniProt: Q9Y237 | TargetFullName: Peptidyl-prolyl cis-trans isomerase NIMA-interacting 4 | Organisim: human | Apparent_Kd_M: 2.353233E-12
Real
Aptamer SeqId: 12720-71 | Target: UBQL4 | UniProt: Q9NRR5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12720-71 | Target: UBQL4 | UniProt: Q9NRR5 | TargetFullName: Ubiquilin-4 | Organisim: human | Apparent_Kd_M: 2.299794E-12
Real
Aptamer SeqId: 12721-4 | Target: TAXB1 | UniProt: Q86VP1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12721-4 | Target: TAXB1 | UniProt: Q86VP1 | TargetFullName: Tax1-binding protein 1 | Organisim: human | Apparent_Kd_M: 1.120895E-11
Real
Aptamer SeqId: 12724-81 | Target: CIRBP | UniProt: Q14011
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12724-81 | Target: CIRBP | UniProt: Q14011 | TargetFullName: Cold-inducible RNA-binding protein | Organisim: human | Apparent_Kd_M: 1.292622E-12
Real
Aptamer SeqId: 12726-3 | Target: RFXAP | UniProt: O00287
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12726-3 | Target: RFXAP | UniProt: O00287 | TargetFullName: Regulatory factor X-associated protein | Organisim: human | Apparent_Kd_M: 2.975559E-12
Real
Aptamer SeqId: 12727-7 | Target: FPRP | UniProt: Q9P2B2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12727-7 | Target: FPRP | UniProt: Q9P2B2 | TargetFullName: Prostaglandin F2 receptor negative regulator | Organisim: human | Apparent_Kd_M: 2.02257E-12
Real
Aptamer SeqId: 12729-12 | Target: PSMG3 | UniProt: Q9BT73
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12729-12 | Target: PSMG3 | UniProt: Q9BT73 | TargetFullName: Proteasome assembly chaperone 3 | Organisim: human | Apparent_Kd_M: 8.188086E-11
Real
Aptamer SeqId: 12730-3 | Target: KNTC2 | UniProt: O14777
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12730-3 | Target: KNTC2 | UniProt: O14777 | TargetFullName: Kinetochore protein NDC80 homolog | Organisim: human | Apparent_Kd_M: 1.539582E-11
Real
Aptamer SeqId: 12731-12 | Target: PKHA7 | UniProt: Q6IQ23
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12731-12 | Target: PKHA7 | UniProt: Q6IQ23 | TargetFullName: Pleckstrin homology domain-containing family A member 7 | Organisim: human | Apparent_Kd_M: 4.040386E-12
Real
Aptamer SeqId: 12732-13 | Target: MPP7 | UniProt: Q5T2T1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12732-13 | Target: MPP7 | UniProt: Q5T2T1 | TargetFullName: MAGUK p55 subfamily member 7 | Organisim: human | Apparent_Kd_M: 3.28527E-12
Real
Aptamer SeqId: 12734-112 | Target: KIF22 | UniProt: Q14807
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12734-112 | Target: KIF22 | UniProt: Q14807 | TargetFullName: Kinesin-like protein KIF22 | Organisim: human | Apparent_Kd_M: 5.99282E-12
Real
Aptamer SeqId: 12735-39 | Target: CSDE1 | UniProt: O75534
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12735-39 | Target: CSDE1 | UniProt: O75534 | TargetFullName: Cold shock domain-containing protein E1 | Organisim: human | Apparent_Kd_M: 1.717886E-11
Real
Aptamer SeqId: 12737-12 | Target: PLSI | UniProt: Q14651
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12737-12 | Target: PLSI | UniProt: Q14651 | TargetFullName: Plastin-1 | Organisim: human | Apparent_Kd_M: 3.281388E-12
Real
Aptamer SeqId: 12738-43 | Target: NISCH | UniProt: Q9Y2I1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12738-43 | Target: NISCH | UniProt: Q9Y2I1 | TargetFullName: Nischarin | Organisim: human | Apparent_Kd_M: 1.012285E-11
Real
Aptamer SeqId: 12740-55 | Target: FEV | UniProt: Q99581
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12740-55 | Target: FEV | UniProt: Q99581 | TargetFullName: Protein FEV | Organisim: human | Apparent_Kd_M: 3.443268E-12
Real
Aptamer SeqId: 12742-160 | Target: TMM8B | UniProt: A6NDV4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12742-160 | Target: TMM8B | UniProt: A6NDV4 | TargetFullName: Transmembrane protein 8B | Organisim: human | Apparent_Kd_M: 1.131862E-10
Real
Aptamer SeqId: 12743-18 | Target: BAG5 | UniProt: Q9UL15
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12743-18 | Target: BAG5 | UniProt: Q9UL15 | TargetFullName: BAG family molecular chaperone regulator 5 | Organisim: human | Apparent_Kd_M: 4.961209E-12
Real
Aptamer SeqId: 12746-4 | Target: CYH4 | UniProt: Q9UIA0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12746-4 | Target: CYH4 | UniProt: Q9UIA0 | TargetFullName: Cytohesin-4 | Organisim: human | Apparent_Kd_M: 2.995725E-12
Real
Aptamer SeqId: 12747-89 | Target: RBM3 | UniProt: P98179
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12747-89 | Target: RBM3 | UniProt: P98179 | TargetFullName: RNA-binding protein 3 | Organisim: human | Apparent_Kd_M: 1.353222E-12
Real
Aptamer SeqId: 12748-6 | Target: BRDT | UniProt: Q58F21
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12748-6 | Target: BRDT | UniProt: Q58F21 | TargetFullName: Bromodomain testis-specific protein | Organisim: human | Apparent_Kd_M: 1.091537E-11
Real
Aptamer SeqId: 12750-9 | Target: LFA-1 beta-2 | UniProt: P05107
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12750-9 | Target: LFA-1 beta-2 | UniProt: P05107 | TargetFullName: Integrin beta-2 | Organisim: human | Apparent_Kd_M: 1.320004E-11
Real
Aptamer SeqId: 12751-26 | Target: ZHX1 | UniProt: Q9UKY1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12751-26 | Target: ZHX1 | UniProt: Q9UKY1 | TargetFullName: Zinc fingers and homeoboxes protein 1 | Organisim: human | Apparent_Kd_M: 2.792077E-12
Real
Aptamer SeqId: 12753-6 | Target: APBB2 | UniProt: Q92870
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12753-6 | Target: APBB2 | UniProt: Q92870 | TargetFullName: Amyloid beta A4 precursor protein-binding family B member 2 | Organisim: human | Apparent_Kd_M: 1.613299E-11
Real
Aptamer SeqId: 12754-14 | Target: CSDC2 | UniProt: Q9Y534
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12754-14 | Target: CSDC2 | UniProt: Q9Y534 | TargetFullName: Cold shock domain-containing protein C2 | Organisim: human | Apparent_Kd_M: 5.859546E-12
Real
Aptamer SeqId: 12756-3 | Target: BACH2 | UniProt: Q9BYV9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12756-3 | Target: BACH2 | UniProt: Q9BYV9 | TargetFullName: Transcription regulator protein BACH2 | Organisim: human | Apparent_Kd_M: 2.242859E-11
Real
Aptamer SeqId: 12758-47 | Target: GRID2 | UniProt: O43424
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12758-47 | Target: GRID2 | UniProt: O43424 | TargetFullName: Glutamate receptor ionotropic; delta-2 | Organisim: human | Apparent_Kd_M: 9.892617E-12
Real
Aptamer SeqId: 12759-47 | Target: DRBP76 | UniProt: Q12906
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12759-47 | Target: DRBP76 | UniProt: Q12906 | TargetFullName: Interleukin enhancer-binding factor 3 | Organisim: human | Apparent_Kd_M: 1.462054E-11
Real
Aptamer SeqId: 12760-34 | Target: ZN774 | UniProt: Q6NX45
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12760-34 | Target: ZN774 | UniProt: Q6NX45 | TargetFullName: Zinc finger protein 774 | Organisim: human | Apparent_Kd_M: 7.587316E-12
Real
Aptamer SeqId: 12761-12 | Target: APBB2 | UniProt: Q92870
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12761-12 | Target: APBB2 | UniProt: Q92870 | TargetFullName: Amyloid beta A4 precursor protein-binding family B member 2 | Organisim: human | Apparent_Kd_M: 7.499269E-12
Real
Aptamer SeqId: 12763-69 | Target: ZN334 | UniProt: Q9HCZ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12763-69 | Target: ZN334 | UniProt: Q9HCZ1 | TargetFullName: Zinc finger protein 334 | Organisim: human | Apparent_Kd_M: 1.35417E-11
Real
Aptamer SeqId: 12764-3 | Target: ELMO1 | UniProt: Q92556
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12764-3 | Target: ELMO1 | UniProt: Q92556 | TargetFullName: Engulfment and cell motility protein 1 | Organisim: human | Apparent_Kd_M: 2.659548E-11
Real
Aptamer SeqId: 12766-33 | Target: GP142 | UniProt: Q7Z601
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12766-33 | Target: GP142 | UniProt: Q7Z601 | TargetFullName: Probable G-protein coupled receptor 142 | Organisim: human | Apparent_Kd_M: 4.367729E-11
Real
Aptamer SeqId: 12768-3 | Target: PPR3B | UniProt: Q86XI6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12768-3 | Target: PPR3B | UniProt: Q86XI6 | TargetFullName: Protein phosphatase 1 regulatory subunit 3B | Organisim: human | Apparent_Kd_M: 7.703609E-11
Real
Aptamer SeqId: 12771-19 | Target: ZN180 | UniProt: Q9UJW8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12771-19 | Target: ZN180 | UniProt: Q9UJW8 | TargetFullName: Zinc finger protein 180 | Organisim: human | Apparent_Kd_M: 3.138149E-12
Real
Aptamer SeqId: 12772-8 | Target: NUP98 | UniProt: P52948
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12772-8 | Target: NUP98 | UniProt: P52948 | TargetFullName: Nuclear pore complex protein Nup98-Nup96 | Organisim: human | Apparent_Kd_M: 8.193839E-12
Real
Aptamer SeqId: 12774-12 | Target: HCN1 | UniProt: O60741
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12774-12 | Target: HCN1 | UniProt: O60741 | TargetFullName: Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 | Organisim: human | Apparent_Kd_M: 1.996694E-11
Real
Aptamer SeqId: 12775-6 | Target: HMGB3 | UniProt: O15347
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12775-6 | Target: HMGB3 | UniProt: O15347 | TargetFullName: High mobility group protein B3 | Organisim: human | Apparent_Kd_M: 5.536468E-12
Real
Aptamer SeqId: 12777-11 | Target: SF01 | UniProt: Q15637
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12777-11 | Target: SF01 | UniProt: Q15637 | TargetFullName: Splicing factor 1 | Organisim: human | Apparent_Kd_M: 2.754613E-12
Real
Aptamer SeqId: 12779-30 | Target: PRDM4 | UniProt: Q9UKN5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12779-30 | Target: PRDM4 | UniProt: Q9UKN5 | TargetFullName: PR domain zinc finger protein 4 | Organisim: human | Apparent_Kd_M: 3.143801E-11
Real
Aptamer SeqId: 12781-2 | Target: TRBP2 | UniProt: Q15633
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12781-2 | Target: TRBP2 | UniProt: Q15633 | TargetFullName: RISC-loading complex subunit TARBP2 | Organisim: human | Apparent_Kd_M: 1.170139E-12
Real
Aptamer SeqId: 12783-29 | Target: HNRPM | UniProt: P52272
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12783-29 | Target: HNRPM | UniProt: P52272 | TargetFullName: Heterogeneous nuclear ribonucleoprotein M | Organisim: human | Apparent_Kd_M: 4.612941E-11
Real
Aptamer SeqId: 12784-10 | Target: APBB3 | UniProt: O95704
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12784-10 | Target: APBB3 | UniProt: O95704 | TargetFullName: Amyloid beta A4 precursor protein-binding family B member 3 | Organisim: human | Apparent_Kd_M: 5.061588E-12
Real
Aptamer SeqId: 12785-49 | Target: KAISO | UniProt: Q86T24
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12785-49 | Target: KAISO | UniProt: Q86T24 | TargetFullName: Transcriptional regulator Kaiso | Organisim: human | Apparent_Kd_M: 1.79E-10
Real
Aptamer SeqId: 12786-61 | Target: GDE5 | UniProt: Q9NPB8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12786-61 | Target: GDE5 | UniProt: Q9NPB8 | TargetFullName: Glycerophosphocholine phosphodiesterase GPCPD1 | Organisim: human | Apparent_Kd_M: 4.624408E-12
Real
Aptamer SeqId: 12787-47 | Target: ZN134 | UniProt: P52741
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12787-47 | Target: ZN134 | UniProt: P52741 | TargetFullName: Zinc finger protein 134 | Organisim: human | Apparent_Kd_M: 3.097576E-13
Real
Aptamer SeqId: 12788-6 | Target: SGF29 | UniProt: Q96ES7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12788-6 | Target: SGF29 | UniProt: Q96ES7 | TargetFullName: SAGA-associated factor 29 homolog | Organisim: human | Apparent_Kd_M: 1.301049E-12
Real
Aptamer SeqId: 12790-10 | Target: CCD51 | UniProt: Q96ER9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12790-10 | Target: CCD51 | UniProt: Q96ER9 | TargetFullName: Coiled-coil domain-containing protein 51 | Organisim: human | Apparent_Kd_M: 7.479178E-12
Real
Aptamer SeqId: 12793-4 | Target: PIWL1 | UniProt: Q96J94
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12793-4 | Target: PIWL1 | UniProt: Q96J94 | TargetFullName: Piwi-like protein 1 | Organisim: human | Apparent_Kd_M: 1.135208E-11
Real
Aptamer SeqId: 12794-6 | Target: NALP4 | UniProt: Q96MN2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12794-6 | Target: NALP4 | UniProt: Q96MN2 | TargetFullName: NACHT; LRR and PYD domains-containing protein 4 | Organisim: human | Apparent_Kd_M: 4.845849E-12
Real
Aptamer SeqId: 12795-2 | Target: ZN566 | UniProt: Q969W8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12795-2 | Target: ZN566 | UniProt: Q969W8 | TargetFullName: Zinc finger protein 566 | Organisim: human | Apparent_Kd_M: 2.21143E-11
Real
Aptamer SeqId: 12796-44 | Target: NUDT3 | UniProt: O95989
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12796-44 | Target: NUDT3 | UniProt: O95989 | TargetFullName: Diphosphoinositol polyphosphate phosphohydrolase 1 | Organisim: human | Apparent_Kd_M: 2.593817E-11
Real
Aptamer SeqId: 12798-46 | Target: S4A8 | UniProt: Q2Y0W8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12798-46 | Target: S4A8 | UniProt: Q2Y0W8 | TargetFullName: Electroneutral sodium bicarbonate exchanger 1 | Organisim: human | Apparent_Kd_M: 1.274041E-11
Real
Aptamer SeqId: 12799-65 | Target: DJC27 | UniProt: Q9NZQ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12799-65 | Target: DJC27 | UniProt: Q9NZQ0 | TargetFullName: DnaJ homolog subfamily C member 27 | Organisim: human | Apparent_Kd_M: 5.695413E-12
Real
Aptamer SeqId: 12800-5 | Target: TPPP2 | UniProt: P59282
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12800-5 | Target: TPPP2 | UniProt: P59282 | TargetFullName: Tubulin polymerization-promoting protein family member 2 | Organisim: human | Apparent_Kd_M: 1.446775E-11
Real
Aptamer SeqId: 12801-33 | Target: IRF2 | UniProt: P14316
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12801-33 | Target: IRF2 | UniProt: P14316 | TargetFullName: Interferon regulatory factor 2 | Organisim: human | Apparent_Kd_M: 3.582017E-12
Real
Aptamer SeqId: 12803-9 | Target: ZN329 | UniProt: Q86UD4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12803-9 | Target: ZN329 | UniProt: Q86UD4 | TargetFullName: Zinc finger protein 329 | Organisim: human | Apparent_Kd_M: 1.842478E-11
Real
Aptamer SeqId: 12804-5 | Target: GMEB2 | UniProt: Q9UKD1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12804-5 | Target: GMEB2 | UniProt: Q9UKD1 | TargetFullName: Glucocorticoid modulatory element-binding protein 2 | Organisim: human | Apparent_Kd_M: 3.452202E-13
Real
Aptamer SeqId: 12807-89 | Target: RHG30 | UniProt: Q7Z6I6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12807-89 | Target: RHG30 | UniProt: Q7Z6I6 | TargetFullName: Rho GTPase-activating protein 30 | Organisim: human | Apparent_Kd_M: 3.43313E-11
Real
Aptamer SeqId: 12808-103 | Target: CHSP1 | UniProt: Q9Y2V2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12808-103 | Target: CHSP1 | UniProt: Q9Y2V2 | TargetFullName: Calcium-regulated heat-stable protein 1 | Organisim: human | Apparent_Kd_M: 3.759425E-11
Real
Aptamer SeqId: 12811-55 | Target: ZN415 | UniProt: Q09FC8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12811-55 | Target: ZN415 | UniProt: Q09FC8 | TargetFullName: Zinc finger protein 415 | Organisim: human | Apparent_Kd_M: 4.174193E-11
Real
Aptamer SeqId: 12812-25 | Target: ACYP2 | UniProt: P14621
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12812-25 | Target: ACYP2 | UniProt: P14621 | TargetFullName: Acylphosphatase-2 | Organisim: human | Apparent_Kd_M: 1.246265E-12
Real
Aptamer SeqId: 12813-18 | Target: EHBP1 | UniProt: Q8NDI1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12813-18 | Target: EHBP1 | UniProt: Q8NDI1 | TargetFullName: EH domain-binding protein 1 | Organisim: human | Apparent_Kd_M: 1.144893E-11
Real
Aptamer SeqId: 12814-17 | Target: RBM40 | UniProt: Q96LT9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12814-17 | Target: RBM40 | UniProt: Q96LT9 | TargetFullName: RNA-binding protein 40 | Organisim: human | Apparent_Kd_M: 1.022523E-12
Real
Aptamer SeqId: 12815-9 | Target: SYIC | UniProt: P41252
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12815-9 | Target: SYIC | UniProt: P41252 | TargetFullName: Isoleucine--tRNA ligase; cytoplasmic | Organisim: human | Apparent_Kd_M: 1.315853E-10
Real
Aptamer SeqId: 12817-1 | Target: GEM | UniProt: P55040
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12817-1 | Target: GEM | UniProt: P55040 | TargetFullName: GTP-binding protein GEM | Organisim: human | Apparent_Kd_M: 6.697787E-11
Real
Aptamer SeqId: 12818-159 | Target: UT2 | UniProt: Q15849
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12818-159 | Target: UT2 | UniProt: Q15849 | TargetFullName: Urea transporter 2 | Organisim: human | Apparent_Kd_M: 2.474021E-12
Real
Aptamer SeqId: 12820-1 | Target: GRAP | UniProt: Q13588
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12820-1 | Target: GRAP | UniProt: Q13588 | TargetFullName: GRB2-related adapter protein | Organisim: human | Apparent_Kd_M: 2.194109E-12
Real
Aptamer SeqId: 12821-6 | Target: NAL10 | UniProt: Q86W26
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12821-6 | Target: NAL10 | UniProt: Q86W26 | TargetFullName: NACHT; LRR and PYD domains-containing protein 10 | Organisim: human | Apparent_Kd_M: 1.071854E-12
Real
Aptamer SeqId: 12822-34 | Target: APBB1 | UniProt: O00213
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12822-34 | Target: APBB1 | UniProt: O00213 | TargetFullName: Amyloid beta A4 precursor protein-binding family B member 1 | Organisim: human | Apparent_Kd_M: 2.41E-11
Real
Aptamer SeqId: 12825-18 | Target: DP13A | UniProt: Q9UKG1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12825-18 | Target: DP13A | UniProt: Q9UKG1 | TargetFullName: DCC-interacting protein 13-alpha | Organisim: human | Apparent_Kd_M: 9.857817E-11
Real
Aptamer SeqId: 12826-5 | Target: SC5A5 | UniProt: Q92911
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12826-5 | Target: SC5A5 | UniProt: Q92911 | TargetFullName: Sodium/iodide cotransporter | Organisim: human | Apparent_Kd_M: 4.57399E-11
Real
Aptamer SeqId: 12827-37 | Target: RGS3 | UniProt: P49796
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12827-37 | Target: RGS3 | UniProt: P49796 | TargetFullName: Regulator of G-protein signaling 3 | Organisim: human | Apparent_Kd_M: 5.744717E-12
Real
Aptamer SeqId: 12830-4 | Target: SAP18 | UniProt: O00422
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12830-4 | Target: SAP18 | UniProt: O00422 | TargetFullName: Histone deacetylase complex subunit SAP18 | Organisim: human | Apparent_Kd_M: 5.6517E-12
Real
Aptamer SeqId: 12831-21 | Target: TESC | UniProt: Q96BS2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12831-21 | Target: TESC | UniProt: Q96BS2 | TargetFullName: Calcineurin B homologous protein 3 | Organisim: human | Apparent_Kd_M: 2.035371E-12
Real
Aptamer SeqId: 12832-10 | Target: ASH2L | UniProt: Q9UBL3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12832-10 | Target: ASH2L | UniProt: Q9UBL3 | TargetFullName: Set1/Ash2 histone methyltransferase complex subunit ASH2 | Organisim: human | Apparent_Kd_M: 4.998902E-11
Real
Aptamer SeqId: 12834-3 | Target: KCNF1 | UniProt: Q9H3M0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12834-3 | Target: KCNF1 | UniProt: Q9H3M0 | TargetFullName: Potassium voltage-gated channel subfamily F member 1 | Organisim: human | Apparent_Kd_M: 4.687532E-12
Real
Aptamer SeqId: 12835-101 | Target: PYDC1 | UniProt: Q8WXC3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12835-101 | Target: PYDC1 | UniProt: Q8WXC3 | TargetFullName: Pyrin domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 1.231938E-11
Real
Aptamer SeqId: 12838-28 | Target: DUS15 | UniProt: Q9H1R2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12838-28 | Target: DUS15 | UniProt: Q9H1R2 | TargetFullName: Dual specificity protein phosphatase 15 | Organisim: human | Apparent_Kd_M: 1.529003E-12
Real
Aptamer SeqId: 12842-43 | Target: STX10 | UniProt: O60499
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12842-43 | Target: STX10 | UniProt: O60499 | TargetFullName: Syntaxin-10 | Organisim: human | Apparent_Kd_M: 7.474717E-11
Real
Aptamer SeqId: 12843-6 | Target: ZN410 | UniProt: Q86VK4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12843-6 | Target: ZN410 | UniProt: Q86VK4 | TargetFullName: Zinc finger protein 410 | Organisim: human | Apparent_Kd_M: 1.806972E-12
Real
Aptamer SeqId: 12844-10 | Target: BAG4 | UniProt: O95429
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12844-10 | Target: BAG4 | UniProt: O95429 | TargetFullName: BAG family molecular chaperone regulator 4 | Organisim: human | Apparent_Kd_M: 4.339676E-11
Real
Aptamer SeqId: 12845-18 | Target: SNX17 | UniProt: Q15036
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12845-18 | Target: SNX17 | UniProt: Q15036 | TargetFullName: Sorting nexin-17 | Organisim: human | Apparent_Kd_M: 1.736673E-11
Real
Aptamer SeqId: 12846-3 | Target: FBXL5 | UniProt: Q9UKA1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12846-3 | Target: FBXL5 | UniProt: Q9UKA1 | TargetFullName: F-box/LRR-repeat protein 5 | Organisim: human | Apparent_Kd_M: 4.929149E-12
Real
Aptamer SeqId: 12847-27 | Target: MCE1 | UniProt: O60942
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12847-27 | Target: MCE1 | UniProt: O60942 | TargetFullName: mRNA-capping enzyme | Organisim: human | Apparent_Kd_M: 9.391767E-11
Real
Aptamer SeqId: 12848-9 | Target: ARHG2 | UniProt: Q92974
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12848-9 | Target: ARHG2 | UniProt: Q92974 | TargetFullName: Rho guanine nucleotide exchange factor 2 | Organisim: human | Apparent_Kd_M: 1.090336E-11
Real
Aptamer SeqId: 12849-25 | Target: GSKIP | UniProt: Q9P0R6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12849-25 | Target: GSKIP | UniProt: Q9P0R6 | TargetFullName: GSK3-beta interaction protein | Organisim: human | Apparent_Kd_M: 2.758829E-11
Real
Aptamer SeqId: 12851-5 | Target: DPOLM | UniProt: Q9NP87
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12851-5 | Target: DPOLM | UniProt: Q9NP87 | TargetFullName: DNA-directed DNA/RNA polymerase mu | Organisim: human | Apparent_Kd_M: 8.0856E-13
Real
Aptamer SeqId: 12853-112 | Target: TMOD2 | UniProt: Q9NZR1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12853-112 | Target: TMOD2 | UniProt: Q9NZR1 | TargetFullName: Tropomodulin-2 | Organisim: human | Apparent_Kd_M: 4.433277E-11
Real
Aptamer SeqId: 12854-3 | Target: TEAD3 | UniProt: Q99594
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12854-3 | Target: TEAD3 | UniProt: Q99594 | TargetFullName: Transcriptional enhancer factor TEF-5 | Organisim: human | Apparent_Kd_M: 4.346938E-12
Real
Aptamer SeqId: 12855-16 | Target: CT032 | UniProt: Q9NQ75
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12855-16 | Target: CT032 | UniProt: Q9NQ75 | TargetFullName: Cas scaffolding protein family member 4 | Organisim: human | Apparent_Kd_M: 8.217991E-12
Real
Aptamer SeqId: 12856-14 | Target: TM237 | UniProt: Q96Q45
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12856-14 | Target: TM237 | UniProt: Q96Q45 | TargetFullName: Transmembrane protein 237 | Organisim: human | Apparent_Kd_M: 4.358254E-11
Real
Aptamer SeqId: 12859-33 | Target: PECI | UniProt: O75521
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12859-33 | Target: PECI | UniProt: O75521 | TargetFullName: Enoyl-CoA delta isomerase 2; mitochondrial | Organisim: human | Apparent_Kd_M: 1.945358E-12
Real
Aptamer SeqId: 12860-7 | Target: cAMP-regulated phosphoprotein 21
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12860-7 | Target: cAMP-regulated phosphoprotein 21 | UniProt: Q9UBL0 | TargetFullName: cAMP-regulated phosphoprotein 21 | Organisim: human | Apparent_Kd_M: 7.39799E-13
Real
Aptamer SeqId: 12861-13 | Target: TMOD3 | UniProt: Q9NYL9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12861-13 | Target: TMOD3 | UniProt: Q9NYL9 | TargetFullName: Tropomodulin-3 | Organisim: human | Apparent_Kd_M: 1.641047E-12
Real
Aptamer SeqId: 12862-14 | Target: CASL | UniProt: Q14511
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12862-14 | Target: CASL | UniProt: Q14511 | TargetFullName: Enhancer of filamentation 1 | Organisim: human | Apparent_Kd_M: 2.794254E-10
Real
Aptamer SeqId: 12864-9 | Target: NIPA4 | UniProt: Q0D2K0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12864-9 | Target: NIPA4 | UniProt: Q0D2K0 | TargetFullName: Magnesium transporter NIPA4 | Organisim: human | Apparent_Kd_M: 2.873819E-10
Real
Aptamer SeqId: 12867-40 | Target: DYLT3 | UniProt: P51808
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12867-40 | Target: DYLT3 | UniProt: P51808 | TargetFullName: Dynein light chain Tctex-type 3 | Organisim: human | Apparent_Kd_M: 1.12043E-11
Real
Aptamer SeqId: 12869-68 | Target: DDX6 | UniProt: P26196
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12869-68 | Target: DDX6 | UniProt: P26196 | TargetFullName: Probable ATP-dependent RNA helicase DDX6 | Organisim: human | Apparent_Kd_M: 3.501141E-12
Real
Aptamer SeqId: 12871-10 | Target: TWF1 | UniProt: Q12792
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12871-10 | Target: TWF1 | UniProt: Q12792 | TargetFullName: Twinfilin-1 | Organisim: human | Apparent_Kd_M: 7.016657E-12
Real
Aptamer SeqId: 12872-35 | Target: CNGA2 | UniProt: Q16280
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12872-35 | Target: CNGA2 | UniProt: Q16280 | TargetFullName: Cyclic nucleotide-gated olfactory channel | Organisim: human | Apparent_Kd_M: 4.545657E-12
Real
Aptamer SeqId: 12873-11 | Target: LEUK | UniProt: P16150
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12873-11 | Target: LEUK | UniProt: P16150 | TargetFullName: Leukosialin | Organisim: human | Apparent_Kd_M: 4.668252E-11
Real
Aptamer SeqId: 12875-28 | Target: UBTD2 | UniProt: Q8WUN7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12875-28 | Target: UBTD2 | UniProt: Q8WUN7 | TargetFullName: Ubiquitin domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 4.090894E-12
Real
Aptamer SeqId: 12876-39 | Target: SPEF1 | UniProt: Q9Y4P9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12876-39 | Target: SPEF1 | UniProt: Q9Y4P9 | TargetFullName: Sperm flagellar protein 1 | Organisim: human | Apparent_Kd_M: 2.132333E-11
Real
Aptamer SeqId: 12878-60 | Target: OSB11 | UniProt: Q9BXB4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12878-60 | Target: OSB11 | UniProt: Q9BXB4 | TargetFullName: Oxysterol-binding protein-related protein 11 | Organisim: human | Apparent_Kd_M: 2.118741E-12
Real
Aptamer SeqId: 12879-5 | Target: p107 | UniProt: P28749
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12879-5 | Target: p107 | UniProt: P28749 | TargetFullName: Retinoblastoma-like protein 1 | Organisim: human | Apparent_Kd_M: 1.066657E-11
Real
Aptamer SeqId: 12880-1 | Target: SV2A | UniProt: Q7L0J3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12880-1 | Target: SV2A | UniProt: Q7L0J3 | TargetFullName: Synaptic vesicle glycoprotein 2A | Organisim: human | Apparent_Kd_M: 1.162094E-11
Real
Aptamer SeqId: 12881-17 | Target: RDH16 | UniProt: O75452
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12881-17 | Target: RDH16 | UniProt: O75452 | TargetFullName: Retinol dehydrogenase 16 | Organisim: human | Apparent_Kd_M: 7.56E-12
Real
Aptamer SeqId: 12882-7 | Target: PAR11 | UniProt: Q9NR21
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12882-7 | Target: PAR11 | UniProt: Q9NR21 | TargetFullName: Poly ADP-ribose polymerase 11 | Organisim: human | Apparent_Kd_M: 3.196593E-12
Real
Aptamer SeqId: 12885-42 | Target: NR1D2 | UniProt: Q14995
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12885-42 | Target: NR1D2 | UniProt: Q14995 | TargetFullName: Nuclear receptor subfamily 1 group D member 2 | Organisim: human | Apparent_Kd_M: 3.085646E-12
Real
Aptamer SeqId: 12888-18 | Target: SAP30 | UniProt: O75446
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12888-18 | Target: SAP30 | UniProt: O75446 | TargetFullName: Histone deacetylase complex subunit SAP30 | Organisim: human | Apparent_Kd_M: 2.393728E-11
Real
Aptamer SeqId: 12891-1 | Target: MILK2 | UniProt: Q8IY33
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12891-1 | Target: MILK2 | UniProt: Q8IY33 | TargetFullName: MICAL-like protein 2 | Organisim: human | Apparent_Kd_M: 6.944057E-12
Real
Aptamer SeqId: 12892-10 | Target: SYTL1 | UniProt: Q8IYJ3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12892-10 | Target: SYTL1 | UniProt: Q8IYJ3 | TargetFullName: Synaptotagmin-like protein 1 | Organisim: human | Apparent_Kd_M: 8.376356E-12
Real
Aptamer SeqId: 12893-159 | Target: IP16 | UniProt: Q16666
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12893-159 | Target: IP16 | UniProt: Q16666 | TargetFullName: Gamma-interferon-inducible protein 16 | Organisim: human | Apparent_Kd_M: 1.728224E-12
Real
Aptamer SeqId: 12894-3 | Target: PAXI1 | UniProt: Q6ZW49
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12894-3 | Target: PAXI1 | UniProt: Q6ZW49 | TargetFullName: PAX-interacting protein 1 | Organisim: human | Apparent_Kd_M: 1.108344E-11
Real
Aptamer SeqId: 12895-28 | Target: DGKB | UniProt: Q9Y6T7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12895-28 | Target: DGKB | UniProt: Q9Y6T7 | TargetFullName: Diacylglycerol kinase beta | Organisim: human | Apparent_Kd_M: 6.512693E-12
Real
Aptamer SeqId: 12898-5 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12898-5 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 6.925559E-13
Real
Aptamer SeqId: 12900-29 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12900-29 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.82E-10
Real
Aptamer SeqId: 12904-180 | Target: cubilin | UniProt: O60494
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12904-180 | Target: cubilin | UniProt: O60494 | TargetFullName: cubilin | Organisim: human | Apparent_Kd_M: 6.891791E-11
Real
Aptamer SeqId: 12906-137 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12906-137 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 5.81E-12
Real
Aptamer SeqId: 12912-25 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12912-25 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 4.580893E-12
Real
Aptamer SeqId: 12915-26 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12915-26 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 4.53E-12
Real
Aptamer SeqId: 12921-51 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12921-51 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.79954E-11
Real
Aptamer SeqId: 12923-51 | Target: Keratin 17 | UniProt: Q04695
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12923-51 | Target: Keratin 17 | UniProt: Q04695 | TargetFullName: Keratin; type I cytoskeletal 17 | Organisim: human | Apparent_Kd_M: 2.152548E-11
Real
Aptamer SeqId: 12925-105 | Target: AXIN2 | UniProt: Q9Y2T1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12925-105 | Target: AXIN2 | UniProt: Q9Y2T1 | TargetFullName: Axin-2 | Organisim: human | Apparent_Kd_M: 2.21E-10
Real
Aptamer SeqId: 12931-16 | Target: MCR | UniProt: P08235
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12931-16 | Target: MCR | UniProt: P08235 | TargetFullName: Mineralocorticoid receptor | Organisim: human | Apparent_Kd_M: 8.134084E-11
Real
Aptamer SeqId: 12933-17 | Target: ENOX1 | UniProt: Q8TC92
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12933-17 | Target: ENOX1 | UniProt: Q8TC92 | TargetFullName: Ecto-NOX disulfide-thiol exchanger 1 | Organisim: human | Apparent_Kd_M: 1.121029E-11
Real
Aptamer SeqId: 12934-1 | Target: HERC5 | UniProt: Q9UII4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12934-1 | Target: HERC5 | UniProt: Q9UII4 | TargetFullName: E3 ISG15--protein ligase HERC5 | Organisim: human | Apparent_Kd_M: 2.021865E-11
Real
Aptamer SeqId: 12936-38 | Target: RLBP1 | UniProt: P12271
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12936-38 | Target: RLBP1 | UniProt: P12271 | TargetFullName: Retinaldehyde-binding protein 1 | Organisim: human | Apparent_Kd_M: 3.437483E-11
Real
Aptamer SeqId: 12939-1 | Target: RPAC1 | UniProt: O15160
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12939-1 | Target: RPAC1 | UniProt: O15160 | TargetFullName: DNA-directed RNA polymerases I and III subunit RPAC1 | Organisim: human | Apparent_Kd_M: 1.027497E-10
Real
Aptamer SeqId: 12940-35 | Target: AL3B1 | UniProt: P43353
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12940-35 | Target: AL3B1 | UniProt: P43353 | TargetFullName: Aldehyde dehydrogenase family 3 member B1 | Organisim: human | Apparent_Kd_M: 1.497219E-11
Real
Aptamer SeqId: 12941-24 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12941-24 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.023319E-10
Real
Aptamer SeqId: 12945-33 | Target: RAB18 | UniProt: Q9NP72
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12945-33 | Target: RAB18 | UniProt: Q9NP72 | TargetFullName: Ras-related protein Rab-18 | Organisim: human | Apparent_Kd_M: 6.300422E-11
Real
Aptamer SeqId: 12954-71 | Target: PPARa | UniProt: Q07869
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12954-71 | Target: PPARa | UniProt: Q07869 | TargetFullName: Peroxisome proliferator-activated receptor alpha | Organisim: human | Apparent_Kd_M: 4.337883E-12
Real
Aptamer SeqId: 12956-40 | Target: KBP | UniProt: Q96EK5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12956-40 | Target: KBP | UniProt: Q96EK5 | TargetFullName: KIF1-binding protein | Organisim: human | Apparent_Kd_M: 6.514977E-13
Real
Aptamer SeqId: 12957-62 | Target: UCR6 | UniProt: P14927
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12957-62 | Target: UCR6 | UniProt: P14927 | TargetFullName: Cytochrome b-c1 complex subunit 7 | Organisim: human | Apparent_Kd_M: 3.298745E-11
Real
Aptamer SeqId: 12958-8 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12958-8 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 5.696918E-12
Real
Aptamer SeqId: 12960-9 | Target: HXK4 | UniProt: P35557
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12960-9 | Target: HXK4 | UniProt: P35557 | TargetFullName: Glucokinase | Organisim: human | Apparent_Kd_M: 1.385112E-10
Real
Aptamer SeqId: 12963-1 | Target: GP107 | UniProt: Q5VW38
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12963-1 | Target: GP107 | UniProt: Q5VW38 | TargetFullName: Protein GPR107 | Organisim: human | Apparent_Kd_M: 1.478297E-11
Real
Aptamer SeqId: 12968-2 | Target: CSRP2 | UniProt: Q16527
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12968-2 | Target: CSRP2 | UniProt: Q16527 | TargetFullName: Cysteine and glycine-rich protein 2 | Organisim: human | Apparent_Kd_M: 1.158485E-10
Real
Aptamer SeqId: 12970-35 | Target: STAU2 | UniProt: Q9NUL3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12970-35 | Target: STAU2 | UniProt: Q9NUL3 | TargetFullName: Double-stranded RNA-binding protein Staufen homolog 2 | Organisim: human | Apparent_Kd_M: 3.020769E-12
Real
Aptamer SeqId: 12975-11 | Target: Keratin 20 | UniProt: P35900
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12975-11 | Target: Keratin 20 | UniProt: P35900 | TargetFullName: Keratin; type I cytoskeletal 20 | Organisim: human | Apparent_Kd_M: 4.782091E-12
Real
Aptamer SeqId: 12976-49 | Target: Vinexin b | UniProt: O60504
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12976-49 | Target: Vinexin b | UniProt: O60504 | TargetFullName: Vinexin b | Organisim: human | Apparent_Kd_M: 7.074201E-12
Real
Aptamer SeqId: 12980-31 | Target: RBM22 | UniProt: Q9NW64
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12980-31 | Target: RBM22 | UniProt: Q9NW64 | TargetFullName: Pre-mRNA-splicing factor RBM22 | Organisim: human | Apparent_Kd_M: 1.467686E-10
Real
Aptamer SeqId: 12986-12 | Target: LIN7C | UniProt: Q9NUP9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12986-12 | Target: LIN7C | UniProt: Q9NUP9 | TargetFullName: Protein lin-7 homolog C | Organisim: human | Apparent_Kd_M: 7.806954E-11
Real
Aptamer SeqId: 12987-12 | Target: SRSF7 | UniProt: Q16629
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12987-12 | Target: SRSF7 | UniProt: Q16629 | TargetFullName: Serine/arginine-rich splicing factor 7 | Organisim: human | Apparent_Kd_M: 4.297553E-11
Real
Aptamer SeqId: 12988-49 | Target: EWS | UniProt: Q01844
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12988-49 | Target: EWS | UniProt: Q01844 | TargetFullName: RNA-binding protein EWS | Organisim: human | Apparent_Kd_M: 8.141322E-12
Real
Aptamer SeqId: 12990-39 | Target: MAP3K3 | UniProt: Q99759
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12990-39 | Target: MAP3K3 | UniProt: Q99759 | TargetFullName: Mitogen-activated protein kinase kinase kinase 3 | Organisim: human | Apparent_Kd_M: 7.362652E-13
Real
Aptamer SeqId: 12991-49 | Target: CUL9 | UniProt: Q8IWT3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12991-49 | Target: CUL9 | UniProt: Q8IWT3 | TargetFullName: Cullin-9 | Organisim: human | Apparent_Kd_M: 1.87E-10
Real
Aptamer SeqId: 12993-21 | Target: NPL4 | UniProt: Q8TAT6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 12993-21 | Target: NPL4 | UniProt: Q8TAT6 | TargetFullName: Nuclear protein localization protein 4 homolog | Organisim: human | Apparent_Kd_M: 5.945236E-12
Real
Aptamer SeqId: 13007-66 | Target: LCN10 | UniProt: Q6JVE6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13007-66 | Target: LCN10 | UniProt: Q6JVE6 | TargetFullName: Epididymal-specific lipocalin-10 | Organisim: human | Apparent_Kd_M: 6.095911E-11
Real
Aptamer SeqId: 13011-20 | Target: RS10 | UniProt: P46783
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13011-20 | Target: RS10 | UniProt: P46783 | TargetFullName: 40S ribosomal protein S10 | Organisim: human | Apparent_Kd_M: 1.547548E-10
Real
Aptamer SeqId: 13013-41 | Target: PRKN2 | UniProt: O60260
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13013-41 | Target: PRKN2 | UniProt: O60260 | TargetFullName: E3 ubiquitin-protein ligase parkin | Organisim: human | Apparent_Kd_M: 2.917207E-11
Real
Aptamer SeqId: 13021-12 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13021-12 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 5.863371E-12
Real
Aptamer SeqId: 13022-20 | Target: P5I11 | UniProt: O14683
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13022-20 | Target: P5I11 | UniProt: O14683 | TargetFullName: Tumor protein p53-inducible protein 11 | Organisim: human | Apparent_Kd_M: 8.638396E-11
Real
Aptamer SeqId: 13023-8 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13023-8 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.971225E-12
Real
Aptamer SeqId: 13025-4 | Target: FRS2 | UniProt: Q8WU20
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13025-4 | Target: FRS2 | UniProt: Q8WU20 | TargetFullName: Fibroblast growth factor receptor substrate 2 | Organisim: human | Apparent_Kd_M: 1.607955E-10
Real
Aptamer SeqId: 13027-20 | Target: CBX7 | UniProt: O95931
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13027-20 | Target: CBX7 | UniProt: O95931 | TargetFullName: Chromobox protein homolog 7 | Organisim: human | Apparent_Kd_M: 6.096448E-12
Real
Aptamer SeqId: 13028-2 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13028-2 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 7.725131E-12
Real
Aptamer SeqId: 13032-1 | Target: BECN1 | UniProt: Q14457
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13032-1 | Target: BECN1 | UniProt: Q14457 | TargetFullName: Beclin-1 | Organisim: human | Apparent_Kd_M: 6.99E-12
Real
Aptamer SeqId: 13039-1 | Target: PP1R8 | UniProt: Q12972
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13039-1 | Target: PP1R8 | UniProt: Q12972 | TargetFullName: Nuclear inhibitor of protein phosphatase 1 | Organisim: human | Apparent_Kd_M: 2.652804E-11
Real
Aptamer SeqId: 13041-47 | Target: TRAF4 | UniProt: Q9BUZ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13041-47 | Target: TRAF4 | UniProt: Q9BUZ4 | TargetFullName: TNF receptor-associated factor 4 | Organisim: human | Apparent_Kd_M: 3.189905E-12
Real
Aptamer SeqId: 13042-7 | Target: KCA10 | UniProt: Q16322
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13042-7 | Target: KCA10 | UniProt: Q16322 | TargetFullName: Potassium voltage-gated channel subfamily A member 10 | Organisim: human | Apparent_Kd_M: 3.377202E-10
Real
Aptamer SeqId: 13043-157 | Target: ATAD2 | UniProt: Q6PL18
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13043-157 | Target: ATAD2 | UniProt: Q6PL18 | TargetFullName: ATPase family AAA domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 2.275165E-11
Real
Aptamer SeqId: 13044-5 | Target: TS101 | UniProt: Q99816
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13044-5 | Target: TS101 | UniProt: Q99816 | TargetFullName: Tumor susceptibility gene 101 protein | Organisim: human | Apparent_Kd_M: 3.338092E-12
Real
Aptamer SeqId: 13053-6 | Target: S6A14 | UniProt: Q9UN76
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13053-6 | Target: S6A14 | UniProt: Q9UN76 | TargetFullName: Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+) | Organisim: human | Apparent_Kd_M: 6.215447E-11
Real
Aptamer SeqId: 13055-53 | Target: PSD1 | UniProt: A5PKW4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13055-53 | Target: PSD1 | UniProt: A5PKW4 | TargetFullName: PH and SEC7 domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 2.816871E-11
Real
Aptamer SeqId: 13056-18 | Target: S6A16 | UniProt: Q9GZN6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13056-18 | Target: S6A16 | UniProt: Q9GZN6 | TargetFullName: Orphan sodium- and chloride-dependent neurotransmitter transporter NTT5 | Organisim: human | Apparent_Kd_M: 3.64955E-12
Real
Aptamer SeqId: 13059-33 | Target: RIFK | UniProt: Q969G6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13059-33 | Target: RIFK | UniProt: Q969G6 | TargetFullName: Riboflavin kinase | Organisim: human | Apparent_Kd_M: 2.697739E-12
Real
Aptamer SeqId: 13062-4 | Target: GMFG | UniProt: O60234
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13062-4 | Target: GMFG | UniProt: O60234 | TargetFullName: Glia maturation factor gamma | Organisim: human | Apparent_Kd_M: 1.028543E-11
Real
Aptamer SeqId: 13066-42 | Target: EDC4 | UniProt: Q6P2E9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13066-42 | Target: EDC4 | UniProt: Q6P2E9 | TargetFullName: Enhancer of mRNA-decapping protein 4 | Organisim: human | Apparent_Kd_M: 3.015356E-12
Real
Aptamer SeqId: 13067-5 | Target: KGP1B | UniProt: Q13976
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13067-5 | Target: KGP1B | UniProt: Q13976 | TargetFullName: cGMP-dependent protein kinase 1; beta isozyme | Organisim: human | Apparent_Kd_M: 7.174044E-11
Real
Aptamer SeqId: 13068-139 | Target: CCS | UniProt: O14618
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13068-139 | Target: CCS | UniProt: O14618 | TargetFullName: Copper chaperone for superoxide dismutase | Organisim: human | Apparent_Kd_M: 3.299687E-10
Real
Aptamer SeqId: 13073-14 | Target: AN32A | UniProt: P39687
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13073-14 | Target: AN32A | UniProt: P39687 | TargetFullName: Acidic leucine-rich nuclear phosphoprotein 32 family member A | Organisim: human | Apparent_Kd_M: 9.26905E-11
Real
Aptamer SeqId: 13076-4 | Target: FXR1 | UniProt: P51114
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13076-4 | Target: FXR1 | UniProt: P51114 | TargetFullName: Fragile X mental retardation syndrome-related protein 1 | Organisim: human | Apparent_Kd_M: 1.32639E-11
Real
Aptamer SeqId: 13078-3 | Target: CETN2 | UniProt: P41208
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13078-3 | Target: CETN2 | UniProt: P41208 | TargetFullName: Centrin-2 | Organisim: human | Apparent_Kd_M: 2.69146E-12
Real
Aptamer SeqId: 13082-9 | Target: UN45A | UniProt: Q9H3U1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13082-9 | Target: UN45A | UniProt: Q9H3U1 | TargetFullName: Protein unc-45 homolog A | Organisim: human | Apparent_Kd_M: 3.42632E-12
Real
Aptamer SeqId: 13083-18 | Target: SYVC | UniProt: P26640
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13083-18 | Target: SYVC | UniProt: P26640 | TargetFullName: Valine--tRNA ligase | Organisim: human | Apparent_Kd_M: 1.392158E-10
Real
Aptamer SeqId: 13085-18 | Target: GLP1R | UniProt: P43220
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13085-18 | Target: GLP1R | UniProt: P43220 | TargetFullName: Glucagon-like peptide 1 receptor | Organisim: human | Apparent_Kd_M: 1.951398E-10
Real
Aptamer SeqId: 13088-397 | Target: BTC | UniProt: P35070
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13088-397 | Target: BTC | UniProt: P35070 | TargetFullName: Betacellulin | Organisim: human | Apparent_Kd_M: 3.03E-11
Real
Aptamer SeqId: 13089-6 | Target: HIF-1a | UniProt: Q16665
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13089-6 | Target: HIF-1a | UniProt: Q16665 | TargetFullName: Hypoxia-inducible factor 1-alpha | Organisim: human | Apparent_Kd_M: 2.04E-10
Real
Aptamer SeqId: 13090-17 | Target: S100A6 | UniProt: P06703
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13090-17 | Target: S100A6 | UniProt: P06703 | TargetFullName: Protein S100-A6 | Organisim: human | Apparent_Kd_M: 2.1E-11
Real
Aptamer SeqId: 13093-6 | Target: SECTM1 | UniProt: Q8WVN6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13093-6 | Target: SECTM1 | UniProt: Q8WVN6 | TargetFullName: Secreted and transmembrane protein 1 | Organisim: human | Apparent_Kd_M: 1.13E-11
Real
Aptamer SeqId: 13094-75 | Target: RSPO3 | UniProt: Q9BXY4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13094-75 | Target: RSPO3 | UniProt: Q9BXY4 | TargetFullName: R-spondin-3 | Organisim: human | Apparent_Kd_M: 2.7E-12
Real
Aptamer SeqId: 13095-51 | Target: PSP | UniProt: P05451
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13095-51 | Target: PSP | UniProt: P05451 | TargetFullName: Lithostathine-1-alpha | Organisim: human | Apparent_Kd_M: 9.1E-13
Real
Aptamer SeqId: 13097-11 | Target: Apoptosis regulator Bcl-W
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13097-11 | Target: Apoptosis regulator Bcl-W | UniProt: Q92843 | TargetFullName: Bcl-2-like protein 2 | Organisim: human | Apparent_Kd_M: 1.68E-11
Real
Aptamer SeqId: 13098-93 | Target: VEGF-D | UniProt: O43915
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13098-93 | Target: VEGF-D | UniProt: O43915 | TargetFullName: Vascular endothelial growth factor D | Organisim: human | Apparent_Kd_M: 6.1E-13
Real
Aptamer SeqId: 13101-60 | Target: SOST | UniProt: Q9BQB4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13101-60 | Target: SOST | UniProt: Q9BQB4 | TargetFullName: Sclerostin | Organisim: human | Apparent_Kd_M: 2.79E-12
Real
Aptamer SeqId: 13102-1 | Target: FAM3D | UniProt: Q96BQ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13102-1 | Target: FAM3D | UniProt: Q96BQ1 | TargetFullName: Protein FAM3D | Organisim: human | Apparent_Kd_M: 1.82E-12
Real
Aptamer SeqId: 13103-125 | Target: CSH | UniProt: P0DML2|P0DML3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13103-125 | Target: CSH | UniProt: P0DML2|P0DML3 | TargetFullName: Chorionic somatomammotropin hormone | Organisim: human | Apparent_Kd_M: 1.24E-11
Real
Aptamer SeqId: 13104-32 | Target: EFNB1 | UniProt: P98172
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13104-32 | Target: EFNB1 | UniProt: P98172 | TargetFullName: Ephrin-B1 | Organisim: human | Apparent_Kd_M: 9.72E-12
Real
Aptamer SeqId: 13105-7 | Target: SNP25 | UniProt: P60880
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13105-7 | Target: SNP25 | UniProt: P60880 | TargetFullName: Synaptosomal-associated protein 25 | Organisim: human | Apparent_Kd_M: 5.57E-11
Real
Aptamer SeqId: 13107-9 | Target: LYPD3 | UniProt: O95274
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13107-9 | Target: LYPD3 | UniProt: O95274 | TargetFullName: Ly6/PLAUR domain-containing protein 3 | Organisim: human | Apparent_Kd_M: 5.39E-11
Real
Aptamer SeqId: 13109-82 | Target: NEGR1 | UniProt: Q7Z3B1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13109-82 | Target: NEGR1 | UniProt: Q7Z3B1 | TargetFullName: Neuronal growth regulator 1 | Organisim: human | Apparent_Kd_M: 6.39E-12
Real
Aptamer SeqId: 13111-79 | Target: BCL6 | UniProt: P41182
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13111-79 | Target: BCL6 | UniProt: P41182 | TargetFullName: B-cell lymphoma 6 protein | Organisim: human | Apparent_Kd_M: 1.71E-11
Real
Aptamer SeqId: 13112-179 | Target: FSTL1 | UniProt: Q12841
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13112-179 | Target: FSTL1 | UniProt: Q12841 | TargetFullName: Follistatin-related protein 1 | Organisim: human | Apparent_Kd_M: 2.74E-12
Real
Aptamer SeqId: 13113-7 | Target: Osteopontin | UniProt: P10451
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13113-7 | Target: Osteopontin | UniProt: P10451 | TargetFullName: Osteopontin | Organisim: human | Apparent_Kd_M: 1.27E-10
Real
Aptamer SeqId: 13114-50 | Target: Lumican | UniProt: P51884
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13114-50 | Target: Lumican | UniProt: P51884 | TargetFullName: Lumican | Organisim: human | Apparent_Kd_M: 1.16E-11
Real
Aptamer SeqId: 13116-25 | Target: CD177 | UniProt: Q8N6Q3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13116-25 | Target: CD177 | UniProt: Q8N6Q3 | TargetFullName: CD177 antigen | Organisim: human | Apparent_Kd_M: 4.21E-12
Real
Aptamer SeqId: 13118-5 | Target: SMOC1 | UniProt: Q9H4F8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13118-5 | Target: SMOC1 | UniProt: Q9H4F8 | TargetFullName: SPARC-related modular calcium-binding protein 1 | Organisim: human | Apparent_Kd_M: 5.63E-12
Real
Aptamer SeqId: 13119-26 | Target: protein Z inhibitor | UniProt: Q9UK55
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13119-26 | Target: protein Z inhibitor | UniProt: Q9UK55 | TargetFullName: Protein Z-dependent protease inhibitor | Organisim: human | Apparent_Kd_M: 1.47E-11
Real
Aptamer SeqId: 13122-19 | Target: FLRT2 | UniProt: O43155
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13122-19 | Target: FLRT2 | UniProt: O43155 | TargetFullName: Leucine-rich repeat transmembrane protein FLRT2 | Organisim: human | Apparent_Kd_M: 4.17E-12
Real
Aptamer SeqId: 13123-3 | Target: FLRT3 | UniProt: Q9NZU0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13123-3 | Target: FLRT3 | UniProt: Q9NZU0 | TargetFullName: Leucine-rich repeat transmembrane protein FLRT3 | Organisim: human | Apparent_Kd_M: 9.11E-12
Real
Aptamer SeqId: 13124-20 | Target: ISLR2 | UniProt: Q6UXK2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13124-20 | Target: ISLR2 | UniProt: Q6UXK2 | TargetFullName: Immunoglobulin superfamily containing leucine-rich repeat protein 2 | Organisim: human | Apparent_Kd_M: 7.07E-12
Real
Aptamer SeqId: 13125-45 | Target: Vitronectin | UniProt: P04004
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13125-45 | Target: Vitronectin | UniProt: P04004 | TargetFullName: Vitronectin | Organisim: human | Apparent_Kd_M: 3.59E-11
Real
Aptamer SeqId: 13126-52 | Target: DSC2 | UniProt: Q02487
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13126-52 | Target: DSC2 | UniProt: Q02487 | TargetFullName: Desmocollin-2 | Organisim: human | Apparent_Kd_M: 1.37E-10
Real
Aptamer SeqId: 13129-40 | Target: LDLR | UniProt: P01130
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13129-40 | Target: LDLR | UniProt: P01130 | TargetFullName: Low-density lipoprotein receptor | Organisim: human | Apparent_Kd_M: 3.02E-11
Real
Aptamer SeqId: 13130-150 | Target: HXK2 | UniProt: P52789
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13130-150 | Target: HXK2 | UniProt: P52789 | TargetFullName: Hexokinase-2 | Organisim: human | Apparent_Kd_M: 1.04E-12
Real
Aptamer SeqId: 13131-5 | Target: HXK1 | UniProt: P19367
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13131-5 | Target: HXK1 | UniProt: P19367 | TargetFullName: Hexokinase-1 | Organisim: human | Apparent_Kd_M: 9.98E-12
Real
Aptamer SeqId: 13132-14 | Target: SEM5A | UniProt: Q13591
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13132-14 | Target: SEM5A | UniProt: Q13591 | TargetFullName: Semaphorin-5A | Organisim: human | Apparent_Kd_M: 3.13E-12
Real
Aptamer SeqId: 13133-73 | Target: LTBP4 | UniProt: Q8N2S1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13133-73 | Target: LTBP4 | UniProt: Q8N2S1 | TargetFullName: Latent-transforming growth factor beta-binding protein 4 | Organisim: human | Apparent_Kd_M: 1.97E-11
Real
Aptamer SeqId: 13228-75 | Target: MDM2 | UniProt: Q00987
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13228-75 | Target: MDM2 | UniProt: Q00987 | TargetFullName: E3 ubiquitin-protein ligase Mdm2 | Organisim: human | Apparent_Kd_M: 9.97E-12
Real
Aptamer SeqId: 13229-20 | Target: MDM4 | UniProt: O15151
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13229-20 | Target: MDM4 | UniProt: O15151 | TargetFullName: Protein Mdm4 | Organisim: human | Apparent_Kd_M: 7.035702E-12
Real
Aptamer SeqId: 13230-174 | Target: IgG2; Kappa | UniProt: P01859
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13230-174 | Target: IgG2; Kappa | UniProt: P01859 | TargetFullName: Ig gamma-2; Kappa | Organisim: human | Apparent_Kd_M: 1.29E-12
Real
Aptamer SeqId: 13231-90 | Target: IgG4; Kappa | UniProt: P01861
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13231-90 | Target: IgG4; Kappa | UniProt: P01861 | TargetFullName: Ig gamma-4; Kappa | Organisim: human | Apparent_Kd_M: 5.534478E-13
Real
Aptamer SeqId: 13236-25 | Target: WNT3A | UniProt: P56704
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13236-25 | Target: WNT3A | UniProt: P56704 | TargetFullName: Protein Wnt-3a | Organisim: human | Apparent_Kd_M: 2.612E-10
Real
Aptamer SeqId: 13240-170 | Target: SHAN1 | UniProt: Q9Y566
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13240-170 | Target: SHAN1 | UniProt: Q9Y566 | TargetFullName: SH3 and multiple ankyrin repeat domains protein 1 | Organisim: human | Apparent_Kd_M: 4.78E-12
Real
Aptamer SeqId: 13242-134 | Target: SHAN3 | UniProt: Q9BYB0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13242-134 | Target: SHAN3 | UniProt: Q9BYB0 | TargetFullName: SH3 and multiple ankyrin repeat domains protein 3 | Organisim: human | Apparent_Kd_M: 1.83E-12
Real
Aptamer SeqId: 13268-45 | Target: WNT5A | UniProt: P41221
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13268-45 | Target: WNT5A | UniProt: P41221 | TargetFullName: Protein Wnt-5a | Organisim: human | Apparent_Kd_M: 5.533821E-11
Real
Aptamer SeqId: 13374-4 | Target: DB113 | UniProt: Q30KQ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13374-4 | Target: DB113 | UniProt: Q30KQ7 | TargetFullName: Beta-defensin 113 | Organisim: human | Apparent_Kd_M: 2.143492E-11
Real
Aptamer SeqId: 13375-48 | Target: SNG3 | UniProt: O43761
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13375-48 | Target: SNG3 | UniProt: O43761 | TargetFullName: Synaptogyrin-3 | Organisim: human | Apparent_Kd_M: 3.779355E-12
Real
Aptamer SeqId: 13377-3 | Target: C56D1 | UniProt: Q8N8Q1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13377-3 | Target: C56D1 | UniProt: Q8N8Q1 | TargetFullName: Cytochrome b561 domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 9.406854E-11
Real
Aptamer SeqId: 13378-80 | Target: YD286 | UniProt: A6NC05
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13378-80 | Target: YD286 | UniProt: A6NC05 | TargetFullName: Glutaredoxin-like protein C5orf63 | Organisim: human | Apparent_Kd_M: 7.83191E-11
Real
Aptamer SeqId: 13381-49 | Target: B4GT1 | UniProt: P15291
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13381-49 | Target: B4GT1 | UniProt: P15291 | TargetFullName: Beta-1;4-galactosyltransferase 1 | Organisim: human | Apparent_Kd_M: 6.127807E-12
Real
Aptamer SeqId: 13384-110 | Target: FUMH | UniProt: P07954
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13384-110 | Target: FUMH | UniProt: P07954 | TargetFullName: Fumarate hydratase; mitochondrial | Organisim: human | Apparent_Kd_M: 1.9314E-11
Real
Aptamer SeqId: 13386-248 | Target: RNF34 | UniProt: Q969K3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13386-248 | Target: RNF34 | UniProt: Q969K3 | TargetFullName: E3 ubiquitin-protein ligase RNF34 | Organisim: human | Apparent_Kd_M: 3.368153E-11
Real
Aptamer SeqId: 13387-55 | Target: EHF | UniProt: Q9NZC4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13387-55 | Target: EHF | UniProt: Q9NZC4 | TargetFullName: ETS homologous factor | Organisim: human | Apparent_Kd_M: 8.281546E-12
Real
Aptamer SeqId: 13388-57 | Target: NEC1 | UniProt: P29120
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13388-57 | Target: NEC1 | UniProt: P29120 | TargetFullName: Neuroendocrine convertase 1 | Organisim: human | Apparent_Kd_M: 7.818448E-11
Real
Aptamer SeqId: 13389-8 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13389-8 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.757617E-11
Real
Aptamer SeqId: 13392-13 | Target: AT1B1 | UniProt: P05026
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13392-13 | Target: AT1B1 | UniProt: P05026 | TargetFullName: Sodium/potassium-transporting ATPase subunit beta-1 | Organisim: human | Apparent_Kd_M: 4.001105E-11
Real
Aptamer SeqId: 13393-46 | Target: DERL1 | UniProt: Q9BUN8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13393-46 | Target: DERL1 | UniProt: Q9BUN8 | TargetFullName: Derlin-1 | Organisim: human | Apparent_Kd_M: 1.080858E-11
Real
Aptamer SeqId: 13397-88 | Target: HBD-2 | UniProt: O15263
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13397-88 | Target: HBD-2 | UniProt: O15263 | TargetFullName: Beta-defensin 4A | Organisim: human | Apparent_Kd_M: 8.903659E-12
Real
Aptamer SeqId: 13399-33 | Target: RELL1 | UniProt: Q8IUW5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13399-33 | Target: RELL1 | UniProt: Q8IUW5 | TargetFullName: RELT-like protein 1 | Organisim: human | Apparent_Kd_M: 3.463651E-11
Real
Aptamer SeqId: 13403-5 | Target: ETV5 | UniProt: P41161
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13403-5 | Target: ETV5 | UniProt: P41161 | TargetFullName: ETS translocation variant 5 | Organisim: human | Apparent_Kd_M: 1.057658E-11
Real
Aptamer SeqId: 13405-61 | Target: ISK2 | UniProt: P20155
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13405-61 | Target: ISK2 | UniProt: P20155 | TargetFullName: Serine protease inhibitor Kazal-type 2 | Organisim: human | Apparent_Kd_M: 4.772475E-12
Real
Aptamer SeqId: 13409-9 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13409-9 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 9.573979E-12
Real
Aptamer SeqId: 13411-21 | Target: RNF41 | UniProt: Q9H4P4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13411-21 | Target: RNF41 | UniProt: Q9H4P4 | TargetFullName: E3 ubiquitin-protein ligase NRDP1 | Organisim: human | Apparent_Kd_M: 8.538704E-12
Real
Aptamer SeqId: 13412-5 | Target: WFDC6 | UniProt: Q9BQY6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13412-5 | Target: WFDC6 | UniProt: Q9BQY6 | TargetFullName: WAP four-disulfide core domain protein 6 | Organisim: human | Apparent_Kd_M: 3.145936E-10
Real
Aptamer SeqId: 13416-8 | Target: T132D | UniProt: Q14C87
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13416-8 | Target: T132D | UniProt: Q14C87 | TargetFullName: Transmembrane protein 132D | Organisim: human | Apparent_Kd_M: 5.077196E-12
Real
Aptamer SeqId: 13421-17 | Target: KISHB | UniProt: Q9NRX6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13421-17 | Target: KISHB | UniProt: Q9NRX6 | TargetFullName: Protein kish-B | Organisim: human | Apparent_Kd_M: 4.06571E-12
Real
Aptamer SeqId: 13422-66 | Target: ENOX2 | UniProt: Q16206
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13422-66 | Target: ENOX2 | UniProt: Q16206 | TargetFullName: Ecto-NOX disulfide-thiol exchanger 2 | Organisim: human | Apparent_Kd_M: 3.04E-12
Real
Aptamer SeqId: 13423-94 | Target: CJ058 | UniProt: Q9BRX8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13423-94 | Target: CJ058 | UniProt: Q9BRX8 | TargetFullName: Redox-regulatory protein FAM213A | Organisim: human | Apparent_Kd_M: 1.518612E-10
Real
Aptamer SeqId: 13424-51 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13424-51 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 6.56E-12
Real
Aptamer SeqId: 13427-66 | Target: MA1C1 | UniProt: Q9NR34
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13427-66 | Target: MA1C1 | UniProt: Q9NR34 | TargetFullName: Mannosyl-oligosaccharide 1;2-alpha-mannosidase IC | Organisim: human | Apparent_Kd_M: 1.677572E-11
Real
Aptamer SeqId: 13429-3 | Target: WF10A | UniProt: Q9H1F0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13429-3 | Target: WF10A | UniProt: Q9H1F0 | TargetFullName: WAP four-disulfide core domain protein 10A | Organisim: human | Apparent_Kd_M: 2.266226E-11
Real
Aptamer SeqId: 13430-50 | Target: UT1 | UniProt: Q13336
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13430-50 | Target: UT1 | UniProt: Q13336 | TargetFullName: Urea transporter 1 | Organisim: human | Apparent_Kd_M: 1.417642E-10
Real
Aptamer SeqId: 13431-74 | Target: F159A | UniProt: Q6UWV7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13431-74 | Target: F159A | UniProt: Q6UWV7 | TargetFullName: Membrane protein FAM159A | Organisim: human | Apparent_Kd_M: 5.851887E-11
Real
Aptamer SeqId: 13434-172 | Target: PARVA | UniProt: Q9NVD7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13434-172 | Target: PARVA | UniProt: Q9NVD7 | TargetFullName: Alpha-parvin | Organisim: human | Apparent_Kd_M: 2.935925E-12
Real
Aptamer SeqId: 13435-31 | Target: IL-20 Rb | UniProt: Q6UXL0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13435-31 | Target: IL-20 Rb | UniProt: Q6UXL0 | TargetFullName: Interleukin-20 receptor subunit beta | Organisim: human | Apparent_Kd_M: 1.579869E-10
Real
Aptamer SeqId: 13436-54 | Target: MAZ | UniProt: P56270
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13436-54 | Target: MAZ | UniProt: P56270 | TargetFullName: Myc-associated zinc finger protein | Organisim: human | Apparent_Kd_M: 7.022378E-12
Real
Aptamer SeqId: 13438-115 | Target: CHRD | UniProt: Q9H2X0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13438-115 | Target: CHRD | UniProt: Q9H2X0 | TargetFullName: Chordin | Organisim: human | Apparent_Kd_M: 3.92091E-11
Real
Aptamer SeqId: 13439-6 | Target: IQCF3 | UniProt: P0C7M6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13439-6 | Target: IQCF3 | UniProt: P0C7M6 | TargetFullName: IQ domain-containing protein F3 | Organisim: human | Apparent_Kd_M: 6.404992E-11
Real
Aptamer SeqId: 13441-30 | Target: DIXC1 | UniProt: Q155Q3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13441-30 | Target: DIXC1 | UniProt: Q155Q3 | TargetFullName: Dixin | Organisim: human | Apparent_Kd_M: 9.07509E-12
Real
Aptamer SeqId: 13447-42 | Target: SPRN | UniProt: Q5BIV9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13447-42 | Target: SPRN | UniProt: Q5BIV9 | TargetFullName: Shadow of prion protein | Organisim: human | Apparent_Kd_M: 1.762366E-10
Real
Aptamer SeqId: 13449-25 | Target: SF3B4 | UniProt: Q15427
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13449-25 | Target: SF3B4 | UniProt: Q15427 | TargetFullName: Splicing factor 3B subunit 4 | Organisim: human | Apparent_Kd_M: 3.404686E-11
Real
Aptamer SeqId: 13450-49 | Target: UBP8 | UniProt: P40818
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13450-49 | Target: UBP8 | UniProt: P40818 | TargetFullName: Ubiquitin carboxyl-terminal hydrolase 8 | Organisim: human | Apparent_Kd_M: 3.309157E-12
Real
Aptamer SeqId: 13451-2 | Target: FNDC4 | UniProt: Q9H6D8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13451-2 | Target: FNDC4 | UniProt: Q9H6D8 | TargetFullName: Fibronectin type III domain-containing protein 4 | Organisim: human | Apparent_Kd_M: 1.015049E-11
Real
Aptamer SeqId: 13452-113 | Target: SIM13 | UniProt: P0DJ93
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13452-113 | Target: SIM13 | UniProt: P0DJ93 | TargetFullName: Small integral membrane protein 13 | Organisim: human | Apparent_Kd_M: 9.551225E-11
Real
Aptamer SeqId: 13453-2 | Target: RM33 | UniProt: O75394
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13453-2 | Target: RM33 | UniProt: O75394 | TargetFullName: 39S ribosomal protein L33; mitochondrial | Organisim: human | Apparent_Kd_M: 1.032518E-10
Real
Aptamer SeqId: 13455-10 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13455-10 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 4.19E-12
Real
Aptamer SeqId: 13457-33 | Target: ELF5 | UniProt: Q9UKW6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13457-33 | Target: ELF5 | UniProt: Q9UKW6 | TargetFullName: ETS-related transcription factor Elf-5 | Organisim: human | Apparent_Kd_M: 1.92799E-12
Real
Aptamer SeqId: 13459-30 | Target: CI167 | UniProt: Q9NXH8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13459-30 | Target: CI167 | UniProt: Q9NXH8 | TargetFullName: Torsin-4A | Organisim: human | Apparent_Kd_M: 2.497011E-10
Real
Aptamer SeqId: 13460-4 | Target: CHAD | UniProt: O15335
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13460-4 | Target: CHAD | UniProt: O15335 | TargetFullName: Chondroadherin | Organisim: human | Apparent_Kd_M: 1.867212E-12
Real
Aptamer SeqId: 13463-1 | Target: PXDN | UniProt: Q92626
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13463-1 | Target: PXDN | UniProt: Q92626 | TargetFullName: Peroxidasin homolog | Organisim: human | Apparent_Kd_M: 1.336751E-11
Real
Aptamer SeqId: 13464-8 | Target: NRAC | UniProt: Q8N912
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13464-8 | Target: NRAC | UniProt: Q8N912 | TargetFullName: Nutritionally-regulated adipose and cardiac enriched protein homolog | Organisim: human | Apparent_Kd_M: 3.227078E-11
Real
Aptamer SeqId: 13465-5 | Target: CCP1 | UniProt: P53805
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13465-5 | Target: CCP1 | UniProt: P53805 | TargetFullName: Calcipressin-1 | Organisim: human | Apparent_Kd_M: 3.397345E-12
Real
Aptamer SeqId: 13468-5 | Target: NEUL4 | UniProt: Q96JN8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13468-5 | Target: NEUL4 | UniProt: Q96JN8 | TargetFullName: Neuralized-like protein 4 | Organisim: human | Apparent_Kd_M: 6.077765E-11
Real
Aptamer SeqId: 13470-43 | Target: PTH1R | UniProt: Q03431
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13470-43 | Target: PTH1R | UniProt: Q03431 | TargetFullName: Parathyroid hormone/parathyroid hormone-related peptide receptor | Organisim: human | Apparent_Kd_M: 1.854714E-11
Real
Aptamer SeqId: 13472-35 | Target: HDHD2 | UniProt: Q9H0R4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13472-35 | Target: HDHD2 | UniProt: Q9H0R4 | TargetFullName: Haloacid dehalogenase-like hydrolase domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 3.632704E-12
Real
Aptamer SeqId: 13473-55 | Target: IP3KA | UniProt: P23677
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13473-55 | Target: IP3KA | UniProt: P23677 | TargetFullName: Inositol-trisphosphate 3-kinase A | Organisim: human | Apparent_Kd_M: 4.875127E-12
Real
Aptamer SeqId: 13474-40 | Target: GSTK1 | UniProt: Q9Y2Q3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13474-40 | Target: GSTK1 | UniProt: Q9Y2Q3 | TargetFullName: Glutathione S-transferase kappa 1 | Organisim: human | Apparent_Kd_M: 3.500664E-12
Real
Aptamer SeqId: 13475-10 | Target: UB2D4 | UniProt: Q9Y2X8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13475-10 | Target: UB2D4 | UniProt: Q9Y2X8 | TargetFullName: Ubiquitin-conjugating enzyme E2 D4 | Organisim: human | Apparent_Kd_M: 1.295704E-11
Real
Aptamer SeqId: 13476-16 | Target: KIN17 | UniProt: O60870
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13476-16 | Target: KIN17 | UniProt: O60870 | TargetFullName: DNA/RNA-binding protein KIN17 | Organisim: human | Apparent_Kd_M: 1.19E-11
Real
Aptamer SeqId: 13477-65 | Target: LT4R1 | UniProt: Q15722
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13477-65 | Target: LT4R1 | UniProt: Q15722 | TargetFullName: Leukotriene B4 receptor 1 | Organisim: human | Apparent_Kd_M: 7.361131E-12
Real
Aptamer SeqId: 13479-8 | Target: F1712 | UniProt: A8MVW0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13479-8 | Target: F1712 | UniProt: A8MVW0 | TargetFullName: Protein FAM171A2 | Organisim: human | Apparent_Kd_M: 4.942294E-11
Real
Aptamer SeqId: 13481-24 | Target: TCEA2 | UniProt: Q15560
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13481-24 | Target: TCEA2 | UniProt: Q15560 | TargetFullName: Transcription elongation factor A protein 2 | Organisim: human | Apparent_Kd_M: 5.06611E-12
Real
Aptamer SeqId: 13482-14 | Target: CNOT1 | UniProt: A5YKK6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13482-14 | Target: CNOT1 | UniProt: A5YKK6 | TargetFullName: CCR4-NOT transcription complex subunit 1 | Organisim: human | Apparent_Kd_M: 1.448598E-12
Real
Aptamer SeqId: 13484-69 | Target: CO1A1 | UniProt: P02452
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13484-69 | Target: CO1A1 | UniProt: P02452 | TargetFullName: Collagen alpha-1(I) chain | Organisim: human | Apparent_Kd_M: 1.01E-10
Real
Aptamer SeqId: 13485-20 | Target: TM87B | UniProt: Q96K49
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13485-20 | Target: TM87B | UniProt: Q96K49 | TargetFullName: Transmembrane protein 87B | Organisim: human | Apparent_Kd_M: 1.432262E-10
Real
Aptamer SeqId: 13486-9 | Target: PKD2 | UniProt: Q13563
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13486-9 | Target: PKD2 | UniProt: Q13563 | TargetFullName: Polycystin-2 | Organisim: human | Apparent_Kd_M: 3.95E-11
Real
Aptamer SeqId: 13487-24 | Target: UN93B | UniProt: Q9H1C4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13487-24 | Target: UN93B | UniProt: Q9H1C4 | TargetFullName: Protein unc-93 homolog B1 | Organisim: human | Apparent_Kd_M: 1.432385E-11
Real
Aptamer SeqId: 13488-3 | Target: ARFP1 | UniProt: P53367
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13488-3 | Target: ARFP1 | UniProt: P53367 | TargetFullName: Arfaptin-1 | Organisim: human | Apparent_Kd_M: 8.60004E-12
Real
Aptamer SeqId: 13490-1 | Target: MPP6 | UniProt: Q9NZW5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13490-1 | Target: MPP6 | UniProt: Q9NZW5 | TargetFullName: MAGUK p55 subfamily member 6 | Organisim: human | Apparent_Kd_M: 2.147962E-11
Real
Aptamer SeqId: 13491-40 | Target: PDE6D | UniProt: O43924
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13491-40 | Target: PDE6D | UniProt: O43924 | TargetFullName: Retinal rod rhodopsin-sensitive cGMP 3';5'-cyclic phosphodiesterase subunit delta | Organisim: human | Apparent_Kd_M: 1.52959E-11
Real
Aptamer SeqId: 13492-44 | Target: HSPA9B | UniProt: P38646
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13492-44 | Target: HSPA9B | UniProt: P38646 | TargetFullName: Stress-70 protein; mitochondrial | Organisim: human | Apparent_Kd_M: 1.044255E-10
Real
Aptamer SeqId: 13493-5 | Target: GRID1 | UniProt: Q9ULK0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13493-5 | Target: GRID1 | UniProt: Q9ULK0 | TargetFullName: Glutamate receptor ionotropic; delta-1 | Organisim: human | Apparent_Kd_M: 1.177711E-11
Real
Aptamer SeqId: 13494-6 | Target: CERS5 | UniProt: Q8N5B7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13494-6 | Target: CERS5 | UniProt: Q8N5B7 | TargetFullName: Ceramide synthase 5 | Organisim: human | Apparent_Kd_M: 4.385256E-11
Real
Aptamer SeqId: 13495-48 | Target: HCAR2 | UniProt: Q8TDS4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13495-48 | Target: HCAR2 | UniProt: Q8TDS4 | TargetFullName: Hydroxycarboxylic acid receptor 2 | Organisim: human | Apparent_Kd_M: 5.7775E-12
Real
Aptamer SeqId: 13496-19 | Target: HMCS1 | UniProt: Q01581
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13496-19 | Target: HMCS1 | UniProt: Q01581 | TargetFullName: Hydroxymethylglutaryl-CoA synthase; cytoplasmic | Organisim: human | Apparent_Kd_M: 1.67E-11
Real
Aptamer SeqId: 13497-34 | Target: EIF3J | UniProt: O75822
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13497-34 | Target: EIF3J | UniProt: O75822 | TargetFullName: Eukaryotic translation initiation factor 3 subunit J | Organisim: human | Apparent_Kd_M: 9.914086E-11
Real
Aptamer SeqId: 13498-1 | Target: MIOX | UniProt: Q9UGB7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13498-1 | Target: MIOX | UniProt: Q9UGB7 | TargetFullName: Inositol oxygenase | Organisim: human | Apparent_Kd_M: 1.771076E-11
Real
Aptamer SeqId: 13499-30 | Target: Coagulation Factor VIII | UniProt: P00451
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13499-30 | Target: Coagulation Factor VIII | UniProt: P00451 | TargetFullName: Coagulation Factor VIII | Organisim: human | Apparent_Kd_M: 7.6E-12
Real
Aptamer SeqId: 13500-9 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13500-9 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.94E-12
Real
Aptamer SeqId: 13501-10 | Target: S35G2 | UniProt: Q8TBE7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13501-10 | Target: S35G2 | UniProt: Q8TBE7 | TargetFullName: Solute carrier family 35 member G2 | Organisim: human | Apparent_Kd_M: 3.722256E-11
Real
Aptamer SeqId: 13502-2 | Target: S2611 | UniProt: Q86WA9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13502-2 | Target: S2611 | UniProt: Q86WA9 | TargetFullName: Sodium-independent sulfate anion transporter | Organisim: human | Apparent_Kd_M: 6.59338E-11
Real
Aptamer SeqId: 13503-19 | Target: PRAF3 | UniProt: O75915
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13503-19 | Target: PRAF3 | UniProt: O75915 | TargetFullName: PRA1 family protein 3 | Organisim: human | Apparent_Kd_M: 6.470203E-12
Real
Aptamer SeqId: 13506-10 | Target: DUS2L | UniProt: Q9NX74
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13506-10 | Target: DUS2L | UniProt: Q9NX74 | TargetFullName: tRNA-dihydrouridine(20) synthase NAD(P)+-like | Organisim: human | Apparent_Kd_M: 4.745746E-12
Real
Aptamer SeqId: 13507-51 | Target: TRADD | UniProt: Q15628
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13507-51 | Target: TRADD | UniProt: Q15628 | TargetFullName: Tumor necrosis factor receptor type 1-associated DEATH domain protein | Organisim: human | Apparent_Kd_M: 2.573341E-11
Real
Aptamer SeqId: 13509-5 | Target: SCAM5 | UniProt: Q8TAC9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13509-5 | Target: SCAM5 | UniProt: Q8TAC9 | TargetFullName: Secretory carrier-associated membrane protein 5 | Organisim: human | Apparent_Kd_M: 1.094814E-10
Real
Aptamer SeqId: 13510-7 | Target: AT2A3 | UniProt: Q93084
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13510-7 | Target: AT2A3 | UniProt: Q93084 | TargetFullName: Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 | Organisim: human | Apparent_Kd_M: 3.817897E-11
Real
Aptamer SeqId: 13511-29 | Target: SATB1 | UniProt: Q01826
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13511-29 | Target: SATB1 | UniProt: Q01826 | TargetFullName: DNA-binding protein SATB1 | Organisim: human | Apparent_Kd_M: 2.569961E-11
Real
Aptamer SeqId: 13512-28 | Target: HNRPR | UniProt: O43390
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13512-28 | Target: HNRPR | UniProt: O43390 | TargetFullName: Heterogeneous nuclear ribonucleoprotein R | Organisim: human | Apparent_Kd_M: 1.7E-11
Real
Aptamer SeqId: 13513-174 | Target: PIAS3 | UniProt: Q9Y6X2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13513-174 | Target: PIAS3 | UniProt: Q9Y6X2 | TargetFullName: E3 SUMO-protein ligase PIAS3 | Organisim: human | Apparent_Kd_M: 6.077345E-11
Real
Aptamer SeqId: 13514-121 | Target: Rab-1C | UniProt: Q15286
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13514-121 | Target: Rab-1C | UniProt: Q15286 | TargetFullName: Ras-related protein Rab-35 | Organisim: human | Apparent_Kd_M: 4.394461E-11
Real
Aptamer SeqId: 13515-8 | Target: RPR1A | UniProt: Q96P16
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13515-8 | Target: RPR1A | UniProt: Q96P16 | TargetFullName: Regulation of nuclear pre-mRNA domain-containing protein 1A | Organisim: human | Apparent_Kd_M: 4.212992E-12
Real
Aptamer SeqId: 13516-46 | Target: TMM85 | UniProt: Q5J8M3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13516-46 | Target: TMM85 | UniProt: Q5J8M3 | TargetFullName: ER membrane protein complex subunit 4 | Organisim: human | Apparent_Kd_M: 5.980225E-12
Real
Aptamer SeqId: 13517-3 | Target: PTHD3 | UniProt: Q3KNS1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13517-3 | Target: PTHD3 | UniProt: Q3KNS1 | TargetFullName: Patched domain-containing protein 3 | Organisim: human | Apparent_Kd_M: 8.155024E-11
Real
Aptamer SeqId: 13518-5 | Target: ASAP2 | UniProt: O43150
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13518-5 | Target: ASAP2 | UniProt: O43150 | TargetFullName: Arf-GAP with SH3 domain; ANK repeat and PH domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 4.97712E-11
Real
Aptamer SeqId: 13519-112 | Target: ARHGP | UniProt: Q86VW2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13519-112 | Target: ARHGP | UniProt: Q86VW2 | TargetFullName: Rho guanine nucleotide exchange factor 25 | Organisim: human | Apparent_Kd_M: 5.788743E-12
Real
Aptamer SeqId: 13522-20 | Target: VISL1 | UniProt: P62760
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13522-20 | Target: VISL1 | UniProt: P62760 | TargetFullName: Visinin-like protein 1 | Organisim: human | Apparent_Kd_M: 8.060738E-11
Real
Aptamer SeqId: 13524-25 | Target: H6ST2 | UniProt: Q96MM7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13524-25 | Target: H6ST2 | UniProt: Q96MM7 | TargetFullName: Heparan-sulfate 6-O-sulfotransferase 2 | Organisim: human | Apparent_Kd_M: 2.316573E-10
Real
Aptamer SeqId: 13525-17 | Target: KCNG4 | UniProt: Q8TDN1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13525-17 | Target: KCNG4 | UniProt: Q8TDN1 | TargetFullName: Potassium voltage-gated channel subfamily G member 4 | Organisim: human | Apparent_Kd_M: 1.20827E-10
Real
Aptamer SeqId: 13526-5 | Target: LA | UniProt: P05455
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13526-5 | Target: LA | UniProt: P05455 | TargetFullName: Lupus La protein | Organisim: human | Apparent_Kd_M: 4.18E-12
Real
Aptamer SeqId: 13529-39 | Target: NP1L2 | UniProt: Q9ULW6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13529-39 | Target: NP1L2 | UniProt: Q9ULW6 | TargetFullName: Nucleosome assembly protein 1-like 2 | Organisim: human | Apparent_Kd_M: 5.257424E-12
Real
Aptamer SeqId: 13530-5 | Target: UR2R | UniProt: Q9UKP6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13530-5 | Target: UR2R | UniProt: Q9UKP6 | TargetFullName: Urotensin-2 receptor | Organisim: human | Apparent_Kd_M: 1.450744E-11
Real
Aptamer SeqId: 13532-25 | Target: NEPR1 | UniProt: Q8N9A8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13532-25 | Target: NEPR1 | UniProt: Q8N9A8 | TargetFullName: Nuclear envelope phosphatase-regulatory subunit 1 | Organisim: human | Apparent_Kd_M: 1.19857E-10
Real
Aptamer SeqId: 13534-20 | Target: MYOM2 | UniProt: P54296
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13534-20 | Target: MYOM2 | UniProt: P54296 | TargetFullName: Myomesin-2 | Organisim: human | Apparent_Kd_M: 2.545047E-11
Real
Aptamer SeqId: 13535-2 | Target: C43BP | UniProt: Q9Y5P4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13535-2 | Target: C43BP | UniProt: Q9Y5P4 | TargetFullName: Collagen type IV alpha-3-binding protein | Organisim: human | Apparent_Kd_M: 4.89E-11
Real
Aptamer SeqId: 13536-56 | Target: POLI | UniProt: Q9UNA4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13536-56 | Target: POLI | UniProt: Q9UNA4 | TargetFullName: DNA polymerase iota | Organisim: human | Apparent_Kd_M: 4.521885E-12
Real
Aptamer SeqId: 13539-131 | Target: KCNN1 | UniProt: Q92952
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13539-131 | Target: KCNN1 | UniProt: Q92952 | TargetFullName: Small conductance calcium-activated potassium channel protein 1 | Organisim: human | Apparent_Kd_M: 6.494594E-12
Real
Aptamer SeqId: 13540-1 | Target: GPR26 | UniProt: Q8NDV2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13540-1 | Target: GPR26 | UniProt: Q8NDV2 | TargetFullName: G-protein coupled receptor 26 | Organisim: human | Apparent_Kd_M: 4.486151E-11
Real
Aptamer SeqId: 13541-1 | Target: MYCT1 | UniProt: Q8N699
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13541-1 | Target: MYCT1 | UniProt: Q8N699 | TargetFullName: Myc target protein 1 | Organisim: human | Apparent_Kd_M: 3.820159E-11
Real
Aptamer SeqId: 13544-9 | Target: HMHA1 | UniProt: Q92619
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13544-9 | Target: HMHA1 | UniProt: Q92619 | TargetFullName: Rho GTPase-activating protein 45 | Organisim: human | Apparent_Kd_M: 9.35991E-12
Real
Aptamer SeqId: 13545-97 | Target: EIF1A | UniProt: Q8N9N8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13545-97 | Target: EIF1A | UniProt: Q8N9N8 | TargetFullName: Probable RNA-binding protein EIF1AD | Organisim: human | Apparent_Kd_M: 4.912507E-12
Real
Aptamer SeqId: 13547-5 | Target: 5HT7R | UniProt: P34969
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13547-5 | Target: 5HT7R | UniProt: P34969 | TargetFullName: 5-hydroxytryptamine receptor 7 | Organisim: human | Apparent_Kd_M: 2.59E-11
Real
Aptamer SeqId: 13548-53 | Target: PPC1A | UniProt: Q5VZY2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13548-53 | Target: PPC1A | UniProt: Q5VZY2 | TargetFullName: Phosphatidate phosphatase PPAPDC1A | Organisim: human | Apparent_Kd_M: 7.001981E-12
Real
Aptamer SeqId: 13549-15 | Target: ADA29 | UniProt: Q9UKF5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13549-15 | Target: ADA29 | UniProt: Q9UKF5 | TargetFullName: Disintegrin and metalloproteinase domain-containing protein 29 | Organisim: human | Apparent_Kd_M: 9.884741E-12
Real
Aptamer SeqId: 13552-7 | Target: SWP70 | UniProt: Q9UH65
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13552-7 | Target: SWP70 | UniProt: Q9UH65 | TargetFullName: Switch-associated protein 70 | Organisim: human | Apparent_Kd_M: 2.288357E-11
Real
Aptamer SeqId: 13553-4 | Target: DCNL3 | UniProt: Q8IWE4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13553-4 | Target: DCNL3 | UniProt: Q8IWE4 | TargetFullName: DCN1-like protein 3 | Organisim: human | Apparent_Kd_M: 2.962673E-11
Real
Aptamer SeqId: 13554-78 | Target: REPI1 | UniProt: Q9BWE0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13554-78 | Target: REPI1 | UniProt: Q9BWE0 | TargetFullName: Replication initiator 1 | Organisim: human | Apparent_Kd_M: 2.067433E-11
Real
Aptamer SeqId: 13556-28 | Target: 5HT2A | UniProt: P28223
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13556-28 | Target: 5HT2A | UniProt: P28223 | TargetFullName: 5-hydroxytryptamine receptor 2A | Organisim: human | Apparent_Kd_M: 2.95E-11
Real
Aptamer SeqId: 13557-3 | Target: Nectin 3 | UniProt: Q9NQS3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13557-3 | Target: Nectin 3 | UniProt: Q9NQS3 | TargetFullName: Nectin-3 | Organisim: human | Apparent_Kd_M: 1.74917E-11
Real
Aptamer SeqId: 13561-5 | Target: 5HT6R | UniProt: P50406
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13561-5 | Target: 5HT6R | UniProt: P50406 | TargetFullName: 5-hydroxytryptamine receptor 6 | Organisim: human | Apparent_Kd_M: 1.7E-11
Real
Aptamer SeqId: 13563-259 | Target: ACBD7 | UniProt: Q8N6N7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13563-259 | Target: ACBD7 | UniProt: Q8N6N7 | TargetFullName: Acyl-CoA-binding domain-containing protein 7 | Organisim: human | Apparent_Kd_M: 7.324428E-12
Real
Aptamer SeqId: 13565-2 | Target: p130 | UniProt: Q08999
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13565-2 | Target: p130 | UniProt: Q08999 | TargetFullName: Retinoblastoma-like protein 2 | Organisim: human | Apparent_Kd_M: 3.59E-10
Real
Aptamer SeqId: 13566-2 | Target: SSU72 | UniProt: Q9NP77
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13566-2 | Target: SSU72 | UniProt: Q9NP77 | TargetFullName: RNA polymerase II subunit A C-terminal domain phosphatase SSU72 | Organisim: human | Apparent_Kd_M: 6.897323E-12
Real
Aptamer SeqId: 13567-1 | Target: DPYL2 | UniProt: Q16555
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13567-1 | Target: DPYL2 | UniProt: Q16555 | TargetFullName: Dihydropyrimidinase-related protein 2 | Organisim: human | Apparent_Kd_M: 8.383723E-12
Real
Aptamer SeqId: 13568-30 | Target: PSMD4 | UniProt: P55036
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13568-30 | Target: PSMD4 | UniProt: P55036 | TargetFullName: 26S proteasome non-ATPase regulatory subunit 4 | Organisim: human | Apparent_Kd_M: 1.53802E-11
Real
Aptamer SeqId: 13570-43 | Target: VIGLN | UniProt: Q00341
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13570-43 | Target: VIGLN | UniProt: Q00341 | TargetFullName: Vigilin | Organisim: human | Apparent_Kd_M: 4.768051E-11
Real
Aptamer SeqId: 13572-43 | Target: PSD11 | UniProt: O00231
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13572-43 | Target: PSD11 | UniProt: O00231 | TargetFullName: 26S proteasome non-ATPase regulatory subunit 11 | Organisim: human | Apparent_Kd_M: 1.812309E-12
Real
Aptamer SeqId: 13573-5 | Target: p21-ARC | UniProt: O15145
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13573-5 | Target: p21-ARC | UniProt: O15145 | TargetFullName: Actin-related protein 2/3 complex subunit 3 | Organisim: human | Apparent_Kd_M: 1.227505E-11
Real
Aptamer SeqId: 13574-50 | Target: RND1 | UniProt: Q92730
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13574-50 | Target: RND1 | UniProt: Q92730 | TargetFullName: Rho-related GTP-binding protein Rho6 | Organisim: human | Apparent_Kd_M: 1.761626E-10
Real
Aptamer SeqId: 13575-40 | Target: DVL2 | UniProt: O14641
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13575-40 | Target: DVL2 | UniProt: O14641 | TargetFullName: Segment polarity protein dishevelled homolog DVL-2 | Organisim: human | Apparent_Kd_M: 4.516577E-11
Real
Aptamer SeqId: 13577-25 | Target: U2AF2 | UniProt: P26368
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13577-25 | Target: U2AF2 | UniProt: P26368 | TargetFullName: Splicing factor U2AF 65 kDa subunit | Organisim: human | Apparent_Kd_M: 6.109471E-11
Real
Aptamer SeqId: 13578-98 | Target: ABLM3 | UniProt: O94929
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13578-98 | Target: ABLM3 | UniProt: O94929 | TargetFullName: Actin-binding LIM protein 3 | Organisim: human | Apparent_Kd_M: 1.42E-10
Real
Aptamer SeqId: 13580-2 | Target: Sperm-associated antigen 2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13580-2 | Target: Sperm-associated antigen 2 | UniProt: Q16222 | TargetFullName: UDP-N-acetylhexosamine pyrophosphorylase | Organisim: human | Apparent_Kd_M: 6.926118E-11
Real
Aptamer SeqId: 13583-19 | Target: Apaf-1 | UniProt: O14727
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13583-19 | Target: Apaf-1 | UniProt: O14727 | TargetFullName: Apoptotic protease-activating factor 1 | Organisim: human | Apparent_Kd_M: 8.321362E-11
Real
Aptamer SeqId: 13587-10 | Target: RGAP1 | UniProt: Q9H0H5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13587-10 | Target: RGAP1 | UniProt: Q9H0H5 | TargetFullName: Rac GTPase-activating protein 1 | Organisim: human | Apparent_Kd_M: 4.201845E-12
Real
Aptamer SeqId: 13588-11 | Target: ANXA9 | UniProt: O76027
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13588-11 | Target: ANXA9 | UniProt: O76027 | TargetFullName: Annexin A9 | Organisim: human | Apparent_Kd_M: 1.959181E-10
Real
Aptamer SeqId: 13589-10 | Target: APBB3 | UniProt: O95704
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13589-10 | Target: APBB3 | UniProt: O95704 | TargetFullName: Amyloid beta A4 precursor protein-binding family B member 3 | Organisim: human | Apparent_Kd_M: 4.77E-11
Real
Aptamer SeqId: 13590-1 | Target: ORN | UniProt: Q9Y3B8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13590-1 | Target: ORN | UniProt: Q9Y3B8 | TargetFullName: Oligoribonuclease; mitochondrial | Organisim: human | Apparent_Kd_M: 2.638814E-12
Real
Aptamer SeqId: 13591-31 | Target: PRI1 | UniProt: P49642
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13591-31 | Target: PRI1 | UniProt: P49642 | TargetFullName: DNA primase small subunit | Organisim: human | Apparent_Kd_M: 1.773282E-11
Real
Aptamer SeqId: 13594-158 | Target: GGA1 | UniProt: Q9UJY5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13594-158 | Target: GGA1 | UniProt: Q9UJY5 | TargetFullName: ADP-ribosylation factor-binding protein GGA1 | Organisim: human | Apparent_Kd_M: 1.207675E-12
Real
Aptamer SeqId: 13595-20 | Target: THTPA | UniProt: Q9BU02
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13595-20 | Target: THTPA | UniProt: Q9BU02 | TargetFullName: Thiamine-triphosphatase | Organisim: human | Apparent_Kd_M: 7.616058E-11
Real
Aptamer SeqId: 13596-3 | Target: RB27B | UniProt: O00194
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13596-3 | Target: RB27B | UniProt: O00194 | TargetFullName: Ras-related protein Rab-27B | Organisim: human | Apparent_Kd_M: 1.384802E-11
Real
Aptamer SeqId: 13597-20 | Target: RAB31 | UniProt: Q13636
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13597-20 | Target: RAB31 | UniProt: Q13636 | TargetFullName: Ras-related protein Rab-31 | Organisim: human | Apparent_Kd_M: 2.552558E-11
Real
Aptamer SeqId: 13599-15 | Target: RABEK | UniProt: Q7Z6M1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13599-15 | Target: RABEK | UniProt: Q7Z6M1 | TargetFullName: Rab9 effector protein with kelch motifs | Organisim: human | Apparent_Kd_M: 3.863279E-11
Real
Aptamer SeqId: 13602-6 | Target: NH2L1 | UniProt: P55769
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13602-6 | Target: NH2L1 | UniProt: P55769 | TargetFullName: NHP2-like protein 1 | Organisim: human | Apparent_Kd_M: 4.339369E-11
Real
Aptamer SeqId: 13603-7 | Target: RFESD | UniProt: Q8TAC1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13603-7 | Target: RFESD | UniProt: Q8TAC1 | TargetFullName: Rieske domain-containing protein | Organisim: human | Apparent_Kd_M: 6.140028E-11
Real
Aptamer SeqId: 13604-27 | Target: NEUL1 | UniProt: O76050
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13604-27 | Target: NEUL1 | UniProt: O76050 | TargetFullName: E3 ubiquitin-protein ligase NEURL1 | Organisim: human | Apparent_Kd_M: 3.597537E-12
Real
Aptamer SeqId: 13605-16 | Target: ANX10 | UniProt: Q9UJ72
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13605-16 | Target: ANX10 | UniProt: Q9UJ72 | TargetFullName: Annexin A10 | Organisim: human | Apparent_Kd_M: 4.030342E-11
Real
Aptamer SeqId: 13609-11 | Target: GTF2I | UniProt: P78347
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13609-11 | Target: GTF2I | UniProt: P78347 | TargetFullName: General transcription factor II-I | Organisim: human | Apparent_Kd_M: 2.454687E-11
Real
Aptamer SeqId: 13610-9 | Target: MAGE-10 | UniProt: P43363
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13610-9 | Target: MAGE-10 | UniProt: P43363 | TargetFullName: Melanoma-associated antigen 10 | Organisim: human | Apparent_Kd_M: 8.163914E-11
Real
Aptamer SeqId: 13612-7 | Target: CYTIP | UniProt: O60759
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13612-7 | Target: CYTIP | UniProt: O60759 | TargetFullName: Cytohesin-interacting protein | Organisim: human | Apparent_Kd_M: 6.930758E-12
Real
Aptamer SeqId: 13613-23 | Target: Adenylate kinase isoenzyme 5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13613-23 | Target: Adenylate kinase isoenzyme 5 | UniProt: Q9Y6K8 | TargetFullName: Adenylate kinase isoenzyme 5 | Organisim: human | Apparent_Kd_M: 1.299997E-10
Real
Aptamer SeqId: 13614-6 | Target: CREB-binding protein | UniProt: Q92793
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13614-6 | Target: CREB-binding protein | UniProt: Q92793 | TargetFullName: CREB-binding protein | Organisim: human | Apparent_Kd_M: 4.557514E-11
Real
Aptamer SeqId: 13615-60 | Target: NCK2 | UniProt: O43639
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13615-60 | Target: NCK2 | UniProt: O43639 | TargetFullName: Cytoplasmic protein NCK2 | Organisim: human | Apparent_Kd_M: 1.83438E-11
Real
Aptamer SeqId: 13618-15 | Target: MD1L1 | UniProt: Q9Y6D9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13618-15 | Target: MD1L1 | UniProt: Q9Y6D9 | TargetFullName: Mitotic spindle assembly checkpoint protein MAD1 | Organisim: human | Apparent_Kd_M: 7.550895E-12
Real
Aptamer SeqId: 13620-10 | Target: ASNA | UniProt: O43681
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13620-10 | Target: ASNA | UniProt: O43681 | TargetFullName: ATPase ASNA1 | Organisim: human | Apparent_Kd_M: 1.341221E-10
Real
Aptamer SeqId: 13621-31 | Target: AP2A2 | UniProt: O94973
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13621-31 | Target: AP2A2 | UniProt: O94973 | TargetFullName: AP-2 complex subunit alpha-2 | Organisim: human | Apparent_Kd_M: 1.65E-12
Real
Aptamer SeqId: 13622-16 | Target: 2A5A | UniProt: Q15172
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13622-16 | Target: 2A5A | UniProt: Q15172 | TargetFullName: Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit alpha isoform | Organisim: human | Apparent_Kd_M: 1.46E-11
Real
Aptamer SeqId: 13623-4 | Target: MLL2 | UniProt: O14686
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13623-4 | Target: MLL2 | UniProt: O14686 | TargetFullName: Histone-lysine N-methyltransferase 2D | Organisim: human | Apparent_Kd_M: 6.62846E-12
Real
Aptamer SeqId: 13624-17 | Target: NADK | UniProt: O95544
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13624-17 | Target: NADK | UniProt: O95544 | TargetFullName: NAD kinase | Organisim: human | Apparent_Kd_M: 3.58828E-12
Real
Aptamer SeqId: 13625-19 | Target: LA | UniProt: P05455
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13625-19 | Target: LA | UniProt: P05455 | TargetFullName: Lupus La protein | Organisim: human | Apparent_Kd_M: 6.49E-11
Real
Aptamer SeqId: 13628-58 | Target: GRB14 | UniProt: Q14449
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13628-58 | Target: GRB14 | UniProt: Q14449 | TargetFullName: Growth factor receptor-bound protein 14 | Organisim: human | Apparent_Kd_M: 1.569638E-10
Real
Aptamer SeqId: 13629-25 | Target: ATG4B | UniProt: Q9Y4P1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13629-25 | Target: ATG4B | UniProt: Q9Y4P1 | TargetFullName: Cysteine protease ATG4B | Organisim: human | Apparent_Kd_M: 5.401874E-11
Real
Aptamer SeqId: 13631-1 | Target: RB binding protein 5 | UniProt: Q15291
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13631-1 | Target: RB binding protein 5 | UniProt: Q15291 | TargetFullName: Retinoblastoma-binding protein 5 | Organisim: human | Apparent_Kd_M: 3.474175E-12
Real
Aptamer SeqId: 13632-10 | Target: Zyxin | UniProt: Q15942
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13632-10 | Target: Zyxin | UniProt: Q15942 | TargetFullName: Zyxin | Organisim: human | Apparent_Kd_M: 1.105713E-11
Real
Aptamer SeqId: 13634-209 | Target: PIR | UniProt: O00625
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13634-209 | Target: PIR | UniProt: O00625 | TargetFullName: Pirin | Organisim: human | Apparent_Kd_M: 4.51501E-12
Real
Aptamer SeqId: 13636-20 | Target: NP1L1 | UniProt: P55209
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13636-20 | Target: NP1L1 | UniProt: P55209 | TargetFullName: Nucleosome assembly protein 1-like 1 | Organisim: human | Apparent_Kd_M: 7.83871E-12
Real
Aptamer SeqId: 13639-101 | Target: USO1 | UniProt: O60763
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13639-101 | Target: USO1 | UniProt: O60763 | TargetFullName: General vesicular transport factor p115 | Organisim: human | Apparent_Kd_M: 1.066422E-10
Real
Aptamer SeqId: 13642-90 | Target: CIG49 | UniProt: O14879
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13642-90 | Target: CIG49 | UniProt: O14879 | TargetFullName: Interferon-induced protein with tetratricopeptide repeats 3 | Organisim: human | Apparent_Kd_M: 8.188334E-12
Real
Aptamer SeqId: 13644-30 | Target: HGS | UniProt: O14964
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13644-30 | Target: HGS | UniProt: O14964 | TargetFullName: Hepatocyte growth factor-regulated tyrosine kinase substrate | Organisim: human | Apparent_Kd_M: 2.250544E-12
Real
Aptamer SeqId: 13645-14 | Target: PRP16 | UniProt: Q92620
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13645-14 | Target: PRP16 | UniProt: Q92620 | TargetFullName: Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 | Organisim: human | Apparent_Kd_M: 5.551291E-11
Real
Aptamer SeqId: 13650-11 | Target: KCIP1 | UniProt: Q9NZI2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13650-11 | Target: KCIP1 | UniProt: Q9NZI2 | TargetFullName: Kv channel-interacting protein 1 | Organisim: human | Apparent_Kd_M: 1.473081E-10
Real
Aptamer SeqId: 13651-54 | Target: ZFP91 | UniProt: Q96JP5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13651-54 | Target: ZFP91 | UniProt: Q96JP5 | TargetFullName: E3 ubiquitin-protein ligase ZFP91 | Organisim: human | Apparent_Kd_M: 9.885553E-12
Real
Aptamer SeqId: 13652-2 | Target: TM1L1 | UniProt: O75674
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13652-2 | Target: TM1L1 | UniProt: O75674 | TargetFullName: TOM1-like protein 1 | Organisim: human | Apparent_Kd_M: 7.911346E-12
Real
Aptamer SeqId: 13653-335 | Target: MACD1 | UniProt: Q9BQ69
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13653-335 | Target: MACD1 | UniProt: Q9BQ69 | TargetFullName: O-acetyl-ADP-ribose deacetylase MACROD1 | Organisim: human | Apparent_Kd_M: 5.74414E-11
Real
Aptamer SeqId: 13654-1 | Target: ROCK2 | UniProt: O75116
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13654-1 | Target: ROCK2 | UniProt: O75116 | TargetFullName: Rho-associated protein kinase 2 | Organisim: human | Apparent_Kd_M: 1.838118E-10
Real
Aptamer SeqId: 13655-34 | Target: Nucleolin | UniProt: P19338
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13655-34 | Target: Nucleolin | UniProt: P19338 | TargetFullName: Nucleolin | Organisim: human | Apparent_Kd_M: 9.192547E-12
Real
Aptamer SeqId: 13657-2 | Target: PNKP | UniProt: Q96T60
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13657-2 | Target: PNKP | UniProt: Q96T60 | TargetFullName: Bifunctional polynucleotide phosphatase/kinase | Organisim: human | Apparent_Kd_M: 9.132099E-12
Real
Aptamer SeqId: 13658-31 | Target: PDGF-CC | UniProt: Q9NRA1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13658-31 | Target: PDGF-CC | UniProt: Q9NRA1 | TargetFullName: Platelet-derived growth factor C | Organisim: human | Apparent_Kd_M: 1.01E-10
Real
Aptamer SeqId: 13659-36 | Target: AT131 | UniProt: Q9HD20
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13659-36 | Target: AT131 | UniProt: Q9HD20 | TargetFullName: Manganese-transporting ATPase 13A1 | Organisim: human | Apparent_Kd_M: 9.708494E-11
Real
Aptamer SeqId: 13665-35 | Target: PP2A; subunit B | UniProt: Q06190
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13665-35 | Target: PP2A; subunit B | UniProt: Q06190 | TargetFullName: Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit alpha | Organisim: human | Apparent_Kd_M: 4.794455E-11
Real
Aptamer SeqId: 13666-222 | Target: Carbonic Anhydrase X | UniProt: Q9NS85
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13666-222 | Target: Carbonic Anhydrase X | UniProt: Q9NS85 | TargetFullName: Carbonic anhydrase-related protein 10 | Organisim: human | Apparent_Kd_M: 2.17E-11
Real
Aptamer SeqId: 13669-6 | Target: FGFR-3 | UniProt: P22607
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13669-6 | Target: FGFR-3 | UniProt: P22607 | TargetFullName: Fibroblast growth factor receptor 3 | Organisim: human | Apparent_Kd_M: 3.4E-12
Real
Aptamer SeqId: 13671-40 | Target: Elastase | UniProt: P08246
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13671-40 | Target: Elastase | UniProt: P08246 | TargetFullName: Neutrophil elastase | Organisim: human | Apparent_Kd_M: 2.09E-12
Real
Aptamer SeqId: 13672-3 | Target: HSP76 | UniProt: P17066
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13672-3 | Target: HSP76 | UniProt: P17066 | TargetFullName: Heat shock 70 kDa protein 6 | Organisim: human | Apparent_Kd_M: 1.50901E-10
Real
Aptamer SeqId: 13673-21 | Target: TCPH | UniProt: Q99832
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13673-21 | Target: TCPH | UniProt: Q99832 | TargetFullName: T-complex protein 1 subunit eta | Organisim: human | Apparent_Kd_M: 6.586271E-12
Real
Aptamer SeqId: 13676-46 | Target: Inhibin bB chain | UniProt: P09529
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13676-46 | Target: Inhibin bB chain | UniProt: P09529 | TargetFullName: Inhibin beta B chain | Organisim: human | Apparent_Kd_M: 9.232558E-12
Real
Aptamer SeqId: 13680-3 | Target: NAB2 | UniProt: Q15742
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13680-3 | Target: NAB2 | UniProt: Q15742 | TargetFullName: NGFI-A-binding protein 2 | Organisim: human | Apparent_Kd_M: 2.075006E-12
Real
Aptamer SeqId: 13681-173 | Target: CSK22 | UniProt: P19784
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13681-173 | Target: CSK22 | UniProt: P19784 | TargetFullName: Casein kinase II subunit alpha' | Organisim: human | Apparent_Kd_M: 9.082997E-12
Real
Aptamer SeqId: 13682-47 | Target: M-CSF R | UniProt: P07333
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13682-47 | Target: M-CSF R | UniProt: P07333 | TargetFullName: Macrophage colony-stimulating factor 1 receptor | Organisim: human | Apparent_Kd_M: 1.0E-12
Real
Aptamer SeqId: 13683-18 | Target: CLCKB | UniProt: P51801
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13683-18 | Target: CLCKB | UniProt: P51801 | TargetFullName: Chloride channel protein ClC-Kb | Organisim: human | Apparent_Kd_M: 5.030059E-11
Real
Aptamer SeqId: 13686-2 | Target: IL-5 Ra | UniProt: Q01344
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13686-2 | Target: IL-5 Ra | UniProt: Q01344 | TargetFullName: Interleukin-5 receptor subunit alpha | Organisim: human | Apparent_Kd_M: 3.07E-11
Real
Aptamer SeqId: 13688-2 | Target: CAPSL | UniProt: Q8WWF8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13688-2 | Target: CAPSL | UniProt: Q8WWF8 | TargetFullName: Calcyphosin-like protein | Organisim: human | Apparent_Kd_M: 8.364098E-12
Real
Aptamer SeqId: 13689-2 | Target: Ornithine decarboxylase | UniProt: P11926
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13689-2 | Target: Ornithine decarboxylase | UniProt: P11926 | TargetFullName: Ornithine decarboxylase | Organisim: human | Apparent_Kd_M: 4.630516E-11
Real
Aptamer SeqId: 13691-10 | Target: SC5A8 | UniProt: Q8N695
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13691-10 | Target: SC5A8 | UniProt: Q8N695 | TargetFullName: Sodium-coupled monocarboxylate transporter 1 | Organisim: human | Apparent_Kd_M: 3.220796E-12
Real
Aptamer SeqId: 13692-154 | Target: WISP-1 | UniProt: O95388
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13692-154 | Target: WISP-1 | UniProt: O95388 | TargetFullName: WNT1-inducible-signaling pathway protein 1 | Organisim: human | Apparent_Kd_M: 3.92E-12
Real
Aptamer SeqId: 13694-24 | Target: TSLP R | UniProt: Q9HC73
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13694-24 | Target: TSLP R | UniProt: Q9HC73 | TargetFullName: Cytokine receptor-like factor 2 | Organisim: human | Apparent_Kd_M: 1.84E-11
Real
Aptamer SeqId: 13697-51 | Target: GPDA | UniProt: P21695
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13697-51 | Target: GPDA | UniProt: P21695 | TargetFullName: Glycerol-3-phosphate dehydrogenase NAD(+); cytoplasmic | Organisim: human | Apparent_Kd_M: 2.28E-12
Real
Aptamer SeqId: 13698-28 | Target: K319L | UniProt: Q8IZA0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13698-28 | Target: K319L | UniProt: Q8IZA0 | TargetFullName: Dyslexia-associated protein KIAA0319-like protein | Organisim: human | Apparent_Kd_M: 1.641937E-10
Real
Aptamer SeqId: 13700-10 | Target: annexin II | UniProt: P07355
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13700-10 | Target: annexin II | UniProt: P07355 | TargetFullName: Annexin A2 | Organisim: human | Apparent_Kd_M: 1.13E-11
Real
Aptamer SeqId: 13704-5 | Target: HMCS2 | UniProt: P54868
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13704-5 | Target: HMCS2 | UniProt: P54868 | TargetFullName: Hydroxymethylglutaryl-CoA synthase; mitochondrial | Organisim: human | Apparent_Kd_M: 3.563167E-11
Real
Aptamer SeqId: 13711-10 | Target: CLH1 | UniProt: Q00610
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13711-10 | Target: CLH1 | UniProt: Q00610 | TargetFullName: Clathrin heavy chain 1 | Organisim: human | Apparent_Kd_M: 1.75018E-11
Real
Aptamer SeqId: 13713-164 | Target: SC22A | UniProt: Q96IW7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13713-164 | Target: SC22A | UniProt: Q96IW7 | TargetFullName: Vesicle-trafficking protein SEC22a | Organisim: human | Apparent_Kd_M: 8.995284E-11
Real
Aptamer SeqId: 13717-15 | Target: FCN2 | UniProt: Q15485
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13717-15 | Target: FCN2 | UniProt: Q15485 | TargetFullName: Ficolin-2 | Organisim: human | Apparent_Kd_M: 8.1E-12
Real
Aptamer SeqId: 13719-19 | Target: PAK4 | UniProt: O96013
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13719-19 | Target: PAK4 | UniProt: O96013 | TargetFullName: Serine/threonine-protein kinase PAK 4 | Organisim: human | Apparent_Kd_M: 3.143172E-12
Real
Aptamer SeqId: 13720-95 | Target: Proteinase-3 | UniProt: P24158
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13720-95 | Target: Proteinase-3 | UniProt: P24158 | TargetFullName: Myeloblastin | Organisim: human | Apparent_Kd_M: 1.15E-11
Real
Aptamer SeqId: 13724-27 | Target: FGF-19 | UniProt: O95750
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13724-27 | Target: FGF-19 | UniProt: O95750 | TargetFullName: Fibroblast growth factor 19 | Organisim: human | Apparent_Kd_M: 1.7E-12
Real
Aptamer SeqId: 13726-4 | Target: B7 | UniProt: P33681
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13726-4 | Target: B7 | UniProt: P33681 | TargetFullName: T-lymphocyte activation antigen CD80 | Organisim: human | Apparent_Kd_M: 1.75E-11
Real
Aptamer SeqId: 13727-44 | Target: SPOP | UniProt: O43791
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13727-44 | Target: SPOP | UniProt: O43791 | TargetFullName: Speckle-type POZ protein | Organisim: human | Apparent_Kd_M: 1.478395E-12
Real
Aptamer SeqId: 13728-19 | Target: ERP29 | UniProt: P30040
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13728-19 | Target: ERP29 | UniProt: P30040 | TargetFullName: Endoplasmic reticulum resident protein 29 | Organisim: human | Apparent_Kd_M: 6.99E-12
Real
Aptamer SeqId: 13729-26 | Target: SFXN5 | UniProt: Q8TD22
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13729-26 | Target: SFXN5 | UniProt: Q8TD22 | TargetFullName: Sideroflexin-5 | Organisim: human | Apparent_Kd_M: 7.117484E-11
Real
Aptamer SeqId: 13733-5 | Target: IL-12 p40 | UniProt: P29460
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13733-5 | Target: IL-12 p40 | UniProt: P29460 | TargetFullName: Interleukin-12 subunit beta | Organisim: human | Apparent_Kd_M: 7.639236E-12
Real
Aptamer SeqId: 13735-1 | Target: RPGP1 | UniProt: P47736
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13735-1 | Target: RPGP1 | UniProt: P47736 | TargetFullName: Rap1 GTPase-activating protein 1 | Organisim: human | Apparent_Kd_M: 1.405821E-10
Real
Aptamer SeqId: 13738-8 | Target: Inhibin bA chain | UniProt: P08476
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13738-8 | Target: Inhibin bA chain | UniProt: P08476 | TargetFullName: Inhibin beta A chain | Organisim: human | Apparent_Kd_M: 1.418923E-11
Real
Aptamer SeqId: 13740-51 | Target: sFRP-3 | UniProt: Q92765
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13740-51 | Target: sFRP-3 | UniProt: Q92765 | TargetFullName: Secreted frizzled-related protein 3 | Organisim: human | Apparent_Kd_M: 1.48E-11
Real
Aptamer SeqId: 13743-56 | Target: CUL4B | UniProt: Q13620
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13743-56 | Target: CUL4B | UniProt: Q13620 | TargetFullName: Cullin-4B | Organisim: human | Apparent_Kd_M: 4.188179E-11
Real
Aptamer SeqId: 13744-37 | Target: IL-3 Ra | UniProt: P26951
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13744-37 | Target: IL-3 Ra | UniProt: P26951 | TargetFullName: Interleukin-3 receptor subunit alpha | Organisim: human | Apparent_Kd_M: 3.36E-12
Real
Aptamer SeqId: 13745-10 | Target: PKD2 | UniProt: Q13563
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13745-10 | Target: PKD2 | UniProt: Q13563 | TargetFullName: Polycystin-2 | Organisim: human | Apparent_Kd_M: 6.61E-11
Real
Aptamer SeqId: 13748-4 | Target: MCP-2 | UniProt: P80075
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13748-4 | Target: MCP-2 | UniProt: P80075 | TargetFullName: C-C motif chemokine 8 | Organisim: human | Apparent_Kd_M: 8.59E-12
Real
Aptamer SeqId: 13926-1 | Target: RMI1 | UniProt: Q9H9A7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13926-1 | Target: RMI1 | UniProt: Q9H9A7 | TargetFullName: RecQ-mediated genome instability protein 1 | Organisim: human | Apparent_Kd_M: 4.160065E-11
Real
Aptamer SeqId: 13929-27 | Target: OCTC | UniProt: Q9UKG9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13929-27 | Target: OCTC | UniProt: Q9UKG9 | TargetFullName: Peroxisomal carnitine O-octanoyltransferase | Organisim: human | Apparent_Kd_M: 3.301688E-12
Real
Aptamer SeqId: 13930-3 | Target: ABC3G | UniProt: Q9HC16
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13930-3 | Target: ABC3G | UniProt: Q9HC16 | TargetFullName: DNA dC->dU-editing enzyme APOBEC-3G | Organisim: human | Apparent_Kd_M: 2.043927E-12
Real
Aptamer SeqId: 13931-22 | Target: PSMD9 | UniProt: O00233
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13931-22 | Target: PSMD9 | UniProt: O00233 | TargetFullName: 26S proteasome non-ATPase regulatory subunit 9 | Organisim: human | Apparent_Kd_M: 1.023567E-11
Real
Aptamer SeqId: 13932-45 | Target: COOL-1 | UniProt: Q14155
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13932-45 | Target: COOL-1 | UniProt: Q14155 | TargetFullName: Rho guanine nucleotide exchange factor 7 | Organisim: human | Apparent_Kd_M: 5.205579E-11
Real
Aptamer SeqId: 13933-276 | Target: NAB1 | UniProt: Q13506
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13933-276 | Target: NAB1 | UniProt: Q13506 | TargetFullName: NGFI-A-binding protein 1 | Organisim: human | Apparent_Kd_M: 6.762284E-12
Real
Aptamer SeqId: 13934-3 | Target: MCF2L | UniProt: O15068
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13934-3 | Target: MCF2L | UniProt: O15068 | TargetFullName: Guanine nucleotide exchange factor DBS | Organisim: human | Apparent_Kd_M: 1.45904E-11
Real
Aptamer SeqId: 13936-24 | Target: PGK2 | UniProt: P07205
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13936-24 | Target: PGK2 | UniProt: P07205 | TargetFullName: Phosphoglycerate kinase 2 | Organisim: human | Apparent_Kd_M: 5.77863E-11
Real
Aptamer SeqId: 13937-75 | Target: CAND1 | UniProt: Q86VP6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13937-75 | Target: CAND1 | UniProt: Q86VP6 | TargetFullName: Cullin-associated NEDD8-dissociated protein 1 | Organisim: human | Apparent_Kd_M: 1.812179E-11
Real
Aptamer SeqId: 13939-14 | Target: UGPA1 | UniProt: Q16851
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13939-14 | Target: UGPA1 | UniProt: Q16851 | TargetFullName: UTP--glucose-1-phosphate uridylyltransferase | Organisim: human | Apparent_Kd_M: 1.412788E-10
Real
Aptamer SeqId: 13940-19 | Target: IP16 | UniProt: Q16666
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13940-19 | Target: IP16 | UniProt: Q16666 | TargetFullName: Gamma-interferon-inducible protein 16 | Organisim: human | Apparent_Kd_M: 1.57E-12
Real
Aptamer SeqId: 13941-82 | Target: SYFM | UniProt: O95363
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13941-82 | Target: SYFM | UniProt: O95363 | TargetFullName: Phenylalanine--tRNA ligase; mitochondrial | Organisim: human | Apparent_Kd_M: 3.553948E-11
Real
Aptamer SeqId: 13942-140 | Target: SPSB1 | UniProt: Q96BD6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13942-140 | Target: SPSB1 | UniProt: Q96BD6 | TargetFullName: SPRY domain-containing SOCS box protein 1 | Organisim: human | Apparent_Kd_M: 4.506301E-11
Real
Aptamer SeqId: 13943-38 | Target: DPY30 | UniProt: Q9C005
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13943-38 | Target: DPY30 | UniProt: Q9C005 | TargetFullName: Protein dpy-30 homolog | Organisim: human | Apparent_Kd_M: 1.940519E-12
Real
Aptamer SeqId: 13944-3 | Target: SULT 1A3 | UniProt: P0DMM9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13944-3 | Target: SULT 1A3 | UniProt: P0DMM9 | TargetFullName: Sulfotransferase 1A3 | Organisim: human | Apparent_Kd_M: 4.448135E-12
Real
Aptamer SeqId: 13946-8 | Target: DDX23 | UniProt: Q9BUQ8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13946-8 | Target: DDX23 | UniProt: Q9BUQ8 | TargetFullName: Probable ATP-dependent RNA helicase DDX23 | Organisim: human | Apparent_Kd_M: 1.420733E-10
Real
Aptamer SeqId: 13947-371 | Target: NUD12 | UniProt: Q9BQG2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13947-371 | Target: NUD12 | UniProt: Q9BQG2 | TargetFullName: Peroxisomal NADH pyrophosphatase NUDT12 | Organisim: human | Apparent_Kd_M: 8.782994E-12
Real
Aptamer SeqId: 13948-50 | Target: GABR2 | UniProt: O75899
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13948-50 | Target: GABR2 | UniProt: O75899 | TargetFullName: Gamma-aminobutyric acid type B receptor subunit 2 | Organisim: human | Apparent_Kd_M: 5.75E-11
Real
Aptamer SeqId: 13950-9 | Target: C43BP | UniProt: Q9Y5P4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13950-9 | Target: C43BP | UniProt: Q9Y5P4 | TargetFullName: Collagen type IV alpha-3-binding protein | Organisim: human | Apparent_Kd_M: 8.89E-13
Real
Aptamer SeqId: 13954-9 | Target: GNA1 | UniProt: Q96EK6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13954-9 | Target: GNA1 | UniProt: Q96EK6 | TargetFullName: Glucosamine 6-phosphate N-acetyltransferase | Organisim: human | Apparent_Kd_M: 4.46E-12
Real
Aptamer SeqId: 13955-33 | Target: DAPK1 | UniProt: P53355
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13955-33 | Target: DAPK1 | UniProt: P53355 | TargetFullName: Death-associated protein kinase 1 | Organisim: human | Apparent_Kd_M: 3.538969E-12
Real
Aptamer SeqId: 13958-5 | Target: RBM46 | UniProt: Q8TBY0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13958-5 | Target: RBM46 | UniProt: Q8TBY0 | TargetFullName: Probable RNA-binding protein 46 | Organisim: human | Apparent_Kd_M: 1.630094E-12
Real
Aptamer SeqId: 13959-7 | Target: LAP | UniProt: P28838
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13959-7 | Target: LAP | UniProt: P28838 | TargetFullName: Cytosol aminopeptidase | Organisim: human | Apparent_Kd_M: 4.58E-12
Real
Aptamer SeqId: 13960-15 | Target: AGAP3 | UniProt: Q96P47
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13960-15 | Target: AGAP3 | UniProt: Q96P47 | TargetFullName: Arf-GAP with GTPase; ANK repeat and PH domain-containing protein 3 | Organisim: human | Apparent_Kd_M: 2.044526E-11
Real
Aptamer SeqId: 13961-18 | Target: KIF3A | UniProt: Q9Y496
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13961-18 | Target: KIF3A | UniProt: Q9Y496 | TargetFullName: Kinesin-like protein KIF3A | Organisim: human | Apparent_Kd_M: 1.539953E-11
Real
Aptamer SeqId: 13963-7 | Target: tollip | UniProt: Q9H0E2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13963-7 | Target: tollip | UniProt: Q9H0E2 | TargetFullName: Toll-interacting protein | Organisim: human | Apparent_Kd_M: 1.159678E-11
Real
Aptamer SeqId: 13966-30 | Target: MYOM3 | UniProt: Q5VTT5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13966-30 | Target: MYOM3 | UniProt: Q5VTT5 | TargetFullName: Myomesin-3 | Organisim: human | Apparent_Kd_M: 1.120706E-10
Real
Aptamer SeqId: 13967-14 | Target: Thioredoxin reductase 1 | UniProt: Q16881
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13967-14 | Target: Thioredoxin reductase 1 | UniProt: Q16881 | TargetFullName: Thioredoxin reductase 1; cytoplasmic | Organisim: human | Apparent_Kd_M: 1.861339E-12
Real
Aptamer SeqId: 13969-24 | Target: IMA7 | UniProt: O60684
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13969-24 | Target: IMA7 | UniProt: O60684 | TargetFullName: Importin subunit alpha-7 | Organisim: human | Apparent_Kd_M: 1.804402E-11
Real
Aptamer SeqId: 13972-4 | Target: DHB14 | UniProt: Q9BPX1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13972-4 | Target: DHB14 | UniProt: Q9BPX1 | TargetFullName: 17-beta-hydroxysteroid dehydrogenase 14 | Organisim: human | Apparent_Kd_M: 8.536608E-12
Real
Aptamer SeqId: 13973-62 | Target: TTL | UniProt: Q8NG68
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13973-62 | Target: TTL | UniProt: Q8NG68 | TargetFullName: Tubulin--tyrosine ligase | Organisim: human | Apparent_Kd_M: 9.483174E-13
Real
Aptamer SeqId: 13975-56 | Target: LIPA1 | UniProt: Q13136
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13975-56 | Target: LIPA1 | UniProt: Q13136 | TargetFullName: Liprin-alpha-1 | Organisim: human | Apparent_Kd_M: 1.070743E-11
Real
Aptamer SeqId: 13976-9 | Target: ARHG1 | UniProt: Q92888
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13976-9 | Target: ARHG1 | UniProt: Q92888 | TargetFullName: Rho guanine nucleotide exchange factor 1 | Organisim: human | Apparent_Kd_M: 4.205003E-11
Real
Aptamer SeqId: 13977-28 | Target: BARD1 | UniProt: Q99728
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13977-28 | Target: BARD1 | UniProt: Q99728 | TargetFullName: BRCA1-associated RING domain protein 1 | Organisim: human | Apparent_Kd_M: 8.907234E-12
Real
Aptamer SeqId: 13978-122 | Target: Tbx3 | UniProt: O15119
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13978-122 | Target: Tbx3 | UniProt: O15119 | TargetFullName: T-box transcription factor TBX3 | Organisim: human | Apparent_Kd_M: 1.852691E-12
Real
Aptamer SeqId: 13979-3 | Target: S26A7 | UniProt: Q8TE54
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13979-3 | Target: S26A7 | UniProt: Q8TE54 | TargetFullName: Anion exchange transporter | Organisim: human | Apparent_Kd_M: 9.697767E-11
Real
Aptamer SeqId: 13982-33 | Target: RGS18 | UniProt: Q9NS28
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13982-33 | Target: RGS18 | UniProt: Q9NS28 | TargetFullName: Regulator of G-protein signaling 18 | Organisim: human | Apparent_Kd_M: 3.216424E-10
Real
Aptamer SeqId: 13983-27 | Target: QOR | UniProt: Q08257
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13983-27 | Target: QOR | UniProt: Q08257 | TargetFullName: Quinone oxidoreductase | Organisim: human | Apparent_Kd_M: 1.384014E-11
Real
Aptamer SeqId: 13984-23 | Target: DDX25 | UniProt: Q9UHL0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13984-23 | Target: DDX25 | UniProt: Q9UHL0 | TargetFullName: ATP-dependent RNA helicase DDX25 | Organisim: human | Apparent_Kd_M: 3.345465E-11
Real
Aptamer SeqId: 13985-12 | Target: SMUF2 | UniProt: Q9HAU4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13985-12 | Target: SMUF2 | UniProt: Q9HAU4 | TargetFullName: E3 ubiquitin-protein ligase SMURF2 | Organisim: human | Apparent_Kd_M: 1.70144E-12
Real
Aptamer SeqId: 13986-6 | Target: LANC1 | UniProt: O43813
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13986-6 | Target: LANC1 | UniProt: O43813 | TargetFullName: LanC-like protein 1 | Organisim: human | Apparent_Kd_M: 6.118636E-12
Real
Aptamer SeqId: 13988-67 | Target: NMRL1 | UniProt: Q9HBL8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13988-67 | Target: NMRL1 | UniProt: Q9HBL8 | TargetFullName: NmrA-like family domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 8.309388E-13
Real
Aptamer SeqId: 13990-1 | Target: pyruvate carboxylase | UniProt: P11498
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13990-1 | Target: pyruvate carboxylase | UniProt: P11498 | TargetFullName: Pyruvate carboxylase; mitochondrial | Organisim: human | Apparent_Kd_M: 1.732678E-11
Real
Aptamer SeqId: 13991-47 | Target: IF4G3 | UniProt: O43432
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13991-47 | Target: IF4G3 | UniProt: O43432 | TargetFullName: Eukaryotic translation initiation factor 4 gamma 3 | Organisim: human | Apparent_Kd_M: 1.187855E-10
Real
Aptamer SeqId: 13992-12 | Target: NSF | UniProt: P46459
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13992-12 | Target: NSF | UniProt: P46459 | TargetFullName: Vesicle-fusing ATPase | Organisim: human | Apparent_Kd_M: 2.394635E-12
Real
Aptamer SeqId: 13993-20 | Target: E41L1 | UniProt: Q9H4G0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13993-20 | Target: E41L1 | UniProt: Q9H4G0 | TargetFullName: Band 4.1-like protein 1 | Organisim: human | Apparent_Kd_M: 6.016881E-12
Real
Aptamer SeqId: 13994-1 | Target: FBRL | UniProt: P22087
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13994-1 | Target: FBRL | UniProt: P22087 | TargetFullName: rRNA 2'-O-methyltransferase fibrillarin | Organisim: human | Apparent_Kd_M: 1.085895E-10
Real
Aptamer SeqId: 13996-16 | Target: COAC | UniProt: Q96CD2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13996-16 | Target: COAC | UniProt: Q96CD2 | TargetFullName: Phosphopantothenoylcysteine decarboxylase | Organisim: human | Apparent_Kd_M: 1.376886E-10
Real
Aptamer SeqId: 13998-26 | Target: PURA1 | UniProt: Q8N142
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 13998-26 | Target: PURA1 | UniProt: Q8N142 | TargetFullName: Adenylosuccinate synthetase isozyme 1 | Organisim: human | Apparent_Kd_M: 4.474693E-12
Real
Aptamer SeqId: 14002-18 | Target: DOCK9 | UniProt: Q9BZ29
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14002-18 | Target: DOCK9 | UniProt: Q9BZ29 | TargetFullName: Dedicator of cytokinesis protein 9 | Organisim: human | Apparent_Kd_M: 3.980992E-12
Real
Aptamer SeqId: 14005-2 | Target: CHD7 | UniProt: Q9P2D1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14005-2 | Target: CHD7 | UniProt: Q9P2D1 | TargetFullName: Chromodomain-helicase-DNA-binding protein 7 | Organisim: human | Apparent_Kd_M: 4.978925E-12
Real
Aptamer SeqId: 14006-36 | Target: GNMT | UniProt: Q14749
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14006-36 | Target: GNMT | UniProt: Q14749 | TargetFullName: Glycine N-methyltransferase | Organisim: human | Apparent_Kd_M: 7.633297E-11
Real
Aptamer SeqId: 14007-22 | Target: PAPS1 | UniProt: O43252
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14007-22 | Target: PAPS1 | UniProt: O43252 | TargetFullName: Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1 | Organisim: human | Apparent_Kd_M: 2.420758E-12
Real
Aptamer SeqId: 14008-22 | Target: DCP1A | UniProt: Q9NPI6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14008-22 | Target: DCP1A | UniProt: Q9NPI6 | TargetFullName: mRNA-decapping enzyme 1A | Organisim: human | Apparent_Kd_M: 2.776297E-11
Real
Aptamer SeqId: 14009-65 | Target: TNFAIP3 | UniProt: P21580
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14009-65 | Target: TNFAIP3 | UniProt: P21580 | TargetFullName: Tumor necrosis factor alpha-induced protein 3 | Organisim: human | Apparent_Kd_M: 3.130362E-11
Real
Aptamer SeqId: 14011-17 | Target: S100A11 | UniProt: P31949
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14011-17 | Target: S100A11 | UniProt: P31949 | TargetFullName: Protein S100-A11 | Organisim: human | Apparent_Kd_M: 1.282973E-10
Real
Aptamer SeqId: 14012-17 | Target: LGP2 | UniProt: Q96C10
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14012-17 | Target: LGP2 | UniProt: Q96C10 | TargetFullName: Probable ATP-dependent RNA helicase DHX58 | Organisim: human | Apparent_Kd_M: 2.859628E-12
Real
Aptamer SeqId: 14013-11 | Target: TANK | UniProt: Q92844
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14013-11 | Target: TANK | UniProt: Q92844 | TargetFullName: TRAF family member-associated NF-kappa-B activator | Organisim: human | Apparent_Kd_M: 8.905018E-11
Real
Aptamer SeqId: 14019-73 | Target: EVPL | UniProt: Q92817
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14019-73 | Target: EVPL | UniProt: Q92817 | TargetFullName: Envoplakin | Organisim: human | Apparent_Kd_M: 2.261611E-12
Real
Aptamer SeqId: 14021-81 | Target: MED4 | UniProt: Q9NPJ6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14021-81 | Target: MED4 | UniProt: Q9NPJ6 | TargetFullName: Mediator of RNA polymerase II transcription subunit 4 | Organisim: human | Apparent_Kd_M: 5.955213E-11
Real
Aptamer SeqId: 14024-196 | Target: EDA | UniProt: Q92838
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14024-196 | Target: EDA | UniProt: Q92838 | TargetFullName: Ectodysplasin-A; secreted form | Organisim: human | Apparent_Kd_M: 1.37E-11
Real
Aptamer SeqId: 14025-18 | Target: 4-1BB | UniProt: Q07011
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14025-18 | Target: 4-1BB | UniProt: Q07011 | TargetFullName: Tumor necrosis factor receptor superfamily member 9 | Organisim: human | Apparent_Kd_M: 8.52E-12
Real
Aptamer SeqId: 14026-24 | Target: IL-17F | UniProt: Q96PD4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14026-24 | Target: IL-17F | UniProt: Q96PD4 | TargetFullName: Interleukin-17F | Organisim: human | Apparent_Kd_M: 4.69E-12
Real
Aptamer SeqId: 14028-22 | Target: P3C2A | UniProt: O00443
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14028-22 | Target: P3C2A | UniProt: O00443 | TargetFullName: Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha | Organisim: human | Apparent_Kd_M: 7.340167E-12
Real
Aptamer SeqId: 14029-42 | Target: CSN2 | UniProt: P61201
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14029-42 | Target: CSN2 | UniProt: P61201 | TargetFullName: COP9 signalosome complex subunit 2 | Organisim: human | Apparent_Kd_M: 3.839305E-11
Real
Aptamer SeqId: 14034-22 | Target: GA733-1 protein | UniProt: P09758
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14034-22 | Target: GA733-1 protein | UniProt: P09758 | TargetFullName: Tumor-associated calcium signal transducer 2 | Organisim: human | Apparent_Kd_M: 8.33E-11
Real
Aptamer SeqId: 14035-13 | Target: TIAM1 | UniProt: Q13009
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14035-13 | Target: TIAM1 | UniProt: Q13009 | TargetFullName: T-lymphoma invasion and metastasis-inducing protein 1 | Organisim: human | Apparent_Kd_M: 1.206542E-11
Real
Aptamer SeqId: 14036-116 | Target: MPDZ | UniProt: O75970
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14036-116 | Target: MPDZ | UniProt: O75970 | TargetFullName: Multiple PDZ domain protein | Organisim: human | Apparent_Kd_M: 1.191479E-11
Real
Aptamer SeqId: 14037-18 | Target: RANB3 | UniProt: Q9H6Z4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14037-18 | Target: RANB3 | UniProt: Q9H6Z4 | TargetFullName: Ran-binding protein 3 | Organisim: human | Apparent_Kd_M: 3.326788E-12
Real
Aptamer SeqId: 14039-33 | Target: kallikrein 5 | UniProt: Q9Y337
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14039-33 | Target: kallikrein 5 | UniProt: Q9Y337 | TargetFullName: Kallikrein-5 | Organisim: human | Apparent_Kd_M: 1.87E-12
Real
Aptamer SeqId: 14043-12 | Target: EEA1 | UniProt: Q15075
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14043-12 | Target: EEA1 | UniProt: Q15075 | TargetFullName: Early endosome antigen 1 | Organisim: human | Apparent_Kd_M: 3.643589E-11
Real
Aptamer SeqId: 14045-12 | Target: NCOA2 | UniProt: Q15596
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14045-12 | Target: NCOA2 | UniProt: Q15596 | TargetFullName: Nuclear receptor coactivator 2 | Organisim: human | Apparent_Kd_M: 3.632351E-12
Real
Aptamer SeqId: 14047-78 | Target: BDNF | UniProt: P23560
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14047-78 | Target: BDNF | UniProt: P23560 | TargetFullName: Brain-derived neurotrophic factor | Organisim: human | Apparent_Kd_M: 6.48E-12
Real
Aptamer SeqId: 14048-7 | Target: IL-1 R AcP | UniProt: Q9NPH3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14048-7 | Target: IL-1 R AcP | UniProt: Q9NPH3 | TargetFullName: Interleukin-1 Receptor accessory protein | Organisim: human | Apparent_Kd_M: 5.14E-12
Real
Aptamer SeqId: 14051-54 | Target: FOXC2 | UniProt: Q99958
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14051-54 | Target: FOXC2 | UniProt: Q99958 | TargetFullName: Forkhead box protein C2 | Organisim: human | Apparent_Kd_M: 1.577293E-12
Real
Aptamer SeqId: 14052-26 | Target: UN13A | UniProt: Q9UPW8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14052-26 | Target: UN13A | UniProt: Q9UPW8 | TargetFullName: Protein unc-13 homolog A | Organisim: human | Apparent_Kd_M: 1.506135E-10
Real
Aptamer SeqId: 14054-17 | Target: IL-15 Ra | UniProt: Q13261
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14054-17 | Target: IL-15 Ra | UniProt: Q13261 | TargetFullName: Interleukin-15 receptor subunit alpha | Organisim: human | Apparent_Kd_M: 2.04E-12
Real
Aptamer SeqId: 14056-4 | Target: Glycoprotein hormones a-chain
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14056-4 | Target: Glycoprotein hormones a-chain | UniProt: P01215 | TargetFullName: Glycoprotein hormones alpha chain | Organisim: human | Apparent_Kd_M: 8.83536E-12
Real
Aptamer SeqId: 14060-67 | Target: NCF4 | UniProt: Q15080
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14060-67 | Target: NCF4 | UniProt: Q15080 | TargetFullName: Neutrophil cytosol factor 4 | Organisim: human | Apparent_Kd_M: 1.739092E-11
Real
Aptamer SeqId: 14061-48 | Target: sRANKL | UniProt: O14788
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14061-48 | Target: sRANKL | UniProt: O14788 | TargetFullName: Tumor necrosis factor ligand superfamily member 11 | Organisim: human | Apparent_Kd_M: 8.83E-11
Real
Aptamer SeqId: 14063-17 | Target: OSM | UniProt: P13725
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14063-17 | Target: OSM | UniProt: P13725 | TargetFullName: Oncostatin-M | Organisim: human | Apparent_Kd_M: 8.74E-12
Real
Aptamer SeqId: 14065-11 | Target: CD5 | UniProt: P06127
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14065-11 | Target: CD5 | UniProt: P06127 | TargetFullName: T-cell surface glycoprotein CD5 | Organisim: human | Apparent_Kd_M: 4.13E-11
Real
Aptamer SeqId: 14066-49 | Target: MAGI2 | UniProt: Q86UL8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14066-49 | Target: MAGI2 | UniProt: Q86UL8 | TargetFullName: Membrane-associated guanylate kinase; WW and PDZ domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 8.034514E-13
Real
Aptamer SeqId: 14067-6 | Target: PKP2 | UniProt: Q99959
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14067-6 | Target: PKP2 | UniProt: Q99959 | TargetFullName: Plakophilin-2 | Organisim: human | Apparent_Kd_M: 2.5792E-12
Real
Aptamer SeqId: 14069-61 | Target: Carbonic Anhydrase IV | UniProt: P22748
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14069-61 | Target: Carbonic Anhydrase IV | UniProt: P22748 | TargetFullName: Carbonic anhydrase 4 | Organisim: human | Apparent_Kd_M: 2.49E-11
Real
Aptamer SeqId: 14070-56 | Target: ITSN1 | UniProt: Q15811
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14070-56 | Target: ITSN1 | UniProt: Q15811 | TargetFullName: Intersectin-1 | Organisim: human | Apparent_Kd_M: 3.671377E-11
Real
Aptamer SeqId: 14074-2 | Target: SHC2 | UniProt: P98077
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14074-2 | Target: SHC2 | UniProt: P98077 | TargetFullName: SHC-transforming protein 2 | Organisim: human | Apparent_Kd_M: 4.668199E-12
Real
Aptamer SeqId: 14076-74 | Target: Cystatin-S | UniProt: P01036
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14076-74 | Target: Cystatin-S | UniProt: P01036 | TargetFullName: Cystatin-S | Organisim: human | Apparent_Kd_M: 6.99E-11
Real
Aptamer SeqId: 14079-14 | Target: IL-18 Ra | UniProt: Q13478
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14079-14 | Target: IL-18 Ra | UniProt: Q13478 | TargetFullName: Interleukin-18 receptor 1 | Organisim: human | Apparent_Kd_M: 1.79E-12
Real
Aptamer SeqId: 14082-56 | Target: TLN2 | UniProt: Q9Y4G6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14082-56 | Target: TLN2 | UniProt: Q9Y4G6 | TargetFullName: Talin-2 | Organisim: human | Apparent_Kd_M: 2.448905E-11
Real
Aptamer SeqId: 14083-25 | Target: SPS1 | UniProt: P49903
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14083-25 | Target: SPS1 | UniProt: P49903 | TargetFullName: Selenide; water dikinase 1 | Organisim: human | Apparent_Kd_M: 1.999658E-12
Real
Aptamer SeqId: 14084-191 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14084-191 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.66E-11
Real
Aptamer SeqId: 14088-38 | Target: IGFBP-6 | UniProt: P24592
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14088-38 | Target: IGFBP-6 | UniProt: P24592 | TargetFullName: Insulin-like growth factor-binding protein 6 | Organisim: human | Apparent_Kd_M: 2.59E-12
Real
Aptamer SeqId: 14090-23 | Target: DEFI6 | UniProt: Q9H4E7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14090-23 | Target: DEFI6 | UniProt: Q9H4E7 | TargetFullName: Differentially expressed in FDCP 6 homolog | Organisim: human | Apparent_Kd_M: 8.0085E-12
Real
Aptamer SeqId: 14091-42 | Target: Carbonyl reductase 3 | UniProt: O75828
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14091-42 | Target: Carbonyl reductase 3 | UniProt: O75828 | TargetFullName: Carbonyl reductase NADPH 3 | Organisim: human | Apparent_Kd_M: 2.646915E-12
Real
Aptamer SeqId: 14093-10 | Target: Flt3 ligand | UniProt: P49771
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14093-10 | Target: Flt3 ligand | UniProt: P49771 | TargetFullName: Fms-related tyrosine kinase 3 ligand | Organisim: human | Apparent_Kd_M: 4.74E-11
Real
Aptamer SeqId: 14094-29 | Target: HB-EGF | UniProt: Q99075
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14094-29 | Target: HB-EGF | UniProt: Q99075 | TargetFullName: Heparin-binding EGF-like growth factor | Organisim: human | Apparent_Kd_M: 4.35E-12
Real
Aptamer SeqId: 14095-1 | Target: NKG2D | UniProt: P26718
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14095-1 | Target: NKG2D | UniProt: P26718 | TargetFullName: NKG2-D type II integral membrane protein | Organisim: human | Apparent_Kd_M: 1.7E-11
Real
Aptamer SeqId: 14098-28 | Target: SYCC | UniProt: P49589
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14098-28 | Target: SYCC | UniProt: P49589 | TargetFullName: Cysteine--tRNA ligase; cytoplasmic | Organisim: human | Apparent_Kd_M: 1.996443E-11
Real
Aptamer SeqId: 14099-20 | Target: PSA4 | UniProt: P25789
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14099-20 | Target: PSA4 | UniProt: P25789 | TargetFullName: Proteasome subunit alpha type-4 | Organisim: human | Apparent_Kd_M: 4.100326E-11
Real
Aptamer SeqId: 14100-63 | Target: C1QC | UniProt: P02747
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14100-63 | Target: C1QC | UniProt: P02747 | TargetFullName: Complement C1q subcomponent subunit C | Organisim: human | Apparent_Kd_M: 1.215308E-10
Real
Aptamer SeqId: 14101-2 | Target: CNTFR alpha | UniProt: P26992
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14101-2 | Target: CNTFR alpha | UniProt: P26992 | TargetFullName: Ciliary neurotrophic factor receptor subunit alpha | Organisim: human | Apparent_Kd_M: 4.29E-11
Real
Aptamer SeqId: 14106-46 | Target: GDP/GTP exchange protein
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14106-46 | Target: GDP/GTP exchange protein | UniProt: P52306 | TargetFullName: Rap1 GTPase-GDP dissociation stimulator 1 | Organisim: human | Apparent_Kd_M: 4.133072E-11
Real
Aptamer SeqId: 14107-1 | Target: MTHFS | UniProt: P49914
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14107-1 | Target: MTHFS | UniProt: P49914 | TargetFullName: 5-formyltetrahydrofolate cyclo-ligase | Organisim: human | Apparent_Kd_M: 1.052282E-12
Real
Aptamer SeqId: 14111-15 | Target: TSP2 | UniProt: P35442
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14111-15 | Target: TSP2 | UniProt: P35442 | TargetFullName: Thrombospondin-2 | Organisim: human | Apparent_Kd_M: 5.22E-12
Real
Aptamer SeqId: 14112-40 | Target: RELT | UniProt: Q969Z4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14112-40 | Target: RELT | UniProt: Q969Z4 | TargetFullName: Tumor necrosis factor receptor superfamily member 19L | Organisim: human | Apparent_Kd_M: 4.1E-12
Real
Aptamer SeqId: 14114-18 | Target: PIANP | UniProt: Q8IYJ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14114-18 | Target: PIANP | UniProt: Q8IYJ0 | TargetFullName: PILR alpha-associated neural protein | Organisim: human | Apparent_Kd_M: 3.02E-11
Real
Aptamer SeqId: 14115-34 | Target: Adrenomedullin | UniProt: P35318
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14115-34 | Target: Adrenomedullin | UniProt: P35318 | TargetFullName: Adrenomedullin | Organisim: human | Apparent_Kd_M: 2.48E-11
Real
Aptamer SeqId: 14116-129 | Target: S100A4 | UniProt: P26447
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14116-129 | Target: S100A4 | UniProt: P26447 | TargetFullName: Protein S100-A4 | Organisim: human | Apparent_Kd_M: 5.8E-11
Real
Aptamer SeqId: 14120-2 | Target: RNF43 | UniProt: Q68DV7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14120-2 | Target: RNF43 | UniProt: Q68DV7 | TargetFullName: E3 ubiquitin-protein ligase RNF43 | Organisim: human | Apparent_Kd_M: 8.36E-12
Real
Aptamer SeqId: 14121-24 | Target: TRAIL R4 | UniProt: Q9UBN6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14121-24 | Target: TRAIL R4 | UniProt: Q9UBN6 | TargetFullName: Tumor necrosis factor receptor superfamily member 10D | Organisim: human | Apparent_Kd_M: 6.0E-12
Real
Aptamer SeqId: 14122-132 | Target: ZNRF3 | UniProt: Q9ULT6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14122-132 | Target: ZNRF3 | UniProt: Q9ULT6 | TargetFullName: E3 ubiquitin-protein ligase ZNRF3 | Organisim: human | Apparent_Kd_M: 3.38E-12
Real
Aptamer SeqId: 14123-34 | Target: GI24 | UniProt: Q9H7M9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14123-34 | Target: GI24 | UniProt: Q9H7M9 | TargetFullName: V-type immunoglobulin domain-containing suppressor of T-cell activation | Organisim: human | Apparent_Kd_M: 6.88E-12
Real
Aptamer SeqId: 14124-6 | Target: Ephrin-A2 | UniProt: O43921
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14124-6 | Target: Ephrin-A2 | UniProt: O43921 | TargetFullName: Ephrin-A2 | Organisim: human | Apparent_Kd_M: 2.18E-12
Real
Aptamer SeqId: 14127-240 | Target: IFN-b | UniProt: P01574
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14127-240 | Target: IFN-b | UniProt: P01574 | TargetFullName: Interferon beta | Organisim: human | Apparent_Kd_M: 9.36E-12
Real
Aptamer SeqId: 14128-121 | Target: IFN10 | UniProt: P01566
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14128-121 | Target: IFN10 | UniProt: P01566 | TargetFullName: Interferon alpha-10 | Organisim: human | Apparent_Kd_M: 8.2E-12
Real
Aptamer SeqId: 14129-1 | Target: IFNA7 | UniProt: P01567
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14129-1 | Target: IFNA7 | UniProt: P01567 | TargetFullName: Interferon alpha-7 | Organisim: human | Apparent_Kd_M: 3.01E-12
Real
Aptamer SeqId: 14131-37 | Target: EFNB2 | UniProt: P52799
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14131-37 | Target: EFNB2 | UniProt: P52799 | TargetFullName: Ephrin-B2 | Organisim: human | Apparent_Kd_M: 3.23E-11
Real
Aptamer SeqId: 14132-21 | Target: HHLA2 | UniProt: Q9UM44
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14132-21 | Target: HHLA2 | UniProt: Q9UM44 | TargetFullName: HERV-H LTR-associating protein 2 | Organisim: human | Apparent_Kd_M: 4.01E-11
Real
Aptamer SeqId: 14133-93 | Target: IL-1 sRII | UniProt: P27930
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14133-93 | Target: IL-1 sRII | UniProt: P27930 | TargetFullName: Interleukin-1 receptor type 2 | Organisim: human | Apparent_Kd_M: 2.47E-12
Real
Aptamer SeqId: 14134-49 | Target: AMGO2 | UniProt: Q86SJ2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14134-49 | Target: AMGO2 | UniProt: Q86SJ2 | TargetFullName: Amphoterin-induced protein 2 | Organisim: human | Apparent_Kd_M: 2.93E-12
Real
Aptamer SeqId: 14135-3 | Target: RXFP1 | UniProt: Q9HBX9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14135-3 | Target: RXFP1 | UniProt: Q9HBX9 | TargetFullName: Relaxin receptor 1 | Organisim: human | Apparent_Kd_M: 5.01E-12
Real
Aptamer SeqId: 14136-234 | Target: C1QR1 | UniProt: Q9NPY3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14136-234 | Target: C1QR1 | UniProt: Q9NPY3 | TargetFullName: Complement component C1q receptor | Organisim: human | Apparent_Kd_M: 1.62E-11
Real
Aptamer SeqId: 14139-16 | Target: NRG4 | UniProt: Q8WWG1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14139-16 | Target: NRG4 | UniProt: Q8WWG1 | TargetFullName: Neuregulin-4 | Organisim: human | Apparent_Kd_M: 8.45E-12
Real
Aptamer SeqId: 14143-8 | Target: H2B2E | UniProt: Q16778
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14143-8 | Target: H2B2E | UniProt: Q16778 | TargetFullName: Histone H2B type 2-E | Organisim: human | Apparent_Kd_M: 5.28E-11
Real
Aptamer SeqId: 14144-3 | Target: H2A3 | UniProt: Q7L7L0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14144-3 | Target: H2A3 | UniProt: Q7L7L0 | TargetFullName: Histone H2A type 3 | Organisim: human | Apparent_Kd_M: 2.0E-11
Real
Aptamer SeqId: 14146-92 | Target: H31 | UniProt: P68431
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14146-92 | Target: H31 | UniProt: P68431 | TargetFullName: Histone H3.1 | Organisim: human | Apparent_Kd_M: 8.4E-11
Real
Aptamer SeqId: 14149-9 | Target: IL-1F8 | UniProt: Q9NZH7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14149-9 | Target: IL-1F8 | UniProt: Q9NZH7 | TargetFullName: Interleukin-36 beta | Organisim: human | Apparent_Kd_M: 4.67E-12
Real
Aptamer SeqId: 14150-7 | Target: IL-1F6 | UniProt: Q9UHA7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14150-7 | Target: IL-1F6 | UniProt: Q9UHA7 | TargetFullName: Interleukin-36 alpha | Organisim: human | Apparent_Kd_M: 1.51E-11
Real
Aptamer SeqId: 14151-4 | Target: UCRP | UniProt: P05161
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14151-4 | Target: UCRP | UniProt: P05161 | TargetFullName: Ubiquitin-like protein ISG15 | Organisim: human | Apparent_Kd_M: 8.76E-12
Real
Aptamer SeqId: 14153-8 | Target: Ephrin-A3 | UniProt: P52797
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14153-8 | Target: Ephrin-A3 | UniProt: P52797 | TargetFullName: Ephrin-A3 | Organisim: human | Apparent_Kd_M: 2.54E-12
Real
Aptamer SeqId: 14156-33 | Target: 14-3-3 protein beta/alpha
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14156-33 | Target: 14-3-3 protein beta/alpha | UniProt: P31946 | TargetFullName: 14-3-3 protein beta/alpha | Organisim: human | Apparent_Kd_M: 2.07E-12
Real
Aptamer SeqId: 14157-21 | Target: 14-3-3E | UniProt: P62258
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14157-21 | Target: 14-3-3E | UniProt: P62258 | TargetFullName: 14-3-3 protein epsilon | Organisim: human | Apparent_Kd_M: 1.09E-11
Real
Aptamer SeqId: 14158-17 | Target: Annexin V | UniProt: P08758
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14158-17 | Target: Annexin V | UniProt: P08758 | TargetFullName: Annexin A5 | Organisim: human | Apparent_Kd_M: 4.69E-11
Real
Aptamer SeqId: 14175-78 | Target: SCP2D | UniProt: Q9UJQ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14175-78 | Target: SCP2D | UniProt: Q9UJQ7 | TargetFullName: SCP2 sterol-binding domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 5.803231E-13
Real
Aptamer SeqId: 14178-18 | Target: CDKN3 | UniProt: Q16667
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14178-18 | Target: CDKN3 | UniProt: Q16667 | TargetFullName: Cyclin-dependent kinase inhibitor 3 | Organisim: human | Apparent_Kd_M: 5.87994E-11
Real
Aptamer SeqId: 14186-13 | Target: RFFL | UniProt: Q8WZ73
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14186-13 | Target: RFFL | UniProt: Q8WZ73 | TargetFullName: E3 ubiquitin-protein ligase rififylin | Organisim: human | Apparent_Kd_M: 2.463989E-11
Real
Aptamer SeqId: 14192-31 | Target: PDCL2 | UniProt: Q8N4E4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14192-31 | Target: PDCL2 | UniProt: Q8N4E4 | TargetFullName: Phosducin-like protein 2 | Organisim: human | Apparent_Kd_M: 1.833322E-10
Real
Aptamer SeqId: 14197-2 | Target: PRDM1 | UniProt: O75626
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14197-2 | Target: PRDM1 | UniProt: O75626 | TargetFullName: PR domain zinc finger protein 1 | Organisim: human | Apparent_Kd_M: 1.82268E-11
Real
Aptamer SeqId: 14203-3 | Target: ANXA7 | UniProt: P20073
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14203-3 | Target: ANXA7 | UniProt: P20073 | TargetFullName: Annexin A7 | Organisim: human | Apparent_Kd_M: 2.881946E-11
Real
Aptamer SeqId: 14204-55 | Target: FOXJ2 | UniProt: Q9P0K8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14204-55 | Target: FOXJ2 | UniProt: Q9P0K8 | TargetFullName: Forkhead box protein J2 | Organisim: human | Apparent_Kd_M: 4.467056E-11
Real
Aptamer SeqId: 14205-6 | Target: HEXI2 | UniProt: Q96MH2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14205-6 | Target: HEXI2 | UniProt: Q96MH2 | TargetFullName: Protein HEXIM2 | Organisim: human | Apparent_Kd_M: 1.275497E-11
Real
Aptamer SeqId: 14206-28 | Target: APBB1 | UniProt: O00213
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14206-28 | Target: APBB1 | UniProt: O00213 | TargetFullName: Amyloid beta A4 precursor protein-binding family B member 1 | Organisim: human | Apparent_Kd_M: 3.15E-11
Real
Aptamer SeqId: 14208-3 | Target: RET7 | UniProt: Q96R05
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14208-3 | Target: RET7 | UniProt: Q96R05 | TargetFullName: Retinoid-binding protein 7 | Organisim: human | Apparent_Kd_M: 6.488497E-13
Real
Aptamer SeqId: 14216-35 | Target: DDX46 | UniProt: Q7L014
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14216-35 | Target: DDX46 | UniProt: Q7L014 | TargetFullName: Probable ATP-dependent RNA helicase DDX46 | Organisim: human | Apparent_Kd_M: 2.384758E-10
Real
Aptamer SeqId: 14226-120 | Target: BHMT2 | UniProt: Q9H2M3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14226-120 | Target: BHMT2 | UniProt: Q9H2M3 | TargetFullName: S-methylmethionine--homocysteine S-methyltransferase BHMT2 | Organisim: human | Apparent_Kd_M: 4.063761E-11
Real
Aptamer SeqId: 14227-21 | Target: MYL6B | UniProt: P14649
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14227-21 | Target: MYL6B | UniProt: P14649 | TargetFullName: Myosin light chain 6B | Organisim: human | Apparent_Kd_M: 3.03451E-11
Real
Aptamer SeqId: 14228-1 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14228-1 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.42166E-12
Real
Aptamer SeqId: 14229-5 | Target: MOCS3 | UniProt: O95396
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14229-5 | Target: MOCS3 | UniProt: O95396 | TargetFullName: Adenylyltransferase and sulfurtransferase MOCS3 | Organisim: human | Apparent_Kd_M: 7.402201E-11
Real
Aptamer SeqId: 14237-1 | Target: HSP 70 | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14237-1 | Target: HSP 70 | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 4.81303E-12
Real
Aptamer SeqId: 14245-195 | Target: SNX7 | UniProt: Q9UNH6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14245-195 | Target: SNX7 | UniProt: Q9UNH6 | TargetFullName: Sorting nexin-7 | Organisim: human | Apparent_Kd_M: 1.331199E-12
Real
Aptamer SeqId: 14246-50 | Target: DOK2 | UniProt: O60496
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14246-50 | Target: DOK2 | UniProt: O60496 | TargetFullName: Docking protein 2 | Organisim: human | Apparent_Kd_M: 6.23E-11
Real
Aptamer SeqId: 14249-68 | Target: TRIM1 | UniProt: Q9UJV3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14249-68 | Target: TRIM1 | UniProt: Q9UJV3 | TargetFullName: Probable E3 ubiquitin-protein ligase MID2 | Organisim: human | Apparent_Kd_M: 5.735354E-13
Real
Aptamer SeqId: 14250-115 | Target: BLMH | UniProt: Q13867
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14250-115 | Target: BLMH | UniProt: Q13867 | TargetFullName: Bleomycin hydrolase | Organisim: human | Apparent_Kd_M: 6.690209E-11
Real
Aptamer SeqId: 14254-27 | Target: PTN4 | UniProt: P29074
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14254-27 | Target: PTN4 | UniProt: P29074 | TargetFullName: Tyrosine-protein phosphatase non-receptor type 4 | Organisim: human | Apparent_Kd_M: 4.455554E-11
Real
Aptamer SeqId: 14256-4 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14256-4 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 9.717701E-13
Real
Aptamer SeqId: 14260-112 | Target: ARHG8 | UniProt: Q7Z628
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14260-112 | Target: ARHG8 | UniProt: Q7Z628 | TargetFullName: Neuroepithelial cell-transforming gene 1 protein | Organisim: human | Apparent_Kd_M: 3.206369E-11
Real
Aptamer SeqId: 14268-4 | Target: SRXN1 | UniProt: Q9BYN0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14268-4 | Target: SRXN1 | UniProt: Q9BYN0 | TargetFullName: Sulfiredoxin-1 | Organisim: human | Apparent_Kd_M: 5.414658E-11
Real
Aptamer SeqId: 14271-23 | Target: RAB6B | UniProt: Q9NRW1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14271-23 | Target: RAB6B | UniProt: Q9NRW1 | TargetFullName: Ras-related protein Rab-6B | Organisim: human | Apparent_Kd_M: 2.957795E-12
Real
Aptamer SeqId: 14273-19 | Target: PPCE | UniProt: P48147
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14273-19 | Target: PPCE | UniProt: P48147 | TargetFullName: Prolyl endopeptidase | Organisim: human | Apparent_Kd_M: 1.480898E-10
Real
Aptamer SeqId: 14283-12 | Target: RAB14 | UniProt: P61106
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14283-12 | Target: RAB14 | UniProt: P61106 | TargetFullName: Ras-related protein Rab-14 | Organisim: human | Apparent_Kd_M: 5.876912E-11
Real
Aptamer SeqId: 14284-23 | Target: E2AK4 | UniProt: Q9P2K8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14284-23 | Target: E2AK4 | UniProt: Q9P2K8 | TargetFullName: eIF-2-alpha kinase GCN2 | Organisim: human | Apparent_Kd_M: 2.459712E-11
Real
Aptamer SeqId: 14286-2 | Target: NF-ATc1 | UniProt: O95644
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14286-2 | Target: NF-ATc1 | UniProt: O95644 | TargetFullName: Nuclear factor of activated T-cells; cytoplasmic 1 | Organisim: human | Apparent_Kd_M: 2.060479E-12
Real
Aptamer SeqId: 14287-6 | Target: RAB5C | UniProt: P51148
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14287-6 | Target: RAB5C | UniProt: P51148 | TargetFullName: Ras-related protein Rab-5C | Organisim: human | Apparent_Kd_M: 9.55246E-12
Real
Aptamer SeqId: 14291-53 | Target: AGAP2 | UniProt: Q99490
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14291-53 | Target: AGAP2 | UniProt: Q99490 | TargetFullName: Arf-GAP with GTPase; ANK repeat and PH domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 1.134714E-12
Real
Aptamer SeqId: 14294-61 | Target: MBD1 | UniProt: Q9UIS9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14294-61 | Target: MBD1 | UniProt: Q9UIS9 | TargetFullName: Methyl-CpG-binding domain protein 1 | Organisim: human | Apparent_Kd_M: 2.028491E-12
Real
Aptamer SeqId: 14308-192 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14308-192 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.556009E-10
Real
Aptamer SeqId: 14309-8 | Target: HNRH1 | UniProt: P31943
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14309-8 | Target: HNRH1 | UniProt: P31943 | TargetFullName: Heterogeneous nuclear ribonucleoprotein H | Organisim: human | Apparent_Kd_M: 8.158204E-11
Real
Aptamer SeqId: 14314-6 | Target: PPIL2 | UniProt: Q13356
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14314-6 | Target: PPIL2 | UniProt: Q13356 | TargetFullName: Peptidyl-prolyl cis-trans isomerase-like 2 | Organisim: human | Apparent_Kd_M: 2.86319E-12
Real
Aptamer SeqId: 14318-1 | Target: VPS29 | UniProt: Q9UBQ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14318-1 | Target: VPS29 | UniProt: Q9UBQ0 | TargetFullName: Vacuolar protein sorting-associated protein 29 | Organisim: human | Apparent_Kd_M: 6.475177E-11
Real
Aptamer SeqId: 14324-52 | Target: CSPG6 | UniProt: Q9UQE7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14324-52 | Target: CSPG6 | UniProt: Q9UQE7 | TargetFullName: Structural maintenance of chromosomes protein 3 | Organisim: human | Apparent_Kd_M: 1.717694E-10
Real
Aptamer SeqId: 14326-4 | Target: UB2E1 | UniProt: P51965
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14326-4 | Target: UB2E1 | UniProt: P51965 | TargetFullName: Ubiquitin-conjugating enzyme E2 E1 | Organisim: human | Apparent_Kd_M: 1.558013E-11
Real
Aptamer SeqId: 14329-4 | Target: DIDO1 | UniProt: Q9BTC0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14329-4 | Target: DIDO1 | UniProt: Q9BTC0 | TargetFullName: Death-inducer obliterator 1 | Organisim: human | Apparent_Kd_M: 1.899148E-11
Real
Aptamer SeqId: 14331-262 | Target: DYLT1 | UniProt: P63172
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14331-262 | Target: DYLT1 | UniProt: P63172 | TargetFullName: Dynein light chain Tctex-type 1 | Organisim: human | Apparent_Kd_M: 1.671838E-10
Real
Aptamer SeqId: 14332-3 | Target: RALA | UniProt: P11233
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14332-3 | Target: RALA | UniProt: P11233 | TargetFullName: Ras-related protein Ral-A | Organisim: human | Apparent_Kd_M: 1.516378E-11
Real
Aptamer SeqId: 14334-3 | Target: RECO | UniProt: P35243
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14334-3 | Target: RECO | UniProt: P35243 | TargetFullName: Recoverin | Organisim: human | Apparent_Kd_M: 1.768303E-10
Real
Aptamer SeqId: 14337-1 | Target: TPPC3 | UniProt: O43617
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14337-1 | Target: TPPC3 | UniProt: O43617 | TargetFullName: Trafficking protein particle complex subunit 3 | Organisim: human | Apparent_Kd_M: 1.34992E-10
Real
Aptamer SeqId: 14341-8 | Target: FA69C | UniProt: Q0P6D2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14341-8 | Target: FA69C | UniProt: Q0P6D2 | TargetFullName: Protein FAM69C | Organisim: human | Apparent_Kd_M: 1.950336E-10
Real
Aptamer SeqId: 14583-49 | Target: Myostatin | UniProt: O14793
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14583-49 | Target: Myostatin | UniProt: O14793 | TargetFullName: Growth/differentiation factor 8 | Organisim: human | Apparent_Kd_M: 7.328018E-12
Real
Aptamer SeqId: 14587-16 | Target: GDF-11 | UniProt: O95390
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14587-16 | Target: GDF-11 | UniProt: O95390 | TargetFullName: Growth/differentiation factor 11 | Organisim: human | Apparent_Kd_M: 2.58E-11
Real
Aptamer SeqId: 14593-152 | Target: F210A | UniProt: Q96ND0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14593-152 | Target: F210A | UniProt: Q96ND0 | TargetFullName: Protein FAM210A | Organisim: human | Apparent_Kd_M: 2.381593E-11
Real
Aptamer SeqId: 14597-5 | Target: SEM6C | UniProt: Q9H3T2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14597-5 | Target: SEM6C | UniProt: Q9H3T2 | TargetFullName: Semaphorin-6C | Organisim: human | Apparent_Kd_M: 1.508063E-11
Real
Aptamer SeqId: 14599-18 | Target: STAB1 | UniProt: Q9NY15
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14599-18 | Target: STAB1 | UniProt: Q9NY15 | TargetFullName: Stabilin-1 | Organisim: human | Apparent_Kd_M: 3.486443E-11
Real
Aptamer SeqId: 14603-51 | Target: KIAA0040 | UniProt: J3QR46
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14603-51 | Target: KIAA0040 | UniProt: J3QR46 | TargetFullName: Uncharacterized protein KIAA0040 | Organisim: human | Apparent_Kd_M: 2.145769E-10
Real
Aptamer SeqId: 14605-2 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14605-2 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.312386E-12
Real
Aptamer SeqId: 14614-41 | Target: CA130 | UniProt: Q5T1S8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14614-41 | Target: CA130 | UniProt: Q5T1S8 | TargetFullName: Noncompact myelin-associated protein | Organisim: human | Apparent_Kd_M: 3.872555E-11
Real
Aptamer SeqId: 14615-46 | Target: KRA24 | UniProt: Q9BYR9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14615-46 | Target: KRA24 | UniProt: Q9BYR9 | TargetFullName: Keratin-associated protein 2-4 | Organisim: human | Apparent_Kd_M: 5.00067E-11
Real
Aptamer SeqId: 14616-16 | Target: ZN382 | UniProt: Q96SR6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14616-16 | Target: ZN382 | UniProt: Q96SR6 | TargetFullName: Zinc finger protein 382 | Organisim: human | Apparent_Kd_M: 4.435869E-12
Real
Aptamer SeqId: 14617-7 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14617-7 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 7.273737E-12
Real
Aptamer SeqId: 14618-26 | Target: ECOP | UniProt: Q96AW1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14618-26 | Target: ECOP | UniProt: Q96AW1 | TargetFullName: Vesicular; overexpressed in cancer; prosurvival protein 1 | Organisim: human | Apparent_Kd_M: 4.35E-10
Real
Aptamer SeqId: 14619-8 | Target: ZN526 | UniProt: Q8TF50
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14619-8 | Target: ZN526 | UniProt: Q8TF50 | TargetFullName: Zinc finger protein 526 | Organisim: human | Apparent_Kd_M: 1.982913E-11
Real
Aptamer SeqId: 14623-26 | Target: SUMO3 | UniProt: P55854
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14623-26 | Target: SUMO3 | UniProt: P55854 | TargetFullName: Small ubiquitin-related modifier 3 | Organisim: human | Apparent_Kd_M: 1.28E-12
Real
Aptamer SeqId: 14624-51 | Target: CTCF | UniProt: P49711
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14624-51 | Target: CTCF | UniProt: P49711 | TargetFullName: Transcriptional repressor CTCF | Organisim: human | Apparent_Kd_M: 5.031899E-12
Real
Aptamer SeqId: 14628-72 | Target: FBX3 | UniProt: Q9UK99
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14628-72 | Target: FBX3 | UniProt: Q9UK99 | TargetFullName: F-box only protein 3 | Organisim: human | Apparent_Kd_M: 1.68E-10
Real
Aptamer SeqId: 14631-22 | Target: DUS16 | UniProt: Q9BY84
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14631-22 | Target: DUS16 | UniProt: Q9BY84 | TargetFullName: Dual specificity protein phosphatase 16 | Organisim: human | Apparent_Kd_M: 5.465475E-11
Real
Aptamer SeqId: 14633-26 | Target: T185A | UniProt: Q8NFB2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14633-26 | Target: T185A | UniProt: Q8NFB2 | TargetFullName: Transmembrane protein 185A | Organisim: human | Apparent_Kd_M: 1.764517E-11
Real
Aptamer SeqId: 14634-13 | Target: LSHR | UniProt: P22888
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14634-13 | Target: LSHR | UniProt: P22888 | TargetFullName: Lutropin-choriogonadotropic hormone receptor | Organisim: human | Apparent_Kd_M: 1.295774E-10
Real
Aptamer SeqId: 14635-28 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14635-28 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.78E-11
Real
Aptamer SeqId: 14636-25 | Target: Ribonuclease UK114 | UniProt: P52758
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14636-25 | Target: Ribonuclease UK114 | UniProt: P52758 | TargetFullName: Ribonuclease UK114 | Organisim: human | Apparent_Kd_M: 6.94646E-12
Real
Aptamer SeqId: 14645-253 | Target: GSTA4 | UniProt: O15217
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14645-253 | Target: GSTA4 | UniProt: O15217 | TargetFullName: Glutathione S-transferase A4 | Organisim: human | Apparent_Kd_M: 3.846705E-11
Real
Aptamer SeqId: 14655-1 | Target: DJC17 | UniProt: Q9NVM6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14655-1 | Target: DJC17 | UniProt: Q9NVM6 | TargetFullName: DnaJ homolog subfamily C member 17 | Organisim: human | Apparent_Kd_M: 1.517149E-12
Real
Aptamer SeqId: 14662-6 | Target: MZF1 | UniProt: P28698
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14662-6 | Target: MZF1 | UniProt: P28698 | TargetFullName: Myeloid zinc finger 1 | Organisim: human | Apparent_Kd_M: 4.495456E-12
Real
Aptamer SeqId: 14663-44 | Target: RNF8 | UniProt: O76064
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14663-44 | Target: RNF8 | UniProt: O76064 | TargetFullName: E3 ubiquitin-protein ligase RNF8 | Organisim: human | Apparent_Kd_M: 9.149981E-11
Real
Aptamer SeqId: 14670-1 | Target: SKIL | UniProt: P12757
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14670-1 | Target: SKIL | UniProt: P12757 | TargetFullName: Ski-like protein | Organisim: human | Apparent_Kd_M: 3.511063E-11
Real
Aptamer SeqId: 14674-63 | Target: PACN3 | UniProt: Q9UKS6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14674-63 | Target: PACN3 | UniProt: Q9UKS6 | TargetFullName: Protein kinase C and casein kinase substrate in neurons protein 3 | Organisim: human | Apparent_Kd_M: 3.123757E-11
Real
Aptamer SeqId: 14675-20 | Target: IF4B | UniProt: P23588
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14675-20 | Target: IF4B | UniProt: P23588 | TargetFullName: Eukaryotic translation initiation factor 4B | Organisim: human | Apparent_Kd_M: 1.335893E-12
Real
Aptamer SeqId: 14684-17 | Target: CAN2 | UniProt: P17655
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14684-17 | Target: CAN2 | UniProt: P17655 | TargetFullName: Calpain-2 catalytic subunit | Organisim: human | Apparent_Kd_M: 1.029195E-11
Real
Aptamer SeqId: 14685-17 | Target: PKB beta | UniProt: P31751
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14685-17 | Target: PKB beta | UniProt: P31751 | TargetFullName: RAC-beta serine/threonine-protein kinase | Organisim: human | Apparent_Kd_M: 8.07E-12
Real
Aptamer SeqId: 14687-6 | Target: M6PBP | UniProt: O60664
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14687-6 | Target: M6PBP | UniProt: O60664 | TargetFullName: Perilipin-3 | Organisim: human | Apparent_Kd_M: 3.174483E-10
Real
Aptamer SeqId: 14688-6 | Target: PTN7 | UniProt: P35236
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14688-6 | Target: PTN7 | UniProt: P35236 | TargetFullName: Tyrosine-protein phosphatase non-receptor type 7 | Organisim: human | Apparent_Kd_M: 1.005664E-11
Real
Aptamer SeqId: 14689-3 | Target: SEC13 | UniProt: P55735
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14689-3 | Target: SEC13 | UniProt: P55735 | TargetFullName: Protein SEC13 homolog | Organisim: human | Apparent_Kd_M: 1.966571E-11
Real
Aptamer SeqId: 14692-3 | Target: ZN276 | UniProt: Q8N554
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14692-3 | Target: ZN276 | UniProt: Q8N554 | TargetFullName: Zinc finger protein 276 | Organisim: human | Apparent_Kd_M: 1.601425E-11
Real
Aptamer SeqId: 14705-1 | Target: VEGF-D | UniProt: O43915
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14705-1 | Target: VEGF-D | UniProt: O43915 | TargetFullName: Vascular endothelial growth factor D | Organisim: human | Apparent_Kd_M: 4.87E-11
Real
Aptamer SeqId: 14708-59 | Target: CO8G | UniProt: P07360
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14708-59 | Target: CO8G | UniProt: P07360 | TargetFullName: Complement component C8 gamma chain | Organisim: human | Apparent_Kd_M: 2.234602E-11
Real
Aptamer SeqId: 14711-27 | Target: Cystatin M | UniProt: Q15828
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14711-27 | Target: Cystatin M | UniProt: Q15828 | TargetFullName: Cystatin-M | Organisim: human | Apparent_Kd_M: 6.64E-12
Real
Aptamer SeqId: 14713-46 | Target: Azurocidin | UniProt: P20160
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14713-46 | Target: Azurocidin | UniProt: P20160 | TargetFullName: Azurocidin | Organisim: human | Apparent_Kd_M: 7.14E-12
Real
Aptamer SeqId: 14747-9 | Target: CRLF1 | UniProt: O75462
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14747-9 | Target: CRLF1 | UniProt: O75462 | TargetFullName: Cytokine receptor-like factor 1 | Organisim: human | Apparent_Kd_M: 4.149359E-11
Real
Aptamer SeqId: 14748-31 | Target: RHG05 | UniProt: Q13017
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 14748-31 | Target: RHG05 | UniProt: Q13017 | TargetFullName: Rho GTPase-activating protein 5 | Organisim: human | Apparent_Kd_M: 2.457874E-12
Real
Aptamer SeqId: 15295-81 | Target: IGF-II | UniProt: P01344
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15295-81 | Target: IGF-II | UniProt: P01344 | TargetFullName: Insulin-like growth factor II | Organisim: human | Apparent_Kd_M: 2.71E-11
Real
Aptamer SeqId: 15297-3 | Target: S100A3 | UniProt: P33764
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15297-3 | Target: S100A3 | UniProt: P33764 | TargetFullName: Protein S100-A3 | Organisim: human | Apparent_Kd_M: 2.59E-12
Real
Aptamer SeqId: 15298-199 | Target: NETO1 | UniProt: Q8TDF5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15298-199 | Target: NETO1 | UniProt: Q8TDF5 | TargetFullName: Neuropilin and tolloid-like protein 1 | Organisim: human | Apparent_Kd_M: 1.31E-11
Real
Aptamer SeqId: 15299-102 | Target: MESD2 | UniProt: Q14696
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15299-102 | Target: MESD2 | UniProt: Q14696 | TargetFullName: LDLR chaperone MESD | Organisim: human | Apparent_Kd_M: 4.52E-12
Real
Aptamer SeqId: 15300-66 | Target: CC134 | UniProt: Q9H6E4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15300-66 | Target: CC134 | UniProt: Q9H6E4 | TargetFullName: Coiled-coil domain-containing protein 134 | Organisim: human | Apparent_Kd_M: 1.28E-12
Real
Aptamer SeqId: 15301-24 | Target: sperm protein 10 | UniProt: P26436
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15301-24 | Target: sperm protein 10 | UniProt: P26436 | TargetFullName: Acrosomal protein SP-10 | Organisim: human | Apparent_Kd_M: 4.54E-10
Real
Aptamer SeqId: 15303-63 | Target: S100A5 | UniProt: P33763
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15303-63 | Target: S100A5 | UniProt: P33763 | TargetFullName: Protein S100-A5 | Organisim: human | Apparent_Kd_M: 5.3E-11
Real
Aptamer SeqId: 15304-1 | Target: PAP1 | UniProt: Q06141
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15304-1 | Target: PAP1 | UniProt: Q06141 | TargetFullName: Regenerating islet-derived protein 3-alpha | Organisim: human | Apparent_Kd_M: 1.23E-12
Real
Aptamer SeqId: 15305-7 | Target: Secretagogin | UniProt: O76038
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15305-7 | Target: Secretagogin | UniProt: O76038 | TargetFullName: Secretagogin | Organisim: human | Apparent_Kd_M: 2.49E-12
Real
Aptamer SeqId: 15306-20 | Target: IgJ | UniProt: P01591
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15306-20 | Target: IgJ | UniProt: P01591 | TargetFullName: Immunoglobulin J chain | Organisim: human | Apparent_Kd_M: 4.35E-11
Real
Aptamer SeqId: 15308-108 | Target: VWC2 | UniProt: Q2TAL6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15308-108 | Target: VWC2 | UniProt: Q2TAL6 | TargetFullName: Brorin | Organisim: human | Apparent_Kd_M: 3.18E-12
Real
Aptamer SeqId: 15310-61 | Target: PRC1 | UniProt: O43663
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15310-61 | Target: PRC1 | UniProt: O43663 | TargetFullName: Protein regulator of cytokinesis 1 | Organisim: human | Apparent_Kd_M: 5.5E-11
Real
Aptamer SeqId: 15312-14 | Target: AGO1 | UniProt: Q9UL18
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15312-14 | Target: AGO1 | UniProt: Q9UL18 | TargetFullName: Protein argonaute-1 | Organisim: human | Apparent_Kd_M: 2.56E-12
Real
Aptamer SeqId: 15313-28 | Target: MD2L1 | UniProt: Q13257
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15313-28 | Target: MD2L1 | UniProt: Q13257 | TargetFullName: Mitotic spindle assembly checkpoint protein MAD2A | Organisim: human | Apparent_Kd_M: 1.0E-11
Real
Aptamer SeqId: 15314-49 | Target: CLIC4 | UniProt: Q9Y696
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15314-49 | Target: CLIC4 | UniProt: Q9Y696 | TargetFullName: Chloride intracellular channel protein 4 | Organisim: human | Apparent_Kd_M: 9.13E-13
Real
Aptamer SeqId: 15315-64 | Target: CUTC | UniProt: Q9NTM9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15315-64 | Target: CUTC | UniProt: Q9NTM9 | TargetFullName: Copper homeostasis protein cutC homolog | Organisim: human | Apparent_Kd_M: 1.09E-11
Real
Aptamer SeqId: 15316-262 | Target: TXN4B | UniProt: Q9NX01
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15316-262 | Target: TXN4B | UniProt: Q9NX01 | TargetFullName: Thioredoxin-like protein 4B | Organisim: human | Apparent_Kd_M: 1.37E-12
Real
Aptamer SeqId: 15318-75 | Target: Calpactin I light chain | UniProt: P60903
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15318-75 | Target: Calpactin I light chain | UniProt: P60903 | TargetFullName: Protein S100-A10 | Organisim: human | Apparent_Kd_M: 3.76E-11
Real
Aptamer SeqId: 15319-226 | Target: CCNA1 | UniProt: P78396
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15319-226 | Target: CCNA1 | UniProt: P78396 | TargetFullName: Cyclin-A1 | Organisim: human | Apparent_Kd_M: 4.566387E-12
Real
Aptamer SeqId: 15321-8 | Target: CPLX2 | UniProt: Q6PUV4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15321-8 | Target: CPLX2 | UniProt: Q6PUV4 | TargetFullName: Complexin-2 | Organisim: human | Apparent_Kd_M: 5.37E-13
Real
Aptamer SeqId: 15322-35 | Target: CRADD | UniProt: P78560
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15322-35 | Target: CRADD | UniProt: P78560 | TargetFullName: Death domain-containing protein CRADD | Organisim: human | Apparent_Kd_M: 1.991715E-11
Real
Aptamer SeqId: 15323-112 | Target: AGO3 | UniProt: Q9H9G7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15323-112 | Target: AGO3 | UniProt: Q9H9G7 | TargetFullName: Protein argonaute-3 | Organisim: human | Apparent_Kd_M: 2.187586E-10
Real
Aptamer SeqId: 15324-58 | Target: Ferritin light chain | UniProt: P02792
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15324-58 | Target: Ferritin light chain | UniProt: P02792 | TargetFullName: Ferritin light chain | Organisim: human | Apparent_Kd_M: 3.04E-11
Real
Aptamer SeqId: 15325-14 | Target: NEUM | UniProt: P17677
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15325-14 | Target: NEUM | UniProt: P17677 | TargetFullName: Neuromodulin | Organisim: human | Apparent_Kd_M: 1.45E-11
Real
Aptamer SeqId: 15326-64 | Target: GBP1 | UniProt: P32455
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15326-64 | Target: GBP1 | UniProt: P32455 | TargetFullName: Guanylate-binding protein 1 | Organisim: human | Apparent_Kd_M: 1.39E-12
Real
Aptamer SeqId: 15329-167 | Target: MAPIP | UniProt: Q9Y2Q5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15329-167 | Target: MAPIP | UniProt: Q9Y2Q5 | TargetFullName: Ragulator complex protein LAMTOR2 | Organisim: human | Apparent_Kd_M: 1.594153E-11
Real
Aptamer SeqId: 15331-47 | Target: RBBP4 | UniProt: Q09028
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15331-47 | Target: RBBP4 | UniProt: Q09028 | TargetFullName: Histone-binding protein RBBP4 | Organisim: human | Apparent_Kd_M: 1.07E-11
Real
Aptamer SeqId: 15333-11 | Target: SDF2 | UniProt: Q99470
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15333-11 | Target: SDF2 | UniProt: Q99470 | TargetFullName: Stromal cell-derived factor 2 | Organisim: human | Apparent_Kd_M: 2.72E-11
Real
Aptamer SeqId: 15336-7 | Target: SELM | UniProt: Q8WWX9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15336-7 | Target: SELM | UniProt: Q8WWX9 | TargetFullName: Selenoprotein M | Organisim: human | Apparent_Kd_M: 1.863418E-12
Real
Aptamer SeqId: 15339-32 | Target: COF2 | UniProt: Q9Y281
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15339-32 | Target: COF2 | UniProt: Q9Y281 | TargetFullName: Cofilin-2 | Organisim: human | Apparent_Kd_M: 7.864838E-11
Real
Aptamer SeqId: 15343-337 | Target: Kininogen HMW Two Chain
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15343-337 | Target: Kininogen; HMW; Two Chain | UniProt: P01042 | TargetFullName: Kininogen; HMW; Two Chain | Organisim: human | Apparent_Kd_M: 5.22E-11
Real
Aptamer SeqId: 15346-31 | Target: IFN-g | UniProt: P01579
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15346-31 | Target: IFN-g | UniProt: P01579 | TargetFullName: Interferon gamma | Organisim: human | Apparent_Kd_M: 6.758157E-11
Real
Aptamer SeqId: 15347-12 | Target: Hemopexin | UniProt: P02790
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15347-12 | Target: Hemopexin | UniProt: P02790 | TargetFullName: Hemopexin | Organisim: human | Apparent_Kd_M: 1.75E-12
Real
Aptamer SeqId: 15358-28 | Target: 7B2 | UniProt: P05408
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15358-28 | Target: 7B2 | UniProt: P05408 | TargetFullName: Neuroendocrine protein 7B2 | Organisim: human | Apparent_Kd_M: 2.43E-12
Real
Aptamer SeqId: 15361-37 | Target: ANKR1 | UniProt: Q15327
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15361-37 | Target: ANKR1 | UniProt: Q15327 | TargetFullName: Ankyrin repeat domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 1.71E-11
Real
Aptamer SeqId: 15363-32 | Target: Apo A-V | UniProt: Q6Q788
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15363-32 | Target: Apo A-V | UniProt: Q6Q788 | TargetFullName: Apolipoprotein A-V | Organisim: human | Apparent_Kd_M: 4.01E-11
Real
Aptamer SeqId: 15364-101 | Target: Apo C-I | UniProt: P02654
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15364-101 | Target: Apo C-I | UniProt: P02654 | TargetFullName: Apolipoprotein C-I | Organisim: human | Apparent_Kd_M: 3.43E-12
Real
Aptamer SeqId: 15365-41 | Target: BAI3 | UniProt: O60242
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15365-41 | Target: BAI3 | UniProt: O60242 | TargetFullName: Adhesion G protein-coupled receptor B3 | Organisim: human | Apparent_Kd_M: 6.0E-12
Real
Aptamer SeqId: 15367-38 | Target: LPLC1 | UniProt: Q8TDL5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15367-38 | Target: LPLC1 | UniProt: Q8TDL5 | TargetFullName: BPI fold-containing family B member 1 | Organisim: human | Apparent_Kd_M: 1.28E-12
Real
Aptamer SeqId: 15368-3 | Target: BMPER | UniProt: Q8N8U9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15368-3 | Target: BMPER | UniProt: Q8N8U9 | TargetFullName: BMP-binding endothelial regulator protein | Organisim: human | Apparent_Kd_M: 5.13E-12
Real
Aptamer SeqId: 15370-5 | Target: BOLA1 | UniProt: Q9Y3E2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15370-5 | Target: BOLA1 | UniProt: Q9Y3E2 | TargetFullName: BolA-like protein 1 | Organisim: human | Apparent_Kd_M: 1.66E-12
Real
Aptamer SeqId: 15372-43 | Target: BRD2 | UniProt: P25440
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15372-43 | Target: BRD2 | UniProt: P25440 | TargetFullName: Bromodomain-containing protein 2 | Organisim: human | Apparent_Kd_M: 2.34E-12
Real
Aptamer SeqId: 15374-15 | Target: CA11 protein | UniProt: Q9NS71
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15374-15 | Target: CA11 protein | UniProt: Q9NS71 | TargetFullName: Gastrokine-1 | Organisim: human | Apparent_Kd_M: 1.68E-10
Real
Aptamer SeqId: 15375-49 | Target: Carboxypeptidase B1 | UniProt: P15086
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15375-49 | Target: Carboxypeptidase B1 | UniProt: P15086 | TargetFullName: Carboxypeptidase B | Organisim: human | Apparent_Kd_M: 3.41E-12
Real
Aptamer SeqId: 15376-134 | Target: CATE | UniProt: P14091
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15376-134 | Target: CATE | UniProt: P14091 | TargetFullName: Cathepsin E | Organisim: human | Apparent_Kd_M: 1.63E-10
Real
Aptamer SeqId: 15381-45 | Target: Discoidin domain receptor 2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15381-45 | Target: Discoidin domain receptor 2 | UniProt: Q16832 | TargetFullName: Discoidin domain-containing receptor 2 | Organisim: human | Apparent_Kd_M: 4.44E-11
Real
Aptamer SeqId: 15383-200 | Target: Endothelin 3 | UniProt: P14138
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15383-200 | Target: Endothelin 3 | UniProt: P14138 | TargetFullName: Endothelin-3 | Organisim: human | Apparent_Kd_M: 6.85E-11
Real
Aptamer SeqId: 15384-15 | Target: KLOTHO | UniProt: Q9UEF7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15384-15 | Target: KLOTHO | UniProt: Q9UEF7 | TargetFullName: Klotho | Organisim: human | Apparent_Kd_M: 1.33E-12
Real
Aptamer SeqId: 15385-116 | Target: FABP2 | UniProt: P12104
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15385-116 | Target: FABP2 | UniProt: P12104 | TargetFullName: Fatty acid-binding protein; intestinal | Organisim: human | Apparent_Kd_M: 1.4E-12
Real
Aptamer SeqId: 15386-7 | Target: FABPA | UniProt: P15090
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15386-7 | Target: FABPA | UniProt: P15090 | TargetFullName: Fatty acid-binding protein; adipocyte | Organisim: human | Apparent_Kd_M: 2.73E-12
Real
Aptamer SeqId: 15387-44 | Target: Neuropilin-2 | UniProt: O60462
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15387-44 | Target: Neuropilin-2 | UniProt: O60462 | TargetFullName: Neuropilin-2 | Organisim: human | Apparent_Kd_M: 7.14E-13
Real
Aptamer SeqId: 15388-24 | Target: FcRIIIa | UniProt: P08637
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15388-24 | Target: FcRIIIa | UniProt: P08637 | TargetFullName: Low affinity immunoglobulin gamma Fc region receptor III-A | Organisim: human | Apparent_Kd_M: 3.29E-11
Real
Aptamer SeqId: 15389-1 | Target: FRDA | UniProt: Q16595
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15389-1 | Target: FRDA | UniProt: Q16595 | TargetFullName: Frataxin; mitochondrial | Organisim: human | Apparent_Kd_M: 9.52E-12
Real
Aptamer SeqId: 15390-3 | Target: Galanin | UniProt: P22466
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15390-3 | Target: Galanin | UniProt: P22466 | TargetFullName: Galanin | Organisim: human | Apparent_Kd_M: 2.51E-11
Real
Aptamer SeqId: 15391-114 | Target: GAS-6 | UniProt: Q14393
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15391-114 | Target: GAS-6 | UniProt: Q14393 | TargetFullName: Growth arrest-specific protein 6 | Organisim: human | Apparent_Kd_M: 1.48E-12
Real
Aptamer SeqId: 15394-79 | Target: UNC5B | UniProt: Q8IZJ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15394-79 | Target: UNC5B | UniProt: Q8IZJ1 | TargetFullName: Netrin receptor UNC5B | Organisim: human | Apparent_Kd_M: 1.73E-12
Real
Aptamer SeqId: 15395-15 | Target: GST M1-1 | UniProt: P09488
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15395-15 | Target: GST M1-1 | UniProt: P09488 | TargetFullName: Glutathione S-transferase Mu 1 | Organisim: human | Apparent_Kd_M: 3.62E-11
Real
Aptamer SeqId: 15398-2 | Target: HERV1 | UniProt: P55789
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15398-2 | Target: HERV1 | UniProt: P55789 | TargetFullName: FAD-linked sulfhydryl oxidase ALR | Organisim: human | Apparent_Kd_M: 1.77E-11
Real
Aptamer SeqId: 15402-2 | Target: ID-1 | UniProt: P41134
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15402-2 | Target: ID-1 | UniProt: P41134 | TargetFullName: DNA-binding protein inhibitor ID-1 | Organisim: human | Apparent_Kd_M: 2.18E-11
Real
Aptamer SeqId: 15403-53 | Target: ID2 | UniProt: Q02363
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15403-53 | Target: ID2 | UniProt: Q02363 | TargetFullName: DNA-binding protein inhibitor ID-2 | Organisim: human | Apparent_Kd_M: 2.23E-11
Real
Aptamer SeqId: 15404-3 | Target: IFN21 | UniProt: P01568
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15404-3 | Target: IFN21 | UniProt: P01568 | TargetFullName: Interferon alpha-21 | Organisim: human | Apparent_Kd_M: 2.64E-12
Real
Aptamer SeqId: 15405-23 | Target: IFNA4 | UniProt: P05014
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15405-23 | Target: IFNA4 | UniProt: P05014 | TargetFullName: Interferon alpha-4 | Organisim: human | Apparent_Kd_M: 2.79E-12
Real
Aptamer SeqId: 15412-40 | Target: KIAP | UniProt: Q96CA5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15412-40 | Target: KIAP | UniProt: Q96CA5 | TargetFullName: Baculoviral IAP repeat-containing protein 7 | Organisim: human | Apparent_Kd_M: 2.53E-11
Real
Aptamer SeqId: 15413-3 | Target: LCAT | UniProt: P04180
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15413-3 | Target: LCAT | UniProt: P04180 | TargetFullName: Phosphatidylcholine-sterol acyltransferase | Organisim: human | Apparent_Kd_M: 5.88E-12
Real
Aptamer SeqId: 15414-316 | Target: LDHA | UniProt: P00338
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15414-316 | Target: LDHA | UniProt: P00338 | TargetFullName: L-lactate dehydrogenase A chain | Organisim: human | Apparent_Kd_M: 8.36E-12
Real
Aptamer SeqId: 15416-54 | Target: LYG2 | UniProt: Q86SG7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15416-54 | Target: LYG2 | UniProt: Q86SG7 | TargetFullName: Lysozyme g-like protein 2 | Organisim: human | Apparent_Kd_M: 1.83E-11
Real
Aptamer SeqId: 15417-3 | Target: Maspin | UniProt: P36952
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15417-3 | Target: Maspin | UniProt: P36952 | TargetFullName: Serpin B5 | Organisim: human | Apparent_Kd_M: 1.21E-11
Real
Aptamer SeqId: 15418-25 | Target: MK10 | UniProt: P53779
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15418-25 | Target: MK10 | UniProt: P53779 | TargetFullName: Mitogen-activated protein kinase 10 | Organisim: human | Apparent_Kd_M: 2.03E-12
Real
Aptamer SeqId: 15419-15 | Target: MMP20 | UniProt: O60882
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15419-15 | Target: MMP20 | UniProt: O60882 | TargetFullName: Matrix metalloproteinase-20 | Organisim: human | Apparent_Kd_M: 1.36E-11
Real
Aptamer SeqId: 15422-12 | Target: MYP2 | UniProt: P02689
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15422-12 | Target: MYP2 | UniProt: P02689 | TargetFullName: Myelin P2 protein | Organisim: human | Apparent_Kd_M: 5.52E-12
Real
Aptamer SeqId: 15426-5 | Target: NEUR1 | UniProt: Q99519
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15426-5 | Target: NEUR1 | UniProt: Q99519 | TargetFullName: Sialidase-1 | Organisim: human | Apparent_Kd_M: 9.93E-12
Real
Aptamer SeqId: 15427-35 | Target: LOXL3 | UniProt: P58215
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15427-35 | Target: LOXL3 | UniProt: P58215 | TargetFullName: Lysyl oxidase homolog 3 | Organisim: human | Apparent_Kd_M: 1.94E-12
Real
Aptamer SeqId: 15430-165 | Target: OPT | UniProt: Q9UBM4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15430-165 | Target: OPT | UniProt: Q9UBM4 | TargetFullName: Opticin | Organisim: human | Apparent_Kd_M: 2.68E-11
Real
Aptamer SeqId: 15431-31 | Target: OTCase | UniProt: P00480
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15431-31 | Target: OTCase | UniProt: P00480 | TargetFullName: Ornithine carbamoyltransferase; mitochondrial | Organisim: human | Apparent_Kd_M: 3.73E-12
Real
Aptamer SeqId: 15432-1 | Target: Otoraplin | UniProt: Q9NRC9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15432-1 | Target: Otoraplin | UniProt: Q9NRC9 | TargetFullName: Otoraplin | Organisim: human | Apparent_Kd_M: 6.68E-11
Real
Aptamer SeqId: 15433-4 | Target: p60-Src | UniProt: P12931
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15433-4 | Target: p60-Src | UniProt: P12931 | TargetFullName: Proto-oncogene tyrosine-protein kinase Src | Organisim: human | Apparent_Kd_M: 1.95E-12
Real
Aptamer SeqId: 15434-5 | Target: PNOC | UniProt: Q13519
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15434-5 | Target: PNOC | UniProt: Q13519 | TargetFullName: Prepronociceptin | Organisim: human | Apparent_Kd_M: 1.84E-11
Real
Aptamer SeqId: 15435-4 | Target: PNP | UniProt: P00491
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15435-4 | Target: PNP | UniProt: P00491 | TargetFullName: Purine nucleoside phosphorylase | Organisim: human | Apparent_Kd_M: 9.23E-12
Real
Aptamer SeqId: 15436-40 | Target: RAMP1 | UniProt: O60894
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15436-40 | Target: RAMP1 | UniProt: O60894 | TargetFullName: Receptor activity-modifying protein 1 | Organisim: human | Apparent_Kd_M: 1.64E-11
Real
Aptamer SeqId: 15437-11 | Target: RAMP3 | UniProt: O60896
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15437-11 | Target: RAMP3 | UniProt: O60896 | TargetFullName: Receptor activity-modifying protein 3 | Organisim: human | Apparent_Kd_M: 1.51E-10
Real
Aptamer SeqId: 15439-21 | Target: RND3 | UniProt: P61587
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15439-21 | Target: RND3 | UniProt: P61587 | TargetFullName: Rho-related GTP-binding protein RhoE | Organisim: human | Apparent_Kd_M: 1.56E-11
Real
Aptamer SeqId: 15440-57 | Target: NEC2 | UniProt: P16519
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15440-57 | Target: NEC2 | UniProt: P16519 | TargetFullName: Neuroendocrine convertase 2 | Organisim: human | Apparent_Kd_M: 5.24E-11
Real
Aptamer SeqId: 15441-6 | Target: SAP3 | UniProt: P17900
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15441-6 | Target: SAP3 | UniProt: P17900 | TargetFullName: Ganglioside GM2 activator | Organisim: human | Apparent_Kd_M: 5.97E-11
Real
Aptamer SeqId: 15444-45 | Target: SCCA2 | UniProt: P48594
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15444-45 | Target: SCCA2 | UniProt: P48594 | TargetFullName: Serpin B4 | Organisim: human | Apparent_Kd_M: 4.56E-11
Real
Aptamer SeqId: 15446-25 | Target: SMDF | UniProt: Q02297
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15446-25 | Target: SMDF | UniProt: Q02297 | TargetFullName: Neuregulin-1; sensory and motor neuron-derived factor isoform | Organisim: human | Apparent_Kd_M: 3.06E-10
Real
Aptamer SeqId: 15447-45 | Target: Sorbitol dehydrogenase | UniProt: Q00796
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15447-45 | Target: Sorbitol dehydrogenase | UniProt: Q00796 | TargetFullName: Sorbitol dehydrogenase | Organisim: human | Apparent_Kd_M: 1.32E-11
Real
Aptamer SeqId: 15448-47 | Target: SQSTM | UniProt: Q13501
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15448-47 | Target: SQSTM | UniProt: Q13501 | TargetFullName: Sequestosome-1 | Organisim: human | Apparent_Kd_M: 1.25E-11
Real
Aptamer SeqId: 15449-33 | Target: TIM-4 | UniProt: Q96H15
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15449-33 | Target: TIM-4 | UniProt: Q96H15 | TargetFullName: T-cell immunoglobulin and mucin domain-containing protein 4 | Organisim: human | Apparent_Kd_M: 1.27E-12
Real
Aptamer SeqId: 15452-5 | Target: 5'-Nucleotidase | UniProt: P21589
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15452-5 | Target: 5'-Nucleotidase | UniProt: P21589 | TargetFullName: 5'-Nucleotidase | Organisim: human | Apparent_Kd_M: 2.08E-12
Real
Aptamer SeqId: 15453-3 | Target: a1-Microglobulin | UniProt: P02760
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15453-3 | Target: a1-Microglobulin | UniProt: P02760 | TargetFullName: Alpha-1-microglobulin | Organisim: human | Apparent_Kd_M: 5.27E-12
Real
Aptamer SeqId: 15455-40 | Target: ADA15 | UniProt: Q13444
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15455-40 | Target: ADA15 | UniProt: Q13444 | TargetFullName: Disintegrin and metalloproteinase domain-containing protein 15 | Organisim: human | Apparent_Kd_M: 4.32E-12
Real
Aptamer SeqId: 15457-14 | Target: Aminopeptidase N | UniProt: P15144
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15457-14 | Target: Aminopeptidase N | UniProt: P15144 | TargetFullName: Aminopeptidase N | Organisim: human | Apparent_Kd_M: 2.32E-11
Real
Aptamer SeqId: 15460-9 | Target: CD26 | UniProt: P27487
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15460-9 | Target: CD26 | UniProt: P27487 | TargetFullName: Dipeptidyl peptidase 4 | Organisim: human | Apparent_Kd_M: 6.38E-11
Real
Aptamer SeqId: 15462-28 | Target: CD8A | UniProt: P01732
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15462-28 | Target: CD8A | UniProt: P01732 | TargetFullName: T-cell surface glycoprotein CD8 alpha chain | Organisim: human | Apparent_Kd_M: 6.32E-12
Real
Aptamer SeqId: 15465-79 | Target: CNPY4 | UniProt: Q8N129
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15465-79 | Target: CNPY4 | UniProt: Q8N129 | TargetFullName: Protein canopy homolog 4 | Organisim: human | Apparent_Kd_M: 8.52E-12
Real
Aptamer SeqId: 15466-30 | Target: CO9A1 | UniProt: P20849
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15466-30 | Target: CO9A1 | UniProt: P20849 | TargetFullName: Collagen alpha-1(IX) chain | Organisim: human | Apparent_Kd_M: 1.32E-12
Real
Aptamer SeqId: 15467-10 | Target: CTHR1 | UniProt: Q96CG8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15467-10 | Target: CTHR1 | UniProt: Q96CG8 | TargetFullName: Collagen triple helix repeat-containing protein 1 | Organisim: human | Apparent_Kd_M: 2.27E-11
Real
Aptamer SeqId: 15468-14 | Target: FHR1 | UniProt: Q03591
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15468-14 | Target: FHR1 | UniProt: Q03591 | TargetFullName: Complement factor H-related protein 1 | Organisim: human | Apparent_Kd_M: 6.1E-12
Real
Aptamer SeqId: 15470-11 | Target: Hexosaminidase B | UniProt: P07686
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15470-11 | Target: Hexosaminidase B | UniProt: P07686 | TargetFullName: Beta-hexosaminidase subunit beta | Organisim: human | Apparent_Kd_M: 1.72E-12
Real
Aptamer SeqId: 15471-29 | Target: LIPR2 | UniProt: P54317
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15471-29 | Target: LIPR2 | UniProt: P54317 | TargetFullName: Pancreatic lipase-related protein 2 | Organisim: human | Apparent_Kd_M: 2.9E-12
Real
Aptamer SeqId: 15472-16 | Target: LRP11 | UniProt: Q86VZ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15472-16 | Target: LRP11 | UniProt: Q86VZ4 | TargetFullName: Low-density lipoprotein receptor-related protein 11 | Organisim: human | Apparent_Kd_M: 2.43E-12
Real
Aptamer SeqId: 15474-7 | Target: PIN1 | UniProt: Q13526
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15474-7 | Target: PIN1 | UniProt: Q13526 | TargetFullName: Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Organisim: human | Apparent_Kd_M: 1.21E-11
Real
Aptamer SeqId: 15475-4 | Target: PLTP | UniProt: P55058
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15475-4 | Target: PLTP | UniProt: P55058 | TargetFullName: Phospholipid transfer protein | Organisim: human | Apparent_Kd_M: 5.93E-12
Real
Aptamer SeqId: 15476-6 | Target: REG3G | UniProt: Q6UW15
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15476-6 | Target: REG3G | UniProt: Q6UW15 | TargetFullName: Regenerating islet-derived protein 3-gamma | Organisim: human | Apparent_Kd_M: 4.83E-13
Real
Aptamer SeqId: 15480-2 | Target: VNN2 | UniProt: O95498
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15480-2 | Target: VNN2 | UniProt: O95498 | TargetFullName: Vascular non-inflammatory molecule 2 | Organisim: human | Apparent_Kd_M: 1.95E-12
Real
Aptamer SeqId: 15481-45 | Target: LL-37 | UniProt: P49913
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15481-45 | Target: LL-37 | UniProt: P49913 | TargetFullName: Antibacterial protein LL-37 | Organisim: human | Apparent_Kd_M: 3.59E-12
Real
Aptamer SeqId: 15482-12 | Target: A2ML1 | UniProt: A8K2U0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15482-12 | Target: A2ML1 | UniProt: A8K2U0 | TargetFullName: Alpha-2-macroglobulin-like protein 1 | Organisim: human | Apparent_Kd_M: 1.04E-11
Real
Aptamer SeqId: 15483-377 | Target: Agrin | UniProt: O00468
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15483-377 | Target: Agrin | UniProt: O00468 | TargetFullName: Agrin | Organisim: human | Apparent_Kd_M: 1.67E-12
Real
Aptamer SeqId: 15486-126 | Target: ABP1 | UniProt: P19801
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15486-126 | Target: ABP1 | UniProt: P19801 | TargetFullName: Amiloride-sensitive amine oxidase copper-containing | Organisim: human | Apparent_Kd_M: 2.45E-12
Real
Aptamer SeqId: 15487-164 | Target: carboxylesterase liver
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15487-164 | Target: carboxylesterase; liver | UniProt: P23141 | TargetFullName: Liver carboxylesterase 1 | Organisim: human | Apparent_Kd_M: 5.9E-11
Real
Aptamer SeqId: 15491-20 | Target: CD248 | UniProt: Q9HCU0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15491-20 | Target: CD248 | UniProt: Q9HCU0 | TargetFullName: Endosialin | Organisim: human | Apparent_Kd_M: 3.17E-12
Real
Aptamer SeqId: 15492-1 | Target: CRIM1 | UniProt: Q9NZV1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15492-1 | Target: CRIM1 | UniProt: Q9NZV1 | TargetFullName: Cysteine-rich motor neuron 1 protein | Organisim: human | Apparent_Kd_M: 2.03E-11
Real
Aptamer SeqId: 15494-11 | Target: FGFP1 | UniProt: Q14512
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15494-11 | Target: FGFP1 | UniProt: Q14512 | TargetFullName: Fibroblast growth factor-binding protein 1 | Organisim: human | Apparent_Kd_M: 1.77E-12
Real
Aptamer SeqId: 15495-9 | Target: FOLR3 | UniProt: P41439
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15495-9 | Target: FOLR3 | UniProt: P41439 | TargetFullName: Folate receptor gamma | Organisim: human | Apparent_Kd_M: 6.78E-11
Real
Aptamer SeqId: 15497-9 | Target: HS3S1 | UniProt: O14792
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15497-9 | Target: HS3S1 | UniProt: O14792 | TargetFullName: Heparan sulfate glucosamine 3-O-sulfotransferase 1 | Organisim: human | Apparent_Kd_M: 1.59E-12
Real
Aptamer SeqId: 15499-11 | Target: Attractin | UniProt: O75882
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15499-11 | Target: Attractin | UniProt: O75882 | TargetFullName: Attractin | Organisim: human | Apparent_Kd_M: 1.81E-11
Real
Aptamer SeqId: 15503-15 | Target: Lefty-A | UniProt: O00292
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15503-15 | Target: Lefty-A | UniProt: O00292 | TargetFullName: Left-right determination factor 2 | Organisim: human | Apparent_Kd_M: 5.94E-12
Real
Aptamer SeqId: 15503-20 | Target: Lefty-A | UniProt: O00292
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15503-20 | Target: Lefty-A | UniProt: O00292 | TargetFullName: Left-right determination factor 2 | Organisim: human | Apparent_Kd_M: 6.95E-12
Real
Aptamer SeqId: 15504-39 | Target: Livin B | UniProt: Q96CA5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15504-39 | Target: Livin B | UniProt: Q96CA5 | TargetFullName: Baculoviral IAP repeat-containing protein 7 Isoform beta | Organisim: human | Apparent_Kd_M: 2.87E-11
Real
Aptamer SeqId: 15506-34 | Target: LRP12 | UniProt: Q9Y561
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15506-34 | Target: LRP12 | UniProt: Q9Y561 | TargetFullName: Low-density lipoprotein receptor-related protein 12 | Organisim: human | Apparent_Kd_M: 1.54E-11
Real
Aptamer SeqId: 15509-2 | Target: NAG | UniProt: P54802
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15509-2 | Target: NAG | UniProt: P54802 | TargetFullName: Alpha-N-acetylglucosaminidase | Organisim: human | Apparent_Kd_M: 1.76E-11
Real
Aptamer SeqId: 15511-37 | Target: NPTXR | UniProt: O95502
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15511-37 | Target: NPTXR | UniProt: O95502 | TargetFullName: Neuronal pentraxin receptor | Organisim: human | Apparent_Kd_M: 3.09E-11
Real
Aptamer SeqId: 15513-108 | Target: Prostasin | UniProt: Q16651
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15513-108 | Target: Prostasin | UniProt: Q16651 | TargetFullName: Prostasin | Organisim: human | Apparent_Kd_M: 1.18E-10
Real
Aptamer SeqId: 15514-26 | Target: Pseudocholinesterase | UniProt: P06276
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15514-26 | Target: Pseudocholinesterase | UniProt: P06276 | TargetFullName: Cholinesterase | Organisim: human | Apparent_Kd_M: 1.85E-12
Real
Aptamer SeqId: 15515-2 | Target: SAA | UniProt: P0DJI8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15515-2 | Target: SAA | UniProt: P0DJI8 | TargetFullName: Serum amyloid A-1 protein | Organisim: human | Apparent_Kd_M: 4.25E-12
Real
Aptamer SeqId: 15516-12 | Target: SAA-4 | UniProt: P35542
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15516-12 | Target: SAA-4 | UniProt: P35542 | TargetFullName: Serum amyloid A-4 protein | Organisim: human | Apparent_Kd_M: 8.03E-12
Real
Aptamer SeqId: 15521-4 | Target: Alcadein alpha-1 | UniProt: O94985
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15521-4 | Target: Alcadein alpha-1 | UniProt: O94985 | TargetFullName: Calsyntenin-1 | Organisim: human | Apparent_Kd_M: 9.6E-11
Real
Aptamer SeqId: 15522-2 | Target: GAPR1 | UniProt: Q9H4G4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15522-2 | Target: GAPR1 | UniProt: Q9H4G4 | TargetFullName: Golgi-associated plant pathogenesis-related protein 1 | Organisim: human | Apparent_Kd_M: 1.9E-12
Real
Aptamer SeqId: 15523-9 | Target: HEM2 | UniProt: P13716
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15523-9 | Target: HEM2 | UniProt: P13716 | TargetFullName: Delta-aminolevulinic acid dehydratase | Organisim: human | Apparent_Kd_M: 2.35E-11
Real
Aptamer SeqId: 15524-30 | Target: PGAM2 | UniProt: P15259
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15524-30 | Target: PGAM2 | UniProt: P15259 | TargetFullName: Phosphoglycerate mutase 2 | Organisim: human | Apparent_Kd_M: 1.3E-11
Real
Aptamer SeqId: 15525-294 | Target: ADH1G | UniProt: P00326
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15525-294 | Target: ADH1G | UniProt: P00326 | TargetFullName: Alcohol dehydrogenase 1C | Organisim: human | Apparent_Kd_M: 3.4E-11
Real
Aptamer SeqId: 15526-33 | Target: GSHB | UniProt: P48637
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15526-33 | Target: GSHB | UniProt: P48637 | TargetFullName: Glutathione synthetase | Organisim: human | Apparent_Kd_M: 1.78E-11
Real
Aptamer SeqId: 15527-90 | Target: DLDH | UniProt: P09622
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15527-90 | Target: DLDH | UniProt: P09622 | TargetFullName: Dihydrolipoyl dehydrogenase; mitochondrial | Organisim: human | Apparent_Kd_M: 1.7E-11
Real
Aptamer SeqId: 15529-33 | Target: Cysteine-rich protein 1 | UniProt: P21291
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15529-33 | Target: Cysteine-rich protein 1 | UniProt: P21291 | TargetFullName: Cysteine and glycine-rich protein 1 | Organisim: human | Apparent_Kd_M: 7.93E-12
Real
Aptamer SeqId: 15530-33 | Target: EphB4 | UniProt: P54760
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15530-33 | Target: EphB4 | UniProt: P54760 | TargetFullName: Ephrin type-B receptor 4 | Organisim: human | Apparent_Kd_M: 1.81E-11
Real
Aptamer SeqId: 15533-97 | Target: Macrophage scavenger receptor
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15533-97 | Target: Macrophage scavenger receptor | UniProt: P21757 | TargetFullName: Macrophage scavenger receptor types I and II | Organisim: human | Apparent_Kd_M: 4.52E-12
Real
Aptamer SeqId: 15534-26 | Target: Malate dehydrogenase 2 | UniProt: P40926
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15534-26 | Target: Malate dehydrogenase 2 | UniProt: P40926 | TargetFullName: Malate dehydrogenase; mitochondrial | Organisim: human | Apparent_Kd_M: 1.37E-12
Real
Aptamer SeqId: 15535-3 | Target: Marapsin | UniProt: Q9BQR3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15535-3 | Target: Marapsin | UniProt: Q9BQR3 | TargetFullName: Serine protease 27 | Organisim: human | Apparent_Kd_M: 1.68E-11
Real
Aptamer SeqId: 15539-15 | Target: SLIK1 | UniProt: Q96PX8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15539-15 | Target: SLIK1 | UniProt: Q96PX8 | TargetFullName: SLIT and NTRK-like protein 1 | Organisim: human | Apparent_Kd_M: 1.63E-11
Real
Aptamer SeqId: 15540-6 | Target: Vimentin | UniProt: P08670
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15540-6 | Target: Vimentin | UniProt: P08670 | TargetFullName: Vimentin | Organisim: human | Apparent_Kd_M: 7.69E-11
Real
Aptamer SeqId: 15542-19 | Target: KCRU | UniProt: P12532
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15542-19 | Target: KCRU | UniProt: P12532 | TargetFullName: Creatine kinase U-type; mitochondrial | Organisim: human | Apparent_Kd_M: 6.25E-12
Real
Aptamer SeqId: 15544-25 | Target: kallikrein 14 | UniProt: Q9P0G3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15544-25 | Target: kallikrein 14 | UniProt: Q9P0G3 | TargetFullName: Kallikrein-14 | Organisim: human | Apparent_Kd_M: 2.31E-12
Real
Aptamer SeqId: 15545-13 | Target: Calcineurin B a | UniProt: P63098
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15545-13 | Target: Calcineurin B a | UniProt: P63098 | TargetFullName: Calcineurin subunit B type 1 | Organisim: human | Apparent_Kd_M: 1.27E-11
Real
Aptamer SeqId: 15548-35 | Target: SERA | UniProt: O43175
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15548-35 | Target: SERA | UniProt: O43175 | TargetFullName: D-3-phosphoglycerate dehydrogenase | Organisim: human | Apparent_Kd_M: 3.69E-11
Real
Aptamer SeqId: 15553-22 | Target: ACES | UniProt: P22303
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15553-22 | Target: ACES | UniProt: P22303 | TargetFullName: Acetylcholinesterase | Organisim: human | Apparent_Kd_M: 2.18E-11
Real
Aptamer SeqId: 15556-49 | Target: Alpha-amylase 2B | UniProt: P19961
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15556-49 | Target: Alpha-amylase 2B | UniProt: P19961 | TargetFullName: Alpha-amylase 2B | Organisim: human | Apparent_Kd_M: 1.43E-11
Real
Aptamer SeqId: 15558-63 | Target: AMPE | UniProt: Q07075
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15558-63 | Target: AMPE | UniProt: Q07075 | TargetFullName: Glutamyl aminopeptidase | Organisim: human | Apparent_Kd_M: 1.55E-11
Real
Aptamer SeqId: 15559-5 | Target: ANTR2 | UniProt: P58335
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15559-5 | Target: ANTR2 | UniProt: P58335 | TargetFullName: Anthrax toxin receptor 2 | Organisim: human | Apparent_Kd_M: 1.0E-10
Real
Aptamer SeqId: 15560-52 | Target: Apo-TC II | UniProt: P20062
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15560-52 | Target: Apo-TC II | UniProt: P20062 | TargetFullName: Transcobalamin-2 | Organisim: human | Apparent_Kd_M: 4.06E-12
Real
Aptamer SeqId: 15562-24 | Target: BGLR | UniProt: P08236
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15562-24 | Target: BGLR | UniProt: P08236 | TargetFullName: Beta-glucuronidase | Organisim: human | Apparent_Kd_M: 2.72E-12
Real
Aptamer SeqId: 15565-102 | Target: CA125 | UniProt: Q8WXI7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15565-102 | Target: CA125 | UniProt: Q8WXI7 | TargetFullName: Mucin-16 | Organisim: human | Apparent_Kd_M: 1.39E-11
Real
Aptamer SeqId: 15566-10 | Target: Calponin-1 | UniProt: P51911
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15566-10 | Target: Calponin-1 | UniProt: P51911 | TargetFullName: Calponin-1 | Organisim: human | Apparent_Kd_M: 1.6E-11
Real
Aptamer SeqId: 15567-2 | Target: CD3-zeta | UniProt: P20963
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15567-2 | Target: CD3-zeta | UniProt: P20963 | TargetFullName: T-cell surface glycoprotein CD3 zeta chain | Organisim: human | Apparent_Kd_M: 2.56E-11
Real
Aptamer SeqId: 15569-15 | Target: Collagen II | UniProt: P02458
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15569-15 | Target: Collagen II | UniProt: P02458 | TargetFullName: Collagen Type II | Organisim: human | Apparent_Kd_M: 1.35E-12
Real
Aptamer SeqId: 15570-99 | Target: Complement receptor type 2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15570-99 | Target: Complement receptor type 2 | UniProt: P20023 | TargetFullName: Complement receptor type 2 | Organisim: human | Apparent_Kd_M: 1.89E-12
Real
Aptamer SeqId: 15573-110 | Target: CSPG3 | UniProt: O14594
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15573-110 | Target: CSPG3 | UniProt: O14594 | TargetFullName: Neurocan core protein | Organisim: human | Apparent_Kd_M: 3.93E-12
Real
Aptamer SeqId: 15574-37 | Target: Cyclin A | UniProt: P20248
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15574-37 | Target: Cyclin A | UniProt: P20248 | TargetFullName: Cyclin-A2 | Organisim: human | Apparent_Kd_M: 8.1E-12
Real
Aptamer SeqId: 15576-158 | Target: ECP | UniProt: P12724
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15576-158 | Target: ECP | UniProt: P12724 | TargetFullName: Eosinophil cationic protein | Organisim: human | Apparent_Kd_M: 4.07E-14
Real
Aptamer SeqId: 15579-26 | Target: ENPP6 | UniProt: Q6UWR7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15579-26 | Target: ENPP6 | UniProt: Q6UWR7 | TargetFullName: Ectonucleotide pyrophosphatase/phosphodiesterase family member 6 | Organisim: human | Apparent_Kd_M: 1.26E-12
Real
Aptamer SeqId: 15580-2 | Target: EPHA7 | UniProt: Q15375
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15580-2 | Target: EPHA7 | UniProt: Q15375 | TargetFullName: Ephrin type-A receptor 7 | Organisim: human | Apparent_Kd_M: 1.18E-10
Real
Aptamer SeqId: 15581-16 | Target: FANK1 | UniProt: Q8TC84
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15581-16 | Target: FANK1 | UniProt: Q8TC84 | TargetFullName: Fibronectin type 3 and ankyrin repeat domains protein 1 | Organisim: human | Apparent_Kd_M: 3.04E-11
Real
Aptamer SeqId: 15582-25 | Target: FCN1 | UniProt: O00602
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15582-25 | Target: FCN1 | UniProt: O00602 | TargetFullName: Ficolin-1 | Organisim: human | Apparent_Kd_M: 3.64E-11
Real
Aptamer SeqId: 15583-18 | Target: FCRLB | UniProt: Q6BAA4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15583-18 | Target: FCRLB | UniProt: Q6BAA4 | TargetFullName: Fc receptor-like B | Organisim: human | Apparent_Kd_M: 1.4E-11
Real
Aptamer SeqId: 15584-9 | Target: FHR2 | UniProt: P36980
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15584-9 | Target: FHR2 | UniProt: P36980 | TargetFullName: Complement factor H-related protein 2 | Organisim: human | Apparent_Kd_M: 5.29E-12
Real
Aptamer SeqId: 15585-304 | Target: fibulin 5 | UniProt: Q9UBX5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15585-304 | Target: fibulin 5 | UniProt: Q9UBX5 | TargetFullName: Fibulin-5 | Organisim: human | Apparent_Kd_M: 3.09E-11
Real
Aptamer SeqId: 15587-20 | Target: FOLR2 | UniProt: P14207
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15587-20 | Target: FOLR2 | UniProt: P14207 | TargetFullName: Folate receptor beta | Organisim: human | Apparent_Kd_M: 9.71E-12
Real
Aptamer SeqId: 15588-17 | Target: galactosidase; alpha | UniProt: P06280
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15588-17 | Target: galactosidase; alpha | UniProt: P06280 | TargetFullName: Alpha-galactosidase A | Organisim: human | Apparent_Kd_M: 1.49E-10
Real
Aptamer SeqId: 15589-1 | Target: Gc-Globulin; Mixed Type | UniProt: P02774
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15589-1 | Target: Gc-Globulin; Mixed Type | UniProt: P02774 | TargetFullName: Vitamin D-binding protein | Organisim: human | Apparent_Kd_M: 3.91E-11
Real
Aptamer SeqId: 15591-28 | Target: Glutathione peroxidase | UniProt: P07203
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15591-28 | Target: Glutathione peroxidase | UniProt: P07203 | TargetFullName: Glutathione peroxidase 1 | Organisim: human | Apparent_Kd_M: 2.35E-11
Real
Aptamer SeqId: 15594-47 | Target: HTRA1 | UniProt: Q92743
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15594-47 | Target: HTRA1 | UniProt: Q92743 | TargetFullName: Serine protease HTRA1 | Organisim: human | Apparent_Kd_M: 1.7E-12
Real
Aptamer SeqId: 15596-7 | Target: HEXI1 | UniProt: O94992
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15596-7 | Target: HEXI1 | UniProt: O94992 | TargetFullName: Protein HEXIM1 | Organisim: human | Apparent_Kd_M: 4.71E-12
Real
Aptamer SeqId: 15602-43 | Target: IL-6 sRa | UniProt: P08887
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15602-43 | Target: IL-6 sRa | UniProt: P08887 | TargetFullName: Interleukin-6 receptor subunit alpha | Organisim: human | Apparent_Kd_M: 1.48E-12
Real
Aptamer SeqId: 15603-20 | Target: Integrin alpha-2 | UniProt: P17301
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15603-20 | Target: Integrin alpha-2 | UniProt: P17301 | TargetFullName: Integrin alpha-2 | Organisim: human | Apparent_Kd_M: 6.38E-12
Real
Aptamer SeqId: 15604-18 | Target: JNK2 | UniProt: P45984
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15604-18 | Target: JNK2 | UniProt: P45984 | TargetFullName: Mitogen-activated protein kinase 9 | Organisim: human | Apparent_Kd_M: 1.25E-11
Real
Aptamer SeqId: 15606-19 | Target: Keratin 19 | UniProt: P08727
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15606-19 | Target: Keratin 19 | UniProt: P08727 | TargetFullName: Keratin; type I cytoskeletal 19 | Organisim: human | Apparent_Kd_M: 5.96E-11
Real
Aptamer SeqId: 15607-56 | Target: KPYR | UniProt: P30613
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15607-56 | Target: KPYR | UniProt: P30613 | TargetFullName: Pyruvate kinase PKLR | Organisim: human | Apparent_Kd_M: 1.55E-11
Real
Aptamer SeqId: 15608-5 | Target: KS6B1 | UniProt: P23443
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15608-5 | Target: KS6B1 | UniProt: P23443 | TargetFullName: Ribosomal protein S6 kinase beta-1 | Organisim: human | Apparent_Kd_M: 3.67E-12
Real
Aptamer SeqId: 15610-72 | Target: LAP | UniProt: P28838
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15610-72 | Target: LAP | UniProt: P28838 | TargetFullName: Cytosol aminopeptidase | Organisim: human | Apparent_Kd_M: 4.89E-12
Real
Aptamer SeqId: 15612-5 | Target: LIN7B | UniProt: Q9HAP6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15612-5 | Target: LIN7B | UniProt: Q9HAP6 | TargetFullName: Protein lin-7 homolog B | Organisim: human | Apparent_Kd_M: 6.99E-12
Real
Aptamer SeqId: 15613-16 | Target: LIPP | UniProt: P16233
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15613-16 | Target: LIPP | UniProt: P16233 | TargetFullName: Pancreatic triacylglycerol lipase | Organisim: human | Apparent_Kd_M: 6.27E-12
Real
Aptamer SeqId: 15614-168 | Target: LIRA2 | UniProt: Q8N149
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15614-168 | Target: LIRA2 | UniProt: Q8N149 | TargetFullName: Leukocyte immunoglobulin-like receptor subfamily A member 2 | Organisim: human | Apparent_Kd_M: 2.54E-11
Real
Aptamer SeqId: 15615-8 | Target: LIRB3 | UniProt: O75022
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15615-8 | Target: LIRB3 | UniProt: O75022 | TargetFullName: Leukocyte immunoglobulin-like receptor subfamily B member 3 | Organisim: human | Apparent_Kd_M: 2.36E-12
Real
Aptamer SeqId: 15617-8 | Target: lymphotactin beta | UniProt: Q9UBD3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15617-8 | Target: lymphotactin beta | UniProt: Q9UBD3 | TargetFullName: Cytokine SCM-1 beta | Organisim: human | Apparent_Kd_M: 5.7E-12
Real
Aptamer SeqId: 15619-49 | Target: MOG | UniProt: Q16653
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15619-49 | Target: MOG | UniProt: Q16653 | TargetFullName: Myelin-oligodendrocyte glycoprotein | Organisim: human | Apparent_Kd_M: 1.16E-11
Real
Aptamer SeqId: 15620-4 | Target: NLGN1 | UniProt: Q8N2Q7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15620-4 | Target: NLGN1 | UniProt: Q8N2Q7 | TargetFullName: Neuroligin-1 | Organisim: human | Apparent_Kd_M: 4.2E-11
Real
Aptamer SeqId: 15622-13 | Target: OBCAM | UniProt: Q14982
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15622-13 | Target: OBCAM | UniProt: Q14982 | TargetFullName: Opioid-binding protein/cell adhesion molecule | Organisim: human | Apparent_Kd_M: 5.72E-11
Real
Aptamer SeqId: 15623-1 | Target: PD-1 | UniProt: Q15116
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15623-1 | Target: PD-1 | UniProt: Q15116 | TargetFullName: Programmed cell death protein 1 | Organisim: human | Apparent_Kd_M: 2.19E-10
Real
Aptamer SeqId: 15626-223 | Target: Perlecan | UniProt: P98160
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15626-223 | Target: Perlecan | UniProt: P98160 | TargetFullName: Basement membrane-specific heparan sulfate proteoglycan core protein | Organisim: human | Apparent_Kd_M: 6.01E-12
Real
Aptamer SeqId: 15627-83 | Target: PKB | UniProt: P31749
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15627-83 | Target: PKB | UniProt: P31749 | TargetFullName: RAC-alpha serine/threonine-protein kinase | Organisim: human | Apparent_Kd_M: 2.7E-12
Real
Aptamer SeqId: 15631-18 | Target: PSG1 | UniProt: P11464
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15631-18 | Target: PSG1 | UniProt: P11464 | TargetFullName: Pregnancy-specific beta-1-glycoprotein 1 | Organisim: human | Apparent_Kd_M: 1.86E-12
Real
Aptamer SeqId: 15633-6 | Target: RBP | UniProt: P02753
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15633-6 | Target: RBP | UniProt: P02753 | TargetFullName: Retinol-binding protein 4 | Organisim: human | Apparent_Kd_M: 3.15E-11
Real
Aptamer SeqId: 15634-139 | Target: SLIT1 | UniProt: O75093
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15634-139 | Target: SLIT1 | UniProt: O75093 | TargetFullName: Slit homolog 1 protein | Organisim: human | Apparent_Kd_M: 1.48E-12
Real
Aptamer SeqId: 15635-4 | Target: SMOC2 | UniProt: Q9H3U7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15635-4 | Target: SMOC2 | UniProt: Q9H3U7 | TargetFullName: SPARC-related modular calcium-binding protein 2 | Organisim: human | Apparent_Kd_M: 3.02E-12
Real
Aptamer SeqId: 15636-49 | Target: SORC1 | UniProt: Q8WY21
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15636-49 | Target: SORC1 | UniProt: Q8WY21 | TargetFullName: VPS10 domain-containing receptor SorCS1 | Organisim: human | Apparent_Kd_M: 9.51E-11
Real
Aptamer SeqId: 15637-38 | Target: SORC3 | UniProt: Q9UPU3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15637-38 | Target: SORC3 | UniProt: Q9UPU3 | TargetFullName: VPS10 domain-containing receptor SorCS3 | Organisim: human | Apparent_Kd_M: 4.32E-11
Real
Aptamer SeqId: 15640-54 | Target: TAGL | UniProt: Q01995
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15640-54 | Target: TAGL | UniProt: Q01995 | TargetFullName: Transgelin | Organisim: human | Apparent_Kd_M: 1.34E-12
Real
Aptamer SeqId: 15641-20 | Target: TEFF1 | UniProt: Q8IYR6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15641-20 | Target: TEFF1 | UniProt: Q8IYR6 | TargetFullName: Tomoregulin-1 | Organisim: human | Apparent_Kd_M: 4.8E-12
Real
Aptamer SeqId: 15644-1 | Target: Biotinidase | UniProt: P43251
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15644-1 | Target: Biotinidase | UniProt: P43251 | TargetFullName: Biotinidase | Organisim: human | Apparent_Kd_M: 4.15E-12
Real
Aptamer SeqId: 15653-9 | Target: COAA1 | UniProt: Q03692
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15653-9 | Target: COAA1 | UniProt: Q03692 | TargetFullName: Collagen alpha-1(X) chain | Organisim: human | Apparent_Kd_M: 5.172025E-11
Real
Aptamer SeqId: 15666-21 | Target: BMP-2 | UniProt: P12643
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15666-21 | Target: BMP-2 | UniProt: P12643 | TargetFullName: Bone morphogenetic protein 2 | Organisim: human | Apparent_Kd_M: 8.54E-12
Real
Aptamer SeqId: 15667-39 | Target: BMP-4 | UniProt: P12644
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15667-39 | Target: BMP-4 | UniProt: P12644 | TargetFullName: Bone morphogenetic protein 4 | Organisim: human | Apparent_Kd_M: 1.31E-11
Real
Aptamer SeqId: 15668-19 | Target: BMP-8 | UniProt: P34820
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15668-19 | Target: BMP-8 | UniProt: P34820 | TargetFullName: Bone morphogenetic protein 8B | Organisim: human | Apparent_Kd_M: 6.53E-11
Real
Aptamer SeqId: 15669-7 | Target: BRAF1 | UniProt: P15056
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15669-7 | Target: BRAF1 | UniProt: P15056 | TargetFullName: Serine/threonine-protein kinase B-raf | Organisim: human | Apparent_Kd_M: 1.3E-11
Real
Aptamer SeqId: 15670-15 | Target: C1QL2 | UniProt: Q7Z5L3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15670-15 | Target: C1QL2 | UniProt: Q7Z5L3 | TargetFullName: Complement C1q-like protein 2 | Organisim: human | Apparent_Kd_M: 3.62E-11
Real
Aptamer SeqId: 15674-3 | Target: CD79A | UniProt: P11912
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15674-3 | Target: CD79A | UniProt: P11912 | TargetFullName: B-cell antigen receptor complex-associated protein alpha chain | Organisim: human | Apparent_Kd_M: 1.78E-11
Real
Aptamer SeqId: 15675-3 | Target: CEBPB | UniProt: P17676
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15675-3 | Target: CEBPB | UniProt: P17676 | TargetFullName: CCAAT/enhancer-binding protein beta | Organisim: human | Apparent_Kd_M: 1.47E-11
Real
Aptamer SeqId: 15678-71 | Target: DKK2 | UniProt: Q9UBU2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15678-71 | Target: DKK2 | UniProt: Q9UBU2 | TargetFullName: Dickkopf-related protein 2 | Organisim: human | Apparent_Kd_M: 3.12E-12
Real
Aptamer SeqId: 15686-49 | Target: INHBC | UniProt: P55103
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15686-49 | Target: INHBC | UniProt: P55103 | TargetFullName: Inhibin beta C chain | Organisim: human | Apparent_Kd_M: 3.08E-11
Real
Aptamer SeqId: 15688-30 | Target: Mannose-binding lectin | UniProt: P49257
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15688-30 | Target: Mannose-binding lectin | UniProt: P49257 | TargetFullName: Protein ERGIC-53 | Organisim: human | Apparent_Kd_M: 1.67E-11
Real
Aptamer SeqId: 15692-300 | Target: NODAL | UniProt: Q96S42
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15692-300 | Target: NODAL | UniProt: Q96S42 | TargetFullName: Nodal homolog | Organisim: human | Apparent_Kd_M: 9.08E-12
Real
Aptamer SeqId: 15693-9 | Target: PgR | UniProt: P06401
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15693-9 | Target: PgR | UniProt: P06401 | TargetFullName: Progesterone receptor | Organisim: human | Apparent_Kd_M: 5.58E-13
Real
Aptamer SeqId: 15698-6 | Target: TXLNA | UniProt: P40222
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 15698-6 | Target: TXLNA | UniProt: P40222 | TargetFullName: Alpha-taxilin | Organisim: human | Apparent_Kd_M: 1.01E-11
Real
Aptamer SeqId: 16015-19 | Target: ALT | UniProt: P24298
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16015-19 | Target: ALT | UniProt: P24298 | TargetFullName: Alanine aminotransferase 1 | Organisim: human | Apparent_Kd_M: 9.43E-11
Real
Aptamer SeqId: 16021-30 | Target: Cadherin-8 | UniProt: P55286
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16021-30 | Target: Cadherin-8 | UniProt: P55286 | TargetFullName: Cadherin-8 | Organisim: human | Apparent_Kd_M: 1.39E-10
Real
Aptamer SeqId: 16035-8 | Target: VEGF sR3 | UniProt: P35916
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16035-8 | Target: VEGF sR3 | UniProt: P35916 | TargetFullName: Vascular endothelial growth factor receptor 3 | Organisim: human | Apparent_Kd_M: 1.385256E-12
Real
Aptamer SeqId: 16043-30 | Target: SHC1 | UniProt: P29353
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16043-30 | Target: SHC1 | UniProt: P29353 | TargetFullName: SHC-transforming protein 1 | Organisim: human | Apparent_Kd_M: 1.782693E-12
Real
Aptamer SeqId: 16049-43 | Target: OLR1 | UniProt: P78380
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16049-43 | Target: OLR1 | UniProt: P78380 | TargetFullName: Oxidized low-density lipoprotein receptor 1 | Organisim: human | Apparent_Kd_M: 6.65E-12
Real
Aptamer SeqId: 16055-3 | Target: complement factor H-related 5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16055-3 | Target: complement factor H-related 5 | UniProt: Q9BXR6 | TargetFullName: Complement factor H-related protein 5 | Organisim: human | Apparent_Kd_M: 5.82E-12
Real
Aptamer SeqId: 16057-6 | Target: IGF-II receptor | UniProt: P11717
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16057-6 | Target: IGF-II receptor | UniProt: P11717 | TargetFullName: Cation-independent mannose-6-phosphate receptor | Organisim: human | Apparent_Kd_M: 3.824875E-11
Real
Aptamer SeqId: 16060-99 | Target: NID2 | UniProt: Q14112
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16060-99 | Target: NID2 | UniProt: Q14112 | TargetFullName: Nidogen-2 | Organisim: human | Apparent_Kd_M: 2.226339E-11
Real
Aptamer SeqId: 16070-7 | Target: WIF-1 | UniProt: Q9Y5W5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16070-7 | Target: WIF-1 | UniProt: Q9Y5W5 | TargetFullName: Wnt inhibitory factor 1 | Organisim: human | Apparent_Kd_M: 2.939165E-12
Real
Aptamer SeqId: 16074-12 | Target: GRB2-related adapter protein 2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16074-12 | Target: GRB2-related adapter protein 2 | UniProt: O75791 | TargetFullName: GRB2-related adapter protein 2 | Organisim: human | Apparent_Kd_M: 1.274287E-11
Real
Aptamer SeqId: 16079-2 | Target: TEC | UniProt: P42680
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16079-2 | Target: TEC | UniProt: P42680 | TargetFullName: Tyrosine-protein kinase Tec | Organisim: human | Apparent_Kd_M: 1.9E-12
Real
Aptamer SeqId: 16081-38 | Target: Aldose reductase-like | UniProt: O60218
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16081-38 | Target: Aldose reductase-like | UniProt: O60218 | TargetFullName: Aldo-keto reductase family 1 member B10 | Organisim: human | Apparent_Kd_M: 1.74E-11
Real
Aptamer SeqId: 16288-17 | Target: EPHA4 | UniProt: P54764
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16288-17 | Target: EPHA4 | UniProt: P54764 | TargetFullName: Ephrin type-A receptor 4 | Organisim: human | Apparent_Kd_M: 3.35E-12
Real
Aptamer SeqId: 16292-288 | Target: GIP | UniProt: P09681
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16292-288 | Target: GIP | UniProt: P09681 | TargetFullName: Gastric inhibitory polypeptide | Organisim: human | Apparent_Kd_M: 1.89E-12
Real
Aptamer SeqId: 16293-1 | Target: Growth hormone-releasing factor
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16293-1 | Target: Growth hormone-releasing factor | UniProt: P01286 | TargetFullName: Somatoliberin | Organisim: human | Apparent_Kd_M: 3.839629E-12
Real
Aptamer SeqId: 16296-43 | Target: LGR5 | UniProt: O75473
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16296-43 | Target: LGR5 | UniProt: O75473 | TargetFullName: Leucine-rich repeat-containing G-protein coupled receptor 5 | Organisim: human | Apparent_Kd_M: 3.29E-12
Real
Aptamer SeqId: 16297-14 | Target: ROBO4 | UniProt: Q8WZ75
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16297-14 | Target: ROBO4 | UniProt: Q8WZ75 | TargetFullName: Roundabout homolog 4 | Organisim: human | Apparent_Kd_M: 2.22E-12
Real
Aptamer SeqId: 16298-84 | Target: sPLA(2)-IID | UniProt: Q9UNK4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16298-84 | Target: sPLA(2)-IID | UniProt: Q9UNK4 | TargetFullName: Group IID secretory phospholipase A2 | Organisim: human | Apparent_Kd_M: 5.94E-11
Real
Aptamer SeqId: 16299-13 | Target: TIGIT | UniProt: Q495A1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16299-13 | Target: TIGIT | UniProt: Q495A1 | TargetFullName: T-cell immunoreceptor with Ig and ITIM domains | Organisim: human | Apparent_Kd_M: 9.49E-11
Real
Aptamer SeqId: 16300-4 | Target: TREM2 | UniProt: Q9NZC2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16300-4 | Target: TREM2 | UniProt: Q9NZC2 | TargetFullName: Triggering receptor expressed on myeloid cells 2 | Organisim: human | Apparent_Kd_M: 4.05E-12
Real
Aptamer SeqId: 16302-11 | Target: SPLC2 | UniProt: Q96DR5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16302-11 | Target: SPLC2 | UniProt: Q96DR5 | TargetFullName: BPI fold-containing family A member 2 | Organisim: human | Apparent_Kd_M: 5.59E-12
Real
Aptamer SeqId: 16304-6 | Target: LGR4 | UniProt: Q9BXB1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16304-6 | Target: LGR4 | UniProt: Q9BXB1 | TargetFullName: Leucine-rich repeat-containing G-protein coupled receptor 4 | Organisim: human | Apparent_Kd_M: 2.84E-11
Real
Aptamer SeqId: 16305-10 | Target: Cadherin-11 | UniProt: P55287
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16305-10 | Target: Cadherin-11 | UniProt: P55287 | TargetFullName: Cadherin-11 | Organisim: human | Apparent_Kd_M: 4.585595E-11
Real
Aptamer SeqId: 16307-22 | Target: UNC5H4 | UniProt: Q6UXZ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16307-22 | Target: UNC5H4 | UniProt: Q6UXZ4 | TargetFullName: Netrin receptor UNC5D | Organisim: human | Apparent_Kd_M: 1.73E-12
Real
Aptamer SeqId: 16308-14 | Target: BTLA | UniProt: Q7Z6A9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16308-14 | Target: BTLA | UniProt: Q7Z6A9 | TargetFullName: B- and T-lymphocyte attenuator | Organisim: human | Apparent_Kd_M: 1.082681E-11
Real
Aptamer SeqId: 16309-30 | Target: Soggy-1 | UniProt: Q9UK85
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16309-30 | Target: Soggy-1 | UniProt: Q9UK85 | TargetFullName: Dickkopf-like protein 1 | Organisim: human | Apparent_Kd_M: 1.59E-11
Real
Aptamer SeqId: 16312-45 | Target: Cadherin-6 | UniProt: P55285
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16312-45 | Target: Cadherin-6 | UniProt: P55285 | TargetFullName: Cadherin-6 | Organisim: human | Apparent_Kd_M: 1.548678E-10
Real
Aptamer SeqId: 16315-105 | Target: VEGF sR1 | UniProt: P17948
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16315-105 | Target: VEGF sR1 | UniProt: P17948 | TargetFullName: Vascular endothelial growth factor receptor 1 | Organisim: human | Apparent_Kd_M: 1.16E-11
Real
Aptamer SeqId: 16317-20 | Target: Desmoglein-3 | UniProt: P32926
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16317-20 | Target: Desmoglein-3 | UniProt: P32926 | TargetFullName: Desmoglein-3 | Organisim: human | Apparent_Kd_M: 2.723323E-11
Real
Aptamer SeqId: 16318-12 | Target: ALK-1 | UniProt: P37023
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16318-12 | Target: ALK-1 | UniProt: P37023 | TargetFullName: Serine/threonine-protein kinase receptor R3 | Organisim: human | Apparent_Kd_M: 3.372926E-12
Real
Aptamer SeqId: 16320-139 | Target: CD320 | UniProt: Q9NPF0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16320-139 | Target: CD320 | UniProt: Q9NPF0 | TargetFullName: CD320 antigen | Organisim: human | Apparent_Kd_M: 1.149189E-10
Real
Aptamer SeqId: 16322-10 | Target: PACAP | UniProt: Q8WU39
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16322-10 | Target: PACAP | UniProt: Q8WU39 | TargetFullName: Marginal zone B- and B1-cell-specific protein | Organisim: human | Apparent_Kd_M: 2.77E-12
Real
Aptamer SeqId: 16323-8 | Target: NRX3A | UniProt: Q9Y4C0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16323-8 | Target: NRX3A | UniProt: Q9Y4C0 | TargetFullName: Neurexin-3 | Organisim: human | Apparent_Kd_M: 1.91E-12
Real
Aptamer SeqId: 16324-38 | Target: TLR1 | UniProt: Q15399
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16324-38 | Target: TLR1 | UniProt: Q15399 | TargetFullName: Toll-like receptor 1 | Organisim: human | Apparent_Kd_M: 6.4E-12
Real
Aptamer SeqId: 16535-61 | Target: GFP_AEQVI | UniProt: P42212
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16535-61 | Target: GFP_AEQVI | UniProt: P42212 | TargetFullName: Green fluorescent protein_AEQVI | Organisim: aequorea victoria (jellyfish) | Apparent_Kd_M: 2.11E-12
Real
Aptamer SeqId: 16536-3 | Target: HMGA1 | UniProt: P17096
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16536-3 | Target: HMGA1 | UniProt: P17096 | TargetFullName: High mobility group protein HMG-I/HMG-Y | Organisim: human | Apparent_Kd_M: 2.78E-12
Real
Aptamer SeqId: 16551-14 | Target: STA5B | UniProt: P51692
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16551-14 | Target: STA5B | UniProt: P51692 | TargetFullName: Signal transducer and activator of transcription 5B | Organisim: human | Apparent_Kd_M: 1.64E-10
Real
Aptamer SeqId: 16558-2 | Target: MYOC | UniProt: Q99972
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16558-2 | Target: MYOC | UniProt: Q99972 | TargetFullName: Myocilin | Organisim: human | Apparent_Kd_M: 2.1E-11
Real
Aptamer SeqId: 16561-9 | Target: Alpha-1B-glycoprotein | UniProt: P04217
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16561-9 | Target: Alpha-1B-glycoprotein | UniProt: P04217 | TargetFullName: Alpha-1B-glycoprotein | Organisim: human | Apparent_Kd_M: 7.37E-11
Real
Aptamer SeqId: 16583-8 | Target: AP4A | UniProt: P50583
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16583-8 | Target: AP4A | UniProt: P50583 | TargetFullName: Bis(5'-nucleosyl)-tetraphosphatase asymmetrical | Organisim: human | Apparent_Kd_M: 2.17E-12
Real
Aptamer SeqId: 16585-16 | Target: B3GN4 | UniProt: Q9C0J1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16585-16 | Target: B3GN4 | UniProt: Q9C0J1 | TargetFullName: N-acetyllactosaminide beta-1;3-N-acetylglucosaminyltransferase 4 | Organisim: human | Apparent_Kd_M: 1.189325E-12
Real
Aptamer SeqId: 16587-1 | Target: Beta-casein | UniProt: P05814
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16587-1 | Target: Beta-casein | UniProt: P05814 | TargetFullName: Beta-casein | Organisim: human | Apparent_Kd_M: 6.11E-11
Real
Aptamer SeqId: 16588-10 | Target: BiP | UniProt: P11021
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16588-10 | Target: BiP | UniProt: P11021 | TargetFullName: 78 kDa glucose-regulated protein | Organisim: human | Apparent_Kd_M: 1.24E-11
Real
Aptamer SeqId: 16591-71 | Target: CHIA | UniProt: Q9BZP6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16591-71 | Target: CHIA | UniProt: Q9BZP6 | TargetFullName: Acidic mammalian chitinase | Organisim: human | Apparent_Kd_M: 1.22E-10
Real
Aptamer SeqId: 16593-3 | Target: FADD | UniProt: Q13158
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16593-3 | Target: FADD | UniProt: Q13158 | TargetFullName: FAS-associated death domain protein | Organisim: human | Apparent_Kd_M: 2.338958E-11
Real
Aptamer SeqId: 16594-44 | Target: FAIM1 | UniProt: Q9NVQ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16594-44 | Target: FAIM1 | UniProt: Q9NVQ4 | TargetFullName: Fas apoptotic inhibitory molecule 1 | Organisim: human | Apparent_Kd_M: 2.17E-11
Real
Aptamer SeqId: 16596-25 | Target: GLRX3 | UniProt: O76003
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16596-25 | Target: GLRX3 | UniProt: O76003 | TargetFullName: Glutaredoxin-3 | Organisim: human | Apparent_Kd_M: 2.248472E-12
Real
Aptamer SeqId: 16597-11 | Target: GLRX5 | UniProt: Q86SX6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16597-11 | Target: GLRX5 | UniProt: Q86SX6 | TargetFullName: Glutaredoxin-related protein 5; mitochondrial | Organisim: human | Apparent_Kd_M: 1.175847E-10
Real
Aptamer SeqId: 16599-38 | Target: GPN1 | UniProt: Q9HCN4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16599-38 | Target: GPN1 | UniProt: Q9HCN4 | TargetFullName: GPN-loop GTPase 1 | Organisim: human | Apparent_Kd_M: 2.381421E-12
Real
Aptamer SeqId: 16605-2 | Target: C1T9A | UniProt: P0C862
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16605-2 | Target: C1T9A | UniProt: P0C862 | TargetFullName: Complement C1q and tumor necrosis factor-related protein 9A | Organisim: human | Apparent_Kd_M: 4.93E-12
Real
Aptamer SeqId: 16606-85 | Target: Aldose reductase | UniProt: P15121
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16606-85 | Target: Aldose reductase | UniProt: P15121 | TargetFullName: Aldose reductase | Organisim: human | Apparent_Kd_M: 8.06E-12
Real
Aptamer SeqId: 16607-78 | Target: Gelsolin | UniProt: P06396
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16607-78 | Target: Gelsolin | UniProt: P06396 | TargetFullName: Gelsolin | Organisim: human | Apparent_Kd_M: 7.360044E-13
Real
Aptamer SeqId: 16609-106 | Target: KIRR2 | UniProt: Q6UWL6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16609-106 | Target: KIRR2 | UniProt: Q6UWL6 | TargetFullName: Kin of IRRE-like protein 2 | Organisim: human | Apparent_Kd_M: 2.406157E-11
Real
Aptamer SeqId: 16610-13 | Target: LRP10 | UniProt: Q7Z4F1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16610-13 | Target: LRP10 | UniProt: Q7Z4F1 | TargetFullName: Low-density lipoprotein receptor-related protein 10 | Organisim: human | Apparent_Kd_M: 1.163579E-12
Real
Aptamer SeqId: 16612-28 | Target: SDC3 | UniProt: O75056
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16612-28 | Target: SDC3 | UniProt: O75056 | TargetFullName: Syndecan-3 | Organisim: human | Apparent_Kd_M: 1.81E-11
Real
Aptamer SeqId: 16613-3 | Target: CAD17 | UniProt: Q12864
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16613-3 | Target: CAD17 | UniProt: Q12864 | TargetFullName: Cadherin-17 | Organisim: human | Apparent_Kd_M: 9.72E-13
Real
Aptamer SeqId: 16614-27 | Target: RSPO1 | UniProt: Q2MKA7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16614-27 | Target: RSPO1 | UniProt: Q2MKA7 | TargetFullName: R-spondin-1 | Organisim: human | Apparent_Kd_M: 7.931083E-13
Real
Aptamer SeqId: 16616-137 | Target: ENOB | UniProt: P13929
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16616-137 | Target: ENOB | UniProt: P13929 | TargetFullName: Beta-enolase | Organisim: human | Apparent_Kd_M: 2.86E-11
Real
Aptamer SeqId: 16617-14 | Target: Caspase-14 | UniProt: P31944
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16617-14 | Target: Caspase-14 | UniProt: P31944 | TargetFullName: Caspase-14 | Organisim: human | Apparent_Kd_M: 2.67E-12
Real
Aptamer SeqId: 16618-7 | Target: CD69 | UniProt: Q07108
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16618-7 | Target: CD69 | UniProt: Q07108 | TargetFullName: Early activation antigen CD69 | Organisim: human | Apparent_Kd_M: 3.09E-12
Real
Aptamer SeqId: 16620-26 | Target: LY75 | UniProt: O60449
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16620-26 | Target: LY75 | UniProt: O60449 | TargetFullName: Lymphocyte antigen 75 | Organisim: human | Apparent_Kd_M: 5.70148E-13
Real
Aptamer SeqId: 16621-77 | Target: AIBP | UniProt: Q8NCW5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16621-77 | Target: AIBP | UniProt: Q8NCW5 | TargetFullName: NAD(P)H-hydrate epimerase | Organisim: human | Apparent_Kd_M: 7.24E-13
Real
Aptamer SeqId: 16746-12 | Target: Activin B | UniProt: P09529
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16746-12 | Target: Activin B | UniProt: P09529 | TargetFullName: Inhibin beta B chain | Organisim: human | Apparent_Kd_M: 1.449156E-11
Real
Aptamer SeqId: 16748-1 | Target: BMP-3 | UniProt: P12645
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16748-1 | Target: BMP-3 | UniProt: P12645 | TargetFullName: Bone morphogenetic protein 3 | Organisim: human | Apparent_Kd_M: 3.414668E-12
Real
Aptamer SeqId: 16749-79 | Target: BMP-3b | UniProt: P55107
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16749-79 | Target: BMP-3b | UniProt: P55107 | TargetFullName: Growth/differentiation factor 10 | Organisim: human | Apparent_Kd_M: 7.444813E-12
Real
Aptamer SeqId: 16751-15 | Target: BNP | UniProt: P16860
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16751-15 | Target: BNP | UniProt: P16860 | TargetFullName: Natriuretic peptides B | Organisim: human | Apparent_Kd_M: 4.058353E-11
Real
Aptamer SeqId: 16753-46 | Target: CO6A2 | UniProt: P12110
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16753-46 | Target: CO6A2 | UniProt: P12110 | TargetFullName: Collagen alpha-2(VI) chain | Organisim: human | Apparent_Kd_M: 3.287554E-11
Real
Aptamer SeqId: 16754-40 | Target: CSKP | UniProt: O14936
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16754-40 | Target: CSKP | UniProt: O14936 | TargetFullName: Peripheral plasma membrane protein CASK | Organisim: human | Apparent_Kd_M: 2.521072E-11
Real
Aptamer SeqId: 16755-195 | Target: GDF-3 | UniProt: Q9NR23
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16755-195 | Target: GDF-3 | UniProt: Q9NR23 | TargetFullName: Growth/differentiation factor 3 | Organisim: human | Apparent_Kd_M: 1.557838E-11
Real
Aptamer SeqId: 16756-30 | Target: GDF7 | UniProt: Q7Z4P5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16756-30 | Target: GDF7 | UniProt: Q7Z4P5 | TargetFullName: Growth/differentiation factor 7 | Organisim: human | Apparent_Kd_M: 4.444178E-12
Real
Aptamer SeqId: 16758-96 | Target: HDGF | UniProt: P51858
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16758-96 | Target: HDGF | UniProt: P51858 | TargetFullName: Hepatoma-derived growth factor | Organisim: human | Apparent_Kd_M: 5.179158E-12
Real
Aptamer SeqId: 16760-2 | Target: IL-26 | UniProt: Q9NPH9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16760-2 | Target: IL-26 | UniProt: Q9NPH9 | TargetFullName: Interleukin-26 | Organisim: human | Apparent_Kd_M: 3.918191E-11
Real
Aptamer SeqId: 16763-11 | Target: LECT2 | UniProt: O14960
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16763-11 | Target: LECT2 | UniProt: O14960 | TargetFullName: Leukocyte cell-derived chemotaxin-2 | Organisim: human | Apparent_Kd_M: 5.907459E-12
Real
Aptamer SeqId: 16765-52 | Target: PBP | UniProt: P02775
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16765-52 | Target: PBP | UniProt: P02775 | TargetFullName: Platelet basic protein | Organisim: human | Apparent_Kd_M: 3.767972E-12
Real
Aptamer SeqId: 16768-3 | Target: PLAK | UniProt: P14923
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16768-3 | Target: PLAK | UniProt: P14923 | TargetFullName: Junction plakoglobin | Organisim: human | Apparent_Kd_M: 2.531416E-11
Real
Aptamer SeqId: 16769-20 | Target: RAC3 | UniProt: P60763
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16769-20 | Target: RAC3 | UniProt: P60763 | TargetFullName: Ras-related C3 botulinum toxin substrate 3 | Organisim: human | Apparent_Kd_M: 5.216645E-11
Real
Aptamer SeqId: 16770-3 | Target: REG1B | UniProt: P48304
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16770-3 | Target: REG1B | UniProt: P48304 | TargetFullName: Lithostathine-1-beta | Organisim: human | Apparent_Kd_M: 2.223966E-12
Real
Aptamer SeqId: 16773-29 | Target: SCUB3 | UniProt: Q8IX30
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16773-29 | Target: SCUB3 | UniProt: Q8IX30 | TargetFullName: Signal peptide; CUB and EGF-like domain-containing protein 3 | Organisim: human | Apparent_Kd_M: 1.339805E-12
Real
Aptamer SeqId: 16780-6 | Target: HSP 70 | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16780-6 | Target: HSP 70 | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 3.149031E-11
Real
Aptamer SeqId: 16781-2 | Target: ENASE | UniProt: Q8NFI3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16781-2 | Target: ENASE | UniProt: Q8NFI3 | TargetFullName: Cytosolic endo-beta-N-acetylglucosaminidase | Organisim: human | Apparent_Kd_M: 2.741606E-12
Real
Aptamer SeqId: 16785-45 | Target: HD-5 | UniProt: Q01523
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16785-45 | Target: HD-5 | UniProt: Q01523 | TargetFullName: Defensin-5 | Organisim: human | Apparent_Kd_M: 1.049737E-11
Real
Aptamer SeqId: 16792-4 | Target: Siglec-5 | UniProt: O15389
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16792-4 | Target: Siglec-5 | UniProt: O15389 | TargetFullName: Sialic acid-binding Ig-like lectin 5 | Organisim: human | Apparent_Kd_M: 8.173935E-12
Real
Aptamer SeqId: 16802-31 | Target: OCAD1 | UniProt: Q9NX40
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16802-31 | Target: OCAD1 | UniProt: Q9NX40 | TargetFullName: OCIA domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 1.308981E-10
Real
Aptamer SeqId: 16803-4 | Target: CALB2 | UniProt: P22676
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16803-4 | Target: CALB2 | UniProt: P22676 | TargetFullName: Calretinin | Organisim: human | Apparent_Kd_M: 6.263958E-12
Real
Aptamer SeqId: 16805-5 | Target: PDE5A | UniProt: O76074
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16805-5 | Target: PDE5A | UniProt: O76074 | TargetFullName: cGMP-specific 3';5'-cyclic phosphodiesterase | Organisim: human | Apparent_Kd_M: 4.827439E-11
Real
Aptamer SeqId: 16807-35 | Target: TNNT3 | UniProt: P45378
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16807-35 | Target: TNNT3 | UniProt: P45378 | TargetFullName: Troponin T; fast skeletal muscle | Organisim: human | Apparent_Kd_M: 1.709123E-11
Real
Aptamer SeqId: 16809-1 | Target: NDKM | UniProt: O00746
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16809-1 | Target: NDKM | UniProt: O00746 | TargetFullName: Nucleoside diphosphate kinase; mitochondrial | Organisim: human | Apparent_Kd_M: 1.43384E-11
Real
Aptamer SeqId: 16810-3 | Target: RhoGDI | UniProt: P31150
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16810-3 | Target: RhoGDI | UniProt: P31150 | TargetFullName: Rab GDP dissociation inhibitor alpha | Organisim: human | Apparent_Kd_M: 2.738634E-11
Real
Aptamer SeqId: 16814-13 | Target: SLIM 1 | UniProt: Q13642
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16814-13 | Target: SLIM 1 | UniProt: Q13642 | TargetFullName: Four and a half LIM domains protein 1 | Organisim: human | Apparent_Kd_M: 3.661102E-11
Real
Aptamer SeqId: 16818-200 | Target: CDCP1 | UniProt: Q9H5V8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16818-200 | Target: CDCP1 | UniProt: Q9H5V8 | TargetFullName: CUB domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 1.693897E-12
Real
Aptamer SeqId: 16823-75 | Target: APOL3 | UniProt: O95236
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16823-75 | Target: APOL3 | UniProt: O95236 | TargetFullName: Apolipoprotein L3 | Organisim: human | Apparent_Kd_M: 8.485199E-11
Real
Aptamer SeqId: 16825-20 | Target: ATX3 | UniProt: P54252
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16825-20 | Target: ATX3 | UniProt: P54252 | TargetFullName: Ataxin-3 | Organisim: human | Apparent_Kd_M: 5.649137E-12
Real
Aptamer SeqId: 16828-8 | Target: Collagen a1(VI) | UniProt: P12109
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16828-8 | Target: Collagen a1(VI) | UniProt: P12109 | TargetFullName: Collagen alpha-1(VI) chain | Organisim: human | Apparent_Kd_M: 4.138864E-12
Real
Aptamer SeqId: 16831-7 | Target: DOK1 | UniProt: Q99704
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16831-7 | Target: DOK1 | UniProt: Q99704 | TargetFullName: Docking protein 1 | Organisim: human | Apparent_Kd_M: 1.164319E-11
Real
Aptamer SeqId: 16836-1 | Target: FHR3 | UniProt: Q02985
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16836-1 | Target: FHR3 | UniProt: Q02985 | TargetFullName: Complement factor H-related protein 3 | Organisim: human | Apparent_Kd_M: 8.229739E-11
Real
Aptamer SeqId: 16837-20 | Target: FLIP | UniProt: O15519
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16837-20 | Target: FLIP | UniProt: O15519 | TargetFullName: CASP8 and FADD-like apoptosis regulator | Organisim: human | Apparent_Kd_M: 3.201695E-12
Real
Aptamer SeqId: 16845-15 | Target: MPZL1 | UniProt: O95297
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16845-15 | Target: MPZL1 | UniProt: O95297 | TargetFullName: Myelin protein zero-like protein 1 | Organisim: human | Apparent_Kd_M: 1.857E-11
Real
Aptamer SeqId: 16847-39 | Target: RAB3B | UniProt: P20337
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16847-39 | Target: RAB3B | UniProt: P20337 | TargetFullName: Ras-related protein Rab-3B | Organisim: human | Apparent_Kd_M: 5.195905E-11
Real
Aptamer SeqId: 16850-5 | Target: RGS5 | UniProt: O15539
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16850-5 | Target: RGS5 | UniProt: O15539 | TargetFullName: Regulator of G-protein signaling 5 | Organisim: human | Apparent_Kd_M: 6.090741E-11
Real
Aptamer SeqId: 16851-50 | Target: SCO2 | UniProt: O43819
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16851-50 | Target: SCO2 | UniProt: O43819 | TargetFullName: Protein SCO2 homolog; mitochondrial | Organisim: human | Apparent_Kd_M: 9.971753E-12
Real
Aptamer SeqId: 16852-10 | Target: NHRF3 | UniProt: Q5T2W1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16852-10 | Target: NHRF3 | UniProt: Q5T2W1 | TargetFullName: Na(+)/H(+) exchange regulatory cofactor NHE-RF3 | Organisim: human | Apparent_Kd_M: 2.459986E-11
Real
Aptamer SeqId: 16853-5 | Target: NRK1 | UniProt: Q9NWW6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16853-5 | Target: NRK1 | UniProt: Q9NWW6 | TargetFullName: Nicotinamide riboside kinase 1 | Organisim: human | Apparent_Kd_M: 3.312692E-11
Real
Aptamer SeqId: 16854-17 | Target: LSM4 | UniProt: Q9Y4Z0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16854-17 | Target: LSM4 | UniProt: Q9Y4Z0 | TargetFullName: U6 snRNA-associated Sm-like protein LSm4 | Organisim: human | Apparent_Kd_M: 3.085535E-11
Real
Aptamer SeqId: 16856-79 | Target: MARE2 | UniProt: Q15555
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16856-79 | Target: MARE2 | UniProt: Q15555 | TargetFullName: Microtubule-associated protein RP/EB family member 2 | Organisim: human | Apparent_Kd_M: 1.536791E-10
Real
Aptamer SeqId: 16857-2 | Target: RAB2A | UniProt: P61019
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16857-2 | Target: RAB2A | UniProt: P61019 | TargetFullName: Ras-related protein Rab-2A | Organisim: human | Apparent_Kd_M: 2.041296E-11
Real
Aptamer SeqId: 16858-384 | Target: RCN3 | UniProt: Q96D15
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16858-384 | Target: RCN3 | UniProt: Q96D15 | TargetFullName: Reticulocalbin-3 | Organisim: human | Apparent_Kd_M: 8.433873E-11
Real
Aptamer SeqId: 16859-100 | Target: SHLB1 | UniProt: Q9Y371
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16859-100 | Target: SHLB1 | UniProt: Q9Y371 | TargetFullName: Endophilin-B1 | Organisim: human | Apparent_Kd_M: 1.195108E-10
Real
Aptamer SeqId: 16863-47 | Target: NANP | UniProt: Q8TBE9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16863-47 | Target: NANP | UniProt: Q8TBE9 | TargetFullName: N-acylneuraminate-9-phosphatase | Organisim: human | Apparent_Kd_M: 5.906363E-11
Real
Aptamer SeqId: 16865-62 | Target: RBP56 | UniProt: Q92804
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16865-62 | Target: RBP56 | UniProt: Q92804 | TargetFullName: TATA-binding protein-associated factor 2N | Organisim: human | Apparent_Kd_M: 1.063287E-11
Real
Aptamer SeqId: 16867-76 | Target: PCTK1 | UniProt: Q00536
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16867-76 | Target: PCTK1 | UniProt: Q00536 | TargetFullName: Cyclin-dependent kinase 16 | Organisim: human | Apparent_Kd_M: 1.421841E-11
Real
Aptamer SeqId: 16872-248 | Target: MAAI | UniProt: O43708
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16872-248 | Target: MAAI | UniProt: O43708 | TargetFullName: Maleylacetoacetate isomerase | Organisim: human | Apparent_Kd_M: 2.291695E-10
Real
Aptamer SeqId: 16875-13 | Target: MGN2 | UniProt: Q96A72
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16875-13 | Target: MGN2 | UniProt: Q96A72 | TargetFullName: Protein mago nashi homolog 2 | Organisim: human | Apparent_Kd_M: 2.663681E-11
Real
Aptamer SeqId: 16877-19 | Target: MSRB2 | UniProt: Q9Y3D2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16877-19 | Target: MSRB2 | UniProt: Q9Y3D2 | TargetFullName: Methionine-R-sulfoxide reductase B2; mitochondrial | Organisim: human | Apparent_Kd_M: 1.133965E-11
Real
Aptamer SeqId: 16882-27 | Target: PHP14 | UniProt: Q9NRX4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16882-27 | Target: PHP14 | UniProt: Q9NRX4 | TargetFullName: 14 kDa phosphohistidine phosphatase | Organisim: human | Apparent_Kd_M: 1.466435E-10
Real
Aptamer SeqId: 16883-57 | Target: RAB4A | UniProt: P20338
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16883-57 | Target: RAB4A | UniProt: P20338 | TargetFullName: Ras-related protein Rab-4A | Organisim: human | Apparent_Kd_M: 9.705301E-12
Real
Aptamer SeqId: 16885-49 | Target: MARE3 | UniProt: Q9UPY8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16885-49 | Target: MARE3 | UniProt: Q9UPY8 | TargetFullName: Microtubule-associated protein RP/EB family member 3 | Organisim: human | Apparent_Kd_M: 2.975868E-12
Real
Aptamer SeqId: 16887-29 | Target: PTH2 | UniProt: Q9Y3E5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16887-29 | Target: PTH2 | UniProt: Q9Y3E5 | TargetFullName: Peptidyl-tRNA hydrolase 2; mitochondrial | Organisim: human | Apparent_Kd_M: 3.464724E-12
Real
Aptamer SeqId: 16890-37 | Target: ATL1 | UniProt: Q8N6G6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16890-37 | Target: ATL1 | UniProt: Q8N6G6 | TargetFullName: ADAMTS-like protein 1 | Organisim: human | Apparent_Kd_M: 1.708191E-12
Real
Aptamer SeqId: 16892-23 | Target: ENPP2 | UniProt: Q13822
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16892-23 | Target: ENPP2 | UniProt: Q13822 | TargetFullName: Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 | Organisim: human | Apparent_Kd_M: 4.055568E-12
Real
Aptamer SeqId: 16899-59 | Target: OSBL9 | UniProt: Q96SU4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16899-59 | Target: OSBL9 | UniProt: Q96SU4 | TargetFullName: Oxysterol-binding protein-related protein 9 | Organisim: human | Apparent_Kd_M: 9.762173E-11
Real
Aptamer SeqId: 16900-29 | Target: MDGA1 | UniProt: Q8NFP4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16900-29 | Target: MDGA1 | UniProt: Q8NFP4 | TargetFullName: MAM domain-containing glycosylphosphatidylinositol anchor protein 1 | Organisim: human | Apparent_Kd_M: 4.919168E-12
Real
Aptamer SeqId: 16902-17 | Target: LAMP1 | UniProt: P11279
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16902-17 | Target: LAMP1 | UniProt: P11279 | TargetFullName: Lysosome-associated membrane glycoprotein 1 | Organisim: human | Apparent_Kd_M: 2.326273E-11
Real
Aptamer SeqId: 16907-3 | Target: Nectin-like protein 3 | UniProt: Q8N3J6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16907-3 | Target: Nectin-like protein 3 | UniProt: Q8N3J6 | TargetFullName: Cell adhesion molecule 2 | Organisim: human | Apparent_Kd_M: 5.62963E-11
Real
Aptamer SeqId: 16908-5 | Target: OMGP | UniProt: P23515
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16908-5 | Target: OMGP | UniProt: P23515 | TargetFullName: Oligodendrocyte-myelin glycoprotein | Organisim: human | Apparent_Kd_M: 3.037119E-12
Real
Aptamer SeqId: 16913-8 | Target: RNT2 | UniProt: O00584
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16913-8 | Target: RNT2 | UniProt: O00584 | TargetFullName: Ribonuclease T2 | Organisim: human | Apparent_Kd_M: 2.100166E-11
Real
Aptamer SeqId: 16914-104 | Target: sCD14 | UniProt: P08571
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16914-104 | Target: sCD14 | UniProt: P08571 | TargetFullName: Monocyte differentiation antigen CD14; soluble | Organisim: human | Apparent_Kd_M: 6.779422E-12
Real
Aptamer SeqId: 16915-153 | Target: SEM4A | UniProt: Q9H3S1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16915-153 | Target: SEM4A | UniProt: Q9H3S1 | TargetFullName: Semaphorin-4A | Organisim: human | Apparent_Kd_M: 9.575184E-13
Real
Aptamer SeqId: 16916-19 | Target: SLIK6 | UniProt: Q9H5Y7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16916-19 | Target: SLIK6 | UniProt: Q9H5Y7 | TargetFullName: SLIT and NTRK-like protein 6 | Organisim: human | Apparent_Kd_M: 3.580543E-12
Real
Aptamer SeqId: 16918-198 | Target: TLR3 | UniProt: O15455
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16918-198 | Target: TLR3 | UniProt: O15455 | TargetFullName: Toll-like receptor 3 | Organisim: human | Apparent_Kd_M: 5.851103E-12
Real
Aptamer SeqId: 16919-1 | Target: ACBP | UniProt: P07108
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16919-1 | Target: ACBP | UniProt: P07108 | TargetFullName: Acyl-CoA-binding protein | Organisim: human | Apparent_Kd_M: 3.516301E-13
Real
Aptamer SeqId: 16922-53 | Target: PLXB3 | UniProt: Q9ULL4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16922-53 | Target: PLXB3 | UniProt: Q9ULL4 | TargetFullName: Plexin-B3 | Organisim: human | Apparent_Kd_M: 1.009782E-11
Real
Aptamer SeqId: 16923-20 | Target: Profilin II | UniProt: P35080
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16923-20 | Target: Profilin II | UniProt: P35080 | TargetFullName: Profilin-2 | Organisim: human | Apparent_Kd_M: 8.507672E-11
Real
Aptamer SeqId: 16926-44 | Target: Alkaline phosphatase liver
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16926-44 | Target: Alkaline phosphatase; liver | UniProt: P05186 | TargetFullName: Alkaline phosphatase; tissue-nonspecific isozyme | Organisim: human | Apparent_Kd_M: 2.563496E-11
Real
Aptamer SeqId: 16927-9 | Target: Coagulation factor XIII
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16927-9 | Target: Coagulation factor XIII | UniProt: P00488|P05160 | TargetFullName: Coagulation factor XIII | Organisim: human | Apparent_Kd_M: 2.05227E-12
Real
Aptamer SeqId: 16932-5 | Target: SULT 1E | UniProt: P49888
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 16932-5 | Target: SULT 1E | UniProt: P49888 | TargetFullName: Estrogen sulfotransferase | Organisim: human | Apparent_Kd_M: 1.74E-11
Real
Aptamer SeqId: 17137-160 | Target: Beta-globin | UniProt: P68871
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17137-160 | Target: Beta-globin | UniProt: P68871 | TargetFullName: Hemoglobin subunit beta | Organisim: human | Apparent_Kd_M: 5.61E-12
Real
Aptamer SeqId: 17138-8 | Target: GST A1-1 | UniProt: P08263
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17138-8 | Target: GST A1-1 | UniProt: P08263 | TargetFullName: Glutathione S-transferase A1 | Organisim: human | Apparent_Kd_M: 7.18E-12
Real
Aptamer SeqId: 17140-57 | Target: PDGFD | UniProt: Q9GZP0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17140-57 | Target: PDGFD | UniProt: Q9GZP0 | TargetFullName: Platelet-derived growth factor D | Organisim: human | Apparent_Kd_M: 2.18E-12
Real
Aptamer SeqId: 17145-1 | Target: S100A8/S100A9 | UniProt: P05109|P06702
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17145-1 | Target: S100A8/S100A9 | UniProt: P05109|P06702 | TargetFullName: Protein S100-A8/A9 heterodimer | Organisim: human | Apparent_Kd_M: 7.72E-11
Real
Aptamer SeqId: 17148-7 | Target: BLVRB | UniProt: P30043
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17148-7 | Target: BLVRB | UniProt: P30043 | TargetFullName: Flavin reductase (NADPH) | Organisim: human | Apparent_Kd_M: 3.39E-12
Real
Aptamer SeqId: 17150-8 | Target: HSP 10 | UniProt: P61604
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17150-8 | Target: HSP 10 | UniProt: P61604 | TargetFullName: 10 kDa heat shock protein; mitochondrial | Organisim: human | Apparent_Kd_M: 2.92E-11
Real
Aptamer SeqId: 17151-84 | Target: IRF-3 | UniProt: Q14653
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17151-84 | Target: IRF-3 | UniProt: Q14653 | TargetFullName: Interferon regulatory factor 3 | Organisim: human | Apparent_Kd_M: 5.34E-12
Real
Aptamer SeqId: 17152-10 | Target: KI2S4 | UniProt: P43632
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17152-10 | Target: KI2S4 | UniProt: P43632 | TargetFullName: Killer cell immunoglobulin-like receptor 2DS4 | Organisim: human | Apparent_Kd_M: 3.66E-12
Real
Aptamer SeqId: 17153-46 | Target: KI2L3 | UniProt: P43628
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17153-46 | Target: KI2L3 | UniProt: P43628 | TargetFullName: Killer cell immunoglobulin-like receptor 2DL3 | Organisim: human | Apparent_Kd_M: 1.71E-13
Real
Aptamer SeqId: 17154-2 | Target: TEBP | UniProt: Q15185
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17154-2 | Target: TEBP | UniProt: Q15185 | TargetFullName: Prostaglandin E synthase 3 | Organisim: human | Apparent_Kd_M: 4.05E-11
Real
Aptamer SeqId: 17155-1 | Target: VPS28 protein homolog | UniProt: Q9UK41
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17155-1 | Target: VPS28 protein homolog | UniProt: Q9UK41 | TargetFullName: Vacuolar protein sorting-associated protein 28 homolog | Organisim: human | Apparent_Kd_M: 1.41E-11
Real
Aptamer SeqId: 17156-72 | Target: DCAK1 | UniProt: O15075
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17156-72 | Target: DCAK1 | UniProt: O15075 | TargetFullName: Serine/threonine-protein kinase DCLK1 | Organisim: human | Apparent_Kd_M: 4.84E-12
Real
Aptamer SeqId: 17158-17 | Target: UB2G1 | UniProt: P62253
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17158-17 | Target: UB2G1 | UniProt: P62253 | TargetFullName: Ubiquitin-conjugating enzyme E2 G1 | Organisim: human | Apparent_Kd_M: 2.79E-11
Real
Aptamer SeqId: 17161-1 | Target: OST48 | UniProt: P39656
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17161-1 | Target: OST48 | UniProt: P39656 | TargetFullName: Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit | Organisim: human | Apparent_Kd_M: 1.43E-11
Real
Aptamer SeqId: 17163-117 | Target: Annexin III | UniProt: P12429
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17163-117 | Target: Annexin III | UniProt: P12429 | TargetFullName: Annexin A3 | Organisim: human | Apparent_Kd_M: 3.06E-11
Real
Aptamer SeqId: 17164-15 | Target: annexin IV | UniProt: P09525
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17164-15 | Target: annexin IV | UniProt: P09525 | TargetFullName: Annexin A4 | Organisim: human | Apparent_Kd_M: 6.69E-12
Real
Aptamer SeqId: 17165-1 | Target: BTG | UniProt: P02775
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17165-1 | Target: BTG | UniProt: P02775 | TargetFullName: Beta-thromboglobulin | Organisim: human | Apparent_Kd_M: 1.47E-12
Real
Aptamer SeqId: 17166-4 | Target: FGF-8F | UniProt: P55075
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17166-4 | Target: FGF-8F | UniProt: P55075 | TargetFullName: Fibroblast growth factor 8 isoform F | Organisim: human | Apparent_Kd_M: 5.54E-12
Real
Aptamer SeqId: 17170-15 | Target: CALCB | UniProt: P10092
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17170-15 | Target: CALCB | UniProt: P10092 | TargetFullName: Calcitonin gene-related peptide 2 | Organisim: human | Apparent_Kd_M: 2.18E-12
Real
Aptamer SeqId: 17172-19 | Target: STAT | UniProt: P02808
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17172-19 | Target: STAT | UniProt: P02808 | TargetFullName: Statherin | Organisim: human | Apparent_Kd_M: 7.12E-12
Real
Aptamer SeqId: 17175-5 | Target: MP2K6 | UniProt: P52564
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17175-5 | Target: MP2K6 | UniProt: P52564 | TargetFullName: Dual specificity mitogen-activated protein kinase kinase 6 | Organisim: human | Apparent_Kd_M: 3.56E-11
Real
Aptamer SeqId: 17176-13 | Target: PSIP1 | UniProt: O75475
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17176-13 | Target: PSIP1 | UniProt: O75475 | TargetFullName: PC4 and SFRS1-interacting protein | Organisim: human | Apparent_Kd_M: 7.295377E-12
Real
Aptamer SeqId: 17195-43 | Target: BAG-1 | UniProt: Q99933
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17195-43 | Target: BAG-1 | UniProt: Q99933 | TargetFullName: BAG family molecular chaperone regulator 1 | Organisim: human | Apparent_Kd_M: 1.498154E-11
Real
Aptamer SeqId: 17196-5 | Target: ClpP endopeptidase | UniProt: Q16740
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17196-5 | Target: ClpP endopeptidase | UniProt: Q16740 | TargetFullName: ATP-dependent Clp protease proteolytic subunit; mitochondrial | Organisim: human | Apparent_Kd_M: 1.711723E-11
Real
Aptamer SeqId: 17199-43 | Target: HIF1N | UniProt: Q9NWT6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17199-43 | Target: HIF1N | UniProt: Q9NWT6 | TargetFullName: Hypoxia-inducible factor 1-alpha inhibitor | Organisim: human | Apparent_Kd_M: 7.51E-11
Real
Aptamer SeqId: 17200-50 | Target: KI2L1 | UniProt: P43626
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17200-50 | Target: KI2L1 | UniProt: P43626 | TargetFullName: Killer cell immunoglobulin-like receptor 2DL1 | Organisim: human | Apparent_Kd_M: 8.06E-11
Real
Aptamer SeqId: 17202-37 | Target: PDCD4 | UniProt: Q53EL6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17202-37 | Target: PDCD4 | UniProt: Q53EL6 | TargetFullName: Programmed cell death protein 4 | Organisim: human | Apparent_Kd_M: 3.12E-11
Real
Aptamer SeqId: 17204-17 | Target: PNMT | UniProt: P11086
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17204-17 | Target: PNMT | UniProt: P11086 | TargetFullName: Phenylethanolamine N-methyltransferase | Organisim: human | Apparent_Kd_M: 4.85E-11
Real
Aptamer SeqId: 17205-21 | Target: RAB5A | UniProt: P20339
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17205-21 | Target: RAB5A | UniProt: P20339 | TargetFullName: Ras-related protein Rab-5A | Organisim: human | Apparent_Kd_M: 2.45E-12
Real
Aptamer SeqId: 17209-27 | Target: ST2B1 | UniProt: O00204
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17209-27 | Target: ST2B1 | UniProt: O00204 | TargetFullName: Sulfotransferase family cytosolic 2B member 1 | Organisim: human | Apparent_Kd_M: 4.79E-12
Real
Aptamer SeqId: 17210-2 | Target: TCL1A | UniProt: P56279
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17210-2 | Target: TCL1A | UniProt: P56279 | TargetFullName: T-cell leukemia/lymphoma protein 1A | Organisim: human | Apparent_Kd_M: 2.41E-11
Real
Aptamer SeqId: 17224-12 | Target: MIME | UniProt: P20774
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17224-12 | Target: MIME | UniProt: P20774 | TargetFullName: Mimecan | Organisim: human | Apparent_Kd_M: 1.9E-10
Real
Aptamer SeqId: 17231-1 | Target: L-plastin | UniProt: P13796
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17231-1 | Target: L-plastin | UniProt: P13796 | TargetFullName: Plastin-2 | Organisim: human | Apparent_Kd_M: 3.19E-12
Real
Aptamer SeqId: 17319-1 | Target: SELH | UniProt: Q8IZQ5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17319-1 | Target: SELH | UniProt: Q8IZQ5 | TargetFullName: Selenoprotein H | Organisim: human | Apparent_Kd_M: 4.18E-11
Real
Aptamer SeqId: 17320-19 | Target: ADPPT | UniProt: Q9NRN7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17320-19 | Target: ADPPT | UniProt: Q9NRN7 | TargetFullName: L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase | Organisim: human | Apparent_Kd_M: 1.52E-12
Real
Aptamer SeqId: 17325-10 | Target: KGUA | UniProt: Q16774
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17325-10 | Target: KGUA | UniProt: Q16774 | TargetFullName: Guanylate kinase | Organisim: human | Apparent_Kd_M: 2.2E-12
Real
Aptamer SeqId: 17326-44 | Target: DUS23 | UniProt: Q9BVJ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17326-44 | Target: DUS23 | UniProt: Q9BVJ7 | TargetFullName: Dual specificity protein phosphatase 23 | Organisim: human | Apparent_Kd_M: 7.64E-11
Real
Aptamer SeqId: 17327-3 | Target: CNPY3 | UniProt: Q9BT09
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17327-3 | Target: CNPY3 | UniProt: Q9BT09 | TargetFullName: Protein canopy homolog 3 | Organisim: human | Apparent_Kd_M: 2.43E-10
Real
Aptamer SeqId: 17329-2 | Target: BDH2 | UniProt: Q9BUT1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17329-2 | Target: BDH2 | UniProt: Q9BUT1 | TargetFullName: 3-hydroxybutyrate dehydrogenase type 2 | Organisim: human | Apparent_Kd_M: 8.37E-12
Real
Aptamer SeqId: 17331-138 | Target: KREM1 | UniProt: Q96MU8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17331-138 | Target: KREM1 | UniProt: Q96MU8 | TargetFullName: Kremen protein 1 | Organisim: human | Apparent_Kd_M: 9.18E-11
Real
Aptamer SeqId: 17332-3 | Target: ARHL2 | UniProt: Q9NX46
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17332-3 | Target: ARHL2 | UniProt: Q9NX46 | TargetFullName: Poly(ADP-ribose) glycohydrolase ARH3 | Organisim: human | Apparent_Kd_M: 8.07E-13
Real
Aptamer SeqId: 17333-20 | Target: ACADM | UniProt: P11310
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17333-20 | Target: ACADM | UniProt: P11310 | TargetFullName: Medium-chain specific acyl-CoA dehydrogenase; mitochondrial | Organisim: human | Apparent_Kd_M: 1.17E-11
Real
Aptamer SeqId: 17335-18 | Target: VAMP2 | UniProt: P63027
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17335-18 | Target: VAMP2 | UniProt: P63027 | TargetFullName: Vesicle-associated membrane protein 2 | Organisim: human | Apparent_Kd_M: 7.84E-12
Real
Aptamer SeqId: 17336-54 | Target: CR3L2 | UniProt: Q70SY1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17336-54 | Target: CR3L2 | UniProt: Q70SY1 | TargetFullName: Cyclic AMP-responsive element-binding protein 3-like protein 2 | Organisim: human | Apparent_Kd_M: 8.86E-11
Real
Aptamer SeqId: 17337-1 | Target: TYY1 | UniProt: P25490
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17337-1 | Target: TYY1 | UniProt: P25490 | TargetFullName: Transcriptional repressor protein YY1 | Organisim: human | Apparent_Kd_M: 3.0E-10
Real
Aptamer SeqId: 17341-89 | Target: THIC | UniProt: Q9BWD1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17341-89 | Target: THIC | UniProt: Q9BWD1 | TargetFullName: Acetyl-CoA acetyltransferase; cytosolic | Organisim: human | Apparent_Kd_M: 1.61E-11
Real
Aptamer SeqId: 17342-13 | Target: AGR3 | UniProt: Q8TD06
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17342-13 | Target: AGR3 | UniProt: Q8TD06 | TargetFullName: Anterior gradient protein 3 | Organisim: human | Apparent_Kd_M: 4.9E-11
Real
Aptamer SeqId: 17343-6 | Target: SNPH | UniProt: O15079
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17343-6 | Target: SNPH | UniProt: O15079 | TargetFullName: Syntaphilin | Organisim: human | Apparent_Kd_M: 2.81E-11
Real
Aptamer SeqId: 17344-23 | Target: STML1 | UniProt: Q9UBI4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17344-23 | Target: STML1 | UniProt: Q9UBI4 | TargetFullName: Stomatin-like protein 1 | Organisim: human | Apparent_Kd_M: 5.79E-11
Real
Aptamer SeqId: 17345-12 | Target: ZADH2 | UniProt: Q8N4Q0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17345-12 | Target: ZADH2 | UniProt: Q8N4Q0 | TargetFullName: Prostaglandin reductase 3 | Organisim: human | Apparent_Kd_M: 2.67E-12
Real
Aptamer SeqId: 17346-61 | Target: FDSCP | UniProt: Q8NFU4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17346-61 | Target: FDSCP | UniProt: Q8NFU4 | TargetFullName: Follicular dendritic cell secreted peptide | Organisim: human | Apparent_Kd_M: 1.65E-11
Real
Aptamer SeqId: 17347-80 | Target: CA080 | UniProt: Q96BJ3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17347-80 | Target: CA080 | UniProt: Q96BJ3 | TargetFullName: Axin interactor; dorsalization-associated protein | Organisim: human | Apparent_Kd_M: 2.15E-12
Real
Aptamer SeqId: 17348-5 | Target: SYJ2B | UniProt: P57105
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17348-5 | Target: SYJ2B | UniProt: P57105 | TargetFullName: Synaptojanin-2-binding protein | Organisim: human | Apparent_Kd_M: 1.11E-11
Real
Aptamer SeqId: 17350-13 | Target: CHM2B | UniProt: Q9UQN3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17350-13 | Target: CHM2B | UniProt: Q9UQN3 | TargetFullName: Charged multivesicular body protein 2b | Organisim: human | Apparent_Kd_M: 1.49E-11
Real
Aptamer SeqId: 17355-56 | Target: SYT4 | UniProt: Q9H2B2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17355-56 | Target: SYT4 | UniProt: Q9H2B2 | TargetFullName: Synaptotagmin-4 | Organisim: human | Apparent_Kd_M: 2.56E-11
Real
Aptamer SeqId: 17356-34 | Target: IL1FA | UniProt: Q8WWZ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17356-34 | Target: IL1FA | UniProt: Q8WWZ1 | TargetFullName: Interleukin-1 family member 10 | Organisim: human | Apparent_Kd_M: 1.27E-10
Real
Aptamer SeqId: 17357-33 | Target: SPCS | UniProt: Q9HD40
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17357-33 | Target: SPCS | UniProt: Q9HD40 | TargetFullName: O-phosphoseryl-tRNA(Sec) selenium transferase | Organisim: human | Apparent_Kd_M: 2.83E-11
Real
Aptamer SeqId: 17362-5 | Target: VHL | UniProt: P40337
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17362-5 | Target: VHL | UniProt: P40337 | TargetFullName: Von Hippel-Lindau disease tumor suppressor | Organisim: human | Apparent_Kd_M: 1.03E-10
Real
Aptamer SeqId: 17364-8 | Target: RU2B | UniProt: P08579
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17364-8 | Target: RU2B | UniProt: P08579 | TargetFullName: U2 small nuclear ribonucleoprotein B'' | Organisim: human | Apparent_Kd_M: 5.41E-12
Real
Aptamer SeqId: 17365-7 | Target: KAT1 | UniProt: Q16773
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17365-7 | Target: KAT1 | UniProt: Q16773 | TargetFullName: Kynurenine--oxoglutarate transaminase 1 | Organisim: human | Apparent_Kd_M: 3.35E-11
Real
Aptamer SeqId: 17366-6 | Target: DCNL1 | UniProt: Q96GG9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17366-6 | Target: DCNL1 | UniProt: Q96GG9 | TargetFullName: DCN1-like protein 1 | Organisim: human | Apparent_Kd_M: 4.43E-11
Real
Aptamer SeqId: 17367-5 | Target: Stathmin | UniProt: P16949
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17367-5 | Target: Stathmin | UniProt: P16949 | TargetFullName: Stathmin | Organisim: human | Apparent_Kd_M: 4.91E-11
Real
Aptamer SeqId: 17370-186 | Target: ABHDA | UniProt: Q9NUJ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17370-186 | Target: ABHDA | UniProt: Q9NUJ1 | TargetFullName: Mycophenolic acid acyl-glucuronide esterase; mitochondrial | Organisim: human | Apparent_Kd_M: 2.37E-11
Real
Aptamer SeqId: 17372-5 | Target: 4EBP1 | UniProt: Q13541
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17372-5 | Target: 4EBP1 | UniProt: Q13541 | TargetFullName: Eukaryotic translation initiation factor 4E-binding protein 1 | Organisim: human | Apparent_Kd_M: 4.91E-11
Real
Aptamer SeqId: 17377-1 | Target: Aldose reductase-like C3 | UniProt: P42330
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17377-1 | Target: Aldose reductase-like C3 | UniProt: P42330 | TargetFullName: Aldo-keto reductase family 1 member C3 | Organisim: human | Apparent_Kd_M: 3.52E-12
Real
Aptamer SeqId: 17380-2 | Target: UBE2K | UniProt: P61086
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17380-2 | Target: UBE2K | UniProt: P61086 | TargetFullName: Ubiquitin-conjugating enzyme E2 K | Organisim: human | Apparent_Kd_M: 4.63E-12
Real
Aptamer SeqId: 17383-4 | Target: STAR5 | UniProt: Q9NSY2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17383-4 | Target: STAR5 | UniProt: Q9NSY2 | TargetFullName: StAR-related lipid transfer protein 5 | Organisim: human | Apparent_Kd_M: 1.73E-12
Real
Aptamer SeqId: 17384-110 | Target: K6PF | UniProt: P08237
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17384-110 | Target: K6PF | UniProt: P08237 | TargetFullName: ATP-dependent 6-phosphofructokinase; muscle type | Organisim: human | Apparent_Kd_M: 1.45E-11
Real
Aptamer SeqId: 17387-27 | Target: IKB-beta | UniProt: Q15653
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17387-27 | Target: IKB-beta | UniProt: Q15653 | TargetFullName: NF-kappa-B inhibitor beta | Organisim: human | Apparent_Kd_M: 5.96E-11
Real
Aptamer SeqId: 17391-10 | Target: SPF45 | UniProt: Q96I25
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17391-10 | Target: SPF45 | UniProt: Q96I25 | TargetFullName: Splicing factor 45 | Organisim: human | Apparent_Kd_M: 1.28E-11
Real
Aptamer SeqId: 17393-13 | Target: SCAD | UniProt: P16219
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17393-13 | Target: SCAD | UniProt: P16219 | TargetFullName: Short-chain specific acyl-CoA dehydrogenase; mitochondrial | Organisim: human | Apparent_Kd_M: 9.15E-12
Real
Aptamer SeqId: 17396-23 | Target: ADH1A | UniProt: P07327
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17396-23 | Target: ADH1A | UniProt: P07327 | TargetFullName: Alcohol dehydrogenase 1A | Organisim: human | Apparent_Kd_M: 6.02E-11
Real
Aptamer SeqId: 17397-8 | Target: DHB11 | UniProt: Q8NBQ5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17397-8 | Target: DHB11 | UniProt: Q8NBQ5 | TargetFullName: Estradiol 17-beta-dehydrogenase 11 | Organisim: human | Apparent_Kd_M: 3.18E-11
Real
Aptamer SeqId: 17398-55 | Target: HO-1 | UniProt: P09601
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17398-55 | Target: HO-1 | UniProt: P09601 | TargetFullName: Heme oxygenase 1 | Organisim: human | Apparent_Kd_M: 2.01E-12
Real
Aptamer SeqId: 17400-71 | Target: ACOT8 | UniProt: O14734
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17400-71 | Target: ACOT8 | UniProt: O14734 | TargetFullName: Acyl-coenzyme A thioesterase 8 | Organisim: human | Apparent_Kd_M: 8.81E-11
Real
Aptamer SeqId: 17403-14 | Target: acyl-Coenzyme A dehydrogenase
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17403-14 | Target: acyl-Coenzyme A dehydrogenase | UniProt: P45954 | TargetFullName: Short/branched chain specific acyl-CoA dehydrogenase; mitochondrial | Organisim: human | Apparent_Kd_M: 4.28E-11
Real
Aptamer SeqId: 17404-5 | Target: ARL5B | UniProt: Q96KC2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17404-5 | Target: ARL5B | UniProt: Q96KC2 | TargetFullName: ADP-ribosylation factor-like protein 5B | Organisim: human | Apparent_Kd_M: 2.27E-11
Real
Aptamer SeqId: 17405-2 | Target: UCHL5 | UniProt: Q9Y5K5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17405-2 | Target: UCHL5 | UniProt: Q9Y5K5 | TargetFullName: Ubiquitin carboxyl-terminal hydrolase isozyme L5 | Organisim: human | Apparent_Kd_M: 2.06E-11
Real
Aptamer SeqId: 17408-2 | Target: PMM1 | UniProt: Q92871
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17408-2 | Target: PMM1 | UniProt: Q92871 | TargetFullName: Phosphomannomutase 1 | Organisim: human | Apparent_Kd_M: 6.25E-11
Real
Aptamer SeqId: 17410-5 | Target: CETN3 | UniProt: O15182
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17410-5 | Target: CETN3 | UniProt: O15182 | TargetFullName: Centrin-3 | Organisim: human | Apparent_Kd_M: 8.76E-12
Real
Aptamer SeqId: 17411-55 | Target: UFD1 | UniProt: Q92890
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17411-55 | Target: UFD1 | UniProt: Q92890 | TargetFullName: Ubiquitin recognition factor in ER-associated degradation protein 1 | Organisim: human | Apparent_Kd_M: 1.95E-11
Real
Aptamer SeqId: 17419-17 | Target: TES | UniProt: Q9UGI8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17419-17 | Target: TES | UniProt: Q9UGI8 | TargetFullName: Testin | Organisim: human | Apparent_Kd_M: 8.55E-11
Real
Aptamer SeqId: 17427-26 | Target: NLGN3 | UniProt: Q9NZ94
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17427-26 | Target: NLGN3 | UniProt: Q9NZ94 | TargetFullName: Neuroligin-3 | Organisim: human | Apparent_Kd_M: 4.35E-12
Real
Aptamer SeqId: 17432-25 | Target: KAD4 | UniProt: P27144
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17432-25 | Target: KAD4 | UniProt: P27144 | TargetFullName: Adenylate kinase 4; mitochondrial | Organisim: human | Apparent_Kd_M: 8.77E-11
Real
Aptamer SeqId: 17435-43 | Target: ETFA | UniProt: P13804
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17435-43 | Target: ETFA | UniProt: P13804 | TargetFullName: Electron transfer flavoprotein subunit alpha; mitochondrial | Organisim: human | Apparent_Kd_M: 2.79E-11
Real
Aptamer SeqId: 17436-193 | Target: CSNK1G2 | UniProt: P78368
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17436-193 | Target: CSNK1G2 | UniProt: P78368 | TargetFullName: Casein kinase I isoform gamma-2 | Organisim: human | Apparent_Kd_M: 4.28E-11
Real
Aptamer SeqId: 17441-4 | Target: Alkaline phosphatase intestine
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17441-4 | Target: Alkaline phosphatase; intestine | UniProt: P09923 | TargetFullName: Intestinal-type alkaline phosphatase | Organisim: human | Apparent_Kd_M: 1.08E-11
Real
Aptamer SeqId: 17447-52 | Target: SFRP4 | UniProt: Q6FHJ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17447-52 | Target: SFRP4 | UniProt: Q6FHJ7 | TargetFullName: Secreted frizzled-related protein 4 | Organisim: human | Apparent_Kd_M: 3.78E-12
Real
Aptamer SeqId: 17449-23 | Target: CD9 | UniProt: P21926
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17449-23 | Target: CD9 | UniProt: P21926 | TargetFullName: CD9 antigen | Organisim: human | Apparent_Kd_M: 2.446283E-10
Real
Aptamer SeqId: 17450-51 | Target: Histidyl-tRNA synthetase
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17450-51 | Target: Histidyl-tRNA synthetase | UniProt: P12081 | TargetFullName: Histidine--tRNA ligase; cytoplasmic | Organisim: human | Apparent_Kd_M: 1.37E-12
Real
Aptamer SeqId: 17451-13 | Target: BIM | UniProt: O43521
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17451-13 | Target: BIM | UniProt: O43521 | TargetFullName: Bcl-2-like protein 11 | Organisim: human | Apparent_Kd_M: 2.069766E-10
Real
Aptamer SeqId: 17453-34 | Target: Ceruloplasmin | UniProt: P00450
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17453-34 | Target: Ceruloplasmin | UniProt: P00450 | TargetFullName: Ceruloplasmin | Organisim: human | Apparent_Kd_M: 1.65E-10
Real
Aptamer SeqId: 17454-15 | Target: EGFL6 | UniProt: Q8IUX8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17454-15 | Target: EGFL6 | UniProt: Q8IUX8 | TargetFullName: Epidermal growth factor-like protein 6 | Organisim: human | Apparent_Kd_M: 2.22E-11
Real
Aptamer SeqId: 17455-42 | Target: FOLR1 | UniProt: P15328
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17455-42 | Target: FOLR1 | UniProt: P15328 | TargetFullName: Folate receptor alpha | Organisim: human | Apparent_Kd_M: 7.05E-12
Real
Aptamer SeqId: 17456-53 | Target: GOLM1 | UniProt: Q8NBJ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17456-53 | Target: GOLM1 | UniProt: Q8NBJ4 | TargetFullName: Golgi membrane protein 1 | Organisim: human | Apparent_Kd_M: 4.74E-12
Real
Aptamer SeqId: 17460-51 | Target: Mx1 | UniProt: P20591
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17460-51 | Target: Mx1 | UniProt: P20591 | TargetFullName: Interferon-induced GTP-binding protein Mx1 | Organisim: human | Apparent_Kd_M: 2.43E-12
Real
Aptamer SeqId: 17462-19 | Target: IRF1 | UniProt: P10914
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17462-19 | Target: IRF1 | UniProt: P10914 | TargetFullName: Interferon regulatory factor 1 | Organisim: human | Apparent_Kd_M: 4.84E-12
Real
Aptamer SeqId: 17466-72 | Target: ACSF2 | UniProt: Q96CM8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17466-72 | Target: ACSF2 | UniProt: Q96CM8 | TargetFullName: Acyl-CoA synthetase family member 2; mitochondrial | Organisim: human | Apparent_Kd_M: 4.64E-12
Real
Aptamer SeqId: 17467-1 | Target: DHRS9 | UniProt: Q9BPW9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17467-1 | Target: DHRS9 | UniProt: Q9BPW9 | TargetFullName: Dehydrogenase/reductase SDR family member 9 | Organisim: human | Apparent_Kd_M: 4.3E-11
Real
Aptamer SeqId: 17468-1 | Target: SUFU | UniProt: Q9UMX1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17468-1 | Target: SUFU | UniProt: Q9UMX1 | TargetFullName: Suppressor of fused homolog | Organisim: human | Apparent_Kd_M: 2.87E-11
Real
Aptamer SeqId: 17474-106 | Target: YETS4 | UniProt: O95619
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17474-106 | Target: YETS4 | UniProt: O95619 | TargetFullName: YEATS domain-containing protein 4 | Organisim: human | Apparent_Kd_M: 3.39E-11
Real
Aptamer SeqId: 17475-18 | Target: TOPK | UniProt: Q96KB5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17475-18 | Target: TOPK | UniProt: Q96KB5 | TargetFullName: Lymphokine-activated killer T-cell-originated protein kinase | Organisim: human | Apparent_Kd_M: 3.19E-11
Real
Aptamer SeqId: 17490-4 | Target: SH3BGRL3-like protein | UniProt: Q9H299
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17490-4 | Target: SH3BGRL3-like protein | UniProt: Q9H299 | TargetFullName: SH3 domain-binding glutamic acid-rich-like protein 3 | Organisim: human | Apparent_Kd_M: 1.144902E-10
Real
Aptamer SeqId: 17495-141 | Target: SIR3 | UniProt: Q9NTG7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17495-141 | Target: SIR3 | UniProt: Q9NTG7 | TargetFullName: NAD-dependent protein deacetylase sirtuin-3; mitochondrial | Organisim: human | Apparent_Kd_M: 1.18E-11
Real
Aptamer SeqId: 17505-125 | Target: NALDL | UniProt: Q9UQQ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17505-125 | Target: NALDL | UniProt: Q9UQQ1 | TargetFullName: N-acetylated-alpha-linked acidic dipeptidase-like protein | Organisim: human | Apparent_Kd_M: 5.08E-11
Real
Aptamer SeqId: 17509-6 | Target: HPPD | UniProt: P32754
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17509-6 | Target: HPPD | UniProt: P32754 | TargetFullName: 4-hydroxyphenylpyruvate dioxygenase | Organisim: human | Apparent_Kd_M: 6.958946E-11
Real
Aptamer SeqId: 17510-7 | Target: SRP14 | UniProt: P37108
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17510-7 | Target: SRP14 | UniProt: P37108 | TargetFullName: Signal recognition particle 14 kDa protein | Organisim: human | Apparent_Kd_M: 3.09E-12
Real
Aptamer SeqId: 17511-10 | Target: RPP30 | UniProt: P78346
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17511-10 | Target: RPP30 | UniProt: P78346 | TargetFullName: Ribonuclease P protein subunit p30 | Organisim: human | Apparent_Kd_M: 9.34E-12
Real
Aptamer SeqId: 17512-2 | Target: NMI | UniProt: Q13287
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17512-2 | Target: NMI | UniProt: Q13287 | TargetFullName: N-myc-interactor | Organisim: human | Apparent_Kd_M: 2.447968E-11
Real
Aptamer SeqId: 17513-11 | Target: ANX11 | UniProt: P50995
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17513-11 | Target: ANX11 | UniProt: P50995 | TargetFullName: Annexin A11 | Organisim: human | Apparent_Kd_M: 3.932212E-11
Real
Aptamer SeqId: 17514-48 | Target: RAB21 | UniProt: Q9UL25
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17514-48 | Target: RAB21 | UniProt: Q9UL25 | TargetFullName: Ras-related protein Rab-21 | Organisim: human | Apparent_Kd_M: 2.406208E-12
Real
Aptamer SeqId: 17515-6 | Target: STCH | UniProt: P48723
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17515-6 | Target: STCH | UniProt: P48723 | TargetFullName: Heat shock 70 kDa protein 13 | Organisim: human | Apparent_Kd_M: 1.12E-11
Real
Aptamer SeqId: 17516-7 | Target: Rab3A | UniProt: P20336
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17516-7 | Target: Rab3A | UniProt: P20336 | TargetFullName: Ras-related protein Rab-3A | Organisim: human | Apparent_Kd_M: 1.78E-12
Real
Aptamer SeqId: 17671-58 | Target: ING4 | UniProt: Q9UNL4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17671-58 | Target: ING4 | UniProt: Q9UNL4 | TargetFullName: Inhibitor of growth protein 4 | Organisim: human | Apparent_Kd_M: 4.01E-11
Real
Aptamer SeqId: 17672-184 | Target: Gastric intrinsic factor
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17672-184 | Target: Gastric intrinsic factor | UniProt: P27352 | TargetFullName: Gastric intrinsic factor | Organisim: human | Apparent_Kd_M: 2.81E-12
Real
Aptamer SeqId: 17673-34 | Target: Carbonic Anhydrase VB | UniProt: Q9Y2D0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17673-34 | Target: Carbonic Anhydrase VB | UniProt: Q9Y2D0 | TargetFullName: Carbonic anhydrase 5B; mitochondrial | Organisim: human | Apparent_Kd_M: 1.85E-11
Real
Aptamer SeqId: 17675-17 | Target: ACO13 | UniProt: Q9NPJ3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17675-17 | Target: ACO13 | UniProt: Q9NPJ3 | TargetFullName: Acyl-coenzyme A thioesterase 13 | Organisim: human | Apparent_Kd_M: 7.95E-12
Real
Aptamer SeqId: 17676-13 | Target: CIP4 | UniProt: Q15642
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17676-13 | Target: CIP4 | UniProt: Q15642 | TargetFullName: Cdc42-interacting protein 4 | Organisim: human | Apparent_Kd_M: 1.26E-11
Real
Aptamer SeqId: 17677-47 | Target: BY55 | UniProt: O95971
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17677-47 | Target: BY55 | UniProt: O95971 | TargetFullName: CD160 antigen | Organisim: human | Apparent_Kd_M: 1.07E-11
Real
Aptamer SeqId: 17680-12 | Target: EPHB1 | UniProt: P54762
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17680-12 | Target: EPHB1 | UniProt: P54762 | TargetFullName: Ephrin type-B receptor 1 | Organisim: human | Apparent_Kd_M: 1.53E-11
Real
Aptamer SeqId: 17682-1 | Target: CD46 | UniProt: P15529
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17682-1 | Target: CD46 | UniProt: P15529 | TargetFullName: Membrane cofactor protein | Organisim: human | Apparent_Kd_M: 3.64E-12
Real
Aptamer SeqId: 17683-2 | Target: COMD9 | UniProt: Q9P000
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17683-2 | Target: COMD9 | UniProt: Q9P000 | TargetFullName: COMM domain-containing protein 9 | Organisim: human | Apparent_Kd_M: 2.84E-11
Real
Aptamer SeqId: 17685-9 | Target: Apo A-IV | UniProt: P06727
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17685-9 | Target: Apo A-IV | UniProt: P06727 | TargetFullName: Apolipoprotein A-IV | Organisim: human | Apparent_Kd_M: 1.57E-11
Real
Aptamer SeqId: 17686-27 | Target: TBCB | UniProt: Q99426
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17686-27 | Target: TBCB | UniProt: Q99426 | TargetFullName: Tubulin-folding cofactor B | Organisim: human | Apparent_Kd_M: 7.31E-12
Real
Aptamer SeqId: 17691-1 | Target: TPP1 | UniProt: O14773
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17691-1 | Target: TPP1 | UniProt: O14773 | TargetFullName: Tripeptidyl-peptidase 1 | Organisim: human | Apparent_Kd_M: 7.59E-12
Real
Aptamer SeqId: 17692-2 | Target: BT3A3 | UniProt: O00478
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17692-2 | Target: BT3A3 | UniProt: O00478 | TargetFullName: Butyrophilin subfamily 3 member A3 | Organisim: human | Apparent_Kd_M: 7.84E-12
Real
Aptamer SeqId: 17693-2 | Target: Septin-6 | UniProt: Q14141
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17693-2 | Target: Septin-6 | UniProt: Q14141 | TargetFullName: Septin-6 | Organisim: human | Apparent_Kd_M: 5.39E-11
Real
Aptamer SeqId: 17694-32 | Target: PSME2 | UniProt: Q9UL46
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17694-32 | Target: PSME2 | UniProt: Q9UL46 | TargetFullName: Proteasome activator complex subunit 2 | Organisim: human | Apparent_Kd_M: 8.28E-12
Real
Aptamer SeqId: 17696-1 | Target: TIRP | UniProt: Q86XR7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17696-1 | Target: TIRP | UniProt: Q86XR7 | TargetFullName: TIR domain-containing adapter molecule 2 | Organisim: human | Apparent_Kd_M: 1.96E-11
Real
Aptamer SeqId: 17697-2 | Target: OVCA2 | UniProt: Q8WZ82
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17697-2 | Target: OVCA2 | UniProt: Q8WZ82 | TargetFullName: Esterase OVCA2 | Organisim: human | Apparent_Kd_M: 2.0E-12
Real
Aptamer SeqId: 17698-15 | Target: WBP2 | UniProt: Q969T9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17698-15 | Target: WBP2 | UniProt: Q969T9 | TargetFullName: WW domain-binding protein 2 | Organisim: human | Apparent_Kd_M: 3.77E-12
Real
Aptamer SeqId: 17699-43 | Target: TIMELESS | UniProt: Q9UNS1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17699-43 | Target: TIMELESS | UniProt: Q9UNS1 | TargetFullName: Protein timeless homolog | Organisim: human | Apparent_Kd_M: 2.52E-12
Real
Aptamer SeqId: 17702-53 | Target: UGT 1A1 | UniProt: P22309
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17702-53 | Target: UGT 1A1 | UniProt: P22309 | TargetFullName: UDP-glucuronosyltransferase 1-1 | Organisim: human | Apparent_Kd_M: 2.23E-11
Real
Aptamer SeqId: 17703-40 | Target: GEMI | UniProt: O75496
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17703-40 | Target: GEMI | UniProt: O75496 | TargetFullName: Geminin | Organisim: human | Apparent_Kd_M: 6.63E-12
Real
Aptamer SeqId: 17704-74 | Target: HS105 | UniProt: Q92598
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17704-74 | Target: HS105 | UniProt: Q92598 | TargetFullName: Heat shock protein 105 kDa | Organisim: human | Apparent_Kd_M: 9.43E-12
Real
Aptamer SeqId: 17706-4 | Target: PPR1A | UniProt: Q13522
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17706-4 | Target: PPR1A | UniProt: Q13522 | TargetFullName: Protein phosphatase 1 regulatory subunit 1A | Organisim: human | Apparent_Kd_M: 4.96E-12
Real
Aptamer SeqId: 17710-40 | Target: TPD53 | UniProt: Q16890
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17710-40 | Target: TPD53 | UniProt: Q16890 | TargetFullName: Tumor protein D53 | Organisim: human | Apparent_Kd_M: 4.18E-12
Real
Aptamer SeqId: 17711-13 | Target: VAMP1 | UniProt: P23763
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17711-13 | Target: VAMP1 | UniProt: P23763 | TargetFullName: Vesicle-associated membrane protein 1 | Organisim: human | Apparent_Kd_M: 2.1E-11
Real
Aptamer SeqId: 17712-7 | Target: IDI1 | UniProt: Q13907
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17712-7 | Target: IDI1 | UniProt: Q13907 | TargetFullName: Isopentenyl-diphosphate Delta-isomerase 1 | Organisim: human | Apparent_Kd_M: 1.9E-11
Real
Aptamer SeqId: 17721-82 | Target: GAS7 | UniProt: O60861
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17721-82 | Target: GAS7 | UniProt: O60861 | TargetFullName: Growth arrest-specific protein 7 | Organisim: human | Apparent_Kd_M: 1.79E-11
Real
Aptamer SeqId: 17722-5 | Target: FKBP52 protein | UniProt: Q02790
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17722-5 | Target: FKBP52 protein | UniProt: Q02790 | TargetFullName: Peptidyl-prolyl cis-trans isomerase FKBP4 | Organisim: human | Apparent_Kd_M: 4.75E-12
Real
Aptamer SeqId: 17724-3 | Target: WWOX | UniProt: Q9NZC7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17724-3 | Target: WWOX | UniProt: Q9NZC7 | TargetFullName: WW domain-containing oxidoreductase | Organisim: human | Apparent_Kd_M: 8.93E-11
Real
Aptamer SeqId: 17725-37 | Target: USH1C | UniProt: Q9Y6N9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17725-37 | Target: USH1C | UniProt: Q9Y6N9 | TargetFullName: Harmonin | Organisim: human | Apparent_Kd_M: 1.21E-11
Real
Aptamer SeqId: 17726-3 | Target: SAR1A | UniProt: Q9NR31
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17726-3 | Target: SAR1A | UniProt: Q9NR31 | TargetFullName: GTP-binding protein SAR1a | Organisim: human | Apparent_Kd_M: 2.92E-11
Real
Aptamer SeqId: 17727-1 | Target: Securin | UniProt: O95997
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17727-1 | Target: Securin | UniProt: O95997 | TargetFullName: Securin | Organisim: human | Apparent_Kd_M: 1.06E-11
Real
Aptamer SeqId: 17728-61 | Target: CHM2A | UniProt: O43633
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17728-61 | Target: CHM2A | UniProt: O43633 | TargetFullName: Charged multivesicular body protein 2a | Organisim: human | Apparent_Kd_M: 2.45E-12
Real
Aptamer SeqId: 17729-20 | Target: UBE2S | UniProt: Q16763
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17729-20 | Target: UBE2S | UniProt: Q16763 | TargetFullName: Ubiquitin-conjugating enzyme E2 S | Organisim: human | Apparent_Kd_M: 9.61E-12
Real
Aptamer SeqId: 17734-13 | Target: a-endosulfine | UniProt: O43768
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17734-13 | Target: a-endosulfine | UniProt: O43768 | TargetFullName: Alpha-endosulfine | Organisim: human | Apparent_Kd_M: 1.02E-11
Real
Aptamer SeqId: 17735-130 | Target: GBRAP | UniProt: O95166
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17735-130 | Target: GBRAP | UniProt: O95166 | TargetFullName: Gamma-aminobutyric acid receptor-associated protein | Organisim: human | Apparent_Kd_M: 2.24E-12
Real
Aptamer SeqId: 17736-105 | Target: APTX | UniProt: Q7Z2E3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17736-105 | Target: APTX | UniProt: Q7Z2E3 | TargetFullName: Aprataxin | Organisim: human | Apparent_Kd_M: 1.51E-11
Real
Aptamer SeqId: 17737-7 | Target: IVD | UniProt: P26440
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17737-7 | Target: IVD | UniProt: P26440 | TargetFullName: Isovaleryl-CoA dehydrogenase; mitochondrial | Organisim: human | Apparent_Kd_M: 5.15E-12
Real
Aptamer SeqId: 17738-7 | Target: CRNN | UniProt: Q9UBG3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17738-7 | Target: CRNN | UniProt: Q9UBG3 | TargetFullName: Cornulin | Organisim: human | Apparent_Kd_M: 4.33E-12
Real
Aptamer SeqId: 17739-1 | Target: HCDH | UniProt: Q16836
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17739-1 | Target: HCDH | UniProt: Q16836 | TargetFullName: Hydroxyacyl-coenzyme A dehydrogenase; mitochondrial | Organisim: human | Apparent_Kd_M: 5.2E-12
Real
Aptamer SeqId: 17742-2 | Target: RRAS | UniProt: P10301
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17742-2 | Target: RRAS | UniProt: P10301 | TargetFullName: Ras-related protein R-Ras | Organisim: human | Apparent_Kd_M: 8.48E-12
Real
Aptamer SeqId: 17743-14 | Target: UBE2A | UniProt: P49459
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17743-14 | Target: UBE2A | UniProt: P49459 | TargetFullName: Ubiquitin-conjugating enzyme E2 A | Organisim: human | Apparent_Kd_M: 4.06E-12
Real
Aptamer SeqId: 17744-31 | Target: RB11A | UniProt: P62491
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17744-31 | Target: RB11A | UniProt: P62491 | TargetFullName: Ras-related protein Rab-11A | Organisim: human | Apparent_Kd_M: 1.22E-11
Real
Aptamer SeqId: 17746-77 | Target: FIS1 | UniProt: Q9Y3D6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17746-77 | Target: FIS1 | UniProt: Q9Y3D6 | TargetFullName: Mitochondrial fission 1 protein | Organisim: human | Apparent_Kd_M: 2.48E-11
Real
Aptamer SeqId: 17747-45 | Target: TRAF1 | UniProt: Q13077
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17747-45 | Target: TRAF1 | UniProt: Q13077 | TargetFullName: TNF receptor-associated factor 1 | Organisim: human | Apparent_Kd_M: 3.26E-11
Real
Aptamer SeqId: 17748-21 | Target: QORX | UniProt: Q53FA7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17748-21 | Target: QORX | UniProt: Q53FA7 | TargetFullName: Quinone oxidoreductase PIG3 | Organisim: human | Apparent_Kd_M: 2.53E-12
Real
Aptamer SeqId: 17750-8 | Target: RIR2 | UniProt: P31350
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17750-8 | Target: RIR2 | UniProt: P31350 | TargetFullName: Ribonucleoside-diphosphate reductase subunit M2 | Organisim: human | Apparent_Kd_M: 3.7E-11
Real
Aptamer SeqId: 17751-68 | Target: CRBB1 | UniProt: P53674
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17751-68 | Target: CRBB1 | UniProt: P53674 | TargetFullName: Beta-crystallin B1 | Organisim: human | Apparent_Kd_M: 6.44E-12
Real
Aptamer SeqId: 17752-24 | Target: Arginase | UniProt: P78540
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17752-24 | Target: Arginase | UniProt: P78540 | TargetFullName: Arginase-2; mitochondrial | Organisim: human | Apparent_Kd_M: 2.08E-11
Real
Aptamer SeqId: 17755-5 | Target: UGDH | UniProt: O60701
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17755-5 | Target: UGDH | UniProt: O60701 | TargetFullName: UDP-glucose 6-dehydrogenase | Organisim: human | Apparent_Kd_M: 4.44E-12
Real
Aptamer SeqId: 17756-69 | Target: DCTD | UniProt: P32321
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17756-69 | Target: DCTD | UniProt: P32321 | TargetFullName: Deoxycytidylate deaminase | Organisim: human | Apparent_Kd_M: 3.48E-11
Real
Aptamer SeqId: 17757-86 | Target: CAB39 | UniProt: Q9Y376
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17757-86 | Target: CAB39 | UniProt: Q9Y376 | TargetFullName: Calcium-binding protein 39 | Organisim: human | Apparent_Kd_M: 1.9E-12
Real
Aptamer SeqId: 17758-79 | Target: DCXR | UniProt: Q7Z4W1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17758-79 | Target: DCXR | UniProt: Q7Z4W1 | TargetFullName: L-xylulose reductase | Organisim: human | Apparent_Kd_M: 1.3E-11
Real
Aptamer SeqId: 17760-128 | Target: WDR5 | UniProt: P61964
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17760-128 | Target: WDR5 | UniProt: P61964 | TargetFullName: WD repeat-containing protein 5 | Organisim: human | Apparent_Kd_M: 8.69E-12
Real
Aptamer SeqId: 17761-2 | Target: NUDT5 | UniProt: Q9UKK9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17761-2 | Target: NUDT5 | UniProt: Q9UKK9 | TargetFullName: ADP-sugar pyrophosphatase | Organisim: human | Apparent_Kd_M: 4.19E-11
Real
Aptamer SeqId: 17764-108 | Target: RHOC | UniProt: P08134
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17764-108 | Target: RHOC | UniProt: P08134 | TargetFullName: Rho-related GTP-binding protein RhoC | Organisim: human | Apparent_Kd_M: 2.19E-11
Real
Aptamer SeqId: 17765-3 | Target: SPN1 | UniProt: O95149
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17765-3 | Target: SPN1 | UniProt: O95149 | TargetFullName: Snurportin-1 | Organisim: human | Apparent_Kd_M: 7.2E-13
Real
Aptamer SeqId: 17766-5 | Target: NCF-1 | UniProt: P14598
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17766-5 | Target: NCF-1 | UniProt: P14598 | TargetFullName: Neutrophil cytosol factor 1 | Organisim: human | Apparent_Kd_M: 3.26E-12
Real
Aptamer SeqId: 17768-50 | Target: HAOX1 | UniProt: Q9UJM8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17768-50 | Target: HAOX1 | UniProt: Q9UJM8 | TargetFullName: Hydroxyacid oxidase 1 | Organisim: human | Apparent_Kd_M: 1.9E-11
Real
Aptamer SeqId: 17769-28 | Target: PCNP | UniProt: Q8WW12
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17769-28 | Target: PCNP | UniProt: Q8WW12 | TargetFullName: PEST proteolytic signal-containing nuclear protein | Organisim: human | Apparent_Kd_M: 5.88E-12
Real
Aptamer SeqId: 17770-42 | Target: EMC8 | UniProt: O43402
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17770-42 | Target: EMC8 | UniProt: O43402 | TargetFullName: ER membrane protein complex subunit 8 | Organisim: human | Apparent_Kd_M: 1.02E-10
Real
Aptamer SeqId: 17771-35 | Target: RPC9 | UniProt: O75575
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17771-35 | Target: RPC9 | UniProt: O75575 | TargetFullName: DNA-directed RNA polymerase III subunit RPC9 | Organisim: human | Apparent_Kd_M: 2.99E-11
Real
Aptamer SeqId: 17772-7 | Target: UBD | UniProt: O15205
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17772-7 | Target: UBD | UniProt: O15205 | TargetFullName: Ubiquitin D | Organisim: human | Apparent_Kd_M: 1.7E-11
Real
Aptamer SeqId: 17773-26 | Target: SNAG | UniProt: Q99747
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17773-26 | Target: SNAG | UniProt: Q99747 | TargetFullName: Gamma-soluble NSF attachment protein | Organisim: human | Apparent_Kd_M: 1.31E-10
Real
Aptamer SeqId: 17774-38 | Target: SMD3 | UniProt: P62318
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17774-38 | Target: SMD3 | UniProt: P62318 | TargetFullName: Small nuclear ribonucleoprotein Sm D3 | Organisim: human | Apparent_Kd_M: 2.085831E-9
Real
Aptamer SeqId: 17775-8 | Target: TAGL3 | UniProt: Q9UI15
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17775-8 | Target: TAGL3 | UniProt: Q9UI15 | TargetFullName: Transgelin-3 | Organisim: human | Apparent_Kd_M: 6.14E-12
Real
Aptamer SeqId: 17776-15 | Target: PECR | UniProt: Q9BY49
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17776-15 | Target: PECR | UniProt: Q9BY49 | TargetFullName: Peroxisomal trans-2-enoyl-CoA reductase | Organisim: human | Apparent_Kd_M: 3.08E-11
Real
Aptamer SeqId: 17777-31 | Target: SDSL | UniProt: Q96GA7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17777-31 | Target: SDSL | UniProt: Q96GA7 | TargetFullName: Serine dehydratase-like | Organisim: human | Apparent_Kd_M: 3.55E-11
Real
Aptamer SeqId: 17778-19 | Target: RAB32 | UniProt: Q13637
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17778-19 | Target: RAB32 | UniProt: Q13637 | TargetFullName: Ras-related protein Rab-32 | Organisim: human | Apparent_Kd_M: 3.36E-11
Real
Aptamer SeqId: 17781-191 | Target: MLP3A | UniProt: Q9H492
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17781-191 | Target: MLP3A | UniProt: Q9H492 | TargetFullName: Microtubule-associated proteins 1A/1B light chain 3A | Organisim: human | Apparent_Kd_M: 4.55E-12
Real
Aptamer SeqId: 17782-23 | Target: THIK | UniProt: P09110
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17782-23 | Target: THIK | UniProt: P09110 | TargetFullName: 3-ketoacyl-CoA thiolase; peroxisomal | Organisim: human | Apparent_Kd_M: 4.71E-11
Real
Aptamer SeqId: 17783-9 | Target: MMAB | UniProt: Q96EY8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17783-9 | Target: MMAB | UniProt: Q96EY8 | TargetFullName: Cob(I)yrinic acid a;c-diamide adenosyltransferase; mitochondrial | Organisim: human | Apparent_Kd_M: 1.2E-11
Real
Aptamer SeqId: 17784-23 | Target: GMFB | UniProt: P60983
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17784-23 | Target: GMFB | UniProt: P60983 | TargetFullName: Glia maturation factor beta | Organisim: human | Apparent_Kd_M: 5.45E-11
Real
Aptamer SeqId: 17785-11 | Target: RCL | UniProt: O43598
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17785-11 | Target: RCL | UniProt: O43598 | TargetFullName: 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 | Organisim: human | Apparent_Kd_M: 2.43E-11
Real
Aptamer SeqId: 17786-5 | Target: GGPPS | UniProt: O95749
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17786-5 | Target: GGPPS | UniProt: O95749 | TargetFullName: Geranylgeranyl pyrophosphate synthase | Organisim: human | Apparent_Kd_M: 9.29E-11
Real
Aptamer SeqId: 17787-1 | Target: Enoyl-CoA hydratase | UniProt: P30084
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17787-1 | Target: Enoyl-CoA hydratase | UniProt: P30084 | TargetFullName: Enoyl-CoA hydratase; mitochondrial | Organisim: human | Apparent_Kd_M: 3.77E-12
Real
Aptamer SeqId: 17789-1 | Target: NADC | UniProt: Q15274
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17789-1 | Target: NADC | UniProt: Q15274 | TargetFullName: Nicotinate-nucleotide pyrophosphorylase carboxylating | Organisim: human | Apparent_Kd_M: 9.37E-11
Real
Aptamer SeqId: 17791-25 | Target: HPCL1 | UniProt: P37235
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17791-25 | Target: HPCL1 | UniProt: P37235 | TargetFullName: Hippocalcin-like protein 1 | Organisim: human | Apparent_Kd_M: 7.89E-12
Real
Aptamer SeqId: 17792-158 | Target: SSDH | UniProt: P51649
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17792-158 | Target: SSDH | UniProt: P51649 | TargetFullName: Succinate-semialdehyde dehydrogenase; mitochondrial | Organisim: human | Apparent_Kd_M: 4.93E-11
Real
Aptamer SeqId: 17793-4 | Target: DIRA1 | UniProt: O95057
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17793-4 | Target: DIRA1 | UniProt: O95057 | TargetFullName: GTP-binding protein Di-Ras1 | Organisim: human | Apparent_Kd_M: 1.93E-11
Real
Aptamer SeqId: 17794-6 | Target: Phosphomannomutase 2 | UniProt: O15305
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17794-6 | Target: Phosphomannomutase 2 | UniProt: O15305 | TargetFullName: Phosphomannomutase 2 | Organisim: human | Apparent_Kd_M: 1.98E-11
Real
Aptamer SeqId: 17795-176 | Target: LSM1 | UniProt: O15116
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17795-176 | Target: LSM1 | UniProt: O15116 | TargetFullName: U6 snRNA-associated Sm-like protein LSm1 | Organisim: human | Apparent_Kd_M: 2.91E-11
Real
Aptamer SeqId: 17796-15 | Target: IMPA1 | UniProt: P29218
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17796-15 | Target: IMPA1 | UniProt: P29218 | TargetFullName: Inositol monophosphatase 1 | Organisim: human | Apparent_Kd_M: 7.9E-11
Real
Aptamer SeqId: 17797-1 | Target: CUL1 | UniProt: Q13616
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17797-1 | Target: CUL1 | UniProt: Q13616 | TargetFullName: Cullin-1 | Organisim: human | Apparent_Kd_M: 4.77E-11
Real
Aptamer SeqId: 17799-9 | Target: 6PGL | UniProt: O95336
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17799-9 | Target: 6PGL | UniProt: O95336 | TargetFullName: 6-phosphogluconolactonase | Organisim: human | Apparent_Kd_M: 2.08E-12
Real
Aptamer SeqId: 17800-33 | Target: SCAND1 | UniProt: P57086
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17800-33 | Target: SCAND1 | UniProt: P57086 | TargetFullName: SCAN domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 3.31E-12
Real
Aptamer SeqId: 17802-4 | Target: SIAS | UniProt: Q9NR45
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17802-4 | Target: SIAS | UniProt: Q9NR45 | TargetFullName: Sialic acid synthase | Organisim: human | Apparent_Kd_M: 1.89E-11
Real
Aptamer SeqId: 17804-102 | Target: PNPO | UniProt: Q9NVS9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17804-102 | Target: PNPO | UniProt: Q9NVS9 | TargetFullName: Pyridoxine-5'-phosphate oxidase | Organisim: human | Apparent_Kd_M: 2.32E-11
Real
Aptamer SeqId: 17805-35 | Target: SPF30 | UniProt: O75940
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17805-35 | Target: SPF30 | UniProt: O75940 | TargetFullName: Survival of motor neuron-related-splicing factor 30 | Organisim: human | Apparent_Kd_M: 4.58E-12
Real
Aptamer SeqId: 17806-6 | Target: Syntenin 1 | UniProt: O00560
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17806-6 | Target: Syntenin 1 | UniProt: O00560 | TargetFullName: Syntenin-1 | Organisim: human | Apparent_Kd_M: 1.82E-12
Real
Aptamer SeqId: 17808-37 | Target: NIT2 | UniProt: Q9NQR4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17808-37 | Target: NIT2 | UniProt: Q9NQR4 | TargetFullName: Omega-amidase NIT2 | Organisim: human | Apparent_Kd_M: 1.51E-11
Real
Aptamer SeqId: 17811-78 | Target: ST1C2 | UniProt: O00338
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17811-78 | Target: ST1C2 | UniProt: O00338 | TargetFullName: Sulfotransferase 1C2 | Organisim: human | Apparent_Kd_M: 1.86E-11
Real
Aptamer SeqId: 17812-2 | Target: TP4A1 | UniProt: Q93096
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17812-2 | Target: TP4A1 | UniProt: Q93096 | TargetFullName: Protein tyrosine phosphatase type IVA 1 | Organisim: human | Apparent_Kd_M: 1.5E-11
Real
Aptamer SeqId: 17813-21 | Target: BPHL | UniProt: Q86WA6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17813-21 | Target: BPHL | UniProt: Q86WA6 | TargetFullName: Valacyclovir hydrolase | Organisim: human | Apparent_Kd_M: 1.24E-11
Real
Aptamer SeqId: 17814-8 | Target: BPNT1 | UniProt: O95861
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17814-8 | Target: BPNT1 | UniProt: O95861 | TargetFullName: 3'(2');5'-bisphosphate nucleotidase 1 | Organisim: human | Apparent_Kd_M: 3.04E-11
Real
Aptamer SeqId: 17816-58 | Target: NCALD | UniProt: P61601
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17816-58 | Target: NCALD | UniProt: P61601 | TargetFullName: Neurocalcin-delta | Organisim: human | Apparent_Kd_M: 3.72E-11
Real
Aptamer SeqId: 17817-22 | Target: DDIT4 | UniProt: Q9NX09
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17817-22 | Target: DDIT4 | UniProt: Q9NX09 | TargetFullName: DNA damage-inducible transcript 4 protein | Organisim: human | Apparent_Kd_M: 9.56E-11
Real
Aptamer SeqId: 17818-22 | Target: SUGT1 | UniProt: Q9Y2Z0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17818-22 | Target: SUGT1 | UniProt: Q9Y2Z0 | TargetFullName: Protein SGT1 homolog | Organisim: human | Apparent_Kd_M: 8.84E-11
Real
Aptamer SeqId: 17819-30 | Target: FAHD1 | UniProt: Q6P587
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17819-30 | Target: FAHD1 | UniProt: Q6P587 | TargetFullName: Acylpyruvase FAHD1; mitochondrial | Organisim: human | Apparent_Kd_M: 2.34E-12
Real
Aptamer SeqId: 17820-170 | Target: MLF1 | UniProt: P58340
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17820-170 | Target: MLF1 | UniProt: P58340 | TargetFullName: Myeloid leukemia factor 1 | Organisim: human | Apparent_Kd_M: 5.455873E-11
Real
Aptamer SeqId: 17821-20 | Target: NMT2 | UniProt: O60551
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17821-20 | Target: NMT2 | UniProt: O60551 | TargetFullName: Glycylpeptide N-tetradecanoyltransferase 2 | Organisim: human | Apparent_Kd_M: 4.73E-12
Real
Aptamer SeqId: 17822-57 | Target: RERG | UniProt: Q96A58
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17822-57 | Target: RERG | UniProt: Q96A58 | TargetFullName: Ras-related and estrogen-regulated growth inhibitor | Organisim: human | Apparent_Kd_M: 3.063918E-11
Real
Aptamer SeqId: 17823-40 | Target: SMD2 | UniProt: P62316
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17823-40 | Target: SMD2 | UniProt: P62316 | TargetFullName: Small nuclear ribonucleoprotein Sm D2 | Organisim: human | Apparent_Kd_M: 1.82E-11
Real
Aptamer SeqId: 17826-341 | Target: EF1D | UniProt: P29692
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17826-341 | Target: EF1D | UniProt: P29692 | TargetFullName: Elongation factor 1-delta | Organisim: human | Apparent_Kd_M: 4.66E-11
Real
Aptamer SeqId: 17827-53 | Target: DLRB2 | UniProt: Q8TF09
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17827-53 | Target: DLRB2 | UniProt: Q8TF09 | TargetFullName: Dynein light chain roadblock-type 2 | Organisim: human | Apparent_Kd_M: 4.17E-11
Real
Aptamer SeqId: 17828-3 | Target: S100A14 | UniProt: Q9HCY8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17828-3 | Target: S100A14 | UniProt: Q9HCY8 | TargetFullName: Protein S100-A14 | Organisim: human | Apparent_Kd_M: 5.88E-11
Real
Aptamer SeqId: 17829-2 | Target: TREX2 | UniProt: Q9BQ50
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17829-2 | Target: TREX2 | UniProt: Q9BQ50 | TargetFullName: Three prime repair exonuclease 2 | Organisim: human | Apparent_Kd_M: 4.39E-11
Real
Aptamer SeqId: 17832-12 | Target: IDI2 | UniProt: Q9BXS1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17832-12 | Target: IDI2 | UniProt: Q9BXS1 | TargetFullName: Isopentenyl-diphosphate delta-isomerase 2 | Organisim: human | Apparent_Kd_M: 1.58E-10
Real
Aptamer SeqId: 17835-28 | Target: ANX13 | UniProt: P27216
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17835-28 | Target: ANX13 | UniProt: P27216 | TargetFullName: Annexin A13 | Organisim: human | Apparent_Kd_M: 1.46E-11
Real
Aptamer SeqId: 17836-17 | Target: S100A16 | UniProt: Q96FQ6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17836-17 | Target: S100A16 | UniProt: Q96FQ6 | TargetFullName: Protein S100-A16 | Organisim: human | Apparent_Kd_M: 1.07E-11
Real
Aptamer SeqId: 17837-5 | Target: CLIC2 | UniProt: O15247
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17837-5 | Target: CLIC2 | UniProt: O15247 | TargetFullName: Chloride intracellular channel protein 2 | Organisim: human | Apparent_Kd_M: 1.5E-12
Real
Aptamer SeqId: 17843-30 | Target: PPCS | UniProt: Q9HAB8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17843-30 | Target: PPCS | UniProt: Q9HAB8 | TargetFullName: Phosphopantothenate--cysteine ligase | Organisim: human | Apparent_Kd_M: 3.07E-12
Real
Aptamer SeqId: 17849-6 | Target: DRG1 | UniProt: Q9Y295
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17849-6 | Target: DRG1 | UniProt: Q9Y295 | TargetFullName: Developmentally-regulated GTP-binding protein 1 | Organisim: human | Apparent_Kd_M: 8.98E-12
Real
Aptamer SeqId: 17850-42 | Target: KLF4 | UniProt: O43474
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17850-42 | Target: KLF4 | UniProt: O43474 | TargetFullName: Krueppel-like factor 4 | Organisim: human | Apparent_Kd_M: 2.66E-11
Real
Aptamer SeqId: 17852-5 | Target: PPME1 | UniProt: Q9Y570
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17852-5 | Target: PPME1 | UniProt: Q9Y570 | TargetFullName: Protein phosphatase methylesterase 1 | Organisim: human | Apparent_Kd_M: 5.24E-12
Real
Aptamer SeqId: 17854-33 | Target: NAA10 | UniProt: P41227
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17854-33 | Target: NAA10 | UniProt: P41227 | TargetFullName: N-alpha-acetyltransferase 10 | Organisim: human | Apparent_Kd_M: 7.04E-12
Real
Aptamer SeqId: 17855-28 | Target: RGS4 | UniProt: P49798
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17855-28 | Target: RGS4 | UniProt: P49798 | TargetFullName: Regulator of G-protein signaling 4 | Organisim: human | Apparent_Kd_M: 4.56E-12
Real
Aptamer SeqId: 17856-23 | Target: NT5M | UniProt: Q9NPB1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17856-23 | Target: NT5M | UniProt: Q9NPB1 | TargetFullName: 5'(3')-deoxyribonucleotidase; mitochondrial | Organisim: human | Apparent_Kd_M: 1.22E-11
Real
Aptamer SeqId: 17857-6 | Target: ACADL | UniProt: P28330
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 17857-6 | Target: ACADL | UniProt: P28330 | TargetFullName: Long-chain specific acyl-CoA dehydrogenase; mitochondrial | Organisim: human | Apparent_Kd_M: 3.1E-11
Real
Aptamer SeqId: 18156-7 | Target: ATG3 | UniProt: Q9NT62
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18156-7 | Target: ATG3 | UniProt: Q9NT62 | TargetFullName: Ubiquitin-like-conjugating enzyme ATG3 | Organisim: human | Apparent_Kd_M: 1.07E-10
Real
Aptamer SeqId: 18158-45 | Target: Caspase-8 | UniProt: Q14790
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18158-45 | Target: Caspase-8 | UniProt: Q14790 | TargetFullName: Caspase-8 | Organisim: human | Apparent_Kd_M: 3.2E-11
Real
Aptamer SeqId: 18160-2 | Target: PIMT | UniProt: P22061
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18160-2 | Target: PIMT | UniProt: P22061 | TargetFullName: Protein-L-isoaspartate(D-aspartate) O-methyltransferase | Organisim: human | Apparent_Kd_M: 7.45E-11
Real
Aptamer SeqId: 18162-167 | Target: IRAK4 | UniProt: Q9NWZ3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18162-167 | Target: IRAK4 | UniProt: Q9NWZ3 | TargetFullName: Interleukin-1 receptor-associated kinase 4 | Organisim: human | Apparent_Kd_M: 1.3E-10
Real
Aptamer SeqId: 18165-181 | Target: UB2V2 | UniProt: Q15819
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18165-181 | Target: UB2V2 | UniProt: Q15819 | TargetFullName: Ubiquitin-conjugating enzyme E2 variant 2 | Organisim: human | Apparent_Kd_M: 2.53E-11
Real
Aptamer SeqId: 18166-4 | Target: RHOB | UniProt: P62745
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18166-4 | Target: RHOB | UniProt: P62745 | TargetFullName: Rho-related GTP-binding protein RhoB | Organisim: human | Apparent_Kd_M: 4.64E-11
Real
Aptamer SeqId: 18170-46 | Target: P5CR1 | UniProt: P32322
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18170-46 | Target: P5CR1 | UniProt: P32322 | TargetFullName: Pyrroline-5-carboxylate reductase 1; mitochondrial | Organisim: human | Apparent_Kd_M: 5.79E-11
Real
Aptamer SeqId: 18172-71 | Target: ASF1A | UniProt: Q9Y294
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18172-71 | Target: ASF1A | UniProt: Q9Y294 | TargetFullName: Histone chaperone ASF1A | Organisim: human | Apparent_Kd_M: 6.8E-12
Real
Aptamer SeqId: 18173-11 | Target: ARK73 | UniProt: O95154
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18173-11 | Target: ARK73 | UniProt: O95154 | TargetFullName: Aflatoxin B1 aldehyde reductase member 3 | Organisim: human | Apparent_Kd_M: 2.73E-12
Real
Aptamer SeqId: 18174-79 | Target: PDC6I | UniProt: Q8WUM4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18174-79 | Target: PDC6I | UniProt: Q8WUM4 | TargetFullName: Programmed cell death 6-interacting protein | Organisim: human | Apparent_Kd_M: 7.36E-12
Real
Aptamer SeqId: 18175-65 | Target: VAT1 | UniProt: Q99536
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18175-65 | Target: VAT1 | UniProt: Q99536 | TargetFullName: Synaptic vesicle membrane protein VAT-1 homolog | Organisim: human | Apparent_Kd_M: 8.4E-12
Real
Aptamer SeqId: 18177-49 | Target: ULA1 | UniProt: Q13564
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18177-49 | Target: ULA1 | UniProt: Q13564 | TargetFullName: NEDD8-activating enzyme E1 regulatory subunit | Organisim: human | Apparent_Kd_M: 3.2E-11
Real
Aptamer SeqId: 18178-13 | Target: SYSC | UniProt: P49591
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18178-13 | Target: SYSC | UniProt: P49591 | TargetFullName: Serine--tRNA ligase; cytoplasmic | Organisim: human | Apparent_Kd_M: 6.11E-11
Real
Aptamer SeqId: 18179-56 | Target: SPSY | UniProt: P52788
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18179-56 | Target: SPSY | UniProt: P52788 | TargetFullName: Spermine synthase | Organisim: human | Apparent_Kd_M: 2.92E-10
Real
Aptamer SeqId: 18180-58 | Target: RT4I1 | UniProt: Q8WWV3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18180-58 | Target: RT4I1 | UniProt: Q8WWV3 | TargetFullName: Reticulon-4-interacting protein 1; mitochondrial | Organisim: human | Apparent_Kd_M: 5.45E-12
Real
Aptamer SeqId: 18181-2 | Target: TSSC4 | UniProt: Q9Y5U2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18181-2 | Target: TSSC4 | UniProt: Q9Y5U2 | TargetFullName: Protein TSSC4 | Organisim: human | Apparent_Kd_M: 8.3E-12
Real
Aptamer SeqId: 18182-24 | Target: PCKGC | UniProt: P35558
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18182-24 | Target: PCKGC | UniProt: P35558 | TargetFullName: Phosphoenolpyruvate carboxykinase; cytosolic GTP | Organisim: human | Apparent_Kd_M: 1.59E-10
Real
Aptamer SeqId: 18183-3 | Target: ARH | UniProt: Q5SW96
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18183-3 | Target: ARH | UniProt: Q5SW96 | TargetFullName: Low density lipoprotein receptor adapter protein 1 | Organisim: human | Apparent_Kd_M: 4.44E-12
Real
Aptamer SeqId: 18184-28 | Target: GUAA | UniProt: P49915
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18184-28 | Target: GUAA | UniProt: P49915 | TargetFullName: GMP synthase glutamine-hydrolyzing | Organisim: human | Apparent_Kd_M: 1.35E-11
Real
Aptamer SeqId: 18185-118 | Target: ALDOB | UniProt: P05062
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18185-118 | Target: ALDOB | UniProt: P05062 | TargetFullName: Fructose-bisphosphate aldolase B | Organisim: human | Apparent_Kd_M: 2.35E-11
Real
Aptamer SeqId: 18186-15 | Target: SYTC | UniProt: P26639
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18186-15 | Target: SYTC | UniProt: P26639 | TargetFullName: Threonine--tRNA ligase; cytoplasmic | Organisim: human | Apparent_Kd_M: 2.42E-11
Real
Aptamer SeqId: 18187-16 | Target: ACY2 | UniProt: P45381
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18187-16 | Target: ACY2 | UniProt: P45381 | TargetFullName: Aspartoacylase | Organisim: human | Apparent_Kd_M: 2.18E-10
Real
Aptamer SeqId: 18188-12 | Target: GATM | UniProt: P50440
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18188-12 | Target: GATM | UniProt: P50440 | TargetFullName: Glycine amidinotransferase; mitochondrial | Organisim: human | Apparent_Kd_M: 1.79E-11
Real
Aptamer SeqId: 18189-12 | Target: VPS25 | UniProt: Q9BRG1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18189-12 | Target: VPS25 | UniProt: Q9BRG1 | TargetFullName: Vacuolar protein-sorting-associated protein 25 | Organisim: human | Apparent_Kd_M: 7.12E-12
Real
Aptamer SeqId: 18190-15 | Target: ICBR | UniProt: P57730
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18190-15 | Target: ICBR | UniProt: P57730 | TargetFullName: Caspase recruitment domain-containing protein 18 | Organisim: human | Apparent_Kd_M: 7.53E-11
Real
Aptamer SeqId: 18191-23 | Target: RANG | UniProt: P43487
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18191-23 | Target: RANG | UniProt: P43487 | TargetFullName: Ran-specific GTPase-activating protein | Organisim: human | Apparent_Kd_M: 1.76E-11
Real
Aptamer SeqId: 18192-69 | Target: MAGE-5 | UniProt: P43359
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18192-69 | Target: MAGE-5 | UniProt: P43359 | TargetFullName: Melanoma-associated antigen 5 | Organisim: human | Apparent_Kd_M: 5.12E-11
Real
Aptamer SeqId: 18193-165 | Target: MO4L1 | UniProt: Q9UBU8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18193-165 | Target: MO4L1 | UniProt: Q9UBU8 | TargetFullName: Mortality factor 4-like protein 1 | Organisim: human | Apparent_Kd_M: 6.37E-12
Real
Aptamer SeqId: 18194-18 | Target: FABP9 | UniProt: Q0Z7S8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18194-18 | Target: FABP9 | UniProt: Q0Z7S8 | TargetFullName: Fatty acid-binding protein 9 | Organisim: human | Apparent_Kd_M: 3.8E-12
Real
Aptamer SeqId: 18195-3 | Target: ORAV1 | UniProt: Q8WV07
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18195-3 | Target: ORAV1 | UniProt: Q8WV07 | TargetFullName: Oral cancer-overexpressed protein 1 | Organisim: human | Apparent_Kd_M: 1.24E-10
Real
Aptamer SeqId: 18197-97 | Target: KCRS | UniProt: P17540
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18197-97 | Target: KCRS | UniProt: P17540 | TargetFullName: Creatine kinase S-type; mitochondrial | Organisim: human | Apparent_Kd_M: 9.21E-11
Real
Aptamer SeqId: 18198-51 | Target: HBAT | UniProt: P09105
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18198-51 | Target: HBAT | UniProt: P09105 | TargetFullName: Hemoglobin subunit theta-1 | Organisim: human | Apparent_Kd_M: 5.66E-11
Real
Aptamer SeqId: 18202-22 | Target: CD37 | UniProt: P11049
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18202-22 | Target: CD37 | UniProt: P11049 | TargetFullName: Leukocyte antigen CD37 | Organisim: human | Apparent_Kd_M: 7.78E-11
Real
Aptamer SeqId: 18204-1 | Target: TCEA1 | UniProt: P23193
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18204-1 | Target: TCEA1 | UniProt: P23193 | TargetFullName: Transcription elongation factor A protein 1 | Organisim: human | Apparent_Kd_M: 3.14E-12
Real
Aptamer SeqId: 18205-123 | Target: MAGE-6 | UniProt: P43360
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18205-123 | Target: MAGE-6 | UniProt: P43360 | TargetFullName: Melanoma-associated antigen 6 | Organisim: human | Apparent_Kd_M: 7.07E-11
Real
Aptamer SeqId: 18206-18 | Target: ADH6 | UniProt: P28332
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18206-18 | Target: ADH6 | UniProt: P28332 | TargetFullName: Alcohol dehydrogenase 6 | Organisim: human | Apparent_Kd_M: 4.14E-12
Real
Aptamer SeqId: 18208-3 | Target: CCNB2 | UniProt: O95067
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18208-3 | Target: CCNB2 | UniProt: O95067 | TargetFullName: G2/mitotic-specific cyclin-B2 | Organisim: human | Apparent_Kd_M: 1.91E-10
Real
Aptamer SeqId: 18210-12 | Target: SPIN1 | UniProt: Q9Y657
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18210-12 | Target: SPIN1 | UniProt: Q9Y657 | TargetFullName: Spindlin-1 | Organisim: human | Apparent_Kd_M: 3.56E-11
Real
Aptamer SeqId: 18213-30 | Target: UBE2F | UniProt: Q969M7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18213-30 | Target: UBE2F | UniProt: Q969M7 | TargetFullName: NEDD8-conjugating enzyme UBE2F | Organisim: human | Apparent_Kd_M: 8.03E-11
Real
Aptamer SeqId: 18214-2 | Target: GSH0 | UniProt: P48507
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18214-2 | Target: GSH0 | UniProt: P48507 | TargetFullName: Glutamate--cysteine ligase regulatory subunit | Organisim: human | Apparent_Kd_M: 9.78E-11
Real
Aptamer SeqId: 18215-5 | Target: THG1 | UniProt: Q9NWX6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18215-5 | Target: THG1 | UniProt: Q9NWX6 | TargetFullName: Probable tRNA(His) guanylyltransferase | Organisim: human | Apparent_Kd_M: 1.51E-11
Real
Aptamer SeqId: 18216-22 | Target: IL-11 RA | UniProt: Q14626
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18216-22 | Target: IL-11 RA | UniProt: Q14626 | TargetFullName: Interleukin-11 receptor subunit alpha | Organisim: human | Apparent_Kd_M: 4.99E-12
Real
Aptamer SeqId: 18218-48 | Target: CB032 | UniProt: Q96F85
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18218-48 | Target: CB032 | UniProt: Q96F85 | TargetFullName: CB1 cannabinoid receptor-interacting protein 1 | Organisim: human | Apparent_Kd_M: 7.11E-12
Real
Aptamer SeqId: 18220-141 | Target: SRA1 | UniProt: Q9HD15
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18220-141 | Target: SRA1 | UniProt: Q9HD15 | TargetFullName: Steroid receptor RNA activator 1 | Organisim: human | Apparent_Kd_M: 1.18E-11
Real
Aptamer SeqId: 18222-34 | Target: SHLB2 | UniProt: Q9NR46
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18222-34 | Target: SHLB2 | UniProt: Q9NR46 | TargetFullName: Endophilin-B2 | Organisim: human | Apparent_Kd_M: 1.26E-11
Real
Aptamer SeqId: 18225-13 | Target: HEBP1 | UniProt: Q9NRV9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18225-13 | Target: HEBP1 | UniProt: Q9NRV9 | TargetFullName: Heme-binding protein 1 | Organisim: human | Apparent_Kd_M: 5.93E-12
Real
Aptamer SeqId: 18226-148 | Target: COX5A | UniProt: P20674
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18226-148 | Target: COX5A | UniProt: P20674 | TargetFullName: Cytochrome c oxidase subunit 5A; mitochondrial | Organisim: human | Apparent_Kd_M: 5.36E-12
Real
Aptamer SeqId: 18227-3 | Target: CDKA2 | UniProt: O75956
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18227-3 | Target: CDKA2 | UniProt: O75956 | TargetFullName: Cyclin-dependent kinase 2-associated protein 2 | Organisim: human | Apparent_Kd_M: 5.7E-12
Real
Aptamer SeqId: 18228-30 | Target: NOP16 | UniProt: Q9Y3C1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18228-30 | Target: NOP16 | UniProt: Q9Y3C1 | TargetFullName: Nucleolar protein 16 | Organisim: human | Apparent_Kd_M: 6.24E-11
Real
Aptamer SeqId: 18231-147 | Target: PRND | UniProt: Q9UKY0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18231-147 | Target: PRND | UniProt: Q9UKY0 | TargetFullName: Prion-like protein doppel | Organisim: human | Apparent_Kd_M: 1.41E-11
Real
Aptamer SeqId: 18232-42 | Target: PI42B | UniProt: P78356
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18232-42 | Target: PI42B | UniProt: P78356 | TargetFullName: Phosphatidylinositol 5-phosphate 4-kinase type-2 beta | Organisim: human | Apparent_Kd_M: 2.0E-11
Real
Aptamer SeqId: 18235-16 | Target: PGP | UniProt: A6NDG6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18235-16 | Target: PGP | UniProt: A6NDG6 | TargetFullName: Glycerol-3-phosphate phosphatase | Organisim: human | Apparent_Kd_M: 6.01E-11
Real
Aptamer SeqId: 18236-3 | Target: LEGL | UniProt: Q3ZCW2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18236-3 | Target: LEGL | UniProt: Q3ZCW2 | TargetFullName: Galectin-related protein | Organisim: human | Apparent_Kd_M: 1.62E-11
Real
Aptamer SeqId: 18237-29 | Target: NRIP3 | UniProt: Q9NQ35
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18237-29 | Target: NRIP3 | UniProt: Q9NQ35 | TargetFullName: Nuclear receptor-interacting protein 3 | Organisim: human | Apparent_Kd_M: 1.12E-11
Real
Aptamer SeqId: 18240-6 | Target: OMP | UniProt: P47874
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18240-6 | Target: OMP | UniProt: P47874 | TargetFullName: Olfactory marker protein | Organisim: human | Apparent_Kd_M: 6.52E-12
Real
Aptamer SeqId: 18241-18 | Target: HEM6 | UniProt: P36551
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18241-18 | Target: HEM6 | UniProt: P36551 | TargetFullName: Oxygen-dependent coproporphyrinogen-III oxidase; mitochondrial | Organisim: human | Apparent_Kd_M: 2.58E-11
Real
Aptamer SeqId: 18242-8 | Target: Sperm protein 17 | UniProt: Q15506
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18242-8 | Target: Sperm protein 17 | UniProt: Q15506 | TargetFullName: Sperm surface protein Sp17 | Organisim: human | Apparent_Kd_M: 1.2E-10
Real
Aptamer SeqId: 18243-9 | Target: Cytidylate kinase | UniProt: P30085
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18243-9 | Target: Cytidylate kinase | UniProt: P30085 | TargetFullName: UMP-CMP kinase | Organisim: human | Apparent_Kd_M: 2.28E-11
Real
Aptamer SeqId: 18244-1 | Target: ANXA7 | UniProt: P20073
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18244-1 | Target: ANXA7 | UniProt: P20073 | TargetFullName: Annexin A7 | Organisim: human | Apparent_Kd_M: 3.4E-11
Real
Aptamer SeqId: 18255-6 | Target: NB5R1 | UniProt: Q9UHQ9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18255-6 | Target: NB5R1 | UniProt: Q9UHQ9 | TargetFullName: NADH-cytochrome b5 reductase 1 | Organisim: human | Apparent_Kd_M: 2.69E-12
Real
Aptamer SeqId: 18257-64 | Target: SRP19 | UniProt: P09132
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18257-64 | Target: SRP19 | UniProt: P09132 | TargetFullName: Signal recognition particle 19 kDa protein | Organisim: human | Apparent_Kd_M: 1.1E-11
Real
Aptamer SeqId: 18259-15 | Target: MEOX2 | UniProt: P50222
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18259-15 | Target: MEOX2 | UniProt: P50222 | TargetFullName: Homeobox protein MOX-2 | Organisim: human | Apparent_Kd_M: 2.57E-12
Real
Aptamer SeqId: 18261-34 | Target: NATD1 | UniProt: Q8N6N6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18261-34 | Target: NATD1 | UniProt: Q8N6N6 | TargetFullName: Protein NATD1 | Organisim: human | Apparent_Kd_M: 2.39E-10
Real
Aptamer SeqId: 18264-12 | Target: CCD25 | UniProt: Q86WR0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18264-12 | Target: CCD25 | UniProt: Q86WR0 | TargetFullName: Coiled-coil domain-containing protein 25 | Organisim: human | Apparent_Kd_M: 2.3E-11
Real
Aptamer SeqId: 18265-18 | Target: ZNF34 | UniProt: Q8IZ26
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18265-18 | Target: ZNF34 | UniProt: Q8IZ26 | TargetFullName: Zinc finger protein 34 | Organisim: human | Apparent_Kd_M: 1.51E-11
Real
Aptamer SeqId: 18267-74 | Target: CAR17 | UniProt: Q5XLA6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18267-74 | Target: CAR17 | UniProt: Q5XLA6 | TargetFullName: Caspase recruitment domain-containing protein 17 | Organisim: human | Apparent_Kd_M: 1.13E-10
Real
Aptamer SeqId: 18268-5 | Target: GAG2A | UniProt: Q6NT46
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18268-5 | Target: GAG2A | UniProt: Q6NT46 | TargetFullName: G antigen 2A | Organisim: human | Apparent_Kd_M: 3.73E-12
Real
Aptamer SeqId: 18270-10 | Target: TAF10 | UniProt: Q12962
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18270-10 | Target: TAF10 | UniProt: Q12962 | TargetFullName: Transcription initiation factor TFIID subunit 10 | Organisim: human | Apparent_Kd_M: 8.14E-11
Real
Aptamer SeqId: 18271-43 | Target: OXSM | UniProt: Q9NWU1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18271-43 | Target: OXSM | UniProt: Q9NWU1 | TargetFullName: 3-oxoacyl-acyl-carrier-protein synthase; mitochondrial | Organisim: human | Apparent_Kd_M: 2.13E-11
Real
Aptamer SeqId: 18273-14 | Target: GGE2D | UniProt: Q9UEU5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18273-14 | Target: GGE2D | UniProt: Q9UEU5 | TargetFullName: G antigen 2D | Organisim: human | Apparent_Kd_M: 2.52E-12
Real
Aptamer SeqId: 18274-2 | Target: SERF2 | UniProt: P84101
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18274-2 | Target: SERF2 | UniProt: P84101 | TargetFullName: Small EDRK-rich factor 2 | Organisim: human | Apparent_Kd_M: 2.59E-11
Real
Aptamer SeqId: 18275-5 | Target: CRIP1 | UniProt: P50238
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18275-5 | Target: CRIP1 | UniProt: P50238 | TargetFullName: Cysteine-rich protein 1 | Organisim: human | Apparent_Kd_M: 4.26E-11
Real
Aptamer SeqId: 18276-34 | Target: TCL1B | UniProt: O95988
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18276-34 | Target: TCL1B | UniProt: O95988 | TargetFullName: T-cell leukemia/lymphoma protein 1B | Organisim: human | Apparent_Kd_M: 7.35E-12
Real
Aptamer SeqId: 18277-28 | Target: TRIA1 | UniProt: O43715
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18277-28 | Target: TRIA1 | UniProt: O43715 | TargetFullName: TP53-regulated inhibitor of apoptosis 1 | Organisim: human | Apparent_Kd_M: 2.4E-11
Real
Aptamer SeqId: 18280-29 | Target: DTD2 | UniProt: Q96FN9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18280-29 | Target: DTD2 | UniProt: Q96FN9 | TargetFullName: Putative D-tyrosyl-tRNA(Tyr) deacylase 2 | Organisim: human | Apparent_Kd_M: 3.1E-12
Real
Aptamer SeqId: 18282-1 | Target: GBG11 | UniProt: P61952
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18282-1 | Target: GBG11 | UniProt: P61952 | TargetFullName: Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-11 | Organisim: human | Apparent_Kd_M: 3.19E-11
Real
Aptamer SeqId: 18284-77 | Target: WWC1 | UniProt: Q8IX03
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18284-77 | Target: WWC1 | UniProt: Q8IX03 | TargetFullName: Protein KIBRA | Organisim: human | Apparent_Kd_M: 1.09E-12
Real
Aptamer SeqId: 18285-6 | Target: SVIP | UniProt: Q8NHG7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18285-6 | Target: SVIP | UniProt: Q8NHG7 | TargetFullName: Small VCP/p97-interacting protein | Organisim: human | Apparent_Kd_M: 8.92E-11
Real
Aptamer SeqId: 18286-3 | Target: ZWINT | UniProt: O95229
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18286-3 | Target: ZWINT | UniProt: O95229 | TargetFullName: ZW10 interactor | Organisim: human | Apparent_Kd_M: 6.42E-12
Real
Aptamer SeqId: 18289-16 | Target: MIP-5 | UniProt: Q16663
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18289-16 | Target: MIP-5 | UniProt: Q16663 | TargetFullName: C-C motif chemokine 15 | Organisim: human | Apparent_Kd_M: 5.06E-12
Real
Aptamer SeqId: 18290-6 | Target: Annexin A8 | UniProt: P13928
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18290-6 | Target: Annexin A8 | UniProt: P13928 | TargetFullName: Annexin A8 | Organisim: human | Apparent_Kd_M: 1.94E-10
Real
Aptamer SeqId: 18291-8 | Target: p21 | UniProt: P38936
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18291-8 | Target: p21 | UniProt: P38936 | TargetFullName: Cyclin-dependent kinase inhibitor 1 | Organisim: human | Apparent_Kd_M: 1.55E-11
Real
Aptamer SeqId: 18294-26 | Target: SOX2 | UniProt: P48431
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18294-26 | Target: SOX2 | UniProt: P48431 | TargetFullName: Transcription factor SOX-2 | Organisim: human | Apparent_Kd_M: 9.63E-12
Real
Aptamer SeqId: 18295-102 | Target: GRHPR | UniProt: Q9UBQ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18295-102 | Target: GRHPR | UniProt: Q9UBQ7 | TargetFullName: Glyoxylate reductase/hydroxypyruvate reductase | Organisim: human | Apparent_Kd_M: 2.94E-12
Real
Aptamer SeqId: 18297-8 | Target: RASM | UniProt: O14807
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18297-8 | Target: RASM | UniProt: O14807 | TargetFullName: Ras-related protein M-Ras | Organisim: human | Apparent_Kd_M: 1.18E-11
Real
Aptamer SeqId: 18299-13 | Target: CPNS1 | UniProt: P04632
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18299-13 | Target: CPNS1 | UniProt: P04632 | TargetFullName: Calpain small subunit 1 | Organisim: human | Apparent_Kd_M: 3.18E-11
Real
Aptamer SeqId: 18300-39 | Target: PURB | UniProt: Q96QR8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18300-39 | Target: PURB | UniProt: Q96QR8 | TargetFullName: Transcriptional activator protein Pur-beta | Organisim: human | Apparent_Kd_M: 1.27E-11
Real
Aptamer SeqId: 18301-10 | Target: NAIF1 | UniProt: Q69YI7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18301-10 | Target: NAIF1 | UniProt: Q69YI7 | TargetFullName: Nuclear apoptosis-inducing factor 1 | Organisim: human | Apparent_Kd_M: 2.35E-11
Real
Aptamer SeqId: 18302-204 | Target: ZWILC | UniProt: Q9H900
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18302-204 | Target: ZWILC | UniProt: Q9H900 | TargetFullName: Protein zwilch homolog | Organisim: human | Apparent_Kd_M: 6.63E-12
Real
Aptamer SeqId: 18303-39 | Target: NEUG | UniProt: Q92686
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18303-39 | Target: NEUG | UniProt: Q92686 | TargetFullName: Neurogranin | Organisim: human | Apparent_Kd_M: 2.0E-12
Real
Aptamer SeqId: 18304-19 | Target: BCCIP | UniProt: Q9P287
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18304-19 | Target: BCCIP | UniProt: Q9P287 | TargetFullName: BRCA2 and CDKN1A-interacting protein | Organisim: human | Apparent_Kd_M: 6.56E-11
Real
Aptamer SeqId: 18306-1 | Target: PALM | UniProt: O75781
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18306-1 | Target: PALM | UniProt: O75781 | TargetFullName: Paralemmin-1 | Organisim: human | Apparent_Kd_M: 3.02E-10
Real
Aptamer SeqId: 18307-71 | Target: PPase 2 | UniProt: Q9H2U2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18307-71 | Target: PPase 2 | UniProt: Q9H2U2 | TargetFullName: Inorganic pyrophosphatase 2; mitochondrial | Organisim: human | Apparent_Kd_M: 3.98E-11
Real
Aptamer SeqId: 18308-30 | Target: STXB6 | UniProt: Q8NFX7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18308-30 | Target: STXB6 | UniProt: Q8NFX7 | TargetFullName: Syntaxin-binding protein 6 | Organisim: human | Apparent_Kd_M: 8.57E-12
Real
Aptamer SeqId: 18309-18 | Target: CISY | UniProt: O75390
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18309-18 | Target: CISY | UniProt: O75390 | TargetFullName: Citrate synthase; mitochondrial | Organisim: human | Apparent_Kd_M: 3.8E-12
Real
Aptamer SeqId: 18310-26 | Target: SELW | UniProt: P63302
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18310-26 | Target: SELW | UniProt: P63302 | TargetFullName: Selenoprotein W | Organisim: human | Apparent_Kd_M: 5.67E-12
Real
Aptamer SeqId: 18311-44 | Target: DCTN6 | UniProt: O00399
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18311-44 | Target: DCTN6 | UniProt: O00399 | TargetFullName: Dynactin subunit 6 | Organisim: human | Apparent_Kd_M: 6.43E-11
Real
Aptamer SeqId: 18312-68 | Target: NDRG3 | UniProt: Q9UGV2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18312-68 | Target: NDRG3 | UniProt: Q9UGV2 | TargetFullName: Protein NDRG3 | Organisim: human | Apparent_Kd_M: 7.3E-11
Real
Aptamer SeqId: 18313-4 | Target: Asparaginase-like protein 1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18313-4 | Target: Asparaginase-like protein 1 | UniProt: Q7L266 | TargetFullName: Isoaspartyl peptidase/L-asparaginase | Organisim: human | Apparent_Kd_M: 3.65E-12
Real
Aptamer SeqId: 18315-38 | Target: RTP4 | UniProt: Q96DX8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18315-38 | Target: RTP4 | UniProt: Q96DX8 | TargetFullName: Receptor-transporting protein 4 | Organisim: human | Apparent_Kd_M: 7.56E-12
Real
Aptamer SeqId: 18316-75 | Target: SEPT3 | UniProt: Q9UH03
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18316-75 | Target: SEPT3 | UniProt: Q9UH03 | TargetFullName: Neuronal-specific septin-3 | Organisim: human | Apparent_Kd_M: 1.68E-10
Real
Aptamer SeqId: 18317-111 | Target: ZFAN5 | UniProt: O76080
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18317-111 | Target: ZFAN5 | UniProt: O76080 | TargetFullName: AN1-type zinc finger protein 5 | Organisim: human | Apparent_Kd_M: 4.56E-12
Real
Aptamer SeqId: 18318-98 | Target: SH3G3 | UniProt: Q99963
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18318-98 | Target: SH3G3 | UniProt: Q99963 | TargetFullName: Endophilin-A3 | Organisim: human | Apparent_Kd_M: 4.88E-12
Real
Aptamer SeqId: 18319-7 | Target: ODPX | UniProt: O00330
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18319-7 | Target: ODPX | UniProt: O00330 | TargetFullName: Pyruvate dehydrogenase protein X component; mitochondrial | Organisim: human | Apparent_Kd_M: 1.04E-12
Real
Aptamer SeqId: 18321-38 | Target: MTDC | UniProt: P13995
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18321-38 | Target: MTDC | UniProt: P13995 | TargetFullName: Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase; mitochondrial | Organisim: human | Apparent_Kd_M: 2.41E-12
Real
Aptamer SeqId: 18322-15 | Target: JMJD6 | UniProt: Q6NYC1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18322-15 | Target: JMJD6 | UniProt: Q6NYC1 | TargetFullName: Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6 | Organisim: human | Apparent_Kd_M: 2.48E-11
Real
Aptamer SeqId: 18323-39 | Target: DRP-1 | UniProt: Q14194
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18323-39 | Target: DRP-1 | UniProt: Q14194 | TargetFullName: Dihydropyrimidinase-related protein 1 | Organisim: human | Apparent_Kd_M: 8.52E-11
Real
Aptamer SeqId: 18324-61 | Target: SUOX | UniProt: P51687
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18324-61 | Target: SUOX | UniProt: P51687 | TargetFullName: Sulfite oxidase; mitochondrial | Organisim: human | Apparent_Kd_M: 3.72E-11
Real
Aptamer SeqId: 18326-50 | Target: MAGA8 | UniProt: P43361
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18326-50 | Target: MAGA8 | UniProt: P43361 | TargetFullName: Melanoma-associated antigen 8 | Organisim: human | Apparent_Kd_M: 8.56E-11
Real
Aptamer SeqId: 18327-6 | Target: SNX5 | UniProt: Q9Y5X3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18327-6 | Target: SNX5 | UniProt: Q9Y5X3 | TargetFullName: Sorting nexin-5 | Organisim: human | Apparent_Kd_M: 3.88E-11
Real
Aptamer SeqId: 18328-36 | Target: P5CR2 | UniProt: Q96C36
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18328-36 | Target: P5CR2 | UniProt: Q96C36 | TargetFullName: Pyrroline-5-carboxylate reductase 2 | Organisim: human | Apparent_Kd_M: 2.29E-10
Real
Aptamer SeqId: 18329-4 | Target: PRPS2 | UniProt: P11908
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18329-4 | Target: PRPS2 | UniProt: P11908 | TargetFullName: Ribose-phosphate pyrophosphokinase 2 | Organisim: human | Apparent_Kd_M: 3.64E-11
Real
Aptamer SeqId: 18330-7 | Target: PGM2 | UniProt: Q96G03
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18330-7 | Target: PGM2 | UniProt: Q96G03 | TargetFullName: Phosphoglucomutase-2 | Organisim: human | Apparent_Kd_M: 1.87E-11
Real
Aptamer SeqId: 18332-17 | Target: CPLX1 | UniProt: O14810
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18332-17 | Target: CPLX1 | UniProt: O14810 | TargetFullName: Complexin-1 | Organisim: human | Apparent_Kd_M: 7.78E-12
Real
Aptamer SeqId: 18337-4 | Target: GMDS | UniProt: O60547
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18337-4 | Target: GMDS | UniProt: O60547 | TargetFullName: GDP-mannose 4;6 dehydratase | Organisim: human | Apparent_Kd_M: 5.31E-11
Real
Aptamer SeqId: 18338-26 | Target: IDH | UniProt: O75874
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18338-26 | Target: IDH | UniProt: O75874 | TargetFullName: Isocitrate dehydrogenase NADP cytoplasmic | Organisim: human | Apparent_Kd_M: 7.36E-11
Real
Aptamer SeqId: 18339-207 | Target: PSB3 | UniProt: P49720
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18339-207 | Target: PSB3 | UniProt: P49720 | TargetFullName: Proteasome subunit beta type-3 | Organisim: human | Apparent_Kd_M: 2.24E-10
Real
Aptamer SeqId: 18340-2 | Target: Proteasome beta chain | UniProt: P28070
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18340-2 | Target: Proteasome beta chain | UniProt: P28070 | TargetFullName: Proteasome subunit beta type-4 | Organisim: human | Apparent_Kd_M: 1.47E-12
Real
Aptamer SeqId: 18342-2 | Target: SERC | UniProt: Q9Y617
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18342-2 | Target: SERC | UniProt: Q9Y617 | TargetFullName: Phosphoserine aminotransferase | Organisim: human | Apparent_Kd_M: 1.66E-11
Real
Aptamer SeqId: 18343-10 | Target: DECR2 | UniProt: Q9NUI1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18343-10 | Target: DECR2 | UniProt: Q9NUI1 | TargetFullName: Peroxisomal 2;4-dienoyl-CoA reductase | Organisim: human | Apparent_Kd_M: 5.58E-11
Real
Aptamer SeqId: 18347-15 | Target: Laminin-2 | UniProt: P24043|P07942|P11047
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18347-15 | Target: Laminin-2 | UniProt: P24043|P07942|P11047 | TargetFullName: Laminin-2 | Organisim: human | Apparent_Kd_M: 4.68E-11
Real
Aptamer SeqId: 18348-89 | Target: HNRPD | UniProt: Q14103
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18348-89 | Target: HNRPD | UniProt: Q14103 | TargetFullName: Heterogeneous nuclear ribonucleoprotein D0 | Organisim: human | Apparent_Kd_M: 2.25E-12
Real
Aptamer SeqId: 18373-13 | Target: Radixin | UniProt: P35241
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18373-13 | Target: Radixin | UniProt: P35241 | TargetFullName: Radixin | Organisim: human | Apparent_Kd_M: 7.82E-13
Real
Aptamer SeqId: 18375-28 | Target: IL-1F5 | UniProt: Q9UBH0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18375-28 | Target: IL-1F5 | UniProt: Q9UBH0 | TargetFullName: Interleukin-36 receptor antagonist protein | Organisim: human | Apparent_Kd_M: 5.65E-12
Real
Aptamer SeqId: 18376-19 | Target: Myosin light chain 1 | UniProt: P08590
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18376-19 | Target: Myosin light chain 1 | UniProt: P08590 | TargetFullName: Myosin light chain 3 | Organisim: human | Apparent_Kd_M: 2.78E-11
Real
Aptamer SeqId: 18380-78 | Target: Albumin | UniProt: P02768
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18380-78 | Target: Albumin | UniProt: P02768 | TargetFullName: Serum albumin | Organisim: human | Apparent_Kd_M: 2.19E-10
Real
Aptamer SeqId: 18381-16 | Target: ALDH-E2 | UniProt: P05091
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18381-16 | Target: ALDH-E2 | UniProt: P05091 | TargetFullName: Aldehyde dehydrogenase; mitochondrial | Organisim: human | Apparent_Kd_M: 6.97E-12
Real
Aptamer SeqId: 18382-109 | Target: Catechol O-methyltransferase
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18382-109 | Target: Catechol O-methyltransferase | UniProt: P21964 | TargetFullName: Catechol O-methyltransferase | Organisim: human | Apparent_Kd_M: 2.7E-11
Real
Aptamer SeqId: 18383-9 | Target: FKBP3 | UniProt: Q00688
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18383-9 | Target: FKBP3 | UniProt: Q00688 | TargetFullName: Peptidyl-prolyl cis-trans isomerase FKBP3 | Organisim: human | Apparent_Kd_M: 9.05E-13
Real
Aptamer SeqId: 18385-4 | Target: PSD10 | UniProt: O75832
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18385-4 | Target: PSD10 | UniProt: O75832 | TargetFullName: 26S proteasome non-ATPase regulatory subunit 10 | Organisim: human | Apparent_Kd_M: 1.79E-11
Real
Aptamer SeqId: 18386-36 | Target: GLRX1 | UniProt: P35754
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18386-36 | Target: GLRX1 | UniProt: P35754 | TargetFullName: Glutaredoxin-1 | Organisim: human | Apparent_Kd_M: 2.7E-11
Real
Aptamer SeqId: 18387-7 | Target: suppression of tumorigenicity 13
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18387-7 | Target: suppression of tumorigenicity 13 | UniProt: P50502 | TargetFullName: Hsc70-interacting protein | Organisim: human | Apparent_Kd_M: 5.66E-12
Real
Aptamer SeqId: 18389-11 | Target: IFNA1 | UniProt: P01562
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18389-11 | Target: IFNA1 | UniProt: P01562 | TargetFullName: Interferon alpha-1/13 | Organisim: human | Apparent_Kd_M: 6.33E-12
Real
Aptamer SeqId: 18392-19 | Target: MAT2B | UniProt: Q9NZL9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18392-19 | Target: MAT2B | UniProt: Q9NZL9 | TargetFullName: Methionine adenosyltransferase 2 subunit beta | Organisim: human | Apparent_Kd_M: 2.6E-12
Real
Aptamer SeqId: 18395-5 | Target: ADPRH | UniProt: P54922
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18395-5 | Target: ADPRH | UniProt: P54922 | TargetFullName: Protein ADP-ribosylarginine hydrolase | Organisim: human | Apparent_Kd_M: 2.6E-10
Real
Aptamer SeqId: 18396-10 | Target: AES | UniProt: Q08117
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18396-10 | Target: AES | UniProt: Q08117 | TargetFullName: Amino-terminal enhancer of split | Organisim: human | Apparent_Kd_M: 9.8E-12
Real
Aptamer SeqId: 18397-5 | Target: AK1C4 | UniProt: P17516
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18397-5 | Target: AK1C4 | UniProt: P17516 | TargetFullName: Aldo-keto reductase family 1 member C4 | Organisim: human | Apparent_Kd_M: 5.28E-12
Real
Aptamer SeqId: 18398-1 | Target: AK1D1 | UniProt: P51857
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18398-1 | Target: AK1D1 | UniProt: P51857 | TargetFullName: 3-oxo-5-beta-steroid 4-dehydrogenase | Organisim: human | Apparent_Kd_M: 1.94E-12
Real
Aptamer SeqId: 18399-1 | Target: AKA7A | UniProt: O43687
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18399-1 | Target: AKA7A | UniProt: O43687 | TargetFullName: A-kinase anchor protein 7 isoforms alpha and beta | Organisim: human | Apparent_Kd_M: 1.81E-10
Real
Aptamer SeqId: 18400-52 | Target: ALKB2 | UniProt: Q6NS38
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18400-52 | Target: ALKB2 | UniProt: Q6NS38 | TargetFullName: DNA oxidative demethylase ALKBH2 | Organisim: human | Apparent_Kd_M: 1.71E-11
Real
Aptamer SeqId: 18401-18 | Target: ALKB3 | UniProt: Q96Q83
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18401-18 | Target: ALKB3 | UniProt: Q96Q83 | TargetFullName: Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3 | Organisim: human | Apparent_Kd_M: 1.82E-11
Real
Aptamer SeqId: 18402-1 | Target: AMERL | UniProt: Q6DCA0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18402-1 | Target: AMERL | UniProt: Q6DCA0 | TargetFullName: AMMECR1-like protein | Organisim: human | Apparent_Kd_M: 8.56E-12
Real
Aptamer SeqId: 18403-25 | Target: AMPD2 | UniProt: Q01433
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18403-25 | Target: AMPD2 | UniProt: Q01433 | TargetFullName: AMP deaminase 2 | Organisim: human | Apparent_Kd_M: 1.15E-10
Real
Aptamer SeqId: 18404-22 | Target: ANR54 | UniProt: Q6NXT1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18404-22 | Target: ANR54 | UniProt: Q6NXT1 | TargetFullName: Ankyrin repeat domain-containing protein 54 | Organisim: human | Apparent_Kd_M: 2.59E-10
Real
Aptamer SeqId: 18405-117 | Target: AP1S2 | UniProt: P56377
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18405-117 | Target: AP1S2 | UniProt: P56377 | TargetFullName: AP-1 complex subunit sigma-2 | Organisim: human | Apparent_Kd_M: 4.02E-11
Real
Aptamer SeqId: 18407-36 | Target: AR2BP | UniProt: Q9Y2Y0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18407-36 | Target: AR2BP | UniProt: Q9Y2Y0 | TargetFullName: ADP-ribosylation factor-like protein 2-binding protein | Organisim: human | Apparent_Kd_M: 2.53E-10
Real
Aptamer SeqId: 18408-26 | Target: ARF4 | UniProt: P18085
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18408-26 | Target: ARF4 | UniProt: P18085 | TargetFullName: ADP-ribosylation factor 4 | Organisim: human | Apparent_Kd_M: 2.79E-11
Real
Aptamer SeqId: 18409-61 | Target: ARF5 | UniProt: P84085
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18409-61 | Target: ARF5 | UniProt: P84085 | TargetFullName: ADP-ribosylation factor 5 | Organisim: human | Apparent_Kd_M: 4.83E-11
Real
Aptamer SeqId: 18410-26 | Target: ARL14 | UniProt: Q8N4G2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18410-26 | Target: ARL14 | UniProt: Q8N4G2 | TargetFullName: ADP-ribosylation factor-like protein 14 | Organisim: human | Apparent_Kd_M: 3.76E-11
Real
Aptamer SeqId: 18411-83 | Target: ARL15 | UniProt: Q9NXU5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18411-83 | Target: ARL15 | UniProt: Q9NXU5 | TargetFullName: ADP-ribosylation factor-like protein 15 | Organisim: human | Apparent_Kd_M: 8.17E-11
Real
Aptamer SeqId: 18413-24 | Target: ARL4D | UniProt: P49703
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18413-24 | Target: ARL4D | UniProt: P49703 | TargetFullName: ADP-ribosylation factor-like protein 4D | Organisim: human | Apparent_Kd_M: 1.91E-10
Real
Aptamer SeqId: 18414-26 | Target: ARL5A | UniProt: Q9Y689
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18414-26 | Target: ARL5A | UniProt: Q9Y689 | TargetFullName: ADP-ribosylation factor-like protein 5A | Organisim: human | Apparent_Kd_M: 3.62E-11
Real
Aptamer SeqId: 18415-16 | Target: ARL6 | UniProt: Q9H0F7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18415-16 | Target: ARL6 | UniProt: Q9H0F7 | TargetFullName: ADP-ribosylation factor-like protein 6 | Organisim: human | Apparent_Kd_M: 5.96E-11
Real
Aptamer SeqId: 18416-3 | Target: ARL9 | UniProt: Q6T311
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18416-3 | Target: ARL9 | UniProt: Q6T311 | TargetFullName: ADP-ribosylation factor-like protein 9 | Organisim: human | Apparent_Kd_M: 9.72E-11
Real
Aptamer SeqId: 18417-3 | Target: AS3MT | UniProt: Q9HBK9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18417-3 | Target: AS3MT | UniProt: Q9HBK9 | TargetFullName: Arsenite methyltransferase | Organisim: human | Apparent_Kd_M: 1.29E-10
Real
Aptamer SeqId: 18419-20 | Target: p16-ARC | UniProt: O15511
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18419-20 | Target: p16-ARC | UniProt: O15511 | TargetFullName: Actin-related protein 2/3 complex subunit 5 | Organisim: human | Apparent_Kd_M: 3.041764E-11
Real
Aptamer SeqId: 18422-41 | Target: ERG19 | UniProt: P53602
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18422-41 | Target: ERG19 | UniProt: P53602 | TargetFullName: Diphosphomevalonate decarboxylase | Organisim: human | Apparent_Kd_M: 1.140803E-10
Real
Aptamer SeqId: 18429-10 | Target: Cadherin E | UniProt: P12830
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18429-10 | Target: Cadherin E | UniProt: P12830 | TargetFullName: Cadherin-1 | Organisim: human | Apparent_Kd_M: 6.38005E-10
Real
Aptamer SeqId: 18432-32 | Target: RALB | UniProt: P11234
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18432-32 | Target: RALB | UniProt: P11234 | TargetFullName: Ras-related protein Ral-B | Organisim: human | Apparent_Kd_M: 1.25E-11
Real
Aptamer SeqId: 18434-141 | Target: TBPL1 | UniProt: P62380
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18434-141 | Target: TBPL1 | UniProt: P62380 | TargetFullName: TATA box-binding protein-like protein 1 | Organisim: human | Apparent_Kd_M: 1.395633E-11
Real
Aptamer SeqId: 18435-40 | Target: UBX2B | UniProt: Q14CS0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18435-40 | Target: UBX2B | UniProt: Q14CS0 | TargetFullName: UBX domain-containing protein 2B | Organisim: human | Apparent_Kd_M: 6.390593E-12
Real
Aptamer SeqId: 18449-33 | Target: PPIG | UniProt: Q13427
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18449-33 | Target: PPIG | UniProt: Q13427 | TargetFullName: Peptidyl-prolyl cis-trans isomerase G | Organisim: human | Apparent_Kd_M: 1.62E-10
Real
Aptamer SeqId: 18458-4 | Target: PGES2 | UniProt: Q9H7Z7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18458-4 | Target: PGES2 | UniProt: Q9H7Z7 | TargetFullName: Prostaglandin E synthase 2 | Organisim: human | Apparent_Kd_M: 7.481023E-12
Real
Aptamer SeqId: 18483-36 | Target: MSS4 | UniProt: P47224
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18483-36 | Target: MSS4 | UniProt: P47224 | TargetFullName: Guanine nucleotide exchange factor MSS4 | Organisim: human | Apparent_Kd_M: 4.695049E-11
Real
Aptamer SeqId: 18813-15 | Target: DD19A | UniProt: Q9NUU7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18813-15 | Target: DD19A | UniProt: Q9NUU7 | TargetFullName: ATP-dependent RNA helicase DDX19A | Organisim: human | Apparent_Kd_M: 2.82E-11
Real
Aptamer SeqId: 18814-21 | Target: Activin AC | UniProt: P08476|P55103
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18814-21 | Target: Activin AC | UniProt: P08476|P55103 | TargetFullName: Inhibin beta A chain:Inhibin beta C chain heterodimer | Organisim: human | Apparent_Kd_M: 6.35E-11
Real
Aptamer SeqId: 18817-50 | Target: CBX1 | UniProt: P83916
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18817-50 | Target: CBX1 | UniProt: P83916 | TargetFullName: Chromobox protein homolog 1 | Organisim: human | Apparent_Kd_M: 7.49E-11
Real
Aptamer SeqId: 18819-21 | Target: PPIC | UniProt: P45877
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18819-21 | Target: PPIC | UniProt: P45877 | TargetFullName: Peptidyl-prolyl cis-trans isomerase C | Organisim: human | Apparent_Kd_M: 5.32E-12
Real
Aptamer SeqId: 18821-9 | Target: C4a | UniProt: P0C0L4|P0C0L5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18821-9 | Target: C4a | UniProt: P0C0L4|P0C0L5 | TargetFullName: C4a anaphylatoxin | Organisim: human | Apparent_Kd_M: 7.64E-11
Real
Aptamer SeqId: 18823-52 | Target: H2B3B | UniProt: Q8N257
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18823-52 | Target: H2B3B | UniProt: Q8N257 | TargetFullName: Histone H2B type 3-B | Organisim: human | Apparent_Kd_M: 1.33E-10
Real
Aptamer SeqId: 18824-7 | Target: IF4A2 | UniProt: Q14240
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18824-7 | Target: IF4A2 | UniProt: Q14240 | TargetFullName: Eukaryotic initiation factor 4A-II | Organisim: human | Apparent_Kd_M: 3.78E-11
Real
Aptamer SeqId: 18829-4 | Target: IF4A1 | UniProt: P60842
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18829-4 | Target: IF4A1 | UniProt: P60842 | TargetFullName: Eukaryotic initiation factor 4A-I | Organisim: human | Apparent_Kd_M: 1.05E-11
Real
Aptamer SeqId: 18830-1 | Target: Omentin | UniProt: Q8WWA0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18830-1 | Target: Omentin | UniProt: Q8WWA0 | TargetFullName: Intelectin-1 | Organisim: human | Apparent_Kd_M: 8.1E-11
Real
Aptamer SeqId: 18831-6 | Target: LRIG1 | UniProt: Q96JA1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18831-6 | Target: LRIG1 | UniProt: Q96JA1 | TargetFullName: Leucine-rich repeats and immunoglobulin-like domains protein 1 | Organisim: human | Apparent_Kd_M: 1.13E-11
Real
Aptamer SeqId: 18832-65 | Target: SAA2 | UniProt: P0DJI9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18832-65 | Target: SAA2 | UniProt: P0DJI9 | TargetFullName: Serum amyloid A-2 protein | Organisim: human | Apparent_Kd_M: 1.21E-10
Real
Aptamer SeqId: 18833-76 | Target: PEA15 | UniProt: Q15121
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18833-76 | Target: PEA15 | UniProt: Q15121 | TargetFullName: Astrocytic phosphoprotein PEA-15 | Organisim: human | Apparent_Kd_M: 3.24E-10
Real
Aptamer SeqId: 18837-9 | Target: SGTB | UniProt: Q96EQ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18837-9 | Target: SGTB | UniProt: Q96EQ0 | TargetFullName: Small glutamine-rich tetratricopeptide repeat-containing protein beta | Organisim: human | Apparent_Kd_M: 3.32E-10
Real
Aptamer SeqId: 18839-24 | Target: Thyroglobulin | UniProt: P01266
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18839-24 | Target: Thyroglobulin | UniProt: P01266 | TargetFullName: Thyroglobulin | Organisim: human | Apparent_Kd_M: 3.73E-11
Real
Aptamer SeqId: 18840-205 | Target: SH21B | UniProt: O14796
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18840-205 | Target: SH21B | UniProt: O14796 | TargetFullName: SH2 domain-containing protein 1B | Organisim: human | Apparent_Kd_M: 1.09E-10
Real
Aptamer SeqId: 18841-1 | Target: SPB13 | UniProt: Q9UIV8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18841-1 | Target: SPB13 | UniProt: Q9UIV8 | TargetFullName: Serpin B13 | Organisim: human | Apparent_Kd_M: 8.16E-11
Real
Aptamer SeqId: 18842-24 | Target: UB2D2 | UniProt: P62837
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18842-24 | Target: UB2D2 | UniProt: P62837 | TargetFullName: Ubiquitin-conjugating enzyme E2 D2 | Organisim: human | Apparent_Kd_M: 3.02E-10
Real
Aptamer SeqId: 18859-7 | Target: 4EBP3 | UniProt: O60516
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18859-7 | Target: 4EBP3 | UniProt: O60516 | TargetFullName: Eukaryotic translation initiation factor 4E-binding protein 3 | Organisim: human | Apparent_Kd_M: 1.62E-10
Real
Aptamer SeqId: 18860-2 | Target: CaMKK alpha | UniProt: Q8N5S9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18860-2 | Target: CaMKK alpha | UniProt: Q8N5S9 | TargetFullName: Calcium/calmodulin-dependent protein kinase kinase 1 | Organisim: human | Apparent_Kd_M: 5.58E-11
Real
Aptamer SeqId: 18863-176 | Target: CHST2 | UniProt: Q9Y4C5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18863-176 | Target: CHST2 | UniProt: Q9Y4C5 | TargetFullName: Carbohydrate sulfotransferase 2 | Organisim: human | Apparent_Kd_M: 2.36E-12
Real
Aptamer SeqId: 18864-7 | Target: TRY3 | UniProt: P35030
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18864-7 | Target: TRY3 | UniProt: P35030 | TargetFullName: Trypsin-3 | Organisim: human | Apparent_Kd_M: 2.87E-12
Real
Aptamer SeqId: 18866-8 | Target: CANB2 | UniProt: Q96LZ3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18866-8 | Target: CANB2 | UniProt: Q96LZ3 | TargetFullName: Calcineurin subunit B type 2 | Organisim: human | Apparent_Kd_M: 7.6E-11
Real
Aptamer SeqId: 18868-7 | Target: CBX3 | UniProt: Q13185
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18868-7 | Target: CBX3 | UniProt: Q13185 | TargetFullName: Chromobox protein homolog 3 | Organisim: human | Apparent_Kd_M: 7.81E-11
Real
Aptamer SeqId: 18870-1 | Target: CD3E | UniProt: P07766
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18870-1 | Target: CD3E | UniProt: P07766 | TargetFullName: T-cell surface glycoprotein CD3 epsilon chain | Organisim: human | Apparent_Kd_M: 4.56E-10
Real
Aptamer SeqId: 18871-24 | Target: AIF1L | UniProt: Q9BQI0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18871-24 | Target: AIF1L | UniProt: Q9BQI0 | TargetFullName: Allograft inflammatory factor 1-like | Organisim: human | Apparent_Kd_M: 6.14E-12
Real
Aptamer SeqId: 18873-8 | Target: CEAM8 | UniProt: P31997
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18873-8 | Target: CEAM8 | UniProt: P31997 | TargetFullName: Carcinoembryonic antigen-related cell adhesion molecule 8 | Organisim: human | Apparent_Kd_M: 6.74E-12
Real
Aptamer SeqId: 18874-66 | Target: CEBPA | UniProt: P49715
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18874-66 | Target: CEBPA | UniProt: P49715 | TargetFullName: CCAAT/enhancer-binding protein alpha | Organisim: human | Apparent_Kd_M: 1.39E-11
Real
Aptamer SeqId: 18875-125 | Target: Chondrocalcin | UniProt: P02458
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18875-125 | Target: Chondrocalcin | UniProt: P02458 | TargetFullName: Chondrocalcin | Organisim: human | Apparent_Kd_M: 5.38E-12
Real
Aptamer SeqId: 18876-77 | Target: CHST4 | UniProt: Q8NCG5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18876-77 | Target: CHST4 | UniProt: Q8NCG5 | TargetFullName: Carbohydrate sulfotransferase 4 | Organisim: human | Apparent_Kd_M: 7.2E-13
Real
Aptamer SeqId: 18877-15 | Target: CNN2 | UniProt: Q99439
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18877-15 | Target: CNN2 | UniProt: Q99439 | TargetFullName: Calponin-2 | Organisim: human | Apparent_Kd_M: 1.63E-10
Real
Aptamer SeqId: 18878-15 | Target: GREM1 | UniProt: O60565
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18878-15 | Target: GREM1 | UniProt: O60565 | TargetFullName: Gremlin-1 | Organisim: human | Apparent_Kd_M: 1.13E-11
Real
Aptamer SeqId: 18880-81 | Target: Collagen Type III | UniProt: P02461
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18880-81 | Target: Collagen Type III | UniProt: P02461 | TargetFullName: Collagen Type III | Organisim: human | Apparent_Kd_M: 9.33E-12
Real
Aptamer SeqId: 18881-7 | Target: CD97 | UniProt: P48960
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18881-7 | Target: CD97 | UniProt: P48960 | TargetFullName: CD97 antigen | Organisim: human | Apparent_Kd_M: 2.54E-10
Real
Aptamer SeqId: 18882-7 | Target: CSTN2 | UniProt: Q9H4D0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18882-7 | Target: CSTN2 | UniProt: Q9H4D0 | TargetFullName: Calsyntenin-2 | Organisim: human | Apparent_Kd_M: 3.81E-12
Real
Aptamer SeqId: 18883-4 | Target: DEST | UniProt: P60981
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18883-4 | Target: DEST | UniProt: P60981 | TargetFullName: Destrin | Organisim: human | Apparent_Kd_M: 7.07E-11
Real
Aptamer SeqId: 18884-22 | Target: DNJB4 | UniProt: Q9UDY4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18884-22 | Target: DNJB4 | UniProt: Q9UDY4 | TargetFullName: DnaJ homolog subfamily B member 4 | Organisim: human | Apparent_Kd_M: 2.24E-11
Real
Aptamer SeqId: 18886-28 | Target: DSCL1 | UniProt: Q8TD84
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18886-28 | Target: DSCL1 | UniProt: Q8TD84 | TargetFullName: Down syndrome cell adhesion molecule-like protein 1 | Organisim: human | Apparent_Kd_M: 3.57E-12
Real
Aptamer SeqId: 18887-7 | Target: ENTP2 | UniProt: Q9Y5L3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18887-7 | Target: ENTP2 | UniProt: Q9Y5L3 | TargetFullName: Ectonucleoside triphosphate diphosphohydrolase 2 | Organisim: human | Apparent_Kd_M: 8.62E-12
Real
Aptamer SeqId: 18888-37 | Target: FBP12 | UniProt: A6NFH5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18888-37 | Target: FBP12 | UniProt: A6NFH5 | TargetFullName: Fatty acid-binding protein 12 | Organisim: human | Apparent_Kd_M: 2.96E-11
Real
Aptamer SeqId: 18890-227 | Target: Fibrinogen B | UniProt: P02675
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18890-227 | Target: Fibrinogen B | UniProt: P02675 | TargetFullName: Fibrinogen beta chain | Organisim: human | Apparent_Kd_M: 9.13E-11
Real
Aptamer SeqId: 18891-98 | Target: GBP2 | UniProt: P32456
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18891-98 | Target: GBP2 | UniProt: P32456 | TargetFullName: Guanylate-binding protein 2 | Organisim: human | Apparent_Kd_M: 1.41E-11
Real
Aptamer SeqId: 18892-48 | Target: GPC4 | UniProt: O75487
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18892-48 | Target: GPC4 | UniProt: O75487 | TargetFullName: Glypican-4 | Organisim: human | Apparent_Kd_M: 1.27E-10
Real
Aptamer SeqId: 18893-26 | Target: GPR56 | UniProt: Q9Y653
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18893-26 | Target: GPR56 | UniProt: Q9Y653 | TargetFullName: Adhesion G-protein coupled receptor G1 | Organisim: human | Apparent_Kd_M: 3.45E-11
Real
Aptamer SeqId: 18894-1 | Target: GPX2 | UniProt: P18283
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18894-1 | Target: GPX2 | UniProt: P18283 | TargetFullName: Glutathione peroxidase 2 | Organisim: human | Apparent_Kd_M: 1.23E-10
Real
Aptamer SeqId: 18895-54 | Target: GSTM4 | UniProt: Q03013
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18895-54 | Target: GSTM4 | UniProt: Q03013 | TargetFullName: Glutathione S-transferase Mu 4 | Organisim: human | Apparent_Kd_M: 7.76E-11
Real
Aptamer SeqId: 18896-23 | Target: H6ST3 | UniProt: Q8IZP7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18896-23 | Target: H6ST3 | UniProt: Q8IZP7 | TargetFullName: Heparan-sulfate 6-O-sulfotransferase 3 | Organisim: human | Apparent_Kd_M: 3.19E-12
Real
Aptamer SeqId: 18897-31 | Target: HDAC2 | UniProt: Q92769
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18897-31 | Target: HDAC2 | UniProt: Q92769 | TargetFullName: Histone deacetylase 2 | Organisim: human | Apparent_Kd_M: 2.21E-11
Real
Aptamer SeqId: 18898-36 | Target: HDGL1 | UniProt: Q5TGJ6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18898-36 | Target: HDGL1 | UniProt: Q5TGJ6 | TargetFullName: Hepatoma-derived growth factor-like protein 1 | Organisim: human | Apparent_Kd_M: 6.62E-11
Real
Aptamer SeqId: 18899-82 | Target: HDGR3 | UniProt: Q9Y3E1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18899-82 | Target: HDGR3 | UniProt: Q9Y3E1 | TargetFullName: Hepatoma-derived growth factor-related protein 3 | Organisim: human | Apparent_Kd_M: 6.17E-12
Real
Aptamer SeqId: 18900-37 | Target: H-ras (WT) | UniProt: P01112
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18900-37 | Target: H-ras (WT) | UniProt: P01112 | TargetFullName: GTPase HRas | Organisim: human | Apparent_Kd_M: 3.49E-11
Real
Aptamer SeqId: 18901-26 | Target: HS71B | UniProt: P0DMV9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18901-26 | Target: HS71B | UniProt: P0DMV9 | TargetFullName: Heat shock 70 kDa protein 1B | Organisim: human | Apparent_Kd_M: 1.12E-10
Real
Aptamer SeqId: 18904-23 | Target: KCC4 | UniProt: Q16566
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18904-23 | Target: KCC4 | UniProt: Q16566 | TargetFullName: Calcium/calmodulin-dependent protein kinase type IV | Organisim: human | Apparent_Kd_M: 5.41E-11
Real
Aptamer SeqId: 18905-5 | Target: Keratin-16 | UniProt: P08779
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18905-5 | Target: Keratin-16 | UniProt: P08779 | TargetFullName: Keratin; type I cytoskeletal 16 | Organisim: human | Apparent_Kd_M: 1.91E-10
Real
Aptamer SeqId: 18907-97 | Target: KI3L1 | UniProt: P43629
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18907-97 | Target: KI3L1 | UniProt: P43629 | TargetFullName: Killer cell immunoglobulin-like receptor 3DL1 | Organisim: human | Apparent_Kd_M: 1.66E-10
Real
Aptamer SeqId: 18909-11 | Target: EXOS8 | UniProt: Q96B26
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18909-11 | Target: EXOS8 | UniProt: Q96B26 | TargetFullName: Exosome complex component RRP43 | Organisim: human | Apparent_Kd_M: 2.91E-11
Real
Aptamer SeqId: 18910-45 | Target: LIN7A | UniProt: O14910
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18910-45 | Target: LIN7A | UniProt: O14910 | TargetFullName: Protein lin-7 homolog A | Organisim: human | Apparent_Kd_M: 6.21E-11
Real
Aptamer SeqId: 18913-3 | Target: Cyclin H | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18913-3 | Target: Cyclin H | UniProt: | TargetFullName: Cyclin-H | Organisim: human | Apparent_Kd_M: 3.72E-12
Real
Aptamer SeqId: 18914-188 | Target: PAFA2 | UniProt: Q99487
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18914-188 | Target: PAFA2 | UniProt: Q99487 | TargetFullName: Platelet-activating factor acetylhydrolase 2; cytoplasmic | Organisim: human | Apparent_Kd_M: 1.92E-11
Real
Aptamer SeqId: 18916-25 | Target: Inosine triphosphatase | UniProt: Q9BY32
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18916-25 | Target: Inosine triphosphatase | UniProt: Q9BY32 | TargetFullName: Inosine triphosphate pyrophosphatase | Organisim: human | Apparent_Kd_M: 1.18E-11
Real
Aptamer SeqId: 18917-53 | Target: Pancreatic alpha-amylase
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18917-53 | Target: Pancreatic alpha-amylase | UniProt: P04746 | TargetFullName: Pancreatic alpha-amylase | Organisim: human | Apparent_Kd_M: 2.74E-12
Real
Aptamer SeqId: 18918-86 | Target: PDE4A | UniProt: P27815
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18918-86 | Target: PDE4A | UniProt: P27815 | TargetFullName: cAMP-specific 3';5'-cyclic phosphodiesterase 4A | Organisim: human | Apparent_Kd_M: 7.82E-11
Real
Aptamer SeqId: 18921-30 | Target: PHEX | UniProt: P78562
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18921-30 | Target: PHEX | UniProt: P78562 | TargetFullName: Phosphate-regulating neutral endopeptidase | Organisim: human | Apparent_Kd_M: 1.73E-12
Real
Aptamer SeqId: 18922-27 | Target: CD68 | UniProt: P34810
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18922-27 | Target: CD68 | UniProt: P34810 | TargetFullName: Macrosialin | Organisim: human | Apparent_Kd_M: 1.75E-10
Real
Aptamer SeqId: 18925-24 | Target: Proteasome subunit alpha type 5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18925-24 | Target: Proteasome subunit alpha type 5 | UniProt: P28066 | TargetFullName: Proteasome subunit alpha type-5 | Organisim: human | Apparent_Kd_M: 1.19E-10
Real
Aptamer SeqId: 18926-7 | Target: PSA3 | UniProt: P25788
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18926-7 | Target: PSA3 | UniProt: P25788 | TargetFullName: Proteasome subunit alpha type-3 | Organisim: human | Apparent_Kd_M: 7.57E-11
Real
Aptamer SeqId: 18927-14 | Target: RET1G | UniProt: Q6H3X3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18927-14 | Target: RET1G | UniProt: Q6H3X3 | TargetFullName: Retinoic acid early transcript 1G protein | Organisim: human | Apparent_Kd_M: 1.3E-10
Real
Aptamer SeqId: 18928-10 | Target: S100Z | UniProt: Q8WXG8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18928-10 | Target: S100Z | UniProt: Q8WXG8 | TargetFullName: Protein S100-Z | Organisim: human | Apparent_Kd_M: 6.25E-12
Real
Aptamer SeqId: 18930-28 | Target: SLIT2 | UniProt: O94813
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18930-28 | Target: SLIT2 | UniProt: O94813 | TargetFullName: Slit homolog 2 protein | Organisim: human | Apparent_Kd_M: 2.485481E-12
Real
Aptamer SeqId: 18931-40 | Target: SLIT3 | UniProt: O75094
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18931-40 | Target: SLIT3 | UniProt: O75094 | TargetFullName: Slit homolog 3 protein | Organisim: human | Apparent_Kd_M: 5.44E-11
Real
Aptamer SeqId: 18932-84 | Target: NMNA1 | UniProt: Q9HAN9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18932-84 | Target: NMNA1 | UniProt: Q9HAN9 | TargetFullName: Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 | Organisim: human | Apparent_Kd_M: 1.46E-10
Real
Aptamer SeqId: 18933-4 | Target: TGM4 | UniProt: P49221
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18933-4 | Target: TGM4 | UniProt: P49221 | TargetFullName: Protein-glutamine gamma-glutamyltransferase 4 | Organisim: human | Apparent_Kd_M: 1.21E-11
Real
Aptamer SeqId: 18934-50 | Target: Tissue transglutaminase | UniProt: P21980
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18934-50 | Target: Tissue transglutaminase | UniProt: P21980 | TargetFullName: Protein-glutamine gamma-glutamyltransferase 2 | Organisim: human | Apparent_Kd_M: 1.95E-11
Real
Aptamer SeqId: 18935-14 | Target: TLR5 | UniProt: O60602
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18935-14 | Target: TLR5 | UniProt: O60602 | TargetFullName: Toll-like receptor 5 | Organisim: human | Apparent_Kd_M: 5.23E-11
Real
Aptamer SeqId: 18938-3 | Target: VLDLR | UniProt: P98155
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18938-3 | Target: VLDLR | UniProt: P98155 | TargetFullName: Very low-density lipoprotein receptor | Organisim: human | Apparent_Kd_M: 1.64E-10
Real
Aptamer SeqId: 18942-11 | Target: PSB9 | UniProt: P28065
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18942-11 | Target: PSB9 | UniProt: P28065 | TargetFullName: Proteasome subunit beta type-9 | Organisim: human | Apparent_Kd_M: 5.57E-11
Real
Aptamer SeqId: 18943-4 | Target: PTGR2 | UniProt: Q8N8N7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18943-4 | Target: PTGR2 | UniProt: Q8N8N7 | TargetFullName: Prostaglandin reductase 2 | Organisim: human | Apparent_Kd_M: 3.27E-11
Real
Aptamer SeqId: 18945-11 | Target: RGS1 | UniProt: Q08116
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18945-11 | Target: RGS1 | UniProt: Q08116 | TargetFullName: Regulator of G-protein signaling 1 | Organisim: human | Apparent_Kd_M: 1.14E-10
Real
Aptamer SeqId: 18947-3 | Target: LRC3B | UniProt: Q96PB8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18947-3 | Target: LRC3B | UniProt: Q96PB8 | TargetFullName: Leucine-rich repeat-containing protein 3B | Organisim: human | Apparent_Kd_M: 9.89E-11
Real
Aptamer SeqId: 18950-13 | Target: RAC2 | UniProt: P15153
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 18950-13 | Target: RAC2 | UniProt: P15153 | TargetFullName: Ras-related C3 botulinum toxin substrate 2 | Organisim: human | Apparent_Kd_M: 2.58E-10
Real
Aptamer SeqId: 19108-50 | Target: MECP2 | UniProt: P51608
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19108-50 | Target: MECP2 | UniProt: P51608 | TargetFullName: Methyl-CpG-binding protein 2 | Organisim: human | Apparent_Kd_M: 4.6E-11
Real
Aptamer SeqId: 19109-32 | Target: TCAL8 | UniProt: Q8IYN2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19109-32 | Target: TCAL8 | UniProt: Q8IYN2 | TargetFullName: Transcription elongation factor A protein-like 8 | Organisim: human | Apparent_Kd_M: 7.925254E-11
Real
Aptamer SeqId: 19110-6 | Target: MEMO1 | UniProt: Q9Y316
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19110-6 | Target: MEMO1 | UniProt: Q9Y316 | TargetFullName: Protein MEMO1 | Organisim: human | Apparent_Kd_M: 4.72E-11
Real
Aptamer SeqId: 19111-10 | Target: UBC12 | UniProt: P61081
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19111-10 | Target: UBC12 | UniProt: P61081 | TargetFullName: NEDD8-conjugating enzyme Ubc12 | Organisim: human | Apparent_Kd_M: 3.06E-11
Real
Aptamer SeqId: 19112-2 | Target: TCAL3 | UniProt: Q969E4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19112-2 | Target: TCAL3 | UniProt: Q969E4 | TargetFullName: Transcription elongation factor A protein-like 3 | Organisim: human | Apparent_Kd_M: 2.34E-11
Real
Aptamer SeqId: 19113-66 | Target: SH3L2 | UniProt: Q9UJC5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19113-66 | Target: SH3L2 | UniProt: Q9UJC5 | TargetFullName: SH3 domain-binding glutamic acid-rich-like protein 2 | Organisim: human | Apparent_Kd_M: 5.78E-12
Real
Aptamer SeqId: 19114-8 | Target: KITM | UniProt: O00142
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19114-8 | Target: KITM | UniProt: O00142 | TargetFullName: Thymidine kinase 2; mitochondrial | Organisim: human | Apparent_Kd_M: 4.0E-11
Real
Aptamer SeqId: 19115-13 | Target: CMBL | UniProt: Q96DG6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19115-13 | Target: CMBL | UniProt: Q96DG6 | TargetFullName: Carboxymethylenebutenolidase homolog | Organisim: human | Apparent_Kd_M: 2.166089E-10
Real
Aptamer SeqId: 19116-1 | Target: MUTED | UniProt: Q8TDH9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19116-1 | Target: MUTED | UniProt: Q8TDH9 | TargetFullName: Biogenesis of lysosome-related organelles complex 1 subunit 5 | Organisim: human | Apparent_Kd_M: 2.27E-10
Real
Aptamer SeqId: 19117-3 | Target: PP14A | UniProt: Q96A00
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19117-3 | Target: PP14A | UniProt: Q96A00 | TargetFullName: Protein phosphatase 1 regulatory subunit 14A | Organisim: human | Apparent_Kd_M: 9.64E-12
Real
Aptamer SeqId: 19118-47 | Target: OSTF1 | UniProt: Q92882
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19118-47 | Target: OSTF1 | UniProt: Q92882 | TargetFullName: Osteoclast-stimulating factor 1 | Organisim: human | Apparent_Kd_M: 4.51E-11
Real
Aptamer SeqId: 19119-10 | Target: DDIT3 | UniProt: P35638
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19119-10 | Target: DDIT3 | UniProt: P35638 | TargetFullName: DNA damage-inducible transcript 3 protein | Organisim: human | Apparent_Kd_M: 4.849107E-11
Real
Aptamer SeqId: 19120-33 | Target: OXDA | UniProt: P14920
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19120-33 | Target: OXDA | UniProt: P14920 | TargetFullName: D-amino-acid oxidase | Organisim: human | Apparent_Kd_M: 1.77E-11
Real
Aptamer SeqId: 19121-3 | Target: UBQL2 | UniProt: Q9UHD9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19121-3 | Target: UBQL2 | UniProt: Q9UHD9 | TargetFullName: Ubiquilin-2 | Organisim: human | Apparent_Kd_M: 1.1E-11
Real
Aptamer SeqId: 19122-47 | Target: ML12B | UniProt: O14950
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19122-47 | Target: ML12B | UniProt: O14950 | TargetFullName: Myosin regulatory light chain 12B | Organisim: human | Apparent_Kd_M: 5.62E-11
Real
Aptamer SeqId: 19123-6 | Target: IKBD | UniProt: Q8NI38
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19123-6 | Target: IKBD | UniProt: Q8NI38 | TargetFullName: NF-kappa-B inhibitor delta | Organisim: human | Apparent_Kd_M: 1.07E-11
Real
Aptamer SeqId: 19124-9 | Target: UBCP1 | UniProt: Q8WVY7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19124-9 | Target: UBCP1 | UniProt: Q8WVY7 | TargetFullName: Ubiquitin-like domain-containing CTD phosphatase 1 | Organisim: human | Apparent_Kd_M: 4.53E-12
Real
Aptamer SeqId: 19125-26 | Target: KAP2 | UniProt: P13861
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19125-26 | Target: KAP2 | UniProt: P13861 | TargetFullName: cAMP-dependent protein kinase type II-alpha regulatory subunit | Organisim: human | Apparent_Kd_M: 3.69E-11
Real
Aptamer SeqId: 19126-4 | Target: C20orf77 | UniProt: Q9NQG5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19126-4 | Target: C20orf77 | UniProt: Q9NQG5 | TargetFullName: Regulation of nuclear pre-mRNA domain-containing protein 1B | Organisim: human | Apparent_Kd_M: 1.212425E-11
Real
Aptamer SeqId: 19127-1 | Target: HSPB6 | UniProt: O14558
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19127-1 | Target: HSPB6 | UniProt: O14558 | TargetFullName: Heat shock protein beta-6 | Organisim: human | Apparent_Kd_M: 3.92E-11
Real
Aptamer SeqId: 19129-15 | Target: MTHFSD | UniProt: Q2M296
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19129-15 | Target: MTHFSD | UniProt: Q2M296 | TargetFullName: Methenyltetrahydrofolate synthase domain-containing protein | Organisim: human | Apparent_Kd_M: 6.41E-12
Real
Aptamer SeqId: 19130-81 | Target: SPB8 | UniProt: P50452
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19130-81 | Target: SPB8 | UniProt: P50452 | TargetFullName: Serpin B8 | Organisim: human | Apparent_Kd_M: 8.31E-12
Real
Aptamer SeqId: 19131-184 | Target: TIAR | UniProt: Q01085
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19131-184 | Target: TIAR | UniProt: Q01085 | TargetFullName: Nucleolysin TIAR | Organisim: human | Apparent_Kd_M: 1.11E-12
Real
Aptamer SeqId: 19132-1 | Target: RM02 | UniProt: Q5T653
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19132-1 | Target: RM02 | UniProt: Q5T653 | TargetFullName: 39S ribosomal protein L2; mitochondrial | Organisim: human | Apparent_Kd_M: 4.38E-11
Real
Aptamer SeqId: 19134-66 | Target: RPAB4 | UniProt: P53803
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19134-66 | Target: RPAB4 | UniProt: P53803 | TargetFullName: DNA-directed RNA polymerases I; II; and III subunit RPABC4 | Organisim: human | Apparent_Kd_M: 1.98E-11
Real
Aptamer SeqId: 19135-5 | Target: Cytosolic 5-nucleotidase III-like protein
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19135-5 | Target: Cytosolic 5'-nucleotidase III-like protein | UniProt: Q969T7 | TargetFullName: 7-methylguanosine phosphate-specific 5'-nucleotidase | Organisim: human | Apparent_Kd_M: 3.694275E-11
Real
Aptamer SeqId: 19136-22 | Target: MMSA | UniProt: Q02252
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19136-22 | Target: MMSA | UniProt: Q02252 | TargetFullName: Methylmalonate-semialdehyde dehydrogenase acylating; mitochondrial | Organisim: human | Apparent_Kd_M: 8.606591E-12
Real
Aptamer SeqId: 19139-3 | Target: HSF2B | UniProt: O75031
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19139-3 | Target: HSF2B | UniProt: O75031 | TargetFullName: Heat shock factor 2-binding protein | Organisim: human | Apparent_Kd_M: 3.199085E-11
Real
Aptamer SeqId: 19141-22 | Target: DAP1 | UniProt: P51397
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19141-22 | Target: DAP1 | UniProt: P51397 | TargetFullName: Death-associated protein 1 | Organisim: human | Apparent_Kd_M: 2.788486E-11
Real
Aptamer SeqId: 19142-39 | Target: DNM3L | UniProt: Q9UJW3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19142-39 | Target: DNM3L | UniProt: Q9UJW3 | TargetFullName: DNA (cytosine-5)-methyltransferase 3-like | Organisim: human | Apparent_Kd_M: 5.01659E-12
Real
Aptamer SeqId: 19143-38 | Target: NB5R2 | UniProt: Q6BCY4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19143-38 | Target: NB5R2 | UniProt: Q6BCY4 | TargetFullName: NADH-cytochrome b5 reductase 2 | Organisim: human | Apparent_Kd_M: 1.813018E-12
Real
Aptamer SeqId: 19144-9 | Target: ITF2 | UniProt: P15884
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19144-9 | Target: ITF2 | UniProt: P15884 | TargetFullName: Transcription factor 4 | Organisim: human | Apparent_Kd_M: 7.501491E-12
Real
Aptamer SeqId: 19145-4 | Target: MREG | UniProt: Q8N565
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19145-4 | Target: MREG | UniProt: Q8N565 | TargetFullName: Melanoregulin | Organisim: human | Apparent_Kd_M: 7.897401E-12
Real
Aptamer SeqId: 19147-6 | Target: PP13 | UniProt: Q9UHV8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19147-6 | Target: PP13 | UniProt: Q9UHV8 | TargetFullName: Galactoside-binding soluble lectin 13 | Organisim: human | Apparent_Kd_M: 9.172513E-11
Real
Aptamer SeqId: 19148-58 | Target: TIM8A | UniProt: O60220
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19148-58 | Target: TIM8A | UniProt: O60220 | TargetFullName: Mitochondrial import inner membrane translocase subunit Tim8 A | Organisim: human | Apparent_Kd_M: 9.132771E-12
Real
Aptamer SeqId: 19150-20 | Target: KPRB | UniProt: O60256
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19150-20 | Target: KPRB | UniProt: O60256 | TargetFullName: Phosphoribosyl pyrophosphate synthase-associated protein 2 | Organisim: human | Apparent_Kd_M: 9.321001E-12
Real
Aptamer SeqId: 19152-4 | Target: IPP2 | UniProt: P41236
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19152-4 | Target: IPP2 | UniProt: P41236 | TargetFullName: Protein phosphatase inhibitor 2 | Organisim: human | Apparent_Kd_M: 1.24E-11
Real
Aptamer SeqId: 19153-53 | Target: MPPD2 | UniProt: Q15777
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19153-53 | Target: MPPD2 | UniProt: Q15777 | TargetFullName: Metallophosphoesterase MPPED2 | Organisim: human | Apparent_Kd_M: 4.077022E-11
Real
Aptamer SeqId: 19154-41 | Target: Protease nexin I | UniProt: P07093
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19154-41 | Target: Protease nexin I | UniProt: P07093 | TargetFullName: Glia-derived nexin | Organisim: human | Apparent_Kd_M: 1.059498E-12
Real
Aptamer SeqId: 19158-1 | Target: PAF | UniProt: Q15004
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19158-1 | Target: PAF | UniProt: Q15004 | TargetFullName: PCNA-associated factor | Organisim: human | Apparent_Kd_M: 2.144228E-11
Real
Aptamer SeqId: 19159-9 | Target: DNA polymerase subunit delta 4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19159-9 | Target: DNA polymerase subunit delta 4 | UniProt: Q9HCU8 | TargetFullName: DNA polymerase delta subunit 4 | Organisim: human | Apparent_Kd_M: 8.302115E-11
Real
Aptamer SeqId: 19161-1 | Target: UBP15 | UniProt: Q9Y4E8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19161-1 | Target: UBP15 | UniProt: Q9Y4E8 | TargetFullName: Ubiquitin carboxyl-terminal hydrolase 15 | Organisim: human | Apparent_Kd_M: 5.533908E-12
Real
Aptamer SeqId: 19163-26 | Target: LRC59 | UniProt: Q96AG4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19163-26 | Target: LRC59 | UniProt: Q96AG4 | TargetFullName: Leucine-rich repeat-containing protein 59 | Organisim: human | Apparent_Kd_M: 8.970088E-12
Real
Aptamer SeqId: 19166-15 | Target: RS19 | UniProt: P39019
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19166-15 | Target: RS19 | UniProt: P39019 | TargetFullName: 40S ribosomal protein S19 | Organisim: human | Apparent_Kd_M: 1.264089E-11
Real
Aptamer SeqId: 19168-71 | Target: PPIP1 | UniProt: O43586
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19168-71 | Target: PPIP1 | UniProt: O43586 | TargetFullName: Proline-serine-threonine phosphatase-interacting protein 1 | Organisim: human | Apparent_Kd_M: 7.223435E-12
Real
Aptamer SeqId: 19169-88 | Target: FIBP | UniProt: O43427
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19169-88 | Target: FIBP | UniProt: O43427 | TargetFullName: Acidic fibroblast growth factor intracellular-binding protein | Organisim: human | Apparent_Kd_M: 6.521447E-12
Real
Aptamer SeqId: 19170-25 | Target: DPOE3 | UniProt: Q9NRF9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19170-25 | Target: DPOE3 | UniProt: Q9NRF9 | TargetFullName: DNA polymerase epsilon subunit 3 | Organisim: human | Apparent_Kd_M: 1.125884E-11
Real
Aptamer SeqId: 19173-5 | Target: ZFAN1 | UniProt: Q8TCF1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19173-5 | Target: ZFAN1 | UniProt: Q8TCF1 | TargetFullName: AN1-type zinc finger protein 1 | Organisim: human | Apparent_Kd_M: 5.14551E-12
Real
Aptamer SeqId: 19174-141 | Target: GOGA7 | UniProt: Q7Z5G4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19174-141 | Target: GOGA7 | UniProt: Q7Z5G4 | TargetFullName: Golgin subfamily A member 7 | Organisim: human | Apparent_Kd_M: 5.875708E-11
Real
Aptamer SeqId: 19175-18 | Target: MARCKSL1 | UniProt: P49006
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19175-18 | Target: MARCKSL1 | UniProt: P49006 | TargetFullName: MARCKS-related protein | Organisim: human | Apparent_Kd_M: 3.423579E-12
Real
Aptamer SeqId: 19176-27 | Target: FA49B | UniProt: Q9NUQ9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19176-27 | Target: FA49B | UniProt: Q9NUQ9 | TargetFullName: Protein FAM49B | Organisim: human | Apparent_Kd_M: 2.732296E-12
Real
Aptamer SeqId: 19177-7 | Target: MOL1A | UniProt: Q7L9L4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19177-7 | Target: MOL1A | UniProt: Q7L9L4 | TargetFullName: MOB kinase activator 1B | Organisim: human | Apparent_Kd_M: 3.197803E-12
Real
Aptamer SeqId: 19180-38 | Target: GULP1 | UniProt: Q9UBP9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19180-38 | Target: GULP1 | UniProt: Q9UBP9 | TargetFullName: PTB domain-containing engulfment adapter protein 1 | Organisim: human | Apparent_Kd_M: 2.76582E-11
Real
Aptamer SeqId: 19183-164 | Target: RL12 | UniProt: P30050
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19183-164 | Target: RL12 | UniProt: P30050 | TargetFullName: 60S ribosomal protein L12 | Organisim: human | Apparent_Kd_M: 4.95137E-12
Real
Aptamer SeqId: 19187-21 | Target: STABP | UniProt: O95630
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19187-21 | Target: STABP | UniProt: O95630 | TargetFullName: STAM-binding protein | Organisim: human | Apparent_Kd_M: 2.13062E-11
Real
Aptamer SeqId: 19188-21 | Target: NAP2L | UniProt: Q99733
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19188-21 | Target: NAP2L | UniProt: Q99733 | TargetFullName: nucleosome assembly protein 1-like 4 | Organisim: human | Apparent_Kd_M: 3.709419E-12
Real
Aptamer SeqId: 19189-2 | Target: UBP14 | UniProt: P54578
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19189-2 | Target: UBP14 | UniProt: P54578 | TargetFullName: Ubiquitin carboxyl-terminal hydrolase 14 | Organisim: human | Apparent_Kd_M: 6.268981E-12
Real
Aptamer SeqId: 19190-4 | Target: UB2L6 | UniProt: O14933
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19190-4 | Target: UB2L6 | UniProt: O14933 | TargetFullName: Ubiquitin/ISG15-conjugating enzyme E2 L6 | Organisim: human | Apparent_Kd_M: 1.848601E-11
Real
Aptamer SeqId: 19193-18 | Target: PFD3 | UniProt: P61758
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19193-18 | Target: PFD3 | UniProt: P61758 | TargetFullName: Prefoldin subunit 3 | Organisim: human | Apparent_Kd_M: 3.718621E-11
Real
Aptamer SeqId: 19194-9 | Target: Histidyl-tRNA synthetase-related
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19194-9 | Target: Histidyl-tRNA synthetase-related | UniProt: Q8TEA8 | TargetFullName: D-tyrosyl-tRNA(Tyr) deacylase 1 | Organisim: human | Apparent_Kd_M: 1.838461E-11
Real
Aptamer SeqId: 19195-85 | Target: RS5 | UniProt: P46782
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19195-85 | Target: RS5 | UniProt: P46782 | TargetFullName: 40S ribosomal protein S5 | Organisim: human | Apparent_Kd_M: 3.623484E-11
Real
Aptamer SeqId: 19196-73 | Target: HOP | UniProt: Q9BPY8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19196-73 | Target: HOP | UniProt: Q9BPY8 | TargetFullName: Homeodomain-only protein | Organisim: human | Apparent_Kd_M: 5.449909E-11
Real
Aptamer SeqId: 19197-95 | Target: THIL | UniProt: P24752
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19197-95 | Target: THIL | UniProt: P24752 | TargetFullName: Acetyl-CoA acetyltransferase; mitochondrial | Organisim: human | Apparent_Kd_M: 6.441777E-12
Real
Aptamer SeqId: 19199-3 | Target: RPB11 | UniProt: P52435
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19199-3 | Target: RPB11 | UniProt: P52435 | TargetFullName: DNA-directed RNA polymerase II subunit RPB11-a | Organisim: human | Apparent_Kd_M: 4.360683E-12
Real
Aptamer SeqId: 19200-16 | Target: NDUA5 | UniProt: Q16718
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19200-16 | Target: NDUA5 | UniProt: Q16718 | TargetFullName: NADH dehydrogenase ubiquinone 1 alpha subcomplex subunit 5 | Organisim: human | Apparent_Kd_M: 4.371611E-11
Real
Aptamer SeqId: 19202-10 | Target: BTK | UniProt: Q06187
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19202-10 | Target: BTK | UniProt: Q06187 | TargetFullName: Tyrosine-protein kinase BTK | Organisim: human | Apparent_Kd_M: 4.988695E-12
Real
Aptamer SeqId: 19206-20 | Target: 8ODP | UniProt: P36639
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19206-20 | Target: 8ODP | UniProt: P36639 | TargetFullName: 7;8-dihydro-8-oxoguanine triphosphatase | Organisim: human | Apparent_Kd_M: 1.782335E-11
Real
Aptamer SeqId: 19207-119 | Target: ADK | UniProt: P55263
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19207-119 | Target: ADK | UniProt: P55263 | TargetFullName: Adenosine kinase | Organisim: human | Apparent_Kd_M: 1.043601E-10
Real
Aptamer SeqId: 19208-8 | Target: Activin RIIA | UniProt: P27037
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19208-8 | Target: Activin RIIA | UniProt: P27037 | TargetFullName: Activin receptor type-2A | Organisim: human | Apparent_Kd_M: 1.099064E-10
Real
Aptamer SeqId: 19209-6 | Target: IKB-alpha | UniProt: P25963
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19209-6 | Target: IKB-alpha | UniProt: P25963 | TargetFullName: NF-kappa-B inhibitor alpha | Organisim: human | Apparent_Kd_M: 2.855595E-11
Real
Aptamer SeqId: 19212-4 | Target: DMBT1 | UniProt: Q9UGM3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19212-4 | Target: DMBT1 | UniProt: Q9UGM3 | TargetFullName: Deleted in malignant brain tumors 1 protein | Organisim: human | Apparent_Kd_M: 9.85769E-11
Real
Aptamer SeqId: 19213-1 | Target: ISK4 | UniProt: O60575
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19213-1 | Target: ISK4 | UniProt: O60575 | TargetFullName: Serine protease inhibitor Kazal-type 4 | Organisim: human | Apparent_Kd_M: 3.967488E-11
Real
Aptamer SeqId: 19215-7 | Target: NDRG1 | UniProt: Q92597
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19215-7 | Target: NDRG1 | UniProt: Q92597 | TargetFullName: Protein NDRG1 | Organisim: human | Apparent_Kd_M: 2.97E-11
Real
Aptamer SeqId: 19219-71 | Target: NTF-2 | UniProt: P61970
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19219-71 | Target: NTF-2 | UniProt: P61970 | TargetFullName: Nuclear transport factor 2 | Organisim: human | Apparent_Kd_M: 2.91E-11
Real
Aptamer SeqId: 19222-124 | Target: RAB5B | UniProt: P61020
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19222-124 | Target: RAB5B | UniProt: P61020 | TargetFullName: Ras-related protein Rab-5B | Organisim: human | Apparent_Kd_M: 1.967878E-12
Real
Aptamer SeqId: 19223-6 | Target: RAB1A | UniProt: P62820
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19223-6 | Target: RAB1A | UniProt: P62820 | TargetFullName: Ras-related protein Rab-1A | Organisim: human | Apparent_Kd_M: 2.384549E-12
Real
Aptamer SeqId: 19224-5 | Target: IF1AY | UniProt: O14602
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19224-5 | Target: IF1AY | UniProt: O14602 | TargetFullName: Eukaryotic translation initiation factor 1A; Y-chromosomal | Organisim: human | Apparent_Kd_M: 1.326179E-12
Real
Aptamer SeqId: 19225-11 | Target: BLNK | UniProt: Q8WV28
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19225-11 | Target: BLNK | UniProt: Q8WV28 | TargetFullName: B-cell linker protein | Organisim: human | Apparent_Kd_M: 2.064143E-11
Real
Aptamer SeqId: 19227-18 | Target: BATF | UniProt: Q16520
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19227-18 | Target: BATF | UniProt: Q16520 | TargetFullName: Basic leucine zipper transcriptional factor ATF-like | Organisim: human | Apparent_Kd_M: 1.04535E-10
Real
Aptamer SeqId: 19228-11 | Target: BAG-2 | UniProt: O95816
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19228-11 | Target: BAG-2 | UniProt: O95816 | TargetFullName: BAG family molecular chaperone regulator 2 | Organisim: human | Apparent_Kd_M: 3.836856E-11
Real
Aptamer SeqId: 19229-92 | Target: HOME1 | UniProt: Q86YM7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19229-92 | Target: HOME1 | UniProt: Q86YM7 | TargetFullName: Homer protein homolog 1 | Organisim: human | Apparent_Kd_M: 1.466573E-11
Real
Aptamer SeqId: 19230-12 | Target: GSTT1 | UniProt: P30711
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19230-12 | Target: GSTT1 | UniProt: P30711 | TargetFullName: Glutathione S-transferase theta-1 | Organisim: human | Apparent_Kd_M: 2.852595E-11
Real
Aptamer SeqId: 19231-22 | Target: PRL-3 | UniProt: O75365
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19231-22 | Target: PRL-3 | UniProt: O75365 | TargetFullName: Protein tyrosine phosphatase type IVA 3 | Organisim: human | Apparent_Kd_M: 1.29E-11
Real
Aptamer SeqId: 19233-75 | Target: ATOX1 | UniProt: O00244
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19233-75 | Target: ATOX1 | UniProt: O00244 | TargetFullName: Copper transport protein ATOX1 | Organisim: human | Apparent_Kd_M: 1.848747E-11
Real
Aptamer SeqId: 19236-24 | Target: TCP4 | UniProt: P53999
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19236-24 | Target: TCP4 | UniProt: P53999 | TargetFullName: Activated RNA polymerase II transcriptional coactivator p15 | Organisim: human | Apparent_Kd_M: 9.020125E-12
Real
Aptamer SeqId: 19237-17 | Target: D-dopachrome decarboxylase
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19237-17 | Target: D-dopachrome decarboxylase | UniProt: P30046 | TargetFullName: D-dopachrome decarboxylase | Organisim: human | Apparent_Kd_M: 6.641272E-11
Real
Aptamer SeqId: 19238-12 | Target: GLNA | UniProt: P15104
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19238-12 | Target: GLNA | UniProt: P15104 | TargetFullName: Glutamine synthetase | Organisim: human | Apparent_Kd_M: 1.925306E-11
Real
Aptamer SeqId: 19239-5 | Target: ARF1 | UniProt: P84077
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19239-5 | Target: ARF1 | UniProt: P84077 | TargetFullName: ADP-ribosylation factor 1 | Organisim: human | Apparent_Kd_M: 5.46195E-12
Real
Aptamer SeqId: 19240-265 | Target: HAP28 | UniProt: Q13442
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19240-265 | Target: HAP28 | UniProt: Q13442 | TargetFullName: 28 kDa heat- and acid-stable phosphoprotein | Organisim: human | Apparent_Kd_M: 1.857245E-11
Real
Aptamer SeqId: 19241-31 | Target: RBP-III | UniProt: P82980
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19241-31 | Target: RBP-III | UniProt: P82980 | TargetFullName: Retinol-binding protein 5 | Organisim: human | Apparent_Kd_M: 1.441323E-12
Real
Aptamer SeqId: 19242-21 | Target: PFD1 | UniProt: O60925
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19242-21 | Target: PFD1 | UniProt: O60925 | TargetFullName: Prefoldin subunit 1 | Organisim: human | Apparent_Kd_M: 1.12E-10
Real
Aptamer SeqId: 19243-2 | Target: PFD2 | UniProt: Q9UHV9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19243-2 | Target: PFD2 | UniProt: Q9UHV9 | TargetFullName: Prefoldin subunit 2 | Organisim: human | Apparent_Kd_M: 1.51E-11
Real
Aptamer SeqId: 19247-1 | Target: UB2D1 | UniProt: P51668
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19247-1 | Target: UB2D1 | UniProt: P51668 | TargetFullName: Ubiquitin-conjugating enzyme E2 D1 | Organisim: human | Apparent_Kd_M: 2.777399E-12
Real
Aptamer SeqId: 19249-18 | Target: SYK | UniProt: Q15046
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19249-18 | Target: SYK | UniProt: Q15046 | TargetFullName: Lysine--tRNA ligase | Organisim: human | Apparent_Kd_M: 1.064767E-12
Real
Aptamer SeqId: 19250-50 | Target: MYCBP | UniProt: Q99417
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19250-50 | Target: MYCBP | UniProt: Q99417 | TargetFullName: C-Myc-binding protein | Organisim: human | Apparent_Kd_M: 3.695883E-12
Real
Aptamer SeqId: 19251-56 | Target: Platelet proteoglycan | UniProt: P10124
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19251-56 | Target: Platelet proteoglycan | UniProt: P10124 | TargetFullName: Serglycin | Organisim: human | Apparent_Kd_M: 8.987261E-12
Real
Aptamer SeqId: 19252-67 | Target: PSB2 | UniProt: P49721
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19252-67 | Target: PSB2 | UniProt: P49721 | TargetFullName: Proteasome subunit beta type-2 | Organisim: human | Apparent_Kd_M: 1.614494E-11
Real
Aptamer SeqId: 19253-82 | Target: RAB2B | UniProt: Q8WUD1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19253-82 | Target: RAB2B | UniProt: Q8WUD1 | TargetFullName: Ras-related protein Rab-2B | Organisim: human | Apparent_Kd_M: 3.659759E-11
Real
Aptamer SeqId: 19254-125 | Target: GMPR1 | UniProt: P36959
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19254-125 | Target: GMPR1 | UniProt: P36959 | TargetFullName: GMP reductase 1 | Organisim: human | Apparent_Kd_M: 1.146786E-11
Real
Aptamer SeqId: 19255-124 | Target: NXT2 | UniProt: Q9NPJ8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19255-124 | Target: NXT2 | UniProt: Q9NPJ8 | TargetFullName: NTF2-related export protein 2 | Organisim: human | Apparent_Kd_M: 7.042508E-12
Real
Aptamer SeqId: 19257-11 | Target: CLCA | UniProt: P09496
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19257-11 | Target: CLCA | UniProt: P09496 | TargetFullName: Clathrin light chain A | Organisim: human | Apparent_Kd_M: 3.367E-11
Real
Aptamer SeqId: 19258-24 | Target: GCDH | UniProt: Q92947
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19258-24 | Target: GCDH | UniProt: Q92947 | TargetFullName: Glutaryl-CoA dehydrogenase; mitochondrial | Organisim: human | Apparent_Kd_M: 7.914749E-12
Real
Aptamer SeqId: 19259-176 | Target: IF2A | UniProt: P05198
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19259-176 | Target: IF2A | UniProt: P05198 | TargetFullName: Eukaryotic translation initiation factor 2 subunit 1 | Organisim: human | Apparent_Kd_M: 2.256247E-11
Real
Aptamer SeqId: 19260-4 | Target: GIPC1 | UniProt: O14908
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19260-4 | Target: GIPC1 | UniProt: O14908 | TargetFullName: PDZ domain-containing protein GIPC1 | Organisim: human | Apparent_Kd_M: 1.773143E-11
Real
Aptamer SeqId: 19261-12 | Target: SDCB2 | UniProt: Q9H190
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19261-12 | Target: SDCB2 | UniProt: Q9H190 | TargetFullName: Syntenin-2 | Organisim: human | Apparent_Kd_M: 1.254117E-12
Real
Aptamer SeqId: 19262-219 | Target: ACADV | UniProt: P49748
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19262-219 | Target: ACADV | UniProt: P49748 | TargetFullName: Very long-chain specific acyl-CoA dehydrogenase; mitochondrial | Organisim: human | Apparent_Kd_M: 1.11796E-11
Real
Aptamer SeqId: 19263-147 | Target: IF4E | UniProt: P06730
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19263-147 | Target: IF4E | UniProt: P06730 | TargetFullName: Eukaryotic translation initiation factor 4E | Organisim: human | Apparent_Kd_M: 2.78964E-12
Real
Aptamer SeqId: 19264-6 | Target: RFA2 | UniProt: P15927
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19264-6 | Target: RFA2 | UniProt: P15927 | TargetFullName: Replication protein A 32 kDa subunit | Organisim: human | Apparent_Kd_M: 1.17358E-10
Real
Aptamer SeqId: 19265-9 | Target: TCPA | UniProt: P17987
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19265-9 | Target: TCPA | UniProt: P17987 | TargetFullName: T-complex protein 1 subunit alpha | Organisim: human | Apparent_Kd_M: 4.938671E-11
Real
Aptamer SeqId: 19266-35 | Target: G3BP1 | UniProt: Q13283
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19266-35 | Target: G3BP1 | UniProt: Q13283 | TargetFullName: Ras GTPase-activating protein-binding protein 1 | Organisim: human | Apparent_Kd_M: 7.868901E-12
Real
Aptamer SeqId: 19267-14 | Target: GLO2 | UniProt: Q16775
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19267-14 | Target: GLO2 | UniProt: Q16775 | TargetFullName: Hydroxyacylglutathione hydrolase; mitochondrial | Organisim: human | Apparent_Kd_M: 3.455165E-12
Real
Aptamer SeqId: 19270-26 | Target: SYYC | UniProt: P54577
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19270-26 | Target: SYYC | UniProt: P54577 | TargetFullName: Tyrosine--tRNA ligase; cytoplasmic | Organisim: human | Apparent_Kd_M: 3.646377E-12
Real
Aptamer SeqId: 19271-64 | Target: GNAI1 | UniProt: P63096
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19271-64 | Target: GNAI1 | UniProt: P63096 | TargetFullName: Guanine nucleotide-binding protein G(i) subunit alpha-1 | Organisim: human | Apparent_Kd_M: 2.774652E-11
Real
Aptamer SeqId: 19272-9 | Target: PEF1 | UniProt: Q9UBV8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19272-9 | Target: PEF1 | UniProt: Q9UBV8 | TargetFullName: Peflin | Organisim: human | Apparent_Kd_M: 1.834456E-11
Real
Aptamer SeqId: 19273-3 | Target: Glutathione reductase | UniProt: P00390
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19273-3 | Target: Glutathione reductase | UniProt: P00390 | TargetFullName: Glutathione reductase; mitochondrial | Organisim: human | Apparent_Kd_M: 9.914427E-12
Real
Aptamer SeqId: 19274-80 | Target: Alpha-1-syntrophin | UniProt: Q13424
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19274-80 | Target: Alpha-1-syntrophin | UniProt: Q13424 | TargetFullName: Alpha-1-syntrophin | Organisim: human | Apparent_Kd_M: 9.412048E-12
Real
Aptamer SeqId: 19275-68 | Target: IDH3G | UniProt: P51553
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19275-68 | Target: IDH3G | UniProt: P51553 | TargetFullName: Isocitrate dehydrogenase NAD subunit gamma; mitochondrial | Organisim: human | Apparent_Kd_M: 5.944485E-12
Real
Aptamer SeqId: 19276-124 | Target: RUXG | UniProt: P62308
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19276-124 | Target: RUXG | UniProt: P62308 | TargetFullName: Small nuclear ribonucleoprotein G | Organisim: human | Apparent_Kd_M: 5.917617E-12
Real
Aptamer SeqId: 19277-4 | Target: KAT | UniProt: Q8NFU3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19277-4 | Target: KAT | UniProt: Q8NFU3 | TargetFullName: Thiosulfate sulfurtransferase/rhodanese-like domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 7.066518E-11
Real
Aptamer SeqId: 19278-19 | Target: RAB1B | UniProt: Q9H0U4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19278-19 | Target: RAB1B | UniProt: Q9H0U4 | TargetFullName: Ras-related protein Rab-1B | Organisim: human | Apparent_Kd_M: 2.845123E-12
Real
Aptamer SeqId: 19279-42 | Target: CRBP | UniProt: P09455
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19279-42 | Target: CRBP | UniProt: P09455 | TargetFullName: Retinol-binding protein 1 | Organisim: human | Apparent_Kd_M: 3.462096E-12
Real
Aptamer SeqId: 19280-29 | Target: UB2D3 | UniProt: P61077
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19280-29 | Target: UB2D3 | UniProt: P61077 | TargetFullName: Ubiquitin-conjugating enzyme E2 D3 | Organisim: human | Apparent_Kd_M: 1.505366E-11
Real
Aptamer SeqId: 19281-86 | Target: MAFG | UniProt: O15525
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19281-86 | Target: MAFG | UniProt: O15525 | TargetFullName: Transcription factor MafG | Organisim: human | Apparent_Kd_M: 1.10119E-11
Real
Aptamer SeqId: 19282-3 | Target: RAB13 | UniProt: P51153
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19282-3 | Target: RAB13 | UniProt: P51153 | TargetFullName: Ras-related protein Rab-13 | Organisim: human | Apparent_Kd_M: 3.547241E-11
Real
Aptamer SeqId: 19286-30 | Target: MLR5 | UniProt: Q02045
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19286-30 | Target: MLR5 | UniProt: Q02045 | TargetFullName: Myosin light chain 5 | Organisim: human | Apparent_Kd_M: 9.616932E-12
Real
Aptamer SeqId: 19287-59 | Target: DENR | UniProt: O43583
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19287-59 | Target: DENR | UniProt: O43583 | TargetFullName: Density-regulated protein | Organisim: human | Apparent_Kd_M: 2.918118E-11
Real
Aptamer SeqId: 19289-29 | Target: DCUP | UniProt: P06132
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19289-29 | Target: DCUP | UniProt: P06132 | TargetFullName: Uroporphyrinogen decarboxylase | Organisim: human | Apparent_Kd_M: 1.142143E-11
Real
Aptamer SeqId: 19290-5 | Target: HPRT | UniProt: P00492
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19290-5 | Target: HPRT | UniProt: P00492 | TargetFullName: Hypoxanthine-guanine phosphoribosyltransferase | Organisim: human | Apparent_Kd_M: 5.30638E-12
Real
Aptamer SeqId: 19291-2 | Target: CASQ2 | UniProt: O14958
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19291-2 | Target: CASQ2 | UniProt: O14958 | TargetFullName: Calsequestrin-2 | Organisim: human | Apparent_Kd_M: 3.154055E-11
Real
Aptamer SeqId: 19293-6 | Target: VP26A | UniProt: O75436
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19293-6 | Target: VP26A | UniProt: O75436 | TargetFullName: Vacuolar protein sorting-associated protein 26A | Organisim: human | Apparent_Kd_M: 4.128258E-12
Real
Aptamer SeqId: 19294-26 | Target: CRIPT | UniProt: Q9P021
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19294-26 | Target: CRIPT | UniProt: Q9P021 | TargetFullName: Cysteine-rich PDZ-binding protein | Organisim: human | Apparent_Kd_M: 6.475773E-12
Real
Aptamer SeqId: 19295-32 | Target: PP1G | UniProt: P36873
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19295-32 | Target: PP1G | UniProt: P36873 | TargetFullName: Serine/threonine-protein phosphatase PP1-gamma catalytic subunit | Organisim: human | Apparent_Kd_M: 7.498895E-12
Real
Aptamer SeqId: 19296-51 | Target: MLRA | UniProt: Q01449
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19296-51 | Target: MLRA | UniProt: Q01449 | TargetFullName: Myosin regulatory light chain 2; atrial isoform | Organisim: human | Apparent_Kd_M: 2.507055E-11
Real
Aptamer SeqId: 19297-4 | Target: G6PD | UniProt: P11413
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19297-4 | Target: G6PD | UniProt: P11413 | TargetFullName: Glucose-6-phosphate 1-dehydrogenase | Organisim: human | Apparent_Kd_M: 3.06316E-12
Real
Aptamer SeqId: 19302-7 | Target: GIMA6 | UniProt: Q6P9H5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19302-7 | Target: GIMA6 | UniProt: Q6P9H5 | TargetFullName: GTPase IMAP family member 6 | Organisim: human | Apparent_Kd_M: 7.18E-11
Real
Aptamer SeqId: 19303-64 | Target: PT117 | UniProt: Q6UWS5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19303-64 | Target: PT117 | UniProt: Q6UWS5 | TargetFullName: Protein PET117 homolog; mitochondrial | Organisim: human | Apparent_Kd_M: 9.945875E-12
Real
Aptamer SeqId: 19310-81 | Target: COPE | UniProt: O14579
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19310-81 | Target: COPE | UniProt: O14579 | TargetFullName: Coatomer subunit epsilon | Organisim: human | Apparent_Kd_M: 3.92E-11
Real
Aptamer SeqId: 19311-15 | Target: CRBS | UniProt: P22914
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19311-15 | Target: CRBS | UniProt: P22914 | TargetFullName: Beta-crystallin S | Organisim: human | Apparent_Kd_M: 5.54E-12
Real
Aptamer SeqId: 19316-2 | Target: HSC20 | UniProt: Q8IWL3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19316-2 | Target: HSC20 | UniProt: Q8IWL3 | TargetFullName: Iron-sulfur cluster co-chaperone protein HscB; mitochondrial | Organisim: human | Apparent_Kd_M: 1.0E-10
Real
Aptamer SeqId: 19317-114 | Target: Prostatic acid phosphatase
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19317-114 | Target: Prostatic acid phosphatase | UniProt: P15309 | TargetFullName: Prostatic acid phosphatase | Organisim: human | Apparent_Kd_M: 2.621277E-11
Real
Aptamer SeqId: 19323-1 | Target: RCAS1 | UniProt: O00559
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19323-1 | Target: RCAS1 | UniProt: O00559 | TargetFullName: Receptor-binding cancer antigen expressed on SiSo cells | Organisim: human | Apparent_Kd_M: 2.808498E-11
Real
Aptamer SeqId: 19325-21 | Target: ABHEB | UniProt: Q96IU4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19325-21 | Target: ABHEB | UniProt: Q96IU4 | TargetFullName: Protein ABHD14B | Organisim: human | Apparent_Kd_M: 7.93E-11
Real
Aptamer SeqId: 19327-31 | Target: Hat1 | UniProt: O14929
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19327-31 | Target: Hat1 | UniProt: O14929 | TargetFullName: Histone acetyltransferase type B catalytic subunit | Organisim: human | Apparent_Kd_M: 9.75E-11
Real
Aptamer SeqId: 19328-51 | Target: Chk2 | UniProt: O96017
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19328-51 | Target: Chk2 | UniProt: O96017 | TargetFullName: Serine/threonine-protein kinase Chk2 | Organisim: human | Apparent_Kd_M: 2.42E-11
Real
Aptamer SeqId: 19329-31 | Target: HIPK3 | UniProt: Q9H422
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19329-31 | Target: HIPK3 | UniProt: Q9H422 | TargetFullName: Homeodomain-interacting protein kinase 3 | Organisim: human | Apparent_Kd_M: 3.12E-12
Real
Aptamer SeqId: 19331-18 | Target: BAIP2 | UniProt: Q9UQB8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19331-18 | Target: BAIP2 | UniProt: Q9UQB8 | TargetFullName: Brain-specific angiogenesis inhibitor 1-associated protein 2 | Organisim: human | Apparent_Kd_M: 3.05585E-11
Real
Aptamer SeqId: 19332-1 | Target: MOBL3 | UniProt: Q9Y3A3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19332-1 | Target: MOBL3 | UniProt: Q9Y3A3 | TargetFullName: MOB-like protein phocein | Organisim: human | Apparent_Kd_M: 4.36E-12
Real
Aptamer SeqId: 19333-4 | Target: hnRNP K | UniProt: P61978
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19333-4 | Target: hnRNP K | UniProt: P61978 | TargetFullName: Heterogeneous nuclear ribonucleoprotein K | Organisim: human | Apparent_Kd_M: 6.813381E-11
Real
Aptamer SeqId: 19334-62 | Target: TXD12 | UniProt: O95881
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19334-62 | Target: TXD12 | UniProt: O95881 | TargetFullName: Thioredoxin domain-containing protein 12 | Organisim: human | Apparent_Kd_M: 5.943266E-12
Real
Aptamer SeqId: 19335-2 | Target: HN1 | UniProt: Q9UK76
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19335-2 | Target: HN1 | UniProt: Q9UK76 | TargetFullName: Hematological and neurological expressed 1 protein | Organisim: human | Apparent_Kd_M: 3.038031E-11
Real
Aptamer SeqId: 19338-3 | Target: LZIC | UniProt: Q8WZA0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19338-3 | Target: LZIC | UniProt: Q8WZA0 | TargetFullName: Protein LZIC | Organisim: human | Apparent_Kd_M: 6.06E-11
Real
Aptamer SeqId: 19341-36 | Target: ACBD6 | UniProt: Q9BR61
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19341-36 | Target: ACBD6 | UniProt: Q9BR61 | TargetFullName: Acyl-CoA-binding domain-containing protein 6 | Organisim: human | Apparent_Kd_M: 7.23E-12
Real
Aptamer SeqId: 19347-37 | Target: Carbonic Anhydrase XII | UniProt: O43570
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19347-37 | Target: Carbonic Anhydrase XII | UniProt: O43570 | TargetFullName: Carbonic anhydrase 12 | Organisim: human | Apparent_Kd_M: 3.114533E-11
Real
Aptamer SeqId: 19353-25 | Target: OSTM1 | UniProt: Q86WC4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19353-25 | Target: OSTM1 | UniProt: Q86WC4 | TargetFullName: Osteopetrosis-associated transmembrane protein 1 | Organisim: human | Apparent_Kd_M: 1.1E-11
Real
Aptamer SeqId: 19356-20 | Target: TM1L2 | UniProt: Q6ZVM7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19356-20 | Target: TM1L2 | UniProt: Q6ZVM7 | TargetFullName: TOM1-like protein 2 | Organisim: human | Apparent_Kd_M: 4.352605E-11
Real
Aptamer SeqId: 19357-11 | Target: VAMP7 | UniProt: P51809
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19357-11 | Target: VAMP7 | UniProt: P51809 | TargetFullName: Vesicle-associated membrane protein 7 | Organisim: human | Apparent_Kd_M: 5.890206E-12
Real
Aptamer SeqId: 19360-22 | Target: LRRT1 | UniProt: Q86UE6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19360-22 | Target: LRRT1 | UniProt: Q86UE6 | TargetFullName: Leucine-rich repeat transmembrane neuronal protein 1 | Organisim: human | Apparent_Kd_M: 5.917151E-12
Real
Aptamer SeqId: 19361-78 | Target: MATN3 | UniProt: O15232
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19361-78 | Target: MATN3 | UniProt: O15232 | TargetFullName: Matrilin-3 | Organisim: human | Apparent_Kd_M: 1.89E-10
Real
Aptamer SeqId: 19364-163 | Target: PCNA | UniProt: P12004
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19364-163 | Target: PCNA | UniProt: P12004 | TargetFullName: Proliferating cell nuclear antigen | Organisim: human | Apparent_Kd_M: 1.03536E-11
Real
Aptamer SeqId: 19365-11 | Target: BCAT2 | UniProt: O15382
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19365-11 | Target: BCAT2 | UniProt: O15382 | TargetFullName: Branched-chain-amino-acid aminotransferase; mitochondrial | Organisim: human | Apparent_Kd_M: 4.242997E-12
Real
Aptamer SeqId: 19366-8 | Target: PEX26 | UniProt: Q7Z412
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19366-8 | Target: PEX26 | UniProt: Q7Z412 | TargetFullName: Peroxisome assembly protein 26 | Organisim: human | Apparent_Kd_M: 1.723281E-10
Real
Aptamer SeqId: 19367-34 | Target: D3D2 | UniProt: P42126
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19367-34 | Target: D3D2 | UniProt: P42126 | TargetFullName: Enoyl-CoA delta isomerase 1; mitochondrial | Organisim: human | Apparent_Kd_M: 2.279256E-11
Real
Aptamer SeqId: 19369-17 | Target: GCNL2 | UniProt: Q92830
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19369-17 | Target: GCNL2 | UniProt: Q92830 | TargetFullName: Histone acetyltransferase KAT2A | Organisim: human | Apparent_Kd_M: 1.367739E-11
Real
Aptamer SeqId: 19370-30 | Target: HS3S4 | UniProt: Q9Y661
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19370-30 | Target: HS3S4 | UniProt: Q9Y661 | TargetFullName: Heparan sulfate glucosamine 3-O-sulfotransferase 4 | Organisim: human | Apparent_Kd_M: 7.197426E-12
Real
Aptamer SeqId: 19372-7 | Target: MDGA2 | UniProt: Q7Z553
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19372-7 | Target: MDGA2 | UniProt: Q7Z553 | TargetFullName: MAM domain-containing glycosylphosphatidylinositol anchor protein 2 | Organisim: human | Apparent_Kd_M: 1.623933E-12
Real
Aptamer SeqId: 19373-3 | Target: MLRM | UniProt: P19105
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19373-3 | Target: MLRM | UniProt: P19105 | TargetFullName: Myosin regulatory light chain 12A | Organisim: human | Apparent_Kd_M: 1.450259E-11
Real
Aptamer SeqId: 19374-72 | Target: MTCP1 | UniProt: P56278
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19374-72 | Target: MTCP1 | UniProt: P56278 | TargetFullName: Protein p13 MTCP-1 | Organisim: human | Apparent_Kd_M: 5.484149E-12
Real
Aptamer SeqId: 19376-74 | Target: NNMT | UniProt: P40261
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19376-74 | Target: NNMT | UniProt: P40261 | TargetFullName: Nicotinamide N-methyltransferase | Organisim: human | Apparent_Kd_M: 1.057059E-11
Real
Aptamer SeqId: 19377-14 | Target: NOE2 | UniProt: O95897
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19377-14 | Target: NOE2 | UniProt: O95897 | TargetFullName: Noelin-2 | Organisim: human | Apparent_Kd_M: 2.76894E-11
Real
Aptamer SeqId: 19379-154 | Target: RAB3D | UniProt: O95716
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19379-154 | Target: RAB3D | UniProt: O95716 | TargetFullName: Ras-related protein Rab-3D | Organisim: human | Apparent_Kd_M: 3.141673E-12
Real
Aptamer SeqId: 19381-7 | Target: RGS21 | UniProt: Q2M5E4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19381-7 | Target: RGS21 | UniProt: Q2M5E4 | TargetFullName: Regulator of G-protein signaling 21 | Organisim: human | Apparent_Kd_M: 7.607231E-12
Real
Aptamer SeqId: 19383-131 | Target: CINP | UniProt: Q9BW66
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19383-131 | Target: CINP | UniProt: Q9BW66 | TargetFullName: Cyclin-dependent kinase 2-interacting protein | Organisim: human | Apparent_Kd_M: 5.964902E-12
Real
Aptamer SeqId: 19388-2 | Target: Cadherin-12 | UniProt: P55289
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19388-2 | Target: Cadherin-12 | UniProt: P55289 | TargetFullName: Cadherin-12 | Organisim: human | Apparent_Kd_M: 1.498474E-10
Real
Aptamer SeqId: 19392-6 | Target: DDAH1 | UniProt: O94760
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19392-6 | Target: DDAH1 | UniProt: O94760 | TargetFullName: N(G);N(G)-dimethylarginine dimethylaminohydrolase 1 | Organisim: human | Apparent_Kd_M: 1.414571E-11
Real
Aptamer SeqId: 19437-61 | Target: L-VEGF165 | UniProt: P15692
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19437-61 | Target: L-VEGF165 | UniProt: P15692 | TargetFullName: Isoform L-VEGF165 | Organisim: human | Apparent_Kd_M: 1.09387E-11
Real
Aptamer SeqId: 19438-68 | Target: SYF2 | UniProt: O95926
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19438-68 | Target: SYF2 | UniProt: O95926 | TargetFullName: Pre-mRNA-splicing factor SYF2 | Organisim: human | Apparent_Kd_M: 3.036319E-11
Real
Aptamer SeqId: 19446-1 | Target: GMPR2 | UniProt: Q9P2T1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19446-1 | Target: GMPR2 | UniProt: Q9P2T1 | TargetFullName: GMP reductase 2 | Organisim: human | Apparent_Kd_M: 1.30711E-11
Real
Aptamer SeqId: 19448-104 | Target: UPP1 | UniProt: Q16831
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19448-104 | Target: UPP1 | UniProt: Q16831 | TargetFullName: Uridine phosphorylase 1 | Organisim: human | Apparent_Kd_M: 1.05E-11
Real
Aptamer SeqId: 19467-3 | Target: RBSK | UniProt: Q9H477
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19467-3 | Target: RBSK | UniProt: Q9H477 | TargetFullName: Ribokinase | Organisim: human | Apparent_Kd_M: 4.367158E-11
Real
Aptamer SeqId: 19482-11 | Target: HDHD3 | UniProt: Q9BSH5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19482-11 | Target: HDHD3 | UniProt: Q9BSH5 | TargetFullName: Haloacid dehalogenase-like hydrolase domain-containing protein 3 | Organisim: human | Apparent_Kd_M: 2.2078E-11
Real
Aptamer SeqId: 19483-16 | Target: KDSR | UniProt: Q06136
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19483-16 | Target: KDSR | UniProt: Q06136 | TargetFullName: 3-ketodihydrosphingosine reductase | Organisim: human | Apparent_Kd_M: 6.93238E-12
Real
Aptamer SeqId: 19488-1 | Target: PDCD6 | UniProt: O75340
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19488-1 | Target: PDCD6 | UniProt: O75340 | TargetFullName: Programmed cell death protein 6 | Organisim: human | Apparent_Kd_M: 8.974219E-12
Real
Aptamer SeqId: 19491-11 | Target: DHB8 | UniProt: Q92506
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19491-11 | Target: DHB8 | UniProt: Q92506 | TargetFullName: Estradiol 17-beta-dehydrogenase 8 | Organisim: human | Apparent_Kd_M: 1.265898E-11
Real
Aptamer SeqId: 19492-5 | Target: KAAG1 | UniProt: Q9UBP8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19492-5 | Target: KAAG1 | UniProt: Q9UBP8 | TargetFullName: Kidney-associated antigen 1 | Organisim: human | Apparent_Kd_M: 3.938085E-12
Real
Aptamer SeqId: 19496-1 | Target: NPL | UniProt: Q9BXD5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19496-1 | Target: NPL | UniProt: Q9BXD5 | TargetFullName: N-acetylneuraminate lyase | Organisim: human | Apparent_Kd_M: 1.436244E-11
Real
Aptamer SeqId: 19503-2 | Target: SNX3 | UniProt: O60493
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19503-2 | Target: SNX3 | UniProt: O60493 | TargetFullName: Sorting nexin-3 | Organisim: human | Apparent_Kd_M: 2.67E-12
Real
Aptamer SeqId: 19504-22 | Target: KTHY | UniProt: P23919
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19504-22 | Target: KTHY | UniProt: P23919 | TargetFullName: Thymidylate kinase | Organisim: human | Apparent_Kd_M: 4.4495E-12
Real
Aptamer SeqId: 19506-6 | Target: GLYAT | UniProt: Q6IB77
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19506-6 | Target: GLYAT | UniProt: Q6IB77 | TargetFullName: Glycine N-acyltransferase | Organisim: human | Apparent_Kd_M: 1.227664E-12
Real
Aptamer SeqId: 19511-8 | Target: DCNL2 | UniProt: Q6PH85
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19511-8 | Target: DCNL2 | UniProt: Q6PH85 | TargetFullName: DCN1-like protein 2 | Organisim: human | Apparent_Kd_M: 1.785239E-11
Real
Aptamer SeqId: 19516-10 | Target: HMGA2 | UniProt: P52926
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19516-10 | Target: HMGA2 | UniProt: P52926 | TargetFullName: High mobility group protein HMGI-C | Organisim: human | Apparent_Kd_M: 8.863154E-12
Real
Aptamer SeqId: 19518-12 | Target: HXK3 | UniProt: P52790
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19518-12 | Target: HXK3 | UniProt: P52790 | TargetFullName: Hexokinase-3 | Organisim: human | Apparent_Kd_M: 4.192696E-11
Real
Aptamer SeqId: 19523-215 | Target: PARK7 | UniProt: Q99497
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19523-215 | Target: PARK7 | UniProt: Q99497 | TargetFullName: Protein DJ-1 | Organisim: human | Apparent_Kd_M: 7.553336E-12
Real
Aptamer SeqId: 19545-145 | Target: Oxidized PARK7 | UniProt: Q99497
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19545-145 | Target: Oxidized PARK7 | UniProt: Q99497 | TargetFullName: Oxidized Protein deglycase DJ-1 | Organisim: human | Apparent_Kd_M: 3.844816E-10
Real
Aptamer SeqId: 19553-14 | Target: STX1a | UniProt: Q16623
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19553-14 | Target: STX1a | UniProt: Q16623 | TargetFullName: Syntaxin-1A | Organisim: human | Apparent_Kd_M: 4.812981E-12
Real
Aptamer SeqId: 19555-1 | Target: SUMO2 | UniProt: P61956
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19555-1 | Target: SUMO2 | UniProt: P61956 | TargetFullName: Small ubiquitin-related modifier 2 | Organisim: human | Apparent_Kd_M: 6.978434E-13
Real
Aptamer SeqId: 19556-12 | Target: Complement receptor type 1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19556-12 | Target: Complement receptor type 1 | UniProt: P17927 | TargetFullName: Complement receptor type 1 | Organisim: human | Apparent_Kd_M: 1.05E-12
Real
Aptamer SeqId: 19557-3 | Target: KLOTB | UniProt: Q86Z14
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19557-3 | Target: KLOTB | UniProt: Q86Z14 | TargetFullName: Beta-klotho | Organisim: human | Apparent_Kd_M: 9.647868E-13
Real
Aptamer SeqId: 19558-10 | Target: LRP4 | UniProt: O75096
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19558-10 | Target: LRP4 | UniProt: O75096 | TargetFullName: Low-density lipoprotein receptor-related protein 4 | Organisim: human | Apparent_Kd_M: 4.075105E-12
Real
Aptamer SeqId: 19560-23 | Target: PLXA4 | UniProt: Q9HCM2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19560-23 | Target: PLXA4 | UniProt: Q9HCM2 | TargetFullName: Plexin-A4 | Organisim: human | Apparent_Kd_M: 1.595146E-12
Real
Aptamer SeqId: 19561-216 | Target: PLXD1 | UniProt: Q9Y4D7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19561-216 | Target: PLXD1 | UniProt: Q9Y4D7 | TargetFullName: Plexin-D1 | Organisim: human | Apparent_Kd_M: 1.789233E-12
Real
Aptamer SeqId: 19562-8 | Target: UBP28 | UniProt: Q96RU2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19562-8 | Target: UBP28 | UniProt: Q96RU2 | TargetFullName: Ubiquitin carboxyl-terminal hydrolase 28 | Organisim: human | Apparent_Kd_M: 1.794333E-10
Real
Aptamer SeqId: 19563-3 | Target: SEZ6L | UniProt: Q9BYH1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19563-3 | Target: SEZ6L | UniProt: Q9BYH1 | TargetFullName: Seizure 6-like protein | Organisim: human | Apparent_Kd_M: 1.832901E-12
Real
Aptamer SeqId: 19564-61 | Target: IRF4 | UniProt: Q15306
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19564-61 | Target: IRF4 | UniProt: Q15306 | TargetFullName: Interferon regulatory factor 4 | Organisim: human | Apparent_Kd_M: 8.31E-12
Real
Aptamer SeqId: 19567-1 | Target: EGFRvIII | UniProt: P00533
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19567-1 | Target: EGFRvIII | UniProt: P00533 | TargetFullName: Epidermal growth factor receptor variant III | Organisim: human | Apparent_Kd_M: 3.73E-11
Real
Aptamer SeqId: 19568-17 | Target: IL-15 | UniProt: P40933
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19568-17 | Target: IL-15 | UniProt: P40933 | TargetFullName: Interleukin-15 | Organisim: human | Apparent_Kd_M: 2.86E-11
Real
Aptamer SeqId: 19570-12 | Target: FGF-8 | UniProt: P55075
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19570-12 | Target: FGF-8 | UniProt: P55075 | TargetFullName: Fibroblast growth factor 8 | Organisim: human | Apparent_Kd_M: 4.43E-12
Real
Aptamer SeqId: 19572-10 | Target: CEBPG | UniProt: P53567
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19572-10 | Target: CEBPG | UniProt: P53567 | TargetFullName: CCAAT/enhancer-binding protein gamma | Organisim: human | Apparent_Kd_M: 1.52E-11
Real
Aptamer SeqId: 19574-5 | Target: gpIIbIIIa | UniProt: P08514|P05106
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19574-5 | Target: gpIIbIIIa | UniProt: P08514|P05106 | TargetFullName: Integrin alpha-IIb: beta-3 complex | Organisim: human | Apparent_Kd_M: 3.74655E-11
Real
Aptamer SeqId: 19575-4 | Target: EPO-R | UniProt: P19235
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19575-4 | Target: EPO-R | UniProt: P19235 | TargetFullName: Erythropoietin receptor | Organisim: human | Apparent_Kd_M: 2.28E-11
Real
Aptamer SeqId: 19578-19 | Target: DOK2 | UniProt: O60496
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19578-19 | Target: DOK2 | UniProt: O60496 | TargetFullName: Docking protein 2 | Organisim: human | Apparent_Kd_M: 5.48E-12
Real
Aptamer SeqId: 19579-5 | Target: HNP-1 | UniProt: P59665
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19579-5 | Target: HNP-1 | UniProt: P59665 | TargetFullName: Neutrophil defensin 1 | Organisim: human | Apparent_Kd_M: 4.36E-12
Real
Aptamer SeqId: 19581-15 | Target: IGFBP-5 | UniProt: P24593
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19581-15 | Target: IGFBP-5 | UniProt: P24593 | TargetFullName: Insulin-like growth factor-binding protein 5 | Organisim: human | Apparent_Kd_M: 3.09E-12
Real
Aptamer SeqId: 19584-33 | Target: FGF9 | UniProt: P31371
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19584-33 | Target: FGF9 | UniProt: P31371 | TargetFullName: Fibroblast growth factor 9 | Organisim: human | Apparent_Kd_M: 2.59E-12
Real
Aptamer SeqId: 19586-89 | Target: RAB3C | UniProt: Q96E17
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19586-89 | Target: RAB3C | UniProt: Q96E17 | TargetFullName: Ras-related protein Rab-3C | Organisim: human | Apparent_Kd_M: 3.008535E-11
Real
Aptamer SeqId: 19587-12 | Target: IMA5 | UniProt: P52294
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19587-12 | Target: IMA5 | UniProt: P52294 | TargetFullName: Importin subunit alpha-5 | Organisim: human | Apparent_Kd_M: 2.63E-11
Real
Aptamer SeqId: 19590-46 | Target: SP-D | UniProt: P35247
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19590-46 | Target: SP-D | UniProt: P35247 | TargetFullName: Pulmonary surfactant-associated protein D | Organisim: human | Apparent_Kd_M: 3.179932E-11
Real
Aptamer SeqId: 19596-18 | Target: BRF-1 | UniProt: Q92994
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19596-18 | Target: BRF-1 | UniProt: Q92994 | TargetFullName: Transcription factor IIIB 90 kDa subunit | Organisim: human | Apparent_Kd_M: 9.36E-11
Real
Aptamer SeqId: 19601-15 | Target: ASB9 | UniProt: Q96DX5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19601-15 | Target: ASB9 | UniProt: Q96DX5 | TargetFullName: Ankyrin repeat and SOCS box protein 9 | Organisim: human | Apparent_Kd_M: 3.842785E-11
Real
Aptamer SeqId: 19602-36 | Target: jun-D | UniProt: P17535
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19602-36 | Target: jun-D | UniProt: P17535 | TargetFullName: Transcription factor jun-D | Organisim: human | Apparent_Kd_M: 5.414665E-12
Real
Aptamer SeqId: 19606-28 | Target: ihh | UniProt: Q14623
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19606-28 | Target: ihh | UniProt: Q14623 | TargetFullName: Indian hedgehog protein | Organisim: human | Apparent_Kd_M: 2.165878E-11
Real
Aptamer SeqId: 19612-3 | Target: CD81 | UniProt: P60033
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19612-3 | Target: CD81 | UniProt: P60033 | TargetFullName: CD81 antigen | Organisim: human | Apparent_Kd_M: 1.952468E-10
Real
Aptamer SeqId: 19614-8 | Target: Holo-TC I | UniProt: P20061
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19614-8 | Target: Holo-TC I | UniProt: P20061 | TargetFullName: Transcobalamin-1 | Organisim: human | Apparent_Kd_M: 3.296429E-12
Real
Aptamer SeqId: 19615-213 | Target: 5NT3 | UniProt: Q9H0P0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19615-213 | Target: 5NT3 | UniProt: Q9H0P0 | TargetFullName: Cytosolic 5'-nucleotidase 3A | Organisim: human | Apparent_Kd_M: 7.602666E-12
Real
Aptamer SeqId: 19616-100 | Target: EFHD1 | UniProt: Q9BUP0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19616-100 | Target: EFHD1 | UniProt: Q9BUP0 | TargetFullName: EF-hand domain-containing protein D1 | Organisim: human | Apparent_Kd_M: 2.021984E-12
Real
Aptamer SeqId: 19617-5 | Target: LTB4DH | UniProt: Q14914
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19617-5 | Target: LTB4DH | UniProt: Q14914 | TargetFullName: Prostaglandin reductase 1 | Organisim: human | Apparent_Kd_M: 1.787524E-12
Real
Aptamer SeqId: 19620-16 | Target: DLG2 | UniProt: Q15700
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19620-16 | Target: DLG2 | UniProt: Q15700 | TargetFullName: Disks large homolog 2 | Organisim: human | Apparent_Kd_M: 2.269593E-12
Real
Aptamer SeqId: 19622-7 | Target: Activin A | UniProt: P08476
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19622-7 | Target: Activin A | UniProt: P08476 | TargetFullName: Inhibin beta A chain | Organisim: human | Apparent_Kd_M: 2.9564E-12
Real
Aptamer SeqId: 19623-26 | Target: 40S ribosomal protein SA
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19623-26 | Target: 40S ribosomal protein SA | UniProt: P08865 | TargetFullName: 40S ribosomal protein SA | Organisim: human | Apparent_Kd_M: 3.783614E-12
Real
Aptamer SeqId: 19631-13 | Target: Kininostatin | UniProt: P01042
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19631-13 | Target: Kininostatin | UniProt: P01042 | TargetFullName: Kininostatin | Organisim: human | Apparent_Kd_M: 5.458265E-11
Real
Aptamer SeqId: 19635-69 | Target: FGL2 | UniProt: Q14314
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19635-69 | Target: FGL2 | UniProt: Q14314 | TargetFullName: Fibroleukin | Organisim: human | Apparent_Kd_M: 3.035508E-11
Real
Aptamer SeqId: 19636-23 | Target: HLA-G | UniProt: P17693
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19636-23 | Target: HLA-G | UniProt: P17693 | TargetFullName: HLA class I histocompatibility antigen; alpha chain G | Organisim: human | Apparent_Kd_M: 1.294933E-10
Real
Aptamer SeqId: 19637-9 | Target: CRH | UniProt: P06850
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19637-9 | Target: CRH | UniProt: P06850 | TargetFullName: Corticoliberin | Organisim: human | Apparent_Kd_M: 2.053152E-11
Real
Aptamer SeqId: 19638-9 | Target: Dynorphin A (1-17) | UniProt: P01213
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19638-9 | Target: Dynorphin A (1-17) | UniProt: P01213 | TargetFullName: Dynorphin A (1-17) | Organisim: human | Apparent_Kd_M: 3.258531E-12
Real
Aptamer SeqId: 19639-53 | Target: IAPP | UniProt: P10997
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19639-53 | Target: IAPP | UniProt: P10997 | TargetFullName: Islet amyloid polypeptide | Organisim: human | Apparent_Kd_M: 5.277639E-12
Real
Aptamer SeqId: 19640-2 | Target: Parathyroid Hormone1-34 | UniProt: P01270
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 19640-2 | Target: Parathyroid Hormone1-34 | UniProt: P01270 | TargetFullName: Parathyroid Hormone1-34 | Organisim: human | Apparent_Kd_M: 1.053322E-11
Real
Aptamer SeqId: 2052-1 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2052-1 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2053-2 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2053-2 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2054-3 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2054-3 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2055-4 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2055-4 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2056-5 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2056-5 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2057-6 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2057-6 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2058-7 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2058-7 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2060-9 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2060-9 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2061-10 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2061-10 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2171-12 | Target: HCE001796 | UniProt: HCE001796
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2171-12 | Target: HCE001796 | UniProt: HCE001796 | TargetFullName: HCE001796 | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2178-55 | Target: HCE003167 | UniProt: HCE003167
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2178-55 | Target: HCE003167 | UniProt: HCE003167 | TargetFullName: HCE003167 | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2182-54 | Target: C4b | UniProt: P0C0L4|P0C0L5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2182-54 | Target: C4b | UniProt: P0C0L4|P0C0L5 | TargetFullName: Complement C4b | Organisim: human | Apparent_Kd_M: 3.02E-11
Real
Aptamer SeqId: 2190-55 | Target: Coagulation Factor XI | UniProt: P03951
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2190-55 | Target: Coagulation Factor XI | UniProt: P03951 | TargetFullName: Coagulation Factor XI | Organisim: human | Apparent_Kd_M: 9.2E-12
Real
Aptamer SeqId: 2192-63 | Target: CTACK | UniProt: Q9Y4X3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2192-63 | Target: CTACK | UniProt: Q9Y4X3 | TargetFullName: C-C motif chemokine 27 | Organisim: human | Apparent_Kd_M: 3.13E-12
Real
Aptamer SeqId: 2194-91 | Target: HCE000414 | UniProt: HCE000414
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2194-91 | Target: HCE000414 | UniProt: HCE000414 | TargetFullName: HCE000414 | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2201-17 | Target: Endostatin | UniProt: P39060
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2201-17 | Target: Endostatin | UniProt: P39060 | TargetFullName: Endostatin | Organisim: human | Apparent_Kd_M: 3.148545E-12
Real
Aptamer SeqId: 2211-9 | Target: TIMP-1 | UniProt: P01033
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2211-9 | Target: TIMP-1 | UniProt: P01033 | TargetFullName: Metalloproteinase inhibitor 1 | Organisim: human | Apparent_Kd_M: 7.22E-12
Real
Aptamer SeqId: 2212-69 | Target: tPA | UniProt: P00750
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2212-69 | Target: tPA | UniProt: P00750 | TargetFullName: Tissue-type plasminogen activator | Organisim: human | Apparent_Kd_M: 3.82E-11
Real
Aptamer SeqId: 2229-54 | Target: HCE003183 | UniProt: HCE003183
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2229-54 | Target: HCE003183 | UniProt: HCE003183 | TargetFullName: HCE003183 | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2247-20 | Target: EG-VEGF | UniProt: P58294
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2247-20 | Target: EG-VEGF | UniProt: P58294 | TargetFullName: Prokineticin-1 | Organisim: human | Apparent_Kd_M: 1.01E-11
Real
Aptamer SeqId: 2249-25 | Target: HCE004333 | UniProt: HCE004333
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2249-25 | Target: HCE004333 | UniProt: HCE004333 | TargetFullName: HCE004333 | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2273-34 | Target: HCE004359 | UniProt: HCE004359
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2273-34 | Target: HCE004359 | UniProt: HCE004359 | TargetFullName: HCE004359 | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2278-61 | Target: TIMP-2 | UniProt: P16035
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2278-61 | Target: TIMP-2 | UniProt: P16035 | TargetFullName: Metalloproteinase inhibitor 2 | Organisim: human | Apparent_Kd_M: 3.08E-12
Real
Aptamer SeqId: 2288-7 | Target: HCE004331 | UniProt: HCE004331
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2288-7 | Target: HCE004331 | UniProt: HCE004331 | TargetFullName: HCE004331 | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2305-52 | Target: HCE003300 | UniProt: HCE003300
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2305-52 | Target: HCE003300 | UniProt: HCE003300 | TargetFullName: HCE003300 | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2312-13 | Target: HCE000483 | UniProt: HCE000483
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2312-13 | Target: HCE000483 | UniProt: HCE000483 | TargetFullName: HCE000483 | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2333-72 | Target: TGF-b1 | UniProt: P01137
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2333-72 | Target: TGF-b1 | UniProt: P01137 | TargetFullName: Transforming growth factor beta-1 | Organisim: human | Apparent_Kd_M: 4.06E-11
Real
Aptamer SeqId: 2359-65 | Target: HCE004152 | UniProt: HCE004152
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2359-65 | Target: HCE004152 | UniProt: HCE004152 | TargetFullName: HCE004152 | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2381-52 | Target: C5 | UniProt: P01031
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2381-52 | Target: C5 | UniProt: P01031 | TargetFullName: Complement C5 | Organisim: human | Apparent_Kd_M: 7.61E-11
Real
Aptamer SeqId: 2418-55 | Target: Apo E | UniProt: P02649
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2418-55 | Target: Apo E | UniProt: P02649 | TargetFullName: Apolipoprotein E | Organisim: human | Apparent_Kd_M: 2.31E-10
Real
Aptamer SeqId: 2421-7 | Target: BDNF | UniProt: P23560
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2421-7 | Target: BDNF | UniProt: P23560 | TargetFullName: Brain-derived neurotrophic factor | Organisim: human | Apparent_Kd_M: 7.05E-12
Real
Aptamer SeqId: 2429-27 | Target: C8 | UniProt: P07357|P07358|P07360
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2429-27 | Target: C8 | UniProt: P07357|P07358|P07360 | TargetFullName: Complement component C8 | Organisim: human | Apparent_Kd_M: 4.82E-11
Real
Aptamer SeqId: 2430-52 | Target: HCE000342 | UniProt: HCE000342
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2430-52 | Target: HCE000342 | UniProt: HCE000342 | TargetFullName: HCE000342 | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2431-17 | Target: Cathepsin G | UniProt: P08311
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2431-17 | Target: Cathepsin G | UniProt: P08311 | TargetFullName: Cathepsin G | Organisim: human | Apparent_Kd_M: 9.96E-11
Real
Aptamer SeqId: 2436-49 | Target: CXCL16; soluble | UniProt: Q9H2A7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2436-49 | Target: CXCL16; soluble | UniProt: Q9H2A7 | TargetFullName: C-X-C motif chemokine 16 | Organisim: human | Apparent_Kd_M: 4.85E-12
Real
Aptamer SeqId: 2441-2 | Target: FGF-10 | UniProt: O15520
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2441-2 | Target: FGF-10 | UniProt: O15520 | TargetFullName: Fibroblast growth factor 10 | Organisim: human | Apparent_Kd_M: 6.58E-12
Real
Aptamer SeqId: 2443-10 | Target: FGF-8B | UniProt: P55075
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2443-10 | Target: FGF-8B | UniProt: P55075 | TargetFullName: Fibroblast growth factor 8 isoform B | Organisim: human | Apparent_Kd_M: 8.61E-11
Real
Aptamer SeqId: 2447-7 | Target: GIIE | UniProt: Q9NZK7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2447-7 | Target: GIIE | UniProt: Q9NZK7 | TargetFullName: Group IIE secretory phospholipase A2 | Organisim: human | Apparent_Kd_M: 3.61E-12
Real
Aptamer SeqId: 2449-1 | Target: GV | UniProt: P39877
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2449-1 | Target: GV | UniProt: P39877 | TargetFullName: Calcium-dependent phospholipase A2 | Organisim: human | Apparent_Kd_M: 9.06E-13
Real
Aptamer SeqId: 2468-62 | Target: MIP-3a | UniProt: P78556
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2468-62 | Target: MIP-3a | UniProt: P78556 | TargetFullName: C-C motif chemokine 20 | Organisim: human | Apparent_Kd_M: 3.97E-12
Real
Aptamer SeqId: 2474-54 | Target: SAP | UniProt: P02743
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2474-54 | Target: SAP | UniProt: P02743 | TargetFullName: Serum amyloid P-component | Organisim: human | Apparent_Kd_M: 7.87E-12
Real
Aptamer SeqId: 2475-1 | Target: SCF sR | UniProt: P10721
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2475-1 | Target: SCF sR | UniProt: P10721 | TargetFullName: Mast/stem cell growth factor receptor Kit | Organisim: human | Apparent_Kd_M: 1.68E-12
Real
Aptamer SeqId: 2480-58 | Target: TIMP-3 | UniProt: P35625
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2480-58 | Target: TIMP-3 | UniProt: P35625 | TargetFullName: Metalloproteinase inhibitor 3 | Organisim: human | Apparent_Kd_M: 1.15E-11
Real
Aptamer SeqId: 2500-2 | Target: Angiopoietin-4 | UniProt: Q9Y264
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2500-2 | Target: Angiopoietin-4 | UniProt: Q9Y264 | TargetFullName: Angiopoietin-4 | Organisim: human | Apparent_Kd_M: 5.41E-12
Real
Aptamer SeqId: 2505-49 | Target: GFRa-3 | UniProt: O60609
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2505-49 | Target: GFRa-3 | UniProt: O60609 | TargetFullName: GDNF family receptor alpha-3 | Organisim: human | Apparent_Kd_M: 4.24E-11
Real
Aptamer SeqId: 2513-7 | Target: HCE000104 | UniProt: HCE000104
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2513-7 | Target: HCE000104 | UniProt: HCE000104 | TargetFullName: HCE000104 | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2514-65 | Target: Ephrin-B3 | UniProt: Q15768
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2514-65 | Target: Ephrin-B3 | UniProt: Q15768 | TargetFullName: Ephrin-B3 | Organisim: human | Apparent_Kd_M: 9.04E-11
Real
Aptamer SeqId: 2515-14 | Target: GFRa-2 | UniProt: O00451
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2515-14 | Target: GFRa-2 | UniProt: O00451 | TargetFullName: GDNF family receptor alpha-2 | Organisim: human | Apparent_Kd_M: 4.34E-12
Real
Aptamer SeqId: 2516-57 | Target: 6Ckine | UniProt: O00585
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2516-57 | Target: 6Ckine | UniProt: O00585 | TargetFullName: C-C motif chemokine 21 | Organisim: human | Apparent_Kd_M: 7.44E-12
Real
Aptamer SeqId: 2524-56 | Target: HMG-1 | UniProt: P09429
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2524-56 | Target: HMG-1 | UniProt: P09429 | TargetFullName: High mobility group protein B1 | Organisim: human | Apparent_Kd_M: 3.71E-11
Real
Aptamer SeqId: 2558-51 | Target: b-Endorphin | UniProt: P01189
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2558-51 | Target: b-Endorphin | UniProt: P01189 | TargetFullName: Beta-endorphin | Organisim: human | Apparent_Kd_M: 6.24E-11
Real
Aptamer SeqId: 2567-5 | Target: Factor I | UniProt: P05156
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2567-5 | Target: Factor I | UniProt: P05156 | TargetFullName: Complement factor I | Organisim: human | Apparent_Kd_M: 8.09E-13
Real
Aptamer SeqId: 2571-12 | Target: IGFBP-3 | UniProt: P17936
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2571-12 | Target: IGFBP-3 | UniProt: P17936 | TargetFullName: Insulin-like growth factor-binding protein 3 | Organisim: human | Apparent_Kd_M: 1.53E-11
Real
Aptamer SeqId: 2578-67 | Target: MCP-1 | UniProt: P13500
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2578-67 | Target: MCP-1 | UniProt: P13500 | TargetFullName: C-C motif chemokine 2 | Organisim: human | Apparent_Kd_M: 6.88E-12
Real
Aptamer SeqId: 2579-17 | Target: MMP-9 | UniProt: P14780
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2579-17 | Target: MMP-9 | UniProt: P14780 | TargetFullName: Matrix metalloproteinase-9 | Organisim: human | Apparent_Kd_M: 2.89E-11
Real
Aptamer SeqId: 2580-83 | Target: Myeloperoxidase | UniProt: P05164
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2580-83 | Target: Myeloperoxidase | UniProt: P05164 | TargetFullName: Myeloperoxidase | Organisim: human | Apparent_Kd_M: 1.7E-12
Real
Aptamer SeqId: 2585-2 | Target: PRL | UniProt: P01236
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2585-2 | Target: PRL | UniProt: P01236 | TargetFullName: Prolactin | Organisim: human | Apparent_Kd_M: 2.35E-11
Real
Aptamer SeqId: 2590-69 | Target: ROR1 | UniProt: Q01973
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2590-69 | Target: ROR1 | UniProt: Q01973 | TargetFullName: Inactive tyrosine-protein kinase transmembrane receptor ROR1 | Organisim: human | Apparent_Kd_M: 4.97E-12
Real
Aptamer SeqId: 2597-8 | Target: VEGF | UniProt: P15692
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2597-8 | Target: VEGF | UniProt: P15692 | TargetFullName: Vascular endothelial growth factor A | Organisim: human | Apparent_Kd_M: 1.29E-11
Real
Aptamer SeqId: 2599-51 | Target: 4-1BB ligand | UniProt: P41273
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2599-51 | Target: 4-1BB ligand | UniProt: P41273 | TargetFullName: Tumor necrosis factor ligand superfamily member 9 | Organisim: human | Apparent_Kd_M: 2.71E-11
Real
Aptamer SeqId: 2602-2 | Target: Angiopoietin-2 | UniProt: O15123
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2602-2 | Target: Angiopoietin-2 | UniProt: O15123 | TargetFullName: Angiopoietin-2 | Organisim: human | Apparent_Kd_M: 1.89E-11
Real
Aptamer SeqId: 2605-49 | Target: CD30 | UniProt: P28908
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2605-49 | Target: CD30 | UniProt: P28908 | TargetFullName: Tumor necrosis factor receptor superfamily member 8 | Organisim: human | Apparent_Kd_M: 1.76E-10
Real
Aptamer SeqId: 2607-54 | Target: CLF-1/CLC Complex | UniProt: O75462|Q9UBD9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2607-54 | Target: CLF-1/CLC Complex | UniProt: O75462|Q9UBD9 | TargetFullName: Cytokine receptor-like factor 1:Cardiotrophin-like cytokine factor 1 Complex | Organisim: human | Apparent_Kd_M: 8.02E-11
Real
Aptamer SeqId: 2609-59 | Target: Cystatin C | UniProt: P01034
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2609-59 | Target: Cystatin C | UniProt: P01034 | TargetFullName: Cystatin-C | Organisim: human | Apparent_Kd_M: 2.23E-11
Real
Aptamer SeqId: 2611-72 | Target: Dtk | UniProt: Q06418
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2611-72 | Target: Dtk | UniProt: Q06418 | TargetFullName: Tyrosine-protein kinase receptor TYRO3 | Organisim: human | Apparent_Kd_M: 2.28E-10
Real
Aptamer SeqId: 2612-5 | Target: eIF-5 | UniProt: P55010
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2612-5 | Target: eIF-5 | UniProt: P55010 | TargetFullName: Eukaryotic translation initiation factor 5 | Organisim: human | Apparent_Kd_M: 3.23E-11
Real
Aptamer SeqId: 2614-28 | Target: Ephrin-A4 | UniProt: P52798
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2614-28 | Target: Ephrin-A4 | UniProt: P52798 | TargetFullName: Ephrin-A4 | Organisim: human | Apparent_Kd_M: 3.68E-11
Real
Aptamer SeqId: 2615-60 | Target: Ephrin-A5 | UniProt: P52803
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2615-60 | Target: Ephrin-A5 | UniProt: P52803 | TargetFullName: Ephrin-A5 | Organisim: human | Apparent_Kd_M: 7.82E-12
Real
Aptamer SeqId: 2616-23 | Target: ERBB2 | UniProt: P04626
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2616-23 | Target: ERBB2 | UniProt: P04626 | TargetFullName: Receptor tyrosine-protein kinase erbB-2 | Organisim: human | Apparent_Kd_M: 2.93E-10
Real
Aptamer SeqId: 2617-56 | Target: ERBB3 | UniProt: P21860
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2617-56 | Target: ERBB3 | UniProt: P21860 | TargetFullName: Receptor tyrosine-protein kinase erbB-3 | Organisim: human | Apparent_Kd_M: 2.35E-12
Real
Aptamer SeqId: 2618-10 | Target: ERBB4 | UniProt: Q15303
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2618-10 | Target: ERBB4 | UniProt: Q15303 | TargetFullName: Receptor tyrosine-protein kinase erbB-4 | Organisim: human | Apparent_Kd_M: 3.05E-10
Real
Aptamer SeqId: 2619-72 | Target: GA733-1 protein | UniProt: P09758
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2619-72 | Target: GA733-1 protein | UniProt: P09758 | TargetFullName: Tumor-associated calcium signal transducer 2 | Organisim: human | Apparent_Kd_M: 3.94E-11
Real
Aptamer SeqId: 2620-4 | Target: gp130; soluble | UniProt: P40189
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2620-4 | Target: gp130; soluble | UniProt: P40189 | TargetFullName: Interleukin-6 receptor subunit beta | Organisim: human | Apparent_Kd_M: 6.379439E-12
Real
Aptamer SeqId: 2622-18 | Target: HO-2 | UniProt: P30519
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2622-18 | Target: HO-2 | UniProt: P30519 | TargetFullName: Heme oxygenase 2 | Organisim: human | Apparent_Kd_M: 7.84E-11
Real
Aptamer SeqId: 2625-53 | Target: HSP 90a/b | UniProt: P07900|P08238
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2625-53 | Target: HSP 90a/b | UniProt: P07900|P08238 | TargetFullName: Heat shock protein HSP 90-alpha/beta | Organisim: human | Apparent_Kd_M: 4.993405E-12
Real
Aptamer SeqId: 2631-50 | Target: IL-10 Rb | UniProt: Q08334
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2631-50 | Target: IL-10 Rb | UniProt: Q08334 | TargetFullName: Interleukin-10 receptor subunit beta | Organisim: human | Apparent_Kd_M: 4.5E-11
Real
Aptamer SeqId: 2632-5 | Target: IL-12 Rb1 | UniProt: P42701
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2632-5 | Target: IL-12 Rb1 | UniProt: P42701 | TargetFullName: Interleukin-12 receptor subunit beta-1 | Organisim: human | Apparent_Kd_M: 1.32E-11
Real
Aptamer SeqId: 2633-52 | Target: IL-13 Ra1 | UniProt: P78552
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2633-52 | Target: IL-13 Ra1 | UniProt: P78552 | TargetFullName: Interleukin-13 receptor subunit alpha-1 | Organisim: human | Apparent_Kd_M: 1.01E-10
Real
Aptamer SeqId: 2634-2 | Target: IL-2 sRg | UniProt: P31785
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2634-2 | Target: IL-2 sRg | UniProt: P31785 | TargetFullName: Cytokine receptor common subunit gamma | Organisim: human | Apparent_Kd_M: 3.08E-11
Real
Aptamer SeqId: 2635-61 | Target: Layilin | UniProt: Q6UX15
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2635-61 | Target: Layilin | UniProt: Q6UX15 | TargetFullName: Layilin | Organisim: human | Apparent_Kd_M: 1.42E-11
Real
Aptamer SeqId: 2636-10 | Target: Lymphotoxin b R | UniProt: P36941
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2636-10 | Target: Lymphotoxin b R | UniProt: P36941 | TargetFullName: Tumor necrosis factor receptor superfamily member 3 | Organisim: human | Apparent_Kd_M: 2.97E-11
Real
Aptamer SeqId: 2637-77 | Target: Macrophage mannose receptor
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2637-77 | Target: Macrophage mannose receptor | UniProt: P22897 | TargetFullName: Macrophage mannose receptor 1 | Organisim: human | Apparent_Kd_M: 1.19E-11
Real
Aptamer SeqId: 2640-3 | Target: MSP R | UniProt: Q04912
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2640-3 | Target: MSP R | UniProt: Q04912 | TargetFullName: Macrophage-stimulating protein receptor | Organisim: human | Apparent_Kd_M: 1.61E-11
Real
Aptamer SeqId: 2642-4 | Target: PAFAH beta subunit | UniProt: P68402
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2642-4 | Target: PAFAH beta subunit | UniProt: P68402 | TargetFullName: Platelet-activating factor acetylhydrolase IB subunit beta | Organisim: human | Apparent_Kd_M: 4.99E-11
Real
Aptamer SeqId: 2643-57 | Target: P-Cadherin | UniProt: P22223
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2643-57 | Target: P-Cadherin | UniProt: P22223 | TargetFullName: Cadherin-3 | Organisim: human | Apparent_Kd_M: 2.49E-11
Real
Aptamer SeqId: 2644-11 | Target: PKC-A | UniProt: P17252
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2644-11 | Target: PKC-A | UniProt: P17252 | TargetFullName: Protein kinase C alpha type | Organisim: human | Apparent_Kd_M: 3.14E-11
Real
Aptamer SeqId: 2645-54 | Target: PKC-Z | UniProt: Q05513
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2645-54 | Target: PKC-Z | UniProt: Q05513 | TargetFullName: Protein kinase C zeta type | Organisim: human | Apparent_Kd_M: 3.81E-11
Real
Aptamer SeqId: 2647-66 | Target: Rab GDP dissociation inhibitor beta
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2647-66 | Target: Rab GDP dissociation inhibitor beta | UniProt: P50395 | TargetFullName: Rab GDP dissociation inhibitor beta | Organisim: human | Apparent_Kd_M: 1.61E-11
Real
Aptamer SeqId: 2649-77 | Target: sICAM-3 | UniProt: P32942
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2649-77 | Target: sICAM-3 | UniProt: P32942 | TargetFullName: Intercellular adhesion molecule 3 | Organisim: human | Apparent_Kd_M: 1.32E-10
Real
Aptamer SeqId: 2652-15 | Target: suPAR | UniProt: Q03405
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2652-15 | Target: suPAR | UniProt: Q03405 | TargetFullName: Urokinase plasminogen activator surface receptor | Organisim: human | Apparent_Kd_M: 6.83E-12
Real
Aptamer SeqId: 2654-19 | Target: TNF sR-I | UniProt: P19438
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2654-19 | Target: TNF sR-I | UniProt: P19438 | TargetFullName: Tumor necrosis factor receptor superfamily member 1A | Organisim: human | Apparent_Kd_M: 2.45E-11
Real
Aptamer SeqId: 2658-27 | Target: TrkC | UniProt: Q16288
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2658-27 | Target: TrkC | UniProt: Q16288 | TargetFullName: NT-3 growth factor receptor | Organisim: human | Apparent_Kd_M: 1.58E-11
Real
Aptamer SeqId: 2665-26 | Target: BCMA | UniProt: Q02223
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2665-26 | Target: BCMA | UniProt: Q02223 | TargetFullName: Tumor necrosis factor receptor superfamily member 17 | Organisim: human | Apparent_Kd_M: 5.43E-11
Real
Aptamer SeqId: 2666-53 | Target: Bone proteoglycan II | UniProt: P07585
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2666-53 | Target: Bone proteoglycan II | UniProt: P07585 | TargetFullName: Decorin | Organisim: human | Apparent_Kd_M: 5.67E-11
Real
Aptamer SeqId: 2668-70 | Target: Calpain I | UniProt: P07384|P04632
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2668-70 | Target: Calpain I | UniProt: P07384|P04632 | TargetFullName: Calpain I | Organisim: human | Apparent_Kd_M: 1.12E-11
Real
Aptamer SeqId: 2677-1 | Target: ERBB1 | UniProt: P00533
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2677-1 | Target: ERBB1 | UniProt: P00533 | TargetFullName: Epidermal growth factor receptor | Organisim: human | Apparent_Kd_M: 6.97E-12
Real
Aptamer SeqId: 2681-23 | Target: HGF | UniProt: P14210
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2681-23 | Target: HGF | UniProt: P14210 | TargetFullName: Hepatocyte growth factor | Organisim: human | Apparent_Kd_M: 1.33E-12
Real
Aptamer SeqId: 2682-68 | Target: HSP 60 | UniProt: P10809
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2682-68 | Target: HSP 60 | UniProt: P10809 | TargetFullName: 60 kDa heat shock protein; mitochondrial | Organisim: human | Apparent_Kd_M: 7.0E-12
Real
Aptamer SeqId: 2683-1 | Target: iC3b | UniProt: P01024
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2683-1 | Target: iC3b | UniProt: P01024 | TargetFullName: Complement C3b; inactivated | Organisim: human | Apparent_Kd_M: 5.28E-13
Real
Aptamer SeqId: 2687-2 | Target: MIA | UniProt: Q16674
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2687-2 | Target: MIA | UniProt: Q16674 | TargetFullName: Melanoma-derived growth regulatory protein | Organisim: human | Apparent_Kd_M: 1.74E-12
Real
Aptamer SeqId: 2692-74 | Target: NPS-PLA2 | UniProt: P14555
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2692-74 | Target: NPS-PLA2 | UniProt: P14555 | TargetFullName: Phospholipase A2; membrane associated | Organisim: human | Apparent_Kd_M: 1.07E-11
Real
Aptamer SeqId: 2693-20 | Target: OSM | UniProt: P13725
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2693-20 | Target: OSM | UniProt: P13725 | TargetFullName: Oncostatin-M | Organisim: human | Apparent_Kd_M: 7.95E-12
Real
Aptamer SeqId: 2695-25 | Target: PECAM-1 | UniProt: P16284
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2695-25 | Target: PECAM-1 | UniProt: P16284 | TargetFullName: Platelet endothelial cell adhesion molecule | Organisim: human | Apparent_Kd_M: 2.43E-11
Real
Aptamer SeqId: 2696-87 | Target: Persephin | UniProt: O60542
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2696-87 | Target: Persephin | UniProt: O60542 | TargetFullName: Persephin | Organisim: human | Apparent_Kd_M: 3.39E-11
Real
Aptamer SeqId: 2697-7 | Target: PF-4 | UniProt: P02776
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2697-7 | Target: PF-4 | UniProt: P02776 | TargetFullName: Platelet factor 4 | Organisim: human | Apparent_Kd_M: 3.75E-12
Real
Aptamer SeqId: 2700-56 | Target: Protein S | UniProt: P07225
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2700-56 | Target: Protein S | UniProt: P07225 | TargetFullName: Vitamin K-dependent protein S | Organisim: human | Apparent_Kd_M: 1.49E-11
Real
Aptamer SeqId: 2704-74 | Target: TACI | UniProt: O14836
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2704-74 | Target: TACI | UniProt: O14836 | TargetFullName: Tumor necrosis factor receptor superfamily member 13B | Organisim: human | Apparent_Kd_M: 1.39E-11
Real
Aptamer SeqId: 2705-5 | Target: TECK | UniProt: O15444
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2705-5 | Target: TECK | UniProt: O15444 | TargetFullName: C-C motif chemokine 25 | Organisim: human | Apparent_Kd_M: 2.82E-12
Real
Aptamer SeqId: 2706-69 | Target: Thyroxine-Binding Globulin
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2706-69 | Target: Thyroxine-Binding Globulin | UniProt: P05543 | TargetFullName: Thyroxine-binding globulin | Organisim: human | Apparent_Kd_M: 1.43E-12
Real
Aptamer SeqId: 2708-54 | Target: TNFSF18 | UniProt: Q9UNG2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2708-54 | Target: TNFSF18 | UniProt: Q9UNG2 | TargetFullName: Tumor necrosis factor ligand superfamily member 18 | Organisim: human | Apparent_Kd_M: 2.5054E-11
Real
Aptamer SeqId: 2714-78 | Target: EMAP-2 | UniProt: Q12904
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2714-78 | Target: EMAP-2 | UniProt: Q12904 | TargetFullName: Endothelial monocyte-activating polypeptide 2 | Organisim: human | Apparent_Kd_M: 8.775512E-12
Real
Aptamer SeqId: 2719-3 | Target: G-CSF-R | UniProt: Q99062
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2719-3 | Target: G-CSF-R | UniProt: Q99062 | TargetFullName: Granulocyte colony-stimulating factor receptor | Organisim: human | Apparent_Kd_M: 9.09E-11
Real
Aptamer SeqId: 2723-9 | Target: IL-1F7 | UniProt: Q9NZH6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2723-9 | Target: IL-1F7 | UniProt: Q9NZH6 | TargetFullName: Interleukin-37 | Organisim: human | Apparent_Kd_M: 4.12E-12
Real
Aptamer SeqId: 2728-62 | Target: Tenascin | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2728-62 | Target: Tenascin | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 9.376657E-11
Real
Aptamer SeqId: 2730-58 | Target: MICA | UniProt: Q29983
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2730-58 | Target: MICA | UniProt: Q29983 | TargetFullName: MHC class I polypeptide-related sequence A | Organisim: human | Apparent_Kd_M: 6.82E-12
Real
Aptamer SeqId: 2731-29 | Target: NADPH-P450 Oxidoreductase
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2731-29 | Target: NADPH-P450 Oxidoreductase | UniProt: P16435 | TargetFullName: NADPH--cytochrome P450 reductase | Organisim: human | Apparent_Kd_M: 1.404035E-11
Real
Aptamer SeqId: 2732-58 | Target: NANOG | UniProt: Q9H9S0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2732-58 | Target: NANOG | UniProt: Q9H9S0 | TargetFullName: Homeobox protein NANOG | Organisim: human | Apparent_Kd_M: 1.37E-11
Real
Aptamer SeqId: 2734-49 | Target: NKp44 | UniProt: O95944
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2734-49 | Target: NKp44 | UniProt: O95944 | TargetFullName: Natural cytotoxicity triggering receptor 2 | Organisim: human | Apparent_Kd_M: 1.131831E-10
Real
Aptamer SeqId: 2737-22 | Target: NovH | UniProt: P48745
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2737-22 | Target: NovH | UniProt: P48745 | TargetFullName: Protein NOV homolog | Organisim: human | Apparent_Kd_M: 1.572713E-11
Real
Aptamer SeqId: 2741-22 | Target: Siglec-6 | UniProt: O43699
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2741-22 | Target: Siglec-6 | UniProt: O43699 | TargetFullName: Sialic acid-binding Ig-like lectin 6 | Organisim: human | Apparent_Kd_M: 1.482731E-11
Real
Aptamer SeqId: 2742-68 | Target: Siglec-7 | UniProt: Q9Y286
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2742-68 | Target: Siglec-7 | UniProt: Q9Y286 | TargetFullName: Sialic acid-binding Ig-like lectin 7 | Organisim: human | Apparent_Kd_M: 7.25E-13
Real
Aptamer SeqId: 2743-5 | Target: Sonic Hedgehog | UniProt: Q15465
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2743-5 | Target: Sonic Hedgehog | UniProt: Q15465 | TargetFullName: Sonic hedgehog protein | Organisim: human | Apparent_Kd_M: 1.2E-12
Real
Aptamer SeqId: 2744-57 | Target: IgG | UniProt: P01857
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2744-57 | Target: IgG | UniProt: P01857 | TargetFullName: Immunoglobulin G | Organisim: human | Apparent_Kd_M: 2.19E-11
Real
Aptamer SeqId: 2747-3 | Target: ULBP-3 | UniProt: Q9BZM4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2747-3 | Target: ULBP-3 | UniProt: Q9BZM4 | TargetFullName: NKG2D ligand 3 | Organisim: human | Apparent_Kd_M: 4.02E-11
Real
Aptamer SeqId: 2750-3 | Target: Apo A-I | UniProt: P02647
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2750-3 | Target: Apo A-I | UniProt: P02647 | TargetFullName: Apolipoprotein A-I | Organisim: human | Apparent_Kd_M: 1.67E-10
Real
Aptamer SeqId: 2752-62 | Target: BMP-14 | UniProt: P43026
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2752-62 | Target: BMP-14 | UniProt: P43026 | TargetFullName: Growth/differentiation factor 5 | Organisim: human | Apparent_Kd_M: 2.05E-11
Real
Aptamer SeqId: 2753-2 | Target: C1q | UniProt: P02745|P02746|P02747
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2753-2 | Target: C1q | UniProt: P02745|P02746|P02747 | TargetFullName: Complement C1q subcomponent | Organisim: human | Apparent_Kd_M: 2.61E-12
Real
Aptamer SeqId: 2754-50 | Target: C3 | UniProt: P01024
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2754-50 | Target: C3 | UniProt: P01024 | TargetFullName: Complement C3 | Organisim: human | Apparent_Kd_M: 8.52E-13
Real
Aptamer SeqId: 2755-8 | Target: Deprecated | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2755-8 | Target: Deprecated | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 6.22E-12
Real
Aptamer SeqId: 2760-2 | Target: DRR1 | UniProt: O95990
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2760-2 | Target: DRR1 | UniProt: O95990 | TargetFullName: Protein FAM107A | Organisim: human | Apparent_Kd_M: 1.12E-10
Real
Aptamer SeqId: 2761-49 | Target: FGF-18 | UniProt: O76093
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2761-49 | Target: FGF-18 | UniProt: O76093 | TargetFullName: Fibroblast growth factor 18 | Organisim: human | Apparent_Kd_M: 4.16E-11
Real
Aptamer SeqId: 2763-66 | Target: FGF-20 | UniProt: Q9NP95
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2763-66 | Target: FGF-20 | UniProt: Q9NP95 | TargetFullName: Fibroblast growth factor 20 | Organisim: human | Apparent_Kd_M: 7.48E-12
Real
Aptamer SeqId: 2765-4 | Target: GDF-11/8 | UniProt: O95390|O14793
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2765-4 | Target: GDF-11/8 | UniProt: O95390|O14793 | TargetFullName: Growth/differentiation factor 11/8 | Organisim: human | Apparent_Kd_M: 4.65E-12
Real
Aptamer SeqId: 2769-3 | Target: HIV-2 Rev | UniProt: P18093
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2769-3 | Target: HIV-2 Rev | UniProt: P18093 | TargetFullName: Protein Rev_HV2BE | Organisim: isolate ben | Apparent_Kd_M: 6.59E-11
Real
Aptamer SeqId: 2770-51 | Target: I-309 | UniProt: P22362
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2770-51 | Target: I-309 | UniProt: P22362 | TargetFullName: C-C motif chemokine 1 | Organisim: human | Apparent_Kd_M: 5.61E-12
Real
Aptamer SeqId: 2771-35 | Target: IGFBP-1 | UniProt: P08833
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2771-35 | Target: IGFBP-1 | UniProt: P08833 | TargetFullName: Insulin-like growth factor-binding protein 1 | Organisim: human | Apparent_Kd_M: 1.03E-11
Real
Aptamer SeqId: 2773-50 | Target: IL-10 | UniProt: P22301
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2773-50 | Target: IL-10 | UniProt: P22301 | TargetFullName: Interleukin-10 | Organisim: human | Apparent_Kd_M: 1.1E-11
Real
Aptamer SeqId: 2774-10 | Target: IL-16 | UniProt: Q14005
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2774-10 | Target: IL-16 | UniProt: Q14005 | TargetFullName: Interleukin-16 | Organisim: human | Apparent_Kd_M: 4.583266E-13
Real
Aptamer SeqId: 2778-10 | Target: IL-22 | UniProt: Q9GZX6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2778-10 | Target: IL-22 | UniProt: Q9GZX6 | TargetFullName: Interleukin-22 | Organisim: human | Apparent_Kd_M: 1.86E-12
Real
Aptamer SeqId: 2780-35 | Target: Lactoferrin | UniProt: P02788
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2780-35 | Target: Lactoferrin | UniProt: P02788 | TargetFullName: Lactotransferrin | Organisim: human | Apparent_Kd_M: 1.5E-12
Real
Aptamer SeqId: 2781-63 | Target: LAG-1 | UniProt: Q8NHW4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2781-63 | Target: LAG-1 | UniProt: Q8NHW4 | TargetFullName: C-C motif chemokine 4-like | Organisim: human | Apparent_Kd_M: 9.07E-12
Real
Aptamer SeqId: 2783-18 | Target: LD78-beta | UniProt: P16619
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2783-18 | Target: LD78-beta | UniProt: P16619 | TargetFullName: C-C motif chemokine 3-like 1 | Organisim: human | Apparent_Kd_M: 3.96E-11
Real
Aptamer SeqId: 2788-55 | Target: MMP-3 | UniProt: P08254
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2788-55 | Target: MMP-3 | UniProt: P08254 | TargetFullName: Stromelysin-1 | Organisim: human | Apparent_Kd_M: 4.53E-11
Real
Aptamer SeqId: 2789-26 | Target: MMP-7 | UniProt: P09237
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2789-26 | Target: MMP-7 | UniProt: P09237 | TargetFullName: Matrilysin | Organisim: human | Apparent_Kd_M: 7.89E-12
Real
Aptamer SeqId: 2790-54 | Target: NAP-2 | UniProt: P02775
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2790-54 | Target: NAP-2 | UniProt: P02775 | TargetFullName: Neutrophil-activating peptide 2 | Organisim: human | Apparent_Kd_M: 4.44E-12
Real
Aptamer SeqId: 2794-60 | Target: SOD | UniProt: P00441
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2794-60 | Target: SOD | UniProt: P00441 | TargetFullName: Superoxide dismutase Cu-Zn | Organisim: human | Apparent_Kd_M: 1.81E-11
Real
Aptamer SeqId: 2796-62 | Target: Fibrinogen | UniProt: P02671|P02675|P02679
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2796-62 | Target: Fibrinogen | UniProt: P02671|P02675|P02679 | TargetFullName: Fibrinogen | Organisim: human | Apparent_Kd_M: 5.84E-12
Real
Aptamer SeqId: 2797-56 | Target: Apo B | UniProt: P04114
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2797-56 | Target: Apo B | UniProt: P04114 | TargetFullName: Apolipoprotein B | Organisim: human | Apparent_Kd_M: 1.24E-11
Real
Aptamer SeqId: 2805-6 | Target: ACE2 | UniProt: Q9BYF1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2805-6 | Target: ACE2 | UniProt: Q9BYF1 | TargetFullName: Angiotensin-converting enzyme 2 | Organisim: human | Apparent_Kd_M: 9.98E-11
Real
Aptamer SeqId: 2806-49 | Target: Activin RIB | UniProt: P36896
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2806-49 | Target: Activin RIB | UniProt: P36896 | TargetFullName: Activin receptor type-1B | Organisim: human | Apparent_Kd_M: 1.65E-10
Real
Aptamer SeqId: 2809-25 | Target: ADAMTS-4 | UniProt: O75173
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2809-25 | Target: ADAMTS-4 | UniProt: O75173 | TargetFullName: A disintegrin and metalloproteinase with thrombospondin motifs 4 | Organisim: human | Apparent_Kd_M: 1.44E-12
Real
Aptamer SeqId: 2811-27 | Target: Angiopoietin-1 | UniProt: Q15389
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2811-27 | Target: Angiopoietin-1 | UniProt: Q15389 | TargetFullName: Angiopoietin-1 | Organisim: human | Apparent_Kd_M: 2.338007E-11
Real
Aptamer SeqId: 2813-11 | Target: ART | UniProt: O00253
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2813-11 | Target: ART | UniProt: O00253 | TargetFullName: Agouti-related protein | Organisim: human | Apparent_Kd_M: 5.700085E-12
Real
Aptamer SeqId: 2816-50 | Target: BCAM | UniProt: P50895
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2816-50 | Target: BCAM | UniProt: P50895 | TargetFullName: Basal Cell Adhesion Molecule | Organisim: human | Apparent_Kd_M: 2.08E-11
Real
Aptamer SeqId: 2819-23 | Target: Cadherin-5 | UniProt: P33151
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2819-23 | Target: Cadherin-5 | UniProt: P33151 | TargetFullName: Cadherin-5 | Organisim: human | Apparent_Kd_M: 3.0E-11
Real
Aptamer SeqId: 2823-7 | Target: COMMD7 | UniProt: Q86VX2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2823-7 | Target: COMMD7 | UniProt: Q86VX2 | TargetFullName: COMM domain-containing protein 7 | Organisim: human | Apparent_Kd_M: 2.259954E-11
Real
Aptamer SeqId: 2826-53 | Target: EDA | UniProt: Q92838
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2826-53 | Target: EDA | UniProt: Q92838 | TargetFullName: Ectodysplasin-A; secreted form | Organisim: human | Apparent_Kd_M: 1.295973E-11
Real
Aptamer SeqId: 2827-23 | Target: Fractalkine/CX3CL-1 | UniProt: P78423
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2827-23 | Target: Fractalkine/CX3CL-1 | UniProt: P78423 | TargetFullName: Fractalkine | Organisim: human | Apparent_Kd_M: 2.43E-11
Real
Aptamer SeqId: 2828-82 | Target: HAI-1 | UniProt: O43278
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2828-82 | Target: HAI-1 | UniProt: O43278 | TargetFullName: Kunitz-type protease inhibitor 1 | Organisim: human | Apparent_Kd_M: 9.73E-12
Real
Aptamer SeqId: 2829-19 | Target: IL-27 | UniProt: Q8NEV9|Q14213
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2829-19 | Target: IL-27 | UniProt: Q8NEV9|Q14213 | TargetFullName: Interleukin-27 | Organisim: human | Apparent_Kd_M: 8.23E-12
Real
Aptamer SeqId: 2831-29 | Target: Kallikrein 11 | UniProt: Q9UBX7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2831-29 | Target: Kallikrein 11 | UniProt: Q9UBX7 | TargetFullName: Kallikrein-11 | Organisim: human | Apparent_Kd_M: 1.76E-11
Real
Aptamer SeqId: 2833-20 | Target: Kallikrein 4 | UniProt: Q9Y5K2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2833-20 | Target: Kallikrein 4 | UniProt: Q9Y5K2 | TargetFullName: Kallikrein-4 | Organisim: human | Apparent_Kd_M: 1.99E-11
Real
Aptamer SeqId: 2834-54 | Target: kallikrein 8 | UniProt: O60259
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2834-54 | Target: kallikrein 8 | UniProt: O60259 | TargetFullName: Kallikrein-8 | Organisim: human | Apparent_Kd_M: 2.15E-11
Real
Aptamer SeqId: 2835-1 | Target: Ku70 | UniProt: P12956
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2835-1 | Target: Ku70 | UniProt: P12956 | TargetFullName: X-ray repair cross-complementing protein 6 | Organisim: human | Apparent_Kd_M: 1.318429E-11
Real
Aptamer SeqId: 2836-68 | Target: Lipocalin 2 | UniProt: P80188
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2836-68 | Target: Lipocalin 2 | UniProt: P80188 | TargetFullName: Neutrophil gelatinase-associated lipocalin | Organisim: human | Apparent_Kd_M: 4.094249E-12
Real
Aptamer SeqId: 2837-3 | Target: Met | UniProt: P08581
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2837-3 | Target: Met | UniProt: P08581 | TargetFullName: Hepatocyte growth factor receptor | Organisim: human | Apparent_Kd_M: 2.43E-12
Real
Aptamer SeqId: 2838-53 | Target: MMP-17 | UniProt: Q9ULZ9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2838-53 | Target: MMP-17 | UniProt: Q9ULZ9 | TargetFullName: Matrix metalloproteinase-17 | Organisim: human | Apparent_Kd_M: 1.88E-10
Real
Aptamer SeqId: 2839-2 | Target: OX40 Ligand | UniProt: P23510
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2839-2 | Target: OX40 Ligand | UniProt: P23510 | TargetFullName: Tumor necrosis factor ligand superfamily member 4 | Organisim: human | Apparent_Kd_M: 1.03E-10
Real
Aptamer SeqId: 2843-13 | Target: SPINT2 | UniProt: O43291
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2843-13 | Target: SPINT2 | UniProt: O43291 | TargetFullName: Kunitz-type protease inhibitor 2 | Organisim: human | Apparent_Kd_M: 3.61E-12
Real
Aptamer SeqId: 2844-53 | Target: sTie-1 | UniProt: P35590
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2844-53 | Target: sTie-1 | UniProt: P35590 | TargetFullName: Tyrosine-protein kinase receptor Tie-1; soluble | Organisim: human | Apparent_Kd_M: 4.38E-11
Real
Aptamer SeqId: 2846-24 | Target: Ubiquitin+1 | UniProt: P62979
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2846-24 | Target: Ubiquitin+1 | UniProt: P62979 | TargetFullName: Ubiquitin+1; truncated mutation for UbB | Organisim: human | Apparent_Kd_M: 9.31E-13
Real
Aptamer SeqId: 2849-49 | Target: AIF1 | UniProt: P55008
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2849-49 | Target: AIF1 | UniProt: P55008 | TargetFullName: Allograft inflammatory factor 1 | Organisim: human | Apparent_Kd_M: 1.07E-11
Real
Aptamer SeqId: 2851-63 | Target: C5a | UniProt: P01031
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2851-63 | Target: C5a | UniProt: P01031 | TargetFullName: C5a anaphylatoxin | Organisim: human | Apparent_Kd_M: 1.45E-11
Real
Aptamer SeqId: 2853-68 | Target: CHK1 | UniProt: O14757
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2853-68 | Target: CHK1 | UniProt: O14757 | TargetFullName: Serine/threonine-protein kinase Chk1 | Organisim: human | Apparent_Kd_M: 7.169917E-12
Real
Aptamer SeqId: 2855-49 | Target: ERK-1 | UniProt: P27361
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2855-49 | Target: ERK-1 | UniProt: P27361 | TargetFullName: Mitogen-activated protein kinase 3 | Organisim: human | Apparent_Kd_M: 4.0E-12
Real
Aptamer SeqId: 2859-69 | Target: HDAC8 | UniProt: Q9BY41
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2859-69 | Target: HDAC8 | UniProt: Q9BY41 | TargetFullName: Histone deacetylase 8 | Organisim: human | Apparent_Kd_M: 1.007847E-11
Real
Aptamer SeqId: 2860-19 | Target: Karyopherin-a2 | UniProt: P52292
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2860-19 | Target: Karyopherin-a2 | UniProt: P52292 | TargetFullName: Importin subunit alpha-1 | Organisim: human | Apparent_Kd_M: 4.42E-11
Real
Aptamer SeqId: 2864-2 | Target: MEK1 | UniProt: Q02750
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2864-2 | Target: MEK1 | UniProt: Q02750 | TargetFullName: Dual specificity mitogen-activated protein kinase kinase 1 | Organisim: human | Apparent_Kd_M: 1.792765E-11
Real
Aptamer SeqId: 2870-29 | Target: RAC1 | UniProt: P63000
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2870-29 | Target: RAC1 | UniProt: P63000 | TargetFullName: Ras-related C3 botulinum toxin substrate 1 | Organisim: human | Apparent_Kd_M: 7.66E-12
Real
Aptamer SeqId: 2871-73 | Target: RAD51 | UniProt: Q06609
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2871-73 | Target: RAD51 | UniProt: Q06609 | TargetFullName: DNA repair protein RAD51 homolog 1 | Organisim: human | Apparent_Kd_M: 3.83E-11
Real
Aptamer SeqId: 2875-15 | Target: TBP | UniProt: P20226
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2875-15 | Target: TBP | UniProt: P20226 | TargetFullName: TATA-box-binding protein | Organisim: human | Apparent_Kd_M: 2.26E-10
Real
Aptamer SeqId: 2876-74 | Target: Topoisomerase I | UniProt: P11387
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2876-74 | Target: Topoisomerase I | UniProt: P11387 | TargetFullName: DNA topoisomerase 1 | Organisim: human | Apparent_Kd_M: 6.27E-11
Real
Aptamer SeqId: 2877-3 | Target: UBC9 | UniProt: P63279
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2877-3 | Target: UBC9 | UniProt: P63279 | TargetFullName: SUMO-conjugating enzyme UBC9 | Organisim: human | Apparent_Kd_M: 1.03E-11
Real
Aptamer SeqId: 2878-66 | Target: YES | UniProt: P07947
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2878-66 | Target: YES | UniProt: P07947 | TargetFullName: Tyrosine-protein kinase Yes | Organisim: human | Apparent_Kd_M: 3.55E-11
Real
Aptamer SeqId: 2879-9 | Target: a1-Antichymotrypsin | UniProt: P01011
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2879-9 | Target: a1-Antichymotrypsin | UniProt: P01011 | TargetFullName: Alpha-1-antichymotrypsin | Organisim: human | Apparent_Kd_M: 2.3E-12
Real
Aptamer SeqId: 2888-49 | Target: C7 | UniProt: P10643
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2888-49 | Target: C7 | UniProt: P10643 | TargetFullName: Complement component C7 | Organisim: human | Apparent_Kd_M: 3.27E-11
Real
Aptamer SeqId: 2889-37 | Target: Cardiotrophin-1 | UniProt: Q16619
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2889-37 | Target: Cardiotrophin-1 | UniProt: Q16619 | TargetFullName: Cardiotrophin-1 | Organisim: human | Apparent_Kd_M: 1.43E-11
Real
Aptamer SeqId: 2890-59 | Target: CCL28 | UniProt: Q9NRJ3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2890-59 | Target: CCL28 | UniProt: Q9NRJ3 | TargetFullName: C-C motif chemokine 28 | Organisim: human | Apparent_Kd_M: 8.18E-12
Real
Aptamer SeqId: 2891-1 | Target: Deprecated | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2891-1 | Target: Deprecated | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 2.16E-10
Real
Aptamer SeqId: 2900-53 | Target: HCC-1 | UniProt: Q16627
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2900-53 | Target: HCC-1 | UniProt: Q16627 | TargetFullName: C-C motif chemokine 14 | Organisim: human | Apparent_Kd_M: 6.07E-11
Real
Aptamer SeqId: 2906-55 | Target: IL-4 | UniProt: P05112
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2906-55 | Target: IL-4 | UniProt: P05112 | TargetFullName: Interleukin-4 | Organisim: human | Apparent_Kd_M: 1.15E-12
Real
Aptamer SeqId: 2911-27 | Target: Midkine | UniProt: P21741
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2911-27 | Target: Midkine | UniProt: P21741 | TargetFullName: Midkine | Organisim: human | Apparent_Kd_M: 5.58E-12
Real
Aptamer SeqId: 2913-1 | Target: MPIF-1 | UniProt: P55773
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2913-1 | Target: MPIF-1 | UniProt: P55773 | TargetFullName: C-C motif chemokine 23 | Organisim: human | Apparent_Kd_M: 4.65E-11
Real
Aptamer SeqId: 2925-9 | Target: PAI-1 | UniProt: P05121
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2925-9 | Target: PAI-1 | UniProt: P05121 | TargetFullName: Plasminogen activator inhibitor 1 | Organisim: human | Apparent_Kd_M: 1.17E-11
Real
Aptamer SeqId: 2937-10 | Target: Deprecated | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2937-10 | Target: Deprecated | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 7.4E-12
Real
Aptamer SeqId: 2938-55 | Target: Deprecated | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2938-55 | Target: Deprecated | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 2.44E-12
Real
Aptamer SeqId: 2939-10 | Target: Artemin | UniProt: Q5T4W7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2939-10 | Target: Artemin | UniProt: Q5T4W7 | TargetFullName: Artemin | Organisim: human | Apparent_Kd_M: 2.75E-11
Real
Aptamer SeqId: 2942-50 | Target: Cytochrome c | UniProt: P99999
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2942-50 | Target: Cytochrome c | UniProt: P99999 | TargetFullName: Cytochrome c | Organisim: human | Apparent_Kd_M: 2.3E-11
Real
Aptamer SeqId: 2943-5 | Target: Cytochrome P450 3A4 | UniProt: P08684
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2943-5 | Target: Cytochrome P450 3A4 | UniProt: P08684 | TargetFullName: Cytochrome P450 3A4 | Organisim: human | Apparent_Kd_M: 5.45E-12
Real
Aptamer SeqId: 2944-66 | Target: DAN | UniProt: P41271
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2944-66 | Target: DAN | UniProt: P41271 | TargetFullName: Neuroblastoma suppressor of tumorigenicity 1 | Organisim: human | Apparent_Kd_M: 2.44E-11
Real
Aptamer SeqId: 2946-52 | Target: Factor D | UniProt: P00746
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2946-52 | Target: Factor D | UniProt: P00746 | TargetFullName: Complement factor D | Organisim: human | Apparent_Kd_M: 1.141147E-10
Real
Aptamer SeqId: 2948-58 | Target: Growth hormone receptor | UniProt: P10912
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2948-58 | Target: Growth hormone receptor | UniProt: P10912 | TargetFullName: Growth hormone receptor | Organisim: human | Apparent_Kd_M: 2.67E-11
Real
Aptamer SeqId: 2949-6 | Target: GX | UniProt: O15496
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2949-6 | Target: GX | UniProt: O15496 | TargetFullName: Group 10 secretory phospholipase A2 | Organisim: human | Apparent_Kd_M: 8.19E-12
Real
Aptamer SeqId: 2950-57 | Target: IGFBP-4 | UniProt: P22692
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2950-57 | Target: IGFBP-4 | UniProt: P22692 | TargetFullName: Insulin-like growth factor-binding protein 4 | Organisim: human | Apparent_Kd_M: 3.66E-12
Real
Aptamer SeqId: 2952-75 | Target: IGF-I | UniProt: P05019
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2952-75 | Target: IGF-I | UniProt: P05019 | TargetFullName: Insulin-like growth factor I | Organisim: human | Apparent_Kd_M: 1.24E-10
Real
Aptamer SeqId: 2953-31 | Target: Luteinizing hormone
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2953-31 | Target: Luteinizing hormone | UniProt: P01215|P01229 | TargetFullName: Luteinizing hormone | Organisim: human | Apparent_Kd_M: 5.35E-11
Real
Aptamer SeqId: 2960-66 | Target: Properdin | UniProt: P27918
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2960-66 | Target: Properdin | UniProt: P27918 | TargetFullName: Properdin | Organisim: human | Apparent_Kd_M: 6.49E-11
Real
Aptamer SeqId: 2961-1 | Target: Protein C | UniProt: P04070
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2961-1 | Target: Protein C | UniProt: P04070 | TargetFullName: Vitamin K-dependent protein C | Organisim: human | Apparent_Kd_M: 3.31E-11
Real
Aptamer SeqId: 2962-50 | Target: PTHrP | UniProt: P12272
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2962-50 | Target: PTHrP | UniProt: P12272 | TargetFullName: Parathyroid hormone-related protein | Organisim: human | Apparent_Kd_M: 2.44E-11
Real
Aptamer SeqId: 2966-65 | Target: SCGF-beta | UniProt: Q9Y240
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2966-65 | Target: SCGF-beta | UniProt: Q9Y240 | TargetFullName: Stem cell growth factor-beta | Organisim: human | Apparent_Kd_M: 9.77E-11
Real
Aptamer SeqId: 2967-8 | Target: VCAM-1 | UniProt: P19320
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2967-8 | Target: VCAM-1 | UniProt: P19320 | TargetFullName: Vascular cell adhesion protein 1 | Organisim: human | Apparent_Kd_M: 1.73E-10
Real
Aptamer SeqId: 2968-61 | Target: TNFSF15 | UniProt: O95150
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2968-61 | Target: TNFSF15 | UniProt: O95150 | TargetFullName: Tumor necrosis factor ligand superfamily member 15 | Organisim: human | Apparent_Kd_M: 2.81E-12
Real
Aptamer SeqId: 2970-60 | Target: AREG | UniProt: P15514
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2970-60 | Target: AREG | UniProt: P15514 | TargetFullName: Amphiregulin | Organisim: human | Apparent_Kd_M: 2.03E-11
Real
Aptamer SeqId: 2972-57 | Target: BMP-7 | UniProt: P18075
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2972-57 | Target: BMP-7 | UniProt: P18075 | TargetFullName: Bone morphogenetic protein 7 | Organisim: human | Apparent_Kd_M: 3.59E-12
Real
Aptamer SeqId: 2973-15 | Target: CD36 ANTIGEN | UniProt: P16671
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2973-15 | Target: CD36 ANTIGEN | UniProt: P16671 | TargetFullName: Platelet glycoprotein 4 | Organisim: human | Apparent_Kd_M: 6.47E-11
Real
Aptamer SeqId: 2974-61 | Target: contactin-1 | UniProt: Q12860
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2974-61 | Target: contactin-1 | UniProt: Q12860 | TargetFullName: Contactin-1 | Organisim: human | Apparent_Kd_M: 3.79E-12
Real
Aptamer SeqId: 2975-19 | Target: CTGF | UniProt: P29279
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2975-19 | Target: CTGF | UniProt: P29279 | TargetFullName: Connective tissue growth factor | Organisim: human | Apparent_Kd_M: 2.31E-11
Real
Aptamer SeqId: 2976-58 | Target: Desmoglein-1 | UniProt: Q02413
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2976-58 | Target: Desmoglein-1 | UniProt: Q02413 | TargetFullName: Desmoglein-1 | Organisim: human | Apparent_Kd_M: 4.76E-11
Real
Aptamer SeqId: 2977-7 | Target: EDAR | UniProt: Q9UNE0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2977-7 | Target: EDAR | UniProt: Q9UNE0 | TargetFullName: Tumor necrosis factor receptor superfamily member EDAR | Organisim: human | Apparent_Kd_M: 2.72E-12
Real
Aptamer SeqId: 2979-8 | Target: ENA-78 | UniProt: P42830
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2979-8 | Target: ENA-78 | UniProt: P42830 | TargetFullName: C-X-C motif chemokine 5 | Organisim: human | Apparent_Kd_M: 1.26E-10
Real
Aptamer SeqId: 2982-82 | Target: Galectin-4 | UniProt: P56470
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2982-82 | Target: Galectin-4 | UniProt: P56470 | TargetFullName: Galectin-4 | Organisim: human | Apparent_Kd_M: 2.27E-12
Real
Aptamer SeqId: 2985-35 | Target: Gro-a | UniProt: P09341
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2985-35 | Target: Gro-a | UniProt: P09341 | TargetFullName: Growth-regulated alpha protein | Organisim: human | Apparent_Kd_M: 7.99284E-12
Real
Aptamer SeqId: 2987-37 | Target: Histone H1.2 | UniProt: P16403
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2987-37 | Target: Histone H1.2 | UniProt: P16403 | TargetFullName: Histone H1.2 | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 2991-9 | Target: IL-1 sRI | UniProt: P14778
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2991-9 | Target: IL-1 sRI | UniProt: P14778 | TargetFullName: Interleukin-1 receptor type 1 | Organisim: human | Apparent_Kd_M: 3.58E-12
Real
Aptamer SeqId: 2992-59 | Target: IL-17 sR | UniProt: Q96F46
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2992-59 | Target: IL-17 sR | UniProt: Q96F46 | TargetFullName: Interleukin-17 receptor A | Organisim: human | Apparent_Kd_M: 2.02E-11
Real
Aptamer SeqId: 2993-1 | Target: IL-18 Rb | UniProt: O95256
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2993-1 | Target: IL-18 Rb | UniProt: O95256 | TargetFullName: Interleukin-18 receptor accessory protein | Organisim: human | Apparent_Kd_M: 3.47E-12
Real
Aptamer SeqId: 2994-71 | Target: IL-1Rrp2 | UniProt: Q9HB29
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2994-71 | Target: IL-1Rrp2 | UniProt: Q9HB29 | TargetFullName: Interleukin-1 receptor-like 2 | Organisim: human | Apparent_Kd_M: 1.889796E-11
Real
Aptamer SeqId: 2997-8 | Target: JAM-B | UniProt: P57087
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2997-8 | Target: JAM-B | UniProt: P57087 | TargetFullName: Junctional adhesion molecule B | Organisim: human | Apparent_Kd_M: 2.56E-11
Real
Aptamer SeqId: 2998-53 | Target: JAM-C | UniProt: Q9BX67
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2998-53 | Target: JAM-C | UniProt: Q9BX67 | TargetFullName: Junctional adhesion molecule C | Organisim: human | Apparent_Kd_M: 4.16E-11
Real
Aptamer SeqId: 2999-6 | Target: LSAMP | UniProt: Q13449
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 2999-6 | Target: LSAMP | UniProt: Q13449 | TargetFullName: Limbic system-associated membrane protein | Organisim: human | Apparent_Kd_M: 4.57E-11
Real
Aptamer SeqId: 3000-66 | Target: MBL | UniProt: P11226
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3000-66 | Target: MBL | UniProt: P11226 | TargetFullName: Mannose-binding protein C | Organisim: human | Apparent_Kd_M: 2.31E-11
Real
Aptamer SeqId: 3003-29 | Target: NKp30 | UniProt: O14931
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3003-29 | Target: NKp30 | UniProt: O14931 | TargetFullName: Natural cytotoxicity triggering receptor 3 | Organisim: human | Apparent_Kd_M: 2.31E-12
Real
Aptamer SeqId: 3004-67 | Target: PD-L2 | UniProt: Q9BQ51
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3004-67 | Target: PD-L2 | UniProt: Q9BQ51 | TargetFullName: Programmed cell death 1 ligand 2 | Organisim: human | Apparent_Kd_M: 3.13E-10
Real
Aptamer SeqId: 3005-5 | Target: PTP-1B | UniProt: P18031
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3005-5 | Target: PTP-1B | UniProt: P18031 | TargetFullName: Tyrosine-protein phosphatase non-receptor type 1 | Organisim: human | Apparent_Kd_M: 1.22E-11
Real
Aptamer SeqId: 3007-7 | Target: Siglec-9 | UniProt: Q9Y336
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3007-7 | Target: Siglec-9 | UniProt: Q9Y336 | TargetFullName: Sialic acid-binding Ig-like lectin 9 | Organisim: human | Apparent_Kd_M: 8.78E-12
Real
Aptamer SeqId: 3009-3 | Target: TGF-b R III | UniProt: Q03167
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3009-3 | Target: TGF-b R III | UniProt: Q03167 | TargetFullName: Transforming growth factor beta receptor type 3 | Organisim: human | Apparent_Kd_M: 4.44E-12
Real
Aptamer SeqId: 3010-53 | Target: TSLP | UniProt: Q969D9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3010-53 | Target: TSLP | UniProt: Q969D9 | TargetFullName: Thymic stromal lymphopoietin | Organisim: human | Apparent_Kd_M: 1.0E-11
Real
Aptamer SeqId: 3022-4 | Target: CTLA-4 | UniProt: P16410
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3022-4 | Target: CTLA-4 | UniProt: P16410 | TargetFullName: Cytotoxic T-lymphocyte protein 4 | Organisim: human | Apparent_Kd_M: 3.63E-11
Real
Aptamer SeqId: 3024-18 | Target: a2-Antiplasmin | UniProt: P08697
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3024-18 | Target: a2-Antiplasmin | UniProt: P08697 | TargetFullName: Alpha-2-antiplasmin | Organisim: human | Apparent_Kd_M: 4.95E-11
Real
Aptamer SeqId: 3025-50 | Target: bFGF | UniProt: P09038
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3025-50 | Target: bFGF | UniProt: P09038 | TargetFullName: Fibroblast growth factor 2 | Organisim: human | Apparent_Kd_M: 3.33E-12
Real
Aptamer SeqId: 3026-5 | Target: Calpastatin | UniProt: P20810
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3026-5 | Target: Calpastatin | UniProt: P20810 | TargetFullName: Calpastatin | Organisim: human | Apparent_Kd_M: 1.8E-10
Real
Aptamer SeqId: 3028-36 | Target: Ck-b-8-1 | UniProt: P55773
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3028-36 | Target: Ck-b-8-1 | UniProt: P55773 | TargetFullName: Ck-beta-8-1 | Organisim: human | Apparent_Kd_M: 9.73E-13
Real
Aptamer SeqId: 3029-52 | Target: DC-SIGN | UniProt: Q9NNX6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3029-52 | Target: DC-SIGN | UniProt: Q9NNX6 | TargetFullName: CD209 antigen | Organisim: human | Apparent_Kd_M: 4.0E-11
Real
Aptamer SeqId: 3030-3 | Target: DC-SIGNR | UniProt: Q9H2X3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3030-3 | Target: DC-SIGNR | UniProt: Q9H2X3 | TargetFullName: C-type lectin domain family 4 member M | Organisim: human | Apparent_Kd_M: 2.88E-11
Real
Aptamer SeqId: 3032-11 | Target: FSH | UniProt: P01215|P01225
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3032-11 | Target: FSH | UniProt: P01215|P01225 | TargetFullName: Follicle stimulating hormone | Organisim: human | Apparent_Kd_M: 4.98E-12
Real
Aptamer SeqId: 3033-57 | Target: Galectin-2 | UniProt: P05162
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3033-57 | Target: Galectin-2 | UniProt: P05162 | TargetFullName: Galectin-2 | Organisim: human | Apparent_Kd_M: 2.89E-11
Real
Aptamer SeqId: 3034-1 | Target: GFAP | UniProt: P14136
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3034-1 | Target: GFAP | UniProt: P14136 | TargetFullName: Glial fibrillary acidic protein | Organisim: human | Apparent_Kd_M: 5.01E-11
Real
Aptamer SeqId: 3035-80 | Target: IL-19 | UniProt: Q9UHD0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3035-80 | Target: IL-19 | UniProt: Q9UHD0 | TargetFullName: Interleukin-19 | Organisim: human | Apparent_Kd_M: 2.89E-12
Real
Aptamer SeqId: 3037-62 | Target: IL-1b | UniProt: P01584
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3037-62 | Target: IL-1b | UniProt: P01584 | TargetFullName: Interleukin-1 beta | Organisim: human | Apparent_Kd_M: 8.08E-11
Real
Aptamer SeqId: 3038-9 | Target: I-TAC | UniProt: O14625
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3038-9 | Target: I-TAC | UniProt: O14625 | TargetFullName: C-X-C motif chemokine 11 | Organisim: human | Apparent_Kd_M: 2.84E-12
Real
Aptamer SeqId: 3040-59 | Target: MIP-1a | UniProt: P10147
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3040-59 | Target: MIP-1a | UniProt: P10147 | TargetFullName: C-C motif chemokine 3 | Organisim: human | Apparent_Kd_M: 4.2E-11
Real
Aptamer SeqId: 3041-55 | Target: MRC2 | UniProt: Q9UBG0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3041-55 | Target: MRC2 | UniProt: Q9UBG0 | TargetFullName: C-type mannose receptor 2 | Organisim: human | Apparent_Kd_M: 2.11E-12
Real
Aptamer SeqId: 3042-7 | Target: Myoglobin | UniProt: P02144
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3042-7 | Target: Myoglobin | UniProt: P02144 | TargetFullName: Myoglobin | Organisim: human | Apparent_Kd_M: 8.92E-12
Real
Aptamer SeqId: 3043-49 | Target: ON | UniProt: P09486
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3043-49 | Target: ON | UniProt: P09486 | TargetFullName: SPARC | Organisim: human | Apparent_Kd_M: 5.73E-12
Real
Aptamer SeqId: 3044-3 | Target: PARC | UniProt: P55774
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3044-3 | Target: PARC | UniProt: P55774 | TargetFullName: C-C motif chemokine 18 | Organisim: human | Apparent_Kd_M: 6.68E-12
Real
Aptamer SeqId: 3045-72 | Target: PTN | UniProt: P21246
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3045-72 | Target: PTN | UniProt: P21246 | TargetFullName: Pleiotrophin | Organisim: human | Apparent_Kd_M: 2.9E-12
Real
Aptamer SeqId: 3046-31 | Target: resistin | UniProt: Q9HD89
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3046-31 | Target: resistin | UniProt: Q9HD89 | TargetFullName: Resistin | Organisim: human | Apparent_Kd_M: 1.26E-11
Real
Aptamer SeqId: 3049-61 | Target: Trypsin | UniProt: P07477
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3049-61 | Target: Trypsin | UniProt: P07477 | TargetFullName: Trypsin-1 | Organisim: human | Apparent_Kd_M: 1.33E-13
Real
Aptamer SeqId: 3050-7 | Target: vWF | UniProt: P04275
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3050-7 | Target: vWF | UniProt: P04275 | TargetFullName: von Willebrand factor | Organisim: human | Apparent_Kd_M: 6.43E-11
Real
Aptamer SeqId: 3052-8 | Target: Fas ligand; soluble | UniProt: P48023
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3052-8 | Target: Fas ligand; soluble | UniProt: P48023 | TargetFullName: Tumor necrosis factor ligand superfamily member 6; soluble form | Organisim: human | Apparent_Kd_M: 1.71E-11
Real
Aptamer SeqId: 3054-3 | Target: Haptoglobin; Mixed Type | UniProt: P00738
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3054-3 | Target: Haptoglobin; Mixed Type | UniProt: P00738 | TargetFullName: Haptoglobin | Organisim: human | Apparent_Kd_M: 1.34E-11
Real
Aptamer SeqId: 3055-54 | Target: IL-4 sR | UniProt: P24394
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3055-54 | Target: IL-4 sR | UniProt: P24394 | TargetFullName: Interleukin-4 receptor subunit alpha | Organisim: human | Apparent_Kd_M: 1.72E-10
Real
Aptamer SeqId: 3057-55 | Target: WISP-1 | UniProt: O95388
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3057-55 | Target: WISP-1 | UniProt: O95388 | TargetFullName: WNT1-inducible-signaling pathway protein 1 | Organisim: human | Apparent_Kd_M: 9.6E-11
Real
Aptamer SeqId: 3059-50 | Target: BAFF | UniProt: Q9Y275
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3059-50 | Target: BAFF | UniProt: Q9Y275 | TargetFullName: Tumor necrosis factor ligand superfamily member 13B | Organisim: human | Apparent_Kd_M: 1.14E-11
Real
Aptamer SeqId: 3060-43 | Target: C9 | UniProt: P02748
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3060-43 | Target: C9 | UniProt: P02748 | TargetFullName: Complement component C9 | Organisim: human | Apparent_Kd_M: 1.57E-12
Real
Aptamer SeqId: 3065-65 | Target: FGF-5 | UniProt: P12034
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3065-65 | Target: FGF-5 | UniProt: P12034 | TargetFullName: Fibroblast growth factor 5 | Organisim: human | Apparent_Kd_M: 4.27E-11
Real
Aptamer SeqId: 3066-12 | Target: Galectin-3 | UniProt: P17931
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3066-12 | Target: Galectin-3 | UniProt: P17931 | TargetFullName: Galectin-3 | Organisim: human | Apparent_Kd_M: 4.9E-12
Real
Aptamer SeqId: 3067-67 | Target: GDF-9 | UniProt: O60383
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3067-67 | Target: GDF-9 | UniProt: O60383 | TargetFullName: Growth/differentiation factor 9 | Organisim: human | Apparent_Kd_M: 3.6E-10
Real
Aptamer SeqId: 3069-52 | Target: IgM | UniProt: P01871
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3069-52 | Target: IgM | UniProt: P01871 | TargetFullName: Immunoglobulin M | Organisim: human | Apparent_Kd_M: 1.34E-10
Real
Aptamer SeqId: 3070-1 | Target: IL-2 | UniProt: P60568
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3070-1 | Target: IL-2 | UniProt: P60568 | TargetFullName: Interleukin-2 | Organisim: human | Apparent_Kd_M: 2.98E-12
Real
Aptamer SeqId: 3072-4 | Target: IL-13 | UniProt: P35225
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3072-4 | Target: IL-13 | UniProt: P35225 | TargetFullName: Interleukin-13 | Organisim: human | Apparent_Kd_M: 3.0E-11
Real
Aptamer SeqId: 3073-51 | Target: IL-18 BPa | UniProt: O95998
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3073-51 | Target: IL-18 BPa | UniProt: O95998 | TargetFullName: Interleukin-18-binding protein | Organisim: human | Apparent_Kd_M: 1.51E-10
Real
Aptamer SeqId: 3074-6 | Target: LBP | UniProt: P18428
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3074-6 | Target: LBP | UniProt: P18428 | TargetFullName: Lipopolysaccharide-binding protein | Organisim: human | Apparent_Kd_M: 1.76E-11
Real
Aptamer SeqId: 3077-66 | Target: Coagulation Factor Xa | UniProt: P00742
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3077-66 | Target: Coagulation Factor Xa | UniProt: P00742 | TargetFullName: Coagulation factor Xa | Organisim: human | Apparent_Kd_M: 4.48E-13
Real
Aptamer SeqId: 3078-1 | Target: PlGF | UniProt: P49763
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3078-1 | Target: PlGF | UniProt: P49763 | TargetFullName: Placenta growth factor | Organisim: human | Apparent_Kd_M: 1.56E-11
Real
Aptamer SeqId: 3079-62 | Target: TIG2 | UniProt: Q99969
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3079-62 | Target: TIG2 | UniProt: Q99969 | TargetFullName: Retinoic acid receptor responder protein 2 | Organisim: human | Apparent_Kd_M: 3.0E-12
Real
Aptamer SeqId: 3081-70 | Target: ULBP-1 | UniProt: Q9BZM6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3081-70 | Target: ULBP-1 | UniProt: Q9BZM6 | TargetFullName: NKG2D ligand 1 | Organisim: human | Apparent_Kd_M: 5.45E-11
Real
Aptamer SeqId: 3082-9 | Target: ULBP-2 | UniProt: Q9BZM5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3082-9 | Target: ULBP-2 | UniProt: Q9BZM5 | TargetFullName: NKG2D ligand 2 | Organisim: human | Apparent_Kd_M: 3.73E-11
Real
Aptamer SeqId: 3083-71 | Target: XEDAR | UniProt: Q9HAV5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3083-71 | Target: XEDAR | UniProt: Q9HAV5 | TargetFullName: Tumor necrosis factor receptor superfamily member 27 | Organisim: human | Apparent_Kd_M: 1.6E-11
Real
Aptamer SeqId: 3091-70 | Target: Aurora kinase A | UniProt: O14965
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3091-70 | Target: Aurora kinase A | UniProt: O14965 | TargetFullName: Aurora kinase A | Organisim: human | Apparent_Kd_M: 2.06E-11
Real
Aptamer SeqId: 3115-64 | Target: MK01 | UniProt: P28482
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3115-64 | Target: MK01 | UniProt: P28482 | TargetFullName: Mitogen-activated protein kinase 1 | Organisim: human | Apparent_Kd_M: 1.23E-12
Real
Aptamer SeqId: 3122-6 | Target: SMAC | UniProt: Q9NR28
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3122-6 | Target: SMAC | UniProt: Q9NR28 | TargetFullName: Diablo homolog; mitochondrial | Organisim: human | Apparent_Kd_M: 1.52E-11
Real
Aptamer SeqId: 3132-1 | Target: VEGF-C | UniProt: P49767
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3132-1 | Target: VEGF-C | UniProt: P49767 | TargetFullName: Vascular endothelial growth factor C | Organisim: human | Apparent_Kd_M: 1.68E-11
Real
Aptamer SeqId: 3143-3 | Target: sCD4 | UniProt: P01730
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3143-3 | Target: sCD4 | UniProt: P01730 | TargetFullName: T-cell surface glycoprotein CD4 | Organisim: human | Apparent_Kd_M: 3.88E-11
Real
Aptamer SeqId: 3148-49 | Target: Gro-b/g | UniProt: P19876|P19875
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3148-49 | Target: Gro-b/g | UniProt: P19876|P19875 | TargetFullName: Gro-beta/gamma | Organisim: human | Apparent_Kd_M: 8.59E-13
Real
Aptamer SeqId: 3151-6 | Target: IL-2 sRa | UniProt: P01589
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3151-6 | Target: IL-2 sRa | UniProt: P01589 | TargetFullName: Interleukin-2 receptor subunit alpha | Organisim: human | Apparent_Kd_M: 1.88E-11
Real
Aptamer SeqId: 3152-57 | Target: TNF sR-II | UniProt: P20333
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3152-57 | Target: TNF sR-II | UniProt: P20333 | TargetFullName: Tumor necrosis factor receptor superfamily member 1B | Organisim: human | Apparent_Kd_M: 1.19E-11
Real
Aptamer SeqId: 3166-92 | Target: Siglec-3 | UniProt: P20138
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3166-92 | Target: Siglec-3 | UniProt: P20138 | TargetFullName: Myeloid cell surface antigen CD33 | Organisim: human | Apparent_Kd_M: 4.5E-11
Real
Aptamer SeqId: 3168-8 | Target: ADAMTS-5 | UniProt: Q9UNA0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3168-8 | Target: ADAMTS-5 | UniProt: Q9UNA0 | TargetFullName: A disintegrin and metalloproteinase with thrombospondin motifs 5 | Organisim: human | Apparent_Kd_M: 8.52E-12
Real
Aptamer SeqId: 3169-70 | Target: IDUA | UniProt: P35475
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3169-70 | Target: IDUA | UniProt: P35475 | TargetFullName: Alpha-L-iduronidase | Organisim: human | Apparent_Kd_M: 4.8E-12
Real
Aptamer SeqId: 3170-6 | Target: AMPM2 | UniProt: P50579
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3170-6 | Target: AMPM2 | UniProt: P50579 | TargetFullName: Methionine aminopeptidase 2 | Organisim: human | Apparent_Kd_M: 5.24E-11
Real
Aptamer SeqId: 3171-57 | Target: amyloid precursor protein
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3171-57 | Target: amyloid precursor protein | UniProt: P05067 | TargetFullName: Amyloid beta A4 protein | Organisim: human | Apparent_Kd_M: 1.11E-11
Real
Aptamer SeqId: 3172-28 | Target: ARSB | UniProt: P15848
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3172-28 | Target: ARSB | UniProt: P15848 | TargetFullName: Arylsulfatase B | Organisim: human | Apparent_Kd_M: 1.35E-11
Real
Aptamer SeqId: 3173-49 | Target: ASAHL | UniProt: Q02083
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3173-49 | Target: ASAHL | UniProt: Q02083 | TargetFullName: N-acylethanolamine-hydrolyzing acid amidase | Organisim: human | Apparent_Kd_M: 1.8E-12
Real
Aptamer SeqId: 3174-2 | Target: ATS1 | UniProt: Q9UHI8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3174-2 | Target: ATS1 | UniProt: Q9UHI8 | TargetFullName: A disintegrin and metalloproteinase with thrombospondin motifs 1 | Organisim: human | Apparent_Kd_M: 4.84E-12
Real
Aptamer SeqId: 3175-51 | Target: ATS13 | UniProt: Q76LX8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3175-51 | Target: ATS13 | UniProt: Q76LX8 | TargetFullName: A disintegrin and metalloproteinase with thrombospondin motifs 13 | Organisim: human | Apparent_Kd_M: 4.84E-12
Real
Aptamer SeqId: 3178-5 | Target: CATC | UniProt: P53634
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3178-5 | Target: CATC | UniProt: P53634 | TargetFullName: Dipeptidyl peptidase 1 | Organisim: human | Apparent_Kd_M: 6.56E-11
Real
Aptamer SeqId: 3179-51 | Target: Cathepsin A | UniProt: P10619
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3179-51 | Target: Cathepsin A | UniProt: P10619 | TargetFullName: Lysosomal protective protein | Organisim: human | Apparent_Kd_M: 3.22E-12
Real
Aptamer SeqId: 3181-50 | Target: Cathepsin S | UniProt: P25774
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3181-50 | Target: Cathepsin S | UniProt: P25774 | TargetFullName: Cathepsin S | Organisim: human | Apparent_Kd_M: 1.12E-11
Real
Aptamer SeqId: 3182-38 | Target: CD39 | UniProt: P49961
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3182-38 | Target: CD39 | UniProt: P49961 | TargetFullName: Ectonucleoside triphosphate diphosphohydrolase 1 | Organisim: human | Apparent_Kd_M: 3.64E-12
Real
Aptamer SeqId: 3184-25 | Target: Coagulation Factor VII | UniProt: P08709
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3184-25 | Target: Coagulation Factor VII | UniProt: P08709 | TargetFullName: Coagulation factor VII | Organisim: human | Apparent_Kd_M: 5.38E-11
Real
Aptamer SeqId: 3186-2 | Target: C2 | UniProt: P06681
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3186-2 | Target: C2 | UniProt: P06681 | TargetFullName: Complement C2 | Organisim: human | Apparent_Kd_M: 1.01E-11
Real
Aptamer SeqId: 3187-52 | Target: CRIS3 | UniProt: P54108
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3187-52 | Target: CRIS3 | UniProt: P54108 | TargetFullName: Cysteine-rich secretory protein 3 | Organisim: human | Apparent_Kd_M: 6.51E-12
Real
Aptamer SeqId: 3189-61 | Target: Enterokinase | UniProt: P98073
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3189-61 | Target: Enterokinase | UniProt: P98073 | TargetFullName: Enteropeptidase | Organisim: human | Apparent_Kd_M: 1.45E-11
Real
Aptamer SeqId: 3191-50 | Target: WFKN1 | UniProt: Q96NZ8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3191-50 | Target: WFKN1 | UniProt: Q96NZ8 | TargetFullName: WAP; kazal; immunoglobulin; kunitz and NTR domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 3.41E-11
Real
Aptamer SeqId: 3192-3 | Target: Glutamate carboxypeptidase
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3192-3 | Target: Glutamate carboxypeptidase | UniProt: Q96KP4 | TargetFullName: Cytosolic non-specific dipeptidase | Organisim: human | Apparent_Kd_M: 1.49E-10
Real
Aptamer SeqId: 3194-36 | Target: GPVI | UniProt: Q9HCN6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3194-36 | Target: GPVI | UniProt: Q9HCN6 | TargetFullName: Platelet glycoprotein VI | Organisim: human | Apparent_Kd_M: 1.39E-12
Real
Aptamer SeqId: 3195-50 | Target: Granulysin | UniProt: P22749
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3195-50 | Target: Granulysin | UniProt: P22749 | TargetFullName: Granulysin | Organisim: human | Apparent_Kd_M: 2.23E-12
Real
Aptamer SeqId: 3196-6 | Target: HPLN1 | UniProt: P10915
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3196-6 | Target: HPLN1 | UniProt: P10915 | TargetFullName: Hyaluronan and proteoglycan link protein 1 | Organisim: human | Apparent_Kd_M: 2.29E-12
Real
Aptamer SeqId: 3197-70 | Target: IDE | UniProt: P14735
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3197-70 | Target: IDE | UniProt: P14735 | TargetFullName: Insulin-degrading enzyme | Organisim: human | Apparent_Kd_M: 6.27E-12
Real
Aptamer SeqId: 3198-4 | Target: IDS | UniProt: P22304
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3198-4 | Target: IDS | UniProt: P22304 | TargetFullName: Iduronate 2-sulfatase | Organisim: human | Apparent_Kd_M: 1.19E-11
Real
Aptamer SeqId: 3199-54 | Target: kallikrein 12 | UniProt: Q9UKR0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3199-54 | Target: kallikrein 12 | UniProt: Q9UKR0 | TargetFullName: Kallikrein-12 | Organisim: human | Apparent_Kd_M: 1.03E-12
Real
Aptamer SeqId: 3201-49 | Target: kallikrein 5 | UniProt: Q9Y337
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3201-49 | Target: kallikrein 5 | UniProt: Q9Y337 | TargetFullName: Kallikrein-5 | Organisim: human | Apparent_Kd_M: 5.1E-13
Real
Aptamer SeqId: 3202-28 | Target: KREM2 | UniProt: Q8NCW0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3202-28 | Target: KREM2 | UniProt: Q8NCW0 | TargetFullName: Kremen protein 2 | Organisim: human | Apparent_Kd_M: 2.07E-11
Real
Aptamer SeqId: 3204-2 | Target: LKHA4 | UniProt: P09960
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3204-2 | Target: LKHA4 | UniProt: P09960 | TargetFullName: Leukotriene A-4 hydrolase | Organisim: human | Apparent_Kd_M: 1.39E-10
Real
Aptamer SeqId: 3206-4 | Target: LYVE1 | UniProt: Q9Y5Y7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3206-4 | Target: LYVE1 | UniProt: Q9Y5Y7 | TargetFullName: Lymphatic vessel endothelial hyaluronic acid receptor 1 | Organisim: human | Apparent_Kd_M: 1.48E-11
Real
Aptamer SeqId: 3209-69 | Target: MEPE | UniProt: Q9NQ76
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3209-69 | Target: MEPE | UniProt: Q9NQ76 | TargetFullName: Matrix extracellular phosphoglycoprotein | Organisim: human | Apparent_Kd_M: 5.9E-11
Real
Aptamer SeqId: 3210-1 | Target: METAP1 | UniProt: P53582
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3210-1 | Target: METAP1 | UniProt: P53582 | TargetFullName: Methionine aminopeptidase 1 | Organisim: human | Apparent_Kd_M: 8.3E-12
Real
Aptamer SeqId: 3212-30 | Target: ASAH2 | UniProt: Q9NR71
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3212-30 | Target: ASAH2 | UniProt: Q9NR71 | TargetFullName: Neutral ceramidase | Organisim: human | Apparent_Kd_M: 1.8E-11
Real
Aptamer SeqId: 3213-65 | Target: Nidogen | UniProt: P14543
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3213-65 | Target: Nidogen | UniProt: P14543 | TargetFullName: Nidogen-1 | Organisim: human | Apparent_Kd_M: 1.1E-10
Real
Aptamer SeqId: 3216-2 | Target: PIGR | UniProt: P01833
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3216-2 | Target: PIGR | UniProt: P01833 | TargetFullName: Polymeric immunoglobulin receptor | Organisim: human | Apparent_Kd_M: 2.79E-12
Real
Aptamer SeqId: 3220-40 | Target: RET | UniProt: P07949
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3220-40 | Target: RET | UniProt: P07949 | TargetFullName: Proto-oncogene tyrosine-protein kinase receptor Ret | Organisim: human | Apparent_Kd_M: 6.66E-12
Real
Aptamer SeqId: 3221-54 | Target: SARP-2 | UniProt: Q8N474
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3221-54 | Target: SARP-2 | UniProt: Q8N474 | TargetFullName: Secreted frizzled-related protein 1 | Organisim: human | Apparent_Kd_M: 6.07E-11
Real
Aptamer SeqId: 3222-11 | Target: Semaphorin 3A | UniProt: Q14563
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3222-11 | Target: Semaphorin 3A | UniProt: Q14563 | TargetFullName: Semaphorin-3A | Organisim: human | Apparent_Kd_M: 7.59E-11
Real
Aptamer SeqId: 3232-28 | Target: TrATPase | UniProt: P13686
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3232-28 | Target: TrATPase | UniProt: P13686 | TargetFullName: Tartrate-resistant acid phosphatase type 5 | Organisim: human | Apparent_Kd_M: 7.26E-12
Real
Aptamer SeqId: 3234-23 | Target: URB | UniProt: Q76M96
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3234-23 | Target: URB | UniProt: Q76M96 | TargetFullName: Coiled-coil domain-containing protein 80 | Organisim: human | Apparent_Kd_M: 2.45E-11
Real
Aptamer SeqId: 3235-50 | Target: WFKN2 | UniProt: Q8TEU8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3235-50 | Target: WFKN2 | UniProt: Q8TEU8 | TargetFullName: WAP; Kazal; immunoglobulin; Kunitz and NTR domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 6.54E-12
Real
Aptamer SeqId: 3280-49 | Target: Aggrecan | UniProt: P16112
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3280-49 | Target: Aggrecan | UniProt: P16112 | TargetFullName: Aggrecan core protein | Organisim: human | Apparent_Kd_M: 1.16E-11
Real
Aptamer SeqId: 3283-21 | Target: BGH3 | UniProt: Q15582
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3283-21 | Target: BGH3 | UniProt: Q15582 | TargetFullName: Transforming growth factor-beta-induced protein ig-h3 | Organisim: human | Apparent_Kd_M: 1.39E-11
Real
Aptamer SeqId: 3284-75 | Target: BGN | UniProt: P21810
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3284-75 | Target: BGN | UniProt: P21810 | TargetFullName: Biglycan | Organisim: human | Apparent_Kd_M: 2.97E-11
Real
Aptamer SeqId: 3285-23 | Target: C1r | UniProt: P00736
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3285-23 | Target: C1r | UniProt: P00736 | TargetFullName: Complement C1r subcomponent | Organisim: human | Apparent_Kd_M: 2.74E-12
Real
Aptamer SeqId: 3290-50 | Target: CD109 | UniProt: Q6YHK3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3290-50 | Target: CD109 | UniProt: Q6YHK3 | TargetFullName: CD109 antigen | Organisim: human | Apparent_Kd_M: 6.33E-11
Real
Aptamer SeqId: 3291-30 | Target: CD23 | UniProt: P06734
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3291-30 | Target: CD23 | UniProt: P06734 | TargetFullName: Low affinity immunoglobulin epsilon Fc receptor | Organisim: human | Apparent_Kd_M: 2.88E-12
Real
Aptamer SeqId: 3292-75 | Target: CD48 | UniProt: P09326
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3292-75 | Target: CD48 | UniProt: P09326 | TargetFullName: CD48 antigen | Organisim: human | Apparent_Kd_M: 3.59E-12
Real
Aptamer SeqId: 3293-2 | Target: CD5L | UniProt: O43866
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3293-2 | Target: CD5L | UniProt: O43866 | TargetFullName: CD5 antigen-like | Organisim: human | Apparent_Kd_M: 1.3E-11
Real
Aptamer SeqId: 3294-55 | Target: CFC1 | UniProt: P0CG37
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3294-55 | Target: CFC1 | UniProt: P0CG37 | TargetFullName: Cryptic protein | Organisim: human | Apparent_Kd_M: 1.76E-11
Real
Aptamer SeqId: 3296-92 | Target: CNTN2 | UniProt: Q02246
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3296-92 | Target: CNTN2 | UniProt: Q02246 | TargetFullName: Contactin-2 | Organisim: human | Apparent_Kd_M: 4.39E-11
Real
Aptamer SeqId: 3298-52 | Target: Contactin-4 | UniProt: Q8IWV2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3298-52 | Target: Contactin-4 | UniProt: Q8IWV2 | TargetFullName: Contactin-4 | Organisim: human | Apparent_Kd_M: 5.74E-12
Real
Aptamer SeqId: 3299-29 | Target: Contactin-5 | UniProt: O94779
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3299-29 | Target: Contactin-5 | UniProt: O94779 | TargetFullName: Contactin-5 | Organisim: human | Apparent_Kd_M: 7.54E-12
Real
Aptamer SeqId: 3302-58 | Target: CYTF | UniProt: O76096
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3302-58 | Target: CYTF | UniProt: O76096 | TargetFullName: Cystatin-F | Organisim: human | Apparent_Kd_M: 1.1E-11
Real
Aptamer SeqId: 3305-6 | Target: DLL4 | UniProt: Q9NR61
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3305-6 | Target: DLL4 | UniProt: Q9NR61 | TargetFullName: Delta-like protein 4 | Organisim: human | Apparent_Kd_M: 1.69E-11
Real
Aptamer SeqId: 3309-2 | Target: FCG2A | UniProt: P12318
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3309-2 | Target: FCG2A | UniProt: P12318 | TargetFullName: Low affinity immunoglobulin gamma Fc region receptor II-a | Organisim: human | Apparent_Kd_M: 7.19E-12
Real
Aptamer SeqId: 3310-62 | Target: FCG2B | UniProt: P31994
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3310-62 | Target: FCG2B | UniProt: P31994 | TargetFullName: Low affinity immunoglobulin gamma Fc region receptor II-b | Organisim: human | Apparent_Kd_M: 2.35E-12
Real
Aptamer SeqId: 3311-27 | Target: FCG3B | UniProt: O75015
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3311-27 | Target: FCG3B | UniProt: O75015 | TargetFullName: Low affinity immunoglobulin gamma Fc region receptor III-B | Organisim: human | Apparent_Kd_M: 8.35E-12
Real
Aptamer SeqId: 3312-64 | Target: FCGR1 | UniProt: P12314
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3312-64 | Target: FCGR1 | UniProt: P12314 | TargetFullName: High affinity immunoglobulin gamma Fc receptor I | Organisim: human | Apparent_Kd_M: 4.5E-12
Real
Aptamer SeqId: 3313-21 | Target: FCN2 | UniProt: Q15485
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3313-21 | Target: FCN2 | UniProt: Q15485 | TargetFullName: Ficolin-2 | Organisim: human | Apparent_Kd_M: 7.94E-10
Real
Aptamer SeqId: 3314-74 | Target: GFRa-1 | UniProt: P56159
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3314-74 | Target: GFRa-1 | UniProt: P56159 | TargetFullName: GDNF family receptor alpha-1 | Organisim: human | Apparent_Kd_M: 1.52E-12
Real
Aptamer SeqId: 3315-15 | Target: GPC2 | UniProt: Q8N158
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3315-15 | Target: GPC2 | UniProt: Q8N158 | TargetFullName: Glypican-2 | Organisim: human | Apparent_Kd_M: 1.76E-11
Real
Aptamer SeqId: 3316-58 | Target: Heparin cofactor II | UniProt: P05546
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3316-58 | Target: Heparin cofactor II | UniProt: P05546 | TargetFullName: Heparin cofactor 2 | Organisim: human | Apparent_Kd_M: 1.6E-11
Real
Aptamer SeqId: 3317-33 | Target: HTRA2 | UniProt: O43464
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3317-33 | Target: HTRA2 | UniProt: O43464 | TargetFullName: Serine protease HTRA2; mitochondrial | Organisim: human | Apparent_Kd_M: 8.69E-12
Real
Aptamer SeqId: 3320-49 | Target: IGFBP-7 | UniProt: Q16270
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3320-49 | Target: IGFBP-7 | UniProt: Q16270 | TargetFullName: Insulin-like growth factor-binding protein 7 | Organisim: human | Apparent_Kd_M: 2.4E-12
Real
Aptamer SeqId: 3321-2 | Target: IL24 | UniProt: Q13007
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3321-2 | Target: IL24 | UniProt: Q13007 | TargetFullName: Interleukin-24 | Organisim: human | Apparent_Kd_M: 1.31E-11
Real
Aptamer SeqId: 3322-52 | Target: LRIG3 | UniProt: Q6UXM1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3322-52 | Target: LRIG3 | UniProt: Q6UXM1 | TargetFullName: Leucine-rich repeats and immunoglobulin-like domains protein 3 | Organisim: human | Apparent_Kd_M: 7.52E-12
Real
Aptamer SeqId: 3323-37 | Target: LRP8 | UniProt: Q14114
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3323-37 | Target: LRP8 | UniProt: Q14114 | TargetFullName: Low-density lipoprotein receptor-related protein 8 | Organisim: human | Apparent_Kd_M: 1.26E-10
Real
Aptamer SeqId: 3324-51 | Target: LY9 | UniProt: Q9HBG7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3324-51 | Target: LY9 | UniProt: Q9HBG7 | TargetFullName: T-lymphocyte surface antigen Ly-9 | Organisim: human | Apparent_Kd_M: 9.26E-12
Real
Aptamer SeqId: 3325-2 | Target: MATN2 | UniProt: O00339
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3325-2 | Target: MATN2 | UniProt: O00339 | TargetFullName: Matrilin-2 | Organisim: human | Apparent_Kd_M: 1.55E-12
Real
Aptamer SeqId: 3326-58 | Target: Nectin-like protein 2 | UniProt: Q9BY67
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3326-58 | Target: Nectin-like protein 2 | UniProt: Q9BY67 | TargetFullName: Cell adhesion molecule 1 | Organisim: human | Apparent_Kd_M: 2.5E-11
Real
Aptamer SeqId: 3327-27 | Target: NET4 | UniProt: Q9HB63
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3327-27 | Target: NET4 | UniProt: Q9HB63 | TargetFullName: Netrin-4 | Organisim: human | Apparent_Kd_M: 1.43E-12
Real
Aptamer SeqId: 3329-14 | Target: PGRP-S | UniProt: O75594
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3329-14 | Target: PGRP-S | UniProt: O75594 | TargetFullName: Peptidoglycan recognition protein 1 | Organisim: human | Apparent_Kd_M: 2.71E-12
Real
Aptamer SeqId: 3331-8 | Target: RGMB | UniProt: Q6NW40
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3331-8 | Target: RGMB | UniProt: Q6NW40 | TargetFullName: RGM domain family member B | Organisim: human | Apparent_Kd_M: 2.35E-12
Real
Aptamer SeqId: 3332-57 | Target: RGM-C | UniProt: Q6ZVN8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3332-57 | Target: RGM-C | UniProt: Q6ZVN8 | TargetFullName: Hemojuvelin | Organisim: human | Apparent_Kd_M: 6.92E-12
Real
Aptamer SeqId: 3336-50 | Target: TFPI | UniProt: P10646
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3336-50 | Target: TFPI | UniProt: P10646 | TargetFullName: Tissue factor pathway inhibitor | Organisim: human | Apparent_Kd_M: 2.28E-12
Real
Aptamer SeqId: 3339-33 | Target: TSP2 | UniProt: P35442
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3339-33 | Target: TSP2 | UniProt: P35442 | TargetFullName: Thrombospondin-2 | Organisim: human | Apparent_Kd_M: 4.47E-11
Real
Aptamer SeqId: 3340-53 | Target: TSP4 | UniProt: P35443
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3340-53 | Target: TSP4 | UniProt: P35443 | TargetFullName: Thrombospondin-4 | Organisim: human | Apparent_Kd_M: 1.51E-10
Real
Aptamer SeqId: 3341-33 | Target: ABL1 | UniProt: P00519
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3341-33 | Target: ABL1 | UniProt: P00519 | TargetFullName: Tyrosine-protein kinase ABL1 | Organisim: human | Apparent_Kd_M: 6.18E-11
Real
Aptamer SeqId: 3342-76 | Target: ABL2 | UniProt: P42684
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3342-76 | Target: ABL2 | UniProt: P42684 | TargetFullName: Abelson tyrosine-protein kinase 2 | Organisim: human | Apparent_Kd_M: 2.75E-11
Real
Aptamer SeqId: 3343-1 | Target: Aminoacylase-1 | UniProt: Q03154
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3343-1 | Target: Aminoacylase-1 | UniProt: Q03154 | TargetFullName: Aminoacylase-1 | Organisim: human | Apparent_Kd_M: 5.6E-12
Real
Aptamer SeqId: 3344-60 | Target: Antithrombin III | UniProt: P01008
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3344-60 | Target: Antithrombin III | UniProt: P01008 | TargetFullName: Antithrombin-III | Organisim: human | Apparent_Kd_M: 2.4E-11
Real
Aptamer SeqId: 3346-72 | Target: AURKB | UniProt: Q96GD4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3346-72 | Target: AURKB | UniProt: Q96GD4 | TargetFullName: Aurora kinase B | Organisim: human | Apparent_Kd_M: 1.32E-11
Real
Aptamer SeqId: 3347-9 | Target: BARK1 | UniProt: P25098
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3347-9 | Target: BARK1 | UniProt: P25098 | TargetFullName: beta-adrenergic receptor kinase 1 | Organisim: human | Apparent_Kd_M: 1.29E-12
Real
Aptamer SeqId: 3348-49 | Target: BMP-1 | UniProt: P13497
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3348-49 | Target: BMP-1 | UniProt: P13497 | TargetFullName: Bone morphogenetic protein 1 | Organisim: human | Apparent_Kd_M: 5.68E-11
Real
Aptamer SeqId: 3350-53 | Target: CAMK2A | UniProt: Q9UQM7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3350-53 | Target: CAMK2A | UniProt: Q9UQM7 | TargetFullName: Calcium/calmodulin-dependent protein kinase type II subunit alpha | Organisim: human | Apparent_Kd_M: 1.19E-11
Real
Aptamer SeqId: 3351-1 | Target: CAMK2B | UniProt: Q13554
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3351-1 | Target: CAMK2B | UniProt: Q13554 | TargetFullName: Calcium/calmodulin-dependent protein kinase type II subunit beta | Organisim: human | Apparent_Kd_M: 4.21E-12
Real
Aptamer SeqId: 3352-80 | Target: Carbonic anhydrase 6 | UniProt: P23280
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3352-80 | Target: Carbonic anhydrase 6 | UniProt: P23280 | TargetFullName: Carbonic anhydrase 6 | Organisim: human | Apparent_Kd_M: 1.01E-11
Real
Aptamer SeqId: 3356-50 | Target: Carbonic anhydrase VII | UniProt: P43166
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3356-50 | Target: Carbonic anhydrase VII | UniProt: P43166 | TargetFullName: Carbonic anhydrase 7 | Organisim: human | Apparent_Kd_M: 1.43E-10
Real
Aptamer SeqId: 3357-67 | Target: CDK2/cyclin A | UniProt: P24941|P20248
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3357-67 | Target: CDK2/cyclin A | UniProt: P24941|P20248 | TargetFullName: Cyclin-dependent kinase 2:Cyclin-A2 complex | Organisim: human | Apparent_Kd_M: 3.36E-12
Real
Aptamer SeqId: 3358-51 | Target: CDK5/p35 | UniProt: Q00535|Q15078
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3358-51 | Target: CDK5/p35 | UniProt: Q00535|Q15078 | TargetFullName: Cyclin-dependent kinase 5:Cyclin-dependent kinase 5 activator 1 complex | Organisim: human | Apparent_Kd_M: 2.46E-11
Real
Aptamer SeqId: 3359-11 | Target: CDK8/cyclin C | UniProt: P49336|P24863
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3359-11 | Target: CDK8/cyclin C | UniProt: P49336|P24863 | TargetFullName: Cyclin-dependent kinase 8:Cyclin-C complex | Organisim: human | Apparent_Kd_M: 5.76E-11
Real
Aptamer SeqId: 3361-26 | Target: CLC4K | UniProt: Q9UJ71
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3361-26 | Target: CLC4K | UniProt: Q9UJ71 | TargetFullName: C-type lectin domain family 4 member K | Organisim: human | Apparent_Kd_M: 1.87E-11
Real
Aptamer SeqId: 3362-61 | Target: CRDL1 | UniProt: Q9BU40
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3362-61 | Target: CRDL1 | UniProt: Q9BU40 | TargetFullName: Chordin-like protein 1 | Organisim: human | Apparent_Kd_M: 7.97E-12
Real
Aptamer SeqId: 3363-31 | Target: CSK | UniProt: P41240
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3363-31 | Target: CSK | UniProt: P41240 | TargetFullName: Tyrosine-protein kinase CSK | Organisim: human | Apparent_Kd_M: 1.88E-12
Real
Aptamer SeqId: 3364-76 | Target: Cathepsin V | UniProt: O60911
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3364-76 | Target: Cathepsin V | UniProt: O60911 | TargetFullName: Cathepsin L2 | Organisim: human | Apparent_Kd_M: 3.6E-12
Real
Aptamer SeqId: 3365-7 | Target: Dkk-4 | UniProt: Q9UBT3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3365-7 | Target: Dkk-4 | UniProt: Q9UBT3 | TargetFullName: Dickkopf-related protein 4 | Organisim: human | Apparent_Kd_M: 1.67E-11
Real
Aptamer SeqId: 3366-51 | Target: ECM1 | UniProt: Q16610
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3366-51 | Target: ECM1 | UniProt: Q16610 | TargetFullName: Extracellular matrix protein 1 | Organisim: human | Apparent_Kd_M: 2.57E-12
Real
Aptamer SeqId: 3367-8 | Target: FETUB | UniProt: Q9UGM5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3367-8 | Target: FETUB | UniProt: Q9UGM5 | TargetFullName: Fetuin-B | Organisim: human | Apparent_Kd_M: 2.9E-12
Real
Aptamer SeqId: 3373-5 | Target: Granzyme H | UniProt: P20718
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3373-5 | Target: Granzyme H | UniProt: P20718 | TargetFullName: Granzyme H | Organisim: human | Apparent_Kd_M: 5.64E-12
Real
Aptamer SeqId: 3374-49 | Target: HCK | UniProt: P08631
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3374-49 | Target: HCK | UniProt: P08631 | TargetFullName: Tyrosine-protein kinase HCK | Organisim: human | Apparent_Kd_M: 1.65E-10
Real
Aptamer SeqId: 3376-49 | Target: IL-17 RD | UniProt: Q8NFM7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3376-49 | Target: IL-17 RD | UniProt: Q8NFM7 | TargetFullName: Interleukin-17 receptor D | Organisim: human | Apparent_Kd_M: 1.41E-11
Real
Aptamer SeqId: 3378-49 | Target: Kallikrein 7 | UniProt: P49862
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3378-49 | Target: Kallikrein 7 | UniProt: P49862 | TargetFullName: Kallikrein-7 | Organisim: human | Apparent_Kd_M: 6.81E-12
Real
Aptamer SeqId: 3379-29 | Target: KPCI | UniProt: P41743
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3379-29 | Target: KPCI | UniProt: P41743 | TargetFullName: Protein kinase C iota type | Organisim: human | Apparent_Kd_M: 4.8E-11
Real
Aptamer SeqId: 3381-24 | Target: LYNB | UniProt: P07948
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3381-24 | Target: LYNB | UniProt: P07948 | TargetFullName: Tyrosine-protein kinase Lyn; isoform B | Organisim: human | Apparent_Kd_M: 5.71E-12
Real
Aptamer SeqId: 3387-1 | Target: PAK3 | UniProt: O75914
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3387-1 | Target: PAK3 | UniProt: O75914 | TargetFullName: Serine/threonine-protein kinase PAK 3 | Organisim: human | Apparent_Kd_M: 3.37E-11
Real
Aptamer SeqId: 3388-58 | Target: PAK7 | UniProt: Q9P286
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3388-58 | Target: PAK7 | UniProt: Q9P286 | TargetFullName: Serine/threonine-protein kinase PAK 5 | Organisim: human | Apparent_Kd_M: 1.59E-12
Real
Aptamer SeqId: 3389-7 | Target: PCI | UniProt: P05154
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3389-7 | Target: PCI | UniProt: P05154 | TargetFullName: Plasma serine protease inhibitor | Organisim: human | Apparent_Kd_M: 6.04E-11
Real
Aptamer SeqId: 3390-72 | Target: PIK3CA/PIK3R1 | UniProt: P42336|P27986
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3390-72 | Target: PIK3CA/PIK3R1 | UniProt: P42336|P27986 | TargetFullName: PIK3CA/PIK3R1 | Organisim: human | Apparent_Kd_M: 2.95E-12
Real
Aptamer SeqId: 3391-10 | Target: PK3CG | UniProt: P48736
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3391-10 | Target: PK3CG | UniProt: P48736 | TargetFullName: Phosphatidylinositol 4;5-bisphosphate 3-kinase catalytic subunit gamma isoform | Organisim: human | Apparent_Kd_M: 1.19E-11
Real
Aptamer SeqId: 3392-68 | Target: PKB a/b/g | UniProt: P31749|P31751|Q9Y243
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3392-68 | Target: PKB a/b/g | UniProt: P31749|P31751|Q9Y243 | TargetFullName: RAC-alpha/beta/gamma serine/threonine-protein kinase | Organisim: human | Apparent_Kd_M: 8.61E-12
Real
Aptamer SeqId: 3394-81 | Target: PLK-1 | UniProt: P53350
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3394-81 | Target: PLK-1 | UniProt: P53350 | TargetFullName: Serine/threonine-protein kinase PLK1 | Organisim: human | Apparent_Kd_M: 1.2E-10
Real
Aptamer SeqId: 3396-54 | Target: Renin | UniProt: P00797
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3396-54 | Target: Renin | UniProt: P00797 | TargetFullName: Renin | Organisim: human | Apparent_Kd_M: 1.09E-12
Real
Aptamer SeqId: 3397-7 | Target: SHP-2 | UniProt: Q06124
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3397-7 | Target: SHP-2 | UniProt: Q06124 | TargetFullName: Tyrosine-protein phosphatase non-receptor type 11 | Organisim: human | Apparent_Kd_M: 3.87E-12
Real
Aptamer SeqId: 3399-31 | Target: STAB2 | UniProt: Q8WWQ8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3399-31 | Target: STAB2 | UniProt: Q8WWQ8 | TargetFullName: Stabilin-2 | Organisim: human | Apparent_Kd_M: 5.1E-12
Real
Aptamer SeqId: 3400-49 | Target: TBK1 | UniProt: Q9UHD2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3400-49 | Target: TBK1 | UniProt: Q9UHD2 | TargetFullName: Serine/threonine-protein kinase TBK1 | Organisim: human | Apparent_Kd_M: 2.61E-11
Real
Aptamer SeqId: 3401-8 | Target: TCPTP | UniProt: P17706
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3401-8 | Target: TCPTP | UniProt: P17706 | TargetFullName: Tyrosine-protein phosphatase non-receptor type 2 | Organisim: human | Apparent_Kd_M: 1.6E-11
Real
Aptamer SeqId: 3403-1 | Target: TPSB2 | UniProt: P20231
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3403-1 | Target: TPSB2 | UniProt: P20231 | TargetFullName: Tryptase beta-2 | Organisim: human | Apparent_Kd_M: 1.1E-12
Real
Aptamer SeqId: 3404-51 | Target: TPSG1 | UniProt: Q9NRR2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3404-51 | Target: TPSG1 | UniProt: Q9NRR2 | TargetFullName: Tryptase gamma | Organisim: human | Apparent_Kd_M: 7.16E-11
Real
Aptamer SeqId: 3405-6 | Target: UFC1 | UniProt: Q9Y3C8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3405-6 | Target: UFC1 | UniProt: Q9Y3C8 | TargetFullName: Ubiquitin-fold modifier-conjugating enzyme 1 | Organisim: human | Apparent_Kd_M: 5.35E-12
Real
Aptamer SeqId: 3412-7 | Target: Bcl-2 | UniProt: P10415
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3412-7 | Target: Bcl-2 | UniProt: P10415 | TargetFullName: Apoptosis regulator Bcl-2 | Organisim: human | Apparent_Kd_M: 5.26E-12
Real
Aptamer SeqId: 3413-50 | Target: BFL1 | UniProt: Q16548
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3413-50 | Target: BFL1 | UniProt: Q16548 | TargetFullName: Bcl-2-related protein A1 | Organisim: human | Apparent_Kd_M: 6.12E-12
Real
Aptamer SeqId: 3414-40 | Target: BMX | UniProt: P51813
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3414-40 | Target: BMX | UniProt: P51813 | TargetFullName: Cytoplasmic tyrosine-protein kinase BMX | Organisim: human | Apparent_Kd_M: 1.12E-11
Real
Aptamer SeqId: 3415-61 | Target: BSP | UniProt: P21815
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3415-61 | Target: BSP | UniProt: P21815 | TargetFullName: Bone sialoprotein 2 | Organisim: human | Apparent_Kd_M: 3.98E-11
Real
Aptamer SeqId: 3418-12 | Target: CAMK1D | UniProt: Q8IU85
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3418-12 | Target: CAMK1D | UniProt: Q8IU85 | TargetFullName: Calcium/calmodulin-dependent protein kinase type 1D | Organisim: human | Apparent_Kd_M: 2.78E-10
Real
Aptamer SeqId: 3419-49 | Target: CAMK2D | UniProt: Q13557
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3419-49 | Target: CAMK2D | UniProt: Q13557 | TargetFullName: Calcium/calmodulin-dependent protein kinase type II subunit delta | Organisim: human | Apparent_Kd_M: 1.81E-12
Real
Aptamer SeqId: 3420-21 | Target: Carbonic anhydrase XIII | UniProt: Q8N1Q1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3420-21 | Target: Carbonic anhydrase XIII | UniProt: Q8N1Q1 | TargetFullName: Carbonic anhydrase 13 | Organisim: human | Apparent_Kd_M: 2.7E-11
Real
Aptamer SeqId: 3421-54 | Target: CD30 Ligand | UniProt: P32971
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3421-54 | Target: CD30 Ligand | UniProt: P32971 | TargetFullName: Tumor necrosis factor ligand superfamily member 8 | Organisim: human | Apparent_Kd_M: 8.87E-12
Real
Aptamer SeqId: 3422-4 | Target: CDK1/cyclin B | UniProt: P06493|P14635
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3422-4 | Target: CDK1/cyclin B | UniProt: P06493|P14635 | TargetFullName: Cyclin-dependent kinase 1:G2/mitotic-specific cyclin-B1 complex | Organisim: human | Apparent_Kd_M: 3.53E-11
Real
Aptamer SeqId: 3423-59 | Target: Chymase | UniProt: P23946
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3423-59 | Target: Chymase | UniProt: P23946 | TargetFullName: Chymase | Organisim: human | Apparent_Kd_M: 3.96E-12
Real
Aptamer SeqId: 3427-63 | Target: CSK21 | UniProt: P68400
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3427-63 | Target: CSK21 | UniProt: P68400 | TargetFullName: Casein kinase II subunit alpha | Organisim: human | Apparent_Kd_M: 1.65E-12
Real
Aptamer SeqId: 3431-54 | Target: EphA1 | UniProt: P21709
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3431-54 | Target: EphA1 | UniProt: P21709 | TargetFullName: Ephrin type-A receptor 1 | Organisim: human | Apparent_Kd_M: 1.82E-11
Real
Aptamer SeqId: 3432-21 | Target: EPHA3 | UniProt: P29320
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3432-21 | Target: EPHA3 | UniProt: P29320 | TargetFullName: Ephrin type-A receptor 3 | Organisim: human | Apparent_Kd_M: 3.24E-11
Real
Aptamer SeqId: 3434-34 | Target: FN1.3 | UniProt: P02751
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3434-34 | Target: FN1.3 | UniProt: P02751 | TargetFullName: Fibronectin Fragment 3 | Organisim: human | Apparent_Kd_M: 2.71E-12
Real
Aptamer SeqId: 3435-53 | Target: FN1.4 | UniProt: P02751
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3435-53 | Target: FN1.4 | UniProt: P02751 | TargetFullName: Fibronectin Fragment 4 | Organisim: human | Apparent_Kd_M: 2.74E-12
Real
Aptamer SeqId: 3437-80 | Target: Flt-3 | UniProt: P36888
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3437-80 | Target: Flt-3 | UniProt: P36888 | TargetFullName: Receptor-type tyrosine-protein kinase FLT3 | Organisim: human | Apparent_Kd_M: 1.6E-11
Real
Aptamer SeqId: 3438-10 | Target: FSTL3 | UniProt: O95633
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3438-10 | Target: FSTL3 | UniProt: O95633 | TargetFullName: Follistatin-related protein 3 | Organisim: human | Apparent_Kd_M: 3.11E-12
Real
Aptamer SeqId: 3440-7 | Target: granzyme A | UniProt: P12544
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3440-7 | Target: granzyme A | UniProt: P12544 | TargetFullName: Granzyme A | Organisim: human | Apparent_Kd_M: 2.31E-12
Real
Aptamer SeqId: 3441-64 | Target: GSK-3 alpha/beta | UniProt: P49840|P49841
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3441-64 | Target: GSK-3 alpha/beta | UniProt: P49840|P49841 | TargetFullName: Glycogen synthase kinase-3 alpha/beta | Organisim: human | Apparent_Kd_M: 4.74E-12
Real
Aptamer SeqId: 3445-53 | Target: IL-15 Ra | UniProt: Q13261
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3445-53 | Target: IL-15 Ra | UniProt: Q13261 | TargetFullName: Interleukin-15 receptor subunit alpha | Organisim: human | Apparent_Kd_M: 8.75E-12
Real
Aptamer SeqId: 3447-64 | Target: IL-8 | UniProt: P10145
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3447-64 | Target: IL-8 | UniProt: P10145 | TargetFullName: Interleukin-8 | Organisim: human | Apparent_Kd_M: 1.1E-11
Real
Aptamer SeqId: 3448-13 | Target: IR | UniProt: P06213
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3448-13 | Target: IR | UniProt: P06213 | TargetFullName: Insulin receptor | Organisim: human | Apparent_Kd_M: 8.9E-12
Real
Aptamer SeqId: 3449-58 | Target: Kallistatin | UniProt: P29622
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3449-58 | Target: Kallistatin | UniProt: P29622 | TargetFullName: Kallistatin | Organisim: human | Apparent_Kd_M: 7.73E-12
Real
Aptamer SeqId: 3450-4 | Target: Kallikrein 6 | UniProt: Q92876
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3450-4 | Target: Kallikrein 6 | UniProt: Q92876 | TargetFullName: Kallikrein-6 | Organisim: human | Apparent_Kd_M: 2.12E-11
Real
Aptamer SeqId: 3452-17 | Target: LCK | UniProt: P06239
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3452-17 | Target: LCK | UniProt: P06239 | TargetFullName: Tyrosine-protein kinase Lck | Organisim: human | Apparent_Kd_M: 2.02E-11
Real
Aptamer SeqId: 3453-87 | Target: LYN | UniProt: P07948
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3453-87 | Target: LYN | UniProt: P07948 | TargetFullName: Tyrosine-protein kinase Lyn | Organisim: human | Apparent_Kd_M: 1.53E-11
Real
Aptamer SeqId: 3457-57 | Target: Periostin | UniProt: Q15063
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3457-57 | Target: Periostin | UniProt: Q15063 | TargetFullName: Periostin | Organisim: human | Apparent_Kd_M: 4.38E-12
Real
Aptamer SeqId: 3459-49 | Target: PDGF Rb | UniProt: P09619
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3459-49 | Target: PDGF Rb | UniProt: P09619 | TargetFullName: Platelet-derived growth factor receptor beta | Organisim: human | Apparent_Kd_M: 1.58E-11
Real
Aptamer SeqId: 3461-58 | Target: PGCB | UniProt: Q96GW7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3461-58 | Target: PGCB | UniProt: Q96GW7 | TargetFullName: Brevican core protein | Organisim: human | Apparent_Kd_M: 4.36E-12
Real
Aptamer SeqId: 3466-8 | Target: PRKACA | UniProt: P17612
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3466-8 | Target: PRKACA | UniProt: P17612 | TargetFullName: cAMP-dependent protein kinase catalytic subunit alpha | Organisim: human | Apparent_Kd_M: 4.89E-11
Real
Aptamer SeqId: 3469-74 | Target: RPS6KA3 | UniProt: P51812
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3469-74 | Target: RPS6KA3 | UniProt: P51812 | TargetFullName: Ribosomal protein S6 kinase alpha-3 | Organisim: human | Apparent_Kd_M: 2.22E-12
Real
Aptamer SeqId: 3470-1 | Target: sE-Selectin | UniProt: P16581
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3470-1 | Target: sE-Selectin | UniProt: P16581 | TargetFullName: E-selectin | Organisim: human | Apparent_Kd_M: 1.23E-12
Real
Aptamer SeqId: 3471-49 | Target: STK16 | UniProt: O75716
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3471-49 | Target: STK16 | UniProt: O75716 | TargetFullName: Serine/threonine-protein kinase 16 | Organisim: human | Apparent_Kd_M: 1.64E-11
Real
Aptamer SeqId: 3472-40 | Target: Survivin | UniProt: O15392
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3472-40 | Target: Survivin | UniProt: O15392 | TargetFullName: Baculoviral IAP repeat-containing protein 5 | Organisim: human | Apparent_Kd_M: 7.73E-12
Real
Aptamer SeqId: 3473-78 | Target: Thrombopoietin Receptor | UniProt: P40238
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3473-78 | Target: Thrombopoietin Receptor | UniProt: P40238 | TargetFullName: Thrombopoietin Receptor | Organisim: human | Apparent_Kd_M: 3.44E-11
Real
Aptamer SeqId: 3474-19 | Target: Thrombospondin-1 | UniProt: P07996
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3474-19 | Target: Thrombospondin-1 | UniProt: P07996 | TargetFullName: Thrombospondin-1 | Organisim: human | Apparent_Kd_M: 1.21E-11
Real
Aptamer SeqId: 3477-63 | Target: TrkA | UniProt: P04629
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3477-63 | Target: TrkA | UniProt: P04629 | TargetFullName: High affinity nerve growth factor receptor | Organisim: human | Apparent_Kd_M: 1.37E-10
Real
Aptamer SeqId: 3480-7 | Target: DUS3 | UniProt: P51452
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3480-7 | Target: DUS3 | UniProt: P51452 | TargetFullName: Dual specificity protein phosphatase 3 | Organisim: human | Apparent_Kd_M: 1.32E-11
Real
Aptamer SeqId: 3481-87 | Target: XPNPEP1 | UniProt: Q9NQW7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3481-87 | Target: XPNPEP1 | UniProt: Q9NQW7 | TargetFullName: Xaa-Pro aminopeptidase 1 | Organisim: human | Apparent_Kd_M: 5.13E-11
Real
Aptamer SeqId: 3484-60 | Target: Angiotensinogen | UniProt: P01019
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3484-60 | Target: Angiotensinogen | UniProt: P01019 | TargetFullName: Angiotensinogen | Organisim: human | Apparent_Kd_M: 5.68E-11
Real
Aptamer SeqId: 3485-28 | Target: b2-Microglobulin | UniProt: P61769
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3485-28 | Target: b2-Microglobulin | UniProt: P61769 | TargetFullName: Beta-2-microglobulin | Organisim: human | Apparent_Kd_M: 6.02E-12
Real
Aptamer SeqId: 3486-58 | Target: b-ECGF | UniProt: P05230
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3486-58 | Target: b-ECGF | UniProt: P05230 | TargetFullName: Fibroblast growth factor 1 | Organisim: human | Apparent_Kd_M: 1.25E-12
Real
Aptamer SeqId: 3487-32 | Target: BLC | UniProt: O43927
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3487-32 | Target: BLC | UniProt: O43927 | TargetFullName: C-X-C motif chemokine 13 | Organisim: human | Apparent_Kd_M: 1.86E-12
Real
Aptamer SeqId: 3488-64 | Target: Catalase | UniProt: P04040
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3488-64 | Target: Catalase | UniProt: P04040 | TargetFullName: Catalase | Organisim: human | Apparent_Kd_M: 1.71E-11
Real
Aptamer SeqId: 3489-9 | Target: CNTF | UniProt: P26441
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3489-9 | Target: CNTF | UniProt: P26441 | TargetFullName: Ciliary neurotrophic factor | Organisim: human | Apparent_Kd_M: 2.37E-12
Real
Aptamer SeqId: 3494-71 | Target: FGF-17 | UniProt: O60258
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3494-71 | Target: FGF-17 | UniProt: O60258 | TargetFullName: Fibroblast growth factor 17 | Organisim: human | Apparent_Kd_M: 1.66E-10
Real
Aptamer SeqId: 3495-15 | Target: GCP-2 | UniProt: P80162
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3495-15 | Target: GCP-2 | UniProt: P80162 | TargetFullName: C-X-C motif chemokine 6 | Organisim: human | Apparent_Kd_M: 5.64E-12
Real
Aptamer SeqId: 3497-13 | Target: IFN-aA | UniProt: P01563
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3497-13 | Target: IFN-aA | UniProt: P01563 | TargetFullName: Interferon alpha-2 | Organisim: human | Apparent_Kd_M: 1.65E-11
Real
Aptamer SeqId: 3499-77 | Target: IL-17B | UniProt: Q9UHF5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3499-77 | Target: IL-17B | UniProt: Q9UHF5 | TargetFullName: Interleukin-17B | Organisim: human | Apparent_Kd_M: 1.06E-12
Real
Aptamer SeqId: 3503-4 | Target: Integrin a1b1 | UniProt: P56199|P05556
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3503-4 | Target: Integrin a1b1 | UniProt: P56199|P05556 | TargetFullName: Integrin alpha-I: beta-1 complex | Organisim: human | Apparent_Kd_M: 7.63E-11
Real
Aptamer SeqId: 3504-58 | Target: LEAP-1 | UniProt: P81172
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3504-58 | Target: LEAP-1 | UniProt: P81172 | TargetFullName: Hepcidin | Organisim: human | Apparent_Kd_M: 1.52E-10
Real
Aptamer SeqId: 3505-6 | Target: Lymphotoxin a1/b2 | UniProt: P01374|Q06643
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3505-6 | Target: Lymphotoxin a1/b2 | UniProt: P01374|Q06643 | TargetFullName: Lymphotoxin alpha1:beta2 | Organisim: human | Apparent_Kd_M: 1.26E-11
Real
Aptamer SeqId: 3506-49 | Target: Lymphotoxin a2/b1 | UniProt: P01374|Q06643
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3506-49 | Target: Lymphotoxin a2/b1 | UniProt: P01374|Q06643 | TargetFullName: Lymphotoxin alpha2:beta1 | Organisim: human | Apparent_Kd_M: 1.69E-12
Real
Aptamer SeqId: 3507-1 | Target: MDH_THETH | UniProt: P10584
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3507-1 | Target: MDH_THETH | UniProt: P10584 | TargetFullName: Malic dehydrogenase_THETH | Organisim: thermus thermophilus | Apparent_Kd_M: 8.35E-12
Real
Aptamer SeqId: 3508-78 | Target: MDC | UniProt: O00626
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3508-78 | Target: MDC | UniProt: O00626 | TargetFullName: C-C motif chemokine 22 | Organisim: human | Apparent_Kd_M: 6.58E-12
Real
Aptamer SeqId: 3512-72 | Target: KAD_GEOSE | UniProt: P27142
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3512-72 | Target: KAD_GEOSE | UniProt: P27142 | TargetFullName: Adenylate kinase_GEOSE | Organisim: geobacillus stearothermophilus (bacillus stearothermophilus) | Apparent_Kd_M: 2.2E-12
Real
Aptamer SeqId: 3516-60 | Target: SDF-1 | UniProt: P48061
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3516-60 | Target: SDF-1 | UniProt: P48061 | TargetFullName: Stromal cell-derived factor 1 | Organisim: human | Apparent_Kd_M: 1.32E-12
Real
Aptamer SeqId: 3518-54 | Target: TAFI | UniProt: Q96IY4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3518-54 | Target: TAFI | UniProt: Q96IY4 | TargetFullName: Carboxypeptidase B2 | Organisim: human | Apparent_Kd_M: 3.93E-12
Real
Aptamer SeqId: 3519-3 | Target: TARC | UniProt: Q92583
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3519-3 | Target: TARC | UniProt: Q92583 | TargetFullName: C-C motif chemokine 17 | Organisim: human | Apparent_Kd_M: 1.06E-12
Real
Aptamer SeqId: 3520-58 | Target: TGF-b3 | UniProt: P10600
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3520-58 | Target: TGF-b3 | UniProt: P10600 | TargetFullName: Transforming growth factor beta-3 | Organisim: human | Apparent_Kd_M: 2.93E-12
Real
Aptamer SeqId: 3521-16 | Target: TSH | UniProt: P01215|P01222
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3521-16 | Target: TSH | UniProt: P01215|P01222 | TargetFullName: Thyroid Stimulating Hormone | Organisim: human | Apparent_Kd_M: 9.75E-12
Real
Aptamer SeqId: 3522-57 | Target: Vasoactive Intestinal Peptide
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3522-57 | Target: Vasoactive Intestinal Peptide | UniProt: P01282 | TargetFullName: Vasoactive Intestinal Peptide | Organisim: human | Apparent_Kd_M: 1.05E-11
Real
Aptamer SeqId: 3525-1 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3525-1 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 3525-2 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3525-2 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 3525-3 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3525-3 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 3525-4 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3525-4 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 3534-14 | Target: CD40 ligand; soluble | UniProt: P29965
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3534-14 | Target: CD40 ligand; soluble | UniProt: P29965 | TargetFullName: CD40 ligand | Organisim: human | Apparent_Kd_M: 6.38E-12
Real
Aptamer SeqId: 3535-84 | Target: DKK1 | UniProt: O94907
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3535-84 | Target: DKK1 | UniProt: O94907 | TargetFullName: Dickkopf-related protein 1 | Organisim: human | Apparent_Kd_M: 1.55E-11
Real
Aptamer SeqId: 3538-26 | Target: dopa decarboxylase | UniProt: P20711
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3538-26 | Target: dopa decarboxylase | UniProt: P20711 | TargetFullName: Aromatic-L-amino-acid decarboxylase | Organisim: human | Apparent_Kd_M: 4.37E-12
Real
Aptamer SeqId: 3554-24 | Target: Adiponectin | UniProt: Q15848
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3554-24 | Target: Adiponectin | UniProt: Q15848 | TargetFullName: Adiponectin | Organisim: human | Apparent_Kd_M: 3.62E-11
Real
Aptamer SeqId: 3580-25 | Target: a1-Antitrypsin | UniProt: P01009
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3580-25 | Target: a1-Antitrypsin | UniProt: P01009 | TargetFullName: Alpha-1-antitrypsin | Organisim: human | Apparent_Kd_M: 3.05E-10
Real
Aptamer SeqId: 3581-53 | Target: a2-HS-Glycoprotein | UniProt: P02765
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3581-53 | Target: a2-HS-Glycoprotein | UniProt: P02765 | TargetFullName: Alpha-2-HS-glycoprotein | Organisim: human | Apparent_Kd_M: 1.14E-10
Real
Aptamer SeqId: 3583-54 | Target: Arylsulfatase A | UniProt: P15289
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3583-54 | Target: Arylsulfatase A | UniProt: P15289 | TargetFullName: Arylsulfatase A | Organisim: human | Apparent_Kd_M: 8.56E-11
Real
Aptamer SeqId: 3585-54 | Target: BASI | UniProt: P35613
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3585-54 | Target: BASI | UniProt: P35613 | TargetFullName: Basigin | Organisim: human | Apparent_Kd_M: 6.94E-11
Real
Aptamer SeqId: 3587-53 | Target: BMP10 | UniProt: O95393
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3587-53 | Target: BMP10 | UniProt: O95393 | TargetFullName: Bone morphogenetic protein 10 | Organisim: human | Apparent_Kd_M: 9.08E-11
Real
Aptamer SeqId: 3592-4 | Target: CAMK1 | UniProt: Q14012
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3592-4 | Target: CAMK1 | UniProt: Q14012 | TargetFullName: Calcium/calmodulin-dependent protein kinase type 1 | Organisim: human | Apparent_Kd_M: 8.0E-11
Real
Aptamer SeqId: 3593-72 | Target: Caspase-3 | UniProt: P42574
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3593-72 | Target: Caspase-3 | UniProt: P42574 | TargetFullName: Caspase-3 | Organisim: human | Apparent_Kd_M: 2.37E-12
Real
Aptamer SeqId: 3600-2 | Target: Chitotriosidase-1 | UniProt: Q13231
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3600-2 | Target: Chitotriosidase-1 | UniProt: Q13231 | TargetFullName: Chitotriosidase-1 | Organisim: human | Apparent_Kd_M: 1.55E-11
Real
Aptamer SeqId: 3603-60 | Target: CLC7A | UniProt: Q9BXN2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3603-60 | Target: CLC7A | UniProt: Q9BXN2 | TargetFullName: C-type lectin domain family 7 member A | Organisim: human | Apparent_Kd_M: 8.329448E-11
Real
Aptamer SeqId: 3605-77 | Target: MASP3 | UniProt: P48740
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3605-77 | Target: MASP3 | UniProt: P48740 | TargetFullName: Mannan-binding lectin serine protease 1 | Organisim: human | Apparent_Kd_M: 2.7E-10
Real
Aptamer SeqId: 3607-71 | Target: DKK3 | UniProt: Q9UBP4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3607-71 | Target: DKK3 | UniProt: Q9UBP4 | TargetFullName: Dickkopf-related protein 3 | Organisim: human | Apparent_Kd_M: 3.38E-11
Real
Aptamer SeqId: 3616-3 | Target: GNS | UniProt: P15586
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3616-3 | Target: GNS | UniProt: P15586 | TargetFullName: N-acetylglucosamine-6-sulfatase | Organisim: human | Apparent_Kd_M: 3.08E-12
Real
Aptamer SeqId: 3617-80 | Target: HGFA | UniProt: Q04756
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3617-80 | Target: HGFA | UniProt: Q04756 | TargetFullName: Hepatocyte growth factor activator | Organisim: human | Apparent_Kd_M: 1.83E-12
Real
Aptamer SeqId: 3620-67 | Target: IL22RA1 | UniProt: Q8N6P7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3620-67 | Target: IL22RA1 | UniProt: Q8N6P7 | TargetFullName: Interleukin-22 receptor subunit alpha-1 | Organisim: human | Apparent_Kd_M: 1.509775E-11
Real
Aptamer SeqId: 3622-33 | Target: LGMN | UniProt: Q99538
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3622-33 | Target: LGMN | UniProt: Q99538 | TargetFullName: Legumain | Organisim: human | Apparent_Kd_M: 6.95E-12
Real
Aptamer SeqId: 3623-84 | Target: LY86 | UniProt: O95711
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3623-84 | Target: LY86 | UniProt: O95711 | TargetFullName: Lymphocyte antigen 86 | Organisim: human | Apparent_Kd_M: 6.62E-11
Real
Aptamer SeqId: 3627-71 | Target: MMEL2 | UniProt: Q495T6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3627-71 | Target: MMEL2 | UniProt: Q495T6 | TargetFullName: Membrane metallo-endopeptidase-like 1 | Organisim: human | Apparent_Kd_M: 5.86E-12
Real
Aptamer SeqId: 3628-3 | Target: MP2K2 | UniProt: P36507
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3628-3 | Target: MP2K2 | UniProt: P36507 | TargetFullName: Dual specificity mitogen-activated protein kinase kinase 2 | Organisim: human | Apparent_Kd_M: 2.58E-11
Real
Aptamer SeqId: 3629-60 | Target: MRCKB | UniProt: Q9Y5S2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3629-60 | Target: MRCKB | UniProt: Q9Y5S2 | TargetFullName: Serine/threonine-protein kinase MRCK beta | Organisim: human | Apparent_Kd_M: 1.25E-10
Real
Aptamer SeqId: 3630-27 | Target: Nectin-like protein 1 | UniProt: Q8N126
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3630-27 | Target: Nectin-like protein 1 | UniProt: Q8N126 | TargetFullName: Cell adhesion molecule 3 | Organisim: human | Apparent_Kd_M: 1.5E-11
Real
Aptamer SeqId: 3640-14 | Target: RAP | UniProt: P30533
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3640-14 | Target: RAP | UniProt: P30533 | TargetFullName: alpha-2-macroglobulin receptor-associated protein | Organisim: human | Apparent_Kd_M: 1.3E-12
Real
Aptamer SeqId: 3647-49 | Target: TLR4:MD-2 complex | UniProt: O00206|Q9Y6Y9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3647-49 | Target: TLR4:MD-2 complex | UniProt: O00206|Q9Y6Y9 | TargetFullName: Toll-like receptor 4:Lymphocyte antigen 96 complex | Organisim: human | Apparent_Kd_M: 2.35E-11
Real
Aptamer SeqId: 3650-8 | Target: GFP_AEQVI | UniProt: P42212
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3650-8 | Target: GFP_AEQVI | UniProt: P42212 | TargetFullName: Green fluorescent protein_AEQVI | Organisim: aequorea victoria (jellyfish) | Apparent_Kd_M: 4.84E-12
Real
Aptamer SeqId: 3651-50 | Target: VEGF sR2 | UniProt: P35968
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3651-50 | Target: VEGF sR2 | UniProt: P35968 | TargetFullName: Vascular endothelial growth factor receptor 2 | Organisim: human | Apparent_Kd_M: 1.06E-11
Real
Aptamer SeqId: 3685-53 | Target: MFRP | UniProt: Q9BY79
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3685-53 | Target: MFRP | UniProt: Q9BY79 | TargetFullName: Membrane frizzled-related protein | Organisim: human | Apparent_Kd_M: 1.25E-11
Real
Aptamer SeqId: 3708-62 | Target: a2-Macroglobulin | UniProt: P01023
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3708-62 | Target: a2-Macroglobulin | UniProt: P01023 | TargetFullName: Alpha-2-macroglobulin | Organisim: human | Apparent_Kd_M: 4.7E-11
Real
Aptamer SeqId: 3710-49 | Target: Angiostatin | UniProt: P00747
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3710-49 | Target: Angiostatin | UniProt: P00747 | TargetFullName: Angiostatin | Organisim: human | Apparent_Kd_M: 3.13E-11
Real
Aptamer SeqId: 3714-49 | Target: CK-MB | UniProt: P12277|P06732
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3714-49 | Target: CK-MB | UniProt: P12277|P06732 | TargetFullName: Creatine kinase M-type:Creatine kinase B-type heterodimer | Organisim: human | Apparent_Kd_M: 6.6E-11
Real
Aptamer SeqId: 3717-23 | Target: LUCI_PHOPY | UniProt: P08659
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3717-23 | Target: LUCI_PHOPY | UniProt: P08659 | TargetFullName: Luciferin 4-monooxygenase_PHOPY | Organisim: photinus pyralis (north american firefly) | Apparent_Kd_M: 1.81E-10
Real
Aptamer SeqId: 3719-2 | Target: p27Kip1 | UniProt: P46527
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3719-2 | Target: p27Kip1 | UniProt: P46527 | TargetFullName: Cyclin-dependent kinase inhibitor 1B | Organisim: human | Apparent_Kd_M: 1.49E-11
Real
Aptamer SeqId: 3721-5 | Target: NOH4_RHIML | UniProt: P06237
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3721-5 | Target: NOH4_RHIML | UniProt: P06237 | TargetFullName: Nodulation protein H_NOH4 | Organisim: rhizobium meliloti (ensifer meliloti) (sinorhizobium meliloti) | Apparent_Kd_M: 1.101054E-11
Real
Aptamer SeqId: 3723-1 | Target: BNP-32 | UniProt: P16860
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3723-1 | Target: BNP-32 | UniProt: P16860 | TargetFullName: Brain natriuretic peptide 32 | Organisim: human | Apparent_Kd_M: 1.78E-10
Real
Aptamer SeqId: 3724-64 | Target: EXE4_HELSU | UniProt: P26349
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3724-64 | Target: EXE4_HELSU | UniProt: P26349 | TargetFullName: Exendin-4_HELSU | Organisim: heloderma suspectum (gila monster) | Apparent_Kd_M: 9.059929E-10
Real
Aptamer SeqId: 3727-35 | Target: PYY | UniProt: P10082
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3727-35 | Target: PYY | UniProt: P10082 | TargetFullName: Peptide YY | Organisim: human | Apparent_Kd_M: 1.95E-11
Real
Aptamer SeqId: 3728-52 | Target: Secretin | UniProt: P09683
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3728-52 | Target: Secretin | UniProt: P09683 | TargetFullName: Secretin | Organisim: human | Apparent_Kd_M: 4.32E-12
Real
Aptamer SeqId: 3730-81 | Target: TNR4 | UniProt: P43489
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3730-81 | Target: TNR4 | UniProt: P43489 | TargetFullName: Tumor necrosis factor receptor superfamily member 4 | Organisim: human | Apparent_Kd_M: 5.56E-11
Real
Aptamer SeqId: 3738-54 | Target: CSF-1 | UniProt: P09603
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3738-54 | Target: CSF-1 | UniProt: P09603 | TargetFullName: Macrophage colony-stimulating factor 1 | Organisim: human | Apparent_Kd_M: 1.06E-11
Real
Aptamer SeqId: 3742-78 | Target: NIGB_SAMNI | UniProt: P33183
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3742-78 | Target: NIGB_SAMNI | UniProt: P33183 | TargetFullName: Nigrin b_SAMNI | Organisim: sambucus nigra (european elder) | Apparent_Kd_M: 5.66E-11
Real
Aptamer SeqId: 3758-68 | Target: Activated Protein C | UniProt: P04070
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3758-68 | Target: Activated Protein C | UniProt: P04070 | TargetFullName: Activated Protein C | Organisim: human | Apparent_Kd_M: 5.31E-12
Real
Aptamer SeqId: 3761-4 | Target: COX-2 | UniProt: P35354
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3761-4 | Target: COX-2 | UniProt: P35354 | TargetFullName: Prostaglandin G/H synthase 2 | Organisim: human | Apparent_Kd_M: 7.14E-11
Real
Aptamer SeqId: 3773-15 | Target: sTie-2 | UniProt: Q02763
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3773-15 | Target: sTie-2 | UniProt: Q02763 | TargetFullName: Angiopoietin-1 receptor; soluble | Organisim: human | Apparent_Kd_M: 9.79E-11
Real
Aptamer SeqId: 3795-6 | Target: ADAM 9 | UniProt: Q13443
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3795-6 | Target: ADAM 9 | UniProt: Q13443 | TargetFullName: Disintegrin and metalloproteinase domain-containing protein 9 | Organisim: human | Apparent_Kd_M: 4.47E-12
Real
Aptamer SeqId: 3796-79 | Target: ANGL4 | UniProt: Q9BY76
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3796-79 | Target: ANGL4 | UniProt: Q9BY76 | TargetFullName: Angiopoietin-related protein 4 | Organisim: human | Apparent_Kd_M: 6.16E-11
Real
Aptamer SeqId: 3797-1 | Target: Cadherin-2 | UniProt: P19022
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3797-1 | Target: Cadherin-2 | UniProt: P19022 | TargetFullName: Cadherin-2 | Organisim: human | Apparent_Kd_M: 3.32E-10
Real
Aptamer SeqId: 3798-71 | Target: Carbonic anhydrase 9 | UniProt: Q16790
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3798-71 | Target: Carbonic anhydrase 9 | UniProt: Q16790 | TargetFullName: Carbonic anhydrase 9 | Organisim: human | Apparent_Kd_M: 7.35E-11
Real
Aptamer SeqId: 3799-11 | Target: Carbonic anhydrase III | UniProt: P07451
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3799-11 | Target: Carbonic anhydrase III | UniProt: P07451 | TargetFullName: Carbonic anhydrase 3 | Organisim: human | Apparent_Kd_M: 1.08E-11
Real
Aptamer SeqId: 3800-71 | Target: CK-BB | UniProt: P12277
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3800-71 | Target: CK-BB | UniProt: P12277 | TargetFullName: Creatine kinase B-type | Organisim: human | Apparent_Kd_M: 5.67E-11
Real
Aptamer SeqId: 3803-10 | Target: CYTD | UniProt: P28325
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3803-10 | Target: CYTD | UniProt: P28325 | TargetFullName: Cystatin-D | Organisim: human | Apparent_Kd_M: 1.26E-11
Real
Aptamer SeqId: 3805-16 | Target: Endocan | UniProt: Q9NQ30
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3805-16 | Target: Endocan | UniProt: Q9NQ30 | TargetFullName: Endothelial cell-specific molecule 1 | Organisim: human | Apparent_Kd_M: 1.41E-11
Real
Aptamer SeqId: 3806-55 | Target: EphA5 | UniProt: P54756
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3806-55 | Target: EphA5 | UniProt: P54756 | TargetFullName: Ephrin type-A receptor 5 | Organisim: human | Apparent_Kd_M: 1.17E-11
Real
Aptamer SeqId: 3807-1 | Target: FGF23 | UniProt: Q9GZV9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3807-1 | Target: FGF23 | UniProt: Q9GZV9 | TargetFullName: Fibroblast growth factor 23 | Organisim: human | Apparent_Kd_M: 5.47E-12
Real
Aptamer SeqId: 3808-76 | Target: FGFR-2 | UniProt: P21802
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3808-76 | Target: FGFR-2 | UniProt: P21802 | TargetFullName: Fibroblast growth factor receptor 2 | Organisim: human | Apparent_Kd_M: 2.66E-11
Real
Aptamer SeqId: 3809-1 | Target: FGFR-3 | UniProt: P22607
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3809-1 | Target: FGFR-3 | UniProt: P22607 | TargetFullName: Fibroblast growth factor receptor 3 | Organisim: human | Apparent_Kd_M: 2.2E-10
Real
Aptamer SeqId: 3810-50 | Target: FGR | UniProt: P09769
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3810-50 | Target: FGR | UniProt: P09769 | TargetFullName: Tyrosine-protein kinase Fgr | Organisim: human | Apparent_Kd_M: 2.84E-11
Real
Aptamer SeqId: 3813-3 | Target: FYN | UniProt: P06241
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3813-3 | Target: FYN | UniProt: P06241 | TargetFullName: Tyrosine-protein kinase Fyn | Organisim: human | Apparent_Kd_M: 3.07E-12
Real
Aptamer SeqId: 3815-14 | Target: IL-12 RB2 | UniProt: Q99665
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3815-14 | Target: IL-12 RB2 | UniProt: Q99665 | TargetFullName: Interleukin-12 receptor subunit beta-2 | Organisim: human | Apparent_Kd_M: 1.05E-11
Real
Aptamer SeqId: 3817-18 | Target: KPCT | UniProt: Q04759
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3817-18 | Target: KPCT | UniProt: Q04759 | TargetFullName: Protein kinase C theta type | Organisim: human | Apparent_Kd_M: 1.32E-11
Real
Aptamer SeqId: 3820-68 | Target: MAPK2 | UniProt: P49137
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3820-68 | Target: MAPK2 | UniProt: P49137 | TargetFullName: MAP kinase-activated protein kinase 2 | Organisim: human | Apparent_Kd_M: 1.08E-11
Real
Aptamer SeqId: 3821-28 | Target: MAPK5 | UniProt: Q8IW41
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3821-28 | Target: MAPK5 | UniProt: Q8IW41 | TargetFullName: MAP kinase-activated protein kinase 5 | Organisim: human | Apparent_Kd_M: 7.95E-12
Real
Aptamer SeqId: 3822-54 | Target: MAPKAPK3 | UniProt: Q16644
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3822-54 | Target: MAPKAPK3 | UniProt: Q16644 | TargetFullName: MAP kinase-activated protein kinase 3 | Organisim: human | Apparent_Kd_M: 4.47E-12
Real
Aptamer SeqId: 3823-9 | Target: MATK | UniProt: P42679
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3823-9 | Target: MATK | UniProt: P42679 | TargetFullName: Megakaryocyte-associated tyrosine-protein kinase | Organisim: human | Apparent_Kd_M: 6.47E-11
Real
Aptamer SeqId: 3825-18 | Target: MK08 | UniProt: P45983
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3825-18 | Target: MK08 | UniProt: P45983 | TargetFullName: Mitogen-activated protein kinase 8 | Organisim: human | Apparent_Kd_M: 5.74E-12
Real
Aptamer SeqId: 3827-22 | Target: PAK6 | UniProt: Q9NQU5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3827-22 | Target: PAK6 | UniProt: Q9NQU5 | TargetFullName: Serine/threonine-protein kinase PAK 6 | Organisim: human | Apparent_Kd_M: 2.9E-11
Real
Aptamer SeqId: 3831-21 | Target: pTEN | UniProt: P60484
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3831-21 | Target: pTEN | UniProt: P60484 | TargetFullName: Phosphatidylinositol 3;4;5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN | Organisim: human | Apparent_Kd_M: 8.29E-11
Real
Aptamer SeqId: 3832-51 | Target: PTK6 | UniProt: Q13882
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3832-51 | Target: PTK6 | UniProt: Q13882 | TargetFullName: Protein-tyrosine kinase 6 | Organisim: human | Apparent_Kd_M: 1.63E-10
Real
Aptamer SeqId: 3835-11 | Target: TLR2 | UniProt: O60603
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3835-11 | Target: TLR2 | UniProt: O60603 | TargetFullName: Toll-like receptor 2 | Organisim: human | Apparent_Kd_M: 4.89E-11
Real
Aptamer SeqId: 3836-51 | Target: UFM1 | UniProt: P61960
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3836-51 | Target: UFM1 | UniProt: P61960 | TargetFullName: Ubiquitin-fold modifier 1 | Organisim: human | Apparent_Kd_M: 2.03E-11
Real
Aptamer SeqId: 3837-6 | Target: ZAP70 | UniProt: P43403
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3837-6 | Target: ZAP70 | UniProt: P43403 | TargetFullName: Tyrosine-protein kinase ZAP-70 | Organisim: human | Apparent_Kd_M: 2.56E-11
Real
Aptamer SeqId: 3839-60 | Target: AIP | UniProt: O00170
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3839-60 | Target: AIP | UniProt: O00170 | TargetFullName: AH receptor-interacting protein | Organisim: human | Apparent_Kd_M: 6.06E-11
Real
Aptamer SeqId: 3844-2 | Target: Cyclophilin A | UniProt: P62937
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3844-2 | Target: Cyclophilin A | UniProt: P62937 | TargetFullName: Peptidyl-prolyl cis-trans isomerase A | Organisim: human | Apparent_Kd_M: 9.81E-13
Real
Aptamer SeqId: 3845-51 | Target: DLRB1 | UniProt: Q9NP97
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3845-51 | Target: DLRB1 | UniProt: Q9NP97 | TargetFullName: Dynein light chain roadblock-type 1 | Organisim: human | Apparent_Kd_M: 2.57E-11
Real
Aptamer SeqId: 3847-56 | Target: ETHE1 | UniProt: O95571
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3847-56 | Target: ETHE1 | UniProt: O95571 | TargetFullName: Persulfide dioxygenase ETHE1; mitochondrial | Organisim: human | Apparent_Kd_M: 3.21E-11
Real
Aptamer SeqId: 3848-14 | Target: GAPDH; liver | UniProt: P04406
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3848-14 | Target: GAPDH; liver | UniProt: P04406 | TargetFullName: Glyceraldehyde-3-phosphate dehydrogenase | Organisim: human | Apparent_Kd_M: 8.75E-12
Real
Aptamer SeqId: 3849-56 | Target: GFP_AEQVI | UniProt: P42212
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3849-56 | Target: GFP_AEQVI | UniProt: P42212 | TargetFullName: Green fluorescent protein_AEQVI | Organisim: aequorea victoria (jellyfish) | Apparent_Kd_M: 1.13E-12
Real
Aptamer SeqId: 3852-19 | Target: HSP 40 | UniProt: P25685
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3852-19 | Target: HSP 40 | UniProt: P25685 | TargetFullName: DnaJ homolog subfamily B member 1 | Organisim: human | Apparent_Kd_M: 3.38E-11
Real
Aptamer SeqId: 3853-56 | Target: MDHC | UniProt: P40925
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3853-56 | Target: MDHC | UniProt: P40925 | TargetFullName: Malate dehydrogenase; cytoplasmic | Organisim: human | Apparent_Kd_M: 4.18E-12
Real
Aptamer SeqId: 3854-24 | Target: NACA | UniProt: Q13765
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3854-24 | Target: NACA | UniProt: Q13765 | TargetFullName: Nascent polypeptide-associated complex subunit alpha | Organisim: human | Apparent_Kd_M: 1.09E-11
Real
Aptamer SeqId: 3855-56 | Target: Peroxiredoxin-1 | UniProt: Q06830
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3855-56 | Target: Peroxiredoxin-1 | UniProt: Q06830 | TargetFullName: Peroxiredoxin-1 | Organisim: human | Apparent_Kd_M: 9.36E-11
Real
Aptamer SeqId: 3858-5 | Target: PPAC | UniProt: P24666
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3858-5 | Target: PPAC | UniProt: P24666 | TargetFullName: Low molecular weight phosphotyrosine protein phosphatase | Organisim: human | Apparent_Kd_M: 3.46E-11
Real
Aptamer SeqId: 3859-50 | Target: PSA1 | UniProt: P25786
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3859-50 | Target: PSA1 | UniProt: P25786 | TargetFullName: Proteasome subunit alpha type-1 | Organisim: human | Apparent_Kd_M: 1.15E-11
Real
Aptamer SeqId: 3860-7 | Target: PSA6 | UniProt: P60900
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3860-7 | Target: PSA6 | UniProt: P60900 | TargetFullName: Proteasome subunit alpha type-6 | Organisim: human | Apparent_Kd_M: 1.17E-10
Real
Aptamer SeqId: 3864-5 | Target: RS7 | UniProt: P62081
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3864-5 | Target: RS7 | UniProt: P62081 | TargetFullName: 40S ribosomal protein S7 | Organisim: human | Apparent_Kd_M: 9.14E-11
Real
Aptamer SeqId: 3866-7 | Target: SBDS | UniProt: Q9Y3A5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3866-7 | Target: SBDS | UniProt: Q9Y3A5 | TargetFullName: Ribosome maturation protein SBDS | Organisim: human | Apparent_Kd_M: 5.57E-11
Real
Aptamer SeqId: 3867-49 | Target: SE6L2 | UniProt: Q6UXD5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3867-49 | Target: SE6L2 | UniProt: Q6UXD5 | TargetFullName: Seizure 6-like protein 2 | Organisim: human | Apparent_Kd_M: 1.1E-10
Real
Aptamer SeqId: 3868-8 | Target: SGTA | UniProt: O43765
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3868-8 | Target: SGTA | UniProt: O43765 | TargetFullName: Small glutamine-rich tetratricopeptide repeat-containing protein alpha | Organisim: human | Apparent_Kd_M: 1.93E-11
Real
Aptamer SeqId: 3872-2 | Target: TCTP | UniProt: P13693
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3872-2 | Target: TCTP | UniProt: P13693 | TargetFullName: Translationally-controlled tumor protein | Organisim: human | Apparent_Kd_M: 9.18E-12
Real
Aptamer SeqId: 3873-51 | Target: TMA | UniProt: P07202
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3873-51 | Target: TMA | UniProt: P07202 | TargetFullName: Thyroid peroxidase | Organisim: human | Apparent_Kd_M: 1.17E-11
Real
Aptamer SeqId: 3874-8 | Target: UB2L3 | UniProt: P68036
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3874-8 | Target: UB2L3 | UniProt: P68036 | TargetFullName: Ubiquitin-conjugating enzyme E2 L3 | Organisim: human | Apparent_Kd_M: 1.08E-11
Real
Aptamer SeqId: 3875-62 | Target: ARI3A | UniProt: Q99856
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3875-62 | Target: ARI3A | UniProt: Q99856 | TargetFullName: AT-rich interactive domain-containing protein 3A | Organisim: human | Apparent_Kd_M: 2.41E-12
Real
Aptamer SeqId: 3879-50 | Target: CDC37 | UniProt: Q16543
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3879-50 | Target: CDC37 | UniProt: Q16543 | TargetFullName: Hsp90 co-chaperone Cdc37 | Organisim: human | Apparent_Kd_M: 2.13E-10
Real
Aptamer SeqId: 3881-49 | Target: DLC8 | UniProt: P63167
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3881-49 | Target: DLC8 | UniProt: P63167 | TargetFullName: Dynein light chain 1; cytoplasmic | Organisim: human | Apparent_Kd_M: 1.34E-10
Real
Aptamer SeqId: 3887-90 | Target: IMB1 | UniProt: Q14974
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3887-90 | Target: IMB1 | UniProt: Q14974 | TargetFullName: Importin subunit beta-1 | Organisim: human | Apparent_Kd_M: 3.16E-11
Real
Aptamer SeqId: 3888-8 | Target: ING1 | UniProt: Q9UK53
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3888-8 | Target: ING1 | UniProt: Q9UK53 | TargetFullName: Inhibitor of growth protein 1 | Organisim: human | Apparent_Kd_M: 1.59E-11
Real
Aptamer SeqId: 3889-64 | Target: Lamin-B1 | UniProt: P20700
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3889-64 | Target: Lamin-B1 | UniProt: P20700 | TargetFullName: Lamin-B1 | Organisim: human | Apparent_Kd_M: 8.66E-12
Real
Aptamer SeqId: 3890-8 | Target: LDH-H 1 | UniProt: P07195
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3890-8 | Target: LDH-H 1 | UniProt: P07195 | TargetFullName: L-lactate dehydrogenase B chain | Organisim: human | Apparent_Kd_M: 1.43E-11
Real
Aptamer SeqId: 3891-56 | Target: MBD4 | UniProt: O95243
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3891-56 | Target: MBD4 | UniProt: O95243 | TargetFullName: Methyl-CpG-binding domain protein 4 | Organisim: human | Apparent_Kd_M: 1.16E-11
Real
Aptamer SeqId: 3892-21 | Target: MED-1 | UniProt: Q15648
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3892-21 | Target: MED-1 | UniProt: Q15648 | TargetFullName: Mediator of RNA polymerase II transcription subunit 1 | Organisim: human | Apparent_Kd_M: 1.25E-10
Real
Aptamer SeqId: 3893-64 | Target: Mesothelin | UniProt: Q13421
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3893-64 | Target: Mesothelin | UniProt: Q13421 | TargetFullName: Mesothelin | Organisim: human | Apparent_Kd_M: 4.16E-11
Real
Aptamer SeqId: 3894-15 | Target: NAGK | UniProt: Q9UJ70
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3894-15 | Target: NAGK | UniProt: Q9UJ70 | TargetFullName: N-acetyl-D-glucosamine kinase | Organisim: human | Apparent_Kd_M: 1.25E-11
Real
Aptamer SeqId: 3896-5 | Target: Phosphoglycerate mutase 1 | UniProt: P18669
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3896-5 | Target: Phosphoglycerate mutase 1 | UniProt: P18669 | TargetFullName: Phosphoglycerate mutase 1 | Organisim: human | Apparent_Kd_M: 7.91E-12
Real
Aptamer SeqId: 3897-61 | Target: PLPP | UniProt: Q96GD0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3897-61 | Target: PLPP | UniProt: Q96GD0 | TargetFullName: Pyridoxal phosphate phosphatase | Organisim: human | Apparent_Kd_M: 2.82E-11
Real
Aptamer SeqId: 3898-5 | Target: PSD7 | UniProt: P51665
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3898-5 | Target: PSD7 | UniProt: P51665 | TargetFullName: 26S proteasome non-ATPase regulatory subunit 7 | Organisim: human | Apparent_Kd_M: 1.06E-10
Real
Aptamer SeqId: 3902-21 | Target: SKP1 | UniProt: P63208
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3902-21 | Target: SKP1 | UniProt: P63208 | TargetFullName: S-phase kinase-associated protein 1 | Organisim: human | Apparent_Kd_M: 4.6E-10
Real
Aptamer SeqId: 3903-49 | Target: Sorting nexin 4 | UniProt: O95219
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3903-49 | Target: Sorting nexin 4 | UniProt: O95219 | TargetFullName: Sorting nexin-4 | Organisim: human | Apparent_Kd_M: 9.04E-12
Real
Aptamer SeqId: 3905-62 | Target: UBE2N | UniProt: P61088
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 3905-62 | Target: UBE2N | UniProt: P61088 | TargetFullName: Ubiquitin-conjugating enzyme E2 N | Organisim: human | Apparent_Kd_M: 8.13E-12
Real
Aptamer SeqId: 4122-12 | Target: discoidin domain receptor 1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4122-12 | Target: discoidin domain receptor 1 | UniProt: Q08345 | TargetFullName: Epithelial discoidin domain-containing receptor 1 | Organisim: human | Apparent_Kd_M: 3.45E-11
Real
Aptamer SeqId: 4123-60 | Target: FGF-4 | UniProt: P08620
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4123-60 | Target: FGF-4 | UniProt: P08620 | TargetFullName: Fibroblast growth factor 4 | Organisim: human | Apparent_Kd_M: 4.17E-12
Real
Aptamer SeqId: 4124-24 | Target: HSP 70 | UniProt: P0DMV8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4124-24 | Target: HSP 70 | UniProt: P0DMV8 | TargetFullName: Heat shock 70 kDa protein 1A | Organisim: human | Apparent_Kd_M: 2.67E-11
Real
Aptamer SeqId: 4125-52 | Target: sRAGE | UniProt: Q15109
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4125-52 | Target: sRAGE | UniProt: Q15109 | TargetFullName: Advanced glycosylation end product-specific receptor; soluble | Organisim: human | Apparent_Kd_M: 5.5E-12
Real
Aptamer SeqId: 4126-22 | Target: BPI | UniProt: P17213
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4126-22 | Target: BPI | UniProt: P17213 | TargetFullName: Bactericidal permeability-increasing protein | Organisim: human | Apparent_Kd_M: 3.336306E-12
Real
Aptamer SeqId: 4127-75 | Target: C6 | UniProt: P13671
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4127-75 | Target: C6 | UniProt: P13671 | TargetFullName: Complement component C6 | Organisim: human | Apparent_Kd_M: 4.98E-12
Real
Aptamer SeqId: 4128-27 | Target: Eotaxin-2 | UniProt: O00175
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4128-27 | Target: Eotaxin-2 | UniProt: O00175 | TargetFullName: C-C motif chemokine 24 | Organisim: human | Apparent_Kd_M: 6.17E-12
Real
Aptamer SeqId: 4129-72 | Target: Factor B | UniProt: P00751
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4129-72 | Target: Factor B | UniProt: P00751 | TargetFullName: Complement factor B | Organisim: human | Apparent_Kd_M: 4.13E-12
Real
Aptamer SeqId: 4130-71 | Target: FGF-6 | UniProt: P10767
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4130-71 | Target: FGF-6 | UniProt: P10767 | TargetFullName: Fibroblast growth factor 6 | Organisim: human | Apparent_Kd_M: 1.63E-11
Real
Aptamer SeqId: 4131-72 | Target: Fibronectin | UniProt: P02751
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4131-72 | Target: Fibronectin | UniProt: P02751 | TargetFullName: Fibronectin | Organisim: human | Apparent_Kd_M: 1.77E-11
Real
Aptamer SeqId: 4132-27 | Target: FST | UniProt: P19883
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4132-27 | Target: FST | UniProt: P19883 | TargetFullName: Follistatin | Organisim: human | Apparent_Kd_M: 1.23E-11
Real
Aptamer SeqId: 4133-54 | Target: Granzyme B | UniProt: P10144
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4133-54 | Target: Granzyme B | UniProt: P10144 | TargetFullName: Granzyme B | Organisim: human | Apparent_Kd_M: 3.41E-12
Real
Aptamer SeqId: 4135-84 | Target: IgE | UniProt: P01854
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4135-84 | Target: IgE | UniProt: P01854 | TargetFullName: Immunoglobulin E | Organisim: human | Apparent_Kd_M: 8.36E-12
Real
Aptamer SeqId: 4136-40 | Target: IL-17D | UniProt: Q8TAD2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4136-40 | Target: IL-17D | UniProt: Q8TAD2 | TargetFullName: Interleukin-17D | Organisim: human | Apparent_Kd_M: 1.15E-11
Real
Aptamer SeqId: 4137-57 | Target: IL-17E | UniProt: Q9H293
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4137-57 | Target: IL-17E | UniProt: Q9H293 | TargetFullName: Interleukin-25 | Organisim: human | Apparent_Kd_M: 2.82E-11
Real
Aptamer SeqId: 4138-25 | Target: IL-20 | UniProt: Q9NYY1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4138-25 | Target: IL-20 | UniProt: Q9NYY1 | TargetFullName: Interleukin-20 | Organisim: human | Apparent_Kd_M: 1.82E-11
Real
Aptamer SeqId: 4140-3 | Target: IL-7 | UniProt: P13232
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4140-3 | Target: IL-7 | UniProt: P13232 | TargetFullName: Interleukin-7 | Organisim: human | Apparent_Kd_M: 5.85E-12
Real
Aptamer SeqId: 4141-79 | Target: IP-10 | UniProt: P02778
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4141-79 | Target: IP-10 | UniProt: P02778 | TargetFullName: C-X-C motif chemokine 10 | Organisim: human | Apparent_Kd_M: 7.34E-12
Real
Aptamer SeqId: 4143-74 | Target: Lymphotactin | UniProt: P47992
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4143-74 | Target: Lymphotactin | UniProt: P47992 | TargetFullName: Lymphotactin | Organisim: human | Apparent_Kd_M: 7.68E-12
Real
Aptamer SeqId: 4144-13 | Target: MCP-4 | UniProt: Q99616
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4144-13 | Target: MCP-4 | UniProt: Q99616 | TargetFullName: C-C motif chemokine 13 | Organisim: human | Apparent_Kd_M: 8.47E-12
Real
Aptamer SeqId: 4145-58 | Target: Neurotrophin-3 | UniProt: P20783
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4145-58 | Target: Neurotrophin-3 | UniProt: P20783 | TargetFullName: Neurotrophin-3 | Organisim: human | Apparent_Kd_M: 2.91E-12
Real
Aptamer SeqId: 4146-58 | Target: Neurotrophin-5 | UniProt: P34130
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4146-58 | Target: Neurotrophin-5 | UniProt: P34130 | TargetFullName: Neurotrophin-4 | Organisim: human | Apparent_Kd_M: 1.38E-11
Real
Aptamer SeqId: 4148-49 | Target: PAPP-A | UniProt: Q13219
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4148-49 | Target: PAPP-A | UniProt: Q13219 | TargetFullName: Pappalysin-1 | Organisim: human | Apparent_Kd_M: 8.63E-12
Real
Aptamer SeqId: 4149-8 | Target: PDGF-BB | UniProt: P01127
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4149-8 | Target: PDGF-BB | UniProt: P01127 | TargetFullName: Platelet-derived growth factor subunit B | Organisim: human | Apparent_Kd_M: 1.92E-11
Real
Aptamer SeqId: 4150-75 | Target: Plasmin | UniProt: P00747
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4150-75 | Target: Plasmin | UniProt: P00747 | TargetFullName: Plasmin | Organisim: human | Apparent_Kd_M: 4.41E-11
Real
Aptamer SeqId: 4151-6 | Target: Plasminogen | UniProt: P00747
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4151-6 | Target: Plasminogen | UniProt: P00747 | TargetFullName: Plasminogen | Organisim: human | Apparent_Kd_M: 1.68E-11
Real
Aptamer SeqId: 4152-58 | Target: Prekallikrein | UniProt: P03952
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4152-58 | Target: Prekallikrein | UniProt: P03952 | TargetFullName: Plasma kallikrein | Organisim: human | Apparent_Kd_M: 1.62E-12
Real
Aptamer SeqId: 4153-11 | Target: alpha-1-antichymotrypsin complex
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4153-11 | Target: alpha-1-antichymotrypsin complex | UniProt: P01011 | TargetFullName: Alpha-1-antichymotrypsin complex | Organisim: human | Apparent_Kd_M: 3.11E-12
Real
Aptamer SeqId: 4154-57 | Target: P-Selectin | UniProt: P16109
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4154-57 | Target: P-Selectin | UniProt: P16109 | TargetFullName: P-selectin | Organisim: human | Apparent_Kd_M: 1.48E-12
Real
Aptamer SeqId: 4155-3 | Target: Tenascin | UniProt: P24821
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4155-3 | Target: Tenascin | UniProt: P24821 | TargetFullName: Tenascin | Organisim: human | Apparent_Kd_M: 4.74E-11
Real
Aptamer SeqId: 4156-74 | Target: TGF-b2 | UniProt: P61812
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4156-74 | Target: TGF-b2 | UniProt: P61812 | TargetFullName: Transforming growth factor beta-2 | Organisim: human | Apparent_Kd_M: 2.47E-11
Real
Aptamer SeqId: 4157-2 | Target: Thrombin | UniProt: P00734
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4157-2 | Target: Thrombin | UniProt: P00734 | TargetFullName: Thrombin | Organisim: human | Apparent_Kd_M: 1.36E-11
Real
Aptamer SeqId: 4158-54 | Target: uPA | UniProt: P00749
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4158-54 | Target: uPA | UniProt: P00749 | TargetFullName: Urokinase-type plasminogen activator | Organisim: human | Apparent_Kd_M: 4.59E-12
Real
Aptamer SeqId: 4159-130 | Target: Factor H | UniProt: P08603
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4159-130 | Target: Factor H | UniProt: P08603 | TargetFullName: Complement factor H | Organisim: human | Apparent_Kd_M: 5.09E-12
Real
Aptamer SeqId: 4160-49 | Target: MMP-2 | UniProt: P08253
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4160-49 | Target: MMP-2 | UniProt: P08253 | TargetFullName: 72 kDa type IV collagenase | Organisim: human | Apparent_Kd_M: 1.42E-11
Real
Aptamer SeqId: 4162-54 | Target: Transferrin | UniProt: P02787
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4162-54 | Target: Transferrin | UniProt: P02787 | TargetFullName: Serotransferrin | Organisim: human | Apparent_Kd_M: 1.32E-11
Real
Aptamer SeqId: 4163-5 | Target: Histone H2A.z | UniProt: P0C0S5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4163-5 | Target: Histone H2A.z | UniProt: P0C0S5 | TargetFullName: Histone H2A.z | Organisim: human | Apparent_Kd_M: 9.8E-10
Real
Aptamer SeqId: 4179-57 | Target: 14-3-3 protein family
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4179-57 | Target: 14-3-3 | UniProt: P31946|P62258|P61981|Q04917|P27348|P63104|P31947 | TargetFullName: 14-3-3 protein family | Organisim: human | Apparent_Kd_M: 1.43E-11
Real
Aptamer SeqId: 4184-43 | Target: 4EBP2 | UniProt: Q13542
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4184-43 | Target: 4EBP2 | UniProt: Q13542 | TargetFullName: Eukaryotic translation initiation factor 4E-binding protein 2 | Organisim: human | Apparent_Kd_M: 7.22E-11
Real
Aptamer SeqId: 4187-49 | Target: 6-Phosphogluconate dehydrogenase
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4187-49 | Target: 6-Phosphogluconate dehydrogenase | UniProt: P52209 | TargetFullName: 6-phosphogluconate dehydrogenase; decarboxylating | Organisim: human | Apparent_Kd_M: 9.6E-12
Real
Aptamer SeqId: 4188-1 | Target: Aflatoxin B1 aldehyde reductase
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4188-1 | Target: Aflatoxin B1 aldehyde reductase | UniProt: O43488 | TargetFullName: Aflatoxin B1 aldehyde reductase member 2 | Organisim: human | Apparent_Kd_M: 1.65E-12
Real
Aptamer SeqId: 4192-10 | Target: AK1A1 | UniProt: P14550
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4192-10 | Target: AK1A1 | UniProt: P14550 | TargetFullName: Alcohol dehydrogenase NADP(+) | Organisim: human | Apparent_Kd_M: 1.27E-11
Real
Aptamer SeqId: 4194-26 | Target: AN32B | UniProt: Q92688
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4194-26 | Target: AN32B | UniProt: Q92688 | TargetFullName: Acidic leucine-rich nuclear phosphoprotein 32 family member B | Organisim: human | Apparent_Kd_M: 1.43E-11
Real
Aptamer SeqId: 4203-50 | Target: Cofilin-1 | UniProt: P23528
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4203-50 | Target: Cofilin-1 | UniProt: P23528 | TargetFullName: Cofilin-1 | Organisim: human | Apparent_Kd_M: 4.98E-11
Real
Aptamer SeqId: 4209-60 | Target: DRG-1 | UniProt: Q9NP79
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4209-60 | Target: DRG-1 | UniProt: Q9NP79 | TargetFullName: Vacuolar protein sorting-associated protein VTA1 homolog | Organisim: human | Apparent_Kd_M: 2.15E-12
Real
Aptamer SeqId: 4212-5 | Target: EP15R | UniProt: Q9UBC2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4212-5 | Target: EP15R | UniProt: Q9UBC2 | TargetFullName: Epidermal growth factor receptor substrate 15-like 1 | Organisim: human | Apparent_Kd_M: 7.55E-11
Real
Aptamer SeqId: 4217-49 | Target: ERAB | UniProt: Q99714
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4217-49 | Target: ERAB | UniProt: Q99714 | TargetFullName: 3-hydroxyacyl-CoA dehydrogenase type-2 | Organisim: human | Apparent_Kd_M: 2.79E-11
Real
Aptamer SeqId: 4220-39 | Target: FER | UniProt: P16591
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4220-39 | Target: FER | UniProt: P16591 | TargetFullName: Tyrosine-protein kinase Fer | Organisim: human | Apparent_Kd_M: 1.57E-12
Real
Aptamer SeqId: 4224-7 | Target: HNRPQ | UniProt: O60506
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4224-7 | Target: HNRPQ | UniProt: O60506 | TargetFullName: Heterogeneous nuclear ribonucleoprotein Q | Organisim: human | Apparent_Kd_M: 2.07E-11
Real
Aptamer SeqId: 4230-1 | Target: IF4G2 | UniProt: P78344
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4230-1 | Target: IF4G2 | UniProt: P78344 | TargetFullName: Eukaryotic translation initiation factor 4 gamma 2 | Organisim: human | Apparent_Kd_M: 1.31E-10
Real
Aptamer SeqId: 4232-19 | Target: IGF-I sR | UniProt: P08069
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4232-19 | Target: IGF-I sR | UniProt: P08069 | TargetFullName: Insulin-like growth factor 1 receptor | Organisim: human | Apparent_Kd_M: 2.65E-11
Real
Aptamer SeqId: 4234-8 | Target: IL-1 R4 | UniProt: Q01638
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4234-8 | Target: IL-1 R4 | UniProt: Q01638 | TargetFullName: Interleukin-1 receptor-like 1 | Organisim: human | Apparent_Kd_M: 3.21E-12
Real
Aptamer SeqId: 4237-70 | Target: LCMT1 | UniProt: Q9UIC8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4237-70 | Target: LCMT1 | UniProt: Q9UIC8 | TargetFullName: Leucine carboxyl methyltransferase 1 | Organisim: human | Apparent_Kd_M: 5.98E-11
Real
Aptamer SeqId: 4240-31 | Target: M2-PK | UniProt: P14618
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4240-31 | Target: M2-PK | UniProt: P14618 | TargetFullName: Pyruvate kinase PKM | Organisim: human | Apparent_Kd_M: 1.42E-11
Real
Aptamer SeqId: 4246-40 | Target: NCAM-L1 | UniProt: P32004
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4246-40 | Target: NCAM-L1 | UniProt: P32004 | TargetFullName: Neural cell adhesion molecule L1 | Organisim: human | Apparent_Kd_M: 1.85E-11
Real
Aptamer SeqId: 4249-64 | Target: NDP kinase B | UniProt: P22392
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4249-64 | Target: NDP kinase B | UniProt: P22392 | TargetFullName: Nucleoside diphosphate kinase B | Organisim: human | Apparent_Kd_M: 9.0E-12
Real
Aptamer SeqId: 4250-23 | Target: NSF1C | UniProt: Q9UNZ2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4250-23 | Target: NSF1C | UniProt: Q9UNZ2 | TargetFullName: NSFL1 cofactor p47 | Organisim: human | Apparent_Kd_M: 2.6E-11
Real
Aptamer SeqId: 4254-6 | Target: NUDC3 | UniProt: Q8IVD9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4254-6 | Target: NUDC3 | UniProt: Q8IVD9 | TargetFullName: NudC domain-containing protein 3 | Organisim: human | Apparent_Kd_M: 1.24E-11
Real
Aptamer SeqId: 4258-15 | Target: PA2G4 | UniProt: Q9UQ80
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4258-15 | Target: PA2G4 | UniProt: Q9UQ80 | TargetFullName: Proliferation-associated protein 2G4 | Organisim: human | Apparent_Kd_M: 4.16E-12
Real
Aptamer SeqId: 4261-55 | Target: paraoxonase 1 | UniProt: P27169
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4261-55 | Target: paraoxonase 1 | UniProt: P27169 | TargetFullName: Serum paraoxonase/arylesterase 1 | Organisim: human | Apparent_Kd_M: 2.18E-11
Real
Aptamer SeqId: 4267-81 | Target: PESC | UniProt: O00541
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4267-81 | Target: PESC | UniProt: O00541 | TargetFullName: Pescadillo homolog | Organisim: human | Apparent_Kd_M: 9.64E-11
Real
Aptamer SeqId: 4271-75 | Target: PFD5 | UniProt: Q99471
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4271-75 | Target: PFD5 | UniProt: Q99471 | TargetFullName: Prefoldin subunit 5 | Organisim: human | Apparent_Kd_M: 3.51E-12
Real
Aptamer SeqId: 4272-46 | Target: PHI | UniProt: P06744
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4272-46 | Target: PHI | UniProt: P06744 | TargetFullName: Glucose-6-phosphate isomerase | Organisim: human | Apparent_Kd_M: 1.44E-10
Real
Aptamer SeqId: 4276-10 | Target: prostatic binding protein
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4276-10 | Target: prostatic binding protein | UniProt: P30086 | TargetFullName: Phosphatidylethanolamine-binding protein 1 | Organisim: human | Apparent_Kd_M: 1.74E-12
Real
Aptamer SeqId: 4278-14 | Target: Protein disulfide-isomerase
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4278-14 | Target: Protein disulfide-isomerase | UniProt: P07237 | TargetFullName: Protein disulfide-isomerase | Organisim: human | Apparent_Kd_M: 1.33E-9
Real
Aptamer SeqId: 4280-47 | Target: PSA2 | UniProt: P25787
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4280-47 | Target: PSA2 | UniProt: P25787 | TargetFullName: Proteasome subunit alpha type-2 | Organisim: human | Apparent_Kd_M: 6.05E-12
Real
Aptamer SeqId: 4282-3 | Target: RAN | UniProt: P62826
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4282-3 | Target: RAN | UniProt: P62826 | TargetFullName: GTP-binding nuclear protein Ran | Organisim: human | Apparent_Kd_M: 7.03E-12
Real
Aptamer SeqId: 4284-18 | Target: RBM39 | UniProt: Q14498
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4284-18 | Target: RBM39 | UniProt: Q14498 | TargetFullName: RNA-binding protein 39 | Organisim: human | Apparent_Kd_M: 8.74E-12
Real
Aptamer SeqId: 4292-5 | Target: SNAA | UniProt: P54920
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4292-5 | Target: SNAA | UniProt: P54920 | TargetFullName: Alpha-soluble NSF attachment protein | Organisim: human | Apparent_Kd_M: 1.4E-12
Real
Aptamer SeqId: 4294-16 | Target: Sphingosine kinase 1 | UniProt: Q9NYA1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4294-16 | Target: Sphingosine kinase 1 | UniProt: Q9NYA1 | TargetFullName: Sphingosine kinase 1 | Organisim: human | Apparent_Kd_M: 2.5E-12
Real
Aptamer SeqId: 4297-62 | Target: Spondin-1 | UniProt: Q9HCB6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4297-62 | Target: Spondin-1 | UniProt: Q9HCB6 | TargetFullName: Spondin-1 | Organisim: human | Apparent_Kd_M: 4.13E-12
Real
Aptamer SeqId: 4301-58 | Target: Thymidine kinase | UniProt: P04183
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4301-58 | Target: Thymidine kinase | UniProt: P04183 | TargetFullName: Thymidine kinase; cytosolic | Organisim: human | Apparent_Kd_M: 8.39E-11
Real
Aptamer SeqId: 4304-18 | Target: transcription factor MLR1 isoform CRA_b
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4304-18 | Target: transcription factor MLR1; isoform CRA_b | UniProt: Q8N3X6 | TargetFullName: Ligand-dependent nuclear receptor corepressor-like protein | Organisim: human | Apparent_Kd_M: 8.98E-12
Real
Aptamer SeqId: 4306-4 | Target: Transketolase | UniProt: P29401
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4306-4 | Target: Transketolase | UniProt: P29401 | TargetFullName: Transketolase | Organisim: human | Apparent_Kd_M: 2.88E-12
Real
Aptamer SeqId: 4309-59 | Target: Triosephosphate isomerase
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4309-59 | Target: Triosephosphate isomerase | UniProt: P60174 | TargetFullName: Triosephosphate isomerase | Organisim: human | Apparent_Kd_M: 1.14E-11
Real
Aptamer SeqId: 4314-12 | Target: XTP3A | UniProt: Q9H773
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4314-12 | Target: XTP3A | UniProt: Q9H773 | TargetFullName: dCTP pyrophosphatase 1 | Organisim: human | Apparent_Kd_M: 5.35E-12
Real
Aptamer SeqId: 4318-12 | Target: PTP-1C | UniProt: P29350
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4318-12 | Target: PTP-1C | UniProt: P29350 | TargetFullName: Tyrosine-protein phosphatase non-receptor type 6 | Organisim: human | Apparent_Kd_M: 3.79E-12
Real
Aptamer SeqId: 4322-28 | Target: AMNLS | UniProt: Q9BXJ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4322-28 | Target: AMNLS | UniProt: Q9BXJ7 | TargetFullName: Protein amnionless | Organisim: human | Apparent_Kd_M: 1.38E-10
Real
Aptamer SeqId: 4324-33 | Target: CYTT | UniProt: P09228
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4324-33 | Target: CYTT | UniProt: P09228 | TargetFullName: Cystatin-SA | Organisim: human | Apparent_Kd_M: 2.59E-11
Real
Aptamer SeqId: 4328-2 | Target: BOC | UniProt: Q9BWV1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4328-2 | Target: BOC | UniProt: Q9BWV1 | TargetFullName: Brother of CDO | Organisim: human | Apparent_Kd_M: 1.79E-12
Real
Aptamer SeqId: 4332-6 | Target: CLC1B | UniProt: Q9P126
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4332-6 | Target: CLC1B | UniProt: Q9P126 | TargetFullName: C-type lectin domain family 1 member B | Organisim: human | Apparent_Kd_M: 1.11E-12
Real
Aptamer SeqId: 4337-49 | Target: CRP | UniProt: P02741
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4337-49 | Target: CRP | UniProt: P02741 | TargetFullName: C-reactive protein | Organisim: human | Apparent_Kd_M: 1.89E-11
Real
Aptamer SeqId: 4342-10 | Target: sICAM-1 | UniProt: P05362
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4342-10 | Target: sICAM-1 | UniProt: P05362 | TargetFullName: Intercellular adhesion molecule 1 | Organisim: human | Apparent_Kd_M: 6.38E-11
Real
Aptamer SeqId: 4355-13 | Target: DAPK2 | UniProt: Q9UIK4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4355-13 | Target: DAPK2 | UniProt: Q9UIK4 | TargetFullName: Death-associated protein kinase 2 | Organisim: human | Apparent_Kd_M: 1.44E-11
Real
Aptamer SeqId: 4359-87 | Target: DYRK3 | UniProt: O43781
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4359-87 | Target: DYRK3 | UniProt: O43781 | TargetFullName: Dual specificity tyrosine-phosphorylation-regulated kinase 3 | Organisim: human | Apparent_Kd_M: 5.53E-12
Real
Aptamer SeqId: 4374-45 | Target: MIC-1 | UniProt: Q99988
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4374-45 | Target: MIC-1 | UniProt: Q99988 | TargetFullName: Growth/differentiation factor 15 | Organisim: human | Apparent_Kd_M: 3.345686E-12
Real
Aptamer SeqId: 4389-2 | Target: DHH | UniProt: O43323
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4389-2 | Target: DHH | UniProt: O43323 | TargetFullName: Desert hedgehog protein N-product | Organisim: human | Apparent_Kd_M: 2.51E-11
Real
Aptamer SeqId: 4392-54 | Target: FGF-12 | UniProt: P61328
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4392-54 | Target: FGF-12 | UniProt: P61328 | TargetFullName: Fibroblast growth factor 12 | Organisim: human | Apparent_Kd_M: 4.15E-11
Real
Aptamer SeqId: 4393-3 | Target: FGF-16 | UniProt: O43320
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4393-3 | Target: FGF-16 | UniProt: O43320 | TargetFullName: Fibroblast growth factor 16 | Organisim: human | Apparent_Kd_M: 3.49E-11
Real
Aptamer SeqId: 4394-71 | Target: FGF-8A | UniProt: P55075
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4394-71 | Target: FGF-8A | UniProt: P55075 | TargetFullName: Fibroblast growth factor 8 isoform A | Organisim: human | Apparent_Kd_M: 1.08E-10
Real
Aptamer SeqId: 4396-54 | Target: IFN-lambda 1 | UniProt: Q8IU54
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4396-54 | Target: IFN-lambda 1 | UniProt: Q8IU54 | TargetFullName: Interferon lambda-1 | Organisim: human | Apparent_Kd_M: 1.08E-12
Real
Aptamer SeqId: 4397-26 | Target: IFN-lambda 2 | UniProt: Q8IZJ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4397-26 | Target: IFN-lambda 2 | UniProt: Q8IZJ0 | TargetFullName: Interferon lambda-2 | Organisim: human | Apparent_Kd_M: 5.22E-12
Real
Aptamer SeqId: 4407-10 | Target: MSP | UniProt: P26927
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4407-10 | Target: MSP | UniProt: P26927 | TargetFullName: Hepatocyte growth factor-like protein | Organisim: human | Apparent_Kd_M: 3.72E-12
Real
Aptamer SeqId: 4413-3 | Target: SLPI | UniProt: P03973
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4413-3 | Target: SLPI | UniProt: P03973 | TargetFullName: Antileukoproteinase | Organisim: human | Apparent_Kd_M: 6.52E-12
Real
Aptamer SeqId: 4420-7 | Target: ADAM12 | UniProt: O43184
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4420-7 | Target: ADAM12 | UniProt: O43184 | TargetFullName: Disintegrin and metalloproteinase domain-containing protein 12 | Organisim: human | Apparent_Kd_M: 4.49E-11
Real
Aptamer SeqId: 4423-77 | Target: BCL2-like 1 protein | UniProt: Q07817
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4423-77 | Target: BCL2-like 1 protein | UniProt: Q07817 | TargetFullName: Bcl-2-like protein 1 | Organisim: human | Apparent_Kd_M: 1.49E-11
Real
Aptamer SeqId: 4429-51 | Target: CHST6 | UniProt: Q9GZX3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4429-51 | Target: CHST6 | UniProt: Q9GZX3 | TargetFullName: Carbohydrate sulfotransferase 6 | Organisim: human | Apparent_Kd_M: 1.07E-10
Real
Aptamer SeqId: 4430-44 | Target: Collectin Kidney 1 | UniProt: Q9BWP8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4430-44 | Target: Collectin Kidney 1 | UniProt: Q9BWP8 | TargetFullName: Collectin-11 | Organisim: human | Apparent_Kd_M: 1.76E-11
Real
Aptamer SeqId: 4435-66 | Target: ENPP7 | UniProt: Q6UWV6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4435-66 | Target: ENPP7 | UniProt: Q6UWV6 | TargetFullName: Ectonucleotide pyrophosphatase/phosphodiesterase family member 7 | Organisim: human | Apparent_Kd_M: 4.89E-12
Real
Aptamer SeqId: 4436-1 | Target: ENTP3 | UniProt: O75355
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4436-1 | Target: ENTP3 | UniProt: O75355 | TargetFullName: Ectonucleoside triphosphate diphosphohydrolase 3 | Organisim: human | Apparent_Kd_M: 1.77E-11
Real
Aptamer SeqId: 4437-56 | Target: ENTP5 | UniProt: O75356
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4437-56 | Target: ENTP5 | UniProt: O75356 | TargetFullName: Ectonucleoside triphosphate diphosphohydrolase 5 | Organisim: human | Apparent_Kd_M: 3.12E-12
Real
Aptamer SeqId: 4440-15 | Target: FCRL3 | UniProt: Q96P31
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4440-15 | Target: FCRL3 | UniProt: Q96P31 | TargetFullName: Fc receptor-like protein 3 | Organisim: human | Apparent_Kd_M: 8.27E-12
Real
Aptamer SeqId: 4453-83 | Target: LRRT3 | UniProt: Q86VH5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4453-83 | Target: LRRT3 | UniProt: Q86VH5 | TargetFullName: Leucine-rich repeat transmembrane neuronal protein 3 | Organisim: human | Apparent_Kd_M: 2.0E-11
Real
Aptamer SeqId: 4455-89 | Target: MFGM | UniProt: Q08431
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4455-89 | Target: MFGM | UniProt: Q08431 | TargetFullName: Lactadherin | Organisim: human | Apparent_Kd_M: 1.92E-11
Real
Aptamer SeqId: 4459-68 | Target: PCSK7 | UniProt: Q16549
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4459-68 | Target: PCSK7 | UniProt: Q16549 | TargetFullName: Proprotein convertase subtilisin/kexin type 7 | Organisim: human | Apparent_Kd_M: 6.38E-12
Real
Aptamer SeqId: 4460-8 | Target: PDPK1 | UniProt: O15530
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4460-8 | Target: PDPK1 | UniProt: O15530 | TargetFullName: 3-phosphoinositide-dependent protein kinase 1 | Organisim: human | Apparent_Kd_M: 1.16E-12
Real
Aptamer SeqId: 4464-10 | Target: Sialoadhesin | UniProt: Q9BZZ2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4464-10 | Target: Sialoadhesin | UniProt: Q9BZZ2 | TargetFullName: Sialoadhesin | Organisim: human | Apparent_Kd_M: 3.842279E-11
Real
Aptamer SeqId: 4467-49 | Target: SPARCL1 | UniProt: Q14515
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4467-49 | Target: SPARCL1 | UniProt: Q14515 | TargetFullName: SPARC-like protein 1 | Organisim: human | Apparent_Kd_M: 1.79E-11
Real
Aptamer SeqId: 4468-21 | Target: SPHK2 | UniProt: Q9NRA0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4468-21 | Target: SPHK2 | UniProt: Q9NRA0 | TargetFullName: Sphingosine kinase 2 | Organisim: human | Apparent_Kd_M: 1.53E-11
Real
Aptamer SeqId: 4469-78 | Target: ST4S6 | UniProt: Q7LFX5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4469-78 | Target: ST4S6 | UniProt: Q7LFX5 | TargetFullName: Carbohydrate sulfotransferase 15 | Organisim: human | Apparent_Kd_M: 6.28E-12
Real
Aptamer SeqId: 4471-50 | Target: TGM3 | UniProt: Q08188
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4471-50 | Target: TGM3 | UniProt: Q08188 | TargetFullName: Protein-glutamine gamma-glutamyltransferase E | Organisim: human | Apparent_Kd_M: 2.94E-12
Real
Aptamer SeqId: 4472-5 | Target: Tropomyosin 2 | UniProt: P07951
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4472-5 | Target: Tropomyosin 2 | UniProt: P07951 | TargetFullName: Tropomyosin beta chain | Organisim: human | Apparent_Kd_M: 8.49E-11
Real
Aptamer SeqId: 4474-19 | Target: Ubiquitin | UniProt: P62979
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4474-19 | Target: Ubiquitin | UniProt: P62979 | TargetFullName: Ubiquitin | Organisim: human | Apparent_Kd_M: 1.02E-11
Real
Aptamer SeqId: 4476-22 | Target: ZAP70 | UniProt: P43403
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4476-22 | Target: ZAP70 | UniProt: P43403 | TargetFullName: Tyrosine-protein kinase ZAP-70 | Organisim: human | Apparent_Kd_M: 1.72E-11
Real
Aptamer SeqId: 4479-14 | Target: C1-Esterase Inhibitor | UniProt: P05155
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4479-14 | Target: C1-Esterase Inhibitor | UniProt: P05155 | TargetFullName: Plasma protease C1 inhibitor | Organisim: human | Apparent_Kd_M: 5.28E-11
Real
Aptamer SeqId: 4480-59 | Target: C3b | UniProt: P01024
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4480-59 | Target: C3b | UniProt: P01024 | TargetFullName: Complement C3b | Organisim: human | Apparent_Kd_M: 4.08E-11
Real
Aptamer SeqId: 4481-34 | Target: C4 | UniProt: P0C0L4|P0C0L5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4481-34 | Target: C4 | UniProt: P0C0L4|P0C0L5 | TargetFullName: Complement C4 | Organisim: human | Apparent_Kd_M: 5.37E-12
Real
Aptamer SeqId: 4482-66 | Target: C5b; 6 Complex | UniProt: P01031|P13671
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4482-66 | Target: C5b; 6 Complex | UniProt: P01031|P13671 | TargetFullName: Complement C5b-C6 complex | Organisim: human | Apparent_Kd_M: 6.57E-13
Real
Aptamer SeqId: 4487-1 | Target: FGF7 | UniProt: P21781
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4487-1 | Target: FGF7 | UniProt: P21781 | TargetFullName: Fibroblast growth factor 7 | Organisim: human | Apparent_Kd_M: 5.23E-12
Real
Aptamer SeqId: 4493-92 | Target: IL-11 | UniProt: P20809
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4493-92 | Target: IL-11 | UniProt: P20809 | TargetFullName: Interleukin-11 | Organisim: human | Apparent_Kd_M: 1.67E-12
Real
Aptamer SeqId: 4496-60 | Target: MMP-12 | UniProt: P39900
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4496-60 | Target: MMP-12 | UniProt: P39900 | TargetFullName: Macrophage metalloelastase | Organisim: human | Apparent_Kd_M: 1.49E-12
Real
Aptamer SeqId: 4498-62 | Target: NCAM-120 | UniProt: P13591
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4498-62 | Target: NCAM-120 | UniProt: P13591 | TargetFullName: Neural cell adhesion molecule 1; 120 kDa isoform | Organisim: human | Apparent_Kd_M: 1.29E-11
Real
Aptamer SeqId: 4499-21 | Target: PDGF-AA | UniProt: P04085
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4499-21 | Target: PDGF-AA | UniProt: P04085 | TargetFullName: Platelet-derived growth factor subunit A | Organisim: human | Apparent_Kd_M: 2.72E-11
Real
Aptamer SeqId: 4500-50 | Target: SCGF-alpha | UniProt: Q9Y240
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4500-50 | Target: SCGF-alpha | UniProt: Q9Y240 | TargetFullName: Stem cell growth factor-alpha | Organisim: human | Apparent_Kd_M: 1.43E-11
Real
Aptamer SeqId: 4533-76 | Target: ATS15 | UniProt: Q8TE58
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4533-76 | Target: ATS15 | UniProt: Q8TE58 | TargetFullName: A disintegrin and metalloproteinase with thrombospondin motifs 15 | Organisim: human | Apparent_Kd_M: 5.372008E-11
Real
Aptamer SeqId: 4534-10 | Target: BSSP4 | UniProt: Q9GZN4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4534-10 | Target: BSSP4 | UniProt: Q9GZN4 | TargetFullName: Brain-specific serine protease 4 | Organisim: human | Apparent_Kd_M: 1.62E-11
Real
Aptamer SeqId: 4535-50 | Target: BST1 | UniProt: Q10588
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4535-50 | Target: BST1 | UniProt: Q10588 | TargetFullName: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 | Organisim: human | Apparent_Kd_M: 1.26E-11
Real
Aptamer SeqId: 4540-11 | Target: CBX5 | UniProt: P45973
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4540-11 | Target: CBX5 | UniProt: P45973 | TargetFullName: Chromobox protein homolog 5 | Organisim: human | Apparent_Kd_M: 2.86E-11
Real
Aptamer SeqId: 4541-49 | Target: CDON | UniProt: Q4KMG0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4541-49 | Target: CDON | UniProt: Q4KMG0 | TargetFullName: Cell adhesion molecule-related/down-regulated by oncogenes | Organisim: human | Apparent_Kd_M: 2.39E-12
Real
Aptamer SeqId: 4542-24 | Target: Clusterin | UniProt: P10909
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4542-24 | Target: Clusterin | UniProt: P10909 | TargetFullName: Clusterin | Organisim: human | Apparent_Kd_M: 5.95E-11
Real
Aptamer SeqId: 4543-65 | Target: CONA1 | UniProt: Q86Y22
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4543-65 | Target: CONA1 | UniProt: Q86Y22 | TargetFullName: Collagen alpha-1(XXIII) chain | Organisim: human | Apparent_Kd_M: 1.43E-10
Real
Aptamer SeqId: 4544-4 | Target: CTAP-III | UniProt: P02775
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4544-4 | Target: CTAP-III | UniProt: P02775 | TargetFullName: Connective tissue-activating peptide III | Organisim: human | Apparent_Kd_M: 3.68E-12
Real
Aptamer SeqId: 4545-53 | Target: DnaJ homolog | UniProt: Q96DA6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4545-53 | Target: DnaJ homolog | UniProt: Q96DA6 | TargetFullName: Mitochondrial import inner membrane translocase subunit TIM14 | Organisim: human | Apparent_Kd_M: 4.22E-12
Real
Aptamer SeqId: 4546-27 | Target: EMR2 | UniProt: Q9UHX3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4546-27 | Target: EMR2 | UniProt: Q9UHX3 | TargetFullName: Adhesion G protein-coupled receptor E2 | Organisim: human | Apparent_Kd_M: 6.88E-11
Real
Aptamer SeqId: 4547-59 | Target: FLRT1 | UniProt: Q9NZU1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4547-59 | Target: FLRT1 | UniProt: Q9NZU1 | TargetFullName: Leucine-rich repeat transmembrane protein FLRT1 | Organisim: human | Apparent_Kd_M: 2.24E-11
Real
Aptamer SeqId: 4548-4 | Target: Fucosyltransferase 3 | UniProt: P21217
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4548-4 | Target: Fucosyltransferase 3 | UniProt: P21217 | TargetFullName: Galactoside 3(4)-L-fucosyltransferase | Organisim: human | Apparent_Kd_M: 8.41E-12
Real
Aptamer SeqId: 4549-78 | Target: FUT5 | UniProt: Q11128
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4549-78 | Target: FUT5 | UniProt: Q11128 | TargetFullName: Alpha-(1;3)-fucosyltransferase 5 | Organisim: human | Apparent_Kd_M: 2.23E-12
Real
Aptamer SeqId: 4551-72 | Target: GP114 | UniProt: Q8IZF4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4551-72 | Target: GP114 | UniProt: Q8IZF4 | TargetFullName: Adhesion G-protein coupled receptor G5 | Organisim: human | Apparent_Kd_M: 6.64E-11
Real
Aptamer SeqId: 4553-65 | Target: HDGR2 | UniProt: Q7Z4V5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4553-65 | Target: HDGR2 | UniProt: Q7Z4V5 | TargetFullName: Hepatoma-derived growth factor-related protein 2 | Organisim: human | Apparent_Kd_M: 6.33E-12
Real
Aptamer SeqId: 4556-10 | Target: IL-34 | UniProt: Q6ZMJ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4556-10 | Target: IL-34 | UniProt: Q6ZMJ4 | TargetFullName: Interleukin-34 | Organisim: human | Apparent_Kd_M: 1.04E-11
Real
Aptamer SeqId: 4557-61 | Target: KIRR3 | UniProt: Q8IZU9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4557-61 | Target: KIRR3 | UniProt: Q8IZU9 | TargetFullName: Kin of IRRE-like protein 3 | Organisim: human | Apparent_Kd_M: 7.41E-12
Real
Aptamer SeqId: 4559-64 | Target: KYNU | UniProt: Q16719
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4559-64 | Target: KYNU | UniProt: Q16719 | TargetFullName: Kynureninase | Organisim: human | Apparent_Kd_M: 4.29E-11
Real
Aptamer SeqId: 4560-34 | Target: LCK | UniProt: P06239
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4560-34 | Target: LCK | UniProt: P06239 | TargetFullName: Tyrosine-protein kinase Lck | Organisim: human | Apparent_Kd_M: 7.67E-12
Real
Aptamer SeqId: 4562-1 | Target: NXPH1 | UniProt: P58417
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4562-1 | Target: NXPH1 | UniProt: P58417 | TargetFullName: Neurexophilin-1 | Organisim: human | Apparent_Kd_M: 1.59E-11
Real
Aptamer SeqId: 4563-61 | Target: PLCG1 | UniProt: P19174
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4563-61 | Target: PLCG1 | UniProt: P19174 | TargetFullName: 1-phosphatidylinositol 4;5-bisphosphate phosphodiesterase gamma-1 | Organisim: human | Apparent_Kd_M: 2.55E-12
Real
Aptamer SeqId: 4564-2 | Target: PLXC1 | UniProt: O60486
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4564-2 | Target: PLXC1 | UniProt: O60486 | TargetFullName: Plexin-C1 | Organisim: human | Apparent_Kd_M: 1.69E-12
Real
Aptamer SeqId: 4566-24 | Target: RSPO2 | UniProt: Q6UXX9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4566-24 | Target: RSPO2 | UniProt: Q6UXX9 | TargetFullName: R-spondin-2 | Organisim: human | Apparent_Kd_M: 9.2E-12
Real
Aptamer SeqId: 4567-82 | Target: SH21A | UniProt: O60880
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4567-82 | Target: SH21A | UniProt: O60880 | TargetFullName: SH2 domain-containing protein 1A | Organisim: human | Apparent_Kd_M: 3.14E-12
Real
Aptamer SeqId: 4568-17 | Target: SLIK5 | UniProt: O94991
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4568-17 | Target: SLIK5 | UniProt: O94991 | TargetFullName: SLIT and NTRK-like protein 5 | Organisim: human | Apparent_Kd_M: 5.22E-12
Real
Aptamer SeqId: 4569-52 | Target: SORC2 | UniProt: Q96PQ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4569-52 | Target: SORC2 | UniProt: Q96PQ0 | TargetFullName: VPS10 domain-containing receptor SorCS2 | Organisim: human | Apparent_Kd_M: 5.04E-11
Real
Aptamer SeqId: 4584-5 | Target: MEL_VESMG | UniProt: P68408
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4584-5 | Target: MEL_VESMG | UniProt: P68408 | TargetFullName: Melittin_VESMG | Organisim: hornet | Apparent_Kd_M: 3.06E-11
Real
Aptamer SeqId: 4588-1 | Target: PH | UniProt: P01298
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4588-1 | Target: PH | UniProt: P01298 | TargetFullName: Pancreatic hormone | Organisim: human | Apparent_Kd_M: 2.26E-11
Real
Aptamer SeqId: 4666-193 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-193 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-194 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-194 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-195 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-195 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-199 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-199 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-200 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-200 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-202 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-202 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-205 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-205 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-206 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-206 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-212 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-212 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-213 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-213 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-214 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-214 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-218 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-218 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-219 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-219 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-220 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-220 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-222 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-222 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-223 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-223 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-224 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-224 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-225 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-225 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-230 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-230 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-232 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-232 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4666-236 | Target: No Protein | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4666-236 | Target: No Protein | UniProt: | TargetFullName: No protein | Organisim: human | Apparent_Kd_M:
Real
Aptamer SeqId: 4673-13 | Target: IL-6 | UniProt: P05231
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4673-13 | Target: IL-6 | UniProt: P05231 | TargetFullName: Interleukin-6 | Organisim: human | Apparent_Kd_M: 4.55E-12
Real
Aptamer SeqId: 4693-72 | Target: 3HIDH | UniProt: P31937
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4693-72 | Target: 3HIDH | UniProt: P31937 | TargetFullName: 3-hydroxyisobutyrate dehydrogenase; mitochondrial | Organisim: human | Apparent_Kd_M: 3.76E-11
Real
Aptamer SeqId: 4697-59 | Target: GM-CSF | UniProt: P04141
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4697-59 | Target: GM-CSF | UniProt: P04141 | TargetFullName: Granulocyte-macrophage colony-stimulating factor | Organisim: human | Apparent_Kd_M: 1.36E-11
Real
Aptamer SeqId: 4703-87 | Target: TNF-b | UniProt: P01374
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4703-87 | Target: TNF-b | UniProt: P01374 | TargetFullName: Lymphotoxin-alpha | Organisim: human | Apparent_Kd_M: 2.92E-10
Real
Aptamer SeqId: 4706-17 | Target: 41 | UniProt: P11171
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4706-17 | Target: 41 | UniProt: P11171 | TargetFullName: Protein 4.1 | Organisim: human | Apparent_Kd_M: 1.01E-11
Real
Aptamer SeqId: 4707-50 | Target: 14-3-3 protein family
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4707-50 | Target: 14-3-3 | UniProt: P31946|P62258|P61981|Q04917|P27348|P63104|P31947 | TargetFullName: 14-3-3 protein family | Organisim: human | Apparent_Kd_M: 4.38E-12
Real
Aptamer SeqId: 4708-3 | Target: 17-beta-HSD 1 | UniProt: P14061
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4708-3 | Target: 17-beta-HSD 1 | UniProt: P14061 | TargetFullName: Estradiol 17-beta-dehydrogenase 1 | Organisim: human | Apparent_Kd_M: 7.89E-13
Real
Aptamer SeqId: 4712-28 | Target: Apo D | UniProt: P05090
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4712-28 | Target: Apo D | UniProt: P05090 | TargetFullName: Apolipoprotein D | Organisim: human | Apparent_Kd_M: 4.64E-11
Real
Aptamer SeqId: 4717-55 | Target: IL-3 | UniProt: P08700
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4717-55 | Target: IL-3 | UniProt: P08700 | TargetFullName: Interleukin-3 | Organisim: human | Apparent_Kd_M: 1.53E-11
Real
Aptamer SeqId: 4718-5 | Target: PPIB | UniProt: P23284
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4718-5 | Target: PPIB | UniProt: P23284 | TargetFullName: Peptidyl-prolyl cis-trans isomerase B | Organisim: human | Apparent_Kd_M: 1.33E-11
Real
Aptamer SeqId: 4719-58 | Target: Protein disulfide isomerase A3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4719-58 | Target: Protein disulfide isomerase A3 | UniProt: P30101 | TargetFullName: Protein disulfide-isomerase A3 | Organisim: human | Apparent_Kd_M: 8.53E-12
Real
Aptamer SeqId: 4721-54 | Target: TFF3 | UniProt: Q07654
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4721-54 | Target: TFF3 | UniProt: Q07654 | TargetFullName: Trefoil factor 3 | Organisim: human | Apparent_Kd_M: 1.49E-12
Real
Aptamer SeqId: 4763-31 | Target: Afamin | UniProt: P43652
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4763-31 | Target: Afamin | UniProt: P43652 | TargetFullName: Afamin | Organisim: human | Apparent_Kd_M: 6.16E-12
Real
Aptamer SeqId: 4769-10 | Target: Olfactomedin-4 | UniProt: Q6UX06
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4769-10 | Target: Olfactomedin-4 | UniProt: Q6UX06 | TargetFullName: Olfactomedin-4 | Organisim: human | Apparent_Kd_M: 2.93E-12
Real
Aptamer SeqId: 4771-10 | Target: ASM3A | UniProt: Q92484
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4771-10 | Target: ASM3A | UniProt: Q92484 | TargetFullName: Acid sphingomyelinase-like phosphodiesterase 3a | Organisim: human | Apparent_Kd_M: 1.48E-11
Real
Aptamer SeqId: 4775-34 | Target: Gelsolin | UniProt: P06396
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4775-34 | Target: Gelsolin | UniProt: P06396 | TargetFullName: Gelsolin | Organisim: human | Apparent_Kd_M: 1.96E-10
Real
Aptamer SeqId: 4785-30 | Target: CBG | UniProt: P08185
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4785-30 | Target: CBG | UniProt: P08185 | TargetFullName: Corticosteroid-binding globulin | Organisim: human | Apparent_Kd_M: 5.52E-11
Real
Aptamer SeqId: 4792-51 | Target: C34 gp41 HIV Fragment | UniProt: Q70626
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4792-51 | Target: C34 gp41 HIV Fragment | UniProt: Q70626 | TargetFullName: gp41 C34 peptide; HIV | Organisim: isolate lw123 | Apparent_Kd_M: 2.5E-11
Real
Aptamer SeqId: 4801-13 | Target: PERL | UniProt: P22079
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4801-13 | Target: PERL | UniProt: P22079 | TargetFullName: Lactoperoxidase | Organisim: human | Apparent_Kd_M: 5.94E-12
Real
Aptamer SeqId: 4807-13 | Target: CO8A1 | UniProt: P27658
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4807-13 | Target: CO8A1 | UniProt: P27658 | TargetFullName: Collagen alpha-1(VIII) chain | Organisim: human | Apparent_Kd_M: 1.09E-11
Real
Aptamer SeqId: 4811-33 | Target: ITI heavy chain H4 | UniProt: Q14624
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4811-33 | Target: ITI heavy chain H4 | UniProt: Q14624 | TargetFullName: Inter-alpha-trypsin inhibitor heavy chain H4 | Organisim: human | Apparent_Kd_M: 2.25E-11
Real
Aptamer SeqId: 4829-43 | Target: STRATIFIN | UniProt: P31947
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4829-43 | Target: STRATIFIN | UniProt: P31947 | TargetFullName: 14-3-3 protein sigma | Organisim: human | Apparent_Kd_M: 2.26E-12
Real
Aptamer SeqId: 4831-4 | Target: sL-Selectin | UniProt: P14151
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4831-4 | Target: sL-Selectin | UniProt: P14151 | TargetFullName: L-Selectin | Organisim: human | Apparent_Kd_M: 2.31E-12
Real
Aptamer SeqId: 4832-75 | Target: TRAIL R1 | UniProt: O00220
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4832-75 | Target: TRAIL R1 | UniProt: O00220 | TargetFullName: Tumor necrosis factor receptor superfamily member 10A | Organisim: human | Apparent_Kd_M: 1.81E-11
Real
Aptamer SeqId: 4834-61 | Target: Epithelial cell kinase | UniProt: P29317
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4834-61 | Target: Epithelial cell kinase | UniProt: P29317 | TargetFullName: Ephrin type-A receptor 2 | Organisim: human | Apparent_Kd_M: 1.07E-11
Real
Aptamer SeqId: 4840-73 | Target: G-CSF | UniProt: P09919
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4840-73 | Target: G-CSF | UniProt: P09919 | TargetFullName: Granulocyte colony-stimulating factor | Organisim: human | Apparent_Kd_M: 3.14E-12
Real
Aptamer SeqId: 4842-62 | Target: Glypican 3 | UniProt: P51654
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4842-62 | Target: Glypican 3 | UniProt: P51654 | TargetFullName: Glypican-3 | Organisim: human | Apparent_Kd_M: 1.46E-12
Real
Aptamer SeqId: 4851-25 | Target: IL-1a | UniProt: P01583
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4851-25 | Target: IL-1a | UniProt: P01583 | TargetFullName: Interleukin-1 alpha | Organisim: human | Apparent_Kd_M: 1.65E-11
Real
Aptamer SeqId: 4862-63 | Target: BMP RII | UniProt: Q13873
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4862-63 | Target: BMP RII | UniProt: Q13873 | TargetFullName: Bone morphogenetic protein receptor type-2 | Organisim: human | Apparent_Kd_M: 2.324111E-11
Real
Aptamer SeqId: 4866-59 | Target: TrkB | UniProt: Q16620
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4866-59 | Target: TrkB | UniProt: Q16620 | TargetFullName: BDNF/NT-3 growth factors receptor | Organisim: human | Apparent_Kd_M: 2.31E-11
Real
Aptamer SeqId: 4867-15 | Target: VEGF121 | UniProt: P15692
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4867-15 | Target: VEGF121 | UniProt: P15692 | TargetFullName: Vascular endothelial growth factor A; isoform 121 | Organisim: human | Apparent_Kd_M: 7.46E-12
Real
Aptamer SeqId: 4874-3 | Target: Angiogenin | UniProt: P03950
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4874-3 | Target: Angiogenin | UniProt: P03950 | TargetFullName: Angiogenin | Organisim: human | Apparent_Kd_M: 2.14E-12
Real
Aptamer SeqId: 4876-32 | Target: Coagulation Factor IX | UniProt: P00740
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4876-32 | Target: Coagulation Factor IX | UniProt: P00740 | TargetFullName: Coagulation factor IX | Organisim: human | Apparent_Kd_M: 5.53E-13
Real
Aptamer SeqId: 4878-3 | Target: Coagulation Factor X | UniProt: P00742
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4878-3 | Target: Coagulation Factor X | UniProt: P00742 | TargetFullName: Coagulation Factor X | Organisim: human | Apparent_Kd_M: 4.36E-12
Real
Aptamer SeqId: 4880-21 | Target: GDF2 | UniProt: Q9UK05
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4880-21 | Target: GDF2 | UniProt: Q9UK05 | TargetFullName: Growth/differentiation factor 2 | Organisim: human | Apparent_Kd_M: 5.95E-12
Real
Aptamer SeqId: 4883-56 | Target: Insulin | UniProt: P01308
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4883-56 | Target: Insulin | UniProt: P01308 | TargetFullName: Insulin | Organisim: human | Apparent_Kd_M: 1.73E-10
Real
Aptamer SeqId: 4886-3 | Target: MCP-3 | UniProt: P80098
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4886-3 | Target: MCP-3 | UniProt: P80098 | TargetFullName: C-C motif chemokine 7 | Organisim: human | Apparent_Kd_M: 7.62E-13
Real
Aptamer SeqId: 4889-82 | Target: WNT7A | UniProt: O00755
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4889-82 | Target: WNT7A | UniProt: O00755 | TargetFullName: Protein Wnt-7a | Organisim: human | Apparent_Kd_M: 8.88E-11
Real
Aptamer SeqId: 4890-10 | Target: ACTH | UniProt: P01189
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4890-10 | Target: ACTH | UniProt: P01189 | TargetFullName: Corticotropin | Organisim: human | Apparent_Kd_M: 5.35E-12
Real
Aptamer SeqId: 4891-50 | Target: Glucagon | UniProt: P01275
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4891-50 | Target: Glucagon | UniProt: P01275 | TargetFullName: Glucagon | Organisim: human | Apparent_Kd_M: 3.56E-11
Real
Aptamer SeqId: 4900-8 | Target: C3a | UniProt: P01024
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4900-8 | Target: C3a | UniProt: P01024 | TargetFullName: C3a anaphylatoxin | Organisim: human | Apparent_Kd_M: 2.57E-12
Real
Aptamer SeqId: 4903-72 | Target: Calcineurin | UniProt: Q08209|P63098
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4903-72 | Target: Calcineurin | UniProt: Q08209|P63098 | TargetFullName: Calcineurin | Organisim: human | Apparent_Kd_M: 7.32E-12
Real
Aptamer SeqId: 4904-7 | Target: Caspase-2 | UniProt: P42575
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4904-7 | Target: Caspase-2 | UniProt: P42575 | TargetFullName: Caspase-2 | Organisim: human | Apparent_Kd_M: 2.78E-10
Real
Aptamer SeqId: 4905-63 | Target: Coactosin-like protein | UniProt: Q14019
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4905-63 | Target: Coactosin-like protein | UniProt: Q14019 | TargetFullName: Coactosin-like protein | Organisim: human | Apparent_Kd_M: 8.1E-11
Real
Aptamer SeqId: 4906-35 | Target: Coagulation Factor V | UniProt: P12259
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4906-35 | Target: Coagulation Factor V | UniProt: P12259 | TargetFullName: Coagulation Factor V | Organisim: human | Apparent_Kd_M: 8.46E-12
Real
Aptamer SeqId: 4907-56 | Target: D-dimer | UniProt: P02671|P02675|P02679
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4907-56 | Target: D-dimer | UniProt: P02671|P02675|P02679 | TargetFullName: D-dimer | Organisim: human | Apparent_Kd_M: 1.07E-10
Real
Aptamer SeqId: 4908-6 | Target: Endoglin | UniProt: P17813
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4908-6 | Target: Endoglin | UniProt: P17813 | TargetFullName: Endoglin | Organisim: human | Apparent_Kd_M: 1.6E-10
Real
Aptamer SeqId: 4909-68 | Target: Galectin-8 | UniProt: O00214
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4909-68 | Target: Galectin-8 | UniProt: O00214 | TargetFullName: Galectin-8 | Organisim: human | Apparent_Kd_M: 2.66E-11
Real
Aptamer SeqId: 4910-21 | Target: GIB | UniProt: P04054
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4910-21 | Target: GIB | UniProt: P04054 | TargetFullName: Phospholipase A2 | Organisim: human | Apparent_Kd_M: 2.0E-11
Real
Aptamer SeqId: 4911-49 | Target: Glutathione S-transferase Pi
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4911-49 | Target: Glutathione S-transferase Pi | UniProt: P09211 | TargetFullName: Glutathione S-transferase P | Organisim: human | Apparent_Kd_M: 9.43E-12
Real
Aptamer SeqId: 4912-17 | Target: GOT1 | UniProt: P17174
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4912-17 | Target: GOT1 | UniProt: P17174 | TargetFullName: Aspartate aminotransferase; cytoplasmic | Organisim: human | Apparent_Kd_M: 8.22E-11
Real
Aptamer SeqId: 4913-78 | Target: HCC-4 | UniProt: O15467
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4913-78 | Target: HCC-4 | UniProt: O15467 | TargetFullName: C-C motif chemokine 16 | Organisim: human | Apparent_Kd_M: 2.91E-12
Real
Aptamer SeqId: 4914-10 | Target: HCG | UniProt: P01215|P01233
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4914-10 | Target: HCG | UniProt: P01215|P01233 | TargetFullName: Human Chorionic Gonadotropin | Organisim: human | Apparent_Kd_M: 5.57E-12
Real
Aptamer SeqId: 4915-64 | Target: Hemoglobin | UniProt: P69905|P68871
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4915-64 | Target: Hemoglobin | UniProt: P69905|P68871 | TargetFullName: Hemoglobin | Organisim: human | Apparent_Kd_M: 3.72E-11
Real
Aptamer SeqId: 4916-2 | Target: IgD | UniProt: P01880
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4916-2 | Target: IgD | UniProt: P01880 | TargetFullName: Immunoglobulin D | Organisim: human | Apparent_Kd_M: 2.79E-10
Real
Aptamer SeqId: 4917-62 | Target: Integrin aVb5 | UniProt: P06756|P18084
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4917-62 | Target: Integrin aVb5 | UniProt: P06756|P18084 | TargetFullName: Integrin alpha-V: beta-5 complex | Organisim: human | Apparent_Kd_M: 4.73E-12
Real
Aptamer SeqId: 4920-10 | Target: Lysozyme | UniProt: P61626
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4920-10 | Target: Lysozyme | UniProt: P61626 | TargetFullName: Lysozyme C | Organisim: human | Apparent_Kd_M: 9.91E-12
Real
Aptamer SeqId: 4922-13 | Target: MIP-3b | UniProt: Q99731
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4922-13 | Target: MIP-3b | UniProt: Q99731 | TargetFullName: C-C motif chemokine 19 | Organisim: human | Apparent_Kd_M: 1.22E-12
Real
Aptamer SeqId: 4923-79 | Target: MIS | UniProt: P03971
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4923-79 | Target: MIS | UniProt: P03971 | TargetFullName: Muellerian-inhibiting factor | Organisim: human | Apparent_Kd_M: 6.77E-12
Real
Aptamer SeqId: 4924-32 | Target: MMP-1 | UniProt: P03956
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4924-32 | Target: MMP-1 | UniProt: P03956 | TargetFullName: Interstitial collagenase | Organisim: human | Apparent_Kd_M: 1.74E-12
Real
Aptamer SeqId: 4925-54 | Target: MMP-13 | UniProt: P45452
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4925-54 | Target: MMP-13 | UniProt: P45452 | TargetFullName: Collagenase 3 | Organisim: human | Apparent_Kd_M: 1.93E-11
Real
Aptamer SeqId: 4929-55 | Target: SHBG | UniProt: P04278
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4929-55 | Target: SHBG | UniProt: P04278 | TargetFullName: Sex hormone-binding globulin | Organisim: human | Apparent_Kd_M: 4.04E-12
Real
Aptamer SeqId: 4930-21 | Target: Stanniocalcin-1 | UniProt: P52823
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4930-21 | Target: Stanniocalcin-1 | UniProt: P52823 | TargetFullName: Stanniocalcin-1 | Organisim: human | Apparent_Kd_M: 2.15E-11
Real
Aptamer SeqId: 4931-59 | Target: TF | UniProt: P13726
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4931-59 | Target: TF | UniProt: P13726 | TargetFullName: Tissue Factor | Organisim: human | Apparent_Kd_M: 9.62E-11
Real
Aptamer SeqId: 4956-2 | Target: EPI | UniProt: O14944
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4956-2 | Target: EPI | UniProt: O14944 | TargetFullName: Epiregulin | Organisim: human | Apparent_Kd_M: 2.29E-11
Real
Aptamer SeqId: 4959-2 | Target: AGR2 | UniProt: O95994
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4959-2 | Target: AGR2 | UniProt: O95994 | TargetFullName: Anterior gradient protein 2 homolog | Organisim: human | Apparent_Kd_M: 1.51E-11
Real
Aptamer SeqId: 4960-72 | Target: annexin I | UniProt: P04083
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4960-72 | Target: annexin I | UniProt: P04083 | TargetFullName: Annexin A1 | Organisim: human | Apparent_Kd_M: 7.05E-12
Real
Aptamer SeqId: 4961-17 | Target: annexin II | UniProt: P07355
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4961-17 | Target: annexin II | UniProt: P07355 | TargetFullName: Annexin A2 | Organisim: human | Apparent_Kd_M: 1.54E-11
Real
Aptamer SeqId: 4962-52 | Target: ARMEL | UniProt: Q49AH0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4962-52 | Target: ARMEL | UniProt: Q49AH0 | TargetFullName: Cerebral dopamine neurotrophic factor | Organisim: human | Apparent_Kd_M: 1.08E-11
Real
Aptamer SeqId: 4963-19 | Target: ARP19 | UniProt: P56211
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4963-19 | Target: ARP19 | UniProt: P56211 | TargetFullName: cAMP-regulated phosphoprotein 19 | Organisim: human | Apparent_Kd_M: 2.68E-11
Real
Aptamer SeqId: 4964-67 | Target: ARTS1 | UniProt: Q9NZ08
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4964-67 | Target: ARTS1 | UniProt: Q9NZ08 | TargetFullName: Endoplasmic reticulum aminopeptidase 1 | Organisim: human | Apparent_Kd_M: 1.85E-12
Real
Aptamer SeqId: 4965-27 | Target: ATP synthase beta chain | UniProt: P06576
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4965-27 | Target: ATP synthase beta chain | UniProt: P06576 | TargetFullName: ATP synthase subunit beta; mitochondrial | Organisim: human | Apparent_Kd_M: 3.18E-11
Real
Aptamer SeqId: 4967-1 | Target: C1QBP | UniProt: Q07021
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4967-1 | Target: C1QBP | UniProt: Q07021 | TargetFullName: Complement component 1 Q subcomponent-binding protein; mitochondrial | Organisim: human | Apparent_Kd_M: 9.65E-11
Real
Aptamer SeqId: 4968-50 | Target: CAPG | UniProt: P40121
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4968-50 | Target: CAPG | UniProt: P40121 | TargetFullName: Macrophage-capping protein | Organisim: human | Apparent_Kd_M: 2.263217E-11
Real
Aptamer SeqId: 4969-2 | Target: Carbonic anhydrase I | UniProt: P00915
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4969-2 | Target: Carbonic anhydrase I | UniProt: P00915 | TargetFullName: Carbonic anhydrase 1 | Organisim: human | Apparent_Kd_M: 1.71E-11
Real
Aptamer SeqId: 4970-55 | Target: carbonic anhydrase II | UniProt: P00918
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4970-55 | Target: carbonic anhydrase II | UniProt: P00918 | TargetFullName: Carbonic anhydrase 2 | Organisim: human | Apparent_Kd_M: 4.94E-11
Real
Aptamer SeqId: 4971-1 | Target: CATZ | UniProt: Q9UBR2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4971-1 | Target: CATZ | UniProt: Q9UBR2 | TargetFullName: Cathepsin Z | Organisim: human | Apparent_Kd_M: 3.267001E-11
Real
Aptamer SeqId: 4973-18 | Target: cIAP-2 | UniProt: Q13489
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4973-18 | Target: cIAP-2 | UniProt: Q13489 | TargetFullName: Baculoviral IAP repeat-containing protein 3 | Organisim: human | Apparent_Kd_M: 8.658367E-11
Real
Aptamer SeqId: 4976-57 | Target: CRK | UniProt: P46108
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4976-57 | Target: CRK | UniProt: P46108 | TargetFullName: Adapter molecule crk | Organisim: human | Apparent_Kd_M: 7.79E-12
Real
Aptamer SeqId: 4978-54 | Target: DBNL | UniProt: Q9UJU6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4978-54 | Target: DBNL | UniProt: Q9UJU6 | TargetFullName: Drebrin-like protein | Organisim: human | Apparent_Kd_M: 3.94E-11
Real
Aptamer SeqId: 4979-34 | Target: DERM | UniProt: Q07507
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4979-34 | Target: DERM | UniProt: Q07507 | TargetFullName: Dermatopontin | Organisim: human | Apparent_Kd_M: 2.72E-11
Real
Aptamer SeqId: 4981-6 | Target: DSC3 | UniProt: Q14574
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4981-6 | Target: DSC3 | UniProt: Q14574 | TargetFullName: Desmocollin-3 | Organisim: human | Apparent_Kd_M: 3.310403E-11
Real
Aptamer SeqId: 4982-54 | Target: Elafin | UniProt: P19957
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4982-54 | Target: Elafin | UniProt: P19957 | TargetFullName: Elafin | Organisim: human | Apparent_Kd_M: 4.8E-12
Real
Aptamer SeqId: 4984-83 | Target: Esterase D | UniProt: P10768
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4984-83 | Target: Esterase D | UniProt: P10768 | TargetFullName: S-formylglutathione hydrolase | Organisim: human | Apparent_Kd_M: 1.19E-10
Real
Aptamer SeqId: 4985-11 | Target: FABPE | UniProt: Q01469
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4985-11 | Target: FABPE | UniProt: Q01469 | TargetFullName: Fatty acid-binding protein; epidermal | Organisim: human | Apparent_Kd_M: 4.09E-11
Real
Aptamer SeqId: 4986-59 | Target: FAK1 | UniProt: Q05397
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4986-59 | Target: FAK1 | UniProt: Q05397 | TargetFullName: Focal adhesion kinase 1 | Organisim: human | Apparent_Kd_M: 4.34E-11
Real
Aptamer SeqId: 4987-17 | Target: FCAR | UniProt: P24071
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4987-17 | Target: FCAR | UniProt: P24071 | TargetFullName: Immunoglobulin alpha Fc receptor | Organisim: human | Apparent_Kd_M: 4.79E-10
Real
Aptamer SeqId: 4988-49 | Target: FGFR4 | UniProt: P22455
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4988-49 | Target: FGFR4 | UniProt: P22455 | TargetFullName: Fibroblast growth factor receptor 4 | Organisim: human | Apparent_Kd_M: 1.88E-10
Real
Aptamer SeqId: 4989-7 | Target: Fibrinogen g-chain dimer | UniProt: P02679
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4989-7 | Target: Fibrinogen g-chain dimer | UniProt: P02679 | TargetFullName: Fibrinogen gamma chain | Organisim: human | Apparent_Kd_M: 3.1E-12
Real
Aptamer SeqId: 4990-87 | Target: GP1BA | UniProt: P07359
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4990-87 | Target: GP1BA | UniProt: P07359 | TargetFullName: Platelet glycoprotein Ib alpha chain | Organisim: human | Apparent_Kd_M: 7.68E-11
Real
Aptamer SeqId: 4991-12 | Target: GPC5 | UniProt: P78333
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4991-12 | Target: GPC5 | UniProt: P78333 | TargetFullName: Glypican-5 | Organisim: human | Apparent_Kd_M: 1.41E-11
Real
Aptamer SeqId: 4992-49 | Target: GRN | UniProt: P28799
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4992-49 | Target: GRN | UniProt: P28799 | TargetFullName: Granulins | Organisim: human | Apparent_Kd_M: 2.41E-12
Real
Aptamer SeqId: 4993-16 | Target: GSTA3 | UniProt: Q16772
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4993-16 | Target: GSTA3 | UniProt: Q16772 | TargetFullName: Glutathione S-transferase A3 | Organisim: human | Apparent_Kd_M: 4.06E-11
Real
Aptamer SeqId: 4995-16 | Target: HPG- | UniProt: P15428
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4995-16 | Target: HPG- | UniProt: P15428 | TargetFullName: 15-hydroxyprostaglandin dehydrogenase NAD(+) | Organisim: human | Apparent_Kd_M: 2.99E-10
Real
Aptamer SeqId: 4996-66 | Target: HRG | UniProt: P04196
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4996-66 | Target: HRG | UniProt: P04196 | TargetFullName: Histidine-rich glycoprotein | Organisim: human | Apparent_Kd_M: 1.25E-11
Real
Aptamer SeqId: 4997-19 | Target: IF4A3 | UniProt: P38919
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 4997-19 | Target: IF4A3 | UniProt: P38919 | TargetFullName: Eukaryotic initiation factor 4A-III | Organisim: human | Apparent_Kd_M: 1.74E-10
Real
Aptamer SeqId: 5000-52 | Target: LG3BP | UniProt: Q08380
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5000-52 | Target: LG3BP | UniProt: Q08380 | TargetFullName: Galectin-3-binding protein | Organisim: human | Apparent_Kd_M: 3.05E-10
Real
Aptamer SeqId: 5001-6 | Target: Mammaglobin 2 | UniProt: O75556
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5001-6 | Target: Mammaglobin 2 | UniProt: O75556 | TargetFullName: Mammaglobin-B | Organisim: human | Apparent_Kd_M: 8.07E-11
Real
Aptamer SeqId: 5002-76 | Target: MMP-14 | UniProt: P50281
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5002-76 | Target: MMP-14 | UniProt: P50281 | TargetFullName: Matrix metalloproteinase-14 | Organisim: human | Apparent_Kd_M: 3.71E-11
Real
Aptamer SeqId: 5004-69 | Target: MK11 | UniProt: Q15759
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5004-69 | Target: MK11 | UniProt: Q15759 | TargetFullName: Mitogen-activated protein kinase 11 | Organisim: human | Apparent_Kd_M: 8.26E-12
Real
Aptamer SeqId: 5005-4 | Target: MK12 | UniProt: P53778
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5005-4 | Target: MK12 | UniProt: P53778 | TargetFullName: Mitogen-activated protein kinase 12 | Organisim: human | Apparent_Kd_M: 4.5E-11
Real
Aptamer SeqId: 5006-71 | Target: MK13 | UniProt: O15264
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5006-71 | Target: MK13 | UniProt: O15264 | TargetFullName: Mitogen-activated protein kinase 13 | Organisim: human | Apparent_Kd_M: 4.15E-12
Real
Aptamer SeqId: 5007-1 | Target: MAPK14 | UniProt: Q16539
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5007-1 | Target: MAPK14 | UniProt: Q16539 | TargetFullName: Mitogen-activated protein kinase 14 | Organisim: human | Apparent_Kd_M: 1.52E-11
Real
Aptamer SeqId: 5008-51 | Target: Mn SOD | UniProt: P04179
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5008-51 | Target: Mn SOD | UniProt: P04179 | TargetFullName: Superoxide dismutase Mn; mitochondrial | Organisim: human | Apparent_Kd_M: 8.25E-11
Real
Aptamer SeqId: 5009-11 | Target: Moesin | UniProt: P26038
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5009-11 | Target: Moesin | UniProt: P26038 | TargetFullName: Moesin | Organisim: human | Apparent_Kd_M: 1.24E-10
Real
Aptamer SeqId: 5011-11 | Target: PBEF | UniProt: P43490
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5011-11 | Target: PBEF | UniProt: P43490 | TargetFullName: Nicotinamide phosphoribosyltransferase | Organisim: human | Apparent_Kd_M: 3.59E-12
Real
Aptamer SeqId: 5012-67 | Target: Myokinase; human | UniProt: P00568
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5012-67 | Target: Myokinase; human | UniProt: P00568 | TargetFullName: Adenylate kinase isoenzyme 1 | Organisim: human | Apparent_Kd_M: 4.42E-12
Real
Aptamer SeqId: 5013-2 | Target: NCC27 | UniProt: O00299
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5013-2 | Target: NCC27 | UniProt: O00299 | TargetFullName: Chloride intracellular channel protein 1 | Organisim: human | Apparent_Kd_M: 2.95E-11
Real
Aptamer SeqId: 5014-49 | Target: NCK1 | UniProt: P16333
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5014-49 | Target: NCK1 | UniProt: P16333 | TargetFullName: Cytoplasmic protein NCK1 | Organisim: human | Apparent_Kd_M: 4.83E-12
Real
Aptamer SeqId: 5015-15 | Target: PAFAH | UniProt: Q13093
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5015-15 | Target: PAFAH | UniProt: Q13093 | TargetFullName: Platelet-activating factor acetylhydrolase | Organisim: human | Apparent_Kd_M: 3.0E-11
Real
Aptamer SeqId: 5017-19 | Target: Peroxiredoxin-5 | UniProt: P30044
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5017-19 | Target: Peroxiredoxin-5 | UniProt: P30044 | TargetFullName: Peroxiredoxin-5; mitochondrial | Organisim: human | Apparent_Kd_M: 1.05E-10
Real
Aptamer SeqId: 5018-68 | Target: Peroxiredoxin-6 | UniProt: P30041
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5018-68 | Target: Peroxiredoxin-6 | UniProt: P30041 | TargetFullName: Peroxiredoxin-6 | Organisim: human | Apparent_Kd_M: 1.66E-11
Real
Aptamer SeqId: 5019-16 | Target: PGP9.5 | UniProt: P09936
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5019-16 | Target: PGP9.5 | UniProt: P09936 | TargetFullName: Ubiquitin carboxyl-terminal hydrolase isozyme L1 | Organisim: human | Apparent_Kd_M: 2.42E-11
Real
Aptamer SeqId: 5020-50 | Target: phosphoglycerate kinase 1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5020-50 | Target: phosphoglycerate kinase 1 | UniProt: P00558 | TargetFullName: Phosphoglycerate kinase 1 | Organisim: human | Apparent_Kd_M: 5.24E-11
Real
Aptamer SeqId: 5021-13 | Target: PPase | UniProt: Q15181
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5021-13 | Target: PPase | UniProt: Q15181 | TargetFullName: Inorganic pyrophosphatase | Organisim: human | Apparent_Kd_M: 2.29E-11
Real
Aptamer SeqId: 5023-23 | Target: PUR8 | UniProt: P30566
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5023-23 | Target: PUR8 | UniProt: P30566 | TargetFullName: Adenylosuccinate lyase | Organisim: human | Apparent_Kd_M: 8.11E-11
Real
Aptamer SeqId: 5024-67 | Target: Rb | UniProt: P06400
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5024-67 | Target: Rb | UniProt: P06400 | TargetFullName: Retinoblastoma-associated protein | Organisim: human | Apparent_Kd_M: 5.47E-11
Real
Aptamer SeqId: 5026-66 | Target: RS3 | UniProt: P23396
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5026-66 | Target: RS3 | UniProt: P23396 | TargetFullName: 40S ribosomal protein S3 | Organisim: human | Apparent_Kd_M: 3.65E-11
Real
Aptamer SeqId: 5028-59 | Target: sCD163 | UniProt: Q86VB7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5028-59 | Target: sCD163 | UniProt: Q86VB7 | TargetFullName: Scavenger receptor cysteine-rich type 1 protein M130 | Organisim: human | Apparent_Kd_M: 4.55E-11
Real
Aptamer SeqId: 5029-3 | Target: SEPR | UniProt: Q12884
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5029-3 | Target: SEPR | UniProt: Q12884 | TargetFullName: Prolyl endopeptidase FAP | Organisim: human | Apparent_Kd_M: 6.12E-11
Real
Aptamer SeqId: 5030-52 | Target: SIRT2 | UniProt: Q8IXJ6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5030-52 | Target: SIRT2 | UniProt: Q8IXJ6 | TargetFullName: NAD-dependent protein deacetylase sirtuin-2 | Organisim: human | Apparent_Kd_M: 4.55E-11
Real
Aptamer SeqId: 5031-10 | Target: SPTA2 | UniProt: Q13813
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5031-10 | Target: SPTA2 | UniProt: Q13813 | TargetFullName: Spectrin alpha chain; non-erythrocytic 1 | Organisim: human | Apparent_Kd_M: 2.72E-10
Real
Aptamer SeqId: 5032-64 | Target: SSRP1 | UniProt: Q08945
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5032-64 | Target: SSRP1 | UniProt: Q08945 | TargetFullName: FACT complex subunit SSRP1 | Organisim: human | Apparent_Kd_M: 8.95E-11
Real
Aptamer SeqId: 5033-27 | Target: Tropomyosin 1 alpha chain
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5033-27 | Target: Tropomyosin 1 alpha chain | UniProt: P09493 | TargetFullName: Tropomyosin alpha-1 chain | Organisim: human | Apparent_Kd_M: 1.53E-11
Real
Aptamer SeqId: 5034-79 | Target: Trypsin 2 | UniProt: P07478
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5034-79 | Target: Trypsin 2 | UniProt: P07478 | TargetFullName: Trypsin-2 | Organisim: human | Apparent_Kd_M: 1.46E-11
Real
Aptamer SeqId: 5035-7 | Target: TS | UniProt: P04818
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5035-7 | Target: TS | UniProt: P04818 | TargetFullName: Thymidylate synthase | Organisim: human | Apparent_Kd_M: 5.12E-11
Real
Aptamer SeqId: 5036-50 | Target: TSG-6 | UniProt: P98066
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5036-50 | Target: TSG-6 | UniProt: P98066 | TargetFullName: Tumor necrosis factor-inducible gene 6 protein | Organisim: human | Apparent_Kd_M: 1.62E-12
Real
Aptamer SeqId: 5060-62 | Target: B7-H1 | UniProt: Q9NZQ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5060-62 | Target: B7-H1 | UniProt: Q9NZQ7 | TargetFullName: Programmed cell death 1 ligand 1 | Organisim: human | Apparent_Kd_M: 1.04E-11
Real
Aptamer SeqId: 5061-27 | Target: B7-H2 | UniProt: O75144
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5061-27 | Target: B7-H2 | UniProt: O75144 | TargetFullName: ICOS ligand | Organisim: human | Apparent_Kd_M: 1.25E-10
Real
Aptamer SeqId: 5062-60 | Target: CD226 | UniProt: Q15762
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5062-60 | Target: CD226 | UniProt: Q15762 | TargetFullName: CD226 antigen | Organisim: human | Apparent_Kd_M: 2.01E-10
Real
Aptamer SeqId: 5063-12 | Target: CD244 | UniProt: Q9BZW8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5063-12 | Target: CD244 | UniProt: Q9BZW8 | TargetFullName: Natural killer cell receptor 2B4 | Organisim: human | Apparent_Kd_M: 2.93E-11
Real
Aptamer SeqId: 5065-8 | Target: CD83 | UniProt: Q01151
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5065-8 | Target: CD83 | UniProt: Q01151 | TargetFullName: CD83 antigen | Organisim: human | Apparent_Kd_M: 5.15E-11
Real
Aptamer SeqId: 5066-134 | Target: CLM6 | UniProt: Q08708
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5066-134 | Target: CLM6 | UniProt: Q08708 | TargetFullName: CMRF35-like molecule 6 | Organisim: human | Apparent_Kd_M: 4.06E-11
Real
Aptamer SeqId: 5069-9 | Target: DAF | UniProt: P08174
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5069-9 | Target: DAF | UniProt: P08174 | TargetFullName: Complement decay-accelerating factor | Organisim: human | Apparent_Kd_M: 1.08E-11
Real
Aptamer SeqId: 5070-76 | Target: DcR3 | UniProt: O95407
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5070-76 | Target: DcR3 | UniProt: O95407 | TargetFullName: Tumor necrosis factor receptor superfamily member 6B | Organisim: human | Apparent_Kd_M: 4.9E-11
Real
Aptamer SeqId: 5076-53 | Target: EPHAA | UniProt: Q5JZY3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5076-53 | Target: EPHAA | UniProt: Q5JZY3 | TargetFullName: Ephrin type-A receptor 10 | Organisim: human | Apparent_Kd_M: 2.46E-12
Real
Aptamer SeqId: 5078-82 | Target: EphB6 | UniProt: O15197
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5078-82 | Target: EphB6 | UniProt: O15197 | TargetFullName: Ephrin type-B receptor 6 | Organisim: human | Apparent_Kd_M: 1.55E-11
Real
Aptamer SeqId: 5082-51 | Target: IL-1 sR9 | UniProt: Q9NP60
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5082-51 | Target: IL-1 sR9 | UniProt: Q9NP60 | TargetFullName: X-linked interleukin-1 receptor accessory protein-like 2 | Organisim: human | Apparent_Kd_M: 1.73E-11
Real
Aptamer SeqId: 5085-18 | Target: IL-20 Ra | UniProt: Q9UHF4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5085-18 | Target: IL-20 Ra | UniProt: Q9UHF4 | TargetFullName: Interleukin-20 receptor subunit alpha | Organisim: human | Apparent_Kd_M: 1.28E-12
Real
Aptamer SeqId: 5087-5 | Target: IL-22BP | UniProt: Q969J5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5087-5 | Target: IL-22BP | UniProt: Q969J5 | TargetFullName: Interleukin-22 receptor subunit alpha-2 | Organisim: human | Apparent_Kd_M: 5.54E-12
Real
Aptamer SeqId: 5088-175 | Target: IL-23 R | UniProt: Q5VWK5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5088-175 | Target: IL-23 R | UniProt: Q5VWK5 | TargetFullName: Interleukin-23 receptor | Organisim: human | Apparent_Kd_M: 2.7E-12
Real
Aptamer SeqId: 5089-11 | Target: IL-7 Ra | UniProt: P16871
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5089-11 | Target: IL-7 Ra | UniProt: P16871 | TargetFullName: Interleukin-7 receptor subunit alpha | Organisim: human | Apparent_Kd_M: 2.06E-11
Real
Aptamer SeqId: 5090-49 | Target: ILT-2 | UniProt: Q8NHL6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5090-49 | Target: ILT-2 | UniProt: Q8NHL6 | TargetFullName: Leukocyte immunoglobulin-like receptor subfamily B member 1 | Organisim: human | Apparent_Kd_M: 4.72E-12
Real
Aptamer SeqId: 5091-28 | Target: ILT-4 | UniProt: Q8N423
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5091-28 | Target: ILT-4 | UniProt: Q8N423 | TargetFullName: Leukocyte immunoglobulin-like receptor subfamily B member 2 | Organisim: human | Apparent_Kd_M: 1.6E-12
Real
Aptamer SeqId: 5092-51 | Target: JAG1 | UniProt: P78504
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5092-51 | Target: JAG1 | UniProt: P78504 | TargetFullName: Protein jagged-1 | Organisim: human | Apparent_Kd_M: 3.99E-12
Real
Aptamer SeqId: 5093-47 | Target: JAG2 | UniProt: Q9Y219
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5093-47 | Target: JAG2 | UniProt: Q9Y219 | TargetFullName: Protein jagged-2 | Organisim: human | Apparent_Kd_M: 1.35E-11
Real
Aptamer SeqId: 5094-62 | Target: JAML1 | UniProt: Q86YT9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5094-62 | Target: JAML1 | UniProt: Q86YT9 | TargetFullName: Junctional adhesion molecule-like | Organisim: human | Apparent_Kd_M: 4.76E-12
Real
Aptamer SeqId: 5095-21 | Target: KI2L4 | UniProt: Q99706
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5095-21 | Target: KI2L4 | UniProt: Q99706 | TargetFullName: Killer cell immunoglobulin-like receptor 2DL4 | Organisim: human | Apparent_Kd_M: 1.08E-10
Real
Aptamer SeqId: 5096-51 | Target: KI3L2 | UniProt: P43630
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5096-51 | Target: KI3L2 | UniProt: P43630 | TargetFullName: Killer cell immunoglobulin-like receptor 3DL2 | Organisim: human | Apparent_Kd_M: 1.62E-10
Real
Aptamer SeqId: 5097-14 | Target: KI3S1 | UniProt: Q14943
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5097-14 | Target: KI3S1 | UniProt: Q14943 | TargetFullName: Killer cell immunoglobulin-like receptor 3DS1 | Organisim: human | Apparent_Kd_M: 1.19E-10
Real
Aptamer SeqId: 5098-79 | Target: KLRF1 | UniProt: Q9NZS2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5098-79 | Target: KLRF1 | UniProt: Q9NZS2 | TargetFullName: Killer cell lectin-like receptor subfamily F member 1 | Organisim: human | Apparent_Kd_M: 8.2E-12
Real
Aptamer SeqId: 5100-53 | Target: LIMP II | UniProt: Q14108
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5100-53 | Target: LIMP II | UniProt: Q14108 | TargetFullName: Lysosome membrane protein 2 | Organisim: human | Apparent_Kd_M: 8.7E-11
Real
Aptamer SeqId: 5102-55 | Target: MICB | UniProt: Q29980
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5102-55 | Target: MICB | UniProt: Q29980 | TargetFullName: MHC class I polypeptide-related sequence B | Organisim: human | Apparent_Kd_M: 7.17E-12
Real
Aptamer SeqId: 5103-30 | Target: MO2R1 | UniProt: Q8TD46
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5103-30 | Target: MO2R1 | UniProt: Q8TD46 | TargetFullName: Cell surface glycoprotein CD200 receptor 1 | Organisim: human | Apparent_Kd_M: 1.73E-10
Real
Aptamer SeqId: 5105-2 | Target: Nogo Receptor | UniProt: Q9BZR6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5105-2 | Target: Nogo Receptor | UniProt: Q9BZR6 | TargetFullName: Reticulon-4 receptor | Organisim: human | Apparent_Kd_M: 1.39E-11
Real
Aptamer SeqId: 5106-52 | Target: NOTC2 | UniProt: Q04721
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5106-52 | Target: NOTC2 | UniProt: Q04721 | TargetFullName: Neurogenic locus notch homolog protein 2 | Organisim: human | Apparent_Kd_M: 1.41E-11
Real
Aptamer SeqId: 5107-7 | Target: Notch 1 | UniProt: P46531
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5107-7 | Target: Notch 1 | UniProt: P46531 | TargetFullName: Neurogenic locus notch homolog protein 1 | Organisim: human | Apparent_Kd_M: 2.38E-12
Real
Aptamer SeqId: 5108-72 | Target: Notch-3 | UniProt: Q9UM47
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5108-72 | Target: Notch-3 | UniProt: Q9UM47 | TargetFullName: Neurogenic locus notch homolog protein 3 | Organisim: human | Apparent_Kd_M: 7.57E-12
Real
Aptamer SeqId: 5109-24 | Target: Nr-CAM | UniProt: Q92823
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5109-24 | Target: Nr-CAM | UniProt: Q92823 | TargetFullName: Neuronal cell adhesion molecule | Organisim: human | Apparent_Kd_M: 5.19E-12
Real
Aptamer SeqId: 5110-84 | Target: NRX1B | UniProt: P58400
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5110-84 | Target: NRX1B | UniProt: P58400 | TargetFullName: Neurexin-1-beta | Organisim: human | Apparent_Kd_M: 4.88E-11
Real
Aptamer SeqId: 5111-15 | Target: NRX3B | UniProt: Q9HDB5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5111-15 | Target: NRX3B | UniProt: Q9HDB5 | TargetFullName: Neurexin-3-beta | Organisim: human | Apparent_Kd_M: 1.05E-11
Real
Aptamer SeqId: 5112-73 | Target: OX2G | UniProt: P41217
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5112-73 | Target: OX2G | UniProt: P41217 | TargetFullName: OX-2 membrane glycoprotein | Organisim: human | Apparent_Kd_M: 2.95E-12
Real
Aptamer SeqId: 5114-65 | Target: Prolactin Receptor | UniProt: P16471
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5114-65 | Target: Prolactin Receptor | UniProt: P16471 | TargetFullName: Prolactin receptor | Organisim: human | Apparent_Kd_M: 8.19E-12
Real
Aptamer SeqId: 5116-62 | Target: ROBO2 | UniProt: Q9HCK4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5116-62 | Target: ROBO2 | UniProt: Q9HCK4 | TargetFullName: Roundabout homolog 2 | Organisim: human | Apparent_Kd_M: 1.12E-12
Real
Aptamer SeqId: 5117-14 | Target: ROBO3 | UniProt: Q96MS0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5117-14 | Target: ROBO3 | UniProt: Q96MS0 | TargetFullName: Roundabout homolog 3 | Organisim: human | Apparent_Kd_M: 4.14E-12
Real
Aptamer SeqId: 5121-3 | Target: SEM6B | UniProt: Q9H3T3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5121-3 | Target: SEM6B | UniProt: Q9H3T3 | TargetFullName: Semaphorin-6B | Organisim: human | Apparent_Kd_M: 8.39E-12
Real
Aptamer SeqId: 5124-69 | Target: sICAM-5 | UniProt: Q9UMF0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5124-69 | Target: sICAM-5 | UniProt: Q9UMF0 | TargetFullName: Intercellular adhesion molecule 5 | Organisim: human | Apparent_Kd_M: 2.54E-12
Real
Aptamer SeqId: 5128-53 | Target: SLAF6 | UniProt: Q96DU3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5128-53 | Target: SLAF6 | UniProt: Q96DU3 | TargetFullName: SLAM family member 6 | Organisim: human | Apparent_Kd_M: 2.3E-10
Real
Aptamer SeqId: 5129-12 | Target: SREC-I | UniProt: Q14162
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5129-12 | Target: SREC-I | UniProt: Q14162 | TargetFullName: Scavenger receptor class F member 1 | Organisim: human | Apparent_Kd_M: 1.09E-12
Real
Aptamer SeqId: 5131-15 | Target: TAJ | UniProt: Q9NS68
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5131-15 | Target: TAJ | UniProt: Q9NS68 | TargetFullName: Tumor necrosis factor receptor superfamily member 19 | Organisim: human | Apparent_Kd_M: 6.0E-11
Real
Aptamer SeqId: 5132-71 | Target: TCCR | UniProt: Q6UWB1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5132-71 | Target: TCCR | UniProt: Q6UWB1 | TargetFullName: Interleukin-27 receptor subunit alpha | Organisim: human | Apparent_Kd_M: 5.46E-12
Real
Aptamer SeqId: 5133-17 | Target: TGF-b R II | UniProt: P37173
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5133-17 | Target: TGF-b R II | UniProt: P37173 | TargetFullName: TGF-beta receptor type-2 | Organisim: human | Apparent_Kd_M: 6.91E-11
Real
Aptamer SeqId: 5134-52 | Target: TIMD3 | UniProt: Q8TDQ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5134-52 | Target: TIMD3 | UniProt: Q8TDQ0 | TargetFullName: Hepatitis A virus cellular receptor 2 | Organisim: human | Apparent_Kd_M: 6.83E-12
Real
Aptamer SeqId: 5138-50 | Target: TWEAKR | UniProt: Q9NP84
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5138-50 | Target: TWEAKR | UniProt: Q9NP84 | TargetFullName: Tumor necrosis factor receptor superfamily member 12A | Organisim: human | Apparent_Kd_M: 3.55E-12
Real
Aptamer SeqId: 5139-32 | Target: UNC5H3 | UniProt: O95185
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5139-32 | Target: UNC5H3 | UniProt: O95185 | TargetFullName: Netrin receptor UNC5C | Organisim: human | Apparent_Kd_M: 1.55E-12
Real
Aptamer SeqId: 5178-5 | Target: PDE7A | UniProt: Q13946
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5178-5 | Target: PDE7A | UniProt: Q13946 | TargetFullName: High affinity cAMP-specific 3';5'-cyclic phosphodiesterase 7A | Organisim: human | Apparent_Kd_M: 2.16E-12
Real
Aptamer SeqId: 5183-53 | Target: AMPK a1b1g1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5183-53 | Target: AMPK a1b1g1 | UniProt: Q13131|Q9Y478|P54619 | TargetFullName: AMP Kinase (alpha1beta1gamma1) | Organisim: human | Apparent_Kd_M: 7.49E-12
Real
Aptamer SeqId: 5196-7 | Target: NMT1 | UniProt: P30419
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5196-7 | Target: NMT1 | UniProt: P30419 | TargetFullName: Glycylpeptide N-tetradecanoyltransferase 1 | Organisim: human | Apparent_Kd_M: 2.86E-11
Real
Aptamer SeqId: 5201-50 | Target: PDE9A | UniProt: O76083
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5201-50 | Target: PDE9A | UniProt: O76083 | TargetFullName: High affinity cGMP-specific 3';5'-cyclic phosphodiesterase 9A | Organisim: human | Apparent_Kd_M: 2.82E-10
Real
Aptamer SeqId: 5202-4 | Target: PPID | UniProt: Q08752
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5202-4 | Target: PPID | UniProt: Q08752 | TargetFullName: Peptidyl-prolyl cis-trans isomerase D | Organisim: human | Apparent_Kd_M: 4.1E-12
Real
Aptamer SeqId: 5204-13 | Target: PSME3 | UniProt: P61289
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5204-13 | Target: PSME3 | UniProt: P61289 | TargetFullName: Proteasome activator complex subunit 3 | Organisim: human | Apparent_Kd_M: 2.52E-10
Real
Aptamer SeqId: 5223-59 | Target: GCKR | UniProt: Q14397
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5223-59 | Target: GCKR | UniProt: Q14397 | TargetFullName: Glucokinase regulatory protein | Organisim: human | Apparent_Kd_M: 1.97E-12
Real
Aptamer SeqId: 5224-20 | Target: CSK21 | UniProt: P68400
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5224-20 | Target: CSK21 | UniProt: P68400 | TargetFullName: Casein kinase II subunit alpha | Organisim: human | Apparent_Kd_M: 9.34E-12
Real
Aptamer SeqId: 5225-50 | Target: CK2-A1:B | UniProt: P68400|P67870
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5225-50 | Target: CK2-A1:B | UniProt: P68400|P67870 | TargetFullName: Casein kinase II 2-alpha:2-beta heterotetramer | Organisim: human | Apparent_Kd_M: 6.48E-12
Real
Aptamer SeqId: 5226-36 | Target: CK2-A2:B | UniProt: P19784|P67870
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5226-36 | Target: CK2-A2:B | UniProt: P19784|P67870 | TargetFullName: Casein kinase II 2-alpha':2-beta heterotetramer | Organisim: human | Apparent_Kd_M: 8.92E-12
Real
Aptamer SeqId: 5227-60 | Target: PDK1 | UniProt: Q15118
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5227-60 | Target: PDK1 | UniProt: Q15118 | TargetFullName: Pyruvate dehydrogenase (acetyl-transferring) kinase isozyme 1; mitochondrial | Organisim: human | Apparent_Kd_M: 2.08E-11
Real
Aptamer SeqId: 5228-25 | Target: KIF23 | UniProt: Q02241
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5228-25 | Target: KIF23 | UniProt: Q02241 | TargetFullName: Kinesin-like protein KIF23 | Organisim: human | Apparent_Kd_M: 2.37E-12
Real
Aptamer SeqId: 5229-90 | Target: IMDH1 | UniProt: P20839
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5229-90 | Target: IMDH1 | UniProt: P20839 | TargetFullName: Inosine-5'-monophosphate dehydrogenase 1 | Organisim: human | Apparent_Kd_M: 7.01E-12
Real
Aptamer SeqId: 5230-99 | Target: HMGR | UniProt: P04035
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5230-99 | Target: HMGR | UniProt: P04035 | TargetFullName: 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Organisim: human | Apparent_Kd_M: 4.09E-13
Real
Aptamer SeqId: 5231-79 | Target: PCSK9 | UniProt: Q8NBP7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5231-79 | Target: PCSK9 | UniProt: Q8NBP7 | TargetFullName: Proprotein convertase subtilisin/kexin type 9 | Organisim: human | Apparent_Kd_M: 8.8E-13
Real
Aptamer SeqId: 5236-2 | Target: NR1D1 | UniProt: P20393
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5236-2 | Target: NR1D1 | UniProt: P20393 | TargetFullName: Nuclear receptor subfamily 1 group D member 1 | Organisim: human | Apparent_Kd_M: 5.64E-11
Real
Aptamer SeqId: 5238-26 | Target: PPIE | UniProt: Q9UNP9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5238-26 | Target: PPIE | UniProt: Q9UNP9 | TargetFullName: Peptidyl-prolyl cis-trans isomerase E | Organisim: human | Apparent_Kd_M: 2.26E-11
Real
Aptamer SeqId: 5242-37 | Target: MP2K4 | UniProt: P45985
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5242-37 | Target: MP2K4 | UniProt: P45985 | TargetFullName: Dual specificity mitogen-activated protein kinase kinase 4 | Organisim: human | Apparent_Kd_M: 9.9E-12
Real
Aptamer SeqId: 5245-40 | Target: AMPK a2b2g1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5245-40 | Target: AMPK a2b2g1 | UniProt: P54646|O43741|P54619 | TargetFullName: AMP Kinase (alpha2beta2gamma1) | Organisim: human | Apparent_Kd_M: 2.07E-11
Real
Aptamer SeqId: 5246-64 | Target: cGMP-stimulated PDE | UniProt: O00408
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5246-64 | Target: cGMP-stimulated PDE | UniProt: O00408 | TargetFullName: cGMP-dependent 3';5'-cyclic phosphodiesterase | Organisim: human | Apparent_Kd_M: 5.96E-11
Real
Aptamer SeqId: 5248-68 | Target: Cyclophilin F | UniProt: P30405
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5248-68 | Target: Cyclophilin F | UniProt: P30405 | TargetFullName: Peptidyl-prolyl cis-trans isomerase F; mitochondrial | Organisim: human | Apparent_Kd_M: 1.44E-11
Real
Aptamer SeqId: 5249-31 | Target: DRAK2 | UniProt: O94768
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5249-31 | Target: DRAK2 | UniProt: O94768 | TargetFullName: Serine/threonine-protein kinase 17B | Organisim: human | Apparent_Kd_M: 8.91E-13
Real
Aptamer SeqId: 5250-53 | Target: IMDH2 | UniProt: P12268
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5250-53 | Target: IMDH2 | UniProt: P12268 | TargetFullName: Inosine-5'-monophosphate dehydrogenase 2 | Organisim: human | Apparent_Kd_M: 2.96E-11
Real
Aptamer SeqId: 5252-33 | Target: PDE11 | UniProt: Q9HCR9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5252-33 | Target: PDE11 | UniProt: Q9HCR9 | TargetFullName: Dual 3';5'-cyclic-AMP and -GMP phosphodiesterase 11A | Organisim: human | Apparent_Kd_M: 4.82E-11
Real
Aptamer SeqId: 5253-1 | Target: PDE1A | UniProt: P54750
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5253-1 | Target: PDE1A | UniProt: P54750 | TargetFullName: Calcium/calmodulin-dependent 3';5'-cyclic nucleotide phosphodiesterase 1A | Organisim: human | Apparent_Kd_M: 2.17E-11
Real
Aptamer SeqId: 5254-69 | Target: PDE3A | UniProt: Q14432
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5254-69 | Target: PDE3A | UniProt: Q14432 | TargetFullName: cGMP-inhibited 3';5'-cyclic phosphodiesterase A | Organisim: human | Apparent_Kd_M: 3.18E-10
Real
Aptamer SeqId: 5255-22 | Target: PDE4D | UniProt: Q08499
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5255-22 | Target: PDE4D | UniProt: Q08499 | TargetFullName: cAMP-specific 3';5'-cyclic phosphodiesterase 4D | Organisim: human | Apparent_Kd_M: 4.2E-10
Real
Aptamer SeqId: 5256-86 | Target: PDE5A | UniProt: O76074
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5256-86 | Target: PDE5A | UniProt: O76074 | TargetFullName: cGMP-specific 3';5'-cyclic phosphodiesterase | Organisim: human | Apparent_Kd_M: 7.9E-12
Real
Aptamer SeqId: 5259-2 | Target: TAK1-TAB1 | UniProt: O43318|Q15750
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5259-2 | Target: TAK1-TAB1 | UniProt: O43318|Q15750 | TargetFullName: Mitogen-activated protein kinase kinase kinase 7:TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 fusion | Organisim: human | Apparent_Kd_M: 1.69E-10
Real
Aptamer SeqId: 5260-80 | Target: TYK2 | UniProt: P29597
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5260-80 | Target: TYK2 | UniProt: P29597 | TargetFullName: Non-receptor tyrosine-protein kinase TYK2 | Organisim: human | Apparent_Kd_M: 2.4E-11
Real
Aptamer SeqId: 5261-13 | Target: ABL2 | UniProt: P42684
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5261-13 | Target: ABL2 | UniProt: P42684 | TargetFullName: Abelson tyrosine-protein kinase 2 | Organisim: human | Apparent_Kd_M: 1.89E-12
Real
Aptamer SeqId: 5262-57 | Target: BCAR3 | UniProt: O75815
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5262-57 | Target: BCAR3 | UniProt: O75815 | TargetFullName: Breast cancer anti-estrogen resistance protein 3 | Organisim: human | Apparent_Kd_M: 7.42E-13
Real
Aptamer SeqId: 5264-65 | Target: calreticulin | UniProt: P27797
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5264-65 | Target: calreticulin | UniProt: P27797 | TargetFullName: Calreticulin | Organisim: human | Apparent_Kd_M: 9.35E-11
Real
Aptamer SeqId: 5265-12 | Target: GRB2-related adapter protein 2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5265-12 | Target: GRB2-related adapter protein 2 | UniProt: O75791 | TargetFullName: GRB2-related adapter protein 2 | Organisim: human | Apparent_Kd_M: 8.05E-12
Real
Aptamer SeqId: 5268-49 | Target: MMP-16 | UniProt: P51512
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5268-49 | Target: MMP-16 | UniProt: P51512 | TargetFullName: Matrix metalloproteinase-16 | Organisim: human | Apparent_Kd_M: 1.55E-11
Real
Aptamer SeqId: 5272-55 | Target: SHC1 | UniProt: P29353
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5272-55 | Target: SHC1 | UniProt: P29353 | TargetFullName: SHC-transforming protein 1 | Organisim: human | Apparent_Kd_M: 1.06E-12
Real
Aptamer SeqId: 5275-28 | Target: VAV | UniProt: P15498
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5275-28 | Target: VAV | UniProt: P15498 | TargetFullName: Proto-oncogene vav | Organisim: human | Apparent_Kd_M: 1.43E-12
Real
Aptamer SeqId: 5280-68 | Target: GHC2 | UniProt: Q9H1K4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5280-68 | Target: GHC2 | UniProt: Q9H1K4 | TargetFullName: Mitochondrial glutamate carrier 2 | Organisim: human | Apparent_Kd_M: 7.44E-11
Real
Aptamer SeqId: 5301-7 | Target: Eotaxin | UniProt: P51671
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5301-7 | Target: Eotaxin | UniProt: P51671 | TargetFullName: Eotaxin | Organisim: human | Apparent_Kd_M: 1.01E-12
Real
Aptamer SeqId: 5307-12 | Target: Coagulation Factor IXab | UniProt: P00740
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5307-12 | Target: Coagulation Factor IXab | UniProt: P00740 | TargetFullName: Coagulation factor IXab | Organisim: human | Apparent_Kd_M: 4.43E-12
Real
Aptamer SeqId: 5312-49 | Target: Deprecated | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5312-49 | Target: Deprecated | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 9.15E-12
Real
Aptamer SeqId: 5315-22 | Target: Troponin T | UniProt: P45379
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5315-22 | Target: Troponin T | UniProt: P45379 | TargetFullName: Troponin T; cardiac muscle | Organisim: human | Apparent_Kd_M: 2.99E-12
Real
Aptamer SeqId: 5316-54 | Target: Prothrombin | UniProt: P00734
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5316-54 | Target: Prothrombin | UniProt: P00734 | TargetFullName: Prothrombin | Organisim: human | Apparent_Kd_M: 1.04E-12
Real
Aptamer SeqId: 5335-73 | Target: annexin VI | UniProt: P08133
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5335-73 | Target: annexin VI | UniProt: P08133 | TargetFullName: Annexin A6 | Organisim: human | Apparent_Kd_M: 7.49E-11
Real
Aptamer SeqId: 5337-64 | Target: B7-2 | UniProt: P42081
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5337-64 | Target: B7-2 | UniProt: P42081 | TargetFullName: T-lymphocyte activation antigen CD86 | Organisim: human | Apparent_Kd_M: 4.75E-11
Real
Aptamer SeqId: 5339-49 | Target: calgranulin B | UniProt: P06702
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5339-49 | Target: calgranulin B | UniProt: P06702 | TargetFullName: Protein S100-A9 | Organisim: human | Apparent_Kd_M: 4.845704E-11
Real
Aptamer SeqId: 5340-24 | Target: Caspase-10 | UniProt: Q92851
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5340-24 | Target: Caspase-10 | UniProt: Q92851 | TargetFullName: Caspase-10 | Organisim: human | Apparent_Kd_M: 7.36E-12
Real
Aptamer SeqId: 5343-74 | Target: CBPE | UniProt: P16870
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5343-74 | Target: CBPE | UniProt: P16870 | TargetFullName: Carboxypeptidase E | Organisim: human | Apparent_Kd_M: 1.56E-11
Real
Aptamer SeqId: 5345-51 | Target: CKAP2 | UniProt: Q8WWK9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5345-51 | Target: CKAP2 | UniProt: Q8WWK9 | TargetFullName: Cytoskeleton-associated protein 2 | Organisim: human | Apparent_Kd_M: 6.06E-11
Real
Aptamer SeqId: 5346-24 | Target: CPNE1 | UniProt: Q99829
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5346-24 | Target: CPNE1 | UniProt: Q99829 | TargetFullName: Copine-1 | Organisim: human | Apparent_Kd_M: 8.92E-12
Real
Aptamer SeqId: 5347-59 | Target: Cyclin B1 | UniProt: P14635
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5347-59 | Target: Cyclin B1 | UniProt: P14635 | TargetFullName: G2/mitotic-specific cyclin-B1 | Organisim: human | Apparent_Kd_M: 4.52E-12
Real
Aptamer SeqId: 5349-69 | Target: DLL1 | UniProt: O00548
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5349-69 | Target: DLL1 | UniProt: O00548 | TargetFullName: Delta-like protein 1 | Organisim: human | Apparent_Kd_M: 3.01E-12
Real
Aptamer SeqId: 5350-14 | Target: GPC6 | UniProt: Q9Y625
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5350-14 | Target: GPC6 | UniProt: Q9Y625 | TargetFullName: Glypican-6 | Organisim: human | Apparent_Kd_M: 1.15E-10
Real
Aptamer SeqId: 5351-52 | Target: hnRNP A2/B1 | UniProt: P22626
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5351-52 | Target: hnRNP A2/B1 | UniProt: P22626 | TargetFullName: Heterogeneous nuclear ribonucleoproteins A2/B1 | Organisim: human | Apparent_Kd_M: 3.75E-12
Real
Aptamer SeqId: 5352-11 | Target: HVEM | UniProt: Q92956
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5352-11 | Target: HVEM | UniProt: Q92956 | TargetFullName: Tumor necrosis factor receptor superfamily member 14 | Organisim: human | Apparent_Kd_M: 8.99E-12
Real
Aptamer SeqId: 5353-89 | Target: IL-1Ra | UniProt: P18510
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5353-89 | Target: IL-1Ra | UniProt: P18510 | TargetFullName: Interleukin-1 receptor antagonist protein | Organisim: human | Apparent_Kd_M: 8.9E-12
Real
Aptamer SeqId: 5354-11 | Target: Keratin 18 | UniProt: P05783
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5354-11 | Target: Keratin 18 | UniProt: P05783 | TargetFullName: Keratin; type I cytoskeletal 18 | Organisim: human | Apparent_Kd_M: 5.63E-11
Real
Aptamer SeqId: 5355-69 | Target: LIGHT | UniProt: O43557
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5355-69 | Target: LIGHT | UniProt: O43557 | TargetFullName: Tumor necrosis factor ligand superfamily member 14 | Organisim: human | Apparent_Kd_M: 5.78E-12
Real
Aptamer SeqId: 5357-60 | Target: NLGNX | UniProt: Q8N0W4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5357-60 | Target: NLGNX | UniProt: Q8N0W4 | TargetFullName: Neuroligin-4; X-linked | Organisim: human | Apparent_Kd_M: 1.24E-12
Real
Aptamer SeqId: 5358-3 | Target: OMD | UniProt: Q99983
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5358-3 | Target: OMD | UniProt: Q99983 | TargetFullName: Osteomodulin | Organisim: human | Apparent_Kd_M: 2.11E-12
Real
Aptamer SeqId: 5359-65 | Target: PIM1 | UniProt: P11309
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5359-65 | Target: PIM1 | UniProt: P11309 | TargetFullName: Serine/threonine-protein kinase pim-1 | Organisim: human | Apparent_Kd_M: 7.23E-11
Real
Aptamer SeqId: 5360-9 | Target: PKB beta | UniProt: P31751
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5360-9 | Target: PKB beta | UniProt: P31751 | TargetFullName: RAC-beta serine/threonine-protein kinase | Organisim: human | Apparent_Kd_M: 2.78E-11
Real
Aptamer SeqId: 5363-51 | Target: Semaphorin 3E | UniProt: O15041
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5363-51 | Target: Semaphorin 3E | UniProt: O15041 | TargetFullName: Semaphorin-3E | Organisim: human | Apparent_Kd_M: 1.47E-12
Real
Aptamer SeqId: 5364-7 | Target: SET | UniProt: Q01105
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5364-7 | Target: SET | UniProt: Q01105 | TargetFullName: Protein SET | Organisim: human | Apparent_Kd_M: 1.031148E-11
Real
Aptamer SeqId: 5383-14 | Target: BAFF Receptor | UniProt: Q96RJ3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5383-14 | Target: BAFF Receptor | UniProt: Q96RJ3 | TargetFullName: Tumor necrosis factor receptor superfamily member 13C | Organisim: human | Apparent_Kd_M: 1.05E-10
Real
Aptamer SeqId: 5392-73 | Target: Fas; soluble | UniProt: P25445
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5392-73 | Target: Fas; soluble | UniProt: P25445 | TargetFullName: Tumor necrosis factor receptor superfamily member 6 | Organisim: human | Apparent_Kd_M: 6.54E-12
Real
Aptamer SeqId: 5400-52 | Target: sLeptin R | UniProt: P48357
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5400-52 | Target: sLeptin R | UniProt: P48357 | TargetFullName: Leptin receptor | Organisim: human | Apparent_Kd_M: 3.66E-12
Real
Aptamer SeqId: 5404-53 | Target: DR6 | UniProt: O75509
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5404-53 | Target: DR6 | UniProt: O75509 | TargetFullName: Tumor necrosis factor receptor superfamily member 21 | Organisim: human | Apparent_Kd_M: 1.73E-12
Real
Aptamer SeqId: 5410-53 | Target: CAD15 | UniProt: P55291
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5410-53 | Target: CAD15 | UniProt: P55291 | TargetFullName: Cadherin-15 | Organisim: human | Apparent_Kd_M: 6.21E-11
Real
Aptamer SeqId: 5412-53 | Target: CD27 | UniProt: P26842
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5412-53 | Target: CD27 | UniProt: P26842 | TargetFullName: CD27 antigen | Organisim: human | Apparent_Kd_M: 4.13E-12
Real
Aptamer SeqId: 5430-66 | Target: SHPS1 | UniProt: P78324
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5430-66 | Target: SHPS1 | UniProt: P78324 | TargetFullName: Tyrosine-protein phosphatase non-receptor type substrate 1 | Organisim: human | Apparent_Kd_M: 4.67E-11
Real
Aptamer SeqId: 5437-63 | Target: FABP | UniProt: P05413
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5437-63 | Target: FABP | UniProt: P05413 | TargetFullName: Fatty acid-binding protein; heart | Organisim: human | Apparent_Kd_M: 5.75E-13
Real
Aptamer SeqId: 5440-26 | Target: Troponin I skeletal fast twitch
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5440-26 | Target: Troponin I; skeletal; fast twitch | UniProt: P48788 | TargetFullName: Troponin I; fast skeletal muscle | Organisim: human | Apparent_Kd_M: 9.79E-12
Real
Aptamer SeqId: 5441-67 | Target: Troponin I | UniProt: P19429
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5441-67 | Target: Troponin I | UniProt: P19429 | TargetFullName: Troponin I; cardiac muscle | Organisim: human | Apparent_Kd_M: 8.64E-13
Real
Aptamer SeqId: 5443-62 | Target: ANP | UniProt: P01160
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5443-62 | Target: ANP | UniProt: P01160 | TargetFullName: Atrial natriuretic factor | Organisim: human | Apparent_Kd_M: 4.27E-11
Real
Aptamer SeqId: 5451-1 | Target: ALCAM | UniProt: Q13740
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5451-1 | Target: ALCAM | UniProt: Q13740 | TargetFullName: CD166 antigen | Organisim: human | Apparent_Kd_M: 1.58E-11
Real
Aptamer SeqId: 5452-71 | Target: ASGR1 | UniProt: P07306
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5452-71 | Target: ASGR1 | UniProt: P07306 | TargetFullName: Asialoglycoprotein receptor 1 | Organisim: human | Apparent_Kd_M: 1.33E-11
Real
Aptamer SeqId: 5456-59 | Target: CNDP1 | UniProt: Q96KN2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5456-59 | Target: CNDP1 | UniProt: Q96KN2 | TargetFullName: Beta-Ala-His dipeptidase | Organisim: human | Apparent_Kd_M: 2.2E-12
Real
Aptamer SeqId: 5457-5 | Target: COLEC12 | UniProt: Q5KU26
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5457-5 | Target: COLEC12 | UniProt: Q5KU26 | TargetFullName: Collectin-12 | Organisim: human | Apparent_Kd_M: 6.33E-12
Real
Aptamer SeqId: 5459-33 | Target: CYTN | UniProt: P01037
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5459-33 | Target: CYTN | UniProt: P01037 | TargetFullName: Cystatin-SN | Organisim: human | Apparent_Kd_M: 1.5E-11
Real
Aptamer SeqId: 5460-60 | Target: DEAD-box protein 19B | UniProt: Q9UMR2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5460-60 | Target: DEAD-box protein 19B | UniProt: Q9UMR2 | TargetFullName: ATP-dependent RNA helicase DDX19B | Organisim: human | Apparent_Kd_M: 1.3E-10
Real
Aptamer SeqId: 5462-62 | Target: Ficolin-3 | UniProt: O75636
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5462-62 | Target: Ficolin-3 | UniProt: O75636 | TargetFullName: Ficolin-3 | Organisim: human | Apparent_Kd_M: 5.63E-11
Real
Aptamer SeqId: 5463-22 | Target: GAS1 | UniProt: P54826
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5463-22 | Target: GAS1 | UniProt: P54826 | TargetFullName: Growth arrest-specific protein 1 | Organisim: human | Apparent_Kd_M: 8.14E-12
Real
Aptamer SeqId: 5464-52 | Target: GRB2 adapter protein | UniProt: P62993
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5464-52 | Target: GRB2 adapter protein | UniProt: P62993 | TargetFullName: Growth factor receptor-bound protein 2 | Organisim: human | Apparent_Kd_M: 9.65E-12
Real
Aptamer SeqId: 5465-32 | Target: H6ST1 | UniProt: O60243
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5465-32 | Target: H6ST1 | UniProt: O60243 | TargetFullName: Heparan-sulfate 6-O-sulfotransferase 1 | Organisim: human | Apparent_Kd_M: 1.8E-12
Real
Aptamer SeqId: 5467-15 | Target: HSP 90b | UniProt: P08238
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5467-15 | Target: HSP 90b | UniProt: P08238 | TargetFullName: Heat shock protein HSP 90-beta | Organisim: human | Apparent_Kd_M: 3.89E-11
Real
Aptamer SeqId: 5468-67 | Target: IL-17 RC | UniProt: Q8NAC3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5468-67 | Target: IL-17 RC | UniProt: Q8NAC3 | TargetFullName: Interleukin-17 receptor C | Organisim: human | Apparent_Kd_M: 2.13E-11
Real
Aptamer SeqId: 5475-10 | Target: PKC-B-II | UniProt: P05771
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5475-10 | Target: PKC-B-II | UniProt: P05771 | TargetFullName: Protein kinase C beta type (splice variant beta-II) | Organisim: human | Apparent_Kd_M: 6.26E-11
Real
Aptamer SeqId: 5476-66 | Target: PKC-G | UniProt: P05129
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5476-66 | Target: PKC-G | UniProt: P05129 | TargetFullName: Protein kinase C gamma type | Organisim: human | Apparent_Kd_M: 1.28E-11
Real
Aptamer SeqId: 5478-50 | Target: PSMA | UniProt: Q04609
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5478-50 | Target: PSMA | UniProt: Q04609 | TargetFullName: Glutamate carboxypeptidase 2 | Organisim: human | Apparent_Kd_M: 3.45E-11
Real
Aptamer SeqId: 5480-49 | Target: RANTES | UniProt: P13501
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5480-49 | Target: RANTES | UniProt: P13501 | TargetFullName: C-C motif chemokine 5 | Organisim: human | Apparent_Kd_M: 1.28E-11
Real
Aptamer SeqId: 5481-16 | Target: RASA1 | UniProt: P20936
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5481-16 | Target: RASA1 | UniProt: P20936 | TargetFullName: Ras GTPase-activating protein 1 | Organisim: human | Apparent_Kd_M: 7.21E-12
Real
Aptamer SeqId: 5483-1 | Target: RGMA | UniProt: Q96B86
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5483-1 | Target: RGMA | UniProt: Q96B86 | TargetFullName: Repulsive guidance molecule A | Organisim: human | Apparent_Kd_M: 2.3E-11
Real
Aptamer SeqId: 5484-63 | Target: RS3A | UniProt: P61247
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5484-63 | Target: RS3A | UniProt: P61247 | TargetFullName: 40S ribosomal protein S3a | Organisim: human | Apparent_Kd_M: 1.46E-11
Real
Aptamer SeqId: 5486-73 | Target: sICAM-2 | UniProt: P13598
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5486-73 | Target: sICAM-2 | UniProt: P13598 | TargetFullName: Intercellular adhesion molecule 2 | Organisim: human | Apparent_Kd_M: 9.91E-11
Real
Aptamer SeqId: 5487-7 | Target: SLAF7 | UniProt: Q9NQ25
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5487-7 | Target: SLAF7 | UniProt: Q9NQ25 | TargetFullName: SLAM family member 7 | Organisim: human | Apparent_Kd_M: 2.57E-12
Real
Aptamer SeqId: 5488-74 | Target: SRCN1 | UniProt: P12931
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5488-74 | Target: SRCN1 | UniProt: P12931 | TargetFullName: Proto-oncogene tyrosine-protein kinase Src | Organisim: human | Apparent_Kd_M: 1.68E-11
Real
Aptamer SeqId: 5489-18 | Target: Stress-induced-phosphoprotein 1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5489-18 | Target: Stress-induced-phosphoprotein 1 | UniProt: P31948 | TargetFullName: Stress-induced-phosphoprotein 1 | Organisim: human | Apparent_Kd_M: 3.68E-12
Real
Aptamer SeqId: 5490-53 | Target: Testican-1 | UniProt: Q08629
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5490-53 | Target: Testican-1 | UniProt: Q08629 | TargetFullName: Testican-1 | Organisim: human | Apparent_Kd_M: 7.4E-11
Real
Aptamer SeqId: 5491-12 | Target: Testican-2 | UniProt: Q92563
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5491-12 | Target: Testican-2 | UniProt: Q92563 | TargetFullName: Testican-2 | Organisim: human | Apparent_Kd_M: 1.26E-12
Real
Aptamer SeqId: 5493-17 | Target: WNK3 | UniProt: Q9BYP7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5493-17 | Target: WNK3 | UniProt: Q9BYP7 | TargetFullName: Serine/threonine-protein kinase WNK3 | Organisim: human | Apparent_Kd_M: 4.11E-12
Real
Aptamer SeqId: 5494-52 | Target: RUXF | UniProt: P62306
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5494-52 | Target: RUXF | UniProt: P62306 | TargetFullName: Small nuclear ribonucleoprotein F | Organisim: human | Apparent_Kd_M: 9.79E-12
Real
Aptamer SeqId: 5508-62 | Target: Cathepsin D | UniProt: P07339
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5508-62 | Target: Cathepsin D | UniProt: P07339 | TargetFullName: Cathepsin D | Organisim: human | Apparent_Kd_M: 1.75E-12
Real
Aptamer SeqId: 5509-7 | Target: EGF | UniProt: P01133
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5509-7 | Target: EGF | UniProt: P01133 | TargetFullName: Epidermal growth factor | Organisim: human | Apparent_Kd_M: 1.38E-10
Real
Aptamer SeqId: 5526-53 | Target: GITR | UniProt: Q9Y5U5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5526-53 | Target: GITR | UniProt: Q9Y5U5 | TargetFullName: Tumor necrosis factor receptor superfamily member 18 | Organisim: human | Apparent_Kd_M: 1.76E-10
Real
Aptamer SeqId: 5532-53 | Target: bFGF-R | UniProt: P11362
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5532-53 | Target: bFGF-R | UniProt: P11362 | TargetFullName: Fibroblast growth factor receptor 1 | Organisim: human | Apparent_Kd_M: 1.76E-12
Real
Aptamer SeqId: 5534-49 | Target: TRAIL R2 | UniProt: O14763
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5534-49 | Target: TRAIL R2 | UniProt: O14763 | TargetFullName: Tumor necrosis factor receptor superfamily member 10B | Organisim: human | Apparent_Kd_M: 1.28E-10
Real
Aptamer SeqId: 5542-22 | Target: NRP1 | UniProt: O14786
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5542-22 | Target: NRP1 | UniProt: O14786 | TargetFullName: Neuropilin-1 | Organisim: human | Apparent_Kd_M: 3.18E-12
Real
Aptamer SeqId: 5581-28 | Target: FGL1 | UniProt: Q08830
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5581-28 | Target: FGL1 | UniProt: Q08830 | TargetFullName: Fibrinogen-like protein 1 | Organisim: human | Apparent_Kd_M: 6.63E-11
Real
Aptamer SeqId: 5583-62 | Target: RYK | UniProt: P34925
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5583-62 | Target: RYK | UniProt: P34925 | TargetFullName: Tyrosine-protein kinase RYK | Organisim: human | Apparent_Kd_M: 6.507064E-11
Real
Aptamer SeqId: 5584-21 | Target: Holo-TC II | UniProt: P20062
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5584-21 | Target: Holo-TC II | UniProt: P20062 | TargetFullName: Holo-Transcobalamin-2 | Organisim: human | Apparent_Kd_M: 4.797939E-12
Real
Aptamer SeqId: 5586-66 | Target: MINP1 | UniProt: Q9UNW1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5586-66 | Target: MINP1 | UniProt: Q9UNW1 | TargetFullName: Multiple inositol polyphosphate phosphatase 1 | Organisim: human | Apparent_Kd_M: 4.742687E-12
Real
Aptamer SeqId: 5590-11 | Target: ZPLD1 | UniProt: Q8TCW7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5590-11 | Target: ZPLD1 | UniProt: Q8TCW7 | TargetFullName: Zona pellucida-like domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 1.53647E-11
Real
Aptamer SeqId: 5593-11 | Target: PDIA5 | UniProt: Q14554
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5593-11 | Target: PDIA5 | UniProt: Q14554 | TargetFullName: Protein disulfide-isomerase A5 | Organisim: human | Apparent_Kd_M: 1.564568E-11
Real
Aptamer SeqId: 5596-75 | Target: CD5 | UniProt: P06127
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5596-75 | Target: CD5 | UniProt: P06127 | TargetFullName: T-cell surface glycoprotein CD5 | Organisim: human | Apparent_Kd_M: 7.57E-11
Real
Aptamer SeqId: 5598-3 | Target: GREM2 | UniProt: Q9H772
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5598-3 | Target: GREM2 | UniProt: Q9H772 | TargetFullName: Gremlin-2 | Organisim: human | Apparent_Kd_M: 3.710353E-11
Real
Aptamer SeqId: 5599-88 | Target: PCYXL | UniProt: Q8NBM8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5599-88 | Target: PCYXL | UniProt: Q8NBM8 | TargetFullName: Prenylcysteine oxidase-like | Organisim: human | Apparent_Kd_M: 1.69197E-11
Real
Aptamer SeqId: 5601-2 | Target: PGRP-L | UniProt: Q96PD5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5601-2 | Target: PGRP-L | UniProt: Q96PD5 | TargetFullName: N-acetylmuramoyl-L-alanine amidase | Organisim: human | Apparent_Kd_M: 4.72E-11
Real
Aptamer SeqId: 5602-62 | Target: RNS10 | UniProt: Q5GAN6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5602-62 | Target: RNS10 | UniProt: Q5GAN6 | TargetFullName: Inactive ribonuclease-like protein 10 | Organisim: human | Apparent_Kd_M: 3.406101E-11
Real
Aptamer SeqId: 5604-30 | Target: HPSE | UniProt: Q9Y251
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5604-30 | Target: HPSE | UniProt: Q9Y251 | TargetFullName: Heparanase | Organisim: human | Apparent_Kd_M: 5.984992E-11
Real
Aptamer SeqId: 5605-77 | Target: MFNG | UniProt: O00587
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5605-77 | Target: MFNG | UniProt: O00587 | TargetFullName: Beta-1;3-N-acetylglucosaminyltransferase manic fringe | Organisim: human | Apparent_Kd_M: 8.188151E-12
Real
Aptamer SeqId: 5606-24 | Target: MFAP1 | UniProt: P55081
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5606-24 | Target: MFAP1 | UniProt: P55081 | TargetFullName: Microfibrillar-associated protein 1 | Organisim: human | Apparent_Kd_M: 4.329375E-12
Real
Aptamer SeqId: 5609-92 | Target: F19A5 | UniProt: Q7Z5A7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5609-92 | Target: F19A5 | UniProt: Q7Z5A7 | TargetFullName: Protein FAM19A5 | Organisim: human | Apparent_Kd_M: 4.54E-11
Real
Aptamer SeqId: 5610-32 | Target: CJ038 | UniProt: Q5VUB5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5610-32 | Target: CJ038 | UniProt: Q5VUB5 | TargetFullName: Protein FAM171A1 | Organisim: human | Apparent_Kd_M: 1.550745E-10
Real
Aptamer SeqId: 5611-56 | Target: D108B | UniProt: Q8NET1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5611-56 | Target: D108B | UniProt: Q8NET1 | TargetFullName: Beta-defensin 108B | Organisim: human | Apparent_Kd_M: 4.034996E-11
Real
Aptamer SeqId: 5612-16 | Target: HINT2 | UniProt: Q9BX68
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5612-16 | Target: HINT2 | UniProt: Q9BX68 | TargetFullName: Histidine triad nucleotide-binding protein 2; mitochondrial | Organisim: human | Apparent_Kd_M: 3.950975E-11
Real
Aptamer SeqId: 5613-75 | Target: NTAL | UniProt: Q9GZY6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5613-75 | Target: NTAL | UniProt: Q9GZY6 | TargetFullName: Linker for activation of T-cells family member 2 | Organisim: human | Apparent_Kd_M: 5.660116E-11
Real
Aptamer SeqId: 5614-44 | Target: CRH | UniProt: P06850
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5614-44 | Target: CRH | UniProt: P06850 | TargetFullName: Corticoliberin | Organisim: human | Apparent_Kd_M: 5.19E-12
Real
Aptamer SeqId: 5615-62 | Target: F172A | UniProt: Q8WUF8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5615-62 | Target: F172A | UniProt: Q8WUF8 | TargetFullName: Protein FAM172A | Organisim: human | Apparent_Kd_M: 1.181401E-10
Real
Aptamer SeqId: 5617-41 | Target: NPFF | UniProt: O15130
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5617-41 | Target: NPFF | UniProt: O15130 | TargetFullName: Pro-FMRFamide-related neuropeptide FF | Organisim: human | Apparent_Kd_M: 1.35448E-11
Real
Aptamer SeqId: 5618-50 | Target: FAM3B | UniProt: P58499
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5618-50 | Target: FAM3B | UniProt: P58499 | TargetFullName: Protein FAM3B | Organisim: human | Apparent_Kd_M: 3.83E-11
Real
Aptamer SeqId: 5620-13 | Target: AMD | UniProt: P19021
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5620-13 | Target: AMD | UniProt: P19021 | TargetFullName: Peptidyl-glycine alpha-amidating monooxygenase | Organisim: human | Apparent_Kd_M: 1.071204E-11
Real
Aptamer SeqId: 5621-64 | Target: THSD1 | UniProt: Q9NS62
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5621-64 | Target: THSD1 | UniProt: Q9NS62 | TargetFullName: Thrombospondin type-1 domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 3.789316E-11
Real
Aptamer SeqId: 5623-11 | Target: CLM1 | UniProt: Q8TDQ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5623-11 | Target: CLM1 | UniProt: Q8TDQ1 | TargetFullName: CMRF35-like molecule 1 | Organisim: human | Apparent_Kd_M: 1.938788E-11
Real
Aptamer SeqId: 5626-20 | Target: CTRC | UniProt: Q99895
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5626-20 | Target: CTRC | UniProt: Q99895 | TargetFullName: Chymotrypsin-C | Organisim: human | Apparent_Kd_M: 6.793299E-11
Real
Aptamer SeqId: 5627-53 | Target: GON1 | UniProt: P01148
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5627-53 | Target: GON1 | UniProt: P01148 | TargetFullName: Progonadoliberin-1 | Organisim: human | Apparent_Kd_M: 2.114084E-11
Real
Aptamer SeqId: 5628-21 | Target: SEM3G | UniProt: Q9NS98
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5628-21 | Target: SEM3G | UniProt: Q9NS98 | TargetFullName: Semaphorin-3G | Organisim: human | Apparent_Kd_M: 2.096476E-11
Real
Aptamer SeqId: 5629-58 | Target: NKG2A | UniProt: P26715
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5629-58 | Target: NKG2A | UniProt: P26715 | TargetFullName: NKG2-A/NKG2-B type II integral membrane protein | Organisim: human | Apparent_Kd_M: 5.382212E-11
Real
Aptamer SeqId: 5630-48 | Target: CM35H | UniProt: Q9UGN4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5630-48 | Target: CM35H | UniProt: Q9UGN4 | TargetFullName: CMRF35-like molecule 8 | Organisim: human | Apparent_Kd_M: 5.58E-12
Real
Aptamer SeqId: 5631-83 | Target: MOTI | UniProt: P12872
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5631-83 | Target: MOTI | UniProt: P12872 | TargetFullName: Promotilin | Organisim: human | Apparent_Kd_M: 1.021714E-10
Real
Aptamer SeqId: 5632-6 | Target: CRAC1 | UniProt: Q9NQ79
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5632-6 | Target: CRAC1 | UniProt: Q9NQ79 | TargetFullName: Cartilage acidic protein 1 | Organisim: human | Apparent_Kd_M: 1.114244E-10
Real
Aptamer SeqId: 5634-39 | Target: OFUT1 | UniProt: Q9H488
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5634-39 | Target: OFUT1 | UniProt: Q9H488 | TargetFullName: GDP-fucose protein O-fucosyltransferase 1 | Organisim: human | Apparent_Kd_M: 1.080884E-11
Real
Aptamer SeqId: 5636-10 | Target: MFAP4 | UniProt: P55083
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5636-10 | Target: MFAP4 | UniProt: P55083 | TargetFullName: Microfibril-associated glycoprotein 4 | Organisim: human | Apparent_Kd_M: 1.088905E-10
Real
Aptamer SeqId: 5637-81 | Target: NTNG1 | UniProt: Q9Y2I2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5637-81 | Target: NTNG1 | UniProt: Q9Y2I2 | TargetFullName: Netrin-G1 | Organisim: human | Apparent_Kd_M: 2.173556E-11
Real
Aptamer SeqId: 5638-23 | Target: GT251 | UniProt: Q8NBJ5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5638-23 | Target: GT251 | UniProt: Q8NBJ5 | TargetFullName: Procollagen galactosyltransferase 1 | Organisim: human | Apparent_Kd_M: 9.092331E-11
Real
Aptamer SeqId: 5639-49 | Target: NETO1 | UniProt: Q8TDF5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5639-49 | Target: NETO1 | UniProt: Q8TDF5 | TargetFullName: Neuropilin and tolloid-like protein 1 | Organisim: human | Apparent_Kd_M: 3.02E-11
Real
Aptamer SeqId: 5643-2 | Target: LCN8 | UniProt: Q6JVE9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5643-2 | Target: LCN8 | UniProt: Q6JVE9 | TargetFullName: Epididymal-specific lipocalin-8 | Organisim: human | Apparent_Kd_M: 1.550936E-11
Real
Aptamer SeqId: 5644-60 | Target: RNAS4 | UniProt: P34096
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5644-60 | Target: RNAS4 | UniProt: P34096 | TargetFullName: Ribonuclease 4 | Organisim: human | Apparent_Kd_M: 4.441821E-11
Real
Aptamer SeqId: 5646-20 | Target: RNAS6 | UniProt: Q93091
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5646-20 | Target: RNAS6 | UniProt: Q93091 | TargetFullName: Ribonuclease K6 | Organisim: human | Apparent_Kd_M: 3.18E-11
Real
Aptamer SeqId: 5648-28 | Target: CTRB2 | UniProt: Q6GPI1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5648-28 | Target: CTRB2 | UniProt: Q6GPI1 | TargetFullName: Chymotrypsinogen B2 | Organisim: human | Apparent_Kd_M: 1.050203E-11
Real
Aptamer SeqId: 5649-83 | Target: PSG4 | UniProt: Q00888
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5649-83 | Target: PSG4 | UniProt: Q00888 | TargetFullName: Pregnancy-specific beta-1-glycoprotein 4 | Organisim: human | Apparent_Kd_M: 1.056322E-11
Real
Aptamer SeqId: 5650-9 | Target: PDIA6 | UniProt: Q15084
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5650-9 | Target: PDIA6 | UniProt: Q15084 | TargetFullName: Protein disulfide-isomerase A6 | Organisim: human | Apparent_Kd_M: 4.48748E-12
Real
Aptamer SeqId: 5651-50 | Target: PSG7 | UniProt: Q13046
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5651-50 | Target: PSG7 | UniProt: Q13046 | TargetFullName: Putative pregnancy-specific beta-1-glycoprotein 7 | Organisim: human | Apparent_Kd_M: 5.86E-12
Real
Aptamer SeqId: 5653-23 | Target: PRS37 | UniProt: A4D1T9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5653-23 | Target: PRS37 | UniProt: A4D1T9 | TargetFullName: Probable inactive serine protease 37 | Organisim: human | Apparent_Kd_M: 1.602967E-11
Real
Aptamer SeqId: 5654-70 | Target: TMX3 | UniProt: Q96JJ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5654-70 | Target: TMX3 | UniProt: Q96JJ7 | TargetFullName: Protein disulfide-isomerase TMX3 | Organisim: human | Apparent_Kd_M: 2.264108E-11
Real
Aptamer SeqId: 5656-53 | Target: PP11 | UniProt: P21128
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5656-53 | Target: PP11 | UniProt: P21128 | TargetFullName: Poly(U)-specific endoribonuclease | Organisim: human | Apparent_Kd_M: 4.860815E-11
Real
Aptamer SeqId: 5657-28 | Target: SIA4A | UniProt: Q11201
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5657-28 | Target: SIA4A | UniProt: Q11201 | TargetFullName: CMP-N-acetylneuraminate-beta-galactosamide-alpha-2;3-sialyltransferase 1 | Organisim: human | Apparent_Kd_M: 2.21399E-11
Real
Aptamer SeqId: 5658-64 | Target: coagulation factor XIII B
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5658-64 | Target: coagulation factor XIII B | UniProt: P05160 | TargetFullName: Coagulation factor XIII B chain | Organisim: human | Apparent_Kd_M: 3.31465E-11
Real
Aptamer SeqId: 5659-11 | Target: TRH | UniProt: P20396
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5659-11 | Target: TRH | UniProt: P20396 | TargetFullName: Pro-Thyrotropin-releasing hormone | Organisim: human | Apparent_Kd_M: 3.427851E-11
Real
Aptamer SeqId: 5660-51 | Target: SOD3 | UniProt: P08294
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5660-51 | Target: SOD3 | UniProt: P08294 | TargetFullName: Extracellular superoxide dismutase Cu-Zn | Organisim: human | Apparent_Kd_M: 4.93E-12
Real
Aptamer SeqId: 5661-15 | Target: IL-18 | UniProt: Q14116
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5661-15 | Target: IL-18 | UniProt: Q14116 | TargetFullName: Interleukin-18 | Organisim: human | Apparent_Kd_M: 1.481881E-10
Real
Aptamer SeqId: 5663-18 | Target: PF4V | UniProt: P10720
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5663-18 | Target: PF4V | UniProt: P10720 | TargetFullName: Platelet factor 4 variant | Organisim: human | Apparent_Kd_M: 2.889615E-11
Real
Aptamer SeqId: 5664-57 | Target: D106A | UniProt: Q8N104
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5664-57 | Target: D106A | UniProt: Q8N104 | TargetFullName: Beta-defensin 106 | Organisim: human | Apparent_Kd_M: 2.472107E-11
Real
Aptamer SeqId: 5667-3 | Target: SEM3B | UniProt: Q13214
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5667-3 | Target: SEM3B | UniProt: Q13214 | TargetFullName: Semaphorin-3B | Organisim: human | Apparent_Kd_M: 2.49395E-11
Real
Aptamer SeqId: 5669-26 | Target: SIRB2 | UniProt: Q5JXA9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5669-26 | Target: SIRB2 | UniProt: Q5JXA9 | TargetFullName: Signal-regulatory protein beta-2 | Organisim: human | Apparent_Kd_M: 1.39E-10
Real
Aptamer SeqId: 5671-1 | Target: Chymotrypsin | UniProt: P17538
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5671-1 | Target: Chymotrypsin | UniProt: P17538 | TargetFullName: Chymotrypsinogen B | Organisim: human | Apparent_Kd_M: 1.283621E-10
Real
Aptamer SeqId: 5675-6 | Target: Tenascin | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5675-6 | Target: Tenascin | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 1.808638E-10
Real
Aptamer SeqId: 5676-54 | Target: ASIP | UniProt: P42127
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5676-54 | Target: ASIP | UniProt: P42127 | TargetFullName: Agouti-signaling protein | Organisim: human | Apparent_Kd_M: 8.547198E-11
Real
Aptamer SeqId: 5677-15 | Target: CB066 | UniProt: Q6UXQ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5677-15 | Target: CB066 | UniProt: Q6UXQ4 | TargetFullName: Uncharacterized protein C2orf66 | Organisim: human | Apparent_Kd_M: 1.281353E-11
Real
Aptamer SeqId: 5679-16 | Target: HBD-3 | UniProt: P81534
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5679-16 | Target: HBD-3 | UniProt: P81534 | TargetFullName: Beta-defensin 103 | Organisim: human | Apparent_Kd_M: 7.6973E-11
Real
Aptamer SeqId: 5680-54 | Target: OBP2B | UniProt: Q9NPH6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5680-54 | Target: OBP2B | UniProt: Q9NPH6 | TargetFullName: Odorant-binding protein 2b | Organisim: human | Apparent_Kd_M: 2.494725E-11
Real
Aptamer SeqId: 5682-13 | Target: VASN | UniProt: Q6EMK4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5682-13 | Target: VASN | UniProt: Q6EMK4 | TargetFullName: Vasorin | Organisim: human | Apparent_Kd_M: 2.322254E-11
Real
Aptamer SeqId: 5687-5 | Target: GLU2B | UniProt: P14314
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5687-5 | Target: GLU2B | UniProt: P14314 | TargetFullName: Glucosidase 2 subunit beta | Organisim: human | Apparent_Kd_M: 1.39267E-11
Real
Aptamer SeqId: 5688-65 | Target: CBLN4 | UniProt: Q9NTU7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5688-65 | Target: CBLN4 | UniProt: Q9NTU7 | TargetFullName: Cerebellin-4 | Organisim: human | Apparent_Kd_M: 2.129453E-11
Real
Aptamer SeqId: 5689-1 | Target: DB112 | UniProt: Q30KQ8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5689-1 | Target: DB112 | UniProt: Q30KQ8 | TargetFullName: Beta-defensin 112 | Organisim: human | Apparent_Kd_M: 3.24E-12
Real
Aptamer SeqId: 5690-49 | Target: TUFT1 | UniProt: Q9NNX1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5690-49 | Target: TUFT1 | UniProt: Q9NNX1 | TargetFullName: Tuftelin | Organisim: human | Apparent_Kd_M: 2.55369E-11
Real
Aptamer SeqId: 5691-2 | Target: CRLD2 | UniProt: Q9H0B8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5691-2 | Target: CRLD2 | UniProt: Q9H0B8 | TargetFullName: Cysteine-rich secretory protein LCCL domain-containing 2 | Organisim: human | Apparent_Kd_M: 3.742972E-11
Real
Aptamer SeqId: 5698-60 | Target: Tenascin-X | UniProt: P22105
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5698-60 | Target: Tenascin-X | UniProt: P22105 | TargetFullName: Tenascin-X | Organisim: human | Apparent_Kd_M: 3.766822E-11
Real
Aptamer SeqId: 5701-81 | Target: Tetranectin | UniProt: P05452
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5701-81 | Target: Tetranectin | UniProt: P05452 | TargetFullName: Tetranectin | Organisim: human | Apparent_Kd_M: 2.41E-11
Real
Aptamer SeqId: 5703-26 | Target: NOE1 | UniProt: Q99784
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5703-26 | Target: NOE1 | UniProt: Q99784 | TargetFullName: Noelin | Organisim: human | Apparent_Kd_M: 2.22E-11
Real
Aptamer SeqId: 5704-74 | Target: Granzyme M | UniProt: P51124
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5704-74 | Target: Granzyme M | UniProt: P51124 | TargetFullName: Granzyme M | Organisim: human | Apparent_Kd_M: 9.425172E-12
Real
Aptamer SeqId: 5707-55 | Target: ELK3 | UniProt: P41970
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5707-55 | Target: ELK3 | UniProt: P41970 | TargetFullName: ETS domain-containing protein Elk-3 | Organisim: human | Apparent_Kd_M: 6.757889E-11
Real
Aptamer SeqId: 5708-1 | Target: LEAP2 | UniProt: Q969E1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5708-1 | Target: LEAP2 | UniProt: Q969E1 | TargetFullName: Liver-expressed antimicrobial peptide 2 | Organisim: human | Apparent_Kd_M: 1.44E-11
Real
Aptamer SeqId: 5713-9 | Target: IFN-lambda 3 | UniProt: Q8IZI9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5713-9 | Target: IFN-lambda 3 | UniProt: Q8IZI9 | TargetFullName: Interferon lambda-3 | Organisim: human | Apparent_Kd_M: 3.469201E-12
Real
Aptamer SeqId: 5714-88 | Target: IFNA6 | UniProt: P05013
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5714-88 | Target: IFNA6 | UniProt: P05013 | TargetFullName: Interferon alpha-6 | Organisim: human | Apparent_Kd_M: 1.750382E-10
Real
Aptamer SeqId: 5715-4 | Target: ABHEA | UniProt: Q9BUJ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5715-4 | Target: ABHEA | UniProt: Q9BUJ0 | TargetFullName: Protein ABHD14A | Organisim: human | Apparent_Kd_M: 5.274607E-11
Real
Aptamer SeqId: 5716-49 | Target: CSAG1 | UniProt: Q6PB30
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5716-49 | Target: CSAG1 | UniProt: Q6PB30 | TargetFullName: Putative chondrosarcoma-associated gene 1 protein | Organisim: human | Apparent_Kd_M: 2.716691E-11
Real
Aptamer SeqId: 5717-2 | Target: CILP | UniProt: O75339
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5717-2 | Target: CILP | UniProt: O75339 | TargetFullName: Cartilage intermediate layer protein 1 | Organisim: human | Apparent_Kd_M: 3.790369E-11
Real
Aptamer SeqId: 5719-66 | Target: CI061 | UniProt: Q15884
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5719-66 | Target: CI061 | UniProt: Q15884 | TargetFullName: Protein FAM189A2 | Organisim: human | Apparent_Kd_M: 1.65E-11
Real
Aptamer SeqId: 5722-78 | Target: Prolylcarboxypeptidase | UniProt: P42785
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5722-78 | Target: Prolylcarboxypeptidase | UniProt: P42785 | TargetFullName: Lysosomal Pro-X carboxypeptidase | Organisim: human | Apparent_Kd_M: 1.15948E-11
Real
Aptamer SeqId: 5723-4 | Target: INSL3 | UniProt: P51460
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5723-4 | Target: INSL3 | UniProt: P51460 | TargetFullName: Insulin-like 3 | Organisim: human | Apparent_Kd_M: 1.608226E-11
Real
Aptamer SeqId: 5724-58 | Target: SBSN | UniProt: Q6UWP8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5724-58 | Target: SBSN | UniProt: Q6UWP8 | TargetFullName: Suprabasin | Organisim: human | Apparent_Kd_M: 6.326337E-11
Real
Aptamer SeqId: 5726-49 | Target: SG11A | UniProt: Q6PDA7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5726-49 | Target: SG11A | UniProt: Q6PDA7 | TargetFullName: Sperm-associated antigen 11A | Organisim: human | Apparent_Kd_M: 1.151562E-11
Real
Aptamer SeqId: 5727-35 | Target: B3GLT | UniProt: Q6Y288
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5727-35 | Target: B3GLT | UniProt: Q6Y288 | TargetFullName: Beta-1;3-glucosyltransferase | Organisim: human | Apparent_Kd_M: 6.733666E-12
Real
Aptamer SeqId: 5728-60 | Target: FCRL1 | UniProt: Q96LA6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5728-60 | Target: FCRL1 | UniProt: Q96LA6 | TargetFullName: Fc receptor-like protein 1 | Organisim: human | Apparent_Kd_M: 9.14E-12
Real
Aptamer SeqId: 5730-60 | Target: BRAK | UniProt: O95715
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5730-60 | Target: BRAK | UniProt: O95715 | TargetFullName: C-X-C motif chemokine 14 | Organisim: human | Apparent_Kd_M: 3.527827E-11
Real
Aptamer SeqId: 5731-1 | Target: ISK6 | UniProt: Q6UWN8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5731-1 | Target: ISK6 | UniProt: Q6UWN8 | TargetFullName: Serine protease inhibitor Kazal-type 6 | Organisim: human | Apparent_Kd_M: 1.194348E-11
Real
Aptamer SeqId: 5734-13 | Target: nectin-4 | UniProt: Q96NY8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5734-13 | Target: nectin-4 | UniProt: Q96NY8 | TargetFullName: Nectin-4 | Organisim: human | Apparent_Kd_M: 4.717683E-12
Real
Aptamer SeqId: 5735-54 | Target: C1GLC | UniProt: Q96EU7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5735-54 | Target: C1GLC | UniProt: Q96EU7 | TargetFullName: C1GALT1-specific chaperone 1 | Organisim: human | Apparent_Kd_M: 9.579592E-12
Real
Aptamer SeqId: 5736-1 | Target: TRML2 | UniProt: Q5T2D2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5736-1 | Target: TRML2 | UniProt: Q5T2D2 | TargetFullName: Trem-like transcript 2 protein | Organisim: human | Apparent_Kd_M: 2.574806E-12
Real
Aptamer SeqId: 5737-61 | Target: SEM4D | UniProt: Q92854
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5737-61 | Target: SEM4D | UniProt: Q92854 | TargetFullName: Semaphorin-4D | Organisim: human | Apparent_Kd_M: 8.411657E-12
Real
Aptamer SeqId: 5738-25 | Target: Tenascin | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5738-25 | Target: Tenascin | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 8.729183E-11
Real
Aptamer SeqId: 5739-75 | Target: KTDAP | UniProt: P60985
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5739-75 | Target: KTDAP | UniProt: P60985 | TargetFullName: Keratinocyte differentiation-associated protein | Organisim: human | Apparent_Kd_M: 4.0188E-11
Real
Aptamer SeqId: 5740-17 | Target: ROBO1 | UniProt: Q9Y6N7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5740-17 | Target: ROBO1 | UniProt: Q9Y6N7 | TargetFullName: Roundabout homolog 1 | Organisim: human | Apparent_Kd_M: 8.638373E-12
Real
Aptamer SeqId: 5742-14 | Target: PPA6 | UniProt: Q9NPH0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5742-14 | Target: PPA6 | UniProt: Q9NPH0 | TargetFullName: Lysophosphatidic acid phosphatase type 6 | Organisim: human | Apparent_Kd_M: 7.672495E-12
Real
Aptamer SeqId: 5743-82 | Target: CART | UniProt: Q16568
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5743-82 | Target: CART | UniProt: Q16568 | TargetFullName: Cocaine- and amphetamine-regulated transcript protein | Organisim: human | Apparent_Kd_M: 1.04362E-10
Real
Aptamer SeqId: 5744-12 | Target: CA056 | UniProt: Q9BUN1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5744-12 | Target: CA056 | UniProt: Q9BUN1 | TargetFullName: Protein MENT | Organisim: human | Apparent_Kd_M: 7.794186E-12
Real
Aptamer SeqId: 5745-64 | Target: PI15 | UniProt: O43692
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5745-64 | Target: PI15 | UniProt: O43692 | TargetFullName: Peptidase inhibitor 15 | Organisim: human | Apparent_Kd_M: 8.871513E-11
Real
Aptamer SeqId: 5748-20 | Target: Acid ceramidase | UniProt: Q13510
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5748-20 | Target: Acid ceramidase | UniProt: Q13510 | TargetFullName: Acid ceramidase | Organisim: human | Apparent_Kd_M: 1.065025E-10
Real
Aptamer SeqId: 5749-53 | Target: COL | UniProt: P04118
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5749-53 | Target: COL | UniProt: P04118 | TargetFullName: Colipase | Organisim: human | Apparent_Kd_M: 4.397143E-11
Real
Aptamer SeqId: 5751-14 | Target: HCCR-1 | UniProt: Q6P1Q0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5751-14 | Target: HCCR-1 | UniProt: Q6P1Q0 | TargetFullName: LETM1 domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 2.190788E-11
Real
Aptamer SeqId: 5752-63 | Target: SUSD3 | UniProt: Q96L08
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5752-63 | Target: SUSD3 | UniProt: Q96L08 | TargetFullName: Sushi domain-containing protein 3 | Organisim: human | Apparent_Kd_M: 1.072831E-11
Real
Aptamer SeqId: 5753-21 | Target: F19A1 | UniProt: Q7Z5A9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5753-21 | Target: F19A1 | UniProt: Q7Z5A9 | TargetFullName: Protein FAM19A1 | Organisim: human | Apparent_Kd_M: 8.166987E-11
Real
Aptamer SeqId: 5754-76 | Target: INSL6 | UniProt: Q9Y581
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5754-76 | Target: INSL6 | UniProt: Q9Y581 | TargetFullName: Insulin-like peptide INSL6 | Organisim: human | Apparent_Kd_M: 4.824118E-11
Real
Aptamer SeqId: 5755-29 | Target: GIP | UniProt: P09681
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5755-29 | Target: GIP | UniProt: P09681 | TargetFullName: Gastric inhibitory polypeptide | Organisim: human | Apparent_Kd_M: 1.79E-11
Real
Aptamer SeqId: 5756-66 | Target: PAPP2 | UniProt: Q9BXP8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5756-66 | Target: PAPP2 | UniProt: Q9BXP8 | TargetFullName: Pappalysin-2 | Organisim: human | Apparent_Kd_M: 5.652476E-11
Real
Aptamer SeqId: 5757-45 | Target: GNAS3 | UniProt: O95467
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5757-45 | Target: GNAS3 | UniProt: O95467 | TargetFullName: Neuroendocrine secretory protein 55 | Organisim: human | Apparent_Kd_M: 9.435249E-12
Real
Aptamer SeqId: 5758-49 | Target: kallikrein 9 | UniProt: Q9UKQ9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5758-49 | Target: kallikrein 9 | UniProt: Q9UKQ9 | TargetFullName: Kallikrein-9 | Organisim: human | Apparent_Kd_M: 2.04435E-11
Real
Aptamer SeqId: 5762-35 | Target: Sperm-associated antigen 11
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5762-35 | Target: Sperm-associated antigen 11 | UniProt: Q08648 | TargetFullName: Sperm-associated antigen 11B | Organisim: human | Apparent_Kd_M: 4.057682E-11
Real
Aptamer SeqId: 5763-67 | Target: HBD-4 | UniProt: Q8WTQ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5763-67 | Target: HBD-4 | UniProt: Q8WTQ1 | TargetFullName: Beta-defensin 104 | Organisim: human | Apparent_Kd_M: 6.307552E-11
Real
Aptamer SeqId: 5764-4 | Target: GALT2 | UniProt: Q10471
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5764-4 | Target: GALT2 | UniProt: Q10471 | TargetFullName: Polypeptide N-acetylgalactosaminyltransferase 2 | Organisim: human | Apparent_Kd_M: 1.796379E-10
Real
Aptamer SeqId: 5765-53 | Target: DB121 | UniProt: Q5J5C9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5765-53 | Target: DB121 | UniProt: Q5J5C9 | TargetFullName: Beta-defensin 121 | Organisim: human | Apparent_Kd_M: 2.622461E-11
Real
Aptamer SeqId: 5792-8 | Target: AFP | UniProt: P02771
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5792-8 | Target: AFP | UniProt: P02771 | TargetFullName: alpha-Fetoprotein | Organisim: human | Apparent_Kd_M: 2.63E-10
Real
Aptamer SeqId: 5798-3 | Target: BID | UniProt: P55957
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5798-3 | Target: BID | UniProt: P55957 | TargetFullName: BH3-interacting domain death agonist | Organisim: human | Apparent_Kd_M: 1.56E-10
Real
Aptamer SeqId: 5801-72 | Target: b-NGF | UniProt: P01138
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5801-72 | Target: b-NGF | UniProt: P01138 | TargetFullName: beta-nerve growth factor | Organisim: human | Apparent_Kd_M: 9.57E-12
Real
Aptamer SeqId: 5803-24 | Target: C3d | UniProt: P01024
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5803-24 | Target: C3d | UniProt: P01024 | TargetFullName: Complement C3d fragment | Organisim: human | Apparent_Kd_M: 7.62E-12
Real
Aptamer SeqId: 5807-77 | Target: CD70 | UniProt: P32970
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5807-77 | Target: CD70 | UniProt: P32970 | TargetFullName: CD70 antigen | Organisim: human | Apparent_Kd_M: 9.24E-11
Real
Aptamer SeqId: 5810-25 | Target: Cripto | UniProt: P13385
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5810-25 | Target: Cripto | UniProt: P13385 | TargetFullName: Teratocarcinoma-derived growth factor 1 | Organisim: human | Apparent_Kd_M: 3.13E-11
Real
Aptamer SeqId: 5813-58 | Target: Epo | UniProt: P01588
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5813-58 | Target: Epo | UniProt: P01588 | TargetFullName: Erythropoietin | Organisim: human | Apparent_Kd_M: 3.74E-12
Real
Aptamer SeqId: 5822-22 | Target: GDNF | UniProt: P39905
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5822-22 | Target: GDNF | UniProt: P39905 | TargetFullName: Glial cell line-derived neurotrophic factor | Organisim: human | Apparent_Kd_M: 1.84E-11
Real
Aptamer SeqId: 5825-49 | Target: IFN-g R1 | UniProt: P15260
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5825-49 | Target: IFN-g R1 | UniProt: P15260 | TargetFullName: Interferon gamma receptor 1 | Organisim: human | Apparent_Kd_M: 1.02E-10
Real
Aptamer SeqId: 5834-18 | Target: IL-9 | UniProt: P15248
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5834-18 | Target: IL-9 | UniProt: P15248 | TargetFullName: Interleukin-9 | Organisim: human | Apparent_Kd_M: 2.41E-12
Real
Aptamer SeqId: 5837-49 | Target: LIF sR | UniProt: P42702
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5837-49 | Target: LIF sR | UniProt: P42702 | TargetFullName: Leukemia inhibitory factor receptor | Organisim: human | Apparent_Kd_M: 1.51E-12
Real
Aptamer SeqId: 5843-60 | Target: NG36 | UniProt: Q96KQ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5843-60 | Target: NG36 | UniProt: Q96KQ7 | TargetFullName: Histone-lysine N-methyltransferase EHMT2 | Organisim: human | Apparent_Kd_M: 2.78E-11
Real
Aptamer SeqId: 5852-6 | Target: S100A12 | UniProt: P80511
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5852-6 | Target: S100A12 | UniProt: P80511 | TargetFullName: Protein S100-A12 | Organisim: human | Apparent_Kd_M: 9.53E-12
Real
Aptamer SeqId: 5854-60 | Target: tau | UniProt: P10636
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5854-60 | Target: tau | UniProt: P10636 | TargetFullName: Microtubule-associated protein tau | Organisim: human | Apparent_Kd_M: 3.31E-11
Real
Aptamer SeqId: 5858-6 | Target: 14-3-3 protein zeta/delta | UniProt: P63104
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5858-6 | Target: 14-3-3 protein zeta/delta | UniProt: P63104 | TargetFullName: 14-3-3 protein zeta/delta | Organisim: human | Apparent_Kd_M: 2.73E-12
Real
Aptamer SeqId: 5861-78 | Target: 3HAO | UniProt: P46952
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5861-78 | Target: 3HAO | UniProt: P46952 | TargetFullName: 3-hydroxyanthranilate 3;4-dioxygenase | Organisim: human | Apparent_Kd_M: 7.28E-11
Real
Aptamer SeqId: 5864-10 | Target: aldolase A | UniProt: P04075
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5864-10 | Target: aldolase A | UniProt: P04075 | TargetFullName: Fructose-bisphosphate aldolase A | Organisim: human | Apparent_Kd_M: 2.37E-11
Real
Aptamer SeqId: 5867-60 | Target: ARGI1 | UniProt: P05089
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5867-60 | Target: ARGI1 | UniProt: P05089 | TargetFullName: Arginase-1 | Organisim: human | Apparent_Kd_M: 2.63E-10
Real
Aptamer SeqId: 5870-23 | Target: BAD | UniProt: Q92934
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5870-23 | Target: BAD | UniProt: Q92934 | TargetFullName: Bcl2-associated agonist of cell death | Organisim: human | Apparent_Kd_M: 1.05E-11
Real
Aptamer SeqId: 5879-51 | Target: Dynactin subunit 2 | UniProt: Q13561
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5879-51 | Target: Dynactin subunit 2 | UniProt: Q13561 | TargetFullName: Dynactin subunit 2 | Organisim: human | Apparent_Kd_M: 1.59E-11
Real
Aptamer SeqId: 5882-34 | Target: EF-1-beta | UniProt: P24534
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5882-34 | Target: EF-1-beta | UniProt: P24534 | TargetFullName: Elongation factor 1-beta | Organisim: human | Apparent_Kd_M: 4.29E-11
Real
Aptamer SeqId: 5885-55 | Target: eIF-4H | UniProt: Q15056
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5885-55 | Target: eIF-4H | UniProt: Q15056 | TargetFullName: Eukaryotic translation initiation factor 4H | Organisim: human | Apparent_Kd_M: 8.87E-12
Real
Aptamer SeqId: 5888-29 | Target: eIF-5A-1 | UniProt: P63241
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5888-29 | Target: eIF-5A-1 | UniProt: P63241 | TargetFullName: Eukaryotic translation initiation factor 5A-1 | Organisim: human | Apparent_Kd_M: 1.39E-10
Real
Aptamer SeqId: 5897-58 | Target: Gastrin-releasing peptide
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5897-58 | Target: Gastrin-releasing peptide | UniProt: P07492 | TargetFullName: Gastrin-releasing peptide | Organisim: human | Apparent_Kd_M: 6.83E-11
Real
Aptamer SeqId: 5900-11 | Target: HINT1 | UniProt: P49773
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5900-11 | Target: HINT1 | UniProt: P49773 | TargetFullName: Histidine triad nucleotide-binding protein 1 | Organisim: human | Apparent_Kd_M: 1.28E-10
Real
Aptamer SeqId: 5903-91 | Target: HSP70 protein 8 | UniProt: P11142
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5903-91 | Target: HSP70 protein 8 | UniProt: P11142 | TargetFullName: Heat shock cognate 71 kDa protein | Organisim: human | Apparent_Kd_M: 1.84E-11
Real
Aptamer SeqId: 5909-51 | Target: Nucleoside diphosphate kinase A
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5909-51 | Target: Nucleoside diphosphate kinase A | UniProt: P15531 | TargetFullName: Nucleoside diphosphate kinase A | Organisim: human | Apparent_Kd_M: 2.95E-11
Real
Aptamer SeqId: 5915-58 | Target: PEX5 | UniProt: P50542
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5915-58 | Target: PEX5 | UniProt: P50542 | TargetFullName: Peroxisomal targeting signal 1 receptor | Organisim: human | Apparent_Kd_M: 4.04E-11
Real
Aptamer SeqId: 5918-5 | Target: PSME1 | UniProt: Q06323
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5918-5 | Target: PSME1 | UniProt: Q06323 | TargetFullName: Proteasome activator complex subunit 1 | Organisim: human | Apparent_Kd_M: 5.1E-12
Real
Aptamer SeqId: 5927-4 | Target: WISP-3 | UniProt: O95389
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5927-4 | Target: WISP-3 | UniProt: O95389 | TargetFullName: WNT1-inducible-signaling pathway protein 3 | Organisim: human | Apparent_Kd_M: 2.92E-11
Real
Aptamer SeqId: 5934-1 | Target: Ferritin | UniProt: P02794|P02792
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5934-1 | Target: Ferritin | UniProt: P02794|P02792 | TargetFullName: Ferritin | Organisim: human | Apparent_Kd_M: 6.31E-12
Real
Aptamer SeqId: 5936-53 | Target: TNF-a | UniProt: P01375
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5936-53 | Target: TNF-a | UniProt: P01375 | TargetFullName: Tumor necrosis factor | Organisim: human | Apparent_Kd_M: 3.65E-12
Real
Aptamer SeqId: 5939-42 | Target: TWEAK | UniProt: O43508
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5939-42 | Target: TWEAK | UniProt: O43508 | TargetFullName: Tumor necrosis factor ligand superfamily member 12 | Organisim: human | Apparent_Kd_M: 2.26E-11
Real
Aptamer SeqId: 5947-90 | Target: Tpo | UniProt: P40225
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5947-90 | Target: Tpo | UniProt: P40225 | TargetFullName: Thrombopoietin | Organisim: human | Apparent_Kd_M: 6.52E-12
Real
Aptamer SeqId: 5954-62 | Target: PTH | UniProt: P01270
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5954-62 | Target: PTH | UniProt: P01270 | TargetFullName: Parathyroid hormone | Organisim: human | Apparent_Kd_M: 1.64E-12
Real
Aptamer SeqId: 5957-30 | Target: Somatostatin-28 | UniProt: P61278
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5957-30 | Target: Somatostatin-28 | UniProt: P61278 | TargetFullName: Somatostatin-28 | Organisim: human | Apparent_Kd_M: 3.97E-11
Real
Aptamer SeqId: 5960-49 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5960-49 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 9.810613E-11
Real
Aptamer SeqId: 5963-9 | Target: Dermokine | UniProt: Q6E0U4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5963-9 | Target: Dermokine | UniProt: Q6E0U4 | TargetFullName: Dermokine | Organisim: human | Apparent_Kd_M: 4.8571E-11
Real
Aptamer SeqId: 5980-55 | Target: BOLA3 | UniProt: Q53S33
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5980-55 | Target: BOLA3 | UniProt: Q53S33 | TargetFullName: BolA-like protein 3 | Organisim: human | Apparent_Kd_M: 1.08E-12
Real
Aptamer SeqId: 5981-6 | Target: ES1 | UniProt: P30042
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5981-6 | Target: ES1 | UniProt: P30042 | TargetFullName: ES1 protein homolog; mitochondrial | Organisim: human | Apparent_Kd_M: 2.273871E-10
Real
Aptamer SeqId: 5988-49 | Target: LIGHT | UniProt: O43557
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 5988-49 | Target: LIGHT | UniProt: O43557 | TargetFullName: Tumor necrosis factor ligand superfamily member 14 | Organisim: human | Apparent_Kd_M: 2.29E-11
Real
Aptamer SeqId: 6020-52 | Target: Urotensin-II | UniProt: O95399
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6020-52 | Target: Urotensin-II | UniProt: O95399 | TargetFullName: Urotensin-2 | Organisim: human | Apparent_Kd_M: 1.519948E-10
Real
Aptamer SeqId: 6022-57 | Target: NELL2 | UniProt: Q99435
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6022-57 | Target: NELL2 | UniProt: Q99435 | TargetFullName: Protein kinase C-binding protein NELL2 | Organisim: human | Apparent_Kd_M: 2.126702E-10
Real
Aptamer SeqId: 6027-31 | Target: REL3 | UniProt: Q8WXF3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6027-31 | Target: REL3 | UniProt: Q8WXF3 | TargetFullName: Relaxin-3 | Organisim: human | Apparent_Kd_M: 6.611203E-12
Real
Aptamer SeqId: 6035-2 | Target: SIAT1 | UniProt: P15907
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6035-2 | Target: SIAT1 | UniProt: P15907 | TargetFullName: Beta-galactoside alpha-2;6-sialyltransferase 1 | Organisim: human | Apparent_Kd_M: 2.735933E-11
Real
Aptamer SeqId: 6036-78 | Target: Deprecated | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6036-78 | Target: Deprecated | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 1.62E-11
Real
Aptamer SeqId: 6037-6 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6037-6 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 7.395124E-12
Real
Aptamer SeqId: 6039-24 | Target: CRHBP | UniProt: P24387
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6039-24 | Target: CRHBP | UniProt: P24387 | TargetFullName: Corticotropin-releasing factor-binding protein | Organisim: human | Apparent_Kd_M: 5.523453E-12
Real
Aptamer SeqId: 6042-52 | Target: Tenascin | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6042-52 | Target: Tenascin | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 1.054136E-10
Real
Aptamer SeqId: 6048-4 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6048-4 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.069818E-12
Real
Aptamer SeqId: 6049-64 | Target: PTPRS | UniProt: Q13332
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6049-64 | Target: PTPRS | UniProt: Q13332 | TargetFullName: Receptor-type tyrosine-protein phosphatase S | Organisim: human | Apparent_Kd_M: 1.381394E-12
Real
Aptamer SeqId: 6054-6 | Target: NXPH3 | UniProt: O95157
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6054-6 | Target: NXPH3 | UniProt: O95157 | TargetFullName: Neurexophilin-3 | Organisim: human | Apparent_Kd_M: 1.211888E-10
Real
Aptamer SeqId: 6060-2 | Target: PIP | UniProt: P12273
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6060-2 | Target: PIP | UniProt: P12273 | TargetFullName: Prolactin-inducible protein | Organisim: human | Apparent_Kd_M: 6.746792E-11
Real
Aptamer SeqId: 6064-4 | Target: TXNDC4 | UniProt: Q9BS26
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6064-4 | Target: TXNDC4 | UniProt: Q9BS26 | TargetFullName: Endoplasmic reticulum resident protein 44 | Organisim: human | Apparent_Kd_M: 8.687695E-11
Real
Aptamer SeqId: 6069-71 | Target: SUMF2 | UniProt: Q8NBJ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6069-71 | Target: SUMF2 | UniProt: Q8NBJ7 | TargetFullName: Sulfatase-modifying factor 2 | Organisim: human | Apparent_Kd_M: 3.255026E-11
Real
Aptamer SeqId: 6070-11 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6070-11 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 6.07E-12
Real
Aptamer SeqId: 6077-63 | Target: CECR1 | UniProt: Q9NZK5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6077-63 | Target: CECR1 | UniProt: Q9NZK5 | TargetFullName: Adenosine deaminase CECR1 | Organisim: human | Apparent_Kd_M: 1.300889E-12
Real
Aptamer SeqId: 6079-59 | Target: ACPL2 | UniProt: Q8TE99
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6079-59 | Target: ACPL2 | UniProt: Q8TE99 | TargetFullName: 2-phosphoxylose phosphatase 1 | Organisim: human | Apparent_Kd_M: 1.620029E-12
Real
Aptamer SeqId: 6081-52 | Target: PCOC2 | UniProt: Q9UKZ9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6081-52 | Target: PCOC2 | UniProt: Q9UKZ9 | TargetFullName: Procollagen C-endopeptidase enhancer 2 | Organisim: human | Apparent_Kd_M: 2.74629E-12
Real
Aptamer SeqId: 6086-15 | Target: CRDL2 | UniProt: Q6WN34
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6086-15 | Target: CRDL2 | UniProt: Q6WN34 | TargetFullName: Chordin-like protein 2 | Organisim: human | Apparent_Kd_M: 9.38812E-12
Real
Aptamer SeqId: 6102-2 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6102-2 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 9.731757E-12
Real
Aptamer SeqId: 6103-70 | Target: FCRL5 | UniProt: Q96RD9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6103-70 | Target: FCRL5 | UniProt: Q96RD9 | TargetFullName: Fc receptor-like protein 5 | Organisim: human | Apparent_Kd_M: 3.414976E-10
Real
Aptamer SeqId: 6107-3 | Target: ELA1 | UniProt: Q9UNI1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6107-3 | Target: ELA1 | UniProt: Q9UNI1 | TargetFullName: Chymotrypsin-like elastase family member 1 | Organisim: human | Apparent_Kd_M: 9.658131E-11
Real
Aptamer SeqId: 6115-40 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6115-40 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.074507E-11
Real
Aptamer SeqId: 6117-4 | Target: NEC2 | UniProt: P16519
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6117-4 | Target: NEC2 | UniProt: P16519 | TargetFullName: Neuroendocrine convertase 2 | Organisim: human | Apparent_Kd_M: 3.4E-11
Real
Aptamer SeqId: 6119-14 | Target: MAMC2 | UniProt: Q7Z304
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6119-14 | Target: MAMC2 | UniProt: Q7Z304 | TargetFullName: MAM domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 1.75E-10
Real
Aptamer SeqId: 6121-5 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6121-5 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.59E-11
Real
Aptamer SeqId: 6123-69 | Target: p53 | UniProt: P04637
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6123-69 | Target: p53 | UniProt: P04637 | TargetFullName: Cellular tumor antigen p53 | Organisim: human | Apparent_Kd_M: 4.249735E-12
Real
Aptamer SeqId: 6151-18 | Target: MP2K3 | UniProt: P46734
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6151-18 | Target: MP2K3 | UniProt: P46734 | TargetFullName: Dual specificity mitogen-activated protein kinase kinase 3 | Organisim: human | Apparent_Kd_M: 2.75E-10
Real
Aptamer SeqId: 6168-11 | Target: p53 R175H | UniProt: P04637
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6168-11 | Target: p53 R175H | UniProt: P04637 | TargetFullName: Cellular tumor antigen p53 R175H mutant | Organisim: human | Apparent_Kd_M: 6.379042E-12
Real
Aptamer SeqId: 6207-10 | Target: prosaposin | UniProt: P07602
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6207-10 | Target: prosaposin | UniProt: P07602 | TargetFullName: Prosaposin | Organisim: human | Apparent_Kd_M: 6.945042E-11
Real
Aptamer SeqId: 6210-100 | Target: IFNA5 | UniProt: P01569
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6210-100 | Target: IFNA5 | UniProt: P01569 | TargetFullName: Interferon alpha-5 | Organisim: human | Apparent_Kd_M: 1.52E-10
Real
Aptamer SeqId: 6213-10 | Target: CGB2 | UniProt: Q6NT52
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6213-10 | Target: CGB2 | UniProt: Q6NT52 | TargetFullName: Choriogonadotropin subunit beta variant 2 | Organisim: human | Apparent_Kd_M: 9.387504E-11
Real
Aptamer SeqId: 6214-84 | Target: IFNA8 | UniProt: P32881
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6214-84 | Target: IFNA8 | UniProt: P32881 | TargetFullName: Interferon alpha-8 | Organisim: human | Apparent_Kd_M: 5.28E-10
Real
Aptamer SeqId: 6219-14 | Target: PDZ11 | UniProt: Q5EBL8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6219-14 | Target: PDZ11 | UniProt: Q5EBL8 | TargetFullName: PDZ domain-containing protein 11 | Organisim: human | Apparent_Kd_M: 2.910885E-10
Real
Aptamer SeqId: 6221-1 | Target: ADPGK | UniProt: Q9BRR6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6221-1 | Target: ADPGK | UniProt: Q9BRR6 | TargetFullName: ADP-dependent glucokinase | Organisim: human | Apparent_Kd_M: 1.633294E-10
Real
Aptamer SeqId: 6223-5 | Target: GUC2B | UniProt: Q16661
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6223-5 | Target: GUC2B | UniProt: Q16661 | TargetFullName: Guanylate cyclase activator 2B | Organisim: human | Apparent_Kd_M: 2.299597E-11
Real
Aptamer SeqId: 6226-69 | Target: EFHA1 | UniProt: Q8IYU8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6226-69 | Target: EFHA1 | UniProt: Q8IYU8 | TargetFullName: Calcium uptake protein 2; mitochondrial | Organisim: human | Apparent_Kd_M: 1.624838E-11
Real
Aptamer SeqId: 6227-1 | Target: kallikrein 10 | UniProt: O43240
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6227-1 | Target: kallikrein 10 | UniProt: O43240 | TargetFullName: Kallikrein-10 | Organisim: human | Apparent_Kd_M: 1.944188E-12
Real
Aptamer SeqId: 6228-58 | Target: sperm acrosome associated 1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6228-58 | Target: sperm acrosome associated 1 | UniProt: Q9HBV2 | TargetFullName: Sperm acrosome membrane-associated protein 1 | Organisim: human | Apparent_Kd_M: 1.01559E-10
Real
Aptamer SeqId: 6230-56 | Target: CER1 | UniProt: O95813
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6230-56 | Target: CER1 | UniProt: O95813 | TargetFullName: Cerberus | Organisim: human | Apparent_Kd_M: 4.26E-12
Real
Aptamer SeqId: 6231-46 | Target: STC2 | UniProt: O76061
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6231-46 | Target: STC2 | UniProt: O76061 | TargetFullName: Stanniocalcin-2 | Organisim: human | Apparent_Kd_M: 1.24E-10
Real
Aptamer SeqId: 6234-74 | Target: VITRN | UniProt: Q6UXI7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6234-74 | Target: VITRN | UniProt: Q6UXI7 | TargetFullName: Vitrin | Organisim: human | Apparent_Kd_M: 1.43E-11
Real
Aptamer SeqId: 6237-11 | Target: FGRL1 | UniProt: Q8N441
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6237-11 | Target: FGRL1 | UniProt: Q8N441 | TargetFullName: Fibroblast growth factor receptor-like 1 | Organisim: human | Apparent_Kd_M: 3.05E-11
Real
Aptamer SeqId: 6238-55 | Target: PSG8 | UniProt: Q9UQ74
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6238-55 | Target: PSG8 | UniProt: Q9UQ74 | TargetFullName: Pregnancy-specific beta-1-glycoprotein 8 | Organisim: human | Apparent_Kd_M: 2.551326E-10
Real
Aptamer SeqId: 6240-70 | Target: RSPO1 | UniProt: Q2MKA7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6240-70 | Target: RSPO1 | UniProt: Q2MKA7 | TargetFullName: R-spondin-1 | Organisim: human | Apparent_Kd_M: 1.470514E-10
Real
Aptamer SeqId: 6245-4 | Target: Nectin-2 | UniProt: Q92692
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6245-4 | Target: Nectin-2 | UniProt: Q92692 | TargetFullName: Nectin-2 | Organisim: human | Apparent_Kd_M: 1.26E-10
Real
Aptamer SeqId: 6247-9 | Target: SIRB1 | UniProt: O00241
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6247-9 | Target: SIRB1 | UniProt: O00241 | TargetFullName: Signal-regulatory protein beta-1 | Organisim: human | Apparent_Kd_M: 9.85E-11
Real
Aptamer SeqId: 6252-62 | Target: Secretoglobin family 3A member 1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6252-62 | Target: Secretoglobin family 3A member 1 | UniProt: Q96QR1 | TargetFullName: Secretoglobin family 3A member 1 | Organisim: human | Apparent_Kd_M: 1.318691E-11
Real
Aptamer SeqId: 6255-74 | Target: CPXM1 | UniProt: Q96SM3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6255-74 | Target: CPXM1 | UniProt: Q96SM3 | TargetFullName: Probable carboxypeptidase X1 | Organisim: human | Apparent_Kd_M: 2.37579E-12
Real
Aptamer SeqId: 6256-9 | Target: LY66C | UniProt: O95867
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6256-9 | Target: LY66C | UniProt: O95867 | TargetFullName: Lymphocyte antigen 6 complex locus protein G6c | Organisim: human | Apparent_Kd_M: 6.735453E-12
Real
Aptamer SeqId: 6257-56 | Target: CGRE1 | UniProt: Q99674
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6257-56 | Target: CGRE1 | UniProt: Q99674 | TargetFullName: Cell growth regulator with EF hand domain protein 1 | Organisim: human | Apparent_Kd_M: 3.387136E-11
Real
Aptamer SeqId: 6259-60 | Target: Tenascin | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6259-60 | Target: Tenascin | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 2.812028E-12
Real
Aptamer SeqId: 6260-14 | Target: Tenascin | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6260-14 | Target: Tenascin | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 3.133958E-12
Real
Aptamer SeqId: 6262-14 | Target: IL-17B R | UniProt: Q9NRM6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6262-14 | Target: IL-17B R | UniProt: Q9NRM6 | TargetFullName: Interleukin-17 receptor B | Organisim: human | Apparent_Kd_M: 4.23E-11
Real
Aptamer SeqId: 6264-9 | Target: CYR61 | UniProt: O00622
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6264-9 | Target: CYR61 | UniProt: O00622 | TargetFullName: Protein CYR61 | Organisim: human | Apparent_Kd_M: 4.71E-12
Real
Aptamer SeqId: 6267-51 | Target: STMN4 | UniProt: Q9H169
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6267-51 | Target: STMN4 | UniProt: Q9H169 | TargetFullName: Stathmin-4 | Organisim: human | Apparent_Kd_M: 1.183131E-11
Real
Aptamer SeqId: 6273-58 | Target: P3H1 | UniProt: Q32P28
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6273-58 | Target: P3H1 | UniProt: Q32P28 | TargetFullName: Prolyl 3-hydroxylase 1 | Organisim: human | Apparent_Kd_M: 2.0E-11
Real
Aptamer SeqId: 6274-15 | Target: WSCD2 | UniProt: Q2TBF2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6274-15 | Target: WSCD2 | UniProt: Q2TBF2 | TargetFullName: WSC domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 2.152435E-11
Real
Aptamer SeqId: 6276-16 | Target: Furin | UniProt: P09958
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6276-16 | Target: Furin | UniProt: P09958 | TargetFullName: Furin | Organisim: human | Apparent_Kd_M: 1.910763E-11
Real
Aptamer SeqId: 6277-55 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6277-55 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.543171E-12
Real
Aptamer SeqId: 6280-11 | Target: PCDH8 | UniProt: O95206
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6280-11 | Target: PCDH8 | UniProt: O95206 | TargetFullName: Protocadherin-8 | Organisim: human | Apparent_Kd_M: 3.025023E-11
Real
Aptamer SeqId: 6281-51 | Target: SIA4B | UniProt: Q16842
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6281-51 | Target: SIA4B | UniProt: Q16842 | TargetFullName: CMP-N-acetylneuraminate-beta-galactosamide-alpha-2;3-sialyltransferase 2 | Organisim: human | Apparent_Kd_M: 7.437269E-12
Real
Aptamer SeqId: 6283-60 | Target: MCEM1 | UniProt: Q8IX19
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6283-60 | Target: MCEM1 | UniProt: Q8IX19 | TargetFullName: Mast cell-expressed membrane protein 1 | Organisim: human | Apparent_Kd_M: 1.418962E-11
Real
Aptamer SeqId: 6284-7 | Target: F150B | UniProt: Q6UX46
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6284-7 | Target: F150B | UniProt: Q6UX46 | TargetFullName: ALK and LTK ligand 2 | Organisim: human | Apparent_Kd_M: 1.174614E-11
Real
Aptamer SeqId: 6285-71 | Target: K0152 | UniProt: Q14165
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6285-71 | Target: K0152 | UniProt: Q14165 | TargetFullName: Malectin | Organisim: human | Apparent_Kd_M: 2.324202E-11
Real
Aptamer SeqId: 6289-78 | Target: RHG36 | UniProt: Q6ZRI8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6289-78 | Target: RHG36 | UniProt: Q6ZRI8 | TargetFullName: Rho GTPase-activating protein 36 | Organisim: human | Apparent_Kd_M: 1.892049E-11
Real
Aptamer SeqId: 6290-3 | Target: UTS2B | UniProt: Q765I0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6290-3 | Target: UTS2B | UniProt: Q765I0 | TargetFullName: Urotensin-2B | Organisim: human | Apparent_Kd_M: 1.785404E-11
Real
Aptamer SeqId: 6291-55 | Target: Alcadein-beta | UniProt: Q9BQT9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6291-55 | Target: Alcadein-beta | UniProt: Q9BQT9 | TargetFullName: Calsyntenin-3 | Organisim: human | Apparent_Kd_M: 3.375357E-11
Real
Aptamer SeqId: 6294-11 | Target: BAGE2 | UniProt: Q86Y30
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6294-11 | Target: BAGE2 | UniProt: Q86Y30 | TargetFullName: B melanoma antigen 2 | Organisim: human | Apparent_Kd_M: 2.747723E-11
Real
Aptamer SeqId: 6295-67 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6295-67 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 9.357712E-12
Real
Aptamer SeqId: 6296-36 | Target: OIT3 | UniProt: Q8WWZ8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6296-36 | Target: OIT3 | UniProt: Q8WWZ8 | TargetFullName: Oncoprotein-induced transcript 3 protein | Organisim: human | Apparent_Kd_M: 7.66E-12
Real
Aptamer SeqId: 6300-14 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6300-14 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.18E-12
Real
Aptamer SeqId: 6304-8 | Target: C1QT1 | UniProt: Q9BXJ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6304-8 | Target: C1QT1 | UniProt: Q9BXJ1 | TargetFullName: Complement C1q tumor necrosis factor-related protein 1 | Organisim: human | Apparent_Kd_M: 1.24E-11
Real
Aptamer SeqId: 6315-58 | Target: PLBL1 | UniProt: Q6P4A8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6315-58 | Target: PLBL1 | UniProt: Q6P4A8 | TargetFullName: Phospholipase B-like 1 | Organisim: human | Apparent_Kd_M: 9.071494E-11
Real
Aptamer SeqId: 6321-65 | Target: PCDGA | UniProt: Q9Y5H3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6321-65 | Target: PCDGA | UniProt: Q9Y5H3 | TargetFullName: Protocadherin gamma-A10 | Organisim: human | Apparent_Kd_M: 1.988317E-11
Real
Aptamer SeqId: 6324-11 | Target: DNSL2 | UniProt: Q92874
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6324-11 | Target: DNSL2 | UniProt: Q92874 | TargetFullName: Deoxyribonuclease-1-like 2 | Organisim: human | Apparent_Kd_M: 1.754243E-11
Real
Aptamer SeqId: 6326-20 | Target: BMP-4 | UniProt: P12644
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6326-20 | Target: BMP-4 | UniProt: P12644 | TargetFullName: Bone morphogenetic protein 4 | Organisim: human | Apparent_Kd_M: 2.15E-11
Real
Aptamer SeqId: 6334-9 | Target: GGT2 | UniProt: P36268
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6334-9 | Target: GGT2 | UniProt: P36268 | TargetFullName: Inactive gamma-glutamyltranspeptidase 2 | Organisim: human | Apparent_Kd_M: 5.068099E-11
Real
Aptamer SeqId: 6340-10 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6340-10 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.352301E-12
Real
Aptamer SeqId: 6342-10 | Target: Nephronectin | UniProt: Q6UXI9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6342-10 | Target: Nephronectin | UniProt: Q6UXI9 | TargetFullName: Nephronectin | Organisim: human | Apparent_Kd_M: 3.648321E-12
Real
Aptamer SeqId: 6350-43 | Target: Apo C-II | UniProt: P02655
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6350-43 | Target: Apo C-II | UniProt: P02655 | TargetFullName: Apolipoprotein C-II | Organisim: human | Apparent_Kd_M: 1.252696E-12
Real
Aptamer SeqId: 6351-55 | Target: CD79B | UniProt: P40259
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6351-55 | Target: CD79B | UniProt: P40259 | TargetFullName: B-cell antigen receptor complex-associated protein beta chain | Organisim: human | Apparent_Kd_M: 3.468736E-12
Real
Aptamer SeqId: 6352-8 | Target: INSRR | UniProt: P14616
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6352-8 | Target: INSRR | UniProt: P14616 | TargetFullName: Insulin receptor-related protein | Organisim: human | Apparent_Kd_M: 2.913889E-12
Real
Aptamer SeqId: 6353-60 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6353-60 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.967951E-12
Real
Aptamer SeqId: 6354-13 | Target: HPHL1 | UniProt: Q6MZM0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6354-13 | Target: HPHL1 | UniProt: Q6MZM0 | TargetFullName: Hephaestin-like protein 1 | Organisim: human | Apparent_Kd_M: 1.685411E-10
Real
Aptamer SeqId: 6357-83 | Target: ELA3B | UniProt: P08861
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6357-83 | Target: ELA3B | UniProt: P08861 | TargetFullName: Chymotrypsin-like elastase family member 3B | Organisim: human | Apparent_Kd_M: 2.458081E-11
Real
Aptamer SeqId: 6359-50 | Target: AGO61 | UniProt: Q8NAT1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6359-50 | Target: AGO61 | UniProt: Q8NAT1 | TargetFullName: Protein O-linked-mannose beta-1;4-N-acetylglucosaminyltransferase 2 | Organisim: human | Apparent_Kd_M: 2.741728E-12
Real
Aptamer SeqId: 6360-7 | Target: DB128 | UniProt: Q7Z7B8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6360-7 | Target: DB128 | UniProt: Q7Z7B8 | TargetFullName: Beta-defensin 128 | Organisim: human | Apparent_Kd_M: 1.260759E-10
Real
Aptamer SeqId: 6361-49 | Target: PTPRR | UniProt: Q15256
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6361-49 | Target: PTPRR | UniProt: Q15256 | TargetFullName: Receptor-type tyrosine-protein phosphatase R | Organisim: human | Apparent_Kd_M: 1.937803E-11
Real
Aptamer SeqId: 6362-6 | Target: AUGN | UniProt: Q9H1Z8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6362-6 | Target: AUGN | UniProt: Q9H1Z8 | TargetFullName: Augurin | Organisim: human | Apparent_Kd_M: 1.500438E-10
Real
Aptamer SeqId: 6363-55 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6363-55 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.130653E-12
Real
Aptamer SeqId: 6364-7 | Target: TPSNR | UniProt: Q9BX59
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6364-7 | Target: TPSNR | UniProt: Q9BX59 | TargetFullName: Tapasin-related protein | Organisim: human | Apparent_Kd_M: 3.590924E-12
Real
Aptamer SeqId: 6365-62 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6365-62 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 9.643011E-11
Real
Aptamer SeqId: 6366-38 | Target: TXD15 | UniProt: Q96J42
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6366-38 | Target: TXD15 | UniProt: Q96J42 | TargetFullName: Thioredoxin domain-containing protein 15 | Organisim: human | Apparent_Kd_M: 2.09E-11
Real
Aptamer SeqId: 6367-66 | Target: fibromodulin | UniProt: Q06828
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6367-66 | Target: fibromodulin | UniProt: Q06828 | TargetFullName: fibromodulin | Organisim: human | Apparent_Kd_M: 1.232158E-10
Real
Aptamer SeqId: 6368-9 | Target: CST1L | UniProt: Q9H114
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6368-9 | Target: CST1L | UniProt: Q9H114 | TargetFullName: Cystatin-like 1 | Organisim: human | Apparent_Kd_M: 3.581922E-12
Real
Aptamer SeqId: 6369-82 | Target: DEAF1 | UniProt: O75398
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6369-82 | Target: DEAF1 | UniProt: O75398 | TargetFullName: Deformed epidermal autoregulatory factor 1 homolog | Organisim: human | Apparent_Kd_M: 1.94858E-11
Real
Aptamer SeqId: 6371-50 | Target: ANGL7 | UniProt: O43827
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6371-50 | Target: ANGL7 | UniProt: O43827 | TargetFullName: Angiopoietin-related protein 7 | Organisim: human | Apparent_Kd_M: 1.603027E-10
Real
Aptamer SeqId: 6372-7 | Target: YBOX2 | UniProt: Q9Y2T7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6372-7 | Target: YBOX2 | UniProt: Q9Y2T7 | TargetFullName: Y-box-binding protein 2 | Organisim: human | Apparent_Kd_M: 2.153723E-11
Real
Aptamer SeqId: 6373-54 | Target: DLK1 | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6373-54 | Target: DLK1 | UniProt: | TargetFullName: Protein delta homolog 1 | Organisim: human | Apparent_Kd_M: 1.642086E-12
Real
Aptamer SeqId: 6375-75 | Target: XXLT1 | UniProt: Q8NBI6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6375-75 | Target: XXLT1 | UniProt: Q8NBI6 | TargetFullName: Xyloside xylosyltransferase 1 | Organisim: human | Apparent_Kd_M: 7.057346E-12
Real
Aptamer SeqId: 6377-54 | Target: LYZL2 | UniProt: Q7Z4W2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6377-54 | Target: LYZL2 | UniProt: Q7Z4W2 | TargetFullName: Lysozyme-like protein 2 | Organisim: human | Apparent_Kd_M: 2.120471E-11
Real
Aptamer SeqId: 6378-2 | Target: CEI | UniProt: Q86SI9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6378-2 | Target: CEI | UniProt: Q86SI9 | TargetFullName: Protein CEI | Organisim: human | Apparent_Kd_M: 5.963488E-11
Real
Aptamer SeqId: 6379-62 | Target: ATL2 | UniProt: Q86TH1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6379-62 | Target: ATL2 | UniProt: Q86TH1 | TargetFullName: ADAMTS-like protein 2 | Organisim: human | Apparent_Kd_M: 2.761828E-12
Real
Aptamer SeqId: 6380-23 | Target: ICT1 | UniProt: Q14197
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6380-23 | Target: ICT1 | UniProt: Q14197 | TargetFullName: Peptidyl-tRNA hydrolase ICT1; mitochondrial | Organisim: human | Apparent_Kd_M: 1.388004E-11
Real
Aptamer SeqId: 6382-17 | Target: MANBA | UniProt: O00462
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6382-17 | Target: MANBA | UniProt: O00462 | TargetFullName: Beta-mannosidase | Organisim: human | Apparent_Kd_M: 1.70677E-10
Real
Aptamer SeqId: 6383-90 | Target: TLL1 | UniProt: O43897
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6383-90 | Target: TLL1 | UniProt: O43897 | TargetFullName: Tolloid-like protein 1 | Organisim: human | Apparent_Kd_M: 5.102399E-12
Real
Aptamer SeqId: 6384-19 | Target: WFDC3 | UniProt: Q8IUB2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6384-19 | Target: WFDC3 | UniProt: Q8IUB2 | TargetFullName: WAP four-disulfide core domain protein 3 | Organisim: human | Apparent_Kd_M: 1.116919E-11
Real
Aptamer SeqId: 6385-63 | Target: VWA1 | UniProt: Q6PCB0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6385-63 | Target: VWA1 | UniProt: Q6PCB0 | TargetFullName: von Willebrand factor A domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 3.216101E-11
Real
Aptamer SeqId: 6386-4 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6386-4 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.551058E-11
Real
Aptamer SeqId: 6388-21 | Target: CC126 | UniProt: Q96EE4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6388-21 | Target: CC126 | UniProt: Q96EE4 | TargetFullName: Coiled-coil domain-containing protein 126 | Organisim: human | Apparent_Kd_M: 9.216758E-12
Real
Aptamer SeqId: 6389-57 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6389-57 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.950667E-11
Real
Aptamer SeqId: 6390-18 | Target: NPS | UniProt: P0C0P6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6390-18 | Target: NPS | UniProt: P0C0P6 | TargetFullName: Neuropeptide S | Organisim: human | Apparent_Kd_M: 1.185476E-11
Real
Aptamer SeqId: 6391-52 | Target: LIRA3 | UniProt: Q8N6C8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6391-52 | Target: LIRA3 | UniProt: Q8N6C8 | TargetFullName: Leukocyte immunoglobulin-like receptor subfamily A member 3 | Organisim: human | Apparent_Kd_M: 3.961649E-12
Real
Aptamer SeqId: 6392-7 | Target: WISP-2 | UniProt: O76076
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6392-7 | Target: WISP-2 | UniProt: O76076 | TargetFullName: WNT1-inducible-signaling pathway protein 2 | Organisim: human | Apparent_Kd_M: 2.235969E-11
Real
Aptamer SeqId: 6393-63 | Target: Endoplasmin | UniProt: P14625
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6393-63 | Target: Endoplasmin | UniProt: P14625 | TargetFullName: Endoplasmin | Organisim: human | Apparent_Kd_M: 1.965207E-11
Real
Aptamer SeqId: 6395-58 | Target: GPHA2 | UniProt: Q96T91
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6395-58 | Target: GPHA2 | UniProt: Q96T91 | TargetFullName: Glycoprotein hormone alpha-2 | Organisim: human | Apparent_Kd_M: 7.591015E-12
Real
Aptamer SeqId: 6398-12 | Target: LONM | UniProt: P36776
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6398-12 | Target: LONM | UniProt: P36776 | TargetFullName: Lon protease homolog; mitochondrial | Organisim: human | Apparent_Kd_M: 8.17E-12
Real
Aptamer SeqId: 6399-52 | Target: D107A | UniProt: Q8IZN7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6399-52 | Target: D107A | UniProt: Q8IZN7 | TargetFullName: Beta-defensin 107 | Organisim: human | Apparent_Kd_M: 2.0E-10
Real
Aptamer SeqId: 6400-33 | Target: P5I13 | UniProt: Q8NBR0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6400-33 | Target: P5I13 | UniProt: Q8NBR0 | TargetFullName: Tumor protein p53-inducible protein 13 | Organisim: human | Apparent_Kd_M: 6.6E-11
Real
Aptamer SeqId: 6401-73 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6401-73 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.825166E-11
Real
Aptamer SeqId: 6402-8 | Target: PILRA isoform FDF03-deltaTM
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6402-8 | Target: PILRA isoform FDF03-deltaTM | UniProt: Q9UKJ1 | TargetFullName: Paired immunoglobulin-like type 2 receptor alpha isoform FDF03-deltaTM | Organisim: human | Apparent_Kd_M: 2.483891E-12
Real
Aptamer SeqId: 6404-20 | Target: C1QRF | UniProt: O75973
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6404-20 | Target: C1QRF | UniProt: O75973 | TargetFullName: C1q-related factor | Organisim: human | Apparent_Kd_M: 1.794246E-11
Real
Aptamer SeqId: 6405-74 | Target: PSG2 | UniProt: P11465
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6405-74 | Target: PSG2 | UniProt: P11465 | TargetFullName: Pregnancy-specific beta-1-glycoprotein 2 | Organisim: human | Apparent_Kd_M: 1.167056E-12
Real
Aptamer SeqId: 6406-3 | Target: NMES1 | UniProt: Q9C002
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6406-3 | Target: NMES1 | UniProt: Q9C002 | TargetFullName: Normal mucosa of esophagus-specific gene 1 protein | Organisim: human | Apparent_Kd_M: 3.140404E-12
Real
Aptamer SeqId: 6407-63 | Target: LAD1 | UniProt: O00515
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6407-63 | Target: LAD1 | UniProt: O00515 | TargetFullName: Ladinin-1 | Organisim: human | Apparent_Kd_M: 6.79E-11
Real
Aptamer SeqId: 6408-2 | Target: INHBC | UniProt: P55103
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6408-2 | Target: INHBC | UniProt: P55103 | TargetFullName: Inhibin beta C chain | Organisim: human | Apparent_Kd_M: 6.0E-11
Real
Aptamer SeqId: 6409-57 | Target: GP116 | UniProt: Q8IZF2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6409-57 | Target: GP116 | UniProt: Q8IZF2 | TargetFullName: Adhesion G protein-coupled receptor F5 | Organisim: human | Apparent_Kd_M: 8.004315E-11
Real
Aptamer SeqId: 6410-26 | Target: INSL4 | UniProt: Q14641
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6410-26 | Target: INSL4 | UniProt: Q14641 | TargetFullName: Early placenta insulin-like peptide | Organisim: human | Apparent_Kd_M: 4.623997E-11
Real
Aptamer SeqId: 6411-58 | Target: DB135 | UniProt: Q30KP9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6411-58 | Target: DB135 | UniProt: Q30KP9 | TargetFullName: Beta-defensin 135 | Organisim: human | Apparent_Kd_M: 3.090139E-11
Real
Aptamer SeqId: 6412-26 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6412-26 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.972528E-12
Real
Aptamer SeqId: 6413-79 | Target: LIPK | UniProt: Q5VXJ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6413-79 | Target: LIPK | UniProt: Q5VXJ0 | TargetFullName: Lipase member K | Organisim: human | Apparent_Kd_M: 1.32E-11
Real
Aptamer SeqId: 6414-8 | Target: OAF | UniProt: Q86UD1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6414-8 | Target: OAF | UniProt: Q86UD1 | TargetFullName: Out at first protein homolog | Organisim: human | Apparent_Kd_M: 9.704727E-12
Real
Aptamer SeqId: 6415-90 | Target: CPN2 | UniProt: P22792
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6415-90 | Target: CPN2 | UniProt: P22792 | TargetFullName: Carboxypeptidase N subunit 2 | Organisim: human | Apparent_Kd_M: 1.517215E-11
Real
Aptamer SeqId: 6416-8 | Target: GKN2 | UniProt: Q86XP6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6416-8 | Target: GKN2 | UniProt: Q86XP6 | TargetFullName: Gastrokine-2 | Organisim: human | Apparent_Kd_M: 1.641471E-10
Real
Aptamer SeqId: 6417-55 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6417-55 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.519256E-11
Real
Aptamer SeqId: 6419-75 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6419-75 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 9.286421E-12
Real
Aptamer SeqId: 6420-4 | Target: SDHF2 | UniProt: Q9NX18
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6420-4 | Target: SDHF2 | UniProt: Q9NX18 | TargetFullName: Succinate dehydrogenase assembly factor 2; mitochondrial | Organisim: human | Apparent_Kd_M: 9.823543E-12
Real
Aptamer SeqId: 6421-52 | Target: IFN16 | UniProt: P05015
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6421-52 | Target: IFN16 | UniProt: P05015 | TargetFullName: Interferon alpha-16 | Organisim: human | Apparent_Kd_M: 4.091017E-12
Real
Aptamer SeqId: 6424-2 | Target: RNS13 | UniProt: Q5GAN3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6424-2 | Target: RNS13 | UniProt: Q5GAN3 | TargetFullName: Probable inactive ribonuclease-like protein 13 | Organisim: human | Apparent_Kd_M: 1.479855E-11
Real
Aptamer SeqId: 6425-87 | Target: MMP19 | UniProt: Q99542
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6425-87 | Target: MMP19 | UniProt: Q99542 | TargetFullName: Matrix metalloproteinase-19 | Organisim: human | Apparent_Kd_M: 2.686982E-12
Real
Aptamer SeqId: 6430-36 | Target: F19A2 | UniProt: Q8N3H0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6430-36 | Target: F19A2 | UniProt: Q8N3H0 | TargetFullName: Protein FAM19A2 | Organisim: human | Apparent_Kd_M: 6.191995E-11
Real
Aptamer SeqId: 6431-68 | Target: PCYOX | UniProt: Q9UHG3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6431-68 | Target: PCYOX | UniProt: Q9UHG3 | TargetFullName: Prenylcysteine oxidase 1 | Organisim: human | Apparent_Kd_M: 1.177655E-10
Real
Aptamer SeqId: 6433-57 | Target: FA20A | UniProt: Q96MK3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6433-57 | Target: FA20A | UniProt: Q96MK3 | TargetFullName: Pseudokinase FAM20A | Organisim: human | Apparent_Kd_M: 6.066204E-11
Real
Aptamer SeqId: 6434-18 | Target: Amine oxidase | UniProt: O75106
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6434-18 | Target: Amine oxidase | UniProt: O75106 | TargetFullName: Retina-specific copper amine oxidase | Organisim: human | Apparent_Kd_M: 3.537468E-12
Real
Aptamer SeqId: 6439-59 | Target: CN093 | UniProt: Q9H972
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6439-59 | Target: CN093 | UniProt: Q9H972 | TargetFullName: Uncharacterized protein C14orf93 | Organisim: human | Apparent_Kd_M: 4.636499E-12
Real
Aptamer SeqId: 6440-31 | Target: MFAP5 | UniProt: Q13361
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6440-31 | Target: MFAP5 | UniProt: Q13361 | TargetFullName: Microfibrillar-associated protein 5 | Organisim: human | Apparent_Kd_M: 1.27682E-11
Real
Aptamer SeqId: 6441-62 | Target: ATS6 | UniProt: Q9UKP5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6441-62 | Target: ATS6 | UniProt: Q9UKP5 | TargetFullName: A disintegrin and metalloproteinase with thrombospondin motifs 6 | Organisim: human | Apparent_Kd_M: 2.561274E-12
Real
Aptamer SeqId: 6442-6 | Target: BAGE3 | UniProt: Q86Y29
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6442-6 | Target: BAGE3 | UniProt: Q86Y29 | TargetFullName: B melanoma antigen 3 | Organisim: human | Apparent_Kd_M: 2.468582E-11
Real
Aptamer SeqId: 6443-68 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6443-68 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.61E-11
Real
Aptamer SeqId: 6444-15 | Target: PSG3 | UniProt: Q16557
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6444-15 | Target: PSG3 | UniProt: Q16557 | TargetFullName: Pregnancy-specific beta-1-glycoprotein 3 | Organisim: human | Apparent_Kd_M: 7.001791E-12
Real
Aptamer SeqId: 6447-73 | Target: PTX3 | UniProt: P26022
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6447-73 | Target: PTX3 | UniProt: P26022 | TargetFullName: Pentraxin-related protein PTX3 | Organisim: human | Apparent_Kd_M: 5.591102E-11
Real
Aptamer SeqId: 6448-36 | Target: Sema E | UniProt: Q99985
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6448-36 | Target: Sema E | UniProt: Q99985 | TargetFullName: Semaphorin-3C | Organisim: human | Apparent_Kd_M: 8.091061E-12
Real
Aptamer SeqId: 6450-8 | Target: FABP6 | UniProt: P51161
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6450-8 | Target: FABP6 | UniProt: P51161 | TargetFullName: Gastrotropin | Organisim: human | Apparent_Kd_M: 2.444607E-11
Real
Aptamer SeqId: 6451-64 | Target: ASPN | UniProt: Q9BXN1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6451-64 | Target: ASPN | UniProt: Q9BXN1 | TargetFullName: Asporin | Organisim: human | Apparent_Kd_M: 4.795251E-12
Real
Aptamer SeqId: 6453-70 | Target: LIRB4 | UniProt: Q8NHJ6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6453-70 | Target: LIRB4 | UniProt: Q8NHJ6 | TargetFullName: Leukocyte immunoglobulin-like receptor subfamily B member 4 | Organisim: human | Apparent_Kd_M: 1.695426E-12
Real
Aptamer SeqId: 6454-38 | Target: Rho-GDIa | UniProt: P52565
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6454-38 | Target: Rho-GDIa | UniProt: P52565 | TargetFullName: Rho GDP-dissociation inhibitor 1 | Organisim: human | Apparent_Kd_M: 9.22161E-11
Real
Aptamer SeqId: 6455-52 | Target: HPLN4 | UniProt: Q86UW8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6455-52 | Target: HPLN4 | UniProt: Q86UW8 | TargetFullName: Hyaluronan and proteoglycan link protein 4 | Organisim: human | Apparent_Kd_M: 2.466674E-12
Real
Aptamer SeqId: 6456-17 | Target: PSG6 | UniProt: Q00889
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6456-17 | Target: PSG6 | UniProt: Q00889 | TargetFullName: Pregnancy-specific beta-1-glycoprotein 6 | Organisim: human | Apparent_Kd_M: 3.118143E-11
Real
Aptamer SeqId: 6457-50 | Target: PCDG1 | UniProt: Q9Y5H4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6457-50 | Target: PCDG1 | UniProt: Q9Y5H4 | TargetFullName: Protocadherin gamma-A1 | Organisim: human | Apparent_Kd_M: 8.107633E-12
Real
Aptamer SeqId: 6458-6 | Target: RPN1 | UniProt: P04843
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6458-6 | Target: RPN1 | UniProt: P04843 | TargetFullName: Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 | Organisim: human | Apparent_Kd_M: 1.051868E-11
Real
Aptamer SeqId: 6461-54 | Target: Apo C-III | UniProt: P02656
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6461-54 | Target: Apo C-III | UniProt: P02656 | TargetFullName: Apolipoprotein C-III | Organisim: human | Apparent_Kd_M: 4.771643E-12
Real
Aptamer SeqId: 6462-12 | Target: TIMP-4 | UniProt: Q99727
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6462-12 | Target: TIMP-4 | UniProt: Q99727 | TargetFullName: Metalloproteinase inhibitor 4 | Organisim: human | Apparent_Kd_M: 2.1318E-12
Real
Aptamer SeqId: 6463-59 | Target: OX26 | UniProt: P83859
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6463-59 | Target: OX26 | UniProt: P83859 | TargetFullName: Orexigenic neuropeptide QRFP | Organisim: human | Apparent_Kd_M: 8.490205E-11
Real
Aptamer SeqId: 6464-40 | Target: PVRIG | UniProt: Q6DKI7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6464-40 | Target: PVRIG | UniProt: Q6DKI7 | TargetFullName: Transmembrane protein PVRIG | Organisim: human | Apparent_Kd_M: 6.44675E-11
Real
Aptamer SeqId: 6466-7 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6466-7 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.195974E-11
Real
Aptamer SeqId: 6467-65 | Target: KTEL1 | UniProt: Q8NBL1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6467-65 | Target: KTEL1 | UniProt: Q8NBL1 | TargetFullName: Protein O-glucosyltransferase 1 | Organisim: human | Apparent_Kd_M: 1.532903E-11
Real
Aptamer SeqId: 6468-37 | Target: TKN4 | UniProt: Q86UU9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6468-37 | Target: TKN4 | UniProt: Q86UU9 | TargetFullName: Tachykinin-4 | Organisim: human | Apparent_Kd_M: 7.593385E-11
Real
Aptamer SeqId: 6469-62 | Target: LY66D | UniProt: O95868
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6469-62 | Target: LY66D | UniProt: O95868 | TargetFullName: Lymphocyte antigen 6 complex locus protein G6d | Organisim: human | Apparent_Kd_M: 1.298921E-10
Real
Aptamer SeqId: 6470-19 | Target: fibulin 1 | UniProt: P23142
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6470-19 | Target: fibulin 1 | UniProt: P23142 | TargetFullName: Fibulin-1 | Organisim: human | Apparent_Kd_M: 1.52E-10
Real
Aptamer SeqId: 6471-53 | Target: FHR4 | UniProt: Q92496
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6471-53 | Target: FHR4 | UniProt: Q92496 | TargetFullName: Complement factor H-related protein 4 | Organisim: human | Apparent_Kd_M: 3.206741E-11
Real
Aptamer SeqId: 6472-40 | Target: GP100 | UniProt: P40967
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6472-40 | Target: GP100 | UniProt: P40967 | TargetFullName: Melanocyte protein PMEL | Organisim: human | Apparent_Kd_M: 1.771007E-10
Real
Aptamer SeqId: 6473-55 | Target: PLUNC | UniProt: Q9NP55
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6473-55 | Target: PLUNC | UniProt: Q9NP55 | TargetFullName: BPI fold-containing family A member 1 | Organisim: human | Apparent_Kd_M: 3.647417E-11
Real
Aptamer SeqId: 6478-2 | Target: IGLO5 | UniProt: A6NGN9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6478-2 | Target: IGLO5 | UniProt: A6NGN9 | TargetFullName: IgLON family member 5 | Organisim: human | Apparent_Kd_M: 2.43965E-11
Real
Aptamer SeqId: 6480-1 | Target: CANT1 | UniProt: Q8WVQ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6480-1 | Target: CANT1 | UniProt: Q8WVQ1 | TargetFullName: Soluble calcium-activated nucleotidase 1 | Organisim: human | Apparent_Kd_M: 8.48842E-11
Real
Aptamer SeqId: 6485-59 | Target: IGLL1 | UniProt: P15814
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6485-59 | Target: IGLL1 | UniProt: P15814 | TargetFullName: Immunoglobulin lambda-like polypeptide 1 | Organisim: human | Apparent_Kd_M: 1.857948E-11
Real
Aptamer SeqId: 6491-59 | Target: kallikrein 15 | UniProt: Q9H2R5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6491-59 | Target: kallikrein 15 | UniProt: Q9H2R5 | TargetFullName: Kallikrein-15 | Organisim: human | Apparent_Kd_M: 1.286854E-12
Real
Aptamer SeqId: 6493-9 | Target: CBPZ | UniProt: Q66K79
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6493-9 | Target: CBPZ | UniProt: Q66K79 | TargetFullName: Carboxypeptidase Z | Organisim: human | Apparent_Kd_M: 5.376207E-11
Real
Aptamer SeqId: 6494-60 | Target: sperm acrosome associated 5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6494-60 | Target: sperm acrosome associated 5 | UniProt: Q96QH8 | TargetFullName: Sperm acrosome-associated protein 5 | Organisim: human | Apparent_Kd_M: 1.824037E-11
Real
Aptamer SeqId: 6495-14 | Target: Endothelin 1 | UniProt: P05305
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6495-14 | Target: Endothelin 1 | UniProt: P05305 | TargetFullName: Endothelin-1 | Organisim: human | Apparent_Kd_M: 1.015502E-11
Real
Aptamer SeqId: 6496-60 | Target: DLK1 | UniProt: P80370
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6496-60 | Target: DLK1 | UniProt: P80370 | TargetFullName: Protein delta homolog 1 | Organisim: human | Apparent_Kd_M: 1.05E-11
Real
Aptamer SeqId: 6497-10 | Target: XLRS1 | UniProt: O15537
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6497-10 | Target: XLRS1 | UniProt: O15537 | TargetFullName: Retinoschisin | Organisim: human | Apparent_Kd_M: 1.266484E-11
Real
Aptamer SeqId: 6504-65 | Target: Lysyl oxidase-like protein 2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6504-65 | Target: Lysyl oxidase-like protein 2 | UniProt: Q9Y4K0 | TargetFullName: Lysyl oxidase homolog 2 | Organisim: human | Apparent_Kd_M: 2.495741E-12
Real
Aptamer SeqId: 6506-54 | Target: TMEDA | UniProt: P49755
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6506-54 | Target: TMEDA | UniProt: P49755 | TargetFullName: Transmembrane emp24 domain-containing protein 10 | Organisim: human | Apparent_Kd_M: 2.693806E-11
Real
Aptamer SeqId: 6507-16 | Target: NCAM2 | UniProt: O15394
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6507-16 | Target: NCAM2 | UniProt: O15394 | TargetFullName: Neural cell adhesion molecule 2 | Organisim: human | Apparent_Kd_M: 2.820561E-11
Real
Aptamer SeqId: 6508-68 | Target: SG1D2 | UniProt: O95969
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6508-68 | Target: SG1D2 | UniProt: O95969 | TargetFullName: Secretoglobin family 1D member 2 | Organisim: human | Apparent_Kd_M: 1.237952E-11
Real
Aptamer SeqId: 6510-56 | Target: RN128 | UniProt: Q8TEB7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6510-56 | Target: RN128 | UniProt: Q8TEB7 | TargetFullName: E3 ubiquitin-protein ligase RNF128 | Organisim: human | Apparent_Kd_M: 1.03E-10
Real
Aptamer SeqId: 6511-17 | Target: F19A4 | UniProt: Q96LR4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6511-17 | Target: F19A4 | UniProt: Q96LR4 | TargetFullName: Protein FAM19A4 | Organisim: human | Apparent_Kd_M: 1.978868E-11
Real
Aptamer SeqId: 6517-14 | Target: BMP-3b | UniProt: P55107
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6517-14 | Target: BMP-3b | UniProt: P55107 | TargetFullName: Growth/differentiation factor 10 | Organisim: human | Apparent_Kd_M: 8.11E-12
Real
Aptamer SeqId: 6518-85 | Target: ghrelin | UniProt: Q9UBU3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6518-85 | Target: ghrelin | UniProt: Q9UBU3 | TargetFullName: Appetite-regulating hormone | Organisim: human | Apparent_Kd_M: 8.42E-12
Real
Aptamer SeqId: 6520-87 | Target: MGP | UniProt: P08493
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6520-87 | Target: MGP | UniProt: P08493 | TargetFullName: Matrix Gla protein | Organisim: human | Apparent_Kd_M: 6.719876E-12
Real
Aptamer SeqId: 6521-35 | Target: NPTX2 | UniProt: P47972
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6521-35 | Target: NPTX2 | UniProt: P47972 | TargetFullName: Neuronal pentraxin-2 | Organisim: human | Apparent_Kd_M: 4.062646E-12
Real
Aptamer SeqId: 6522-57 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6522-57 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 5.825209E-11
Real
Aptamer SeqId: 6525-17 | Target: DUSP13 | UniProt: Q6B8I1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6525-17 | Target: DUSP13 | UniProt: Q6B8I1 | TargetFullName: Dual specificity protein phosphatase 13 isoform A | Organisim: human | Apparent_Kd_M: 8.089877E-12
Real
Aptamer SeqId: 6526-77 | Target: OBP2A | UniProt: Q9NY56
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6526-77 | Target: OBP2A | UniProt: Q9NY56 | TargetFullName: Odorant-binding protein 2a | Organisim: human | Apparent_Kd_M: 2.692759E-12
Real
Aptamer SeqId: 6527-1 | Target: TRIL | UniProt: Q7L0X0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6527-1 | Target: TRIL | UniProt: Q7L0X0 | TargetFullName: TLR4 interactor with leucine rich repeats | Organisim: human | Apparent_Kd_M: 4.04E-12
Real
Aptamer SeqId: 6528-95 | Target: EXTL2 | UniProt: Q9UBQ6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6528-95 | Target: EXTL2 | UniProt: Q9UBQ6 | TargetFullName: Exostosin-like 2 | Organisim: human | Apparent_Kd_M: 2.042332E-11
Real
Aptamer SeqId: 6530-63 | Target: PROL1 | UniProt: Q99935
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6530-63 | Target: PROL1 | UniProt: Q99935 | TargetFullName: Opiorphin prepropeptide | Organisim: human | Apparent_Kd_M: 1.493071E-11
Real
Aptamer SeqId: 6531-29 | Target: F162A | UniProt: Q96A26
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6531-29 | Target: F162A | UniProt: Q96A26 | TargetFullName: Protein FAM162A | Organisim: human | Apparent_Kd_M: 1.822529E-11
Real
Aptamer SeqId: 6533-20 | Target: DNS2B | UniProt: Q8WZ79
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6533-20 | Target: DNS2B | UniProt: Q8WZ79 | TargetFullName: Deoxyribonuclease-2-beta | Organisim: human | Apparent_Kd_M: 9.64153E-12
Real
Aptamer SeqId: 6536-54 | Target: LAML2 | UniProt: Q8NHP8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6536-54 | Target: LAML2 | UniProt: Q8NHP8 | TargetFullName: Putative phospholipase B-like 2 | Organisim: human | Apparent_Kd_M: 7.482411E-11
Real
Aptamer SeqId: 6538-90 | Target: K2013 | UniProt: Q8IYS2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6538-90 | Target: K2013 | UniProt: Q8IYS2 | TargetFullName: Uncharacterized protein KIAA2013 | Organisim: human | Apparent_Kd_M: 1.047975E-12
Real
Aptamer SeqId: 6543-182 | Target: PRRP | UniProt: P81277
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6543-182 | Target: PRRP | UniProt: P81277 | TargetFullName: Prolactin-releasing peptide | Organisim: human | Apparent_Kd_M: 1.950023E-11
Real
Aptamer SeqId: 6544-33 | Target: NELL1 | UniProt: Q92832
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6544-33 | Target: NELL1 | UniProt: Q92832 | TargetFullName: Protein kinase C-binding protein NELL1 | Organisim: human | Apparent_Kd_M: 6.646086E-12
Real
Aptamer SeqId: 6545-58 | Target: PRIO | UniProt: P04156
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6545-58 | Target: PRIO | UniProt: P04156 | TargetFullName: Major prion protein | Organisim: human | Apparent_Kd_M: 1.259962E-10
Real
Aptamer SeqId: 6547-83 | Target: TM11D | UniProt: O60235
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6547-83 | Target: TM11D | UniProt: O60235 | TargetFullName: Transmembrane protease serine 11D | Organisim: human | Apparent_Kd_M: 1.117375E-11
Real
Aptamer SeqId: 6549-60 | Target: VTM2L | UniProt: Q96N03
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6549-60 | Target: VTM2L | UniProt: Q96N03 | TargetFullName: V-set and transmembrane domain-containing protein 2-like protein | Organisim: human | Apparent_Kd_M: 2.078715E-12
Real
Aptamer SeqId: 6550-4 | Target: ICAM4 | UniProt: Q14773
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6550-4 | Target: ICAM4 | UniProt: Q14773 | TargetFullName: Intercellular adhesion molecule 4 | Organisim: human | Apparent_Kd_M: 2.43E-11
Real
Aptamer SeqId: 6551-94 | Target: Vaspin | UniProt: Q8IW75
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6551-94 | Target: Vaspin | UniProt: Q8IW75 | TargetFullName: Serpin A12 | Organisim: human | Apparent_Kd_M: 4.880764E-12
Real
Aptamer SeqId: 6553-68 | Target: CCD19 | UniProt: Q9UL16
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6553-68 | Target: CCD19 | UniProt: Q9UL16 | TargetFullName: Cilia- and flagella-associated protein 45 | Organisim: human | Apparent_Kd_M: 1.002896E-11
Real
Aptamer SeqId: 6555-58 | Target: Stomatin-like protein 2 | UniProt: Q9UJZ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6555-58 | Target: Stomatin-like protein 2 | UniProt: Q9UJZ1 | TargetFullName: Stomatin-like protein 2; mitochondrial | Organisim: human | Apparent_Kd_M: 6.53599E-12
Real
Aptamer SeqId: 6556-5 | Target: ENPP5 | UniProt: Q9UJA9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6556-5 | Target: ENPP5 | UniProt: Q9UJA9 | TargetFullName: Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 | Organisim: human | Apparent_Kd_M: 4.518232E-12
Real
Aptamer SeqId: 6557-50 | Target: LRC15 | UniProt: Q8TF66
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6557-50 | Target: LRC15 | UniProt: Q8TF66 | TargetFullName: Leucine-rich repeat-containing protein 15 | Organisim: human | Apparent_Kd_M: 4.364592E-12
Real
Aptamer SeqId: 6558-5 | Target: COL10 | UniProt: Q9Y6Z7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6558-5 | Target: COL10 | UniProt: Q9Y6Z7 | TargetFullName: Collectin-10 | Organisim: human | Apparent_Kd_M: 9.344111E-12
Real
Aptamer SeqId: 6561-77 | Target: Ig K chain V-I region HK102-like
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6561-77 | Target: Ig K chain V-I region HK102-like | UniProt: | TargetFullName: Ig Kappa chain V-I region HK102- like | Organisim: human | Apparent_Kd_M: 1.011005E-10
Real
Aptamer SeqId: 6563-78 | Target: HSP 70 | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6563-78 | Target: HSP 70 | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 5.567233E-12
Real
Aptamer SeqId: 6570-1 | Target: CODA1 | UniProt: Q5TAT6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6570-1 | Target: CODA1 | UniProt: Q5TAT6 | TargetFullName: Collagen alpha-1(XIII) chain | Organisim: human | Apparent_Kd_M: 1.422908E-11
Real
Aptamer SeqId: 6571-75 | Target: CQ078 | UniProt: Q8N4C9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6571-75 | Target: CQ078 | UniProt: Q8N4C9 | TargetFullName: Uncharacterized protein C17orf78 | Organisim: human | Apparent_Kd_M: 8.52E-12
Real
Aptamer SeqId: 6572-10 | Target: LRRT4 | UniProt: Q86VH4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6572-10 | Target: LRRT4 | UniProt: Q86VH4 | TargetFullName: Leucine-rich repeat transmembrane neuronal protein 4 | Organisim: human | Apparent_Kd_M: 4.58E-12
Real
Aptamer SeqId: 6574-11 | Target: FAIM3 | UniProt: O60667
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6574-11 | Target: FAIM3 | UniProt: O60667 | TargetFullName: Fas apoptotic inhibitory molecule 3 | Organisim: human | Apparent_Kd_M: 3.999935E-11
Real
Aptamer SeqId: 6576-1 | Target: ART4 | UniProt: Q93070
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6576-1 | Target: ART4 | UniProt: Q93070 | TargetFullName: Ecto-ADP-ribosyltransferase 4 | Organisim: human | Apparent_Kd_M: 5.11E-11
Real
Aptamer SeqId: 6577-64 | Target: LAMA4 | UniProt: Q16363
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6577-64 | Target: LAMA4 | UniProt: Q16363 | TargetFullName: Laminin subunit alpha-4 | Organisim: human | Apparent_Kd_M: 4.369937E-11
Real
Aptamer SeqId: 6578-29 | Target: TNMD | UniProt: Q9H2S6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6578-29 | Target: TNMD | UniProt: Q9H2S6 | TargetFullName: Tenomodulin | Organisim: human | Apparent_Kd_M: 1.154869E-11
Real
Aptamer SeqId: 6580-29 | Target: Pregnancy zone protein | UniProt: P20742
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6580-29 | Target: Pregnancy zone protein | UniProt: P20742 | TargetFullName: Pregnancy zone protein | Organisim: human | Apparent_Kd_M: 5.383221E-11
Real
Aptamer SeqId: 6584-1 | Target: SRCH | UniProt: P23327
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6584-1 | Target: SRCH | UniProt: P23327 | TargetFullName: Sarcoplasmic reticulum histidine-rich calcium-binding protein | Organisim: human | Apparent_Kd_M: 2.427834E-11
Real
Aptamer SeqId: 6586-19 | Target: ADA11 | UniProt: O75078
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6586-19 | Target: ADA11 | UniProt: O75078 | TargetFullName: Disintegrin and metalloproteinase domain-containing protein 11 | Organisim: human | Apparent_Kd_M: 4.814859E-12
Real
Aptamer SeqId: 6587-6 | Target: LRFN5 | UniProt: Q96NI6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6587-6 | Target: LRFN5 | UniProt: Q96NI6 | TargetFullName: Leucine-rich repeat and fibronectin type-III domain-containing protein 5 | Organisim: human | Apparent_Kd_M: 5.884121E-12
Real
Aptamer SeqId: 6593-5 | Target: GALT3 | UniProt: Q14435
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6593-5 | Target: GALT3 | UniProt: Q14435 | TargetFullName: Polypeptide N-acetylgalactosaminyltransferase 3 | Organisim: human | Apparent_Kd_M: 9.146254E-12
Real
Aptamer SeqId: 6594-64 | Target: SMDC1 | UniProt: Q9NPB0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6594-64 | Target: SMDC1 | UniProt: Q9NPB0 | TargetFullName: SAYSvFN domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 1.791185E-11
Real
Aptamer SeqId: 6597-24 | Target: TM157 | UniProt: Q8TBP5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6597-24 | Target: TM157 | UniProt: Q8TBP5 | TargetFullName: Membrane protein FAM174A | Organisim: human | Apparent_Kd_M: 2.915167E-12
Real
Aptamer SeqId: 6599-5 | Target: APCD1 | UniProt: Q8J025
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6599-5 | Target: APCD1 | UniProt: Q8J025 | TargetFullName: Protein APCDD1 | Organisim: human | Apparent_Kd_M: 2.948456E-12
Real
Aptamer SeqId: 6600-70 | Target: RELL2 | UniProt: Q8NC24
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6600-70 | Target: RELL2 | UniProt: Q8NC24 | TargetFullName: RELT-like protein 2 | Organisim: human | Apparent_Kd_M: 5.272156E-11
Real
Aptamer SeqId: 6603-18 | Target: KALM | UniProt: P23352
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6603-18 | Target: KALM | UniProt: P23352 | TargetFullName: Anosmin-1 | Organisim: human | Apparent_Kd_M: 5.413777E-11
Real
Aptamer SeqId: 6604-59 | Target: CD031 | UniProt: Q8TB73
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6604-59 | Target: CD031 | UniProt: Q8TB73 | TargetFullName: Protein NDNF | Organisim: human | Apparent_Kd_M: 2.366832E-11
Real
Aptamer SeqId: 6605-17 | Target: IGFALS | UniProt: P35858
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6605-17 | Target: IGFALS | UniProt: P35858 | TargetFullName: Insulin-like growth factor-binding protein complex acid labile subunit | Organisim: human | Apparent_Kd_M: 2.611866E-12
Real
Aptamer SeqId: 6606-61 | Target: KISS1 | UniProt: Q15726
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6606-61 | Target: KISS1 | UniProt: Q15726 | TargetFullName: Metastasis-suppressor KiSS-1 | Organisim: human | Apparent_Kd_M: 6.556847E-11
Real
Aptamer SeqId: 6609-22 | Target: CN37 | UniProt: P09543
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6609-22 | Target: CN37 | UniProt: P09543 | TargetFullName: 2';3'-cyclic-nucleotide 3'-phosphodiesterase | Organisim: human | Apparent_Kd_M: 4.690567E-12
Real
Aptamer SeqId: 6611-8 | Target: KDEL1 | UniProt: Q6UW63
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6611-8 | Target: KDEL1 | UniProt: Q6UW63 | TargetFullName: KDEL motif-containing protein 1 | Organisim: human | Apparent_Kd_M: 5.244319E-12
Real
Aptamer SeqId: 6612-90 | Target: CP079 | UniProt: Q6PL45
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6612-90 | Target: CP079 | UniProt: Q6PL45 | TargetFullName: BRICHOS domain-containing protein 5 | Organisim: human | Apparent_Kd_M: 1.308895E-11
Real
Aptamer SeqId: 6617-12 | Target: FCRL6 | UniProt: Q6DN72
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6617-12 | Target: FCRL6 | UniProt: Q6DN72 | TargetFullName: Fc receptor-like protein 6 | Organisim: human | Apparent_Kd_M: 8.3941E-12
Real
Aptamer SeqId: 6620-82 | Target: LIGO1 | UniProt: Q96FE5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6620-82 | Target: LIGO1 | UniProt: Q96FE5 | TargetFullName: Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 | Organisim: human | Apparent_Kd_M: 1.052755E-11
Real
Aptamer SeqId: 6621-10 | Target: REL2 | UniProt: P04090
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6621-10 | Target: REL2 | UniProt: P04090 | TargetFullName: Prorelaxin H2 | Organisim: human | Apparent_Kd_M: 5.453934E-12
Real
Aptamer SeqId: 6622-90 | Target: APEL | UniProt: Q9ULZ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6622-90 | Target: APEL | UniProt: Q9ULZ1 | TargetFullName: Apelin | Organisim: human | Apparent_Kd_M: 2.582089E-11
Real
Aptamer SeqId: 6624-94 | Target: WNT11 | UniProt: O96014
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6624-94 | Target: WNT11 | UniProt: O96014 | TargetFullName: Protein Wnt-11 | Organisim: human | Apparent_Kd_M: 2.228506E-11
Real
Aptamer SeqId: 6625-31 | Target: ATAD1 | UniProt: Q8NBU5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6625-31 | Target: ATAD1 | UniProt: Q8NBU5 | TargetFullName: ATPase family AAA domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 8.519485E-12
Real
Aptamer SeqId: 6626-81 | Target: CHSTC | UniProt: Q9NRB3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6626-81 | Target: CHSTC | UniProt: Q9NRB3 | TargetFullName: Carbohydrate sulfotransferase 12 | Organisim: human | Apparent_Kd_M: 2.549013E-11
Real
Aptamer SeqId: 6627-25 | Target: LIPR1 | UniProt: P54315
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6627-25 | Target: LIPR1 | UniProt: P54315 | TargetFullName: Inactive pancreatic lipase-related protein 1 | Organisim: human | Apparent_Kd_M: 4.14632E-12
Real
Aptamer SeqId: 6629-3 | Target: HBD-1 | UniProt: P60022
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6629-3 | Target: HBD-1 | UniProt: P60022 | TargetFullName: Beta-defensin 1 | Organisim: human | Apparent_Kd_M: 4.494471E-12
Real
Aptamer SeqId: 6631-17 | Target: CO9A1 | UniProt: P20849
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6631-17 | Target: CO9A1 | UniProt: P20849 | TargetFullName: Collagen alpha-1(IX) chain | Organisim: human | Apparent_Kd_M: 7.41E-12
Real
Aptamer SeqId: 6633-43 | Target: UPK3L | UniProt: B0FP48
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6633-43 | Target: UPK3L | UniProt: B0FP48 | TargetFullName: Uroplakin-3b-like protein | Organisim: human | Apparent_Kd_M: 2.688382E-11
Real
Aptamer SeqId: 6641-60 | Target: PolyUbiquitin K48 | UniProt: P0CG47
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6641-60 | Target: PolyUbiquitin K48 | UniProt: P0CG47 | TargetFullName: PolyUbiquitin K48-linked | Organisim: human | Apparent_Kd_M: 7.9E-12
Real
Aptamer SeqId: 6647-55 | Target: PolyUbiquitin K63 | UniProt: P0CG48
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6647-55 | Target: PolyUbiquitin K63 | UniProt: P0CG48 | TargetFullName: PolyUbiquitin K63-linked | Organisim: human | Apparent_Kd_M: 1.44E-12
Real
Aptamer SeqId: 6649-51 | Target: NET1 | UniProt: O95631
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6649-51 | Target: NET1 | UniProt: O95631 | TargetFullName: Netrin-1 | Organisim: human | Apparent_Kd_M: 4.93E-11
Real
Aptamer SeqId: 6651-74 | Target: PolyUbiquitin K48 | UniProt: P0CG47
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6651-74 | Target: PolyUbiquitin K48 | UniProt: P0CG47 | TargetFullName: PolyUbiquitin K48-linked | Organisim: human | Apparent_Kd_M: 1.23E-11
Real
Aptamer SeqId: 6653-58 | Target: CD47 | UniProt: Q08722
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6653-58 | Target: CD47 | UniProt: Q08722 | TargetFullName: Leukocyte surface antigen CD47 | Organisim: human | Apparent_Kd_M: 1.24E-11
Real
Aptamer SeqId: 6706-18 | Target: PPBN | UniProt: P10696
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6706-18 | Target: PPBN | UniProt: P10696 | TargetFullName: Alkaline phosphatase; placental-like | Organisim: human | Apparent_Kd_M: 2.21E-11
Real
Aptamer SeqId: 6713-4 | Target: LRP11 | UniProt: Q86VZ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6713-4 | Target: LRP11 | UniProt: Q86VZ4 | TargetFullName: Low-density lipoprotein receptor-related protein 11 | Organisim: human | Apparent_Kd_M: 4.292451E-11
Real
Aptamer SeqId: 6715-63 | Target: PPBN | UniProt: P10696
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6715-63 | Target: PPBN | UniProt: P10696 | TargetFullName: Alkaline phosphatase; placental-like | Organisim: human | Apparent_Kd_M: 4.026601E-11
Real
Aptamer SeqId: 6895-1 | Target: TR | UniProt: P02786
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6895-1 | Target: TR | UniProt: P02786 | TargetFullName: Transferrin receptor protein 1 | Organisim: human | Apparent_Kd_M: 4.27E-11
Real
Aptamer SeqId: 6896-3 | Target: CA162 | UniProt: Q8NEQ5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6896-3 | Target: CA162 | UniProt: Q8NEQ5 | TargetFullName: Transmembrane protein C1orf162 | Organisim: human | Apparent_Kd_M: 2.55758E-11
Real
Aptamer SeqId: 6897-38 | Target: B3GA3 | UniProt: O94766
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6897-38 | Target: B3GA3 | UniProt: O94766 | TargetFullName: Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3 | Organisim: human | Apparent_Kd_M: 3.963414E-10
Real
Aptamer SeqId: 6899-37 | Target: PHS2 | UniProt: Q9H0N5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6899-37 | Target: PHS2 | UniProt: Q9H0N5 | TargetFullName: Pterin-4-alpha-carbinolamine dehydratase 2 | Organisim: human | Apparent_Kd_M: 1.120383E-11
Real
Aptamer SeqId: 6900-30 | Target: UB2J1 | UniProt: Q9Y385
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6900-30 | Target: UB2J1 | UniProt: Q9Y385 | TargetFullName: Ubiquitin-conjugating enzyme E2 J1 | Organisim: human | Apparent_Kd_M: 5.088807E-11
Real
Aptamer SeqId: 6904-14 | Target: LRRT2 | UniProt: O43300
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6904-14 | Target: LRRT2 | UniProt: O43300 | TargetFullName: Leucine-rich repeat transmembrane neuronal protein 2 | Organisim: human | Apparent_Kd_M: 6.27471E-13
Real
Aptamer SeqId: 6907-17 | Target: TMC5A | UniProt: Q8N6Q1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6907-17 | Target: TMC5A | UniProt: Q8N6Q1 | TargetFullName: Transmembrane and coiled-coil domain-containing protein 5A | Organisim: human | Apparent_Kd_M: 8.331894E-11
Real
Aptamer SeqId: 6909-40 | Target: MGAT2 | UniProt: Q10469
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6909-40 | Target: MGAT2 | UniProt: Q10469 | TargetFullName: Alpha-1;6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase | Organisim: human | Apparent_Kd_M: 2.312675E-11
Real
Aptamer SeqId: 6911-103 | Target: CLC6A | UniProt: Q6EIG7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6911-103 | Target: CLC6A | UniProt: Q6EIG7 | TargetFullName: C-type lectin domain family 6 member A | Organisim: human | Apparent_Kd_M: 1.152124E-11
Real
Aptamer SeqId: 6912-6 | Target: EFHA2 | UniProt: Q86XE3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6912-6 | Target: EFHA2 | UniProt: Q86XE3 | TargetFullName: Calcium uptake protein 3; mitochondrial | Organisim: human | Apparent_Kd_M: 3.796102E-12
Real
Aptamer SeqId: 6913-189 | Target: HMG-2 | UniProt: P26583
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6913-189 | Target: HMG-2 | UniProt: P26583 | TargetFullName: High mobility group protein B2 | Organisim: human | Apparent_Kd_M: 1.8E-12
Real
Aptamer SeqId: 6915-2 | Target: C16L2 | UniProt: Q6UWJ8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6915-2 | Target: C16L2 | UniProt: Q6UWJ8 | TargetFullName: CD164 sialomucin-like 2 protein | Organisim: human | Apparent_Kd_M: 1.169193E-10
Real
Aptamer SeqId: 6917-49 | Target: LRRC3 | UniProt: Q9BY71
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6917-49 | Target: LRRC3 | UniProt: Q9BY71 | TargetFullName: Leucine-rich repeat-containing protein 3 | Organisim: human | Apparent_Kd_M: 2.531386E-12
Real
Aptamer SeqId: 6918-183 | Target: CCKN | UniProt: P06307
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6918-183 | Target: CCKN | UniProt: P06307 | TargetFullName: Cholecystokinin | Organisim: human | Apparent_Kd_M: 3.014752E-11
Real
Aptamer SeqId: 6919-3 | Target: HBAZ | UniProt: P02008
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6919-3 | Target: HBAZ | UniProt: P02008 | TargetFullName: Hemoglobin subunit zeta | Organisim: human | Apparent_Kd_M: 1.12E-11
Real
Aptamer SeqId: 6920-1 | Target: GFRAL | UniProt: Q6UXV0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6920-1 | Target: GFRAL | UniProt: Q6UXV0 | TargetFullName: GDNF family receptor alpha-like | Organisim: human | Apparent_Kd_M: 2.846468E-12
Real
Aptamer SeqId: 6921-24 | Target: B4GT3 | UniProt: O60512
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6921-24 | Target: B4GT3 | UniProt: O60512 | TargetFullName: Beta-1;4-galactosyltransferase 3 | Organisim: human | Apparent_Kd_M: 5.875243E-11
Real
Aptamer SeqId: 6923-1 | Target: PLOD2 | UniProt: O00469
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6923-1 | Target: PLOD2 | UniProt: O00469 | TargetFullName: Procollagen-lysine;2-oxoglutarate 5-dioxygenase 2 | Organisim: human | Apparent_Kd_M: 6.53E-12
Real
Aptamer SeqId: 6925-26 | Target: SNX8 | UniProt: Q9Y5X2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6925-26 | Target: SNX8 | UniProt: Q9Y5X2 | TargetFullName: Sorting nexin-8 | Organisim: human | Apparent_Kd_M: 6.169727E-12
Real
Aptamer SeqId: 6927-7 | Target: NDST1 | UniProt: P52848
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6927-7 | Target: NDST1 | UniProt: P52848 | TargetFullName: Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1 | Organisim: human | Apparent_Kd_M: 8.073237E-13
Real
Aptamer SeqId: 6929-10 | Target: SIA8C | UniProt: O43173
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6929-10 | Target: SIA8C | UniProt: O43173 | TargetFullName: Sia-alpha-2;3-Gal-beta-1;4-GlcNAc-R:alpha 2;8-sialyltransferase | Organisim: human | Apparent_Kd_M: 4.993419E-12
Real
Aptamer SeqId: 6930-95 | Target: SIA8F | UniProt: P61647
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6930-95 | Target: SIA8F | UniProt: P61647 | TargetFullName: Alpha-2;8-sialyltransferase 8F | Organisim: human | Apparent_Kd_M: 1.043889E-10
Real
Aptamer SeqId: 6932-42 | Target: ITA5 | UniProt: P08648
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6932-42 | Target: ITA5 | UniProt: P08648 | TargetFullName: Integrin alpha-5 | Organisim: human | Apparent_Kd_M: 2.230537E-10
Real
Aptamer SeqId: 6933-20 | Target: RM34 | UniProt: Q9BQ48
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6933-20 | Target: RM34 | UniProt: Q9BQ48 | TargetFullName: 39S ribosomal protein L34; mitochondrial | Organisim: human | Apparent_Kd_M: 1.776216E-11
Real
Aptamer SeqId: 6934-8 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6934-8 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.603209E-11
Real
Aptamer SeqId: 6936-7 | Target: PMEPA | UniProt: Q969W9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6936-7 | Target: PMEPA | UniProt: Q969W9 | TargetFullName: Protein TMEPAI | Organisim: human | Apparent_Kd_M: 7.35848E-12
Real
Aptamer SeqId: 6937-251 | Target: CA043 | UniProt: Q9BWL3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6937-251 | Target: CA043 | UniProt: Q9BWL3 | TargetFullName: Uncharacterized protein C1orf43 | Organisim: human | Apparent_Kd_M: 1.464564E-11
Real
Aptamer SeqId: 6938-21 | Target: PCDGC | UniProt: O60330
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6938-21 | Target: PCDGC | UniProt: O60330 | TargetFullName: Protocadherin gamma-A12 | Organisim: human | Apparent_Kd_M: 1.151376E-10
Real
Aptamer SeqId: 6940-18 | Target: JPH1 | UniProt: Q9HDC5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6940-18 | Target: JPH1 | UniProt: Q9HDC5 | TargetFullName: Junctophilin-1 | Organisim: human | Apparent_Kd_M: 1.269947E-11
Real
Aptamer SeqId: 6941-11 | Target: SUMF1 | UniProt: Q8NBK3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6941-11 | Target: SUMF1 | UniProt: Q8NBK3 | TargetFullName: Sulfatase-modifying factor 1 | Organisim: human | Apparent_Kd_M: 1.987705E-10
Real
Aptamer SeqId: 6947-4 | Target: SIA10 | UniProt: Q9Y274
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6947-4 | Target: SIA10 | UniProt: Q9Y274 | TargetFullName: Type 2 lactosamine alpha-2;3-sialyltransferase | Organisim: human | Apparent_Kd_M: 2.531747E-12
Real
Aptamer SeqId: 6948-82 | Target: FIG4 | UniProt: Q92562
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6948-82 | Target: FIG4 | UniProt: Q92562 | TargetFullName: Polyphosphoinositide phosphatase | Organisim: human | Apparent_Kd_M: 8.858766E-11
Real
Aptamer SeqId: 6951-26 | Target: ASIC4 | UniProt: Q96FT7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6951-26 | Target: ASIC4 | UniProt: Q96FT7 | TargetFullName: Acid-sensing ion channel 4 | Organisim: human | Apparent_Kd_M: 1.533205E-11
Real
Aptamer SeqId: 6955-68 | Target: SNX1 | UniProt: Q13596
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6955-68 | Target: SNX1 | UniProt: Q13596 | TargetFullName: Sorting nexin-1 | Organisim: human | Apparent_Kd_M: 2.33E-11
Real
Aptamer SeqId: 6961-14 | Target: IGFL3 | UniProt: Q6UXB1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6961-14 | Target: IGFL3 | UniProt: Q6UXB1 | TargetFullName: Insulin growth factor-like family member 3 | Organisim: human | Apparent_Kd_M: 1.257984E-10
Real
Aptamer SeqId: 6962-5 | Target: DRB3 | UniProt: P79483
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6962-5 | Target: DRB3 | UniProt: P79483 | TargetFullName: HLA class II histocompatibility antigen; DR beta 3 chain | Organisim: human | Apparent_Kd_M: 2.823101E-11
Real
Aptamer SeqId: 6965-19 | Target: CNTP2 | UniProt: Q9UHC6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6965-19 | Target: CNTP2 | UniProt: Q9UHC6 | TargetFullName: Contactin-associated protein-like 2 | Organisim: human | Apparent_Kd_M: 1.709871E-12
Real
Aptamer SeqId: 6966-144 | Target: STX1B | UniProt: P61266
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6966-144 | Target: STX1B | UniProt: P61266 | TargetFullName: Syntaxin-1B | Organisim: human | Apparent_Kd_M: 1.865861E-10
Real
Aptamer SeqId: 6967-5 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6967-5 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 5.723744E-12
Real
Aptamer SeqId: 6969-14 | Target: WFDC5 | UniProt: Q8TCV5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6969-14 | Target: WFDC5 | UniProt: Q8TCV5 | TargetFullName: WAP four-disulfide core domain protein 5 | Organisim: human | Apparent_Kd_M: 1.273881E-10
Real
Aptamer SeqId: 6974-6 | Target: HG2A | UniProt: P04233
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6974-6 | Target: HG2A | UniProt: P04233 | TargetFullName: HLA class II histocompatibility antigen gamma chain | Organisim: human | Apparent_Kd_M: 1.94E-11
Real
Aptamer SeqId: 6975-52 | Target: SNAPN | UniProt: O95295
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6975-52 | Target: SNAPN | UniProt: O95295 | TargetFullName: SNARE-associated protein Snapin | Organisim: human | Apparent_Kd_M: 1.50499E-11
Real
Aptamer SeqId: 6984-6 | Target: IGSF8 | UniProt: Q969P0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6984-6 | Target: IGSF8 | UniProt: Q969P0 | TargetFullName: Immunoglobulin superfamily member 8 | Organisim: human | Apparent_Kd_M: 3.478251E-12
Real
Aptamer SeqId: 6986-17 | Target: HS3SB | UniProt: Q9Y662
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6986-17 | Target: HS3SB | UniProt: Q9Y662 | TargetFullName: Heparan sulfate glucosamine 3-O-sulfotransferase 3B1 | Organisim: human | Apparent_Kd_M: 5.792256E-11
Real
Aptamer SeqId: 6990-44 | Target: SDF2L | UniProt: Q9HCN8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6990-44 | Target: SDF2L | UniProt: Q9HCN8 | TargetFullName: Stromal cell-derived factor 2-like protein 1 | Organisim: human | Apparent_Kd_M: 4.549655E-11
Real
Aptamer SeqId: 6991-24 | Target: FUT9 | UniProt: Q9Y231
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6991-24 | Target: FUT9 | UniProt: Q9Y231 | TargetFullName: Alpha-(1;3)-fucosyltransferase 9 | Organisim: human | Apparent_Kd_M: 1.745618E-10
Real
Aptamer SeqId: 6992-67 | Target: HBD | UniProt: P02042
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6992-67 | Target: HBD | UniProt: P02042 | TargetFullName: Hemoglobin subunit delta | Organisim: human | Apparent_Kd_M: 2.24E-10
Real
Aptamer SeqId: 6994-19 | Target: CC018 | UniProt: Q9UK00
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6994-19 | Target: CC018 | UniProt: Q9UK00 | TargetFullName: Uncharacterized protein C3orf18 | Organisim: human | Apparent_Kd_M: 2.502114E-10
Real
Aptamer SeqId: 6997-32 | Target: RAB26 | UniProt: Q9ULW5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6997-32 | Target: RAB26 | UniProt: Q9ULW5 | TargetFullName: Ras-related protein Rab-26 | Organisim: human | Apparent_Kd_M: 1.952732E-10
Real
Aptamer SeqId: 6998-106 | Target: HAAH | UniProt: Q12797
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 6998-106 | Target: HAAH | UniProt: Q12797 | TargetFullName: Aspartyl/asparaginyl beta-hydroxylase | Organisim: human | Apparent_Kd_M: 8.45882E-12
Real
Aptamer SeqId: 7003-4 | Target: GLT10 | UniProt: Q86SR1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7003-4 | Target: GLT10 | UniProt: Q86SR1 | TargetFullName: Polypeptide N-acetylgalactosaminyltransferase 10 | Organisim: human | Apparent_Kd_M: 6.371791E-11
Real
Aptamer SeqId: 7006-4 | Target: COPA1 | UniProt: Q9BXS0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7006-4 | Target: COPA1 | UniProt: Q9BXS0 | TargetFullName: Collagen alpha-1(XXV) chain | Organisim: human | Apparent_Kd_M: 2.833975E-11
Real
Aptamer SeqId: 7007-24 | Target: TRAPPC4 | UniProt: Q9Y296
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7007-24 | Target: TRAPPC4 | UniProt: Q9Y296 | TargetFullName: Trafficking protein particle complex subunit 4 | Organisim: human | Apparent_Kd_M: 1.706947E-11
Real
Aptamer SeqId: 7009-8 | Target: CD72 | UniProt: P21854
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7009-8 | Target: CD72 | UniProt: P21854 | TargetFullName: B-cell differentiation antigen CD72 | Organisim: human | Apparent_Kd_M: 2.12E-11
Real
Aptamer SeqId: 7011-8 | Target: KCIP4 | UniProt: Q6PIL6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7011-8 | Target: KCIP4 | UniProt: Q6PIL6 | TargetFullName: Kv channel-interacting protein 4 | Organisim: human | Apparent_Kd_M: 4.886963E-11
Real
Aptamer SeqId: 7014-27 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7014-27 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.016404E-12
Real
Aptamer SeqId: 7015-8 | Target: LIRB5 | UniProt: O75023
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7015-8 | Target: LIRB5 | UniProt: O75023 | TargetFullName: Leukocyte immunoglobulin-like receptor subfamily B member 5 | Organisim: human | Apparent_Kd_M: 6.719643E-12
Real
Aptamer SeqId: 7016-12 | Target: GCNT1 | UniProt: Q02742
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7016-12 | Target: GCNT1 | UniProt: Q02742 | TargetFullName: Beta-1;3-galactosyl-O-glycosyl-glycoprotein beta-1;6-N-acetylglucosaminyltransferase | Organisim: human | Apparent_Kd_M: 2.42E-10
Real
Aptamer SeqId: 7018-10 | Target: TSR3 | UniProt: Q9UJK0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7018-10 | Target: TSR3 | UniProt: Q9UJK0 | TargetFullName: Ribosome biogenesis protein TSR3 homolog | Organisim: human | Apparent_Kd_M: 2.141036E-10
Real
Aptamer SeqId: 7019-13 | Target: Semaphorin-7A | UniProt: O75326
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7019-13 | Target: Semaphorin-7A | UniProt: O75326 | TargetFullName: Semaphorin-7A | Organisim: human | Apparent_Kd_M: 3.562159E-11
Real
Aptamer SeqId: 7020-13 | Target: CHST5 | UniProt: Q9GZS9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7020-13 | Target: CHST5 | UniProt: Q9GZS9 | TargetFullName: Carbohydrate sulfotransferase 5 | Organisim: human | Apparent_Kd_M: 3.176733E-11
Real
Aptamer SeqId: 7034-4 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7034-4 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 5.747067E-11
Real
Aptamer SeqId: 7038-45 | Target: SIA8D | UniProt: Q92187
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7038-45 | Target: SIA8D | UniProt: Q92187 | TargetFullName: CMP-N-acetylneuraminate-poly-alpha-2;8-sialyltransferase | Organisim: human | Apparent_Kd_M: 3.193587E-11
Real
Aptamer SeqId: 7045-4 | Target: BNIP3 | UniProt: Q12983
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7045-4 | Target: BNIP3 | UniProt: Q12983 | TargetFullName: BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 | Organisim: human | Apparent_Kd_M: 5.761044E-11
Real
Aptamer SeqId: 7046-6 | Target: CT173 | UniProt: Q96LM9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7046-6 | Target: CT173 | UniProt: Q96LM9 | TargetFullName: Uncharacterized protein C20orf173 | Organisim: human | Apparent_Kd_M: 2.13E-10
Real
Aptamer SeqId: 7048-4 | Target: CEA19 | UniProt: Q7Z692
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7048-4 | Target: CEA19 | UniProt: Q7Z692 | TargetFullName: Carcinoembryonic antigen-related cell adhesion molecule 19 | Organisim: human | Apparent_Kd_M: 2.177148E-10
Real
Aptamer SeqId: 7049-2 | Target: ADAM 23 | UniProt: O75077
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7049-2 | Target: ADAM 23 | UniProt: O75077 | TargetFullName: Disintegrin and metalloproteinase domain-containing protein 23 | Organisim: human | Apparent_Kd_M: 6.99852E-12
Real
Aptamer SeqId: 7050-5 | Target: NEGR1 | UniProt: Q7Z3B1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7050-5 | Target: NEGR1 | UniProt: Q7Z3B1 | TargetFullName: Neuronal growth regulator 1 | Organisim: human | Apparent_Kd_M: 6.44E-11
Real
Aptamer SeqId: 7054-87 | Target: CLC2D | UniProt: Q9UHP7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7054-87 | Target: CLC2D | UniProt: Q9UHP7 | TargetFullName: C-type lectin domain family 2 member D | Organisim: human | Apparent_Kd_M: 2.186042E-10
Real
Aptamer SeqId: 7057-18 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7057-18 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.045897E-11
Real
Aptamer SeqId: 7059-14 | Target: LIRA6 | UniProt: Q6PI73
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7059-14 | Target: LIRA6 | UniProt: Q6PI73 | TargetFullName: Leukocyte immunoglobulin-like receptor subfamily A member 6 | Organisim: human | Apparent_Kd_M: 2.70774E-11
Real
Aptamer SeqId: 7060-2 | Target: ERO1A | UniProt: Q96HE7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7060-2 | Target: ERO1A | UniProt: Q96HE7 | TargetFullName: ERO1-like protein alpha | Organisim: human | Apparent_Kd_M: 2.298602E-11
Real
Aptamer SeqId: 7064-2 | Target: VAMP8 | UniProt: Q9BV40
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7064-2 | Target: VAMP8 | UniProt: Q9BV40 | TargetFullName: Vesicle-associated membrane protein 8 | Organisim: human | Apparent_Kd_M: 4.167692E-12
Real
Aptamer SeqId: 7065-1 | Target: G6B | UniProt: O95866
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7065-1 | Target: G6B | UniProt: O95866 | TargetFullName: Protein G6b | Organisim: human | Apparent_Kd_M: 4.26E-12
Real
Aptamer SeqId: 7066-199 | Target: F209B | UniProt: Q5JX69
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7066-199 | Target: F209B | UniProt: Q5JX69 | TargetFullName: Protein FAM209B | Organisim: human | Apparent_Kd_M: 2.427769E-10
Real
Aptamer SeqId: 7069-9 | Target: TSNA1 | UniProt: Q96NA8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7069-9 | Target: TSNA1 | UniProt: Q96NA8 | TargetFullName: t-SNARE domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 8.357362E-11
Real
Aptamer SeqId: 7070-25 | Target: KELL | UniProt: P23276
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7070-25 | Target: KELL | UniProt: P23276 | TargetFullName: Kell blood group glycoprotein | Organisim: human | Apparent_Kd_M: 5.825511E-12
Real
Aptamer SeqId: 7071-23 | Target: MA1B1 | UniProt: Q9UKM7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7071-23 | Target: MA1B1 | UniProt: Q9UKM7 | TargetFullName: Endoplasmic reticulum mannosyl-oligosaccharide 1;2-alpha-mannosidase | Organisim: human | Apparent_Kd_M: 1.622742E-11
Real
Aptamer SeqId: 7073-69 | Target: CV015 | UniProt: Q8WYQ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7073-69 | Target: CV015 | UniProt: Q8WYQ4 | TargetFullName: Uncharacterized protein C22orf15 | Organisim: human | Apparent_Kd_M: 1.165503E-12
Real
Aptamer SeqId: 7076-17 | Target: ECEL1 | UniProt: O95672
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7076-17 | Target: ECEL1 | UniProt: O95672 | TargetFullName: Endothelin-converting enzyme-like 1 | Organisim: human | Apparent_Kd_M: 1.753178E-10
Real
Aptamer SeqId: 7077-9 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7077-9 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 8.895499E-12
Real
Aptamer SeqId: 7081-2 | Target: BT3A1 | UniProt: O00481
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7081-2 | Target: BT3A1 | UniProt: O00481 | TargetFullName: Butyrophilin subfamily 3 member A1 | Organisim: human | Apparent_Kd_M: 1.562424E-10
Real
Aptamer SeqId: 7082-2 | Target: B3GN6 | UniProt: Q6ZMB0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7082-2 | Target: B3GN6 | UniProt: Q6ZMB0 | TargetFullName: UDP-GlcNAc:betaGal beta-1;3-N-acetylglucosaminyltransferase 6 | Organisim: human | Apparent_Kd_M: 8.449109E-12
Real
Aptamer SeqId: 7083-74 | Target: MATN4 | UniProt: O95460
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7083-74 | Target: MATN4 | UniProt: O95460 | TargetFullName: Matrilin-4 | Organisim: human | Apparent_Kd_M: 1.945107E-11
Real
Aptamer SeqId: 7084-1 | Target: DRAXI | UniProt: Q8NBI3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7084-1 | Target: DRAXI | UniProt: Q8NBI3 | TargetFullName: Draxin | Organisim: human | Apparent_Kd_M: 3.020077E-11
Real
Aptamer SeqId: 7085-81 | Target: CDSN | UniProt: Q15517
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7085-81 | Target: CDSN | UniProt: Q15517 | TargetFullName: Corneodesmosin | Organisim: human | Apparent_Kd_M: 1.561106E-11
Real
Aptamer SeqId: 7089-42 | Target: SYT11 | UniProt: Q9BT88
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7089-42 | Target: SYT11 | UniProt: Q9BT88 | TargetFullName: Synaptotagmin-11 | Organisim: human | Apparent_Kd_M: 5.158153E-12
Real
Aptamer SeqId: 7090-17 | Target: GALT1 | UniProt: Q10472
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7090-17 | Target: GALT1 | UniProt: Q10472 | TargetFullName: Polypeptide N-acetylgalactosaminyltransferase 1 | Organisim: human | Apparent_Kd_M: 4.21479E-11
Real
Aptamer SeqId: 7092-7 | Target: PDILT | UniProt: Q8N807
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7092-7 | Target: PDILT | UniProt: Q8N807 | TargetFullName: Protein disulfide-isomerase-like protein of the testis | Organisim: human | Apparent_Kd_M: 7.863994E-11
Real
Aptamer SeqId: 7096-30 | Target: RMD1 | UniProt: Q96DB5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7096-30 | Target: RMD1 | UniProt: Q96DB5 | TargetFullName: Regulator of microtubule dynamics protein 1 | Organisim: human | Apparent_Kd_M: 9.146878E-12
Real
Aptamer SeqId: 7097-8 | Target: CDY1 | UniProt: Q9Y6F8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7097-8 | Target: CDY1 | UniProt: Q9Y6F8 | TargetFullName: Testis-specific chromodomain protein Y 1 | Organisim: human | Apparent_Kd_M: 8.755242E-12
Real
Aptamer SeqId: 7099-33 | Target: FSTL5 | UniProt: Q8N475
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7099-33 | Target: FSTL5 | UniProt: Q8N475 | TargetFullName: Follistatin-related protein 5 | Organisim: human | Apparent_Kd_M: 1.070847E-11
Real
Aptamer SeqId: 7100-31 | Target: CD2 | UniProt: P06729
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7100-31 | Target: CD2 | UniProt: P06729 | TargetFullName: T-cell surface antigen CD2 | Organisim: human | Apparent_Kd_M: 2.863343E-10
Real
Aptamer SeqId: 7104-71 | Target: CABP7 | UniProt: Q86V35
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7104-71 | Target: CABP7 | UniProt: Q86V35 | TargetFullName: Calcium-binding protein 7 | Organisim: human | Apparent_Kd_M: 1.35E-10
Real
Aptamer SeqId: 7105-7 | Target: CABL2 | UniProt: Q9BTV7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7105-7 | Target: CABL2 | UniProt: Q9BTV7 | TargetFullName: CDK5 and ABL1 enzyme substrate 2 | Organisim: human | Apparent_Kd_M: 2.731885E-11
Real
Aptamer SeqId: 7106-37 | Target: PLACL | UniProt: Q86WS3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7106-37 | Target: PLACL | UniProt: Q86WS3 | TargetFullName: Oocyte-secreted protein 2 | Organisim: human | Apparent_Kd_M: 5.501814E-11
Real
Aptamer SeqId: 7108-7 | Target: CS077 | UniProt: O75264
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7108-7 | Target: CS077 | UniProt: O75264 | TargetFullName: Small integral membrane protein 24 | Organisim: human | Apparent_Kd_M: 4.962675E-12
Real
Aptamer SeqId: 7110-2 | Target: DJB11 | UniProt: Q9UBS4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7110-2 | Target: DJB11 | UniProt: Q9UBS4 | TargetFullName: DnaJ homolog subfamily B member 11 | Organisim: human | Apparent_Kd_M: 4.567925E-11
Real
Aptamer SeqId: 7113-1 | Target: GRPE1 | UniProt: Q9HAV7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7113-1 | Target: GRPE1 | UniProt: Q9HAV7 | TargetFullName: GrpE protein homolog 1; mitochondrial | Organisim: human | Apparent_Kd_M: 2.988692E-11
Real
Aptamer SeqId: 7115-5 | Target: Semenogelin | UniProt: P04279
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7115-5 | Target: Semenogelin | UniProt: P04279 | TargetFullName: Semenogelin-1 | Organisim: human | Apparent_Kd_M: 3.1632E-11
Real
Aptamer SeqId: 7116-31 | Target: OSCAR | UniProt: Q8IYS5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7116-31 | Target: OSCAR | UniProt: Q8IYS5 | TargetFullName: Osteoclast-associated immunoglobulin-like receptor | Organisim: human | Apparent_Kd_M: 3.159295E-11
Real
Aptamer SeqId: 7117-21 | Target: SPI2 | UniProt: O75830
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7117-21 | Target: SPI2 | UniProt: O75830 | TargetFullName: Serpin I2 | Organisim: human | Apparent_Kd_M: 7.469633E-11
Real
Aptamer SeqId: 7118-24 | Target: IGDC3 | UniProt: Q8IVU1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7118-24 | Target: IGDC3 | UniProt: Q8IVU1 | TargetFullName: Immunoglobulin superfamily DCC subclass member 3 | Organisim: human | Apparent_Kd_M: 2.005522E-11
Real
Aptamer SeqId: 7121-2 | Target: SYT7 | UniProt: O43581
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7121-2 | Target: SYT7 | UniProt: O43581 | TargetFullName: Synaptotagmin-7 | Organisim: human | Apparent_Kd_M: 1.075285E-11
Real
Aptamer SeqId: 7123-25 | Target: RM52 | UniProt: Q86TS9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7123-25 | Target: RM52 | UniProt: Q86TS9 | TargetFullName: 39S ribosomal protein L52; mitochondrial | Organisim: human | Apparent_Kd_M: 4.316134E-11
Real
Aptamer SeqId: 7124-18 | Target: IL-21 | UniProt: Q9HBE4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7124-18 | Target: IL-21 | UniProt: Q9HBE4 | TargetFullName: Interleukin-21 | Organisim: human | Apparent_Kd_M: 4.35044E-12
Real
Aptamer SeqId: 7125-4 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7125-4 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 6.39479E-12
Real
Aptamer SeqId: 7127-3 | Target: Apo A-II | UniProt: P02652
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7127-3 | Target: Apo A-II | UniProt: P02652 | TargetFullName: Apolipoprotein A-II | Organisim: human | Apparent_Kd_M: 1.06102E-11
Real
Aptamer SeqId: 7128-9 | Target: VWA2 | UniProt: Q5GFL6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7128-9 | Target: VWA2 | UniProt: Q5GFL6 | TargetFullName: von Willebrand factor A domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 3.111178E-11
Real
Aptamer SeqId: 7130-4 | Target: LAIR2 | UniProt: Q6ISS4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7130-4 | Target: LAIR2 | UniProt: Q6ISS4 | TargetFullName: Leukocyte-associated immunoglobulin-like receptor 2 | Organisim: human | Apparent_Kd_M: 1.557383E-11
Real
Aptamer SeqId: 7131-207 | Target: Tenascin | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7131-207 | Target: Tenascin | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 5.173196E-11
Real
Aptamer SeqId: 7132-55 | Target: C1QL4 | UniProt: Q86Z23
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7132-55 | Target: C1QL4 | UniProt: Q86Z23 | TargetFullName: Complement C1q-like protein 4 | Organisim: human | Apparent_Kd_M: 1.745356E-11
Real
Aptamer SeqId: 7136-7 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7136-7 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 5.44E-13
Real
Aptamer SeqId: 7137-8 | Target: MSRA | UniProt: Q9UJ68
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7137-8 | Target: MSRA | UniProt: Q9UJ68 | TargetFullName: Mitochondrial peptide methionine sulfoxide reductase | Organisim: human | Apparent_Kd_M: 1.836359E-10
Real
Aptamer SeqId: 7139-14 | Target: SLIK4 | UniProt: Q8IW52
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7139-14 | Target: SLIK4 | UniProt: Q8IW52 | TargetFullName: SLIT and NTRK-like protein 4 | Organisim: human | Apparent_Kd_M: 3.564829E-11
Real
Aptamer SeqId: 7140-1 | Target: ELA2A | UniProt: P08217
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7140-1 | Target: ELA2A | UniProt: P08217 | TargetFullName: Chymotrypsin-like elastase family member 2A | Organisim: human | Apparent_Kd_M: 1.91096E-11
Real
Aptamer SeqId: 7141-21 | Target: MGT4B | UniProt: Q9UQ53
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7141-21 | Target: MGT4B | UniProt: Q9UQ53 | TargetFullName: Alpha-1;3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B | Organisim: human | Apparent_Kd_M: 1.46E-11
Real
Aptamer SeqId: 7142-5 | Target: CBPN | UniProt: P15169
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7142-5 | Target: CBPN | UniProt: P15169 | TargetFullName: Carboxypeptidase N catalytic chain | Organisim: human | Apparent_Kd_M: 1.387727E-11
Real
Aptamer SeqId: 7143-9 | Target: GNT2C | UniProt: Q8NFS9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7143-9 | Target: GNT2C | UniProt: Q8NFS9 | TargetFullName: N-acetyllactosaminide beta-1;6-N-acetylglucosaminyl-transferase; isoform C | Organisim: human | Apparent_Kd_M: 1.582344E-10
Real
Aptamer SeqId: 7144-234 | Target: KAZD1 | UniProt: Q96I82
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7144-234 | Target: KAZD1 | UniProt: Q96I82 | TargetFullName: Kazal-type serine protease inhibitor domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 2.52183E-11
Real
Aptamer SeqId: 7145-1 | Target: ITIH3 | UniProt: Q06033
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7145-1 | Target: ITIH3 | UniProt: Q06033 | TargetFullName: Inter-alpha-trypsin inhibitor heavy chain H3 | Organisim: human | Apparent_Kd_M: 7.335923E-11
Real
Aptamer SeqId: 7146-16 | Target: PDIA4 | UniProt: P13667
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7146-16 | Target: PDIA4 | UniProt: P13667 | TargetFullName: Protein disulfide-isomerase A4 | Organisim: human | Apparent_Kd_M: 4.67E-11
Real
Aptamer SeqId: 7147-35 | Target: WFDC8 | UniProt: Q8IUA0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7147-35 | Target: WFDC8 | UniProt: Q8IUA0 | TargetFullName: WAP four-disulfide core domain protein 8 | Organisim: human | Apparent_Kd_M: 9.347653E-12
Real
Aptamer SeqId: 7148-42 | Target: F173A | UniProt: Q9BQD7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7148-42 | Target: F173A | UniProt: Q9BQD7 | TargetFullName: Protein FAM173A | Organisim: human | Apparent_Kd_M: 2.330027E-11
Real
Aptamer SeqId: 7153-66 | Target: NGRN | UniProt: Q9NPE2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7153-66 | Target: NGRN | UniProt: Q9NPE2 | TargetFullName: Neugrin | Organisim: human | Apparent_Kd_M: 8.050365E-12
Real
Aptamer SeqId: 7154-92 | Target: CF058 | UniProt: Q6P5S2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7154-92 | Target: CF058 | UniProt: Q6P5S2 | TargetFullName: Protein LEG1 homolog | Organisim: human | Apparent_Kd_M: 1.856635E-11
Real
Aptamer SeqId: 7155-46 | Target: C4b-binding protein beta chain
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7155-46 | Target: C4b-binding protein beta chain | UniProt: P20851 | TargetFullName: C4b-binding protein beta chain | Organisim: human | Apparent_Kd_M: 2.240317E-11
Real
Aptamer SeqId: 7156-2 | Target: FUT10 | UniProt: Q6P4F1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7156-2 | Target: FUT10 | UniProt: Q6P4F1 | TargetFullName: Alpha-(1;3)-fucosyltransferase 10 | Organisim: human | Apparent_Kd_M: 2.90943E-12
Real
Aptamer SeqId: 7157-22 | Target: PCDA4 | UniProt: Q9UN74
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7157-22 | Target: PCDA4 | UniProt: Q9UN74 | TargetFullName: Protocadherin alpha-4 | Organisim: human | Apparent_Kd_M: 5.02E-11
Real
Aptamer SeqId: 7161-25 | Target: G6PE | UniProt: O95479
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7161-25 | Target: G6PE | UniProt: O95479 | TargetFullName: GDH/6PGL endoplasmic bifunctional protein | Organisim: human | Apparent_Kd_M: 1.264998E-11
Real
Aptamer SeqId: 7163-26 | Target: lacritin | UniProt: Q9GZZ8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7163-26 | Target: lacritin | UniProt: Q9GZZ8 | TargetFullName: Extracellular glycoprotein lacritin | Organisim: human | Apparent_Kd_M: 1.636109E-11
Real
Aptamer SeqId: 7167-102 | Target: VAPA | UniProt: Q9P0L0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7167-102 | Target: VAPA | UniProt: Q9P0L0 | TargetFullName: Vesicle-associated membrane protein-associated protein A | Organisim: human | Apparent_Kd_M: 4.382126E-12
Real
Aptamer SeqId: 7173-141 | Target: T132C | UniProt: Q8N3T6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7173-141 | Target: T132C | UniProt: Q8N3T6 | TargetFullName: Transmembrane protein 132C | Organisim: human | Apparent_Kd_M: 4.98E-11
Real
Aptamer SeqId: 7175-4 | Target: PCDG2 | UniProt: Q9Y5H1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7175-4 | Target: PCDG2 | UniProt: Q9Y5H1 | TargetFullName: Protocadherin gamma-A2 | Organisim: human | Apparent_Kd_M: 8.195621E-11
Real
Aptamer SeqId: 7178-59 | Target: DEPP | UniProt: Q9NTK1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7178-59 | Target: DEPP | UniProt: Q9NTK1 | TargetFullName: Protein DEPP | Organisim: human | Apparent_Kd_M: 3.500687E-11
Real
Aptamer SeqId: 7179-69 | Target: NFASC | UniProt: O94856
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7179-69 | Target: NFASC | UniProt: O94856 | TargetFullName: Neurofascin | Organisim: human | Apparent_Kd_M: 2.799038E-12
Real
Aptamer SeqId: 7180-114 | Target: IFN14 | UniProt: P01570
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7180-114 | Target: IFN14 | UniProt: P01570 | TargetFullName: Interferon alpha-14 | Organisim: human | Apparent_Kd_M: 2.536957E-11
Real
Aptamer SeqId: 7181-17 | Target: VAPB | UniProt: O95292
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7181-17 | Target: VAPB | UniProt: O95292 | TargetFullName: Vesicle-associated membrane protein-associated protein B/C | Organisim: human | Apparent_Kd_M: 9.282958E-12
Real
Aptamer SeqId: 7183-102 | Target: TD26 | UniProt: Q6UXH0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7183-102 | Target: TD26 | UniProt: Q6UXH0 | TargetFullName: Angiopoietin-like protein 8 | Organisim: human | Apparent_Kd_M: 6.735987E-12
Real
Aptamer SeqId: 7184-13 | Target: CEAM7 | UniProt: Q14002
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7184-13 | Target: CEAM7 | UniProt: Q14002 | TargetFullName: Carcinoembryonic antigen-related cell adhesion molecule 7 | Organisim: human | Apparent_Kd_M: 5.335929E-11
Real
Aptamer SeqId: 7185-29 | Target: GPV | UniProt: P40197
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7185-29 | Target: GPV | UniProt: P40197 | TargetFullName: Platelet glycoprotein V | Organisim: human | Apparent_Kd_M: 2.483899E-12
Real
Aptamer SeqId: 7186-111 | Target: STX3 | UniProt: Q13277
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7186-111 | Target: STX3 | UniProt: Q13277 | TargetFullName: Syntaxin-3 | Organisim: human | Apparent_Kd_M: 2.228013E-11
Real
Aptamer SeqId: 7187-3 | Target: PPM1L | UniProt: Q5SGD2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7187-3 | Target: PPM1L | UniProt: Q5SGD2 | TargetFullName: Protein phosphatase 1L | Organisim: human | Apparent_Kd_M: 3.34554E-10
Real
Aptamer SeqId: 7189-55 | Target: CHST3 | UniProt: Q7LGC8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7189-55 | Target: CHST3 | UniProt: Q7LGC8 | TargetFullName: Carbohydrate sulfotransferase 3 | Organisim: human | Apparent_Kd_M: 1.448659E-10
Real
Aptamer SeqId: 7191-32 | Target: SLMAP | UniProt: Q14BN4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7191-32 | Target: SLMAP | UniProt: Q14BN4 | TargetFullName: Sarcolemmal membrane-associated protein | Organisim: human | Apparent_Kd_M: 6.22E-11
Real
Aptamer SeqId: 7192-37 | Target: CRF2-12 | UniProt: Q8IU57
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7192-37 | Target: CRF2-12 | UniProt: Q8IU57 | TargetFullName: Interferon lambda receptor 1 | Organisim: human | Apparent_Kd_M: 1.933193E-11
Real
Aptamer SeqId: 7193-98 | Target: PCDC1 | UniProt: Q9H158
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7193-98 | Target: PCDC1 | UniProt: Q9H158 | TargetFullName: Protocadherin alpha-C1 | Organisim: human | Apparent_Kd_M: 1.281087E-10
Real
Aptamer SeqId: 7194-36 | Target: NPTN | UniProt: Q9Y639
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7194-36 | Target: NPTN | UniProt: Q9Y639 | TargetFullName: Neuroplastin | Organisim: human | Apparent_Kd_M: 3.220418E-12
Real
Aptamer SeqId: 7196-21 | Target: IFN-w | UniProt: P05000
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7196-21 | Target: IFN-w | UniProt: P05000 | TargetFullName: Interferon omega-1 | Organisim: human | Apparent_Kd_M: 2.574077E-12
Real
Aptamer SeqId: 7197-2 | Target: DJC15 | UniProt: Q9Y5T4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7197-2 | Target: DJC15 | UniProt: Q9Y5T4 | TargetFullName: DnaJ homolog subfamily C member 15 | Organisim: human | Apparent_Kd_M: 4.613849E-11
Real
Aptamer SeqId: 7198-197 | Target: FA20B | UniProt: O75063
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7198-197 | Target: FA20B | UniProt: O75063 | TargetFullName: Glycosaminoglycan xylosylkinase | Organisim: human | Apparent_Kd_M: 1.869451E-12
Real
Aptamer SeqId: 7199-3 | Target: SYN3 | UniProt: O14994
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7199-3 | Target: SYN3 | UniProt: O14994 | TargetFullName: Synapsin-3 | Organisim: human | Apparent_Kd_M: 1.441807E-10
Real
Aptamer SeqId: 7200-4 | Target: LRFN2 | UniProt: Q9ULH4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7200-4 | Target: LRFN2 | UniProt: Q9ULH4 | TargetFullName: Leucine-rich repeat and fibronectin type-III domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 4.721949E-12
Real
Aptamer SeqId: 7201-5 | Target: ISCU | UniProt: Q9H1K1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7201-5 | Target: ISCU | UniProt: Q9H1K1 | TargetFullName: Iron-sulfur cluster assembly enzyme ISCU; mitochondrial | Organisim: human | Apparent_Kd_M: 3.288003E-11
Real
Aptamer SeqId: 7202-107 | Target: SEMA6C | UniProt: Q9H3T2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7202-107 | Target: SEMA6C | UniProt: Q9H3T2 | TargetFullName: Semaphorin-6C | Organisim: human | Apparent_Kd_M: 2.381011E-11
Real
Aptamer SeqId: 7203-125 | Target: RFNG | UniProt: Q9Y644
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7203-125 | Target: RFNG | UniProt: Q9Y644 | TargetFullName: Beta-1;3-N-acetylglucosaminyltransferase radical fringe | Organisim: human | Apparent_Kd_M: 7.58E-12
Real
Aptamer SeqId: 7204-1 | Target: CEA21 | UniProt: Q3KPI0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7204-1 | Target: CEA21 | UniProt: Q3KPI0 | TargetFullName: Carcinoembryonic antigen-related cell adhesion molecule 21 | Organisim: human | Apparent_Kd_M: 5.923975E-11
Real
Aptamer SeqId: 7206-20 | Target: F16P1 | UniProt: P09467
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7206-20 | Target: F16P1 | UniProt: P09467 | TargetFullName: Fructose-1;6-bisphosphatase 1 | Organisim: human | Apparent_Kd_M: 2.073657E-11
Real
Aptamer SeqId: 7207-4 | Target: RED | UniProt: Q13123
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7207-4 | Target: RED | UniProt: Q13123 | TargetFullName: Protein Red | Organisim: human | Apparent_Kd_M: 1.264217E-11
Real
Aptamer SeqId: 7208-60 | Target: MGT4C | UniProt: Q9UBM8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7208-60 | Target: MGT4C | UniProt: Q9UBM8 | TargetFullName: Alpha-1;3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase C | Organisim: human | Apparent_Kd_M: 8.334868E-12
Real
Aptamer SeqId: 7210-25 | Target: Amyloid-like protein 1 | UniProt: P51693
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7210-25 | Target: Amyloid-like protein 1 | UniProt: P51693 | TargetFullName: Amyloid-like protein 1 | Organisim: human | Apparent_Kd_M: 1.393736E-12
Real
Aptamer SeqId: 7211-2 | Target: RNase 1 | UniProt: P07998
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7211-2 | Target: RNase 1 | UniProt: P07998 | TargetFullName: Ribonuclease pancreatic | Organisim: human | Apparent_Kd_M: 5.118885E-10
Real
Aptamer SeqId: 7215-18 | Target: NADH-cytochrome b5 reductase
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7215-18 | Target: NADH-cytochrome b5 reductase | UniProt: P00387 | TargetFullName: NADH-cytochrome b5 reductase 3 | Organisim: human | Apparent_Kd_M: 7.979516E-11
Real
Aptamer SeqId: 7218-87 | Target: AT1B2 | UniProt: P14415
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7218-87 | Target: AT1B2 | UniProt: P14415 | TargetFullName: Sodium/potassium-transporting ATPase subunit beta-2 | Organisim: human | Apparent_Kd_M: 2.464043E-12
Real
Aptamer SeqId: 7219-152 | Target: HSP 70 | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7219-152 | Target: HSP 70 | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 2.334565E-11
Real
Aptamer SeqId: 7221-56 | Target: CKAP4 | UniProt: Q07065
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7221-56 | Target: CKAP4 | UniProt: Q07065 | TargetFullName: Cytoskeleton-associated protein 4 | Organisim: human | Apparent_Kd_M: 2.541661E-10
Real
Aptamer SeqId: 7223-60 | Target: S100A13 | UniProt: Q99584
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7223-60 | Target: S100A13 | UniProt: Q99584 | TargetFullName: Protein S100-A13 | Organisim: human | Apparent_Kd_M: 1.719686E-10
Real
Aptamer SeqId: 7224-11 | Target: TRAT1 | UniProt: Q6PIZ9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7224-11 | Target: TRAT1 | UniProt: Q6PIZ9 | TargetFullName: T-cell receptor-associated transmembrane adapter 1 | Organisim: human | Apparent_Kd_M: 2.083566E-10
Real
Aptamer SeqId: 7225-51 | Target: MMGT1 | UniProt: Q8N4V1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7225-51 | Target: MMGT1 | UniProt: Q8N4V1 | TargetFullName: Membrane magnesium transporter 1 | Organisim: human | Apparent_Kd_M: 8.208988E-11
Real
Aptamer SeqId: 7227-75 | Target: COCH | UniProt: O43405
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7227-75 | Target: COCH | UniProt: O43405 | TargetFullName: Cochlin | Organisim: human | Apparent_Kd_M: 1.009731E-12
Real
Aptamer SeqId: 7228-2 | Target: SIA7F | UniProt: Q969X2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7228-2 | Target: SIA7F | UniProt: Q969X2 | TargetFullName: Alpha-N-acetylgalactosaminide alpha-2;6-sialyltransferase 6 | Organisim: human | Apparent_Kd_M: 3.944138E-11
Real
Aptamer SeqId: 7231-37 | Target: TM11A | UniProt: Q6ZMR5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7231-37 | Target: TM11A | UniProt: Q6ZMR5 | TargetFullName: Transmembrane protease serine 11A | Organisim: human | Apparent_Kd_M: 3.235025E-12
Real
Aptamer SeqId: 7233-73 | Target: P2RX6 | UniProt: O15547
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7233-73 | Target: P2RX6 | UniProt: O15547 | TargetFullName: P2X purinoceptor 6 | Organisim: human | Apparent_Kd_M: 2.7794E-12
Real
Aptamer SeqId: 7234-12 | Target: GT252 | UniProt: Q8IYK4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7234-12 | Target: GT252 | UniProt: Q8IYK4 | TargetFullName: Procollagen galactosyltransferase 2 | Organisim: human | Apparent_Kd_M: 4.708019E-12
Real
Aptamer SeqId: 7240-2 | Target: MBTP1 | UniProt: Q14703
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7240-2 | Target: MBTP1 | UniProt: Q14703 | TargetFullName: Membrane-bound transcription factor site-1 protease | Organisim: human | Apparent_Kd_M: 1.849621E-11
Real
Aptamer SeqId: 7242-14 | Target: CJ072 | UniProt: Q8IW00
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7242-14 | Target: CJ072 | UniProt: Q8IW00 | TargetFullName: V-set and transmembrane domain-containing protein 4 | Organisim: human | Apparent_Kd_M: 1.454001E-10
Real
Aptamer SeqId: 7244-16 | Target: TM149 | UniProt: Q9H665
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7244-16 | Target: TM149 | UniProt: Q9H665 | TargetFullName: IGF-like family receptor 1 | Organisim: human | Apparent_Kd_M: 1.205365E-11
Real
Aptamer SeqId: 7245-2 | Target: CELF2 | UniProt: O95319
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7245-2 | Target: CELF2 | UniProt: O95319 | TargetFullName: CUGBP Elav-like family member 2 | Organisim: human | Apparent_Kd_M: 2.454089E-10
Real
Aptamer SeqId: 7246-4 | Target: FREM2 | UniProt: Q5SZK8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7246-4 | Target: FREM2 | UniProt: Q5SZK8 | TargetFullName: FRAS1-related extracellular matrix protein 2 | Organisim: human | Apparent_Kd_M: 1.682385E-10
Real
Aptamer SeqId: 7247-1 | Target: GORAB | UniProt: Q5T7V8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7247-1 | Target: GORAB | UniProt: Q5T7V8 | TargetFullName: RAB6-interacting golgin | Organisim: human | Apparent_Kd_M: 5.611159E-11
Real
Aptamer SeqId: 7249-307 | Target: B2L10 | UniProt: Q9HD36
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7249-307 | Target: B2L10 | UniProt: Q9HD36 | TargetFullName: Bcl-2-like protein 10 | Organisim: human | Apparent_Kd_M: 1.147467E-10
Real
Aptamer SeqId: 7251-64 | Target: C1QT3 | UniProt: Q9BXJ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7251-64 | Target: C1QT3 | UniProt: Q9BXJ4 | TargetFullName: Complement C1q tumor necrosis factor-related protein 3 | Organisim: human | Apparent_Kd_M: 2.31E-10
Real
Aptamer SeqId: 7253-6 | Target: QKI | UniProt: Q96PU8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7253-6 | Target: QKI | UniProt: Q96PU8 | TargetFullName: Protein quaking | Organisim: human | Apparent_Kd_M: 7.214447E-11
Real
Aptamer SeqId: 7257-18 | Target: TIP39 | UniProt: Q96A98
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7257-18 | Target: TIP39 | UniProt: Q96A98 | TargetFullName: Tuberoinfundibular peptide of 39 residues | Organisim: human | Apparent_Kd_M: 3.384162E-12
Real
Aptamer SeqId: 7258-5 | Target: EMBP | UniProt: P13727
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7258-5 | Target: EMBP | UniProt: P13727 | TargetFullName: Bone marrow proteoglycan | Organisim: human | Apparent_Kd_M: 1.521429E-11
Real
Aptamer SeqId: 7262-191 | Target: CHSTE | UniProt: Q8NCH0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7262-191 | Target: CHSTE | UniProt: Q8NCH0 | TargetFullName: Carbohydrate sulfotransferase 14 | Organisim: human | Apparent_Kd_M: 3.023693E-12
Real
Aptamer SeqId: 7265-32 | Target: OSTN | UniProt: P61366
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7265-32 | Target: OSTN | UniProt: P61366 | TargetFullName: Osteocrin | Organisim: human | Apparent_Kd_M: 2.950333E-11
Real
Aptamer SeqId: 7266-4 | Target: SPA9 | UniProt: Q86WD7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7266-4 | Target: SPA9 | UniProt: Q86WD7 | TargetFullName: Serpin A9 | Organisim: human | Apparent_Kd_M: 2.100763E-12
Real
Aptamer SeqId: 7267-2 | Target: LCB2 | UniProt: O15270
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7267-2 | Target: LCB2 | UniProt: O15270 | TargetFullName: Serine palmitoyltransferase 2 | Organisim: human | Apparent_Kd_M: 2.267334E-10
Real
Aptamer SeqId: 7551-33 | Target: LRC32 | UniProt: Q14392
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7551-33 | Target: LRC32 | UniProt: Q14392 | TargetFullName: Leucine-rich repeat-containing protein 32 | Organisim: human | Apparent_Kd_M: 4.937785E-12
Real
Aptamer SeqId: 7624-19 | Target: ANK2 | UniProt: Q01484
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7624-19 | Target: ANK2 | UniProt: Q01484 | TargetFullName: Ankyrin-2 | Organisim: human | Apparent_Kd_M: 3.24E-11
Real
Aptamer SeqId: 7625-27 | Target: 14-3-3 protein theta | UniProt: P27348
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7625-27 | Target: 14-3-3 protein theta | UniProt: P27348 | TargetFullName: 14-3-3 protein theta | Organisim: human | Apparent_Kd_M: 1.13E-10
Real
Aptamer SeqId: 7628-40 | Target: CREL1 | UniProt: Q96HD1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7628-40 | Target: CREL1 | UniProt: Q96HD1 | TargetFullName: Cysteine-rich with EGF-like domain protein 1 | Organisim: human | Apparent_Kd_M: 5.77E-12
Real
Aptamer SeqId: 7638-30 | Target: Lectin mannose-binding 2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7638-30 | Target: Lectin; mannose-binding 2 | UniProt: Q12907 | TargetFullName: Vesicular integral-membrane protein VIP36 | Organisim: human | Apparent_Kd_M: 6.94E-12
Real
Aptamer SeqId: 7648-9 | Target: MYPC1 | UniProt: Q00872
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7648-9 | Target: MYPC1 | UniProt: Q00872 | TargetFullName: Myosin-binding protein C; slow-type | Organisim: human | Apparent_Kd_M: 2.31E-12
Real
Aptamer SeqId: 7655-11 | Target: N-terminal pro-BNP | UniProt: P16860
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7655-11 | Target: N-terminal pro-BNP | UniProt: P16860 | TargetFullName: N-terminal pro-BNP | Organisim: human | Apparent_Kd_M: 1.83E-12
Real
Aptamer SeqId: 7696-3 | Target: NBR1 | UniProt: Q14596
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7696-3 | Target: NBR1 | UniProt: Q14596 | TargetFullName: Next to BRCA1 gene 1 protein | Organisim: human | Apparent_Kd_M: 1.149229E-9
Real
Aptamer SeqId: 7713-102 | Target: FMR1 | UniProt: Q06787
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7713-102 | Target: FMR1 | UniProt: Q06787 | TargetFullName: Fragile X mental retardation protein 1 | Organisim: human | Apparent_Kd_M: 1.163933E-10
Real
Aptamer SeqId: 7717-95 | Target: CFTR | UniProt: P13569
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7717-95 | Target: CFTR | UniProt: P13569 | TargetFullName: Cystic fibrosis transmembrane conductance regulator | Organisim: human | Apparent_Kd_M: 6.814283E-12
Real
Aptamer SeqId: 7732-45 | Target: VAMP4 | UniProt: O75379
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7732-45 | Target: VAMP4 | UniProt: O75379 | TargetFullName: Vesicle-associated membrane protein 4 | Organisim: human | Apparent_Kd_M: 1.393479E-11
Real
Aptamer SeqId: 7736-28 | Target: OPALI | UniProt: Q96PE5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7736-28 | Target: OPALI | UniProt: Q96PE5 | TargetFullName: Opalin | Organisim: human | Apparent_Kd_M: 1.029892E-10
Real
Aptamer SeqId: 7737-76 | Target: ITB6 | UniProt: P18564
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7737-76 | Target: ITB6 | UniProt: P18564 | TargetFullName: Integrin beta-6 | Organisim: human | Apparent_Kd_M: 1.033911E-10
Real
Aptamer SeqId: 7738-299 | Target: STX2 | UniProt: P32856
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7738-299 | Target: STX2 | UniProt: P32856 | TargetFullName: Syntaxin-2 | Organisim: human | Apparent_Kd_M: 1.452103E-11
Real
Aptamer SeqId: 7740-33 | Target: FATE1 | UniProt: Q969F0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7740-33 | Target: FATE1 | UniProt: Q969F0 | TargetFullName: Fetal and adult testis-expressed transcript protein | Organisim: human | Apparent_Kd_M: 5.511694E-11
Real
Aptamer SeqId: 7741-111 | Target: RTF1 | UniProt: Q92541
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7741-111 | Target: RTF1 | UniProt: Q92541 | TargetFullName: RNA polymerase-associated protein RTF1 homolog | Organisim: human | Apparent_Kd_M: 5.295403E-11
Real
Aptamer SeqId: 7742-11 | Target: RN148 | UniProt: Q8N7C7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7742-11 | Target: RN148 | UniProt: Q8N7C7 | TargetFullName: RING finger protein 148 | Organisim: human | Apparent_Kd_M: 1.85E-10
Real
Aptamer SeqId: 7743-5 | Target: TIM50 | UniProt: Q3ZCQ8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7743-5 | Target: TIM50 | UniProt: Q3ZCQ8 | TargetFullName: Mitochondrial import inner membrane translocase subunit TIM50 | Organisim: human | Apparent_Kd_M: 1.920235E-11
Real
Aptamer SeqId: 7745-3 | Target: ZCD1 | UniProt: Q9NZ45
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7745-3 | Target: ZCD1 | UniProt: Q9NZ45 | TargetFullName: CDGSH iron-sulfur domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 7.167482E-11
Real
Aptamer SeqId: 7746-230 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7746-230 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.020184E-10
Real
Aptamer SeqId: 7747-47 | Target: NDUBB | UniProt: Q9NX14
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7747-47 | Target: NDUBB | UniProt: Q9NX14 | TargetFullName: NADH dehydrogenase ubiquinone 1 beta subcomplex subunit 11; mitochondrial | Organisim: human | Apparent_Kd_M: 3.829652E-11
Real
Aptamer SeqId: 7748-11 | Target: NDUV2 | UniProt: P19404
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7748-11 | Target: NDUV2 | UniProt: P19404 | TargetFullName: NADH dehydrogenase ubiquinone flavoprotein 2; mitochondrial | Organisim: human | Apparent_Kd_M: 9.996318E-12
Real
Aptamer SeqId: 7751-121 | Target: SARP-1 | UniProt: Q96HF1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7751-121 | Target: SARP-1 | UniProt: Q96HF1 | TargetFullName: Secreted frizzled-related protein 2 | Organisim: human | Apparent_Kd_M: 6.66863E-11
Real
Aptamer SeqId: 7752-31 | Target: CLC4D | UniProt: Q8WXI8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7752-31 | Target: CLC4D | UniProt: Q8WXI8 | TargetFullName: C-type lectin domain family 4 member D | Organisim: human | Apparent_Kd_M: 1.709018E-11
Real
Aptamer SeqId: 7753-21 | Target: HTAI2 | UniProt: Q9BUP3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7753-21 | Target: HTAI2 | UniProt: Q9BUP3 | TargetFullName: Oxidoreductase HTATIP2 | Organisim: human | Apparent_Kd_M: 6.34E-12
Real
Aptamer SeqId: 7754-11 | Target: JAG1 | UniProt: P78504
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7754-11 | Target: JAG1 | UniProt: P78504 | TargetFullName: Protein jagged-1 | Organisim: human | Apparent_Kd_M: 5.27E-11
Real
Aptamer SeqId: 7755-37 | Target: ITB5 | UniProt: P18084
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7755-37 | Target: ITB5 | UniProt: P18084 | TargetFullName: Integrin beta-5 | Organisim: human | Apparent_Kd_M: 2.350152E-11
Real
Aptamer SeqId: 7757-5 | Target: DQA2 | UniProt: P01906
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7757-5 | Target: DQA2 | UniProt: P01906 | TargetFullName: HLA class II histocompatibility antigen; DQ alpha 2 chain | Organisim: human | Apparent_Kd_M: 1.198247E-11
Real
Aptamer SeqId: 7758-217 | Target: RN215 | UniProt: Q9Y6U7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7758-217 | Target: RN215 | UniProt: Q9Y6U7 | TargetFullName: RING finger protein 215 | Organisim: human | Apparent_Kd_M: 1.62E-10
Real
Aptamer SeqId: 7761-125 | Target: CHKB | UniProt: Q9Y259
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7761-125 | Target: CHKB | UniProt: Q9Y259 | TargetFullName: Choline/ethanolamine kinase | Organisim: human | Apparent_Kd_M: 1.91E-12
Real
Aptamer SeqId: 7762-30 | Target: SNN | UniProt: O75324
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7762-30 | Target: SNN | UniProt: O75324 | TargetFullName: Stannin | Organisim: human | Apparent_Kd_M: 3.013219E-10
Real
Aptamer SeqId: 7763-25 | Target: Cadherin-11 | UniProt: P55287
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7763-25 | Target: Cadherin-11 | UniProt: P55287 | TargetFullName: Cadherin-11 | Organisim: human | Apparent_Kd_M: 4.03E-12
Real
Aptamer SeqId: 7765-15 | Target: ITM2A | UniProt: O43736
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7765-15 | Target: ITM2A | UniProt: O43736 | TargetFullName: Integral membrane protein 2A | Organisim: human | Apparent_Kd_M: 2.15E-10
Real
Aptamer SeqId: 7766-25 | Target: ZP4 | UniProt: Q12836
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7766-25 | Target: ZP4 | UniProt: Q12836 | TargetFullName: Zona pellucida sperm-binding protein 4 | Organisim: human | Apparent_Kd_M: 6.09E-11
Real
Aptamer SeqId: 7767-1 | Target: CF126 | UniProt: Q6UWE3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7767-1 | Target: CF126 | UniProt: Q6UWE3 | TargetFullName: Colipase-like protein 2 | Organisim: human | Apparent_Kd_M: 3.85737E-11
Real
Aptamer SeqId: 7769-29 | Target: 3BP2 | UniProt: P78314
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7769-29 | Target: 3BP2 | UniProt: P78314 | TargetFullName: SH3 domain-binding protein 2 | Organisim: human | Apparent_Kd_M: 3.79E-12
Real
Aptamer SeqId: 7770-25 | Target: NFU1 | UniProt: Q9UMS0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7770-25 | Target: NFU1 | UniProt: Q9UMS0 | TargetFullName: NFU1 iron-sulfur cluster scaffold homolog; mitochondrial | Organisim: human | Apparent_Kd_M: 4.667899E-11
Real
Aptamer SeqId: 7773-20 | Target: KI2L2 | UniProt: P43627
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7773-20 | Target: KI2L2 | UniProt: P43627 | TargetFullName: Killer cell immunoglobulin-like receptor 2DL2 | Organisim: human | Apparent_Kd_M: 7.724129E-11
Real
Aptamer SeqId: 7776-20 | Target: UNC5B | UniProt: Q8IZJ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7776-20 | Target: UNC5B | UniProt: Q8IZJ1 | TargetFullName: Netrin receptor UNC5B | Organisim: human | Apparent_Kd_M: 9.7E-12
Real
Aptamer SeqId: 7778-104 | Target: BINCA | UniProt: Q96LW7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7778-104 | Target: BINCA | UniProt: Q96LW7 | TargetFullName: Caspase recruitment domain-containing protein 19 | Organisim: human | Apparent_Kd_M: 9.466718E-12
Real
Aptamer SeqId: 7779-86 | Target: CHSTB | UniProt: Q9NPF2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7779-86 | Target: CHSTB | UniProt: Q9NPF2 | TargetFullName: Carbohydrate sulfotransferase 11 | Organisim: human | Apparent_Kd_M: 1.622318E-11
Real
Aptamer SeqId: 7782-34 | Target: EP3B | UniProt: P56851
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7782-34 | Target: EP3B | UniProt: P56851 | TargetFullName: Epididymal secretory protein E3-beta | Organisim: human | Apparent_Kd_M: 1.358993E-11
Real
Aptamer SeqId: 7784-1 | Target: Kininogen; HMW | UniProt: P01042
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7784-1 | Target: Kininogen; HMW | UniProt: P01042 | TargetFullName: Kininogen-1 | Organisim: human | Apparent_Kd_M: 1.02E-11
Real
Aptamer SeqId: 7785-1 | Target: Ephrin-B3 | UniProt: Q15768
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7785-1 | Target: Ephrin-B3 | UniProt: Q15768 | TargetFullName: Ephrin-B3 | Organisim: human | Apparent_Kd_M: 8.11E-11
Real
Aptamer SeqId: 7786-83 | Target: CLC2B | UniProt: Q92478
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7786-83 | Target: CLC2B | UniProt: Q92478 | TargetFullName: C-type lectin domain family 2 member B | Organisim: human | Apparent_Kd_M: 6.030364E-11
Real
Aptamer SeqId: 7787-25 | Target: LIRA5 | UniProt: A6NI73
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7787-25 | Target: LIRA5 | UniProt: A6NI73 | TargetFullName: Leukocyte immunoglobulin-like receptor subfamily A member 5 | Organisim: human | Apparent_Kd_M: 2.71E-12
Real
Aptamer SeqId: 7788-1 | Target: CF6 | UniProt: P18859
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7788-1 | Target: CF6 | UniProt: P18859 | TargetFullName: ATP synthase-coupling factor 6; mitochondrial | Organisim: human | Apparent_Kd_M: 4.936004E-12
Real
Aptamer SeqId: 7789-182 | Target: PRDX4 | UniProt: Q13162
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7789-182 | Target: PRDX4 | UniProt: Q13162 | TargetFullName: Peroxiredoxin-4 | Organisim: human | Apparent_Kd_M: 2.6E-10
Real
Aptamer SeqId: 7790-21 | Target: LIF | UniProt: P15018
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7790-21 | Target: LIF | UniProt: P15018 | TargetFullName: Leukemia inhibitory factor | Organisim: human | Apparent_Kd_M: 6.330612E-11
Real
Aptamer SeqId: 7792-58 | Target: CC90B | UniProt: Q9GZT6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7792-58 | Target: CC90B | UniProt: Q9GZT6 | TargetFullName: Coiled-coil domain-containing protein 90B; mitochondrial | Organisim: human | Apparent_Kd_M: 1.563322E-11
Real
Aptamer SeqId: 7795-14 | Target: NKG2E | UniProt: Q07444
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7795-14 | Target: NKG2E | UniProt: Q07444 | TargetFullName: NKG2-E type II integral membrane protein | Organisim: human | Apparent_Kd_M: 1.03E-11
Real
Aptamer SeqId: 7796-10 | Target: CD79A | UniProt: P11912
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7796-10 | Target: CD79A | UniProt: P11912 | TargetFullName: B-cell antigen receptor complex-associated protein alpha chain | Organisim: human | Apparent_Kd_M: 2.85E-12
Real
Aptamer SeqId: 7797-11 | Target: CC167 | UniProt: Q9P0B6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7797-11 | Target: CC167 | UniProt: Q9P0B6 | TargetFullName: Coiled-coil domain-containing protein 167 | Organisim: human | Apparent_Kd_M: 9.698634E-12
Real
Aptamer SeqId: 7800-85 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7800-85 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.75321E-10
Real
Aptamer SeqId: 7801-30 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7801-30 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 6.25E-13
Real
Aptamer SeqId: 7802-53 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7802-53 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.328118E-11
Real
Aptamer SeqId: 7803-4 | Target: CHST1 | UniProt: O43916
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7803-4 | Target: CHST1 | UniProt: O43916 | TargetFullName: Carbohydrate sulfotransferase 1 | Organisim: human | Apparent_Kd_M: 7.685588E-12
Real
Aptamer SeqId: 7805-52 | Target: GOS-28 | UniProt: O95249
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7805-52 | Target: GOS-28 | UniProt: O95249 | TargetFullName: Golgi SNAP receptor complex member 1 | Organisim: human | Apparent_Kd_M: 3.315634E-11
Real
Aptamer SeqId: 7806-33 | Target: B4GT7 | UniProt: Q9UBV7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7806-33 | Target: B4GT7 | UniProt: Q9UBV7 | TargetFullName: Beta-1;4-galactosyltransferase 7 | Organisim: human | Apparent_Kd_M: 3.05794E-12
Real
Aptamer SeqId: 7808-5 | Target: GLCE | UniProt: O94923
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7808-5 | Target: GLCE | UniProt: O94923 | TargetFullName: D-glucuronyl C5-epimerase | Organisim: human | Apparent_Kd_M: 1.738994E-11
Real
Aptamer SeqId: 7809-22 | Target: SPAT9 | UniProt: Q9BWV2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7809-22 | Target: SPAT9 | UniProt: Q9BWV2 | TargetFullName: Spermatogenesis-associated protein 9 | Organisim: human | Apparent_Kd_M: 9.54325E-12
Real
Aptamer SeqId: 7810-20 | Target: C1QTNF5 | UniProt: Q9BXJ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7810-20 | Target: C1QTNF5 | UniProt: Q9BXJ0 | TargetFullName: Complement C1q tumor necrosis factor-related protein 5 | Organisim: human | Apparent_Kd_M: 1.175769E-11
Real
Aptamer SeqId: 7813-6 | Target: Alkaline phosphatase placental
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7813-6 | Target: Alkaline phosphatase; placental | UniProt: P05187 | TargetFullName: Alkaline phosphatase; placental type | Organisim: human | Apparent_Kd_M: 1.07E-11
Real
Aptamer SeqId: 7815-49 | Target: IBPL1 | UniProt: Q8WX77
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7815-49 | Target: IBPL1 | UniProt: Q8WX77 | TargetFullName: Insulin-like growth factor-binding protein-like 1 | Organisim: human | Apparent_Kd_M: 8.581667E-11
Real
Aptamer SeqId: 7816-23 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7816-23 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.35E-12
Real
Aptamer SeqId: 7817-36 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7817-36 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 7.183505E-12
Real
Aptamer SeqId: 7818-101 | Target: GBP6 | UniProt: Q6ZN66
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7818-101 | Target: GBP6 | UniProt: Q6ZN66 | TargetFullName: Guanylate-binding protein 6 | Organisim: human | Apparent_Kd_M: 1.32E-10
Real
Aptamer SeqId: 7821-6 | Target: C1D | UniProt: Q13901
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7821-6 | Target: C1D | UniProt: Q13901 | TargetFullName: Nuclear nucleic acid-binding protein C1D | Organisim: human | Apparent_Kd_M: 5.648232E-11
Real
Aptamer SeqId: 7822-11 | Target: HRSL2 | UniProt: Q9NWW9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7822-11 | Target: HRSL2 | UniProt: Q9NWW9 | TargetFullName: HRAS-like suppressor 2 | Organisim: human | Apparent_Kd_M: 8.534368E-12
Real
Aptamer SeqId: 7823-22 | Target: SIA7B | UniProt: Q9UJ37
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7823-22 | Target: SIA7B | UniProt: Q9UJ37 | TargetFullName: Alpha-N-acetylgalactosaminide alpha-2;6-sialyltransferase 2 | Organisim: human | Apparent_Kd_M: 1.84311E-11
Real
Aptamer SeqId: 7824-88 | Target: MSRB3 | UniProt: Q8IXL7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7824-88 | Target: MSRB3 | UniProt: Q8IXL7 | TargetFullName: Methionine-R-sulfoxide reductase B3 | Organisim: human | Apparent_Kd_M: 3.594169E-11
Real
Aptamer SeqId: 7825-7 | Target: ABD12 | UniProt: Q8N2K0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7825-7 | Target: ABD12 | UniProt: Q8N2K0 | TargetFullName: Monoacylglycerol lipase ABHD12 | Organisim: human | Apparent_Kd_M: 5.45E-12
Real
Aptamer SeqId: 7826-1 | Target: DCLK3 | UniProt: Q9C098
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7826-1 | Target: DCLK3 | UniProt: Q9C098 | TargetFullName: Serine/threonine-protein kinase DCLK3 | Organisim: human | Apparent_Kd_M: 1.384729E-10
Real
Aptamer SeqId: 7827-20 | Target: ADA32 | UniProt: Q8TC27
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7827-20 | Target: ADA32 | UniProt: Q8TC27 | TargetFullName: Disintegrin and metalloproteinase domain-containing protein 32 | Organisim: human | Apparent_Kd_M: 2.006212E-11
Real
Aptamer SeqId: 7835-2 | Target: BNI3L | UniProt: O60238
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7835-2 | Target: BNI3L | UniProt: O60238 | TargetFullName: BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like | Organisim: human | Apparent_Kd_M: 5.09E-11
Real
Aptamer SeqId: 7838-27 | Target: SMR3A | UniProt: Q99954
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7838-27 | Target: SMR3A | UniProt: Q99954 | TargetFullName: Submaxillary gland androgen-regulated protein 3A | Organisim: human | Apparent_Kd_M: 6.039508E-11
Real
Aptamer SeqId: 7839-99 | Target: F19A3 | UniProt: Q7Z5A8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7839-99 | Target: F19A3 | UniProt: Q7Z5A8 | TargetFullName: Protein FAM19A3 | Organisim: human | Apparent_Kd_M: 3.687957E-10
Real
Aptamer SeqId: 7841-84 | Target: ESAM | UniProt: Q96AP7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7841-84 | Target: ESAM | UniProt: Q96AP7 | TargetFullName: Endothelial cell-selective adhesion molecule | Organisim: human | Apparent_Kd_M: 4.43E-12
Real
Aptamer SeqId: 7842-52 | Target: SERF1 | UniProt: O75920
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7842-52 | Target: SERF1 | UniProt: O75920 | TargetFullName: Small EDRK-rich factor 1 | Organisim: human | Apparent_Kd_M: 2.579044E-11
Real
Aptamer SeqId: 7843-152 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7843-152 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 9.937217E-12
Real
Aptamer SeqId: 7846-44 | Target: PSG11 | UniProt: Q9UQ72
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7846-44 | Target: PSG11 | UniProt: Q9UQ72 | TargetFullName: Pregnancy-specific beta-1-glycoprotein 11 | Organisim: human | Apparent_Kd_M: 9.11E-11
Real
Aptamer SeqId: 7847-66 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7847-66 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.24E-11
Real
Aptamer SeqId: 7849-3 | Target: Glutaminyl cyclase | UniProt: Q16769
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7849-3 | Target: Glutaminyl cyclase | UniProt: Q16769 | TargetFullName: Glutaminyl-peptide cyclotransferase | Organisim: human | Apparent_Kd_M: 8.455663E-11
Real
Aptamer SeqId: 7850-1 | Target: COX42 | UniProt: Q96KJ9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7850-1 | Target: COX42 | UniProt: Q96KJ9 | TargetFullName: Cytochrome c oxidase subunit 4 isoform 2; mitochondrial | Organisim: human | Apparent_Kd_M: 1.492417E-11
Real
Aptamer SeqId: 7851-30 | Target: ANR46 | UniProt: Q86W74
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7851-30 | Target: ANR46 | UniProt: Q86W74 | TargetFullName: Ankyrin repeat domain-containing protein 46 | Organisim: human | Apparent_Kd_M: 1.18E-10
Real
Aptamer SeqId: 7852-9 | Target: IF3M | UniProt: Q9H2K0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7852-9 | Target: IF3M | UniProt: Q9H2K0 | TargetFullName: Translation initiation factor IF-3; mitochondrial | Organisim: human | Apparent_Kd_M: 4.057324E-12
Real
Aptamer SeqId: 7853-19 | Target: SCO1 | UniProt: O75880
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7853-19 | Target: SCO1 | UniProt: O75880 | TargetFullName: Protein SCO1 homolog; mitochondrial | Organisim: human | Apparent_Kd_M: 1.132019E-10
Real
Aptamer SeqId: 7854-38 | Target: NR3L1 | UniProt: Q68D85
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7854-38 | Target: NR3L1 | UniProt: Q68D85 | TargetFullName: Natural cytotoxicity triggering receptor 3 ligand 1 | Organisim: human | Apparent_Kd_M: 4.90931E-11
Real
Aptamer SeqId: 7856-51 | Target: F151A | UniProt: Q8WW52
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7856-51 | Target: F151A | UniProt: Q8WW52 | TargetFullName: Protein FAM151A | Organisim: human | Apparent_Kd_M: 1.219101E-11
Real
Aptamer SeqId: 7857-22 | Target: NEUT | UniProt: P30990
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7857-22 | Target: NEUT | UniProt: P30990 | TargetFullName: Neurotensin/neuromedin N | Organisim: human | Apparent_Kd_M: 6.964586E-12
Real
Aptamer SeqId: 7859-21 | Target: PCDGK | UniProt: Q9UN70
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7859-21 | Target: PCDGK | UniProt: Q9UN70 | TargetFullName: Protocadherin gamma-C3 | Organisim: human | Apparent_Kd_M: 5.789088E-12
Real
Aptamer SeqId: 7860-9 | Target: HERC4 | UniProt: Q5GLZ8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7860-9 | Target: HERC4 | UniProt: Q5GLZ8 | TargetFullName: Probable E3 ubiquitin-protein ligase HERC4 | Organisim: human | Apparent_Kd_M: 2.910066E-10
Real
Aptamer SeqId: 7861-9 | Target: ROR2 | UniProt: Q01974
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7861-9 | Target: ROR2 | UniProt: Q01974 | TargetFullName: Tyrosine-protein kinase transmembrane receptor ROR2 | Organisim: human | Apparent_Kd_M: 1.79E-12
Real
Aptamer SeqId: 7863-50 | Target: PGRC1 | UniProt: O00264
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7863-50 | Target: PGRC1 | UniProt: O00264 | TargetFullName: Membrane-associated progesterone receptor component 1 | Organisim: human | Apparent_Kd_M: 4.251275E-11
Real
Aptamer SeqId: 7864-3 | Target: SIGL8 | UniProt: Q9NYZ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7864-3 | Target: SIGL8 | UniProt: Q9NYZ4 | TargetFullName: Sialic acid-binding Ig-like lectin 8 | Organisim: human | Apparent_Kd_M: 3.573035E-10
Real
Aptamer SeqId: 7865-126 | Target: HRSL3 | UniProt: P53816
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7865-126 | Target: HRSL3 | UniProt: P53816 | TargetFullName: HRAS-like suppressor 3 | Organisim: human | Apparent_Kd_M: 1.332664E-10
Real
Aptamer SeqId: 7866-11 | Target: DJC30 | UniProt: Q96LL9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7866-11 | Target: DJC30 | UniProt: Q96LL9 | TargetFullName: DnaJ homolog subfamily C member 30 | Organisim: human | Apparent_Kd_M: 1.334317E-11
Real
Aptamer SeqId: 7867-154 | Target: SIA7A | UniProt: Q9NSC7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7867-154 | Target: SIA7A | UniProt: Q9NSC7 | TargetFullName: Alpha-N-acetylgalactosaminide alpha-2;6-sialyltransferase 1 | Organisim: human | Apparent_Kd_M: 6.932508E-12
Real
Aptamer SeqId: 7871-16 | Target: T132A | UniProt: Q24JP5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7871-16 | Target: T132A | UniProt: Q24JP5 | TargetFullName: Transmembrane protein 132A | Organisim: human | Apparent_Kd_M: 3.949906E-12
Real
Aptamer SeqId: 7872-5 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7872-5 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.999362E-11
Real
Aptamer SeqId: 7873-32 | Target: TSSK2 | UniProt: Q96PF2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7873-32 | Target: TSSK2 | UniProt: Q96PF2 | TargetFullName: Testis-specific serine/threonine-protein kinase 2 | Organisim: human | Apparent_Kd_M: 5.765698E-11
Real
Aptamer SeqId: 7875-86 | Target: PLEK | UniProt: P08567
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7875-86 | Target: PLEK | UniProt: P08567 | TargetFullName: Pleckstrin | Organisim: human | Apparent_Kd_M: 6.018212E-12
Real
Aptamer SeqId: 7878-2 | Target: SC61B | UniProt: P60468
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7878-2 | Target: SC61B | UniProt: P60468 | TargetFullName: Protein transport protein Sec61 subunit beta | Organisim: human | Apparent_Kd_M: 1.791472E-11
Real
Aptamer SeqId: 7879-12 | Target: Cytochrome P450 3A4 | UniProt: P08684
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7879-12 | Target: Cytochrome P450 3A4 | UniProt: P08684 | TargetFullName: Cytochrome P450 3A4 | Organisim: human | Apparent_Kd_M: 2.23E-11
Real
Aptamer SeqId: 7880-9 | Target: PSA1 | UniProt: P25786
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7880-9 | Target: PSA1 | UniProt: P25786 | TargetFullName: Proteasome subunit alpha type-1 | Organisim: human | Apparent_Kd_M: 8.5E-11
Real
Aptamer SeqId: 7881-244 | Target: PAR16 | UniProt: Q8N5Y8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7881-244 | Target: PAR16 | UniProt: Q8N5Y8 | TargetFullName: Mono ADP-ribose polymerase PARP16 | Organisim: human | Apparent_Kd_M: 2.682631E-12
Real
Aptamer SeqId: 7886-26 | Target: SPTC1 | UniProt: O15269
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7886-26 | Target: SPTC1 | UniProt: O15269 | TargetFullName: Serine palmitoyltransferase 1 | Organisim: human | Apparent_Kd_M: 7.26904E-12
Real
Aptamer SeqId: 7887-57 | Target: COX5B | UniProt: P10606
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7887-57 | Target: COX5B | UniProt: P10606 | TargetFullName: Cytochrome c oxidase subunit 5B; mitochondrial | Organisim: human | Apparent_Kd_M: 2.85E-10
Real
Aptamer SeqId: 7888-58 | Target: CCD56 | UniProt: Q9Y2R0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7888-58 | Target: CCD56 | UniProt: Q9Y2R0 | TargetFullName: Cytochrome c oxidase assembly factor 3 homolog; mitochondrial | Organisim: human | Apparent_Kd_M: 1.778919E-10
Real
Aptamer SeqId: 7890-68 | Target: DPP10 | UniProt: Q8N608
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7890-68 | Target: DPP10 | UniProt: Q8N608 | TargetFullName: Inactive dipeptidyl peptidase 10 | Organisim: human | Apparent_Kd_M: 1.6E-10
Real
Aptamer SeqId: 7891-45 | Target: UGT 1A6 | UniProt: P19224
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7891-45 | Target: UGT 1A6 | UniProt: P19224 | TargetFullName: UDP-glucuronosyltransferase 1-6 | Organisim: human | Apparent_Kd_M: 3.935566E-12
Real
Aptamer SeqId: 7892-132 | Target: K1467 | UniProt: A2RU67
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7892-132 | Target: K1467 | UniProt: A2RU67 | TargetFullName: Protein FAM234B | Organisim: human | Apparent_Kd_M: 2.27E-12
Real
Aptamer SeqId: 7894-155 | Target: FGF-3 | UniProt: P11487
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7894-155 | Target: FGF-3 | UniProt: P11487 | TargetFullName: Fibroblast growth factor 3 | Organisim: human | Apparent_Kd_M: 2.282123E-11
Real
Aptamer SeqId: 7895-108 | Target: MRAP | UniProt: Q8TCY5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7895-108 | Target: MRAP | UniProt: Q8TCY5 | TargetFullName: Melanocortin-2 receptor accessory protein | Organisim: human | Apparent_Kd_M: 1.15808E-11
Real
Aptamer SeqId: 7897-75 | Target: DLG3 | UniProt: Q92796
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7897-75 | Target: DLG3 | UniProt: Q92796 | TargetFullName: Disks large homolog 3 | Organisim: human | Apparent_Kd_M: 1.056206E-11
Real
Aptamer SeqId: 7898-29 | Target: MDM1 | UniProt: Q8TC05
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7898-29 | Target: MDM1 | UniProt: Q8TC05 | TargetFullName: Nuclear protein MDM1 | Organisim: human | Apparent_Kd_M: 4.316497E-12
Real
Aptamer SeqId: 7903-18 | Target: VAMP3 | UniProt: Q15836
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7903-18 | Target: VAMP3 | UniProt: Q15836 | TargetFullName: Vesicle-associated membrane protein 3 | Organisim: human | Apparent_Kd_M: 9.896858E-12
Real
Aptamer SeqId: 7905-30 | Target: HPT | UniProt: P00738
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7905-30 | Target: HPT | UniProt: P00738 | TargetFullName: Haptoglobin | Organisim: human | Apparent_Kd_M: 1.780947E-11
Real
Aptamer SeqId: 7910-41 | Target: LRFN1 | UniProt: Q9P244
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7910-41 | Target: LRFN1 | UniProt: Q9P244 | TargetFullName: Leucine-rich repeat and fibronectin type III domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 8.670075E-11
Real
Aptamer SeqId: 7911-29 | Target: SCN4B | UniProt: Q8IWT1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7911-29 | Target: SCN4B | UniProt: Q8IWT1 | TargetFullName: Sodium channel subunit beta-4 | Organisim: human | Apparent_Kd_M: 1.335426E-11
Real
Aptamer SeqId: 7916-10 | Target: S100A7 | UniProt: P31151
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7916-10 | Target: S100A7 | UniProt: P31151 | TargetFullName: Protein S100-A7 | Organisim: human | Apparent_Kd_M: 3.05E-12
Real
Aptamer SeqId: 7917-17 | Target: CBPD | UniProt: O75976
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7917-17 | Target: CBPD | UniProt: O75976 | TargetFullName: Carboxypeptidase D | Organisim: human | Apparent_Kd_M: 9.322247E-11
Real
Aptamer SeqId: 7918-114 | Target: Amylase; alpha 1A | UniProt: P04745
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7918-114 | Target: Amylase; alpha 1A | UniProt: P04745 | TargetFullName: Alpha-amylase 1 | Organisim: human | Apparent_Kd_M: 1.21E-11
Real
Aptamer SeqId: 7920-30 | Target: SIA8B | UniProt: Q92186
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7920-30 | Target: SIA8B | UniProt: Q92186 | TargetFullName: Alpha-2;8-sialyltransferase 8B | Organisim: human | Apparent_Kd_M: 5.253099E-11
Real
Aptamer SeqId: 7921-65 | Target: FJX1 | UniProt: Q86VR8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7921-65 | Target: FJX1 | UniProt: Q86VR8 | TargetFullName: Four-jointed box protein 1 | Organisim: human | Apparent_Kd_M: 3.261788E-12
Real
Aptamer SeqId: 7922-5 | Target: Adrenomedullin | UniProt: P35318
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7922-5 | Target: Adrenomedullin | UniProt: P35318 | TargetFullName: Adrenomedullin | Organisim: human | Apparent_Kd_M: 2.36E-11
Real
Aptamer SeqId: 7923-41 | Target: SEM4C | UniProt: Q9C0C4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7923-41 | Target: SEM4C | UniProt: Q9C0C4 | TargetFullName: Semaphorin-4C | Organisim: human | Apparent_Kd_M: 3.76059E-11
Real
Aptamer SeqId: 7924-7 | Target: CD3G | UniProt: P09693
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7924-7 | Target: CD3G | UniProt: P09693 | TargetFullName: T-cell surface glycoprotein CD3 gamma chain | Organisim: human | Apparent_Kd_M: 1.596429E-10
Real
Aptamer SeqId: 7925-18 | Target: CL070 | UniProt: A6NFE2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7925-18 | Target: CL070 | UniProt: A6NFE2 | TargetFullName: Single-pass membrane and coiled-coil domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 9.508422E-12
Real
Aptamer SeqId: 7926-13 | Target: SPIT3 | UniProt: P49223
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7926-13 | Target: SPIT3 | UniProt: P49223 | TargetFullName: Kunitz-type protease inhibitor 3 | Organisim: human | Apparent_Kd_M: 4.94E-12
Real
Aptamer SeqId: 7927-16 | Target: SIA7E | UniProt: Q9BVH7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7927-16 | Target: SIA7E | UniProt: Q9BVH7 | TargetFullName: Alpha-N-acetylgalactosaminide alpha-2;6-sialyltransferase 5 | Organisim: human | Apparent_Kd_M: 7.807617E-12
Real
Aptamer SeqId: 7928-183 | Target: TPST1 | UniProt: O60507
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7928-183 | Target: TPST1 | UniProt: O60507 | TargetFullName: Protein-tyrosine sulfotransferase 1 | Organisim: human | Apparent_Kd_M: 1.337043E-11
Real
Aptamer SeqId: 7930-3 | Target: EXOS1 | UniProt: Q9Y3B2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7930-3 | Target: EXOS1 | UniProt: Q9Y3B2 | TargetFullName: Exosome complex component CSL4 | Organisim: human | Apparent_Kd_M: 2.0E-10
Real
Aptamer SeqId: 7932-23 | Target: SYT8 | UniProt: Q8NBV8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7932-23 | Target: SYT8 | UniProt: Q8NBV8 | TargetFullName: Synaptotagmin-8 | Organisim: human | Apparent_Kd_M: 3.70615E-10
Real
Aptamer SeqId: 7933-75 | Target: ADA22 | UniProt: Q9P0K1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7933-75 | Target: ADA22 | UniProt: Q9P0K1 | TargetFullName: Disintegrin and metalloproteinase domain-containing protein 22 | Organisim: human | Apparent_Kd_M: 3.886273E-12
Real
Aptamer SeqId: 7934-11 | Target: NDRG4 | UniProt: Q9ULP0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7934-11 | Target: NDRG4 | UniProt: Q9ULP0 | TargetFullName: Protein NDRG4 | Organisim: human | Apparent_Kd_M: 2.939887E-10
Real
Aptamer SeqId: 7935-26 | Target: LARGE | UniProt: O95461
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7935-26 | Target: LARGE | UniProt: O95461 | TargetFullName: Glycosyltransferase-like protein LARGE1 | Organisim: human | Apparent_Kd_M: 4.654612E-12
Real
Aptamer SeqId: 7939-1 | Target: CC055 | UniProt: A1A4F0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7939-1 | Target: CC055 | UniProt: A1A4F0 | TargetFullName: Putative uncharacterized protein PQLC2L | Organisim: human | Apparent_Kd_M: 1.82E-10
Real
Aptamer SeqId: 7943-16 | Target: CUZD1 | UniProt: Q86UP6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7943-16 | Target: CUZD1 | UniProt: Q86UP6 | TargetFullName: CUB and zona pellucida-like domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 9.254376E-11
Real
Aptamer SeqId: 7944-1 | Target: KI3L3 | UniProt: Q8N743
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7944-1 | Target: KI3L3 | UniProt: Q8N743 | TargetFullName: Killer cell immunoglobulin-like receptor 3DL3 | Organisim: human | Apparent_Kd_M: 1.31E-11
Real
Aptamer SeqId: 7945-10 | Target: Semaphorin-6A | UniProt: Q9H2E6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7945-10 | Target: Semaphorin-6A | UniProt: Q9H2E6 | TargetFullName: Semaphorin-6A | Organisim: human | Apparent_Kd_M: 7.82E-12
Real
Aptamer SeqId: 7947-19 | Target: AP4AT | UniProt: Q96N21
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7947-19 | Target: AP4AT | UniProt: Q96N21 | TargetFullName: AP-4 complex accessory subunit tepsin | Organisim: human | Apparent_Kd_M: 4.753621E-11
Real
Aptamer SeqId: 7948-129 | Target: GLTD2 | UniProt: A6NH11
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7948-129 | Target: GLTD2 | UniProt: A6NH11 | TargetFullName: Glycolipid transfer protein domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 1.765909E-11
Real
Aptamer SeqId: 7950-142 | Target: BTNL9 | UniProt: Q6UXG8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7950-142 | Target: BTNL9 | UniProt: Q6UXG8 | TargetFullName: Butyrophilin-like protein 9 | Organisim: human | Apparent_Kd_M: 1.53E-10
Real
Aptamer SeqId: 7952-2 | Target: VTI1A | UniProt: Q96AJ9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7952-2 | Target: VTI1A | UniProt: Q96AJ9 | TargetFullName: Vesicle transport through interaction with t-SNAREs homolog 1A | Organisim: human | Apparent_Kd_M: 1.80367E-11
Real
Aptamer SeqId: 7953-20 | Target: SLAF1 | UniProt: Q13291
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7953-20 | Target: SLAF1 | UniProt: Q13291 | TargetFullName: Signaling lymphocytic activation molecule | Organisim: human | Apparent_Kd_M: 1.617373E-10
Real
Aptamer SeqId: 7955-195 | Target: ITI heavy chain H1 | UniProt: P19827
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7955-195 | Target: ITI heavy chain H1 | UniProt: P19827 | TargetFullName: Inter-alpha-trypsin inhibitor heavy chain H1 | Organisim: human | Apparent_Kd_M: 2.759817E-11
Real
Aptamer SeqId: 7956-11 | Target: MOS1 | UniProt: Q5TGZ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7956-11 | Target: MOS1 | UniProt: Q5TGZ0 | TargetFullName: MICOS complex subunit MIC10 | Organisim: human | Apparent_Kd_M: 1.037936E-11
Real
Aptamer SeqId: 7957-2 | Target: SCG3 | UniProt: Q8WXD2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7957-2 | Target: SCG3 | UniProt: Q8WXD2 | TargetFullName: Secretogranin-3 | Organisim: human | Apparent_Kd_M: 1.21442E-11
Real
Aptamer SeqId: 7959-34 | Target: CADH7 | UniProt: Q9ULB5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7959-34 | Target: CADH7 | UniProt: Q9ULB5 | TargetFullName: Cadherin-7 | Organisim: human | Apparent_Kd_M: 1.07E-11
Real
Aptamer SeqId: 7960-53 | Target: POTEG | UniProt: Q6S5H5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7960-53 | Target: POTEG | UniProt: Q6S5H5 | TargetFullName: POTE ankyrin domain family member G | Organisim: human | Apparent_Kd_M: 2.906228E-10
Real
Aptamer SeqId: 7962-11 | Target: ISK8 | UniProt: P0C7L1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7962-11 | Target: ISK8 | UniProt: P0C7L1 | TargetFullName: Serine protease inhibitor Kazal-type 8 | Organisim: human | Apparent_Kd_M: 4.190992E-11
Real
Aptamer SeqId: 7963-36 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7963-36 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.532591E-11
Real
Aptamer SeqId: 7967-38 | Target: POTEM | UniProt: A6NI47
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7967-38 | Target: POTEM | UniProt: A6NI47 | TargetFullName: Putative POTE ankyrin domain family member M | Organisim: human | Apparent_Kd_M: 7.602262E-11
Real
Aptamer SeqId: 7968-15 | Target: CRTAM | UniProt: O95727
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7968-15 | Target: CRTAM | UniProt: O95727 | TargetFullName: Cytotoxic and regulatory T-cell molecule | Organisim: human | Apparent_Kd_M: 1.22E-11
Real
Aptamer SeqId: 7969-163 | Target: WFD11 | UniProt: Q8NEX6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7969-163 | Target: WFD11 | UniProt: Q8NEX6 | TargetFullName: Protein WFDC11 | Organisim: human | Apparent_Kd_M: 6.248364E-11
Real
Aptamer SeqId: 7970-315 | Target: NAR3 | UniProt: Q13508
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7970-315 | Target: NAR3 | UniProt: Q13508 | TargetFullName: Ecto-ADP-ribosyltransferase 3 | Organisim: human | Apparent_Kd_M: 1.33E-11
Real
Aptamer SeqId: 7975-97 | Target: UNC5A | UniProt: Q6ZN44
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7975-97 | Target: UNC5A | UniProt: Q6ZN44 | TargetFullName: Netrin receptor UNC5A | Organisim: human | Apparent_Kd_M: 1.321916E-11
Real
Aptamer SeqId: 7976-19 | Target: FRS1L | UniProt: Q9P0K9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7976-19 | Target: FRS1L | UniProt: Q9P0K9 | TargetFullName: DOMON domain-containing protein FRRS1L | Organisim: human | Apparent_Kd_M: 3.192368E-11
Real
Aptamer SeqId: 7980-72 | Target: B3GN2 | UniProt: Q9NY97
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7980-72 | Target: B3GN2 | UniProt: Q9NY97 | TargetFullName: N-acetyllactosaminide beta-1;3-N-acetylglucosaminyltransferase 2 | Organisim: human | Apparent_Kd_M: 2.141297E-11
Real
Aptamer SeqId: 7981-230 | Target: B3GT6 | UniProt: Q96L58
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7981-230 | Target: B3GT6 | UniProt: Q96L58 | TargetFullName: Beta-1;3-galactosyltransferase 6 | Organisim: human | Apparent_Kd_M: 3.108879E-11
Real
Aptamer SeqId: 7982-10 | Target: RM32 | UniProt: Q9BYC8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7982-10 | Target: RM32 | UniProt: Q9BYC8 | TargetFullName: 39S ribosomal protein L32; mitochondrial | Organisim: human | Apparent_Kd_M: 1.812824E-11
Real
Aptamer SeqId: 7983-1 | Target: PCDGM | UniProt: Q9Y5F6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7983-1 | Target: PCDGM | UniProt: Q9Y5F6 | TargetFullName: Protocadherin gamma-C5 | Organisim: human | Apparent_Kd_M: 1.678747E-11
Real
Aptamer SeqId: 7986-98 | Target: NALD2 | UniProt: Q9Y3Q0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7986-98 | Target: NALD2 | UniProt: Q9Y3Q0 | TargetFullName: N-acetylated-alpha-linked acidic dipeptidase 2 | Organisim: human | Apparent_Kd_M: 1.303427E-10
Real
Aptamer SeqId: 7989-5 | Target: CA226 | UniProt: A1L170
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7989-5 | Target: CA226 | UniProt: A1L170 | TargetFullName: Uncharacterized protein C1orf226 | Organisim: human | Apparent_Kd_M: 3.026286E-10
Real
Aptamer SeqId: 7991-54 | Target: IQCF1 | UniProt: Q8N6M8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7991-54 | Target: IQCF1 | UniProt: Q8N6M8 | TargetFullName: IQ domain-containing protein F1 | Organisim: human | Apparent_Kd_M: 1.95E-10
Real
Aptamer SeqId: 7992-3 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7992-3 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.031898E-10
Real
Aptamer SeqId: 7993-23 | Target: ASTL | UniProt: Q6HA08
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7993-23 | Target: ASTL | UniProt: Q6HA08 | TargetFullName: Astacin-like metalloendopeptidase | Organisim: human | Apparent_Kd_M: 8.206606E-12
Real
Aptamer SeqId: 7994-41 | Target: ERO1B | UniProt: Q86YB8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7994-41 | Target: ERO1B | UniProt: Q86YB8 | TargetFullName: ERO1-like protein beta | Organisim: human | Apparent_Kd_M: 9.887859E-11
Real
Aptamer SeqId: 7995-16 | Target: VWC2L | UniProt: B2RUY7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7995-16 | Target: VWC2L | UniProt: B2RUY7 | TargetFullName: von Willebrand factor C domain-containing protein 2-like | Organisim: human | Apparent_Kd_M: 2.512963E-10
Real
Aptamer SeqId: 7997-118 | Target: DOC2B | UniProt: Q14184
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7997-118 | Target: DOC2B | UniProt: Q14184 | TargetFullName: Double C2-like domain-containing protein beta | Organisim: human | Apparent_Kd_M: 6.188603E-11
Real
Aptamer SeqId: 7999-23 | Target: CD39 | UniProt: P49961
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 7999-23 | Target: CD39 | UniProt: P49961 | TargetFullName: Ectonucleoside triphosphate diphosphohydrolase 1 | Organisim: human | Apparent_Kd_M: 6.25E-12
Real
Aptamer SeqId: 8000-17 | Target: KI2LA | UniProt: Q8N109
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8000-17 | Target: KI2LA | UniProt: Q8N109 | TargetFullName: Killer cell immunoglobulin-like receptor 2DL5A | Organisim: human | Apparent_Kd_M: 6.23E-12
Real
Aptamer SeqId: 8002-27 | Target: Spinesin | UniProt: Q9H3S3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8002-27 | Target: Spinesin | UniProt: Q9H3S3 | TargetFullName: Transmembrane protease serine 5 | Organisim: human | Apparent_Kd_M: 7.263001E-11
Real
Aptamer SeqId: 8003-57 | Target: LGI3 | UniProt: Q8N145
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8003-57 | Target: LGI3 | UniProt: Q8N145 | TargetFullName: Leucine-rich repeat LGI family member 3 | Organisim: human | Apparent_Kd_M: 1.391593E-11
Real
Aptamer SeqId: 8004-15 | Target: G3PT | UniProt: O14556
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8004-15 | Target: G3PT | UniProt: O14556 | TargetFullName: Glyceraldehyde-3-phosphate dehydrogenase; testis-specific | Organisim: human | Apparent_Kd_M: 1.15102E-10
Real
Aptamer SeqId: 8005-1 | Target: MXRA7 | UniProt: P84157
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8005-1 | Target: MXRA7 | UniProt: P84157 | TargetFullName: Matrix-remodeling-associated protein 7 | Organisim: human | Apparent_Kd_M: 1.12E-10
Real
Aptamer SeqId: 8006-12 | Target: DJB12 | UniProt: Q9NXW2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8006-12 | Target: DJB12 | UniProt: Q9NXW2 | TargetFullName: DnaJ homolog subfamily B member 12 | Organisim: human | Apparent_Kd_M: 3.262026E-12
Real
Aptamer SeqId: 8007-19 | Target: Cathepsin B | UniProt: P07858
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8007-19 | Target: Cathepsin B | UniProt: P07858 | TargetFullName: Cathepsin B | Organisim: human | Apparent_Kd_M: 5.47E-12
Real
Aptamer SeqId: 8008-28 | Target: HRK | UniProt: O00198
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8008-28 | Target: HRK | UniProt: O00198 | TargetFullName: Activator of apoptosis harakiri | Organisim: human | Apparent_Kd_M: 2.69E-10
Real
Aptamer SeqId: 8009-121 | Target: SURF1 | UniProt: Q15526
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8009-121 | Target: SURF1 | UniProt: Q15526 | TargetFullName: Surfeit locus protein 1 | Organisim: human | Apparent_Kd_M: 1.62E-11
Real
Aptamer SeqId: 8011-96 | Target: PAPL | UniProt: Q6ZNF0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8011-96 | Target: PAPL | UniProt: Q6ZNF0 | TargetFullName: Iron/zinc purple acid phosphatase-like protein | Organisim: human | Apparent_Kd_M: 1.91963E-12
Real
Aptamer SeqId: 8013-9 | Target: LMA2L | UniProt: Q9H0V9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8013-9 | Target: LMA2L | UniProt: Q9H0V9 | TargetFullName: VIP36-like protein | Organisim: human | Apparent_Kd_M: 8.824464E-12
Real
Aptamer SeqId: 8014-359 | Target: MANEA | UniProt: Q5SRI9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8014-359 | Target: MANEA | UniProt: Q5SRI9 | TargetFullName: Glycoprotein endo-alpha-1;2-mannosidase | Organisim: human | Apparent_Kd_M: 6.917222E-12
Real
Aptamer SeqId: 8015-144 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8015-144 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.948895E-11
Real
Aptamer SeqId: 8016-19 | Target: DNJC4 | UniProt: Q9NNZ3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8016-19 | Target: DNJC4 | UniProt: Q9NNZ3 | TargetFullName: DnaJ homolog subfamily C member 4 | Organisim: human | Apparent_Kd_M: 3.52E-11
Real
Aptamer SeqId: 8017-23 | Target: FXRD1 | UniProt: Q96CU9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8017-23 | Target: FXRD1 | UniProt: Q96CU9 | TargetFullName: FAD-dependent oxidoreductase domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 5.022978E-11
Real
Aptamer SeqId: 8018-43 | Target: VSIG2 | UniProt: Q96IQ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8018-43 | Target: VSIG2 | UniProt: Q96IQ7 | TargetFullName: V-set and immunoglobulin domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 1.71E-11
Real
Aptamer SeqId: 8019-73 | Target: STMN3 | UniProt: Q9NZ72
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8019-73 | Target: STMN3 | UniProt: Q9NZ72 | TargetFullName: Stathmin-3 | Organisim: human | Apparent_Kd_M: 7.31E-11
Real
Aptamer SeqId: 8021-59 | Target: RM14 | UniProt: Q6P1L8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8021-59 | Target: RM14 | UniProt: Q6P1L8 | TargetFullName: 39S ribosomal protein L14; mitochondrial | Organisim: human | Apparent_Kd_M: 2.871166E-10
Real
Aptamer SeqId: 8023-23 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8023-23 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 4.949324E-11
Real
Aptamer SeqId: 8024-64 | Target: TPST2 | UniProt: O60704
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8024-64 | Target: TPST2 | UniProt: O60704 | TargetFullName: Protein-tyrosine sulfotransferase 2 | Organisim: human | Apparent_Kd_M: 6.990052E-11
Real
Aptamer SeqId: 8028-22 | Target: SPINK5 | UniProt: Q9NQ38
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8028-22 | Target: SPINK5 | UniProt: Q9NQ38 | TargetFullName: Serine protease inhibitor Kazal-type 5 | Organisim: human | Apparent_Kd_M: 3.323798E-11
Real
Aptamer SeqId: 8029-35 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8029-35 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.14915E-11
Real
Aptamer SeqId: 8031-11 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8031-11 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.265995E-11
Real
Aptamer SeqId: 8032-23 | Target: MCCD1 | UniProt: P59942
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8032-23 | Target: MCCD1 | UniProt: P59942 | TargetFullName: Mitochondrial coiled-coil domain protein 1 | Organisim: human | Apparent_Kd_M: 2.117015E-10
Real
Aptamer SeqId: 8033-1 | Target: DJC18 | UniProt: Q9H819
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8033-1 | Target: DJC18 | UniProt: Q9H819 | TargetFullName: DnaJ homolog subfamily C member 18 | Organisim: human | Apparent_Kd_M: 6.477627E-12
Real
Aptamer SeqId: 8034-6 | Target: DRGX | UniProt: A6NNA5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8034-6 | Target: DRGX | UniProt: A6NNA5 | TargetFullName: Dorsal root ganglia homeobox protein | Organisim: human | Apparent_Kd_M: 6.083276E-12
Real
Aptamer SeqId: 8035-6 | Target: CA198 | UniProt: Q9H425
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8035-6 | Target: CA198 | UniProt: Q9H425 | TargetFullName: Uncharacterized protein C1orf198 | Organisim: human | Apparent_Kd_M: 2.386915E-11
Real
Aptamer SeqId: 8036-75 | Target: FSHB | UniProt: P01225
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8036-75 | Target: FSHB | UniProt: P01225 | TargetFullName: Follitropin subunit beta | Organisim: human | Apparent_Kd_M: 1.073358E-10
Real
Aptamer SeqId: 8038-41 | Target: NSDHL | UniProt: Q15738
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8038-41 | Target: NSDHL | UniProt: Q15738 | TargetFullName: Sterol-4-alpha-carboxylate 3-dehydrogenase; decarboxylating | Organisim: human | Apparent_Kd_M: 8.993994E-12
Real
Aptamer SeqId: 8039-41 | Target: F177A | UniProt: Q8N128
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8039-41 | Target: F177A | UniProt: Q8N128 | TargetFullName: Protein FAM177A1 | Organisim: human | Apparent_Kd_M: 3.920842E-11
Real
Aptamer SeqId: 8040-9 | Target: LEMD1 | UniProt: Q68G75
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8040-9 | Target: LEMD1 | UniProt: Q68G75 | TargetFullName: LEM domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 9.174705E-12
Real
Aptamer SeqId: 8041-5 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8041-5 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.437274E-11
Real
Aptamer SeqId: 8042-88 | Target: ISK9 | UniProt: Q5DT21
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8042-88 | Target: ISK9 | UniProt: Q5DT21 | TargetFullName: Serine protease inhibitor Kazal-type 9 | Organisim: human | Apparent_Kd_M: 5.090768E-11
Real
Aptamer SeqId: 8043-153 | Target: COMP | UniProt: P49747
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8043-153 | Target: COMP | UniProt: P49747 | TargetFullName: Cartilage oligomeric matrix protein | Organisim: human | Apparent_Kd_M: 2.720908E-10
Real
Aptamer SeqId: 8044-90 | Target: XG | UniProt: P55808
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8044-90 | Target: XG | UniProt: P55808 | TargetFullName: Glycoprotein Xg | Organisim: human | Apparent_Kd_M: 4.7E-11
Real
Aptamer SeqId: 8045-3 | Target: KI3L3 | UniProt: Q8N743
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8045-3 | Target: KI3L3 | UniProt: Q8N743 | TargetFullName: Killer cell immunoglobulin-like receptor 3DL3 | Organisim: human | Apparent_Kd_M: 1.66E-10
Real
Aptamer SeqId: 8046-9 | Target: Galectin-1 | UniProt: P09382
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8046-9 | Target: Galectin-1 | UniProt: P09382 | TargetFullName: Galectin-1 | Organisim: human | Apparent_Kd_M: 2.818388E-10
Real
Aptamer SeqId: 8048-9 | Target: FTMT | UniProt: Q8N4E7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8048-9 | Target: FTMT | UniProt: Q8N4E7 | TargetFullName: Ferritin; mitochondrial | Organisim: human | Apparent_Kd_M: 6.26E-11
Real
Aptamer SeqId: 8051-10 | Target: AGGF1 | UniProt: Q8N302
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8051-10 | Target: AGGF1 | UniProt: Q8N302 | TargetFullName: Angiogenic factor with G patch and FHA domains 1 | Organisim: human | Apparent_Kd_M: 4.472491E-11
Real
Aptamer SeqId: 8053-16 | Target: DJB14 | UniProt: Q8TBM8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8053-16 | Target: DJB14 | UniProt: Q8TBM8 | TargetFullName: DnaJ homolog subfamily B member 14 | Organisim: human | Apparent_Kd_M: 6.58E-12
Real
Aptamer SeqId: 8055-33 | Target: IDD | UniProt: P98153
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8055-33 | Target: IDD | UniProt: P98153 | TargetFullName: Integral membrane protein DGCR2/IDD | Organisim: human | Apparent_Kd_M: 1.594547E-11
Real
Aptamer SeqId: 8057-78 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8057-78 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.931321E-12
Real
Aptamer SeqId: 8059-1 | Target: Tpo | UniProt: P40225
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8059-1 | Target: Tpo | UniProt: P40225 | TargetFullName: Thrombopoietin | Organisim: human | Apparent_Kd_M: 4.72E-12
Real
Aptamer SeqId: 8060-7 | Target: NRG2 | UniProt: O14511
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8060-7 | Target: NRG2 | UniProt: O14511 | TargetFullName: Pro-neuregulin-2; membrane-bound isoform | Organisim: human | Apparent_Kd_M: 1.510965E-11
Real
Aptamer SeqId: 8061-102 | Target: F171B | UniProt: Q6P995
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8061-102 | Target: F171B | UniProt: Q6P995 | TargetFullName: Protein FAM171B | Organisim: human | Apparent_Kd_M: 2.07E-11
Real
Aptamer SeqId: 8062-15 | Target: F176B | UniProt: Q9NVM1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8062-15 | Target: F176B | UniProt: Q9NVM1 | TargetFullName: Protein eva-1 homolog B | Organisim: human | Apparent_Kd_M: 3.303676E-11
Real
Aptamer SeqId: 8064-125 | Target: Poliovirus receptor | UniProt: P15151
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8064-125 | Target: Poliovirus receptor | UniProt: P15151 | TargetFullName: Poliovirus receptor | Organisim: human | Apparent_Kd_M: 3.766836E-10
Real
Aptamer SeqId: 8065-245 | Target: PATE4 | UniProt: P0C8F1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8065-245 | Target: PATE4 | UniProt: P0C8F1 | TargetFullName: Prostate and testis expressed protein 4 | Organisim: human | Apparent_Kd_M: 1.137321E-11
Real
Aptamer SeqId: 8066-38 | Target: SYT9 | UniProt: Q86SS6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8066-38 | Target: SYT9 | UniProt: Q86SS6 | TargetFullName: Synaptotagmin-9 | Organisim: human | Apparent_Kd_M: 1.006136E-11
Real
Aptamer SeqId: 8067-21 | Target: KCNE3 | UniProt: Q9Y6H6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8067-21 | Target: KCNE3 | UniProt: Q9Y6H6 | TargetFullName: Potassium voltage-gated channel subfamily E member 3 | Organisim: human | Apparent_Kd_M: 1.47E-10
Real
Aptamer SeqId: 8068-43 | Target: K1161 | UniProt: Q6NSJ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8068-43 | Target: K1161 | UniProt: Q6NSJ0 | TargetFullName: Uncharacterized family 31 glucosidase KIAA1161 | Organisim: human | Apparent_Kd_M: 9.69E-11
Real
Aptamer SeqId: 8069-85 | Target: CD3E | UniProt: P07766
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8069-85 | Target: CD3E | UniProt: P07766 | TargetFullName: T-cell surface glycoprotein CD3 epsilon chain | Organisim: human | Apparent_Kd_M: 1.11E-11
Real
Aptamer SeqId: 8070-88 | Target: DLG4 | UniProt: P78352
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8070-88 | Target: DLG4 | UniProt: P78352 | TargetFullName: Disks large homolog 4 | Organisim: human | Apparent_Kd_M: 2.572475E-12
Real
Aptamer SeqId: 8071-114 | Target: PCDB7 | UniProt: Q9Y5E2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8071-114 | Target: PCDB7 | UniProt: Q9Y5E2 | TargetFullName: Protocadherin beta-7 | Organisim: human | Apparent_Kd_M: 1.695905E-10
Real
Aptamer SeqId: 8072-19 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8072-19 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.537184E-11
Real
Aptamer SeqId: 8074-32 | Target: TMM70 | UniProt: Q9BUB7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8074-32 | Target: TMM70 | UniProt: Q9BUB7 | TargetFullName: Transmembrane protein 70; mitochondrial | Organisim: human | Apparent_Kd_M: 6.607048E-11
Real
Aptamer SeqId: 8076-4 | Target: SACA3 | UniProt: Q8IXA5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8076-4 | Target: SACA3 | UniProt: Q8IXA5 | TargetFullName: Sperm acrosome membrane-associated protein 3 | Organisim: human | Apparent_Kd_M: 4.597139E-12
Real
Aptamer SeqId: 8078-15 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8078-15 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 7.889328E-12
Real
Aptamer SeqId: 8079-39 | Target: EID3 | UniProt: Q8N140
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8079-39 | Target: EID3 | UniProt: Q8N140 | TargetFullName: EP300-interacting inhibitor of differentiation 3 | Organisim: human | Apparent_Kd_M: 5.220835E-11
Real
Aptamer SeqId: 8080-24 | Target: PSMP | UniProt: Q1L6U9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8080-24 | Target: PSMP | UniProt: Q1L6U9 | TargetFullName: Prostate-associated microseminoprotein | Organisim: human | Apparent_Kd_M: 1.114506E-11
Real
Aptamer SeqId: 8081-55 | Target: PLD5 | UniProt: Q8N7P1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8081-55 | Target: PLD5 | UniProt: Q8N7P1 | TargetFullName: Inactive phospholipase D5 | Organisim: human | Apparent_Kd_M: 8.555169E-11
Real
Aptamer SeqId: 8085-10 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8085-10 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.82E-11
Real
Aptamer SeqId: 8086-49 | Target: ITM2B | UniProt: Q9Y287
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8086-49 | Target: ITM2B | UniProt: Q9Y287 | TargetFullName: Integral membrane protein 2B | Organisim: human | Apparent_Kd_M: 1.418411E-10
Real
Aptamer SeqId: 8087-250 | Target: RNF13 | UniProt: O43567
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8087-250 | Target: RNF13 | UniProt: O43567 | TargetFullName: E3 ubiquitin-protein ligase RNF13 | Organisim: human | Apparent_Kd_M: 2.649727E-11
Real
Aptamer SeqId: 8088-56 | Target: CA210 | UniProt: Q8IVY1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8088-56 | Target: CA210 | UniProt: Q8IVY1 | TargetFullName: Type III endosome membrane protein TEMP | Organisim: human | Apparent_Kd_M: 7.416853E-12
Real
Aptamer SeqId: 8089-173 | Target: NR4A1 | UniProt: P22736
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8089-173 | Target: NR4A1 | UniProt: P22736 | TargetFullName: Nuclear receptor subfamily 4 group A member 1 | Organisim: human | Apparent_Kd_M: 4.24552E-11
Real
Aptamer SeqId: 8093-13 | Target: K1161 | UniProt: Q6NSJ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8093-13 | Target: K1161 | UniProt: Q6NSJ0 | TargetFullName: Uncharacterized family 31 glucosidase KIAA1161 | Organisim: human | Apparent_Kd_M: 1.24E-11
Real
Aptamer SeqId: 8094-20 | Target: CISD2 | UniProt: Q8N5K1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8094-20 | Target: CISD2 | UniProt: Q8N5K1 | TargetFullName: CDGSH iron-sulfur domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 2.57849E-11
Real
Aptamer SeqId: 8097-77 | Target: LIPN | UniProt: Q5VXI9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8097-77 | Target: LIPN | UniProt: Q5VXI9 | TargetFullName: Lipase member N | Organisim: human | Apparent_Kd_M: 3.750358E-12
Real
Aptamer SeqId: 8098-37 | Target: THAS | UniProt: P24557
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8098-37 | Target: THAS | UniProt: P24557 | TargetFullName: Thromboxane-A synthase | Organisim: human | Apparent_Kd_M: 1.954798E-10
Real
Aptamer SeqId: 8099-42 | Target: SPON2 | UniProt: Q9BUD6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8099-42 | Target: SPON2 | UniProt: Q9BUD6 | TargetFullName: Spondin-2 | Organisim: human | Apparent_Kd_M: 4.628419E-12
Real
Aptamer SeqId: 8100-15 | Target: ADM2 | UniProt: Q7Z4H4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8100-15 | Target: ADM2 | UniProt: Q7Z4H4 | TargetFullName: ADM2 | Organisim: human | Apparent_Kd_M: 9.938457E-12
Real
Aptamer SeqId: 8102-239 | Target: CA186 | UniProt: Q6ZWK4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8102-239 | Target: CA186 | UniProt: Q6ZWK4 | TargetFullName: Uncharacterized protein C1orf186 | Organisim: human | Apparent_Kd_M: 1.322364E-10
Real
Aptamer SeqId: 8104-21 | Target: IL-10 Ra | UniProt: Q13651
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8104-21 | Target: IL-10 Ra | UniProt: Q13651 | TargetFullName: Interleukin-10 receptor subunit alpha | Organisim: human | Apparent_Kd_M: 1.63E-10
Real
Aptamer SeqId: 8106-15 | Target: SSRA | UniProt: P43307
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8106-15 | Target: SSRA | UniProt: P43307 | TargetFullName: Translocon-associated protein subunit alpha | Organisim: human | Apparent_Kd_M: 2.992605E-11
Real
Aptamer SeqId: 8107-12 | Target: TM234 | UniProt: Q8WY98
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8107-12 | Target: TM234 | UniProt: Q8WY98 | TargetFullName: Transmembrane protein 234 | Organisim: human | Apparent_Kd_M: 7.40099E-11
Real
Aptamer SeqId: 8219-14 | Target: ZG16 | UniProt: O60844
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8219-14 | Target: ZG16 | UniProt: O60844 | TargetFullName: Zymogen granule membrane protein 16 | Organisim: human | Apparent_Kd_M: 7.69E-12
Real
Aptamer SeqId: 8220-15 | Target: CJ035 | UniProt: Q96D05
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8220-15 | Target: CJ035 | UniProt: Q96D05 | TargetFullName: Uncharacterized protein C10orf35 | Organisim: human | Apparent_Kd_M: 4.683084E-11
Real
Aptamer SeqId: 8221-19 | Target: MIF | UniProt: P14174
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8221-19 | Target: MIF | UniProt: P14174 | TargetFullName: Macrophage migration inhibitory factor | Organisim: human | Apparent_Kd_M: 3.06E-11
Real
Aptamer SeqId: 8222-49 | Target: CDHR3 | UniProt: Q6ZTQ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8222-49 | Target: CDHR3 | UniProt: Q6ZTQ4 | TargetFullName: Cadherin-related family member 3 | Organisim: human | Apparent_Kd_M: 4.68E-12
Real
Aptamer SeqId: 8225-86 | Target: EPHB2 | UniProt: P29323
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8225-86 | Target: EPHB2 | UniProt: P29323 | TargetFullName: Ephrin type-B receptor 2 | Organisim: human | Apparent_Kd_M: 1.22E-12
Real
Aptamer SeqId: 8228-10 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8228-10 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.183098E-11
Real
Aptamer SeqId: 8229-1 | Target: GXLT1 | UniProt: Q4G148
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8229-1 | Target: GXLT1 | UniProt: Q4G148 | TargetFullName: Glucoside xylosyltransferase 1 | Organisim: human | Apparent_Kd_M: 1.981038E-11
Real
Aptamer SeqId: 8231-122 | Target: VEGF sR1 | UniProt: P17948
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8231-122 | Target: VEGF sR1 | UniProt: P17948 | TargetFullName: Vascular endothelial growth factor receptor 1 | Organisim: human | Apparent_Kd_M: 7.56E-11
Real
Aptamer SeqId: 8233-2 | Target: ITIH5 | UniProt: Q86UX2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8233-2 | Target: ITIH5 | UniProt: Q86UX2 | TargetFullName: Inter-alpha-trypsin inhibitor heavy chain H5 | Organisim: human | Apparent_Kd_M: 1.62059E-12
Real
Aptamer SeqId: 8235-48 | Target: SCG1 | UniProt: P05060
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8235-48 | Target: SCG1 | UniProt: P05060 | TargetFullName: Secretogranin-1 | Organisim: human | Apparent_Kd_M: 2.672539E-11
Real
Aptamer SeqId: 8236-8 | Target: CR032 | UniProt: Q8TCD1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8236-8 | Target: CR032 | UniProt: Q8TCD1 | TargetFullName: UPF0729 protein C18orf32 | Organisim: human | Apparent_Kd_M: 7.584924E-12
Real
Aptamer SeqId: 8237-56 | Target: SOSD1 | UniProt: Q6X4U4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8237-56 | Target: SOSD1 | UniProt: Q6X4U4 | TargetFullName: Sclerostin domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 7.989003E-11
Real
Aptamer SeqId: 8242-9 | Target: CLC2L | UniProt: P0C7M8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8242-9 | Target: CLC2L | UniProt: P0C7M8 | TargetFullName: C-type lectin domain family 2 member L | Organisim: human | Apparent_Kd_M: 1.719982E-10
Real
Aptamer SeqId: 8243-55 | Target: TATI | UniProt: P00995
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8243-55 | Target: TATI | UniProt: P00995 | TargetFullName: Serine protease inhibitor Kazal-type 1 | Organisim: human | Apparent_Kd_M: 1.140135E-11
Real
Aptamer SeqId: 8244-16 | Target: FUT8 | UniProt: Q9BYC5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8244-16 | Target: FUT8 | UniProt: Q9BYC5 | TargetFullName: Alpha-(1;6)-fucosyltransferase | Organisim: human | Apparent_Kd_M: 1.639499E-12
Real
Aptamer SeqId: 8245-27 | Target: sICAM-5 | UniProt: Q9UMF0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8245-27 | Target: sICAM-5 | UniProt: Q9UMF0 | TargetFullName: Intercellular adhesion molecule 5 | Organisim: human | Apparent_Kd_M: 7.39E-12
Real
Aptamer SeqId: 8248-222 | Target: SIG14 | UniProt: Q08ET2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8248-222 | Target: SIG14 | UniProt: Q08ET2 | TargetFullName: Sialic acid-binding Ig-like lectin 14 | Organisim: human | Apparent_Kd_M: 1.08E-12
Real
Aptamer SeqId: 8249-124 | Target: ALK | UniProt: Q9UM73
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8249-124 | Target: ALK | UniProt: Q9UM73 | TargetFullName: ALK tyrosine kinase receptor | Organisim: human | Apparent_Kd_M: 4.848776E-11
Real
Aptamer SeqId: 8250-2 | Target: PTPRJ | UniProt: Q12913
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8250-2 | Target: PTPRJ | UniProt: Q12913 | TargetFullName: Receptor-type tyrosine-protein phosphatase eta | Organisim: human | Apparent_Kd_M: 1.15E-10
Real
Aptamer SeqId: 8252-2 | Target: NOTUM | UniProt: Q6P988
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8252-2 | Target: NOTUM | UniProt: Q6P988 | TargetFullName: Palmitoleoyl-protein carboxylesterase NOTUM | Organisim: human | Apparent_Kd_M: 2.994046E-11
Real
Aptamer SeqId: 8253-2 | Target: PMGT1 | UniProt: Q8WZA1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8253-2 | Target: PMGT1 | UniProt: Q8WZA1 | TargetFullName: Protein O-linked-mannose beta-1;2-N-acetylglucosaminyltransferase 1 | Organisim: human | Apparent_Kd_M: 3.032504E-11
Real
Aptamer SeqId: 8255-34 | Target: MRVI1 | UniProt: Q9Y6F6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8255-34 | Target: MRVI1 | UniProt: Q9Y6F6 | TargetFullName: Protein MRVI1 | Organisim: human | Apparent_Kd_M: 4.947062E-11
Real
Aptamer SeqId: 8258-22 | Target: UXS1 | UniProt: Q8NBZ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8258-22 | Target: UXS1 | UniProt: Q8NBZ7 | TargetFullName: UDP-glucuronic acid decarboxylase 1 | Organisim: human | Apparent_Kd_M: 6.20996E-11
Real
Aptamer SeqId: 8259-25 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8259-25 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.915895E-11
Real
Aptamer SeqId: 8260-13 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8260-13 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.583933E-11
Real
Aptamer SeqId: 8261-51 | Target: STOM | UniProt: P27105
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8261-51 | Target: STOM | UniProt: P27105 | TargetFullName: Erythrocyte band 7 integral membrane protein | Organisim: human | Apparent_Kd_M: 6.57876E-11
Real
Aptamer SeqId: 8263-64 | Target: CR056 | UniProt: Q8TAI1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8263-64 | Target: CR056 | UniProt: Q8TAI1 | TargetFullName: TYMS opposite strand protein | Organisim: human | Apparent_Kd_M: 8.217893E-11
Real
Aptamer SeqId: 8265-225 | Target: LAP2B | UniProt: P42167
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8265-225 | Target: LAP2B | UniProt: P42167 | TargetFullName: Lamina-associated polypeptide 2; isoforms beta/gamma | Organisim: human | Apparent_Kd_M: 6.250331E-12
Real
Aptamer SeqId: 8268-98 | Target: HS3SA | UniProt: Q9Y663
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8268-98 | Target: HS3SA | UniProt: Q9Y663 | TargetFullName: Heparan sulfate glucosamine 3-O-sulfotransferase 3A1 | Organisim: human | Apparent_Kd_M: 1.005689E-11
Real
Aptamer SeqId: 8269-327 | Target: ARSK | UniProt: Q6UWY0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8269-327 | Target: ARSK | UniProt: Q6UWY0 | TargetFullName: Arylsulfatase K | Organisim: human | Apparent_Kd_M: 4.866251E-11
Real
Aptamer SeqId: 8271-24 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8271-24 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 9.883936E-12
Real
Aptamer SeqId: 8272-22 | Target: DHB7 | UniProt: P56937
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8272-22 | Target: DHB7 | UniProt: P56937 | TargetFullName: 3-keto-steroid reductase | Organisim: human | Apparent_Kd_M: 2.5E-11
Real
Aptamer SeqId: 8273-84 | Target: IL31R | UniProt: Q8NI17
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8273-84 | Target: IL31R | UniProt: Q8NI17 | TargetFullName: Interleukin-31 receptor subunit alpha | Organisim: human | Apparent_Kd_M: 4.709172E-11
Real
Aptamer SeqId: 8274-64 | Target: Syntaxin-7 | UniProt: O15400
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8274-64 | Target: Syntaxin-7 | UniProt: O15400 | TargetFullName: Syntaxin-7 | Organisim: human | Apparent_Kd_M: 8.278391E-12
Real
Aptamer SeqId: 8275-31 | Target: PEAR1 | UniProt: Q5VY43
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8275-31 | Target: PEAR1 | UniProt: Q5VY43 | TargetFullName: Platelet endothelial aggregation receptor 1 | Organisim: human | Apparent_Kd_M: 6.97E-12
Real
Aptamer SeqId: 8282-15 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8282-15 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.165559E-11
Real
Aptamer SeqId: 8285-64 | Target: PACA | UniProt: P18509
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8285-64 | Target: PACA | UniProt: P18509 | TargetFullName: Pituitary adenylate cyclase-activating polypeptide | Organisim: human | Apparent_Kd_M: 2.767171E-11
Real
Aptamer SeqId: 8286-44 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8286-44 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.199095E-11
Real
Aptamer SeqId: 8288-27 | Target: b2-Glycoprotein I | UniProt: P02749
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8288-27 | Target: b2-Glycoprotein I | UniProt: P02749 | TargetFullName: Beta-2-glycoprotein 1 | Organisim: human | Apparent_Kd_M: 4.18E-12
Real
Aptamer SeqId: 8289-8 | Target: GPNMB | UniProt: Q14956
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8289-8 | Target: GPNMB | UniProt: Q14956 | TargetFullName: Transmembrane glycoprotein NMB | Organisim: human | Apparent_Kd_M: 1.74E-12
Real
Aptamer SeqId: 8290-1 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8290-1 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.863769E-11
Real
Aptamer SeqId: 8296-117 | Target: KDEL2 | UniProt: Q7Z4H8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8296-117 | Target: KDEL2 | UniProt: Q7Z4H8 | TargetFullName: KDEL motif-containing protein 2 | Organisim: human | Apparent_Kd_M: 8.667411E-12
Real
Aptamer SeqId: 8297-8 | Target: DJC10 | UniProt: Q8IXB1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8297-8 | Target: DJC10 | UniProt: Q8IXB1 | TargetFullName: DnaJ homolog subfamily C member 10 | Organisim: human | Apparent_Kd_M: 1.49155E-11
Real
Aptamer SeqId: 8298-8 | Target: CG045 | UniProt: Q8WWF3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8298-8 | Target: CG045 | UniProt: Q8WWF3 | TargetFullName: Serine-rich single-pass membrane protein 1 | Organisim: human | Apparent_Kd_M: 1.588024E-11
Real
Aptamer SeqId: 8299-66 | Target: LIRA4 | UniProt: P59901
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8299-66 | Target: LIRA4 | UniProt: P59901 | TargetFullName: Leukocyte immunoglobulin-like receptor subfamily A member 4 | Organisim: human | Apparent_Kd_M: 1.70822E-10
Real
Aptamer SeqId: 8300-82 | Target: PEX14 | UniProt: O75381
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8300-82 | Target: PEX14 | UniProt: O75381 | TargetFullName: Peroxisomal membrane protein PEX14 | Organisim: human | Apparent_Kd_M: 7.7E-13
Real
Aptamer SeqId: 8303-102 | Target: MYG1 | UniProt: Q9HB07
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8303-102 | Target: MYG1 | UniProt: Q9HB07 | TargetFullName: UPF0160 protein MYG1; mitochondrial | Organisim: human | Apparent_Kd_M: 2.327342E-11
Real
Aptamer SeqId: 8304-50 | Target: OPG | UniProt: O00300
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8304-50 | Target: OPG | UniProt: O00300 | TargetFullName: Tumor necrosis factor receptor superfamily member 11B | Organisim: human | Apparent_Kd_M: 3.52E-12
Real
Aptamer SeqId: 8305-18 | Target: SULF2 | UniProt: Q8IWU5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8305-18 | Target: SULF2 | UniProt: Q8IWU5 | TargetFullName: Extracellular sulfatase Sulf-2 | Organisim: human | Apparent_Kd_M: 9.234543E-12
Real
Aptamer SeqId: 8306-54 | Target: TMG1 | UniProt: O14668
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8306-54 | Target: TMG1 | UniProt: O14668 | TargetFullName: Transmembrane gamma-carboxyglutamic acid protein 1 | Organisim: human | Apparent_Kd_M: 4.55E-12
Real
Aptamer SeqId: 8307-47 | Target: CK068 | UniProt: Q9H3H3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8307-47 | Target: CK068 | UniProt: Q9H3H3 | TargetFullName: UPF0696 protein C11orf68 | Organisim: human | Apparent_Kd_M: 1.376207E-11
Real
Aptamer SeqId: 8309-12 | Target: HYAL1 | UniProt: Q12794
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8309-12 | Target: HYAL1 | UniProt: Q12794 | TargetFullName: Hyaluronidase-1 | Organisim: human | Apparent_Kd_M: 3.472387E-11
Real
Aptamer SeqId: 8310-6 | Target: U773 | UniProt: Q96DA0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8310-6 | Target: U773 | UniProt: Q96DA0 | TargetFullName: Zymogen granule protein 16 homolog B | Organisim: human | Apparent_Kd_M: 1.651995E-11
Real
Aptamer SeqId: 8315-5 | Target: DB119 | UniProt: Q8N690
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8315-5 | Target: DB119 | UniProt: Q8N690 | TargetFullName: Beta-defensin 119 | Organisim: human | Apparent_Kd_M: 3.6E-11
Real
Aptamer SeqId: 8316-36 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8316-36 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.96E-12
Real
Aptamer SeqId: 8318-13 | Target: SPRE1 | UniProt: Q7Z699
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8318-13 | Target: SPRE1 | UniProt: Q7Z699 | TargetFullName: Sprouty-related; EVH1 domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 2.243762E-12
Real
Aptamer SeqId: 8320-5 | Target: SLTM | UniProt: Q9NWH9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8320-5 | Target: SLTM | UniProt: Q9NWH9 | TargetFullName: SAFB-like transcription modulator | Organisim: human | Apparent_Kd_M: 6.64205E-12
Real
Aptamer SeqId: 8321-27 | Target: ZN843 | UniProt: Q8N446
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8321-27 | Target: ZN843 | UniProt: Q8N446 | TargetFullName: Zinc finger protein 843 | Organisim: human | Apparent_Kd_M: 1.52905E-11
Real
Aptamer SeqId: 8323-163 | Target: TFF3 | UniProt: Q07654
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8323-163 | Target: TFF3 | UniProt: Q07654 | TargetFullName: Trefoil factor 3 | Organisim: human | Apparent_Kd_M: 3.05E-11
Real
Aptamer SeqId: 8325-37 | Target: ADH4 | UniProt: P08319
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8325-37 | Target: ADH4 | UniProt: P08319 | TargetFullName: Alcohol dehydrogenase 4 | Organisim: human | Apparent_Kd_M: 5.307125E-11
Real
Aptamer SeqId: 8326-63 | Target: SIGIRR | UniProt: Q6IA17
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8326-63 | Target: SIGIRR | UniProt: Q6IA17 | TargetFullName: Single Ig IL-1-related receptor | Organisim: human | Apparent_Kd_M: 7.011596E-11
Real
Aptamer SeqId: 8327-26 | Target: DPEP2 | UniProt: Q9H4A9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8327-26 | Target: DPEP2 | UniProt: Q9H4A9 | TargetFullName: Dipeptidase 2 | Organisim: human | Apparent_Kd_M: 5.678713E-12
Real
Aptamer SeqId: 8328-9 | Target: EKI1 | UniProt: Q9HBU6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8328-9 | Target: EKI1 | UniProt: Q9HBU6 | TargetFullName: Ethanolamine kinase 1 | Organisim: human | Apparent_Kd_M: 3.542787E-11
Real
Aptamer SeqId: 8334-65 | Target: TCP11 | UniProt: Q8WWU5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8334-65 | Target: TCP11 | UniProt: Q8WWU5 | TargetFullName: T-complex protein 11 homolog | Organisim: human | Apparent_Kd_M: 2.131431E-10
Real
Aptamer SeqId: 8336-267 | Target: GRM1C | UniProt: Q8IYS0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8336-267 | Target: GRM1C | UniProt: Q8IYS0 | TargetFullName: GRAM domain-containing protein 1C | Organisim: human | Apparent_Kd_M: 1.84E-11
Real
Aptamer SeqId: 8337-65 | Target: PTPRU | UniProt: Q92729
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8337-65 | Target: PTPRU | UniProt: Q92729 | TargetFullName: Receptor-type tyrosine-protein phosphatase U | Organisim: human | Apparent_Kd_M: 1.339168E-12
Real
Aptamer SeqId: 8340-9 | Target: DB110 | UniProt: Q30KQ9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8340-9 | Target: DB110 | UniProt: Q30KQ9 | TargetFullName: Beta-defensin 110 | Organisim: human | Apparent_Kd_M: 1.749178E-10
Real
Aptamer SeqId: 8343-224 | Target: PAPOG | UniProt: Q9BWT3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8343-224 | Target: PAPOG | UniProt: Q9BWT3 | TargetFullName: Poly(A) polymerase gamma | Organisim: human | Apparent_Kd_M: 1.060761E-10
Real
Aptamer SeqId: 8345-27 | Target: GPX7 | UniProt: Q96SL4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8345-27 | Target: GPX7 | UniProt: Q96SL4 | TargetFullName: Glutathione peroxidase 7 | Organisim: human | Apparent_Kd_M: 3.362084E-11
Real
Aptamer SeqId: 8346-9 | Target: DPP2 | UniProt: Q9UHL4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8346-9 | Target: DPP2 | UniProt: Q9UHL4 | TargetFullName: Dipeptidyl peptidase 2 | Organisim: human | Apparent_Kd_M: 4.92E-11
Real
Aptamer SeqId: 8347-222 | Target: DB129 | UniProt: Q9H1M3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8347-222 | Target: DB129 | UniProt: Q9H1M3 | TargetFullName: Beta-defensin 129 | Organisim: human | Apparent_Kd_M: 8.160712E-12
Real
Aptamer SeqId: 8351-17 | Target: PRS57 | UniProt: Q6UWY2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8351-17 | Target: PRS57 | UniProt: Q6UWY2 | TargetFullName: Serine protease 57 | Organisim: human | Apparent_Kd_M: 1.063001E-11
Real
Aptamer SeqId: 8352-26 | Target: SIG12 | UniProt: Q96PQ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8352-26 | Target: SIG12 | UniProt: Q96PQ1 | TargetFullName: Sialic acid-binding Ig-like lectin 12 | Organisim: human | Apparent_Kd_M: 6.73E-11
Real
Aptamer SeqId: 8353-15 | Target: SCN2B | UniProt: O60939
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8353-15 | Target: SCN2B | UniProt: O60939 | TargetFullName: Sodium channel subunit beta-2 | Organisim: human | Apparent_Kd_M: 8.333218E-12
Real
Aptamer SeqId: 8355-80 | Target: ISM1 | UniProt: B1AKI9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8355-80 | Target: ISM1 | UniProt: B1AKI9 | TargetFullName: Isthmin-1 | Organisim: human | Apparent_Kd_M: 5.323204E-11
Real
Aptamer SeqId: 8356-88 | Target: NEU1 | UniProt: P01178
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8356-88 | Target: NEU1 | UniProt: P01178 | TargetFullName: Oxytocin-neurophysin 1 | Organisim: human | Apparent_Kd_M: 1.32E-10
Real
Aptamer SeqId: 8357-43 | Target: ST4A1 | UniProt: Q9BR01
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8357-43 | Target: ST4A1 | UniProt: Q9BR01 | TargetFullName: Sulfotransferase 4A1 | Organisim: human | Apparent_Kd_M: 1.181908E-11
Real
Aptamer SeqId: 8358-30 | Target: Peroxiredoxin-3 | UniProt: P30048
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8358-30 | Target: Peroxiredoxin-3 | UniProt: P30048 | TargetFullName: Thioredoxin-dependent peroxide reductase; mitochondrial | Organisim: human | Apparent_Kd_M: 2.5E-10
Real
Aptamer SeqId: 8360-169 | Target: NKp46 | UniProt: O76036
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8360-169 | Target: NKp46 | UniProt: O76036 | TargetFullName: Natural cytotoxicity triggering receptor 1 | Organisim: human | Apparent_Kd_M: 3.385701E-11
Real
Aptamer SeqId: 8363-18 | Target: K132L | UniProt: A8MWY0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8363-18 | Target: K132L | UniProt: A8MWY0 | TargetFullName: UPF0577 protein KIAA1324-like | Organisim: human | Apparent_Kd_M: 4.014134E-10
Real
Aptamer SeqId: 8364-74 | Target: UST | UniProt: Q9Y2C2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8364-74 | Target: UST | UniProt: Q9Y2C2 | TargetFullName: Uronyl 2-sulfotransferase | Organisim: human | Apparent_Kd_M: 3.033817E-11
Real
Aptamer SeqId: 8366-19 | Target: CA115 | UniProt: Q9H7X2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8366-19 | Target: CA115 | UniProt: Q9H7X2 | TargetFullName: Uncharacterized protein C1orf115 | Organisim: human | Apparent_Kd_M: 3.718016E-11
Real
Aptamer SeqId: 8367-142 | Target: VSIG1 | UniProt: Q86XK7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8367-142 | Target: VSIG1 | UniProt: Q86XK7 | TargetFullName: V-set and immunoglobulin domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 1.066161E-11
Real
Aptamer SeqId: 8368-102 | Target: TNF sR-II | UniProt: P20333
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8368-102 | Target: TNF sR-II | UniProt: P20333 | TargetFullName: Tumor necrosis factor receptor superfamily member 1B | Organisim: human | Apparent_Kd_M: 2.452055E-12
Real
Aptamer SeqId: 8369-102 | Target: DAG1 | UniProt: Q14118
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8369-102 | Target: DAG1 | UniProt: Q14118 | TargetFullName: Dystroglycan | Organisim: human | Apparent_Kd_M: 3.913924E-11
Real
Aptamer SeqId: 8372-29 | Target: CDHR1 | UniProt: Q96JP9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8372-29 | Target: CDHR1 | UniProt: Q96JP9 | TargetFullName: Cadherin-related family member 1 | Organisim: human | Apparent_Kd_M: 3.590441E-11
Real
Aptamer SeqId: 8374-5 | Target: NGF R | UniProt: P08138
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8374-5 | Target: NGF R | UniProt: P08138 | TargetFullName: Tumor necrosis factor receptor superfamily member 16 | Organisim: human | Apparent_Kd_M: 1.409537E-11
Real
Aptamer SeqId: 8376-25 | Target: LSHB | UniProt: P01229
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8376-25 | Target: LSHB | UniProt: P01229 | TargetFullName: Lutropin subunit beta | Organisim: human | Apparent_Kd_M: 2.810139E-11
Real
Aptamer SeqId: 8377-87 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8377-87 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.2364E-10
Real
Aptamer SeqId: 8378-3 | Target: LDOC1 | UniProt: O95751
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8378-3 | Target: LDOC1 | UniProt: O95751 | TargetFullName: Protein LDOC1 | Organisim: human | Apparent_Kd_M: 8.42E-11
Real
Aptamer SeqId: 8380-244 | Target: DLK1 | UniProt: P80370
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8380-244 | Target: DLK1 | UniProt: P80370 | TargetFullName: Protein delta homolog 1 | Organisim: human | Apparent_Kd_M: 5.72E-11
Real
Aptamer SeqId: 8381-18 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8381-18 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.335547E-11
Real
Aptamer SeqId: 8382-47 | Target: MAPK5 | UniProt: Q8IW41
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8382-47 | Target: MAPK5 | UniProt: Q8IW41 | TargetFullName: MAP kinase-activated protein kinase 5 | Organisim: human | Apparent_Kd_M: 9.69567E-12
Real
Aptamer SeqId: 8383-20 | Target: CK094 | UniProt: C9JXX5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8383-20 | Target: CK094 | UniProt: C9JXX5 | TargetFullName: Uncharacterized protein C11orf94 | Organisim: human | Apparent_Kd_M: 1.334377E-11
Real
Aptamer SeqId: 8386-11 | Target: PATE | UniProt: Q8WXA2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8386-11 | Target: PATE | UniProt: Q8WXA2 | TargetFullName: Prostate and testis expressed protein 1 | Organisim: human | Apparent_Kd_M: 2.345996E-10
Real
Aptamer SeqId: 8388-24 | Target: Spastin | UniProt: Q9UBP0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8388-24 | Target: Spastin | UniProt: Q9UBP0 | TargetFullName: Spastin | Organisim: human | Apparent_Kd_M: 2.581677E-11
Real
Aptamer SeqId: 8389-8 | Target: CN16B | UniProt: Q0VAA2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8389-8 | Target: CN16B | UniProt: Q0VAA2 | TargetFullName: Leucine-rich repeat-containing protein 74A | Organisim: human | Apparent_Kd_M: 3.05524E-11
Real
Aptamer SeqId: 8390-25 | Target: CX7A1 | UniProt: P24310
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8390-25 | Target: CX7A1 | UniProt: P24310 | TargetFullName: Cytochrome c oxidase subunit 7A1; mitochondrial | Organisim: human | Apparent_Kd_M: 3.353739E-12
Real
Aptamer SeqId: 8391-12 | Target: DB115 | UniProt: Q30KQ5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8391-12 | Target: DB115 | UniProt: Q30KQ5 | TargetFullName: Beta-defensin 115 | Organisim: human | Apparent_Kd_M: 5.259342E-12
Real
Aptamer SeqId: 8394-56 | Target: RNase 2 | UniProt: P10153
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8394-56 | Target: RNase 2 | UniProt: P10153 | TargetFullName: Non-secretory ribonuclease | Organisim: human | Apparent_Kd_M: 8.147688E-11
Real
Aptamer SeqId: 8396-42 | Target: FAAH2 | UniProt: Q6GMR7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8396-42 | Target: FAAH2 | UniProt: Q6GMR7 | TargetFullName: Fatty-acid amide hydrolase 2 | Organisim: human | Apparent_Kd_M: 6.903415E-12
Real
Aptamer SeqId: 8397-147 | Target: QSOX2 | UniProt: Q6ZRP7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8397-147 | Target: QSOX2 | UniProt: Q6ZRP7 | TargetFullName: Sulfhydryl oxidase 2 | Organisim: human | Apparent_Kd_M: 9.25572E-11
Real
Aptamer SeqId: 8398-277 | Target: RAR-responsive protein TIG1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8398-277 | Target: RAR-responsive protein TIG1 | UniProt: P49788 | TargetFullName: Retinoic acid receptor responder protein 1 | Organisim: human | Apparent_Kd_M: 1.992652E-12
Real
Aptamer SeqId: 8399-6 | Target: DRAK2 | UniProt: O94768
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8399-6 | Target: DRAK2 | UniProt: O94768 | TargetFullName: Serine/threonine-protein kinase 17B | Organisim: human | Apparent_Kd_M: 7.14E-12
Real
Aptamer SeqId: 8400-74 | Target: Gastrin-releasing peptide
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8400-74 | Target: Gastrin-releasing peptide | UniProt: P07492 | TargetFullName: Gastrin-releasing peptide | Organisim: human | Apparent_Kd_M: 6.11E-12
Real
Aptamer SeqId: 8402-22 | Target: CYTL1 | UniProt: Q9NRR1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8402-22 | Target: CYTL1 | UniProt: Q9NRR1 | TargetFullName: Cytokine-like protein 1 | Organisim: human | Apparent_Kd_M: 1.365328E-11
Real
Aptamer SeqId: 8403-18 | Target: Fatty acid synthase | UniProt: P49327
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8403-18 | Target: Fatty acid synthase | UniProt: P49327 | TargetFullName: Fatty acid synthase | Organisim: human | Apparent_Kd_M: 8.416629E-12
Real
Aptamer SeqId: 8404-102 | Target: BolA-like protein 2 | UniProt: Q9H3K6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8404-102 | Target: BolA-like protein 2 | UniProt: Q9H3K6 | TargetFullName: BolA-like protein 2 | Organisim: human | Apparent_Kd_M: 1.344734E-11
Real
Aptamer SeqId: 8405-108 | Target: ADAM 10 | UniProt: O14672
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8405-108 | Target: ADAM 10 | UniProt: O14672 | TargetFullName: Disintegrin and metalloproteinase domain-containing protein 10 | Organisim: human | Apparent_Kd_M: 1.152552E-10
Real
Aptamer SeqId: 8406-17 | Target: IGF-I | UniProt: P05019
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8406-17 | Target: IGF-I | UniProt: P05019 | TargetFullName: Insulin-like growth factor I | Organisim: human | Apparent_Kd_M: 1.67E-10
Real
Aptamer SeqId: 8409-3 | Target: RSPO2 | UniProt: Q6UXX9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8409-3 | Target: RSPO2 | UniProt: Q6UXX9 | TargetFullName: R-spondin-2 | Organisim: human | Apparent_Kd_M: 4.269587E-12
Real
Aptamer SeqId: 8424-269 | Target: b-Catenin | UniProt: P35222
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8424-269 | Target: b-Catenin | UniProt: P35222 | TargetFullName: Catenin beta-1 | Organisim: human | Apparent_Kd_M: 1.434611E-11
Real
Aptamer SeqId: 8427-118 | Target: RSPO3 | UniProt: Q9BXY4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8427-118 | Target: RSPO3 | UniProt: Q9BXY4 | TargetFullName: R-spondin-3 | Organisim: human | Apparent_Kd_M: 1.499766E-12
Real
Aptamer SeqId: 8428-102 | Target: NTRI | UniProt: Q9P121
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8428-102 | Target: NTRI | UniProt: Q9P121 | TargetFullName: Neurotrimin | Organisim: human | Apparent_Kd_M: 4.058838E-12
Real
Aptamer SeqId: 8429-16 | Target: AXIN2 | UniProt: Q9Y2T1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8429-16 | Target: AXIN2 | UniProt: Q9Y2T1 | TargetFullName: Axin-2 | Organisim: human | Apparent_Kd_M: 1.550853E-11
Real
Aptamer SeqId: 8443-9 | Target: Magainin-1_XENLA | UniProt: P11006
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8443-9 | Target: Magainin-1_XENLA | UniProt: P11006 | TargetFullName: Magainin-1; Xenopus laevis | Organisim: african clawed frog | Apparent_Kd_M: 1.016537E-11
Real
Aptamer SeqId: 8444-3 | Target: Magainin-2_XENLA | UniProt: P11006
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8444-3 | Target: Magainin-2_XENLA | UniProt: P11006 | TargetFullName: Magainin-2_XENLA | Organisim: african clawed frog | Apparent_Kd_M: 2.39E-10
Real
Aptamer SeqId: 8444-46 | Target: Magainin-2_XENLA | UniProt: P11006
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8444-46 | Target: Magainin-2_XENLA | UniProt: P11006 | TargetFullName: Magainin-2_XENLA | Organisim: african clawed frog | Apparent_Kd_M: 3.17E-11
Real
Aptamer SeqId: 8445-184 | Target: MEL_VESMG | UniProt: P68408
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8445-184 | Target: MEL_VESMG | UniProt: P68408 | TargetFullName: Melittin_VESMG | Organisim: hornet | Apparent_Kd_M: 1.3E-11
Real
Aptamer SeqId: 8445-54 | Target: MEL_VESMG | UniProt: P68408
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8445-54 | Target: MEL_VESMG | UniProt: P68408 | TargetFullName: Melittin_VESMG | Organisim: hornet | Apparent_Kd_M: 3.83E-11
Real
Aptamer SeqId: 8446-4 | Target: PACAP-27 | UniProt: P18509
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8446-4 | Target: PACAP-27 | UniProt: P18509 | TargetFullName: Pituitary adenylate cyclase-activating polypeptide 27 | Organisim: human | Apparent_Kd_M: 3.76E-12
Real
Aptamer SeqId: 8447-11 | Target: ghrelin | UniProt: Q9UBU3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8447-11 | Target: ghrelin | UniProt: Q9UBU3 | TargetFullName: Appetite-regulating hormone | Organisim: human | Apparent_Kd_M: 6.48E-11
Real
Aptamer SeqId: 8449-103 | Target: EXE4_HELSU | UniProt: P26349
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8449-103 | Target: EXE4_HELSU | UniProt: P26349 | TargetFullName: Exendin-4_HELSU | Organisim: heloderma suspectum (gila monster) | Apparent_Kd_M: 3.96E-11
Real
Aptamer SeqId: 8449-124 | Target: EXE4_HELSU | UniProt: P26349
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8449-124 | Target: EXE4_HELSU | UniProt: P26349 | TargetFullName: Exendin-4_HELSU | Organisim: heloderma suspectum (gila monster) | Apparent_Kd_M: 4.7E-11
Real
Aptamer SeqId: 8450-36 | Target: PACAP-38 | UniProt: P18509
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8450-36 | Target: PACAP-38 | UniProt: P18509 | TargetFullName: Pituitary adenylate cyclase-activating polypeptide 38 | Organisim: human | Apparent_Kd_M: 3.53E-11
Real
Aptamer SeqId: 8458-111 | Target: a-Synuclein | UniProt: P37840
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8458-111 | Target: a-Synuclein | UniProt: P37840 | TargetFullName: Alpha-synuclein | Organisim: human | Apparent_Kd_M: 1.76E-11
Real
Aptamer SeqId: 8459-10 | Target: BMP-6 | UniProt: P22004
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8459-10 | Target: BMP-6 | UniProt: P22004 | TargetFullName: Bone morphogenetic protein 6 | Organisim: human | Apparent_Kd_M: 3.05E-12
Real
Aptamer SeqId: 8462-18 | Target: HGH | UniProt: P01241
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8462-18 | Target: HGH | UniProt: P01241 | TargetFullName: Somatotropin | Organisim: human | Apparent_Kd_M: 4.16E-12
Real
Aptamer SeqId: 8464-31 | Target: RSPO4 | UniProt: Q2I0M5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8464-31 | Target: RSPO4 | UniProt: Q2I0M5 | TargetFullName: R-spondin-4 | Organisim: human | Apparent_Kd_M: 1.54E-12
Real
Aptamer SeqId: 8465-52 | Target: Cathepsin H | UniProt: P09668
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8465-52 | Target: Cathepsin H | UniProt: P09668 | TargetFullName: Cathepsin H | Organisim: human | Apparent_Kd_M: 9.88E-11
Real
Aptamer SeqId: 8467-9 | Target: Activin AB | UniProt: P08476|P09529
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8467-9 | Target: Activin AB | UniProt: P08476|P09529 | TargetFullName: Inhibin beta A chain:Inhibin beta B chain heterodimer | Organisim: human | Apparent_Kd_M: 2.59E-11
Real
Aptamer SeqId: 8468-19 | Target: PSA | UniProt: P07288
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8468-19 | Target: PSA | UniProt: P07288 | TargetFullName: Prostate-specific antigen | Organisim: human | Apparent_Kd_M: 5.21E-13
Real
Aptamer SeqId: 8469-41 | Target: IGFBP-2 | UniProt: P18065
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8469-41 | Target: IGFBP-2 | UniProt: P18065 | TargetFullName: Insulin-like growth factor-binding protein 2 | Organisim: human | Apparent_Kd_M: 2.52E-12
Real
Aptamer SeqId: 8470-213 | Target: RNase H1 | UniProt: O60930
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8470-213 | Target: RNase H1 | UniProt: O60930 | TargetFullName: Ribonuclease H1 | Organisim: human | Apparent_Kd_M: 4.92E-12
Real
Aptamer SeqId: 8471-53 | Target: Allophycocyanin_CYACA
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8471-53 | Target: Allophycocyanin_CYACA | UniProt: Q9TLS8|Q9TLS7 | TargetFullName: Allophycocyanin_CYACA | Organisim: cyanidium caldarium | Apparent_Kd_M: 4.256983E-13
Real
Aptamer SeqId: 8476-11 | Target: CgA | UniProt: P10645
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8476-11 | Target: CgA | UniProt: P10645 | TargetFullName: Chromogranin-A | Organisim: human | Apparent_Kd_M: 1.29E-11
Real
Aptamer SeqId: 8479-4 | Target: MMP-10 | UniProt: P09238
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8479-4 | Target: MMP-10 | UniProt: P09238 | TargetFullName: Stromelysin-2 | Organisim: human | Apparent_Kd_M: 9.37E-12
Real
Aptamer SeqId: 8480-29 | Target: FBLN3 | UniProt: Q12805
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8480-29 | Target: FBLN3 | UniProt: Q12805 | TargetFullName: EGF-containing fibulin-like extracellular matrix protein 1 | Organisim: human | Apparent_Kd_M: 4.05E-11
Real
Aptamer SeqId: 8481-26 | Target: MDH_THETH | UniProt: P10584
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8481-26 | Target: MDH_THETH | UniProt: P10584 | TargetFullName: Malic dehydrogenase_THETH | Organisim: thermus thermophilus | Apparent_Kd_M: 6.98E-12
Real
Aptamer SeqId: 8481-44 | Target: MDH_THETH | UniProt: P10584
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8481-44 | Target: MDH_THETH | UniProt: P10584 | TargetFullName: Malic dehydrogenase_THETH | Organisim: thermus thermophilus | Apparent_Kd_M: 4.67E-12
Real
Aptamer SeqId: 8482-39 | Target: NIGB_SAMNI | UniProt: P33183
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8482-39 | Target: NIGB_SAMNI | UniProt: P33183 | TargetFullName: Nigrin b_SAMNI | Organisim: sambucus nigra (european elder) | Apparent_Kd_M: 8.52E-11
Real
Aptamer SeqId: 8483-5 | Target: LUCI_PHOPY | UniProt: P08659
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8483-5 | Target: LUCI_PHOPY | UniProt: P08659 | TargetFullName: Luciferin 4-monooxygenase_PHOPY | Organisim: photinus pyralis (north american firefly) | Apparent_Kd_M: 2.23E-12
Real
Aptamer SeqId: 8484-24 | Target: Leptin | UniProt: P41159
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8484-24 | Target: Leptin | UniProt: P41159 | TargetFullName: Leptin | Organisim: human | Apparent_Kd_M: 9.57E-12
Real
Aptamer SeqId: 8485-7 | Target: KEAP1 | UniProt: Q14145
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8485-7 | Target: KEAP1 | UniProt: Q14145 | TargetFullName: Kelch-like ECH-associated protein 1 | Organisim: human | Apparent_Kd_M: 1.56E-10
Real
Aptamer SeqId: 8518-55 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8518-55 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.381388E-11
Real
Aptamer SeqId: 8520-8 | Target: ADA30 | UniProt: Q9UKF2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8520-8 | Target: ADA30 | UniProt: Q9UKF2 | TargetFullName: Disintegrin and metalloproteinase domain-containing protein 30 | Organisim: human | Apparent_Kd_M: 6.414023E-11
Real
Aptamer SeqId: 8529-1 | Target: TRAIL R2 | UniProt: O14763
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8529-1 | Target: TRAIL R2 | UniProt: O14763 | TargetFullName: Tumor necrosis factor receptor superfamily member 10B | Organisim: human | Apparent_Kd_M: 6.956581E-11
Real
Aptamer SeqId: 8535-102 | Target: Dermokine | UniProt: Q6E0U4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8535-102 | Target: Dermokine | UniProt: Q6E0U4 | TargetFullName: Dermokine | Organisim: human | Apparent_Kd_M: 1.23E-11
Real
Aptamer SeqId: 8556-5 | Target: F134B | UniProt: Q9H6L5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8556-5 | Target: F134B | UniProt: Q9H6L5 | TargetFullName: Protein FAM134B | Organisim: human | Apparent_Kd_M: 8.522849E-12
Real
Aptamer SeqId: 8565-160 | Target: PLVAP | UniProt: Q9BX97
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8565-160 | Target: PLVAP | UniProt: Q9BX97 | TargetFullName: Plasmalemma vesicle-associated protein | Organisim: human | Apparent_Kd_M: 8.708012E-11
Real
Aptamer SeqId: 8569-147 | Target: ARL8B | UniProt: Q9NVJ2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8569-147 | Target: ARL8B | UniProt: Q9NVJ2 | TargetFullName: ADP-ribosylation factor-like protein 8B | Organisim: human | Apparent_Kd_M: 5.734724E-11
Real
Aptamer SeqId: 8578-45 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8578-45 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 8.603605E-12
Real
Aptamer SeqId: 8587-21 | Target: ISK52 | UniProt: Q6IE38
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8587-21 | Target: ISK52 | UniProt: Q6IE38 | TargetFullName: Serine protease inhibitor Kazal-type 14 | Organisim: human | Apparent_Kd_M: 9.204797E-11
Real
Aptamer SeqId: 8589-13 | Target: CDCP1 | UniProt: Q9H5V8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8589-13 | Target: CDCP1 | UniProt: Q9H5V8 | TargetFullName: CUB domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 1.74E-11
Real
Aptamer SeqId: 8595-75 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8595-75 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 8.671581E-12
Real
Aptamer SeqId: 8597-1 | Target: TMEM9 | UniProt: Q9P0T7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8597-1 | Target: TMEM9 | UniProt: Q9P0T7 | TargetFullName: Transmembrane protein 9 | Organisim: human | Apparent_Kd_M: 6.768618E-11
Real
Aptamer SeqId: 8601-167 | Target: sLRP1 | UniProt: Q07954
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8601-167 | Target: sLRP1 | UniProt: Q07954 | TargetFullName: Low-density lipoprotein receptor-related protein 1; soluble | Organisim: human | Apparent_Kd_M: 4.244327E-11
Real
Aptamer SeqId: 8606-39 | Target: GPNMB | UniProt: Q14956
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8606-39 | Target: GPNMB | UniProt: Q14956 | TargetFullName: Transmembrane glycoprotein NMB | Organisim: human | Apparent_Kd_M: 2.12E-12
Real
Aptamer SeqId: 8613-97 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8613-97 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.46E-10
Real
Aptamer SeqId: 8619-12 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8619-12 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.036687E-12
Real
Aptamer SeqId: 8631-13 | Target: ERMAP | UniProt: Q96PL5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8631-13 | Target: ERMAP | UniProt: Q96PL5 | TargetFullName: Erythroid membrane-associated protein | Organisim: human | Apparent_Kd_M: 1.58E-11
Real
Aptamer SeqId: 8633-18 | Target: RN128 | UniProt: Q8TEB7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8633-18 | Target: RN128 | UniProt: Q8TEB7 | TargetFullName: E3 ubiquitin-protein ligase RNF128 | Organisim: human | Apparent_Kd_M: 8.37E-11
Real
Aptamer SeqId: 8634-187 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8634-187 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.664723E-12
Real
Aptamer SeqId: 8635-283 | Target: ZPBP1 | UniProt: Q9BS86
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8635-283 | Target: ZPBP1 | UniProt: Q9BS86 | TargetFullName: Zona pellucida-binding protein 1 | Organisim: human | Apparent_Kd_M: 2.698971E-10
Real
Aptamer SeqId: 8646-61 | Target: LRRT4 | UniProt: Q86VH4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8646-61 | Target: LRRT4 | UniProt: Q86VH4 | TargetFullName: Leucine-rich repeat transmembrane neuronal protein 4 | Organisim: human | Apparent_Kd_M: 2.49E-11
Real
Aptamer SeqId: 8653-132 | Target: DNJC4 | UniProt: Q9NNZ3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8653-132 | Target: DNJC4 | UniProt: Q9NNZ3 | TargetFullName: DnaJ homolog subfamily C member 4 | Organisim: human | Apparent_Kd_M: 7.26E-11
Real
Aptamer SeqId: 8654-13 | Target: ADAM 10 | UniProt: O14672
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8654-13 | Target: ADAM 10 | UniProt: O14672 | TargetFullName: Disintegrin and metalloproteinase domain-containing protein 10 | Organisim: human | Apparent_Kd_M: 3.19393E-10
Real
Aptamer SeqId: 8659-68 | Target: G6B | UniProt: O95866
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8659-68 | Target: G6B | UniProt: O95866 | TargetFullName: Protein G6b | Organisim: human | Apparent_Kd_M: 1.31E-11
Real
Aptamer SeqId: 8660-5 | Target: OLFL3 | UniProt: Q9NRN5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8660-5 | Target: OLFL3 | UniProt: Q9NRN5 | TargetFullName: Olfactomedin-like protein 3 | Organisim: human | Apparent_Kd_M: 3.32E-11
Real
Aptamer SeqId: 8664-36 | Target: PKDCC | UniProt: Q504Y2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8664-36 | Target: PKDCC | UniProt: Q504Y2 | TargetFullName: Extracellular tyrosine-protein kinase PKDCC | Organisim: human | Apparent_Kd_M: 2.814014E-11
Real
Aptamer SeqId: 8667-42 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8667-42 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 9.73E-11
Real
Aptamer SeqId: 8671-378 | Target: TPPC5 | UniProt: Q8IUR0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8671-378 | Target: TPPC5 | UniProt: Q8IUR0 | TargetFullName: Trafficking protein particle complex subunit 5 | Organisim: human | Apparent_Kd_M: 4.984448E-11
Real
Aptamer SeqId: 8675-79 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8675-79 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.01E-11
Real
Aptamer SeqId: 8681-93 | Target: PGRC2 | UniProt: O15173
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8681-93 | Target: PGRC2 | UniProt: O15173 | TargetFullName: Membrane-associated progesterone receptor component 2 | Organisim: human | Apparent_Kd_M: 5.43E-11
Real
Aptamer SeqId: 8686-342 | Target: HIKES | UniProt: Q53FT3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8686-342 | Target: HIKES | UniProt: Q53FT3 | TargetFullName: Protein Hikeshi | Organisim: human | Apparent_Kd_M: 1.181642E-11
Real
Aptamer SeqId: 8687-26 | Target: T106B | UniProt: Q9NUM4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8687-26 | Target: T106B | UniProt: Q9NUM4 | TargetFullName: Transmembrane protein 106B | Organisim: human | Apparent_Kd_M: 3.108046E-11
Real
Aptamer SeqId: 8690-25 | Target: CAV3 | UniProt: P56539
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8690-25 | Target: CAV3 | UniProt: P56539 | TargetFullName: Caveolin-3 | Organisim: human | Apparent_Kd_M: 6.867748E-11
Real
Aptamer SeqId: 8696-15 | Target: G3ST1 | UniProt: Q99999
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8696-15 | Target: G3ST1 | UniProt: Q99999 | TargetFullName: Galactosylceramide sulfotransferase | Organisim: human | Apparent_Kd_M: 4.299585E-11
Real
Aptamer SeqId: 8697-38 | Target: Glypican 1 | UniProt: P35052
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8697-38 | Target: Glypican 1 | UniProt: P35052 | TargetFullName: Glypican-1 | Organisim: human | Apparent_Kd_M: 2.794155E-11
Real
Aptamer SeqId: 8699-43 | Target: CRIM1 | UniProt: Q9NZV1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8699-43 | Target: CRIM1 | UniProt: Q9NZV1 | TargetFullName: Cysteine-rich motor neuron 1 protein | Organisim: human | Apparent_Kd_M: 8.26E-11
Real
Aptamer SeqId: 8700-325 | Target: GLT11 | UniProt: Q8NCW6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8700-325 | Target: GLT11 | UniProt: Q8NCW6 | TargetFullName: Polypeptide N-acetylgalactosaminyltransferase 11 | Organisim: human | Apparent_Kd_M: 7.608824E-11
Real
Aptamer SeqId: 8748-45 | Target: HG2A | UniProt: P04233
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8748-45 | Target: HG2A | UniProt: P04233 | TargetFullName: HLA class II histocompatibility antigen gamma chain | Organisim: human | Apparent_Kd_M: 1.31E-11
Real
Aptamer SeqId: 8749-194 | Target: CD1D | UniProt: P15813
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8749-194 | Target: CD1D | UniProt: P15813 | TargetFullName: Antigen-presenting glycoprotein CD1d | Organisim: human | Apparent_Kd_M: 5.53E-12
Real
Aptamer SeqId: 8750-46 | Target: Vinculin | UniProt: P18206
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8750-46 | Target: Vinculin | UniProt: P18206 | TargetFullName: Vinculin | Organisim: human | Apparent_Kd_M: 5.758763E-12
Real
Aptamer SeqId: 8752-6 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8752-6 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 4.953772E-11
Real
Aptamer SeqId: 8754-5 | Target: NMU | UniProt: P48645
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8754-5 | Target: NMU | UniProt: P48645 | TargetFullName: Neuromedin-U | Organisim: human | Apparent_Kd_M: 1.078694E-10
Real
Aptamer SeqId: 8755-202 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8755-202 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.867771E-11
Real
Aptamer SeqId: 8756-41 | Target: KCE1L | UniProt: Q9UJ90
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8756-41 | Target: KCE1L | UniProt: Q9UJ90 | TargetFullName: Potassium voltage-gated channel subfamily E regulatory beta subunit 5 | Organisim: human | Apparent_Kd_M: 3.31E-12
Real
Aptamer SeqId: 8758-2 | Target: PCDA7 | UniProt: Q9UN72
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8758-2 | Target: PCDA7 | UniProt: Q9UN72 | TargetFullName: Protocadherin alpha-7 | Organisim: human | Apparent_Kd_M: 2.130822E-11
Real
Aptamer SeqId: 8759-29 | Target: a1 4-Galactosyltransferase
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8759-29 | Target: a1;4-Galactosyltransferase | UniProt: Q9NPC4 | TargetFullName: Lactosylceramide 4-alpha-galactosyltransferase | Organisim: human | Apparent_Kd_M: 6.95E-12
Real
Aptamer SeqId: 8760-10 | Target: DCNL5 | UniProt: Q9BTE7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8760-10 | Target: DCNL5 | UniProt: Q9BTE7 | TargetFullName: DCN1-like protein 5 | Organisim: human | Apparent_Kd_M: 6.284481E-11
Real
Aptamer SeqId: 8761-7 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8761-7 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.34E-12
Real
Aptamer SeqId: 8766-29 | Target: LIRA5 | UniProt: A6NI73
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8766-29 | Target: LIRA5 | UniProt: A6NI73 | TargetFullName: Leukocyte immunoglobulin-like receptor subfamily A member 5 | Organisim: human | Apparent_Kd_M: 4.05E-11
Real
Aptamer SeqId: 8767-44 | Target: Endothelin-converting enzyme 1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8767-44 | Target: Endothelin-converting enzyme 1 | UniProt: P42892 | TargetFullName: Endothelin-converting enzyme 1 | Organisim: human | Apparent_Kd_M: 9.9E-13
Real
Aptamer SeqId: 8768-4 | Target: Bcl-10 | UniProt: O95999
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8768-4 | Target: Bcl-10 | UniProt: O95999 | TargetFullName: B-cell lymphoma/leukemia 10 | Organisim: human | Apparent_Kd_M: 2.988377E-12
Real
Aptamer SeqId: 8769-30 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8769-30 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 5.01E-12
Real
Aptamer SeqId: 8770-136 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8770-136 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.45E-12
Real
Aptamer SeqId: 8772-5 | Target: EFNB2 | UniProt: P52799
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8772-5 | Target: EFNB2 | UniProt: P52799 | TargetFullName: Ephrin-B2 | Organisim: human | Apparent_Kd_M: 6.34E-12
Real
Aptamer SeqId: 8773-172 | Target: EMIL3 | UniProt: Q9NT22
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8773-172 | Target: EMIL3 | UniProt: Q9NT22 | TargetFullName: EMILIN-3 | Organisim: human | Apparent_Kd_M: 6.14E-11
Real
Aptamer SeqId: 8775-61 | Target: FA24B | UniProt: Q8N5W8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8775-61 | Target: FA24B | UniProt: Q8N5W8 | TargetFullName: Protein FAM24B | Organisim: human | Apparent_Kd_M: 2.920255E-11
Real
Aptamer SeqId: 8776-10 | Target: ERLN1 | UniProt: O75477
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8776-10 | Target: ERLN1 | UniProt: O75477 | TargetFullName: Erlin-1 | Organisim: human | Apparent_Kd_M: 3.058568E-12
Real
Aptamer SeqId: 8777-5 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8777-5 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 9.770226E-12
Real
Aptamer SeqId: 8778-3 | Target: Noggin | UniProt: Q13253
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8778-3 | Target: Noggin | UniProt: Q13253 | TargetFullName: Noggin | Organisim: human | Apparent_Kd_M: 6.56E-12
Real
Aptamer SeqId: 8780-2 | Target: PCD10 | UniProt: Q9P2E7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8780-2 | Target: PCD10 | UniProt: Q9P2E7 | TargetFullName: Protocadherin-10 | Organisim: human | Apparent_Kd_M: 1.28E-11
Real
Aptamer SeqId: 8783-216 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8783-216 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.467928E-11
Real
Aptamer SeqId: 8784-7 | Target: F175A | UniProt: Q6UWZ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8784-7 | Target: F175A | UniProt: Q6UWZ7 | TargetFullName: BRCA1-A complex subunit Abraxas | Organisim: human | Apparent_Kd_M: 2.883754E-12
Real
Aptamer SeqId: 8785-1 | Target: ARMC5 | UniProt: Q96C12
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8785-1 | Target: ARMC5 | UniProt: Q96C12 | TargetFullName: Armadillo repeat-containing protein 5 | Organisim: human | Apparent_Kd_M: 9.94E-12
Real
Aptamer SeqId: 8786-6 | Target: F171B | UniProt: Q6P995
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8786-6 | Target: F171B | UniProt: Q6P995 | TargetFullName: Protein FAM171B | Organisim: human | Apparent_Kd_M: 1.1E-12
Real
Aptamer SeqId: 8787-21 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8787-21 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.168468E-11
Real
Aptamer SeqId: 8791-151 | Target: Carbonic Anhydrase VA | UniProt: P35218
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8791-151 | Target: Carbonic Anhydrase VA | UniProt: P35218 | TargetFullName: Carbonic anhydrase 5A; mitochondrial | Organisim: human | Apparent_Kd_M: 2.280843E-12
Real
Aptamer SeqId: 8792-17 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8792-17 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 8.400153E-12
Real
Aptamer SeqId: 8793-13 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8793-13 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.501193E-12
Real
Aptamer SeqId: 8794-13 | Target: DPEP1 | UniProt: P16444
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8794-13 | Target: DPEP1 | UniProt: P16444 | TargetFullName: Dipeptidase 1 | Organisim: human | Apparent_Kd_M: 9.69E-11
Real
Aptamer SeqId: 8795-48 | Target: TR | UniProt: P02786
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8795-48 | Target: TR | UniProt: P02786 | TargetFullName: Transferrin receptor protein 1 | Organisim: human | Apparent_Kd_M: 6.35E-11
Real
Aptamer SeqId: 8800-14 | Target: TTC17 | UniProt: Q96AE7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8800-14 | Target: TTC17 | UniProt: Q96AE7 | TargetFullName: Tetratricopeptide repeat protein 17 | Organisim: human | Apparent_Kd_M: 6.86E-11
Real
Aptamer SeqId: 8802-24 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8802-24 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 6.94E-12
Real
Aptamer SeqId: 8803-61 | Target: nectin-1 gamma | UniProt: Q15223
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8803-61 | Target: nectin-1 gamma | UniProt: Q15223 | TargetFullName: Nectin-1; isoform gamma | Organisim: human | Apparent_Kd_M: 8.67E-11
Real
Aptamer SeqId: 8804-39 | Target: COKA1 | UniProt: Q9P218
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8804-39 | Target: COKA1 | UniProt: Q9P218 | TargetFullName: Collagen alpha-1(XX) chain | Organisim: human | Apparent_Kd_M: 1.037699E-11
Real
Aptamer SeqId: 8806-18 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8806-18 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.20428E-11
Real
Aptamer SeqId: 8807-13 | Target: SNX1 | UniProt: Q13596
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8807-13 | Target: SNX1 | UniProt: Q13596 | TargetFullName: Sorting nexin-1 | Organisim: human | Apparent_Kd_M: 4.22E-12
Real
Aptamer SeqId: 8808-90 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8808-90 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.94E-11
Real
Aptamer SeqId: 8810-26 | Target: HEPACAM | UniProt: Q14CZ8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8810-26 | Target: HEPACAM | UniProt: Q14CZ8 | TargetFullName: Hepatocyte cell adhesion molecule | Organisim: human | Apparent_Kd_M: 1.789094E-11
Real
Aptamer SeqId: 8811-24 | Target: BAMBI | UniProt: Q13145
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8811-24 | Target: BAMBI | UniProt: Q13145 | TargetFullName: BMP and activin membrane-bound inhibitor homolog | Organisim: human | Apparent_Kd_M: 6.14E-11
Real
Aptamer SeqId: 8813-160 | Target: Thioredoxin | UniProt: P10599
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8813-160 | Target: Thioredoxin | UniProt: P10599 | TargetFullName: Thioredoxin | Organisim: human | Apparent_Kd_M: 5.91E-11
Real
Aptamer SeqId: 8814-33 | Target: SAPL1 | UniProt: Q6NUJ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8814-33 | Target: SAPL1 | UniProt: Q6NUJ1 | TargetFullName: Proactivator polypeptide-like 1 | Organisim: human | Apparent_Kd_M: 1.589073E-12
Real
Aptamer SeqId: 8815-1 | Target: OLFL1 | UniProt: Q6UWY5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8815-1 | Target: OLFL1 | UniProt: Q6UWY5 | TargetFullName: Olfactomedin-like protein 1 | Organisim: human | Apparent_Kd_M: 1.058171E-10
Real
Aptamer SeqId: 8817-29 | Target: CENPV | UniProt: Q7Z7K6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8817-29 | Target: CENPV | UniProt: Q7Z7K6 | TargetFullName: Centromere protein V | Organisim: human | Apparent_Kd_M: 7.64716E-12
Real
Aptamer SeqId: 8818-13 | Target: INGR2 | UniProt: P38484
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8818-13 | Target: INGR2 | UniProt: P38484 | TargetFullName: Interferon gamma receptor 2 | Organisim: human | Apparent_Kd_M: 7.43E-11
Real
Aptamer SeqId: 8820-2 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8820-2 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.205364E-11
Real
Aptamer SeqId: 8822-163 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8822-163 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.632684E-12
Real
Aptamer SeqId: 8824-2 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8824-2 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.94E-12
Real
Aptamer SeqId: 8825-4 | Target: PILRA | UniProt: Q9UKJ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8825-4 | Target: PILRA | UniProt: Q9UKJ1 | TargetFullName: Paired immunoglobulin-like type 2 receptor alpha | Organisim: human | Apparent_Kd_M: 6.76E-12
Real
Aptamer SeqId: 8828-21 | Target: ESRP1 | UniProt: Q6NXG1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8828-21 | Target: ESRP1 | UniProt: Q6NXG1 | TargetFullName: Epithelial splicing regulatory protein 1 | Organisim: human | Apparent_Kd_M: 7.556231E-12
Real
Aptamer SeqId: 8832-55 | Target: BST-2 | UniProt: Q10589
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8832-55 | Target: BST-2 | UniProt: Q10589 | TargetFullName: Bone marrow stromal antigen 2 | Organisim: human | Apparent_Kd_M: 1.131147E-11
Real
Aptamer SeqId: 8833-20 | Target: TRAIL | UniProt: P50591
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8833-20 | Target: TRAIL | UniProt: P50591 | TargetFullName: Tumor necrosis factor ligand superfamily member 10 | Organisim: human | Apparent_Kd_M: 6.335906E-11
Real
Aptamer SeqId: 8834-58 | Target: Calnexin | UniProt: P27824
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8834-58 | Target: Calnexin | UniProt: P27824 | TargetFullName: Calnexin | Organisim: human | Apparent_Kd_M: 1.146332E-11
Real
Aptamer SeqId: 8837-8 | Target: MFA3L | UniProt: O75121
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8837-8 | Target: MFA3L | UniProt: O75121 | TargetFullName: Microfibrillar-associated protein 3-like | Organisim: human | Apparent_Kd_M: 6.890754E-12
Real
Aptamer SeqId: 8838-10 | Target: CASC4 | UniProt: Q6P4E1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8838-10 | Target: CASC4 | UniProt: Q6P4E1 | TargetFullName: Protein CASC4 | Organisim: human | Apparent_Kd_M: 2.967975E-11
Real
Aptamer SeqId: 8839-4 | Target: Metaxin-2 | UniProt: O75431
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8839-4 | Target: Metaxin-2 | UniProt: O75431 | TargetFullName: Metaxin-2 | Organisim: human | Apparent_Kd_M: 5.605279E-11
Real
Aptamer SeqId: 8840-61 | Target: C1s | UniProt: P09871
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8840-61 | Target: C1s | UniProt: P09871 | TargetFullName: Complement C1s subcomponent | Organisim: human | Apparent_Kd_M: 1.689441E-11
Real
Aptamer SeqId: 8841-65 | Target: CILP2 | UniProt: Q8IUL8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8841-65 | Target: CILP2 | UniProt: Q8IUL8 | TargetFullName: Cartilage intermediate layer protein 2 | Organisim: human | Apparent_Kd_M: 4.067676E-12
Real
Aptamer SeqId: 8842-16 | Target: GRM1C | UniProt: Q8IYS0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8842-16 | Target: GRM1C | UniProt: Q8IYS0 | TargetFullName: GRAM domain-containing protein 1C | Organisim: human | Apparent_Kd_M: 1.18E-10
Real
Aptamer SeqId: 8843-34 | Target: MRF | UniProt: Q9Y2G1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8843-34 | Target: MRF | UniProt: Q9Y2G1 | TargetFullName: Myelin regulatory factor | Organisim: human | Apparent_Kd_M: 3.323251E-11
Real
Aptamer SeqId: 8845-2 | Target: ATS3 | UniProt: O15072
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8845-2 | Target: ATS3 | UniProt: O15072 | TargetFullName: A disintegrin and metalloproteinase with thrombospondin motifs 3 | Organisim: human | Apparent_Kd_M: 2.974789E-11
Real
Aptamer SeqId: 8850-5 | Target: PA2GC | UniProt: Q5R387
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8850-5 | Target: PA2GC | UniProt: Q5R387 | TargetFullName: Putative inactive group IIC secretory phospholipase A2 | Organisim: human | Apparent_Kd_M: 3.223819E-11
Real
Aptamer SeqId: 8852-10 | Target: SUN3 | UniProt: Q8TAQ9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8852-10 | Target: SUN3 | UniProt: Q8TAQ9 | TargetFullName: SUN domain-containing protein 3 | Organisim: human | Apparent_Kd_M: 2.749897E-11
Real
Aptamer SeqId: 8853-2 | Target: CLC4A | UniProt: Q9UMR7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8853-2 | Target: CLC4A | UniProt: Q9UMR7 | TargetFullName: C-type lectin domain family 4 member A | Organisim: human | Apparent_Kd_M: 8.033008E-11
Real
Aptamer SeqId: 8858-21 | Target: BATF3 | UniProt: Q9NR55
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8858-21 | Target: BATF3 | UniProt: Q9NR55 | TargetFullName: Basic leucine zipper transcriptional factor ATF-like 3 | Organisim: human | Apparent_Kd_M: 1.237616E-11
Real
Aptamer SeqId: 8859-51 | Target: CAH11 | UniProt: O75493
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8859-51 | Target: CAH11 | UniProt: O75493 | TargetFullName: Carbonic anhydrase-related protein 11 | Organisim: human | Apparent_Kd_M: 8.017669E-12
Real
Aptamer SeqId: 8863-3 | Target: P85A | UniProt: P27986
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8863-3 | Target: P85A | UniProt: P27986 | TargetFullName: Phosphatidylinositol 3-kinase regulatory subunit alpha | Organisim: human | Apparent_Kd_M: 5.061582E-12
Real
Aptamer SeqId: 8864-59 | Target: CENPW | UniProt: Q5EE01
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8864-59 | Target: CENPW | UniProt: Q5EE01 | TargetFullName: Centromere protein W | Organisim: human | Apparent_Kd_M: 6.146169E-12
Real
Aptamer SeqId: 8866-53 | Target: QPCTL | UniProt: Q9NXS2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8866-53 | Target: QPCTL | UniProt: Q9NXS2 | TargetFullName: Glutaminyl-peptide cyclotransferase-like protein | Organisim: human | Apparent_Kd_M: 6.273073E-12
Real
Aptamer SeqId: 8867-18 | Target: Glycodelin | UniProt: P09466
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8867-18 | Target: Glycodelin | UniProt: P09466 | TargetFullName: Glycodelin | Organisim: human | Apparent_Kd_M: 3.21E-11
Real
Aptamer SeqId: 8868-4 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8868-4 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.453598E-11
Real
Aptamer SeqId: 8869-5 | Target: BT2A1 | UniProt: Q7KYR7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8869-5 | Target: BT2A1 | UniProt: Q7KYR7 | TargetFullName: Butyrophilin subfamily 2 member A1 | Organisim: human | Apparent_Kd_M: 8.56533E-11
Real
Aptamer SeqId: 8870-38 | Target: NPM1 | UniProt: P06748
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8870-38 | Target: NPM1 | UniProt: P06748 | TargetFullName: Nucleophosmin | Organisim: human | Apparent_Kd_M: 2.490283E-10
Real
Aptamer SeqId: 8872-1 | Target: SC61G | UniProt: P60059
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8872-1 | Target: SC61G | UniProt: P60059 | TargetFullName: Protein transport protein Sec61 subunit gamma | Organisim: human | Apparent_Kd_M: 1.080654E-11
Real
Aptamer SeqId: 8874-53 | Target: CLN5 | UniProt: O75503
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8874-53 | Target: CLN5 | UniProt: O75503 | TargetFullName: Ceroid-lipofuscinosis neuronal protein 5 | Organisim: human | Apparent_Kd_M: 2.44E-11
Real
Aptamer SeqId: 8876-51 | Target: NRX2B | UniProt: P58401
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8876-51 | Target: NRX2B | UniProt: P58401 | TargetFullName: Neurexin-2-beta | Organisim: human | Apparent_Kd_M: 5.023218E-12
Real
Aptamer SeqId: 8877-22 | Target: F176C | UniProt: P58658
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8877-22 | Target: F176C | UniProt: P58658 | TargetFullName: Protein eva-1 homolog C | Organisim: human | Apparent_Kd_M: 2.28E-11
Real
Aptamer SeqId: 8878-48 | Target: YTDC1 | UniProt: Q96MU7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8878-48 | Target: YTDC1 | UniProt: Q96MU7 | TargetFullName: YTH domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 2.212952E-12
Real
Aptamer SeqId: 8882-1 | Target: ADAM 17 | UniProt: P78536
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8882-1 | Target: ADAM 17 | UniProt: P78536 | TargetFullName: Disintegrin and metalloproteinase domain-containing protein 17 | Organisim: human | Apparent_Kd_M: 2.29E-11
Real
Aptamer SeqId: 8885-6 | Target: CA2D3 | UniProt: Q8IZS8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8885-6 | Target: CA2D3 | UniProt: Q8IZS8 | TargetFullName: Voltage-dependent calcium channel subunit alpha-2/delta-3 | Organisim: human | Apparent_Kd_M: 2.914052E-11
Real
Aptamer SeqId: 8887-21 | Target: NUDC | UniProt: Q9Y266
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8887-21 | Target: NUDC | UniProt: Q9Y266 | TargetFullName: Nuclear migration protein nudC | Organisim: human | Apparent_Kd_M: 5.44E-12
Real
Aptamer SeqId: 8888-33 | Target: CX068 | UniProt: A6NGZ8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8888-33 | Target: CX068 | UniProt: A6NGZ8 | TargetFullName: Small integral membrane protein 9 | Organisim: human | Apparent_Kd_M: 2.172526E-11
Real
Aptamer SeqId: 8889-5 | Target: CCPG1 | UniProt: Q9ULG6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8889-5 | Target: CCPG1 | UniProt: Q9ULG6 | TargetFullName: Cell cycle progression protein 1 | Organisim: human | Apparent_Kd_M: 3.937674E-12
Real
Aptamer SeqId: 8890-9 | Target: T132B | UniProt: Q14DG7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8890-9 | Target: T132B | UniProt: Q14DG7 | TargetFullName: Transmembrane protein 132B | Organisim: human | Apparent_Kd_M: 1.711747E-12
Real
Aptamer SeqId: 8891-7 | Target: CPVL | UniProt: Q9H3G5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8891-7 | Target: CPVL | UniProt: Q9H3G5 | TargetFullName: Probable serine carboxypeptidase CPVL | Organisim: human | Apparent_Kd_M: 1.64856E-11
Real
Aptamer SeqId: 8892-14 | Target: PEAR1 | UniProt: Q5VY43
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8892-14 | Target: PEAR1 | UniProt: Q5VY43 | TargetFullName: Platelet endothelial aggregation receptor 1 | Organisim: human | Apparent_Kd_M: 3.02E-11
Real
Aptamer SeqId: 8893-29 | Target: PARP | UniProt: P09874
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8893-29 | Target: PARP | UniProt: P09874 | TargetFullName: Poly ADP-ribose polymerase 1 | Organisim: human | Apparent_Kd_M: 1.52E-11
Real
Aptamer SeqId: 8894-80 | Target: hnRNP A/B | UniProt: Q99729
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8894-80 | Target: hnRNP A/B | UniProt: Q99729 | TargetFullName: Heterogeneous nuclear ribonucleoprotein A/B | Organisim: human | Apparent_Kd_M: 8.69E-13
Real
Aptamer SeqId: 8897-3 | Target: L37A2 | UniProt: A6NM11
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8897-3 | Target: L37A2 | UniProt: A6NM11 | TargetFullName: Leucine-rich repeat-containing protein 37A2 | Organisim: human | Apparent_Kd_M: 3.366414E-11
Real
Aptamer SeqId: 8898-19 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8898-19 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 6.215711E-12
Real
Aptamer SeqId: 8899-75 | Target: UD18 | UniProt: Q9HAW9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8899-75 | Target: UD18 | UniProt: Q9HAW9 | TargetFullName: UDP-glucuronosyltransferase 1-8 | Organisim: human | Apparent_Kd_M: 2.352172E-11
Real
Aptamer SeqId: 8900-28 | Target: NEO1 | UniProt: Q92859
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8900-28 | Target: NEO1 | UniProt: Q92859 | TargetFullName: Neogenin | Organisim: human | Apparent_Kd_M: 7.102043E-12
Real
Aptamer SeqId: 8901-40 | Target: Deprecated | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8901-40 | Target: Deprecated | UniProt: | TargetFullName: | Organisim: human | Apparent_Kd_M: 7.967902E-12
Real
Aptamer SeqId: 8903-1 | Target: COX6C | UniProt: P09669
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8903-1 | Target: COX6C | UniProt: P09669 | TargetFullName: Cytochrome c oxidase subunit 6C | Organisim: human | Apparent_Kd_M: 6.744751E-12
Real
Aptamer SeqId: 8905-20 | Target: KCMB3 | UniProt: Q9NPA1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8905-20 | Target: KCMB3 | UniProt: Q9NPA1 | TargetFullName: Calcium-activated potassium channel subunit beta-3 | Organisim: human | Apparent_Kd_M: 1.032584E-11
Real
Aptamer SeqId: 8906-60 | Target: LRTM2 | UniProt: Q8N967
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8906-60 | Target: LRTM2 | UniProt: Q8N967 | TargetFullName: Leucine-rich repeat and transmembrane domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 9.454653E-13
Real
Aptamer SeqId: 8907-11 | Target: UD2A1 | UniProt: Q9Y4X1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8907-11 | Target: UD2A1 | UniProt: Q9Y4X1 | TargetFullName: UDP-glucuronosyltransferase 2A1 | Organisim: human | Apparent_Kd_M: 7.4672E-12
Real
Aptamer SeqId: 8908-14 | Target: KCE1L | UniProt: Q9UJ90
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8908-14 | Target: KCE1L | UniProt: Q9UJ90 | TargetFullName: Potassium voltage-gated channel subfamily E regulatory beta subunit 5 | Organisim: human | Apparent_Kd_M: 6.47E-12
Real
Aptamer SeqId: 8909-77 | Target: GNPI1 | UniProt: P46926
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8909-77 | Target: GNPI1 | UniProt: P46926 | TargetFullName: Glucosamine-6-phosphate isomerase 1 | Organisim: human | Apparent_Kd_M: 3.450125E-12
Real
Aptamer SeqId: 8913-22 | Target: SIG11 | UniProt: Q96RL6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8913-22 | Target: SIG11 | UniProt: Q96RL6 | TargetFullName: Sialic acid-binding Ig-like lectin 11 | Organisim: human | Apparent_Kd_M: 1.301892E-10
Real
Aptamer SeqId: 8916-32 | Target: STIM1 | UniProt: Q13586
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8916-32 | Target: STIM1 | UniProt: Q13586 | TargetFullName: Stromal interaction molecule 1 | Organisim: human | Apparent_Kd_M: 5.12E-12
Real
Aptamer SeqId: 8918-64 | Target: FAK2 | UniProt: Q14289
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8918-64 | Target: FAK2 | UniProt: Q14289 | TargetFullName: Protein-tyrosine kinase 2-beta | Organisim: human | Apparent_Kd_M: 2.5E-12
Real
Aptamer SeqId: 8921-139 | Target: PABP2 | UniProt: Q86U42
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8921-139 | Target: PABP2 | UniProt: Q86U42 | TargetFullName: Polyadenylate-binding protein 2 | Organisim: human | Apparent_Kd_M: 8.796106E-11
Real
Aptamer SeqId: 8922-4 | Target: TMCC3 | UniProt: Q9ULS5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8922-4 | Target: TMCC3 | UniProt: Q9ULS5 | TargetFullName: Transmembrane and coiled-coil domains protein 3 | Organisim: human | Apparent_Kd_M: 4.06E-11
Real
Aptamer SeqId: 8923-94 | Target: GLTL1 | UniProt: Q8N428
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8923-94 | Target: GLTL1 | UniProt: Q8N428 | TargetFullName: Polypeptide N-acetylgalactosaminyltransferase 16 | Organisim: human | Apparent_Kd_M: 3.457662E-12
Real
Aptamer SeqId: 8924-55 | Target: CALY | UniProt: Q9NYX4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8924-55 | Target: CALY | UniProt: Q9NYX4 | TargetFullName: Neuron-specific vesicular protein calcyon | Organisim: human | Apparent_Kd_M: 5.96E-11
Real
Aptamer SeqId: 8925-25 | Target: RIR2B | UniProt: Q7LG56
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8925-25 | Target: RIR2B | UniProt: Q7LG56 | TargetFullName: Ribonucleoside-diphosphate reductase subunit M2 B | Organisim: human | Apparent_Kd_M: 5.03E-12
Real
Aptamer SeqId: 8927-6 | Target: CG073 | UniProt: E0CX11
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8927-6 | Target: CG073 | UniProt: E0CX11 | TargetFullName: Uncharacterized protein C7orf73 | Organisim: human | Apparent_Kd_M: 1.098438E-10
Real
Aptamer SeqId: 8929-7 | Target: BDP1 | UniProt: A6H8Y1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8929-7 | Target: BDP1 | UniProt: A6H8Y1 | TargetFullName: Transcription factor TFIIIB component B'' homolog | Organisim: human | Apparent_Kd_M: 7.493924E-12
Real
Aptamer SeqId: 8931-124 | Target: G0S2 | UniProt: P27469
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8931-124 | Target: G0S2 | UniProt: P27469 | TargetFullName: G0/G1 switch protein 2 | Organisim: human | Apparent_Kd_M: 1.338412E-11
Real
Aptamer SeqId: 8932-1 | Target: ENTP6 | UniProt: O75354
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8932-1 | Target: ENTP6 | UniProt: O75354 | TargetFullName: Ectonucleoside triphosphate diphosphohydrolase 6 | Organisim: human | Apparent_Kd_M: 2.076181E-11
Real
Aptamer SeqId: 8933-84 | Target: MEF2C | UniProt: Q06413
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8933-84 | Target: MEF2C | UniProt: Q06413 | TargetFullName: Myocyte-specific enhancer factor 2C | Organisim: human | Apparent_Kd_M: 1.888053E-12
Real
Aptamer SeqId: 8935-22 | Target: MRP6 | UniProt: O95255
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8935-22 | Target: MRP6 | UniProt: O95255 | TargetFullName: Multidrug resistance-associated protein 6 | Organisim: human | Apparent_Kd_M: 3.130753E-11
Real
Aptamer SeqId: 8941-4 | Target: NLGN3 | UniProt: Q9NZ94
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8941-4 | Target: NLGN3 | UniProt: Q9NZ94 | TargetFullName: Neuroligin-3 | Organisim: human | Apparent_Kd_M: 1.53E-12
Real
Aptamer SeqId: 8942-2 | Target: RM21 | UniProt: Q7Z2W9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8942-2 | Target: RM21 | UniProt: Q7Z2W9 | TargetFullName: 39S ribosomal protein L21; mitochondrial | Organisim: human | Apparent_Kd_M: 2.938094E-11
Real
Aptamer SeqId: 8944-42 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8944-42 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.54E-11
Real
Aptamer SeqId: 8945-7 | Target: F175B | UniProt: Q15018
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8945-7 | Target: F175B | UniProt: Q15018 | TargetFullName: BRISC complex subunit Abro1 | Organisim: human | Apparent_Kd_M: 6.67E-12
Real
Aptamer SeqId: 8946-38 | Target: NR1H4 | UniProt: Q96RI1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8946-38 | Target: NR1H4 | UniProt: Q96RI1 | TargetFullName: Bile acid receptor | Organisim: human | Apparent_Kd_M: 1.823857E-11
Real
Aptamer SeqId: 8947-268 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8947-268 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 9.612346E-12
Real
Aptamer SeqId: 8948-13 | Target: ADA19 | UniProt: Q9H013
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8948-13 | Target: ADA19 | UniProt: Q9H013 | TargetFullName: Disintegrin and metalloproteinase domain-containing protein 19 | Organisim: human | Apparent_Kd_M: 1.02E-11
Real
Aptamer SeqId: 8949-3 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8949-3 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.38E-12
Real
Aptamer SeqId: 8950-4 | Target: CLCA2 | UniProt: Q9UQC9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8950-4 | Target: CLCA2 | UniProt: Q9UQC9 | TargetFullName: Calcium-activated chloride channel regulator 2 | Organisim: human | Apparent_Kd_M: 3.008883E-11
Real
Aptamer SeqId: 8951-162 | Target: CSPG4 | UniProt: Q6UVK1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8951-162 | Target: CSPG4 | UniProt: Q6UVK1 | TargetFullName: Chondroitin sulfate proteoglycan 4 | Organisim: human | Apparent_Kd_M: 2.600951E-12
Real
Aptamer SeqId: 8953-47 | Target: HDGF | UniProt: P51858
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8953-47 | Target: HDGF | UniProt: P51858 | TargetFullName: Hepatoma-derived growth factor | Organisim: human | Apparent_Kd_M: 8.03E-12
Real
Aptamer SeqId: 8954-30 | Target: M4K1 | UniProt: Q92918
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8954-30 | Target: M4K1 | UniProt: Q92918 | TargetFullName: Mitogen-activated protein kinase kinase kinase kinase 1 | Organisim: human | Apparent_Kd_M: 2.082788E-11
Real
Aptamer SeqId: 8955-60 | Target: GL8D1 | UniProt: Q68CQ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8955-60 | Target: GL8D1 | UniProt: Q68CQ7 | TargetFullName: Glycosyltransferase 8 domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 6.375928E-11
Real
Aptamer SeqId: 8956-96 | Target: SREC-II | UniProt: Q96GP6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8956-96 | Target: SREC-II | UniProt: Q96GP6 | TargetFullName: Scavenger receptor class F member 2 | Organisim: human | Apparent_Kd_M: 8.79E-12
Real
Aptamer SeqId: 8957-72 | Target: XTP3B | UniProt: Q96DZ1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8957-72 | Target: XTP3B | UniProt: Q96DZ1 | TargetFullName: Endoplasmic reticulum lectin 1 | Organisim: human | Apparent_Kd_M: 7.188528E-12
Real
Aptamer SeqId: 8958-51 | Target: CHL1 | UniProt: O00533
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8958-51 | Target: CHL1 | UniProt: O00533 | TargetFullName: Neural cell adhesion molecule L1-like protein | Organisim: human | Apparent_Kd_M: 2.04E-12
Real
Aptamer SeqId: 8959-61 | Target: ADAM 17 | UniProt: P78536
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8959-61 | Target: ADAM 17 | UniProt: P78536 | TargetFullName: Disintegrin and metalloproteinase domain-containing protein 17 | Organisim: human | Apparent_Kd_M: 4.49E-11
Real
Aptamer SeqId: 8960-3 | Target: LRAP | UniProt: Q6P179
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8960-3 | Target: LRAP | UniProt: Q6P179 | TargetFullName: Endoplasmic reticulum aminopeptidase 2 | Organisim: human | Apparent_Kd_M: 4.953124E-12
Real
Aptamer SeqId: 8962-48 | Target: KS6B1 | UniProt: P23443
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8962-48 | Target: KS6B1 | UniProt: P23443 | TargetFullName: Ribosomal protein S6 kinase beta-1 | Organisim: human | Apparent_Kd_M: 2.37E-11
Real
Aptamer SeqId: 8963-8 | Target: Vti1-rp1 | UniProt: Q9UEU0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8963-8 | Target: Vti1-rp1 | UniProt: Q9UEU0 | TargetFullName: Vesicle transport through interaction with t-SNAREs homolog 1B | Organisim: human | Apparent_Kd_M: 2.640325E-12
Real
Aptamer SeqId: 8964-14 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8964-14 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.33E-11
Real
Aptamer SeqId: 8967-6 | Target: DUS26 | UniProt: Q9BV47
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8967-6 | Target: DUS26 | UniProt: Q9BV47 | TargetFullName: Dual specificity protein phosphatase 26 | Organisim: human | Apparent_Kd_M: 2.441575E-11
Real
Aptamer SeqId: 8969-49 | Target: CD14 | UniProt: P08571
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8969-49 | Target: CD14 | UniProt: P08571 | TargetFullName: Monocyte differentiation antigen CD14 | Organisim: human | Apparent_Kd_M: 1.993792E-12
Real
Aptamer SeqId: 8970-9 | Target: RIPK2 | UniProt: O43353
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8970-9 | Target: RIPK2 | UniProt: O43353 | TargetFullName: Receptor-interacting serine/threonine-protein kinase 2 | Organisim: human | Apparent_Kd_M: 1.96E-10
Real
Aptamer SeqId: 8971-9 | Target: NRX1A | UniProt: Q9ULB1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8971-9 | Target: NRX1A | UniProt: Q9ULB1 | TargetFullName: Neurexin-1 | Organisim: human | Apparent_Kd_M: 1.106772E-11
Real
Aptamer SeqId: 8973-23 | Target: FCRL4 | UniProt: Q96PJ5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8973-23 | Target: FCRL4 | UniProt: Q96PJ5 | TargetFullName: Fc receptor-like protein 4 | Organisim: human | Apparent_Kd_M: 4.38E-12
Real
Aptamer SeqId: 8974-172 | Target: COFA1 | UniProt: P39059
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8974-172 | Target: COFA1 | UniProt: P39059 | TargetFullName: Collagen alpha-1(XV) chain | Organisim: human | Apparent_Kd_M: 3.613182E-12
Real
Aptamer SeqId: 8975-26 | Target: RCD1 | UniProt: Q92600
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8975-26 | Target: RCD1 | UniProt: Q92600 | TargetFullName: Cell differentiation protein RCD1 homolog | Organisim: human | Apparent_Kd_M: 7.895752E-12
Real
Aptamer SeqId: 8976-13 | Target: B4GN1 | UniProt: Q00973
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8976-13 | Target: B4GN1 | UniProt: Q00973 | TargetFullName: Beta-1;4 N-acetylgalactosaminyltransferase 1 | Organisim: human | Apparent_Kd_M: 1.184943E-10
Real
Aptamer SeqId: 8978-30 | Target: M4K3 | UniProt: Q8IVH8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8978-30 | Target: M4K3 | UniProt: Q8IVH8 | TargetFullName: Mitogen-activated protein kinase kinase kinase kinase 3 | Organisim: human | Apparent_Kd_M: 1.374491E-11
Real
Aptamer SeqId: 8979-1 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8979-1 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 6.808517E-13
Real
Aptamer SeqId: 8980-19 | Target: MO2R2 | UniProt: Q6Q8B3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8980-19 | Target: MO2R2 | UniProt: Q6Q8B3 | TargetFullName: Cell surface glycoprotein CD200 receptor 2 | Organisim: human | Apparent_Kd_M: 6.094786E-11
Real
Aptamer SeqId: 8982-65 | Target: TSP3 | UniProt: P49746
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8982-65 | Target: TSP3 | UniProt: P49746 | TargetFullName: Thrombospondin-3 | Organisim: human | Apparent_Kd_M: 2.90397E-12
Real
Aptamer SeqId: 8983-7 | Target: GOLM1 | UniProt: Q8NBJ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8983-7 | Target: GOLM1 | UniProt: Q8NBJ4 | TargetFullName: Golgi membrane protein 1 | Organisim: human | Apparent_Kd_M: 4.34E-12
Real
Aptamer SeqId: 8985-13 | Target: SRAC1 | UniProt: Q96JX3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8985-13 | Target: SRAC1 | UniProt: Q96JX3 | TargetFullName: Protein SERAC1 | Organisim: human | Apparent_Kd_M: 1.863821E-11
Real
Aptamer SeqId: 8989-40 | Target: SCUB1 | UniProt: Q8IWY4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8989-40 | Target: SCUB1 | UniProt: Q8IWY4 | TargetFullName: Signal peptide; CUB and EGF-like domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 1.828633E-11
Real
Aptamer SeqId: 8990-42 | Target: AT1B3 | UniProt: P54709
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8990-42 | Target: AT1B3 | UniProt: P54709 | TargetFullName: Sodium/potassium-transporting ATPase subunit beta-3 | Organisim: human | Apparent_Kd_M: 2.167251E-12
Real
Aptamer SeqId: 8991-115 | Target: FCRL4 | UniProt: Q96PJ5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8991-115 | Target: FCRL4 | UniProt: Q96PJ5 | TargetFullName: Fc receptor-like protein 4 | Organisim: human | Apparent_Kd_M: 1.95E-10
Real
Aptamer SeqId: 8992-1 | Target: TMEM2 | UniProt: Q9UHN6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8992-1 | Target: TMEM2 | UniProt: Q9UHN6 | TargetFullName: Transmembrane protein 2 | Organisim: human | Apparent_Kd_M: 1.414496E-11
Real
Aptamer SeqId: 8993-151 | Target: RIPK2 | UniProt: O43353
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8993-151 | Target: RIPK2 | UniProt: O43353 | TargetFullName: Receptor-interacting serine/threonine-protein kinase 2 | Organisim: human | Apparent_Kd_M: 2.37E-11
Real
Aptamer SeqId: 8994-65 | Target: SLAMF8 | UniProt: Q9P0V8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8994-65 | Target: SLAMF8 | UniProt: Q9P0V8 | TargetFullName: SLAM family member 8 | Organisim: human | Apparent_Kd_M: 4.057493E-11
Real
Aptamer SeqId: 8998-15 | Target: HS3S4 | UniProt: Q9Y661
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8998-15 | Target: HS3S4 | UniProt: Q9Y661 | TargetFullName: Heparan sulfate glucosamine 3-O-sulfotransferase 4 | Organisim: human | Apparent_Kd_M: 4.37E-12
Real
Aptamer SeqId: 8999-19 | Target: CEAM3 | UniProt: P40198
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 8999-19 | Target: CEAM3 | UniProt: P40198 | TargetFullName: Carcinoembryonic antigen-related cell adhesion molecule 3 | Organisim: human | Apparent_Kd_M: 1.123368E-10
Real
Aptamer SeqId: 9000-177 | Target: SLC31 | UniProt: Q07837
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9000-177 | Target: SLC31 | UniProt: Q07837 | TargetFullName: Neutral and basic amino acid transport protein rBAT | Organisim: human | Apparent_Kd_M: 9.488766E-11
Real
Aptamer SeqId: 9002-36 | Target: SPA11 | UniProt: Q86U17
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9002-36 | Target: SPA11 | UniProt: Q86U17 | TargetFullName: Serpin A11 | Organisim: human | Apparent_Kd_M: 1.533984E-11
Real
Aptamer SeqId: 9003-99 | Target: MARCO | UniProt: Q9UEW3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9003-99 | Target: MARCO | UniProt: Q9UEW3 | TargetFullName: Macrophage receptor MARCO | Organisim: human | Apparent_Kd_M: 1.462149E-10
Real
Aptamer SeqId: 9004-24 | Target: CR001 | UniProt: O15165
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9004-24 | Target: CR001 | UniProt: O15165 | TargetFullName: Low-density lipoprotein receptor class A domain-containing protein 4 | Organisim: human | Apparent_Kd_M: 1.142413E-11
Real
Aptamer SeqId: 9005-16 | Target: PLXA1 | UniProt: Q9UIW2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9005-16 | Target: PLXA1 | UniProt: Q9UIW2 | TargetFullName: Plexin-A1 | Organisim: human | Apparent_Kd_M: 3.98902E-12
Real
Aptamer SeqId: 9008-6 | Target: TMG1 | UniProt: O14668
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9008-6 | Target: TMG1 | UniProt: O14668 | TargetFullName: Transmembrane gamma-carboxyglutamic acid protein 1 | Organisim: human | Apparent_Kd_M: 1.8E-12
Real
Aptamer SeqId: 9010-3 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9010-3 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.089875E-11
Real
Aptamer SeqId: 9012-1 | Target: PRP6 | UniProt: O94906
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9012-1 | Target: PRP6 | UniProt: O94906 | TargetFullName: Pre-mRNA-processing factor 6 | Organisim: human | Apparent_Kd_M: 1.76E-12
Real
Aptamer SeqId: 9014-18 | Target: TMM25 | UniProt: Q86YD3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9014-18 | Target: TMM25 | UniProt: Q86YD3 | TargetFullName: Transmembrane protein 25 | Organisim: human | Apparent_Kd_M: 8.276182E-11
Real
Aptamer SeqId: 9015-1 | Target: PRG3 | UniProt: Q9Y2Y8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9015-1 | Target: PRG3 | UniProt: Q9Y2Y8 | TargetFullName: Proteoglycan 3 | Organisim: human | Apparent_Kd_M: 2.729369E-11
Real
Aptamer SeqId: 9016-12 | Target: NR1H2 | UniProt: P55055
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9016-12 | Target: NR1H2 | UniProt: P55055 | TargetFullName: Oxysterols receptor LXR-beta | Organisim: human | Apparent_Kd_M: 2.683337E-11
Real
Aptamer SeqId: 9017-58 | Target: LPH | UniProt: P09848
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9017-58 | Target: LPH | UniProt: P09848 | TargetFullName: Lactase-phlorizin hydrolase | Organisim: human | Apparent_Kd_M: 2.523141E-11
Real
Aptamer SeqId: 9018-38 | Target: PCD10 | UniProt: Q9P2E7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9018-38 | Target: PCD10 | UniProt: Q9P2E7 | TargetFullName: Protocadherin-10 | Organisim: human | Apparent_Kd_M: 9.64E-11
Real
Aptamer SeqId: 9021-1 | Target: TIM-1 | UniProt: Q96D42
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9021-1 | Target: TIM-1 | UniProt: Q96D42 | TargetFullName: Hepatitis A virus cellular receptor 1 | Organisim: human | Apparent_Kd_M: 5.07E-12
Real
Aptamer SeqId: 9022-49 | Target: DB132 | UniProt: Q7Z7B7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9022-49 | Target: DB132 | UniProt: Q7Z7B7 | TargetFullName: Beta-defensin 132 | Organisim: human | Apparent_Kd_M: 2.670471E-11
Real
Aptamer SeqId: 9023-9 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9023-9 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 6.17E-13
Real
Aptamer SeqId: 9025-5 | Target: AHSP | UniProt: Q9NZD4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9025-5 | Target: AHSP | UniProt: Q9NZD4 | TargetFullName: Alpha-hemoglobin-stabilizing protein | Organisim: human | Apparent_Kd_M: 5.715717E-11
Real
Aptamer SeqId: 9026-40 | Target: BTNL8 | UniProt: Q6UX41
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9026-40 | Target: BTNL8 | UniProt: Q6UX41 | TargetFullName: Butyrophilin-like protein 8 | Organisim: human | Apparent_Kd_M: 8.555269E-11
Real
Aptamer SeqId: 9027-10 | Target: NLGN2 | UniProt: Q8NFZ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9027-10 | Target: NLGN2 | UniProt: Q8NFZ4 | TargetFullName: Neuroligin-2 | Organisim: human | Apparent_Kd_M: 4.06E-12
Real
Aptamer SeqId: 9028-5 | Target: PAPD1 | UniProt: Q9NVV4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9028-5 | Target: PAPD1 | UniProt: Q9NVV4 | TargetFullName: Poly(A) RNA polymerase; mitochondrial | Organisim: human | Apparent_Kd_M: 8.823446E-12
Real
Aptamer SeqId: 9030-56 | Target: CQ089 | UniProt: A1L188
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9030-56 | Target: CQ089 | UniProt: A1L188 | TargetFullName: Uncharacterized protein C17orf89 | Organisim: human | Apparent_Kd_M: 1.007547E-11
Real
Aptamer SeqId: 9032-30 | Target: ROS1 | UniProt: P08922
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9032-30 | Target: ROS1 | UniProt: P08922 | TargetFullName: Proto-oncogene tyrosine-protein kinase ROS | Organisim: human | Apparent_Kd_M: 1.45594E-12
Real
Aptamer SeqId: 9035-2 | Target: MXI1 | UniProt: P50539
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9035-2 | Target: MXI1 | UniProt: P50539 | TargetFullName: MAX-interacting protein 1 | Organisim: human | Apparent_Kd_M: 1.094203E-11
Real
Aptamer SeqId: 9037-1 | Target: STX18 | UniProt: Q9P2W9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9037-1 | Target: STX18 | UniProt: Q9P2W9 | TargetFullName: Syntaxin-18 | Organisim: human | Apparent_Kd_M: 7.431641E-11
Real
Aptamer SeqId: 9038-12 | Target: JTB | UniProt: O76095
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9038-12 | Target: JTB | UniProt: O76095 | TargetFullName: Protein JTB | Organisim: human | Apparent_Kd_M: 5.751648E-12
Real
Aptamer SeqId: 9039-47 | Target: TOIP1 | UniProt: Q5JTV8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9039-47 | Target: TOIP1 | UniProt: Q5JTV8 | TargetFullName: Torsin-1A-interacting protein 1 | Organisim: human | Apparent_Kd_M: 2.75E-11
Real
Aptamer SeqId: 9040-144 | Target: EPDR1 | UniProt: Q9UM22
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9040-144 | Target: EPDR1 | UniProt: Q9UM22 | TargetFullName: Mammalian ependymin-related protein 1 | Organisim: human | Apparent_Kd_M: 1.852025E-10
Real
Aptamer SeqId: 9043-7 | Target: TFP11 | UniProt: Q9UBB9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9043-7 | Target: TFP11 | UniProt: Q9UBB9 | TargetFullName: Tuftelin-interacting protein 11 | Organisim: human | Apparent_Kd_M: 7.634652E-12
Real
Aptamer SeqId: 9044-1 | Target: CNTP5 | UniProt: Q8WYK1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9044-1 | Target: CNTP5 | UniProt: Q8WYK1 | TargetFullName: Contactin-associated protein-like 5 | Organisim: human | Apparent_Kd_M: 9.303757E-12
Real
Aptamer SeqId: 9045-3 | Target: S27A2 | UniProt: O14975
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9045-3 | Target: S27A2 | UniProt: O14975 | TargetFullName: Very long-chain acyl-CoA synthetase | Organisim: human | Apparent_Kd_M: 1.411928E-11
Real
Aptamer SeqId: 9046-46 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9046-46 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 9.68E-13
Real
Aptamer SeqId: 9049-2 | Target: MOT4 | UniProt: O15427
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9049-2 | Target: MOT4 | UniProt: O15427 | TargetFullName: Monocarboxylate transporter 4 | Organisim: human | Apparent_Kd_M: 1.786768E-11
Real
Aptamer SeqId: 9050-170 | Target: CA063 | UniProt: Q9BUV0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9050-170 | Target: CA063 | UniProt: Q9BUV0 | TargetFullName: Arginine/serine-rich protein 1 | Organisim: human | Apparent_Kd_M: 1.36672E-11
Real
Aptamer SeqId: 9051-13 | Target: IL32 | UniProt: P24001
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9051-13 | Target: IL32 | UniProt: P24001 | TargetFullName: Interleukin-32 | Organisim: human | Apparent_Kd_M: 1.62E-11
Real
Aptamer SeqId: 9053-16 | Target: CRIP2 | UniProt: P52943
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9053-16 | Target: CRIP2 | UniProt: P52943 | TargetFullName: Cysteine-rich protein 2 | Organisim: human | Apparent_Kd_M: 8.812649E-11
Real
Aptamer SeqId: 9054-8 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9054-8 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 7.245978E-12
Real
Aptamer SeqId: 9055-81 | Target: MYZAP | UniProt: P0CAP1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9055-81 | Target: MYZAP | UniProt: P0CAP1 | TargetFullName: Myocardial zonula adherens protein | Organisim: human | Apparent_Kd_M: 6.12E-12
Real
Aptamer SeqId: 9057-19 | Target: ADRM1 | UniProt: Q16186
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9057-19 | Target: ADRM1 | UniProt: Q16186 | TargetFullName: Proteasomal ubiquitin receptor ADRM1 | Organisim: human | Apparent_Kd_M: 5.415682E-11
Real
Aptamer SeqId: 9058-1 | Target: TIM21 | UniProt: Q9BVV7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9058-1 | Target: TIM21 | UniProt: Q9BVV7 | TargetFullName: Mitochondrial import inner membrane translocase subunit Tim21 | Organisim: human | Apparent_Kd_M: 4.528955E-12
Real
Aptamer SeqId: 9059-14 | Target: RPGF5 | UniProt: Q92565
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9059-14 | Target: RPGF5 | UniProt: Q92565 | TargetFullName: Rap guanine nucleotide exchange factor 5 | Organisim: human | Apparent_Kd_M: 8.734675E-11
Real
Aptamer SeqId: 9060-27 | Target: TUTLB | UniProt: Q9UPX0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9060-27 | Target: TUTLB | UniProt: Q9UPX0 | TargetFullName: Protein turtle homolog B | Organisim: human | Apparent_Kd_M: 1.75571E-11
Real
Aptamer SeqId: 9061-3 | Target: ARHGA | UniProt: O15013
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9061-3 | Target: ARHGA | UniProt: O15013 | TargetFullName: Rho guanine nucleotide exchange factor 10 | Organisim: human | Apparent_Kd_M: 2.381391E-11
Real
Aptamer SeqId: 9063-9 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9063-9 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.26E-11
Real
Aptamer SeqId: 9064-12 | Target: RN215 | UniProt: Q9Y6U7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9064-12 | Target: RN215 | UniProt: Q9Y6U7 | TargetFullName: RING finger protein 215 | Organisim: human | Apparent_Kd_M: 1.94E-10
Real
Aptamer SeqId: 9067-152 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9067-152 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 6.86E-12
Real
Aptamer SeqId: 9068-17 | Target: JKIP3 | UniProt: Q5VZ66
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9068-17 | Target: JKIP3 | UniProt: Q5VZ66 | TargetFullName: Janus kinase and microtubule-interacting protein 3 | Organisim: human | Apparent_Kd_M: 2.866844E-11
Real
Aptamer SeqId: 9070-1 | Target: CQ067 | UniProt: Q0P5P2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9070-1 | Target: CQ067 | UniProt: Q0P5P2 | TargetFullName: Uncharacterized protein C17orf67 | Organisim: human | Apparent_Kd_M: 1.08E-11
Real
Aptamer SeqId: 9073-35 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9073-35 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.545875E-11
Real
Aptamer SeqId: 9074-6 | Target: CE004 | UniProt: Q96IV6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9074-6 | Target: CE004 | UniProt: Q96IV6 | TargetFullName: Fatty acid hydroxylase domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 3.015646E-10
Real
Aptamer SeqId: 9075-121 | Target: K1024 | UniProt: Q9UPX6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9075-121 | Target: K1024 | UniProt: Q9UPX6 | TargetFullName: UPF0258 protein KIAA1024 | Organisim: human | Apparent_Kd_M: 5.11069E-11
Real
Aptamer SeqId: 9076-25 | Target: PENK | UniProt: P01210
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9076-25 | Target: PENK | UniProt: P01210 | TargetFullName: Proenkephalin-A | Organisim: human | Apparent_Kd_M: 3.741179E-12
Real
Aptamer SeqId: 9077-10 | Target: MA1A2 | UniProt: O60476
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9077-10 | Target: MA1A2 | UniProt: O60476 | TargetFullName: Mannosyl-oligosaccharide 1;2-alpha-mannosidase IB | Organisim: human | Apparent_Kd_M: 4.354173E-12
Real
Aptamer SeqId: 9078-207 | Target: SNTB1 | UniProt: Q13884
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9078-207 | Target: SNTB1 | UniProt: Q13884 | TargetFullName: Beta-1-syntrophin | Organisim: human | Apparent_Kd_M: 2.460806E-10
Real
Aptamer SeqId: 9080-1 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9080-1 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 4.86E-11
Real
Aptamer SeqId: 9081-39 | Target: ZNT3 | UniProt: Q99726
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9081-39 | Target: ZNT3 | UniProt: Q99726 | TargetFullName: Zinc transporter 3 | Organisim: human | Apparent_Kd_M: 1.271315E-10
Real
Aptamer SeqId: 9082-25 | Target: SE1L2 | UniProt: Q5TEA6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9082-25 | Target: SE1L2 | UniProt: Q5TEA6 | TargetFullName: Protein sel-1 homolog 2 | Organisim: human | Apparent_Kd_M: 1.828958E-10
Real
Aptamer SeqId: 9087-8 | Target: NHLC3 | UniProt: Q5JS37
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9087-8 | Target: NHLC3 | UniProt: Q5JS37 | TargetFullName: NHL repeat-containing protein 3 | Organisim: human | Apparent_Kd_M: 3.536141E-11
Real
Aptamer SeqId: 9088-20 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9088-20 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.030379E-11
Real
Aptamer SeqId: 9089-77 | Target: JPH3 | UniProt: Q8WXH2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9089-77 | Target: JPH3 | UniProt: Q8WXH2 | TargetFullName: Junctophilin-3 | Organisim: human | Apparent_Kd_M: 6.249853E-11
Real
Aptamer SeqId: 9090-9 | Target: SYTL4 | UniProt: Q96C24
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9090-9 | Target: SYTL4 | UniProt: Q96C24 | TargetFullName: Synaptotagmin-like protein 4 | Organisim: human | Apparent_Kd_M: 9.9E-12
Real
Aptamer SeqId: 9092-33 | Target: ANGL1 | UniProt: O95841
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9092-33 | Target: ANGL1 | UniProt: O95841 | TargetFullName: Angiopoietin-related protein 1 | Organisim: human | Apparent_Kd_M: 8.9E-11
Real
Aptamer SeqId: 9094-5 | Target: CLC4C | UniProt: Q8WTT0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9094-5 | Target: CLC4C | UniProt: Q8WTT0 | TargetFullName: C-type lectin domain family 4 member C | Organisim: human | Apparent_Kd_M: 9.951627E-12
Real
Aptamer SeqId: 9095-5 | Target: MTFR1 | UniProt: Q15390
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9095-5 | Target: MTFR1 | UniProt: Q15390 | TargetFullName: Mitochondrial fission regulator 1 | Organisim: human | Apparent_Kd_M: 3.477547E-11
Real
Aptamer SeqId: 9097-5 | Target: K1324 | UniProt: Q6UXG2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9097-5 | Target: K1324 | UniProt: Q6UXG2 | TargetFullName: UPF0577 protein KIAA1324 | Organisim: human | Apparent_Kd_M: 1.5E-11
Real
Aptamer SeqId: 9099-19 | Target: SYT5 | UniProt: O00445
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9099-19 | Target: SYT5 | UniProt: O00445 | TargetFullName: Synaptotagmin-5 | Organisim: human | Apparent_Kd_M: 7.706502E-11
Real
Aptamer SeqId: 9100-32 | Target: CE046 | UniProt: Q6UWT4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9100-32 | Target: CE046 | UniProt: Q6UWT4 | TargetFullName: Uncharacterized protein C5orf46 | Organisim: human | Apparent_Kd_M: 1.566704E-10
Real
Aptamer SeqId: 9102-28 | Target: ZFY27 | UniProt: Q5T4F4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9102-28 | Target: ZFY27 | UniProt: Q5T4F4 | TargetFullName: Protrudin | Organisim: human | Apparent_Kd_M: 1.5E-11
Real
Aptamer SeqId: 9106-87 | Target: LYSM4 | UniProt: Q5XG99
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9106-87 | Target: LYSM4 | UniProt: Q5XG99 | TargetFullName: LysM and putative peptidoglycan-binding domain-containing protein 4 | Organisim: human | Apparent_Kd_M: 2.29579E-11
Real
Aptamer SeqId: 9107-59 | Target: ARM10 | UniProt: Q8N2F6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9107-59 | Target: ARM10 | UniProt: Q8N2F6 | TargetFullName: Armadillo repeat-containing protein 10 | Organisim: human | Apparent_Kd_M: 2.123994E-10
Real
Aptamer SeqId: 9108-48 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9108-48 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.609323E-13
Real
Aptamer SeqId: 9110-2 | Target: SYT17 | UniProt: Q9BSW7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9110-2 | Target: SYT17 | UniProt: Q9BSW7 | TargetFullName: Synaptotagmin-17 | Organisim: human | Apparent_Kd_M: 8.364912E-11
Real
Aptamer SeqId: 9111-40 | Target: JPH4 | UniProt: Q96JJ6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9111-40 | Target: JPH4 | UniProt: Q96JJ6 | TargetFullName: Junctophilin-4 | Organisim: human | Apparent_Kd_M: 1.793929E-10
Real
Aptamer SeqId: 9114-84 | Target: UROL1 | UniProt: Q5DID0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9114-84 | Target: UROL1 | UniProt: Q5DID0 | TargetFullName: Uromodulin-like 1 | Organisim: human | Apparent_Kd_M: 8.131073E-12
Real
Aptamer SeqId: 9115-78 | Target: ADEC1 | UniProt: O15204
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9115-78 | Target: ADEC1 | UniProt: O15204 | TargetFullName: ADAM DEC1 | Organisim: human | Apparent_Kd_M: 2.967875E-10
Real
Aptamer SeqId: 9116-28 | Target: HECA2 | UniProt: A8MVW5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9116-28 | Target: HECA2 | UniProt: A8MVW5 | TargetFullName: HEPACAM family member 2 | Organisim: human | Apparent_Kd_M: 1.38E-11
Real
Aptamer SeqId: 9117-4 | Target: IL-1F9 | UniProt: Q9NZH8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9117-4 | Target: IL-1F9 | UniProt: Q9NZH8 | TargetFullName: Interleukin-36 gamma | Organisim: human | Apparent_Kd_M: 3.52526E-11
Real
Aptamer SeqId: 9118-7 | Target: PSD2 | UniProt: Q9BQI7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9118-7 | Target: PSD2 | UniProt: Q9BQI7 | TargetFullName: PH and SEC7 domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 4.372099E-11
Real
Aptamer SeqId: 9121-28 | Target: FUT2 | UniProt: Q10981
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9121-28 | Target: FUT2 | UniProt: Q10981 | TargetFullName: Galactoside 2-alpha-L-fucosyltransferase 2 | Organisim: human | Apparent_Kd_M: 1.413621E-10
Real
Aptamer SeqId: 9122-8 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9122-8 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 4.603303E-11
Real
Aptamer SeqId: 9123-18 | Target: DOS | UniProt: Q8N350
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9123-18 | Target: DOS | UniProt: Q8N350 | TargetFullName: Protein Dos | Organisim: human | Apparent_Kd_M: 1.08496E-10
Real
Aptamer SeqId: 9125-23 | Target: MASP3 | UniProt: P48740
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9125-23 | Target: MASP3 | UniProt: P48740 | TargetFullName: Mannan-binding lectin serine protease 1 | Organisim: human | Apparent_Kd_M: 5.58E-11
Real
Aptamer SeqId: 9126-171 | Target: NT5D3 | UniProt: Q86UY8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9126-171 | Target: NT5D3 | UniProt: Q86UY8 | TargetFullName: 5'-nucleotidase domain-containing protein 3 | Organisim: human | Apparent_Kd_M: 9.567969E-11
Real
Aptamer SeqId: 9127-4 | Target: S26A5 | UniProt: P58743
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9127-4 | Target: S26A5 | UniProt: P58743 | TargetFullName: Prestin | Organisim: human | Apparent_Kd_M: 2.430013E-11
Real
Aptamer SeqId: 9128-34 | Target: FLRT3 | UniProt: Q9NZU0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9128-34 | Target: FLRT3 | UniProt: Q9NZU0 | TargetFullName: Leucine-rich repeat transmembrane protein FLRT3 | Organisim: human | Apparent_Kd_M: 5.03E-11
Real
Aptamer SeqId: 9168-31 | Target: Eotaxin-3 | UniProt: Q9Y258
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9168-31 | Target: Eotaxin-3 | UniProt: Q9Y258 | TargetFullName: C-C motif chemokine 26 | Organisim: human | Apparent_Kd_M: 2.34E-12
Real
Aptamer SeqId: 9170-24 | Target: IL-17 | UniProt: Q16552
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9170-24 | Target: IL-17 | UniProt: Q16552 | TargetFullName: Interleukin-17A | Organisim: human | Apparent_Kd_M: 1.0E-11
Real
Aptamer SeqId: 9171-11 | Target: CSRP3 | UniProt: P50461
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9171-11 | Target: CSRP3 | UniProt: P50461 | TargetFullName: Cysteine and glycine-rich protein 3 | Organisim: human | Apparent_Kd_M: 1.9E-11
Real
Aptamer SeqId: 9172-69 | Target: MMP-8 | UniProt: P22894
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9172-69 | Target: MMP-8 | UniProt: P22894 | TargetFullName: Neutrophil collagenase | Organisim: human | Apparent_Kd_M: 3.51E-12
Real
Aptamer SeqId: 9173-21 | Target: PGM1 | UniProt: P36871
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9173-21 | Target: PGM1 | UniProt: P36871 | TargetFullName: Phosphoglucomutase-1 | Organisim: human | Apparent_Kd_M: 1.68E-11
Real
Aptamer SeqId: 9175-48 | Target: DSCAM | UniProt: O60469
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9175-48 | Target: DSCAM | UniProt: O60469 | TargetFullName: Down syndrome cell adhesion molecule | Organisim: human | Apparent_Kd_M: 3.01E-12
Real
Aptamer SeqId: 9176-3 | Target: MUC1 | UniProt: P15941
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9176-3 | Target: MUC1 | UniProt: P15941 | TargetFullName: Mucin-1 | Organisim: human | Apparent_Kd_M: 6.28E-11
Real
Aptamer SeqId: 9177-6 | Target: FAM3B | UniProt: P58499
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9177-6 | Target: FAM3B | UniProt: P58499 | TargetFullName: Protein FAM3B | Organisim: human | Apparent_Kd_M: 1.11E-11
Real
Aptamer SeqId: 9178-30 | Target: NEUREGULIN-1 | UniProt: Q02297
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9178-30 | Target: NEUREGULIN-1 | UniProt: Q02297 | TargetFullName: Neuregulin-1 | Organisim: human | Apparent_Kd_M: 1.74E-12
Real
Aptamer SeqId: 9180-6 | Target: INGR2 | UniProt: P38484
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9180-6 | Target: INGR2 | UniProt: P38484 | TargetFullName: Interferon gamma receptor 2 | Organisim: human | Apparent_Kd_M: 9.7E-11
Real
Aptamer SeqId: 9182-3 | Target: sLRP1 | UniProt: Q07954
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9182-3 | Target: sLRP1 | UniProt: Q07954 | TargetFullName: Low-density lipoprotein receptor-related protein 1; soluble | Organisim: human | Apparent_Kd_M: 2.54E-11
Real
Aptamer SeqId: 9183-7 | Target: IFN-a/b R1 | UniProt: P17181
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9183-7 | Target: IFN-a/b R1 | UniProt: P17181 | TargetFullName: Interferon alpha/beta receptor 1 | Organisim: human | Apparent_Kd_M: 4.16E-11
Real
Aptamer SeqId: 9185-15 | Target: TFF1 | UniProt: P04155
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9185-15 | Target: TFF1 | UniProt: P04155 | TargetFullName: Trefoil factor 1 | Organisim: human | Apparent_Kd_M: 1.96E-12
Real
Aptamer SeqId: 9187-2 | Target: HMGN1 | UniProt: P05114
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9187-2 | Target: HMGN1 | UniProt: P05114 | TargetFullName: Non-histone chromosomal protein HMG-14 | Organisim: human | Apparent_Kd_M: 1.0E-11
Real
Aptamer SeqId: 9188-119 | Target: MIG | UniProt: Q07325
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9188-119 | Target: MIG | UniProt: Q07325 | TargetFullName: C-X-C motif chemokine 9 | Organisim: human | Apparent_Kd_M: 1.0E-11
Real
Aptamer SeqId: 9190-7 | Target: CD63 | UniProt: P08962
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9190-7 | Target: CD63 | UniProt: P08962 | TargetFullName: CD63 antigen | Organisim: human | Apparent_Kd_M: 1.44E-12
Real
Aptamer SeqId: 9191-8 | Target: Trefoil factor 2 | UniProt: Q03403
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9191-8 | Target: Trefoil factor 2 | UniProt: Q03403 | TargetFullName: Trefoil factor 2 | Organisim: human | Apparent_Kd_M: 9.4E-12
Real
Aptamer SeqId: 9196-8 | Target: Galectin-7 | UniProt: P47929
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9196-8 | Target: Galectin-7 | UniProt: P47929 | TargetFullName: Galectin-7 | Organisim: human | Apparent_Kd_M: 3.44E-11
Real
Aptamer SeqId: 9197-4 | Target: LEG9 | UniProt: O00182
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9197-4 | Target: LEG9 | UniProt: O00182 | TargetFullName: Galectin-9 | Organisim: human | Apparent_Kd_M: 1.04E-11
Real
Aptamer SeqId: 9199-6 | Target: UB2G2 | UniProt: P60604
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9199-6 | Target: UB2G2 | UniProt: P60604 | TargetFullName: Ubiquitin-conjugating enzyme E2 G2 | Organisim: human | Apparent_Kd_M: 1.82E-11
Real
Aptamer SeqId: 9201-13 | Target: Transgelin-2 | UniProt: P37802
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9201-13 | Target: Transgelin-2 | UniProt: P37802 | TargetFullName: Transgelin-2 | Organisim: human | Apparent_Kd_M: 8.69E-11
Real
Aptamer SeqId: 9202-309 | Target: ATPO | UniProt: P48047
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9202-309 | Target: ATPO | UniProt: P48047 | TargetFullName: ATP synthase subunit O; mitochondrial | Organisim: human | Apparent_Kd_M: 3.51E-13
Real
Aptamer SeqId: 9204-33 | Target: Corticotropin-lipotropin | UniProt: P01189
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9204-33 | Target: Corticotropin-lipotropin | UniProt: P01189 | TargetFullName: Pro-opiomelanocortin | Organisim: human | Apparent_Kd_M: 7.29E-12
Real
Aptamer SeqId: 9207-60 | Target: QORL1 | UniProt: O95825
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9207-60 | Target: QORL1 | UniProt: O95825 | TargetFullName: Quinone oxidoreductase-like protein 1 | Organisim: human | Apparent_Kd_M: 2.77E-11
Real
Aptamer SeqId: 9211-19 | Target: PEDF | UniProt: P36955
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9211-19 | Target: PEDF | UniProt: P36955 | TargetFullName: Pigment epithelium-derived factor | Organisim: human | Apparent_Kd_M: 1.71E-11
Real
Aptamer SeqId: 9212-22 | Target: CATF | UniProt: Q9UBX1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9212-22 | Target: CATF | UniProt: Q9UBX1 | TargetFullName: Cathepsin F | Organisim: human | Apparent_Kd_M: 1.4E-11
Real
Aptamer SeqId: 9213-24 | Target: FTCD | UniProt: O95954
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9213-24 | Target: FTCD | UniProt: O95954 | TargetFullName: Formimidoyltransferase-cyclodeaminase | Organisim: human | Apparent_Kd_M: 2.71E-12
Real
Aptamer SeqId: 9215-117 | Target: UBP25 | UniProt: Q9UHP3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9215-117 | Target: UBP25 | UniProt: Q9UHP3 | TargetFullName: Ubiquitin carboxyl-terminal hydrolase 25 | Organisim: human | Apparent_Kd_M: 6.69E-11
Real
Aptamer SeqId: 9216-100 | Target: PLXB2 | UniProt: O15031
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9216-100 | Target: PLXB2 | UniProt: O15031 | TargetFullName: Plexin-B2 | Organisim: human | Apparent_Kd_M: 3.62E-11
Real
Aptamer SeqId: 9219-70 | Target: NENF | UniProt: Q9UMX5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9219-70 | Target: NENF | UniProt: Q9UMX5 | TargetFullName: Neudesin | Organisim: human | Apparent_Kd_M: 3.465395E-11
Real
Aptamer SeqId: 9220-7 | Target: EPHB3 | UniProt: P54753
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9220-7 | Target: EPHB3 | UniProt: P54753 | TargetFullName: Ephrin type-B receptor 3 | Organisim: human | Apparent_Kd_M: 2.275568E-10
Real
Aptamer SeqId: 9221-6 | Target: IPIL1 | UniProt: Q6GPH6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9221-6 | Target: IPIL1 | UniProt: Q6GPH6 | TargetFullName: Inositol 1;4;5-trisphosphate receptor-interacting protein-like 1 | Organisim: human | Apparent_Kd_M: 1.750415E-11
Real
Aptamer SeqId: 9223-11 | Target: ARMET | UniProt: P55145
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9223-11 | Target: ARMET | UniProt: P55145 | TargetFullName: Mesencephalic astrocyte-derived neurotrophic factor | Organisim: human | Apparent_Kd_M: 1.182797E-11
Real
Aptamer SeqId: 9226-6 | Target: TMUB2 | UniProt: Q71RG4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9226-6 | Target: TMUB2 | UniProt: Q71RG4 | TargetFullName: Transmembrane and ubiquitin-like domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 2.951953E-11
Real
Aptamer SeqId: 9229-9 | Target: CTRL | UniProt: P40313
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9229-9 | Target: CTRL | UniProt: P40313 | TargetFullName: Chymotrypsin-like protease CTRL-1 | Organisim: human | Apparent_Kd_M: 5.143201E-11
Real
Aptamer SeqId: 9231-23 | Target: IMPA3 | UniProt: Q9NX62
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9231-23 | Target: IMPA3 | UniProt: Q9NX62 | TargetFullName: Inositol monophosphatase 3 | Organisim: human | Apparent_Kd_M: 2.930909E-11
Real
Aptamer SeqId: 9233-71 | Target: TFPI -2 | UniProt: P48307
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9233-71 | Target: TFPI -2 | UniProt: P48307 | TargetFullName: Tissue factor pathway inhibitor 2 | Organisim: human | Apparent_Kd_M: 7.476052E-11
Real
Aptamer SeqId: 9234-8 | Target: TWSG1 | UniProt: Q9GZX9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9234-8 | Target: TWSG1 | UniProt: Q9GZX9 | TargetFullName: Twisted gastrulation protein homolog 1 | Organisim: human | Apparent_Kd_M: 2.93101E-11
Real
Aptamer SeqId: 9235-3 | Target: PXDC1 | UniProt: Q8IUK5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9235-3 | Target: PXDC1 | UniProt: Q8IUK5 | TargetFullName: Plexin domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 5.68138E-11
Real
Aptamer SeqId: 9237-54 | Target: Lysosomal acid phosphatase
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9237-54 | Target: Lysosomal acid phosphatase | UniProt: P11117 | TargetFullName: Lysosomal acid phosphatase | Organisim: human | Apparent_Kd_M: 4.953519E-11
Real
Aptamer SeqId: 9241-40 | Target: SIRPG | UniProt: Q9P1W8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9241-40 | Target: SIRPG | UniProt: Q9P1W8 | TargetFullName: Signal-regulatory protein gamma | Organisim: human | Apparent_Kd_M: 1.063151E-10
Real
Aptamer SeqId: 9243-10 | Target: LYG1 | UniProt: Q8N1E2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9243-10 | Target: LYG1 | UniProt: Q8N1E2 | TargetFullName: Lysozyme g-like protein 1 | Organisim: human | Apparent_Kd_M: 4.033643E-11
Real
Aptamer SeqId: 9244-27 | Target: PPT1 | UniProt: P50897
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9244-27 | Target: PPT1 | UniProt: P50897 | TargetFullName: Palmitoyl-protein thioesterase 1 | Organisim: human | Apparent_Kd_M: 3.68873E-12
Real
Aptamer SeqId: 9246-1 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9246-1 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 4.518742E-11
Real
Aptamer SeqId: 9248-36 | Target: CS010 | UniProt: Q969H8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9248-36 | Target: CS010 | UniProt: Q969H8 | TargetFullName: Myeloid-derived growth factor | Organisim: human | Apparent_Kd_M: 5.762784E-10
Real
Aptamer SeqId: 9249-17 | Target: TMEM9 | UniProt: Q9P0T7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9249-17 | Target: TMEM9 | UniProt: Q9P0T7 | TargetFullName: Transmembrane protein 9 | Organisim: human | Apparent_Kd_M: 4.683144E-11
Real
Aptamer SeqId: 9251-28 | Target: MA2B2 | UniProt: Q9Y2E5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9251-28 | Target: MA2B2 | UniProt: Q9Y2E5 | TargetFullName: Epididymis-specific alpha-mannosidase | Organisim: human | Apparent_Kd_M: 7.272952E-12
Real
Aptamer SeqId: 9253-52 | Target: BGAT | UniProt: P16442
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9253-52 | Target: BGAT | UniProt: P16442 | TargetFullName: Histo-blood group ABO system transferase | Organisim: human | Apparent_Kd_M: 4.535182E-12
Real
Aptamer SeqId: 9254-18 | Target: FCERA | UniProt: P12319
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9254-18 | Target: FCERA | UniProt: P12319 | TargetFullName: High affinity immunoglobulin epsilon receptor subunit alpha | Organisim: human | Apparent_Kd_M: 2.160748E-11
Real
Aptamer SeqId: 9255-5 | Target: IL-17C | UniProt: Q9P0M4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9255-5 | Target: IL-17C | UniProt: Q9P0M4 | TargetFullName: Interleukin-17C | Organisim: human | Apparent_Kd_M: 3.03617E-12
Real
Aptamer SeqId: 9256-78 | Target: NPTX1 | UniProt: Q15818
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9256-78 | Target: NPTX1 | UniProt: Q15818 | TargetFullName: Neuronal pentraxin-1 | Organisim: human | Apparent_Kd_M: 1.520808E-11
Real
Aptamer SeqId: 9257-14 | Target: TACO1 | UniProt: Q9BSH4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9257-14 | Target: TACO1 | UniProt: Q9BSH4 | TargetFullName: Translational activator of cytochrome c oxidase 1 | Organisim: human | Apparent_Kd_M: 5.949225E-12
Real
Aptamer SeqId: 9258-14 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9258-14 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.243115E-10
Real
Aptamer SeqId: 9263-57 | Target: SIAE | UniProt: Q9HAT2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9263-57 | Target: SIAE | UniProt: Q9HAT2 | TargetFullName: Sialate O-acetylesterase | Organisim: human | Apparent_Kd_M: 3.954396E-11
Real
Aptamer SeqId: 9264-11 | Target: CATO | UniProt: P43234
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9264-11 | Target: CATO | UniProt: P43234 | TargetFullName: Cathepsin O | Organisim: human | Apparent_Kd_M: 5.162219E-11
Real
Aptamer SeqId: 9265-10 | Target: GLIP1 | UniProt: P48060
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9265-10 | Target: GLIP1 | UniProt: P48060 | TargetFullName: Glioma pathogenesis-related protein 1 | Organisim: human | Apparent_Kd_M: 1.759888E-11
Real
Aptamer SeqId: 9266-1 | Target: sTREM-1 | UniProt: Q9NP99
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9266-1 | Target: sTREM-1 | UniProt: Q9NP99 | TargetFullName: Triggering receptor expressed on myeloid cells 1 | Organisim: human | Apparent_Kd_M: 1.480024E-11
Real
Aptamer SeqId: 9267-2 | Target: CBPA4 | UniProt: Q9UI42
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9267-2 | Target: CBPA4 | UniProt: Q9UI42 | TargetFullName: Carboxypeptidase A4 | Organisim: human | Apparent_Kd_M: 3.032838E-12
Real
Aptamer SeqId: 9271-101 | Target: STIM1 | UniProt: Q13586
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9271-101 | Target: STIM1 | UniProt: Q13586 | TargetFullName: Stromal interaction molecule 1 | Organisim: human | Apparent_Kd_M: 6.564064E-11
Real
Aptamer SeqId: 9275-2 | Target: Siglec-5 | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9275-2 | Target: Siglec-5 | UniProt: | TargetFullName: Sialic acid-binding Ig-like lectin 5 | Organisim: human | Apparent_Kd_M: 5.39668E-12
Real
Aptamer SeqId: 9276-7 | Target: CBPA2 | UniProt: P48052
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9276-7 | Target: CBPA2 | UniProt: P48052 | TargetFullName: Carboxypeptidase A2 | Organisim: human | Apparent_Kd_M: 8.214512E-12
Real
Aptamer SeqId: 9278-9 | Target: SDF-1 | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9278-9 | Target: SDF-1 | UniProt: | TargetFullName: Stromal cell-derived factor 1 | Organisim: human | Apparent_Kd_M: 1.705199E-12
Real
Aptamer SeqId: 9281-50 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9281-50 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.07562E-10
Real
Aptamer SeqId: 9282-12 | Target: CRIS2 | UniProt: P16562
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9282-12 | Target: CRIS2 | UniProt: P16562 | TargetFullName: Cysteine-rich secretory protein 2 | Organisim: human | Apparent_Kd_M: 5.232475E-12
Real
Aptamer SeqId: 9283-8 | Target: CD44 | UniProt: P16070
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9283-8 | Target: CD44 | UniProt: P16070 | TargetFullName: CD44 antigen | Organisim: human | Apparent_Kd_M: 6.190248E-11
Real
Aptamer SeqId: 9287-6 | Target: SPRE | UniProt: P35270
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9287-6 | Target: SPRE | UniProt: P35270 | TargetFullName: Sepiapterin reductase | Organisim: human | Apparent_Kd_M: 1.80508E-10
Real
Aptamer SeqId: 9288-7 | Target: FKBP7 | UniProt: Q9Y680
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9288-7 | Target: FKBP7 | UniProt: Q9Y680 | TargetFullName: Peptidyl-prolyl cis-trans isomerase FKBP7 | Organisim: human | Apparent_Kd_M: 9.40715E-12
Real
Aptamer SeqId: 9290-8 | Target: RMD3 | UniProt: Q96TC7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9290-8 | Target: RMD3 | UniProt: Q96TC7 | TargetFullName: Regulator of microtubule dynamics protein 3 | Organisim: human | Apparent_Kd_M: 3.103174E-11
Real
Aptamer SeqId: 9294-45 | Target: MFAP2 | UniProt: P55001
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9294-45 | Target: MFAP2 | UniProt: P55001 | TargetFullName: Microfibrillar-associated protein 2 | Organisim: human | Apparent_Kd_M: 2.457214E-11
Real
Aptamer SeqId: 9296-15 | Target: PTPRD | UniProt: P23468
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9296-15 | Target: PTPRD | UniProt: P23468 | TargetFullName: Receptor-type tyrosine-protein phosphatase delta | Organisim: human | Apparent_Kd_M: 1.360495E-12
Real
Aptamer SeqId: 9297-12 | Target: B3GN8 | UniProt: Q7Z7M8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9297-12 | Target: B3GN8 | UniProt: Q7Z7M8 | TargetFullName: UDP-GlcNAc:betaGal beta-1;3-N-acetylglucosaminyltransferase 8 | Organisim: human | Apparent_Kd_M: 6.541243E-11
Real
Aptamer SeqId: 9302-90 | Target: G45IP | UniProt: Q8TAE8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9302-90 | Target: G45IP | UniProt: Q8TAE8 | TargetFullName: Growth arrest and DNA damage-inducible proteins-interacting protein 1 | Organisim: human | Apparent_Kd_M: 5.12E-11
Real
Aptamer SeqId: 9306-7 | Target: DB118 | UniProt: Q96PH6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9306-7 | Target: DB118 | UniProt: Q96PH6 | TargetFullName: Beta-defensin 118 | Organisim: human | Apparent_Kd_M: 4.236814E-11
Real
Aptamer SeqId: 9310-2 | Target: CD8B | UniProt: P10966
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9310-2 | Target: CD8B | UniProt: P10966 | TargetFullName: T-cell surface glycoprotein CD8 beta chain | Organisim: human | Apparent_Kd_M: 6.776121E-11
Real
Aptamer SeqId: 9312-8 | Target: AZGP1 | UniProt: P25311
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9312-8 | Target: AZGP1 | UniProt: P25311 | TargetFullName: Zinc-alpha-2-glycoprotein | Organisim: human | Apparent_Kd_M: 4.44937E-11
Real
Aptamer SeqId: 9313-27 | Target: CBLN1 | UniProt: P23435
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9313-27 | Target: CBLN1 | UniProt: P23435 | TargetFullName: Cerebellin-1 | Organisim: human | Apparent_Kd_M: 1.369743E-11
Real
Aptamer SeqId: 9314-9 | Target: PSG5 | UniProt: Q15238
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9314-9 | Target: PSG5 | UniProt: Q15238 | TargetFullName: Pregnancy-specific beta-1-glycoprotein 5 | Organisim: human | Apparent_Kd_M: 7.575096E-12
Real
Aptamer SeqId: 9315-16 | Target: MUL1 | UniProt: Q969V5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9315-16 | Target: MUL1 | UniProt: Q969V5 | TargetFullName: Mitochondrial ubiquitin ligase activator of NFKB 1 | Organisim: human | Apparent_Kd_M: 3.719568E-12
Real
Aptamer SeqId: 9316-67 | Target: WFDC1 | UniProt: Q9HC57
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9316-67 | Target: WFDC1 | UniProt: Q9HC57 | TargetFullName: WAP four-disulfide core domain protein 1 | Organisim: human | Apparent_Kd_M: 5.075056E-11
Real
Aptamer SeqId: 9317-4 | Target: LRC25 | UniProt: Q8N386
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9317-4 | Target: LRC25 | UniProt: Q8N386 | TargetFullName: Leucine-rich repeat-containing protein 25 | Organisim: human | Apparent_Kd_M: 4.381817E-11
Real
Aptamer SeqId: 9319-59 | Target: TMED4 | UniProt: Q7Z7H5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9319-59 | Target: TMED4 | UniProt: Q7Z7H5 | TargetFullName: Transmembrane emp24 domain-containing protein 4 | Organisim: human | Apparent_Kd_M: 1.73844E-12
Real
Aptamer SeqId: 9321-400 | Target: NMB | UniProt: P08949
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9321-400 | Target: NMB | UniProt: P08949 | TargetFullName: Neuromedin-B | Organisim: human | Apparent_Kd_M: 1.878266E-11
Real
Aptamer SeqId: 9322-15 | Target: RCN1 | UniProt: Q15293
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9322-15 | Target: RCN1 | UniProt: Q15293 | TargetFullName: Reticulocalbin-1 | Organisim: human | Apparent_Kd_M: 4.349429E-12
Real
Aptamer SeqId: 9326-33 | Target: ITI heavy chain H2 | UniProt: P19823
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9326-33 | Target: ITI heavy chain H2 | UniProt: P19823 | TargetFullName: Inter-alpha-trypsin inhibitor heavy chain H2 | Organisim: human | Apparent_Kd_M: 1.543716E-11
Real
Aptamer SeqId: 9327-3 | Target: LYPD1 | UniProt: Q8N2G4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9327-3 | Target: LYPD1 | UniProt: Q8N2G4 | TargetFullName: Ly6/PLAUR domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 1.758913E-10
Real
Aptamer SeqId: 9329-28 | Target: TRML1 | UniProt: Q86YW5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9329-28 | Target: TRML1 | UniProt: Q86YW5 | TargetFullName: Trem-like transcript 1 protein | Organisim: human | Apparent_Kd_M: 1.132413E-11
Real
Aptamer SeqId: 9332-6 | Target: DB136 | UniProt: Q30KP8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9332-6 | Target: DB136 | UniProt: Q30KP8 | TargetFullName: Beta-defensin 136 | Organisim: human | Apparent_Kd_M: 5.477111E-11
Real
Aptamer SeqId: 9333-59 | Target: ERP27 | UniProt: Q96DN0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9333-59 | Target: ERP27 | UniProt: Q96DN0 | TargetFullName: Endoplasmic reticulum resident protein 27 | Organisim: human | Apparent_Kd_M: 3.198817E-11
Real
Aptamer SeqId: 9335-28 | Target: PSG9 | UniProt: Q00887
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9335-28 | Target: PSG9 | UniProt: Q00887 | TargetFullName: Pregnancy-specific beta-1-glycoprotein 9 | Organisim: human | Apparent_Kd_M: 1.699024E-12
Real
Aptamer SeqId: 9337-43 | Target: TKN1 | UniProt: P20366
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9337-43 | Target: TKN1 | UniProt: P20366 | TargetFullName: Protachykinin-1 | Organisim: human | Apparent_Kd_M: 3.678823E-11
Real
Aptamer SeqId: 9338-2 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9338-2 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.233121E-12
Real
Aptamer SeqId: 9339-204 | Target: FKBP2 | UniProt: P26885
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9339-204 | Target: FKBP2 | UniProt: P26885 | TargetFullName: Peptidyl-prolyl cis-trans isomerase FKBP2 | Organisim: human | Apparent_Kd_M: 6.431814E-11
Real
Aptamer SeqId: 9340-17 | Target: FKB14 | UniProt: Q9NWM8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9340-17 | Target: FKB14 | UniProt: Q9NWM8 | TargetFullName: Peptidyl-prolyl cis-trans isomerase FKBP14 | Organisim: human | Apparent_Kd_M: 1.009916E-11
Real
Aptamer SeqId: 9341-1 | Target: PDGFD | UniProt: Q9GZP0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9341-1 | Target: PDGFD | UniProt: Q9GZP0 | TargetFullName: Platelet-derived growth factor D | Organisim: human | Apparent_Kd_M: 7.124924E-13
Real
Aptamer SeqId: 9343-16 | Target: IL-2 sRb | UniProt: P14784
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9343-16 | Target: IL-2 sRb | UniProt: P14784 | TargetFullName: Interleukin-2 receptor subunit beta | Organisim: human | Apparent_Kd_M: 2.238077E-12
Real
Aptamer SeqId: 9345-436 | Target: WFD13 | UniProt: Q8IUB5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9345-436 | Target: WFD13 | UniProt: Q8IUB5 | TargetFullName: WAP four-disulfide core domain protein 13 | Organisim: human | Apparent_Kd_M: 4.414798E-12
Real
Aptamer SeqId: 9347-13 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9347-13 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 8.005206E-12
Real
Aptamer SeqId: 9348-1 | Target: C1RL1 | UniProt: Q9NZP8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9348-1 | Target: C1RL1 | UniProt: Q9NZP8 | TargetFullName: Complement C1r subcomponent-like protein | Organisim: human | Apparent_Kd_M: 3.822779E-11
Real
Aptamer SeqId: 9350-3 | Target: FSTL4 | UniProt: Q6MZW2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9350-3 | Target: FSTL4 | UniProt: Q6MZW2 | TargetFullName: Follistatin-related protein 4 | Organisim: human | Apparent_Kd_M: 6.525048E-11
Real
Aptamer SeqId: 9353-8 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9353-8 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.325738E-11
Real
Aptamer SeqId: 9355-26 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9355-26 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 4.586252E-12
Real
Aptamer SeqId: 9357-4 | Target: CREG1 | UniProt: O75629
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9357-4 | Target: CREG1 | UniProt: O75629 | TargetFullName: Protein CREG1 | Organisim: human | Apparent_Kd_M: 2.245605E-11
Real
Aptamer SeqId: 9358-3 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9358-3 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.040479E-11
Real
Aptamer SeqId: 9359-9 | Target: EGFL9 | UniProt: Q6UY11
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9359-9 | Target: EGFL9 | UniProt: Q6UY11 | TargetFullName: Protein delta homolog 2 | Organisim: human | Apparent_Kd_M: 2.045348E-11
Real
Aptamer SeqId: 9360-33 | Target: EDIL3 | UniProt: O43854
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9360-33 | Target: EDIL3 | UniProt: O43854 | TargetFullName: EGF-like repeat and discoidin I-like domain-containing protein 3 | Organisim: human | Apparent_Kd_M: 3.29142E-12
Real
Aptamer SeqId: 9361-7 | Target: PCDC2 | UniProt: Q9Y5I4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9361-7 | Target: PCDC2 | UniProt: Q9Y5I4 | TargetFullName: Protocadherin alpha-C2 | Organisim: human | Apparent_Kd_M: 2.150466E-10
Real
Aptamer SeqId: 9362-11 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9362-11 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.252226E-11
Real
Aptamer SeqId: 9363-11 | Target: CX048 | UniProt: Q8WUE5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9363-11 | Target: CX048 | UniProt: Q8WUE5 | TargetFullName: Cancer/testis antigen 55 | Organisim: human | Apparent_Kd_M: 1.728021E-10
Real
Aptamer SeqId: 9365-91 | Target: EYS | UniProt: Q5T1H1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9365-91 | Target: EYS | UniProt: Q5T1H1 | TargetFullName: Protein eyes shut homolog | Organisim: human | Apparent_Kd_M: 2.813507E-10
Real
Aptamer SeqId: 9366-54 | Target: IL-21 sR | UniProt: Q9HBE5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9366-54 | Target: IL-21 sR | UniProt: Q9HBE5 | TargetFullName: Interleukin-21 receptor | Organisim: human | Apparent_Kd_M: 9.166879E-11
Real
Aptamer SeqId: 9368-64 | Target: LRTM1 | UniProt: Q9HBL6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9368-64 | Target: LRTM1 | UniProt: Q9HBL6 | TargetFullName: Leucine-rich repeat and transmembrane domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 1.997289E-11
Real
Aptamer SeqId: 9369-174 | Target: NGL1 | UniProt: Q9HCJ2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9369-174 | Target: NGL1 | UniProt: Q9HCJ2 | TargetFullName: Leucine-rich repeat-containing protein 4C | Organisim: human | Apparent_Kd_M: 1.350296E-11
Real
Aptamer SeqId: 9370-69 | Target: GGH | UniProt: Q92820
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9370-69 | Target: GGH | UniProt: Q92820 | TargetFullName: Gamma-glutamyl hydrolase | Organisim: human | Apparent_Kd_M: 1.05E-10
Real
Aptamer SeqId: 9372-157 | Target: MPZL2 | UniProt: O60487
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9372-157 | Target: MPZL2 | UniProt: O60487 | TargetFullName: Myelin protein zero-like protein 2 | Organisim: human | Apparent_Kd_M: 3.786995E-10
Real
Aptamer SeqId: 9373-405 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9373-405 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 8.846208E-12
Real
Aptamer SeqId: 9374-24 | Target: NNAT | UniProt: Q16517
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9374-24 | Target: NNAT | UniProt: Q16517 | TargetFullName: Neuronatin | Organisim: human | Apparent_Kd_M: 4.881379E-11
Real
Aptamer SeqId: 9377-25 | Target: SCF | UniProt: P21583
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9377-25 | Target: SCF | UniProt: P21583 | TargetFullName: Kit ligand | Organisim: human | Apparent_Kd_M: 1.219602E-10
Real
Aptamer SeqId: 9378-6 | Target: FBCD1 | UniProt: Q8N539
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9378-6 | Target: FBCD1 | UniProt: Q8N539 | TargetFullName: Fibrinogen C domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 9.644376E-12
Real
Aptamer SeqId: 9379-248 | Target: CX069 | UniProt: Q96HG1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9379-248 | Target: CX069 | UniProt: Q96HG1 | TargetFullName: Small integral membrane protein 10 | Organisim: human | Apparent_Kd_M: 3.230824E-11
Real
Aptamer SeqId: 9380-2 | Target: sPLA(2)-XIII | UniProt: Q9BX93
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9380-2 | Target: sPLA(2)-XIII | UniProt: Q9BX93 | TargetFullName: Group XIIB secretory phospholipase A2-like protein | Organisim: human | Apparent_Kd_M: 7.78E-12
Real
Aptamer SeqId: 9383-24 | Target: CH3L2 | UniProt: Q15782
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9383-24 | Target: CH3L2 | UniProt: Q15782 | TargetFullName: Chitinase-3-like protein 2 | Organisim: human | Apparent_Kd_M: 6.646729E-11
Real
Aptamer SeqId: 9384-17 | Target: Cathelicidin peptide | UniProt: P49913
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9384-17 | Target: Cathelicidin peptide | UniProt: P49913 | TargetFullName: Cathelicidin antimicrobial peptide | Organisim: human | Apparent_Kd_M: 1.28E-10
Real
Aptamer SeqId: 9385-4 | Target: GAA | UniProt: P10253
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9385-4 | Target: GAA | UniProt: P10253 | TargetFullName: Lysosomal alpha-glucosidase | Organisim: human | Apparent_Kd_M: 3.010004E-11
Real
Aptamer SeqId: 9386-42 | Target: TTC9B | UniProt: Q8N6N2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9386-42 | Target: TTC9B | UniProt: Q8N6N2 | TargetFullName: Tetratricopeptide repeat protein 9B | Organisim: human | Apparent_Kd_M: 6.669466E-12
Real
Aptamer SeqId: 9387-13 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9387-13 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 5.060672E-11
Real
Aptamer SeqId: 9388-18 | Target: MCEE | UniProt: Q96PE7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9388-18 | Target: MCEE | UniProt: Q96PE7 | TargetFullName: Methylmalonyl-CoA epimerase; mitochondrial | Organisim: human | Apparent_Kd_M: 2.632592E-12
Real
Aptamer SeqId: 9389-12 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9389-12 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.042654E-11
Real
Aptamer SeqId: 9391-60 | Target: PCSK1 | UniProt: Q9UHG2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9391-60 | Target: PCSK1 | UniProt: Q9UHG2 | TargetFullName: ProSAAS | Organisim: human | Apparent_Kd_M: 7.482995E-11
Real
Aptamer SeqId: 9392-43 | Target: MGT4A | UniProt: Q9UM21
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9392-43 | Target: MGT4A | UniProt: Q9UM21 | TargetFullName: Alpha-1;3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A | Organisim: human | Apparent_Kd_M: 1.781285E-10
Real
Aptamer SeqId: 9394-19 | Target: Aminopeptidase | UniProt: Q9Y646
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9394-19 | Target: Aminopeptidase | UniProt: Q9Y646 | TargetFullName: Carboxypeptidase Q | Organisim: human | Apparent_Kd_M: 9.981058E-12
Real
Aptamer SeqId: 9398-30 | Target: GALP | UniProt: Q9UBC7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9398-30 | Target: GALP | UniProt: Q9UBC7 | TargetFullName: Galanin-like peptide | Organisim: human | Apparent_Kd_M: 5.574856E-11
Real
Aptamer SeqId: 9401-57 | Target: CB089 | UniProt: Q86V40
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9401-57 | Target: CB089 | UniProt: Q86V40 | TargetFullName: Metalloprotease TIKI1 | Organisim: human | Apparent_Kd_M: 1.246193E-10
Real
Aptamer SeqId: 9402-18 | Target: DCBD1 | UniProt: Q8N8Z6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9402-18 | Target: DCBD1 | UniProt: Q8N8Z6 | TargetFullName: Discoidin; CUB and LCCL domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 8.054044E-11
Real
Aptamer SeqId: 9409-11 | Target: TRYB1 | UniProt: Q15661
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9409-11 | Target: TRYB1 | UniProt: Q15661 | TargetFullName: Tryptase beta-1 | Organisim: human | Apparent_Kd_M: 2.158659E-12
Real
Aptamer SeqId: 9412-52 | Target: Activin RIIB | UniProt: Q13705
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9412-52 | Target: Activin RIIB | UniProt: Q13705 | TargetFullName: Activin receptor type-2B | Organisim: human | Apparent_Kd_M: 3.431124E-12
Real
Aptamer SeqId: 9416-77 | Target: CBPM | UniProt: P14384
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9416-77 | Target: CBPM | UniProt: P14384 | TargetFullName: Carboxypeptidase M | Organisim: human | Apparent_Kd_M: 3.595236E-12
Real
Aptamer SeqId: 9439-454 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9439-454 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.435378E-11
Real
Aptamer SeqId: 9443-137 | Target: cathepsin K | UniProt: P43235
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9443-137 | Target: cathepsin K | UniProt: P43235 | TargetFullName: Cathepsin K | Organisim: human | Apparent_Kd_M: 1.394358E-11
Real
Aptamer SeqId: 9444-70 | Target: DGCR6 | UniProt: Q14129
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9444-70 | Target: DGCR6 | UniProt: Q14129 | TargetFullName: Protein DGCR6 | Organisim: human | Apparent_Kd_M: 4.428885E-11
Real
Aptamer SeqId: 9445-44 | Target: CS018 | UniProt: Q8NEA5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9445-44 | Target: CS018 | UniProt: Q8NEA5 | TargetFullName: Uncharacterized protein C19orf18 | Organisim: human | Apparent_Kd_M: 2.013016E-11
Real
Aptamer SeqId: 9449-150 | Target: C4b-binding protein alpha chain
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9449-150 | Target: C4b-binding protein alpha chain | UniProt: P04003 | TargetFullName: C4b-binding protein alpha chain | Organisim: human | Apparent_Kd_M: 8.775205E-10
Real
Aptamer SeqId: 9450-18 | Target: CDKA1 | UniProt: O14519
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9450-18 | Target: CDKA1 | UniProt: O14519 | TargetFullName: Cyclin-dependent kinase 2-associated protein 1 | Organisim: human | Apparent_Kd_M: 6.738343E-12
Real
Aptamer SeqId: 9451-20 | Target: Uromodulin | UniProt: P07911
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9451-20 | Target: Uromodulin | UniProt: P07911 | TargetFullName: Uromodulin | Organisim: human | Apparent_Kd_M: 6.882476E-11
Real
Aptamer SeqId: 9453-12 | Target: VEGF-B | UniProt: P49765
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9453-12 | Target: VEGF-B | UniProt: P49765 | TargetFullName: Vascular endothelial growth factor B | Organisim: human | Apparent_Kd_M: 1.033138E-11
Real
Aptamer SeqId: 9457-3 | Target: CAV2 | UniProt: P51636
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9457-3 | Target: CAV2 | UniProt: P51636 | TargetFullName: Caveolin-2 | Organisim: human | Apparent_Kd_M: 4.065596E-11
Real
Aptamer SeqId: 9459-7 | Target: Fas; soluble | UniProt: P25445
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9459-7 | Target: Fas; soluble | UniProt: P25445 | TargetFullName: Tumor necrosis factor receptor superfamily member 6 | Organisim: human | Apparent_Kd_M: 1.026872E-11
Real
Aptamer SeqId: 9463-26 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9463-26 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.686686E-12
Real
Aptamer SeqId: 9467-24 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9467-24 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.074336E-11
Real
Aptamer SeqId: 9468-8 | Target: Lectin; mannose-binding 2 | UniProt: Q12907
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9468-8 | Target: Lectin; mannose-binding 2 | UniProt: Q12907 | TargetFullName: Vesicular integral-membrane protein VIP36 | Organisim: human | Apparent_Kd_M: 2.179075E-12
Real
Aptamer SeqId: 9470-15 | Target: MET24 | UniProt: Q5JXM2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9470-15 | Target: MET24 | UniProt: Q5JXM2 | TargetFullName: Methyltransferase-like protein 24 | Organisim: human | Apparent_Kd_M: 2.292963E-11
Real
Aptamer SeqId: 9474-22 | Target: ASGR2 | UniProt: P07307
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9474-22 | Target: ASGR2 | UniProt: P07307 | TargetFullName: Asialoglycoprotein receptor 2 | Organisim: human | Apparent_Kd_M: 7.531957E-11
Real
Aptamer SeqId: 9475-22 | Target: GPX5 | UniProt: O75715
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9475-22 | Target: GPX5 | UniProt: O75715 | TargetFullName: Epididymal secretory glutathione peroxidase | Organisim: human | Apparent_Kd_M: 2.102851E-10
Real
Aptamer SeqId: 9478-69 | Target: KPRA | UniProt: Q14558
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9478-69 | Target: KPRA | UniProt: Q14558 | TargetFullName: Phosphoribosyl pyrophosphate synthase-associated protein 1 | Organisim: human | Apparent_Kd_M: 4.190513E-11
Real
Aptamer SeqId: 9482-110 | Target: NUDT9 | UniProt: Q9BW91
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9482-110 | Target: NUDT9 | UniProt: Q9BW91 | TargetFullName: ADP-ribose pyrophosphatase; mitochondrial | Organisim: human | Apparent_Kd_M: 1.278504E-12
Real
Aptamer SeqId: 9484-75 | Target: Desmoglein-2 | UniProt: Q14126
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9484-75 | Target: Desmoglein-2 | UniProt: Q14126 | TargetFullName: Desmoglein-2 | Organisim: human | Apparent_Kd_M: 5.692999E-11
Real
Aptamer SeqId: 9486-13 | Target: DB125 | UniProt: Q8N687
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9486-13 | Target: DB125 | UniProt: Q8N687 | TargetFullName: Beta-defensin 125 | Organisim: human | Apparent_Kd_M: 7.180709E-11
Real
Aptamer SeqId: 9487-60 | Target: Growth hormone-releasing factor
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9487-60 | Target: Growth hormone-releasing factor | UniProt: P01286 | TargetFullName: Somatoliberin | Organisim: human | Apparent_Kd_M: 3.979898E-11
Real
Aptamer SeqId: 9490-3 | Target: CD032 | UniProt: Q8N8J7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9490-3 | Target: CD032 | UniProt: Q8N8J7 | TargetFullName: Uncharacterized protein C4orf32 | Organisim: human | Apparent_Kd_M: 2.964129E-11
Real
Aptamer SeqId: 9491-13 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9491-13 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 6.000729E-11
Real
Aptamer SeqId: 9492-5 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9492-5 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.40634E-11
Real
Aptamer SeqId: 9493-56 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9493-56 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.067572E-10
Real
Aptamer SeqId: 9495-10 | Target: VCC1 | UniProt: Q6UXB2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9495-10 | Target: VCC1 | UniProt: Q6UXB2 | TargetFullName: C-X-C motif chemokine 17 | Organisim: human | Apparent_Kd_M: 4.154463E-10
Real
Aptamer SeqId: 9497-3 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9497-3 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 5.160125E-12
Real
Aptamer SeqId: 9500-5 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9500-5 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.473797E-11
Real
Aptamer SeqId: 9503-1 | Target: NMS | UniProt: Q5H8A3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9503-1 | Target: NMS | UniProt: Q5H8A3 | TargetFullName: Neuromedin-S | Organisim: human | Apparent_Kd_M: 2.930654E-11
Real
Aptamer SeqId: 9504-19 | Target: RB27A | UniProt: P51159
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9504-19 | Target: RB27A | UniProt: P51159 | TargetFullName: Ras-related protein Rab-27A | Organisim: human | Apparent_Kd_M: 1.873664E-10
Real
Aptamer SeqId: 9506-10 | Target: Apo L1 | UniProt: O14791
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9506-10 | Target: Apo L1 | UniProt: O14791 | TargetFullName: Apolipoprotein L1 | Organisim: human | Apparent_Kd_M: 3.526054E-12
Real
Aptamer SeqId: 9508-104 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9508-104 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.658566E-12
Real
Aptamer SeqId: 9509-4 | Target: TM38B | UniProt: Q9NVV0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9509-4 | Target: TM38B | UniProt: Q9NVV0 | TargetFullName: Trimeric intracellular cation channel type B | Organisim: human | Apparent_Kd_M: 2.600566E-10
Real
Aptamer SeqId: 9511-61 | Target: NXPH2 | UniProt: O95156
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9511-61 | Target: NXPH2 | UniProt: O95156 | TargetFullName: Neurexophilin-2 | Organisim: human | Apparent_Kd_M: 2.435817E-11
Real
Aptamer SeqId: 9512-24 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9512-24 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.395444E-11
Real
Aptamer SeqId: 9513-9 | Target: FGF22 | UniProt: Q9HCT0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9513-9 | Target: FGF22 | UniProt: Q9HCT0 | TargetFullName: Fibroblast growth factor 22 | Organisim: human | Apparent_Kd_M: 1.433623E-10
Real
Aptamer SeqId: 9518-95 | Target: PLA1A | UniProt: Q53H76
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9518-95 | Target: PLA1A | UniProt: Q53H76 | TargetFullName: Phospholipase A1 member A | Organisim: human | Apparent_Kd_M: 3.218665E-10
Real
Aptamer SeqId: 9522-3 | Target: AIF | UniProt: O95831
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9522-3 | Target: AIF | UniProt: O95831 | TargetFullName: Apoptosis-inducing factor 1; mitochondrial | Organisim: human | Apparent_Kd_M: 6.472734E-11
Real
Aptamer SeqId: 9523-34 | Target: ITM2C | UniProt: Q9NQX7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9523-34 | Target: ITM2C | UniProt: Q9NQX7 | TargetFullName: Integral membrane protein 2C | Organisim: human | Apparent_Kd_M: 1.068517E-10
Real
Aptamer SeqId: 9524-46 | Target: S31D4 | UniProt: Q6ZUB0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9524-46 | Target: S31D4 | UniProt: Q6ZUB0 | TargetFullName: Putative spermatogenesis-associated protein 31D4 | Organisim: human | Apparent_Kd_M: 1.405188E-10
Real
Aptamer SeqId: 9525-1 | Target: PTK7 | UniProt: Q13308
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9525-1 | Target: PTK7 | UniProt: Q13308 | TargetFullName: Inactive tyrosine-protein kinase 7 | Organisim: human | Apparent_Kd_M: 1.136495E-10
Real
Aptamer SeqId: 9526-3 | Target: COLL1 | UniProt: A2RUU4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9526-3 | Target: COLL1 | UniProt: A2RUU4 | TargetFullName: Colipase-like protein 1 | Organisim: human | Apparent_Kd_M: 6.17041E-11
Real
Aptamer SeqId: 9530-6 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9530-6 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.615199E-12
Real
Aptamer SeqId: 9531-24 | Target: LST1 | UniProt: O00453
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9531-24 | Target: LST1 | UniProt: O00453 | TargetFullName: Leukocyte-specific transcript 1 protein | Organisim: human | Apparent_Kd_M: 1.033033E-11
Real
Aptamer SeqId: 9532-5 | Target: WBP1L | UniProt: Q9NX94
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9532-5 | Target: WBP1L | UniProt: Q9NX94 | TargetFullName: WW domain binding protein 1-like | Organisim: human | Apparent_Kd_M: 5.892026E-12
Real
Aptamer SeqId: 9535-14 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9535-14 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 3.375149E-10
Real
Aptamer SeqId: 9536-16 | Target: EP3A | UniProt: Q14507
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9536-16 | Target: EP3A | UniProt: Q14507 | TargetFullName: Epididymal secretory protein E3-alpha | Organisim: human | Apparent_Kd_M: 7.326717E-11
Real
Aptamer SeqId: 9539-25 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9539-25 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 8.366936E-11
Real
Aptamer SeqId: 9541-15 | Target: B3GT1 | UniProt: Q9Y5Z6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9541-15 | Target: B3GT1 | UniProt: Q9Y5Z6 | TargetFullName: Beta-1;3-galactosyltransferase 1 | Organisim: human | Apparent_Kd_M: 6.742607E-11
Real
Aptamer SeqId: 9543-131 | Target: COG8 | UniProt: Q96MW5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9543-131 | Target: COG8 | UniProt: Q96MW5 | TargetFullName: Conserved oligomeric Golgi complex subunit 8 | Organisim: human | Apparent_Kd_M: 7.740219E-12
Real
Aptamer SeqId: 9544-24 | Target: CG069 | UniProt: Q9H7B7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9544-24 | Target: CG069 | UniProt: Q9H7B7 | TargetFullName: Uncharacterized protein C7orf69 | Organisim: human | Apparent_Kd_M: 1.077323E-10
Real
Aptamer SeqId: 9545-156 | Target: Granzyme K | UniProt: P49863
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9545-156 | Target: Granzyme K | UniProt: P49863 | TargetFullName: Granzyme K | Organisim: human | Apparent_Kd_M: 8.85015E-11
Real
Aptamer SeqId: 9547-29 | Target: EMID1 | UniProt: Q96A84
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9547-29 | Target: EMID1 | UniProt: Q96A84 | TargetFullName: EMI domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 1.103009E-11
Real
Aptamer SeqId: 9550-153 | Target: TTC17 | UniProt: Q96AE7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9550-153 | Target: TTC17 | UniProt: Q96AE7 | TargetFullName: Tetratricopeptide repeat protein 17 | Organisim: human | Apparent_Kd_M: 1.16024E-10
Real
Aptamer SeqId: 9557-5 | Target: MANS1 | UniProt: Q9H8J5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9557-5 | Target: MANS1 | UniProt: Q9H8J5 | TargetFullName: MANSC domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 4.111841E-12
Real
Aptamer SeqId: 9561-21 | Target: CSPG2 | UniProt: P13611
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9561-21 | Target: CSPG2 | UniProt: P13611 | TargetFullName: Versican core protein | Organisim: human | Apparent_Kd_M: 9.765808E-12
Real
Aptamer SeqId: 9565-6 | Target: PAWR | UniProt: Q96IZ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9565-6 | Target: PAWR | UniProt: Q96IZ0 | TargetFullName: PRKC apoptosis WT1 regulator protein | Organisim: human | Apparent_Kd_M: 6.358591E-11
Real
Aptamer SeqId: 9566-103 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9566-103 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.876763E-11
Real
Aptamer SeqId: 9568-289 | Target: FCAMR | UniProt: Q8WWV6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9568-289 | Target: FCAMR | UniProt: Q8WWV6 | TargetFullName: High affinity immunoglobulin alpha and immunoglobulin mu Fc receptor | Organisim: human | Apparent_Kd_M: 2.666147E-11
Real
Aptamer SeqId: 9573-108 | Target: TXD11 | UniProt: Q6PKC3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9573-108 | Target: TXD11 | UniProt: Q6PKC3 | TargetFullName: Thioredoxin domain-containing protein 11 | Organisim: human | Apparent_Kd_M: 8.783749E-12
Real
Aptamer SeqId: 9574-11 | Target: BIN1 | UniProt: O00499
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9574-11 | Target: BIN1 | UniProt: O00499 | TargetFullName: Myc box-dependent-interacting protein 1 | Organisim: human | Apparent_Kd_M: 5.17945E-12
Real
Aptamer SeqId: 9576-58 | Target: MNX1 | UniProt: P50219
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9576-58 | Target: MNX1 | UniProt: P50219 | TargetFullName: Motor neuron and pancreas homeobox protein 1 | Organisim: human | Apparent_Kd_M: 1.96112E-11
Real
Aptamer SeqId: 9577-26 | Target: SYT2 | UniProt: Q8N9I0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9577-26 | Target: SYT2 | UniProt: Q8N9I0 | TargetFullName: Synaptotagmin-2 | Organisim: human | Apparent_Kd_M: 2.121199E-12
Real
Aptamer SeqId: 9578-263 | Target: MANS4 | UniProt: A6NHS7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9578-263 | Target: MANS4 | UniProt: A6NHS7 | TargetFullName: MANSC domain-containing protein 4 | Organisim: human | Apparent_Kd_M: 3.246052E-12
Real
Aptamer SeqId: 9579-59 | Target: TMG4 | UniProt: Q9BZD6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9579-59 | Target: TMG4 | UniProt: Q9BZD6 | TargetFullName: Transmembrane gamma-carboxyglutamic acid protein 4 | Organisim: human | Apparent_Kd_M: 3.29337E-11
Real
Aptamer SeqId: 9580-5 | Target: Laminin gamma-2 | UniProt: Q13753
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9580-5 | Target: Laminin gamma-2 | UniProt: Q13753 | TargetFullName: Laminin subunit gamma-2 | Organisim: human | Apparent_Kd_M: 5.166967E-11
Real
Aptamer SeqId: 9581-4 | Target: PRP6 | UniProt: O94906
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9581-4 | Target: PRP6 | UniProt: O94906 | TargetFullName: Pre-mRNA-processing factor 6 | Organisim: human | Apparent_Kd_M: 8.929032E-12
Real
Aptamer SeqId: 9582-93 | Target: SUSD1 | UniProt: Q6UWL2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9582-93 | Target: SUSD1 | UniProt: Q6UWL2 | TargetFullName: Sushi domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 3.195472E-12
Real
Aptamer SeqId: 9583-17 | Target: RNF24 | UniProt: Q9Y225
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9583-17 | Target: RNF24 | UniProt: Q9Y225 | TargetFullName: RING finger protein 24 | Organisim: human | Apparent_Kd_M: 7.696511E-11
Real
Aptamer SeqId: 9584-105 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9584-105 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.261278E-11
Real
Aptamer SeqId: 9585-80 | Target: ACAM | UniProt: Q9H6B4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9585-80 | Target: ACAM | UniProt: Q9H6B4 | TargetFullName: CXADR-like membrane protein | Organisim: human | Apparent_Kd_M: 2.815404E-11
Real
Aptamer SeqId: 9590-10 | Target: COX7R | UniProt: O14548
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9590-10 | Target: COX7R | UniProt: O14548 | TargetFullName: Cytochrome c oxidase subunit 7A-related protein; mitochondrial | Organisim: human | Apparent_Kd_M: 2.293517E-11
Real
Aptamer SeqId: 9594-30 | Target: ZNT5 | UniProt: Q8TAD4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9594-30 | Target: ZNT5 | UniProt: Q8TAD4 | TargetFullName: Zinc transporter 5 | Organisim: human | Apparent_Kd_M: 1.654355E-10
Real
Aptamer SeqId: 9595-11 | Target: B4GT2 | UniProt: O60909
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9595-11 | Target: B4GT2 | UniProt: O60909 | TargetFullName: Beta-1;4-galactosyltransferase 2 | Organisim: human | Apparent_Kd_M: 9.425846E-12
Real
Aptamer SeqId: 9598-23 | Target: CSMD1 | UniProt: Q96PZ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9598-23 | Target: CSMD1 | UniProt: Q96PZ7 | TargetFullName: CUB and sushi domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 3.198582E-12
Real
Aptamer SeqId: 9599-6 | Target: PIANP | UniProt: Q8IYJ0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9599-6 | Target: PIANP | UniProt: Q8IYJ0 | TargetFullName: PILR alpha-associated neural protein | Organisim: human | Apparent_Kd_M: 2.562663E-12
Real
Aptamer SeqId: 9600-55 | Target: THS7A | UniProt: Q9UPZ6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9600-55 | Target: THS7A | UniProt: Q9UPZ6 | TargetFullName: Thrombospondin type-1 domain-containing protein 7A | Organisim: human | Apparent_Kd_M: 5.305308E-11
Real
Aptamer SeqId: 9606-4 | Target: P210L | UniProt: Q5VU65
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9606-4 | Target: P210L | UniProt: Q5VU65 | TargetFullName: Nuclear pore membrane glycoprotein 210-like | Organisim: human | Apparent_Kd_M: 1.041356E-11
Real
Aptamer SeqId: 9607-39 | Target: CD040 | UniProt: Q6MZM9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9607-39 | Target: CD040 | UniProt: Q6MZM9 | TargetFullName: Proline-rich protein 27 | Organisim: human | Apparent_Kd_M: 4.033716E-11
Real
Aptamer SeqId: 9609-25 | Target: ZN275 | UniProt: Q9NSD4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9609-25 | Target: ZN275 | UniProt: Q9NSD4 | TargetFullName: Zinc finger protein 275 | Organisim: human | Apparent_Kd_M: 8.643724E-11
Real
Aptamer SeqId: 9613-16 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9613-16 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 7.315692E-11
Real
Aptamer SeqId: 9638-2 | Target: TIGIT | UniProt: Q495A1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9638-2 | Target: TIGIT | UniProt: Q495A1 | TargetFullName: T-cell immunoreceptor with Ig and ITIM domains | Organisim: human | Apparent_Kd_M: 1.75E-11
Real
Aptamer SeqId: 9713-67 | Target: PGFRL | UniProt: Q15198
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9713-67 | Target: PGFRL | UniProt: Q15198 | TargetFullName: Platelet-derived growth factor receptor-like protein | Organisim: human | Apparent_Kd_M: 2.547737E-11
Real
Aptamer SeqId: 9715-15 | Target: IGSF3 | UniProt: O75054
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9715-15 | Target: IGSF3 | UniProt: O75054 | TargetFullName: Immunoglobulin superfamily member 3 | Organisim: human | Apparent_Kd_M: 1.155386E-11
Real
Aptamer SeqId: 9719-145 | Target: MMP-16 | UniProt: P51512
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9719-145 | Target: MMP-16 | UniProt: P51512 | TargetFullName: Matrix metalloproteinase-16 | Organisim: human | Apparent_Kd_M: 2.141334E-12
Real
Aptamer SeqId: 9723-105 | Target: EMILIN-3 | UniProt: Q9H8L6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9723-105 | Target: EMILIN-3 | UniProt: Q9H8L6 | TargetFullName: Multimerin-2 | Organisim: human | Apparent_Kd_M: 8.330176E-11
Real
Aptamer SeqId: 9728-4 | Target: CIP1 | UniProt: Q9NPC3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9728-4 | Target: CIP1 | UniProt: Q9NPC3 | TargetFullName: E3 ubiquitin-protein ligase CCNB1IP1 | Organisim: human | Apparent_Kd_M: 4.610692E-12
Real
Aptamer SeqId: 9730-22 | Target: GHDC | UniProt: Q8N2G8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9730-22 | Target: GHDC | UniProt: Q8N2G8 | TargetFullName: GH3 domain-containing protein | Organisim: human | Apparent_Kd_M: 3.473794E-10
Real
Aptamer SeqId: 9735-44 | Target: TACT | UniProt: P40200
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9735-44 | Target: TACT | UniProt: P40200 | TargetFullName: T-cell surface protein tactile | Organisim: human | Apparent_Kd_M: 7.635263E-11
Real
Aptamer SeqId: 9738-7 | Target: FAF2 | UniProt: Q96CS3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9738-7 | Target: FAF2 | UniProt: Q96CS3 | TargetFullName: FAS-associated factor 2 | Organisim: human | Apparent_Kd_M: 1.102649E-12
Real
Aptamer SeqId: 9739-4 | Target: MSH2 | UniProt: P43246
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9739-4 | Target: MSH2 | UniProt: P43246 | TargetFullName: DNA mismatch repair protein Msh2 | Organisim: human | Apparent_Kd_M: 1.733793E-11
Real
Aptamer SeqId: 9742-59 | Target: BAT1 | UniProt: Q13838
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9742-59 | Target: BAT1 | UniProt: Q13838 | TargetFullName: Spliceosome RNA helicase DDX39B | Organisim: human | Apparent_Kd_M: 3.99148E-12
Real
Aptamer SeqId: 9744-139 | Target: DNJA4 | UniProt: Q8WW22
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9744-139 | Target: DNJA4 | UniProt: Q8WW22 | TargetFullName: DnaJ homolog subfamily A member 4 | Organisim: human | Apparent_Kd_M: 8.646424E-12
Real
Aptamer SeqId: 9745-20 | Target: IF4E2 | UniProt: O60573
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9745-20 | Target: IF4E2 | UniProt: O60573 | TargetFullName: Eukaryotic translation initiation factor 4E type 2 | Organisim: human | Apparent_Kd_M: 1.836128E-11
Real
Aptamer SeqId: 9747-48 | Target: MARK3 | UniProt: P27448
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9747-48 | Target: MARK3 | UniProt: P27448 | TargetFullName: MAP/microtubule affinity-regulating kinase 3 | Organisim: human | Apparent_Kd_M: 2.044785E-10
Real
Aptamer SeqId: 9748-31 | Target: GSTM3-3 | UniProt: P21266
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9748-31 | Target: GSTM3-3 | UniProt: P21266 | TargetFullName: Glutathione S-transferase Mu 3 | Organisim: human | Apparent_Kd_M: 1.161925E-11
Real
Aptamer SeqId: 9751-72 | Target: NSEP1 | UniProt: P67809
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9751-72 | Target: NSEP1 | UniProt: P67809 | TargetFullName: Nuclease-sensitive element-binding protein 1 | Organisim: human | Apparent_Kd_M: 2.227368E-11
Real
Aptamer SeqId: 9753-17 | Target: Ezrin | UniProt: P15311
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9753-17 | Target: Ezrin | UniProt: P15311 | TargetFullName: Ezrin | Organisim: human | Apparent_Kd_M: 8.719149E-12
Real
Aptamer SeqId: 9754-33 | Target: Quinone reductase 2 | UniProt: P16083
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9754-33 | Target: Quinone reductase 2 | UniProt: P16083 | TargetFullName: Ribosyldihydronicotinamide dehydrogenase quinone | Organisim: human | Apparent_Kd_M: 6.841689E-11
Real
Aptamer SeqId: 9757-29 | Target: ENAH | UniProt: Q8N8S7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9757-29 | Target: ENAH | UniProt: Q8N8S7 | TargetFullName: Protein enabled homolog | Organisim: human | Apparent_Kd_M: 1.544523E-11
Real
Aptamer SeqId: 9758-17 | Target: RS4X | UniProt: P62701
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9758-17 | Target: RS4X | UniProt: P62701 | TargetFullName: 40S ribosomal protein S4; X isoform | Organisim: human | Apparent_Kd_M: 1.179148E-10
Real
Aptamer SeqId: 9759-13 | Target: INDO | UniProt: P14902
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9759-13 | Target: INDO | UniProt: P14902 | TargetFullName: Indoleamine 2;3-dioxygenase 1 | Organisim: human | Apparent_Kd_M: 1.269456E-11
Real
Aptamer SeqId: 9762-14 | Target: VASP | UniProt: P50552
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9762-14 | Target: VASP | UniProt: P50552 | TargetFullName: Vasodilator-stimulated phosphoprotein | Organisim: human | Apparent_Kd_M: 6.433772E-12
Real
Aptamer SeqId: 9764-79 | Target: HNRPF | UniProt: P52597
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9764-79 | Target: HNRPF | UniProt: P52597 | TargetFullName: Heterogeneous nuclear ribonucleoprotein F | Organisim: human | Apparent_Kd_M: 1.533539E-11
Real
Aptamer SeqId: 9765-4 | Target: NDE1 | UniProt: Q9NXR1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9765-4 | Target: NDE1 | UniProt: Q9NXR1 | TargetFullName: Nuclear distribution protein nudE homolog 1 | Organisim: human | Apparent_Kd_M: 1.070902E-10
Real
Aptamer SeqId: 9767-22 | Target: RIPP1 | UniProt: Q0D2K3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9767-22 | Target: RIPP1 | UniProt: Q0D2K3 | TargetFullName: Protein ripply1 | Organisim: human | Apparent_Kd_M: 1.351735E-10
Real
Aptamer SeqId: 9769-48 | Target: DNER | UniProt: Q8NFT8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9769-48 | Target: DNER | UniProt: Q8NFT8 | TargetFullName: Delta and Notch-like epidermal growth factor-related receptor | Organisim: human | Apparent_Kd_M: 1.223573E-10
Real
Aptamer SeqId: 9772-153 | Target: NLGN2 | UniProt: Q8NFZ4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9772-153 | Target: NLGN2 | UniProt: Q8NFZ4 | TargetFullName: Neuroligin-2 | Organisim: human | Apparent_Kd_M: 4.096905E-12
Real
Aptamer SeqId: 9773-15 | Target: RN149 | UniProt: Q8NC42
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9773-15 | Target: RN149 | UniProt: Q8NC42 | TargetFullName: E3 ubiquitin-protein ligase RNF149 | Organisim: human | Apparent_Kd_M: 2.983498E-10
Real
Aptamer SeqId: 9774-59 | Target: RN150 | UniProt: Q9ULK6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9774-59 | Target: RN150 | UniProt: Q9ULK6 | TargetFullName: RING finger protein 150 | Organisim: human | Apparent_Kd_M: 3.016095E-11
Real
Aptamer SeqId: 9778-45 | Target: TM52B | UniProt: Q4KMG9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9778-45 | Target: TM52B | UniProt: Q4KMG9 | TargetFullName: Transmembrane protein 52B | Organisim: human | Apparent_Kd_M: 2.304784E-10
Real
Aptamer SeqId: 9779-63 | Target: HERP2 | UniProt: Q9BSE4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9779-63 | Target: HERP2 | UniProt: Q9BSE4 | TargetFullName: Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 2 protein | Organisim: human | Apparent_Kd_M: 1.879274E-10
Real
Aptamer SeqId: 9783-75 | Target: DJC11 | UniProt: Q9NVH1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9783-75 | Target: DJC11 | UniProt: Q9NVH1 | TargetFullName: DnaJ homolog subfamily C member 11 | Organisim: human | Apparent_Kd_M: 1.383299E-11
Real
Aptamer SeqId: 9786-310 | Target: IEX1 | UniProt: P46695
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9786-310 | Target: IEX1 | UniProt: P46695 | TargetFullName: Radiation-inducible immediate-early gene IEX-1 | Organisim: human | Apparent_Kd_M: 8.958664E-11
Real
Aptamer SeqId: 9789-52 | Target: Nesprin-2 | UniProt: Q8WXH0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9789-52 | Target: Nesprin-2 | UniProt: Q8WXH0 | TargetFullName: Nesprin-2 | Organisim: human | Apparent_Kd_M: 1.444874E-11
Real
Aptamer SeqId: 9790-28 | Target: BR serine/threonine kinase 2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9790-28 | Target: BR serine/threonine kinase 2 | UniProt: Q8IWQ3 | TargetFullName: Serine/threonine-protein kinase BRSK2 | Organisim: human | Apparent_Kd_M: 1.536622E-11
Real
Aptamer SeqId: 9793-145 | Target: IGDC4 | UniProt: Q8TDY8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9793-145 | Target: IGDC4 | UniProt: Q8TDY8 | TargetFullName: Immunoglobulin superfamily DCC subclass member 4 | Organisim: human | Apparent_Kd_M: 9.339202E-12
Real
Aptamer SeqId: 9794-17 | Target: ADCK4 | UniProt: Q96D53
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9794-17 | Target: ADCK4 | UniProt: Q96D53 | TargetFullName: AarF domain-containing protein kinase 4 | Organisim: human | Apparent_Kd_M: 8.143169E-11
Real
Aptamer SeqId: 9796-4 | Target: CEL | UniProt: P19835
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9796-4 | Target: CEL | UniProt: P19835 | TargetFullName: Bile salt-activated lipase | Organisim: human | Apparent_Kd_M: 1.068903E-11
Real
Aptamer SeqId: 9799-3 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9799-3 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 7.318714E-12
Real
Aptamer SeqId: 9800-20 | Target: NDUB8 | UniProt: O95169
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9800-20 | Target: NDUB8 | UniProt: O95169 | TargetFullName: NADH dehydrogenase ubiquinone 1 beta subcomplex subunit 8; mitochondrial | Organisim: human | Apparent_Kd_M: 2.691945E-11
Real
Aptamer SeqId: 9802-27 | Target: PLPL2 | UniProt: Q96AD5
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9802-27 | Target: PLPL2 | UniProt: Q96AD5 | TargetFullName: Patatin-like phospholipase domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 1.301096E-10
Real
Aptamer SeqId: 9804-11 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9804-11 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.360879E-12
Real
Aptamer SeqId: 9805-51 | Target: SEM4B | UniProt: Q9NPR2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9805-51 | Target: SEM4B | UniProt: Q9NPR2 | TargetFullName: Semaphorin-4B | Organisim: human | Apparent_Kd_M: 4.850947E-10
Real
Aptamer SeqId: 9808-41 | Target: TNR6B | UniProt: Q9UPQ9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9808-41 | Target: TNR6B | UniProt: Q9UPQ9 | TargetFullName: Trinucleotide repeat-containing gene 6B protein | Organisim: human | Apparent_Kd_M: 3.985204E-11
Real
Aptamer SeqId: 9815-5 | Target: RHG01 | UniProt: Q07960
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9815-5 | Target: RHG01 | UniProt: Q07960 | TargetFullName: Rho GTPase-activating protein 1 | Organisim: human | Apparent_Kd_M: 3.418986E-11
Real
Aptamer SeqId: 9816-37 | Target: ISOC1 | UniProt: Q96CN7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9816-37 | Target: ISOC1 | UniProt: Q96CN7 | TargetFullName: Isochorismatase domain-containing protein 1 | Organisim: human | Apparent_Kd_M: 9.952201E-12
Real
Aptamer SeqId: 9819-110 | Target: Mcl-1 | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9819-110 | Target: Mcl-1 | UniProt: | TargetFullName: Induced myeloid leukemia cell differentiation protein Mcl-1 | Organisim: human | Apparent_Kd_M: 7.790727E-12
Real
Aptamer SeqId: 9823-2 | Target: DYR | UniProt: P00374
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9823-2 | Target: DYR | UniProt: P00374 | TargetFullName: Dihydrofolate reductase | Organisim: human | Apparent_Kd_M: 1.318774E-11
Real
Aptamer SeqId: 9826-135 | Target: Fragile histidine triad protein
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9826-135 | Target: Fragile histidine triad protein | UniProt: P49789 | TargetFullName: Bis(5'-adenosyl)-triphosphatase | Organisim: human | Apparent_Kd_M: 4.558285E-12
Real
Aptamer SeqId: 9828-86 | Target: LDHC | UniProt: P07864
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9828-86 | Target: LDHC | UniProt: P07864 | TargetFullName: L-lactate dehydrogenase C chain | Organisim: human | Apparent_Kd_M: 1.604893E-11
Real
Aptamer SeqId: 9829-91 | Target: SULT 2A1 | UniProt: Q06520
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9829-91 | Target: SULT 2A1 | UniProt: Q06520 | TargetFullName: Bile salt sulfotransferase | Organisim: human | Apparent_Kd_M: 4.48356E-12
Real
Aptamer SeqId: 9830-109 | Target: VAV3 | UniProt: Q9UKW4
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9830-109 | Target: VAV3 | UniProt: Q9UKW4 | TargetFullName: Guanine nucleotide exchange factor VAV3 | Organisim: human | Apparent_Kd_M: 2.637339E-12
Real
Aptamer SeqId: 9831-12 | Target: G3BP2 | UniProt: Q9UN86
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9831-12 | Target: G3BP2 | UniProt: Q9UN86 | TargetFullName: Ras GTPase-activating protein-binding protein 2 | Organisim: human | Apparent_Kd_M: 9.202797E-12
Real
Aptamer SeqId: 9832-33 | Target: HGD | UniProt: Q93099
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9832-33 | Target: HGD | UniProt: Q93099 | TargetFullName: Homogentisate 1;2-dioxygenase | Organisim: human | Apparent_Kd_M: 2.152875E-11
Real
Aptamer SeqId: 9834-62 | Target: ADH1B | UniProt: P00325
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9834-62 | Target: ADH1B | UniProt: P00325 | TargetFullName: Alcohol dehydrogenase 1B | Organisim: human | Apparent_Kd_M: 6.699684E-11
Real
Aptamer SeqId: 9835-16 | Target: AL1A3 | UniProt: P47895
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9835-16 | Target: AL1A3 | UniProt: P47895 | TargetFullName: Aldehyde dehydrogenase family 1 member A3 | Organisim: human | Apparent_Kd_M: 1.979651E-10
Real
Aptamer SeqId: 9836-20 | Target: DCK | UniProt: P27707
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9836-20 | Target: DCK | UniProt: P27707 | TargetFullName: Deoxycytidine kinase | Organisim: human | Apparent_Kd_M: 2.429662E-12
Real
Aptamer SeqId: 9837-60 | Target: NAD(P)H dehydrogenase | UniProt: P15559
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9837-60 | Target: NAD(P)H dehydrogenase | UniProt: P15559 | TargetFullName: NAD(P)H dehydrogenase quinone 1 | Organisim: human | Apparent_Kd_M: 5.591784E-13
Real
Aptamer SeqId: 9838-4 | Target: SMAD1 | UniProt: Q15797
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9838-4 | Target: SMAD1 | UniProt: Q15797 | TargetFullName: Mothers against decapentaplegic homolog 1 | Organisim: human | Apparent_Kd_M: 2.00055E-11
Real
Aptamer SeqId: 9839-148 | Target: Tirap | UniProt: P58753
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9839-148 | Target: Tirap | UniProt: P58753 | TargetFullName: Toll/interleukin-1 receptor domain-containing adapter protein | Organisim: human | Apparent_Kd_M: 1.086674E-11
Real
Aptamer SeqId: 9840-2 | Target: Cdc42Hs | UniProt: P60953
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9840-2 | Target: Cdc42Hs | UniProt: P60953 | TargetFullName: Cell division control protein 42 homolog | Organisim: human | Apparent_Kd_M: 1.735028E-11
Real
Aptamer SeqId: 9841-197 | Target: Multifunctional protein ADE2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9841-197 | Target: Multifunctional protein ADE2 | UniProt: P22234 | TargetFullName: Multifunctional protein ADE2 | Organisim: human | Apparent_Kd_M: 8.345578E-11
Real
Aptamer SeqId: 9842-2 | Target: b-Catenin | UniProt: P35222
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9842-2 | Target: b-Catenin | UniProt: P35222 | TargetFullName: Catenin beta-1 | Organisim: human | Apparent_Kd_M: 2.154416E-12
Real
Aptamer SeqId: 9843-5 | Target: ACTN1 | UniProt: P12814
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9843-5 | Target: ACTN1 | UniProt: P12814 | TargetFullName: Alpha-actinin-1 | Organisim: human | Apparent_Kd_M: 1.902555E-11
Real
Aptamer SeqId: 9844-138 | Target: ACTN2 | UniProt: P35609
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9844-138 | Target: ACTN2 | UniProt: P35609 | TargetFullName: Alpha-actinin-2 | Organisim: human | Apparent_Kd_M: 2.859785E-13
Real
Aptamer SeqId: 9846-32 | Target: Rho-GDI beta | UniProt: P52566
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9846-32 | Target: Rho-GDI beta | UniProt: P52566 | TargetFullName: Rho GDP-dissociation inhibitor 2 | Organisim: human | Apparent_Kd_M: 1.062164E-11
Real
Aptamer SeqId: 9847-21 | Target: TGIF2 | UniProt: Q9GZN2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9847-21 | Target: TGIF2 | UniProt: Q9GZN2 | TargetFullName: Homeobox protein TGIF2 | Organisim: human | Apparent_Kd_M: 3.01802E-12
Real
Aptamer SeqId: 9848-22 | Target: Cyclin H | UniProt: P51946
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9848-22 | Target: Cyclin H | UniProt: P51946 | TargetFullName: Cyclin-H | Organisim: human | Apparent_Kd_M: 3.805136E-12
Real
Aptamer SeqId: 9849-13 | Target: APEX1 | UniProt: P27695
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9849-13 | Target: APEX1 | UniProt: P27695 | TargetFullName: DNA-(apurinic or apyrimidinic site) lyase | Organisim: human | Apparent_Kd_M: 1.67134E-12
Real
Aptamer SeqId: 9850-38 | Target: IF1AX | UniProt: P47813
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9850-38 | Target: IF1AX | UniProt: P47813 | TargetFullName: Eukaryotic translation initiation factor 1A; X-chromosomal | Organisim: human | Apparent_Kd_M: 5.199095E-11
Real
Aptamer SeqId: 9853-3 | Target: IFIT2 | UniProt: P09913
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9853-3 | Target: IFIT2 | UniProt: P09913 | TargetFullName: Interferon-induced protein with tetratricopeptide repeats 2 | Organisim: human | Apparent_Kd_M: 7.619957E-12
Real
Aptamer SeqId: 9855-10 | Target: Rho A | UniProt: P61586
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9855-10 | Target: Rho A | UniProt: P61586 | TargetFullName: Transforming protein RhoA | Organisim: human | Apparent_Kd_M: 6.383195E-13
Real
Aptamer SeqId: 9856-22 | Target: DHYS | UniProt: P49366
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9856-22 | Target: DHYS | UniProt: P49366 | TargetFullName: Deoxyhypusine synthase | Organisim: human | Apparent_Kd_M: 4.116456E-11
Real
Aptamer SeqId: 9859-180 | Target: SSAT-1 | UniProt: P21673
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9859-180 | Target: SSAT-1 | UniProt: P21673 | TargetFullName: Diamine acetyltransferase 1 | Organisim: human | Apparent_Kd_M: 2.215399E-11
Real
Aptamer SeqId: 9863-1 | Target: Tropomyosin 4 | UniProt: P67936
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9863-1 | Target: Tropomyosin 4 | UniProt: P67936 | TargetFullName: Tropomyosin alpha-4 chain | Organisim: human | Apparent_Kd_M: 1.120614E-11
Real
Aptamer SeqId: 9864-38 | Target: TTC1 | UniProt: Q99614
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9864-38 | Target: TTC1 | UniProt: Q99614 | TargetFullName: Tetratricopeptide repeat protein 1 | Organisim: human | Apparent_Kd_M: 6.96733E-12
Real
Aptamer SeqId: 9865-40 | Target: UBE2B | UniProt: P63146
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9865-40 | Target: UBE2B | UniProt: P63146 | TargetFullName: Ubiquitin-conjugating enzyme E2 B | Organisim: human | Apparent_Kd_M: 7.757858E-11
Real
Aptamer SeqId: 9867-23 | Target: F16P2 | UniProt: O00757
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9867-23 | Target: F16P2 | UniProt: O00757 | TargetFullName: Fructose-1;6-bisphosphatase isozyme 2 | Organisim: human | Apparent_Kd_M: 1.699066E-12
Real
Aptamer SeqId: 9869-28 | Target: NF-kappa-B p105 | UniProt: P19838
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9869-28 | Target: NF-kappa-B p105 | UniProt: P19838 | TargetFullName: Nuclear factor NF-kappa-B p105 subunit | Organisim: human | Apparent_Kd_M: 5.889158E-12
Real
Aptamer SeqId: 9870-17 | Target: SYWC | UniProt: P23381
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9870-17 | Target: SYWC | UniProt: P23381 | TargetFullName: Tryptophan--tRNA ligase; cytoplasmic | Organisim: human | Apparent_Kd_M: 3.08E-12
Real
Aptamer SeqId: 9872-23 | Target: CTNA2 | UniProt: P26232
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9872-23 | Target: CTNA2 | UniProt: P26232 | TargetFullName: Catenin alpha-2 | Organisim: human | Apparent_Kd_M: 2.129183E-12
Real
Aptamer SeqId: 9873-17 | Target: ERRalpha | UniProt: P11474
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9873-17 | Target: ERRalpha | UniProt: P11474 | TargetFullName: Steroid hormone receptor ERR1 | Organisim: human | Apparent_Kd_M: 2.789678E-11
Real
Aptamer SeqId: 9874-28 | Target: p15-INK4b | UniProt: P42772
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9874-28 | Target: p15-INK4b | UniProt: P42772 | TargetFullName: Cyclin-dependent kinase 4 inhibitor B | Organisim: human | Apparent_Kd_M: 3.113053E-11
Real
Aptamer SeqId: 9875-107 | Target: THOC1 | UniProt: Q96FV9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9875-107 | Target: THOC1 | UniProt: Q96FV9 | TargetFullName: THO complex subunit 1 | Organisim: human | Apparent_Kd_M: 5.465579E-11
Real
Aptamer SeqId: 9876-20 | Target: aldolase C | UniProt: P09972
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9876-20 | Target: aldolase C | UniProt: P09972 | TargetFullName: Fructose-bisphosphate aldolase C | Organisim: human | Apparent_Kd_M: 1.48E-11
Real
Aptamer SeqId: 9877-28 | Target: CRKL | UniProt: P46109
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9877-28 | Target: CRKL | UniProt: P46109 | TargetFullName: Crk-like protein | Organisim: human | Apparent_Kd_M: 2.863793E-12
Real
Aptamer SeqId: 9880-33 | Target: T23O | UniProt: P48775
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9880-33 | Target: T23O | UniProt: P48775 | TargetFullName: Tryptophan 2;3-dioxygenase | Organisim: human | Apparent_Kd_M: 5.110391E-11
Real
Aptamer SeqId: 9883-29 | Target: Glyoxalase I | UniProt: Q04760
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9883-29 | Target: Glyoxalase I | UniProt: Q04760 | TargetFullName: Lactoylglutathione lyase | Organisim: human | Apparent_Kd_M: 2.514988E-11
Real
Aptamer SeqId: 9884-8 | Target: PPIL1 | UniProt: Q9Y3C6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9884-8 | Target: PPIL1 | UniProt: Q9Y3C6 | TargetFullName: Peptidyl-prolyl cis-trans isomerase-like 1 | Organisim: human | Apparent_Kd_M: 8.103752E-11
Real
Aptamer SeqId: 9885-41 | Target: RAP2A | UniProt: P10114
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9885-41 | Target: RAP2A | UniProt: P10114 | TargetFullName: Ras-related protein Rap-2a | Organisim: human | Apparent_Kd_M: 2.096902E-11
Real
Aptamer SeqId: 9886-28 | Target: XRCC4 | UniProt: Q13426
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9886-28 | Target: XRCC4 | UniProt: Q13426 | TargetFullName: DNA repair protein XRCC4 | Organisim: human | Apparent_Kd_M: 1.469693E-11
Real
Aptamer SeqId: 9887-40 | Target: RBBP6 | UniProt: Q7Z6E9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9887-40 | Target: RBBP6 | UniProt: Q7Z6E9 | TargetFullName: E3 ubiquitin-protein ligase RBBP6 | Organisim: human | Apparent_Kd_M: 2.37E-11
Real
Aptamer SeqId: 9889-42 | Target: AF1L1 | UniProt: Q8TED9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9889-42 | Target: AF1L1 | UniProt: Q8TED9 | TargetFullName: Actin filament-associated protein 1-like 1 | Organisim: human | Apparent_Kd_M: 8.652232E-12
Real
Aptamer SeqId: 9893-27 | Target: Ornithine decarboxylase antizyme
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9893-27 | Target: Ornithine decarboxylase antizyme | UniProt: P54368 | TargetFullName: Ornithine decarboxylase antizyme 1 | Organisim: human | Apparent_Kd_M: 4.392866E-12
Real
Aptamer SeqId: 9894-13 | Target: MYO6 | UniProt: Q9UM54
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9894-13 | Target: MYO6 | UniProt: Q9UM54 | TargetFullName: Unconventional myosin-VI | Organisim: human | Apparent_Kd_M: 4.086388E-12
Real
Aptamer SeqId: 9895-77 | Target: XPF | UniProt: Q92889
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9895-77 | Target: XPF | UniProt: Q92889 | TargetFullName: DNA repair endonuclease XPF | Organisim: human | Apparent_Kd_M: 1.835656E-11
Real
Aptamer SeqId: 9896-21 | Target: FOXGB | UniProt: P55316
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9896-21 | Target: FOXGB | UniProt: P55316 | TargetFullName: Forkhead box protein G1 | Organisim: human | Apparent_Kd_M: 5.04E-13
Real
Aptamer SeqId: 9897-9 | Target: MCM6 | UniProt: Q14566
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9897-9 | Target: MCM6 | UniProt: Q14566 | TargetFullName: DNA replication licensing factor MCM6 | Organisim: human | Apparent_Kd_M: 8.165406E-11
Real
Aptamer SeqId: 9898-161 | Target: ARI1A | UniProt: O14497
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9898-161 | Target: ARI1A | UniProt: O14497 | TargetFullName: AT-rich interactive domain-containing protein 1A | Organisim: human | Apparent_Kd_M: 1.704294E-11
Real
Aptamer SeqId: 9899-28 | Target: KIF1C | UniProt: O43896
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9899-28 | Target: KIF1C | UniProt: O43896 | TargetFullName: Kinesin-like protein KIF1C | Organisim: human | Apparent_Kd_M: 1.689836E-10
Real
Aptamer SeqId: 9900-36 | Target: NFH | UniProt: P12036
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9900-36 | Target: NFH | UniProt: P12036 | TargetFullName: Neurofilament heavy polypeptide | Organisim: human | Apparent_Kd_M: 2.580986E-12
Real
Aptamer SeqId: 9901-28 | Target: EGLN1 | UniProt: Q9GZT9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9901-28 | Target: EGLN1 | UniProt: Q9GZT9 | TargetFullName: Egl nine homolog 1 | Organisim: human | Apparent_Kd_M: 1.378629E-12
Real
Aptamer SeqId: 9905-8 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9905-8 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 2.119802E-11
Real
Aptamer SeqId: 9906-21 | Target: TICN3 | UniProt: Q9BQ16
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9906-21 | Target: TICN3 | UniProt: Q9BQ16 | TargetFullName: Testican-3 | Organisim: human | Apparent_Kd_M: 8.536491E-12
Real
Aptamer SeqId: 9907-216 | Target: Tankyrase-1 | UniProt: O95271
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9907-216 | Target: Tankyrase-1 | UniProt: O95271 | TargetFullName: Tankyrase-1 | Organisim: human | Apparent_Kd_M: 3.016627E-11
Real
Aptamer SeqId: 9909-4 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9909-4 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 1.829845E-12
Real
Aptamer SeqId: 9910-9 | Target: MTAP | UniProt: Q13126
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9910-9 | Target: MTAP | UniProt: Q13126 | TargetFullName: S-methyl-5'-thioadenosine phosphorylase | Organisim: human | Apparent_Kd_M: 2.611022E-11
Real
Aptamer SeqId: 9913-4 | Target: RRBP1 | UniProt: Q9P2E9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9913-4 | Target: RRBP1 | UniProt: Q9P2E9 | TargetFullName: Ribosome-binding protein 1 | Organisim: human | Apparent_Kd_M: 5.866914E-12
Real
Aptamer SeqId: 9916-146 | Target: LRC4B | UniProt: Q9NT99
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9916-146 | Target: LRC4B | UniProt: Q9NT99 | TargetFullName: Leucine-rich repeat-containing protein 4B | Organisim: human | Apparent_Kd_M: 6.017747E-11
Real
Aptamer SeqId: 9917-16 | Target: Fc_MOUSE | UniProt:
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9917-16 | Target: Fc_MOUSE | UniProt: | TargetFullName: | Organisim: mouse | Apparent_Kd_M: 8.997413E-12
Real
Aptamer SeqId: 9918-23 | Target: Calbindin D28 | UniProt: P05937
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9918-23 | Target: Calbindin D28 | UniProt: P05937 | TargetFullName: Calbindin | Organisim: human | Apparent_Kd_M: 2.86627E-10
Real
Aptamer SeqId: 9923-6 | Target: SOS1 | UniProt: Q07889
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9923-6 | Target: SOS1 | UniProt: Q07889 | TargetFullName: Son of sevenless homolog 1 | Organisim: human | Apparent_Kd_M: 1.266014E-11
Real
Aptamer SeqId: 9925-56 | Target: SREC-II | UniProt: Q96GP6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9925-56 | Target: SREC-II | UniProt: Q96GP6 | TargetFullName: Scavenger receptor class F member 2 | Organisim: human | Apparent_Kd_M: 2.359879E-11
Real
Aptamer SeqId: 9926-4 | Target: S100P | UniProt: P25815
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9926-4 | Target: S100P | UniProt: P25815 | TargetFullName: Protein S100-P | Organisim: human | Apparent_Kd_M: 4.099221E-10
Real
Aptamer SeqId: 9927-96 | Target: TENS4 | UniProt: Q8IZW8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9927-96 | Target: TENS4 | UniProt: Q8IZW8 | TargetFullName: Tensin-4 | Organisim: human | Apparent_Kd_M: 5.56782E-11
Real
Aptamer SeqId: 9928-125 | Target: LECT1 | UniProt: O75829
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9928-125 | Target: LECT1 | UniProt: O75829 | TargetFullName: Leukocyte cell-derived chemotaxin 1 | Organisim: human | Apparent_Kd_M: 4.619483E-11
Real
Aptamer SeqId: 9929-16 | Target: DHB7 | UniProt: P56937
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9929-16 | Target: DHB7 | UniProt: P56937 | TargetFullName: 3-keto-steroid reductase | Organisim: human | Apparent_Kd_M: 5.287485E-11
Real
Aptamer SeqId: 9930-48 | Target: GABR2 | UniProt: O75899
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9930-48 | Target: GABR2 | UniProt: O75899 | TargetFullName: Gamma-aminobutyric acid type B receptor subunit 2 | Organisim: human | Apparent_Kd_M: 2.826891E-11
Real
Aptamer SeqId: 9931-20 | Target: Keratin-1 | UniProt: P04264
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9931-20 | Target: Keratin-1 | UniProt: P04264 | TargetFullName: Keratin; type II cytoskeletal 1 | Organisim: human | Apparent_Kd_M: 7.503065E-12
Real
Aptamer SeqId: 9932-49 | Target: SEM4F | UniProt: O95754
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9932-49 | Target: SEM4F | UniProt: O95754 | TargetFullName: Semaphorin-4F | Organisim: human | Apparent_Kd_M: 2.970112E-12
Real
Aptamer SeqId: 9933-49 | Target: AT1B4 | UniProt: Q9UN42
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9933-49 | Target: AT1B4 | UniProt: Q9UN42 | TargetFullName: Protein ATP1B4 | Organisim: human | Apparent_Kd_M: 7.73363E-11
Real
Aptamer SeqId: 9934-29 | Target: PIPNA | UniProt: Q00169
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9934-29 | Target: PIPNA | UniProt: Q00169 | TargetFullName: Phosphatidylinositol transfer protein alpha isoform | Organisim: human | Apparent_Kd_M: 4.414651E-11
Real
Aptamer SeqId: 9936-27 | Target: LNX1 | UniProt: Q8TBB1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9936-27 | Target: LNX1 | UniProt: Q8TBB1 | TargetFullName: E3 ubiquitin-protein ligase LNX | Organisim: human | Apparent_Kd_M: 2.835494E-10
Real
Aptamer SeqId: 9937-7 | Target: CXA1 | UniProt: P17302
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9937-7 | Target: CXA1 | UniProt: P17302 | TargetFullName: Gap junction alpha-1 protein | Organisim: human | Apparent_Kd_M: 4.827497E-12
Real
Aptamer SeqId: 9940-35 | Target: DUS28 | UniProt: Q4G0W2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9940-35 | Target: DUS28 | UniProt: Q4G0W2 | TargetFullName: Dual specificity phosphatase 28 | Organisim: human | Apparent_Kd_M: 1.661009E-11
Real
Aptamer SeqId: 9941-70 | Target: PCDB1 | UniProt: Q9Y5F3
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9941-70 | Target: PCDB1 | UniProt: Q9Y5F3 | TargetFullName: Protocadherin beta-1 | Organisim: human | Apparent_Kd_M: 3.192822E-11
Real
Aptamer SeqId: 9942-2 | Target: NXT1 | UniProt: Q9UKK6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9942-2 | Target: NXT1 | UniProt: Q9UKK6 | TargetFullName: NTF2-related export protein 1 | Organisim: human | Apparent_Kd_M: 1.399311E-12
Real
Aptamer SeqId: 9947-22 | Target: TOPB1 | UniProt: Q92547
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9947-22 | Target: TOPB1 | UniProt: Q92547 | TargetFullName: DNA topoisomerase 2-binding protein 1 | Organisim: human | Apparent_Kd_M: 4.948617E-12
Real
Aptamer SeqId: 9950-229 | Target: LAG-3 | UniProt: P18627
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9950-229 | Target: LAG-3 | UniProt: P18627 | TargetFullName: Lymphocyte activation gene 3 protein | Organisim: human | Apparent_Kd_M: 4.561892E-12
Real
Aptamer SeqId: 9951-36 | Target: FBXL4 | UniProt: Q9UKA2
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9951-36 | Target: FBXL4 | UniProt: Q9UKA2 | TargetFullName: F-box/LRR-repeat protein 4 | Organisim: human | Apparent_Kd_M: 4.406228E-12
Real
Aptamer SeqId: 9952-57 | Target: TFAM | UniProt: Q00059
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9952-57 | Target: TFAM | UniProt: Q00059 | TargetFullName: Transcription factor A; mitochondrial | Organisim: human | Apparent_Kd_M: 3.301148E-11
Real
Aptamer SeqId: 9954-2 | Target: NPPL3 | UniProt: Q92617
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9954-2 | Target: NPPL3 | UniProt: Q92617 | TargetFullName: Nuclear pore complex-interacting protein family member B3 | Organisim: human | Apparent_Kd_M: 2.11101E-10
Real
Aptamer SeqId: 9955-40 | Target: RN148 | UniProt: Q8N7C7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9955-40 | Target: RN148 | UniProt: Q8N7C7 | TargetFullName: RING finger protein 148 | Organisim: human | Apparent_Kd_M: 1.360985E-10
Real
Aptamer SeqId: 9956-7 | Target: ADA15 | UniProt: Q13444
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9956-7 | Target: ADA15 | UniProt: Q13444 | TargetFullName: Disintegrin and metalloproteinase domain-containing protein 15 | Organisim: human | Apparent_Kd_M: 1.323101E-11
Real
Aptamer SeqId: 9957-9 | Target: RN114 | UniProt: Q9Y508
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9957-9 | Target: RN114 | UniProt: Q9Y508 | TargetFullName: E3 ubiquitin-protein ligase RNF114 | Organisim: human | Apparent_Kd_M: 2.111665E-11
Real
Aptamer SeqId: 9959-60 | Target: TM59L | UniProt: Q9UK28
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9959-60 | Target: TM59L | UniProt: Q9UK28 | TargetFullName: Transmembrane protein 59-like | Organisim: human | Apparent_Kd_M: 2.482952E-10
Real
Aptamer SeqId: 9960-2 | Target: TBCD5 | UniProt: Q92609
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9960-2 | Target: TBCD5 | UniProt: Q92609 | TargetFullName: TBC1 domain family member 5 | Organisim: human | Apparent_Kd_M: 9.275158E-12
Real
Aptamer SeqId: 9962-1 | Target: MUCDL | UniProt: Q9HBB8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9962-1 | Target: MUCDL | UniProt: Q9HBB8 | TargetFullName: Cadherin-related family member 5 | Organisim: human | Apparent_Kd_M: 4.511979E-11
Real
Aptamer SeqId: 9963-19 | Target: PCDBA | UniProt: Q9UN67
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9963-19 | Target: PCDBA | UniProt: Q9UN67 | TargetFullName: Protocadherin beta-10 | Organisim: human | Apparent_Kd_M: 5.419752E-11
Real
Aptamer SeqId: 9964-10 | Target: MYZAP | UniProt: P0CAP1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9964-10 | Target: MYZAP | UniProt: P0CAP1 | TargetFullName: Myocardial zonula adherens protein | Organisim: human | Apparent_Kd_M: 4.957583E-12
Real
Aptamer SeqId: 9969-8 | Target: S22AG | UniProt: Q86VW1
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9969-8 | Target: S22AG | UniProt: Q86VW1 | TargetFullName: Solute carrier family 22 member 16 | Organisim: human | Apparent_Kd_M: 2.93512E-11
Real
Aptamer SeqId: 9970-7 | Target: UBXN4 | UniProt: Q92575
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9970-7 | Target: UBXN4 | UniProt: Q92575 | TargetFullName: UBX domain-containing protein 4 | Organisim: human | Apparent_Kd_M: 4.017147E-12
Real
Aptamer SeqId: 9971-5 | Target: CSMD2 | UniProt: Q7Z408
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9971-5 | Target: CSMD2 | UniProt: Q7Z408 | TargetFullName: CUB and sushi domain-containing protein 2 | Organisim: human | Apparent_Kd_M: 3.25592E-12
Real
Aptamer SeqId: 9974-8 | Target: DLL3 | UniProt: Q9NYJ7
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9974-8 | Target: DLL3 | UniProt: Q9NYJ7 | TargetFullName: Delta-like protein 3 | Organisim: human | Apparent_Kd_M: 1.142051E-10
Real
Aptamer SeqId: 9979-13 | Target: AMGO1 | UniProt: Q86WK6
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9979-13 | Target: AMGO1 | UniProt: Q86WK6 | TargetFullName: Amphoterin-induced protein 1 | Organisim: human | Apparent_Kd_M: 8.891196E-12
Real
Aptamer SeqId: 9981-18 | Target: K1467 | UniProt: A2RU67
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9981-18 | Target: K1467 | UniProt: A2RU67 | TargetFullName: Protein FAM234B | Organisim: human | Apparent_Kd_M: 9.978888E-12
Real
Aptamer SeqId: 9983-97 | Target: PRS35 | UniProt: Q8N3Z0
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9983-97 | Target: PRS35 | UniProt: Q8N3Z0 | TargetFullName: Inactive serine protease 35 | Organisim: human | Apparent_Kd_M: 3.116451E-10
Real
Aptamer SeqId: 9984-12 | Target: YIPF6 | UniProt: Q96EC8
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9984-12 | Target: YIPF6 | UniProt: Q96EC8 | TargetFullName: Protein YIPF6 | Organisim: human | Apparent_Kd_M: 1.508299E-11
Real
Aptamer SeqId: 9986-14 | Target: Neuropeptide W | UniProt: Q8N729
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9986-14 | Target: Neuropeptide W | UniProt: Q8N729 | TargetFullName: Neuropeptide W | Organisim: human | Apparent_Kd_M: 9.007485E-11
Real
Aptamer SeqId: 9989-12 | Target: LRC24 | UniProt: Q50LG9
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9989-12 | Target: LRC24 | UniProt: Q50LG9 | TargetFullName: Leucine-rich repeat-containing protein 24 | Organisim: human | Apparent_Kd_M: 1.127049E-10
Real
Aptamer SeqId: 9993-11 | Target: ZN264 | UniProt: O43296
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9993-11 | Target: ZN264 | UniProt: O43296 | TargetFullName: Zinc finger protein 264 | Organisim: human | Apparent_Kd_M: 4.172888E-11
Real
Aptamer SeqId: 9994-217 | Target: ATP4B | UniProt: P51164
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9994-217 | Target: ATP4B | UniProt: P51164 | TargetFullName: Potassium-transporting ATPase subunit beta | Organisim: human | Apparent_Kd_M: 3.593211E-11
Real
Aptamer SeqId: 9995-6 | Target: DUT | UniProt: P33316
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9995-6 | Target: DUT | UniProt: P33316 | TargetFullName: Deoxyuridine 5'-triphosphate nucleotidohydrolase; mitochondrial | Organisim: human | Apparent_Kd_M: 1.687954E-11
Real
Aptamer SeqId: 9997-12 | Target: UBXN4 | UniProt: Q92575
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9997-12 | Target: UBXN4 | UniProt: Q92575 | TargetFullName: UBX domain-containing protein 4 | Organisim: human | Apparent_Kd_M: 5.798382E-12
Real
Aptamer SeqId: 9999-1 | Target: IRF6 | UniProt: O14896
Phase 2 data. Somalogic Aptamer analysis used to determine protein concentrations in Fenland EDTA-plasma samples from baseline examinations of all Fenland participants | SeqId: 9999-1 | Target: IRF6 | UniProt: O14896 | TargetFullName: Interferon regulatory factor 6 | Organisim: human | Apparent_Kd_M: 3.161946E-11
Real
Cln variable: Shift worker
Phase 2 data. Variable to indicate shift worker (1=ticked shift work in GenQ) - cleaned
Real
Av breaks occ1 breaks/hr
Phase 2 data. Average number of breaks interrupting sitting time while doing occupation 1. (breaks/hr)
Real
Av breaks occ2 breaks/hr
Phase 2 data. Average number of breaks interrupting sitting time while doing occupation 2. (breaks/hr)
Real
Av breaks occupation breaks/hr
Phase 2 data. The average number breaks interrupting sitting time while doing an occupation. Average of reported breaks during occupation 1 and occupation 2. (breaks/hr)
Real
Av breaks watching TV breaks/hr
Phase 2 data. Average number of breaks interrupting sitting time while watching TV. (breaks/hr)
Real
None
Phase 2 data. Wyman Dillon comment if Q completion date is not legible and why.
Text
None
Phase 2 data. Wyman Dillon comment if scanning of ID sticker fails stating that scanning failed and why if known for 7DSB form
Text
Avg of multiple sleep times
Phase 2 data. 1 = Average of multiple sleep times used as participant reported two or more sleep times.
Categorical
Completion date flag-codes in dictionary
Phase 2 data. Flag the completion date of questionnaire as it was: 1 = had to be cleaned/changed due to typos; minus 10 variable or data entry issues; 2 = completion date was missing therefore last day of Actiheart wear imputed; 3 = completion date was outside of data collection dates therefore last day of Actiheart wear imputed; 4 = no completion date or Actiheart/free-living file to use therefore date will still be missing.
Categorical
Flag for double qnr entry for pt
Phase 2 data. 1 = flag to indicate there were two different questionnaire entries for the participant. One entry was chosen based on the entry matching the actiheart wear dates. Note this was not always possible; therefore the most complete entry was used in these cases.
Categorical
Flag for empty questionnaire
Phase 2 data. Flag to indicate if the questionnaire was empty/participant did not complete. 1 = flagged by data management as fully empty questionnaire/participant did not complete any of the questions; 2 = participant did not complete any of the questions however there was a comment in the comments variable to indicate this. All variables (included those imputed e.g. Completion Date) set to missing for those flagged as empty.
Categorical
Sleep duration data
Phase 2 data. 1 = Weekday or weekend sleep durations flagged as duration <=3 hours or >=14 hours. Sleep duration data set to missing for these.
Categorical
Flag for total sedentary time p/day
Phase 2 data. Flag to indicate if total sedentary time per day is >1440 minutes. 1 = total sedetary time >1440 minutes; 2 = total sedetary time not including sleep >1440 minutes. Variable values are not capped in the dataset at 1440 but flagged here for information.
Categorical
7DSBR comment from participant
Phase 2 data. 7-day sedentary behaviour recall comment from participant. If any additional comments appear on ANY page of the questionnaire please enter them as page number and the comment.
Text
Wkday get up time decimal
Phase 2 data. Get up time on a weekday from reported get up hour; minutes and am/pm variable. (decimal)
Real
Wkend get up time decimal
Phase 2 data. Get up time on a weekend day from reported get up hour; minutes and am/pm variable. (decimal)
Real
Wkday go sleep time decimal
Phase 2 data. Go to sleep time on a weekday from reported go sleep hour; minutes and am/pm variable. (decimal)
Real
Wkend go to sleep time decimal
Phase 2 data. Go to sleep time on a weekend day from reported go sleep hour; minutes and am/pm variable. (decimal)
Real
Date (day) 7DSBQ filled in
Phase 2 data. Date 7DSBQ was filled in by participant; day. Format DD (eg 01 for January).
Date
Date (month) 7DSBQ filled in
Phase 2 data. Date 7DSBQ was filled in by participant; month. Format MM (eg 02 for February).
Date
Date (year) 7DSBQ filled in
Phase 2 data. Date 7DSBQ was filled in by participant; year. Format YYYY (4-digits).
Date
Date 7DSBQ filled in
Phase 2 data. Date 7DSBQ was filled in by participant; date. Format DD-Mon-YYYY (eg 01-Jan-2000 for 01 January 2000). Generated from QCompletionDate_Day; QCompletionDate_Month; QCompletionDate_Year variables. Cleaned. Variable is flagged if has been cleaned or imputed - see variable FLAG_CompletionDate for details.
Date
None
Phase 2 data. Tracker variable created by DMT. 1 = paper; 2 = electronic; 3 = private network study db; 9 = paper and electronic;
Real
7DSB form version number
Phase 2 data. 7DSB form version number. Version numbers available: 2 = v 2.0 120914; 3 = V3.0_160117. Cleaned.
Categorical
None
Phase 2 data. 7DSB form version number. Version numbers available: 2 = v 2.0 120914; 3 = V3.0_160117;
Real
Go to sleep time on weekday am/pm
Phase 2 data. SLEEPING AND NAPPING. Questionnaire read -Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you go to sleep on a weekday? This variable is am or pm on a weekday. Cleaned.
Time
Go to sleep time on weekday (am/pm)
Phase 2 data. SLEEPING AND NAPPING. Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you go to sleep on a weekday? Am or pm on a weekday.-1 = left blank; -4 = range entered; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Go to sleep time on weekday hr
Phase 2 data. SLEEPING AND NAPPING. Questionnaire read -Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you go to sleep on a weekday? This variable is the hour value on a weekday. Hour and minutes entered as separate variables. Cleaned.
Time
Go to sleep time on weekday (hr)
Phase 2 data. SLEEPING AND NAPPING. Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you go to sleep on a weekday? Hour and minutes entered as separate values - hour value on a weekday. -1 = left blank; -4 = range entered; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Go to sleep time on weekday min
Phase 2 data. SLEEPING AND NAPPING. Questionnaire read -Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you go to sleep on a weekday? This variable is the minutes value on a weekday. Hour and minutes entered as separate variables. Cleaned.
Time
Get up time on weekday am/pm
Phase 2 data. SLEEPING AND NAPPING. Questionnaire read -Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you get up on a weekday? This variable is am or pm on a weekday. Cleaned.
Time
Get up time on weekday hr
Phase 2 data. SLEEPING AND NAPPING. Questionnaire read - Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you get up on a weekday? This variable is the hour value on a weekday. Hour and minutes entered as separate variables. Cleaned.
Time
Get up time on weekday min
Phase 2 data. SLEEPING AND NAPPING. Questionnaire read -Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you get up on a weekday? This variable is the minutes value on a weekday. Hour and minutes entered as separate variables. Cleaned.
Time
Go to sleep time on weekday (min)
Phase 2 data. SLEEPING AND NAPPING. Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you go to sleep on a weekday? Hour and minutes entered as separate values - minutes value on a weekday. -1 = left blank; -4 = range entered; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Get up time on weekday (am/pm)
Phase 2 data. SLEEPING AND NAPPING. Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you get up on a weekday? Am or pm on a weekday. -1 = left blank; -4 = range entered; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Get up time on weekday (hr)
Phase 2 data. SLEEPING AND NAPPING. Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you get up on a weekday? Hour and minutes entered as separate values - hour value on a weekday. Hour and minutes entered as separate values - hour value on a weekday. -1 = left blank; -4 = range entered; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Get up time on weekday (min)
Phase 2 data. SLEEPING AND NAPPING. Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you get up on a weekday? Hour and minutes entered as separate values - minutes value on a weekday. -1 = left blank; -4 = range entered; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Go sleep time weekend day am/pm
Phase 2 data. SLEEPING AND NAPPING. Questionnaire read -Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you go to sleep on a weekend day? This variable is am or pm on a weekend day. Cleaned.
Time
Go sleep time weekend day (am/pm)
Phase 2 data. SLEEPING AND NAPPING. Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you go to sleep on a weekday? Am or pm on a weekend day. -1 = left blank; -4 = range entered; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Go sleep time weekend day hr
Phase 2 data. SLEEPING AND NAPPING. Questionnaire read -Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you go to sleep on a weekend day? This variable is the hour value on a weekend day. Hour and minutes entered as separate variables. Cleaned.
Time
Go sleep time weekend day min
Phase 2 data. SLEEPING AND NAPPING. Questionnaire read -Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you go to sleep on a weekend day? This variable is the minutes value on a weekend day. Hour and minutes entered as separate variables. Cleaned.
Time
Get up time on weekend day am/pm
Phase 2 data. SLEEPING AND NAPPING. Questionnaire read -Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you get up on a weekend day? This variable is am or pm on a weekend day. Cleaned.
Categorical
Get up time on weekend day hr
Phase 2 data. SLEEPING AND NAPPING. Questionnaire read -Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you get up on a weekend day? This variable is the hour value on a weekend day. Hour and minutes entered as separate variables. Cleaned.
Time
Go sleep time weekend day (hr)
Phase 2 data. SLEEPING AND NAPPING. Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you go to sleep on a weekday? Hour and minutes entered as separate values - hour value on a weekend day.. -1 = left blank; -4 = range entered; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Go sleep time weekend day (min)
Phase 2 data. SLEEPING AND NAPPING. Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you go to sleep on a weekday? Hour and minutes entered as separate values - minutes value on a weekend day. -1 = left blank; -4 = range entered; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Get up time on weekend day (am/pm)
Phase 2 data. SLEEPING AND NAPPING. Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you get up on a weekday? Am or pm on a weekend day. -1 = left blank; -4 = range entered; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Get up time on weekend day (hr)
Phase 2 data. SLEEPING AND NAPPING. Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you get up on a weekday? Hour and minutes entered as separate values - hour value on a weekday. Hour and minutes entered as separate values - hour value on a weekend day. -1 = left blank; -4 = range entered; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Get up time on weekend day min
Phase 2 data. SLEEPING AND NAPPING. Questionnaire read -Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you get up on a weekend day? This variable is the minutes value on a weekend day. Hour and minutes entered as separate variables. Cleaned.
Time
Get up time on weekend day (min)
Phase 2 data. SLEEPING AND NAPPING. Think about what time you went to sleep and got up in the last 7 days. If you had variable sleeping patterns (eg you did shift work) please record the average time you went to bed and got up on weekdays and on weekend days. Do not include reading or watching TV before falling asleep or after waking. This is part of section 5. 1. In the last 7 days at what time did you get up on a weekday? Hour and minutes entered as separate values - minutes value on a weekend day. -1 = left blank; -4 = range entered; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Dur of nap on a weekday min
Phase 2 data. SLEEPING AND NAPPING. Questionnaire read -A nap is a brief period of sleep often during the day. A nap can be taken on a sofa as well as in a bed. 2. In the last 7 days on average how long did you nap per day on a weekday? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day napping on a weekday.
Real
Dur of nap on a weekday min
Phase 2 data. SLEEPING AND NAPPING. A nap is a brief period of sleep often during the day. A nap can be taken on a sofa as well as in a bed. 2. In the last 7 days on average how long did you nap per day on a weekday?. 1 = No daily napping; 2 = 1-15 min; 3 = 15-30 min; 4 = 30-45 min; 5 = 45 min - 1 hour; 6 = more than one hour a day; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Dur of nap on a weekend day min
Phase 2 data. SLEEPING AND NAPPING. Questionnaire read -A nap is a brief period of sleep often during the day. A nap can be taken on a sofa as well as in a bed. 2. In the last 7 days on average how long did you nap per day on a weekend day? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day napping on a weekend day.
Real
Dur of nap on a weekend day min
Phase 2 data. SLEEPING AND NAPPING. A nap is a brief period of sleep often during the day. A nap can be taken on a sofa as well as in a bed. 2. In the last 7 days on average how long did you nap per day on a weekend day?. 1 = No daily napping; 2 = 1-15 min; 3 = 15-30 min; 4 = 30-45 min; 5 = 45 min - 1 hour; 6 = more than one hour a day; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Sitting wkday breakfast min
Phase 2 data. MEALS. Questionnaire read -Please think about the amount of time you spent sitting for breakfast; lunch and dinner; on average in the last 7 days. DO INCLUDE time spent sitting for breakfast lunch dinner or snacks (at home; work) also when you were reading chatting to other people or listening to the radio. For example if you spent 30 minutes sitting for breakfast while reading the newspaper or for lunch while working then include this in this section. 3. In the last 7 days on average; how long did you sit for each of these meals per day? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting during breakfast on a weekday.
Real
Sitting wkday breakfast min
Phase 2 data. MEALS. Please think about the amount of time you spent sitting for breakfast; lunch and dinner; on average in the last 7 days. DO INCLUDE time spent sitting for breakfast lunch dinner or snacks (at home; work) also when you were reading chatting to other people or listening to the radio. For example if you spent 30 minutes sitting for breakfast while reading the newspaper or for lunch while working then include this in this section. 3. In the last 7 days on average; how long did you sit for each of these meals per day? WEEKDAY - BREAKFAST 1 = none; 2 = 1-10 min; 3 = 10-20 min; 4 = 20-30 min; 5 = 30-45 min; 6 = 45 min - 1 hour; 7 = more than one hour a day; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Sitting wkday lunch min
Phase 2 data. MEALS. Questionnaire read -Please think about the amount of time you spent sitting for breakfast; lunch and dinner; on average in the last 7 days. DO INCLUDE time spent sitting for breakfast lunch dinner or snacks (at home; work) also when you were reading chatting to other people or listening to the radio. For example if you spent 30 minutes sitting for breakfast while reading the newspaper or for lunch while working then include this in this section. 3. In the last 7 days on average; how long did you sit for each of these meals per day? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting during lunch on a weekday.
Real
Sitting wkday lunch min
Phase 2 data. MEALS. Please think about the amount of time you spent sitting for breakfast; lunch and dinner; on average in the last 7 days. DO INCLUDE time spent sitting for breakfast lunch dinner or snacks (at home; work) also when you were reading chatting to other people or listening to the radio. For example if you spent 30 minutes sitting for breakfast while reading the newspaper or for lunch while working then include this in this section. 3. In the last 7 days on average; how long did you sit for each of these meals per day? WEEKDAY - LUNCH. 1 = none; 2 = 1-10 min; 3 = 10-20 min; 4 = 20-30 min; 5 = 30-45 min; 6 = 45 min - 1 hour; 7 = more than one hour a day; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Sitting wkday dinner min
Phase 2 data. MEALS. Questionnaire read -Please think about the amount of time you spent sitting for breakfast; lunch and dinner; on average in the last 7 days. DO INCLUDE time spent sitting for breakfast lunch dinner or snacks (at home; work) also when you were reading chatting to other people or listening to the radio. For example if you spent 30 minutes sitting for breakfast while reading the newspaper or for lunch while working then include this in this section. 3. In the last 7 days on average; how long did you sit for each of these meals per day? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting during dinner on a weekday.
Real
Sitting wkday dinner min
Phase 2 data. MEALS. Please think about the amount of time you spent sitting for breakfast; lunch and dinner; on average in the last 7 days. DO INCLUDE time spent sitting for breakfast lunch dinner or snacks (at home; work …) also when you were reading chatting to other people or listening to the radio. For example if you spent 30 minutes sitting for breakfast while reading the newspaper or for lunch while working then include this in this section. 3. In the last 7 days on average; how long did you sit for each of these meals per day? WEEKDAY - DINNER 1 = none; 2 = 1-10 min; 3 = 10-20 min; 4 = 20-30 min; 5 = 30-45 min; 6 = 45 min - 1 hour; 7 = more than one hour a day; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Working studying or volunteering
Phase 2 data. TRANSPORTATION. Questionnaire read -4. Have you been working studying or volunteering (referred to as occupation) in the last 7 days? Occupation refers to three different types of activities: work; study and volunteering. Work refers to all tasks done to earn money. Study refers to educational activities. Volunteering refers to work that you do for no pay such as helping in a sports club. Please think about all three of these categories for the following questions? 2 = yes; 3 = no; -1 = left blank. Cleaned.
Categorical
Working/studying/volunteering
Phase 2 data. TRANSPORTATION. 4. Have you been working studying or volunteering (referred to as occupation) in the last 7 days? Occupation refers to three different types of activities: work; study and volunteering. Work refers to all tasks done to earn money. Study refers to educational activities. Volunteering refers to work that you do for no pay such as helping in a sports club. Please think about all three of these categories for the following questions. 2 = yes; 3 = no; -1 = left blank; -5 = more than one selected;
Categorical
Days sitting travel to/from occ1
Phase 2 data. TRAVELLING TO AND FROM OCC. Questionnaire read -This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. The questions are about travelling to and from your occupation - travelling as part of your occupation and getting about apart from your occupation. DO NOT include cycling on a pedal bicycle. 5. In the last 7 days how many days a week did you sit while travelling to and from your occupation 1? In number of days. Cleaned.
Real
Sitting wkend day lunch min
Phase 2 data. MEALS. Questionnaire read -Please think about the amount of time you spent sitting for breakfast; lunch and dinner; on average in the last 7 days. DO INCLUDE time spent sitting for breakfast lunch dinner or snacks (at home; work) also when you were reading chatting to other people or listening to the radio. For example if you spent 30 minutes sitting for breakfast while reading the newspaper or for lunch while working then include this in this section. 3. In the last 7 days on average; how long did you sit for each of these meals per day? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting during lunch on a weekend day.
Real
Sitting wkend day lunch min
Phase 2 data. MEALS. Please think about the amount of time you spent sitting for breakfast; lunch and dinner; on average in the last 7 days. DO INCLUDE time spent sitting for breakfast lunch dinner or snacks (at home; work) also when you were reading chatting to other people or listening to the radio. For example if you spent 30 minutes sitting for breakfast while reading the newspaper or for lunch while working then include this in this section. 3. In the last 7 days on average; how long did you sit for each of these meals per day? WEEKEND DAY - BREAKFAST 1 = none; 2 = 1-10 min; 3 = 10-20 min; 4 = 20-30 min; 5 = 30-45 min; 6 = 45 min - 1 hour; 7 = more than one hour a day; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Sitting wkend day dinner min
Phase 2 data. MEALS. Questionnaire read -Please think about the amount of time you spent sitting for breakfast; lunch and dinner; on average in the last 7 days. DO INCLUDE time spent sitting for breakfast lunch dinner or snacks (at home; work) also when you were reading chatting to other people or listening to the radio. For example if you spent 30 minutes sitting for breakfast while reading the newspaper or for lunch while working then include this in this section. 3. In the last 7 days on average; how long did you sit for each of these meals per day? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting during dinner on a weekend day.
Real
Sitting wkend day dinner min
Phase 2 data. MEALS. Please think about the amount of time you spent sitting for breakfast; lunch and dinner; on average in the last 7 days. DO INCLUDE time spent sitting for breakfast lunch dinner or snacks (at home; work) also when you were reading chatting to other people or listening to the radio. For example if you spent 30 minutes sitting for breakfast while reading the newspaper or for lunch while working then include this in this section. 3. In the last 7 days on average; how long did you sit for each of these meals per day? WEEKEND DAY - LUNCH. 1 = none; 2 = 1-10 min; 3 = 10-20 min; 4 = 20-30 min; 5 = 30-45 min; 6 = 45 min - 1 hour; 7 = more than one hour a day; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Sitting wkday snack min
Phase 2 data. MEALS. Questionnaire read -Please think about the amount of time you spent sitting for breakfast; lunch and dinner; on average in the last 7 days. DO INCLUDE time spent sitting for breakfast lunch dinner or snacks (at home; work) also when you were reading chatting to other people or listening to the radio. For example if you spent 30 minutes sitting for breakfast while reading the newspaper or for lunch while working then include this in this section. 3. In the last 7 days on average; how long did you sit for each of these meals per day? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting while snacking on a weekday.
Real
Days sitting travel to/from occ1
Phase 2 data. TRAVELLING TO AND FROM OCC. This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. The questions are about travelling to and from your occupation - travelling as part of your occupation and getting about apart from your occupation. DO NOT include cycling on a pedal bicycle. 5. In the last 7 days how many days a week did you sit while travelling to and from your occupation 1? In number of days. -1 = left blank; -4 = range entered;
Real
Days sitting travel to/from occ2
Phase 2 data. TRAVELLING TO AND FROM OCC. Questionnaire read -This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. The questions are about travelling to and from your occupation - travelling as part of your occupation and getting about apart from your occupation. DO NOT include cycling on a pedal bicycle. 5. In the last 7 days how many days a week did you sit while travelling to and from your occupation 2? In number of days. Cleaned.
Real
Days sitting travel to/from occ2
Phase 2 data. TRAVELLING TO AND FROM OCC. This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. The questions are about travelling to and from your occupation - travelling as part of your occupation and getting about apart from your occupation. DO NOT include cycling on a pedal bicycle. 5. In the last 7 days how many days a week did you sit while travelling to and from your occupation 2? In number of days. -1 = left blank; -4 = range entered;
Real
Days sitting travel part of occ1
Phase 2 data. TRAVELLING AS PART OF OCC. Questionnaire read -This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. Now think about the time you sit while travelling as part of your occupation 1 for example driving from one customer to another - driving a taxi etc. DO NOT include cycling on a pedal bicycle. 7. In the last 7 days how many days a week did you sit while travelling as part of your occupation? In number in days. Cleaned.
Real
Sitting wkday snack min
Phase 2 data. MEALS. Please think about the amount of time you spent sitting for breakfast; lunch and dinner; on average in the last 7 days. DO INCLUDE time spent sitting for breakfast lunch dinner or snacks (at home; work) also when you were reading chatting to other people or listening to the radio. For example if you spent 30 minutes sitting for breakfast while reading the newspaper or for lunch while working then include this in this section. 3. In the last 7 days on average; how long did you sit for each of these meals per day? WEEKEND DAY - DINNER 1 = none; 2 = 1-10 min; 3 = 10-20 min; 4 = 20-30 min; 5 = 30-45 min; 6 = 45 min - 1 hour; 7 = more than one hour a day; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Sitting wkend day breakfast min
Phase 2 data. MEALS. Questionnaire read -Please think about the amount of time you spent sitting for breakfast; lunch and dinner; on average in the last 7 days. DO INCLUDE time spent sitting for breakfast lunch dinner or snacks (at home; work) also when you were reading chatting to other people or listening to the radio. For example if you spent 30 minutes sitting for breakfast while reading the newspaper or for lunch while working then include this in this section. 3. In the last 7 days on average; how long did you sit for each of these meals per day? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting during breakfast on a weekend day.
Real
Sitting wkend day breakfast min
Phase 2 data. MEALS. Please think about the amount of time you spent sitting for breakfast; lunch and dinner; on average in the last 7 days. DO INCLUDE time spent sitting for breakfast lunch dinner or snacks (at home; work) also when you were reading chatting to other people or listening to the radio. For example if you spent 30 minutes sitting for breakfast while reading the newspaper or for lunch while working then include this in this section. 3. In the last 7 days on average; how long did you sit for each of these meals per day? WEEKDAY - SNACKS 1 = none; 2 = 1-10 min; 3 = 10-20 min; 4 = 20-30 min; 5 = 30-45 min; 6 = 45 min - 1 hour; 7 = more than one hour a day; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Sitting wkend day snack min
Phase 2 data. MEALS. Questionnaire read -Please think about the amount of time you spent sitting for breakfast; lunch and dinner; on average in the last 7 days. DO INCLUDE time spent sitting for breakfast lunch dinner or snacks (at home; work) also when you were reading chatting to other people or listening to the radio. For example if you spent 30 minutes sitting for breakfast while reading the newspaper or for lunch while working then include this in this section. 3. In the last 7 days on average; how long did you sit for each of these meals per day? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting while snacking on a weekend day.
Real
Sitting wkend day snack min
Phase 2 data. MEALS. Please think about the amount of time you spent sitting for breakfast; lunch and dinner; on average in the last 7 days. DO INCLUDE time spent sitting for breakfast lunch dinner or snacks (at home; work) also when you were reading chatting to other people or listening to the radio. For example if you spent 30 minutes sitting for breakfast while reading the newspaper or for lunch while working then include this in this section. 3. In the last 7 days on average; how long did you sit for each of these meals per day? WEEKEND DAY - SNACKS 1 = none; 2 = 1-10 min; 3 = 10-20 min; 4 = 20-30 min; 5 = 30-45 min; 6 = 45 min - 1 hour; 7 = more than one hour a day; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Days sitting travel part of occ1
Phase 2 data. TRAVELLING AS PART OF OCC. This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. Now think about the time you sit while travelling as part of your occupation 1 for example driving from one customer to another - driving a taxi etc. DO NOT include cycling on a pedal bicycle. 7. In the last 7 days how many days a week did you sit while travelling as part of your occupation? In number in days. -1 = left blank; -4 = range entered;
Real
Days sitting travel part of occ2
Phase 2 data. TRAVELLING AS PART OF OCC. Questionnaire read -This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. Now think about the time you sit while travelling as part of your occupation 2 for example driving from one customer to another - driving a taxi etc. DO NOT include cycling on a pedal bicycle. 7. In the last 7 days how many days a week did you sit while travelling as part of your occupation? In number in days. Cleaned.
Real
Days sitting travel part of occ2
Phase 2 data. TRAVELLING AS PART OF OCC. This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. Now think about the time you sit while travelling as part of your occupation 2 for example driving from one customer to another - driving a taxi etc. DO NOT include cycling on a pedal bicycle. 7. In the last 7 days how many days a week did you sit while travelling as part of your occupation? In number in days. -1 = left blank; -4 = range entered;
Real
Occupation in last 7 days
Phase 2 data. WORK STUDY VOLUNTEERING. Questionnaire read -This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 10. Did you have an occupation in the last 7 days? 2 = yes; 3 = no; -1 = left blank. Cleaned.
Categorical
Wkday sitting watch TV min
Phase 2 data. SCREEN TIME. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. 17. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? WATCHING TV; dvds/videos on a WEEKDAY. DO include meals while sitting and watching TV? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying while watching TV on a weekday.
Real
Wkday sitting while TV min
Phase 2 data. SCREEN TIME. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. 17. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? WATCHING TV; dvds/videos on a WEEKDAY. DO include meals while sitting and watching TV. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Wkend sitting watch TV min
Phase 2 data. SCREEN TIME. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. 17. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? WATCHING TV; dvds/videos on a WEEKEND DAY. DO include meals while sitting and watching TV? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying while watching TV on a weekend day.
Real
Wkend sitting while TV min
Phase 2 data. SCREEN TIME. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. 17. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? WATCHING TV; dvds/videos on a WEEKEND DAY. DO include meals while sitting and watching TV. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Wkday sit using computer min
Phase 2 data. SCREEN TIME. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. 17. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? USING COMPUTER apart from work (internet; e-mail; chat; networking (Facebook) on a WEEKDAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying while using a computer apart from work on a weekday.
Real
Occupation in last 7 days (2=Y;3=N)
Phase 2 data. WORK STUDY VOLUNTEERING. This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 10. Did you have an occupation in the last 7 days? If you did not have an occupation in the last 7 days please skip to section 5. 2 = yes; 3 = no; -1 = left blank; -5 = more than one selected;
Categorical
Type of occupation1
Phase 2 data. WORK STUDY VOLUNTEERING. Questionnaire read -This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 11a. Type of occupation 1? 1 = work; 2 = study; 3 = volunteering. If more than one type of occupation was selected; kept information by coding with decimal e.g.?(-5)1 and ? recoded as 1.2. Cleaned.
Categorical
Type of occ1
Phase 2 data. WORK STUDY VOLUNTEERING. This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 11a. Type of occupation 1. 1 = work; 2 = study; 3 = volunteering; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions;
Categorical
Name of occupation 1
Phase 2 data. WORK STUDY VOLUNTEERING. Questionnaire read -This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 12a. Name of occupation 1 (e.g. receptionist)? -1 = left blank.
Text
Wkday sit using computer min
Phase 2 data. SCREEN TIME. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. 17. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? USING COMPUTER apart from work (internet; e-mail; chat; networking (Facebook;…)) on a WEEKDAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Wkend sit using computer min
Phase 2 data. SCREEN TIME. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. 17. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? USING COMPUTER apart from work (internet; e-mail; chat; networking (Facebook) on a WEEKEND DAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying while using a computer apart from work on a weekend day.
Real
Wkend sit using computer min
Phase 2 data. SCREEN TIME. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. 17. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? USING COMPUTER apart from work (internet; e-mail; chat; networking (Facebook;…)) on a WEEKEND DAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Wkday sit computer games min
Phase 2 data. SCREEN TIME. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. 17. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? PLAYING COMPUTER GAMES (playstation; Xbox etc) do NOT included non-sitting games; on a WEEKDAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying while playing computer games on a weekday.
Real
Wkday sit computer games min
Phase 2 data. SCREEN TIME. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. 17. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? PLAYING COMPUTER GAMES (playstation; Xbox etc) do NOT included non-sitting games; on a WEEKDAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Name of occupation 1
Phase 2 data. WORK STUDY VOLUNTEERING. This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 12a. Name of occupation 1 (e.g. receptionist). -1 = left blank;
Text
Number of days doing occ1
Phase 2 data. WORK STUDY VOLUNTEERING OCC 1. Questionnaire read -This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 13a. How many days did you do occupation 1 in the last 7 days? In number of days. Cleaned.
Real
Number of days doing occ1
Phase 2 data. WORK STUDY VOLUNTEERING OCC 1. This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 13a. How many days did you do occupation 1 in the last 7 days? In number of days. -1 = left blank; -4 = range entered;
Real
Freq interrupt sitting time occ1
Phase 2 data. WORK STUDY VOLUNTEERING OCC 1. Questionnaire read -This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 15a. In the last 7 days on average how many times per day did you interrupt your sitting time while doing occupation 1 for example by standing up; walking somewhere or getting a coffee? Cleaned. Number/day.
Real
Wkend sit computer games min
Phase 2 data. SCREEN TIME. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. 17. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? PLAYING COMPUTER GAMES (playstation; Xbox etc) do NOT included non-sitting games; on a WEEKEND DAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying while playing computer games on a weekend day.
Real
Wkend sit computer games min
Phase 2 data. SCREEN TIME. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. 17. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? PLAYING COMPUTER GAMES (playstation; Xbox etc) do NOT included non-sitting games; on a WEEKEND DAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Wkday time sit travel not from occ
Phase 2 data. GETTING ABOUT. Questionnaire read -This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. Now think about the time you sit while getting about apart from your occupation for example when going to the supermarket; going to visit friends etc. Please include time spent sitting to and from your destination. DO NOT include cycling on a pedal bicycle. 9. In the last 7 days on average how long did you sit for getting about apart from your occupation per day on a WEEKDAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting while travelling for getting about apart from your occupation on a weekday.
Real
Wkd time sit travel apart from occ
Phase 2 data. GETTING ABOUT. This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. Now think about the time you sit while getting about apart from your occupation for example when going to the supermarket; going to visit friends etc. Please include time spent sitting to and from your destination. DO NOT include cycling on a pedal bicycle. 9. In the last 7 days on average how long did you sit for getting about apart from your occupation per day on a WEEKDAY? 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30-45 min; 5 = 45 min -1 hour; 6 = 1-1.5 hours; 7 = 1.5-2 hours; 8 = 2-2.5 hours; 9 = 2.5-3 hours; 10 = 3-4 hours; 11 = 4-5 hours; 12 = 5-6 hours ; 13 = 6-7 hours; 14 = More than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Wkend time sit travel not from occ
Phase 2 data. GETTING ABOUT. Questionnaire read -This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. Now think about the time you sit while getting about apart from your occupation for example when going to the supermarket; going to visit friends etc. Please include time spent sitting to and from your destination. DO NOT include cycling on a pedal bicycle. 9. In the last 7 days on average how long did you sit for getting about apart from your occupation per day on a WEEKEND DAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting while travelling for getting about apart from your occupation on a weekend day.
Real
Freq interrupt sitting time occ1
Phase 2 data. WORK STUDY VOLUNTEERING OCC 1. This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 15a. In the last 7 days on average how many times per day did you interrupt your sitting time while doing occupation 1 for example by standing up; walking somewhere or getting a coffee? -1 = left blank; -4 = range entered;
Real
Second occupation
Phase 2 data. WORK STUDY VOLUNTEERING OCC 2. Questionnaire read -This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 16. Did you have a second occupation in the last 7 days? 2 = yes; 3 = no; -1 = left blank. Cleaned.
Categorical
Second occupation
Phase 2 data. WORK STUDY VOLUNTEERING OCC 2. This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 16. Did you have a second occupation in the last 7 days? 2 = yes; 3 = no; -1 = left blank; -5 = more than one selected;
Categorical
Type of occupation2
Phase 2 data. WORK STUDY VOLUNTEERING OCC 2. This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 11b. Type of occupation 2. 1 = work; 2 = study; 3 = volunteering. If more than one type of occupation was selected; kept information by coding with decimal e.g.?(-5)1 and ? recoded as 1.2. Cleaned.
Categorical
Wknd time sit travel apart from occ
Phase 2 data. GETTING ABOUT. This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. Now think about the time you sit while getting about apart from your occupation for example when going to the supermarket; going to visit friends etc. Please include time spent sitting to and from your destination. DO NOT include cycling on a pedal bicycle. 9. In the last 7 days on average how long did you sit for getting about apart from your occupation per day on a WEEKEND DAY? 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30-45 min; 5 = 45 min -1 hour; 6 = 1-1.5 hours; 7 = 1.5-2 hours; 8 = 2-2.5 hours; 9 = 2.5-3 hours; 10 = 3-4 hours; 11 = 4-5 hours; 12 = 5-6 hours ; 13 = 6-7 hours; 14 = More than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Time sit travel to/from occ1 min
Phase 2 data. TRAVELLING TO AND FROM OCC. Questionnaire read -This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. The questions are about travelling to and from your occupation - travelling as part of your occupation and getting about apart from your occupation. DO NOT include cycling on a pedal bicycle. 6. In the last 7 days on average how long did you sit while travelling to and from your occupation 1 on such a day? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting while travelling to and from occupation 1.
Real
Time sit travel to/from occ1 (min)
Phase 2 data. TRAVELLING TO AND FROM OCC. This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. The questions are about travelling to and from your occupation - travelling as part of your occupation and getting about apart from your occupation. DO NOT include cycling on a pedal bicycle. 6. In the last 7 days on average how long did you sit while travelling to and from your occupation 1 on such a day? 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30-45 min; 5 = 45 min -1 hour; 6 = 1-1.5 hours; 7 = 1.5-2 hours; 8 = 2-2.5 hours; 9 = 2.5-3 hours; 10 = 3-4 hours; 11 = 4-5 hours; 12 = 5-6 hours ; 13 = 6-7 hours; 14 = More than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Time sit travel to/from occ2 min
Phase 2 data. TRAVELLING TO AND FROM OCC. Questionnaire read -This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. The questions are about travelling to and from your occupation - travelling as part of your occupation and getting about apart from your occupation. DO NOT include cycling on a pedal bicycle. 6. In the last 7 days on average how long did you sit while travelling to and from your occupation 2 on such a day? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting while travelling to and from occupation 2.
Real
Time sit travel to/from occ2 (min)
Phase 2 data. TRAVELLING TO AND FROM OCC. This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. The questions are about travelling to and from your occupation - travelling as part of your occupation and getting about apart from your occupation. DO NOT include cycling on a pedal bicycle. 6. In the last 7 days on average how long did you sit while travelling to and from your occupation 2 on such a day? 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30-45 min; 5 = 45 min -1 hour; 6 = 1-1.5 hours; 7 = 1.5-2 hours; 8 = 2-2.5 hours; 9 = 2.5-3 hours; 10 = 3-4 hours; 11 = 4-5 hours; 12 = 5-6 hours ; 13 = 6-7 hours; 14 = More than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Type of occ2
Phase 2 data. WORK STUDY VOLUNTEERING OCC 2. This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 11b. Type of occupation 2. 1 = work; 2 = study; 3 = volunteering; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions;
Categorical
Name of occupation 2
Phase 2 data. WORK STUDY VOLUNTEERING OCC 2. Questionnaire read -This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 12B. Name of occupation 2 (e.g. receptionist)? -1 = left blank.
Text
Name of occupation 2
Phase 2 data. WORK STUDY VOLUNTEERING OCC 2. This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 12B. Name of occupation 2 (e.g. receptionist). -1 = left blank;
Text
Number of days doing occ2
Phase 2 data. WORK STUDY VOLUNTEERING OCC 2. Questionnaire read -This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 13B. How many days did you do occupation 2 in the last 7 days? In number of days. Cleaned.
Real
Number of days doing occ2
Phase 2 data. WORK STUDY VOLUNTEERING OCC 2. This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 13B. How many days did you do occupation 2 in the last 7 days? In number of days. -1 = left blank; -4 = range entered;
Real
Time sit travel part of occ1 min
Phase 2 data. TRAVELLING AS PART OF OCC. Questionnaire read -This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. Now think about the time you sit while travelling as part of your occupation 1 for example driving from one customer to another - driving a taxi etc. DO NOT include cycling on a pedal bicycle. 8. In the last 7 days on average how long did you sit while travelling as part of your occupation 1 on such a day? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting while travelling as part of occupation 1.
Real
Time sit travel part of occ1 (min)
Phase 2 data. TRAVELLING AS PART OF OCC. This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. Now think about the time you sit while travelling as part of your occupation 1 for example driving from one customer to another - driving a taxi etc. DO NOT include cycling on a pedal bicycle. 8. In the last 7 days on average how long did you sit while travelling as part of your occupation 1 on such a day? 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30-45 min; 5 = 45 min -1 hour; 6 = 1-1.5 hours; 7 = 1.5-2 hours; 8 = 2-2.5 hours; 9 = 2.5-3 hours; 10 = 3-4 hours; 11 = 4-5 hours; 12 = 5-6 hours ; 13 = 6-7 hours; 14 = More than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Time sit travel part of occ2 min
Phase 2 data. TRAVELLING AS PART OF OCC. Questionnaire read -This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. Now think about the time you sit while travelling as part of your occupation 1 for example driving from one customer to another - driving a taxi etc. DO NOT include cycling on a pedal bicycle. 8. In the last 7 days on average how long did you sit while travelling as part of your occupation 2 on such a day? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting while travelling as part of occupation 2.
Real
Time sit travel part of occ2 (min)
Phase 2 data. TRAVELLING AS PART OF OCC. This section refers to the time you spent sitting during transportation (travelling in a car - bus - train - on a motorbike etc.) in the last 7 days. Now think about the time you sit while travelling as part of your occupation 1 for example driving from one customer to another - driving a taxi etc. DO NOT include cycling on a pedal bicycle. 8. In the last 7 days on average how long did you sit while travelling as part of your occupation 2 on such a day? 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30-45 min; 5 = 45 min -1 hour; 6 = 1-1.5 hours; 7 = 1.5-2 hours; 8 = 2-2.5 hours; 9 = 2.5-3 hours; 10 = 3-4 hours; 11 = 4-5 hours; 12 = 5-6 hours ; 13 = 6-7 hours; 14 = More than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Time sitting while doing occ1
Phase 2 data. WORK STUDY VOLUNTEERING OCC 1. Questionnaire read -This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 14a. In the last 7 days on average how much time per day did you spend sitting while doing occupation 1? Do NOT include time spent sitting for transportation (in a car - bus - train - on a motorbike etc.) either for travelling to and from this occupation or as part of this occupation or breakfast; lunch or dinner as these were part of section 2 and 3? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting while doing occupation 1.
Real
Freq interrupt sitting time occ2
Phase 2 data. WORK STUDY VOLUNTEERING OCC 2. Questionnaire read -This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 15B. In the last 7 days on average how many times per day did you interrupt your sitting time while doing occupation 2 for example by standing up; walking somewhere or getting a coffee? Cleaned. Number/day.
Real
Freq interrupt sitting time occ2
Phase 2 data. WORK STUDY VOLUNTEERING OCC 2. This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 15B. In the last 7 days on average how many times per day did you interrupt your sitting time while doing occupation 2 for example by standing up; walking somewhere or getting a coffee? -1 = left blank; -4 = range entered;
Real
Freq interrupt TV sitting time
Phase 2 data. SCREEN TIME. Questionnaire read -Now think about the total time you spent watching TV in the last 7 days. If you did not watch TV in the last 7 days please skip to the Other activities section below. If you did watch TV in the last 7 days please answer the questions below. 18. In the last 7 days on average how many times per day did you interrupt your sitting time while watching TV? for example by standing up; walking somewhere or getting a drink? In number of times? Number/day. Cleaned.
Real
Freq interrupt TV sitting time
Phase 2 data. SCREEN TIME. Now think about the total time you spent watching TV in the last 7 days. If you did not watch TV in the last 7 days please skip to the Other activities section below. If you did watch TV in the last 7 dayS please answer the questions below. 18. In the last 7 days on average how many times per day did you interrupt your sitting time while watching TV? for example by standing up; walking somewhere or getting a drink? In number of times. -1 = left blank; -4 = range entered;
Real
Time sitting while doing occ1
Phase 2 data. WORK STUDY VOLUNTEERING OCC 1. This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 14a. In the last 7 days on average how much time per day did you spend sitting while doing occupation 1? Do NOT include time spent sitting for transportation (in a car - bus - train - on a motorbike etc.) either for travelling to and from this occupation or as part of this occupation. This was part of section 3 or breakfast - lunch or dinner. This was part of section 2. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = 7-8 hours; 12 = more than 8 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Time sitting while doing occ2
Phase 2 data. WORK STUDY VOLUNTEERING OCC 2. Questionnaire read -This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 14B. In the last 7 days on average how much time per day did you spend sitting while doing occupation 2? Do NOT include time spent sitting for transportation (in a car - bus - train - on a motorbike etc.) either for travelling to and from this occupation or as part of this occupation or breakfast; lunch or dinner as these were part of section 2 and 3? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting while doing occupation 2.
Real
Time spentsitting while doing occ2
Phase 2 data. WORK STUDY VOLUNTEERING OCC 2. This section is about the time you spent sitting during your occupation which refers to work - study and volunteering. Please think about all three of these categories for the following questions. 14B. In the last 7 days on average how much time per day did you spend sitting while doing occupation 2? Do NOT include time spent sitting for transportation (in a car - bus - train - on a motorbike etc.) either for travelling to and from this occupation or as part of this occupation. This was part of section 3 or breakfast - lunch or dinner. This was part of section 2. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = 7-8 hours; 12 = more than 8 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Wkday sitting reading min
Phase 2 data. OTHER ACTIVITIES. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING WHILE READING (book; magazine; newspaper; ) on a WEEKDAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying down while reading on a weekday.
Real
Wkday sitting reading min
Phase 2 data. OTHER ACTIVITIES. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING WHILE READING (book; magazine; newspaper; ). on a WEEKDAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Av sed travel apart from occmin
Phase 2 data. Total sedentary time travelling apart from occupation. Calculated and weighted by weekday and weekend day sedentary travelling time. (mins/day)
Real
Av day sed caring min
Phase 2 data. Average time spent sitting while caring; weighted by weekday and weekend day. (mins/day)
Real
Av sed computer; non-occ min
Phase 2 data. Average day sedentary time while using a computer apart from work; weighted by weekday and weekend day. (mins/day)
Real
Av sed non-occ computer min
Phase 2 data. Average day sedentary time while using a computer for non-occupational use. Calculated from tot_dur_comp_day and tot_dur_game_day; weighted by weekday and weekend day. (mins/day)
Real
Wkday sed non-occ computer min
Phase 2 data. Weekday sedentary time while using a computer for non-occupational use. Calculated from dE17_3_dur_comp_wd_c and dE17_5_dur_game_wd_c. (mins/day)
Real
Wkend sed non-occ computer min
Phase 2 data. Weekend day sedentary time while using a computer for non-occupational use. Calculated from dE17_4_dur_comp_wndd_c dE17_6_dur_game_wndd_c. (mins/day)
Real
Wkend sitting reading min
Phase 2 data. OTHER ACTIVITIES. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING WHILE READING (book; magazine; newspaper) on a WEEKEND DAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying down while reading on a weekend day.
Real
Wkend sitting reading min
Phase 2 data. OTHER ACTIVITIES. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING WHILE READING (book; magazine; newspaper; ). on a WEEKEND DAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Wkday sitting household min
Phase 2 data. OTHER ACTIVITIES. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING WHILE DOING HOUSEHOLD TASKS (cooking; ironing) on a WEEKDAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying down while doing household tasks on a weekday.
Real
Wkday sitting household min
Phase 2 data. OTHER ACTIVITIES. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING WHILE DOING HOUSEHOLD TASKS (cooking; ironing; ). on a WEEKDAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Av sed computer games min
Phase 2 data. Average day sedentary time while playing computer games; weighted by weekday and weekend day. (mins/day)
Real
Av day sed hobbies min
Phase 2 data. Average time spent sitting for hobbies; weighted by weekday and weekend day. (mins/day)
Real
Av day sed household min
Phase 2 data. Average time spent sitting while doing household tasks; weighted by weekday and weekend day. (mins/day)
Real
Av meals sed time min
Phase 2 data. Weighted average time spent sedentary during meal times. Calculated from and weighted by weekday and weekend sedentary time during meals. (mins/day)
Real
Wkday meals sed time min
Phase 2 data. Weekday time spent sedentary during meal times. (mins/day)
Real
Wkend meals sed time min
Phase 2 data. Weekend day time spent sedentary during meal times. (mins/day)
Real
Av day sed music min
Phase 2 data. Average time spent sitting while listening to music; weighted by weekday and weekend day. (mins/day)
Real
Average napping duration min
Phase 2 data. Weighted average day napping duration calculated from weekday and weekend napping durations. (mins/day)
Real
Av occ sed time min
Phase 2 data. Total occupational sedentary time calculated from sedentary time during occupation 1 and occupation 2. (mins/day)
Real
Av day sed other acts min
Phase 2 data. Average time spent sitting for other activities (activity not previously listed); weighted by weekday and weekend day. (mins/day)
Real
Wkend sitting household min
Phase 2 data. OTHER ACTIVITIES. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING WHILE DOING HOUSEHOLD TASKS (cooking; ironing; ) on a WEEKEND DAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying down while doing household tasks on a weekend day.
Real
Wkend sitting household min
Phase 2 data. OTHER ACTIVITIES. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING WHILE DOING HOUSEHOLD TASKS (cooking; ironing; ). on a WEEKEND DAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Wkday sitting caring min
Phase 2 data. OTHER ACTIVITIES. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING WHILE CARING (for children; grandchildren; elderly or disabled relatives; ) on a WEEKDAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying down while caring on a weekday.
Real
Wkday sitting caring min
Phase 2 data. OTHER ACTIVITIES. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING WHILE CARING (for children; grandchildren; elderly or disabled relatives; ). on a WEEKDAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Av day total other sed min
Phase 2 data. Average day total sedentary time of all other activities (e.g. reading; household tasks etc.) Weighted by weekday and weekend day. (mins/day)
Real
Wkday total other sed min
Phase 2 data. Weekday total sedentary time of all other activities (e.g. reading; household tasks etc.) (mins/day)
Real
Wkend day total other sed min
Phase 2 data. Weekend day total sedentary time of all other activities (e.g. reading; household tasks etc.) (mins/day)
Real
Av sed travel part of occ min
Phase 2 data. Total sedentary time travelling as part of occupation. Calculated from sedetary time travelling as part of occupation 1 and occupation 2. (mins/day)
Real
Av day sed reading min
Phase 2 data. Average time spent sitting while reading; weighted by weekday and weekend day. (mins/day)
Real
Av day total sed screen time min
Phase 2 data. Average day total screen time sedentary time (including TV viewing; non-occupational computer use and computer games sedentary time). Weighted by weekday and weekend day. (mins/day)
Real
Wkday sed screen time min
Phase 2 data. Weekday total screen time sedentary time (including TV viewing; non-occupational computer use and computer games sedentary time). (mins/day)
Real
Wkend day sed screen time min
Phase 2 data. Weekend day total screen time sedentary time (including TV viewing; non-occupational computer use and computer games sedentary time). (mins/day)
Real
Wkend sitting caring min
Phase 2 data. OTHER ACTIVITIES. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING WHILE CARING (for children; grandchildren; elderly or disabled relatives) on a WEEKEND DAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying down while caring on a weekend day.
Real
Wkend sitting caring min
Phase 2 data. OTHER ACTIVITIES. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING WHILE CARING (for children; grandchildren; elderly or disabled relatives; ). on a WEEKEND DAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Wkday sitting hobbies min
Phase 2 data. OTHER ACTIVITIES. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING FOR HOBBIES (platying piano; cards; doing crosswords; ) on a WEEKDAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying down for hobbies on a weekday.
Real
Wkday sitting hobbies min
Phase 2 data. OTHER ACTIVITIES. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING FOR HOBBIES (platying piano; cards; doing crosswords; ). on a WEEKDAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Av day total sed time min
Phase 2 data. Average day total sedentary time (including sleep; meal time; occupation; screen time etc.) Weighted by weekday and weekend. (mins/day)
Real
Av day total sed time awake min
Phase 2 data. Average day total sedentary time (awake time only but including meal time; occupation; screen time etc.) Weighted by weekday and weekend. (mins/day)
Real
Av sleep dur exc napping min
Phase 2 data. Weighted average day sleep duration (excluding napping) calculated from weekday and weekend day sleep durations. (mins/day)
Real
Av sleep dur inc napping min
Phase 2 data. Average sleep duration including napping calculated from weighted average of sleep and nap durations (mins/day)
Real
Wkday sleep dur inc nap min
Phase 2 data. Weekday sleep duration including napping calculated from reported weekday sleep times and napping durations. (mins/day)
Real
Wkend sleep dur inc nap min
Phase 2 data. Weekend day sleep duration including napping calculated from reported weekend day sleep times and napping durations (mins/day)
Real
Av day sed socialising min
Phase 2 data. Average time spent sitting for socialising; weighted by weekday and weekend day. (mins/day)
Real
Av sed travel to/from occ min
Phase 2 data. Total sedentary time travelling to and from occupation. Calculated from sedetary time travelling to and from occupation 1 and occupation 2. (mins/day)
Real
Wkend sitting hobbies min
Phase 2 data. OTHER ACTIVITIES. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING FOR HOBBIES (playing piano; cards; doing crosswords) on a WEEKEND DAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying down for hobbies on a weekend day.
Real
Wkend sitting hobbies min
Phase 2 data. OTHER ACTIVITIES. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING FOR HOBBIES (platying piano; cards; doing crosswords; ). on a WEEKEND DAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Wkday sitting socialising min
Phase 2 data. OTHER ACTIVITIES. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING FOR SOCIALISING (visiting friends; pub; cinema; sporting event) on a WEEKDAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying down while socialising on a weekday.
Real
Wkday sitting socialising min
Phase 2 data. OTHER ACTIVITIES. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING FOR SOCIALISING (visiting friends; pub; cinema; sporting event; ). on a WEEKDAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Av total sed transport min
Phase 2 data. Total transportation sedentary time. Calculated from total occupational sedentary time travelling and total sedentary time travelling apart from occupation. (mins/day)
Real
Av sed occ transport min
Phase 2 data. Total occupational sedentary time travelling. Calculated from sedentary time travelling to and from occupation 1 and 2 and sedentary time as part of occupation 1 and 2. (mins/day)
Real
Av sed time watching TV min
Phase 2 data. Weighted average sedentary time while watching TV; calculated from weekday and weekend day TV viewing sedentary time (dE17_1_dur_tv_wd_c and dE17_2_dur_tv_wndd_c). (mins/day)
Real
Wkday sed time watching TV hr/d
Phase 2 data. Weekday TV viewing sedentary time. (hrs/day)
Real
Wkend sed time watching TV hr/d
Phase 2 data. Weekend day TV viewing sedentary time. (hrs/day)
Real
None
Phase 2 data. Wyman Dillon batch number for 7DSB data entry batch
Text
Wkday sleep duration decimal
Phase 2 data. Sleep duration on a weekday calculated from go sleep and get up times (decimal)
Real
Wkend sleep duration decimal
Phase 2 data. Sleep duration on a weekend day calculated from go sleep and get up times (decimal)
Real
Cln variable: Skiing hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Skiing or snowboarding. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Wkend sitting socialising min
Phase 2 data. OTHER ACTIVITIES. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING FOR SOCIALISING (visiting friends; pub; cinema; sporting event; ) on a WEEKEND DAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying down while socialising on a weekend day.
Real
Wkend sitting socialising min
Phase 2 data. OTHER ACTIVITIES. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING FOR SOCIALISING (visiting friends; pub; cinema; sporting event; ). on a WEEKEND DAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Wkday sitting music min
Phase 2 data. OTHER ACTIVITIES. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING WHILE LISTENING TO MUSIC (radio; CD; MP3; iPOD; ) on a WEEKDAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying down while listening to music on a weekday.
Real
Wkday sitting music min
Phase 2 data. OTHER ACTIVITIES. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING WHILE LISTENING TO MUSIC (radio; CD; MP3; iPOD; ). on a WEEKDAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Skiing or snowboarding hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Skiing Or snowboarding. -1 = left blank. DO NOT USE THIS VARIABLE. Use SkiHr_CLEAN_P2 instead.
Real
Cln variable: Skiing min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Skiing or snowboarding. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Skiing or snowboarding min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Skiing Or Snowboarding. -1 = left blank. DO NOT USE THIS VARIABLE. Use SkiMin_CLEAN_P2 instead.
Real
Cln variable: Skiing
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Skiing or snowboarding. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Skiing or snowboarding
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Skiing or snowboarding. DO NOT USE THIS VARIABLE. Use Ski_CLEAN_P2 instead.
Real
Skiing or snowboarding
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Skiing or snowboarding. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Wkend sitting music min
Phase 2 data. OTHER ACTIVITIES. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING WHILE LISTENING TO MUSIC (radio; CD; MP3; iPOD; ) on a WEEKEND DAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying down while listening to music on a weekend day.
Real
Wkend sitting music min
Phase 2 data. OTHER ACTIVITIES. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING WHILE LISTENING TO MUSIC (radio; CD; MP3; iPOD; ). on a WEEKEND DAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Name of other sitting activity
Phase 2 data. OTHER ACTIVITIES. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING FOR OTHER ACTIVITIES write below? Name of other activitiy that is not previously listed. -1 = left blank.
Text
Name of other sitting activity
Phase 2 data. OTHER ACTIVITIES. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING FOR OTHER ACTIVITIES write below (radio; CD; MP3; iPOD; ). on a WEEKDAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Wkday sitting other act min
Phase 2 data. OTHER ACTIVITIES. Questionnaire read:?This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING FOR OTHER ACTIVITIES on a WEEKDAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying down for other activities (activity not previously listed) on a weekday.
Real
Sleep HR during AH free living
Phase 2 data. Sleeping Heart Rate during AH (Actiheart) free living. The SHR is set as the average ofthe highest value of the thirty lowest minute-by-minute HR readings during each 24 hr day when the monitor was worn.
Real
Weighted avg daily sleep duration
Phase 2 data. Weighted average daily sleep duration (hours) from cleaned GenQ sleep times
Real
Assigned Sleep duration (hours)
Phase 2 data. Derived with method 2. Assigned Sleep duration (hours)
Real
Agilent slide barcode
Phase 2 data. Agilent slide barcode
Text
Wkday sitting other act min
Phase 2 data. OTHER ACTIVITIES. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING FOR OTHER ACTIVITIES write below (radio; CD; MP3; iPOD; ). on a WEEKEND DAY. 1 = None; 2 = 1-15 min; 3 = 15-30 min; 4 = 30 min - 1 hour; 5 = 1 -2 hours; 6 = 2-3 hours; 7 = 3-4 hours; 8 =4-5 hours; 9 = 5-6 hours; 10 = 6-7 hours; 11 = more than 7 hours; -1 = left blank; -5 = more than 1 selected; -10 = does not fit any other instructions; -51 = both crosses and ticks used and tick is weighted as the correct one (-51) 1 AND 4 - 4 where the dominant (ticked) value is repeated at the end;
Categorical
Wkend sitting other act min
Phase 2 data. OTHER ACTIVITIES. Questionnaire read -This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING FOR OTHER ACTIVITIES write below (radio; CD; MP3; iPOD). on a WEEKEND DAY? Questionnaire values were reported in categories of time E.g. 1-15mins. Values cleaned and standardised to minutes (mid point of category used) to produce minutes per day sitting or lying down for other activities (activity not previously listed) on a weekend day.
Real
Wkend sitting other act min
Phase 2 data. OTHER ACTIVITIES. This last section refers to the time you spent sitting or lying down during other activities in the last 7 days. Remember each period of sitting down should only be entered once. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. Please remember that each period of sitting down should only be entered once. Please; do not include time already reported in the Meals section. 19. In the last 7 days on average how long did you spend sitting or lying down in the following activities per day? SITTING FOR OTHER ACTIVITIES write below. Name. -1 = left blank;
Real
Sitting-lying last 7 days
Phase 2 data. Questionnaire read-These questions are about the amount of time that you spent sitting or lying down in the last 7 days. This questionnaire is organised into five sections; each asking about sitting or lying down in different settings. Compare your amount of sitting time over the last 7 days with a typical week for you. Each period of sitting down should only be entered once on this questionnaire. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. If there is a big difference between different weekdays or between different weekend days for some answers then tick the box which is nearest to the average for those weekdays or weekend days in the last 7 days. The focus of this questionnaire is sitting and lying while doing the activities specified below. If some of these activities also involved standing or walking around please try to only include the time spent sitting and lying during these activities. If you tick the wrong box please put a large cross through it and then tick the correct box. In the last 7 days my amount of sitting was? 1 = Much less than normal; 2 = A little less than normal; 3 = About the same; 4 = A little more than normal; 5 = A lot more than normal; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction. Cleaned
Categorical
Smoking History
Phase 2 data. Current Smoking Consumption History / Status. Derived from GenQ Qs by DM team JAVA script. Pls request G_SMOKE variable as well. 0 = never smoked; 1 = ex smoker; 2 = current; 9 = not known;
Categorical
Smoking Status Code
Phase 2 data. Smoking status as deduced by study team based on Gen Q entry by participant. Used for feedback to GP along with blood test results. This should not be used for data analysis but could be used for cross-checking. Use main set of smoking variables derived from General quetionnaire for anlysis. 1 = ex smoker; 2 = current smoker; 0 = never smoked;
Categorical
Smoking Status
Phase 2 data. Whether volunteer smokes has previously quit smoking (and year) or never smoked. Free text data item which can provide additional information to SmokingStatusCode. Used for participant and GP feedback only. Not for analysis
Text
Snack Given
Phase 2 data. Details of Snack Given prior to exercise. Related to Hemocue results. Free text
Text
Cln variable: Snooker Billiards hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Snooker Billiards Or Darts. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Snooker billiards or darts hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Snooker Billiards Or Darts. -1 = left blank. DO NOT USE THIS VARIABLE. Use snookerBillardsDartsHr_CLEAN_P2 instead.
Real
Sitting time in the last 7 days
Phase 2 data. These questions are about the amount of time that you spent sitting or lying down in the last 7 days. This questionnaire is organised into five sections; each asking about sitting or lying down in different settings. Compare your amount of sitting time over the last 7 days with a typical week for you. Each period of sitting down should only be entered once on this questionnaire. For example if you spent one hour sitting on the sofa reading a book while you were listening to music count this time as one hour reading if this was your main focus. Do not also count this as one hour listening to music. If there is a big difference between different weekdays or between different weekend days for some answers then tick the box which is nearest to the average for those weekdays or weekend days in the last 7 days. The focus of this questionnaire is sitting and lying while doing the activities specified below. If some of these activities also involved standing or walking around please try to only include the time spent sitting and lying during these activities. If you tick the wrong box please put a large cross through it and then tick the correct box. In the last 7 days my amount of sitting was? 1 = Much less than normal; 2 = A little less than normal; 3 = About the same; 4 = A little more than normal; 5 = A lot more than normal; -1 = left blank; -5 = more than one selected; -10 = does not fit with any other instruction;
Categorical
Cln variable: Snooker Billiards min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Snooker Billiards Or Darts. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Snooker billiards or darts min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Snooker Billiards Or Darts. -1 = left blank. DO NOT USE THIS VARIABLE. Use snookerBillardsDartsMin_CLEAN_P2 instead.
Real
Cln variable: Snooker Billiards
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Snooker Billiards Or Darts. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Snooker billiards or darts
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Snooker billiards or darts. DO NOT USE THIS VARIABLE. Use snookerBillardsDarts_CLEAN_P2 instead.
Real
Snooker Billiards or Darts
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Snooker Billiards Or Darts. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Vegetable Soups bowl
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Meat Soups bowl
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Sauces eg white sauce cheese sauce
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Tomato Ketchup tablespoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Pickles chutney tablespoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Marmite Bovril teaspoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Jam Marmalade honey teaspoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Peanut Butter teaspoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Cln variable: Squash hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Squash. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Squash hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Squash. -1 = left blank. DO NOT USE THIS VARIABLE. Use squashHr_CLEAN_P2 instead.
Real
Cln variable: Squash min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Squash. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Squash min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Squash. -1 = left blank. DO NOT USE THIS VARIABLE. Use squashMin_CLEAN_P2 instead.
Real
Cln variable: Squash
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Squash. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Squash
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Squash. DO NOT USE THIS VARIABLE. Use squash_CLEAN_P2 instead.
Real
Squash
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Squash. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
No times stairs climbed home wkday
Phase 2 data. Questionnaire reads D4. Stair climbing at home. Number of times you climbed up a flight of stairs (approx 10 steps) each day at home on a weekday. Average over the last 4 weeks. 1 = none; 2 = 1 to 5 times a day; 3 = 6 to 10 times a day; 4 = 11 to 15 times a day; 5 = 16 to 20 times a day; 6 = more than 20 times a day; -1 = left blank; -5 = more than one selected;
Categorical
No times stairs climbed home wknday
Phase 2 data. Questionnaire reads D4. Stair climbing at home. Number of times you climbed up a flight of stairs (approx 10 steps) each day at home on a weekend day. Average over the last 4 weeks. 1 = none; 2 = 1 to 5 times a day; 3 = 6 to 10 times a day; 4 = 11 to 15 times a day; 5 = 16 to 20 times a day; 6 = more than 20 times a day; -1 = left blank; -5 = more than one selected;
Categorical
Anthro team Study Support Comments
Phase 2 data. Anthro team Study Support Comments on tests performed data quality or samples missing. No data available for participants not included in R6 or earlier.
Text
Sponge puddings ready made
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Milk puddings
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Ice cream choc ices
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Chocolates single or squares
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Chocolate snack bars
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Sweets toffees mints
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Sugar added to tea coffee cereal teaspoon
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Crisps or other packet snacks
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Peanuts or other nuts
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Sweet biscuits chocolate
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Sweet biscuits plain
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Cakes: fruit; sponge; home baked
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Cakes: fruit; sponge; ready made
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Buns pastries scones flapjacks home baked
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Buns pastries scones flapjacks ready made
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Fruit pies tarts crumbles home baked
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Fruit pies tarts crumbles ready made
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Sponge puddings home baked
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Cln variable: Swimming - Compt hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Swimming - Competitive. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Swimming competitive hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Swimming - Competitive. -1 = left blank. DO NOT USE THIS VARIABLE. Use swimCompHr_CLEAN_P2 instead.
Real
Cln variable: Swimming - Compt min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Swimming - Competitive. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Swimming competitive min
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Swimming - Competitive. -1 = left blank. DO NOT USE THIS VARIABLE. Use swimCompMin_CLEAN_P2 instead.
Real
Cln variable: Swimming - Compt
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Swimming - Competitive . Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Swimming competitive
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Swimming - Competitive. DO NOT USE THIS VARIABLE. Use swimComp_CLEAN_P2 instead.
Real
Swimming - Competitive
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Swimming - Competitive . Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Cln variable: Swimming-leisure hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Swimming - leisure. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Swimming leisure hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Swimming - leisure. -1 = left blank. DO NOT USE THIS VARIABLE. Use swimLeisHr_CLEAN_P2 instead.
Real
Cln variable: Swimming-leisure min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Swimming - leisure. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Swimming leisure min
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Swimming - leisure. -1 = left blank. DO NOT USE THIS VARIABLE. Use swimLeisMin_CLEAN_P2 instead.
Real
Cln variable: Swimming - leisure
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Swimming - leisure. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Swimming leisure
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Swimming - leisure. DO NOT USE THIS VARIABLE. Use swimLeis_CLEAN_P2 instead.
Real
Swimming - leisure
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Swimming - leisure. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Cln variable: Table Tennis hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Table Tennis. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Table tennis hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Table Tennis. -1 = left blank. DO NOT USE THIS VARIABLE. Use tableTennisHr_CLEAN_P2 instead.
Real
Cln variable: Table Tennis min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Table Tennis. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Table tennis min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Table Tennis. -1 = left blank. DO NOT USE THIS VARIABLE. Use tableTennisMin_CLEAN_P2 instead.
Real
Cln variable: Table Tennis
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Table Tennis. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Table tennis
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Table tennis. DO NOT USE THIS VARIABLE. Use tableTennis_CLEAN_P2 instead.
Real
Table Tennis
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Table Tennis. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Avg Daily TEE during AH free living
Phase 2 data. Average Daily Total Energy Expenditure during AH free living (TEE). Calculated in commercial software (REE+AEE+DIT). Average kcal/day. For purpose of volunteer feedback only.
Real
None
Phase 2 data. Derived with method 2. Template number used for processing (1 is standard)
Text
Cln variable: Tennis badminton hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Tennis Or Badminton. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Tennis or badminton hrs
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in hours) you spent doing the activity per episode. Tennis Or Badminton. -1 = left blank. -1 = left blank. DO NOT USE THIS VARIABLE. Use tennisBadmintonHr_CLEAN_P2 instead.
Real
Cln variable: Tennis badminton min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Tennis Or Badminton. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Tennis or badminton min
Phase 2 data. Questionnaire reads D14. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Tennis Or Badminton. -1 = left blank. DO NOT USE THIS VARIABLE. Use tennisBadmintonMin_CLEAN_P2 instead.
Real
Cln variable: Tennis or badminton
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Tennis or badminton. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Tennis or badminton
Phase 2 data. Questionnaire reads D14. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks.Tennis or badminton. DO NOT USE THIS VARIABLE. Use tennisBadminton_CLEAN_P2 instead.
Real
Tennis or badminton
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Tennis or badminton. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Ten Year Age Group
Phase 2 data. Age group the volunteer belonged to at the time of their phase 2 clinical appointment where age groups have been split up into groups of 10 years. Derived by data management team based on AgeAtTest_DM_Attended_P2. Can be used where precise age cannot be released or in not required.
Text
Treadmill Test length in Minutes
Phase 2 data. Treadmill Test length in Minutes (Un-cleaned) For purpose of volunteer feedback only. The data is as it was used for feedback to the participant and will not have been changed if after feedback the data was found to contain an error.
Integer
Test length in seconds
Phase 2 data. Test length in seconds (Un-cleaned) For purpose of volunteer feedback only. The data is as it was used for feedback to the participant and will not have been changed if after feedback the data was found to contain an error. Use cleaned variables from main Actiheart dataset instead.
Integer
Time of start of treadmill test
Phase 2 data. Time of start of treadmill test in Hrs:Mins:Secs
Time
Treadmill test stop Pre HR criteria
Phase 2 data. Data as entered on Study database. For study coordination purposes and QC only. Was the treadmill test stopped Pre HR criteria? 0 = no; 1 = yes;
Categorical
Reason test stop Pre HR criteria
Phase 2 data. Data as entered on Study database. For study coordination purposes and QC only. If the treadmill test stopped Pre HR criteria please tell us why. 1 = Limited-medication; 2 = Limited ECG/Med review; 3 = joint pain/injury; 4 = Volunteer requested to stop; 5 = Inappropriate footwear/clothing; 6 = Loss of polar signal; 7 = Unwell; 8 = Time constraints; 9 = Volunteer unsteady on treadmill; 10 = Other-please note in comments; 11 = RER > 1.1;
Categorical
Time 120 min blood sample taken
Phase 2 data. Exact time 120 min blood sample was taken. For QC and filed team use. Not for analysis
Time
Total MET hours
Phase 2 data. Derived with method 2. Total reported duration (hours) of activity times intensity (MET) METhrs/d
Real
Total MET hrs plus unaccounted hrs
Phase 2 data. Derived with method 2. Total reported (plus unaccounted) duration (hours) of activity times intensity (MET) METhrs/d
Real
Total reported hrs of activity
Phase 2 data. Derived with method 2. Total reported duration (hours) of activity hrs/d
Real
Triglyceride 0 minutes
Phase 2 data. Serum Triglyceride measurement taken at 0 minutes in mmol/l
Real
Urine ACR
Phase 2 data. Urine ACR (Albumin/Creatinine Ratio) measurement in mg/mmol/L
Real
Urine Albumin
Phase 2 data. Urine Albumin measurement in mg/l. Raw data; Cleaned data provide in variable G_Uralbumin with x_Threshold and x_Com variables provided for clarification.
Real
Urine Creatinine
Phase 2 data. Urine Creatinine measurement in mmol/l. Raw data. Cleaned data provide in variable G_UrCreatinine with x_Threshold and x_Com variables provided for clarification.
Real
Urea 0 minutes
Phase 2 data. Serum Urea measurement taken at 0 minutes in mmol/l
Real
Pt fasted prior taking urine sample
Phase 2 data. Data as entered on Study database. Did participant fast prior to taking of urine sample. Fasted - not fasted - unknown
Text
US Abdominal Completed by
Phase 2 data. Initials/ID of staff member who completed the abdominal Ultrsound
Text
Ultrasound Entered
Phase 2 data. Ultrasound entered? 0 = no; 1 = yes;
Categorical
US Liver Completed by
Phase 2 data. Initials/ID of staff member who completed the liver Ultrsound
Text
Results Validation Status
Phase 2 data. Measurement is either OK; or OutOfRange; or Invalid; or InvalidOutOfRange. This status is based on any one of the results fields being inavlid or out of range
Text
Parsnips
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Leeks
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Onions
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Garlic
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Mushrooms
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
SweetPeppers
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Beansprouts
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
GreenSalad
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Watercress
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Tomatoes
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Carrots
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Sweetcorn
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Beetroot
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Coleslaw
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Avocado
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
BakedBeans
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
DriedLentils
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Tofu
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Spinach
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Broccoli
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
BrusselsSprouts
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Cabbage
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Peas
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Beans
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Marrow
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Cauliflower
Phase 2 data. FFQ questionnaire ELY-PQ-3-204 reads Please estimate your average food use as best you can and please answer every question - do not leave ANY lines blank. Foods and Amounts; Average use last year. 1 = Never or less than once a month; 2 = 1-3 per month; 3 = Once a week; 4 = 2-4 per week; 5 = 5-6 per week; 6 = Once a day; 7 = 2-3 per day; 8 = 4-5 per day; 9 = 6+ per day; -1 = left blank; -5 = more than one selected;
Categorical
Cln variable: Qnr version no
Phase 2 data. Derived with method 2. Questionnaire version number
Text
Time spent at vigorous intensity activity work not inc
Phase 2 data. Derived with method 2. Time spent at vigorous intensity activity; No work and no other acts hrs/d
Real
Time spent at vigorous intensity activity work inc
Phase 2 data. Derived with method 2. Time spent at vigorous intensity activity; Work inc but no other acts hrs/d
Real
Vitamin C Results
Data produced by UCL from blood samples in umol/l. Raw data; cleaned data provided in variable G_VitaminCResult with x_Threshold and x_Com variables provided for clarification.
Real
QCd Vitamin C result
Phase 2 data. QCd Vitamin C result in umol/l. Where VitaminCResult_P2_Raw data is questionable it has been removed by the DM team and a comment has been provided in VitaminC_P2_DMcomment
Real
Raw Vitamin C result
Phase 2 data. raw Vitamin C result as received from lab in umol/l
Real
DM comment on raw VitC data
Phase 2 data. Data management comment on raw VitC data in table to clarify data QC
Text
Lab Vitamin C analysis comment
Phase 2 data. Laboratory analysis comment for phase 2 Vitamin C analysis.
Text
VO2max calculation
Phase 2 data. Data as entered on Study database. New variable to calculate VO2max using a different algorithm. Values used for participant feedback only. Not for analysis. Use fitness variables in main actiheart dataset instead
Real
Walk Test Walking Aid Type
Phase 2 data. Walk Test Walking Aid Type. Data as entered on Study database. For study coordination purposes and QC only. Use cleaned Walk test variables from main Actiheart dataset instead.
Text
Walk Test walking aid used
Phase 2 data. Walk Test walking aid used. Data as entered on Study database. For study coordination purposes and QC only. Use cleaned Walk test variables from main Actiheart dataset instead. 0 = no; 1 = yes;
Categorical
Cln variable: Walking pleasure hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Walking for pleasure (not as a means of transport). Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Walking for pleasure hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Walking for pleasure (not as a means of transport). -1 = left blank. DO NOT USE THIS VARIABLE. Use walkPleasureHr_CLEAN_P2 instead.
Real
Cln variable: Walking pleasure min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Walking for pleasure (not as a means of transport). Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Walking for pleasure min
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Walking for pleasure (not as a means of transport). -1 = left blank. DO NOT USE THIS VARIABLE. Use walkPleasureMin_CLEAN_P2 instead.
Real
Cln variable: Walking pleasure
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Walking for pleasure (not as a means of transport). Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Walking for pleasure
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Walking for pleasure (not as a means of transport). DO NOT USE THIS VARIABLE. Use walkPleasure_CLEAN_P2 instead.
Real
Walking for pleasure
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Walking for pleasure (not as a means of transport). Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Walk Test Comments
Phase 2 data. Walk Test Comments. Data as entered on Study database. For study coordination purposes and QC only. Use cleaned Walk test variables from main Actiheart dataset instead.
Text
Walk Test Distance
Phase 2 data. Walk Test Distance. Data as entered on Study database. For study coordination purposes and QC only. Use cleaned Walk test variables from main Actiheart dataset instead.
Integer
Walk Test Entered
Phase 2 data. Walk test data entered? 0 = no; 1 = yes;
Categorical
Walk Test number of laps
Phase 2 data. Walk Test number of laps. Data as entered on Study database. For study coordination purposes and QC only. Use cleaned Walk test variables from main Actiheart dataset instead.
Integer
Walk length minutes
Phase 2 data. Walk length minutes. Data as entered on Study database. For study coordination purposes and QC only. Use cleaned Walk test variables from main Actiheart dataset instead.
Real
Walk Test length Seconds
Phase 2 data. Walk Test length Seconds. Data as entered on Study database. For study coordination purposes and QC only. Use cleaned Walk test variables from main Actiheart dataset instead.
Integer
Walk Test Standing HR
Phase 2 data. Walk Test Standing HR. Data as entered on Study database. For participant feedback only. Use cleaned Walk test variables from main Actiheart dataset instead.
Integer
Walk Test Start time
Phase 2 data. Walk Test Start time. Data as entered on Study database. For study coordination purposes and QC only. Use cleaned Walk test variables from main Actiheart dataset instead.
Time
Cln variable: Watering the lawn hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Watering the lawn or garden. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Watering the lawn or garden hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Watering the lawn or garden. -1 = left blank. DO NOT USE THIS VARIABLE. Use waterLawnHr_CLEAN_P2 instead.
Real
Cln variable: Watering the lawn min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Watering the lawn or garden. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Watering the lawn or garden min
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Watering the lawn or garden. -1 = left blank. DO NOT USE THIS VARIABLE. Use waterLawnMin_CLEAN_P2 instead.
Real
Cln variable: Watering the lawn
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Watering the lawn or garden. Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Watering the lawn or garden
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Watering the lawn or garden. DO NOT USE THIS VARIABLE. Use waterLawn_CLEAN_P2 instead.
Real
Watering the lawn or garden
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Watering the lawn or garden. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Cln variable: WeedingorPruning hrs
Phase 2 data. Please indicate the average length of time (in hours) you spent doing the activity per episode. Weeding or Pruning. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Weeding or Pruning hrs
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Weeding or Pruning. -1 = left blank. DO NOT USE THIS VARIABLE. Use weedPruneHr_CLEAN_P2 instead.
Real
Cln variable: WeedingorPruning min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Weeding or Pruning. Error codes cleaned by DM team with this rule: AVG_TEXT (average returned as text with no rounding). And then -10 errors cleaned by PA team. -1 = left blank.
Real
Weeding or Pruning min
Phase 2 data. Please indicate the average length of time (in additional minutes) you spent doing the activity per episode. Weeding or Pruning. -1 = left blank. DO NOT USE THIS VARIABLE. Use weedPruneMin_CLEAN_P2 instead.
Real
Cln variable: Weeding or Pruning
Phase 2 data. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Weeding or Pruning.Error codes cleaned by DM team. And then -10 errors cleaned by PA team. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -9 = not completed; -10 = any text as written;
Categorical
Weeding or Pruning
Phase 2 data. Questionnaire reads D13. Please indicate the average length of time (in hours) you spent doing the activity per episode. Weeding or Pruning. DO NOT USE THIS VARIABLE. Use weedPrune_CLEAN_P2 instead.
Real
Weeding or Pruning
Phase 2 data. Data sources are varname_T1 and varname_T2 where the raw uncleaned data was normalised to the same data entry codes and then pooled into this new variable. Do not use. Use _CLEAN variable instead. Please indicate how often (total number of times) you did the activity on average over the last 4 weeks. Weeding or Pruning. Data normalised to DE template 1 data. 1 = None; 2 = once in last 4 wks; 3 = 2-3 times in last 4 wks; 4 = once a week; 5 = 2-3 times a week; 6 = 4-5 times a week; 7 = every day; -1 = left blank; -5 = more than one selected; -10 = any text as written;
Categorical
Cln variable: Wkday go to bed time
Phase 2 data. Weekday go to bed time (from General Q) - cleaned 24hr format
Time
No Wk days worked in a typical wk
Phase 2 data. Questionnaire reads Think about a typical week in the last 4 weeks. Enter how many days a week you worked on a week and a weekend day. Number of WEEK days worked In a typical week. ELECTRONIC F0RM ONLY additional instructions: please enter 0 if not worked.
Real
Cln variable: Wkday wake time
Phase 2 data. Weekday wake time (from General Q) - cleaned 24hr format
Time
Weekday daily sleep duration
Phase 2 data. Weekday daily sleep duration (hours) from cleaned GenQ sleep times
Real
Cln variable: Wknd day bed time
Phase 2 data. Weekend day go to bed time (from General Q) - cleaned 24hr format
Time
No Wkn days worked in a typical wk
Phase 2 data. Questionnaire reads Think about a typical week in the last 4 weeks. Enter how many days a week you worked on a week and a weekend day. Number of WEEKEND days worked In a typical week. ELECTRONIC F0RM ONLY additional instructions: please enter 0 if not worked.
Real
Cln variable: Wknd day wake time
Phase 2 data. Weekend day wake time (from General Q) - cleaned 24hr format
Time
Wknd day daily sleep duration
Phase 2 data. Weekend day daily sleep duration (hours) from cleaned GenQ sleep times
Time
Work from home status
Phase 2 data. Work from home status of Fenland phase 2 participants according to self-report and postcode information (-9 = missing; 0 = works from home as home postcode equal to work postcode; 1 = self-reported works from home; 2= works outside of home)
Categorical
Hrs worked excluding travel 1 wk
Phase 2 data. ELECTRONIC FORM ONLY: Please answer this section only if you have been in paid employment at any time during the last 4 weeks or you have done regular organised voluntary work. During the last 4 weeks how many hours work did you do per week (excluding travel)? 1 week ago. -1 = left blank
Real
Extra min worked excluding travel
Phase 2 data. ELECTRONIC FORM ONLY: Please answer this section only if you have been in paid employment at any time during the last 4 weeks or you have done regular organised voluntary work. During the last 4 weeks how many extra minutes work did you do per week (excluding travel)? 1 week ago. -1 = left blank
Real
Reason hrs not worked 1 week ago
Phase 2 data. Questionnaire reads D6. During the last 4 weeks how many hours work did you do per week? If 0 hours were worked 1 week ago record reason why. Merged data from PAPER and ELECTRONIC FORMS. 1 = Holiday; 3 = Other;
Categorical
Work hrs excluding travel 1 week
Phase 2 data. Questionnaire reads D6. During the last 4 weeks how many hours did you work per week? Work hours (excluding travel) 1 week ago. Free text variable only collected on paper Questionnaire. Answer should be in total number of hours that week. Added -9 to electronic records to indicate data not collected
Real
Hrs worked excluding travel 2 wks
Phase 2 data. ELECTRONIC FORM ONLY: Please answer this section only if you have been in paid employment at any time during the last 4 weeks or you have done regular organised voluntary work. During the last 4 weeks how many hours work did you do per week (excluding travel)? 2 weeks ago. -1 = left blank
Real
Extra min worked excluding travel
Phase 2 data. ELECTRONIC FORM ONLY: Please answer this section only if you have been in paid employment at any time during the last 4 weeks or you have done regular organised voluntary work. During the last 4 weeks how many extra minutes work did you do per week (excluding travel)? 2 weeks ago. -1 = left blank
Real
Reason hrs not worked 2 week ago
Phase 2 data. Questionnaire reads D6. During the last 4 weeks how many hours work did you do per week? If 0 hours were worked 2 week ago record reason why. Merged data from PAPER and ELECTRONIC FORMS. 1 = Holiday; 3 = Other;
Categorical
Work hrs excluding travel 2 weeks
Phase 2 data. Questionnaire reads D6. During the last 4 weeks how many hours did you work per week? Work hours (excluding travel) 2 weeks ago. Free text variable only collected on paper Questionnaire. Answer should be in total number of hours that week. Added -9 to electronic records to indicate data not collected
Real
Hrs worked excluding travel 3 wks
Phase 2 data. ELECTRONIC FORM ONLY: Please answer this section only if you have been in paid employment at any time during the last 4 weeks or you have done regular organised voluntary work. During the last 4 weeks how many hours work did you do per week (excluding travel)? 3 weeks ago. -1 = left blank
Real
Extra min worked excluding travel
Phase 2 data. ELECTRONIC FORM ONLY: Please answer this section only if you have been in paid employment at any time during the last 4 weeks or you have done regular organised voluntary work. During the last 4 weeks how many extra minutes work did you do per week (excluding travel)? 3 weeks ago. -1 = left blank
Real
Reason hrs not worked 3 week ago
Phase 2 data. Questionnaire reads D6. During the last 4 weeks how many hours work did you do per week? If 0 hours were worked 3 week ago record reason why. Merged data from PAPER and ELECTRONIC FORMS. 1 = Holiday; 3 = Other;
Categorical
Work hrs excluding travel 3 weeks
Phase 2 data. Questionnaire reads D6. During the last 4 weeks how many hours did you work per week? Work hours (excluding travel) 3 weeks ago. Free text variable only collected on paper Questionnaire. Answer should be in total number of hours that week. Added -9 to electronic records to indicate data not collected
Real
Hrs worked excluding travel 4 wks
Phase 2 data. ELECTRONIC FORM ONLY: Please answer this section only if you have been in paid employment at any time during the last 4 weeks or you have done regular organised voluntary work. During the last 4 weeks how many hours work did you do per week (excluding travel)? 4 weeks ago. -1 = left blank
Real
Extra min worked excluding travel
Phase 2 data. ELECTRONIC FORM ONLY: Please answer this section only if you have been in paid employment at any time during the last 4 weeks or you have done regular organised voluntary work. During the last 4 weeks how many extra minutes work did you do per week (excluding travel)? 4 weeks ago. -1 = left blank
Real
Reason hrs not worked 4 week ago
Phase 2 data. Questionnaire reads D6. During the last 4 weeks how many hours work did you do per week? If 0 hours were worked 4 week ago record reason why. Merged data from PAPER and ELECTRONIC FORMS. 1 = Holiday; 3 = Other;
Categorical
Work hrs excluding travel 4 weeks
Phase 2 data. Questionnaire reads D6. During the last 4 weeks how many hours did you work per week? Work hours (excluding travel) 4 weeks ago. Free text variable only collected on paper Questionnaire. Answer should be in total number of hours that week. Added -9 to electronic records to indicate data not collected
Real
Work address
Phase 2 data. Questionnaire reads D11. If work postcode not known please give your work address. Data as entered by participant. -1 = left blank
Text
Work Postcode
Phase 2 data. Questionnaire reads D11. What is the postcode for your main place of work during the last 4 weeks? Data as entered by participant. -1 = left blank
Text
Cln variable: Type and amount of PA
Phase 2 data. We would like to know the type and amount of physical activity involved in your work. Please tick the one option that best corresponds with your occupation(s) in the last 4 weeks.Error codes cleaned by DM team with this rule: AVG#RDOWN_TEXT. And then -10
Real
Type and amount of PA in work
Phase 2 data. Questionnaire reads D7. We would like to know the type and amount of physical activity involved in your work. Please tick the one option that best corresponds with your occupation(s) in the last 4 weeks. SEDENTARY: you spend most of your time sitting such as in an office. STANDING occupation: You spend most of your time standing or walking however your work does not require intense physical effort eg shop assistant hairdresser guard. MANUAL work: This involves some physical effort including handling of heavy objects and use of tools eg plumber electrician carpenter. HEAVY MANUAL work: This implies very vigorous activity including handling of very heavy objects eg dock worker miner bricklayer construction worker. 1 = sedentary; 2 = standing; 3 = manual work; 4 = heavy manual work; DO NOT USE THIS VARIABLE. Use Worktype_CLEAN_P2 instead.
Categorical
Work domain AEE
Phase 2 data. Derived with method 2. Work domain activity energy expenditure net METhrs/d
Real
Work location changed btwn phases
Phase 2 data. Work location changed between phases 1 and 2 including those that started working from home during study period (-9 = missing; 1 = no job address change 2 = job address change)
Categorical
Work domain energy expenditure
Phase 2 data. Derived with method 2. Work domain energy expenditure METhrs/d
Real
Work domain PAEE
Phase 2 data. Derived with method 2. Work domain activity energy expenditure kJ/kg/d
Real
Description work postcode missing
Phase 2 data. Description of work postcode missings of Fenland phase 2 participants according to postcode data (-9 = outside of study area;-99 = no work information; -999 = invalid work address data/more than one workplace; -9999 = retired; 1 = valid postcode data)
Categorical
Cln variable: Work postcode
Phase 2 data. Cleaned Phase 2 Work Postcode based on data entered into the contact database transcribed from the phase 2 measrurment questionnaire. -1 = Unknown left blank unspecific postcode unit or multiple postcode unit options;-2 = Retired
Categorical
Cmnt missing values Work postcode
Phase 2 data. Comment related to missing values in Work_postcode_cleaned_P2
Text
Cnt of supermarkets 1 mile Pts work
Phase 2 data. Count of supermarkets within a 1 mile Eucladian distance of participants' work Fenland phase 2 (-9 = missing)
Integer
Cnt of takeaways 1 mile Pts work
Phase 2 data. Count of takeaways within a 1 mile Eucladian distance of participants' work Fenland phase 2 (-9 = missing)
Integer
Wrist acc issued to pt
Phase 2 data. Data as entered on Study database. For study coordination purposes and QC only. Has wrist accelerometer been issued to particpant? 0 = no; 1 = yes;
Categorical
Wrist worn acc used treadmil test
Phase 2 data. Data as entered on Study database. For study coordination purposes and QC only. Wrist worn accelerometer used for treadmil test? 0 = no; 1 = yes;
Categorical
Cln variable: Travel wrk by bicycle
Phase 2 data. Travel to and from work in the last 4 weeks. How did you normally travel to work? Bicycle. Error codes cleaned by DM team with this rule: AVG#RUP_AVG#RUP_TEXT. And then -10 errors cleaned by PA team.
Real
Travel to work by bicycle
Phase 2 data. Questionnaire reads D10. Travel to and from work in the last 4 weeks. How did you normally travel to work? By Bicycle; 1 = always; 2 = usually; 3 = occasionally; 4 = never or rarely; DO NOT USE THIS VARIABLE. Use Wrkbybicycle_CLEAN_P2 instead.
Categorical
Cln variable: Travel wrk by car
Phase 2 data. Travel to and from work in the last 4 weeks. How did you normally travel to work? Car. Error codes cleaned by DM team with this rule: AVG#RUP_AVG#RUP_TEXT. And then -10 errors cleaned by PA team.
Real
Travel to work by car
Phase 2 data. Questionnaire reads D10. Travel to and from work in the last 4 weeks. How did you normally travel to work? By Car; 1 = always; 2 = usually; 3 = occasionally; 4 = never or rarely; DO NOT USE THIS VARIABLE. Use Wrkbycar_CLEAN_P2 instead.
Categorical
Cln variable: Travel wrk walking
Phase 2 data. Travel to and from work in the last 4 weeks. How did you normally travel to work? Walking. Error codes cleaned by DM team with this rule: AVG#RUP_AVG#RUP_TEXT. And then -10 errors cleaned by PA team.
Real
Travel to work walking
Phase 2 data. Questionnaire reads D10. Travel to and from work in the last 4 weeks. How did you normally travel to work? Walking; 1 = always; 2 = usually; 3 = occasionally; 4 = never or rarely; DO NOT USE THIS VARIABLE. Use Wrkbyfoot_CLEAN_P2 instead.
Categorical
Cln variable: Travel wrk pub trans
Phase 2 data. Travel to and from work in the last 4 weeks. How did you normally travel to work? Public transport. Error codes cleaned by DM team with this rule: AVG#RUP_AVG#RUP_TEXT. And then -10 errors cleaned by PA team.
Real
Travel to work by public transport
Phase 2 data. Questionnaire reads D10. Travel to and from work in the last 4 weeks. How did you normally travel to work? By works or Public transport; 1 = always; 2 = usually; 3 = occasionally; 4 = never or rarely; DO NOT USE THIS VARIABLE. Use Wrkbypubtran_CLEAN_P2 instead.
Categorical
Work from home
Phase 2 data. Travel to and from work in the last 4 weeks. What is the approximate distance from your home to your work? COLLECTED ON PAPER Q ONLY: If work from home tick here and enter 0 for distance. 1 = ticked; -1 = left blank;
Real
Cln variable: Dist Home-work in kms
Phase 2 data. RPAQ data. Distance Home-work in kilometres. Data derived from other data entered.Error codes cleaned by DM team with this rule: AVG_TEXT. And then -10 errors cleaned by PA team.
Real
Approx distance home to work kms
Phase 2 data. Questionnaire reads D8. Travel to and from work in the last 4 weeks. What is the approximate distance from your home to your work? In kilometres. Data as entered by participant. -1 = left blank. DO NOT USE THIS VARIABLE. Use Wrkkms_CLEAN_P2 instead.
Real
Cln variable: Dist Home-work miles
Phase 2 data. Distance Home-work in miles. Data derived from other data entered. Data cleaned.
Real
Approx distance home to work miles
Phase 2 data. Questionnaire reads D8. Travel to and from work in the last 4 weeks. What is the approximate distance from your home to your work? In miles. Data as entered by participant. -1 = left blank. DO NOT USE THIS VARIABLE. Use Wrkmiles_CLEAN_P2 instead.
Real
Work from multiple locations
Phase 2 data. Derived by using data from WrkMultipleLocations_p_P2; WrkMultipleLocations_e_P2 and WrkFromHome_P2. Refer to Wrkmiles_P2 and Wrkkms_P2 if needed. 1 = works from home; 2 = works from multiple location; -1 = not answered left blank; -10 = estimated average distance from home to work (unit unknown);
Categorical
Cln variable: Travel wrk per wk
Phase 2 data. Travel to and from work in the last 4 weeks. How many times per week did you travel from home to your main place of work? Count outward journeys only.Error codes cleaned by DM team with this rule: AVG_AVG_TEXT. And then -10 errors cleaned by PA team.
Real
Times per wk travel home to work
Phase 2 data. Questionnaire reads D9. Travel to and from work in the last 4 weeks. How many times per week did you travel from home to your main place of work? Count outward journeys only. -1 = left blank. DO NOT USE THIS VARIABLE. Use Wrktimesperweek_CLEAN_P2 instead.
Real
Filter by: Display page Set page size Total 230
Name
Type
Description
OUTPUT
All raw data variables related to Three factor eating questionnaire as completed by participant.
OUTPUT
All raw data variables related to Participant address as completed by participant.
OUTPUT
All variables derived from General Questionnaire Education variables as completed by participant.
OUTPUT
All merged variables fromGeneral Questionnaire Education variables as completed by participant.
OUTPUT
All raw data variables related to General Questionnaire Education variables as completed by participant.
OUTPUT
All cleaned Bread variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned Cereal variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned Dairy And Fats variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned drinks variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned Eating Habits variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned FatsCookOrBake variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned FatsOnBreadOrVeg variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All Alcohol variables derived from Food Frequency Questionnaire using FETA v2.53
OUTPUT
All Bread variables derived from Food Frequency Questionnaire using FETA v2.53
OUTPUT
All Cereal variables derived from Food Frequency Questionnaire using FETA v2.53
OUTPUT
All Dairy And Fats variables derived from Food Frequency Questionnaire using FETA v2.53
OUTPUT
All Drinks variables derived from Food Frequency Questionnaire using FETA v2.53
OUTPUT
All Fats On Bread Or Vegs variables derived from Food Frequency Questionnaire using FETA v2.53
OUTPUT
All Food group variables derived from Food Frequency Questionnaire using FETA v2.53
OUTPUT
All Flavonoid variables derived from Food Frequency Questionnaire using FETA v2.53
OUTPUT
All Foods variables derived from Food Frequency Questionnaire using FETA v2.53
OUTPUT
All Fruits variables derived from Food Frequency Questionnaire using FETA v2.53
OUTPUT
All Nutrients variables derived from Food Frequency Questionnaire using FETA v2.53
OUTPUT
All Other variables derived from Food Frequency Questionnaire using FETA v2.53
OUTPUT
All Potato Rice or Pasta variables derived from Food Frequency Questionnaire using FETA v2.53
OUTPUT
All Soup Sauce or Spread variables derived from Food Frequency Questionnaire using FETA v2.53
OUTPUT
All Sweets or Snacks variables derived from Food Frequency Questionnaire using FETA v2.53
OUTPUT
All Vegetable variables derived from Food Frequency Questionnaire using FETA v2.53
OUTPUT
All cleaned Fish variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned Frequency of Fried Food variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned Meat variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned Meat and Fish variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned Fish variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned Merged variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned Milk variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned OtherFoods variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned PotRicePasta variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All raw variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All raw Drinks variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All raw Fruit variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All raw SweetsSnacks variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned Salt variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned SoupSauceSpreads variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned Dietary Supplements variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All cleaned Vegetables variables related to Food Frequency Questionnaire as completed by participant.
OUTPUT
All Cleaned variables related to General questionnaire as completed by participant.
OUTPUT
All Blood Urine Glucose variables related to Lab measurements completed during participant site visit.
OUTPUT
All physical activity variables related to Measurement Questionnaires completed during participant site visit.
OUTPUT
All variables related to Measurement Questionnaires completed during participant site visit.
OUTPUT
All Clinical Anthropology variables related to Measurement Questionnaires completed during participant site visit.
OUTPUT
All DEXA variables related to Measurement Questionnaires completed during participant site visit.
OUTPUT
All Liver Review variables related to Measurement Questionnaires completed during participant site visit.
OUTPUT
All Physical Activity variables related to Measurement Questionnaires completed during participant site visit.
OUTPUT
All Ultrasound variables related to Measurement Questionnaires completed during participant site visit.
OUTPUT
All Actiheart monitor variables created by Physical Activity team not for general release
OUTPUT
REE variables in first REE data derivation project; have been replaced by REE set 2 variables
OUTPUT
All Activity At Work variables as present on Recent Physical Activity Questionnaire
OUTPUT
All Activity At Home variables as present on Recent Physical Activity Questionnaire
OUTPUT
All Normalised recreation variables related to Recent Physical Activity Questionnaire
OUTPUT
All raw (uncleaned data) variables as present on Recent Physical Activity Questionnaire
OUTPUT
All Recreation variables as present on Recent Physical Activity Questionnaire
OUTPUT
All Template1 recreation variables related to Recent Physical Activity Questionnaire
OUTPUT
All Template2 recreation variables related to Recent Physical Activity Questionnaire
Export the variable list:
Variable id
Variable name